<SEC-DOCUMENT>0001410578-23-000234.txt : 20230309
<SEC-HEADER>0001410578-23-000234.hdr.sgml : 20230309
<ACCEPTANCE-DATETIME>20230309164748
ACCESSION NUMBER:		0001410578-23-000234
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		100
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230309
DATE AS OF CHANGE:		20230309

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cytosorbents Corp
		CENTRAL INDEX KEY:			0001175151
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				980373793
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36792
		FILM NUMBER:		23720371

	BUSINESS ADDRESS:	
		STREET 1:		305 COLLEGE ROAD EAST
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540
		BUSINESS PHONE:		973-329-8885

	MAIL ADDRESS:	
		STREET 1:		305 COLLEGE ROAD EAST
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MedaSorb Technologies CORP
		DATE OF NAME CHANGE:	20060807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GILDER ENTERPRISES INC
		DATE OF NAME CHANGE:	20020611
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ctso-20221231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.2.0.4 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/9/2023 9:43:18 PM -->
      <!-- iXBRL Library version: 1.0.8405.27969 -->
      <!-- iXBRL Service Job ID: 75dc5636-dc5b-44fb-98c0-ccd8d8ff812b -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ctso="http://www.cytosorbents.com/20221231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" xs:nil="true" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" name="us-gaap:CommitmentsAndContingencies" id="Hidden_D3AsnHpxPkq8SV8Mnnog1w"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" xs:nil="true" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_rqgEISEScES0gDtBbJYfdg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" xs:nil="true" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" name="us-gaap:PreferredStockValue" id="Hidden_hEV81X3h9UOJEdBsx3b6bQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" xs:nil="true" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" name="us-gaap:PreferredStockValue" id="Hidden_WcE7qIcf6U2Unn00kGtBEA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" sign="-" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_zNIJAnaRR0CqAJo82LC6XA">0.75</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_A3L_kI-Jk0-EUNRql5ERcw">0.57</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" sign="-" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_v5TbsPJIpkCU_eSgu2R0tQ">0.20</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_1BftEmQrCEGZd_4tI3AJmA">43573215</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_HOA4Wyebo0eApwihM9dwIA">43359186</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_N8FoVDtPi0CNhRZPSqthVQ">38818990</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" name="ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm" id="Hidden_1iWKOSTEYEW4rgjnocsyQg">P0Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" name="ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm" id="Hidden_gFEztX83IEan5vGYiG_KkA">P0Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" name="ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm" id="Hidden_7Cm8_uxCP0mv3QQAha4gkQ">P0Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" name="ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm" id="Hidden_rBumodlmnUK-p_-iado5iw">P0Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" name="ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm" id="Hidden_GQpp15AqqkCIMuMwEM8NqQ">P0Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" name="ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm" id="Hidden_amo3-ZcwWEWCT2ol91T9ZQ">P0Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm" id="Hidden_SbJXsQ3BuU-Usd0OT4w7GA">P0Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm" id="Hidden_4-HPXTyq0kWo5cJ4Z0sPVw">P0Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm" id="Hidden_We0d8r7iWEWg62NYW1m7vA">P0Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" sign="-" contextRef="Duration_1_1_2022_To_3_31_2022__Bto-66MgUq_eQRwKUyq1Q" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_MUpMpWeHk0aBUZ2MDd26VA">0.21</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" sign="-" contextRef="Duration_4_1_2022_To_6_30_2022_mLayX3PX1Eqci3SfMDv1YQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_oXJA3y4UJUasTNz9MDnPsg">0.25</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" sign="-" contextRef="Duration_7_1_2022_To_9_30_2022_2eoa-jebUE-H6uey7YKWmQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_3-kL6JZPV0i6pqW7QNx0aA">0.28</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" sign="-" contextRef="Duration_10_1_2022_To_12_31_2022_7D4gmEOvZEuddtCJGzA8ow" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_-0c_lfDGEkqIWrJYOWqHZg">0.02</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" sign="-" contextRef="Duration_1_1_2021_To_3_31_2021_zXigQoQBgUGOxC_vaZv8ag" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_gC8GmjKZIE-UrlDfCE1KUg">0.10</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" sign="-" contextRef="Duration_4_1_2021_To_6_30_2021_KUS8bQMU0UaIknV605S_VA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_SAhtz1HqJEKTOk7YM9gT3A">0.11</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" sign="-" contextRef="Duration_7_1_2021_To_9_30_2021_bc1_H1o8GkWXj53DijdBKA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_W735XDkRFEey5S0CoME8Fg">0.15</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" sign="-" contextRef="Duration_10_1_2021_To_12_31_2021_PTkhRTY9_0uo1BKc7O3ElQ" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_boXR5GlxQkyOQtUsZQrz_g">0.25</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" sign="-" contextRef="Duration_1_1_2020_To_3_31_2020_0j8Adr0DO0CTdQHPhErCZw" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_SqGHfpNVQUevlbriuIdhVg">0.10</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" sign="-" contextRef="Duration_4_1_2020_To_6_30_2020_pfUWsTXCTUSP48AZxdHHPw" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_Lb2al7sI0EWr3LUyy8IGLw">0.08</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" sign="-" contextRef="Duration_7_1_2020_To_9_30_2020_BlNvdmBrgEeKoL8Hm4r3Dw" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_3AW966jREEaC8BynrHPevA">0.02</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_10_1_2020_To_12_31_2020_asiudZouf0qo-UGg2Gf0lw" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_cLNeaf2svkq70K-ImasqNw">0.00</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:AmendmentFlag" id="Tc_CU_sydlIsUWfqRKartI5UA_2_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:DocumentFiscalYearFocus" id="Tc_I-I0qkxrPkWdVvYG2lwFuA_3_1">2022</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:DocumentFiscalPeriodFocus" id="Tc_sz6AbnUQxkO4eLsvlZzBzw_4_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:EntityCentralIndexKey" id="Tc_OvFDZXlxJ0aXCVNZpJRkKQ_6_1">0001175151</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:CurrentFiscalYearEndDate" id="Tc_kA3xcw_Dmk-N1BD6VL27Wg_7_1">--12-31</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_z7CAybzy_UCwWIryUIV6Kw">43635715</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_VfGFfPUiNEutikrelXHK5g">43478487</ix:nonFraction><ix:nonNumeric contextRef="Duration_6_1_2014_To_6_30_2014_xxa151rza0iR7WYHq7r7TA" name="ctso:DefinedContributionEligibilityTerm" id="Hidden_wRQ8gwA2pEGU2CW7c2BqBw">P3M</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_odV670fJEUWMoiqxIvk3sw" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_bnG0W-eC-kmqWIE1UDcudQ">0.333</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_4_12_2021_To_4_12_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_fFXJv_RDXUGqaL5uxC9OHA" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_yBkqj_djEEmSnjqOn-lNAA">0.333</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_8_10_2022_To_8_10_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_WpLhK-DurECWLOlefRpvAg" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_CzwcUS2bLUKcKWPHYGPuIw">0.333</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_8_10_2022_To_8_10_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_VaRbgm5QaE6YvFr9Fe1yBQ" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_Qn9ZRP_XUUuujsh4uxHgPw">0.333</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_csIBECZEpEyijv9iV3T9sQ" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_9VkzXAfHnkmSs1ntMN_DvA">0.333</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_ctso_ShareBasedCompensationAwardTrancheFourMember_8iSlUywhskW943wT9Tsmag" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_FavK8EuO0EiMvQzxKsEdyg">0.333</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_ctso_ShareBasedCompensationAwardTrancheFiveMember_FzLPW6Bz_0Ck1LOSUNIRiw" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_XAf3tkw7FEWYcbQI9IZMZw">0.333</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_4_1_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_Ayo8OWQvq0qpn_0X3Xab7g" decimals="-5" name="us-gaap:OperatingLeaseLiability" id="Hidden_i35CHnl1HUSihsVEqT6O2A">11600000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_4_1_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsEuropeGmbhMember_eGPb2XlfmU655buQQmU81A" decimals="0" name="us-gaap:OperatingLeaseLiability" id="Hidden_cxtzS31VrUm4rMIV9MB8Iw">594000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_iXELXapUCkaeE4AvVxSU8g">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_OpzAs5-aA0elOwLb22GMjg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_ftW8B_sRc0q8TfEsntsdDA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_a7ThlUoBZUCRE07FyDdzfQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_4_12_2021_To_4_12_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1MKAMb2CmEmA_P42dMcHxw" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_NhvWl8VkYEiywUdQUWqfYg">0.333</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_4_12_2021_To_4_12_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_qyOWI6GyLE-X4I8r0-tdDg" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_riKmZAfAA0-fmSAyyqKphA">0.333</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_8_10_2022_To_8_10_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_hiVRtHV7O0qUATFHrPDRvg" decimals="3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Hidden_IU4zNU0S4UKy1kEa3REKsg">0.333</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TwoThousandAndEighteenSuccessFeeLetterMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_jQs_7-pzMUy3U65XTi21yQ" name="ctso:NumberOfDaysForStockPriceThreshold" id="Hidden_TWKGB9Ns70-hcCjqFg2ORA">P5D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_FirstTrancheMember_GIGD6kvI2kuyoTLKEpk95A" name="ctso:NumberOfDaysForStockPriceThreshold" id="Hidden_0ax9yhmTV0OKMkdCNohxKw">P5D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_SecondTrancheMember_QxsVP0Jock-3r1DvUA8aiw" name="ctso:NumberOfDaysForStockPriceThreshold" id="Hidden_2iU3HFYDDUKoxhoqRgX4wQ">P5D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_ThirdTrancheMember_4sLxmtU1v0S4Yllbg0FfOA" name="ctso:NumberOfDaysForStockPriceThreshold" id="Hidden_pwbH1ZIm4UCeZREcP1cczw">P5D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_cD_zR9lLbk6OW7lmBqw0ow" name="ctso:TermOfCustomerContracts" id="Hidden_4sWYxGr9T0-FAHL1y2CyEw">P1Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="ctso-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xyJVnNq5GE65HtHRW1yDeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_ctso_SeniorManagerOneMember_EkCzFw0rWU-KctkMbIExAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ctso:SeniorManagerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_W4GwiG3lh02utgH-gE4rTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:February282020PerformanceBasedAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_9TJLsXlp6keoHyL-cuizXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:August102022PerformanceBasedAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_f4vXsZkMOkGxq_tl33elVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:April122021PerformanceBasedAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_aC79nG-enkiG4Z0Gnm5v8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_nkcE0lA3-kOw0oD7CH9c4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:February282020PerformanceBasedAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_1LwXDf6m7E-dzAi4ZxI8Aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:August102022PerformanceBasedAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_SehbEFp_LU-TNiW5F5VEKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:April122021PerformanceBasedAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_psiceOjXQ0i-ao__lRK5JQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:February282020PerformanceBasedAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_HkC9ceLZZUStae-rY3krow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:August102022PerformanceBasedAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_XLL9youqcUedryG1mnniUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:April122021PerformanceBasedAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_10_2022_To_8_10_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_iCD0wE1zAkmoNYobFgX5Pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:August102022PerformanceBasedAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-10</xbrli:startDate><xbrli:endDate>2022-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_ctso_SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Nw7O66qjS0-HrTuFoxU-Ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ctso:SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_ctso_SecondFortyFiveThousandRestrictedAwardMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OfWgsCZPdEyRfpWz5t_BNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ctso:SecondFortyFiveThousandRestrictedAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_12_2021_To_4_12_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_SBFV77lhyUaB_1ayr35kYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:April122021PerformanceBasedAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-12</xbrli:startDate><xbrli:endDate>2021-04-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_28_2020_To_2_28_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_5NQR2_FtYk-1wNb9Sb1pdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:February282020PerformanceBasedAwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-28</xbrli:startDate><xbrli:endDate>2020-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2mGFz-g8vkCyKxzLGK8rRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AUSvWy58u0K_IquBEJ7-vQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oumECbNlIE2GMtb6QWOHIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yxInglK_2kaHDsFiaiSgNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_v2r2g5cGPUySlMPbJ6gPWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2fpskYPtCkGXfgvSbLwICg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0_qpfUCFWUSQSBVH2kIqyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pIxGvrDdvkqEyu4JVd03fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5CrlobMDMUOFaODMa0mJMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_NadUN92cUUGeapWWnvOPNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dtYzBB8BaU-3fEcIk5-5qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cDcxImQXYUeh0lvoITev4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_KPMkIaBOA06ekPfEU2CpFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4ADrrvzo1k2uJb6rtAoZXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CCqJgm4tjU2Hhj1W3f863A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PV_DrHkTQkGQmIt0QmW81A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_93L6HhBk5E-Lnf3ZqLpS2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TwoThousandAndEighteenSuccessFeeLetterMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_fb08ojpZuEqeebxD3osGJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TwoThousandAndEighteenSuccessFeeLetterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ctso_ExercisePriceRangeOneMember_L6XbyOqHWUaHFIu4xBQwEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ctso:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_10_2022_To_8_10_2022_srt_TitleOfIndividualAxis_ctso_EmployeeOneMember_eZMz_a7KzUiEra_Pmj1NYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ctso:EmployeeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-10</xbrli:startDate><xbrli:endDate>2022-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_9CuY3bMLoUmlRHItGFexPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_LDp3_ulEB0afY5sDrxWyfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_ctso_SeniorManagerTwoMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QTMNRUs4tkaHSWZeL2Z8fQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ctso:SeniorManagerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_ctso_SeniorManagerOneMember_cYnbKOhq3E6GCga5UwXuXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ctso:SeniorManagerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ctso_ExercisePriceRangeOneMember_HTSesPowQUOWzfbwBPWjzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ctso:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_ctso_EmployeeTwoMember_hcg34RZmk0K7-aUhwgreaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ctso:EmployeeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_10_2022_To_8_10_2022_srt_TitleOfIndividualAxis_ctso_SeniorManagerTwoMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1_iS7zVj_kqq7qBilIFwhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ctso:SeniorManagerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-10</xbrli:startDate><xbrli:endDate>2022-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_10_2022_To_8_10_2022_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_kivuCiqiL0uHjYHAlIe0SA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-10</xbrli:startDate><xbrli:endDate>2022-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_10_2022_To_8_10_2022_srt_TitleOfIndividualAxis_ctso_SeniorManagerOneMember_aJeyvmrvQEamT-sApwGPVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ctso:SeniorManagerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-10</xbrli:startDate><xbrli:endDate>2022-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_10_2022_To_8_10_2022_srt_TitleOfIndividualAxis_ctso_EmployeeTwoMember_n4em8eT-K0OI3zntmzwTHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ctso:EmployeeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-10</xbrli:startDate><xbrli:endDate>2022-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_28_2020_To_2_28_2020_mNnHVlwuKUOZDnoPp6ppuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-28</xbrli:startDate><xbrli:endDate>2020-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Nt-mKk9tE0qaMLa__XLlLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_-5TVQVqcmkOUL9z5tTJN-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2spOJmTsWEmdS8OMyOGHWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_04OJEbPdOkKtPazUq59qpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JpCj6cd7kkiLmP4iVXwtlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_trOIsNzUZk6mTrRFdkZXPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_psdWAFNFkke9A5usGouslg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Jxgd6wgc-UifuA3mjZhm-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_CN57L8kRSkSlPVn_ICCXgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YALsQfAeSkWG8axpq3Cw1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_yN5CzvOjU0uH_kVOetojHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_K10SpTMdF0G5KR4K3WxOyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_FP86LptQuUeU7YsuzIQCcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_tP00N7KMo06ixWdu6bREiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_6fnzkcGGB0ChZUoAaGWn2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Jq6o95e4y0O88aEPmR333A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_DdpipDIQPE6CFjGjSAk4pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_vk8cRgr4tEGiUUmMORIpUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q_I0IFjrfEKL74vm4tWeYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_-zjLmD1sFUWIlQznMjsRvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_L5xd_BU2AUihTjDpJG0EAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_HkkTwSE4WEOHm13LfqHxoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_tCzPxpUUDkurigM_UymlEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Qq1T1vf_pkWNzHvrbos3EA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lKSpWReKk0eWMdrErwptxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_SozA6YZi2kKt1YD5fTj12g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom2.98To3.91Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_rxvDjksKlEOKtNVfXCde1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom2.98To3.91Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_wMhxRA4mxUGyr5aQSg53cQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom4.46To11.39Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_eGE4Htw5vUiAfnNKM05dQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom4.46To11.39Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_uD4JXkNMnUCEqqr147HBXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom5.00To10.58Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_a0ICslhLlEaiPjkyJ39i8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom5.00To10.58Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_A3_FWcLzlUqUUdWwNDHlOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom2.98To3.91Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_4nmfCjwDv0eiv9Xvjheotg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom4.46To11.39Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_Mkkar0ZT7EGL5951qJggtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom5.00To10.58Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_ntPA1TgJd0OfX_mWQ4DWuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom2.98To3.91Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_cXJTOYaNgUKPUItB-_WwrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom2.98To3.91Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_jZM8bjchokCOiKcRmPF3Ug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom4.46To11.39Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_8gw5_ggnZkerQU2oAT6--g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom4.46To11.39Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_DYCHwOrJcUSzRA20VoqbmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom5.00To10.58Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_9h926km2lEC7N26veE3DSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom5.00To10.58Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_S71qz6TZI0CfuhmZ6yul1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_9vRyYMxhI0WaNHqaWqGMHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_10_2022_To_8_10_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_WpLhK-DurECWLOlefRpvAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:August102022PerformanceBasedAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-10</xbrli:startDate><xbrli:endDate>2022-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_10_2022_To_8_10_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_hiVRtHV7O0qUATFHrPDRvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:August102022PerformanceBasedAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-10</xbrli:startDate><xbrli:endDate>2022-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_10_2022_To_8_10_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_VaRbgm5QaE6YvFr9Fe1yBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:April122021PerformanceBasedAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-10</xbrli:startDate><xbrli:endDate>2022-08-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_csIBECZEpEyijv9iV3T9sQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_ctso_ShareBasedCompensationAwardTrancheFourMember_8iSlUywhskW943wT9Tsmag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">ctso:ShareBasedCompensationAwardTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_ctso_ShareBasedCompensationAwardTrancheFiveMember_FzLPW6Bz_0Ck1LOSUNIRiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">ctso:ShareBasedCompensationAwardTrancheFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_12_2021_To_4_12_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1MKAMb2CmEmA_P42dMcHxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:April122021PerformanceBasedAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-12</xbrli:startDate><xbrli:endDate>2021-04-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_12_2021_To_4_12_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_qyOWI6GyLE-X4I8r0-tdDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:April122021PerformanceBasedAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-12</xbrli:startDate><xbrli:endDate>2021-04-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_12_2021_To_4_12_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_fFXJv_RDXUGqaL5uxC9OHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:April122021PerformanceBasedAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-12</xbrli:startDate><xbrli:endDate>2021-04-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_28_2020_To_2_28_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_MBhOBM-5iEqeLJwUm4lpZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:February282020PerformanceBasedAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-28</xbrli:startDate><xbrli:endDate>2020-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_28_2020_To_2_28_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_odV670fJEUWMoiqxIvk3sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:February282020PerformanceBasedAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-28</xbrli:startDate><xbrli:endDate>2020-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_22_2019_To_7_22_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_July222019PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_i5Y6ctTfQkOWKcDW4oDCbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:July222019PerformanceBasedAwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-22</xbrli:startDate><xbrli:endDate>2019-07-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2021_us-gaap_LeaseContractualTermAxis_ctso_TwentiethAmendmentToLeaseMember_wrqHEmK560ePWOyCLlAXAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ctso:TwentiethAmendmentToLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_LeaseContractualTermAxis_ctso_TwentiethAmendmentToLeaseMember_jYak7TFeK0qURMnjm2T8DA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ctso:TwentiethAmendmentToLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_PD6J30gR5EKT9_6EoKYJeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_RoyaltyAgreementsMember_BXoz6wUE6keu3xUP3R0XpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_RoyaltyAgreementsMember_rdfbeFkWfkyrD5IQ3VfUwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_LicenseAgreementMember_S4h6KrieY0yFrU840BqKzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ctso:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_RoyaltyAgreementsMember_CA354vfky0OFd_1E5K6eQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_LicenseAgreementMember_U7A4z9C5Qk6CY4PDRbXTqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ctso:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_nqaL2-pOqECJbRrVf3pvdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ctso:AllOtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_OsNNOJGgGESiK9DlqyfB8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_dfAHrsFp2E6oinjJ00Mtqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_hvHgr5Vvo06FhAv5d7bNKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_GB3izD4hs0eaNYDtQMtZdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ctso:AllOtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_sb5j1GuT4Eys3LqScvVX2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_NZxEE0JdaUaTuS77svmYtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_vmt8r9ikk0aev-F4z3pADg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_gmpCbnM0wEWJOVVOWqPBQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ctso:AllOtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_tOnDtJIL0UqvBIiQr68NeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_ZscEfHJXA0ChpTkNTqDj8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_WXkclWPOXk-aO6LslEVKtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_ZhVhCO9-WUWruNBvh_NrbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ctso:AllOtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_eeMsQ5mBMEaBmXTojZOwqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_3PyNg5XDT0qvzYh6YJ8lww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_73_wiDAntkqkT8Vf6yVyrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_4xdvMPyNJE2TidM1dnfXSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_xMUd5SWGqEmdLXxwWDooqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_qMcmuIE2xU-kOZeBMfsP5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_H13OncAn9U2imjaSPSyd5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_HBdMLlMQGE-9IpPghuUK2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_T8rLz83ayUi_sdvVUUukQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_ctso_OtherSalesMember_IHmx8Gx6dUC4YavDmDyL_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctso:OtherSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_Gir4cGdvtkGYyi8G96HfRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DirectMember_XS_Uh4IEcEeCPxJehbgjrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_ctso_CytoSorbSalesMember_kZjj3Qm1nkaD0BliSjoSlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctso:CytoSorbSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_dHpKJ66LdEuPGffrdOOnGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ctso:AllOtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_-zkrbwSc80qnJ_4yNjEqoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_3K7sqcTX4UWhfYo-xNN6bA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_JVeLOYDILkWMpirfcvOUkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_NeBUdimYUkWFDNDnPD3CnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ctso:AllOtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_ZANpAs_ejE2twTb1k2pdig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_RJXSLiJzd02uK0ssKMKg7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_sQvISkQQ3UKBDgXPufGqUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_tKPWLILXVE2h95fQt2uIvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ctso:AllOtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_I2ChB-9AP0S0q8UrImX6ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_ZlfzimG38UyKkvdPjtVHWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_b8AI_7G0G0umDEyvgW9dOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_nymBapNFM0u97cDmYtNcKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ctso:AllOtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_4RHTqNRNFESnd9qrz5_cCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_l7Cg7koCpUySLneSLrO0Zg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_BjelKy9GsEOR7gq0nA95tQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_YIGCSpdP6UqYoJUTKv7p7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_EtLLdZY6mEyFOKLjp4Uv1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_O-d7ZVaWAUytjn4uAGiAxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_KSZxi4zg7keBU37J2Y0-8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_FklCHZPwzUeeNeeNvzpgvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_2s9vyN8oyESnIA9BeyMmsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_ctso_OtherSalesMember_3KZRlFeRi0y0ti0yyXPoAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctso:OtherSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_Ahb2Ft23iEuFgHVNXLFShQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DirectMember_agZO3qBuDE-w-pXujZLoyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_ctso_CytoSorbSalesMember_F2WUYm6g20mo5wFD0_w32Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctso:CytoSorbSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_mH41MxVhmkGct0J07XEN1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ctso:AllOtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_ix4FCkAs6kWXANuYn55BGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_REqz0wSSUEO2inn9gwE8Rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_gfv9AQKB10GMbME_bmBdWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_MriDhsC_C0qBVC8cxkY0Bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ctso:AllOtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_d8LbBpFImkegbFV6bTyQPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_yC2fiJcIZ028vV2ALBTiiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_2dyyoRP_xEmVYml_OXHP7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_7NOqCHyL_kKAzrJSLXbLAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ctso:AllOtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_Tv8sVQFDs0OjBBDw_jDtKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_ZzNQcZHrw0GnVCIADz0a6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_KOQGfIkSGE2fpCi1ZL7vYA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_QXov_wgwTEe9iec6EImaQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ctso:AllOtherCountriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_GHt6jI9HW0amSQTDjBZQSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_fzhPwuLPukmrUdi_ToPDPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_BQH7e5DFwU-i1ithowcxIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_S0fxf7nq1EOlWiL9Q6JU9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_ht_XRtUdc0KZKqw23eRvcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_0DuN_YUs0k2g6B7WoQuymA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_dd7aX6AZn0ivW75vs1ACmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_0YTXyfGCvkOAHMRBYujAGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_cwj5unG_WkCRIuQlwJ3dwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_ctso_OtherSalesMember_k-QiwnuCrUiE_vu6WfajCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctso:OtherSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_UrGxGvJgzkO7B8scLF4L5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DirectMember_tT74xtzFukKomPVrAOvfwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_ctso_CytoSorbSalesMember_Q4Ry_8jnRU-WR-Sk5cdeNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctso:CytoSorbSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_4_2020_To_12_4_2020_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_p4SKdwcjlUmUAUo8kjQ2Mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-04</xbrli:startDate><xbrli:endDate>2020-12-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_31_2019_To_7_31_2019_us-gaap_DebtInstrumentAxis_ctso_TermBLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_dfnbFaTYTUmSkV-OaNfp9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermBLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-31</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_zAGlt-XrpU6zeCKAysx8Ww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_ajPw7PYg8UiVzGNH8PRoGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_IZ1_4AiozUyl0mH6SNTEkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_qNxrnXfXMEWT6PBBrE_I6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_xx0SVCBDQUagyE9b8Y2GGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_6WgRDm9zw06JdogbPOBBsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_RcD8hxX4B0W360TpBmU_BA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_p-0pfYqTZ0CXdqB9tDZcLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_GAn4Sc5mekKFBtkNb6Zzyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_27_2022_To_12_27_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_us-gaap_VestingAxis_ctso_FirstTrancheMember_u7MsHPmZk0W0eFrHTCS5fA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermCLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">ctso:FirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-27</xbrli:startDate><xbrli:endDate>2022-12-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_x19ESOfGok2hRnIOnFg4-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_VA7E7P_1tEG-K6jM8v-kFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_v7r-si-0bUuq1lcCsElNgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_ERD_klH89EySV0xsixbjKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_3Qdgi4LpIkSQMymN-mkajA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_9IC6hTCjW06NGRwHHe3tNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_HgsYwDdKM0Wf4EOABgWuUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_srt_StatementScenarioAxis_ctso_OperatingLeaseInitialEarlyTermMember_lxWMtc2sTkqH38xAKIWoPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ctso:CytosorbentsMedicalIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ctso:OperatingLeaseInitialEarlyTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_srt_StatementScenarioAxis_ctso_OperatingLeaseFirstYearOfRemainingLeaseTermMember_9vqNICnuOkyckL02PYBIQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ctso:CytosorbentsMedicalIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ctso:OperatingLeaseFirstYearOfRemainingLeaseTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_srt_StatementScenarioAxis_ctso_OperatingLeaseEarlyTermMember_tAFcc_W5NUuJIEBULRt2Ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ctso:CytosorbentsMedicalIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ctso:OperatingLeaseEarlyTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_4_1_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsEuropeGmbhMember_qOdCgqh6606refmoxrQP8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ctso:CytosorbentsEuropeGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_OhlDyppT50CWSs02U8PSrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5uYZTUv4DUKuTOvKAyxCSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_41gqsgDpOECDOvWP118t8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_31_2019_us-gaap_DebtInstrumentAxis_ctso_TermBLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_hAgUOUh5k0aAxSE_lGDIoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermBLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_ThirdTrancheMember_NUg-LV9OMEK0n6Tmc-tODA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermCLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">ctso:ThirdTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_SecondTrancheMember_djf_g158KE-plo3cylyfTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermCLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">ctso:SecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_FirstTrancheMember_FBkEgEL2JUK-hSNbubMUvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermCLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">ctso:FirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_19_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_xoInVW7g4UOFsRz944IiQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermCLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_1_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsEuropeGmbhMember_eGPb2XlfmU655buQQmU81A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ctso:CytosorbentsEuropeGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_1_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_Ayo8OWQvq0qpn_0X3Xab7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ctso:CytosorbentsMedicalIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_lBauhAm9gkWSn63bQjLUkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2023_us-gaap_LossContingenciesByNatureOfContingencyAxis_ctso_PayrollTaxAuditMember_UY7_k4-eREeBnQGR_XMpGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ctso:PayrollTaxAuditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_LossContingenciesByNatureOfContingencyAxis_ctso_PayrollTaxAuditMember_5kmrsmoK8EWvYJIbVVsujg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ctso:PayrollTaxAuditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_LossContingenciesByNatureOfContingencyAxis_ctso_AdditionalSocialSecurityAndVatTaxesMember_dTAIANEpM0y9wSbH-curug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ctso:AdditionalSocialSecurityAndVatTaxesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember_q-pVwR_fx0mA5G4MI1uuxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ctso:FiniteLivedIntangibleAssetsPatentsIssuedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember_zXch2gFj5k-awN9bccQ9Eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ctso:FiniteLivedIntangibleAssetsPatentApplicationsPendingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember_s0omtWKNx0m-GCD2Twq8Aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ctso:FiniteLivedIntangibleAssetsPatentsIssuedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember_JaV5Z95jAEioF4LjVm9rgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ctso:FiniteLivedIntangibleAssetsPatentApplicationsPendingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_8lddL3hShE2PxAKw1cffhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2017_To_12_31_2017_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember__1pqeGKP1UqWAJ53fXSkdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_12_31_2022_7D4gmEOvZEuddtCJGzA8ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_2eoa-jebUE-H6uey7YKWmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_mLayX3PX1Eqci3SfMDv1YQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022__Bto-66MgUq_eQRwKUyq1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2021_To_12_31_2021_PTkhRTY9_0uo1BKc7O3ElQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_9_30_2021_bc1_H1o8GkWXj53DijdBKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_KUS8bQMU0UaIknV605S_VA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_3_31_2021_zXigQoQBgUGOxC_vaZv8ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_12_31_2020_asiudZouf0qo-UGg2Gf0lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2020_To_9_30_2020_BlNvdmBrgEeKoL8Hm4r3Dw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_pfUWsTXCTUSP48AZxdHHPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_3_31_2020_0j8Adr0DO0CTdQHPhErCZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_1_1_2021_srt_StatementScenarioAxis_ctso_ParticipantsContributionOver3AndMaximum5Member_VI70pNF1dE6bwaLkkkQQzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ctso:ParticipantsContributionOver3AndMaximum5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_1_1_2021_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_ctso_ParticipantsContributionOver3AndMaximum5Member_MBEUr3qmWkaFIgPeH_HMOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ctso:ParticipantsContributionOver3AndMaximum5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_1_1_2021_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_ctso_ParticipantsContributionOver3AndMaximum5Member_QRs03j8L6kalwqqJ7bMG6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ctso:ParticipantsContributionOver3AndMaximum5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_1_1_2021_srt_StatementScenarioAxis_ctso_ParticipantsContributionUpto3PercentMember_MgDr1mCwaUS6-T40vC8X3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ctso:ParticipantsContributionUpto3PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_19_2022_us-gaap_DebtInstrumentAxis_ctso_NonRefundableClosingFeeMember_3fpymeUzzE2FKaJZ7vfyhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:NonRefundableClosingFeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_4_2020_us-gaap_BalanceSheetLocationAxis_ctso_ClosingFeeMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_VrBaHTNN5kGqpNZC5_45yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ctso:ClosingFeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_7_1_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_46J-BH5GlUuzquHLcvZsUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_1_1_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_ZrffNf8uWkC-rlhEGrcMag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_19_2022_us-gaap_DebtInstrumentAxis_ctso_NewTermLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_KKLXo5WGZkqln7K51iiuOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:NewTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_us-gaap_DebtInstrumentAxis_us-gaap_LetterOfCreditMember_qtkd0jaAzUeu79V_NBPfXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ctso:CytosorbentsMedicalIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_4_2020_us-gaap_DebtInstrumentAxis_ctso_NewTermLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_sKTK-0jXM02ZfmOBWGS5TQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:NewTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_29_2018_us-gaap_DebtInstrumentAxis_ctso_TermLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_us-gaap_VestingAxis_ctso_FirstTrancheMember_yHGvHKFK2USNqJh92uWr0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">ctso:FirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_29_2018_us-gaap_DebtInstrumentAxis_ctso_TermBLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_us-gaap_VestingAxis_ctso_SecondTrancheMember_e3qGkUg1VUKoGjKsBJiqOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermBLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">ctso:SecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_29_2018_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_yAsPHUNuqEirJNj907ZTrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2016_us-gaap_DebtInstrumentAxis_ctso_NewTermLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_ArZA6xiPjEidCYt_-Y-R-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:NewTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2016_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_hpLFtiZhmUiQm4GvwoFZtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_pd77Iy0ZEkG2yi4BhLTLbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CreditFacilityAxis_us-gaap_CreditCardMember_10pNVCROt0uc0geHUcOPJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CreditCardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_19_2022_To_1_19_2022_us-gaap_DebtInstrumentAxis_ctso_NewTermLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_V4YNPqwfQU-fUTcMCuVGXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:NewTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-19</xbrli:startDate><xbrli:endDate>2022-01-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_CargoAndFreightMember_3_4JFM6ghEqxTBICweYCOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:CargoAndFreightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_CargoAndFreightMember_XgZFDtyGV0-mrreoqyHhdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:CargoAndFreightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_gIfXHjckYEyJZbVZyvB2YQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_nWvJKC0AfUO7Aa2fnEopNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_njwH72hw8kSaSTYNHO-w9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_7s12QoX9F0W4teGHuyLFlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_hE-GjhoHb06AQqRidhWP3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2019_88geVJQ2uUywvKJuak2-eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_ctso_TwoThousandFourteenStockOptionPlanMember_283few-Y1k-s142NM7ToRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:TwoThousandFourteenStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_ctso_StockOptionPlanOneMember_RNyPCy3gyE2TqeZtAiyN2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:StockOptionPlanOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_6_oqjbutzEKQogf2y7UC6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsEuropeGmbhMember_WYlLNzD2gES86ALGoqLgDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ctso:CytosorbentsEuropeGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ctso_StockOptionsAndWarrantsMember_yk7BYg1b80i8SXV12unwZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ctso:StockOptionsAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ctso_StockOptionsAndWarrantsMember_N7MNifr70EazP8jJCCRNdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ctso:StockOptionsAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ctso_StockOptionsAndWarrantsMember_yWq0uJF810qiMA_nrGtcuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ctso:StockOptionsAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_ctso_EmployeeTwoMember_5EVkiMRvd0id4GEDS-DjOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ctso:EmployeeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_ctso_EmployeeOneMember_apbG-USk6kiuOe_Y22t91A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ctso:EmployeeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5G127XWFxUipm8wjbbrV0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_7_2023_CcpBUzS37kyiXYDxNeBq9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_ctso_OneDistributorMember_XK7cgrbnyk-5EtW1e3KAjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ctso:OneDistributorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_v0fFN3Ebi0qVBjU54fspcg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_KP3JJIYFZk6xK_VoVW7UbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_Ow1UbuwxYkCiv37yEeEpfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_cD_zR9lLbk6OW7lmBqw0ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_Df_fcOfuVUyrXQ2v2oxuSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T3OJIOaoZ0K5JyfOQDRhQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WaPfkCKsqkGJrOEo8CCMJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jAS_rLmGI0SmIJDwwikaWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ymoFl7EJPE6epQ4SBcMfbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_4_1_2022_AQ3DZUBay0mJk2oEUwh-kQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_12_2021_To_4_12_2021_4mWKwyxxWEKyj2QfIoh1PQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-12</xbrli:startDate><xbrli:endDate>2021-04-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_12_2021_To_4_12_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_s_j74aK2uUqG5xOlSbxT3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-12</xbrli:startDate><xbrli:endDate>2021-04-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_LicenseAgreementMember_vd_rm61d5EKX2A6aRANNWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ctso:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_11_2003_To_8_11_2003_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_RoyaltyAgreementsMember_xFt-mbbZrkmdsbIlITDLxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2003-08-11</xbrli:startDate><xbrli:endDate>2003-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ctso_TwoThousandAndEighteenSuccessFeeLetterMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_V6EvzE1VNkqz5b11S3A0zQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TwoThousandAndEighteenSuccessFeeLetterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ctso_TwoThousandAndEighteenSuccessFeeLetterMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_x3N7mO34SEWKzky3MgxbHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TwoThousandAndEighteenSuccessFeeLetterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_id_BW-goZE-wjX2tVerJSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ctso:CytosorbentsMedicalIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_-_7LrVATRkuKuxUmrfdQ2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ctso:CytosorbentsMedicalIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US__KJwJevVx06LgV-mH407GA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ctso:CytosorbentsMedicalIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_soDgpwwWtUaODzy8fGjUCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ctso:CytosorbentsMedicalIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TwoThousandAndEighteenSuccessFeeLetterMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_jQs_7-pzMUy3U65XTi21yQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TwoThousandAndEighteenSuccessFeeLetterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_ThirdTrancheMember_4sLxmtU1v0S4Yllbg0FfOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermCLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">ctso:ThirdTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_SecondTrancheMember_QxsVP0Jock-3r1DvUA8aiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermCLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">ctso:SecondTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_FirstTrancheMember_GIGD6kvI2kuyoTLKEpk95A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermCLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">ctso:FirstTrancheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_LicenseAgreementMember_raDmOQBLY0ys677paSR3hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ctso:LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_CargoAndFreightMember_vWKDoEIhEUOKRvy4A7Wi5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:CargoAndFreightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_1_1_2019_Qy5PqaSx0EaQbNj8WsHlmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_31_2022_ifdIznn7QEeHunrEw3Jhtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2014_To_6_30_2014_xxa151rza0iR7WYHq7r7TA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-06-01</xbrli:startDate><xbrli:endDate>2014-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_19_2022_To_1_19_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_g4Y2bbaH8UunO1A9gJrzYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermCLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-19</xbrli:startDate><xbrli:endDate>2022-01-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_30_2021_To_12_30_2021_dei_LegalEntityAxis_ctso_JefferiesLlcAndB.RileyFbrIncMember_XwgIgRkXJ0ileyIAI7HBTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ctso:JefferiesLlcAndB.RileyFbrIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-30</xbrli:startDate><xbrli:endDate>2021-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_30_2021_dei_LegalEntityAxis_ctso_JefferiesLlcAndB.RileyFbrIncMember_7Vao9teehUSAKLxbCXXGsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ctso:JefferiesLlcAndB.RileyFbrIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_14_2021_ia1syTvHG0S77AERC2Hqwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2021_To_9_30_2021_srt_StatementGeographicalAxis_country_DE_R18Zrff15UWiG7PQAHXLAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_4_30_2021_us-gaap_LeaseContractualTermAxis_ctso_TwentiethAmendmentToLeaseMember_gauFszu_JEOFrdWykocnUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ctso:TwentiethAmendmentToLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001175151</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_country_S-K5wYygeEuMMDPQgfGhxg"><xbrli:measure>ctso:country</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_00R0j3K4HUiRlSslEJQMxQ"><xbrli:measure>ctso:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_patent_iyucGb4rrEygLz5tIoEXtA"><xbrli:measure>ctso:patent</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USN_5UGkHjTMLU6EeMbjOjtcEQ"><xbrli:measure>iso4217:USN</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqm_5jCoQZf8skWtJMe7yh0D_w"><xbrli:measure>utr:sqm</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_ecc913d8_ed27_4661_9436_515bdba7bcb4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:4pt 0pt 0pt 0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Washington, D</b>. <b style="font-weight:bold;">C</b>. <b style="font-weight:bold;">20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><b style="font-size:8pt;font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:DocumentType" id="Narr_S5u_0h0_skSBh-VyCnAFqQ"><b style="font-size:8pt;font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">(Mark One)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_6e7470e3_a4df_40b5_9957_abcff572947d"></a><a id="Tc_PoT1LGsQwEycma5rKN7wsw_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:DocumentAnnualReport" id="Tc_PR3oEAMVDUm8OoCClF7iYw_1_1"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 or 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;">For the fiscal&#160;year ended </span><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:DocumentPeriodEndDate" id="Narr_BwvrGGm8hU6Y8XvxqfUbaQ"><span style="font-size:8pt;">December&#160;31, 2022</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">or</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_436804e8_2796_4cab_9eb4_e344704c3417"></a><a id="Tc_rK4NZUUFVE-q46lltDOS7g_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:0.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:DocumentTransitionReport" id="Tc_gp5C8JrliEif7M9UEbgXOA_1_1"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:93.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 or 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;">Commission file number </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:EntityFileNumber" id="Narr_d0yzbZseakemo4TE_EX0Og"><span style="font-size:8pt;">001-36792</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:EntityRegistrantName" id="Narr_ajiwCEgs_kSNF8JZkYEIsA"><b style="font-weight:bold;">CYTOSORBENTS CORPORATION</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_afd2a5ef_09b4_4c1d_98f1_4fe159852388"></a><a id="Tc_3Nfr73LzKUusW0OCo3hRCA_1_0"></a><a id="Tc_kAYktpNkCkSGbBs8mKPkqA_1_2"></a><a id="Tc_-b9W1uIbJkSIpjCf8MUkDg_2_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:EntityIncorporationStateCountryCode" id="Tc_riOKXFGLUUmF3Vaji7rIWg_0_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:EntityTaxIdentificationNumber" id="Tc_JU7U16amYkmsfKWGf_Uo9g_0_2"><b style="font-size:8pt;font-weight:bold;">98-0373793</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(State or other jurisdiction of incorporation or</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">organization)</p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:EntityAddressAddressLine1" id="Narr_xpXk5YJSpEm-52jgg6Iz0Q"><b style="font-size:8pt;font-weight:bold;">305 College Road East</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:EntityAddressCityOrTown" id="Narr_qJ6X_hnVl0aJW8aoct8Lqw"><b style="font-size:8pt;font-weight:bold;">Princeton</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:EntityAddressStateOrProvince" id="Narr_XNUIeCgnJEurw0NYcOcNIQ"><b style="font-size:8pt;font-weight:bold;">New Jersey</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:EntityAddressPostalZipCode" id="Narr_r9kDdiA8MkemyKDTd9ro-Q"><b style="font-size:8pt;font-weight:bold;">08540</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">(Address of principal executive offices) (Zip Code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;">Registrant&#8217;s telephone number, including area code </span><b style="font-size:8pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:CityAreaCode" id="Narr_pB-hy_jBrECpjpaBOrfypw"><b style="font-size:8pt;font-weight:bold;">732</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:LocalPhoneNumber" id="Narr_xMTs8fT4QEmGa8lc2ahlWw"><b style="font-size:8pt;font-weight:bold;">329-8885</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_16a62c38_aaa2_4151_a2eb_6958f931278c"></a><a id="Tc_zUtudwUVJUiOhgwyOd9tYg_0_0"></a><a id="Tc_Gyq8zEM-zUyPCM53NP1lQQ_0_2"></a><a id="Tc_ns345DCJjE66w357RMEc6w_0_4"></a><a id="Tc_BgRwGNaUVEm_yqnLjHfSrg_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:31.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Title of each class:</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Trading Symbol</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Name of each exchange on which registered:</p></td></tr><tr><td style="vertical-align:top;width:31.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:Security12bTitle" id="Tc_vOlxE-1hLUuAlYz9Wa9p2g_1_0"><b style="font-size:8pt;font-weight:bold;">Common Stock, $0.001 par value</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:TradingSymbol" id="Tc_cfgt9FCyj06D7Sc4VQwXXw_1_2"><span style="font-size:8pt;">CTSO</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">The </b><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:SecurityExchangeName" id="Narr_jW7RdxQ9pEu-JaxSivzjcw"><b style="font-size:8pt;font-weight:bold;">Nasdaq</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> Stock Market LLC</b><b style="font-size:8pt;font-weight:bold;"><br /></b><b style="font-size:8pt;font-weight:bold;">(Nasdaq Capital Market)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: None</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> Yes </span><span style="font-family:'Wingdings';font-size:8pt;">&#254;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_YjqBsL4qrUaqEXN7utZtgQ"><span style="font-size:8pt;">No</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> Yes </span><span style="font-family:'Wingdings';font-size:8pt;">&#254;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:EntityVoluntaryFilers" id="Narr_3YMGim3JoEi42QpjKAD_7A"><span style="font-size:8pt;">No</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-family:'Wingdings';font-size:8pt;">&#254;</span><span style="font-size:8pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:EntityCurrentReportingStatus" id="Narr_ckrk4I8GUEe6oarCzpmPog"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> No</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:EntityInteractiveDataCurrent" id="Narr_cwFHZdtjv0aFOzrSYAECQA"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Wingdings';font-size:8pt;">&#254;</span><span style="font-size:8pt;"> &#160;No </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and emerging growth company in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Large Accelerated Filer <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;text-indent:0pt;margin:0pt;">Accelerated Filer <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:EntityFilerCategory" id="Narr_jO__zmSLY0mCWcvauUAC9A"><span style="font-size:8pt;">Non-accelerated Filer</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;&#160;&#160; </span><span style="font-family:'Wingdings';font-size:8pt;">&#254;</span><span style="font-size:8pt;">&#160;&#160;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Smaller reporting company</span><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:EntitySmallBusiness" id="Narr_ZStrR_tMOE6QTMVDBLxYXw"><span style="font-family:'Wingdings';font-size:8pt;">&#254;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Emerging growth company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:EntityEmergingGrowthCompany" id="Narr_v0qdsNMOxkie0d3jw6UiHw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="font-size:8pt;"> </span><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:IcfrAuditorAttestationFlag" id="Narr_fLev7MtxBUON3hCarerVGQ"><span style="font-family:'Wingdings';font-size:8pt;">&#254;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> Yes </span><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:EntityShellCompany" id="Narr_0kkpjSlGxkGMSUDvWJN4ug"><span style="font-family:'Wingdings';font-size:8pt;">&#254;</span></ix:nonNumeric><span style="font-size:8pt;"> No</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">The aggregate market value of the common stock of the registrant held by non-affiliates as of December 31, 2022 was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" name="dei:EntityPublicFloat" id="Narr_Rwvzej4ZoEm_N8e799jA9w">61,461,000</ix:nonFraction> based upon the closing price reported for such date on the Nasdaq Capital Market. As of March 7, 2023, there were outstanding <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_7_2023_CcpBUzS37kyiXYDxNeBq9w" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_w8NO2vY5p028AOY-84d2zw">43,663,009</ix:nonFraction> shares of the registrant&#8217;s common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 4pt 0pt;">Documents incorporated by reference:</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 4pt 0pt;">Portions of the registrant&#8217;s definitive proxy statement to be filed pursuant to Regulation 14A within 120&#160;days after the end of the registrant&#8217;s fiscal&#160;year are incorporated by reference into Part&#160;III of this Form&#160;10-K and certain documents are incorporated by reference into Part&#160;IV of this Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3165abb0_7907_43b7_b46e_9fb70cd20859"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CYTOSORBENTS CORPORATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ANNUAL REPORT ON FORM&#160;10-K</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTI_43845"><span style="font-style:normal;font-weight:normal;">PART&#160;I</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_474705"><span style="font-style:normal;font-weight:normal;">Item&#160;1. Business.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_6435"><span style="font-style:normal;font-weight:normal;">Item&#160;1A. Risk Factors.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">47</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_377036"><span style="font-style:normal;font-weight:normal;">Item&#160;1B. Unresolved Staff Comments.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">61</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_489629"><span style="font-style:normal;font-weight:normal;">Item&#160;2. Properties.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">61</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_168100"><span style="font-style:normal;font-weight:normal;">Item&#160;3. Legal Proceedings.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">61</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_528378"><span style="font-style:normal;font-weight:normal;">Item&#160;4. Mine Safety Disclosures.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">62</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTII_26266"><span style="font-style:normal;font-weight:normal;">PART&#160;II</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommon_854774"><span style="font-style:normal;font-weight:normal;">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">62</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6SelectedFinancialData_161884"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span><span style="font-style:normal;font-weight:normal;"> </span><span style="font-style:normal;font-weight:normal;">Reserved</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">62</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussion_675843"><span style="font-style:normal;font-weight:normal;">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">63</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitative_332696"><span style="font-style:normal;font-weight:normal;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">70</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item&#160;8. Financial Statements and Supplementary Data.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">70</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreements_449418"><span style="font-style:normal;font-weight:normal;">Item&#160;9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">70</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_8889"><span style="font-style:normal;font-weight:normal;">Item&#160;9A. Controls and Procedures.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">70</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_93888"><span style="font-style:normal;font-weight:normal;">Item&#160;9B. Other Information.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">71</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9CDisclosureRegardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspection.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">71</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIII_135582"><span style="font-style:normal;font-weight:normal;">PART&#160;III</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsExecutive_646044"><span style="font-style:normal;font-weight:normal;">Item&#160;10. Directors, Executive Officers and Corporate Governance.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">71</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_213048"><span style="font-style:normal;font-weight:normal;">Item&#160;11. Executive Compensation.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">72</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertain_469677"><span style="font-style:normal;font-weight:normal;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">72</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13CertainRelationships_177588"><span style="font-style:normal;font-weight:normal;">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">72</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccounting_380347"><span style="font-style:normal;font-weight:normal;">Item&#160;14. Principal Accounting Fees and Services.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">72</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIV_315404"><span style="font-style:normal;font-weight:normal;">Part&#160;IV</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15Exhibits_936320"><span style="font-style:normal;font-weight:normal;">Item&#160;15. Exhibits, Financial Statement Schedules.</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">72</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:normal;width:91.99%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16Form10KSummary_750435"><span style="font-style:normal;font-weight:normal;">Item&#160;16. Form&#160;10-K Summary</span></a></p></td><td style="vertical-align:bottom;white-space:normal;width:2.31%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:normal;width:5.69%;margin:0pt;padding:0pt 0pt 1pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">75</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">i</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_04278772_2006_45d1_86b5_e243ed531b5e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">CAUTIONARY NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form&#160;10-K, or this Report, contains &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&#160;21E of the Securities Exchange Act of 1934, or the Exchange Act. Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;may,&#8221; &#8220;seek,&#8221; &#8220;plan,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;forecast,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; negatives thereof or similar expressions. These forward-looking statements are found at various places throughout this Report and include information concerning possible or assumed future results of our operations; business strategies; future cash flows; financing plans; plans and objectives of management; any other statements regarding future operations, future cash needs, business plans and future financial results, and any other statements that are not historical facts. Unless otherwise indicated, the terms &#8220;CytoSorbents,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to CytoSorbents Corporation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, forward-looking statements also are included in our other periodic reports on Forms 10-Q and 8-K, in our press releases, in our presentations, on our website and in other materials released to the public. Any or all of the forward-looking statements included in this Report and in any other reports or public statements made by us are not guarantees of future performance and may turn out to be inaccurate. These forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject to risks, uncertainties and other factors. Many of those factors are outside of our control and could cause actual results to differ materially from the results expressed or implied by those forward-looking statements. In light of these risks, uncertainties and assumptions, the events described in the forward-looking statements might not occur or might occur to a different extent or at a different time than we have described. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of the applicable Report or public statement. All subsequent written and oral forward-looking statements concerning other matters addressed in this Report or public statement and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise. For discussion of factors that we believe could cause our actual results to differ materially from expected and historical results see &#8220;Item&#160;1A&#160;&#8212; Risk Factors&#8221; below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">TRADEMARKS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Report includes our trademarks and trade names, such as &#8220;CytoSorb,&#8221; &#8220;CytoSorb XL,&#8221; &#8220;ECOS-300CY,&#8221; &#8220;BetaSorb,&#8221; &#8220;ContrastSorb,&#8221; &#8220;DrugSorb,&#8221; &#8220;HemoDefend-RBC,&#8221; &#8220;HemoDefend-BGA, &#8220;K+ontrol&#8221; and &#8220;VetResQ,&#8221; which are protected under applicable intellectual property laws and are the property of CytoSorbents Corporation and its subsidiaries. This Report also contains the trademarks, trade names and service marks of other companies, which are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this Report may appear without the &#8482;, &#174;, or <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties&#8217; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">ii</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9147b5b0_478a_4a9e_93c1_10f2eb80dbbe"></a><a id="PARTI_43845"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;I</p><a id="Item1Business_474705"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item&#160;1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a leader in the treatment of life-threatening conditions in the intensive care (&#8220;ICU&#8221;) and cardiac surgery using blood purification via our proprietary polymer adsorption technology. We have a number of products commercialized and in development based on this technology platform. Our flagship product, CytoSorb&#174;, is already commercialized, and is being used to reduce deadly uncontrolled inflammation and dangerous substances in hospitalized patients around the world, with the goal of preventing or treating multiple organ failure, bleeding, and other potentially fatal complications. Organ failure is the cause of nearly half of all deaths in the ICU, with little to improve clinical outcome. CytoSorb, is approved in the European Union (&#8220;EU&#8221;) as an effective extracorporeal cytokine absorber, designed to reduce the &#8220;cytokine storm&#8221; or &#8220;cytokine release syndrome&#8221; that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. These are conditions where the mortality is extremely high, yet few to no effective treatments exist. In May 2018, we received a label expansion for CytoSorb covering use of the device for the removal of bilirubin and myoglobin in the treatment of liver disease and trauma, respectively. In January 2020, we received CE-Mark label expansion for CytoSorb covering the use of the device for the removal of the anti-platelet agent, ticagrelor, in patients undergoing surgery requiring cardiopulmonary bypass. In April 2020, the United States Food and Drug Administration (the &#8220;FDA&#8221;) granted Breakthrough Device Designation to CytoSorb for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery. In April 2020, we announced that the U.S. FDA has granted U.S. Emergency Use Authorization (&#8220;EUA&#8221;) of CytoSorb for use in critically ill patients with COVID-19 infection and respiratory failure. In May 2020, we received a CE-Mark label expansion for CytoSorb for the removal of rivaroxaban during cardiothoracic surgery requiring cardiopulmonary bypass. In August 2021, the Company announced that it was granted a second Breakthrough Device Designation for its DrugSorb-ATR Antithrombotic Removal System by the FDA to remove the direct oral anticoagulants, rivaroxaban and apixaban. The Company has initiated two U.S. clinical trials evaluating the use of DrugSorb-ATR during cardiothoracic surgery to remove ticagrelor, apixaban and rivaroxaban to prevent or reduce perioperative bleeding complications in pursuit of U.S. FDA marketing approval. The first clinical trial, STAR-T, is underway and currently enrolling patients. We currently anticipate that the second clinical trial, STAR-D, which was previously postponed, will resume patient enrollment once the STAR-T trial is completed. We believe CytoSorb has the potential to be used in many other inflammatory conditions, including the treatment of autoimmune disease flares, and other applications in cancer, such as cancer cachexia. More than 195,000 cumulative CytoSorb devices have been utilized globally as of December 31, 2022 in critical illnesses and in cardiac surgery. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The technology is protected by 18 issued U.S. patents and multiple international patents, with applications pending both in the U.S. and internationally. We have numerous product candidates under development based upon this unique blood purification technology, including CytoSorb XL, HemoDefend, ContrastSorb, DrugSorb, DrugSorb-ATR and others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2011, CytoSorb was &#8220;CE Marked&#8221; in the EU as an extracorporeal cytokine adsorber indicated for use in clinical situations where cytokines are elevated, allowing for commercial marketing. The CE Mark demonstrates that a conformity assessment has been carried out and the product complies with the Medical Devices Directive. The goal of CytoSorb is to prevent or treat organ failure by reducing cytokine storm and the potentially deadly systemic inflammatory response syndrome (&#8220;SIRS&#8221;) in diseases such as sepsis, trauma, burn injury, acute respiratory distress syndrome, pancreatitis, liver failure, and many others. Organ failure is the leading cause of death in the ICU, and remains a major unmet medical need, with little more than supportive care therapy (e.g., mechanical ventilation, dialysis, vasopressors, fluid support, etc.) as treatment options. By potentially preventing or treating organ failure, CytoSorb may improve clinical outcome, including survival, while reducing the need for costly ICU treatment, thereby potentially saving significant healthcare costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our CE Mark enables CytoSorb to be sold throughout the European Union and member states of the European Economic Area. In addition, many countries outside the EU accept the CE Mark for medical devices but may also require registration with or without additional clinical studies. The broad indication for which CytoSorb is CE marked allows it to be used &#8220;on-label&#8221; in diseases where cytokines are elevated including, but not limited to, critical illnesses such as those mentioned above, autoimmune disease flares, cancer cachexia, and many other conditions where cytokine-induced inflammation plays a detrimental role.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cytokines are small proteins that normally stimulate and regulate the immune response. However, in certain diseases, particularly life-threatening conditions commonly seen in the ICU, such as sepsis and infection, trauma, acute respiratory distress syndrome (&#8220;ARDS&#8221;), severe burn injury, liver failure, and acute pancreatitis, cytokines are often produced in vast excess&#160;&#8211; a condition known as cytokine storm. Left unchecked, this cytokine storm can lead to severe maladaptive SIRS that can then cause cell death, multiple organ dysfunction syndrome, and multiple organ failure. Failure of vital organs such as the heart, lungs, and kidneys, accounts for nearly half of all deaths in the ICU, despite the wide availability of supportive care therapies, or &#8220;life support&#8221;, such as dialysis, mechanical ventilation, extracorporeal membrane oxygenation, and vasopressors. By replacing the function of failed organs, these supportive care therapies can initially help to keep patients alive, but do not help patients recover faster, and in many cases can increase the risk of dangerous complications. Unlike these supportive care therapies, the goal of the CytoSorb cytokine adsorber is to proactively prevent or treat organ failure by reducing cytokine storm and reducing the maladaptive SIRS response. In doing so, CytoSorb targets the reduction in the severity of patient illness and the need for intensive care, while potentially improving clinical outcome and saving healthcare costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of the CE Mark approval process, we completed our randomized, controlled, European Sepsis Trial amongst 14 trial sites in Germany in 2011, with enrollment of 100 patients with sepsis and respiratory failure. The trial established that CytoSorb was sufficiently safe in this critically-ill population, and that it was able to broadly reduce key cytokines in the blood of these patients. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to CE Marking, we also achieved ISO 13485:2003 Full Quality Systems certification, an internationally recognized quality standard designed to ensure that medical device manufacturers have the necessary comprehensive management systems in place to safely design, develop, manufacture and distribute medical devices in the EU. In the past, we manufactured CytoSorb at our older manufacturing facilities in New Jersey for commercial sales abroad and for additional clinical studies. Upon expanding our facility in June 2018, we quadrupled our manufacturing capacity and completed an audit upgrade from an ISO 13485:2003 certification to an ISO 13485:2016 certification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In late June 2012, following the establishment of our European subsidiary, CytoSorbents Europe GmbH, a wholly-owned operating subsidiary of CytoSorbents Corporation, we began the commercial launch of CytoSorb in Germany. The fourth quarter of 2012 represented the first quarter of direct sales with the full sales team in place. During this period, we expanded our direct sales efforts to include both Austria and Switzerland. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Fiscal year 2013 represented the first full year of CytoSorb commercialization. We focused our direct sales efforts in Germany, Austria and Switzerland. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2016, we established CytoSorbents Switzerland GmbH, a wholly-owned subsidiary of CytoSorbents Europe GmbH, to conduct marketing and direct sales in Switzerland. This subsidiary began operations during the second quarter of 2016. In 2017, we further expanded our direct sales efforts into Belgium and Luxembourg.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2018, the approved uses of CytoSorb in the E.U. were expanded to include the removal of bilirubin in liver disease, and the removal of myoglobin in trauma.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 5, 2019, the Company announced the expansion of direct sales of CytoSorb for all applications to Poland and the Netherlands, and critical care applications to Sweden, Denmark and Norway. In 2021, the Company expanded direct sales to include all indications in Sweden, Denmark and Norway. As part of this effort, the Company established CytoSorbents Poland Sp. z.o.o., a wholly-owned subsidiary of CytoSorbents Europe GmbH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the third quarter of 2019, we established CytoSorbents UK Limited, a wholly-owned subsidiary of CytoSorbents Medical,&#160;Inc., to manage our clinical trial activities in the United Kingdom.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2019, we announced that CytoSorb had received renewal of its European Union CE Mark through May&#160;2024 and ISO 13485:2016 Full Quality Assurance System certification of its manufacturing facility through September&#160;2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2020, we received CE-Mark label expansion approving the use of CytoSorb to remove the anti-platelet agent, ticagrelor, in cardiac patients during surgery requiring cardiopulmonary bypass.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2020, the Company announced that the FDA granted EUA of CytoSorb for use in critically ill patients infected with COVID-19. Under the EUA, the Company can make CytoSorb available, through commercial sales, to all hospitals in the United States for use in patients, 18 years of age or older, with confirmed COVID-19 infection who are admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure who have early acute lung injury or acute respiratory distress syndrome (ARDS), severe disease, or life-threatening illness resulting in respiratory failure, septic shock, and/or multiple organ dysfunction or failure. <span style="letter-spacing:-0.05pt;">The CytoSorb device has neither been cleared nor approved for the indication to treat patients with COVID-19 infection. </span>The EUA will be effective until a declaration is made that the circumstances justifying the EUA have terminated or until revoked by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In April 2020, the Company also announced that the FDA had granted Breakthrough Device Designation to CytoSorb for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery. The Breakthrough Devices Program provides for more effective treatment of life-threatening or irreversibly debilitating disease or conditions, in this case the need to reverse the effects of ticagrelor in emergent or urgent cardiac surgery that can otherwise cause a high risk of serious or life-threatening bleeding. Through Breakthrough Designation, the FDA intends to work with CytoSorbents to expedite the development, assessment, and regulatory review of the Company&#8217;s proprietary polymer adsorption technology for the removal of ticagrelor, while maintaining statutory standards of regulatory approval (e.g., 510(k), </span><i style="font-style:italic;background:#ffffff;">de novo</i><span style="background:#ffffff;"> 510(k) or premarket approval) consistent with the FDA&#8217;s mission to protect and promote public health. In July 2021, the Company received full approval of its Investigational Device Exemption (&#8220;IDE&#8221;) by the FDA to conduct the pivotal STAR-T (Safe and Timely Antithrombotic Removal &#8211; Ticagrelor) double-blind, randomized control trial (&#8220;RCT&#8221;) for up to 120 patients in the United States to support FDA marketing approval of DrugSorb-ATR, which is based on the same proprietary polymer technology as CytoSorb.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In May 2020, we received CE-Mark label expansion approving the use of CytoSorb for the removal of rivaroxaban, a widely-used Factor Xa inhibitor and novel oral anticoagulant, during cardiothoracic surgery requiring cardiopulmonary bypass. With this announcement, and the E.U. approval in January 2020 to remove ticagrelor, for the same indication, CytoSorb is providing cardiac surgeons and perfusionists an easy-to-use and rapid new treatment option to help reduce the risk of serious and potentially fatal perioperative bleeding complications caused by these two drugs, in separate categories of blood thinners.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In October 2020, we announced the E.U. approval of the ECOS-300CY cartridge for the removal of inflammatory mediators during </span><i style="font-style:italic;background:#ffffff;">ex vivo</i><span style="background:#ffffff;"> organ perfusion under CE Mark designation, with the goal of helping to preserve or improve the health and quality of solid organs to be transplanted. CytoSorbents also announced a partnership with Aferetica srl to provide the ECOS-300CY cartridge under the exclusive trade name, PerSorb&#8482;, that is compatible with Aferetica&#8217;s PerLife&#8482; </span><i style="font-style:italic;background:#ffffff;">ex vivo</i><span style="background:#ffffff;"> organ perfusion system, recently approved in the E.U. as well. In 2021, commercialization of PerSorb&#8482; and Aferetica&#8217;s PerLife&#8482; </span><i style="font-style:italic;background:#ffffff;">ex vivo</i><span style="background:#ffffff;"> organ perfusion system commenced in Italy. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In June 2021, we began construction on the Company&#8217;s new global headquarters and state-of-the-art manufacturing facility following the lease of a 48,500 square foot mixed-use facility in Princeton, New Jersey. The new production facility was designed to support annual sales of up to $400 million while improving product gross margins and allowing space for future product line expansions. The new production facility successfully passed its E.U. notified body audit in early 2022, and received ISO 13485 certification from its E.U. notified body in September 2022, clearing the way for full manufacturing of CytoSorb, DrugSorb-ATR, ECOS-300CY from this site.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In August 2021, the Company announced that it was granted a second Breakthrough Device designation for its DrugSorb-ATR Antithrombotic Removal System by the U.S. Food and Drug Administration (FDA). This Breakthrough Device designation covers the removal of the Direct Oral Anticoagulants (DOACs) apixaban and rivaroxaban in a cardiopulmonary bypass circuit to reduce the likelihood of serious perioperative bleeding during urgent cardiothoracic surgery. In October 2021, the Company also received full FDA approval of an IDE application to conduct a double-blind, randomized, controlled clinical study for up to 120 patients entitled, &#8220;Safe and Timely Antithrombotic Removal &#8211; Direct Oral Anticoagulants (STAR-D),&#8221; in the United States to support FDA marketing approval. This trial is currently paused until the anticipated completion of the STAR-T trial.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">If FDA marketing approval is obtained for either the removal of ticagrelor or direct oral anticoagulants indications, the device would be marketed as DrugSorb-ATR in the United States. The DrugSorb-ATR Antithrombotic Removal System is based on the same polymer technology as CytoSorb. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In May 2022, the Company announced that it entered into a 3-year preferred supplier agreement with the private German hospital network, Asklepios, making CytoSorb available without restrictions to all of the approximate 170 healthcare facilities across 14 states throughout Germany at which Asklepios operates. This includes Asklepios Klinik St. Georg in Hamburg, Germany, which pioneered the use of CytoSorb to remove antithrombotic drugs during cardiothoracic surgery and is well-known for their seminal publication on CytoSorb use for this application during emergency cardiac surgery in patients at high risk of bleeding.</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In June 2022, the Company announced that, following a successful pilot program in three countries, the Company signed an expanded non-exclusive agreement with Nikkiso Europe GmbH (&#8220;Nikkiso&#8221;) to distribute Nikkiso&#8217;s PureADJUST stand-alone hemoperfusion pump and accessories in a total of 14 countries. In addition to securing the rights to sell Nikkiso&#8217;s stand-alone pump and accessories in Germany, Austria, and Luxembourg, the Company entered into an expanded multi-country reseller agreement with Nikkiso covering the following countries: Belgium, Bosnia and Herzegovina, Croatia, Finland, France, Iceland, Lichtenstein, Poland, Serbia, Slovenia and Switzerland. The Company will provide field support services in these countries.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In August 2022, the Company entered into a Marketing Agreement (the &#8220;Marketing Agreement&#8221;) with Fresenius Medical Care Deutschland GmbH (&#8220;Fresenius&#8221;), which expands the Company&#8217;s strategic partnership with Fresenius by establishing a multi-stage global collaboration to combat life-threatening diseases in critical care. The Marketing Agreement provides for the combined marketing and promotion of CytoSorb with Fresenius&#8217; critical care products by Fresenius&#8217; marketing organization worldwide, excluding the United States. The Marketing Agreement has an initial term of three years, with an automatic renewal for an additional two years at the end of such initial term, subject to earlier termination by either of the parties (the &#8220;Term&#8221;). Compared to the prior co-marketing agreement between the parties, the Marketing Agreement intends to increase the commitments from both parties and to ensure an ongoing and consistent level of marketing and promotional activity specifically focused around CytoSorb, where Fresenius will actively market and promote CytoSorb as the featured blood purification therapy for removal of cytokines, bilirubin, and myoglobin on its critical care platforms. Specifically, the Marketing Agreement provides that various Fresenius-led in-person, virtual, social media, and web-based marketing programs and events will feature the CytoSorb therapy and highlight the cooperation between the two companies in the field of critical care during the Term.</span> <span style="background:#ffffff;">To help support the increased marketing and promotional efforts of the expanded collaboration, CytoSorbents has agreed to subsidize a portion of the marketing costs through a royalty payment to Fresenius Medical Care based on CytoSorb sales in the intensive care unit on Fresenius Medical Care platforms, excluding the United States. In addition to strengthening and expanding the global marketing of CytoSorb, the Company and Fresenius also plan to work together to bring new innovative solutions to the market. The Marketing Agreement also includes the certification of compatibility of CytoSorb for usage on Fresenius&#8217; current critical care platforms. Certain initial activities have been completed with the formal of this program expected to occur sometime in 2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In addition, there are many investigator-initiated and additional Company sponsored trials that are currently planned, enrolling, or completed in Europe and in other countries abroad, using our blood purification technology that may provide valuable information regarding the use of the device in the treatment of different conditions such as sepsis, cardio-pulmonary bypass surgery, liver failure, COVID-19, organ transplant and many others. If successful, these studies may help to drive additional usage and adoption of our blood purification technologies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have complemented our direct sales efforts with sales to distributors and/or strategic corporate partners. For more information regarding our distributors and strategic partners, refer to the Sales and Marketing section in Item 1 of this Report. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Overall, we have established either direct sales or distribution (via distributors or strategic partners) of CytoSorb in more than 75 countries worldwide. Registration of CytoSorb is typically required in each of these countries prior to active commercialization. With CE Mark approval, this can be typically achieved within several months in EU countries. Outside of the EU, the process is more variable and can take several months to more than a year due to different requirements for documentation and clinical data. Variability in the timing of registration affects the initiation of active commercialization in these countries, which affects the timing of expected CytoSorb sales. We actively support all of our distributors and strategic partners in the product registration process. We cannot generally predict the timing of these registrations, and there can be no guarantee that we will ultimately achieve registration in countries where we have established distribution. Outside of the EU, CytoSorb has distribution in Turkey, India, Sri Lanka, Australia, New Zealand, Russia, Serbia, Vietnam, Malaysia, Hong Kong, Chile, Panama, Costa Rica, Colombia, Brazil, Mexico, Argentina, Per&#250;, Guatemala, Ecuador, Bolivia, the Dominican Republic, El Salvador, Iceland, Israel, UAE, Iran, Saudi Arabia and other Middle Eastern countries, and South Korea. We cannot guarantee that we will generate meaningful sales in the countries where we have established registration, due to other factors such as market adoption and reimbursement. We continuously evaluate other potential distributor and strategic partner networks in other countries that accept CE Mark approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2020, we announced an agreement with China Medical System Holdings Limited (&#8220;CMS&#8221;), a well-established, innovation-driven specialty pharma with a focus on sales and marketing in China and Asia, to bring CytoSorb to mainland China to treat critically-ill patients with COVID-19 (fka Wuhan or 2019-nCoV) coronavirus infection. Under the terms of the agreement, CytoSorbents and CMS agreed to partner together to earn regulatory clearance to import CytoSorb into China under the &#8220;fast-track&#8221; review process established by the National Medical Products Administration of the People&#8217;s Republic of China (NMPA) to respond to the 2019 novel coronavirus (COVID-19) pandemic. CytoSorbents donated the initial CytoSorb devices and provided product, training, and support to CMS to introduce CytoSorb initially into four hospitals in the Wuhan, China area. The therapy was used in severe COVID-19 coronavirus patients with a systemic inflammatory response being treated with either continuous renal replacement therapy (CRRT) or extracorporeal membrane oxygenation (ECMO). The use of CytoSorb for the treatment of patients with severe COVID-19 coronavirus infection is considered exploratory in nature in China and is currently not yet approved for commercial purposes in mainland China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to our direct and distributor commercial channels, we have a number of strategic partners to market and/or distribute CytoSorb. These partners include Biocon Biologics Limited, Fresenius Medical Care AG, B. Braun Avitum AG, Aferetica s.r.l., and Terumo Cardiovascular Group. For detailed information regarding these partnerships, see the section entitled &#8220;Commercial and Research Partners&#8221; in Item 1 of this Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The market focus for CytoSorb is the prevention or treatment of organ failure in life-threatening conditions, including commonly seen illnesses in the ICU such as infection and sepsis, trauma, burn injury, ARDS, and others. Severe sepsis and septic shock, a potentially life-threatening systemic inflammatory response to a serious infection, accounts for approximately 10% to 20% of all ICU admissions, and is responsible for an estimated one in every five deaths worldwide. Sepsis is one of the largest target markets for CytoSorb. Sepsis is a major unmet medical need with no approved products in the U.S. or Europe to treat it. As with other critical care illnesses, multiple organ failure is the primary cause of death in sepsis. When used with standard of care therapy, that includes antibiotics, the goal of CytoSorb in sepsis is to reduce excessive levels of cytokines and other inflammatory toxins, to help reduce the SIRS response and either prevent or treat organ failure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the sepsis indication, we intend to conduct or support additional clinical studies in sepsis, cardiac surgery, and other critical care diseases where CytoSorb could be used, such as ARDS, trauma, severe burn injury, acute pancreatitis, and in other acute conditions that may benefit by the reduction of cytokines in the bloodstream. Some examples include the prevention of post-operative complications of cardiac surgery (cardiopulmonary bypass surgery) and damage to organs donated for transplant prior to organ harvest. We intend to generate additional clinical data to expand the scope of clinical experience for marketing purposes, to increase the number of treated patients, and to support potential future publications and regulatory submissions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2014, we completed a single arm, dose ranging trial in Germany amongst several clinical trial sites to evaluate the safety and efficacy of CytoSorb when used 24 hours per day for seven&#160;days, each day with a new device. These additional dosing data were used to support the label expansion to increase treatment time from 6 hours, the initial approval, to 24 hours of treatment. This study also provided additional treatment options for CytoSorb, helped to support the positive clinical data from our first European Sepsis Trial, and helped to shape the trial protocol for a pivotal sepsis study.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to sepsis and other critical care applications, cardiac surgery is an important application for CytoSorb in the European market. There are approximately one million cardiac surgery procedures performed annually in the U.S. and EU combined including, for example, coronary artery bypass graft surgery, valve replacement surgery, heart and lung transplant, congenital heart defect repair, aortic reconstruction, and left ventricular assist device (&#8220;LVAD&#8221;) implantation. Cardiac surgery can result in inflammation and the production of high levels of inflammatory mediators, such as cytokines, activated complement, and toxic plasma free hemoglobin released by hemolysis. These can lead to post-operative complications such as respiratory failure, circulatory failure, and acute kidney injury. CytoSorb has a unique competitive advantage as the only cytokine and free hemoglobin removal technology that can be used during the operative procedure and can be easily installed in a bypass circuit in a heart-lung machine without the need for an additional pump. Direct cytokine and hemoglobin removal with CytoSorb enables it to replace the former market for leukoreduction filters in cardiac surgery that attempt to indirectly reduce cytokines by capturing cytokine-producing leukocytes &#8211; an inefficient and suboptimal approach. A more recent application is the use of CytoSorb during cardiothoracic surgery to prevent or reduce perioperative bleeding by removing the blood thinners, ticagrelor and rivaroxaban.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company is currently conducting the following clinical trials:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:12.5%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Country</b></p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:16.67%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trial Name</b></p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:44.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Indication</b></p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:17.48%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Status</b></p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">United&#160;States</p></td><td style="vertical-align:top;width:3.34%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:16.67%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">STAR-T</p></td><td style="vertical-align:top;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.15%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Ticagrelor Removal During Cardiac Surgery</p></td><td style="vertical-align:top;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:17.48%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Enrolling</p></td></tr><tr><td style="vertical-align:bottom;width:12.5%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">United&#160;States</p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:16.67%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">STAR-D</p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Direct Anticoagulants Removal During Cardiac Surgery</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Temporarily paused</p></td></tr><tr><td style="vertical-align:top;width:12.5%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">United&#160;States</p></td><td style="vertical-align:top;width:3.34%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.67%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">CTC Registry</p></td><td style="vertical-align:top;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">CytoSorb in COVID-19 patients on ECMO under EUA</p></td><td style="vertical-align:top;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:17.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Completed</p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">Germany</p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.67%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">PROCYSS</p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Refractory Septic Shock Patients</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Enrolling</p></td></tr><tr><td style="vertical-align:top;width:12.5%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">International</p></td><td style="vertical-align:top;width:3.34%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.67%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">STAR Registry</p></td><td style="vertical-align:top;width:3.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Real world outcomes in antithrombotic removal</p></td><td style="vertical-align:top;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:17.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Enrolling</p></td></tr><tr><td style="vertical-align:top;width:12.5%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:justify;text-indent:-7.2pt;margin:0pt;">International</p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:16.67%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">COSMOS Registry</p></td><td style="vertical-align:top;width:3.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:44.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Real world outcomes in multiple critical care applications</p></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:17.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">Enrolling</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">For further detailed information regarding our clinical trial strategy, see the section entitled &#8220;Clinical Studies&#8221; of this Item 1 of this Report.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Even though we have obtained CE Mark approval for CytoSorb, no guarantee or assurance can be given that our CytoSorb product will work as intended or that we will be able to obtain FDA approval to sell CytoSorb in the U.S. or approval in any other country or jurisdiction.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">We have been successful in obtaining technology development contracts from multiple U.S. governmental agencies, such as the National Institutes of Health and the U.S. Department of Defense, including the Defense Advanced Research Projects Agency (&#8220;DARPA&#8221;), the U.S. Army, the U.S. Air Force, Special Operations Command, and Joint Program Executive Office (JPEO). See the section entitled &#8220;Government Research Grants&#8221; of this Item 1 of this Report for information regarding the specific grants.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2023, our goal is to successfully complete the STAR-T trial, finalize our data analysis, and file for U.S. FDA and Health Canada regulatory approvals. We are preparing for commercialization of DrugSorb-ATR in the U.S. In addition, we are seeing improvements in market conditions, and we are focused on a return to sales growth in our existing markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Corporate History</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We were originally organized as a Delaware limited liability company in August&#160;1997 as Advanced Renal Technologies,&#160;LLC. We changed our name to RenalTech International, LLC in November&#160;1998, and to MedaSorb Technologies, LLC in October&#160;2003. In December&#160;2005, MedaSorb Technologies, LLC converted from a limited liability company to a corporation, called MedaSorb Technologies,&#160;Inc. Separately, Gilder Enterprises,&#160;Inc., was incorporated in Nevada on April 25, 2002, and was originally engaged in the business of installing and operating computer networks that provided high-speed access to the Internet. On June&#160;30, 2006, Gilder Enterprises, Inc disposed of its original business, and pursuant to an Agreement and Plan of Merger, acquired all of the stock of MedaSorb Technologies,&#160;Inc., in a merger, and the business of MedaSorb Technologies,&#160;Inc. became its business. Following the merger, in July&#160;2006, we changed our name to MedaSorb Technologies Corporation. In November&#160;2008, we changed the name of our operating subsidiary from MedaSorb Technologies,&#160;Inc. to CytoSorbents,&#160;Inc. In May&#160;2010, we finalized the name change of MedaSorb Technologies Corporation to CytoSorbents Corporation. On October&#160;28, 2014, we changed the name of our operating subsidiary from CytoSorbents,&#160;Inc. to CytoSorbents Medical,&#160;Inc.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;3, 2014, we effected a twenty-five-for-one (25:1) reverse split of our common stock. As a result of this reverse stock split, shares of our common stock outstanding were reduced by approximately 96%. Immediately after the reverse stock split, pursuant to an Agreement and Plan of Merger dated December&#160;3, 2014, we changed our state of incorporation from the State of Nevada to the State of Delaware, whereby we merged with and into our wholly-owned Delaware subsidiary. At the effective time of the merger, (i)&#160;we merged with and into our Delaware subsidiary, (ii)&#160;our separate corporate existence in Nevada ceased to exist, (iii)&#160;the Delaware subsidiary became the surviving corporation, (iv)&#160;the certificate of incorporation, as amended and restated, and the bylaws of the Delaware subsidiary became our certificate of incorporation and bylaws, and (v)&#160;each share of our common stock outstanding immediately prior to the effective time was converted into one fully-paid and non-assessable share of our common stock as a Delaware corporation. The reverse stock split, the merger and the Agreement and Plan of Merger were approved by our Board of Directors and stockholders representing a majority of our then-outstanding common stock. All references to &#8220;us&#8221;, &#8220;we&#8221;, or the Company, on or after December&#160;3, 2014, refer to CytoSorbents Corporation, a Delaware corporation. CytoSorbents Corporation uplisted to, and began trading on, the NASDAQ Capital Markets on December 23, 2014.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our executive offices are located at 305 College Road East, Princeton, New Jersey 08540, and our telephone number is (732) 329-8885. Our website address is <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">http://www.cytosorbents.com</span>. We have included our website address as an inactive textual reference only. We make available free of charge through our website our Annual Reports on Form 10-K, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material, or furnish it to the SEC. We also similarly make available, free of charge on our website, the reports filed with the SEC by our executive officers, directors and 10% stockholders pursuant to Section 16 under the Exchange Act as soon as reasonably practicable after copies of those filings are provided to us by those persons. We are not including the information contained at <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">http://www.cytosorbents.com</span>, or at any other website address, as part of, or incorporating it by reference into, this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have been engaged in research and development and product commercialization and have raised approximately $215 million from investors as of December 31, 2022. These proceeds have been used to fund the development of multiple product applications, to conduct clinical studies, to establish in-house manufacturing capacity to meet commercial and clinical testing needs, expand our intellectual property through additional patents, to develop extensive proprietary know-how with regard to our products and to commercialize our products internationally.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have raised funds through various means including convertible note offerings, equity transactions, and term loans. Our most recent financing transactions are discussed below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">July 24, 2020 Offering</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July 24, 2020, the Company closed an underwritten public offering of 6,052,631 shares of its common stock at a public offering price of $9.50 per share (the &#8220;Offering&#8221;). The Company completed the Offering pursuant to the terms of an Underwriting Agreement, dated as of July 21, 2020, by and among the Company and Cowen and Company, LLC and SVB Leerink LLC, as representatives of the several underwriters named therein. The Company received gross proceeds of approximately $57.5 million from the Offering and after deducting the underwriting discounts and commissions and fees and expenses payable by the Company in connection with the Offering, the Company received net proceeds of approximately $53.8 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Shelf Registration</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:none;">On July 14, 2021, the Company filed a registration statement on Form S-3 with the SEC, which was amended on July 20, 2021 and declared effective by the SEC on July 27, 2021 (as amended, the &#8220;2021 Shelf&#8221;). The 2021 Shelf enables the Company to offer and sell, in one or more offerings, any combination of common stock, preferred stock, senior or subordinated debt securities, warrants and units, up to a total dollar amount of $150 million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Open Market Sale Agreement with Jefferies LLC</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">On December 30, 2021, the Company entered into an Open Market Sale Agreement (the &#8220;Sale Agreement&#8221;) with Jefferies LLC (the &#8220;Agent&#8221;), pursuant to which the Company could sell, from time to time, at its option, shares of the Company&#8217;s common stock having an aggregate offering price of up to $25 million through the Agent, as the Company&#8217;s sales agent. All shares of the Company&#8217;s common stock offered and sold, or to be offered and sold under the Sale Agreement would have been issued and sold pursuant to the Company&#8217;s 2021 Shelf by methods deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, in block transactions or if specified by the Company, in privately negotiated transactions.</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Subject to the terms of the Sales Agreement, the Agent is required to use their commercially reasonable efforts consistent with their normal sales and trading practices to sell the shares of the Company&#8217;s common stock from time to time, based upon the Company&#8217;s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company is required to pay the Agent a commission of up to 3.0% of the gross proceeds from the sale of the shares of the Company&#8217;s common stock sold thereunder, if any. There were no sales pursuant to the Sale Agreement during the years ended December 31, 2022 and 2021. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:12pt 0pt 12pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">We have been engaged in research and development since inception. Since 2012, we have been awarded an aggregate of approximately $40.3 million in grants, contracts, and other non-dilutive funding from DARPA ($3.8M over 5 years), the U.S. Army ($100K Phase I SBIR; $50K Phase I option, $803K Phase II SBIR, $443K Phase II enhancement), the U.S. Air Force $3.0M Rapid Innovation Fund, the Congressionally Directed Medical Research Program Office, (&#8220;CDMRP&#8221;, $718K), the National Heart, Lung and Blood Institute and USSOCOM ($203K Phase I SBIR; $1.5M Phase II SBIR; $3.0M Bridge SBIR), the Joint Program Executive Office &#8211; Chemical and Biological Defense, (JPEO-CBD), ($150K Phase I and Phase I option, $1.0M Phase II), the U.S. Army Peritoneal dialysis/mesh packing for hyperkalemia ($150K Phase I SBIR, $1.0M Phase II, $1.5M Sequential Phase II), Universal Plasma ($150K Phase I and 1.0M Phase II STTR; $2.9M US Army and CDMRP Rapid Innovation Fund; $4.4M CDMRP; $1.1M US Army Sequential Phase II; $2M DMRDP; and $4.3M JWMRP), Lipopolysaccharide Adsorption In Sepsis (National Institution of General Medical Sciences $282K), the U.S. Air Force program ($75K), New Jersey Technology Business Tax Certificate Program for research related expenses ($6.7M), and others to further develop our technologies for sepsis, trauma and burn injury, and blood transfusions, respectively. Some payments are based on achieving certain technology milestones.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Technology, Products and Applications</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">For approximately the past half-century, the field of blood purification has been focused on hemodialysis, a mature, well-accepted medical technique primarily used to sustain the lives of patients with permanent or temporary loss of kidney function. It is widely understood by the medical community that dialysis has inherent limitations in that its ability to remove toxic substances from blood drops precipitously as the size of toxins increases. Our hemocompatible adsorbent technology helps to address this shortcoming by removing toxins and toxic compounds largely untouched by dialysis technology.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Our polymer adsorbent technology can remove many different substances from whole blood and physiologic fluids, including for example, drugs, bioactive lipids, inflammatory mediators such as cytokines, free hemoglobin, and bacterial toxins, immunoglobulin, bilirubin, and myoglobin, depending on the polymer construct. The technology has been used in a wide variety of acute healthcare applications including, but not limited to, the adjunctive treatment and/or prevention of sepsis; the treatment of other critical care illnesses such as severe burn injury, trauma, acute respiratory distress syndrome, liver failure, and pancreatitis; the prevention of post-operative complications of cardiopulmonary bypass surgery; the treatment of cytokine release syndrome in cancer immunotherapy, the prevention of damage to organs donated by brain-dead donors prior to organ harvest; the removal of non-infectious contaminants in transfused blood products; the treatment of drug overdose, and the removal of antithrombotic drugs during cardiothoracic surgery that could otherwise cause severe perioperative bleeding. These applications vary by cause and complexity as well as by severity but share a common characteristic, i.e., high concentrations of inflammatory mediators,toxins, or drugs in the circulating blood.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Our flagship product, CytoSorb, animal-targeted VetResQ, DrugSorb-ATR, ECOS-300CY, and other product candidates under development, including CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K</span><sup style="font-size:7.5pt;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">+</sup><span style="font-weight:normal;">ontrol, and others consist of a cartridge containing adsorbent, porous polymer beads, although the polymers used in these devices are physically different. The cartridges incorporate industry standard connectors at either end of the device, which connect directly to the extracorporeal circuit (bloodlines) in series with a dialyzer as a standalone device. The extracorporeal circuit consists of plastic blood tubing, our blood filtration cartridges containing adsorbent polymer beads, pressure monitoring gauges, and a blood pump to maintain blood flow. The patient&#8217;s blood is accessed through a catheter inserted into his or her veins. The catheter is connected to the extracorporeal circuit and the blood pump draws blood from the patient, pumps it through the cartridge and returns it back to the patient in a closed loop system. All of these devices are expected to be compatible with standard blood pumps or hemodialysis machines used commonly in hospitals and will therefore not require hospitals to purchase additional expensive equipment and will require minimal training. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The polymer beads designed for the HemoDefend platform are intended to be used in multiple configurations, including a point-of-transfusion in-line filter between the blood bag and the patient, as well as a patent-pending &#8220;Beads in a Bag&#8221; configuration, where the beads are placed directly into a blood storage bag.</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Markets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:none;">CytoSorb, through its ability to bind mediators that regulate inflammation, is a critical care-focused immunotherapy. Critical care medicine includes the treatment of patients with serious or life-threatening conditions who require comprehensive care in the ICU, with highly skilled physicians and nurses and advanced technologies to support critical organ function to keep patients alive. Examples of such conditions include severe sepsis and septic shock, severe burn injury, trauma, acute respiratory distress syndrome, acute liver disease, and severe acute pancreatitis. In the U.S., an estimated $110 billion or 0.7% of the U.S. gross domestic product is spent annually on critical care medicine. In larger hospitals, critical care treatment accounts for up to 20% of a hospital&#8217;s overall budget and often results in financial losses for the hospital.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:none;">In many critical care illnesses, the mortality is often higher than 30%. A major cause of death is multiple organ failure, where vital organs such as the lungs, kidneys, heart and liver are damaged and no longer function properly. These patients are kept alive with supportive care therapy, or &#8220;life support&#8221;, such as mechanical ventilation, dialysis, extracorporeal liver support, and vasopressor treatment, that is designed to keep the patient from dying while using careful patient management to tip the balance towards gradual recovery over time. Unfortunately, most supportive care therapies only help to keep patients alive by supporting organ function but do not help reverse the underlying causes of organ failure and do not help patients recover more quickly. Because of this, the treatment course is often poorly defined and highly variable, leading to lengthy ICU stays, a higher risk of adverse outcomes from hospital acquired infections, medical errors, and other factors, as well as exorbitant costs. There is an urgent need for more effective &#8220;active&#8221; therapies that can help to reverse or prevent organ failure. Our main product, CytoSorb, is a unique cytokine adsorber designed to try to address this void, by reducing &#8220;cytokine storm&#8221; and working to reduce the subsequent deadly inflammation that can lead to organ failure and death. In May 2018, the approved indications for use of CytoSorb in the EU were expanded to include the removal of bilirubin in liver disease, and the removal of myoglobin in trauma. In 2020, the Company received CE-Mark label expansions for CytoSorb to remove the anti-platelet agent ticagrelor and the direct oral anticoagulant rivaroxaban in patients undergoing cardiac surgery on cardiopulmonary bypass.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:none;">In addition to critical care, CytoSorb is used in many applications related to cardiac surgery. Intra-operatively, CytoSorb is either used to help stabilize patients with serious conditions such as infective endocarditis, or to prevent post-operative complications such as acute kidney injury, vasoplegia, respiratory failure, infection, and others. CytoSorb is also used intra-operatively to remove blood thinners to prevent or reduce bleeding and associated complications during cardiothoracic surgery. Post-operatively, CytoSorb is used in the intensive care unit to treat the post-operative systemic inflammatory response syndrome (post-op SIRS), sepsis, and other complications.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:none;">Together the total addressable market for these numerous critical care and cardiac surgery applications with CytoSorb is estimated to be in excess of $30 billion worldwide.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Sepsis</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Sepsis is characterized by a systemic inflammatory response triggered by a severe infection. It is commonly seen in the ICU, accounting for approximately 10% to 20% of all ICU admissions. However, there are currently no approved products that are available to treat sepsis in the U.S. or EU. A 2020 study published in The Lancet estimated that there were 49 million new cases of sepsis globally, killing 11 million people every year. The researchers estimate that 1 in every 5 deaths worldwide is due to sepsis. Data released by the Healthcare Cost and Utilization Project (H-CUP) identified approximately 1.6 million cases of sepsis each&#160;year in the U.S. According to the CDC, the incidence of serious infection and sepsis has doubled in the U.S. in the past 10&#160;years. The main driver of sepsis incidence is the aging demographic, specifically patients who are older than age 65 who are more prone to infection and now account for two-thirds of patients hospitalized for sepsis and the majority of sepsis deaths. Other factors contributing to the increase in sepsis incidence include the spread of antibiotic resistant bacteria like methicillin-resistant Staphylococcus aureus (&#8220;MRSA&#8221;), an increase in co-morbid conditions like HIV, cancer, obesity, and diabetes that increases the risk of infection, an increasing use of implantable devices like artificial hips, knees and heart valves that are prone to colonization by bacteria, and the appearance of new highly virulent or contagious strains of common pathogens such as H3N2 or H1N1 influenza, COVID-19 coronavirus, and others.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are generally three categories of sepsis, including mild to moderate sepsis, severe sepsis and septic shock. Mild to moderate sepsis typically occurs with an infection that is responsive to antibiotics or antiviral medication. An example is a patient with self-limiting influenza or a treatable community acquired pneumonia. Mortality is generally very low. Severe sepsis is sepsis with evidence of organ dysfunction. An example is a patient who develops respiratory failure due to a severe pneumonia and requires mechanical ventilation in the ICU. Severe sepsis has a mortality rate of approximately 20% to 25% despite the use of antibiotics and the highest level of available care. Septic shock, or severe sepsis with low blood pressure that is not responsive to fluid resuscitation, is the most serious form of sepsis with an expected mortality in excess of 40% to 50%, and up to 80-100% if it is refractory to vasopressors and other therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In sepsis, there are two major problems: the infection and the body&#8217;s immune response to the infection. Antibiotics are the main therapy used to treat the triggering infection, and although antibiotic resistance is growing, the infection is often eventually controlled. However, it is the body&#8217;s immune response to this infection that frequently leads to the most devastating damage. In recognition of this, in 2016 the 3<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">rd</sup> International Consensus Definition Task Force re-defined sepsis as &#8220;life-threatening organ dysfunction due to a dysregulated host response to infection.&#8221; The body&#8217;s immune system normally produces large amounts of inflammatory mediators called cytokines to help stimulate and regulate the immune response during an infection. In severe infection, however, many people suffer from a massive, unregulated overproduction of cytokines, often termed &#8220;cytokine storm&#8221; that can kill cells and damage organs, leading to multiple organ dysfunction syndrome and multiple organ failure, and in many cases death. Until recently, there have been no available therapies in the U.S. or EU that can control the aberrant immune response and cytokine storm. Our CytoSorb device is a first-in-class, clinically-proven broad-spectrum extracorporeal cytokine adsorber currently approved for sale in the E.U. The goal of CytoSorb is to prevent or treat organ failure by reducing cytokine storm and controlling a &#8220;run-away&#8221; immune response, while antibiotics work to control the actual infection. CytoSorb has been evaluated in the randomized, controlled European Sepsis Trial in 100 patients in Germany with predominantly septic shock and acute respiratory distress syndrome or acute lung injury. CytoSorb demonstrated the ability to reduce a broad range of cytokines from the blood of critically ill patients. In a post-hoc analysis, this was associated with improvements in clinical outcome in two high-risk patient populations &#8211; those with very high cytokine levels and patients 65 years of age and older. We have completed a follow-up dosing study at several clinical trial sites in Germany, supporting the safety of continuous treatment, exchanging a new device daily for up to 7 days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The only treatment that had been approved to treat sepsis in the U.S. or EU was Xigris from Eli Lilly. Because of concerns of cost, limited efficacy, and potentially dangerous side effects including the increased risk of fatal bleeding events such as intracranial bleeding for those at risk, and also because of problems with reimbursement, worldwide sales of Xigris decreased from $160M in 2009 to $104M in 2010. In October&#160;2011, following its PROWESS SHOCK trial that demonstrated no benefit in mortality in septic shock patients, Lilly voluntarily withdrew Xigris from all markets worldwide, and is no longer available as a treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:none;">Development of many experimental therapies has been discontinued, including Eritoran from Eisai, CytoFab from BTG/Astra Zeneca, Talactoferrin from Agennix, tranexemic acid from Leading Biosciences, selective cytapheresis from CytoPheryx, and others.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:none;">For more information regarding our competitors, see the section entitled &#8220;Competition&#8221; in Item 1 of this report. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:none;">Severe sepsis and septic shock patients are among the most difficult and expensive patients to treat in a hospital. Because of this, we believe that cost savings to hospitals and/or clinical efficacy, rather than the cost of treatment itself, will be the determining factor in the adoption of CytoSorb in the treatment of sepsis. CytoSorb is approved in the EU and is being sold directly in Germany, Austria, Switzerland, Belgium, Luxembourg, Poland, Norway, Denmark, Sweden, the United Kingdom and the Netherlands with our own direct sales force. In December 2016, we announced the achievement of a dedicated reimbursement procedure code for CytoSorb therapy in Germany, providing for specific and enhanced reimbursement in the largest medical device market in Europe. We have established strategic partnerships with Fresenius Medical Care, the world&#8217;s largest dialysis company, for distribution of CytoSorb for critical care applications in France, Finland, the Czech Republic, Colombia, Ecuador, Mexico, and Korea, and Terumo Cardiovascular, the largest cardiac surgery disposables company, for exclusive distribution of the CytoSorb Cardiopulmonary Bypass Kit in France. We are also partnered with Biocon Biologics Limited, India&#8217;s largest biopharmaceutical company, for exclusive distribution of CytoSorb in India, Sri Lanka, and other select emerging markets. In March 2021, we announced a strategic partnership with B. Braun Avitum AG, and the launch of a global co-marketing agreement to promote the use of CytoSorb with B. Braun&#8217;s latest OMNI&#174; continuous blood purification platform and OMNIset&#174; Plus bloodline set (set version 3.0 or higher). We have ongoing discussions with potential corporate partners and independent distributors to market CytoSorb in other select EU countries and in other countries outside the EU that accept CE Mark approval. We have established direct sales or distribution of CytoSorb in approximately&#160;75 countries worldwide.</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:none;">We estimate that the market potential in Europe for CytoSorb is larger than that in the U.S. For example, in the U.S. there are an estimated 1.6 million cases of sepsis each year, while the European Sepsis Alliance estimates 3.4 million individuals in Europe become septic each year. In Germany alone, according to the Center of Sepsis Control and Care, there are approximately 175,000 cases of severe sepsis each year. Germany is the largest medical device market in Europe and the third largest in the world.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:none;">Sepsis patients are treated in the ICU for 12 to 18 days on average and for a total of 20 to 25 days in the hospital. A typical severe sepsis or septic shock patient in the U.S. costs approximately $45,000 to $60,000 to treat without using CytoSorb. CytoSorb therapy for sepsis typically costs in the range of $1,000 to $5,000, depending on the number of treatments. The goal of therapy is to not only improve clinical outcomes, but to also reduce the severity of illness and reduce the need for costly ICU care (estimated at approximately $4,300 per day in the ICU in the U.S.). The cost of CytoSorb therapy represents a fraction of what is currently spent on the treatment of patients with sepsis and would be cost-effective if it decreased ICU stay by one to two days. Based upon this price point, the total addressable market for CytoSorb for the treatment of sepsis in the U.S. and EU is approximately $6 billion to $8 billion.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Cardiac Surgery</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are approximately 500,000 cardiac surgery procedures performed on cardiopulmonary bypass annually in the U.S., another 500,000 in the EU, and approximately a total of 1.5 million procedures worldwide. These include relatively common procedures including coronary artery bypass graft surgery, valve replacement surgery, heart and lung transplantation, aortic reconstruction, congenital heart defect repair, and LVAD placements for the treatment of heart failure. Cardiac surgery can result in inflammation and the production of high levels of inflammatory cytokines, activation of complement, as well as hemolysis, causing the release of free hemoglobin. These can lead to post-operative complications including infection, pulmonary, renal, and neurological dysfunction. Complications lead to longer ICU recovery times and hospital stays, increased morbidity and mortality, and higher costs. An average coronary artery bypass graft procedure already costs approximately $36,000 in the U.S. without complications. According to the National Foundation for Transplants, a heart and lung transplant plus first year expenses total $1.2 million in the U.S. Valve replacement surgery for infective endocarditis is poorly reimbursed and may cost up to $150,000-$250,000 in the U.S. The use of CytoSorb to reduce cytokines and other inflammatory mediators during and after the surgical procedure may prevent or mitigate these post-operative complications. During the procedure, the CytoSorb adsorber can be easily incorporated in the heart-lung machine circuit without the need for a separate pump, a unique competitive advantage over other technologies. After the surgery, CytoSorb can continue to be used similarly to dialysis on patients that develop a severe post-operative inflammatory response with hemodynamic instability. Modified ultrafiltration is sometimes used after termination of cardiopulmonary bypass in cardiac surgery to remove excess fluid and inflammatory substances but has had mixed effect. The peri-procedural total addressable market for CytoSorb in the U.S. and EU in cardiothoracic surgery procedures is estimated to be $500 million to $1 billion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Removal of Antithrombotic Drugs in Cardiac Patients During Surgery Requiring Cardiopulmonary Bypass</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The role of antithrombotics, a category that includes both antiplatelet and anticoagulant drugs in cardiovascular medicine is constantly growing. Antiplatelet drugs are routinely used in patients with atherosclerotic cardiovascular disease such coronary disease, vascular disease or stroke. In the acute management of these patients, especially when they need interventional procedures such as stent placement therapy is escalated using two antiplatelet drugs (dual antiplatelet therapy - DAPT). Ticagrelor (Astra Zeneca - Brilinta<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, Brilique<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>) is considered best in class and is one of the most commonly used anti-platelet drugs to reduce the risk of cardiac death, heart attacks, and strokes in patients with either a history of a heart attack, or those actively undergoing percutaneous coronary intervention (PCI) with stent placement for acute coronary syndrome or heart attack. On the other hand, patients with atrial fibrillation or venous thrombosis require chronic anticoagulation. A new category of drugs called Direct Oral Anticoagulants (DOAC) is now the new standard of care with tens of millions of patients relying on them for lifelong protection. The two leaders in the category, apixaban (Bristol Myers Squibb - Eliquis<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>) and rivaroxaban (Janssen and Bayer - Xarelto<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>) are estimated to reach 40 billion USD in sales by 2026.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There is a clear and large unmet medical need when patients on these antithrombotic agents need to undergo surgery due to the very high risk of bleeding. Specifically, in patients on these drugs requiring urgent or emergent cardiac surgery the risk of major fatal/life-threatening bleeding has been reported to be as high as 65%. This scenario is most common in patients presenting with an acute coronary syndrome (ACS). In the U.S. alone there are approximately 1.1 million ACS hospital admissions annually. CytoSorb is able to very efficiently remove ticagrelor and DOACs from blood and is approved in the EU for the removal of both ticagrelor and rivaroxaban during cardiothoracic surgery requiring cardiopulmonary bypass. The use of CytoSorb during emergency coronary artery bypass surgery (CABG) in patients on ticagrelor or rivaroxaban significantly reduced periooperative bleeding complications in a landmark observational study and had projected cost savings of approximately $5,000 per patient, including the cost of the device. In the U.S. and Canada, the Company is currently conducting the pivotal, randomized, controlled STAR-T trial to evaluate the potential ability of the DrugSorb-ATR antithrombotic removal system, which uses an equivalent polymer technology to CytoSorb, to reduce perioperative bleeding risk in patients undergoing cardiothoracic surgery in the presence of ticagrelor. The Company expects to resume the STAR-D trial, targeting a reduction in perioperative bleeding risk in cardiothoracic surgery through the removal of the direct oral anticoagulants, apixaban and rivaroxaban, upon completion of the STAR-T trial. The STAR-T trial and STAR-D trial (if resumed), if successful, are each intended to independently support U.S. FDA marketing approval for DrugSorb-ATR for this indication., or the direct oral anticoagulants, apixaban and rivaroxaban, respectively. The Company expects to resume the STAR-D trial upon completion of the STAR-T trial. The STAR-T trial and STAR-D trial (if resumed), are each intended to independently support U.S. FDA marketing approval for DrugSorb-ATR for this indication. The initial annual addressable market in the U.S. to remove these drugs during cardiothoracic surgery is estimated between $500 million to $750 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Acute Respiratory Distress Syndrome</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Acute lung injury (&#8220;ALI&#8221;) and acute respiratory distress syndrome (ARDS) are two of the most serious conditions on the continuum of respiratory failure when both lungs are compromised by inflammation and fluid infiltration, severely compromising their ability to both oxygenate the blood and rid the blood of carbon dioxide produced by the body. There are an estimated 165,000 cases of ARDS in the U.S. each year, with even more cases in the EU. During the COVID-19 pandemic in 2020-2021, ALI and ARDS contributed or were responsible for more than 900,000 deaths in the U.S. alone. Patients with ALI and ARDS typically require mechanical ventilation, and sometimes extracorporeal membrane oxygenation (ECMO) therapy if the lungs become so diseased that mechanical ventilation fails, to help achieve adequate oxygenation of the blood. Patients on mechanical ventilation are at high risk of ongoing ventilator-induced lung injury, oxygen toxicity, barotrauma, ventilator-acquired pneumonias, and other hospital acquired infections, and outcome is significantly dependent on the presence of other organ dysfunction as well as co-morbid conditions such as pre-existing lung disease (e.g., emphysema or chronic obstructive pulmonary disease) and age. Because of this, mortality has been high (16-33%) even with modern medicine and ventilation techniques. ALI and ARDS can be precipitated by a number of conditions including pneumonia and other infections, burn and smoke inhalation injury, aspiration, reperfusion injury and shock. Cytokine injury plays a major role in the vascular compromise and cell-mediated damage to the lung through tight junction disruption of respiratory endothelium, leading to capillary leak syndrome, and other factors. Reduction of cytokine levels may either prevent or mitigate lung injury, enabling patients to wean from mechanical ventilation and ECMO faster, potentially reducing numerous sequelae such as infection, pneumothoraces, and respiratory muscle deconditioning, and allow faster ICU discharge, thereby potentially saving costs. CytoSorb treatment of patients with either ALI or ARDS in the setting of sepsis was the subject of our European Sepsis Trial where in a post-hoc analysis in patients with very high cytokine levels, we observed faster ventilator weaning in CytoSorb treated patients that showed a statistical trend towards benefit. Published results from our U.S. CytoSorb Therapy in COVID-19 (CTC) registry in the medical journal, Frontiers in Medicine, in December 2021, demonstrated that in 52 consecutive patients from 5 U.S. ECMO centers, 90-day survival was 73% in critically ill COVID-19 patients who failed mechanical ventilation and were treated with ECMO and CytoSorb under FDA Emergency Use Authorization. The CTC Registry completed enrollment at 100 patients, confirming 90-day survival of 74%. For context, 90-day survival was 53% (as of December 2022) among more than 7,300 adult patients in the North American cohort of the Extracorporeal Life Support Organization (ELSO) COVID-19 ECMO Registry. Future, prospectively defined, larger studies are required to confirm these findings. Although a number of therapies have been tried such as nitric oxide, surfactant therapy, and others, only corticosteroids, such a dexamethasone or methylprednisolone, have demonstrated mortality benefit in patients with ARDS. For example, in critically ill COVID-19 patients on mechanical ventilation, the RECOVERY study demonstrated use of once daily dexamethasone led to a reduction in mortality from 41.4% control to 29.3% treatment. In general, patients studied in the RECOVERY study were not as severely ill as those treated for refractory respiratory failure with CytoSorb and ECMO in the CTC Registry. Techniques to improve ventilation and reduce ongoing lung injury are also being used. For example, low tidal volume ventilation has been demonstrated to improve mortality (31.0% as compared to 39.8% control) in this patient population in the ARDSNet Trial. Prone positioning, or placing a patient chest-side down, in severe ARDS patients in order to redistribute gravity-dependent pulmonary edema and allow ventilation of collapsed or atelectatic alveoli, is also used, following studies that suggest benefit including the PROSEVA trial (16% vs 32.8% in the control). However, even with these interventions, we believe mortality is still unacceptably high. The total addressable market for CytoSorb to treat ARDS and ALI in the EU is estimated to be between $500 million to $1.25 billion, and approximately $2 billion for the U.S. and EU combined.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Severe Burn Injury</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the U.S., there are approximately 2.4 million burn injuries per year, with 650,000 treated by medical professionals and approximately 75,000 requiring hospitalization. Aggressive modern management of burn injury, including debridement, skin grafts, anti-microbial dressings and mechanical ventilation for smoke and chemical inhalation injury has led to significant improvements in survival of burn injury to approximately 95% on average at leading burns centers. However, there remains a need for better therapies to reduce the mortality in those patients with large burns and inhalation injury as well as to reduce complications of burn injury and hospital length of stay for all patients. According to National Burn Repository Data, the average hospital stay for burn patients is directly correlated with the percent total body surface area (&#8220;TBSA&#8221;) burned. Every 1% increase of TBSA burned equates to approximately 1 additional day in the hospital. A single patient with more than 30% TBSA burned who survives, is hospitalized for an average of 30 days and costs approximately $200,000 to treat. Major causes of death following severe burn and smoke inhalation injury are multiple organ failure (hemodynamic shock, respiratory failure, acute renal failure) and sepsis, particularly in patients with greater than 30% TBSA burns. Burns and inhalation injury lead to severe systemic and localized lung inflammation, loss of fluid, and cytokine overproduction. This &#8220;cytokine storm&#8221; causes numerous problems, including: hypovolemic shock and inadequate oxygen and blood flow to critical organs, ARDS preventing adequate oxygenation of blood, capillary leakage resulting in tissue edema and intravascular depletion, hypermetabolism leading to massive protein degradation and catabolism and is also associated with increased risk of infection, impaired healing, severe weakness and delayed recovery, immune dysfunction causing a higher risk of secondary infections (wound infections, pneumonia) and sepsis, and direct apoptosis and cell-mediated killing of cells, leading to organ damage. Up to a third of severe hospitalized burn patients develop multiple organ failure and sepsis that can often lead to complicated, extended hospital courses, or death. Broad reduction of cytokine storm has not been previously feasible and represents a novel approach to limiting or reversing organ failure, potentially enabling more rapid mechanical ventilation weaning, prevention of shock, reversal of the hypermetabolic state encouraging faster healing and patient recovery, reducing hospital costs, and potentially improving survival. The total addressable market in the EU for CytoSorb to address burn and smoke inhalation injury is estimated at $150 million to $350 million and up to $600 million for the U.S. and EU combined.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Trauma</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">According to the National Center for Health Statistics, in the U.S., there are more than 31 million visits to hospital emergency rooms, with 1.9 million hospitalizations, and 167,000 deaths every year due to injury. The leading causes of injury are trauma from motor vehicle accidents, being struck by an object or other person, and falls. Trauma is a well-known trigger of the immune response and a surge in cytokine production or cytokine storm. In trauma, cytokine storm contributes to the systemic inflammatory response syndrome triggering a cascade of events that cause cell death, organ damage, organ failure and often death. Cytokine storm exacerbates physical trauma in many ways. For instance, trauma can cause hypovolemic shock due to blood loss, while cytokine storm causes capillary leak and intravascular volume loss, and triggers nitric oxide production that causes cardiac depression and peripheral dilation. Shock can lead to a lack of oxygenated blood flow to vital organs, causing organ injury. Severe systemic inflammation and cytokine storm can lead to ALI and ARDS as is often seen in ischemia and reperfusion injury following severe bleeding injuries. Penetrating wound injury from bullets, shrapnel and knives, can lead to infection and sepsis, another significant cause of organ failure in trauma. Complicating matters is the breakdown of damaged skeletal muscle, or rhabdomyolysis, from blunt trauma that can lead to a massive release of myoglobin into the blood that can crystallize in the kidneys, leading to acute kidney injury and renal failure. Renal failure in trauma is associated with a significant increase in expected mortality. Cytokine and myoglobin reduction by CytoSorb and related technologies may have benefit in trauma, potentially improving clinical outcome. In May 2018, the approved indications for use of CytoSorb in the EU were expanded to include the removal of myoglobin in trauma. The total addressable market for CytoSorb for the treatment of trauma is estimated to be $1.5 billion to $2.0 billion in the U.S. and the EU.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Trauma patients on antithrombotic drugs represent an especially challenging cohort since any necessary surgery would be associated with very high bleeding risk. The ability of CytoSorb to efficiently remove some of the most popular antithrombotic drugs may represent an additional mode of benefit to improve clinical outcomes in trauma patients.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Acute Liver Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Chronic liver disease afflicts an estimated 850 million people worldwide, or 11% of the world population, due to the prevalence of viral hepatitis infection, alcohol abuse, and non-alcoholic steatohepatitis (NASH or &#8220;fatty liver&#8221;). Chronic liver disease is blamed for nearly one million deaths a year, with another one million dying of hepatic cancer and acute hepatitis. In the U.S., liver disease is the second leading cause of death from digestive disease, and the 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> leading cause of death amongst men. Many patients with advanced chronic liver disease will develop an acute exacerbation or decompensation (&#8220;acute-on-chronic&#8221;) of their disease, with associated inflammation and cytokine elevation, often requiring hospitalization. Also, many patients will present with acute hepatitis triggered by viral infection or alcohol. A range of symptoms, depending on the severity of illness include jaundice (high bilirubin), variceal hemorrhage, cognitive dysfunction and hepatic encephalopathy, ascites, coagulopathy, renal failure, liver failure, and others. The extracorporeal blood purification of liver toxins such as bilirubin has been used to help treat patients and is often called &#8220;liver dialysis&#8221;. Current liver dialysis therapies include MARS (Molecular Adsorbent Recirculation System; Baxter), Prometheus (Fresenius), SPAD (single pass albumin dialysis), and others. However, none of these therapies can remove cytokines, key elements in acute-on-chronic exacerbations and cases of acute hepatitis. CytoSorb represents a potentially superior liver dialysis therapy, as it can remove both liver toxins such as bilirubin and bile salts, as well as cytokines. In May 2018, the approved indications for use of CytoSorb in theEU were expanded to include the removal of bilirubin in liver disease. The total addressable market for CytoSorb for the treatment of acute-on-chronic liver disease, acute hepatitis, and acute liver failure is estimated to bed more than $15 billion worldwide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Severe Acute Pancreatitis</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Acute pancreatitis is the inflammation of the pancreas that results in the local release of digestive enzymes and chemicals that cause severe inflammation, necrosis and hemorrhage of the pancreas and local tissues. Approximately 210,000 people in the U.S. are hospitalized each&#160;year with acute pancreatitis with roughly 20% requiring ICU care. It is caused most frequently by a blockage of the pancreatic duct or biliary duct with gallstones, cancer, hyperlipidemia, or from excessive alcohol use. Severe acute pancreatitis is characterized by severe pain, inflammation, and edema in the abdominal cavity, as well as progressive systemic inflammation, generalized edema, and multiple organ failure that is correlated with high levels of cytokines and digestive enzymes in the blood. Little can be done to treat severe acute pancreatitis today, except for pancreatic duct decompression with endoscopic techniques, supportive care therapy, pain control, enteral tube feeding, and fluid support. ICU stay is frequently measured in weeks and although overall ICU mortality is approximately 10%, patients with multiple organ failure have a much higher risk of death. CytoSorb may potentially benefit overall outcomes in episodes of acute pancreatitis by removing a diverse set of toxins and cytokines from blood. The total addressable market for CytoSorb for the treatment of severe acute pancreatitis in the U.S. and EU is estimated to be between $400 million to $600 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Cancer Cachexia and Cancer Immunotherapy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cancer cachexia is a progressive wasting syndrome characterized by rapid weight loss, anorexia, and physical debilitation that significantly contributes to death in many cancer patients. Cancer cachexia is a systemic inflammatory condition, driven by excessive pro-inflammatory cytokines and other factors, that cripples the patient&#8217;s physical and immunologic reserve to fight cancer. Despite afflicting millions of patients worldwide each&#160;year, there are no effective approved treatments for cancer cachexia, with only symptomatic treatments available. CytoSorb blood purification may stop or reverse cancer cachexia through broad reduction of cytokines and other inflammatory mediators, when treated over time. For example, CytoSorb efficiently removes TNF-alpha (originally called &#8220;cachectin&#8221; or &#8220;cachexin&#8221; when first isolated in cancer cachexia patients) and other major pro-inflammatory cytokines including IL-1, IL-6, and gamma interferon that can cause cachexia. This broad immunotherapy approach may lead to improved clinical outcomes while reducing patient suffering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CytoSorb may also represent a rescue or salvage therapy in activated CAR T-cell cancer immunotherapy, where cytokine release syndrome (i.e. CRS or cytokine storm) is common, and can lead to organ failure and death in certain patients. In the CRS literature, researchers have drawn parallels to both macrophage activating syndrome and secondary hemophagocytic lymphohistiocytosis (HLH) which produce a similar clinical picture and cytokine storm profile. CytoSorb has been used successfully in many cases of secondary HLH. In March&#160;2017, the pioneer of CAR T-cell immunotherapy, Dr.&#160;Carl June&#160;at University of Pennsylvania, joined our scientific advisory board. In 2017, both Kymriah from University of Pennsylvania and Novartis, and Yescarta from Kite Pharma and Gilead Sciences, received FDA approval for the treatment of certain hematologic cancers. In early 2020, the first two case reports of CRS successfully treated with the adjunctive use of CytoSorb were published.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The total addressable market for CytoSorb for the treatment of cancer cachexia and cancer in the U.S. and EU is estimated to be in excess of $4 billion.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Organ Transplant and Brain-Dead Organ Donors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are in excess of 6,000 brain dead organ donors each&#160;year in the United States; worldwide, the number of these organ donors is estimated to be at least double the U.S. brain dead organ donor population. There is a severe shortage of donor organs. Currently, there are more than 100,000 individuals on transplant waiting lists in the United States. Cytokine storm is common in these organ donors, resulting in reduced viability of potential donor organs. The potential use of CytoSorb hemoperfusion to control cytokine storm in brain dead organ donors could increase the number of viable organs harvested from the donor pool and improve the survival of transplanted organs. A proof-of-concept pilot study using our technology in human brain dead donors has been published. In addition, CytoSorb treatment in a porcine animal model of brain death demonstrated a reduction in cytokines as well as a preservation of cardiac function compared to untreated controls.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2020, CytoSorbents announced the EU approval of the ECOS-300CY cartridge for the removal of inflammatory mediators during <i style="font-style:italic;">ex vivo</i> organ perfusion, with the goal of either preserving organ function in healthy organs, or rehabilitating dysfunctional organs that would otherwise have been discarded. We believe the ECOS-300CY cartridge has the potential to expand the organ donor pool. According to Eurotransplant, there were approximately 6,400 transplants from deceased donors and roughly 14,000 patients on waiting list for organs in Europe last year. In the United States, UNOS cites more than 41,000 organ transplants in 2020, with approximately 106,000 patients on the waiting list. This represents a U.S. and European total addressable market for the ECOS-300CY device of approximately $400 million to $600 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Blood Transfusions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The HemoDefend platform is a development-stage technology designed to be a practical, low cost, and effective way to safeguard the quality and safety of the blood supply. In the U.S. alone, 15 million packed red blood cell (&#8220;pRBC&#8221;) transfusions and another 15 million transfusions of other blood products (e.g., platelet, plasma, and cryoprecipitate) are administered each&#160;year with an average of 10% of all U.S. hospital admissions requiring a blood transfusion. The sheer volume of transfusions, not just in the U.S., but worldwide, complicates an already difficult task of maintaining a safe and reliable blood supply. Trauma, invasive operative procedures, critical care illnesses, supportive care in cancer, military usage, and inherited blood disorders are just some of the drivers of the use of transfused blood. In war, hemorrhage from trauma is a leading cause of preventable death, accounting for an estimated 30% to 40% of all fatalities. For example, in Operation Iraqi Freedom, due to a high rate of penetrating wound injuries, up to 8% of admissions required massive transfusions, defined as 10 units of blood or more in the first 24 hours. There is a clear need for a stable and safe source of blood products. However, blood shortages are common and exacerbated by the finite lifespan of blood. According to the Red Cross, pRBC units have a refrigerated life span of 42&#160;days. However, many medical experts believe there is an increased risk of infection and transfusion reactions once stored blood ages beyond two weeks. Transfusion-related acute lung injury is the leading cause of non-hemolytic transfusion-related morbidity and mortality, with an incidence of 1 in 2,000-5,000 transfusions and a mortality rate of up to 10%. Fatal cases of transfusion-related acute lung injury have been most closely related to anti-HLA or anti-granulocyte antibodies found in a donor&#8217;s transfused blood. Other early transfusion reactions such as transfusion-associated dyspnea, fever and allergic reactions occur in 3% to 5% of all transfusions and can vary in severity depending on the patient&#8217;s condition. These are caused by cytokines, bioactive lipids, free hemoglobin, toxins, foreign antigens, and a number of other inflammatory mediators that accumulate in transfused blood products during storage. Leukoreduction can remove the majority of white cells that can produce new cytokines but cannot eliminate those cytokines already in blood, and cannot otherwise remove other causative agents such as free hemoglobin and antibodies. Automated washing of pRBC is effective but is impractical due to the time, cost, and logistics of washing each unit of blood. The HemoDefend platform is a potentially superior alternative to purify blood transfusion products to these methods. The total addressable market for HemoDefend is more than $500 million for pRBCs alone. CytoSorbents has also received grant and contract funding to develop the HemoDefend platform to enable both universal plasma and fresh whole blood transfusions through the reduction of anti-A and anti-B blood group antibodies. Today, plasma and whole blood products must be carefully blood-type matched to prevent potentially fatal hemolytic transfusion reactions in the recipient, caused by the accidental administration of mismatched blood products. The reduction of anti-A and anti-B antibodies could potentially reduce or eliminate this risk, allowing for a broader range of available donors and simplifying the transfusion process. According to the American Red Cross, nearly 10,000 units of plasma are needed daily in the United States, or more than 3.5 million units a year. The World Health Organization (WHO) reports that plasma is transfused at a rate of 2.2 &#8211; 18.9 units per 1,000 population (median 7.7 units) globally. In westernized countries alone, with a population of 1.5 billion, there are approximately 12 million units of plasma administered each year. The total addressable market for HemoDefend-BGA in transfusion medicine in westernized countries alone is an estimated $400 million to $600 million and represents a fraction of the global market.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Radiocontrast Removal</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ContrastSorb is a development-stage blood purification technology that is being optimized for the removal of IV contrast from blood in order to prevent contrast -induced nephropathy (&#8220;CIN&#8221;). CIN is the acute loss of renal function within the first 48 hours following IV contrast administration. IV contrast is widely administered to patients undergoing CT scans, to enhance the images and make it easier to identify anatomic structures. IV contrast is also administered during invasive and interventional cardiovascular procedures in the brain, heart, limbs, and other parts of the body to diagnose and treat atherosclerosis (narrowing of blood vessels due to cholesterol deposits), vascular injury, aneurysms, etc. For example, an estimated 10 million coronary angiograms are performed worldwide each year to diagnose and treat coronary artery disease by placing coronary stents, performing balloon angioplasty, or atherectomy (removal of plaque in arteries). Overall, there are an estimated 80 million doses of IV contrast administered worldwide each year, split between approximately 65 million contrast-enhanced CT scans, 10 million coronary angiograms, and 5 million conventional angiograms. There are an estimated 30 million doses administered each year in the U.S. alone. The reported risk of CIN in patients undergoing contrast enhanced CT scans has been reported to be 2% to 13%. For coronary intervention, the risk has been estimated to be as high as 20% to 30% in high risk patients with pre-existing renal insufficiency, long-term diabetes, hypertension, congestive heart failure, and older age. The use of low osmolar IV contrast, hydration of patients pre-procedure, orally administration of N-acetylcysteine, and other agents to prevent CIN have demonstrated modest benefit in some clinical studies, but in many cases, the results across studies have been equivocal and inconsistent. In high risk patients, the direct removal of IV contrast from the blood with ContrastSorb to prevent CIN represents a potentially more effective alternative. The worldwide market opportunity for ContrastSorb in this high risk group is approximately $1 billion to $2 billion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Drug Removal</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">DrugSorb is a development-stage blood purification technology that is capable of removing a wide variety of drugs and chemicals from blood, as a potential treatment for drug overdose, drug toxicity, toxic chemical exposure, use in high-dose regional chemotherapy, and other applications. It has demonstrated extremely high single pass removal efficiency of a number of different drugs that exceeds the extraction capability of hemodialysis or other filtration technologies. It is similar in action to activated charcoal hemoperfusion cartridges that have been available for many&#160;years, but has the advantage of having inherent biocompatibility and hemocompatibility without coatings, and can be easily customized for specific agents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Chronic Kidney Failure</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The National Kidney Foundation estimates that more than 20 million Americans have chronic kidney disease. Left untreated, chronic kidney disease can ultimately lead to chronic kidney failure, which requires a kidney transplant or chronic dialysis (generally three times per week) to sustain life. There are approximately 500,000 patients in the U.S. currently receiving chronic dialysis and more than 3.0 million worldwide. Approximately 66% of patients with chronic kidney disease are treated with hemodialysis. One of the problems with standard high-flux dialysis is the limited ability to remove certain mid-molecular weight toxins such as &#946;<sub style="font-size:7.5pt;vertical-align:sub;">2</sub>&#160;-microglobulin. Over time, &#946;<sub style="font-size:7.5pt;vertical-align:sub;">2</sub>&#160;-microglobulin can accumulate and cause amyloidosis in joints and elsewhere in the musculoskeletal system, leading to pain and disability. Our BetaSorb device is intended to remove these mid-molecular weight toxins when used in conjunction with standard dialysis. Standard dialysis care typically involves three sessions per week, averaging approximately 150 sessions per&#160;year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Products</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The polymer adsorbent technology used in our products can remove middle molecular weight toxins, such as cytokines, from blood and physiologic fluids. All of the potential applications described below (i.e., the adjunctive treatment and/or prevention of sepsis; the adjunctive treatment and/or prevention of other critical care conditions such as acute respiratory distress syndrome, burn injury, trauma and pancreatitis; the prevention of damage to organs donated by brain-dead donors prior to organ harvest; the prevention of post-operative complications of cardiopulmonary bypass surgery; the prevention of kidney injury from IV contrast; and the treatment of chronic kidney failure) share in common high concentrations of toxins in the circulating blood. However, because of the limited studies we have conducted to date, we are subject to substantial risk that our technology will have little or no effect on the treatment of any of these indications. In 2011, we completed our European Sepsis Trial of our CytoSorb device. The study was a randomized, open label, controlled clinical study in 14 sites in Germany of 100 critically ill patients with predominantly septic shock and respiratory failure. The trial successfully demonstrated the ability of CytoSorb to reduce levels of key cytokines from whole blood in treated patients, and that treatment was safe in these critically-ill patients with multiple organ failure. We completed the CytoSorb technical file review with our notified body and CytoSorb subsequently received EU regulatory approval under the CE Mark as an extracorporeal cytokine adsorber indicated for use in any clinical situation where cytokines are elevated. Given sufficient and timely financial resources, we intend to continue to commercialize in Europe and conduct additional clinical studies of our products. However, there can be no assurance that we will ever obtain regulatory approval for any other device, or that the CytoSorb device will be able to generate significant sales.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We manufacture the CytoSorb device at our facility located in Princeton, New Jersey. We purchase our raw materials from multiple vendors located primarily in the United States. We believe that our risk of an interruption in the supply of our raw materials is minimal due to the use of multiple vendors and the availability of alternate vendors. We do not have contractual minimum finished goods inventory requirements, however our practice is to maintain a minimum inventory level sufficient to provide a supply of products for the next three months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">The CytoSorb Device (Critical Care)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">APPLICATION: Adjunctive Therapy in the Treatment of Sepsis</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Sepsis is a potentially life-threatening disease defined as &#8220;life-threatening organ dysfunction caused by a dysregulated host response to an infection&#8221;. Sepsis is mediated by high levels of inflammatory mediators such as cytokines, which are released into the bloodstream as part of the body&#8217;s immune response to severe infection or injury. Excessive concentrations of these mediators cause severe inflammation and damage healthy tissues, which can lead to organ dysfunction and failure. Organ failure is the leading cause of death in the ICU. Sepsis is very expensive to treat and has a high mortality rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Potential Benefits:</span> To the extent our adsorbent blood purification technology is able to prevent or reduce the accumulation of cytokines, toxins, or other inflammatory mediators in the circulating blood, we believe our products may be able to prevent or mitigate severe inflammation, organ dysfunction and failure in sepsis patients. Therapeutic goals as an adjunctive therapy include improved clinical outcome, reduced ICU and total hospitalization time, and reduced hospital costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Background and Rationale:</span> We believe that the effective treatment of sepsis the largest market for our technology. Severe sepsis (sepsis with organ dysfunction) and septic shock (severe sepsis with persistent hypotension despite fluid resuscitation) carries mortality rates of between 20% and 80%. Death can occur within hours or&#160;days, depending on many variables, including cause, severity, patient age and co-morbidities. There are approximately 1.6 million new cases of sepsis in the U.S. each&#160;year; and based on a recent 2020 The Lancet study, the worldwide incidence is estimated to be 49 million cases annually, accounting for 1 in every 5 deaths globally. The incidence of sepsis is also rising due to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an aging population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased incidence of antibiotic resistance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increase in co-morbid conditions like cancer and diabetes; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased use of indwelling medical devices that are susceptible to infection.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the U.S. alone, treatment of sepsis costs nearly $20 billion annually. According to the CDC, sepsis is a top ten cause of death in the U.S. The incidence of sepsis is believed to be under-reported as the primary infection (i.e., pneumonia, pyelonephritis, etc.) is often cited as the cause of death.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An effective treatment for sepsis has been elusive. Pharmaceutical companies have been trying to develop drug therapies to treat the condition. With the exception of Xigris<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> from Eli Lilly, no other products have been approved in either the U.S. or Europe for the treatment of sepsis. In 2011, after completing a follow up study required by the FDA, it was subsequently determined that Xigris&#174; did not have a statistically significant mortality benefit, and Eli Lilly withdrew Xigris&#174; from all markets worldwide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many medical professionals believe that blood purification for the treatment of sepsis holds tremendous promise. Studies using dialysis and hemofiltration technology have been encouraging, but have only had limited benefit to sepsis patients. The reason for this appears to be rooted in a primary limitation of dialysis technology itself: the inability of standard dialysis to effectively and efficiently remove significant quantities of larger toxins such as cytokines from circulating blood. CytoSorb has demonstrated the ability to safely reduce key cytokines in the blood of septic patients with multiple organ failure in our European Sepsis Trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The ability of CytoSorb to interact safely with blood (hemocompatibility) has been demonstrated through ISO 10993 testing, which includes testing for hemocompatibility, biocompatibility, cytotoxicity, genotoxicity, acute sensitivity and complement activation. CytoSorb use has been considered safe and well-tolerated in more than 195,000 devices utilized as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CytoSorb has been designed to achieve broad-spectrum removal of both pro- and anti-inflammatory cytokines, preventing or reducing the accumulation of high concentrations in the bloodstream. It also removes a wide range of inflammatory mediators such as activated complement, bacterial toxins, myoglobin, free hemoglobin, bilirubin, and many others. This approach is intended to modulate the immune response without causing damage to the immune system.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Projected Timeline:</span> In 2011, the CytoSorb adsorber received EU regulatory approval under the CE Mark as an extracorporeal cytokine adsorber to be used in clinical situations where cytokines are elevated. Our U.S. manufacturing facility has also achieved ISO 13485:2003 Full Quality Systems certification, an internationally recognized quality standard designed to ensure that medical device manufacturers have the necessary comprehensive management systems in place to safely design, develop, manufacture and distribute medical devices in the EU. We are currently manufacturing our CytoSorb device for commercial sale in the EU. We are currently selling CytoSorb in Germany, Austria, Switzerland, Belgium, Luxembourg, Poland, Norway, Finland, Sweden, Denmark, the United Kingdom and the Netherlands with a direct sales force. Based on its CE Mark approval, CytoSorb can also be sold throughout all 27 countries of the EU, the United Kingdom and countries outside the EU that will accept European regulatory approval with registration. Overall, we have established either direct sales or distribution (via distributors or strategic partners) of CytoSorb in more than 75 countries worldwide. Registration of CytoSorb is typically required in each of these countries prior to active commercialization. With CE Mark approval, this can be typically achieved within several months in EU countries. Outside of the EU, the process is more variable and can take months to more than a year due to different requirements for documentation and clinical data. Variability in the timing of registration affects the initiation of active commercialization in these countries, which affects the timing of expected CytoSorb sales. We actively support all of our distributors and strategic partners in the product registration process. Outside of the EU, CytoSorb has distribution in Turkey, India, Sri Lanka, Australia, New Zealand, Russia, Serbia, Vietnam, Malaysia, Hong Kong, Chile, Panama, Costa Rica, Colombia, Brazil, Mexico, <span style="background:#ffffff;">Argentina</span><span style="background:#ffffff;">, Per&#250;,&#160;</span><span style="background:#ffffff;">Guatemala</span><span style="background:#ffffff;">,&#160;</span><span style="background:#ffffff;">Ecuador</span><span style="background:#ffffff;">,&#160;</span><span style="background:#ffffff;">Bolivia</span><span style="background:#ffffff;">, the&#160;</span><span style="background:#ffffff;">Dominican Republic</span><span style="background:#ffffff;">,&#160;</span><span style="background:#ffffff;">El Salvador</span><span style="background:#ffffff;">, </span>Iceland, Israel, UAE, Iran, Saudi Arabia and other Middle Eastern countries, and South Korea. We cannot generally predict the timing of these registrations, and there can be no guarantee that we will ultimately achieve registration in countries where we have established distribution. We also cannot guarantee that we will generate meaningful sales in the countries where we have established registration, due to other factors such as market adoption and reimbursement. We are currently actively evaluating other potential distributor and strategic partner networks in other major countries that accept CE Mark approval. With sufficient resources and continued positive clinical data, assuming availability of adequate and timely funding, and continued positive results from our clinical studies, we intend to continue our commercialization plans for our product worldwide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">APPLICATION: Adjunctive Therapy in Other Critical Care Applications</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Potential Benefits:</span> Cytokine-mediated organ damage and immune suppression can increase the risk of death and infection in patients with commonly seen critical care illnesses such as acute respiratory distress syndrome, severe burn injury, trauma and pancreatitis. By reducing both pro- and anti-inflammatory cytokines, CytoSorb has the potential to reduce the systemic inflammatory response and:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prevent or mitigate multiple organ dysfunction syndrome (&#8220;MODS&#8221;) and/or multiple organ failure (&#8220;MOF&#8221;);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prevent or reduce secondary infections;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduce the need for expensive life-sparing supportive care therapies such as mechanical ventilation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduce the need for ICU care, freeing expensive critical care resources, and reducing hospital costs and costs to the healthcare system.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 58.3pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Background and Rationale:</span> A shared feature of many life-threatening conditions seen in the ICU is severe inflammation (either sepsis or systemic inflammatory response syndrome) due to an over-reactive immune system and high levels of cytokines that can cause or contribute to organ dysfunction, organ failure and patient death. Examples of such conditions include severe burn injury, trauma, acute respiratory distress syndrome and severe acute pancreatitis. MODS and MOF are common causes of death in these illnesses and mortality is directly correlated with the number of organs involved. There are currently few active therapies to prevent or treat MODS or MOF. If CytoSorb can reduce direct or indirect cytokine injury of organs, it may mitigate MODS or MOF, improve overall patient outcome and reduce costs of treatment. In addition, secondary infection, such as ventilator-acquired pneumonia, urinary tract infections, or catheter-related line infections, are another major cause of morbidity and mortality in all patients treated in the ICU that increase with longer ICU stay. Prolonged illness, malnutrition, age, multiple interventional procedures, and exposure to antibiotic resistant pathogens are just some of the many risk factors for functional immune suppression and infection. In sepsis and SIRS, the overexpression of pro-inflammatory cytokines can also cause a depletion of immune effector cells through apoptosis and other means, and anti-inflammatory cytokines can cause profound immune suppression, both major risk factors for infection.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Projected Timeline:</span> The EU CE Mark approval for CytoSorb as an extracorporeal cytokine adsorber and its broad approved indication to be used in any clinical situation where cytokines are elevated, allows it to be used &#8220;on label&#8221; in critical care applications such as acute respiratory distress syndrome, severe burn injury, trauma, liver failure, and pancreatitis, and in other conditions where cytokine storm, sepsis and/or SIRS plays a prominent role in disease pathology. In addition, the expanded indications for use label now includes reduction of bilirubin and reduction of myoglobin, further strengthens the on-label use of the technology for the treatment of liver disease, and severe trauma, respectively. Our goal is to stimulate investigator-initiated clinical studies with our device for these applications. Currently, we have many investigator-initiated or company-sponsored studies being planned, enrolling, or completed. We have been moving forward in parallel with a program to further understand the potential benefit of CytoSorb hemoadsorption in these conditions through additional investigational animal studies and potential human pilot studies in the U.S. funded either directly by us, through grants, or through third parties. Commencement of these and other formal studies is contingent upon adequate funding and, in the case of U.S. human studies, FDA IDE approval of the respective human trial protocols.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">APPLICATION: Prevention and treatment of perioperative complications of cardiopulmonary bypass surgery</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Potential Benefits:</span> If CytoSorb is able to prevent or reduce high levels of cytokines, free hemoglobin, and other inflammatory mediators from accumulating in the bloodstream during and following cardiac surgery, we anticipate that post-operative complications of cardiopulmonary bypass surgery may be able to be prevented or mitigated. In addition, CytoSorb can remove certain antithrombotic drugs such as ticagrelor and rivaroxaban during cardiopulmonary bypass in patients requiring urgent or emergent surgery. The primary goals for these applications are to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduce ventilator and oxygen therapy requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduce post-operative complications such as ARDS, acute kidney injury, post-perfusion syndrome, and the SIRS;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduce length of stay in hospital ICUs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduce the total cost of patient care;and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduce the risk of perioperative bleeding complications such as need for blood and platelet transfusions, re-thoracotomy, and death.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 58.3pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Background and Rationale:</span> Due to the highly invasive nature of cardiopulmonary bypass surgery, high levels of cytokines are produced by the body, triggering severe inflammation. In addition, hemolysis of red blood cells frequently occurs, resulting in the release of free hemoglobin into the bloodstream. These inflammatory mediators can lead to post-operative complications. CytoSorb is the only cytokine reduction technology approved in the EU that can be used intraoperatively in a bypass circuit in a heart-lung machine during cardiopulmonary bypass without the need for another machine. If our products are able to prevent or reduce the accumulation of cytokines or free hemoglobin in a patient&#8217;s blood stream, we may be able to prevent or mitigate post-operative complications caused by an excessive or protracted inflammatory response to the surgery. Intraoperative use of CytoSorb on high-risk cardiac surgery patients, such as those with infective endocarditis, aortic dissection, or heart or lung transplantation, where the risk of post-operative complications is the highest, is one of our main markets. The use of CytoSorb in the post-operative period to treat postoperative SIRS is another application of the technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2020, CytoSorb was approved to remove the anti-platelet agent, ticagrelor, during cardiac surgery involving cardiopulmonary bypass via label expansion of its CE Mark. Ticagrelor (Brilinta&#174;, Astra Zeneca) is a widely used anti-platelet agent used to decrease cardiovascular risk and risk of stroke in patients with a known history of heart disease or heart attack. It is also widely used during dual-anti platelet therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention and stent placement. However, when patients on ticagrelor require emergent or urgent cardiac surgery, up to 65% of patients will have severe or massive peri-operative bleeding complications that contributes to a high risk of death and major costs to the healthcare system. CytoSorb has already demonstrated the ability to remove ticagrelor rapidly and efficiently from human blood <i style="font-style:italic;">in vitro</i>. Meanwhile, a retrospective case series reported by clinicians at Asklepios Klinik St. Georg in Hamburg, Germany on the investigational use of CytoSorb to reverse the effects of ticagrelor during emergency cardiac surgery demonstrated a greatly reduced risk of bleeding complications and the need for repeat surgery to explore the source of bleeding, with extrapolations showing projected cost savings of &#163;3,982, or approximately $5,000 USD, per patient in a U.K. based study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CytoSorb was also approved for the removal of rivaroxaban, a widely used Factor Xa inhibitor and novel oral anticoagulant, during cardiothoracic surgery requiring cardiopulmonary bypass via label expansion of its CE Mark. This new category of drugs called Direct Oral Anticoagulants (DOAC) is now the new standard of care with tens of millions of patients relying on them for chronic, often lifelong protection. The two leaders in the category are apixaban (Bristol Myers Squibb - Eliquis<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>) and rivaroxaban (Janssen and Bayer - Xarelto<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>).</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Projected Timeline:</span> Cardiac surgeons, cardiac perfusionists, and cardiothoracic ICU intensivists in Germany, Austria, and other countries have now used CytoSorb intra-operatively and post-operatively in more than 50,000 treatments in cardiac surgery patients. This application is also the focus of number of planned and enrolling company-sponsored and investigator-initiated studies of DrugSorb-ATR in the United States and CytoSorb in Europe.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2021, we received full FDA approval of an Investigational Device Exemption (IDE) application to conduct a double-blind, randomized, controlled clinical study in 120 patients entitled, &#8220;<b style="font-weight:bold;">S</b>afe and <b style="font-weight:bold;">T</b>imely <b style="font-weight:bold;">A</b>ntithrombotic <b style="font-weight:bold;">R</b>emoval &#8211; <b style="font-weight:bold;">T</b>icagrelor (<b style="font-weight:bold;">STAR-T</b>),&#8221; in the United States to support FDA marketing approval. This was done under the previously announced FDA Breakthrough Device Designation granted for the removal of ticagrelor in a cardiopulmonary bypass circuit to reduce the likelihood of serious perioperative bleeding during urgent cardiac surgery. In October 2021, the first patient was enrolled and the STAR-T study is now actively recruiting at multiple U.S. sites. In November 2022, the first milestone was completed with the first one-third of patients enrolled, triggering the first Data Safety Monitoring Board (DSMB) meeting. The DSMB recommended to continue the study as planned without any modifications. In 2022, we also received FDA approval to expand the study to Canada and subsequently received Health Canada approval allowing inclusion of Canadian sites into the STAR-T trial in January 2023. &#160;Enrollment is expected to be complete during summer of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2021, we also received full FDA approval of an Investigational Device Exemption (IDE) application to conduct a double-blind, randomized, controlled clinical study for up to 120 patients entitled, &#8220;<b style="font-weight:bold;">S</b>afe and <b style="font-weight:bold;">T</b>imely <b style="font-weight:bold;">A</b>ntithrombotic <b style="font-weight:bold;">R</b>emoval &#8211; <b style="font-weight:bold;">D</b>irect Oral Anticoagulants (<b style="font-weight:bold;">STAR-D</b>),&#8221; in the United States to support FDA marketing approval. This was done under the previously announced 2<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">nd</sup> FDA Breakthrough Device Designation granted for our DrugSorb-ATR Antithrombotic Removal System. This Breakthrough Device designation covers the removal of the Direct Oral Anticoagulants (DOACs) apixaban and rivaroxaban in a cardiopulmonary bypass circuit to reduce the likelihood of serious perioperative bleeding during urgent cardiac surgery. The study was placed on temporary enrollment hold in November of 2022 for business reasons and is scheduled to resume enrollment upon completion of the STAR-T trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For further detailed information regarding our clinical trial strategy, see the section entitled &#8220;Clinical Studies&#8221; of this Item 1 of this Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">APPLICATION: Maintaining or improving the quality of solid organs harvested from donors for organ transplant</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Potential Benefits:</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ECOS-300CY: Solid organ transplant is very costly, and the success of the transplant is heavily dependent upon the health and quality of the harvested organs. ECOS-300CY was designed to maintain or improve the quality of these organs prior to transplant in an <i style="font-style:italic;">ex vivo</i> perfusion system, and may have the benefit of improving outcomes in organ transplant and also increasing the availability of organs by rehabilitating organs that would have otherwise been discarded. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CytoSorb: By preventing or reducing high-levels of cytokines from accumulating in the bloodstream of brain-dead organ donors, we believe CytoSorb may be able to mitigate organ dysfunction and failure, which results from severe inflammation following brain-death. The primary goals for this application are:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">improving the viability of organs which can be harvested from brain-dead organ donors, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increasing the likelihood of organ survival following transplant.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Background and Rationale:</span> When brain death occurs, the body responds by generating large quantities of inflammatory cytokines. This process is similar to the systemic inflammatory response syndrome and sepsis. A high&#160;percentage of donated organs are never transplanted due to this response, which damages healthy organs and prevents transplant. In addition, inflammation in the donor may damage organs that are harvested and reduce the probability of graft survival following transplant. CytoSorb treatment in a porcine animal model of brain death demonstrated a reduction in cytokines as well as a preservation of cardiac function compared to untreated controls.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There is a shortage of donated organs worldwide, with more than 100,000 people currently on the waiting list for organ transplants in the U.S. alone. Because there are an insufficient number of organs donated to satisfy demand, it is vital to maximize the number of viable organs donated, and optimize the probability of organ survival following transplant.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Projected Timeline:</span> ECOS-300CY: The ECOS-300CY was approved in the E.U. for the removal of inflammatory mediators during <i style="font-style:italic;">ex vivo</i> organ perfusion under CE Mark designation in 2020. CytoSorbents announced a partnership with Aferetica srl to provide the ECOS-300CY cartridge under the exclusive trade name, PerSorb&#8482;, that is compatible with Aferetica&#8217;s PerLife&#8482; <i style="font-style:italic;">ex vivo</i> organ perfusion system, recently approved in the E.U. as well. In 2021, commercialization of PerSorb&#8482; and Aferetica&#8217;s PerLife&#8482; <i style="font-style:italic;">ex vivo</i> organ perfusion system commenced in Italy. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CytoSorb for brain dead organ donors: Studies have been conducted under a $1 million grant from the Health Resources and Services Administration (&#8220;HRSA&#8221;), an agency of the U.S. Department of Health and Human Services. Researchers at the University of Pittsburgh Medical Center and the University of Texas, Houston Medical Center have completed the observational and dosing phases of the project. The results were published in Critical Care Medicine, January&#160;2008. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-line:none;">The VetResQ Device (Animal Health Critical Care)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">APPLICATION: Adjunctive Therapy in the Treatment of Sepsis, Pancreatitis and Other Critical Illnesses in Animals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Potential Benefits and Rationale:</span> In January&#160;2017, the VetResQ device became commercially available for the United States veterinary market. VetResQ is a broad-spectrum blood purification adsorber based upon similar underlying technology to CytoSorb and has been configured in 3 sizes (50, 150 and 300mL sized cartridges) to accommodate treatment of small, medium, and large animals such as cats, dogs, and high-value animals such as foals and horses. <span style="color:#26282a;">VetResQ is compatible with standard hemodialysis, continuous renal replacement therapy (&#8220;CRRT&#8221;), and hemoperfusion blood pumps. </span>Like CytoSorb, VetResQ is designed to help treat (via hemoadsorption of cytokines, bacterial toxins and other inflammatory mediators) deadly inflammation and toxic injury in animals with critical illnesses such as septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, drug intoxication, heat stroke and lung injury. Critical illness in animals is similar to that in humans. <span style="color:#26282a;">Based upon cumulative studies, VetResQ is capable of reducing a broad range of excessive inflammatory mediators and toxins that could otherwise cause direct tissue injury or serious systemic inflammation that can rapidly lead to instability, organ failure, and death. VetResQ is available in the U.S. only for veterinary animal usage and is not for human use.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Projected Timeline</span>: VetResQ is available for commercial purchase for animal health applications in the United States. The FDA was notified of the launch in 2016 and we have provided the FDA with the related instructions for use and a marketing brochure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">The CytoSorb-XL Device (Critical Care)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">APPLICATION: Adjunctive Therapy in the Treatment of Sepsis and other critical illnesses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Potential Benefits and Rationale:</span> The CytoSorb-XL device is a next-generation porous polymer under advanced development and targets the same markets as CytoSorb. Through novel patent-pending chemistry, CytoSorb-XL adds the ability to reduce Gram negative bacterial endotoxin (lipopolysaccharide) to broad spectrum cytokine, exotoxin, and other inflammatory mediator removal. CytoSorb-XL removed comparable amounts of endotoxin when compared <i style="font-style:italic;">in vitro</i> against the leading standalone endotoxin filter, Toraymyxin (Toray, Japan). This could potentially increase the effectiveness of CytoSorb in sepsis and septic shock caused by Gram negative bacteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Projected Timeline</span>: CytoSorb-XL is in advanced pre-clinical development as a potential next generation polymer to CytoSorb. It is expected to follow a similar path to E.U. approval as CytoSorb, expected within 4 to 5&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">The HemoDefend Blood Purification Technology Platform (Acute and Critical Care)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">APPLICATION: Reduction of contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Potential Benefits:</span> The HemoDefend RBC blood purification technology platform is designed to reduce contaminants in the blood supply that can cause transfusion reactions or disease. It is a development stage technology that is not yet approved in any markets, but is comprised of our highly advanced, biocompatible, polymer bead technology. If this technology is successfully developed and then incorporated into a regulatory approved product, it could have a number of important benefits, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduce the risk of transfusion reactions and improve patient outcome;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">improve the quality, or extend the shelf life of stored blood products;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">improve the availability of blood and reduce blood shortages by reducing the limitations of donors to donate blood; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allow easier processing of blood.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Background and Rationale:</span> The HemoDefend technology platform was built upon our successes in designing and manufacturing porous polymer beads that can remove cytokines. We have expanded the technology to be able to remove substances as small as drugs and bioactive lipids, to proteins as large as antibodies from blood that can cause transfusion reactions and disease. Although the frequency of these reactions are relatively low (approximately 3% to 5%), the sheer number of blood transfusions is so large, that the number of transfusion reactions, ranging from mild to life-threatening, is substantial, ranging from several hundreds of thousands to millions of reactions each&#160;year. In critically-ill patients, the risk of transfusion reactions is significantly higher than in the general population and can increase the risk of death because their underlying illnesses have depleted protective mechanisms and have primed their bodies to respond more vigorously to transfusion-associated insults.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A number of retrospective studies have also suggested that administration of older blood leads to increased adverse events and even increased mortality, compared with blood recently harvested. Biological studies have demonstrated the accumulation of erythrocyte storage lesions that compromise the function and structural integrity of packed red blood cells and have also demonstrated the accumulation of substances such as free hemoglobin, bioactive lipids, potassium, and others during blood storage that can lead to transfusion reactions. Three adult, prospective, randomized, controlled studies were designed to evaluate the morbidity and mortality in cardiovascular surgery patients (RECESS) and critically ill patients (ABLE and TRANSFUSE), treated with either &#8220;new or fresh&#8221; or &#8220;older&#8221; blood. <span style="color:#141823;">The RECESS Trial was a randomized, controlled trial in a total of 1,098 evaluable patients undergoing complex cardiac surgery given fresh blood (&#8804;10&#160;days old) as compared to older blood (&#8805;21&#160;days old). The overall conclusion was that the age of blood had no statistically significant impact on the progression to organ dysfunction (as measured by the multiple organ dysfunction syndrome score) or death. However, a statistically significant increase in hepatobiliary-related serious adverse events (5% fresh vs 9% older, p=0.02) was related to hyperbilirubinemia, possibly caused by hemolysis and release of free hemoglobin in old blood. The serious adverse event rate in both new and old blood groups was approximately 50%, which is considered high for this group of patients. There are many details and subgroup analyses that were not discussed, particularly an analysis of those patients receiving more units of blood than average, as the risk of adverse events is cumulative. The ABLE Trial was a randomized, controlled trial in 2,430 critically-ill patients receiving either fresh (&#8804; 7&#160;days) or standard issue blood. There was no difference in 90-day mortality between the two groups.</span> The TRANSFUSE Trial was a large scale RCT in Australia evaluating the impact of age of leukodepleted pRBCs (short-term storage: 11.8&#160;days mean, N=2,457, mean 4.1 units transfused; long-term storage: 22.4&#160;days mean, N=2,462) on 90-day mortality in critically-ill patients. There was no significant difference in 90-day mortality (24.8% mortality short-term storage vs 24.1% long-term storage) though there were statistically more febrile non-hemolytic transfusion reactions (n=123; 5% short-term storage vs n=88; 3.6% long-term storage). Also, patients who had short-term storage blood with APACHE III &gt; 21.5% (median risk), demonstrated higher mortality (37.7% vs 34% long-term storage, p=0.05). The outcomes of these trials do not alter the current pressing need for better solutions to purify transfused blood products, particularly in patients who receive massive transfusions defined as more than 10 pRBC units in 24 hours, those patients who receive blood chronically, and pediatric patients, in order to reduce transfusion-related adverse events and improve clinical outcome but suggest that age of blood is not the critical factor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Projected Timeline:</span> The HemoDefend platform is a development stage product based on our advanced polymer technology. The base polymer is ISO 10993 biocompatible, meeting standards for biocompatibility, hemocompatibility, cytotoxicity, genotoxicity, acute sensitivity and complement activation. HemoDefend has demonstrated the <i style="font-style:italic;">in vitro</i> removal of many different substances from blood such as antibodies, free hemoglobin, potassium, cytokines and bioactive lipids. We have also prototyped a number of different implementations of the HemoDefend technology, including the &#8220;Beads in a Bag&#8221; blood treatment blood storage bag, and standard in-line blood filters. The technology has been supported by the NHLBI, a division of the National Institute of Health, under a Phase I SBIR, an awarded $1.5 million Phase II SBIR contract (funded by NHLBI and U.S. Special Operations Command (USSOCOM)), and more recently under a $3 million multi-year Phase IIB bridge contract funded by NHLBI. Barring additional delays due to the COVID-19 pandemic, including nationwide blood shortages, we expect to advance the in-line filter to human testing in the next 12 - 18 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">APPLICATION: Removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Potential Benefits:</span> The HemoDefend-BGA blood purification technology platform is designed to reduce anti-A and anti-B antibodies in plasma and whole blood. The goal is to either enable the production of universal plasma or enable fresh warm whole blood transfusions. If this technology is successfully developed and then incorporated into a regulatory approved product, it could have a number of important benefits, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduce the risk of transfusion reactions and improve patient outcome;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eliminate the need to blood-type plasma, improving its availability</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enable the use of low titer whole blood, ideal for trauma resuscitation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">easier processing of blood products.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Background and Rationale:</span> Plasma is the straw-colored, cell-free portion of whole blood. It contains a wide range of important substances such as electrolytes, hormones, proteins such as albumin, clotting factors, and antibodies. The transfusion of plasma, or plasma-derived products, is used widely to help save the lives of trauma and bleeding victims, septic and other critically-ill patients, and patients with life-threatening blood coagulation and autoimmune disorders. Approximately 4.0 million units of plasma are transfused annually in the United States alone. With the exception of the relatively uncommon Type AB, or &#8220;universal&#8221; plasma, most plasma contains blood-type specific antibodies and must be cross-matched with the intended recipient ahead of time or risk serious transfusion reactions. By reducing these blood-type specific antibodies, the goal is to create a cost-effective, reliable, and expanded source of &#8220;universal&#8221; plasma that can be administered immediately, without blood-typing, in a wide range of emergent and non-emergent situations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Projected Timeline: </span>The HemoDefend-BGA platform is a development stage product based on our advanced blood purification technology. Prototype filtration devices have been evaluated by a government agency, resulting in excellent depletion of both anti-A and anti-B antibodies. Work is continuing to advance these prototypes to clinical study-ready devices. This work has received cumulative funding of approximately $15.9 million in Phase I and II Small Business Technology Transfer (STTR) funding by the U.S. Army Medical Research Acquisition Activity (USAMRAA), U.S. Army Medical Research and Materiel Command (USAMRMC), Defense Health Agency, CDMRP, DMRDP, and JWMRP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">K</span><sup style="font-size:7.5pt;line-height:100%;text-decoration-line:underline;text-decoration-style:solid;top:0pt;vertical-align:top;">+</sup><span style="text-decoration-line:underline;text-decoration-style:solid;">ontrol (Acute and Critical Care)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">APPLICATION: Treatment of severe hyperkalemia that can occur in patients with life-threatening conditions such as trauma, burn injury, kidney failure, tumor lysis syndrome, and those with no access to dialysis</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Potential Benefits:</span> K<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup>ontrol was developed to rapidly treat severe hyperkalemia by reducing potassium in the blood. Although hemodialysis remains the definitive treatment for severe hyperkalemia, K<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup>ontrol represents a simpler, and more flexible alternative. The primary goals for this application are to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Enable the rapid treatment of deadly hyperkalemia without the need for hemodialysis</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Prevent potentially fatal cardiac arrhythmias following severe injury</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Improve survival in victims in remote areas and during prolonged field care in combat</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Background and Rationale:</span> Potassium is an important electrolyte in the body that is present inside cells at high concentrations, with the amount in blood tightly regulated. Following injury to cells by, for example, trauma, burn injury, ischemia, or cytotoxic drugs, such cells will continuously leak high levels of potassium into the blood, resulting in hyperkalemia. The kidneys normally excrete excess potassium from the blood, but when compromised, as in critically-ill patients suffering from kidney failure or in chronic dialysis patients with end-stage kidney disease, the levels of blood potassium can rapidly rise unabated. When the potassium level in the blood exceeds a concentration of 6.0 mmol/L (normal 3.6&#160;- 5.2 mmol/L), the risk of heart arrhythmias and sudden cardiac death increases significantly. Orally administered potassium sorbents such as Kayexalate&#174; (Sanofi-Aventis) and Veltassa&#174; (Relypsa) are only recommended for the non-emergent lowering of mild to moderate hyperkalemia, while the use of insulin and glucose to drive potassium into cells in severe hyperkalemia is only a temporary strategy. Dialysis has been the definitive treatment of severe hyperkalemia, but requires a large dialysis machine, electricity, bags of dialysate, a skilled technician, and prolonged treatment times that are not practical in certain situations such as in remote locations, during prolonged field care in combat, in areas that lack modern medical facilities, or in situations where the numbers of victims outstrip available dialysis equipment and supplies. Because of this, there is a major need for simple, but effective ways to rapidly treat severe hyperkalemia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Hyperkalemia is a common problem and has been reported to occur in 1.7-5.2% of hospitalized patients in a number of studies. It has also been recognized as a serious complication of combat injury since World War II, when hyperkalemia and acute kidney injury was associated with a mortality rate of 90%, and was a leading cause of post-traumatic death in the Korean War, until the advent of dialysis therapy. In the wars in Iraq and Afghanistan, an estimated 5.8% of all combat casualties developed hyperkalemia within 48 hours of injury. Even in non-crush traumatic injury, severe hyperkalemia (&gt;6 mmol/L) occurred in approximately 20% of patients. Hyperkalemia was also observed in approximately 16% of victims of natural disasters such as earthquakes, where crush injury is common.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Projected Timeline:</span> K<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup>ontrol has demonstrated the ability to reduce potassium in several animal models of hyperkalemia and is currently being optimized with funding support from the U.S. Army and Defense Health Agency under a Phase I and Phase II SBIR contract for a total of $1.5 million and a $3 million Rapid Innovation Fund (RIF) award from the U.S. Air Force Materiel Command. We are currently discussing the potential clinical development plan of K<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup>ontrol with the FDA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">ContrastSorb (Radiology and Interventional Radiology)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">APPLICATION: Removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure, in order to reduce the risk of contrast-induced nephropathy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Potential Benefits:</span> IV contrast can lead to CIN, in susceptible patients. Risk factors include chronic kidney disease and renal insufficiency caused by age, diabetes, congestive heart failure, long-standing hypertension, and others co-morbid illnesses. CIN can lead to increased risk of patient morbidity and mortality. Removal of IV contrast by ContrastSorb may:</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">reduce the risk of acute kidney injury</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-family:'Symbol';">&#183;</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">improve the safety of these procedures and reduce the risk of morbidity and mortality</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Background and Rationale:</span> Contrast-induced nephropathy is the acute loss of renal function within the first 48 hours following IV contrast administration. IV contrast is widely administered to patients undergoing CT scans, to enhance the images and make it easier to identify anatomic structures. IV contrast is also administered during vascular interventional radiology procedures and angiography of blood vessels in the brain, heart, limbs, and other parts of the body to diagnose and treat atherosclerosis (narrowing of blood vessels due to cholesterol deposits), vascular injury, aneurysms, etc. The reported risk of CIN undergoing contrast enhanced CT scans has been reported to be 2% to 13%. For coronary intervention, the risk has been estimated to be as high as 20% to 30% in high risk patients with pre-existing renal insufficiency, and other risk factors. The use of low osmolar IV contrast, hydration of patients pre-procedure, orally administration of N-acetylcysteine, and other agents to prevent CIN have demonstrated modest benefit in some clinical studies, but in many cases, the results across studies have been equivocal and inconsistent. In high risk patients, the direct removal of IV contrast from the blood with ContrastSorb to prevent CIN represents a potentially more effective alternative.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Projected Timeline:</span> ContrastSorb has demonstrated the high efficiency single pass removal of IV contrast and is in the process of optimization. The underlying polymer is made of the same ISO 10993 biocompatible polymer as CytoSorb, but with different structural characteristics. The ContrastSorb device is a hemoperfusion device similar in construction to CytoSorb and BetaSorb. Assuming successful optimization of the ContrastSorb polymer, safety and efficacy of IV contrast removal will need to be established in human clinical studies. We seek to out-license this technology to a potential strategic partner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">The BetaSorb Device (Chronic Care)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">APPLICATION: Prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Potential Benefits:</span> If BetaSorb is able to prevent or reduce high levels of metabolic waste products from accumulating in the blood and tissues of long-term dialysis patients, we anticipate that certain health complications characteristic to these patients can be prevented or mitigated. The primary goals for this application are to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">improve and maintain the general health of dialysis patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduce disability and improve the quality of life of these patients</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduce the total cost of patient care; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increase life expectancy.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Background and Rationale:</span> Our BetaSorb device is intended for use on patients suffering from chronic kidney failure who rely on long-term dialysis therapy to sustain life. Due to the widely recognized inability of dialysis to remove larger proteins from blood, metabolic waste products, such as beta<sub style="font-size:7.5pt;vertical-align:sub;">2</sub>-microglobulin, accumulate to toxic levels and are deposited in the joints and tissues of patients. Specific toxins known to accumulate in these patients have been linked to their severe health complications, increased healthcare costs, and reduced quality of life.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Researchers also believe that the accumulation of toxins may play an important role in the significantly reduced life expectancy experienced by dialysis patients. In the U.S., the average life expectancy of a dialysis patient is five&#160;years. Industry research has identified links between many of these toxins and poor patient outcomes. If our BetaSorb device is able to routinely remove these toxins during dialysis and prevent or reduce their accumulation, we expect our BetaSorb device could maintain or improve patient health in the long-term. We believe that by reducing the incidence of health complications, the annual cost of patient care would be reduced and life expectancy increased.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The poor health experienced by beta<sub style="font-size:7.5pt;vertical-align:sub;">2</sub>-microglobulin patients is illustrated by the fact that in the U.S. alone, more than $33 billion is spent annually caring for this patient population according to the United States Renal Data System, at a cost of approximately $88,000 per patient annually.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Projected Timeline:</span> We have collected a significant amount of empirical data for the development of this application. As the developer of this technology, we had to undertake extensive research, as no comparable technology was available for reference purposes. We have completed four human pilot studies, including a clinical pilot of six patients in California for up to 24 weeks in which our BetaSorb device removed the targeted toxin, beta<sub style="font-size:7.5pt;vertical-align:sub;">2</sub>-microglobulin, as expected. In total, we have sponsored clinical studies utilizing our BetaSorb device on 20 patients involving approximately 345 total treatments. Each study was conducted by clinic or hospital personnel with us providing technical assistance as requested.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As discussed above, due to practical and economic considerations, we are focusing our efforts and resources on commercializing our CytoSorb device for critical care and cardiac surgery applications. Following commercial introduction of the CytoSorb device, and with sufficient additional resources, we may continue development of the BetaSorb resin and may conduct additional clinical studies using the BetaSorb device in the treatment of end stage renal disease patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Commercial and Research Partners</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Biocon Biologics Limited</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2013, we entered into a distribution agreement with Biocon Biologics Limited, (&#8220;Biocon&#8221;), India&#8217;s largest biopharmaceuticals company, under which Biocon was granted exclusive commercialization rights to the CytoSorb therapy in India and select emerging markets, initially focused on sepsis. Biocon committed to annual minimum purchases to maintain exclusivity. In October 2014, the Biocon partnership was expanded to include all critical care applications and cardiac surgery. In addition, Biocon committed to higher annual minimum purchases of CytoSorb to maintain distribution exclusivity and committed to conduct and publish results from multiple investigator-initiated studies and patient case studies. Under the terms of the expanded partnership, the term of the distribution agreement was extended to December 2022. We are currently negotiating an additional extension to this agreement. On May 27, 2020, Biocon announced that CytoSorb has received approval from the Drugs Controller General of India to treat COVID-19 patients in certain instances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Fresenius Medical Care AG</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2014, we entered into a multi-country strategic partnership with Fresenius Medical Care AG&#160;&amp; Co KGaA (together with its affiliates, as appropriate, &#8220;Fresenius&#8221;) to commercialize the CytoSorb therapy. Under the agreement reflecting the terms of the partnership, Fresenius was granted exclusive rights to distribute CytoSorb for critical care applications in France, Poland, Sweden, Denmark, Norway, and Finland. The partnership allows Fresenius to offer an innovative and easy way to use blood purification therapy for removing cytokines in patients that are treated in the ICU. To promote the success of CytoSorb, Fresenius agreed to also engage in the ongoing clinical development of the product. This includes the support and publication of a number of small case series and patient case reports as well as the potential for future larger, clinical collaborations. In May&#160;2016, Fresenius launched the product in the six countries for which it was granted exclusive distribution rights. In January&#160;2017, the Fresenius partnership was expanded pursuant to a revised three-year agreement. The terms of the revised agreement extended Fresenius&#8217; exclusive distributorship of CytoSorb for all critical care applications in their existing territories through 2019 and include guaranteed minimum quarterly orders and payments, evaluable every one and a half&#160;years.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At the same time, we entered into a comprehensive co-marketing agreement with Fresenius. Under the terms of the co-marketing agreement, CytoSorbents and Fresenius agreed to jointly market CytoSorb to Fresenius&#8217; critical care customer base in all countries where CytoSorb is being actively commercialized. CytoSorb continues to be sold by our direct sales force or through our international network of distributors and partners, while Fresenius sells all ancillary products to their customers. Fresenius further provides written endorsements of CytoSorb for use with their multiFiltrate and multiFiltratePRO acute care dialysis machines that can be used by us and our distribution partners to promote CytoSorb worldwide. Training and preparation for this co-marketing program began in five initial countries in 2017 and is continuing, with implementation of the co-marketing program in additional countries planned for the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2018, the Fresenius agreement signed in December 2014 was amended, to grant Fresenius exclusive distribution rights for the Czech Republic and Finland and all critical care medicine and ICU applications on dialysis or ECMO machines for France. In addition, in 2019, Poland, Sweden, Denmark, and Norway were transitioned into the co-marketing program, while guaranteed minimum quarterly purchases and payments requirements were removed. In January 2022, we converted the agreement with Fresenius in France, Finland, and the Czech Republic to be non-exclusive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, also in December 2018, we entered into agreements to expand the partnership with Fresenius into South Korea and Mexico. Under the terms of these agreements, Fresenius has exclusive rights to distribute CytoSorb for acute care and other hospital applications in South Korea and Mexico. Registration clearance was obtained from the South Korean and Mexican health authorities in 2021 and 2020, respectively. These multi-year agreements include an initial stocking order and are subject to annual minimum purchases of CytoSorb to maintain exclusivity. These agreements, which commenced on January 1, 2019, have an initial term of three years and automatically renew for an additional two years unless terminated by either party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2020, we entered into agreements to expand the partnership with Fresenius into Colombia and Ecuador.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2022, the Company entered into a Marketing Agreement (the &#8220;Marketing Agreement&#8221;) with Fresenius, which expanded the Company&#8217;s current strategic partnership with Fresenius by establishing a multi-stage global collaboration to combat life-threatening diseases in critical care. The Marketing Agreement provides for the combined marketing and promotion of CytoSorb with Fresenius&#8217; critical care products by Fresenius&#8217; marketing organization worldwide, excluding the United States. The Marketing Agreement has an initial term of three years, with an automatic renewal for an additional two years at the end of such initial term, subject to earlier termination by either of the parties (the &#8220;Term&#8221;). Compared to the prior co-marketing agreement between the parties, the Marketing Agreement intends to increase the commitments from both parties and to ensure an ongoing and consistent level of marketing and promotional activity specifically focused around CytoSorb, where Fresenius will actively market and promote CytoSorb as the featured blood purification therapy for removal of cytokines, bilirubin, and myoglobin on its critical care platforms. Specifically, the Marketing Agreement provides that various Fresenius-led in-person, virtual, social media, and web-based marketing programs and events will feature the CytoSorb therapy and highlight the cooperation between the two companies in the field of critical care during the Term. To help support the increased marketing and promotional efforts of the expanded collaboration, CytoSorbents has agreed to subsidize a portion of the marketing costs through a royalty payment to Fresenius Medical Care based on CytoSorb sales in the intensive care unit on Fresenius Medical Care platforms, excluding the United States. In addition to strengthening and expanding the global marketing of CytoSorb, the Company and Fresenius also plan to work together to bring new innovative solutions to the market. The Marketing Agreement also includes the certification of compatibility of CytoSorb for usage on Fresenius&#8217; current critical care platforms. Certain initial activities have been completed with the formal launch of this program expected to occur sometime in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Aferetica s.r.l.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2015, we entered into a distribution agreement with Aferetica s.r.l., a distributor based in Bologna, Italy that specializes in the sale of certain medical products and devices, specifically extracorporeal therapies, in the critical care, cardiac surgery and liver disease markets (&#8220;Aferetica&#8221;). Under the terms of the agreement, we granted Aferetica the exclusive right to distribute CytoSorb in Italy, San Marino and the Vatican for application in CRRT (Continuous Renal Replacement Therapies), dialysis and hemoperfusion machine run treatments, as described in the agreement. In connection with the grant of distribution rights, Aferetica agreed to certain minimum purchase and inventory requirements. Aferetica further agreed not to market or sell products competitive with CytoSorb in Italy, San Marino and the Vatican. The agreement was renewed through 2023.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, in September 2017, we announced a partnership with Aferetica to provide dedicated, branded sorbent cartridges for use with Aferetica&#8217;s proprietary PerLife&#8482; ex-vivo organ perfusion system, with the goal of rehabilitating or preserving the function solid organs destined for eventual transplant. In July 2018, Aferetica and CytoSorbents debuted the PerLife&#8482; system for organ preservation at the 27<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> International Congress of the Transplantation Society. In the fourth quarter of 2020, Aferetica announced CE Mark registration of the PerLife system. At the same time, CytoSorbents announced CE Mark approval of the ECOS-300CY cartridge for the removal of inflammatory mediators during <i style="font-style:italic;">ex vivo</i> perfusion, which has been designated, PerSorb&#8482;, a trade name exclusive to the PerLife system. In August 2021, we announced that commercialization of PerSorb(TM) and Aferetica&#8217;s PerLife(TM) <i style="font-style:italic;">ex vivo</i> organ perfusion system commenced in various European countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Terumo Cardiovascular Group</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2016, we entered into a multi-country strategic partnership with Terumo Cardiovascular Group (&#8220;Terumo&#8221;) to commercialize CytoSorb for cardiac surgery applications. Under the terms of the agreement, Terumo has exclusive rights to distribute the CytoSorb CPB procedure pack for intra-operative use during cardiac surgery in France, Sweden, Denmark, Norway, Finland and Iceland. Terumo launched CytoSorb in its six exclusive countries in December 2016. In 2021, the agreement was revised to a non-exclusive collaboration agreement in Sweden, Denmark, Norway and Iceland. This agreement allows the Company to sell directly to customers in these countries for the cardiac surgery application. supported by marketing and promotional activities with Terumo. Financial terms of this agreement have not been disclosed. This agreement expired on March 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 1, 2023, we amended and restated the original distribution agreement from October 2016. Under the terms of the amended and restated agreement, Terumo will have non-exclusive distribution rights in France to promote and sell the CytoSorb CPB procedure pack for intra-operative use during cardiac surgery at specifically named hospitals in France. The amended and restated agreement allows the Company to sell directly to other hospital customers in France for the cardiac surgery application. Financial terms of this agreement have not been disclosed. The agreement terminates on December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2020, we announced an initial collaboration with Terumo to exclusively sell CytoSorb to hospitals in ten U.S. COVID-19 hotspot states including Alabama, Arizona, California, Georgia, Louisiana, Mississippi, New Mexico, Oregon, Texas, and Washington. CytoSorb previously received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for use in adult, critically ill COVID-19 patients with imminent or confirmed respiratory failure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">B. Braun Avitum AG</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2021, we announced announce the launch of a global co-marketing agreement with B. Braun Avitum AG, one of the world&#8217;s leading manufacturers of medical devices and pharmaceutical products and services, to promote the use of CytoSorb<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> with B. Braun&#8217;s latest OMNI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> continuous blood purification platform and OMNIset<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> Plus bloodline set (set version 3.0 or higher). The CytoSorb<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> adsorber is used in critical care for the extracorporeal removal of cytokines and inflammatory mediators from the bloodstream and can be operated with the B. Braun OMNI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> acute dialysis machine. B. Braun will supply the market with the OMNI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and OMNIset<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> Plus while CytoSorbents and its network of direct sales, strategic partners, and distributors will continue to supply the market with CytoSorb<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>. This global co-marketing agreement applies to the countries where both products are registered (U.S. market is specifically excluded). Financial terms of this agreement have not been disclosed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Nikkiso Europe GmbH</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2022, the Company announced that, following a successful pilot program in three countries, the Company signed an expanded non-exclusive agreement with Nikkiso Europe GmbH (&#8220;Nikkiso&#8221;) to distribute Nikkiso&#8217;s PureADJUST stand-alone hemoperfusion pump and accessories in a total of 14 countries. In addition to securing the rights to sell Nikkiso&#8217;s stand-alone pump and accessories in Germany, Austria, and Luxembourg, the Company entered into an expanded multi-country reseller agreement with Nikkiso covering the following countries: Belgium, Bosnia and Herzegovina, Croatia, Finland, France, Iceland, Lichtenstein, Poland, Serbia, Slovenia and Switzerland. The Company will also be able to provide field support services in these countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">University of Pittsburgh Medical Center</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Two government research grants by the National Institutes of Health (&#8220;NIH&#8221;) and the U.S. Department of Health and Human Services were awarded to investigators at the University of Pittsburgh to explore the use of adsorbent polymers in the treatment of sepsis and organ transplant preservation. Under &#8220;Sub Award Agreements&#8221; with the University of Pittsburgh, we developed polymers for use in these studies.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A grant of $1 million was awarded to the University of Pittsburgh Medical Center in 2003. The project sought to improve the quantity and viability of organs donated for transplant by using CytoSorb to detoxify the donor&#8217;s blood. The observational and dosing phases of the study, involving 30 viable donors and eight non-viable donors, respectively, have been completed. The next phase of this study, the treatment phase, was planned to involve viable donors. However, we are not currently focusing our efforts on the commercialization of CytoSorb for application in organ donors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2005, the University of Pittsburgh Medical Center was awarded a grant of approximately $7 million from NIH entitled &#8220;Systems Engineering of a Pheresis Intervention for Sepsis (SEPsIS)&#8221; to study the use of our adsorbent polymer technology in the treatment of severe sepsis. The study, which lasted for a total of five&#160;years, commenced in September&#160;2005. Under a SubAward Agreement, we worked with researchers at the University of Pittsburgh&#160;- Critical Care Medicine Department. We believe that the only polymers used in this study were polymers we have developed specifically for use in the study, which are similar to the polymers used in our devices. Under the SubAward Agreement, for our efforts in support of the grant during 2006 through 2010, we received approximately $402,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Dr. John Kellum, a member of the UPMC faculty since 1994, was the Chairman of our Sepsis Advisory Board. On March 1, 2021, Dr. Kellum became the Chief Medical Officer for Toronto, Canada-based Spectral Medical, Inc. Concurrent with his appointment at Spectral, Dr. Kellum formally resigned from our Advisory Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Advisory Boards</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time our management meets with scientific advisors to obtain expert opinions on basic science, critical care medicine and cardiac surgery.We compensate all our SAB members according to fair market value and reimburse them for their travel expenses when attending meetings in person.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Royalty Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2003, in order to induce Guillermina Vega Montiel, a principal member of RenalTech International, LLC at the time, to make a $4 million investment in RenalTech International, LLC, Ms. Montiel was granted a perpetual royalty (the &#8220;Royalty&#8221;) equal to three percent of all gross revenues received by us from sales of CytoSorb in the applications of sepsis, cardiopulmonary bypass surgery, organ donor, chemotherapy and inflammation control. In addition, for her investment, Ms. Montiel received 1,230,770 membership units of RenalTech International, LLC. Such membership units ultimately were converted into and became 7,420 shares of our common stock following our June 30, 2006 merger. In February 2017, all rights, title and interest to the Royalty was assigned to The Robert Shipley Living Trust. In November 2022, all rights, title and interest to the Royalty was assigned to ROKK, LLC. For the year ended December 31, 2022 we have recorded royalty costs of approximately $849,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 1, 2022, the Company entered into the Marketing Agreement with Fresenius, which expands the Company&#8217;s strategic partnership with Fresenius by establishing a multi-stage global collaboration to combat life-threatening diseases in critical care. The Marketing Agreement has an initial term of three years, with an automatic renewal for an additional two years at the end of such initial term, subject to earlier termination by either of the parties (the &#8220;Term&#8221;) To help support the increased marketing and promotional efforts of the expanded collaboration, the Company has agreed to subsidize a portion of the marketing costs through royalty payments to Fresenius. Initially, the Marketing Agreement provides for royalty payments equal to 0.9% of the Company&#8217;s net sales of CytoSorb products made during the Term (excluding net sales in the United States). This initial royalty rate was determined based on certain assumptions regarding the percentage of the Company&#8217;s sale of CytoSorb products that are used with the Fresenius critical care platforms in the intensive care unit outside of the United States but is subject to adjustment if the Company determines that the underlying assumptions have changed significantly. For the year ended December 31, 2022, the Company did not record any expense related to this agreement as Fresenius did not commence any marketing activities as defined by the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2003, Purolite filed a lawsuit against us asserting, among other things, co-ownership and co-inventorship of certain of our patents. On September&#160;1, 2006, the United States District Court for the Eastern District of Pennsylvania approved a Stipulated Order and Settlement Agreement under which we and Purolite agreed to the settlement of the action. The Settlement Agreement provides us with the exclusive right to use our patented technology and proprietary know how relating to adsorbent polymers for a period of 18&#160;years. In particular, the Settlement Agreement relates to several of our issued patents and several of our pending patent applications covering our biocompatible polymeric resins, our methods of producing these polymers, and the methods of using the polymers to remove impurities from physiological fluids, such as blood.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Settlement Agreement, we have agreed to pay Purolite royalties of 2.5% to 5% on the sale of those of our products, if and when those products are sold commercially, that are used in direct contact with blood or, in certain cases, in direct contact with a physiological fluid other than blood. The royalty payments provided for under the Settlement Agreement would apply to our currently envisioned CytoSorb, VetResQ, and BetaSorb products. For the&#160;year ended December 31, 2022 per the terms of the license agreement we have recorded royalty costs of approximately $1,416,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Following the expiration of the 18-year term of the Settlement Agreement, the patents and patent applications that are the subject of the Settlement Agreement should have expired under current patent laws, and the technology claimed in them will be available to the public. However, we have additional issued patents separate from those in this Settlement Agreement, and patents pending worldwide that may extend patent protection of our core technology. We will also continue to exclusively own any confidential and proprietary know how.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Product Payment&#160;&amp; Reimbursement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:none;">CytoSorb</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Germany</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective January&#160;1, 2017, we achieved a dedicated reimbursement code in Germany that provides for specific and enhanced reimbursement for our CytoSorb device. We believe in most cases that this dedicated reimbursement code provides our customers in Germany with reimbursement that not only covers the cost of the device, but the procedural costs as well. Reimbursement can also be covered by the standard &#8220;diagnosis related group&#8221; (&#8220;DRG&#8221;) acute care reimbursement. Under this system, hospitals would purchase CytoSorb and subtract the cost from a pre-determined lump-sum payment made by the payor to the hospital based on the patient&#8217;s diagnosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Switzerland</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2019, CytoSorb was assigned a procedure code from the Swiss Federal Statistical Office, a division of the Federal Department of Home Affairs in Switzerland under the category &#8220;Adsorption of Cytokines and Interleukin&#8221;. During 2020, this code category was replaced by a new category entitled &#8220;Extracorporeal Adsorption of Specific Substances&#8221;. Use of this code gives Swiss hospitals the ability to collect cost data related to CytoSorb treatments. In 2021, SwissDRG performed the first cost analysis of CytoSorb. This analysis showed that there were no additional treatment costs associated with use of CytoSorb against the relevant DRGs, suggesting CytoSorb may be cost neutral or even cost-saving across all indications. The Company is working with these Swiss hospitals to publish the analysis. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Europe (excluding Germany and Switzerland)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Payment for our CytoSorb device in patients with life-threatening illnesses is country dependent in Europe. Most European markets issue reimbursement for standard therapies only, i.e. those recommended in relevant treatment guidelines. The Company is currently conducting randomized controlled trials (RCTs) to achieve this in all major indications. In the meantime, we are leveraging health economics, local data generation and KOL management in all major territories, with our partners and local sales teams, such as France, England, Italy, Spain, Russia, Belgium, Netherlands, Luxembourg, Poland, Sweden, Norway, Denmark and Finland. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United Kingdom, market access and reimbursement of drugs, medical devices and diagnostics is heavily dependent on the guidance published by the National Institute for Health and Care Excellence (NICE). In 2021, NICE published its report on CytoSorb for the removal of ticagrelor in urgent and emergent cardiac surgery patients in a MedTech Innovation Briefing (MIB) called &#8220;CytoSorb for reducing risk of bleeding during cardiac surgery&#8221;. The MIB highlights the safety and efficacy of CytoSorb in this indication, as well its innovative nature and the substantial cost savings CytoSorb generates and has aided adoption in the UK. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Markets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CytoSorb is currently marketed and distributed in more than 75 countries around the world. It is generally paid for through the standard DRG (diagnosis related group) payment, dedicated reimbursement codes, tender orders, private insurance, and/or self-pay. We are actively pursuing generation of new procedure codes in many countries we are currently serving. Across all countries, we are mitigating financial barriers though use of health economics, local data generation and targeted KOL management.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2022, we disclosed that the Israeli Ministry of Health (MoH) had approved national reimbursement for CytoSorb in certain cardiac surgery indications, including the intraoperative treatment for urgent or emergency cardiac surgery in patients treated with ticagrelor or rivaroxaban, the intraoperative treatment during cardiac surgery in patients with acute infective endocarditis, and the intraoperative treatment during surgery for correction of aortic dissection. In the same month, we announced that the Turkish Ministry of Health had approved national reimbursement for CytoSorb, which is now a reimbursed catalog product in the State Supply Office of Turkey (DMO) portal and can be purchased directly by hospitals and physicians without restrictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">United States</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Critical care applications such as those targeted by our CytoSorb device involve a high mortality rate and extended hospitalization, coupled with extremely expensive ICU time. In view of these high costs and high mortality rates, we believe acceptance of our proprietary technology by critical care practitioners and hospital administrators will primarily depend on safety and efficacy factors rather than solely based on cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CytoSorb is not yet approved in the U.S. but has received FDA Emergency Use Authorization in April 2020 for use in adult critically ill COVID-19 patients with imminent or confirmed respiratory failure. There is currently no specific reimbursement for CytoSorb in the U.S. Payment for our CytoSorb device in the U.S. for this application falls under the DRG prospective repayment system, which is currently the predominant inpatient hospital reimbursement methodology in the U.S., that was increased for COVID-19 applications as part of the CARES Act. Under this system, hospital reimbursement is generally based upon pre-determined amounts payable for specific diagnoses (e.g. septic shock with respiratory failure), regardless of the number of services provided during the patient&#8217;s stay. If CytoSorb can improve outcomes and reduce the costs of ICU treatment and hospital length of stay, it could potentially save hospitals a significant amount of money.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2021, the Centers for the Centers for Medicare &amp; Medicaid Services (CMS) announced the Medicare Coverage of Innovative Technology (MCIT) pathway that will provide national Medicare coverage as early as the same day as FDA market authorization for Breakthrough Designated medical devices, where coverage would last 4 years. Although this program was rescinded by CMS in November 2021, a legislative version of the program is currently contained within the CARES 2.0 bill, though not yet approved. In addition, CMS has announced a new initiative called &#8220;Transitional Coverage for Emerging Technologies&#8221; (TCET) as a potential replacement for MCIT, with more detail planned for April 2023. &#160;If passed, either of these programs may be applicable to DrugSorb-ATR, if it can achieve U.S. approval for the removal of ticagrelor and Direct Oral Anticoagulants (DOACs) apixaban and rivaroxaban during emergent or urgent cardiothoracic surgery. These indications were granted FDA Breakthrough Designation in April 2020 and August 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">General</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our core adsorbent porous polymer bead technology is used in our marketed products, such as the CytoSorb, ECOS-300CY, and VetResQ cartridges, and other products under advanced development, such as CytoSorb XL and DrugSorb-ATR. We believe these products represent a unique approach to disease states and health complications associated with the presence of larger toxins (often referred to as middle molecular weight toxins) and poorly dialyzable drugs in the bloodstream, including sepsis, acute respiratory distress syndrome, trauma, severe burn injury, pancreatitis, post-operative complications of cardiac surgery, damage to organs donated for transplant prior to organ harvest, renal disease and drug intoxication. For example, researchers have explored the potential of using standard membrane-based dialysis technology to treat patients suffering from sepsis. These techniques are unable to effectively remove the middle molecular weight toxins. We have demonstrated the ability of CytoSorb to reduce key cytokines in the blood of human patients with predominantly septic shock and acute respiratory distress syndrome. In a post-hoc subgroup analysis of our European Sepsis Trial, we have also demonstrated statistically significant improvements in mortality in patients at high risk of death, including patients with either very high cytokine levels or patients older than age 65, both of which have a high predicted mortality. Larger studies are needed to confirm these preliminary data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are three common forms of blood purification, including hemodialysis, hemofiltration, and hemoperfusion. All modes are generally supported by standard hemodialysis machines. All take blood out of the body to remove toxins and unwanted substances from blood, and utilize extracorporeal circuits and blood pumps. Dialysis and hemofiltration remove substances from blood by diffusion and ultrafiltration, respectively, through a semi-permeable membrane, allowing the passage of certain sized molecules across the membrane, but preventing the passage of other, larger molecules. Hemoperfusion utilizes solid or porous sorbents to remove substances based on pore capture and surface adsorption, not filtration.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CytoSorb is a hemoperfusion cartridge, using an adsorbent of specified pore size, which controls the size of the molecules which can pass into the adsorbent and vastly increases the area available for surface adsorption. As blood flows over our polymer adsorbent, middle molecules such as cytokines flow into the polymer adsorbent and are adsorbed. Our devices do not use semipermeable membranes or dialysate. In addition, our devices do not remove fluids from the blood like hemodialysis or hemofiltration. Accordingly, we believe that our technology has significant advantages as compared to traditional dialysis techniques, including ease of use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our HemoDefend platform is a development-stage technology utilizing a mixture of proprietary porous polymer beads that target the removal of contaminants that can cause transfusion reactions or cause disease in patients receiving transfused blood products. The HemoDefend beads can be used in multiple configurations, including the common in-line filter between the blood bag and the patient as well as a unique, patent-pending &#8220;Beads in a Bag&#8221; treatment configuration, where the beads are placed directly into a blood storage bag.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Sepsis</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Researchers have explored the potential of using existing membrane-based dialysis technologies to treat patients suffering from sepsis. These techniques are unable to effectively remove middle molecular weight toxins, which leading researchers have shown to cause and complicate sepsis. The same experts believe that a blood purification technique that efficiently removes, or significantly reduces, the circulating concentrations of such toxins might represent a successful therapeutic option. CytoSorb has demonstrated the ability to remove middle molecular weight toxins, such as cytokines, from circulating blood in a statistically significant manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Medical research during the past two decades has focused on drug interventions aimed at chemically blocking or suppressing the function of one or two inflammatory agents. In hindsight, some researchers now believe this approach has little chance of significantly improving patient outcomes because of the complex pathways and multiple chemical factors at play. Clinical studies of these drug therapies have been largely unsuccessful. An Eli Lilly drug, Xigris&#174;, cleared by the FDA in November&#160;2001, is the first and only drug to be approved for the treatment of severe sepsis. Clinical studies demonstrated that use of Xigris&#174; resulted in an average absolute 6% reduction in 28-day mortality, and an absolute 13% reduction in 28-day mortality in the most severe sepsis patients. The drug was controversial and considered expensive when compared to the&#160;percentage of patients who benefit. In 2011, after completing a follow up study required by the FDA, it was subsequently determined that Xigris&#174; did not have a statistically significant mortality benefit, and in October&#160;2011, Eli Lilly withdrew Xigris&#174; from all markets worldwide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Development of many experimental therapies has been discontinued, including Eritoran from Eisai, CytoFab from BTG/Astra Zeneca, Talactoferrin from Agennix, tranexemic acid from Leading Biosciences, selective cytapheresis from CytoPheryx, and others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">COVID-19 disrupted many clinical studies in 2020 and 2021. Notable active Phase III trials in sepsis include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Initiated in November&#160;2012, the 800 patient Phase III randomized controlled SCARLET study began for Recomodulin (ART 123, Artisan/Asahi Kasei), a recombinant human thrombomodulin, for the treatment of septic patients with coagulopathy. In 2019, the results of the study were published in JAMA, demonstrating no benefit in 28-day all-cause mortality. The 800 patient Phase III SCARLET-2 randomized, controlled trial, evaluating Recomodulin in patients with sepsis and coagulopathy, was scheduled to begin in July&#160;2019, but was withdrawn to be amended following the results of the SCARLET trial. The status of the trial is unknown.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Atox Bio, a development stage company in clinical studies with peptide therapeutics that are designed to prevent superactivation of the immune response by certain toxins such as toxic shock syndrome toxin. It is currently focused on necrotizing soft tissue infections. The investigational peptide, AB103 or Reltecimod, binds to the CD28 co-stimulatory receptor to attempt to restore the host&#8217;s appropriate immune response to severe infections and was evaluated in the ACCUTE Trial, a Phase III randomized controlled trial in 60 investigative sites in the U.S in 290 patients with necrotizing soft tissue infections. The primary endpoint of the study was based on a modified Intent-to-treat (mITT) analysis of a primary composite endpoint that was defined as: alive at day 28, &#8804; 3 debridements, no amputation beyond first operation, and day 14 mSOFA &#8804; 1 with &#8805; 3 point reduction (organ dysfunction resolution). A prespecified, per protocol (PP) analysis excluded 17 patients with major protocol violations before unblinding. There was no difference in 28-day mortality of 15% in each group, and the study did not reach significant improvement in the primary endpoint in the pre-defined mITT population. However, in the PP analysis that excluded 17 patients, the company claims clinical composite endpoint success of 54.3% treatment vs 40.3% control. In December 2020, Atox Bio announced that they had filed an NDA under the FDA Accelerated Approval Program with a PDUFA date of September 30, 2021. To date, no publicly available update has been provided.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Spectral Medical,&#160;Inc. collaborated with Toray on the EUPHRATES trial, combining an endotoxin assay with extracorporeal endotoxin removal by Toraymyxin, a polymyxin-B immobilized polystyrene fiber cartridge. The study began in June&#160;2010 and completed enrollment of 450 patients in June&#160;2016. Endotoxemia is a result of Gram negative sepsis, which only accounts for 45% of cases of sepsis. It is a potent stimulator of cytokine storm. However, all anti-endotoxin strategies have failed pivotal studies to date, believed to be the result of intervening too late in the sepsis cascade. In October&#160;2016, Spectral announced top-line results that the trial did not meet the main goal of absolute reduction in 28-day all-cause mortality, but reiterated safety of treatment and potential benefit in the sickest group of patients (multiple organ dysfunction score &gt; 9). A secondary analysis of the sub-population of patients with septic shock and high circulating endotoxin activity also failed to demonstrate a beneficial effect of Toraymyxin on 28-day mortality in sepsis, however, an exploratory post-hoc analysis of the suggested trends toward improvements in changes in mean arterial pressure and ventilator-free&#160;days. In February&#160;2019, Spectral announced an amendment of the original EUPHRATES trial to enroll an additional 150 septic shock patients under the TIGRIS expansion, in patients with a MODS score &gt; 9 and an EAA level between 0.60 and 0.90, and will analyze the combined data from these two trials using a Bayesian statistical approach. Based on the 179 patients from the EUPHRATES trial, treated patients had a mortality of 38% (N=90) compared to 48% mortality in the control (N=89), but not statistically significant. The TIGRIS study will be in US sites only, randomized (2:1), open label trial, with an additional 150 new patients (100 treated, 50 control) to be added. As of January 12, 2023, 50 patients of the targeted 150 patients have been enrolled, with an expansion of trial sites to a total of 25, with 15 currently active.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Enlivex has developed an investigational cell-based therapy called Allocetra that is an infusion of donor mononuclear cells that have been chemically induced to be apoptotic. Once infused, the patient&#8217;s macrophages and dendritic cells phagocytose these apoptotic cells which purportedly then causes them to reduce inflammatory signals that results in immune modulation. In September 2021, Enlivex announced the start of a Phase IIb study using Allocetra in severe and critical COVID-19 patients with acute respiratory distress syndrome (ARDS). In November 2021, Enlivex reported that Allocetra is being evaluated in a randomized, controlled, Phase II multi-center trial in patients with pneumonia-associated sepsis. It is expected to enroll 120-160 patients across 4 cohorts of varying doses of Allocetra or placebo. The primary endpoints of the trial are safety and change in SOFA score from baseline at 28 days. As of February 2023, enrollment has not been disclosed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2017, a single center, retrospective, non-randomized, unblinded before-after clinical study evaluating the effect of hydrocortisone, intravenous Vitamin C, and thiamine in a total of 94 patients with severe sepsis and septic shock was published suggesting a significant decrease in hospital mortality of 8.5% (4 of 47 treated) versus mortality of 40.4% (19 of 47 control), p&lt;0.001. Mechanistically, Vitamin C is an antioxidant that scavenges free oxygen radicals, and plays a role in preserving endothelial function and microcirculatory flow. Thiamine is a co-factor of pyruvate dehydrogenase that is a key step in the conversion of lactate to pyruvate to acetyl-CoA, then to the Krebs cycle, leading to a consumption of lactate. Steroids are anti-inflammatory. Vitamin C or steroids alone have not demonstrated a significant benefit in patients with severe sepsis and septic shock in large scale clinical trials. Also, multiple large scale randomized controlled trials have since failed to demonstrate clinical or mortality benefit including VICTAS, VITAMINS, ACTS, and others. The authors of these studies do not recommend the routine use of the combination of Vitamin C, corticosteroids, and thiamine in septic shock patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Using a medical device to treat sepsis remains a relatively novel treatment approach. Toray Industries currently markets an endotoxin removal cartridge called Toraymyxin&#8482; for the treatment of sepsis in Europe, Japan, and 16 other countries, but is not yet approved in the United States. Toraymyxin does not directly reduce cytokines. Spectral Medical&#160;Inc. has obtained exclusive development and commercial rights in the U.S. for Toraymyxin, with plans to combine the use of its endotoxin activity assay to create a theranostic product. Spectral collaborated with Toray on the EUPHRATES trial. As noted above, the EUPHRATES trial failed to demonstrate its primary endpoint. Spectral is now pursuing an amendment to the EUPHRATES trial, called TIGRIS. There have been now several large scale studies failing to demonstrate a benefit of Toraymyxin on 28-day mortality in sepsis. Toraymyxin represents a competitive, although potentially complementary, therapeutic approach to CytoSorb.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2017, Baxter re-launched oXiris in the E.U., a hollow-fiber acrylonitrile and methalylsulfonate (AN69) membrane hemofilter coated with polyethyleneimine (PEI) that was originally launched by Gambro in 2008 for use in hemodialysis as a strategy to treat acute kidney injury and gram negative septic shock while reducing endotoxin. The filter itself has not changed. However, Baxter has expanded the label to now include reduction of cytokines based on a set of <i style="font-style:italic;">in vitro</i> experiments evaluating cytokine reduction from recirculating plasma over two hours. As of February 2022, clinicaltrials.gov currently lists 12 small studies recruiting, evaluating oXiris in the fields of sepsis and cardiac surgery. In 2020, oXiris received FDA Emergency Use Authorization for use in adult critically ill COVID-19 patients in imminent or confirmed respiratory failure. In October 2020, results from 4 hospitals on 37 patients from its OxirisNet Registry in the journal, Critical Care. Mortality was 66.6% in patients receiving oXiris treatment after 14 days from admission, and a mortality of 47.4% mortality when used earlier. In addition, Baxter also launched the Theranova mid-molecular weight cutoff or high retention onset (HRO) hemodialysis membrane outside the U.S. to improve the efficiency of hemodialysis, claiming improved mid-molecular weight substance removal. Neither oXiris nor Theranova are approved in the U.S. for treatment of sepsis or respiratory failure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each of the following technologies claims to remove inflammatory mediators such as cytokines, or to treat sepsis, and represents a potential competitive alternative to CytoSorb. However, to our knowledge, none of these technologies are approved in the U.S. and none are approved in the European Union to reduce cytokines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Toray markets its Hemofeel CH1.0 polymethylmethacrylate membrane (&#8220;PMMA&#8221;) in Japan and it has been used in several non-controlled, or historically controlled, clinical or case studies treating patients with sepsis, acute respiratory distress syndrome and pancreatitis. We are not aware of any prospective, randomized controlled studies using this PMMA hemofilter in patients with sepsis. Without such studies, it is difficult to assess the true impact of this technology in these conditions. Gambro AB launched its Prismaflex eXeed system in August&#160;2009 and introduced the SepteX high molecular weight cutoff hemodialyzer in Europe, intended to treat patients with acute renal failure and the removal of inflammatory mediators from blood. Gambro also launched the oXiris dialyzer, based upon the AN69 CRRT membrane, to bind endotoxin. As noted above, Baxter acquired Gambro in 2013. Fresenius had launched a high molecular weight cut off filter in response to SepteX called the Ultraflux EMiC2. To our knowledge, there has been a lack of published data on the treatment of sepsis with these devices. Bellco S.R.L, acquired by Medtronic in February&#160;2016, also sells the CPFA (coupled plasma filtration and adsorption) system in Europe. This uses a sorbent cartridge to remove cytokines from plasma. However, because the sorbent cannot treat blood directly, it requires the cost and complexity of an additional plasma separator to treat blood. In April&#160;2018, Medtronic issued a field safety notice informing all users of CPFA that the COMPACT-2 study using CPFA in septic shock patients was terminated early due to observed higher mortality rates in septic shock patients receiving CPFA therapy compared to patients receiving standard care. We believe that CytoSorb, which can treat whole blood directly, and which works with standard hemodialysis pumps already found in hospitals worldwide, has significant competitive advantages compared to these multi-cartridge sorbent systems.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Kaneka Corporation currently markets Lixelle&#8482;, a modified porous cellulosic bead, for the removal of beta<sub style="font-size:7.5pt;vertical-align:sub;">2</sub>&#8211;microglobulin during hemodialysis in Japan. To our knowledge, no large, randomized, controlled trials have been conducted with Lixelle as a treatment for sepsis. Kaneka obtained U.S. humanitarian device exemption for Lixelle in March&#160;2015, but is restricted to treating amyloidosis in chronic dialysis patients. To our knowledge, none of the following technologies are approved in the U.S. and none are approved for cytokine reduction or as a therapy to treat sepsis in the EU. Jafron Biomedical is an integrated dialysis public company in China selling dialysis machines and hemodialysis and hemoperfusion cartridges containing a neutral microporous adsorption resin to purify blood of toxins in liver failure, critical illness, poisoning, and autoimmune diseases. According to clinicaltrials.gov, there are 5 investigator-initiated studies evaluating Jafron&#8217;s technology in sepsis, cardiac and respiratory failure and liver disease. Jafron is currently recruiting a 144 patient efficacy and safety study in China using its CA330 cartridge to reduce IL-6 in septic patients. The status of the trial has not been updated since February 2019. Another investigator-initiated RCT evaluating the HA-330 device in 200 patients with norepinephrine-resistant septic shock (CLEANSE) began in Thailand in November 2021 and is still enrolling. Foshan Biosun Medical Technology Co, Ltd, and Baihe Medical Technology Co, market hemoperfusion cartridges under the BioSky brand name, including the MG series claiming cytokine reduction, and the DX series for bilirubin reduction. ExThera Medical Corporation is a privately held company that has developed its Seraph&#8482; (Selective Removal by Apheresis) platform that consists of heparin coated, solid polyurethane beads. Heparin has the ability to bind some, but not all viruses, bacteria, toxins and cytokines. In in vitro studies using 1 mL of human septic blood, there was no statistically different change in IL-6 or Interferon-gamma compared to control, but effected a ~50% reduction in TNF-alpha. This inability to remove a broad range of cytokines will likely limit its efficacy as a treatment in sepsis. It has repositioned Seraph&#8482; as a pathogen removal technology, and has completed a 15 patient CE Mark registration trial in Germany evaluating the safety and efficacy of bacterial removal from blood. It received EU CE-Mark approval in July 2019, and established distribution in Germany, Italy and Benelux. In 2020, Seraph received FDA Emergency Use Authorization for use in adult critically ill COVID-19 patients to reduce pathogens and inflammatory mediators from the bloodstream. In 2021 and 2022, Exthera expanded distribution to market Seraph in select European countries and Mexico with Fresenius to remove certain bacterial and viral pathogens during dialysis. We believe our CytoSorb cartridge has significant competitive, technological, and/or economic advantages over systems by these other companies.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Acute Respiratory Distress Syndrome</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Treatment of ARDS is predominantly supportive care using supplemental oxygen, careful fluid management, multiple modes of ventilation incorporating the concepts of low tidal volume, ventilation and prone positioning, and extracorporeal membrane oxygenation (&#8220;ECMO&#8221;). Although a number of pharmacologic therapies have been tried such as nitric oxide, surfactant therapy, and others, only corticosteroids, such a dexamethasone or methylprednisolone, have demonstrated mortality benefit in patients with ARDS. For example, in critically ill COVID-19 patients on mechanical ventilation, the RECOVERY study demonstrated use of once daily dexamethasone led to a reduction in mortality from 41.4% control to 29.3% treatment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See &#8220;Markets: Acute Respiratory Distress Syndrome&#8221; above for a more detailed discussion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Severe Burn Injury</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Modern management of severe burn injury patients involves a combination of therapies. From a burn standpoint, patients undergo active escharotomy and debridement of burns, the use of skin grafts and substitutes, anti-microbial dressings and negative pressure dressings. Tight fluid control, nutrition, prevention of hypothermia and infection are also priorities. Smoke and chemical inhalation injury in burn victims is also common and increasing as a cause of death in severe burn injury. Carbon monoxide and cyanide poisoning is also an issue. Supplemental oxygen, mechanical ventilation, and ECMO are often required and are the mainstay of supportive care treatment. Recently continuous renal replacement therapy has been used to treat patients with acute kidney injury with an improvement in survival compared to a historical control cohort. We believe CytoSorb therapy may yield improved results. We are not aware of any specific products approved to directly address inhalational lung injury or multiple organ failure in severe burn injury.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Trauma</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Trauma management initially involves respiratory, hemodynamic and physical stabilization of the patient. However, in the&#160;days to weeks that ensue, the focus shifts to preventing or treating organ failure and preventing or treating infection. We are not aware of any specific therapies to prevent or treat multiple organ dysfunction or multiple organ failure in trauma. Rhabdomyolysis, or the breakdown of muscle fibers due to crush injury or other means, occurs in trauma and can lead to acute kidney injury or renal failure. Aggressive hydration, urine alkalinization, and forced diuresis are the main therapies to prevent renal injury. Continuous hemodiafiltration with super-high-flux membranes has demonstrated modest myoglobin clearance but was associated with albumin loss. In general, however, most extracorporeal therapies are not well-suited to remove myoglobin. CytoSorb reduces myoglobin, and other polymers under development, reduces myoglobin, some without significant losses of albumin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Severe Acute Pancreatitis</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Treatment of severe acute pancreatitis is predominantly supportive care focused on aggressive hydration, enteral nutrition and pain control. Mechanical ventilation, hemodialysis and vasopressor use is common in cases of multiple organ failure. In cases where cholelithiasis or other obstruction is the underlying cause of the pancreatitis, endoscopic retrograde cholangiopancreatography and/or stent placement can be used to relieve the obstruction. Antibiotics are often instituted to prevent or treat infection. Surgery is sometimes indicated to remove or drain necrotic or infected portions of the pancreas. To our knowledge, there are no other specific treatments approved to treat severe acute pancreatitis or multiple organ failure that is caused by systemic inflammation in this disease.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Cardiopulmonary Bypass Surgery</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Previously, leukocyte reduction filters sold by Pall Corporation, Terumo Medical Corporation and others were used in the cardiopulmonary bypass circuit to reduce cytokine-producing white blood cells from blood. They did not remove cytokines, free hemoglobin, or activated complement directly and were not considered by many to be an effective solution for the reduction of these substances. Other than blood compatible sorbent technologies, we are not aware of any practical competitive approaches for removing cytokines, free hemoglobin, activated complement, and a broad range of other inflammatory mediators in patients undergoing cardiopulmonary bypass during cardiac surgery. To our knowledge, CytoSorb is the leading cytokine reduction therapy capable of being placed directly into a bypass circuit in the heart-lung machine and used during cardiopulmonary bypass without the need for another pump. Modified ultrafiltration is sometimes used after termination of cardiopulmonary bypass in cardiac surgery to remove excess fluid and inflammatory substances, but has had mixed benefit. Cell saver machines that collect and wash pericardial shed blood is one potential alternative, but is typically done in batches and not a real-time filter during surgery. Alternative therapies such as &#8220;off-pump&#8221; surgeries are available but &#8220;post-bypass&#8221; syndrome and cytokine production still remain a problem in this less invasive, but more technically challenging procedure. CytoSorb has been used in both on-pump and off-pump procedures. CytoSorb is also being used with a dialysis machine to treat the development of a post-cardiac surgery systemic inflammatory response syndrome, a deadly complication of open-heart surgery that if left untreated, can lead to multiple organ dysfunction syndrome, multiple organ failure, and potentially death.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Radiocontrast Removal</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ContrastSorb has demonstrated the rapid, high efficiency single pass removal of IV contrast. The use of low osmolar IV contrast, oral administration of N-acetylcysteine, and other agents to prevent CIN have demonstrated modest benefit in some clinical studies, but in many cases, the results across studies have been equivocal and inconsistent. Hydration of high risk patients pre-procedure is standard of care but has limited efficacy. PLC Medical Systems,&#160;Inc., now Renalguard Solutions, received CE Mark approval for its RenalGuard system in 2007. RenalGuard encourages excretion of IV contrast and a reduction of CIN, by administering IV hydration that matches urine output in patients receiving a loop diuretic. Hemodialysis can remove IV contrast, but is relatively slow (46% at 1 hour, 65% at 2 hours, and 75% at 3 hours) in chronic renal failure patients who lack normal renal clearance. In high risk patients, the rapid and direct removal of IV contrast from the blood with ContrastSorb to prevent CIN represents a potentially more effective alternative.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Drug Intoxication</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Treatment of patients suffering from drug overdose often involves a number of pharmacological treatments and mechanical interventions to detoxify and stabilize the patient. Mechanical interventions include procedures such as gastric lavage, activated charcoal, whole bowel irrigation and extracorporeal blood purification. Each method has its own limitations, many of which are associated with the timing of administration following overdose. Blood purification with therapeutic plasma exchange, high flux dialyzers or with activated charcoal cartridges by Gambro, Fresenius, Nephros and others are typically efficient at removing hydrophilic drugs that are not protein bound. However, they are inefficient at removing drugs that have a large volume of distribution, or drugs that are hydrophobic or lipophilic. Many drugs of overdose fall into this category. The administration of lipid emulsions, such as Intralipid, have been used with some success to create a depot for lipophilic drugs. Resin based hemoperfusion devices have been used to remove lipophilic drugs that are protein bound, but have historically had issues of biocompatibility. DrugSorb is a highly biocompatible resin-based hemoperfusion device that can remove a wide range of drugs of overdose <i style="font-style:italic;">in vitro</i> very rapidly, with high single pass removal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Chronic Dialysis</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although standard dialysis treatment effectively removes urea and creatinine from the blood stream (which are normally filtered by functioning kidneys), standard dialysis has not been effective in removing beta<sub style="font-size:7.5pt;vertical-align:sub;">2</sub> -microglobulin toxins from the blood of patients suffering from chronic kidney failure. High flux dialyzers, and mid to high molecular weight cutoff filters by Baxter, Fresenius, Nephros and others are capable of removing some beta<sub style="font-size:7.5pt;vertical-align:sub;">2</sub>-microglobulin. However, we believe our technology would significantly improve clearance of this and other toxins. Kaneka markets Lixelle&#8482;, a cellulosic resin, outside the US to remove beta<sub style="font-size:7.5pt;vertical-align:sub;">2</sub>-microglobulin in dialysis patients. In March 2015, Lixelle received Humanitarian Device Exemption (&#8220;HDE&#8221;) approval in the U.S. for the treatment of beta-amyloidosis and removal of beta<sub style="font-size:7.5pt;vertical-align:sub;">2</sub>&#8211;microglobulin, a complication of chronic dialysis. HDE approval applies to the treatment of diseases with an incidence of less than 8,000 cases a year in the U.S. annually. Other than those mentioned above and blood compatible sorbents, we know of no other device, medication or therapy considered directly competitive with our technology. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Use for Organ Transplant in </span><i style="font-style:italic;text-decoration-line:underline;text-decoration-style:solid;">Ex Vivo</i><span style="text-decoration-line:underline;text-decoration-style:solid;"> Organ Perfusion Systems </span><span style="text-decoration-line:none;">or in the</span><span style="text-decoration-line:underline;text-decoration-style:solid;"> Treatment of Organ Dysfunction in Brain-Dead Organ Donors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are not aware of any directly competitive products to address the application of our technology for the mitigation of organ dysfunction and failure resulting from severe inflammation following brain-death, <i style="font-style:italic;">or in the removal of inflammatory mediators during ex vivo organ perfusion</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Removal of Antithrombotics such as Ticagrelor and Direct Oral Anticoagulants in Cardiac Patients During Surgery Requiring Cardiopulmonary Bypass</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are more than $20 billion in annual worldwide sales of anti-thrombotic drugs such as the P2Y<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">12</sup> platelet inhibitors (e.g. clopidogrel, ticagrelor, prasugrel), and the Direct Oral AntiCoagulants (DOAC) comprising of direct thrombin inhibitors (dabigatran), and Factor Xa inhibitors (e.g. apixaban, rivaroxaban, edoxaban). These are generally used to reduce thromboembolic events in a wide range of applications, including dual anti-platelet therapy in percutaneous coronary intervention and stent placement, myocardial infarction, stroke, peripheral artery disease, atrial fibrillation, deep vein thrombosis, pulmonary embolus, and others. For example, ticagrelor (Brilinta&#174;, Astra Zeneca) is a widely-used anti-platelet agent used to decrease cardiovascular risk in patients with acute coronary syndromes or a past history of heart attack. It is also widely used during as part of the dual-anti platelet therapy regimen in patients undergoing percutaneous coronary intervention and stent placement. However, when patients on ticagrelor require emergent or urgent cardiac surgery, up to 65% of patients will have severe or massive peri-operative bleeding complications that contributes to a high risk of morbidity and death and major costs to the healthcare system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To our knowledge, CytoSorb is the only therapy approved for the removal of ticagrelor and rivaroxaban (Xarelto&#174;, Janssen, Bayer) in the E.U. during cardiopulmonary bypass in urgent or emergent cardiopulmonary bypass. The only recommended alternative is to wait for 3 to 5 days to allow natural drug elimination and washout prior to surgery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CytoSorb has already demonstrated the ability to remove ticagrelor rapidly and efficiently from human blood <i style="font-style:italic;">in vitro</i>. Meanwhile, a retrospective case series reported by clinicians at Asklepios Klinik St. Georg in Hamburg, Germany on the investigational use of CytoSorb to reverse the effects of ticagrelor and the Factor Xa inhibitor, rivaroxaban, during emergency cardiac surgery demonstrated a greatly reduced risk of bleeding complications and the need for repeat surgery to explore the source of bleeding. Extrapolations of the clinical benefits showed projected cost savings of &#163;3,982, or approximately $5,000 USD, per patient in a U.K. based economics study. In 2020, CytoSorb received E.U. CE Mark label expansion to remove ticagrelor and rivaroxaban during cardiac surgery involving cardiopulmonary bypass via label expansion of its CE Mark. In 2021, we also began enrolling the STAR (Safe and Timely Antithrombotic Removal) international registry collecting real world evidence in this application. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the U.S., we are currently executing the U.S. STAR-T (Safe and Timely Antithrombotic Removal of Ticagrelor, ) pivotal randomized, controlled clinical trials designed to support U.S. FDA Marketing approval of the DrugSorb-ATR antithrombotic removal system, which uses an equivalent polymer technology to CytoSorb.The use of platelet transfusions, Kcentra<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (CSL Behring; four factor prothrombin complex concentrate; reversal for warfarin anticoagulation), Andexxa<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (recombinant Factor Xa; AstraZeneca; reversal for rivaroxaban and apixaban), Praxbind<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (idarucizumab, Boeringer Ingelheim; reversal agent for dabigatran) and other interventions have either not demonstrated consistent benefit, or are not used because of potential safety concerns, in the reversal of antithrombotics in the setting of cardiopulmonary bypass. We anticipate resuming the STAR-D (Safe and Timely Antithrombotic Removal of DOACs) trial upon completion of the STAR-T trial.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">PhaseBio, a now defunct clinical-stage biopharmaceutical company, had licensed an intravenously administered monoclonal antibody fragment with high affinity reversal agent for ticagrelor called bentracimab (PB2452) from Medimmune, a division of AstraZeneca. PhaseBio paid AstraZeneca $100,000 upfront, with $68 million in potential future milestones. &#160;AstraZeneca owned approximately 5% of PhaseBio&#8217;s stock. The FDA granted Breakthrough Therapy designation for PB2452 in April 2019. &#160;PhaseBio was conducting its U.S. REVERSE-IT (Rapid and SustainEd ReVERSal of TicagrElor &#8211; Intervention Trial) study, a Phase 3, prospective, multi-center, open-label, single-arm trial designed to study reversal of the antiplatelet effects of ticagrelor with bentracimab to treat patients who present with uncontrolled major or life-threatening bleeding or when used prophylactically in patients who require urgent surgery or an invasive procedure to prevent bleeding. In November 2021, PhaseBio presented top-line data from an interim analysis of the study, having enrolled 142 patients who required urgent surgery or an invasive procedure and 8 patients with an uncontrolled major or life-threatening bleed. For the end-point analysis, 129 patients had analyzable platelet data, 122 had data on adjudicated hemostasis. Investigators reported a rapid reversal of anti-platelet activity in both subgroups. Among surgical patients, 66.4% had mild GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries bleeding scale) bleeding, and 33.6% had moderate GUSTO bleeding perioperatively. Treatment-emergent adverse events (i.e. adverse events that were not present prior to treatment initiation or an event already present that worsens in either intensity or frequency following exposure to the treatment) were reported by 92.7% of enrolled patients. Four patients died (2.8%): two with septic shock, and two with cardiogenic shock. Of 150 patients, eight patients (5.3%) had thrombotic events, including two ischemic strokes, one transient ischemic attack, three myocardial infarctions, and two with arterial thromboembolisms in the right lower extremity. The FDA had recommended an interim analysis of approximately 100 patients, comprising approximately 50 patients in each arm, in order to support the submission of a Biologics License Application (BLA) for accelerated approval of bentracimab. In November 2021, PhaseBio announced that it continues to enroll more patients into the uncontrolled major or life-threatening bleeding arm of the study and intends to submit a BLA for both subgroups by Summer 2022. &#160;However, in October 2022, PhaseBio filed for Chapter 11 bankruptcy. &#160;The bentracimab asset was transferred to PhaseBio&#8217;s creditor, SFJ Pharmaceuticals in December 2022, that expects to file the BLA in mid-2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Meanwhile, Andexxa is a Factor Xa analog that competes for binding to Factor Xa inhibitors. Due to the short duration of action, pro-thrombotic effect, interference with heparin anticoagulation, and very high cost, it is not indicated to reduce the risk of perioperative bleeding in cardiac surgery. CytoSorb has demonstrated very efficient removal of all the major drugs of the DOAC category in clinical use today including rivaroxaban (Xarelto&#174;; Bayer, Janssen), apixaban (Eliquis&#174;, Bristol-Myers Squibb), edoxaban (Savaysa&#174;, Daiichi-Sankyo) and dabigatran (Pradaxa&#174;, Boehringer Ingelheim).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that CytoSorb and DrugSorb-ATR, if it receives FDA marketing approval in the United States, would represent a more cost-effective, readily available, and easy to implement solution for ticagrelor or DOAC reversal in cardiac surgery than these biologic alternatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">HemoDefend Purification Technology Platform for Transfused Blood Products</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are only a few directly competitive approved products to address the removal of substances from blood and blood products that can cause transfusion reactions. Leukoreduction (Haemonetics, Terumo-BCT, Hemerus Corporation, others) is widely used in transfusion medicine and can remove the majority of white cells that can produce new cytokines but cannot eliminate those cytokines already in blood, and cannot otherwise remove other causative agents. Automated washing of pRBC is very effective at cleansing contaminants from blood, but is impractical due to the time, cost, materials, and logistics of washing each unit of blood and is not widely used. Blood filters that utilize affinity technologies are in development to remove certain substances such as antibodies from blood, but have other issues, such as cost and concern about the stability or leachability of the affinity technology. The HemoDefend platform represents a potentially superior alternative to these methods, as it can provide comprehensive removal of a wide variety of contaminants that can trigger transfusion reactions without washing blood, requires no additional equipment, energy source, or manipulation, and can be incorporated directly into the blood storage bag or used as an in-line blood filter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical Studies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are focusing our company sponsored clinical research efforts on critical care and cardiac surgery applications of our technology.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Critical Care</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2011, CytoSorb received EU regulatory approval under the CE Mark as an extracorporeal cytokine adsorber to be used in clinical situations where cytokines are elevated. As part of the CE Mark process, in 2011 we completed our randomized, controlled, European Sepsis Trial amongst 14 trial sites in Germany, with enrollment of 100 patients with sepsis and respiratory failure. The trial established that CytoSorb was well-tolerated and safe with no serious device related adverse events reported. The trial also demonstrated the ability of CytoSorb to reduce cytokines such as IL-6 from the blood of septic patients. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2020, we received U.S. FDA Emergency Use Authorization for the treatment of adult critically ill COVID-19 patients with confirmed or imminent respiratory failure. The U.S. <b style="font-weight:bold;">C</b>ytoSorb <b style="font-weight:bold;">T</b>herapy in <b style="font-weight:bold;">C</b>OVID-19 (<b style="font-weight:bold;">CTC</b>) <b style="font-weight:bold;">Registry</b> was launched to capture outcomes and device utilization patterns from multiple U.S. participating centers. Initial results on critically ill COVID-19 patients on extracorporeal membrane oxygenation (ECMO) treated with CytoSorb at participating U.S. centers showed high survival rates (73%) compared with the international benchmark Extracorporeal Life Support Organization (ELSO) Registry. The initial CTC results on the first 52 critically ill patients from five U.S. ECMO centers were presented at the International Symposium of Intensive Care Medicine conference in August 2021 in Brussels, Belgium, and published in the peer reviewed journal Frontiers in Medicine. The CTC registry completed enrollment with 100 patients from five centers, and the final results mirror the high survival (74%) seen in the previous analysis, and have been submitted for publication. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The German <b style="font-weight:bold;">PROCYSS</b> multicenter, randomized controlled trial evaluating the ability of CytoSorb to restore hemodynamic stability in patients with refractory septic shock is now actively enrolling. The speed of enrollment remains uncertain due to COVID-19 related institutional research staff shortages, however we anticipate conditions to improve in the second half of 2023 which should help recruitment toward the next milestone of the interim analysis after 50% enrollment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The international <b style="font-weight:bold;">COSMOS</b> <b style="font-weight:bold;">Registry</b> was designed to capture real world outcomes and device utilization patterns across multiple critical care indications including but not limited to sepsis, acute respiratory failure, postoperative vasoplegia, acute liver failure, and acute pancreatitis. The Registry is actively enrolling in Spain and Germany with plans to expand in more countries in 2023. The intent of the Registry is to report outcomes at international conferences and submit the results for publication on a rolling basis as enrollment progresses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Cardiac Surgery</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2020, CytoSorb received European Union CE Mark label expansion to include the removal of ticagrelor during cardiopulmonary bypass in patients undergoing cardiothoracic surgery. In May 2020, CytoSorb also received European Union CE Mark label expansion to include rivaroxaban removal for the same indication. The international <b style="font-weight:bold;">S</b>afe and <b style="font-weight:bold;">T</b>imely <b style="font-weight:bold;">A</b>ntithrombotic <b style="font-weight:bold;">R</b>emoval (<b style="font-weight:bold;">STAR</b>) <b style="font-weight:bold;">Registry</b> is designed to capture real world clinical and health economic outcomes with intraoperative antithrombotic drug removal. The Registry is actively recruiting in the U.K., Germany, Austria and Sweden and is planned to expand to additional countries in 2023. The intent of the Registry is to report outcomes at international conferences and submit the results for publication on a rolling basis as enrollment progresses with estimated first data readouts in 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In July 2021, we received full FDA approval of an Investigational Device Exemption (IDE) application to conduct a double-blind, randomized, controlled clinical study in 120 patients entitled, &#8220;<b style="font-weight:bold;">S</b>afe and <b style="font-weight:bold;">T</b>imely <b style="font-weight:bold;">A</b>ntithrombotic <b style="font-weight:bold;">R</b>emoval &#8211; <b style="font-weight:bold;">T</b>icagrelor (<b style="font-weight:bold;">STAR-T</b>),&#8221; in the United States to support FDA marketing approval. This was done under the previously announced FDA Breakthrough Device Designation granted for the removal of ticagrelor in a cardiopulmonary bypass circuit to reduce the likelihood of serious perioperative bleeding during urgent cardiac surgery. In October 2021, the first patient was enrolled, and the STAR-T study is now actively recruiting at multiple U.S. sites. In November 2022, the first milestone was completed with the first one-third of patients enrolled, triggering the first Data Safety Monitoring Board (DSMB) meeting. The DSMB recommended to continue the study as planned without any modifications. In 2022, we also received FDA approval to expand the study to Canada and subsequently received Health Canada approval allowing inclusion of Canadian sites into the STAR-T trial in January 2023. In early 2023, the study exceeded 50% enrollment and is expected to reach the 2<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">nd</sup> milestone of 67% enrollment in the spring of 2023 triggering another DSMB safety review. The study is expected to reach 100% enrollment sometime in the summer of 2023. Based on the accelerated enrollment rate and expected evaluation period associated with an interim analysis, we are considering foregoing the interim analysis and proceeding to study completion and final analysis. Should we choose to forego the interim analysis, we would be required to notify the FDA.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2021, we also received full FDA approval of an Investigational Device Exemption (IDE) application to conduct a double-blind, randomized, controlled clinical study for up to 120 patients entitled, &#8220;<b style="font-weight:bold;">S</b>afe and <b style="font-weight:bold;">T</b>imely <b style="font-weight:bold;">A</b>ntithrombotic <b style="font-weight:bold;">R</b>emoval &#8211; <b style="font-weight:bold;">D</b>irect Oral Anticoagulants (<b style="font-weight:bold;">STAR-D</b>),&#8221; in the United States to support FDA marketing approval. This was done under the previously announced 2<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">nd</sup> FDA Breakthrough Device Designation granted for our DrugSorb-ATR Antithrombotic Removal System. This Breakthrough Device designation covers the removal of the Direct Oral Anticoagulants (DOACs) apixaban and rivaroxaban in a cardiopulmonary bypass circuit to reduce the likelihood of serious perioperative bleeding during urgent cardiac surgery. Study enrollment was paused in November of 2022 for business reasons and is scheduled to resume after completion of the STAR-T trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">COVID-19 Business Update</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">COVID-19 patients develop life-threatening complications such as acute respiratory distress syndrome (ARDS), shock (i.e., a potentially fatal drop in blood pressure), kidney failure, acute cardiac injury, thromboses and emboli, and secondary bacterial infections. The underlying cause for these complications is often a massive, systemic inflammatory response, leading to the damage of vital organs such as the lungs, heart, and kidneys, and ultimately multiple organ failure and death in many cases. Hypercoagulability, thought triggered by inflammation, and resulting thromboembolic events such as pulmonary emboli and thrombotic microangiopathy, play another critical role in the pathophysiology of COVID-19 infection and severity of illness. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The use of CytoSorb in patients infected with COVID-19 in Italy, China, Germany and France began in March 2020. CytoSorb has now been used to treat dangerous inflammation and related life-threatening complications in more than 7,650 COVID-19 patients in more than 30 countries as of December 31, 2022. Based upon initial data and reports from physicians treating these complications, CytoSorb use has generally been associated with a marked reduction in cytokine storm and inflammation, improved lung function, weaning from mechanical ventilation, decannulation from extracorporeal membrane oxygenation (ECMO), and a reversal of shock. CytoSorb has been specifically recommended in the Italy Brescia Renal COVID Task Force Guidelines to treat patients with severe COVID-19 infection and Stage 3 renal failure on continuous renal replacement therapy. CytoSorb has also been recommended in the National Treatment Guidelines from Panama for Adult COVID-19 Patients if patients have either refractory shock or have severe or refractory respiratory failure requiring either high ventilator support or extracorporeal membrane oxygenation. CytoSorb has received approval from the Drugs Controller General of India to treat COVID-19 patients in certain instances. CytoSorb has also received approval to treat patients with COVID-19 from the Israel Ministry of Health (AMAR). In January 2021, Health Canada granted Medical Device Authorization for the importation, sale, and emergency use of CytoSorb in hospitalized COVID-19 patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The use of CytoSorb has not been approved in the U.S. by the FDA. However, under certain circumstances, investigational medical devices that have not yet been FDA-approved may be made available for emergency use in the U.S. under the FDA&#8217;s Expanded Access Program (&#8220;EAP&#8221;). On April 13, 2020, we announced that the FDA, in a different program than the EAP, granted U.S. Emergency Use Authorization (EUA) of CytoSorb for use in adult critically ill COVID-19 patients. Under the EUA, CytoSorbents can make CytoSorb available, through commercial sales, to all hospitals in the U.S. for use in patients, 18 years of age or older, with confirmed COVID-19 infection who are admitted to the intensive care unit with confirmed or imminent respiratory failure and who have early acute lung injury or ARDS, severe disease, or life-threatening illness resulting in respiratory failure, septic shock, and/or multiple organ dysfunction or failure. The CytoSorb device has been authorized by FDA under an EUA. It has neither been cleared nor approved for the indication to treat patients with COVID-19 infection. The EUA will be effective until a declaration is made that the circumstances justifying the EUA have terminated or until revoked by the FDA. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The U.S. CTC (CytoSorb Therapy in COVID-19) Registry was launched to capture outcomes and device utilization patterns from multiple U.S. participating centers. Primary results on observed ICU mortality of COVID-19 patients with acute respiratory distress syndrome (ARDS) requiring extracorporeal membrane oxygenation (ECMO) and treated with CytoSorb according to FDA EUA criteria were presented at the International Symposium of Intensive Care Medicine conference in September 2021 in Brussels, Belgium. In December 2021, we announced the publication of these results in the peer-reviewed journal <i style="font-style:italic;">Frontiers in Medicine</i>. The CTC Registry has completed enrollment and the final results confirming high survival (74%) were presented at the European Society of Intensive Care Medicine conference in October 2022 and also have been submitted for publication. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Government Research Grants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have historically been successful in obtaining technology development contracts from governmental agencies such as the National Institutes of Health and the U.S. Department of Defense, including the Defense Advanced Research Projects Agency (&#8220;DARPA&#8221;), the U.S. Army, U.S. Special Operations Command (&#8220;USSOCOM&#8221;), the U.S. Air Force, Air Force Material Command (&#8220;USAF/AFMC&#8221;) and others. Currently, we have ongoing projects funded, in part, by the U.S. Army Medical Research Acquisition Activity (&#8220;USAMRAA&#8221;), the NHLBI, and the USAF/AFMC. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2017, we were awarded a Phase II SBIR contract to continue development of CytoSorb for fungal mycotoxin blood purification. This program focused on demonstrating the ability of CytoSorb to adsorb mycotoxins <i style="font-style:italic;">in vivo</i> and improve survival in animals. This contract, W911QY-17-C-0007, provided for maximum funding of $999,996 over two years. This program was funded by the Joint Program Executive Office - Chemical and Biological Defense (&#8220;CBD&#8221;) SBIR program. We received $999,996 in funding under this contract and no further funding remains under this contract. Our performance under this contract has been completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2017, the Company was awarded a Congressionally Directed Medical Research Program (&#8220;CDMRP&#8221;) Phase I contract to improve delayed evacuation and prolonged field care for severe burn injury via novel hemoadsorptive and hydration therapies. This work is being funded by the USAMRAA under contract number W81WH-17-2-0013. This contract provides for maximum funding of $719,000 over four years. As of December 31, 2022, we received $719,000 and have no further funding remaining under this contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2017, the Company was awarded a Phase II SBIR contract for its development program entitled &#8220;Investigation of a sorbent-based potassium adsorber for the treatment of hyperkalemia induced by traumatic injury and acute kidney injury&#8221;. The purpose of this contract is to continue development of two novel and distinct treatment options for life-threatening hyperkalemia. This work is being funded by the USAMRAA under contract W81XWH-17-C-0142 and provides for maximum funding of $999,871. As of December 31, 2022, we received $999,871 and no further funding remains under this contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2018, the Company was awarded a Phase IIB Bridge SBIR contract by the NHLBI to facilitate and accelerate the commercialization of our HemoDefend blood purification technology for the purification of pRBC transfusions. The contract, entitled &#8220;pRBCs Contaminant Removal with Hemocompatible Porous Polymer Beads&#8221; (award number 2R44HL141928-03), provides for maximum funding of approximately $2,971,000 over a three-year period. As of December 31, 2022, we received approximately $2,386,000 in funding under this contract and have approximately $585,000 remaining under this contract. Under the terms of this contract, we must make a matching contribution equal to the funds awarded thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2019, the Company was awarded a Rapid Innovation Fund contract by the USAF/AFMC to develop a simple, easy-to-use renal support system to treat severe hyperkalemia. The contract, entitled &#8220;K+ontrol Renal Support System for Reduction of Hyperkalemia&#8221; (award number FA8650-19-C-6065), provides for maximum funding of approximately $2,960,000 over a two-year period. As of December 31, 2022, we received approximately $2,396,000 funding under this contract and have approximately $564,000 remaining under this contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2020, the Company was awarded a two-year Defense Health Agency Small Business Technology transfer (STTR) Phase III contract to advance its HemoDefend-BGA plasma and whole blood adsorber to human clinical trials. (award number <i style="font-style:italic;">W81XWH20C0050</i>), provides for maximum funding of approximately $2,897,000 over a two-year period. As of December 31, 2022, we received approximately $2,472,000 funding under this contract and have approximately $425,000 remaining under this contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>In July 2020, the Company was a three-year contract awarded by the Assistant Secretary of Defense for Health Affairs, endorsed by the Department of Defense office of the Congressionally Directed Medical Research Programs (CDMRP), as part of a Peer Reviewed Medical Research Program Technology/ Therapeutic Development Award to complete preclinical development of the HemoDefend&#8482;-BGA plasma and whole blood adsorber (award number W81XWH2010712). This award provides for maximum funding of approximately $4,422,000 over a three-year period. As of December 31, 2022, we received approximately $1,825,000 funding under this contract and have approximately $2,596,000 remaining under this contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2020, the Company was awarded a two-year SBIR Sequential Phase II contract by the U.S. Army Medical Research Acquisition Activity (USAMRAA), to optimize development of the HemoDefend-BGA&#8482; adsorber (award number W81XWH20C0087). This award provides for maximum funding of approximately $1,100,000 over a two-year period. As of December 31, 2022, we received approximately $840,000 funding under this contract and have approximately $260,000 remaining under this contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 19, 2021, the Company received notification that it received a U.S. Army Medical Research Acquisition Activity Award (the &#8220;USAMRAAA&#8221;) entitled &#8220;Investigation of a potassium adsorber for the treatment of hyperkalemia induced by traumatic injury and acute kidney injury in austere medicine.&#8221; The USAMRAAA Phase II Sequential Award, for up to $1,499,987, was granted to the Company to continue development of two novel and distinct treatment options for life-threatening hyperkalemia. This award is being funded by the USAMRAAA under Contract No. W81XWH21C0045. As of December 31, 2022, we have received $871,000 funding under the contract and have approximately $629,000 remaining under the contract.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 9, 2022, the Company received a U.S. Army Medical Research Acquisition Activity Award (the &#8220;USAMRAAA&#8221;) entitled &#8220;Demonstration of the Safety and Efficacy of Field-Ready Blood Group Antibody (BGA) Adsorber in the Porcine Universal Transfusion Model.&#8221; The Department of Defense (DoD) Defense Medical Research and Development Program (DMRDP) Joint Program Committee 6 (JPC-6) Combat Casualty Care Research Program (CCCRP) Battlefield Resuscitation for the Immediate Stabilization of Combat Casualties Award, for up to $1,977,024, was granted to the Company to validate the safety and efficacy of the BGA device in a preclinical study in pigs. This award is being funded by the USAMRAAA under Contract No. W81XWH-22-1-0235. As of December 31, 2022, we have received $124,000 funding under the contract and have approximately $1,853,000 remaining under the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 22, 2022, the Company received a U.S. Army Medical Research Acquisition Activity Award (the &#8220;USAMRAAA&#8221;) entitled &#8220;Integrating Isoagglutinin Reduction for a Universal Dried Plasma Product for Battlefield and First Responder Use.&#8221; This three-year Phase III contract, which is valued at $4,292,641, is to be used to customize the design of the HemoDefend-BGA&#8482; filter for sterile integration into collections systems for freeze-dried plasma processing to generate freeze-dried universal plasma. Without the need for blood typing, widespread availability of universal plasma could help save lives via faster emergency treatment in both civilian and military settings. This award is being funded by the USAMRAAA under Contract No. W81XWH-22-C0046. As of December 31, 2022, we have received $35,000 funding under the contract and have approximately $4,257,000 remaining under the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 29. 2022, the Company was granted a Phase I Small Business Innovation Research (SBIR) award entitled &#8220;Novel Extracorporeal Therapy for the Reversal of Septic Shock and Restoring Hemodynamic Stability&#8221; by the National Institute of General Medical Sciences (NIGMS), a division of the U.S. National Institutes of Health. This eight-month award, which is valued at $281,835, will allow CytoSorbents to test the ability of its novel and existing polymers to remove cytokines and lipopolysaccharide (LPS) endotoxin, a well-known potent and deadly trigger of sepsis and septic shock, from septic porcine plasma. As of December 31, 2022, we have received $29,000 funding under the contract and have approximately $253,000 remaining under the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 1, 2022, the Company was granted a Phase I Small Business Innovation Research (SBIR) award by AFWERX, a United States Air Force program with the goal of fostering a culture of innovation within the service. This three-month award, which is valued at $74,955, will allow CytoSorbents to perform customer discovery within the Department of the Air Force (DAF) and to better understand DAF end-user needs and help define product requirements for our solution to prevent and treat certain infectious diseases that threaten warfighters. As of December 31, 2022, we have received $18,000 funding under the contract and have approximately $57,000 remaining under the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business could be adversely impacted by automatic cuts in Federal spending. The American Taxpayer Relief Act (&#8220;ATRA&#8221;) of 2012, referred to generally as the fiscal cliff deal, that went into effect on March 1, 2013, enacted automatic spending cuts of nearly $1 trillion over the next 10 years (commonly known as sequestration) that were included under the Budget Control Act of 2011. Sequestration may delay payments under the SBIR grant agreements, although no material delays have occurred to date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The COVID-19 pandemic also has slowed progress on executing and invoicing for our funded grant and contract programs. This was due to social distancing and remote working requirements in our laboratories and at the facilities of our collaborators. Given the uncertain nature of COVID-19, we cannot predict the future impact of the pandemic on our research and development efforts and on our revenue recognition of grant revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> </span>These grants represent a substantial research cost savings to us and we believe demonstrate the strong interest of the medical and scientific communities in our technology. We are also exploring potential eligibility in several other government-sponsored grant programs which could, if approved, represent a future source of non-dilutive funds for our research programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The medical devices that we manufacture are subject to regulation by numerous regulatory bodies, including the FDA and comparable international regulatory agencies. These agencies require manufacturers of medical devices to comply with applicable laws and regulations governing the development, testing, manufacturing, labeling, marketing and distribution of medical devices. Devices are generally subject to varying levels of regulatory control, the most comprehensive of which require that a clinical evaluation be conducted before a device receives approval for commercial distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">&#160;</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the EU, medical devices that we manufacture are required to comply with the Medical Devices Directive 93/42/EC (&#8220;MDD&#8221;) and obtain CE Mark certification in order to market medical devices. The CE Mark certification, granted following approval from an independent notified body, is an EU-wide international symbol evidencing adherence to quality assurance standards and compliance with the MDD or other applicable European Medical Devices Directives. Distributors of medical devices may also be required to comply with other foreign regulations, such as Ministry of Health Labor and Welfare approval in Japan. The time required to obtain these foreign approvals to market our products may be longer or shorter than that required in the U.S., and requirements for those approvals may differ from those required by the FDA. In Europe, our devices are classified as Class IIb, and conform to the MDD. As of May 27, 2021, devices that have not received CE Mark renewal under the MDD or where existing device or processes are substantially amended, certification would be required in accordance with the new European Union Medical Device Regulation (&#8220;MDR&#8221;). However, devices already certified under the MDD can continue to use the CE Mark under the MDD until the expiry of those MDD CE certificates and in August of 2019, we announced that CytoSorb received renewal of its EU CE Mark through May 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2011, we successfully completed our technical file review with our notified body and received approval to apply the CE Mark to the CytoSorb device as an extracorporeal cytokine adsorber. We also achieved ISO 13485:2003 Full Quality Systems certification, an internationally recognized quality standard designed to ensure that medical device manufacturers have the necessary comprehensive management systems in place to safely design, develop, manufacture and distribute medical devices in the EU. In February 2015, we extended the coverage of our ISO 13485 Certificate with the inclusion of Canadian Quality Systems requirements, however, Canada has replaced this earlier program with the Medical Device Single Audit Program (&#8220;MDSAP&#8221;) and the Company is now evaluating the requirements for this certification. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since 2011, CytoSorbents has maintained a valid ISO13485 certificate. In July 2018, we successfully completed an audit upgrade from an ISO 13485:2003 certification to an ISO 13485:2016 certification, valid through 2019. Subsequent surveillance and recertification audits have been successfully completed to maintain the certification. In April 2022, we successfully completed an annual ISO 13485:2016 surveillance audit that encompassed both the Deer Park manufacturing site and the new manufacturing facility at 305 College Road East, Princeton, NJ. &#160;In September 2022, we received ISO 13485 Certification of this new facility, clearing the way for full manufacturing of CytoSorb, DrugSorb-ATR, and ECOS-300C from this site.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the EU, as in other geographies, there are limits to the claims we are allowed to make, associated with the use of our devices. Specifically, claims that are made are required to be included in our Clinical Evaluation Report, which is part of the conformity assessment process conducted by the Notified Body. If our claims exceed the assessed claims, either regarding performance or intended uses, we may be subject to regulatory actions, which could include customer notifications or even product or literature (i.e. labeling) recalls.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the U.S., specific permission from FDA to distribute a new device is usually required (that is, other than in the case of very low risk devices), and we expect that some form of marketing authorization will be necessary for our devices. Marketing authorization is generally sought and obtained in one of three ways. The first process requires that a pre-market notification (510(k) Submission) be made to the FDA to demonstrate that the device is as safe and effective as, or &#8220;substantially equivalent&#8221; to, a legally marketed device that is not subject to pre-market approval (&#8220;PMA&#8221;). A legally marketed device is a device that (i) was legally marketed prior to May 28, 1976, (ii) has been reclassified from Class III to Class II or I, or (iii) has been found to be substantially equivalent to another legally marketed device following a 510(k) Submission. The legally marketed device to which equivalence is drawn is known as the &#8220;predicate&#8221; device. Applicants must submit descriptive data and, when necessary, performance data to establish that the device is substantially equivalent to a predicate device. In some instances, data from human clinical studies must also be submitted in support of a 510(k) Submission. If so, these data must be collected in a manner that conforms with specific requirements in accordance with federal regulations including the Investigational Device Exemption (IDE) and human subject protections or &#8220;Good Clinical Practice&#8221; regulations. After the 510(k) application is submitted, the applicant cannot market the device unless FDA issues &#8220;510(k) clearance&#8221; deeming the device substantially equivalent. The FDA&#8217;s 510(k) review process usually takes from three to six months, but may take longer. The FDA may require additional information, including clinical data, to make a determination regarding substantial equivalence. After an applicant has obtained clearance, changes to the device which do not significantly affect safety or effectiveness can generally be made without additional 510(k) Submissions, but evaluation of whether a new 510(k) is needed is a complex regulatory issue, and changes must be evaluated on an ongoing basis to determine whether a proposed change triggers the need for a new 510(k), or even PMA.The 510(k) clearance pathway is not available for all devices: whether it is a suitable path to market depends on several factors, including regulatory classifications, the intended use of the device, and technical and risk-related issues for the device. Should a suitable predicate device not be available, the second pathway is the 510(k) De Novo request. The <i style="font-style:italic;">de novo</i> pathway is available for medium risk novel device technologies, including novel device changes, that have not been previously classified by FDA and for which there is no suitable predicate device. To obtain marketing authorization via the <i style="font-style:italic;">de novo</i> pathway, the applicant must show that the subject device can be reclassified as Class I or Class II. The <i style="font-style:italic;">de novo</i> request pathway typically requires additional testing data, which includes clinical data.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The third, more rigorous, process requires that an application for PMA be made to the FDA to demonstrate that the device is safe and effective for its intended use as manufactured. This approval process applies to most Class III devices. A PMA submission is the most rigorous FDA premarket submission type for devices and includes data regarding design, materials, bench and animal testing, and human clinical data for the medical device. Again, clinical trials are subject to extensive FDA regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Following completion of clinical trials, an applicant will submit a PMA with the required data. Within 45&#160;days after a PMA is received by the FDA, the agency will notify the applicant whether the application has been &#8220;filed&#8221; (a threshold determination that the application is sufficiently complete to begin an in-depth review), then a substantive review period begins on the date of filing. Although the stated regulatory timeframe for the FDA&#8217;s review of PMAs is 180&#160;days, FDA does not meet this goal for all applications; review often takes at least one&#160;year and may take significantly longer. During this review period, the FDA may request additional information or clarification of information already provided. Also, during the review period, an advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA. In addition, the FDA will conduct a pre-approval inspection of the manufacturing facilities to evaluate compliance with the FDA&#8217;s Quality System Regulation (&#8220;OSR&#8221;), which requires manufacturers to implement and follow design, testing, control, documentation and other quality assurance and good manufacturing practice procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Following review of a PMA, the FDA will authorize commercial distribution if it determines there is reasonable assurance that the medical device is safe and effective for its intended purpose. This determination is based on the benefit outweighing the risk for the population intended to be treated with the device. Alternatively, the agency may issue an &#8220;approvable letter&#8221; or &#8220;not approvable letter&#8221; identifying deficiencies of varying degrees or issue an order denying approval. The PMA process is much more detailed, time-consuming, and expensive than the 510(k)&#160;process. Also, FDA may impose a variety of conditions on the approval of a PMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Regardless of the path to FDA clearance or approval, both before and after a device for the U.S. market is commercially released, we would have ongoing responsibilities under FDA regulations. The FDA reviews design and manufacturing practices, labeling and record keeping, complaint handling, and manufacturers&#8217; required reports of adverse events and device malfunctions and other information to identify potential problems with marketed medical devices. We would also be subject to periodic inspection by the FDA for compliance with the FDA&#8217;s QSR requirements, as mentioned above. In addition, the FDA and other U.S. regulatory bodies (including the Federal Trade Commission, the Office of the Inspector General of the Department of Health and Human Services, the Department of Justice (DOJ), and various state Attorneys General) monitor the manner in which we promote and advertise our products. Although physicians are permitted to use their medical judgment to employ medical devices for indications other than those cleared or approved by the FDA, we are prohibited from promoting products for such &#8220;off-label&#8221; uses and can only market our products for cleared or approved uses. If the FDA were to conclude that we are not in compliance with applicable laws or regulations, or that any of our medical devices are ineffective or pose an unreasonable health risk, the FDA could require us to notify health professionals and others that the devices present unreasonable risks of substantial harm to the public health; order a recall, repair, replacement, or refund of such devices, detain or seize adulterated or misbranded medical devices; or ban such medical devices. The FDA may also impose operating restrictions, enjoin and/or restrain certain conduct resulting in violations of applicable law pertaining to medical devices, including a hold on approving new devices until issues are resolved to its satisfaction, and work with the DOJ to assess civil or criminal penalties against our officers, employees, or us. Conduct giving rise to civil or criminal penalties may also form the basis for private civil litigation by third-party payers or other persons allegedly harmed by our conduct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 10, 2020 the FDA granted CytoSorbents Emergency Use Authorization of CytoSorb to treat patients 18 years of age or older, with confirmed COVID-19 admitted to the ICU with confirmed or imminent respiratory failure. Per the FDA, &#8220;The Emergency Use Authorization (EUA) authority allows the FDA to help strengthen the nation&#8217;s public health protections against chemical, biological, radiological, and nuclear (CBRN) threats by facilitating the availability and use of medical countermeasures needed during public health emergencies. Under Section 564 of the Federal Food, Drug, and Cosmetic Act (the &#8220;Act&#8221;), the FDA commissioner may allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening disease or conditions caused by CBRN threat agents when there are no adequate, approved, and available alternatives.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">EUA is an authorization limited in scope and, subject to FDA discretion regarding EUA duration. Devices with EUA are neither formally cleared nor approved for the indication to treat patients with COVID-19 infection. Such devices are authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the device under Section 564(b)(l) of the Act, 21 U.S.C &#167; 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. The FDA can at its discretion cancel the EUA approval when there is no longer a threat to public health.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The placement of our devices in the U.S. market would be subject to regulation by the U.S. Department of Health and Human Services and comparable state agencies responsible for reimbursement and regulation of health care items and services. U.S. laws and regulations are imposed primarily in connection with the Medicare and Medicaid programs, as well as the government&#8217;s interest in regulating the quality and cost of health care.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Federal health care laws apply when we or customers submit claims for items or services that are reimbursed under Medicare, Medicaid, or other federally-funded health care programs. The principal federal laws include: (1)&#160;the False Claims Act which prohibits the submission of false or otherwise improper claims for payment to a federally-funded health care program; (2)&#160;the Anti-Kickback Statute which prohibits offers to pay or receive remuneration of any kind for the purpose of inducing or rewarding referrals of items or services reimbursable by a Federal health care program; (3)&#160;the Stark law which prohibits physicians from referring Medicare or Medicaid patients to a provider that bills these programs for the provision of certain designated health services if the physician (or a member of the physician&#8217;s immediate family) has a financial relationship with that provider; and (4)&#160;health care fraud statutes that prohibit false statements and improper claims to any third-party payer. There are often similar state false claims, anti-kickback, and anti-self referral and insurance laws that apply to state-funded Medicaid and other health care programs and private third-party payers and some state laws apply regardless of payor (i.e., even in self-pay scenarios). These and other laws (including, for example, the Physician Payment Sunshine Act and state transparency and compliance laws) will become increasingly important as we progress toward commercialization in the U.S. In addition, the U.S. Foreign Corrupt Practices Act can be used to prosecute companies in the U.S. for arrangements with physicians, or other parties outside the U.S. if the physician or party is a government official of another country and the arrangement violates the law of that country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The laws applicable to us are subject to change, and subject to evolving interpretations. If a governmental authority were to conclude that we are not in compliance with applicable laws and regulations, we and our officers and employees could be subject to severe criminal and civil penalties including substantial fines and damages, and exclusion from participation as a supplier of product to beneficiaries covered by Medicare or Medicaid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The process of obtaining clearance or approval to market products is costly and time-consuming in virtually all of the major markets in which we expect to sell products and may delay the marketing and sale of our products. Countries around the world have recently adopted more stringent regulatory requirements, which are expected to add to the delays and uncertainties associated with new product releases, as well as the pre-clinical, clinical and regulatory costs of supporting those releases. No assurance can be given that any of our other medical devices will be approved on a timely basis, if at all, or that our CytoSorb&#174; device will be approved for CE Mark labeling under the MDR in other potential medical applications or that it will be approved for cytokine adsorption in markets not covered by the CE Mark on a timely basis, or at all. In addition, regulations regarding the development, manufacture and sale of medical devices are subject to future change. We cannot predict what impact, if any, those changes might have on our business. Failure to comply with regulatory requirements could have a material adverse effect on our business, financial condition, and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pertaining to our VetResQ&#8482; device (offered for veterinary use only), in the U.S., the FDA does not require submission of a 510(k), PMA, or any other pre-market review application for devices used in veterinary medicine. Device manufacturers who exclusively manufacture or distribute veterinary devices are not required to register their establishments and list veterinary devices and are exempt from some post-marketing reporting. FDA does have regulatory oversight over veterinary devices and can take appropriate regulatory action. It is the responsibility of the manufacturer and/or distributor of these articles to assure that these animal devices are safe, effective, and properly labeled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Exported devices are subject to the regulatory requirements of each country to which the device is exported. Some countries do not have medical device regulations, but in most foreign countries medical devices are regulated. Frequently, device companies may choose to seek and obtain regulatory approval of a device in a foreign country prior to application in the U.S., as we have done, given the differing regulatory requirements. However, this does not ensure approval of a device in the U.S.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Sales and Marketing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In 2012, we established our European subsidiary, CytoSorbents Europe GmbH, a wholly-owned subsidiary of CytoSorbents Corporation. Following the completion of a controlled market release in late June 2012, CytoSorb was formally launched in Germany with reimbursement established at more than $500 per cartridge. We recruited Dr. Christian Steiner, MD as our Vice President of Sales and Marketing and hired three additional sales representatives. The fourth quarter of 2012 was the first full quarter of direct CytoSorb sales with our sales force in place. We began expansion into Austria, where reimbursement for CytoSorb is now available, and Switzerland. In March 2016, we established CytoSorbents Switzerland GmbH, a wholly-owned subsidiary of CytoSorbents Europe GmbH, to conduct marketing and direct sales in Switzerland. This subsidiary began operations during the second quarter of 2016. In 2017 we began direct sales in Belgium and Luxembourg. On March 5, 2019, the Company announced the expansion of direct sales of CytoSorb for all applications to Poland and the Netherlands, and critical care applications to Sweden, Denmark and Norway. In 2021, we expanded direct sales to include all applications in Sweden, Denmark and Norway. As part of this effort, the Company established CytoSorbents Poland Sp. z.o.o. and in 2022 we established CytoSorbents France SAS as wholly-owned subsidiaries of CytoSorbents Europe GmbH. From the beginning of the controlled market release in the fourth quarter of 2011 through December 31, 2022, we achieved cumulative sales of CytoSorb of approximately $181.7 million. During this time period, the CytoSorb device represented substantially all of our product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are approved to sell CytoSorb in all 27 countries in the EU, including Germany, Italy, France and Spain as well as the United Kingdom, and currently have either direct sales or distributors or strategic partnerships in more than 75 countries worldwide. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Registration of CytoSorb is typically required in each of these countries prior to active commercialization, in a process that can take several months to more than a year to achieve. Variability in the timing of registration affects the initiation of active commercialization in these countries, which affects the timing of expected CytoSorb sales. We cannot generally predict the timing of these registrations, and there can be no guarantee that we will ultimately achieve registration in countries where we have established distribution. Outside of the EU, CytoSorb has distribution in Turkey, India, Sri Lanka, Australia, New Zealand, Russia, Serbia, Vietnam, Malaysia, Hong Kong, Chile, Panama, Costa Rica, Colombia, Brazil, Mexico, Argentina, Per&#250;, Peru, Guatemala, Ecuador, Bolivia, the Dominican Republic, El Salvador, Iceland, Israel, UAE, Iran, Saudi Arabia and other Middle Eastern countries, and South Korea. We cannot guarantee that we will generate meaningful sales in the countries where we have established registration, due to other factors such as market adoption and reimbursement. We continuously evaluate other potential distributor and strategic partner networks in other countries that accept CE Mark approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to our direct and distributor commercial channels, we have a number of strategic partners to market and distribute CytoSorb. These partners include Biocon Biologics Limited, Fresenius Medical Care AG, B. Braun Avitum AG, Aferetica s.r.l. and Terumo Cardiovascular Group. In August 2022, we expanded our partnership with Fresenius Medical Care to a global marketing collaboration. For detailed information regarding these partnerships, see the section entitled &#8220;Commercial and Research Partners&#8221; in item 1 of this report.</p><a id="FIS_UNIDENTIFIED_TABLE_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of our revenues are from product sales in Germany. Substantially all of our grant and other income are from government agencies in the United States.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the years ended 2022, 2021 and 2020, no agency, distributor or direct customer represented more than 10 percent of the Company&#8217;s total revenue. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Orders received for product from both direct customers and distributors are fulfilled upon receipt. Accordingly, we have no significant sales backlog.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Intellectual Property and Patent Litigation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The medical device market in which we primarily participate is in large part technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. However, intellectual property litigation to defend or create market advantage is inherently complex, unpredictable and is expensive to pursue. Litigation often is not ultimately resolved until an appeal process is completed and appellate courts frequently overturn lower court patent decisions.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These forces frequently drive settlement not only of individual cases, but also of a series of pending and potentially related and unrelated cases. In addition, although monetary and injunctive relief is typically sought, remedies are generally not determined until the conclusion of the proceedings and are frequently modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other forums, both domestic and international.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We rely on a combination of patents, trademarks, trade secrets and non-disclosure agreements to protect our intellectual property. As of March 9, 2023, our patent portfolio includes 18 issued United States patents as well as multiple issued foreign patents and pending patent applications both in the U.S. and internationally, directed to various compositions and methods of use related to our blood purification technologies, which are expected to expire between 2023 and 2038 absent any patent term extensions. Management believes that any near-term expiring patents will not have a significant impact on our ongoing business. The following table provides a brief description of our patents that have been issued in the U.S.:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.69%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:61.39%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.34%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:8.37%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.69%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:61.39%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:9.34%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:bottom;width:8.37%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td></tr><tr><td style="vertical-align:bottom;width:7.69%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Product</b></p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:61.39%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Patent</b></p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:9.34%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Patent</b></p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:8.37%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Patent</b></p></td></tr><tr><td style="vertical-align:bottom;width:7.69%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Group</b></p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:61.39%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description/Indications</b></p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.34%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration</b></p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:8.37%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Type</b></p></td></tr><tr><td style="vertical-align:top;width:7.69%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">CytoSorb</p></td><td style="vertical-align:top;width:1.51%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:61.39%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hemocompatible Polymer Systems and Related Devices</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.41%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20&#160;Years</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.34%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7/6/2023</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:8.37%;background:#cceeff;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Standard</p></td></tr><tr><td style="vertical-align:top;width:7.69%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">CytoSorb</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:61.39%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Size-Selective Hemoperfusion Polymeric Adsorbents</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20&#160;Years</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/20/2026</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Standard</p></td></tr><tr><td style="vertical-align:top;width:7.69%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">CytoSorb</p></td><td style="vertical-align:top;width:1.51%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:61.39%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Size-Selective Hemoperfusion Polymeric Adsorbents</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20&#160;Years</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.34%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/20/2026</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.37%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Standard</p></td></tr><tr><td style="vertical-align:top;width:7.69%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">CytoSorb</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:61.39%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Size-Selective Hemoperfusion Polymeric Adsorbents</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20&#160;Years</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11/20/2026</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Standard</p></td></tr><tr><td style="vertical-align:top;width:7.69%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">CytoSorb</p></td><td style="vertical-align:top;width:1.51%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:61.39%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Method of Treating Inflammation</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20&#160;Years</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.34%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/31/2031</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.37%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Standard</p></td></tr><tr><td style="vertical-align:top;width:7.69%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">CytoSorb</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:61.39%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Method of Treating Inflammation</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20&#160;Years</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4/1/2031</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Standard</p></td></tr><tr><td style="vertical-align:top;width:7.69%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">CytoSorb</p></td><td style="vertical-align:top;width:1.51%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:61.39%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Method of Treating Inflammation</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20&#160;Years</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.34%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4/1/2031</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.37%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Standard</p></td></tr><tr><td style="vertical-align:top;width:7.69%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">CytoSorb</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:61.39%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Method of Treating Inflammation</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20&#160;Years</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4/1/2031</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Standard</p></td></tr><tr><td style="vertical-align:top;width:7.69%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">CytoSorb</p></td><td style="vertical-align:top;width:1.51%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:61.39%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Method of Treating Inflammation</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20&#160;Years</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.34%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4/30/2031</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.37%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Standard</p></td></tr><tr><td style="vertical-align:top;width:7.69%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">CytoSorb</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:61.39%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Polymer Modification</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20&#160;Years</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12/31/2031</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Standard</p></td></tr><tr><td style="vertical-align:top;width:7.69%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">CytoSorb</p></td><td style="vertical-align:top;width:1.51%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:61.39%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Method of Removal of Impurities from Whole Blood</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20&#160;Years</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:9.34%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1/6/2032</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:8.37%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Standard</p></td></tr><tr><td style="vertical-align:top;width:7.69%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CytoSorb</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:61.39%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Use of Polymeric Sorbent Polymers</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20 Years</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8/10/2032</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Standard</p></td></tr><tr><td style="vertical-align:top;width:7.69%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CytoSorb</p></td><td style="vertical-align:top;width:1.51%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:61.39%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hemocompatible Modifiers</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20 Years</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.34%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3/31/2034</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.37%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Standard</p></td></tr><tr><td style="vertical-align:top;width:7.69%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CytoSorb</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:61.39%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Method of Treating Acute Radiation Syndrome</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20 Years</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/22/2035</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Standard</p></td></tr><tr><td style="vertical-align:top;width:7.69%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CytoSorb</p></td><td style="vertical-align:top;width:1.51%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:61.39%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Use of Gastrointestinally Administered Porous Sorbent Polymers</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20 Years</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.34%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/22/2035</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.37%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Standard</p></td></tr><tr><td style="vertical-align:top;width:7.69%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CytoSorb</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:61.39%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hemocompatible Porous Beads</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20 Years</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/21/2036</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Standard</p></td></tr><tr><td style="vertical-align:top;width:7.69%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CytoSorb</p></td><td style="vertical-align:top;width:1.51%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:61.39%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Removal of Endotoxemia</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.41%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20 Years</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.34%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5/17/2037</p></td><td style="vertical-align:top;width:1.08%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.37%;background:#cceeff;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Standard</p></td></tr><tr><td style="vertical-align:top;width:7.69%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CytoSorb</p></td><td style="vertical-align:top;width:1.51%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:61.39%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Method of Removing Toxins From Blood</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;white-space:nowrap;width:8.41%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20 Years</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.34%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7/30/2038</p></td><td style="vertical-align:top;width:1.08%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.37%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Standard</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that pending patent applications will result in issued patents, that patents issued to us will not be challenged or circumvented by competitors, or that such patents will be found to be valid or sufficiently broad to protect our technology or to provide us with a competitive advantage. Certain of these patents also have foreign counterparts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also rely on non-disclosure and non-competition agreements with employees, consultants and other parties to protect, in part, trade secrets and other proprietary technology. There can be no assurance that these agreements will not be breached, that we will have adequate remedies for any breach, that others will not independently develop equivalent proprietary information or that third parties will not otherwise gain access to our trade secrets and proprietary knowledge.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may find it necessary to initiate litigation to enforce our patent rights, to protect our trade secrets or know-how and to determine the scope and validity of the proprietary rights of others. Patent litigation can be costly and time-consuming, and there can be no assurance that our litigation expenses will not be significant in the future or that the outcome of litigation will be favorable to us. Accordingly, we may seek to settle some or all of our pending litigation described below. Settlement may include cross-licensing of the patents which are the subject of the litigation as well as our other intellectual property and may involve monetary payments to or from third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently hold multiple trademarks including CytoSorb<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, ECOS-300CY<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, VetResQ<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, HemoDefend&#8482;, BetaSorb&#8482;,DrugSorb&#8482;, and K<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup>ontrol<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup>. We have spent considerable resources registering the trademark and building brand awareness and equity of the CytoSorb<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> tradename, which has been used in commerce since 2006. We expect to maintain and defend our various trademarks to the fullest extent possible.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Environmental</span> <span style="font-style:italic;">Matters</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that there are no compliance issues associated with applicable environmental laws and regulations that would have a material adverse effect on us or our business. We incur waste removal costs in connection with both our solid and liquid wastes which are byproducts of our manufacturing process. We utilize the services of various qualified contractors to dispose of these waste products. These waste removal costs amounted to approximately $384,000 for the&#160;year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Employees</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of March 7, 2023, we had 198 full-time and part-time employees. We also utilize consultants and temporary service providers who are not our employees, as necessary. None of our employees are represented by a labor union or are subject to collective-bargaining agreements and we believe we have good relationships with our employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3bf00590_6113_4e19_b8ae_f90fd49b59a8"></a><a id="Item1ARiskFactors_6435"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item 1A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks Related to our Business and our Industry</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have a history of losses and expect to incur substantial future losses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have experienced substantial operating losses since inception. As of December 31, 2022, we had an accumulated deficit of approximately $253,998,000, which included net losses of approximately $32,813,000, $24,559,000 and $7,837,000 for the years ended December 31, 2022, 2021 and 2020, respectively. Our losses have resulted principally from costs incurred in the research and development of our polymer technology, clinical studies and general and administrative expenses. We intend to conduct significant additional research, development, and clinical study activities which, together with expenses incurred for the establishment of manufacturing arrangements and a marketing and distribution presence and other general and administrative expenses, are expected to result in continuing net losses for the foreseeable future. The amount of future losses and when, if ever, we will achieve profitability are uncertain. Our ability to achieve profitability will depend, among other things, on continued adoption and usage of our products in the market, obtaining additional regulatory approvals in markets not covered by the CE mark, establishing sales and marketing arrangements with third parties, satisfactory reimbursement in key territories, and raising sufficient funds to finance our activities. No assurance can be given that our product development efforts will be successful, that our current CE Mark will enable us to achieve profitability, that additional regulatory approvals in other countries will be obtained, that any of our products will be manufactured at a competitive cost and will be of acceptable quality, that reimbursement will be available or satisfactory, that we will be able to achieve profitability or that profitability, if achieved, can be sustained, or our ability to raise additional capital when needed or on terms acceptable to us. Our failure with respect to any or all of these matters would have a material adverse effect on our business, operating results, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may require additional capital in the future to fund our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, we had current assets of approximately $33.8 million, including cash, cash equivalents and restricted cash on hand of approximately $23.8 million and current liabilities of approximately $9.7 million. For year ended December 31, 2022, our cash burn, which we define as the total of cash used in operating and investing activities from our statement of cash flows, was approximately $35 million, which included approximately $6.3 million of capital spending and improvements related to our new manufacturing facility and corporate headquarters. Our current and historical cash burn is not necessarily indicative of our future use of cash and cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are currently adequately capitalized but will require additional financing in the future in order to complete additional clinical studies and to support the commercialization of our proposed products. There can be no assurance that we will be successful in our capital raising efforts. The amount of long-term capital needed is expected to depend on many factors, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">rate of sales growth and adoption of our products in the marketplace;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product gross margin;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continued progress and cost of our research and development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">progress and costs associated with pre-clinical studies and clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the time and costs involved in obtaining regulatory clearance in other countries and/or for other indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs related to business development activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of developing sales, marketing and distribution channels;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market acceptance and reimbursement of our products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cost for training physicians and other health care personnel.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have an effective shelf registration statement dated July 14, 2021 with the SEC which enables us to raise up to $150 million in one or more offerings, through the issuance and sale of any combination of equity securities, debt securities, warrants and units. All of this amount is available as we have not utilized the existing shelf. All of the $25 million of our total shelf amount allocated to our ATM facility was available as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July 24, 2020, the Company closed on the Offering of 6,052,631 shares of its common stock at a public offering price of $9.50 per share. The Company completed the Offering pursuant to the terms of an Underwriting Agreement, dated as of July 21, 2020, by and among the Company and Cowen and Company, LLC and SVB Leerink LLC, as representatives of the several underwriters named therein. The Company received gross proceeds of approximately $57.5 million from the Offering. After deducting the underwriting discounts and commissions and fees and expenses payable by the Company in connection with the Offering, the Company received net proceeds of approximately $53.8 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 30, 2021, we entered into an Open Market Sale Agreement with Jefferies LLC (the &#8220;Sale Agreement&#8221;). Pursuant to the Sale Agreement we may offer to sell, from time to time, shares of our common stock, up to a maximum of $25,000,000. There were no sales pursuant to the Sale Agreement during the year ended December 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 19, 2022 (the &#8220;Fourth Amendment Closing Date&#8221;), the Company closed on the Fourth Amendment (the &#8220;Fourth Amendment&#8221;) of its Amended Loan and Security Agreement with Bridge Bank. Under the terms of the Amendment, the Company received a commitment from Bridge Bank to provide a new term loan of up to $15 million, if needed until December 31, 2022. On December 27, 2022, the Company drew down the first $5 million tranche of the Term C loans available under the terms of the Fourth Amendment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 28, 2022 (the &#8220;Fifth Amendment Date&#8221;), the Company entered into the Fifth Amendment of its Amended Loan and Security Agreement with Bridge Bank. The Fifth Amendment extends the draw period under the Fourth Amendment to the earlier of (i) March 1, 2023 and (ii) the occurrence of an Event of Default. On March&#160;9,&#160;2023, the Company entered into the Sixth Amendment of its Amended Loan and Security Agreement. The Sixth Amendment further extends the draw period to March&#160;24,&#160;2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Despite the foregoing, we will require additional financing in the future. Should the financing we require be unavailable to us, or on terms unacceptable to us when we require it, the consequences could have a material adverse effect on our business, operating results, financial condition and prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, in the event that additional funds are obtained through arrangements with collaborative partners or other non-dilutive sources, we may have to relinquish economic and/or proprietary rights to some of our technologies or products under development that we would otherwise seek to develop or commercialize by ourselves. Such events may have a material adverse effect on our business, operating results, financial condition and prospects.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:11pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">A pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, may materially and adversely affect our business and operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">The outbreak of COVID-19 originated in Wuhan, China in December 2019 and has since spread around the globe. On March 11, 2020, the World Health Organization declared the outbreak a pandemic. The COVID-19 pandemic is affecting the United States and global economies and is likely to continue to affect our operations and those of third parties on which we rely, including by causing disruptions in our global supply chain, our ability to obtain raw materials, the manufacturing of and short-term demand for our lead product, CytoSorb, the commercialization of CytoSorb, our research and development activities, and the conduct of current and future clinical trials. In addition, the COVID-19 pandemic has affected and is likely to continue to affect the operations of the U.S. Food and Drug Administration and other health authorities, which could result in delays of reviews and approvals, including with respect to DrugSorb-ATR and our product candidates. The evolving COVID-19 pandemic has impacted and is likely to continue to directly or indirectly impact our clinical trials, including but not limited to, the anticipated completion date of these trials and the pace of enrollment in our clinical trials for at least the next several months and possibly longer as patients may avoid or may not be able to travel to healthcare facilities and physicians&#8217; offices unless due to a health emergency and clinical trial staff can no longer get to the clinic. Such facilities and offices have and may continue to be required to focus limited resources on non-clinical trial matters, including treatment of COVID-19 patients, and may not be available, in whole or in part, for clinical trial services. There may be new or further delays in patient enrollment in the PROCYSS and the STAR clinical trials. For example, in April 2021 we stopped the TISORB single arm study due to continued delays and poor enrollment caused by the COVID-19 pandemic in the U.K., in favor of redirecting those resources to the U.S. STAR-T randomized, controlled trial and in November 2022, we temporarily paused the STAR-D trial for business reasons. In addition, employee disruptions and remote working environments related to the COVID-19 pandemic and the federal, state and local responses to such virus, could materially impact the efficiency and pace with which we work and develop our product candidates, our ability to execute and invoice upon government grants and contracts, and the manufacturing of CytoSorb. As of the date of this filing, our manufacturing facilities remain operational and we have resumed research and development activities that were temporarily suspended as a result of the COVID-19 pandemic, however we have experienced, and may continue to experience, challenges in hiring necessary staff members to conduct our research and development activities, including technical staff. Further, while the potential economic impact brought on by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce our ability to access capital, which could negatively impact our short-term and long-term liquidity. Additionally, the stock market has been unusually volatile during and following the COVID-19 outbreak and such volatility may continue. Macro factors have impacted, and may continue to negatively impact, our critical care and cardiac surgery markets, including in certain geographies such as Germany. For example,</span> <span style="color:#231f20;">widespread staffing shortages, decreased availability of hospital beds, fewer patients, increased hospital restrictions resulting in decreased access of our sales representatives to hospitals and fewer sales meetings with physicians resulted in lower-than-expected sales of CytoSorb during the years ended December 31, 2022 and 2021, respectively, and may contribute to lower-than-expected sales of CytoSorb in the future. To date, during certain periods of the COVID-19 pandemic, our stock price fluctuated significantly, and such fluctuation will likely continue to occur. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, financing or clinical trial activities or on healthcare systems or the global economy as a whole. However, these effects could have a material impact on our liquidity, capital resources, operations and business and those of the third parties on which we rely. The Company estimated that approximately $0.3 million and $6.3 million of its 2022 and 2021 product sales, respectively, were related to the treatment of COVID-19 patients. As the pandemic continues to ease and the amount of our revenues attributable to the treatment of COVID-19 is reduced, it is uncertain whether the Company will be able to replace some or all of this revenue in the future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;font-style:italic;font-weight:bold;">Our operating results are subject to seasonal fluctuation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">Our total revenue and product sales are subject to seasonal fluctuation. Our sales seasonality is affected by a number of factors, including but not limited to, hospital budgets and buying patterns, customer, employee and healthcare worker vacation schedules, religious, national, and state holidays, scientific and medical conference schedules, seasonal illnesses such as influenza, seasonal or weather-related differences in hospital admissions and the timing of insurance benefits, among others. Our normal seasonality cycle has also been impacted by the COVID-19 pandemic and related events, making it more difficult to predict and determine a more consistent seasonality trend. See &#8220;A pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, may materially and adversely affect our business and operations.&#8221; As a result, seasonality has had, and we expect it to continue to have, an impact on our results of operations.</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Although historically we have been a research and development company, we are in the process of commercializing our products. There can be no assurance that we will be successful in developing and expanding commercial operations or balancing our research and development activities with our commercialization activities</span><i style="font-style:italic;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have historically been engaged primarily in research and development activities and have generated limited revenues to date. With the launch of our CytoSorb product in the EU and elsewhere, there can be no assurance that we will be able to successfully manage the balance of our research and development operations with our planned commercial enterprise. Potential investors should be aware of the problems, delays, expenses and difficulties frequently encountered by an enterprise in balancing development, which include unanticipated problems relating to testing, product registration, product labeling, regulatory compliance and manufacturing, with commercialization, which includes problems with market adoption, reimbursement, marketing problems and additional costs. Our products and product candidates will require significant additional research and testing, and we will need to overcome significant regulatory burdens prior to commercialization in other countries, such as the U.S., and for ongoing compliance for our CE Mark. Although we believe we are currently adequately capitalized, we will need to raise additional funds to complete additional clinical studies and obtain regulatory approvals in other countries before we can begin selling our products in markets not covered by our CE Mark. There can be no assurance that after the expenditure of substantial funds and efforts, we will successfully develop and commercialize any products, generate any significant revenues or ever achieve and maintain a substantial level of sales of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If users of our products are unable to obtain adequate reimbursement from third-party payers, or if reimbursement is not available in specific countries, or if new restrictive legislation is adopted, market acceptance of our products may be limited and we may not achieve anticipated revenues.&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The continuing efforts of government and insurance companies, health maintenance organizations and other payers of healthcare costs to contain or reduce costs of health care may affect our future revenues and profitability, the future revenues and profitability of our potential customers, suppliers and collaborative partners, and the availability of capital. For example, in certain foreign markets, pricing or profitability of medical devices is subject to government control. In the United States, given recent federal and state government initiatives directed at lowering the total cost of health care, the U.S. Congress and state legislatures will likely continue to focus on health care reform, the cost of medical devices and on the reform of the Medicare and Medicaid systems. While we cannot predict whether any such legislative or regulatory proposals will be adopted, the announcement or adoption of these proposals could materially harm our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ability to commercialize our products will depend in part on the extent to which appropriate reimbursement levels for the cost of our products and related treatment are obtained by governmental authorities, private health insurers and other organizations, such as health maintenance organizations (&#8220;HMOs&#8221;). Third-party payers are increasingly challenging the prices charged for medical care. Also, the trend toward managed health care in the United States and the concurrent growth of organizations such as HMOs, which could control or significantly influence the purchase of health care services and medical devices, as well as legislative proposals to reform health care or reduce government insurance programs, may all result in lower prices for our products. The cost containment measures that health care payers and providers are instituting and the effect of any health care reform could materially harm our ability to operate profitably.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Outside of the United States, reimbursement systems vary significantly by country. Many foreign markets often have a combination of government-managed and privately-managed healthcare systems that govern reimbursement for medical devices and related procedures. Socialized medicine is common in the EU, and reimbursement and the pricing of medical devices is generally subject to governmental control. Application for reimbursement, subsequent approvals, if any, and pricing negotiations with governmental authorities can take considerable time after a device has been CE marked. Private insurance has similar challenges. CytoSorb is currently reimbursed in Germany under government-funded insurance, and in other countries may be covered under the diagnosis-related group (&#8220;DRG&#8221;), or &#8220;lump sum payment&#8221; reimbursement, or other generalized reimbursement for acute care medical products. We are continuously working to obtain or improve upon the type and amount of reimbursement available to us in countries where CytoSorb is available, and as we attempt to move from an existing reimbursement platform to a new reimbursement platform, we may experience interruptions and/or reductions in the amount available for reimbursement. Because of this, there can be no assurance that new reimbursement will be obtained or that existing reimbursement will continue or that such reimbursement will be sufficient to adequately cover the cost of the device or treatment. As a result, our future revenues, profitability and access to capital may be negatively affected by any interruption or reduction in amounts of reimbursement. We plan to seek reimbursement for our product in other EU and non-EU countries to help further adoption. There can be no assurance when, or if, this additional reimbursement might be approved.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We depend upon key personnel who may terminate their employment with us at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 7, 2023, we had 198 full-time and part-time employees as well as several consultants and temporary employees. Our success will depend to a significant degree upon the continued services of our key management team and advisors, including, Dr. Phillip Chan, our Chief Executive Officer; Kathleen P. Bloch, our Chief Financial Officer; Vincent Capponi, our President and Chief Operating Officer and Dr. Efthymios Deliargyris, our Chief Medical Officer. On July 30, 2019, we entered into amended and restated executive employment agreements with its principal executives, Dr. Phillip P. Chan, Chief Executive Officer, Vincent Capponi, President and Chief Operating Officer, and Kathleen P. Bloch, Chief Financial Officer. Each of the agreements had an initial term of three years and were retroactively effective as of January 1, 2019. On April 12, 2020, CytoSorbents Corporation entered into an executive employment agreement with Dr. Efthymios Deliargyris, who began employment as Chief Medical Officer on May 1, 2020, with an initial term that expires on December 31, 2021. After the expiration of the initial terms, the employment agreements automatically renew for additional terms of one year unless either party provides written notice of non-renewal at least 60 days prior to a renewal. The employment agreements for the Named Executive Officers above have automatically renewed for another year term. On September 30, 2022, Ms. Bloch notified the Company of her intention to retire effective March 31, 2023. A search has been initiated for Ms. Bloch&#8217;s replacement. Ms. Bloch and the Company expect to enter into a consulting arrangement under which Ms. Bloch will continue to provide services to the Company in a limited capacity following the effective date of her retirement. There can be no assurance that key management personnel or other members of our management team and advisors will continue to provide services to us. In addition, our success will depend on our ability to attract and retain other highly skilled personnel. We may be unable to recruit such personnel on a timely basis, if at all. Management and other employees may voluntarily terminate their employment with us at any time. Additionally, the increasing demand for qualified personnel may make it more difficult for us to attract and retain qualified employees. Changing demographics and labor work force trends may make it difficult for us to replace departing employees at our manufacturing and other facilities and we may experience increased turnover rates. U.S. labor market conditions are currently challenging and labor shortages have been exacerbated during and following the COVID-19 pandemic. These conditions are expected to persist into 2023 and may lead to higher labor costs. If we fail to attract and retain qualified personnel, or if we experience labor shortages, we may experience higher costs and other difficulties. The loss of services of key personnel, or the inability to attract and retain additional qualified personnel, could result in delays in development or approval of our products, loss of sales and diversion of management resources. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Acceptance of our medical devices in the marketplace is uncertain, and failure to achieve market acceptance will prevent or delay our ability to generate revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our future financial performance will depend, at least in part, upon the introduction and customer acceptance of our products. Even with CE mark approval for our CytoSorb device as a cytokine adsorber, our products and product candidates may not achieve market acceptance in the countries that recognize and accept the CE mark. Additional approvals from other regulatory authorities (such as the FDA) will be required before we can market our device in countries not covered by the CE mark. There is no guarantee that we will be able to achieve additional regulatory approvals, and even if we do, our products may not achieve market acceptance in the countries covered by such approvals. The degree of market acceptance will depend upon a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the receipt of regulatory clearance of marketing claims for the uses that we are developing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the establishment and demonstration of the advantages, safety and efficacy of our polymer technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">pricing and reimbursement policies of government and third-party payers such as insurance companies, health maintenance organizations and other health plan administrators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the development by our competitors of products or product candidates that are similar or identical to ours;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to attract corporate partners, including medical device companies, to assist in commercializing our products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to effectively market our products.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Physicians, patients, payers or the medical community in general may be unwilling to accept, utilize or recommend any of our products. Approval of our CytoSorb device as a cytokine adsorber as well as the data we have gathered in our clinical studies to support device usage in this indication may not be sufficient for market acceptance in the medical community. We may also need to conduct additional clinical studies to gather additional data for marketing purposes. If we are unable to obtain regulatory approval or commercialize and market our products when planned, we may not achieve any market acceptance or generate revenue.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain and maintain patent protection for our products and product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products and product candidates similar or identical to ours, and our ability to successfully commercialize our products and product candidates may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercial success will depend, in part, on our ability to obtain and maintain patent protection in the United States and other countries with respect to our products and product candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our products and product candidates that are important to our business. We cannot be certain that patents will be issued or granted with respect to applications that are currently pending or that we apply for in the future with respect to one or more of our products and product candidates, or that issued or granted patents will not later be found to be invalid and/or unenforceable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, distribution partners, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The patent position of medical device companies generally is highly uncertain, involves complex legal and factual questions and has in recent&#160;years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued, and even if issued, the patents may not meaningfully protect our products or product candidates, effectively prevent competitors and third parties from commercializing competitive products or otherwise provide us with any competitive advantage. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative products in a non-infringing manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Changes in the patent laws, implementing regulations or interpretation of the patent laws in the United States and other countries may also diminish the value of our patents or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States, and many companies have encountered significant difficulties in protecting and defending such rights in foreign jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot be certain that our patents and patent rights will be effective in protecting our products, product candidates and technologies.&#160;In addition, our existing patents are scheduled to expire between 2023 and 2038. Failure to protect such assets may have a material adverse effect on our business, operations, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may face litigation from third parties claiming that our products infringe on their intellectual property rights, or seek to challenge the validity of our patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our future success is also dependent in part on the strength of our intellectual property, trade secrets and know-how, which have been developed from&#160;years of research and development. In addition to the previously settled &#8220;Purolite&#8221; litigation discussed below, we may be exposed to additional future litigation by third parties seeking to challenge the validity of our rights based on claims that our technologies, products or activities infringe the intellectual property rights of others or are invalid, or that we have misappropriated the trade secrets of others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we have sought to contract with large, established manufacturers to supply commercial quantities of our adsorbent polymers. As a result, we have disclosed, under confidentiality agreements, various aspects of our technology with potential manufacturers. We believe that these disclosures, while necessary for our business, have resulted in the attempt by potential suppliers to improperly assert ownership claims to our technology in an attempt to gain an advantage in negotiating manufacturing rights.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We previously engaged in discussions with the Brotech Corporation and its affiliate, Purolite International,&#160;Inc. (collectively referred to as &#8220;Purolite&#8221;), which had demonstrated a strong interest in being our polymer manufacturer. For a period of time beginning in December&#160;1998, Purolite engaged in efforts to develop and optimize the manufacturing process needed to produce our polymer products on a commercial scale. However, the parties eventually decided not to proceed. In 2003, Purolite filed a lawsuit against us asserting, among other things, co-ownership and co-inventorship of certain of our patents. On September&#160;1, 2006, the United States District Court for the Eastern District of Pennsylvania approved a Stipulated Order and Settlement Agreement under which we and Purolite agreed to the settlement of the action. The Settlement Agreement provides us with the exclusive right to use our patented technology and proprietary know how relating to adsorbent polymers for a period of 18&#160;years. Under the terms of the Settlement Agreement, we have agreed to pay Purolite royalties of 2.5% to 5% on the sale of certain of our products through 2024, after which time no royalties will be due under this settlement agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The expiration or loss of patent protection may adversely affect our future revenues and operating earnings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We rely on patent, trademark, trade secret and other intellectual property protection in the discovery, development, manufacturing, and sale of our products and product candidates. In particular, patent protection is important in the development and eventual commercialization of our products and product candidates. Patents covering our products and product candidates normally provide market exclusivity, which is important in order for our products and product candidates to become profitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our existing patents are scheduled to expire between 2023 and 2038. While we are seeking additional patent coverage which may protect the technology underlying these patents, there can be no assurances that such additional patent protection will be granted, or if granted, that these patents will not be infringed upon or otherwise held enforceable. Even if we are successful in obtaining a patent, patents have a limited lifespan. In the United States, the natural expiration of a utility patent typically is generally 20&#160;years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Without patent protection for our products and product candidates, we may be open to competition from generic versions of such methods and devices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have commenced the process of seeking regulatory approvals of our products and product candidates, but the approval process involves lengthy and costly clinical studies and is, in large part, not in our control. The failure to obtain government approvals, internationally or domestically, for our products and product candidates, or to comply with ongoing governmental regulations could prevent, delay or limit introduction or sale of our products and result in the failure to achieve revenues or maintain our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CytoSorb has already achieved marketing authorization in the EU under the CE marking process and the Medical Devices Directive. It is manufactured at our manufacturing facility in New Jersey under ISO 13485 Full Quality Systems certification. The manufacturing and marketing of our products is subject to extensive and rigorous government regulation in the EU, as well as in the U.S. and in other countries. In the U.S. and other countries, the process of obtaining and maintaining required regulatory approvals is lengthy, expensive, and uncertain. There can be no assurance that we will ever obtain the necessary additional approvals to sell our products in the United States or other non-EU countries. Even if we do ultimately receive FDA approval or clearance for any of our products, we will be subject to extensive ongoing regulation. While we have received approval from our notified body to apply the CE mark to our CytoSorb device, we will be subject to extensive ongoing regulation and auditing requirements to maintain the CE mark.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our products are subject to international regulation as medical devices under the Medical Devices Directive and, once our CE Mark under MDD expires in May 2024 will be subject to the new European Union Medical Device Regulation (&#8220;MDR&#8221;). In Europe, which we expect to provide the initial market for our products, the notified body and Competent Authority govern, where applicable, development, clinical studies, labeling, manufacturing, registration, notification, clearance or approval, marketing, distribution, record keeping, and reporting requirements for medical devices. Different regulatory requirements may apply to our products depending on how they are categorized by the notified body under these laws. Current international regulations classify our CytoSorb device as a Class&#160;IIb device. Even though we have received CE mark certification of the CytoSorb device, there can be no assurance that we will be able to continue to comply with the required annual auditing requirements or other international regulatory requirements that may be applicable. In addition, there can be no assurance that government regulations applicable to our products or the interpretation of those regulations will not change. The extent of potentially adverse government regulation that might arise from future legislation or administrative action cannot be predicted. There can be no assurances that reimbursement will be granted or that additional clinical data will be required to establish reimbursement.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we fail to maintain the CE Mark in the European Union, we will not be able to commercially sell and market CytoSorb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2011, CytoSorb, was &#8220;CE marked&#8221; in the EU as an extracorporeal cytokine adsorber indicated for use in clinical situations where cytokines are elevated, allowing for commercial marketing. The CE Mark demonstrates that a conformity assessment has been carried out and the product complies with the Medical Devices Directive. A re-certification audit was conducted in April&#160;2019. The successful completion of this audit CE-certifies CytoSorb under the current Medical Device Directive (93/42/EEC) until May&#160;2024. Prior to the expiration of such certificate, we will apply for certification under the new Medical Devices Regulation (MDR). Failure to certify CytoSorb under the Medical Devices Regulation will prevent us from using the CE mark for commercial distribution of CytoSorb in the European Union. Any new product that we submit for the CE Mark after August&#160;2019 must be approved under the new Medical Devices Regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, if:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we are not able to obtain re-certification for CytoSorb&#8217;s current use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we are not able to do so in time before the existing certificate expires;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CytoSorb does not meet the new (and more stringent) requirements under the Medical Devices Regulation; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any variation in the uses for which the CE Mark has been affixed CytoSorb requires us to perform further research or to modify the technical documentation required to affix the CE Mark, our revenues and operating results could be adversely affected and our reputation could be harmed.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may pursue various indications for our product candidates, and they may be subject to different FDA regulatory pathways for marketing authorization, and under the jurisdiction of different FDA review divisions within the FDA&#8217;s Office of Device Evaluation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As we seek to determine commercially viable indications for our product candidates, we may consider pursuing a variety of indications that may be approved through one of several different FDA regulatory clearance or approval pathways, and under the jurisdiction of different FDA review divisions within the FDA&#8217;s Office of Device Evaluation. We expect the pathways available to us will be impacted by the FDA regulatory history of the category of &#8220;sorbent hemoperfusion systems&#8221; and our options may also be impacted by the FDA&#8217;s interpretations and application of these and other regulatory standards to our product candidates. The regulatory pathways available to us may impact the level and type of data necessary to support our applications, and the post-marketing requirements to which we and our products will be subject.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner, affect whether government agencies promptly pay amounts awarded under grants from such agencies, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The ability of the FDA to review and approve new drugs and medical devices can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the FDA have fluctuated in recent&#160;years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and medical devices to be reviewed and/or approved by necessary government agencies as well as affect whether we receive timely payment of amounts awarded to us under grants and contracts with government agencies which would adversely affect our business. For example, over the last several&#160;years, including from December&#160;22, 2018 until January&#160;25, 2019, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns&#160;could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Clinical study results for our CytoSorb and/or DrugSorb-ATR device may not be indicative of our future clinical study results, and we cannot assure you that any clinical study results will lead to results sufficient for necessary regulatory clearances or product sales. Additionally, clinical and pre-clinical data is susceptible to varying interpretations, which could delay, limit, reduce, or prevent additional regulatory clearances or product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To date, we have conducted limited clinical studies on our CytoSorb and DrugSorb-ATR product. There can be no assurance that we will successfully complete additional clinical studies or that our current or future clinical studies will lead to results necessary to receive additional regulatory approvals in markets not covered by the CE Mark. While clinical studies conducted by us and others have produced results we believe to be encouraging, data already obtained, or in the future obtained, from pre-clinical studies and clinical studies do not necessarily predict the results that will be obtained from later pre-clinical studies and clinical studies. CytoSorb, DrugSorb-ATR and our other products and product candidates may fail to show the desired safety and efficacy in clinical development despite positive results in previous studies, which could result in decreased sales of our products and product candidates and have an adverse effect on our business and results of operations. Moreover, pre-clinical and clinical data are susceptible to varying interpretations, which could delay, limit or prevent additional regulatory approvals in markets not covered by the CE Mark. A number of companies in the medical device and pharmaceutical industries have suffered significant setbacks in advanced clinical studies, even after promising results in earlier studies. The failure to adequately demonstrate the safety and effectiveness of CytoSorb, DrugSorb-ATR or another product under development could delay or prevent regulatory clearance of the device, resulting in delays to commercialization, and could materially harm our business and results of operations. Even though we have received approval to apply the CE Mark to our CytoSorb device as a cytokine adsorber, there can be no assurance that we will be able to receive approval under the MDR for other potential applications of CytoSorb, or that we will receive regulatory clearance or marketing approval from authorities in other targeted regions or countries. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We rely extensively on research and testing facilities at various universities and institutions, which could adversely affect us should we lose access to those facilities. At the same time, relationships with these individuals and entities are the subject of heightened scrutiny and may present the potential for future healthcare enforcement risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we have our own research laboratories and clinical facilities, we collaborate with numerous institutions, universities and commercial entities to conduct research and studies of our products. We currently maintain a good working relationship with these parties. However, should the situation change, the cost and time to establish or locate alternative research and development facilities could be substantial and delay gaining CE Mark for other potential applications of our products, our other product candidates or technologies, and/or FDA approval and commercializing our products. In addition, our interactions, communications, and financial relationships with these individuals and entities present future healthcare enforcement risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are and will be exposed to product liability risks, and clinical and preclinical liability risks, which could place a substantial financial burden upon us should we be sued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business exposes us to potential product liability and other liability risks that are inherent in the testing, manufacturing and marketing of medical devices. We cannot be sure that claims will not be asserted against us. A successful liability claim or series of claims brought against us could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot give assurances that we will be able to continue to obtain or maintain adequate product liability insurance on acceptable terms, if at all, or that such insurance will provide adequate coverage against potential liabilities. Claims or losses in excess of any product liability insurance coverage that we may obtain could have a material adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain university and other relationships are important to our business and may potentially result in conflicts of interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We work with many medical and clinical advisors in critical care, cardiac surgery, trauma, and other areas who are associated with healthcare institutions. Their association with these institutions may currently or in the future involve conflicting interests in the event they or these institutions enter into consulting or other arrangements with competitors of ours.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have limited manufacturing experience and capabilities, we may not be able to manufacture sufficient quantities at an acceptable cost or quality, or without shut-downs or delays.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In March 2011, we received approval from our notified body to apply the CE Mark to our CytoSorb device for commercial sale as a cytokine adsorber. We also achieved ISO 13485:2003 Full Quality Systems certification, and have since upgraded to ISO 13485:2016 Full Quality Systems certification, an internationally recognized quality standard designed to ensure that medical device manufacturers have the necessary comprehensive management systems in place to safely design, develop, manufacture and distribute medical devices in the EU. We manufacture CytoSorb at our manufacturing facilities in New Jersey for sale in the EU and around the world, as well as for additional clinical studies. Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA requirements, including ensuring that quality control and manufacturing procedures conform to current Good Manufacturing Practices (&#8220;cGMP&#8221;) for medical devices, as set forth in the QSR. As such, we are subject to continual review and periodic inspections to assess compliance with cGMP/QSR requirements as required by our International notified body. Accordingly, we must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. We have limited experience in establishing, supervising and conducting commercial manufacturing. If we or the third-party manufacturers of our products fail to adequately establish, supervise and conduct all aspects of the manufacturing processes, we may not be able to commercialize our products on a timely basis, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Due to our limited marketing, sales and distribution experience, we may be unsuccessful in our efforts to sell our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to enter into agreements with third parties for the commercial marketing, and distribution of our products. There can be no assurance that parties we may engage to market and distribute our products will:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfy their financial or contractual obligations to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adequately market our products; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not offer, design, manufacture or promote competing products.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If for any reason any party we engage is unable or chooses not to perform its obligations under our marketing and distribution agreement, we would experience delays in product sales and incur increased costs, which would harm our business and financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Weakness in the global economy, and in particular in the United States and Europe, could negatively impact our revenue and operating results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The United States and Europe and other economies may suffer from uncertainty, volatility, disruption, and other adverse conditions, such as inflation or the rising cost of energy, and these conditions have adversely impacted and may continue to adversely impact the business community and the financial markets. Adverse economic and financial market conditions may negatively affect our markets, thereby negatively impacting our revenue and operating results. As a result, if economic and financial market conditions weaken or deteriorate, then our revenue and operating results, including our ability to grow and expand our business and operations, could be materially and adversely affected. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our results of operations can be significantly affected by foreign currency fluctuations and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of our revenues is currently derived in the local currencies of the foreign jurisdictions in which our products are sold. Accordingly, we are subject to risks relating to fluctuations in currency exchange rates. In the future, and especially as we further expand our sales efforts in international markets, our customers will increasingly make payments in non-U.S. currencies. Fluctuations in foreign currency exchange rates could affect our revenues, operating costs and operating margins. In addition, currency devaluation can result in a loss to us if we hold deposits of that currency or if it reduces the cost-competitiveness of our products. We cannot predict the effect of future&#160;exchange rate&#160;fluctuations on our operating results.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">If we are unable to convince physicians and other health care providers as to the benefits of our products, we may incur delays or additional expense in our attempt to establish market acceptance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Broad use of our products may require physicians and other health care providers to be informed about our products and their intended benefits, often supported by clinical data. The time and cost of such an educational process, and obtaining such clinical data may be substantial. Inability to successfully carry out this education process, or obtain adequate positive clinical data, may adversely affect market acceptance of our products. We may be unable to educate physicians regarding our products in sufficient numbers or in a timely manner to achieve our marketing plans or to achieve product acceptance. Any delay in physician education may materially delay or reduce demand for our products. In addition, we may expend significant funds towards physician education before any acceptance or demand for our products is created, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">The market for our products is rapidly changing and competitive, and new devices and drugs, which may be developed by others, could impair our ability to maintain and grow our business and remain competitive.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The medical device and pharmaceutical industries are subject to rapid and substantial technological change. Developments by others may render our technologies and products noncompetitive or obsolete. We also may be unable to keep pace with technological developments and other market factors. Technological competition from medical device, pharmaceutical and biotechnology companies, universities, governmental entities and others diversifying into the field is intense and is expected to increase. Many of these entities have significantly greater research and development capabilities and budgets than we do, as well as substantially more marketing, manufacturing, financial and managerial resources. These entities represent significant competition for us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business could be harmed by adverse economic conditions in Germany, our primary geographical market, or by economic and/or political instability in the EU or elsewhere caused by Brexit, trade conflicts, or other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the&#160;year ended December 31, 2022, we derived a majority of our net product sales from sales in Germany. Despite modest European and global growth, there are many economic and political issues that could negatively impact the health of Germany&#8217;s economy, the broader EU economy, and the world economy overall. Examples include the uncertainty over the implications of the United Kingdom&#8217;s exit from the EU, also known as &#8220;Brexit,&#8221; economic instability in a number of EU member countries, and changes in the political leadership in the EU and United States. Germany and other European countries face additional risks to their local economies, some of which include the impact of foreign exchange fluctuations, unemployment, tightening of monetary policy, the economic burden of immigration, diminished liquidity and reliance on debt, the rising cost of healthcare, and other factors. In addition, the German government, insurance companies, health maintenance organizations and other payers of healthcare costs continue to focus on healthcare reform and containment of healthcare costs. We cannot predict whether Germany&#8217;s economy will continue to grow or decline consistent with the overall global economy, which decline would negatively impact the demand for medical devices and healthcare technologies generally and lead to reduced spending on the products we provide. In addition, continued healthcare cost containment efforts may result in lower prices and a reduction or elimination of reimbursement for our products. Due to the concentration of our product sales in this country, any of the foregoing may have a negative impact on our revenues, business operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Significant economic downturns or international trade disruptions or disputes could adversely affect our business and operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Significant portions of our business are conducted in Europe, including the U.K.; Asia; and other international geographies. Interruptions in international relationships such as the recent exit by the U.K. from the EU, or the rapidly evolving conflict between Russia and Ukraine, and trade disputes such as the current trade negotiations between the U.S. and China, could result in changes to regulations governing our products and our intellectual property, disruption of our manufacturing or commercial operations, our inability to timely engage with and collect payment from customers in Russia and other affected regions, or otherwise affect our ability to do business. Additionally, global events such as the current COVID-19 coronavirus pandemic and the conflict in Ukraine, that have or could, slow worldwide economies, disrupt travel and trade, and destabilize financial markets, may interfere with our ability to raise capital, sell and market our products, obtain reimbursement and payment of our products, or reduce the ability of our customers to pay for our product. Although these global problems transcend our company and afflict companies across industries and borders, these and similar events could adversely affect us, or our business partners or customers.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our business may be negatively affected if the United States and/or the countries in which we sell our products participate in wars,&#160;military actions or are otherwise the target of international terrorism.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Involvement in a war or other military action or international acts of terrorism may cause significant disruption to commerce throughout the world. To the extent that such disruptions result in (i) delays or cancellations of customer orders, (ii) a general decrease in consumer spending on healthcare technology, (iii) our inability to effectively market and distribute our products globally (iv) our inability to timely engage with and collect payment from our customers or (v) our inability to access capital markets, our business and results of operations could be materially and adversely affected. For example, in response to the conflict between Russia and Ukraine, the United States has imposed and may further impose, and other countries may additionally impose, broad sanctions or other restrictive actions against governmental and other entities in Russia. CytoSorb is currently distributed in Russia. While the existing sanctions do not currently prohibit the distribution of CytoSorb in Russia, additional sanctions may be imposed in the future that could prevent us from selling CytoSorb in this or other affected regions. Additionally, further escalation of geopolitical tensions could have a broader impact that extends into other markets where we do business. We are unable to predict whether acts of international terrorism or the involvement in a war or other military actions by the United States and/or the countries in which we sell or distribute our products, including Russia, will result in any long-term commercial disruptions or if such involvement or responses will have any long-term material adverse effect on our business, results of operations, or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We could be adversely affected by violations of the Foreign Corrupt Practices Act and similar worldwide anti-bribery laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to the Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;), which generally prohibits companies and their intermediaries from making payments to non-U.S. government officials for the purpose of obtaining or retaining business or securing any other improper advantage. We are also subject to anti-bribery laws in the jurisdictions in which we operate. Although we have policies and procedures designed to ensure that we, our employees and our agents comply with the FCPA and other anti-bribery laws, there is no assurance that such policies or procedures will protect us against liability under the FCPA or other laws for actions taken by our agents, employees and intermediaries with respect to our business or any businesses that we acquire. We do business in a number of countries in which FCPA violations by other companies have recently been enforced. Failure to comply with the FCPA, other anti-bribery laws or other laws governing the conduct of business with foreign government entities, including local laws, could disrupt our business and lead to severe criminal and civil penalties, including imprisonment, criminal and civil fines, loss of our export licenses, suspension of our ability to do business with the federal government, denial of government reimbursement for our products and/or exclusion from participation in government healthcare programs. Other remedial measures could include further changes or enhancements to our procedures, policies, and controls and potential personnel changes and/or disciplinary actions, any of which could have a material adverse effect on our business, financial condition, results of operations and liquidity. We could also be adversely affected by any allegation that we violated such laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">We are subject to governmental export and import controls that could impair our ability to compete in international markets due to licensing requirements and subject us to liability if we are not in compliance with applicable laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our products are subject to export control and import laws, tariffs, and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls. Exports of our products must be made in compliance with these laws, tariffs, and regulations. If we fail to comply with these laws, tariffs, and regulations, we and certain of our employees could be subject to substantial civil or criminal penalties, including the possible loss of export or import privileges; fines, which may be imposed on us and responsible employees or managers; and, in extreme cases, the incarceration of responsible employees or managers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, changes in our products or changes in applicable export or import laws, tariffs, and regulations may create delays in the introduction and sale of our products in international markets or, in some cases, prevent the export or import of our products to certain countries, governments or persons altogether. Any change in export or import laws and regulations, shift in the enforcement or scope of existing laws, tariffs, and regulations, or change in the countries, governments, persons, products, or technologies targeted by such laws, tariffs, and regulations, could also result in decreased use of our products, or in our decreased ability to export or sell our products to existing or potential customers. Any decreased use of our products or limitation on our ability to export or sell our products would likely adversely affect our business, financial condition and results of operations.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cyberattacks and other security breaches could compromise our proprietary and confidential information which could harm our business and reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of our business, we generate, collect and store proprietary information, including intellectual property and business information, as well as employee personal data. The secure storage, maintenance, and transmission of and access to this information is important to our operations our day-to-day business and our reputation. Security breaches have become more common across industries. Computer hackers may attempt to penetrate our computer systems and, if successful, misappropriate our proprietary and confidential information including e-mails and other electronic communications, as well as our intellectual property and business data. In addition, an employee, contractor, or other third-party with whom we do business may attempt to obtain such information, and may purposefully or inadvertently cause a breach involving such information. Further, while many of our employees and certain suppliers with whom we do business operate in a remote working environment during the COVID-19 pandemic, the risk of cybersecurity attacks, particularly through phishing, are increased. We have recently experienced multiple attempts by third parties to penetrate our computer systems. While we have certain safeguards in place to reduce the risk of and detect cyber-attacks, as well as limit the potential exposure of proprietary and confidential information, including multi-layer security protections, our information technology networks and infrastructure may be vulnerable to unpermitted access by hackers or other breaches powered by new and sophisticated technologies, or employee error or malfeasance. Further, we may not be immediately aware of any unpermitted access by hacker or other breaches and we may be unable to quickly and effectively remediate any such breaches. Any such compromise of our data security and access to, or public disclosure or loss of, confidential business or proprietary information could disrupt our operations, damage our reputation, provide our competitors with valuable information, and subject us to additional costs which could adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our failure to comply with data protection laws and regulations could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">European Union member states and other foreign jurisdictions, including Switzerland, have adopted data protection laws and regulations which impose significant compliance obligations. Moreover, the collection and use of personal health data in the European Union, which was formerly governed by the provisions of the European Union Data Protection Directive, was replaced with the European Union General Data Protection Regulation, or the GDPR, in May&#160;2018. The GDPR, which is wide-ranging in scope, imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach notification and the use of third party processors in connection with the processing of personal data. The GDPR also imposes strict rules&#160;on the transfer of personal data out of the European Union to the United States, provides an enforcement authority and imposes large penalties for noncompliance, including the potential for fines of up to &#8364;20&#160;million or 4% of the annual global revenues of the noncompliant company, whichever is greater. The recent implementation of the GDPR has increased our responsibility and liability in relation to personal data that we process, including in clinical trials, and we may in the future be required to put in place additional mechanisms to ensure compliance with the GDPR, which could divert management&#8217;s attention and increase our cost of doing business. In addition, new regulation or legislative actions regarding data privacy and security (together with applicable industry standards) may increase our costs of doing business. In this regard, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data protection in the United States, the European Union and other jurisdictions, and we cannot determine the impact such future laws, regulations and standards may have on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the U.S., even for companies that are not &#8220;covered entities&#8221; or business associates&#8221; under HIPAA, the U.S. Federal Trade Commission, or the FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section&#160;5(a)&#160;of the Federal Trade Commission Act, or the FTCA, 15 U.S.C &#167; 45(a). The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Medical data is considered sensitive data that merits stronger safeguards. The FTC&#8217;s guidance for appropriately securing consumers&#8217; personal information is similar to what is required by the HIPAA Security Rule. Some state privacy and security laws apply more broadly than HIPAA and associated regulations. For example, California recently enacted legislation&#160;&#8211; the California Consumer Privacy Act, or CCPA&#160;&#8211; which went into effect January&#160;1, 2020. The CCPA, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. Legislators have stated that they intend to propose amendments to the CCPA before it goes into effect, and the California Attorney General will issue clarifying regulations. Although the law includes limited exceptions, including for certain information collected as part of clinical trials as specified in the law, it may regulate or impact our processing of personal information depending on the context. It remains unclear what, if any, modifications will be made to this legislation or how it will be interpreted.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Risks Connected to Our Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">The price of our common stock has been highly volatile due to factors that will continue to affect the price of our stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our common stock closed as high as $4.23 and as low as $1.03 per share between January 1, 2022 and December 31, 2022 on Nasdaq. On March 7, 2023, the closing price of our common stock, as reported on Nasdaq, was $3.80. Historically, medical device company securities such as our common stock have experienced extreme price fluctuations. Some of the factors leading to this volatility include, but are not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fluctuations in our operating results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of product releases by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of clinical data, analyst or media reports;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of acquisitions and/or partnerships by us and our competitors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general market conditions.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There is no assurance that the price of our common stock will not continue to be volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Directors, executive officers and principal stockholders own a significant&#160;percentage of the shares of common stock, which will limit your ability to influence corporate matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our directors, executive officers and principal stockholders together beneficially own a significant percentage of the voting control of the common stock on a fully diluted basis. Accordingly, these stockholders could have a significant influence over the outcome of any corporate transaction or other matter submitted to stockholders for approval, including mergers, consolidations and the sale of all or substantially all of our assets and also could prevent or cause a change in control. The interests of these stockholders may differ from the interests of our other stockholders. Third parties may be discouraged from making a tender offer or bid to acquire us because of this concentration of ownership. As of December 31, 2022, two shareholders hold 10.4% of our shares and our directors and officers hold 6.7% of our shares on a fully diluted basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our Board of Directors may, without stockholder approval, issue and fix the terms of shares of preferred stock and issue additional shares of common stock adversely affecting the rights of holders of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;3, 2014, we effected a twenty-five-for-one (25:1) reverse split of our common stock. Immediately after the reverse stock split, we changed our state of incorporation from the State of Nevada to the State of Delaware pursuant to an Agreement and Plan of Merger, dated December&#160;3, 2014, whereby we merged with and into our recently formed, wholly-owned Delaware subsidiary. Pursuant to the Agreement and Plan of Merger effecting the merger, we adopted the certificate of incorporation, as amended and restated, and bylaws of our Delaware subsidiary as our certificate of incorporation and bylaws at effective time of the merger. As a result, our certificate of incorporation, as amended and restated, authorizes the issuance of up to 5,000,000 shares of &#8220;blank check&#8221; preferred stock, with such designation rights and preferences as may be determined from time to time by the Board of Directors. Currently, our certificate of incorporation, as amended and restated, which was effective June&#160;12, 2019, authorizes the issuance of up to 100,000,000 shares of common stock, of which approximately 56,364,000 shares remain available for issuance as of December 31, 2022 and may be issued by us without stockholder approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Anti-takeover provisions in our charter documents and under Delaware law could prevent or delay transactions that our stockholders may favor and may prevent stockholders from changing the direction of our business or our management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">After giving effect to our merger into our wholly-owned Delaware subsidiary, provisions of our certificate of incorporation, as amended and restated, and bylaws may discourage, delay or prevent a merger or acquisition that our stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares, and may also frustrate or prevent any attempt by stockholders to change the direction or management of us. For example, these provisions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorize the issuance of &#8220;blank check&#8221; preferred stock without any need for action by stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eliminate the ability of stockholders to call special meetings of stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibit stockholder action by written consent; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on by stockholders at stockholder meetings.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Compliance with changing corporate governance and public disclosure regulations may result in additional expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Keeping abreast of, and in compliance with, changing laws, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act of 2002, new SEC regulations will require an increased amount of management attention and external resources. We intend to continue to invest all reasonably necessary resources to comply with evolving standards, which may result in increased general and administrative expense and a diversion of management time and attention from revenue-generating activities to compliance activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our common stock is thinly traded on The Nasdaq Capital Market exchange and no assurances can be made about stock performance, liquidity, or maintenance of our Nasdaq listing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to December&#160;23, 2014, our common stock was quoted on the OTCQB, which provided significantly less liquidity than a securities exchange (such as the New York Stock Exchange or the Nasdaq Stock Market). On December&#160;17, 2014, our common stock was approved for trading on Nasdaq. Beginning on December&#160;23, 2014, our common stock began trading on Nasdaq under the symbol &#8220;CTSO.&#8221; Although currently listed on Nasdaq, there can be no assurance that we will continue to meet Nasdaq&#8217;s minimum listing requirements or that of any other national exchange. In addition, there can be no assurances that a liquid market will be created for our common stock. If we are unable to maintain listing on Nasdaq or if a liquid market for our common stock does not develop, our common stock may remain thinly traded.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Future sales of our common stock may cause our share price to fall.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On December 30, 2021 we entered into an Open Market Sale Agreement with Jefferies LLC (the &#8220;Sale Agreement&#8221;). Pursuant to the Sale Agreement we may offer to sell, from time to time shares of our common stock through &#8220;at-the-market&#8221; offerings, up to a maximum of $25,000,000. We are not obligated to make or continue to make any sale of shares of our common stock under the &#8220;at-the-market&#8221; offerings. Although any sale of securities pursuant to the &#8220;at-the-market&#8221; offerings will result in a concomitant increase in cash for each share sold, it may result in shareholder dilution and may cause our share price to fall.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_3f33b3f3_f8d4_4fd4_8870_df2079e32e21"></a><a id="Item1BUnresolvedStaffComments_377036"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item 1B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unresolved Staff Comments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_1822f97e_e00b_4a3a_94c0_f2695bc1cdef"></a><a id="Item2Properties_489629"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item 2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Properties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently operate one facility in Princeton, New Jersey and two facilities in Berlin, Germany as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In March 2021, we entered into a lease agreement for a new 48,511 square foot operating facility at 305 College Road East, Princeton, New Jersey, which contains office, laboratory, manufacturing and warehouse space. The lease commenced in April 2021 and expires in March 2037. As of February 2023, our monthly rent payment is approximately $114,000.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our office facility leases in Berlin, Germany requires combined base rent payments amounting to approximately $12,100 per month. The initial lease term of both leases ends August 31, 2026. In addition, the Company is obligated to monthly operating expenses of approximately $3,000 per month. Both leases have a five-year option to renew that would extend the lease term to August 31, 2031.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our warehouse facility lease in Berlin, Germany commenced on April 1, 2021 and requires monthly payments of base rent of approximately $7,800 and other costs of approximately $240 and has a term of five years. The lease also has an option to extend the lease term for an additional five-year period through March 31, 2031.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In the opinion of management, the leased properties are adequately insured, are in good condition and suitable for the conduct of our business. We also collaborate with numerous institutions, universities and commercial entities who conduct research and testing of our products at their facilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_9efff50f_cf68_4ca3_994c_12156c0a2720"></a><a id="Item3LegalProceedings_168100"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item 3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Legal Proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are from time to time subject to claims and litigation arising in the ordinary course of business. We intend to defend vigorously against any future claims and litigation. We are not currently a party to any legal proceedings.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b90f440b_2d9e_43d9_a3c2_073da074a502"></a><a id="Item4MineSafetyDisclosures_528378"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Item 4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mine Safety Disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_8dc7627a_817f_49a4_83ef_c5e9b726b3b0"></a><a id="PARTII_26266"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="Item5MarketforRegistrantsCommon_854774"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-align:justify;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">Item 5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Market Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Beginning on December&#160;23, 2014, our common stock began trading on Nasdaq under the symbol &#8220;CTSO.&#8221; Previously, the Company&#8217;s common stock traded in the over-the counter-market on the OTC Bulletin Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Approximate Number of Equity Security Holders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of February 13, 2023, there were approximately 11,200 stockholders of record. Because shares of our common stock are held by depositaries, brokers and other nominees, the number of beneficial holders of our shares is larger than the number of stockholders of record.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Issuer Purchases of Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There were no repurchases of the Company&#8217;s securities during the&#160;year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Sales of Unregistered Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We had no sales of unregistered securities in 2022 that have not been previously disclosed in a Current Report on Form&#160;8-K or Quarterly Report on Form&#160;10-Q.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_67950b2f_7614_4833_8e36_5c3cda7e86d4"></a><a id="Item6SelectedFinancialData_161884"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Item 6. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;[Reserved]</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_962bf3fb_8ff2_4bdf_81e9_c2fbb27ce3e2"></a><a id="Item7ManagementsDiscussion_675843"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following discussion and analysis of the results of operations and financial condition for the fiscal years ended December 31, 2022, 2021 and 2020 should be read in conjunction with our financial statements, and the notes to those financial statements that are included elsewhere in this Report.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a leader in the treatment of life-threatening conditions in the intensive care (&#8220;ICU&#8221;) and cardiac surgery using blood purification via our proprietary polymer adsorption technology. We have a number of products commercialized and in development based on this technology platform. Our flagship product, CytoSorb&#174;, is already commercialized, and is being used to reduce deadly uncontrolled inflammation and dangerous substances in hospitalized patients around the world, with the goal of preventing or treating multiple organ failure, bleeding, and other potentially fatal complications. Organ failure is the cause of nearly half of all deaths in the ICU, with little to improve clinical outcome. CytoSorb, is approved in the European Union (&#8220;EU&#8221;) as an effective extracorporeal cytokine absorber, designed to reduce the &#8220;cytokine storm&#8221; or &#8220;cytokine release syndrome&#8221; that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. These are conditions where the mortality is extremely high, yet few to no effective treatments exist. In May 2018, we received a label expansion for CytoSorb covering use of the device for the removal of bilirubin and myoglobin in the treatment of liver disease and trauma, respectively. In January 2020, we received CE-Mark label expansion for CytoSorb covering the use of the device for the removal of the anti-platelet agent, ticagrelor, in patients undergoing surgery requiring cardiopulmonary bypass. In April 2020, the United States Food and Drug Administration (the &#8220;FDA&#8221;) granted Breakthrough Device Designation to CytoSorb for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery. In April 2020, we announced that the U.S. FDA has granted U.S. Emergency Use Authorization (&#8220;EUA&#8221;) of CytoSorb for use in critically ill patients with COVID-19 infection and respiratory failure. In May 2020, we received a CE-Mark label expansion for CytoSorb for the removal of rivaroxaban during cardiothoracic surgery requiring cardiopulmonary bypass. In August 2021, the Company announced that it was granted a second Breakthrough Device Designation for its DrugSorb-ATR Antithrombotic Removal System by the FDA to remove the direct oral anticoagulants, rivaroxaban and apixaban. The Company has initiated a pivotal randomized, controlled clinical trial in the U.S. and Canada, called the STAR-T trial, evaluating the use of DrugSorb-ATR during cardiothoracic surgery to remove ticagrelor to prevent or reduce perioperative bleeding complications in pursuit of U.S. FDA and Health Canada marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CytoSorb is used during and after cardiac surgery to remove inflammatory mediators, such as cytokines, activated complement, and free hemoglobin that can lead to post-operative complications such as acute kidney injury, lung injury, shock, and stroke. We believe CytoSorb has the potential to be used in many other inflammatory conditions, including the treatment of autoimmune disease flares, cytokine release syndrome in cancer immunotherapy, and other applications in cancer, such as cancer cachexia. CytoSorb has been used globally in more than 195,000 human treatments to date in critical illnesses and in cardiac surgery. CytoSorb has received CE-Mark label expansions for the removal of bilirubin (liver disease), myoglobin (trauma) and both ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in critically-ill COVID-19 patients with imminent or confirmed respiratory failure, in defined circumstances. The EUA will be effective until a declaration is made that the circumstances justifying the EUA have terminated or until revoked by the FDA. CytoSorb has been used globally in more than 7,650 human treatments to date in COVID-19 patients. CytoSorb has also been granted FDA Breakthrough Designation for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery. CytoSorb was also granted a second FDA Breakthrough Device designation for the removal of the Direct Oral Anticoagulants (DOACs) apixaban and rivaroxaban in a cardiopulmonary bypass circuit to reduce the likelihood of serious perioperative bleeding during urgent cardiothoracic surgery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The technology is protected by 18 issued U.S. patents and multiple international patents, with applications pending both in the U.S. and internationally. We have numerous other product candidates under development based upon this unique blood purification technology, including CytoSorb XL, K<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup>ontrol, HemoDefend-RBC, HemoDefend-BGA, ContrastSorb, DrugSorb, DrugSorb-ATR and others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our proprietary polymer technologies form the basis of a broad technology portfolio. Some of our products and product candidates include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CytoSorb &#8212; an extracorporeal hemoperfusion cartridge approved in the EU for cytokine removal, with the goal of reducing SIRS and sepsis and preventing or treating organ failure.</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">DrugSorb-ATR &#8212; an investigational extracorporeal antithrombotic removal system based on the same polymer technology as CytoSorb that is being evaluated in the U.S. STAR-T and future STAR-D pivotal randomized, controlled trials to reduce the level of antithrombotic drugs, ticagrelor, apixaban and rivaroxaban to reduce bleeding complications in patients undergoing cardiothoracic surgery while on these drugs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ECOS-300CY &#8212; an adsorption cartridge approved in the E.U. for use with </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">ex vivo</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> organ perfusion systems to remove cytokines and other inflammatory mediators in the organ perfusate, with the goal of maintaining or improving solid organ function prior to transplant. In 2021, commercialization of PerSorb&#8482; and Aferetica&#8217;s PerLife&#8482; </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">ex vivo</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> organ perfusion system commenced in Italy.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">CytoSorb XL &#8212; an intended next generation successor to CytoSorb currently in advanced pre-clinical testing designed to reduce a broad range of cytokines and inflammatory mediators, including lipopolysaccharide endotoxin, from blood.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">VetResQ &#8212; a broad spectrum blood purification adsorber designed to help treat deadly inflammation and toxic injury in animals with critical illnesses such as septic shock, toxic shock syndrome, severe systemic inflammation, toxin-mediated diseases, pancreatitis, trauma, liver failure, and drug intoxication. VetResQ is being commercialized in the United States.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HemoDefend-RBC&#8212;a development-stage blood purification technology designed to remove non-infectious contaminants in blood transfusion products, with the goal of reducing transfusion reactions and improving the quality and safety of blood. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HemoDefend-BGA&#8212;a development-stage purification technology that can remove anti-A and anti-B antibodies from plasma and whole blood, to enable &#8220;universal plasma,&#8221; and safer whole blood transfusions, respectively.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">K</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">+</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ontrol&#8212;a development-stage blood purification technology designed to reduce excessive levels of potassium in the blood that can be fatal in severe hyperkalemia.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ContrastSorb&#8212;a development-stage extracorporeal hemoperfusion cartridge designed to remove IV contrast from the blood of high-risk patients undergoing radiological imaging with contrast, or interventional radiology procedures such as cardiac catheterization and angioplasty. The goal of ContrastSorb is to prevent contrast-induced nephropathy.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">DrugSorb&#8212;a development-stage extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood (e.g., drug overdose, high dose regional chemotherapy).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">BetaSorb&#8212;a development-stage extracorporeal hemoperfusion cartridge designed to remove mid-molecular weight toxins, such as b2-microglobulin, that standard high-flux dialysis cannot remove effectively. The goal of BetaSorb is to improve the efficacy of dialysis or hemofiltration.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have been successful in obtaining technology development contracts from governmental agencies such as the National Institutes of Health and the U.S. Department of Defense, including the Defense Advanced Research Projects Agency, or DARPA, the U.S. Army, the U.S. Air Force, U.S. Special Operations Command, and others.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comparison of the&#160;year ended December 31, 2022 and 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenues:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2022, we generated total revenue, which includes product revenue and grant income, of approximately $34,689,000 as compared to revenues of approximately $43,166,000 for the year ended December 31, 2021, a decrease of approximately $8,477,000, or 20%. Revenue from product sales was approximately $29,360,000 for the year ended December 31, 2022, as compared to approximately $40,109,000 in the year ended December 31, 2021, a decrease of approximately $10,749,000 or 27%. Direct sales decreased by approximately $8,983,000 and distributor sales decreased by approximately $1,766,000 during the year ended December 31, 2022 as compared to the year ended December 31, 2021. Sales to hospitals in the United States under the EUA granted by the FDA amounted to approximately $300,000 for the year ended December 31, 2022, as compared to approximately $1,690,000 in 2021. Though difficult to quantify, we estimate that approximately $300,000 and approximately $6,300,000 of total product sales during the years ended December 31, 2022 and 2021 was due to the demand for CytoSorb to treat COVID-19 patients. In addition, as a result of the decrease in the average exchange rate of the Euro to the U.S. dollar, 2022 product sales were negatively impacted by approximately $3,127,000. For the year ended December 31, 2022, the average exchange rate of the Euro to the U.S. dollar was $1.05 as compared to an average exchange rate of $1.18 for the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grant income was approximately $5,329,000 for the year ended December 31, 2022 as compared to approximately $3,057,000 for the year ended December 31, 2021, an increase of approximately $2,272,000, or 74%. During the year ended December 31, 2021, our research and development employees were either deployed to work-from-home status or reassigned to assist in activities related to increasing the production of CytoSorb. In 2022, research and development employees were assigned primarily to grant related activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cost of Revenue:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2022 and 2021, cost of revenue was approximately $13,956,000 and $11,047,000, respectively, an increase of approximately $2,909,000. This increase was due to an increase in grant cost of revenue of approximately $2,210,000 due to the increase in billable hours charged to our grant related projects. Product cost of revenues increased approximately $698,000 during the year ended December 31, 2022 as compared to the year ended December 31, 2021. This increase was primarily due to an equipment failure of a refrigeration unit at our new manufacturing facility that caused a net write-off (after insurance proceeds) of approximately $300,000 of work-in-process inventory (see Note 2 to the financial statements) and inefficiencies associated with lower production due to a decrease in production volume and inefficiencies associated with relocating our production activities to the new facility. Product gross margins were approximately 70% for the year ended December 31, 2022 and approximately 80% for the year ended December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Gross Profit:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Gross profit was approximately $20,733,000 for the year ended December 31, 2022, a decrease of approximately $11,385,000 or 35%, versus gross profit of $32,118,000 in 2021. This decrease is attributed to lower sales, the inventory write-off related to an equipment failure and inefficiencies associated with the process of relocating our production activities to the new facility as discussed above. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our research and development costs were approximately $15,119,000 and $16,381,000 for the years ended December 31, 2022 and 2021, respectively, a decrease of approximately $1,262,000, or 8%. This decrease was due to a decrease in clinical trial related costs of approximately $2,448,000, due primarily to the temporary pause of our STAR-D clinical trial in the U.S. and the discontinuation of the Hep-On-Fire clinical trial in Germany, a decrease in rent expense to research and development of approximately $685,000 related to our new facility and a decrease in non-grant related research and development costs of approximately $187,000. These decreases were offset by an increase in salaries related to our clinical trial activities of approximately $1,694,000 due to the hiring of additional clinical expertise and an increase in other research and development labor costs of approximately $364,000 related to the hiring of additional scientific expertise.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Legal, Financial and Other Consulting Expenses:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our legal, financial and other consulting costs were approximately $2,848,000 and $2,732,000 for the years ended December 31, 2022 and 2021, respectively, an increase of approximately $116,000, or 4%. This increase was due to an increase in legal fees of approximately $685,000 due to the abandonment of certain issued patents and patent applications and an increase in accounting fees of approximately $169,000. These increases were offset by a decrease in consulting fees of approximately $396,000 and a decrease in hiring fees of approximately $342,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Selling, General and Administrative Expenses:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our selling, general and administrative expenses were approximately $34,288,000 and $35,750,000 for the years ended December 31, 2022 and 2021, respectively, a decrease of approximately $1,462,000, or 4%. This decrease was due to a decrease of salary and commission costs of approximately $594,000 due to a reduction in commissions due to lower sales, a decrease in royalty expense of approximately $915,000 due to lower sales, a decrease in non-cash restricted stock expense of approximately $1,771,000 related to restricted stock units granted to the Company&#8217;s executive officers, a decrease in non-cash stock compensation expense of approximately $597,000 and a decrease in other general and administrative expenses of approximately $324,000. These decreases were offset by an increase sales and marketing costs, which include advertising and conference attendance, of approximately $797,000, an increase in travel and entertainment costs of approximately $530,000 and an increase in occupancy costs of approximately $1,412,000 related to the rent expense on our new manufacturing facility. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Gain (Loss) on Foreign Currency Transactions:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2022, the loss on foreign currency transactions was approximately $2,449,000, as compared to a loss on foreign currency transactions of approximately $2,578,000 for the year ended December 31, 2021. The 2022 loss is directly related to the decrease of the exchange rate of the Euro as of December 31, 2022 as compared to December 31, 2021. The exchange rate of the Euro to the U.S. dollar was $1.07 per Euro at December 31, 2022 as compared to $1.14 per Euro at December 31, 2021. The 2021 loss is directly related to the decrease in the exchange rate of the Euro as of December 31, 2021, as compared to December 31, 2020. The exchange rate of the Euro to the U.S. dollar was $1.14 per Euro at December 31, 2021 as compared to $1.22 per Euro at December 31, 2020. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Benefit from Income Taxes:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our benefit from income taxes was approximately $1,093,000 and $736,000 for the years ended December 31, 2022 and 2021, respectively. These benefits were realized by utilizing the New Jersey Technology Business Tax Certificate Transfer Program whereby the State of New Jersey allows us to sell a portion of our state net operating losses to a third party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Comparison of the year ended December 31, 2021 and 2020</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenues:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2021, we generated total revenue, which includes product revenue and grant income, of approximately $43,166,000 as compared to revenues of approximately $41,005,000 for the year ended December 31, 2020, an increase of approximately $2,161,000, or 5%. Revenue from product sales was approximately $40,109,000 for the year ended December 31, 2021, as compared to approximately $39,453,000 in the year ended December 31, 2020, an increase of approximately $656,000 or 2%. Direct sales increased by approximately $361,000 and distributor sales increased by approximately $295,000 during the year ended December 31, 2021 as compared to the year ended December 31, 2020. Sales to hospitals in the United States under the EUA granted by the FDA amounted to approximately $1,690,000 for the year ended December 31, 2021, as compared to approximately $1,341,000 in 2020. Though difficult to quantify, we estimate that approximately $6.3 million and $9.4 million of total product sales during the years ended December 31, 2021 and 2020 was due to the demand for CytoSorb to treat COVID-19 patients. In addition, as a result of the increase in the average exchange rate of the Euro to the U.S. dollar, sales were positively impacted by approximately $1,207,000. For the year ended December 31, 2021, the average exchange rate of the Euro to the U.S. dollar was $1.18 as compared to an average exchange rate of $1.14 for the year ended December 31, 2020.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Cost of Revenue:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2021 and 2020, cost of revenue was approximately $11,047,000 and $11,052,000, respectively, a decrease of approximately $5,000. Product cost of revenues decreased approximately $1,447,000 during the year ended December 31, 2021 as compared to the year ended December 31, 2020. This decrease was related to certain costs associated with the rapid ramp-up of production during the year ended December 31, 2020 that did not recur during the year ended December 31, 2021. These decreases were offset by the negative impact of non-recurring costs related to prior years tariffs as a result of an audit by the German Customs Authorities of approximately $732,000 and the offsetting non-recurring positive impact of the Employee Retention Tax Credit of approximately $388,000, both of which were recorded in the first quarter of 2021. Product gross margins were approximately 80% for the year ended December 31, 2021 and approximately 76% for the year ended December 31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Gross Profit:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Gross profit was approximately $32,118,000 for the year ended December 31, 2021, an increase of approximately $2,166,000 or 7%, over gross profit of $29,952,000 in 2020. This increase is attributed to the reasons discussed above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our research and development costs were approximately $16,381,000 and $8,811,000 for the years ended December 31, 2021 and 2020, respectively, an increase of approximately $7,570,000, or 86%. This increase was due to an increase in clinical trial and related costs of approximately $4,670,000, due primarily to the start-up of our STAR-T and STAR-D clinical trials in the <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">U.S. and our PROCYSS and Hep-On-Fire clinical trials in Germany,</span> an increase in salaries related to our clinical trial activities of approximately $1,620,000 due to the hiring of additional clinical expertise, an increase in rent expense of approximately $943,000 related to rent expense on our new facility, an increase in other research and development labor costs of approximately $294,000 related to the hiring of additional scientific expertise and an increase in other research and development costs of approximately $43,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Legal, Financial and Other Consulting Expenses:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our legal, financial and other consulting costs were approximately $2,732,000 and $3,048,000 for the years ended December 31, 2021 and 2020, respectively, a decrease of approximately $316,000, or 10%. This decrease was due to due to a decrease in hiring fees of approximately $319,000, a decrease in legal fees of approximately $263,000, and a decrease in accounting fees of approximately $28,000. These increases were offset by an increase in consulting fees of approximately $294,000 related to certain corporate initiatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Selling, General and Administrative Expenses:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our selling, general and administrative expenses were approximately $35,750,000 and $28,464,000 for the years ended December 31, 2021 and 2020, respectively, an increase of approximately $7,286,000, or 26%. This increase is related to an increase in salaries, commissions and related costs of approximately $4,476,000, an increase in non-cash restricted stock expense of approximately $989,000 related to restricted stock units granted to the Company&#8217;s executive officers, an increase in non-cash stock option compensation expense of approximately $507,000, an increase in commercial insurance of approximately $280,000, an increase in sales and marketing costs, which include advertising and conference attendance of approximately $1,152,000 and an increase in travel and entertainment costs of approximately $121,000. These increases were offset by a decrease in contracted public relations costs of approximately $210,000 and a decrease in other general and administrative expenses of approximately $29,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Interest Expense, Net:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2021, interest income, net was approximately $28,000, as compared to interest expense, net of approximately $1,201,000 for the year ended December 31, 2020. This decrease in net interest expense of approximately $1,229,000 was the result of the payoff of our outstanding term loans with Bridge Bank in December of 2020.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Gain (Loss) on Foreign Currency Transactions:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2021, the loss on foreign currency transactions was approximately $2,578,000, as compared to a gain on foreign currency transactions of approximately $2,607,000 for the year ended December 31, 2020. The 2021 loss is directly related to the decrease of the exchange rate of the Euro at December 31, 2021 as compared to December 31, 2020. The exchange rate of the Euro to the U.S. dollar was $1.14 per Euro at December 31, 2021 as compared to $1.22 per Euro at December 31, 2020. The 2020 gain is directly related to the increase in the exchange rate of the Euro at December 31, 2020, as compared to December 31, 2019. The exchange rate of the Euro to the U.S. dollar was $1.22 per Euro at December 31, 2019 as compared to $1.12 per Euro at December 31, 2019. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Benefit from Income Taxes:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our benefit from income taxes was approximately $736,000 and $1,127,000 for the years ended December 31, 2021 and 2020, respectively. These benefits were realized by utilizing the New Jersey Technology Business Tax Certificate Transfer Program whereby the State of New Jersey allows us to sell a portion of our state net operating losses to a third party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since inception, our operations have been primarily financed through the private and public placement of our debt and equity securities. At December 31, 2022, we had current assets of approximately $33,760,000 including cash, cash equivalents and restricted cash on hand of approximately $23,832,000 and had current liabilities of approximately $9,715,000. All of the $25 million of our total shelf amount allocated to our ATM facility was available as of December 31, 2022. On December 27, 2022, we drew down the first $5 million tranche of the Term C loans available under the terms of our Amended Loan and Security Agreement with Bridge Bank (see below). Also, we expect to receive approximately $1,093,000 in cash from the approved sale of our net operating losses and research and development credits from the State of New Jersey in the first half of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, cash, cash equivalents and restricted cash were $23.8 million compared to $53.8 million as of December 31, 2021. After taking into account the $5 million related to our debt drawdown, our 2022 cash burn was approximately $35.0 million. This cash burn was due to lower-than-expected sales volumes, product gross margins that were lower due to decreased production volumes, and operating efficiencies associated with the move to our new manufacturing facility, capital expenditures of approximately $6.3 million related to our new facility and other factors (e.g. a delay in realizing savings from cost cutting due to notice periods and labor laws in Europe). A reduction in product gross margins from 80% in 2021 to 70% in 2022, unfavorably impacted our cash burn by approximately $2.9 million. We expect product gross margins to return to previous levels as we transition production fully to the new facility by the end of this year, end the lease at our Deer Park Drive facility, and begin to capture anticipated manufacturing efficiencies driven by expected improvement in market conditions and increased product demand.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are also managing our resources proactively, continuing to invest in key areas such as our U.S. clinical program. while driving cost-cutting throughout our Company. At the beginning of Q2 2022, we began instituting tighter cost controls and have reduced our headcount (including full and part-time employees and consultants) internationally by 10%, with the goal of reducing our cash burn. In addition, we have shifted our R&amp;D headcount to funded grant programs, where we have an $11.5 million backlog as of December&#160;31, 2022. Some of our costs savings of our headcount reduction are not yet visible in our results due to notice periods and labor laws in Europe but will be reflected in our 2023 operating budget. Meanwhile, we are working diligently to prioritize activities that we believe have a near-term return on investment and advance our strategic priorities, which cutting non-core or non-essential activities and spend. Our goal is, through a combination of driving an increase in sales and gross margin, and cutting costs, to significantly reduce our cash burn and to extend our operating runway with the resources we have.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based upon the foregoing, we believe that we have sufficient cash to fund the Company&#8217;s operations beyond twelve months from the issuance of the consolidated financial statements included elsewhere in this Annual Report on Form 10-K. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Loan and Security Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company and its wholly-owned subsidiary, CytoSorbents Medical, Inc. (together, the &#8220;Borrower&#8221;), are parties to that certain Loan and Security Agreement (&#8220;Original Agreement&#8221;) with Bridge Bank, a division of Western Alliance Bank, (the &#8220;Bank&#8221;), which was most recently amended on January 19, 2022 (the &#8220;Fourth Amendment Date&#8221;) under that certain Fourth Amendment to the Amended and Restated Loan and Security Agreement (the &#8220;Fourth Amendment&#8221; and the Original Agreement, as so amended, the &#8220;Loan Agreement&#8221;). Under the Loan Agreement, the Bank has agreed to loan a tranche of term loans in the aggregate amount of $15 million, which are available for the Company to draw down at its sole discretion in three tranches of $5 million each at any time during the period commencing on the Fourth Amendment Date and ending on the earlier of (i) December 31, 2022 and (ii) the occurrence of an Event of Default (as defined in the Loan Agreement) (the &#8220;Term C Loan&#8221;). On December 27, 2022, the Company drew down the first $5 million tranche of the Term C loans available under the terms of the Fourth Amendment. On December 28, 2022 (the &#8220;Fifth Amendment Date&#8221;), the Company entered into the Fifth Amendment of its Amended Loan and Security Agreement with Bridge Bank. The Fifth Amendment extends the draw period under the Fourth Amendment to the earlier of (i) March 1, 2023 and (ii) the occurrence of an Event of Default. On March&#160;9,&#160;2023, the Company entered into the Sixth Amendment of its Amended Loan and Security Agreement. The Sixth Amendment further extends the draw period to March&#160;24,&#160;2023. For further discussion regarding the Loan Agreement and the Term C Loan, please see Note 7 &#8211; Long Term Debt to our Consolidated Financial Statements, included elsewhere in this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies and Estimates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. We believe the following critical accounting policies and estimates have significant effect in the preparation of our consolidated financial statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Patents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Legal costs incurred to establish patents are capitalized. When patents are issued, capitalized costs are amortized on the straight-line method over the related patent term. In the event a patent is abandoned, the net book value of the patent is written off.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Revenue Recognition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Product Sales:</i> Revenues from sales of products to both direct and distributor/strategic partner customers are recognized at the time when control passes to the customer, in accordance with the terms of their respective contracts. Recognition of revenue occurs as each performance obligation is completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Grant Revenue:</i> Revenue from grant income is based on contractual agreements with various agencies of the United States government. Certain agreements provide for reimbursement of costs, other agreements provide for reimbursement of costs and an overhead margin and certain agreements are performance based, where revenue is earned based upon the achievement of milestones outlined in the contract. Revenues are recognized when the associated performance obligation is fulfilled. Costs are recorded as incurred. Amounts invoiced in excess of costs actually incurred on fixed price contracts are classified as deferred revenue and are included in accrued expenses and other current liabilities in the consolidated balance sheet. Costs subject to reimbursement by these grants have been reflected as costs of revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Research and Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All research and development costs, payments to laboratories, research consultants and costs related to clinical trials and studies are expensed when incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock Based-Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We account for our stock-based compensation under the recognition requirements of accounting standards for accounting for stock-based compensation for employees and directors whereby each option granted is valued at fair market value on the date of grant. Under these accounting standards, the fair value of each option is estimated on the date of grant using the Black-Scholes option pricing model.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also follow the guidance of accounting standards for accounting for equity instruments that are issued to other than employees for acquiring, or in conjunction with selling, goods or services for equity instruments issued to consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Lease Commitments</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently operate our leased facility in Princeton, New Jersey and two leased facilities in Berlin, Germany as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In March 2021, we entered into a lease agreement for a new 48,511 square foot operating facility at 305 College Road East, Princeton, New Jersey, which contains office, laboratory, manufacturing and warehouse space. The lease commenced in April 2021 and expires in March 2037. As of February 2023, our monthly base rent is approximately $114,000.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our office facility leases in Berlin, Germany requires combined base rent payments amounting to approximately $12,100 per month. The initial lease term of both leases ends August 31, 2026. In addition, the Company is obligated to monthly operating expenses of approximately $3,000 per month. Both leases have a five-year option to renew that would extend the lease term to August 31, 2031.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our warehouse facility lease in Berlin, Germany commenced on April 1, 2021 and requires monthly payments of base rent of approximately $7,800 and other costs of approximately $240 and has a term of five years. The lease also has an option to extend the lease term for an additional five-year period through March 31, 2031.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_c804a6ac_a541_4933_a5e9_2936e6933b48"></a><a id="Item7AQuantitativeandQualitative_332696"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 7A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are exposed to certain market risks in the ordinary course of business. These risks result primarily from changes in foreign currency exchange rates and interest rates. In addition, international operations are subject to risks related to differing economic conditions, changes in political climate, differing tax structures and other regulations and restrictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">To date we have not utilized derivative financial instruments or derivative commodity instruments. We do not expect to employ these or other strategies to hedge market risk in the foreseeable future. Cash is held in checking, savings, and money market funds, which are subject to minimal credit and market risk. We generate sales in both dollars and euros most significantly, the majority of our sales are in Euros and changes in the exchange rate of the Euro to the U.S. dollar may positively or negatively impact our revenue. On the other hand, should sales decline due to a devaluation of the Euro relative to the U.S. dollar, expenses related to our European subsidiary would also decline. This produces a natural currency hedge. We believe that the market risks associated with these financial instruments are immaterial, although there can be no guarantee that these market risks will be immaterial to us in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_7b303854_d063_4ae5_a6ea_cb25c03748a1"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Financial Statements and notes thereto are included elsewhere in this Annual Report on Form&#160;10-K and incorporated herein by reference. See Item&#160;15 of Part&#160;IV.</p><a id="_10f24966_0a3e_4de4_8fee_90589642d591"></a><a id="Item9ChangesinandDisagreements_449418"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_bc2d69fd_0fa7_429c_8cf5_016a84ccccdf"></a><a id="Item9AControlsandProcedures_8889"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 9A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In accordance with Rules&#160;13a-15 and 15d-15, under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), we carried out an evaluation, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2022, to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is (1)&#160;recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules&#160;and forms and (2)&#160;accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management&#8217;s report on internal control over financial reporting procedures (as defined in Rule&#160;13a-15(f)&#160;under the Exchange Act) is included with the financial statements reflected in Item&#160;8 of this Annual Report on Form&#160;10-K and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Attestation Report of the Registered Public Accounting Firm</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WithumSmith+Brown, PC, the independent registered public accounting firm that audited the financial statements of included in Item&#160;8 of this Annual Report on Form&#160;10-K, has issued an attestation report on the effectiveness of our internal control over financial reporting as of December 31, 2022. This report is included with the financial statements included in Item&#160;8 of this Annual Report on Form&#160;10-K and incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">No change in our internal control over financial reporting occurred during the fiscal quarter ended December 31, 2022 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_282c86c0_d394_44ba_8de3_5be8b9232147"></a><a id="Item9BOtherInformation_93888"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 9B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_2e4db027_c082_4964_b904_6279e7baa05b"></a><a id="Item9CDisclosureRegardingForeignJurisdic"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 9C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosure Regarding Foreign Jurisdictions that Prevent Inspection.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_aedbecf5_6985_4299_8171_6354b3d78976"></a><a id="PARTIII_135582"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="Item10DirectorsExecutive_646044"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 10.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Directors, Executive Officers and Control Persons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Information required to be disclosed by this Item with respect to our executive officers is incorporated in this Annual Report on Form 10-K by reference from the section entitled &#8220;Officers and Key Employees&#8221; contained in our definitive proxy statement for our 2023 annual meeting of stockholders scheduled to be held on June 6, 2023, which we intend to file within 120 days of the end of our fiscal year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Information required to be disclosed by this Item about our board of directors is incorporated in this Annual Report on Form 10-K by reference from the section entitled &#8220;Nomination and Election of Directors&#8221; contained in our definitive proxy statement for our 2023 annual meeting of stockholders scheduled to be held on June 6, 2023, which we intend to file within 120 days of the end of our fiscal year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent required, information required to be disclosed by this Item about the Section 16(a) compliance of our directors and executive officers is incorporated in this Annual Report on Form 10-K by reference from the section entitled &#8220;Section 16(a) Beneficial Ownership Reporting Compliance&#8221; contained in our definitive proxy statement for our 2023 annual meeting of stockholders scheduled to be held on June 6, 2023, which we intend to file within 120 days of the end of our fiscal year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Information required to be disclosed by this Item about our board of directors, the audit committee of our board of directors, our audit committee financial expert, our Code of Business Conduct and Ethics, and other corporate governance matters is incorporated in this Annual Report on Form 10-K by reference from the section entitled &#8220;Board of Directors and Corporate Governance Matters&#8221; contained in our definitive proxy statement for our 2023 annual meeting of stockholders scheduled to be held on June 6, 2023, which we intend to file within 120 days of the end of our fiscal year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The text of our Code of Business Conduct and Ethics, which applies to our directors and employees (including our principal executive officer, principal financial officer, and principal accounting officer or controller, and persons performing similar functions), is posted in the &#8220;Corporate Governance&#8221; section of our website, www.cytosorbents.com. A copy of the Code of Business Conduct and Ethics can be obtained free of charge on our website. We intend to disclose on our website any amendments to, or waivers from, our Code of Business Conduct and Ethics that are required to be disclosed pursuant to the rules of the Securities and Exchange Commission and The Nasdaq Stock Market.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information presented on our website is not a part of this Annual Report on Form 10-K and the reference to our website is intended to be an inactive textual reference only.</p><a id="_f678ebf7_b5cd_4395_a600_b3957c39cd06"></a><a id="Item11ExecutiveCompensation_213048"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Executive Compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Information required to be disclosed by this Item is incorporated in this Annual Report on Form 10-K by reference from the sections entitled &#8220;Executive Compensation,&#8221; &#8220;Director Compensation&#8221; and &#8220;Board of Directors and Corporate Governance Matters&#8221; contained in our definitive proxy statement for our 2023 annual meeting of stockholders scheduled to be held on June 6, 2023, which we intend to file within 120 days of the end of our fiscal year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_2ece8eab_7d63_4667_8e53_f497a6c18f67"></a><a id="Item12SecurityOwnershipofCertain_469677"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Information required to be disclosed by this Item is incorporated in this Annual Report on Form 10-K by reference from the sections entitled &#8220;Principal Stockholders,&#8221; &#8220;Stock Ownership of Directors, Nominees for Director, and Executive Officers&#8221; and &#8220;Equity Compensation Plan Information&#8221; contained in our definitive proxy statement for our 2023 annual meeting of stockholders scheduled to be held on June 6, 2023, which we intend to file within 120 days of the end of our fiscal year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e474099f_f0a0_488d_86c3_e1b02eb1dcb6"></a><a id="Item13CertainRelationships_177588"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Certain Relationships and Related Transactions and Director Independence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Information required to be disclosed by this Item is incorporated in this Annual Report on Form 10-K by reference from the section(s) entitled &#8220;Certain Relationships and Related Party Transactions&#8221; and &#8220;Board of Directors and Corporate Governance Matters,&#8221; &#8220;Compensation for Executive Officers and Directors, &#8220;Compensation Committee Interlocks and Insider Participation&#8221; and &#8220;Compensation Committee Report&#8221; contained in our definitive proxy statement for our 2023 annual meeting of stockholders scheduled to be held on June 6, 2023, which we intend to file within 120 days of the end of our fiscal year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_efa06cd2_4c20_4dd1_87b6_80c19e152409"></a><a id="Item14PrincipalAccounting_380347"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Principal Accounting Fees and Services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">This information required to be disclosed by this Item is incorporated in this Annual Report on Form 10-K by reference from the section entitled &#8220;Audit and Other Fees&#8221; contained in our definitive proxy statement for our 2022 annual meeting of stockholders scheduled to be held on June 6, 2023, which we intend to file within 120 days of the end of our fiscal year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_f0b818f2_6cd7_47b8_9358_d1b23b713300"></a><a id="PARTIV_315404"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;IV</p><a id="Item15Exhibits_936320"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 15.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits, Financial Statement Schedules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Schedules:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The following consolidated financial statements and reports of independent registered public accounting firm are included herein:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:94%;margin:0pt;padding:0pt 0.75pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:94%;margin:0pt;padding:0pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ReportofIndependentRegistered_62145"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-3</p></td></tr><tr><td style="vertical-align:top;width:94%;margin:0pt;padding:0pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#BALANCESHEETS_482564"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets</span></a></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:top;width:94%;margin:0pt;padding:0pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#COMPREHENSIVELOSS_723576"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:top;width:94%;margin:0pt;padding:0pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#EQUITY_583355"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Changes in Stockholders&#8217; Equity</span></a></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-7</p></td></tr><tr><td style="vertical-align:top;width:94%;margin:0pt;padding:0pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CASHFLOWS_61773"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows</span></a></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-8</p></td></tr><tr><td style="vertical-align:top;width:94%;margin:0pt;padding:0pt 0.75pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NotestoConsolidatedFinancialStatements_9"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:6%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-9</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;Financial Statement Schedules</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;List of Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">No.</b></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000114420419030840/tv523529_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated Certificate of Incorporation, dated June&#160;12, 2019 (incorporated by reference to Exhibit&#160;3.1 to the Registrant&#8217;s Current Report on Form&#160;8-K filed on June&#160;13, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000110465920000438/tm1928370d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws of CytoSorbents Corporation (incorporated by reference to Exhibit&#160;3.1 to the Registrant&#8217;s Current Report on Form&#160;8-K filed on April 8, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.1*</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000141057822000331/ctso-20211231xex4d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Capital Stock of CytoSorbents Corporation (incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Annual Report on Form 10-K filed on March 10, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1+</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000114420419037670/tv526294_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement, dated as of July&#160;30, 2019, by and between CytoSorbents Medical,&#160;Inc. and Phillip P. Chan (incorporated by reference to Exhibit&#160;10.1 of the Registrant&#8217;s current report on Form&#160;8-K filed on August&#160;5, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.2+</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000114420419037670/tv526294_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement, dated as of July&#160;30 2019, by and between CytoSorbents Medical,&#160;Inc. and Vincent Capponi (incorporated by reference to Exhibit&#160;10.2 of the Registrant&#8217;s current report on Form&#160;8-K filed on August&#160;5, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.3+</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000114420419037670/tv526294_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement, dated as of July&#160;30, 2019, by and between CytoSorbents Medical,&#160;Inc. and Kathleen P. Bloch (incorporated by reference to Exhibit&#160;10.3 of the Registrant&#8217;s current report on Form&#160;8-K filed on August&#160;5, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.4+</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000114420416079926/v431082_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consulting Agreement with Dr.&#160;Robert Bartlett Effective as of January&#160;1, 2015 (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Current Report on Form&#160;8-K filed on February&#160;9, 2016).</span></a> </p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.5+</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000114420415020124/v404798_ex10-4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease Agreement between Princeton Corporate Plaza LLC and the Registrant dated as of March&#160;9, 2000 (incorporated by reference to Exhibit&#160;10.4 to the Registrant&#8217;s Annual Report on Form&#160;10-K filed on March&#160;31, 2015).</span></a> </p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.6</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000114420415020124/v404798_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Lease Agreement between Princeton Corporate Plaza LLC and the Registrant dated as of December&#160;12, 2014 (incorporated by reference to Exhibit&#160;10.5 to the Registrant&#8217;s Annual Report on Form&#160;10-K filed on March&#160;31, 2015).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.7</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000114420416099906/v438473_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourteenth Amendment to Lease Agreement by and between the Registrant and Princeton Corporate Plaza, LLC, dated April&#160;1, 2016 (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Quarterly Report on Form&#160;10-Q filed on May&#160;9, 2016).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.8</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000114420416099906/v438473_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Fourteenth Amendment to Lease Agreement by and between the Registrant and Princeton Corporate Plaza LLC, dated August&#160;5, 2016 (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Quarterly Report on Form&#160;10-Q filed on May&#160;9, 2016).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.9</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000114420419037883/tv525984_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Eighteenth Amendment to Lease Agreement by and between the Registrant and Princeton Corporate Plaza, LLC, dated January&#160;4, 2019 (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Quarterly Report on Form&#160;10-Q filed on August&#160;6, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.10</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000114420415020124/v404798_ex10-6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Royalty Agreement between Guillermina Vega Montiel and the Registrant dated as of August&#160;11, 2003 (incorporated by reference to Exhibit&#160;10.6 to the Registrant&#8217;s Annual Report on Form&#160;10-K filed on March&#160;31, 2015).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.11*</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ctso-20221231xex10d11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Assignment and Assumption of Certain Royalty Rights, dated as of November 22, 2022, by and among Robert Shipley Living Trust, ROKK, LLC, and CytoSorbents Medical, Inc.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.12</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000114420406037617/v052359_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Stipulated Order and Settlement Agreement between Bro-Tech Corporation, Purolite International&#160;Ltd. And the Registrant, dated August&#160;7, 2006 (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s current report on Form&#160;8-K filed on September&#160;8, 2006).</span></a></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.13&#8224;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000114420415020124/v404798_ex10-8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Distribution Agreement between Biocon Biologics Limited and the Registrant dated as of September&#160;20, 2013 (incorporated by reference to Exhibit&#160;10.8 to the Registrant&#8217;s Annual Report on Form&#160;10-K filed on March&#160;31, 2015).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.14&#8224;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000114420415020124/v404798_ex10-9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to the Distribution Agreement between Biocon Biologics Limited and the Registrant, dated October&#160;30, 2014 (incorporated by reference to Exhibit&#160;10.9 to the Registrant&#8217;s Annual Report on Form&#160;10-K filed on March&#160;31, 2015).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.15+</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000114420406027604/v046558_ex10-5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">CytoSorbents Corporation 2006 Long-Term Incentive Plan (incorporated by reference to Exhibit&#160;10.5 to the Registrant&#8217;s Current Report on Form&#160;8-K filed on July&#160;6, 2006).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.16+</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000114420414065015/v392126_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No.&#160;1 to the CytoSorbents Corporation 2006 Long-Term Incentive Plan (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s registration statement on Form&#160;S-8, filed on November&#160;4, 2014).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.17</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000114420419041664/tv528194_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Registration Statement on Form S-8, filed with the SEC on August 26, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.18</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000114420418019104/tv489997_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Loan and Security Agreement, dated as of March&#160;29, 2018, by and among CytoSorbents Corporation, CytoSorbents Medical,&#160;Inc. and Western Alliance Bank (incorporated by reference to Exhibit&#160;10.1 to Registrant&#8217;s Current Report on Form&#160;8-K filed on April&#160;4, 2018).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.19</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000114420419037679/tv526768_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Amended and Restated Loan and Security Agreement, dated as of July&#160;30, 2019, by and among CytoSorbents Corporation, CytoSorbents Medical,&#160;Inc. and Western Alliance Bank (incorporated by reference to Exhibit&#160;10.1 of the Registrant&#8217;s current report on Form&#160;8-K filed on August&#160;5, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.20</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000110465920134213/tm2038095d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Amended and Restated Loan and Security Agreement, dated as of December 4, 2020, by and among CytoSorbents Corporation, CytoSorbents Medical, Inc. and Western Alliance Bank (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed on December 10, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.21</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000110465922005949/tm223143d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to the Amended and Restated Loan and Security Agreement, dated as of January&#160;19, 2022, by and among CytoSorbents Corporation, CytoSorbents Medical,&#160;Inc. and Western Alliance Bank (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Current Report on Form 8-K filed on January 20, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.22</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000110465922130966/tm2233609d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amendment to the Amended and Restated Loan and Security Agreement, dated as of December 28, 2022, by and among CytoSorbents Corporation, CytoSorbents Medical, Inc. and Western Alliance Bank (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed on December 29, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.23</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000114420418019104/tv489997_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Success Fee Letter, dated as of March 29, 2018, by and among CytoSorbents Corporation, CytoSorbents Medical, Inc. and Western Alliance Bank (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K filed on April 2, 2018).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.24</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000110465922005949/tm223143d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Success Fee Letter, dated as of January 19, 2022, by and among CytoSorbents Corporation, CytoSorbents Medical, Inc. and Western Alliance Bank (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K filed on January 20, 2022).</span></a> </p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.25&#8224;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000114420419012774/tv514648_ex10-23.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exclusive Distribution Agreement, dated as of September 26, 2014, by and between CytoSorbents Europe GmbH and Aferetica s.r.l. (incorporated by reference to Exhibit 10.23 of Registrant&#8217;s Annual Report on Form 10-K filed on March 7, 2019).</span></a> </p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.26&#8224;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000114420419012774/tv514648_ex10-24.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Exclusive Distribution Agreement, dated December 15, 2014, by and between CytoSorbents Europe GmbH and Aferetica s.r.l (incorporated by reference to Exhibit 10.24 of Registrant&#8217;s Annual Report on Form 10-K filed on March 7, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.27</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000110465921154805/tm2136586d1_ex1-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Open Market Sale AgreementSM, dated as of December 30, 2021, by and between CytoSorbents Corporation and Jefferies LLC (incorporated by reference from Exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on December 30, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.28</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000141057822002932/ctso-20220930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Marketing Agreement, dated as of August 1, 2022, by and between CytoSorbents Corporation and Fresenius Medical Care Deutschland GmbH (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on November 3, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.29</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1175151/000110465921044778/tm2111354d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease, dated as of March 26, 2021, by and between 300 CR LLC and CytoSorbents Medical, Inc. (incorporated by reference from Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on March 31, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.30*</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ctso-20221231xex10d30.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Sixth Amendment to the Amended and Restated Loan and Security Agreement, dated as of March 8, 2023, by and among CytoSorbents Corporation, CytoSorbents Medical, Inc. and Western Alliance Bank.</span></a> </p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">21.1*</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ctso-20221231xex21d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">List of Subsidiaries.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23.1*</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ctso-20221231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of WithumSmith+Brown, PC.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.1*</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ctso-20221231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of the Chief Executive Officer pursuant to Rules&#160;13a-14(a)&#160;and 15d-14(a), as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.2*</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ctso-20221231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of the Chief Financial Officer pursuant to Rules&#160;13a-14(a)&#160;and 15d-14(a), as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.1*</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ctso-20221231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of the Chief Executive Officer pursuant to 18 U.S.C Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.2*</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ctso-20221231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of the Chief Financial Officer pursuant to 18 U.S.C Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following materials from CytoSorbents Form 10-K for the fiscal year ended December 31, 2021, formatted in Extensible Business Reporting Language (XBRL): (1) Consolidated Balance Sheets at December 31, 2022 and December 31, 2021, (iii) Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2022, 2021 and 2020, (iii) Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity/(Deficit) for the years ended December 31, 2022, 2021 and 2020, (iv) Consolidated Statements of Cash Flows for the years ended December 31, 2022, 2021 and 2020, and (v) Notes to the Consolidated Financial Statements.</p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:89.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Filed or furnished herewith.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">+</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Management contract or compensatory plan or arrangement of the Registrant required to be filed as an exhibit to this Annual Report.</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">&#8224;</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">Confidential treatment has been requested for certain portions of this exhibit. The confidential portions of this exhibit have been omitted and filed separately with Securities and Exchange Commission.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are being furnished and not filed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_2ec03f55_8605_4ccf_84df_3880c6d7fa11"></a><a id="Item16Form10KSummary_750435"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 16.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form 10-K Summary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_dc13bbe0_9ca9_4da8_9a34_2e807f56de83"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In accordance with Section&#160;13 or 15(d)&#160;of the Exchange Act, CytoSorbents Corporation has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on this 9<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> day of March, 2023.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:51.42%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:top;width:48.57%;margin:0pt;padding:0pt 2.79pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CYTOSORBENTS CORPORATION</p></td></tr><tr><td style="vertical-align:top;width:51.42%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.13%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.43%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:51.42%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.13%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.43%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">/s/ Dr.&#160;Phillip P. Chan</i></p></td></tr><tr><td style="vertical-align:top;width:51.42%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.13%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.43%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dr.&#160;Phillip P. Chan</p></td></tr><tr><td style="vertical-align:top;width:51.42%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.13%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.43%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:24%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:21.53%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.53%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:24%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">/s/ Dr.&#160;Phillip P. Chan</i></p></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer (Principal</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.53%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 9, 2023</p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Dr.&#160;Phillip P. Chan</p></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Executive Officer) and Director</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.53%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.53%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">/s/ Kathleen P. Bloch</i></p></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.53%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 9, 2023</p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Kathleen P. Bloch</p></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.53%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.53%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">/s/ Al Kraus</i></p></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chairman of the Board</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.53%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 9, 2023</p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Al Kraus</p></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.53%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.53%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">/s/ Alan D. Sobel</i></p></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.53%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 9, 2023</p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Alan D. Sobel</p></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.53%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.53%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">/s/ Edward R. Jones</i></p></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.53%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 9, 2023</p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Edward R. Jones</p></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.53%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.53%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">/s/Michael G. Bator</i></p></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.53%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 9, 2023</p></td></tr><tr><td style="vertical-align:top;width:24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Michael G. Bator</p></td><td style="vertical-align:top;width:2.24%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.22%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:21.53%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2b08a7d5_39d5_4cac_bbcc_c711597af21f"></a><a id="_Hlk96739442"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">FINANCIAL STATEMENTS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:92.72%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:92.72%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:92.72%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ManagementsReportonInternal_256629"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Report on Internal Control Over Financial Reporting</span></a></p></td><td style="vertical-align:bottom;width:7.27%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:top;width:92.72%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:92.72%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ReportofIndependentRegistered_62145"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a></p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-3</p></td></tr><tr><td style="vertical-align:top;width:92.72%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:92.72%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#BALANCESHEETS_482564"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets at December 31, 2022 and 2021</span></a></p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:top;width:92.72%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:92.72%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#STATEMENTSOFOPERATIONS_793529"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Operations and Comprehensive Loss for the&#160;years ended December 31, 2022, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:top;width:92.72%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:92.72%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#STOCKHOLDERSEQUITY_474006"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Changes in Stockholders&#8217; Equity for the&#160;years ended December 31, 2022, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-7</p></td></tr><tr><td style="vertical-align:top;width:92.72%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:92.72%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CASHFLOWS_61773"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the&#160;years ended December 31, 2022, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-8</p></td></tr><tr><td style="vertical-align:top;width:92.72%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:92.72%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NotestoConsolidatedFinancialStatements_9"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:7.27%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-9</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="ManagementsReportonInternal_256629"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Management&#8217;s Report on Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule&#160;13a-15(f)&#160;and 15d-15(f)&#160;under the Exchange Act. The Company&#8217;s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company&#8217;s assets that could have a material effect on the financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Further, because of changes in conditions, effectiveness of internal control over financial reporting may vary over time. Management, with the participation of the Chief Executive Officer and the Chief Financial Officer, working with an external consultant, conducted an evaluation of the effectiveness of internal control over financial reporting based on the framework in <i style="font-style:italic;">Internal-Control&#160;&#8211;Integrated Framework</i> issued in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, management concluded that internal control over financial reporting was effective as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:AuditorName" id="Narr_pf0M0V_IKkaKhmJVI-He8w">WithumSmith+Brown, PC</ix:nonNumeric>, the independent registered public accounting firm that audited the Company&#8217;s consolidated financial statements included in this Annual Report on Form 10-K, was engaged to audit our internal controls over financial reporting. Their report appears on page F-3.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:49%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">/s/ Dr.&#160;Phillip P. Chan</i></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:49%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">/s/ Kathleen P. Bloch</i></p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Dr.&#160;Phillip P. Chan</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Kathleen P. Bloch</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Executive Officer</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Principal Executive Officer)</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Principal Financial Officer)</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March&#160;9, 2023</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b3217f1d_0a10_4651_9308_1ca4c40761c5"></a><a id="ReportofIndependentRegistered_62145"></a><a id="Report_905864"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Board of Directors and Stockholders,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cytosorbents Corporation:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Opinion on the Consolidated Financial Statements and Internal Control Over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying consolidated balance sheets of Cytosorbents Corporation (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, and the related consolidated statements of operations and comprehensive loss, changes in stockholders&#8217; equity, and cash flows, for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). We also have audited the Company&#8217;s internal control over financial reporting as of December 31, 2022, based on the criteria established in <i style="font-style:italic;">Internal Control-Integrated Framework </i>(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America. &#160;Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2022, based on criteria established in <i style="font-style:italic;">Internal Control-Integrated Framework </i>(2013) issued by the COSO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Basis for Opinions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying management&#8217;s report on internal control over financial reporting. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements and an opinion on the Company&#8217;s internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Definition and Limitations of Internal Control Over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">An entity&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. An entity&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the entity; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America, and that receipts and expenditures of the entity are being made only in accordance with authorizations of management and directors of the entity; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the entity&#8217;s assets that could have a material effect on the financial statements.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Critical Audit Matter</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Stock Based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Description of the Matter</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed in Notes 2 and 11 of the consolidated financial statements, the Company grants stock-based awards including stock options, restricted stock units and performance-based stock awards to their employees, board of directors, and consultants as compensation for their service. The Company recorded approximately $3,424,000 of stock-based compensation expense during the year ended December 31, 2022. Certain awards include performance conditions that only vest if those conditions are met, and the quantity of awards received can range based on the level of performance achieved. In 2022, the Company granted 2,528,800 of such awards and recorded stock-based compensation expense related to these performance awards of approximately $180,440.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Auditing the Company&#8217;s accounting for stock-based compensation required complex auditor judgment due to the number and the variety of the types of equity awards, the subjectivity of assumptions used to value stock-based awards and the frequent use of performance-based vesting conditions. In particular, judgment was required to evaluate the nature of the annual performance conditions, as well as to assess the satisfaction of the performance targets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">How we Addressed the Matter in our Audit</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Addressing the matter involved obtaining an understanding, evaluating the design and testing the operating effectiveness of controls over the Company&#8217;s process for determining stock-based compensation expense, including testing management&#8217;s review controls over the underlying calculations, the significant assumptions used in valuing certain awards, identification of the terms of the performance conditions and the key inputs used in determining the outcome of each performance condition. We assessed the appropriateness of judgments made by management in determining key assumptions related to the awards. &#160;We tested the accuracy of the data used in measuring the awards by agreeing the underlying inputs, such as grant date, grant price, performance targets and vesting terms, among others, back to source documents, such as compensation meeting minutes or award letters. Additionally, we tested the related valuation report on volatility prepared by the Company&#8217;s specialists by involving our internal valuation specialists to assess the valuation methodologies and assumptions used. We determined whether performance targets were satisfied in accordance with the contractual conditions through review of source documents, press releases, and board minutes and recalculated grant date fair value by multiplying the awarded quantity of awards by the grant price. We also evaluated the adequacy of the Company&#8217;s stock-based compensation disclosures included in Notes 2 and 11 in relation to this matter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">We have served as the Company&#8217;s auditor since 2004.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">/s/ WithumSmith+Brown, PC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 2.5pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:AuditorLocation" id="Narr__TfgQajlNECl4SFifW16Ww">East Brunswick, New Jersey</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 2.5pt 0pt;">March&#160;9, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">PCAOB ID Number <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="dei:AuditorFirmId" id="Narr_8rebRNMZ9kOZJfDRgzellw">100</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b4b08890_3cd0_4f2d_ac3e_9bcd3e48460c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CYTOSORBENTS CORPORATION</p><a id="BALANCESHEETS_870597"></a><a id="BALANCESHEETS_482564"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_b958059f_96e7_4cd4_9c1a_249c18519586"></a><a id="Tc_4Ss-hQGyp0qM6bFkBYOlPw_2_0"></a><a id="Tc_-ieUFGLBnkq-JTBGwgURvg_2_2"></a><a id="Tc_4v9t0Hfci0Oe8l80J9ngXg_2_5"></a><a id="Tc_zce4XUsJ20Wolzd7Xw8tVw_4_0"></a><a id="Tc_O-UVF6ZzmkO8Hn-b1crWNQ_5_0"></a><a id="Tc_ESd86uj7ZUikf44t9pAOHg_6_0"></a><a id="Tc_vu3TNekIbEGLihqm43Fggw_6_2"></a><a id="Tc_IIk1eGIiV0WdLOpkO1cKXQ_6_5"></a><a id="Tc_uuTIEJjgXUGber8yxnAqyQ_7_0"></a><a id="Tc_HBj2neyNWUybDjZB_MLMcQ_8_0"></a><a id="Tc_gRDmQoo3s0qaN9L5AEnZeg_9_0"></a><a id="Tc_QSbxNVvR5U-UXwZZm1S-tQ_10_0"></a><a id="Tc_MebUBikCAk6R70JY0Mjpzg_12_0"></a><a id="Tc_rWPgoY0xD0uL2GqH_nIL-w_13_0"></a><a id="Tc_W77PvWIuhEe4nwElVw0FhA_14_0"></a><a id="Tc_QVCdwmq3lE2opClZdBSZTw_15_0"></a><a id="Tc_Kk47pMzDpU6tvZCDfmc0RA_16_0"></a><a id="Tc_eX_XT48B9UiiNtwAB_e9ow_16_2"></a><a id="Tc_VJxqht3MwUK9kJPJxnUh8w_16_5"></a><a id="Tc_7jiHoj3h2E2PUQPJQzQNeg_18_0"></a><a id="Tc_EfIdjIkA7UuoFugEojFqPQ_19_0"></a><a id="Tc_Jf8cJVoOLky1tzj4eIhxyA_20_0"></a><a id="Tc_MtH-I7VkO0mPEcpsRO9lkA_20_2"></a><a id="Tc_nAkjtGTYOEypYpQvPZz_5A_20_5"></a><a id="Tc_Ou5JjHTrjkWDA7RV633itA_21_0"></a><a id="Tc_wTwKO5Xu5Ue1a_3aRJ-ogw_22_0"></a><a id="Tc_Kxx61gSOpkCb1ZYqeLCLvg_23_0"></a><a id="Tc_qsYH_NHfH0iQrXDdbzBuiw_24_0"></a><a id="Tc_zxJuCwienkiHyOHkw0CYlw_25_0"></a><a id="Tc_3wQ8DlZ2m0ORWLV3ExKkHw_25_6"></a><a id="Tc_uNoSiTryQk2T6kJ9udRHpg_26_0"></a><a id="Tc_chUqT3xCe0WQk-jlxx2nag_28_0"></a><a id="Tc_lk3U88aOCkOXf6tTdEy2-Q_29_0"></a><a id="Tc_4EO4j20TKEyrqgMUalZtFQ_30_0"></a><a id="_cffbe764_9cae_4828_b06e_708bad266285"></a><a id="_cffbe764_9cae_4828_b06e_708bad266285_2"></a><a id="_cffbe764_9cae_4828_b06e_708bad266285_3"></a><a id="_cd688509_a286_457c_8d87_a9389c44bcf4"></a><a id="_cd688509_a286_457c_8d87_a9389c44bcf4_2"></a><a id="_cd688509_a286_457c_8d87_a9389c44bcf4_3"></a><a id="Tc_TuJhcNYfFUeqWXjTlJYEIg_31_0"></a><a id="Tc_nQZ33X0nJkatYe5aysj-2g_32_0"></a><a id="Tc_5lerUV43fECD5NVBlht7MA_33_0"></a><a id="Tc_efI6w6UQ6U6XUtQXArF7wg_34_0"></a><a id="Tc_MtysgcHKSUintq4mROaUpg_35_0"></a><a id="Tc_7tG-lkW6B0u_TQ3sSO4ACw_36_0"></a><a id="Tc_xWvPogq4dUmGJX46GWld7g_36_2"></a><a id="Tc_3Pt-LqIVjU6fYMy3IT2vjg_36_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">ASSETS</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Current Assets:</p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_foiSZEzqTUuVbv93UmvntQ_6_3">22,144,567</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_zyw7udcjV0qdkhyYlYTcpg_6_6">52,137,707</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:67.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Grants and accounts receivable, net of allowance for doubtful accounts of $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" id="Narr_frA9Wpx4s0Svh01VfjO9jg">76,041</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="0" id="Narr__GA0vGLIsUqIVtoWQt1gpQ">60,539</ix:nonFraction> at December 31, 2022 and 2021, respectively</p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="Tc_RRTtWwLj6EyaJwKagDtI4Q_7_3">5,664,941</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="Tc_8ec2B1stb0CGOjGk5zk1gQ_7_6">4,523,430</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Inventories</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="Tc_slG4AF0khUaIroPh67PHLA_8_3">3,461,586</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="0" id="Tc_Y9FUnE5XGUqHgd8zSsViXA_8_6">4,766,098</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_UoYG6mNX-k6zvhF8JB_7zg_9_3">2,488,597</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_97qA0oIMrkaEtnK97Vzm1g_9_6">2,871,655</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total current assets</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_EEo5fqI-rEuooMAEiE5Jdw_10_3">33,759,691</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_zQ3nS2esSkC7N_kmOT0zxw_10_6">64,298,890</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment - net</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_xqJmKi9pRkiXhH2TRw87Gw_12_3">10,743,032</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_YdbIJzuF5ECBlJrHlxbQPg_12_6">5,150,886</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash </p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" id="Tc_5ZD7aMs_tUeUlpWcRJ-NDw_13_3">1,687,459</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" id="Tc_usLa3-TeVUe329ixZTFjNw_13_6">1,687,459</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use asset</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_hOVWDauFhkq08pRFin2nmg_14_3">12,603,901</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_n8T75im19EepbqkXoK-xow_14_6">13,423,472</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other assets</p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="Tc_BGcAHe5bIkeIMo1tSQWJ3A_15_3">4,437,447</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="Tc_ItpRCjtfWUy3RJgVPEhQWw_15_6">4,958,575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total Assets</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_CmABNI3F6kaaLtlK0oQcAQ_16_3">63,231,530</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_rN3323m9d06PS2nKAEl8fg_16_6">89,519,282</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Current Liabilities:</p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_x7TEzPLIukqaxAw_bJ3u5w_20_3">1,655,173</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_IkkYjrYClEWmaC8Bfbpegg_20_6">2,805,235</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="ctso:AccruedExpensesAndOtherCurrentLiabilities" scale="0" id="Tc_-7TPPO-6QUeFuZRxR1E90A_21_3">7,950,440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="ctso:AccruedExpensesAndOtherCurrentLiabilities" scale="0" id="Tc_61aVREOFuk66VjFWl7lj_A_21_6">10,314,341</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Lease liability &#8211; current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_x_e5gN5fHkyfq9gLqqcrHQ_22_3">108,939</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_7j4gnNHTtUWVQTrM2qHRQQ_22_6">570,566</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_INrz1lGQvU2qeDys9KbV6w_23_3">9,714,552</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_RoCMQhjtsUy_PE4VHXA7uQ_23_6">13,690,142</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Lease liability, net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_k_BAW7GhEUCZ2z8trQktuA_24_3">13,142,005</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_Jcpu7km_pkC_SxS4rxpcfw_24_6">13,250,943</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Long-term debt</p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="0" id="Tc__t_HmH_3zUKKRYXbOh6M1g_25_3">5,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total Liabilities</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_rEkrQHzi9EqczpzaIBwy-w_26_3">27,856,557</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_pU-PxCoBWEqSc67QLr6sbA_26_6">26,941,085</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Commitments and Contingencies (Note&#160;10)</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#8217; Equity:</p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:67.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Preferred Stock, Par Value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_zDRLB8HDskezTG9bLWAQBg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_zY1DU_uL1Uec2zMbCXTqQQ">0.001</ix:nonFraction></ix:nonFraction>, <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_gbeaPxxgyk-6Zvz2nGSWLQ"><ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_H1kN4L8ZsUiYr3niMmwSTg">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; no shares issued and outstanding at December 31, 2022 and 2021</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_hEV81X3h9UOJEdBsx3b6bQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_WcE7qIcf6U2Unn00kGtBEA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8212;</span></span></p></td></tr><tr><td style="vertical-align:middle;width:67.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Common Stock, Par Value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_gAkKkF-cWUeNVvnwFmqhfA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_L-kbCvBA4EquzhCTcTisoQ">0.001</ix:nonFraction></ix:nonFraction>, <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_ojb-JIYP106cxQj-ZF-b5g"><ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_3xjYID6QTkKVmN2pjwqpXg">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_XIxQECPQc0C2zZhO3s62yQ">43,635,715</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_uQeBcALoQECKEaUBzAKpYg">43,478,487</ix:nonFraction> shares issued and <span style="-sec-ix-hidden:Hidden_z7CAybzy_UCwWIryUIV6Kw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at December 31, 2022 and <span style="-sec-ix-hidden:Hidden_VfGFfPUiNEutikrelXHK5g;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2021</span></span>, respectively</p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_sHhsbGSxDUKLDpl6dxUt-g_31_3">43,635</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_721Vc5vLRUCEjGecMSDe1w_31_6">43,478</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_FtyEtTUHdkyI420WPcDOYw_32_3">287,000,021</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_b7AtcIfo0UOcHUC-JSXWbA_32_6">283,194,429</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated other comprehensive income</p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" id="Tc_9lIxuZy9MUGA8aeWjJfG7Q_33_3">2,329,195</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="0" id="Tc_DKz3aMuBl0KB6y7KndfxGQ_33_6">525,585</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_cWPJd_-nF0-QwvFXPHdv4A_34_3">253,997,878</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_E6QZHwny80i5Wr2s9g5XMw_34_6">221,185,295</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_sbxyq1YlK0qTrojW2jWJJg_35_3">35,374,973</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_WjKbbQ3mCkaNWByhJisdFQ_35_6">62,578,197</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total Liabilities and Stockholders&#8217; Equity</p></td><td style="vertical-align:bottom;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_atXpyeUMMES7d7SJ9kBL6A_36_3">63,231,530</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_mqSkmJicfUq5DFAqf6X-Lw_36_6">89,519,282</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Notes&#160;to Consolidated Financial Statements are an integral part of these statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_505a1b76_233e_4b80_b400_1ad9df9f6eab"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CYTOSORBENTS CORPORATION</p><a id="STATEMENTSOFOPERATIONS_793529"></a><a id="COMPREHENSIVELOSS_723576"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_ac2a91b0_89c2_4f44_a48b_111b32412575"></a><a id="Tc_-2RWs7Mbs06w0LazClSbGw_1_2"></a><a id="Tc_5-wlY6MYwkSlQquOCbwajQ_1_5"></a><a id="Tc_ff79uxMavEaq6GgRPKYeAQ_1_8"></a><a id="Tc_NDdao-nm5kiVTD8oYuEfnQ_2_2"></a><a id="Tc_CKhmuKlNxEGxhk2ipJPy9w_2_5"></a><a id="Tc_3vsL14kBkUiGWhNpu-Zt8g_2_8"></a><a id="Tc_NlJr6VydI0awxab1z09h7Q_3_2"></a><a id="Tc_o_9HwznSREa4Nc5k0n67pw_3_5"></a><a id="Tc_kjhHWChcE06U7rxxNLpKoA_3_8"></a><a id="Tc_I3JCHob7Dk-OI2G1ukmGGg_4_0"></a><a id="Tc_ET3QXj5IXkWt2WsPh8vrrw_5_0"></a><a id="Tc_7vi8qpl8GUeUrp9M25XE6w_5_2"></a><a id="Tc_Ih0lwkw6xUSECI_gjwSgHg_5_5"></a><a id="Tc_iUgASm_F4EqoF5mGDn7OWA_5_8"></a><a id="Tc_uuCfRHa11k-YZ5KMK1sHuQ_6_0"></a><a id="Tc_cOwAINhfE02UYwOS5nn4Xw_7_0"></a><a id="Tc_RdSppmRzskKPIDhc4mKR9A_8_0"></a><a id="Tc_Mmx0y3sW7EywwP3Qg__YSg_9_0"></a><a id="Tc_ZnIDU6m690WX3S8gB_zFDA_10_0"></a><a id="Tc_KxgKyGuI70akApPzF9Speg_11_0"></a><a id="Tc_By2yu2ghBEmGS0ED_o03uw_12_0"></a><a id="Tc_z5yCvxiEq0i29Zd1VSxyiw_13_0"></a><a id="Tc_nBljlAHqHUe-VtZyDRdUnQ_14_0"></a><a id="Tc_uHcwiZy3DUOohKWMqwx11g_15_0"></a><a id="Tc_rZRvCdjDOUKzqJnA5mXoBQ_16_0"></a><a id="Tc_B9PUH7jLP0KVjb-Niz9A1w_17_0"></a><a id="Tc_DTjRGKP1yke47imJdTUv_A_18_0"></a><a id="Tc_oHMaiqUhYE2av4J8M_Lrfg_19_0"></a><a id="Tc_HSkN4xzT0kSM1B1dTlbatQ_20_0"></a><a id="Tc_8HjMGXuqOk6wkOdSg8P6ZQ_21_0"></a><a id="Tc_CJ49fgLHME6m9Dd-4Tx9BA_21_6"></a><a id="Tc_2FAfdYxJOkCOwD2jIgHq4A_21_9"></a><a id="Tc_JqeCKqGPp06x4dzeJkBApg_22_0"></a><a id="Tc_7Rq3u6gtE0qUIkBXnUEwig_24_0"></a><a id="Tc_Eorz8C84ckejIhOsPENynA_26_0"></a><a id="Tc_TvyN9VK_1kO0jXQdCyE2jA_28_0"></a><a id="Tc_gbvonV5TAE2eH_LmDr90SA_28_2"></a><a id="Tc_bZ-xS1Lmk0KOBPpgWv9SmA_28_5"></a><a id="Tc_i_ui-y7F-kaYpUq-7-_v6g_28_8"></a><a id="Tc_KB1BIGL8GkusgNSlzhN_Kg_30_0"></a><a id="Tc_y1uJceupIEaYbeqNGA8G2A_32_0"></a><a id="Tc_KEziRBidtUS6X-CL-rF6mw_34_0"></a><a id="Tc_Ny3pZg5dkUGYH5WF3aMuZA_35_0"></a><a id="Tc_NF_TkjE4K063-IX9W5kmrg_35_2"></a><a id="Tc_qrDUKhoWUESvMmlatKLqlQ_35_5"></a><a id="Tc_0orAp5hTv0GqUfI-F-Da7A_35_8"></a><a id="Tc_y_EtKEPgzE-0sQCE2yE1ag_36_0"></a><a id="Tc_KXDT0XoXWUOzkxSSAdcy2Q_37_0"></a><a id="Tc_5LQUIMaZJkS3zc5yHltmUA_38_0"></a><a id="Tc_TLZqFC7aKEujgB-YRRQAaA_38_2"></a><a id="Tc_mxF-rwcRhEG_WR3UXt-x7Q_38_5"></a><a id="Tc_ZYGSUgV2KkuYgGybDGkhPA_38_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Revenue:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">CytoSorb sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_ctso_CytoSorbSalesMember_kZjj3Qm1nkaD0BliSjoSlg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_GB98JvSPbkiIoiRZQR2qcA_5_3">28,572,709</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_ctso_CytoSorbSalesMember_F2WUYm6g20mo5wFD0_w32Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_HanlCTyKu0iKKYw6uBBOqg_5_6">39,996,700</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_ctso_CytoSorbSalesMember_Q4Ry_8jnRU-WR-Sk5cdeNA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_DxcX0JYuM0y01a7_n5jq6A_5_9">39,342,102</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_ctso_OtherSalesMember_IHmx8Gx6dUC4YavDmDyL_g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_wR8PzHzA70afj8WKYwS0NQ_6_3">787,201</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_ctso_OtherSalesMember_3KZRlFeRi0y0ti0yyXPoAQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_VgNrUtTBcEeQUGMY4dGrlg_6_6">111,867</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_ctso_OtherSalesMember_k-QiwnuCrUiE_vu6WfajCg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_O7HtHyRJfk6B7O4C4w4UZA_6_9">110,400</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 18pt;">Total product sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_H13OncAn9U2imjaSPSyd5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_jVzB526lYkir29UtPBZ1_Q_7_3">29,359,910</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_KSZxi4zg7keBU37J2Y0-8w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_tgpG37ObjEewoaw3TBccaA_7_6">40,108,567</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_dd7aX6AZn0ivW75vs1ACmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_Co4yr_dJF0KqQ-fZGvEUbg_7_9">39,452,502</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Grant income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_HBdMLlMQGE-9IpPghuUK2Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_lmQURR2ohEyePBKnjVoMrw_8_3">5,328,899</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_FklCHZPwzUeeNeeNvzpgvw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_gRyBXgewOUaSyHTxN2ksXA_8_6">3,056,960</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_0YTXyfGCvkOAHMRBYujAGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_Yazz5GeLs0uhHZTKMo_QMg_8_9">1,552,099</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_yiGBOS8ZNkqUR8YNj52ddA_9_3">34,688,809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_ZiBrtZyrNU6fWEtlNpABlg_9_6">43,165,527</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_sCbWmYyq8k2Natht0l61eA_9_9">41,004,601</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cost of revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="Tc_V2BlHn58LkuexrvEqBhkcA_10_3">13,955,752</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="Tc_Qros_KRK4UyVfSy3u1WtWQ_10_6">11,047,350</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="Tc_mpamAiMF6U6WtmUhQkF2Ag_10_9">11,052,409</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Gross profit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="0" id="Tc_I8RNJ8Gfh0WCqQsUFZprwg_11_3">20,733,057</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="0" id="Tc_fPMYN_FR1kOzbwP3TSd2-Q_11_6">32,118,177</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="0" id="Tc_RZZMOcBJr06FfoRmTx4sBw_11_9">29,952,192</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_jkSz2w5oy0eiuxWWjfI4aA_13_3">15,118,907</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_MZYNCjzo90yOFsF3j_mT7A_13_6">16,380,930</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_j8asV9Pn4UO86SJzWTjrUA_13_9">8,810,561</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Legal, financial and other consulting</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfessionalFees" scale="0" id="Tc_n6HQa_R1Ak-dflrnwtp0Bg_14_3">2,847,899</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfessionalFees" scale="0" id="Tc_ZsJWsaXL20GsE4tvYAT0Dg_14_6">2,731,515</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfessionalFees" scale="0" id="Tc_aIP3jQ4bEUCUclHXPl6CAw_14_9">3,048,242</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" id="Tc_0M42NyJj9kOOQMEzanswYw_15_3">34,288,130</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" id="Tc_zsHJjSulWEaYpaFs_XQ5Jg_15_6">35,750,477</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="0" id="Tc_CqqtkG5mt0mxwc68PyAVAg_15_9">28,463,723</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_O9Exfeu3606657-fxHLotg_16_3">52,254,936</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_JyjNLUo8F0-qcysL2ANNhQ_16_6">54,862,922</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_Bh9k_bw8L0KM-Y8QeRF9tA_16_9">40,322,526</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_qAFKBCxJukS-KUkOquCH1w_17_3">31,521,879</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_UXnd9DEtckaSaniXSXtNOg_17_6">22,744,745</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_3n4q7JSOXkKReDib77R0zA_17_9">10,370,334</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Interest (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_nx5ODGSmYU-BhGLV9_s47Q_19_3">132,597</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" id="Tc_flLn3AOud0q3RkkUtBy8NA_19_6">28,007</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" sign="-" scale="0" id="Tc_3ft3gwNEyEi_M18LMyeoFw_19_9">1,201,067</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Gain (loss) on foreign currency transactions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="0" id="Tc_IsFh7K9GpkCvstj0umOoYg_20_3">2,448,583</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="0" id="Tc_8-5hFgjMiE-FDaxb9jGZbA_20_6">2,577,913</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="Tc_djAhv8zD00KxcijDjpOWeA_20_9">2,607,139</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Miscellaneous expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="ctso:MiscellaneousIncome" sign="-" scale="0" id="Tc_KDaGJ21cF0Sg7Ff4N7jRXQ_21_3">67,303</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="0" id="Tc_Cpw5BsUEmE2hsuFASStY4A_22_3">2,383,289</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="0" id="Tc_A1lFAULxg0eoeoZt-Nnq7w_22_6">2,549,906</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="Tc_UUPC4g0KWESIU8dTpSFh-Q_22_9">1,406,072</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Loss before benefit from income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_zedBc21PA0-bsOrpTmN9vw_24_3">33,905,168</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_9m_rfK7lGkeZzwvsop7CsA_24_6">25,294,651</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_C_rZXp9Xk0-y34Es7pq1OA_24_9">8,964,262</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Benefit from income taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="0" id="Tc_hTh56gUgkEiVEUBI1i_QAA_26_3">1,092,585</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="0" id="Tc_N0oCwIdWpU63qil1hAPo0w_26_6">736,003</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="0" id="Tc_-7kqjE5RmkimwQCVGhdWLw_26_9">1,127,074</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_mapN4D6likmStI8HzfOSGg_28_3">32,812,583</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_3JNpIIN_JESXkPK9GLdwhw_28_6">24,558,648</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_YXffGfVt6E-gnoyPJFzl_Q_28_9">7,837,188</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted net loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_zNIJAnaRR0CqAJo82LC6XA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_NJH6P-nmL0SZOU2qIdgusQ_30_3">0.75</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_A3L_kI-Jk0-EUNRql5ERcw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_9rHNx-Npsk-5kk4EtAe27w_30_6">0.57</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_v5TbsPJIpkCU_eSgu2R0tQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_Q2QjOvEuxEWZjqnBX8PL0A_30_9">0.20</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average number of shares of common stock outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_J4wClybs006lYF2qnxzF6w_32_3">43,573,215</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Y4xxPBoijUa9CDy80tJCVg_32_6">43,359,186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_dJa5jjbPbUmd3zmZ9zijQQ_32_9">38,818,990</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_r2bST1YteU-40M1QaWiIbQ_35_3">32,812,583</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_NAeCRf64wEepccK0jxbLDQ_35_6">24,558,648</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_q4I_gTumIk-hx0eba-W8vg_35_9">7,837,188</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive income (loss):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Foreign currency translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="Tc_uWn0zbEZ-UmShzz-CpVsKg_37_3">1,803,610</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="Tc_x73oJWCxCkyOgViv8ukY_w_37_6">2,259,663</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="0" id="Tc_6VLY66j1VUSSCvIOuTCzUw_37_9">2,260,056</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_NvzhNhE9TUONDhbrpbZ1XQ_38_3">31,008,973</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_mvbckGb-Z0GkRrPecLKztg_38_6">22,298,985</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_hocOg9GLtkaXCCUPKX9Tew_38_9">10,097,244</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Notes&#160;to Consolidated Financial Statements are an integral part of these statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c71df25e_96bb_49dc_abd1_208dc8b9933c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CYTOSORBENTS CORPORATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF CHANGES IN</p><a id="STOCKHOLDERSEQUITY_474006"></a><a id="EQUITY_583355"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">FOR THE&#160;YEARS ENDED DECEMBER 31, 2022, 2021 and 2020</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d26de28e_500a_4ccb_9c0a_7ff1bd0b6357"></a><a id="Tc_B7Ho7nnZRk6leJLfckkSyw_1_10"></a><a id="Tc_L-Vyymmeo0eQ9uhwLVfRqw_2_10"></a><a id="Tc_pmARlCcV60-amf8H-j8Ktw_3_2"></a><a id="Tc_7H6f_emR1UGoxe2h4VNEnA_3_7"></a><a id="Tc_lcILKf9VeEegj10mZQSGiw_3_10"></a><a id="Tc_38j7x-kjYkWWEWQ2vrXn4Q_3_13"></a><a id="Tc_-RGn29jwJ0206jMPivxP8g_3_16"></a><a id="Tc_i0R7BdNqb0KWmY-npu38Eg_4_2"></a><a id="Tc_HiRWopDSRkuMNF9OcAuKoQ_4_4"></a><a id="Tc_ardPZDFMYUutv4A-oveLVA_4_7"></a><a id="Tc_4OChyHemnEGQO4zhLcsPOg_4_10"></a><a id="Tc_PsaAzu-3jUa5z14vdWvO8Q_4_13"></a><a id="Tc_RjQJUcKfVUaSIta_asCQuQ_4_16"></a><a id="Tc_ZmEAOSKZkUKUNjTRbnixRw_6_0"></a><a id="Tc_nyP1YuYX40mur29bdyH4vQ_6_4"></a><a id="Tc_dMclRIhxGU-w578IN21CSg_6_7"></a><a id="Tc_zJ4CTlK1DEeZ92tHQp_ZMA_6_10"></a><a id="Tc_vrC4M6B_B0uJABFSkh1GYA_6_13"></a><a id="Tc_OmR1Bf0bdEaEDNl4mTvozg_6_16"></a><a id="Tc_uTXCz0kZtEKz1zh6Zii52Q_7_0"></a><a id="Tc_OudV_hB3jUqo--mA7iPSZw_7_2"></a><a id="Tc_xNjOXDTLv0Cw9cpztK7q6A_7_5"></a><a id="Tc_ajW8eH7DjEmEiPKMPZ6uvw_7_11"></a><a id="Tc_DW2-6ccf9kKkpBJFduJJwg_7_14"></a><a id="Tc_aO9p0Vm570SNDC7UTbQVCQ_8_0"></a><a id="Tc_ziqEBsJYPk2FG_m_Rv8w5g_8_11"></a><a id="Tc_A_mJFrCCvkKOZpyeU3tepQ_8_14"></a><a id="Tc__YQZaFfG50KCOsqerStFjQ_9_0"></a><a id="Tc_X5uh2Noihk28ub1YKsX29w_9_11"></a><a id="Tc_kNlizC6TYEGU2kayydYsYQ_9_14"></a><a id="Tc_yzNW_UP730S-u1zLbWw9Mg_10_0"></a><a id="Tc_v4SX0Bh4HUaaGSDdde_RQQ_10_11"></a><a id="Tc_W5QFbXyEv0-bu14aICeU2Q_10_14"></a><a id="Tc_bT4JeJ2nP0S8XHHpUh18Xg_11_0"></a><a id="Tc_VKyTrQEcIE2Gn-yQuFI7ig_11_11"></a><a id="Tc_8q_5tSWZG0a3Y4pz4VagBg_11_14"></a><a id="Tc_t_RFuWN6iUGcIrFIajItmQ_11_17"></a><a id="Tc_bOwn9mtbZUaEq74oJuKI9w_12_0"></a><a id="Tc_lMrCdl29YEmfSRRxG8fiBg_12_2"></a><a id="Tc_iijR8-sYm0ibe1sRikW-Zw_12_5"></a><a id="Tc_9Zi1CXzHBUy_WyjRkxtjdg_12_8"></a><a id="Tc_oVAOskcLokq3wxkxqoaGdA_12_14"></a><a id="Tc_Vy4mJqJ4Ak6ElDoPvo_f6Q_13_0"></a><a id="Tc_jjJT8i_UXkWObmhHw-gkcQ_13_2"></a><a id="Tc_7LAiVGCsoUWxoAt0E4H4Ew_13_5"></a><a id="Tc_5f5xc_z2f0-FbSFJhkd9HA_13_8"></a><a id="Tc_L3cORcVbwUSg22pp7g_3ZA_13_11"></a><a id="Tc_5CCH7mNgnUWtG8J1GQcd8A_14_0"></a><a id="Tc_0vilzuwXnkuj9nmT5E4kNQ_15_0"></a><a id="Tc_k4xuQTHd-EWETXuGkF3c3w_15_2"></a><a id="Tc_eibaOmy0AUeekcyjxeMBSg_15_5"></a><a id="Tc_uJzUMntG1UGH1pBDUcYCaw_15_11"></a><a id="Tc_xNZSg-ofo0K9J601ookQSQ_15_14"></a><a id="Tc_tOD9qSTTxEma0OAKx2iqig_16_0"></a><a id="Tc_FFR1xv4L5kqmvGCkAJFlhQ_16_2"></a><a id="Tc_fYnbmTCjskmqq_-CCUigIw_16_5"></a><a id="Tc_1Q2FwVklrUathSmmEVLOfA_16_11"></a><a id="Tc_6HOvl2ScdE66IqnGiLTxAw_16_14"></a><a id="Tc_z0w-6H8_sU2z9VjxTpzyug_17_0"></a><a id="Tc_Jo3mLUhBykmxw15Fr1B0bw_17_11"></a><a id="Tc_I8o7M-I1FE6sXjBkAtSwEg_17_14"></a><a id="Tc_M_Lgmy0I5E6mUCksvaBXkA_18_0"></a><a id="Tc_T4XkfhhhYkymg4qJId4Kug_18_11"></a><a id="Tc_HQCnrV9G7kOclceLD5bEvA_18_14"></a><a id="Tc_mJCuAlk68kGvOeAHN1h3Jw_19_0"></a><a id="Tc_PmzDUvbjR0e7UQtz7DSnSw_19_11"></a><a id="Tc_YpUEaBjU8UOmkHgGHnUiBw_19_14"></a><a id="Tc_vvVNT2S3pUOkvhe6KrUj3Q_20_0"></a><a id="Tc_V8k-2mqSiUCTqGGfoe8_yg_20_2"></a><a id="Tc_4lzpnPFhI0WlVI7k-QlYbw_20_5"></a><a id="Tc_oPj1tVwTbEaUbUotoRjNXw_20_8"></a><a id="Tc_YrUaZH_ttUOQwPFZLRmJeA_20_14"></a><a id="Tc_c1nfDEyqAEGOObSQuDmvFA_21_0"></a><a id="Tc_9u_8KxbIhE6Bmy85TYpZ6g_21_2"></a><a id="Tc_d0lUJ253u0qLVkDM-XfnOA_21_5"></a><a id="Tc_qrSQXvT-uECEI6zpboJo5A_21_8"></a><a id="Tc_im6oNVO9UUiW2KdGSo61lQ_21_11"></a><a id="Tc_DrJEmRR0q0GhQZgFoXrvaA_22_0"></a><a id="Tc_qG-DZj9e3kyJ_ht5__RZJg_23_0"></a><a id="Tc_fYozVrYLOU6QIJKV5rd-ZA_23_2"></a><a id="Tc_y9udwkjfJE-RotXK_IgRTQ_23_5"></a><a id="Tc_nfpvRRmPjk2yTCdLLhwG2w_23_11"></a><a id="Tc_rZgdJmG1Fk-SwoyXxAtwpA_23_14"></a><a id="Tc_Bcfn6Om2rkeRu5zUOeCYkg_24_0"></a><a id="Tc_eMFS8VyacUyyiLQ7SeiQ2w_24_2"></a><a id="Tc_Q81OPP3HSkOglG1VZp7-4Q_24_5"></a><a id="Tc_YyC4rcECikWV1bbP3-uYpw_24_11"></a><a id="Tc_ercWzb2xDkWrx_NItjpIkA_24_14"></a><a id="Tc_s5nLNi-Bc0ukkB7vebpiiQ_25_0"></a><a id="Tc_eoIXrsdYAUe-Zca48N7FCQ_25_11"></a><a id="Tc_ZwifvrC8RUKv0l5osGzydA_25_14"></a><a id="Tc_F6cETt9YP0eyfxM8SMNauQ_26_0"></a><a id="Tc_31umYPJzR02iAPG2AxEx-Q_26_2"></a><a id="Tc_d1sucSK9MUu705Hx2rXJgA_26_5"></a><a id="Tc__990QOMhDkqjml5EB7FKFA_26_8"></a><a id="Tc_UhEjH6Zc2UmrcBJxvnZiMQ_26_14"></a><a id="Tc_C6EmsALP9kuQJ1NfC0UrGQ_27_0"></a><a id="Tc_C5n7ppN-106WyvLGq_BoNg_27_11"></a><a id="Tc_r8NZmuKg8UeERqHCg40SVw_27_14"></a><a id="Tc_Sm5PGXTQLE-5FC3ggfa6Fw_28_0"></a><a id="Tc_rcIQ6mLsAUucYWEJlQz8bg_28_2"></a><a id="Tc_8b0REKMI0UiDoDPyHTl4pQ_28_5"></a><a id="Tc_kZXEdtbb5UC3SfPK4sIWWA_28_8"></a><a id="Tc_IRHlyfwWvkOvyhMDhCLzLg_28_11"></a><a id="Tc_5_u4OzEnvk-KOvLX3fOe0w_29_0"></a><a id="Tc_0KN15DCnNUmvG5b-oRcb1A_29_4"></a><a id="Tc_kbriDbyNpEebdoKAJ2INPA_29_7"></a><a id="Tc_3AMZxO2-0kCjg02yiwsB1Q_29_10"></a><a id="Tc_XIJud5cocE64ALIyW5jW7g_29_13"></a><a id="Tc_ZQh4SRMba0KEjItoYiFLcw_29_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Par&#160;value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Income (Loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_93L6HhBk5E-Lnf3ZqLpS2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_L-LwGGXlJ0qTBxm7LTK-Xw_6_2">32,616,107</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_93L6HhBk5E-Lnf3ZqLpS2A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_4kA0qYfiHkqYXhSq0Qyu9g_6_5">32,616</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cDcxImQXYUeh0lvoITev4A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_GBVR54qu_kmLiVJAn5f8fQ_6_8">191,648,907</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_KPMkIaBOA06ekPfEU2CpFw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_xyCBNfMEr0C8lFz3OSAT_Q_6_11">525,978</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dtYzBB8BaU-3fEcIk5-5qw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_hccLjRLdS0GHoZhE7tESEw_6_14">188,789,459</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2019_6_oqjbutzEKQogf2y7UC6g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_gADO-iJgpUu9wJhpxjGDZQ_6_17">3,418,042</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation&#160;- employees, consultants and directors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WaPfkCKsqkGJrOEo8CCMJw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_nz9zUzk39UugyxxcQ74jEg_7_8">3,513,671</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_jeav7TfzIE-YtMnPoHlzXA_7_17">3,513,671</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock - offerings, net of fees incurred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ymoFl7EJPE6epQ4SBcMfbw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_xQqPtdp9ZkOoO-SqQUyctQ_8_2">10,163,256</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ymoFl7EJPE6epQ4SBcMfbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_n4E4aU4iWEeWRKe7NAAc2Q_8_5">10,162</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WaPfkCKsqkGJrOEo8CCMJw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_RyZGbt6d80arb3Tcqetfgw_8_8">80,203,846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_5dOiml91XkCqas6Y-ElRsw_8_17">80,214,008</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of restricted stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ymoFl7EJPE6epQ4SBcMfbw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_NKk6_XP8mESI80O5pMzMoA_9_2">87,728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ymoFl7EJPE6epQ4SBcMfbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_7yejkmqjGEevTqTaHUr4jw_9_5">88</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WaPfkCKsqkGJrOEo8CCMJw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_V3Pl7j6MMEOvVWvFrpWqkQ_9_8">657,692</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_YUhhSDSb00GpNvGQLrMDUQ_9_17">657,780</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ymoFl7EJPE6epQ4SBcMfbw" decimals="INF" format="ixt:numdotdecimal" name="ctso:StockIssuedDuringPeriodSharesStockCashOptionsExercised" scale="0" id="Tc_DF6GTzdD7U6wNdSw10jHsg_10_2">341,507</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ymoFl7EJPE6epQ4SBcMfbw" decimals="0" format="ixt:numdotdecimal" name="ctso:StockIssuedDuringPeriodValueStockCashOptionsExercised" scale="0" id="Tc_kDbbb6mvQU-TIrGH5M_xNA_10_5">342</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WaPfkCKsqkGJrOEo8CCMJw" decimals="0" format="ixt:numdotdecimal" name="ctso:StockIssuedDuringPeriodValueStockCashOptionsExercised" scale="0" id="Tc_K3pC_9U5gkCgV63DVvJrkA_10_8">1,508,980</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="ctso:StockIssuedDuringPeriodValueStockCashOptionsExercised" scale="0" id="Tc_wVV1EfsmqkykUmXqPcOcDw_10_17">1,509,322</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cashless exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ymoFl7EJPE6epQ4SBcMfbw" decimals="INF" format="ixt:numdotdecimal" name="ctso:StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions" scale="0" id="Tc_mrZp-ZYLMUqvMpsVCyNgkw_11_2">13,401</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ymoFl7EJPE6epQ4SBcMfbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_BXa9eC96zESPWAU51YW3Uw_11_5">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WaPfkCKsqkGJrOEo8CCMJw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" sign="-" scale="0" id="Tc_OGWPzwTsRkyq6bpG8eCNYg_11_8">14</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive income, foreign currency translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_v7r-si-0bUuq1lcCsElNgA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="0" id="Tc_8P_kQ3vXsU-DKrEC4PuCIg_12_11">2,260,056</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" sign="-" scale="0" id="Tc_UsGzNTn8IUSQR36Bgm1uQA_12_17">2,260,056</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_41gqsgDpOECDOvWP118t8w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_wlhr7UyM3kGJF9N8mB_H_w_13_14">7,837,188</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_WZr3uxNIS0yw47hgIqRY_w_13_17">7,837,188</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PV_DrHkTQkGQmIt0QmW81A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_x30RCdmbqEiAhDaCyqSCIg_14_2">43,221,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PV_DrHkTQkGQmIt0QmW81A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_zToQ4arwok65z3dmmqyn_g_14_5">43,222</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5CrlobMDMUOFaODMa0mJMQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_tuTKeIynAU2molaIFMLFbA_14_8">277,533,082</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_NadUN92cUUGeapWWnvOPNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_ce3DmRe49EyCN6Biebs_Kg_14_11">1,734,078</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pIxGvrDdvkqEyu4JVd03fw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_5EOgkuFy2UO3GM4jFkUTvQ_14_14">196,626,647</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_tLBEYTabOUGekk4Vufra3w_14_17">79,215,579</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation&#160;- employees, consultants and directors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T3OJIOaoZ0K5JyfOQDRhQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_wR94-m_KUEe5TSMBa0ctQQ_15_8">4,020,819</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_LVk5fBlauEumBoFW7FXhTg_15_17">4,020,819</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock - offerings, net of fees incurred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T3OJIOaoZ0K5JyfOQDRhQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" sign="-" scale="0" id="Tc_NlQPZC_T0EW7yVo3r85FcQ_16_8">90,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" sign="-" scale="0" id="Tc_UD6DPFmrqEmRjbv_Boeh_A_16_17">90,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of restricted stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jAS_rLmGI0SmIJDwwikaWw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_vqQWZB6oGUmNpFb9WBYicg_17_2">106,662</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jAS_rLmGI0SmIJDwwikaWw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_INJmsIIAv0K1nK55Q4ygfQ_17_5">107</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T3OJIOaoZ0K5JyfOQDRhQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_1rxdyNPrIEWK9QZFOYKGxg_17_8">928,310</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_QzEHnrtDp0CdEJFfToPkqQ_17_17">928,417</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jAS_rLmGI0SmIJDwwikaWw" decimals="INF" format="ixt:numdotdecimal" name="ctso:StockIssuedDuringPeriodSharesStockCashOptionsExercised" scale="0" id="Tc_wU7HWYLLRUi79xBRZ8CWxQ_18_2">139,102</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jAS_rLmGI0SmIJDwwikaWw" decimals="0" format="ixt:numdotdecimal" name="ctso:StockIssuedDuringPeriodValueStockCashOptionsExercised" scale="0" id="Tc_-endv7KjdkqUSjI7vIu8vQ_18_5">139</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T3OJIOaoZ0K5JyfOQDRhQA" decimals="0" format="ixt:numdotdecimal" name="ctso:StockIssuedDuringPeriodValueStockCashOptionsExercised" scale="0" id="Tc_uaCAKaeYXkyt3axF6styIQ_18_8">805,060</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="ctso:StockIssuedDuringPeriodValueStockCashOptionsExercised" scale="0" id="Tc_j0zhq8f5WUm6hjSUcS5YVg_18_17">805,199</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cashless exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jAS_rLmGI0SmIJDwwikaWw" decimals="INF" format="ixt:numdotdecimal" name="ctso:StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions" scale="0" id="Tc_R4G-xXui7EO9O-Wxoxu60Q_19_2">10,724</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jAS_rLmGI0SmIJDwwikaWw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_w_tzmTf9AESSCZraB6MRUg_19_5">10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T3OJIOaoZ0K5JyfOQDRhQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" sign="-" scale="0" id="Tc_cOhoDdp_TEei2bad3Ej8gQ_19_8">2,842</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" sign="-" scale="0" id="Tc_NGG1-rfQy0Sw6XQ1T7d5MQ_19_17">2,832</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive income, foreign currency translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_VA7E7P_1tEG-K6jM8v-kFA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="Tc_fQXiGRSvq06TcUOH0R6wCQ_20_11">2,259,663</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="Tc_E5mraqrrg0uvF845vFfvEQ_20_17">2,259,663</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5uYZTUv4DUKuTOvKAyxCSQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_c-uACdKNP0mQ3drgj6i5ZQ_21_14">24,558,648</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_ABha_BuwOE2vlk89M3hVEA_21_17">24,558,648</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CCqJgm4tjU2Hhj1W3f863A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_-vavTwvETk-nGsieuVROlA_22_2">43,478,487</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CCqJgm4tjU2Hhj1W3f863A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_fQ9Al2VNU06I2VALHuHIYQ_22_5">43,478</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2fpskYPtCkGXfgvSbLwICg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_G1Amz3WZ7EujibCBK0cHoQ_22_8">283,194,429</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0_qpfUCFWUSQSBVH2kIqyw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_90jusGUgJUuu_zlyjO8ufw_22_11">525,585</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_v2r2g5cGPUySlMPbJ6gPWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_Jng_m0jL80GVEMyQR-qCKA_22_14">221,185,295</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_g-_nPvCZB0qHqnBTe9vu2w_22_17">62,578,197</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stock-based compensation&#160;- employees, consultants and directors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5G127XWFxUipm8wjbbrV0Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_bKrbggeSHEKiZDLDZbYM7w_23_8">3,423,517</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_1yNAMj4R5k6KbXVmVh1yrQ_23_17">3,423,517</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Legal/audit fees related to ATM offering</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5G127XWFxUipm8wjbbrV0Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" id="Tc_bvvPLl7WiUeIuEyL_RwIaw_24_8">40,358</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="0" id="Tc_sIoS0hElykG5iaoNqfP1eQ_24_17">40,358</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of restricted stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2mGFz-g8vkCyKxzLGK8rRg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_PI04fhskO0GLe3rB5FByZQ_25_2">144,728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2mGFz-g8vkCyKxzLGK8rRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_swk1-WS31E2oivtvT5mEhg_25_5">145</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5G127XWFxUipm8wjbbrV0Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc__E40p5XDlUSWYkg3QKZomQ_25_8">379,946</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" id="Tc_QtcSIcAoIEupmVGRQ_MX4Q_25_17">380,091</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive loss, foreign currency translation adjustment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_x19ESOfGok2hRnIOnFg4-w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="Tc_KWPvPkFCnEO8VLNOpzgFJQ_26_11">1,803,610</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="0" id="Tc_poXnq8EFbkW1VcH2GAt5Yw_26_17">1,803,610</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Stock issued to vendor in lieu of cash payment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2mGFz-g8vkCyKxzLGK8rRg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="Tc_vAWi9OfmOkKh6Qn8XWvZKA_27_2">12,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2mGFz-g8vkCyKxzLGK8rRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_AprNp-P3IE-izAd_TR2d3g_27_5">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5G127XWFxUipm8wjbbrV0Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_c4qI9eDRikGY6YpUM75N7Q_27_8">42,487</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_Nggsyvku1k632WyNC0dJsw_27_17">42,499</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_OhlDyppT50CWSs02U8PSrA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_s_qHGZGCpkewuhv0AG5mRA_28_14">32,812,583</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_NKnbz4o5QE-F1i9wztRqpw_28_17">32,812,583</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4ADrrvzo1k2uJb6rtAoZXA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_X8PA6czPgkCFb96ziti-0g_29_2">43,635,715</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4ADrrvzo1k2uJb6rtAoZXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_5lof_pof_EuVB02pV-pSRQ_29_5">43,635</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oumECbNlIE2GMtb6QWOHIw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_gkPXNaDMakap-uIqwa88Ow_29_8">287,000,021</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yxInglK_2kaHDsFiaiSgNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc__U0MBF3RhEyZ7oSFfUZ5tA_29_11">2,329,195</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AUSvWy58u0K_IquBEJ7-vQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_F5ZQ-DGDU0eYnbzHJbtIBA_29_14">253,997,878</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_OV1xtWTsekOe7uLxCO08_w_29_17">35,374,973</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Notes&#160;to Consolidated Financial Statements are an integral part of these statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8669252f_e7da_42e0_831f_777e198922a1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CYTOSORBENTS CORPORATION</p><a id="CASHFLOWS_61773"></a><a id="CASHFLOWS_672416"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_9b6872df_3d5d_4180_ac92_c6e303e49a93"></a><a id="Tc_e8HcwCpXzUSOsWXor_25wQ_1_2"></a><a id="Tc_p3-QzeFYQUiqrGgpdd0ByA_1_5"></a><a id="Tc_psSZrMMqSkysPZa-jHMAfw_1_8"></a><a id="Tc_5h13cHphU02iZZx4s23HtA_2_2"></a><a id="Tc_SRq56pFvC0CpAGMpil0AFg_2_5"></a><a id="Tc_WuqKpBU6X0uS1v1F0zmD4w_2_8"></a><a id="Tc_jrl6t1vgT0aeK1SwbIBp3Q_3_2"></a><a id="Tc_SE5hP5ZBNEiygLKHT6eAHw_3_5"></a><a id="Tc_8LCVCAJUWUun20M67pFGAw_3_8"></a><a id="Tc_3sU2CF5MR0ycXrTrWOVVOw_4_0"></a><a id="Tc_ipb16hOS9kODH1p0QXzgrA_5_0"></a><a id="Tc_4ufXEW6W0E6AfTv39Ea2oA_5_2"></a><a id="Tc_e1PqbhcRhkeLZO1GTEimdw_5_5"></a><a id="Tc_ZDB8B2XuZUyr1cC8tVU5Bg_5_8"></a><a id="Tc_MVp9Cx_RW06GgbXpCvLM-A_6_0"></a><a id="Tc_lo-VZ1O69kO2d_CnachbRw_7_0"></a><a id="Tc_izOqzXuwfEylkZrjSDsCUw_8_0"></a><a id="Tc_-ah2CVlJNEuri6w0L46wGg_9_0"></a><a id="Tc_GowFInYNoEuYVh_hz3zL_g_9_9"></a><a id="Tc_7jwFOiElhkObJ206D4uEGg_10_0"></a><a id="Tc_OAR9NoCGlE2uUIDl_24WpQ_11_0"></a><a id="Tc_B0pzzcCj0Uy0wSCLdRh6Pw_11_6"></a><a id="Tc_-viLH3OLAE2JhvuUqJsjHA_11_9"></a><a id="Tc_TLFBOQ66JEieeOV2q9ZSXQ_12_0"></a><a id="Tc_nkPcc0B9DU2O4YgvtTOxMA_12_6"></a><a id="Tc_6QyYxVUMlECEHaJ2TAubrg_12_9"></a><a id="Tc_HFviJje97UGCNArnaAkAAg_13_0"></a><a id="Tc_4s5kVKKaYEW1kUNNHHCV9A_14_0"></a><a id="Tc_MfrGglPtxkiHAfft9AoCag_15_0"></a><a id="Tc_qyGSkwP54E-oD74upyqNbQ_15_3"></a><a id="Tc_O6jWKCKRHk6pOsyRnMNovA_15_6"></a><a id="Tc_c_OO0rK5tkmwonfyokdo-Q_16_0"></a><a id="Tc_VdyzD4o34EamYjmA6cL0Zw_17_0"></a><a id="Tc_tVYY5B_sCkyTzxTrYV2xzg_18_0"></a><a id="Tc_6bA1liNUVEql_SZOPfuOeA_19_0"></a><a id="Tc_MM6FyZNGZEilTQYJELQ3tg_20_0"></a><a id="Tc_sSJngtX7UkuyxuIG7v9oRA_20_9"></a><a id="Tc_KpUNI60-jUWYFHg8KuBzfw_21_0"></a><a id="Tc_VMriOlO9PkmJjOryp2ceUw_22_0"></a><a id="Tc_IYrabYDrIk-vbtnRpI2Kng_24_0"></a><a id="Tc_d3kkSAMHEUGlPXQIrwaAqg_25_0"></a><a id="Tc_V7MN_BWaQ0CpkhkRcatdAQ_26_0"></a><a id="Tc_J4btQ4szIUmIZj15U_Enhg_27_0"></a><a id="Tc__d5m-sNpEkycNeRgPOphjQ_29_0"></a><a id="Tc_AxQNHOfD3UGzQq-yee5H0g_30_0"></a><a id="Tc_UKDZ5sZVw0i-_-_U1QU5xA_30_6"></a><a id="Tc_-LCqir3epUOlWaNtjekJhw_31_0"></a><a id="Tc_-t98KFaJ3U67DQCLjr3Bvw_31_3"></a><a id="Tc_T3seUCO8fkKI9x1jv5mbHA_31_6"></a><a id="Tc_NZj01Bmn4USqhHha1dIJeg_32_0"></a><a id="Tc_v227QdAjuU-gCAnkeDL2yg_32_3"></a><a id="Tc_t-SfEsCHX0ieAAZlhwmDzA_32_6"></a><a id="Tc_2p5JH0MnMUiO4uZepzwipA_33_0"></a><a id="Tc_qgniNP77gk20cTOIHAD1mQ_33_3"></a><a id="Tc_a4FguNRt4Uy8TB8nGvnu7g_33_6"></a><a id="Tc_N-2QINKLgk-9rasrFOTuGA_33_9"></a><a id="Tc_4WegiX_x30y92COGSekDWQ_34_0"></a><a id="Tc_tVDTzRmPnUG0T8HYUfg1TQ_35_0"></a><a id="Tc_5GS-9kMFfUiRIm2v3uTJ8Q_35_3"></a><a id="Tc_ExibwObmR025EFXx7lfj1Q_36_0"></a><a id="Tc_a6c603q0X06cnXcYqqXHNA_36_3"></a><a id="Tc_Vrct9Bj-XkOzGdektKvjPw_36_6"></a><a id="Tc_BEpeqz3w2ke94r0zgny-sg_36_9"></a><a id="Tc_FPuAztea00iPDhvDEDoZjA_37_0"></a><a id="Tc_FVWFEKUNpkicE3ftAlFt-w_38_0"></a><a id="Tc_0GArJC3IY02buxQEX57JsQ_39_0"></a><a id="Tc_m85r2frksUaPR1CLKa0rGg_41_0"></a><a id="Tc_QodBpNrRfkqzbke53sfMFg_42_0"></a><a id="Tc_tGlLTGHLE02r_a7ErwoLSg_42_2"></a><a id="Tc_K8mSGO4r4U-Yt60HFsLfjA_42_5"></a><a id="Tc_buwx-ESe10WblEMWb2XmxA_42_8"></a><a id="Tc_1plbAVXkREuJdbF3cb2CGw_44_0"></a><a id="Tc_39jSdG_bYEyvCRQSwggEPg_45_0"></a><a id="Tc_I1RLs2fAUEC7CKgYqwTm9w_45_2"></a><a id="Tc_tGnD5vCccUW8Q30wZVQSzQ_45_3"></a><a id="Tc_JKaBmTVJ60ysVWqUF35U3g_45_5"></a><a id="Tc_P_yKDXJ0yE2tnne-Jwdi6Q_45_6"></a><a id="Tc_FOXeozRz1UeA_3iOFbEo6w_45_8"></a><a id="Tc_6kM-R60R20WFu8qihHbXOg_47_0"></a><a id="Tc_pfd9vgzn1ESNeTY0SoUdsQ_48_0"></a><a id="Tc_RT8F7PkciE-FofXbCFYwVw_48_2"></a><a id="Tc_UKfv6Ggc2Uaz9rUgoKo-FQ_48_6"></a><a id="Tc_8zkAH7sAyEefFd5N54W6Ew_48_9"></a><a id="Tc_h2FmZLOMDEqojzm8vD5WfQ_49_0"></a><a id="Tc_FunuWsvJb0mc6QaK64wGbA_49_2"></a><a id="Tc_nSNBzHT0-0ujW-lLFEfhzw_49_6"></a><a id="Tc_qmiYsKm3k024RZKx7UYaxw_49_9"></a><a id="Tc_42nF69hivUe8bnjrXbUm2g_50_0"></a><a id="Tc_DtnZI-HKk0WWx5wqYSQ4xg_50_2"></a><a id="Tc_edfIi-Dgd0-oV_FOVgWkhg_50_5"></a><a id="Tc_PhxFQFDUjkyHg13dPDwVzA_50_8"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_nbT6oafBRkmY_3YaN5JCjg_5_3">32,812,583</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_TJNs5UpU9EG6dCywj7RaYQ_5_6">24,558,648</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_0Jwf52hxF0qA2RHZEDdLTQ_5_9">7,837,188</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Non-cash compensation</p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" id="Tc_FGZLts0dbE63RWzwh3NjfQ_7_3">376,574</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" id="Tc_T_bBLtE0UE-8g9zqKTnyAw_7_6">2,183,317</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" id="Tc_YaqhkgCst0KTCwk7CkeDuA_7_9">1,193,949</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="0" id="Tc_ujqepajiQkyt2Ho7NGh5oA_8_3">882,621</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="0" id="Tc_c_FZOwWGRECZOJJ3h6_xeQ_8_6">731,578</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortization" scale="0" id="Tc_oJp5hVpNlUyWE5WnSCmOiQ_8_9">660,788</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of right-of-use asset</p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" id="Tc_N_0TYcDjvkuwzgEIJrz8ww_9_3">249,008</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" id="Tc_jx4hGj4BQ0a60cWlOeqWDg_9_6">398,035</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Bad debt expense (recovery)</p></td><td style="vertical-align:bottom;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" sign="-" scale="0" id="Tc_7K2NUj6q3EW1UCb9896g8w_10_3">8,354</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" sign="-" scale="0" id="Tc_9NdsOF23Q0S_O1jL5Lg-Sw_10_6">512</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" sign="-" scale="0" id="Tc_RbNZtEldsUquq08A338IuQ_10_9">102,310</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Loss on disposal of fixed assets</p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="0" id="Tc_5q-iwi7Fnkmum9hppY5Srg_11_3">132,303</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Impairment of patents</p></td><td style="vertical-align:bottom;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="0" id="Tc_UIIsZhcpj0SPu3iot2r2Xg_12_3">635,606</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Foreign currency transaction (gains) losses</p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" sign="-" scale="0" id="Tc_L6hhrydNtkinpuPJX7zL_w_13_3">2,448,583</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" sign="-" scale="0" id="Tc_E94zkNK3VUitj_eOvU6oNA_13_6">2,577,913</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="0" id="Tc_4RCzzDnBfk2IoRG1x-ZHCQ_13_9">2,607,139</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_kevs0H5e80iwlRY_lqYT5Q_14_3">3,423,517</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_daA4VdUgPEqQ28zENMD6kw_14_6">4,020,819</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_K2I_-ixvA0mmAXgmqKbvLg_14_9">3,513,671</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of loan acquisition costs</p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="ctso:AmortizationOfLoanAcquisitionCosts" scale="0" id="Tc_taRp8WTMXkq-KYTAIxuw8g_15_9">322,812</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Grants and accounts receivable</p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="Tc_MCifYyChI0em5emB1P_z2A_17_3">1,288,422</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="0" id="Tc_ZxvRV9KAmUiIPzWJGcrXsA_17_6">420,578</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="Tc_-60tM55gv0W28nc6_C9QIg_17_9">326,860</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Inventories</p></td><td style="vertical-align:bottom;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" sign="-" scale="0" id="Tc_-MXP0CRmSUuYl7v0JFkQfQ_18_3">945,352</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="Tc_G981KidXrUyVay_uBv8JBQ_18_6">2,350,547</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="0" id="Tc_q60Qa5eRGk-EVBTxLv3nuA_18_9">461,512</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_8yXN6nTHeECRSp3CFPgpCg_19_3">22,187</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="0" id="Tc_OQSTpmlTu0GuP5kTljM5gA_19_6">280,915</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_3tY9mrBzV0CzkuLrsn-jWA_19_9">1,076,849</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other assets</p></td><td style="vertical-align:bottom;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" sign="-" scale="0" id="Tc_gX6hiYoJNk-xQQzW1QWQzQ_20_3">52,678</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="0" id="Tc_DPB8lKWsvkGtOpbV63K37w_20_6">135,857</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="0" id="Tc_7Caj_Hl-6kaN90G5YVxECQ_21_3">3,248,978</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="Tc_580b1fBC90iqg-68Tf_wKA_21_6">2,426,810</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" id="Tc_ATM6nytMdUu9yKwC8DOhdg_21_9">1,107,352</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_NYTe4aMqYU-4S2W0DleLHw_22_3">28,234,282</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_Wc7e2dsqtkielLWuo2GxZg_22_6">14,005,599</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_iRz-W3IPjEWFrVrL8sm_Pg_22_9">5,613,286</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from investing activities:</p></td><td style="vertical-align:bottom;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="Tc_SPdGxKXhnk2VwGRHP0bR9Q_25_3">6,087,365</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="Tc_0FDvnhNMbk-MQFS83_WtmA_25_6">3,641,248</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" id="Tc_uEKfzgTS4kKrS9s03-HSwQ_25_9">708,395</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Patent costs</p></td><td style="vertical-align:bottom;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="Tc_tzTlXlXAakSwQtHlxw3Ivw_26_3">368,211</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="Tc_Eu-IAxV0E0eztV4FD-tjDQ_26_6">640,013</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="0" id="Tc_zApAYlb4OE66u1a6RHt5qA_26_9">967,823</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_NsT-Y6AsnkSGxF5ebm-yPA_27_3">6,455,576</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_pGMMu_-cHUKyoWZkGLIvIA_27_6">4,281,261</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_gSrV36DZzkaAW8FGPW2qOA_27_9">1,676,218</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from long-term debt</p></td><td style="vertical-align:bottom;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="0" id="Tc_AGmAS_wKBUKayTXEEcmo5A_30_3">5,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="0" id="Tc_wj56BM0U8020bfnuEp7S0Q_30_9">1,410,900</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Repayment of long-term debt</p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="0" id="Tc_ogDDZvcZBUScSNtv_5NwAQ_31_9">16,410,900</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Final fee on long-term debt</p></td><td style="vertical-align:bottom;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="ctso:PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument" scale="0" id="Tc_PbwdGumjlkGr6VsSEph1Ng_32_9">375,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Payment of loan acquisition costs</p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Equity contributions&#160;- net of fees incurred</p></td><td style="vertical-align:bottom;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="ctso:PaymentsForEquityContributionsNetOfFeesIncurred" scale="0" id="Tc_h3mmkbgrvEum_Ho7naPI3g_34_3">40,358</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="ctso:PaymentsForEquityContributionsNetOfFeesIncurred" scale="0" id="Tc_HKaKbOOR5kGudjecTQ5oHQ_34_6">90,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="ctso:PaymentsForEquityContributionsNetOfFeesIncurred" sign="-" scale="0" id="Tc_v-LWfDzinUqvDU8C2Ajz2Q_34_9">80,214,008</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_nMUC6sveW0GmBcGZ6568LQ_35_6">805,199</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_Q4gEVdgfEUqzmaKjtWA9-A_35_9">1,509,322</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from exercise of warrants</p></td><td style="vertical-align:bottom;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_X3vkwFu7x0ivdGJSwPTDSg_37_3">4,959,642</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_tZVVIsdALE2BOOcqVPegnw_37_6">715,199</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_OmKDlWhnI0ixO4OLDlSVwg_37_9">66,348,330</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Effect of exchange rates on cash</p></td><td style="vertical-align:bottom;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="0" id="Tc_D9nYyIpLOUW9t0Qt8qHIWw_38_3">262,924</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="0" id="Tc_IZOHKoVqM0eEcTijt91WvA_38_6">24,774</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" id="Tc_TZwr_hYLqU6FbBsgJhyyCw_38_9">130,357</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net change in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_nzw-9TBva0ywf0i_Jl4f0A_39_3">29,993,140</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_vo_Leb_n3kacsYpbQrEmYQ_39_6">17,596,435</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="Tc_1vHptUUEFEmnyG6nSdOnPQ_39_9">59,189,183</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash at beginning of&#160;year</p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_vhatQPCY5kKuqHy0rRFKBA_41_3">53,825,166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_o-TMaovzMUy236uBYGwcbA_41_6">71,421,601</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2019_6_oqjbutzEKQogf2y7UC6g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_aTpBlzrXAkSwUPo7XyJH9A_41_9">12,232,418</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash at end of year</p></td><td style="vertical-align:bottom;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_N1mfcS_780ymDaP8K7V86A_42_3">23,832,026</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_Yz8xsLsvGEK6Wm5Gz0BkGw_42_6">53,825,166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_9S69T09G-kiWHHa2qhvX9w_42_9">71,421,601</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Supplemental disclosure of cash flow information:</p></td><td style="vertical-align:bottom;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid during the year for interest</p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" id="Tc_m4u_fk_Nb0SLiRV9OGBPxw_45_9">1,127,647</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Supplemental disclosure of non-cash financing activities:</p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock to vendor in lieu of cash payment </p></td><td style="vertical-align:bottom;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="Tc_AxDIIYmSoU-TOxI1AXF5fw_48_3">42,499</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:54.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Capital expenditures included in accounts payable</p></td><td style="vertical-align:bottom;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="0" id="Tc_L0_moJA-LkOMR9_azdhpzQ_49_3">359,965</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:54.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Settlement of accrued bonuses with restricted stock units</p></td><td style="vertical-align:bottom;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssued1" scale="0" id="Tc_zUeMbrfQ906MZ1W8yrIGtQ_50_3">380,091</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssued1" scale="0" id="Tc_b3jdQTVlJE6fOil42UgzhA_50_6">928,417</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssued1" scale="0" id="Tc_CcJB_dqsLEi5OUJhwHeXXg_50_9">657,780</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Notes&#160;to Consolidated Financial Statements are an integral part of these statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_aaf1492b_46c6_4ba9_9078_d29bcae2aa2f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CYTOSORBENTS CORPORATION</p><a id="NotestoConsolidatedFinancialStatements_9"></a><a id="NotestoConsolidatedFinancial_753805"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">Notes&#160;to Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">December 31, 2022</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:BasisOfAccounting" id="Tb_XtKZNXh82U-5YtCRue-g_Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. BASIS OF PRESENTATION:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the results of CytoSorbents Corporation (the &#8220;Parent&#8221;), CytoSorbents Medical Inc., its wholly owned operating subsidiary (the &#8220;Subsidiary&#8221;), and CytoSorbents Europe GmbH, its wholly owned European subsidiary (the &#8220;European Subsidiary&#8221;). In addition, the consolidated financial statements include CytoSorbents Switzerland GmbH, CytoSorbents Poland Sp. z.o.o., CytoSorbents Medical UK Limited, and CytoSorbents France SAS, the wholly owned subsidiaries of CytoSorbents Europe GmbH, and CytoSorbents UK Limited, a wholly owned subsidiary of CytoSorbents Medical, Inc. These entities are collectively referred to as the &#8220;Company&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In years prior to December 31, 2020, the Company&#8217;s consolidated financial statements were prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As of December 31, 2022, the Company&#8217;s cash, cash equivalents and restricted cash balances were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Cash" scale="6" id="Narr_PNGhVCBj_ku--JN-2T496A">23.8</ix:nonFraction> million, which the Company expects will fund the Company&#8217;s operations beyond twelve months from the issuance of these consolidated financial statements. As a result, the Company has determined that the going concern risk has been substantially mitigated.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="Tb_d0tM0TDKMkeqOpBAImrrxQ" continuedAt="Tb_d0tM0TDKMkeqOpBAImrrxQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="ctso:NatureOfBusinessPolicyPolicyTextBlock" id="Tb_k7jeSVsjRU-R4aEg4WMzJw" continuedAt="Tb_k7jeSVsjRU-R4aEg4WMzJw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Nature of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification. The Company, through its subsidiary CytoSorbents Medical, Inc. (formerly known as CytoSorbents, Inc.), is engaged in the research, development and commercialization of medical devices with its blood purification technology platform which incorporates a proprietary adsorbent, porous polymer technology. The Company, through its wholly owned European subsidiary, CytoSorbents Europe GmbH, conducts sales and marketing related operations for the CytoSorb device. In March 2016, the Company formed CytoSorbents Switzerland GmbH, a wholly owned subsidiary of CytoSorbents Europe GmbH. This subsidiary, which began operations during the second quarter of 2016, provides marketing and direct sales services in Switzerland. In November 2018, the Company formed CytoSorbents Poland Sp. z.o.o., a wholly owned subsidiary of CytoSorbents Europe GmbH. This subsidiary, which began operations during the first quarter of 2019, provides marketing and direct sales services in Poland. In the third quarter of 2019, the Company formed CytoSorbents UK Limited, a wholly owned subsidiary of CytoSorbents Medical, Inc., which is responsible for the management of the Company&#8217;s clinical trial activities in the United Kingdom. In March 2022, the Company formed CytoSorbents Medical UK Limited to provide marketing and direct sales services in the United Kingdom and the Republic of Ireland. In October 2022, the Company formed CytoSorbents France SAS to provide marketing and direct sales services in France. CytoSorb, the Company&#8217;s flagship product, was approved in the European Union (&#8220;EU&#8221;) in March 2011 and is currently being marketed and distributed in more than <ix:nonFraction unitRef="Unit_Standard_country_S-K5wYygeEuMMDPQgfGhxg" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="INF" format="ixt:numdotdecimal" name="ctso:NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed" scale="0" id="Narr_rqZ6K_yZqkCl6zrIJfXanQ">75</ix:nonFraction> countries around the world, as an effective extracorporeal cytokine absorber, designed to reduce the &#8220;cytokine storm&#8221; or &#8220;cytokine release syndrome&#8221; seen in critical illnesses that may result in massive inflammation, organ failure, and patient death. In May 2018, the Company received a label extension for CytoSorb covering use of the device for the removal of bilirubin and myoglobin which allows for the use of the device in the treatment of liver failure and trauma, respectively. CytoSorb is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. In January 2020, CytoSorb received EU CE Mark label expansion to include the removal of ticagrelor during cardiopulmonary bypass in patients undergoing cardiothoracic surgery. In May 2020, CytoSorb also received EU CE Mark label expansion to include rivaroxaban removal for the same indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2020, CytoSorb received United States Food and Drug Administration (&#8220;FDA&#8221;) Emergency Use Authorization (&#8220;EUA&#8221;) of CytoSorb for use in adult critically-ill COVID-19 patients with imminent or confirmed respiratory failure. The CytoSorb device has neither been cleared nor approved for the indication to treat patients with COVID-19 infection. The EUA will be effective until a declaration is made that the circumstances justifying the EUA have terminated or until revoked by the FDA.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_d0tM0TDKMkeqOpBAImrrxQ_cont1" continuedAt="Tb_d0tM0TDKMkeqOpBAImrrxQ_cont2"><ix:continuation id="Tb_k7jeSVsjRU-R4aEg4WMzJw_cont1" continuedAt="Tb_k7jeSVsjRU-R4aEg4WMzJw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2020, the Company also announced that the FDA had granted Breakthrough Designation for its DrugSorb-ATR Antithrombotic Removal System for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery. The Breakthrough Devices Program provides for more effective treatment of life-threatening or irreversibly debilitating disease or conditions, in this case the need to reverse the effects of ticagrelor in emergent or urgent cardiac surgery that can otherwise cause a high risk of serious or life-threatening bleeding. Through Breakthrough Designation, the FDA intends to work with CytoSorbents to expedite the development, assessment, and regulatory review of CytoSorbents&#8217; technology for the removal of ticagrelor, while maintaining statutory standards of regulatory approval (e.g., 510(k), <i style="font-style:italic;">de novo</i> 510(k) or premarket approval) consistent with the FDA&#8217;s mission to protect and promote public health. In July 2021, the Company received full approval of its Investigative Device Exemption (&#8220;IDE&#8221;) to conduct the pivotal STAR-T (Safe and Timely Antithrombotic Removal &#8211; Ticagrelor) double-blind randomized control trial (&#8220;RCT&#8221;) for up to 120 patients in the United States to support FDA marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2021, the Company announced that it was granted a second Breakthrough Device designation for its DrugSorb-ATR Antithrombotic Removal System by the FDA. This Breakthrough Device designation covers the removal of the Direct Oral Anticoagulants (DOACs) apixaban and rivaroxaban in a cardiopulmonary bypass circuit to reduce the likelihood of serious perioperative bleeding during urgent cardiothoracic surgery. In October 2021, the Company also received full FDA approval of an IDE application to conduct a double-blind, randomized, controlled clinical study for up to 120 patients entitled, &#8220;Safe and Timely Antithrombotic Removal &#8211; Direct Oral Anticoagulants (STAR-D),&#8221; in the United States to support FDA marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If FDA marketing approval is obtained for either the removal of ticagrelor or direct oral anticoagulants indications, the device would be marketed as DrugSorb-ATR in the United States. The DrugSorb-ATR Antithrombotic Removal System is based on the same polymer technology as CytoSorb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2022, the Company announced that the Company entered into a 3-year preferred supplier agreement with Asklepios, making CytoSorb available without restrictions to all of the approximate 170 healthcare facilities across 14 states throughout Germany at which Asklepios operates. This includes Asklepios Klinik St. Georg in Hamburg, Germany, which pioneered the use of CytoSorb to remove antithrombotic drugs during cardiothoracic surgery, and is well-known for their seminal publication on CytoSorb use for this application during emergency cardiac surgery in patients at high risk of bleeding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2022, the Company announced that, following a successful pilot program in three countries, the Company signed an expanded non-exclusive agreement with Nikkiso Europe GmbH (&#8220;Nikkiso&#8221;) to distribute Nikkiso&#8217;s PureADJUST stand-alone hemoperfusion pump and accessories in a total of 14 countries. In addition to securing the rights to sell Nikkiso&#8217;s stand-alone pump and accessories in Germany, Austria, and Luxembourg, the Company entered into an expanded multi-country reseller agreement with Nikkiso covering the following countries: Belgium, Bosnia and Herzegovina, Croatia, Finland, France, Iceland, Lichtenstein, Poland, Serbia, Slovenia and Switzerland. The Company will also be able to provide field support services in these countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2022, the Company entered into a Marketing Agreement (the &#8220;Marketing Agreement&#8221;) with Fresenius Medical Care Deutschland GmbH (&#8220;Fresenius&#8221;), which expands the Company&#8217;s strategic partnership with Fresenius by establishing a multi-stage global collaboration to combat life-threatening diseases in critical care. The Marketing Agreement provides for the combined marketing and promotion of CytoSorb with Fresenius&#8217; critical care products by Fresenius&#8217; marketing organization worldwide, excluding the United States. The Marketing Agreement has an initial term of three years, with an automatic renewal for an additional two years at the end of such initial term, subject to earlier termination by either of the parties (the &#8220;Term&#8221;). Compared to the prior co-marketing agreement between the parties, the Marketing Agreement intends to increase the commitments from both parties and to ensure an ongoing and consistent level of marketing and promotional activity specifically focused around CytoSorb, where Fresenius will actively market and promote CytoSorb as the featured blood purification therapy for removal of cytokines, bilirubin, and myoglobin on its critical care platforms. Specifically, the Marketing Agreement provides that various Fresenius-led in-person, virtual, social media, and web-based marketing programs and events will feature the CytoSorb therapy and highlight the cooperation between the two companies in the field of critical care during the Term. To help support the increased marketing and promotional efforts of the expanded collaboration, CytoSorbents has agreed to subsidize a portion of the marketing costs through a royalty payment to Fresenius Medical Care based on CytoSorb sales in the intensive care unit on Fresenius Medical Care platforms, excluding the United States. In addition to strengthening and expanding the global marketing of CytoSorb, the Company and Fresenius also plan to work together to bring new innovative solutions to the market. The Marketing Agreement also includes the certification of compatibility of CytoSorb for usage on Fresenius&#8217; current critical care platforms. Certain initial activities have been completed with the formal launch of this program expected to occur sometime in 2023.</p></ix:continuation></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_gIFkAulRQUymQt7L3m15ew_1_2"></a><a id="Tc_bu_onkajX0Gh4d3pF2jRHQ_2_3"></a><a id="Tc_wp-0FqbwaEe9BfOmQHJ19Q_2_6"></a><a id="Tc_onArf6rrcEazxQuKayFC8A_3_0"></a><a id="Tc_KoJKWvKj2UKN6nSLZJH2lQ_3_2"></a><a id="Tc_l69eIx-klEKcm6A3WMrUEA_3_5"></a><a id="Tc_RRlZrNGwtkGpM4cTHXSImg_4_0"></a><a id="Tc_5ptmwOWD5UusmhmyI9wg_w_5_0"></a><a id="Tc_-0GI26cIhEytcULrg7ezDA_5_2"></a><a id="Tc_nobzvhGv6kukoUY2kTWh2A_5_5"></a><ix:continuation id="Tb_d0tM0TDKMkeqOpBAImrrxQ_cont2" continuedAt="Tb_d0tM0TDKMkeqOpBAImrrxQ_cont3"><ix:continuation id="Tb_k7jeSVsjRU-R4aEg4WMzJw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The technology is based upon biocompatible, highly porous polymer sorbent beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company has numerous products under development based upon this unique blood purification technology, which is protected by <ix:nonFraction unitRef="Unit_Standard_patent_iyucGb4rrEygLz5tIoEXtA" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="INF" format="ixt:numdotdecimal" name="ctso:NumberOfPatentsUnitedStates" scale="0" id="Narr_Yl04DjUm5Eu9v3S8Q2AvSA">18</ix:nonFraction> issued U.S. patents and multiple international patents, with applications pending both in the U.S. and internationally, including HemoDefend, ContrastSorb, DrugSorb, DrugSorb-ATR and others. These patents and patent applications are directed to various compositions and methods of use related to the Company&#8217;s blood purification technologies and are expected to expire between 2023 and 2038, absent any patent term extensions. Management believes that any near-term expiring patents will not have a significant impact on the Company&#8217;s ongoing business.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="ctso:StockMarketListingPolicyPolicyTextBlock" id="Tb_Y62CZ6wEj0O2eXCy7UTlyg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Market Listing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;17, 2014 the Company&#8217;s common stock was approved for listing on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;), and it began trading on Nasdaq on December&#160;23, 2014 under the symbol &#8220;CTSO&#8221;. Previously, the Company&#8217;s common stock traded in the over-the-counter-market on the OTC Bulletin Board.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="ctso:ConsolidationAndForeignCurrencyTranslationPolicyPolicyTextBlock" id="Tb__vortbNCa0G6ITGW_bEDnA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Consolidation and Foreign Currency Translation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of CytoSorbents Corporation and its wholly owned subsidiaries, CytoSorbents Medical, Inc. and CytoSorbents Europe GmbH. In addition, the consolidated financial statements include CytoSorbents Switzerland GmbH, CytoSorbents Poland Sp. z.o.o., CytoSorbents Medical UK Limited and CytoSorbents France SAS, wholly owned subsidiaries of CytoSorbents Europe GmbH, and CytoSorbents UK Limited, a wholly owned subsidiary of CytoSorbents Medical, Inc. All significant intercompany transactions and balances have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Translation gains and losses resulting from the process of remeasuring into the United States of America dollar, the foreign currency financial statements of the European subsidiary, for which the United States of America dollar is the functional currency, are included in operations. Foreign currency transaction gain (loss) included in net loss amounted to approximately $(<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="ctso:ForeignCurrencyTransactionGainLossExcludingTax" sign="-" scale="0" id="Narr_atXaV90tyE64yFEmOchDCA">2,448,000</ix:nonFraction>), $(<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="ctso:ForeignCurrencyTransactionGainLossExcludingTax" sign="-" scale="0" id="Narr_EgXE6xtpaUqLjptdeOSVGA">2,578,000</ix:nonFraction>) and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="ctso:ForeignCurrencyTransactionGainLossExcludingTax" scale="0" id="Narr_Depquy9HHUGQZAKGrg0Nbw">2,607,000</ix:nonFraction> for the years ended December 31, 2022, 2021 and 2020, respectively. The Company translates assets and liabilities of the European subsidiary, whose functional currency is their local currency, at the exchange rate in effect at the balance sheet date. The Company translates revenue and expenses at the daily average exchange rates. The Company includes accumulated net translation adjustments in accumulated other comprehensive income (loss) as a component of stockholders&#8217; equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_-nu9ZPiv-0i1kkTtpA-kuQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid instruments purchased with an original maturity of three&#160;months or less to be cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of cash and cash equivalents and restricted cash and cash equivalents to amounts shown in the consolidated balance sheets and consolidated statements of cash flows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="ctso:ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock" id="Tb_aWE5qIXHiUCaxNwGqMlpFw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_v4zLB0VDNk-MENAm4AFgpw_3_3">22,144,567</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_mhiLrj-LoUS07DiHL4cnIw_3_6">52,137,707</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="0" id="Tc_Iq9JC6HRZEWPFzn5QTDVfg_4_3">1,687,459</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="0" id="Tc_mTgOhxiTJE694iNGc5g1_w_4_6">1,687,459</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_FuBbsDET0kyaXDL-m_5XdA_5_3">23,832,026</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_GNPm7nVHtUOj-HSuKuKW0A_5_6">53,825,166</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="Tb_1aSdw7tW_EWKYbltcYoroQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s total restricted cash in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="0" id="Narr_vXqEoIA8fkC9AnTBLxAIrw">1,687,459</ix:nonFraction> consists of cash of $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_pd77Iy0ZEkG2yi4BhLTLbw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCollateralAmount" scale="0" id="Narr_zLu5zeILHkGW7crrLes-Fg">1,467,459</ix:nonFraction> that the Company is obligated to maintain as collateral for the outstanding letter of credit with Bridge Bank that was provided to the landlord of the College Road facility as security and cash of $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_us-gaap_CreditFacilityAxis_us-gaap_CreditCardMember_10pNVCROt0uc0geHUcOPJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCollateralAmount" scale="0" id="Narr_aMpsK-Xhm0aS-DhVyfl6GA">220,000</ix:nonFraction> that the Company is obligated to maintain as collateral for the credit limit on the Company&#8217;s credit card account.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="Tb_FjJbYhLOxEi9Xv2gM-0O6w" continuedAt="Tb_FjJbYhLOxEi9Xv2gM-0O6w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grants and Accounts Receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grants receivable represent amounts due from U.S. government agencies and are included in grants and accounts Receivable in the accompanying consolidated balance sheets.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_d0tM0TDKMkeqOpBAImrrxQ_cont3" continuedAt="Tb_d0tM0TDKMkeqOpBAImrrxQ_cont4"><ix:continuation id="Tb_FjJbYhLOxEi9Xv2gM-0O6w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable are unsecured, non-interest-bearing customer obligations due under normal trade terms. The Company sells its devices to various hospitals and distributors. The Company performs ongoing credit evaluations of customers&#8217; financial condition. Management reviews accounts receivable periodically to determine collectability. Balances that are determined to be uncollectible are reserved in the allowance for doubtful accounts.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:InventoryPolicyTextBlock" id="Tb_ZK8YUadA_0-RVaE35Npe3g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Inventories</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Inventories are valued at the lower of cost or net realizable value. Cost is determined using a first-in first-out (&#8220;FIFO&#8221;) basis. At December 31, 2022 and 2021, the Company&#8217;s inventory was comprised of finished goods, which amounted to $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="0" id="Narr_bLoj7FiQ-UC1EFkQKP-Jyg">1,567,871</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="0" id="Narr_QUOTk2A-8ky1b1OWds1icg">3,084,606</ix:nonFraction>, respectively, work in process which amounted to $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="0" id="Narr_Lmh9QnwbiUut8px3GtCwXA">1,280,368</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="0" id="Narr_YzcFUBQnpUuGcmDnaZtWJA">1,322,736</ix:nonFraction>, respectively, and raw materials which amounted to $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="0" id="Narr_UxRWXW_VUk2a3pbHGbGwOQ">613,347</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="0" id="Narr_cMNJrpE_60SO6MOWsn97Bg">358,756</ix:nonFraction>, respectively. Devices used in clinical trials or for research and development purposes are removed from inventory and charged to research and development expenses at the time of their use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2022, the Company experienced an equipment failure of a refrigeration unit at its new College Road manufacturing facility. This equipment stored various items of work-in-process inventory. The Company determined all the items that were stored in this unit were required to be scrapped. The value of this inventory was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_9_30_2022_lBauhAm9gkWSn63bQjLUkw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InventoryAdjustments" scale="0" id="Narr_sfAOJHj_mkWe5vdV7YqfBg">599,000</ix:nonFraction>. Accordingly, this inventory was written off and was included in cost of goods sold at the time of the loss in September 2022. The Company filed a claim with its insurance carrier related to this loss. In December 2022, the claim was approved in the amount of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_CargoAndFreightMember_vWKDoEIhEUOKRvy4A7Wi5w" decimals="0" format="ixt:numdotdecimal" name="ctso:InsuranceSettlementReceivableForLossOnInventoryRecordedAsReductionToCostOfGoodsSold" scale="0" id="Narr_fwr3hycSRECLKudURkBVZQ">299,000</ix:nonFraction> and, accordingly, has been recorded as a reduction to cost of goods sold in the accompanying consolidated statement of operations and comprehensive loss.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_Lol91fFtZkqurTyJGcpXUg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are recorded at cost less accumulated depreciation. Depreciation of property and equipment is provided for by the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the lesser of their economic useful lives or the term of the related leases. Gains and losses on depreciable assets retired or sold are recognized in the statements of operations in the&#160;year of disposal. Repairs and maintenance expenditures are expensed as incurred.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="Tb_YbLOQKQkUkOjXBYav-LjWQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Legal costs incurred to establish patents are capitalized. When patents are issued, capitalized costs are amortized on the straight-line method over the related patent term. In the event a patent is abandoned, the net book value of the patent is written off.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_yYzwdMj-7ku7EYitshRDcg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment or Disposal of Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company assesses the impairment of patents and other long-lived assets under accounting standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value. During the year ended December 31, 2022, the Company wrote-off patent costs of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="ctso:WroteOffPatentsCosts" scale="0" id="Narr_Zki293W9f0CVl9C_LvFMMQ">636,000</ix:nonFraction> related to the impairment of certain issued patents and pending patent applications in certain specific jurisdictions, the abandonment of certain patent defense costs that are no longer being pursued and the abandonment of certain pending patent application costs in the ordinary course of business.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_BPfgeEcJY0Cz8CGyq5E6BA" continuedAt="Tb_BPfgeEcJY0Cz8CGyq5E6BA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Product Sales:</i> Revenues from sales of products to both direct and distributor/strategic partner customers are recognized at the time when control passes to the customer, in accordance with the terms of their respective contracts. Recognition of revenue occurs as each performance obligation is completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Grant Revenue: </i>Revenue from grant income is based on contractual agreements with various agencies of the U.S. government. Certain agreements provide for reimbursement of costs, other agreements provide for reimbursement of costs and an overhead margin and certain agreements are performance based, where revenue is earned based upon the achievement of milestones outlined in the contract. Revenues are recognized when the associated performance obligation is fulfilled. Costs are recorded as incurred. Amounts invoiced in excess of costs actually incurred on fixed price contracts are classified as deferred revenue and are included in accrued expenses and other current liabilities in the consolidated balance sheets. Costs subject to reimbursement by these grants have been reflected as costs of revenue.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_d0tM0TDKMkeqOpBAImrrxQ_cont4" continuedAt="Tb_d0tM0TDKMkeqOpBAImrrxQ_cont5"><ix:continuation id="Tb_BPfgeEcJY0Cz8CGyq5E6BA_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_626F5jiU_0iyMjKUNQYW5A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All research and development costs, payments to laboratories, research consultants and costs related to clinical trials and studies are expensed when incurred.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="Tb_Nr_UwEugdk6SGO75Zr59sQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Advertising Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Advertising costs are charged to activities when incurred. Advertising expense amounted to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="0" id="Narr_mDUv65SLU0WqGG9RKwcdmQ">582,000</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="0" id="Narr_PZSeHs5D70K2-0vabgkOrA">615,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdvertisingExpense" scale="0" id="Narr_SB-pi8FKcUq2N9JSFe3a_g">285,000</ix:nonFraction> in 2022, 2021 and 2020, respectively, and is included in selling, general, and administrative expenses in the consolidated statements of operations and comprehensive loss.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_XXq03edQ7UK9ncqo5hpDGQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Income taxes are accounted for under the asset and liability method prescribed by accounting standards for accounting for income taxes. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax asset will not be realized. Under Section 382 of the Internal Revenue Code, the net operating losses generated prior to the previously completed reverse merger may be limited due to the change in ownership. Additionally, net operating losses generated subsequent to the reverse merger may be limited in the event of changes in ownership. In 2017, the Tax Cuts and Jobs Act reduced the U.S. federal corporate tax rate from <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember__1pqeGKP1UqWAJ53fXSkdQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_1_0QvogFVkWyRwfb5xW2vg">35</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_8lddL3hShE2PxAKw1cffhA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_7PwZ_v_ybUuabPsNgZrmHg">21</ix:nonFraction>%. See Note&#160;9 for the impact of the tax rate change on deferred tax assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company follows the accounting standards associated with uncertain tax provisions. The Company had <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_P4teFaLYP0aNGiJC9vmhUQ"><ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_I56T4INlXkuKvf3va6MP0A">no</ix:nonFraction></ix:nonFraction> unrecognized tax benefits as of December 31, 2022 or 2021. The Company files tax returns in the U.S. federal and state jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company utilizes the Technology Business Tax Certificate Transfer Program to sell a portion of its New Jersey Net Operating Loss tax carryforwards and Research and Development credits to an industrial company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CytoSorbents Europe GmbH, CytoSorbents Switzerland GmbH, CytoSorbents Poland Sp. z.o.o., CytoSorbents UK Limited, CytoSorbents Medical UK Limited and CytoSorbents France file an annual corporate tax return, a VAT return and a trade tax return in Germany, Switzerland, Poland, France and the United Kingdom, respectively.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:UseOfEstimates" id="Tb_dgmdiNS3L0mq7pIpfcysZA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets, liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. The valuation of options granted, allowance for doubtful accounts and recoverability of patents are significant estimates in these consolidated financial statements.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_ePNWe1F1m0ST-Re4tosRdA" continuedAt="Tb_ePNWe1F1m0ST-Re4tosRdA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of the Company&#8217;s revenues are from product sales in Germany. Substantially all of the Company&#8217;s grant and other income are from grant agencies in the United States. (See Note&#160;3 for further information relating to the Company&#8217;s revenue.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, two distributors accounted for approximately <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="2" format="ixt:numdotdecimal" name="ctso:ThresholdUsedForCalculatingConcentrationOfRisk" scale="-2" id="Narr_RQfVNngErEKzYg8E5Kba1g">27</ix:nonFraction>% of outstanding grants and accounts receivables. As of December 31, 2021, one distributor accounted for approximately <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_ctso_OneDistributorMember_XK7cgrbnyk-5EtW1e3KAjQ" decimals="2" format="ixt:numdotdecimal" name="ctso:ThresholdUsedForCalculatingConcentrationOfRisk" scale="-2" id="Narr_CeWLUPma4kql44fAqMwKLQ">12</ix:nonFraction>% of outstanding grants and accounts receivables. For the years ended December 31, 2022, 2021 and 2020, no agency, distributor/strategic partners or direct customer represented more than <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_Ow1UbuwxYkCiv37yEeEpfA" decimals="2" format="ixt:numdotdecimal" name="ctso:ThresholdUsedForCalculatingConcentrationOfRisk" scale="-2" id="Narr_bpA5JW2RPUOnvDm1616yBQ"><ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_KP3JJIYFZk6xK_VoVW7UbA" decimals="2" format="ixt:numdotdecimal" name="ctso:ThresholdUsedForCalculatingConcentrationOfRisk" scale="-2" id="Narr_CxYL8_TYTUST0RkbDFjE0g"><ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_v0fFN3Ebi0qVBjU54fspcg" decimals="2" format="ixt:numdotdecimal" name="ctso:ThresholdUsedForCalculatingConcentrationOfRisk" scale="-2" id="Narr_9WXBdyp450OENnt74f-f5A">10</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the Company&#8217;s total revenue.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_d0tM0TDKMkeqOpBAImrrxQ_cont5"><ix:continuation id="Tb_ePNWe1F1m0ST-Re4tosRdA_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_P45j8bvkw0ORgmn7T1SdLw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their short-term nature.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_HkgTCpb0xkGxM5OlQsYmJw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss per Common Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed using the treasury stock method on the basis of the weighted-average number of shares of common stock plus the dilutive effect of potential common shares outstanding during the period. Dilutive potential common shares include outstanding warrants, stock options and restricted shares. The computation of diluted net loss per share does not assume conversion, exercise or contingent exercise of securities that would have an anti-dilutive effect on earnings (see Note&#160;12).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_ygkc94GFrEORex5NIfGz4g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its stock-based compensation under the recognition requirements of accounting standards for accounting for stock-based compensation for employees and directors whereby each option granted is valued at fair market value on the date of grant. Under these accounting standards, the fair value of each option is estimated on the date of grant using the Black-Scholes option pricing model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company also follows the guidance of accounting standards for accounting for equity instruments that are issued to non-employees for acquiring, or in conjunction with selling, goods or services for equity instruments issued to consultants.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="ctso:ShippingAndHandlingCostsPolicyPolicyTextBlock" id="Tb_Mr-ikk-hX0S-B67I0SnUWg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Shipping and Handling Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The cost of shipping product to customers and distributors is typically borne by the customer or distributor. The Company records shipping and handling costs in cost of revenue. Total freight costs amounted to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_CargoAndFreightMember_vWKDoEIhEUOKRvy4A7Wi5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="Narr_Mw49AgIkeEyzE0f9D88A1A">297,000</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_CargoAndFreightMember_3_4JFM6ghEqxTBICweYCOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="Narr_4N9O4HuLwUCyaQey7EVCFA">276,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_CargoAndFreightMember_XgZFDtyGV0-mrreoqyHhdQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="0" id="Narr_W8OEME9j_EGsDjFn_8AM1w">560,000</ix:nonFraction> for the&#160;years ended December 31, 2022, 2021 and 2020, respectively.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_2FHDbY1jOEOHpHrLHTzFiA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Effect of Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2021, the Financial Accounting Standards Board (the &#8220;FASB&#8221;), issued Accounting Standards Update No. 2021-10 entitled, &#8220;Government Assistance (Topic 832) Disclosures by Business Entities about Government Assistance&#8221; (the &#8220;ASU&#8221;). This ASU will require enhanced disclosures related to the Company&#8217;s contracts with the U.S. government. The ASU is effective for annual periods beginning after December 15, 2021. The Company implemented the provisions of this ASU during 2022.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June 2016, the FASB, issued ASU No. 2016-13 entitled, &#8220;Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221;. This ASU provides guidance on the calculation of credit losses, which includes the allowance for doubtful accounts on trade accounts receivable. The updated guidance is effective for public entities for fiscal years beginning after December 15, 2022. The Company is evaluating the impact of the updated guidance but does not believe that this will have a significant impact on its financial statements.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c5d9fe8e_0594_485c_af00_29f2a31a8b86"></a><a id="Tc_5-rZMZfz7UeBf0SNINuplA_1_8"></a><a id="Tc_kBRkFIF8z0mRCAM2laZHbw_2_5"></a><a id="Tc_Zx9BMsgEI0yjQQGK5N2UMg_2_8"></a><a id="Tc_gEiYzB7XLkazSVcUgBEztA_3_2"></a><a id="Tc_OGK8s67TBEiBhU0mKc6ahQ_3_5"></a><a id="Tc_iin5B9-YAkKMb2EBs9gmCQ_3_8"></a><a id="Tc_lCTt8iZQQU-N13zo9wWTDA_3_11"></a><a id="Tc_CP4pfOLXfkq9qVUL4zEDhA_4_0"></a><a id="Tc_oitQO2n5v0iMIVmW8lKZKA_5_0"></a><a id="Tc_rS75cTcmpUS8Xa-rSsbCvA_5_2"></a><a id="Tc_aougWVN_qkSzEEwGZgNnSw_5_5"></a><a id="Tc_ndC0pZUSAEGRUNkQDvLWfQ_5_8"></a><a id="Tc_X8FM5SA44kO--RDoaDpXKQ_5_11"></a><a id="Tc_oEAV_s1gUkijo6ZIJbGGkA_6_0"></a><a id="Tc_Hc-xfHUQbEu2wEQE-FL8Bw_7_0"></a><a id="Tc_N3KCs8PTKEOksena6ukBZQ_8_0"></a><a id="Tc_446yribQyEGU2IgPXsGZgw_9_0"></a><a id="Tc_krd_5TVl7Uqa-flNkXS2pQ_10_0"></a><a id="Tc_pXpjRjNzl0uIJKgJPrhCAw_12_0"></a><a id="Tc_pVGsFsmsPEKO39MdUrCtrg_12_2"></a><a id="Tc_jOAdt2LNvkezLzKiUJMavw_12_5"></a><a id="Tc_DR3MaBqOQkGdn_vx3tU_Sg_12_8"></a><a id="Tc_Lfngzif2I0GcZLaT90vlGg_12_11"></a><a id="_7b52658c_2b79_46a5_82ff_26a0693fedae"></a><a id="Tc_1-wHqrO6LkWpHekObi-F2Q_1_8"></a><a id="Tc_oSqntOxuvEemfCxBOmRH-g_2_5"></a><a id="Tc_zp-YZszeQEmZOT-2VNyJMA_2_8"></a><a id="Tc_EYOGOrblMkWESpfiqC9kqA_3_2"></a><a id="Tc_uqKfRBtCQkym6SJBlXC8Qw_3_5"></a><a id="Tc_y6Y9AogFtUe_KrzCeKPymA_3_8"></a><a id="Tc_-v5PswloUkKHzrZwgmXyQg_3_11"></a><a id="Tc_J99kYBKpiUeagBSAbLa31g_4_0"></a><a id="Tc_9cVyfzkw7UKDVdD4nKA9hw_5_0"></a><a id="Tc_LKHp3BWdz0Sd1n_2Tu5HYA_5_2"></a><a id="Tc_m9oWAyaPMUqLOBWk7Iis-Q_5_5"></a><a id="Tc_9AExHhR1EUy1zt9VeMMNBQ_5_8"></a><a id="Tc_QYxVKqbqw0-vzLMMGioS_Q_5_11"></a><a id="Tc_OSSZ_Olfrk-ZO14oGha99Q_6_0"></a><a id="Tc_KZ7BQyR-9UuL494ARGZINQ_7_0"></a><a id="Tc_KyCdKQexTkmQi26KxNpf9g_8_0"></a><a id="Tc_UugpcX7aFE6-fKy_Qvl-wQ_9_0"></a><a id="Tc_TLmqcdaOHU6qGYGnBSsR3A_10_0"></a><a id="Tc_JzieHQaL9kecw5Gy75bcXg_12_0"></a><a id="Tc_Ypg1xyZVgUyiS42MVJLV3A_12_2"></a><a id="Tc_f_YV-0zkTU-_Bb_4plRU2A_12_5"></a><a id="Tc_zJ2fKa7wiEKKUcREpzN5Rw_12_8"></a><a id="Tc_YiF6pusAfEWGGIGxybeeSw_12_11"></a><a id="_a2d60384_8a3e_4899_a151_cb249907dce2"></a><a id="Tc_EW_luv3tDEKaRhR9_PqRng_1_8"></a><a id="Tc_abFUsAvAPk-dBDEp3zLovA_2_5"></a><a id="Tc_CVaiWPKutESTFBxqK6a0vw_2_8"></a><a id="Tc_pQVrfJSeNkebLbFHV5Ffsw_3_2"></a><a id="Tc_x9WZM7EA4EaT6FtqhSKLDw_3_5"></a><a id="Tc_k-EzpgSQfECKl7FNa5bs8A_3_8"></a><a id="Tc_q7lwLGU6-0WubohYuEE_1A_3_11"></a><a id="Tc_nC0f9Kh_P06tzGNdFRXJvw_4_0"></a><a id="Tc_VOAIeqTurkCzP7xxry47Pw_5_0"></a><a id="Tc_-qdFV_OABUqxmKe0fFVKNA_5_2"></a><a id="Tc_k7Z7oCpEJEqNZtpcDNppeg_5_5"></a><a id="Tc_5uX-XMCuuUGV-rCuegC5Og_5_8"></a><a id="Tc_CoGjLJ_1A0euva9nWmpOAQ_5_11"></a><a id="Tc_O65VIrHMkkWTGu961rQeyg_6_0"></a><a id="Tc_KvjIuLAPhU27VBuUeobTMA_7_0"></a><a id="Tc_UqYas0lgkUCZxlTayQq9fQ_8_0"></a><a id="Tc_oiD00vDm4keG7ZUBdts6dg_9_0"></a><a id="Tc_RzCqxyZjYUuEhlbB5MOyAw_10_0"></a><a id="Tc_LifnZ-gzz0GzTZLYoCgOtQ_12_0"></a><a id="Tc_RBBo9OJYeEmjvyq8HLHcqg_12_2"></a><a id="Tc_H7lNH6kAmUaCIKohSDxwAA_12_5"></a><a id="Tc_sLijNPbG_UmNEuNEWZsAAQ_12_8"></a><a id="Tc_PMrO82TXrUaDev2YU5cx3g_12_11"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="Tb_BgbvgOWbZkGCYav7hgiLug" continuedAt="Tb_BgbvgOWbZkGCYav7hgiLug_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. REVENUE:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="Tb_nLZWJkxoaES_H1eQuDCgnQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table disaggregates the Company&#8217;s revenue by customer type and geographic area for the&#160;year ended December 31, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">United&#160;States</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Distributors/</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Government</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Direct</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Strategic&#160;Partners</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Agencies</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Product sales:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_tOnDtJIL0UqvBIiQr68NeQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_dpH7QWwH_UKci4t-1WGgOQ_5_3">787,201</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_sb5j1GuT4Eys3LqScvVX2A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_xvJY4Zyn-UmnYubxBwF1hQ_5_6">181,750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_OsNNOJGgGESiK9DlqyfB8w" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_Mtia5gV35kGEJ_4FlfBZCQ_5_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_eeMsQ5mBMEaBmXTojZOwqQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_BxyMkaOVukeuzAumA_ibow_5_12">968,951</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Germany</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_ZscEfHJXA0ChpTkNTqDj8Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_gWC7OGyOu0CaJSzG4JCQlA_6_3">12,566,437</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_NZxEE0JdaUaTuS77svmYtA" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_UrL3U1PK_E-0BdyjwG41ig_6_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_dfAHrsFp2E6oinjJ00Mtqg" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_h6vnykgQ6UuDvS-DqjHsQw_6_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_3PyNg5XDT0qvzYh6YJ8lww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_AmYvaPmdOkeaAa8EeL6SNQ_6_12">12,566,437</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">All other countries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_gmpCbnM0wEWJOVVOWqPBQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_X52IuIK30UGF5qYLKEpi_A_7_3">4,705,580</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_GB3izD4hs0eaNYDtQMtZdQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_qgJ_zPhYlEuQX0T8ZaqBOg_7_6">11,118,942</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_nqaL2-pOqECJbRrVf3pvdw" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_-6ruOKpE60KsKIaiUQjBng_7_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_ZhVhCO9-WUWruNBvh_NrbQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_EkFvkjn-lkKeS4U_eZ47-w_7_12">15,824,522</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total product revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_qMcmuIE2xU-kOZeBMfsP5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_hvi15BTFW0OyQqgmcs_Ogg_8_3">18,059,218</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_xMUd5SWGqEmdLXxwWDooqw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_AQGhgzbAbUqkqCx4BYhCog_8_6">11,300,692</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_4xdvMPyNJE2TidM1dnfXSg" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_bIz4gscU7UGnOV-STDHR-g_8_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_H13OncAn9U2imjaSPSyd5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_AiQ6zzgwdEa0bXsNbO_aCg_8_12">29,359,910</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_WXkclWPOXk-aO6LslEVKtw" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_V9kiffZTAEC5nrVOOVp_Dw_10_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_vmt8r9ikk0aev-F4z3pADg" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_ec7EjicCQkCzPHxCwUCu8g_10_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_hvHgr5Vvo06FhAv5d7bNKA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_2sdApeJBqUC28665oFrHMQ_10_9">5,328,899</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_73_wiDAntkqkT8Vf6yVyrg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_BpGvZNYtBk6nOdhVsF3-MQ_10_12">5,328,899</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DirectMember_XS_Uh4IEcEeCPxJehbgjrA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_VkBDLA90nEG-Hb3S_jg-4A_12_3">18,059,218</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_Gir4cGdvtkGYyi8G96HfRg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_88BiA1kHPUuNXpLKqwGUOw_12_6">11,300,692</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_T8rLz83ayUi_sdvVUUukQw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_AiVSz4Cq70WzeKLIH9LR2w_12_9">5,328,899</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_s-gm_ucj_EmdynhhC1QWrA_12_12">34,688,809</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table disaggregates the Company&#8217;s revenue by customer type and geographic area for the&#160;year ended December&#160;31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">United&#160;States</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Distributors/</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Government</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Direct</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Strategic&#160;Partners</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Agencies</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Product sales:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_I2ChB-9AP0S0q8UrImX6ag" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_OKdPuL7tmkiU6ZGtEqUc_g_5_3">189,167</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_ZANpAs_ejE2twTb1k2pdig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_pY-b4dSZhkqkzTY-UVNZrQ_5_6">1,500,700</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_-zkrbwSc80qnJ_4yNjEqoQ" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_2wwv3ZX6yk2v6mZxnRO_nA_5_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_4RHTqNRNFESnd9qrz5_cCA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_IfATIZfbD0isWkvMYpjpoA_5_12">1,689,867</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Germany</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_ZlfzimG38UyKkvdPjtVHWw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_0XXwzreBZUGtfoIdpcnC_w_6_3">21,006,432</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_RJXSLiJzd02uK0ssKMKg7w" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_lXxRlwFOvUqN949dE8EuYg_6_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_3K7sqcTX4UWhfYo-xNN6bA" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_oLvJR7Uvo0y6j6d5qAAovw_6_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_l7Cg7koCpUySLneSLrO0Zg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_cAwMKuDaLkCknaMWU0nd-Q_6_12">21,006,432</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">All other countries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_tKPWLILXVE2h95fQt2uIvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_UQQy4g8bqk6WvimdL-GgEA_7_3">5,846,256</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_NeBUdimYUkWFDNDnPD3CnA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_prkAtj2nEEartgaK1P1O2A_7_6">11,566,012</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_dHpKJ66LdEuPGffrdOOnGg" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_PktYwwRMz0axlZn93wEJWw_7_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_nymBapNFM0u97cDmYtNcKw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_7Vf9-IlxkUaBQ7ZhTCsepA_7_12">17,412,268</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total product revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_O-d7ZVaWAUytjn4uAGiAxw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_85ZX5bnJZEqem94GoE5MSA_8_3">27,041,855</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_EtLLdZY6mEyFOKLjp4Uv1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_adjnJ4xa-EuI5XmnvEIUaA_8_6">13,066,712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_YIGCSpdP6UqYoJUTKv7p7w" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_rVDdwgc7A0e9ThCW3g0RRg_8_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_KSZxi4zg7keBU37J2Y0-8w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_xZObgm1MX0Gwe-6jZxYhMA_8_12">40,108,567</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_b8AI_7G0G0umDEyvgW9dOw" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_OgFTrk9AxUGxzehuAiwE4w_10_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_sQvISkQQ3UKBDgXPufGqUw" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_6x3zUwHgjUWxzQUAjXUL6A_10_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_JVeLOYDILkWMpirfcvOUkg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_ut621C4ao0eUzQsA3BmoaQ_10_9">3,056,960</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_BjelKy9GsEOR7gq0nA95tQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_cCqRHPYksEiSEjD06j7oJg_10_12">3,056,960</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DirectMember_agZO3qBuDE-w-pXujZLoyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_73pg871c6EqjdOhLTQjwNw_12_3">27,041,855</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_Ahb2Ft23iEuFgHVNXLFShQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_SYa6EL4sYEefUlg03YvqLQ_12_6">13,066,712</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_2s9vyN8oyESnIA9BeyMmsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_q_qw4duWNkCiGLmURtw4NQ_12_9">3,056,960</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_rN1_6zQTQ0eji3iph1Moxw_12_12">43,165,527</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table disaggregates the Company&#8217;s revenue by customer type and geographic area for the&#160;year ended December&#160;31, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">United&#160;States</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Distributors/</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Government</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Direct</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Strategic&#160;Partners</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Agencies</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Product sales:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_Tv8sVQFDs0OjBBDw_jDtKg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_qq7AL3aDXUmdwHi_1OHisg_5_3">1,148,300</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_d8LbBpFImkegbFV6bTyQPA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_QgnoH07rAUunQQr7LSjE-A_5_6">192,900</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_ix4FCkAs6kWXANuYn55BGw" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_OeJuu0_7cEiWnqY2v5mTRg_5_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_GHt6jI9HW0amSQTDjBZQSg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_wWNYTm2kskGQrZy_rpnBQw_5_12">1,341,200</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Germany</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_ZzNQcZHrw0GnVCIADz0a6w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_PzMeQ3-tKkeayqKqiL5RAQ_6_3">20,257,410</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_yC2fiJcIZ028vV2ALBTiiA" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_Z-61zJPJ602VCl76O7BoMg_6_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_REqz0wSSUEO2inn9gwE8Rw" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_8vjKQaso6UmQOXV1mNdnbw_6_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_fzhPwuLPukmrUdi_ToPDPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_nbWg5vrXQUCo5EGYdJzUuA_6_12">20,257,410</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">All other countries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_7NOqCHyL_kKAzrJSLXbLAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_PZpKILjbbE-dM8xjGbA43w_7_3">5,275,619</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_MriDhsC_C0qBVC8cxkY0Bg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_LtzeNgZuMkyp_FMdXu6iJQ_7_6">12,578,273</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_mH41MxVhmkGct0J07XEN1w" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_AeFe8G4YQUe61z2mRhQOIA_7_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_QXov_wgwTEe9iec6EImaQQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_uXQ_9CyWGkCeiKvV_T7bjQ_7_12">17,853,892</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total product revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_0DuN_YUs0k2g6B7WoQuymA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_tJUp9qIu4U268zsTpHCvvw_8_3">26,681,329</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_ht_XRtUdc0KZKqw23eRvcg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_ZRFmCWTFOkWBjGtU4L7SFA_8_6">12,771,173</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_S0fxf7nq1EOlWiL9Q6JU9g" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_KGc_y7q0Z0iugz94RT4GEA_8_9">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_dd7aX6AZn0ivW75vs1ACmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_Z4nS0dC060KIY0_QgTfbMg_8_12">39,452,502</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_KOQGfIkSGE2fpCi1ZL7vYA" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_Nkvr6mXkjk6L6c8x6HgfYg_10_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_2dyyoRP_xEmVYml_OXHP7w" decimals="0" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_KFNbDwbrr0WEVN_28Ga9Rg_10_6">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_gfv9AQKB10GMbME_bmBdWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_aKzeXfYAm06jmcDqRilPyw_10_9">1,552,099</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_BQH7e5DFwU-i1ithowcxIA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_1DF-HIsLF0ejnbfYA8mY7Q_10_12">1,552,099</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DirectMember_tT74xtzFukKomPVrAOvfwg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_7m37bwPMCESNnZQrsFfGaw_12_3">26,681,329</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_UrGxGvJgzkO7B8scLF4L5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_AtatfeGZPkewQJAv_Trm5g_12_6">12,771,173</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_cwj5unG_WkCRIuQlwJ3dwQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_n2FY6115ykSE9pwkMWyhuw_12_9">1,552,099</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_Jo1WjvDjoUG4TxYnqe0Tzw_12_12">41,004,601</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has <ix:nonFraction unitRef="Unit_Standard_item_00R0j3K4HUiRlSslEJQMxQ" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="INF" format="ixt-sec:numwordsen" name="ctso:NumberOfPrimaryRevenueStreams" scale="0" id="Narr_c1z-WAM-JEyYR711VM1dHg">two</ix:nonFraction> primary revenue streams: (1)&#160;sales of the CytoSorb device and related device accessories and (2)&#160;grant income from contracts with various agencies of the United States government. Both of these revenue streams are within the scope of this accounting pronouncement. The following is a brief description of each revenue stream.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_BgbvgOWbZkGCYav7hgiLug_cont1" continuedAt="Tb_BgbvgOWbZkGCYav7hgiLug_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">CytoSorb Sales</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company sells its CytoSorb device using both its own sales force (direct sales) and through the use of distributors and/or strategic partners. The majority of sales of the device are outside the U.S., as CytoSorb is not yet approved for commercial sale in the United States. However, in April 2020, the Company was granted Emergency Use Authorization (&#8220;EUA&#8221;) of CytoSorb for use in critically-ill patients infected with COVID-19 by the FDA. Direct sales outside the United States relate to sales to hospitals located in Germany, Switzerland, Austria, Belgium, Luxembourg, Poland, the Netherlands, Sweden, Denmark, Norway and the United Kingdom. Direct sales are fulfilled from the Company&#8217;s office in Berlin, Germany. There are no formal sales contracts with any direct customers relating to product price or minimum purchase requirements. However, there are agreements in place with certain direct customers that provide for either free of charge product or rebate credits based upon achieving minimum purchase levels. The Company records the value of these items earned as a reduction of revenue. These customers submit purchase orders and the order is fulfilled and shipped directly to the customer. Prices to all direct customers are based on a standard price list based on the packaged quantity (6 packs vs. 12 packs).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Distributor and strategic partner sales make up the remaining product sales. These distributors are located in various countries throughout the world. The Company has a formal written contract with each distributor/strategic partner. These contracts have terms ranging from <span style="-sec-ix-hidden:Hidden_4sWYxGr9T0-FAHL1y2CyEw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span> to <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_Df_fcOfuVUyrXQ2v2oxuSQ" format="ixt-sec:durwordsen" name="ctso:TermOfCustomerContracts" id="Narr_jfpBaKyDGkusjnb-M_zURA">5 years</ix:nonNumeric> in length, with <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" format="ixt-sec:durwordsen" name="ctso:TermOfCustomerContracts" id="Narr_piAx0vYIBkO9TjaHRhTjkg">three years</ix:nonNumeric> being the typical term. In addition, certain distributors are eligible for volume discount pricing if their unit sales are in excess of the base amount in the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Most distributor&#8217;s/strategic partner&#8217;s contracts have minimum annual purchase requirements in order to maintain exclusivity in their respective territories.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There is no additional consideration or monetary penalty that would be required to be paid to CytoSorbents if a distributor does not meet the minimum purchase commitments included in the contract, however, at the discretion of the Company, the distributor may lose its exclusive rights in the territory if such commitments are not met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Government Grants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has been the recipient of numerous grant contracts from various agencies of the U.S. government. The purpose of these grant contracts is to perform various research and development activities. The type of research required is outlined in each contract. These contracts fall into one of the following categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Fixed price &#8211; the Company invoices the contract amount in equal installments over the term of the contract without regard to the timing of the costs incurred related to this contract. If billings on fixed price contracts exceed the costs incurred, revenue will be deferred to the extent of the excess billings.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cost reimbursement &#8211; the Company submits monthly invoices during the term of the contract for the amount of direct costs incurred during that month plus an agreed percentage that relates to allowable overhead and general and administrative expenses. Cumulative amounts invoiced may not exceed the maximum amount of funding stipulated in the contract.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cost plus &#8211; this type of contract is similar to a cost reimbursement contract but this type also allows for the Company to additionally invoice for a fee amount that is included in the contract.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Performance based - the Company submits invoices only upon the achievement of the milestones listed in the contract. The amount to be invoiced for each milestone is documented in the contract.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">These government contracts have terms ranging from three months to four years. The Company may apply for an extension of the term of the contract in order to complete its research and development activities but would not receive additional funding during the extension period in excess of the original contract. See Note 2 regarding the accounting policies related to these contracts.</p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_IYCmjR5hN0u0EnNpjbxB7g_1_2"></a><a id="Tc_13dRe2yyokqtaGDmgPqZtw_1_5"></a><a id="Tc_No7XFju8m0uUZuO2RG_vjg_2_0"></a><a id="Tc_uzN-bLVyPEyGOChvo8gS1Q_2_2"></a><a id="Tc_AtqHUIx8DEGljxRQ-mghWw_2_5"></a><a id="Tc_AZnosLTkME-4TwEytTwPCg_3_0"></a><a id="Tc_v-yueOlwXEepGPgF0R_hrg_3_2"></a><a id="Tc_Wwilr0wVzk20pmWOxtdrAQ_3_5"></a><ix:continuation id="Tb_BgbvgOWbZkGCYav7hgiLug_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In summary, the contracts the Company has with customers are the distributor/strategic partner contracts related to CytoSorb product sales, agreements with direct customers related to free-of-charge product and credit rebates based upon achieving minimum purchase levels, and contracts with various government agencies related to the Company&#8217;s grants. The Company does not currently incur any outside/third-party incremental costs to obtain any of these contracts. The Company does incur internal costs, primarily salary related costs, to obtain the contracts related to the government grants. Company employees spend time reviewing the program requirements and developing the budget and related proposal to submit to the grantor agency. There may additionally be travel expenditures involved with meeting with government agency officials during the negotiation of the contract. These internal costs are expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table provides information about receivables and contract liabilities from contracts with customers:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="Tb_Xeo-SqELpkO4p2MWxt4Kew" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.89%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contract receivables, which are included in grants and accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="0" id="Tc_Fl2RmWFJvUiOMfdKU73rXQ_2_3">3,822,452</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="0" id="Tc_BPaCrsF7Tkq41Xlmz5waDA_2_6">3,000,708</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contract liabilities, which are included in accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenue" scale="0" id="Tc_J6neahkOIEuT47X2pGa4SA_3_3">1,694,906</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenue" scale="0" id="Tc_yT5ayFq2DkO572Fk1bfRQA_3_6">2,251,177</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Contract receivables represent balances due from product sales to distributors amounting to $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_gIfXHjckYEyJZbVZyvB2YQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="0" id="Narr_GmnL4nZS7ESPPL06qsHK_g">2,944,031</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_njwH72hw8kSaSTYNHO-w9A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="0" id="Narr_6nUuKlet30-uFMQt_qlTrA">2,265,159</ix:nonFraction> at December 31, 2022 and 2021, respectively, and billed and unbilled amounts due on government contracts amounting to $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_nWvJKC0AfUO7Aa2fnEopNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="0" id="Narr_ZXWgiJuoykOeDgUkLSSlRg">878,421</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_7s12QoX9F0W4teGHuyLFlQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="0" id="Narr_1zS0j1n0jEKok-LrVQup_Q">735,549</ix:nonFraction> at December 31, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Contract liabilities represent the value of free of charge goods and credit rebates earned in accordance with the terms of certain direct customer agreements, which amounted to $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="ctso:ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent" scale="0" id="Narr_CHrkGLkQoUCSba2oxwbqxg">178,134</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="ctso:ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent" scale="0" id="Narr_EED_GPwJSke7zH1ZELLWjg">303,824</ix:nonFraction> at December 31, 2022 and 2021, respectively, and deferred grant revenue related to the billing on fixed price government contracts in excess of costs incurred, which amounted to $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="ctso:ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent" scale="0" id="Narr_MvjvK5uzEEqI3tOc-9OoCQ">1,516,772</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="ctso:ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent" scale="0" id="Narr_VPPrFUbWGkO3iCKuZBaH6w">1,947,343</ix:nonFraction> at December 31, 2022 and 2021, respectively.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_voRTMC7QCUWzKG1v7Te5zQ_1_8"></a><a id="Tc_QWvngnkmNkq0Av3Yw4j9qA_2_8"></a><a id="Tc_aqYP3c2Bc0GK-nYB0ZN5rQ_3_0"></a><a id="Tc_42mqornSskSwFeiDGvGszw_3_2"></a><a id="Tc_X5qdEMBEGEOKsaFm_s3CYg_3_5"></a><a id="Tc_4vwpq5TfCk6SLB-e_0dKng_3_8"></a><a id="Tc_F_j_NQQM80K5_Wu_XTBwaw_5_0"></a><a id="Tc_E8zlP-mookq0-UpKVJIlYQ_5_2"></a><a id="Tc_Yc4jmwpIbEm96C2pFqwKRQ_5_5"></a><a id="Tc_NibTwbEJOEyxBenNcP5FGg_6_0"></a><a id="Tc_FVbaamHbLEW1KKXqWZuZ5g_6_8"></a><a id="Tc_qv3Y-9Zv3EixaFn7n-pC-w_7_0"></a><a id="Tc_ElvOy1Xl2UyHiw4BPoDPeg_7_8"></a><a id="Tc_ROuz2KGWhkif9jagJ3bJvg_9_0"></a><a id="Tc_jxFgS4npo0Skb88GUTJB3Q_10_0"></a><a id="Tc_jgp-eUiTQUKpzx7KnjaAeg_10_2"></a><a id="Tc_Fn_M7SSY0kOinlFkoi3t_Q_10_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_z0l_9RNbXEi9xKSCDArVlQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. PROPERTY AND EQUIPMENT, NET:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Property and equipment&#160;- net, consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_V7gdo6bu20GOaywaO8cwIw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Depreciation/</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Period</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_xx0SVCBDQUagyE9b8Y2GGA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_ZXr1klZuPkmNr1KTKT-swg_5_3">1,306,267</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_p-0pfYqTZ0CXdqB9tDZcLA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_GA6q-eqolUivjhniycebtg_5_6">1,424,476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_IZ1_4AiozUyl0mH6SNTEkw" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_-0hSyBPmV0CbukUcGxGVQA_5_8">7&#160;years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Equipment and computers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_6WgRDm9zw06JdogbPOBBsA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_uH-cZyj9mUqu2Jex7lqh3Q_6_3">5,131,934</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_GAn4Sc5mekKFBtkNb6Zzyg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_cLIBPT9YJ0C2PSxJuCF8hw_6_6">5,863,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_zAGlt-XrpU6zeCKAysx8Ww" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_yLqIPd6hpk68u_pMkMDIGw">3</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_ajPw7PYg8UiVzGNH8PRoGQ" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_lazeLOBBSEuG5NFUFIvJZA">7&#160;years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_qNxrnXfXMEWT6PBBrE_I6w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_VLUV2jbxBUGeuRHCadQiqg_7_3">6,201,523</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_RcD8hxX4B0W360TpBmU_BA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_it93osbqWUyWa4HxGf9nKQ_7_6">2,623,356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Lesser of term of lease or estimated useful life</p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_tw-covgF9UeDgK0uz68Qnw_8_3">12,639,724</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_-tZW-xGId0emyyWQHQaJkA_8_6">9,911,505</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Tc_XQvgyy3KhkuJ6h9PfQ5Hkw_9_3">1,896,692</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Tc_xvSXUh1ooE-CLAh-6fOKHw_9_6">4,760,619</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Property and Equipment, Net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_k_VeM1l4hkaBExv1KFfDiA_10_3">10,743,032</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_WP8TXYJYx0qwejO_RXZHCQ_10_6">5,150,886</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Depreciation expense for the&#160;years ended December 31, 2022, 2021 and 2020 amounted to $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Narr_Iq1doRGy00m4wlHeNuPYIA">688,565</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Narr_ChVBnhjbJUa6BHQCiubIQw">571,156</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Narr_IEUrLLFPMEefs6eS43zLfw">553,946</ix:nonFraction> respectively.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_LQvrtSy3QUiZZlz4moDC1g_1_0"></a><a id="Tc_wRJty-fo_EWZe-5BZasEsg_1_2"></a><a id="Tc_qME6v_DWAUa3_rIgEbLYRQ_1_5"></a><a id="Tc_RzK9zF5IjU22KoR5TiS1GA_3_0"></a><a id="Tc_oHmQRPJ2skCV_XcnTu6Saw_3_2"></a><a id="Tc_FUqNNsH1S0G8Xjn4W8PbzQ_3_5"></a><a id="Tc_iLcyjJ1bbECWpVXYQQRH_g_4_0"></a><a id="Tc_fjRfNrct3EeUXvVCTOg33Q_5_0"></a><a id="Tc_3yvLXK3VK0y-zasYx_FMYA_6_0"></a><a id="Tc_HqvIQZiqFEGZhp_DY0VJ-Q_7_0"></a><a id="Tc_kY_7AYmYEU-QMmEgEs2KZg_8_0"></a><a id="Tc_TyB03W9SdUm9SA48Ya3cVg_8_2"></a><a id="Tc_shM2M1e-NUqCZV490IF5tA_8_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:OtherAssetsDisclosureTextBlock" id="Tb_igbrNlsCeUWdUp2jPl5r3A" continuedAt="Tb_igbrNlsCeUWdUp2jPl5r3A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. OTHER ASSETS:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Other assets consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:ScheduleOfOtherAssetsTableTextBlock" id="Tb_dEUy5Q3dvEylM3FA_E6sLw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Patent applications pending</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember_zXch2gFj5k-awN9bccQ9Eg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="Tc_SsI6Xn4nW0ezS9eIOLZWgg_3_3">2,466,341</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember_JaV5Z95jAEioF4LjVm9rgw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="Tc_TqmdGwf3LEWmuOlsN2VCEA_3_6">2,717,701</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Patents issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember_q-pVwR_fx0mA5G4MI1uuxw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="Tc_DgoMxL4VWkyKr-YfFgi24Q_4_3">2,773,191</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember_s0omtWKNx0m-GCD2Twq8Aw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="0" id="Tc_28soOJJVDUSXJuXdjpjuFQ_4_6">2,641,603</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less accumulated amortization of patents issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="Tc_E_EfLukby0WT8zAWrp--9Q_5_3">848,999</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="0" id="Tc_3NKRUrg9yUWUVyLTHMWu8w_5_6">657,320</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Patents, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="Tc_ZfHnjpftm0WQk8-SuLnPaQ_6_3">4,390,533</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="0" id="Tc_PJdsSAI9OkuxxxDibjgtoA_6_6">4,701,984</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="Tc_RFyjhQgPa0mMqjB6Ojerzg_7_3">46,914</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="Tc_BJB5bsDJVUOQRwt7Cjxxgw_7_6">256,591</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="Tc_m0fWIpgGKkuOeftELtV4IQ_8_3">4,437,447</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="Tc_91lI1lptXUqjk5pNlhzkdA_8_6">4,958,575</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Amortization expense amounted to $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentForAmortization" scale="0" id="Narr__WJGbadd1EqFBs1RKrQeUQ">194,056</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentForAmortization" scale="0" id="Narr_ccDh6f-Y7UahAWFIbGejPQ">160,422</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentForAmortization" scale="0" id="Narr_S1GdBcVw-ki1EWKF7I4Z4g">106,842</ix:nonFraction> for the&#160;years ended December 31, 2022, 2021 and 2020, respectively.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_igbrNlsCeUWdUp2jPl5r3A_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Amortization expense for the next five&#160;years will be approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="0" id="Narr_cW_MDOtGzEmkIDAPYs7mnw">201,000</ix:nonFraction> for the&#160;year ending December&#160;31, 2023; approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="0" id="Narr_iVKLl0KMjU6RJJVcCJw_XQ">201,000</ix:nonFraction> for the&#160;year ending December&#160;31, 2024; approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="0" id="Narr_0T9pTV0WskWnkT7QwSjAkQ">201,000</ix:nonFraction> for the&#160;year ending December&#160;31, 2025; approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="0" id="Narr_yolljL6pZ0au-glj5YOtpg">200,000</ix:nonFraction> for the year ending December 31, 2026 and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="0" id="Narr_yLLd4y0rtkGzb6Z-IKBdjQ">196,000</ix:nonFraction> for the year ending December 31, 2027.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_tNn6kNYW50qokTgXEnwWvQ_1_0"></a><a id="Tc_m40pWbX4QU6-cbV89R9g1Q_1_2"></a><a id="Tc_0DI1ZrwlGUCG1NOfgZwtUg_1_5"></a><a id="Tc_oayWdbDvm0ysWNMPb7hZBw_2_0"></a><a id="Tc_nFaso9Aun0mE-FHLDpPBzg_2_2"></a><a id="Tc_Aoe_5Cxy1E-ZE50fW2j71w_2_5"></a><a id="Tc_F8p6z5mPlE6W_HiG2ZXl9Q_3_0"></a><a id="Tc_78WtMJAMJEu30YiFemiJSw_4_0"></a><a id="Tc_NXemopVJjUiuEDkkFNPgsg_5_0"></a><a id="Tc_FWw1Ux84ukurk3TVod8Olg_6_0"></a><a id="Tc_18qhzXUnwUunqBtWQknFaw_7_0"></a><a id="Tc_bPnOVLp68EiAW4-UQNjEmA_8_0"></a><a id="Tc_5T2-5e9cvEyyDv-eYigeig_9_0"></a><a id="Tc_PbyM5_RTnEuxCR4Su0CS9g_10_0"></a><a id="Tc_sHxYB_wJ7kulRwrfeJj2Fg_11_0"></a><a id="Tc_pyx7OK-frECG3brGIH2GKQ_12_0"></a><a id="Tc_QBTevu4SH0C6L0LU6epjKA_13_0"></a><a id="Tc_8QIpKOJFJEC7kVxMuSXGiQ_14_2"></a><a id="Tc_QID4-lrmgEKpC14O0PlAig_14_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="Tb_GYWlmQWUQES4QYAQ68Bg_Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued expenses and other current liabilities consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="ctso:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" id="Tb_c_3oGux8FkyluRC_6uBQ3g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued salaries and commissions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="ctso:AccruedSalariesAndCommissionsCurrent" scale="0" id="Tc_aE6iXkRkeECENd1-tsmwVA_2_3">2,862,930</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="ctso:AccruedSalariesAndCommissionsCurrent" scale="0" id="Tc_xLuwkDOKYUG5g1kgEIKx6A_2_6">3,270,715</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="Tc__Nna3E3MPkW01usf5OpZHA_3_3">1,516,772</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="Tc_J6L_E6gpZ0quB5b5--p2_g_3_6">1,947,353</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical studies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="ctso:ClinicalStudyCostsPayableCurrent" scale="0" id="Tc_mAVlAy8u7EqdSHonpsv5DA_4_3">1,115,123</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="ctso:ClinicalStudyCostsPayableCurrent" scale="0" id="Tc_aHsXfzs_5kuMdBgm-E_4Ug_4_6">1,767,826</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_DAEMgZkK70GOblHywjd_1A_5_3">850,630</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_rwG_NjqVU0Siv-g2UMSuKg_5_6">1,044,088</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_dSeL9H_ZREOQcWuzc_ArTg_6_3">622,353</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_dTlbd1tNwkGmX5JBfTDFAg_6_6">314,068</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="0" id="Tc_pWv33swKIUKQB694CSCCsw_7_3">592,398</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="0" id="Tc_IrHVa30m-0iNOPUkQInMtg_7_6">769,262</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer rebates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="ctso:CustomerRebates" scale="0" id="Tc_zyHWDFS80kiElccQWuIRcg_8_3">166,065</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="ctso:CustomerRebates" scale="0" id="Tc_NX4-HxrsbE6oNxajYeRfyw_8_6">214,119</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Travel and entertainment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="ctso:AccruedTravelAndEntertainmentExpenseCurrent" scale="0" id="Tc_f8KCD2L6mkWJgzncM2oWBA_9_3">99,316</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="ctso:AccruedTravelAndEntertainmentExpenseCurrent" scale="0" id="Tc_7EmpJ3JhHUy2nMiVSFr4jg_9_6">88,850</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Board of Director fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="ctso:AccruedDirectorFeesCurrent" scale="0" id="Tc__eAfcOkDbESMrqWp0JJOKw_10_3">97,426</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="ctso:AccruedDirectorFeesCurrent" scale="0" id="Tc_msBnXSuTrEOsgfD9xT_0TA_10_6">71,381</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales, payroll and income taxes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="ctso:SalesPayrollAndIncomeTaxesPayableCurrent" scale="0" id="Tc__XWv9gN7wEO-fgSx6G9n2w_11_3">21,871</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="ctso:SalesPayrollAndIncomeTaxesPayableCurrent" scale="0" id="Tc_eNXCntoqHEqGcNAYjuoCCQ_11_6">785,818</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPayableCurrent" scale="0" id="Tc_neLZ6ADjhE2w1ZM-_0MVJw_12_3">5,556</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:zerodash" name="us-gaap:InterestPayableCurrent" scale="0" id="Tc_xaaF8v_l40WTCIxtUKnqUQ_12_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Congresses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:zerodash" name="ctso:CongressesPayableCurrent" scale="0" id="Tc_qYSYGe1m6ky2sotW-OnU2A_13_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="ctso:CongressesPayableCurrent" scale="0" id="Tc_rXe-9bVM1ESyEX6W7GttkQ_13_6">40,861</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="ctso:AccruedExpensesAndOtherCurrentLiabilities" scale="0" id="Tc_ZYgUDd8l_kmknQ2WHhHx7w_14_3">7,950,440</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="ctso:AccruedExpensesAndOtherCurrentLiabilities" scale="0" id="Tc_-Sf_XE_bBUKRIdm3ifu5ug_14_6">10,314,341</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:LongTermDebtTextBlock" id="Tb_Ey9R7XBrcU6QSvm0mD1cpQ" continuedAt="Tb_Ey9R7XBrcU6QSvm0mD1cpQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. LONG-TERM DEBT:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June&#160;30, 2016, the Company and its wholly owned subsidiary, CytoSorbents Medical,&#160;Inc. (together, the &#8220;Borrower&#8221;), entered into a Loan and Security Agreement with Bridge Bank, a division of Western Alliance Bank, (the &#8220;Bank&#8221;), pursuant to which the Company borrowed $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_6_30_2016_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_hpLFtiZhmUiQm4GvwoFZtw" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_V0C-gIcN1USPVCZv8C4TQQ">10</ix:nonFraction> million in two equal tranches of $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_6_30_2016_us-gaap_DebtInstrumentAxis_ctso_NewTermLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_ArZA6xiPjEidCYt_-Y-R-w" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_fuLlDVhdtkKlfXbHj99cCg">5</ix:nonFraction> million (the &#8220;Original Term Loans&#8221;). On March&#160;29, 2018, the Original Term Loans were refinanced with the Bank pursuant to an Amended and Restated Loan and Security Agreement by and between the Bank and the Borrower (the &#8220;Amended and Restated Loan and Security Agreement&#8221;), under which the Bank agreed to loan the Borrower up to an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_3_29_2018_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_yAsPHUNuqEirJNj907ZTrg" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_S4CG1GzMckWOUU5S5VtSqg">15</ix:nonFraction> million to be disbursed in two tranches (1)&#160;one tranche of $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_3_29_2018_us-gaap_DebtInstrumentAxis_ctso_TermLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_us-gaap_VestingAxis_ctso_FirstTrancheMember_yHGvHKFK2USNqJh92uWr0g" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_KeEBRJAfi0SU9iZwSDtFhg">10</ix:nonFraction> million (the &#8220;Term A Loan&#8221;), which was funded on the Closing Date and used to refinance the Original Term Loans, and (2)&#160;a second tranche of $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_3_29_2018_us-gaap_DebtInstrumentAxis_ctso_TermBLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_us-gaap_VestingAxis_ctso_SecondTrancheMember_e3qGkUg1VUKoGjKsBJiqOw" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_SnUsXLTBcEaul2TPSnVV6w">5</ix:nonFraction> million which may be disbursed at the Borrower&#8217;s sole request prior to March&#160;31, 2019 provided certain conditions are met (the &#8220;Term B Loan&#8221; and together with the Term A Loan, the &#8220;Term Loans&#8221;). On July 31, 2019, the Borrower entered into the First Amendment to the Amended and Restated Loan and Security Agreement (the &#8220;First Amendment&#8221;) with the Bank, which amended certain provisions of the Amended and Restated Loan and Security Agreement and the 2018 Success Fee Letter (the &#8220;2018 Letter&#8221;). In connection with the execution of the First Amendment, the draw period for the Term B Loan was extended to August 15, 2019 and the Company drew down the full $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_7_31_2019_To_7_31_2019_us-gaap_DebtInstrumentAxis_ctso_TermBLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_dfnbFaTYTUmSkV-OaNfp9g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="Narr_hxap2tpSWUSyRLjVz9fZDQ">5.0</ix:nonFraction> million Term B Loan on the Settlement Date, bringing the total outstanding debt to $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_7_31_2019_us-gaap_DebtInstrumentAxis_ctso_TermBLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_hAgUOUh5k0aAxSE_lGDIoA" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="Narr_5zrlEVPmkE2z9ZtsQaUWuQ">15</ix:nonFraction> million at July 31, 2019. The proceeds of Term Loans were used for general business requirements in accordance with the Amended and Restated Loan and Security Agreement. On December 4, 2020 (the &#8220;Third Amendment Closing Date&#8221;), the Company closed on the Third Amendment (the &#8220;Third Amendment&#8221;) of its Amended Loan and Security Agreement with Bridge Bank. Under the terms of the Amendment, the Company repaid the outstanding principal balance of its existing $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_12_4_2020_To_12_4_2020_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_p4SKdwcjlUmUAUo8kjQ2Mg" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="Narr_fdulep9DgUaEUrkHrAMd5A">15</ix:nonFraction> million term loans and simultaneously received a commitment from Bridge Bank to provide a new term loan of $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_4_2020_us-gaap_DebtInstrumentAxis_ctso_NewTermLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_sKTK-0jXM02ZfmOBWGS5TQ" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_HHYP5aJ24U2gt8yl9uFd4g">15</ix:nonFraction> million, if needed. On January 19, 2022 (the &#8220;Fourth Amendment Closing Date&#8221;), the Company closed on the Fourth Amendment (the &#8220;Fourth Amendment&#8221;) of its Amended Loan and Security Agreement with Bridge Bank. Under the terms of the Amendment, the Company received a commitment from Bridge Bank to provide a new term loan of up to $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_1_19_2022_us-gaap_DebtInstrumentAxis_ctso_NewTermLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_KKLXo5WGZkqln7K51iiuOg" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_5_y-VahBQ0KKZWRt8cxwZw">15</ix:nonFraction> million, if needed and entered into the Fourth Amendment Success Fee Letter (the &#8220;2022 Success Fee Letter&#8221;). On December 28, 2022 (the &#8220;Fifth Amendment Date&#8221;), the Company entered into the Fifth Amendment of its Amended Loan and Security Agreement with Bridge Bank. The Fifth Amendment extends the draw period under the Fourth Amendment to the earlier of (i) March 1, 2023 and (ii) the occurrence of an Event of Default. On March&#160;9,&#160;2023, the Company entered into the Sixth Amendment of its Amended Loan and Security Agreement. The Sixth Amendment further extends the draw period to March&#160;24,&#160;2023.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Ey9R7XBrcU6QSvm0mD1cpQ_cont1" continuedAt="Tb_Ey9R7XBrcU6QSvm0mD1cpQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Fourth Amendment provides a tranche of term loans (the &#8220;Term C Loans&#8221;) in the aggregate amount of $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_1_19_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_xoInVW7g4UOFsRz944IiQQ" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_aviqU9Y8AUKp2xe6SU2gkw">15</ix:nonFraction> million, which are available for the Company to draw down at its sole discretion in three tranches of $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_1_19_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_xoInVW7g4UOFsRz944IiQQ" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" scale="6" id="Narr_no7xNfjvc0q0Gl_3Qpl1jQ">5</ix:nonFraction> million each at any time during the period commencing on the Fourth Amendment Date and ending on the earlier of (i) December 31, 2022 and (ii) the occurrence of an Event of Default (as defined in the Amended Loan and Security Agreement). The Term C Loans shall bear interest at the Index Rate (defined in the Amendment as the greater of 3.25% or the Prime Rate as published by the Wall Street Journal on the last business date of the month immediately preceding the month in which the interest will accrue) plus <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_19_2022_To_1_19_2022_us-gaap_DebtInstrumentAxis_ctso_NewTermLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_V4YNPqwfQU-fUTcMCuVGXg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="Narr_dIDyMOsERU-dBKc0BdcNMQ">1.25</ix:nonFraction>%. Pursuant to the Fourth Amendment, interest on the Term C Loans is subject to an interest rate cap of <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_19_2022_To_1_19_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_g4Y2bbaH8UunO1A9gJrzYg" decimals="4" format="ixt:numdotdecimal" name="ctso:DebtInstrumentCapInterestRate" scale="-2" id="Narr_1mDHwvKPqEm0bmAp581HRg">8.00</ix:nonFraction>%. On December 27, 2022, the Company drew down the first $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_12_27_2022_To_12_27_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_us-gaap_VestingAxis_ctso_FirstTrancheMember_u7MsHPmZk0W0eFrHTCS5fA" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="Narr_CvLDB8uid06MkV-H9xtIiA">5</ix:nonFraction> million tranche of the Term C loans available under the terms of the Fourth Amendment. Under the terms of the Fourth Amendment, commencing on February 1, 2023, the Company is required to make monthly payments of interest only through December 2023. The interest-only period will be further extended through June 2024 provided the Company has met both the required reserves test and the seventy-five percent test, as set forth in the Fourth Amendment, as of November 30, 2023. Commencing on January 1, 2024, if the Company does not meet both the required reserves test and the seventy-five percent test, the Company shall make equal monthly payments of principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2024_To_1_1_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_ZrffNf8uWkC-rlhEGrcMag" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPayment" scale="0" id="Narr_UY4F-GdcXkO6UbUV9vnAhQ">208,333</ix:nonFraction>, together with accrued and unpaid interest. Commencing on July 1, 2024, if the Company meets both the required reserves test and the seventy-five percent test, the Company shall make equal monthly payments of principal of $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_7_1_2024_To_7_1_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_46J-BH5GlUuzquHLcvZsUQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPayment" scale="0" id="Narr_3M-cuidA8k6dIqC2nDzR2Q">277,778</ix:nonFraction>, together with accrued and unpaid interest. In either event, all unpaid principal and accrued and unpaid interest shall be due and payable in full on December 1, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On the Fourth Amendment Closing Date, the Company was required to pay a non-refundable closing fee of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_1_19_2022_us-gaap_DebtInstrumentAxis_ctso_NonRefundableClosingFeeMember_3fpymeUzzE2FKaJZ7vfyhg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" id="Narr_B3FDvzvcB0Sc-vTnPnPHWA">18,750</ix:nonFraction>, which was amortized as a monthly charge to interest expense. On the Third Amendment Closing Date, the Company paid a non-refundable closing fee of $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_4_2020_us-gaap_BalanceSheetLocationAxis_ctso_ClosingFeeMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_VrBaHTNN5kGqpNZC5_45yw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" id="Narr_8yjbf-hdk0qFquSDKb_JSQ">75,000</ix:nonFraction>, which was amortized as a charge to interest expense. In addition, the Amended and Restated Loan and Security Agreement requires the Company to pay a non-refundable final fee equal to <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="3" format="ixt:numdotdecimal" name="ctso:DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent" scale="-2" id="Narr_gR6FHqy_okK4VohR7Xnd-w">2.5</ix:nonFraction>% of the principal amount of the Term Loan funded upon the earlier of the (i) the maturity date or (ii) termination of the Term Loans via acceleration or prepayment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s and CytoSorbents Medical, Inc.&#8217;s obligations under the Amended and Restated Loan and Security Agreement are joint and severable and are secured by a first priority security interest in favor of the Bank with respect to the Company&#8217;s Shares (as defined in the Amended and Restated Loan and Security Agreement) and the Borrower&#8217;s Collateral (as defined in the Amended and Restated Loan and Security Agreement, which definition excludes the Borrower&#8217;s intellectual property and other customary exceptions).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2018 Success Fee Letter:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the amended 2018 Letter, the Borrower shall pay to the Bank a success fee in the amount equal to <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TwoThousandAndEighteenSuccessFeeLetterMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_jQs_7-pzMUy3U65XTi21yQ" decimals="4" format="ixt:numdotdecimal" name="ctso:PercentageOfSuccessFee" scale="-2" id="Narr_JDjKQWhzQESE-0Dxxn5WPQ">6.37</ix:nonFraction>% of the funded amount of the Term B Loan (as defined in the Restated Loan and Security Agreement) (the &#8220;Success Fee&#8221;) upon the first occurrence of any of the following events: (a)&#160;a sale or other disposition by the Borrower of all or substantially all of its assets; (b)&#160;a merger or consolidation of the Borrower into or with another person or entity, where the holders of the Borrower&#8217;s outstanding voting equity securities as of immediately prior to such merger or consolidation hold less than a majority of the issued and outstanding voting equity securities of the successor or surviving person or entity as of immediately following the consummation of such merger or consolidation; (c)&#160;a transaction or a series of related transactions in which any &#8220;person&#8221; or &#8220;group&#8221; (within the meaning of Section&#160;13(d)&#160;and 14(d)(2)&#160;of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) becomes the &#8220;beneficial owner&#8221; (as defined in Rule&#160;13d-3 under the Exchange Act), directly or indirectly, of a sufficient number of shares of all classes of stock then outstanding of the Borrower ordinarily entitled to vote in the election of directors, empowering such &#8220;person&#8221; or &#8220;group&#8221; to elect a majority of the Board of Directors of the Borrower, who did not have such power before such transaction; or (d)&#160;the closing price per share for the Company&#8217;s common stock on the Nasdaq Capital Market being the greater of (i)&#160;<ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ctso_TwoThousandAndEighteenSuccessFeeLetterMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_x3N7mO34SEWKzky3MgxbHA" decimals="2" format="ixt:numdotdecimal" name="ctso:PercentageOfClosingPriceOnCommonStock" scale="-2" id="Narr_NUA86jBtn0mrf1ka5Nx8mA">70</ix:nonFraction>% or more over $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TwoThousandAndEighteenSuccessFeeLetterMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_fb08ojpZuEqeebxD3osGJQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_3-NQV8k2x0KV1PmVnaQXnA">7.05</ix:nonFraction>, the closing price of the Company&#8217;s common stock on March&#160;29, 2018 (after giving effect to any stock splits or consolidations effected after the date thereof) for <span style="-sec-ix-hidden:Hidden_TWKGB9Ns70-hcCjqFg2ORA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span> successive business&#160;days, or (ii)&#160;at least <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ctso_TwoThousandAndEighteenSuccessFeeLetterMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_V6EvzE1VNkqz5b11S3A0zQ" decimals="4" format="ixt:numdotdecimal" name="ctso:PercentageOfClosingPriceOnCommonStock" scale="-2" id="Narr_UdU9Zgq93kaHdq3LMxZgiw">26.13</ix:nonFraction>% more than the average price of Company&#8217;s common stock for the 365-day period ending on the date of the funding of the Term B Loan. This obligation shall terminate on the fifth anniversary of the funding of the Term B Loan and shall survive the termination of the loan agreement and the prepayment of the Term B Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2022 Success Fee Letter:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the 2022 Success Fee Letter, the Borrower will pay to the Bank a success fee equal to (i) <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_FirstTrancheMember_GIGD6kvI2kuyoTLKEpk95A" decimals="2" format="ixt:numdotdecimal" name="ctso:PercentageOfSuccessFee" scale="-2" id="Narr_vRc52-OtxUGqjaXflJkftA">1</ix:nonFraction>% of $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_FirstTrancheMember_FBkEgEL2JUK-hSNbubMUvw" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_0jiftSAbLEenpJiLsnGgGw">5</ix:nonFraction> million if the Company draws down the first tranche of the Term C Loan and is payable only if the Company&#8217;s stock price equals or exceeds $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_FirstTrancheMember_FBkEgEL2JUK-hSNbubMUvw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_crjZKQ7E00GMcZacN0t-RA">8</ix:nonFraction> for <span style="-sec-ix-hidden:Hidden_0ax9yhmTV0OKMkdCNohxKw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span> consecutive trading days; (ii) <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_SecondTrancheMember_QxsVP0Jock-3r1DvUA8aiw" decimals="3" format="ixt:numdotdecimal" name="ctso:PercentageOfSuccessFee" scale="-2" id="Narr_FqHvpx8v4UefCBtD6zV3ig">1.5</ix:nonFraction>% of $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_SecondTrancheMember_djf_g158KE-plo3cylyfTw" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="Narr_-InT-Zp8WEWJbS4cevkCpw">5</ix:nonFraction> million if the Company draws down the second tranche of the Term C Loan and is payable only if the Company&#8217;s stock price equals or exceeds $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_SecondTrancheMember_djf_g158KE-plo3cylyfTw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_qaxeUPPcsEmt3HwKyikfkg">10</ix:nonFraction> for <span style="-sec-ix-hidden:Hidden_2iU3HFYDDUKoxhoqRgX4wQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span> consecutive trading days; and (iii) <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_ThirdTrancheMember_4sLxmtU1v0S4Yllbg0FfOA" decimals="2" format="ixt:numdotdecimal" name="ctso:PercentageOfSuccessFee" scale="-2" id="Narr_xDqz9dKucE6CYZyl4iMpDQ">2</ix:nonFraction>% of $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_ThirdTrancheMember_NUg-LV9OMEK0n6Tmc-tODA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="0" id="Narr_Zdw5BsjSNUeuPKIJVoy-uQ">5,000,000</ix:nonFraction> if the Company draws down the third tranche of the Term C Loan and is payable only if the Company&#8217;s stock price equals or exceeds $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_ThirdTrancheMember_NUg-LV9OMEK0n6Tmc-tODA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_4ifnPTzFD0-CyTmY07VLXQ">12</ix:nonFraction> for <span style="-sec-ix-hidden:Hidden_pwbH1ZIm4UCeZREcP1cczw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span> consecutive trading days (together, the &#8220;Success Fee&#8221;). Borrower may pay the Success Fee in cash or in shares of common stock, at Borrower&#8217;s sole discretion. The right of Bank to receive the Success Fees and the obligation of the Borrower to pay the Success Fees hereunder shall terminate on the date that is fifth anniversary of the funding date of the last Term C Loans made but shall survive the termination of the Loan Agreement and any prepayment of the Term C Loans.</p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_9055601e_fcfc_4d1b_aaef_78f78ef1e22b"></a><a id="Tc_cK-jXKHTaU6ta0zkH8emgw_1_0"></a><a id="Tc_9yPpoF2vEEGKYrpGJ80XhA_1_2"></a><a id="Tc_iVRygIBS9UmtAnHQhOBSRQ_2_0"></a><a id="Tc_M9KUTUbPcEODJpqrRC0oVQ_2_3"></a><a id="Tc__jkchIvejEeUeutmIGPz7A_3_0"></a><a id="Tc_ZWn3rWPWUE-gF6t6_GkWzg_3_2"></a><a id="_0e6b44d1_02ee_414d_b258_86a3a3dd0792"></a><a id="Tc_oq_-zC6vXEew1HxLPfmosQ_1_0"></a><a id="Tc_T4XyG35RvEutUxoplkLzyA_1_2"></a><a id="Tc__1c5FIGGiEKp9EXmuHM5HA_1_3"></a><a id="Tc_N5c7BZX8GUSA6L0O3EfqdA_2_0"></a><a id="Tc_JQS0y7Xt1kWbYEXfip19CA_3_0"></a><a id="Tc_sFflgxoe6UWm-WctfBQwWw_4_0"></a><a id="Tc_fMEZF5pdRUSbPS3s35tkDQ_4_2"></a><ix:continuation id="Tb_Ey9R7XBrcU6QSvm0mD1cpQ_cont2"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="Tb_GmpmhnXPC06ct5AqHUnz0Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Long-term debt consists of the following as of December 31, 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Principal amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="0" id="Tc_1kl3DeV_JESyFKB4IFDlXA_1_3">5,000,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Less Current maturities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Long-term debt net of current maturities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="0" id="Tc_jmvLm8PwwUS5JVnQ6JTAwg_3_3">5,000,000</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="Tb_sYw-b90wcEC_RxATBucekQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Principal payments of long-term debt are due as follows during the years ending December 31:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" id="Tc_FlmdHJHl-0uhZMWOqKLTAA_2_3">2,500,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" id="Tc_ozko2yp1dkacqTms8TeuZQ_3_3">2,500,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="0" id="Tc_OaQCV6mMR0-VJJ612aEvXw_4_3">5,000,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_mA9NNI4rU0WU3MmpM3LL8Q" continuedAt="Tb_mA9NNI4rU0WU3MmpM3LL8Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8. LEASES:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases its operating facilities in both the United States and Germany under operating lease agreements. In March 2021, CytoSorbents Medical Inc. entered into a lease agreement for a new operating facility at 305 College Road East, Princeton, New Jersey, which contains office, laboratory, manufacturing and warehouse space. The lease commenced on June 1, 2021. The Early Term commenced on June 1, 2021 and lasted until September 30, 2021. The lease also contains <ix:nonFraction unitRef="Unit_Standard_item_00R0j3K4HUiRlSslEJQMxQ" contextRef="As_Of_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_soDgpwwWtUaODzy8fGjUCA" decimals="INF" format="ixt-sec:numwordsen" name="ctso:NumberOfTimesLeaseRenewalAvailable" scale="0" id="Narr_RMSonooNNEqqPe0fIEA1Dw">two</ix:nonFraction> <ix:nonNumeric contextRef="As_Of_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_soDgpwwWtUaODzy8fGjUCA" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_G5igBS2FaEWV15XEAhnPxQ">five-year</ix:nonNumeric> renewal options; however, the Company has determined that it is not likely that they will exercise these options. Commencing on September 30, 2021, the remaining lease term will last for <ix:nonNumeric contextRef="As_Of_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_-_7LrVATRkuKuxUmrfdQ2w" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="Narr_FOVXTUELK0Okl3usi88oaw">15.5</ix:nonNumeric> years. The lease requires monthly rental payments of $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_3_1_2021_To_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_srt_StatementScenarioAxis_ctso_OperatingLeaseInitialEarlyTermMember_lxWMtc2sTkqH38xAKIWoPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="Narr_4CKszcZCPEafLgFCjEVYgg">25,208</ix:nonFraction> for the Initial Early Term, $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_3_1_2021_To_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_srt_StatementScenarioAxis_ctso_OperatingLeaseEarlyTermMember_tAFcc_W5NUuJIEBULRt2Ig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="Narr_lBUXGNO_YUe0RRLfbW_3tw">88,254</ix:nonFraction> for the Early Term and initial monthly payments of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_3_1_2021_To_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_srt_StatementScenarioAxis_ctso_OperatingLeaseFirstYearOfRemainingLeaseTermMember_9vqNICnuOkyckL02PYBIQQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="Narr_ahCCAPhfs0GmAgRp6EPGQA">111,171</ix:nonFraction> in the first year of the remaining term. Following the first year of the remaining term, the annual base rent will increase by approximately <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_3_1_2021_To_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US__KJwJevVx06LgV-mH407GA" decimals="4" format="ixt:numdotdecimal" name="ctso:OperatingLeasesAnnualRentExpenseIncrementRate" scale="-2" id="Narr_kaf6GezjsUOyuKOHM49zpw">2.75</ix:nonFraction>% annually over the remaining term. The lease also contains <ix:nonNumeric contextRef="Duration_3_1_2021_To_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_id_BW-goZE-wjX2tVerJSw" format="ixt-sec:durwordsen" name="ctso:OperatingLeasesRentAbatementTerm" id="Narr_skWuCRJfDkGoq4P6NsPEoQ">six months</ix:nonNumeric> of rent abatement (months 1, 2, 3, 25, 26 and 27 of the remaining lease term). In addition to the base rent, payments of operating expenses and real estate taxes will be required. These payments are to be based on actual amounts incurred during 2021 multiplied by the Company&#8217;s share of the total building space (<ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="As_Of_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_-_7LrVATRkuKuxUmrfdQ2w" decimals="3" format="ixt:numdotdecimal" name="ctso:PercentageOfTotalBuildingSpaceOccupied" scale="-2" id="Narr_gwJ378vwgUivM5jAuskWOA">92.3</ix:nonFraction>%). The landlord will also provide an allowance of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_-_7LrVATRkuKuxUmrfdQ2w" decimals="0" format="ixt:numdotdecimal" name="ctso:OperatingLeasesBuildingImprovementAllowanceReceivable" scale="0" id="Narr_bj0VbKftAkyWxR3pZzApNg">1,455,000</ix:nonFraction> related to certain building improvements as outlined in the lease. In April 2021, the Company provided the landlord with a letter of credit in the amount of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_4_30_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_us-gaap_DebtInstrumentAxis_us-gaap_LetterOfCreditMember_qtkd0jaAzUeu79V_NBPfXg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_7sh_x5PRYkmncnTwVfiusw">1,467,000</ix:nonFraction> as security. The Company has determined that this lease should be treated as an operating lease in accordance with the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) 842. On April 1, 2021, the Company recorded a Right-of-Use asset and related lease <span style="-sec-ix-hidden:Hidden_i35CHnl1HUSihsVEqT6O2A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liability</span></span> of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_4_1_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_Ayo8OWQvq0qpn_0X3Xab7g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_aEJv7VdC4k2wiW9gnrPyMg">11.6</ix:nonFraction> million, which represents the estimated present value of the lease payments at the commencement date discounted at the Company&#8217;s incremental borrowing rate of <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="As_Of_4_1_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_Ayo8OWQvq0qpn_0X3Xab7g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="Narr_AWiDdHouw0SS_jarxHLOKA">9.8</ix:nonFraction>%. In addition, due to the six months of rent abatement and annual base rent escalations during the remaining lease term that commenced on September 30, 2021, the Company will recognize rent expense on this lease on a straight-line basis over the remaining term of the lease for the difference between the rent expense recognized and the required payments under the lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2021, the Company entered into a Twentieth Amendment to Lease with the landlord at the existing Monmouth Junction facility which became effective May 31, 2021. This amendment extended the term of the lease for the Company&#8217;s previous facility to May 31, 2022. The Company&#8217;s base rent was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_4_1_2021_To_4_30_2021_us-gaap_LeaseContractualTermAxis_ctso_TwentiethAmendmentToLeaseMember_gauFszu_JEOFrdWykocnUw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="Narr_JlPrdcjaLU248BjipyDFeg">35,000</ix:nonFraction> per month. In addition, the Company was obligated to pay monthly operating expenses of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_4_1_2021_To_4_30_2021_us-gaap_LeaseContractualTermAxis_ctso_TwentiethAmendmentToLeaseMember_gauFszu_JEOFrdWykocnUw" decimals="0" format="ixt:numdotdecimal" name="ctso:AdditionalOperatingLeasesRentExpenseNet" scale="0" id="Narr_AM7e9zeoMEedTTRvNVzYRg">30,000</ix:nonFraction> per month. Under the terms of this amendment, the Company vacated a portion of the space as of May 31, 2022. The Company continued to lease the remaining space until December 31, 2022, at which time the lease terminated and the Company vacated the space. The Company&#8217;s base rent for the remaining space was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_4_1_2021_To_4_30_2021_us-gaap_LeaseContractualTermAxis_ctso_TwentiethAmendmentToLeaseMember_gauFszu_JEOFrdWykocnUw" decimals="0" format="ixt:numdotdecimal" name="ctso:OperatingLeaseBaseRentForRemainingSpace" scale="0" id="Narr_jzvjybl6VE2TNGIV8lXYOg">20,000</ix:nonFraction> per month. Monthly operating expenses were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_4_1_2021_To_4_30_2021_us-gaap_LeaseContractualTermAxis_ctso_TwentiethAmendmentToLeaseMember_gauFszu_JEOFrdWykocnUw" decimals="0" format="ixt:numdotdecimal" name="ctso:MonthlyOperatingExpenses" scale="0" id="Narr_km5e9SgoqU2bZRN0TJAcIQ">11,000</ix:nonFraction> per month. In addition, the Company agreed to increase its security deposit by approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2020_us-gaap_LeaseContractualTermAxis_ctso_TwentiethAmendmentToLeaseMember_jYak7TFeK0qURMnjm2T8DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="Narr_cWER79EM0kS-oVtrNhEOzQ">54,000</ix:nonFraction> to a total of $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_4_30_2021_us-gaap_LeaseContractualTermAxis_ctso_TwentiethAmendmentToLeaseMember_wrqHEmK560ePWOyCLlAXAA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="0" id="Narr_NjvHcM9qV0aRYD8dCiBWiw">150,000</ix:nonFraction>. At the end of the lease term, the entire security deposit was paid to the landlord for the purpose of making any needed repairs to the vacated premises, and the Company has no further obligation to pay for repairs to the vacated premises. Effective April 1, 2021, the Company adjusted its incremental borrowing rate to the incremental borrowing rate used in the College Road lease and recalculated the right of use asset and lease liability under the amended terms of this lease. In addition, the Company also adjusted the incremental borrowing rate and related right of use asset and lease liability on the existing Germany office lease effective April 1, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2021, the Company extended its two operating leases for its office facility in Germany. These leases require combined base rent payments amounting to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_9_1_2021_To_9_30_2021_srt_StatementGeographicalAxis_country_DE_R18Zrff15UWiG7PQAHXLAg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="Narr_egzC1RLLGkehGmZsjmJItA">12,100</ix:nonFraction> per month. The initial lease term of both leases ends August 31, 2026. In addition, the Company is obligated to monthly operating expenses of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_9_1_2021_To_9_30_2021_srt_StatementGeographicalAxis_country_DE_R18Zrff15UWiG7PQAHXLAg" decimals="0" format="ixt:numdotdecimal" name="ctso:AdditionalOperatingLeasesRentExpenseNet" scale="0" id="Narr_4vYgzP7JgUa_KLFYCd3lSQ">3,000</ix:nonFraction> per month. Both leases have a five-year option to renew that would extend the lease term to August 31, 2031. There are no provisions in the leases to increase the base rent during the renewal period. There were no lease incentives and no initial direct costs were incurred related to these leases.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c5ee8d97_74c5_4f48_a5d3_5f1cc5f3a7d8"></a><a id="Tc_syZ1zTa_-0-MCEwG04SOLg_1_2"></a><a id="Tc_aWncNS4A_kiEnCfA2Ik1dg_2_2"></a><a id="Tc_gPAnRrcXJEi8Ytq4Y3EK9A_2_5"></a><a id="Tc_aQetvwMKH0ikZrS3jk1Z8g_3_0"></a><a id="Tc_O_SZXHhC0k6k7nvloxzsGw_3_2"></a><a id="Tc_UfqwZEqGUECtxYMDc0dTAg_3_5"></a><a id="Tc_43KtfMRQYkaZeyIMHt0IdA_5_0"></a><a id="Tc_n6ULjhb1BEynRJNCUHyipg_5_2"></a><a id="Tc_nBKayj2FUUyGEl0XYoAUgw_5_5"></a><a id="Tc_er2pItU7NkCUZhjleSwWRQ_6_0"></a><a id="Tc_q9F6TB7hq0iA51LT38tOMg_7_0"></a><a id="Tc_njIoINMKhUO_4lXH9dex0g_7_2"></a><a id="Tc_-XMUrqJCcECn1fg6WQPb9A_7_5"></a><a id="_ba24877b_b4bc_4031_98f0_46d61d38b75e"></a><a id="Tc_k6_ICk1TJUaIlgTIwTASFg_1_0"></a><a id="Tc_e8LTBnxbKkyEciSqm3WtLA_1_2"></a><a id="Tc_ekz7DmzD306D9BthuN5i3g_2_0"></a><a id="Tc_2xAmNvwhK0-FyIDTl02qWg_3_0"></a><a id="Tc_bEaWnUxIY0GrGMVJZ-jdeA_4_0"></a><a id="Tc_vFRJCxQ-RkyaEkj88u6TOA_5_0"></a><a id="Tc_2qEGVyoAEkumwg4iKq0AwA_6_0"></a><a id="Tc_ZXpLmLeBYkOlpYMlsiuacA_7_0"></a><a id="Tc_MEWfDHZKfECbTrFkhx9Eiw_8_0"></a><a id="Tc_yUYgpLG0JU6Uemv_rVhUIA_9_0"></a><a id="Tc_xwi_NfgLEkSgqrQmyY2qXg_9_2"></a><ix:continuation id="Tb_mA9NNI4rU0WU3MmpM3LL8Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2021, CytoSorbents Europe GmbH entered into a lease for <ix:nonFraction unitRef="Unit_Standard_sqm_5jCoQZf8skWtJMe7yh0D_w" contextRef="As_Of_1_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsEuropeGmbhMember_WYlLNzD2gES86ALGoqLgDg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfLand" scale="0" id="Narr_KkDPaAFPSkeTME2YdXvGrA">1,068</ix:nonFraction> square meters of additional warehouse space. The lease commenced on April 1, 2021 and requires monthly payments of base rent of $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_4_1_2021_To_4_1_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsEuropeGmbhMember_qOdCgqh6606refmoxrQP8Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="0" id="Narr_Y5_6N6Y6yEKBHMkQmhx65A">7,784</ix:nonFraction> and other costs of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_4_1_2021_To_4_1_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsEuropeGmbhMember_qOdCgqh6606refmoxrQP8Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="0" id="Narr_pJ6bZcGf8UKqnBH9RF713g">239</ix:nonFraction> and has a term of five years. The lease also has an option to extend the lease term for an additional <ix:nonNumeric contextRef="As_Of_4_1_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsEuropeGmbhMember_eGPb2XlfmU655buQQmU81A" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_bH5l24kSv0OJCw8dISuT0A">five-year</ix:nonNumeric> period through March 31, 2031. The Company has determined that this lease should be treated as an operating lease in accordance with the provisions of ASC 842. On April 1, 2020, the Company recorded a Right-of-Use asset and related lease <span style="-sec-ix-hidden:Hidden_cxtzS31VrUm4rMIV9MB8Iw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liability</span></span> at the estimated present value of the lease payments at the commencement date of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_4_1_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsEuropeGmbhMember_eGPb2XlfmU655buQQmU81A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Narr_4Jl7ir19pEGVoLNYLGRlpA">594,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Right-of-Use Asset and Lease Liability:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s consolidated balance sheets reflect the value of the right-of-use asset and related lease liability. This value was calculated based on the present value of the remaining base rent lease payments. The remaining lease payments include all expected renewals for all periods as the Company has determined that it is probable that the renewal options will be exercised under each of the lease agreements. The discount rate used was the Company&#8217;s incremental borrowing rate, which is <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="Narr_y-zdy2gFDE6rQJh7dMD5KA">9.8</ix:nonFraction>%, as the Company could not determine the rate implicit in the lease. As a result, the value of the right-of-use asset and related lease liability is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="ctso:LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock" id="Tb_-_CuBJ8hrU2Xte-HLI0VfA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:70.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_gl87T5-v2kqiYXl_FOZBrg_3_3">12,603,901</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Tc_SB6PJbQZ2kWCTgjM05GqPw_3_6">13,423,472</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="Tc_lkcnfstgTUS76BNNYFicWg_5_3">13,250,944</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="Tc_xaIOX_oHLk2QWWmql2v4OQ_5_6">13,821,509</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_T7mw2DYEkES9mYK3LfspAw_6_3">108,939</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" id="Tc_v7BwObkX0kiwXOM3z-w0kw_6_6">570,566</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease liability, net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_9_qIfZY7Zkuh-tGe_KwZ0w_7_3">13,142,005</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" id="Tc_bQDS_nIsVEW68rC9udiOKw_7_6">13,250,943</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_-mnXGrCUBUW2ddb9EDyIAA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The maturities of the lease liabilities are as follows as of December 31, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" id="Tc_k0PJSrHa8UeQ2KNqsqJZqQ_1_3">1,266,346</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="0" id="Tc_GGssQJmia0i1rkEjUlCO5Q_2_3">1,656,678</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="0" id="Tc_g7nXIHMUr06ZVsxoeWKOSw_3_3">1,695,677</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="0" id="Tc_YvsnLhUT0USKDm1l5fMDXw_4_3">1,735,747</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="0" id="Tc_0ILJTmxOmUegGgBcFpYAqw_5_3">1,776,920</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="ctso:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" scale="0" id="Tc_DXkXXBejZ0uMRKbtj9ZKvA_6_3">17,232,300</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="0" id="Tc_qoYpCbW4902GBZHxS_sD2A_7_3">25,363,668</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="0" id="Tc_XBCrERL2eUuHsmfdAgLlTg_8_3">12,112,724</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="0" id="Tc_A-QtHWBKpkypV8rnZFGFFw_9_3">13,250,944</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2022, 2021 and 2020, operating cash flows paid in connection with operating leases amounted to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Narr_77KCP-XDYUeKPT6tvY87Ig">2,935,000</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Narr_qBK8G8R1m0GAs5spK-k9WQ">1,968,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="0" id="Narr_LrAbLHLhpkC74vNOzvWqpQ">937,000</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2022 and 2021, the weighted average remaining lease term was <ix:nonNumeric contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_NmcwmpQQ_0WgyEPCrir_pw">12.4</ix:nonNumeric> years and <ix:nonNumeric contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_WyJSLOysxUu8501A-I6l0g">14.3</ix:nonNumeric> years, respectively.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_439f0adf_b9d6_41da_bae3_570d89ed3bf6"></a><a id="Tc_wxrk9KXEDEyFCEXvu3cnJQ_1_2"></a><a id="Tc_p_dFlGzjXkiHATnqi5zitw_2_2"></a><a id="Tc_DwPPfwOQXE26gvF_-hj_iA_2_5"></a><a id="Tc_igF86lGx1E29VwoU_jfyOw_2_8"></a><a id="Tc_vqlbSUqGcUGyVh4bCzRxpQ_3_0"></a><a id="Tc_MprCA6iCO0CooMxna18VFg_3_2"></a><a id="Tc__X9sunJ-kUmbkJL8vmqKLw_3_5"></a><a id="Tc_6b6qra9epUuBkucDkFdYZw_3_8"></a><a id="Tc_J5B0pckFZEeg4yH7szTaoQ_4_0"></a><a id="Tc_B0rpGT1j6kaIaqBBUvbmXQ_5_0"></a><a id="Tc_qtzZScCPLEyyMlSH9OHwhg_5_2"></a><a id="Tc_z5UvpSux4kGdfTzCKEkNFQ_5_5"></a><a id="Tc_15STxmJiY0m6cK0o7diuRg_5_8"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_-atYA5VEBUqxAZ6evMS3Dw" continuedAt="Tb_-atYA5VEBUqxAZ6evMS3Dw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. INCOME TAXES:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under FASB ASC 740 (&#8220;ASC 740&#8221;). Deferred income tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="Tb_kbR71WxG1kqdYFVjqjNPCg" continuedAt="Tb_kbR71WxG1kqdYFVjqjNPCg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company&#8217;s consolidated loss before income taxes for the years ended December 31, 2022, 2021 and 2020 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:60.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="0" id="Tc_kH97QOxYEUanSW0ZgOqVRQ_3_3">21,155,203</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="0" id="Tc_SR-ULXRSD0eCph_hKqs7BQ_3_6">18,829,797</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" sign="-" scale="0" id="Tc_IdcdNKaRQ0SOvg4OTQN0jQ_3_9">5,682,628</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:60.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="0" id="Tc_rthbTincakOnIyiI8QfdBA_4_3">12,749,965</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="0" id="Tc_MifFmIXIkE68J_9N7sF9_A_4_6">6,464,854</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" sign="-" scale="0" id="Tc_ysvCCApKx0OHVZiBDa_o8w_4_9">3,281,634</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:60.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="ctso:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests" sign="-" scale="0" id="Tc_LLfJbAHma0mcQRFspwsshQ_5_3">33,905,168</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="ctso:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests" sign="-" scale="0" id="Tc_JEd3JjURPE-wrsVZS9BUhA_5_6">25,294,651</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="ctso:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests" sign="-" scale="0" id="Tc_xLHq7WB5qUOOsxgYL-lVMQ_5_9">8,964,262</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_33423533_fd84_4552_91e1_fadf12bc633d"></a><a id="Tc_yhNQNJFS8U-vHXzsNI2SrA_1_2"></a><a id="Tc_ya1yenHCbUuQF_wys2OMOQ_2_2"></a><a id="Tc_bscrBDElQU-jZ44UIBQ1_Q_2_5"></a><a id="Tc_7OrEnl3Hzki46to0VBgS5Q_2_8"></a><a id="Tc_nc6XtmfwckuX3twI3wYHJQ_3_0"></a><a id="Tc_GwrN6S31SkSqEptz8lwLbg_3_2"></a><a id="Tc_Y4Z63uE-w02v428rjgdf-A_3_5"></a><a id="Tc_iH5wQUsajEaDp6GYf4e62A_3_8"></a><a id="Tc_5BqoK8wTT0ODZYrUemiBrA_4_0"></a><a id="Tc_1lKM2gh8m0C7aybLp3SnoA_4_3"></a><a id="Tc_bVn0hQZfEUWNQ-StardA9g_4_6"></a><a id="Tc_1qmIbLgPCkmXRldRnTgbxQ_4_9"></a><a id="Tc_RK0yEJNfs0OGFl8PVIAf8w_5_2"></a><a id="Tc_F2iBYp5AzUSpRAU9PaGdmw_5_5"></a><a id="Tc_OwiZdOlk002bd91ok1xKtA_5_8"></a><ix:continuation id="Tb_-atYA5VEBUqxAZ6evMS3Dw_cont1" continuedAt="Tb_-atYA5VEBUqxAZ6evMS3Dw_cont2"><ix:continuation id="Tb_kbR71WxG1kqdYFVjqjNPCg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_omEK38qxsUOPJ1oMI0lWfw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The benefit from income taxes consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:60.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">State Tax, including sale of New Jersey losses &amp; credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" sign="-" scale="0" id="Tc_1DQmwvv8dk-jWGTNAgwipA_3_3">1,092,585</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" sign="-" scale="0" id="Tc_7yh7WXzMDE2-eDywhA_U3w_3_6">736,003</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" sign="-" scale="0" id="Tc_chZ9Sc1-RkK57urHykX1WQ_3_9">1,127,074</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:60.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Foreign tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:60.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="0" id="Tc_NLvKbLfzQE6hDW7J2j6lFg_5_3">1,092,585</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="0" id="Tc_TxmxtDffvUOUEvQemrdpow_5_6">736,003</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="0" id="Tc_XRsSBvWp00WV3ou8jS3lKw_5_9">1,127,074</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has deemed any foreign earnings will be indefinitely reinvested. Currently, foreign operations have resulted in an accumulated deficit. The Company will continue to analyze their stance if their circumstances change in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company had federal net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_9IC6hTCjW06NGRwHHe3tNg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_kb4WWZXYOU-c36e2T4wdaw">87.4</ix:nonFraction> million, state NOL carry forwards of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_ERD_klH89EySV0xsixbjKg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_Fv_bzr_EB0COfku5aBU0hQ">5.5</ix:nonFraction> million, and foreign NOL carry forwards of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_3Qdgi4LpIkSQMymN-mkajA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_dBicCka5VE2CxQZ2MnXXOg">42.7</ix:nonFraction> million, which may be available to offset future taxable income, if any. The federal NOL carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_NrTvJYZvgEG1gpSbBwYUGA">47.8</ix:nonFraction> million, if not utilized, will expire between 2022 and 2037. The federal NOL carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2018_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_HgsYwDdKM0Wf4EOABgWuUQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_w9iCXhGpi0m3wLuPlEhJyg">39.6</ix:nonFraction> million generated since 2018 are subject to an <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:OperatingLossCarryforwardsLimitationsOnUse" id="Narr_1CSdAfRRlU2oCQ3l3StC0A">80% limitation on taxable income</ix:nonNumeric>, do not expire and will carry forward indefinitely. The state NOL carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_ERD_klH89EySV0xsixbjKg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_JvKUCXLQIEy4yA8ynWHTCg">5.5</ix:nonFraction> million, if not utilized, will begin to expire in 2042. As of December 31, 2022, the Company had Federal and state research and development tax credit carryforwards of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_9IC6hTCjW06NGRwHHe3tNg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_xbkp0-a1wUOTaTdc6XdU7A">3.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_ERD_klH89EySV0xsixbjKg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_43rWi2eLFUSB-I1K3oCx1w">0.3</ix:nonFraction> million, respectively, available to reduce future tax liabilities, which will begin to expire at various dates starting in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The NOL carry forwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. The NOLs may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Section 382 of the Internal Revenue Code of 1986, as amended, as well as similar state tax provisions. In addition to the new provisions enacted under the Tax Cuts and Jobs Act, this could limit the amount of NOLs that the Company can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will generally be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We record tax benefits related to uncertain tax positions taken or expected to be taken on a tax return when such benefits meet a more likely than not threshold. We recognize interest related to unrecognized tax benefits in interest expense and penalties in operating expenses. Currently, the Company is not accounting for any uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">U.S. Tax Reform</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Due to The Tax Cuts and Jobs Act of 2017 (TCJA) there was a change in the deductibility of research and experimental expenditures that took effect for taxable periods that begin after December 31, 2021. Prior to January 1, 2022, the Company expensed research and experimental expenditures under &#167;174(a) in the year that books recognized the expense. The Company has adopted &#167;174(b) for taxable years 2022 and beyond. Domestic and foreign research and experimental expenditures will be capitalized and amortized over a period no less than 60 months and 180 months, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sale of Net Operating Losses (NOLs)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company may be eligible, from time to time, to receive cash from the sale of its New Jersey Net Operating Losses and R&amp;D tax credits under the State of New Jersey Technology Business Tax Certificate Transfer Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company will receive a net cash amount of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="ctso:ProceedsFromSaleOfNetOperatingLossCarryforwards" scale="0" id="Narr_czjM3JxM6UyaLimH9N3hww">1,093,000</ix:nonFraction> from the approved sale of the 2021 state NOL and research and development credits in the first half of 2023.</p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a76ad88e_bf56_4547_a6aa_39bd12eedca3"></a><a id="Tc_t12hO1FW_kqA6KMP3QeIYw_1_2"></a><a id="Tc_2HkHFAzHvEiuUc491h__9A_2_2"></a><a id="Tc_Vl1NcDaHAUCBloK821KClw_2_5"></a><a id="Tc_OtOy5OFqjUe0MLeijsmtaw_2_8"></a><a id="Tc_fZ94QVg6f0GQmVfrUQGrGg_3_0"></a><a id="Tc_obNpXSF3WkqPAhw5ahcu2Q_4_0"></a><a id="Tc_WZMUrpy_F0m8TnjM4vGMUA_4_2"></a><a id="Tc__yKJwvxQpUuRjhRM09Z8KA_4_5"></a><a id="Tc_7Vzy9Ml7aU6mYrq5BEzetg_4_8"></a><a id="Tc_BC5yURPlSEOYzaifCEbN7g_5_0"></a><a id="Tc_btDz8yTRkkac07P4z7l0vQ_6_0"></a><a id="Tc_r9O6kiYiH0Oeb-iHTReW5w_7_0"></a><a id="Tc_YE3ZnPMpiUG52qUBV66owg_8_0"></a><a id="Tc_bqHxUWxFzk2J6KDj223f2Q_9_0"></a><a id="Tc_SfHXPCP62EWwxZwMJyLipg_9_6"></a><a id="Tc_Y9GQRadToU2TpkpWHp-96Q_9_9"></a><a id="Tc_gnkY7dcV8k2oy7Kc5Z6DCQ_10_0"></a><a id="Tc_KPv3mCqL_UG295I0gEs5Cg_11_0"></a><a id="Tc_18Vhwca0j0qU7kn16R861g_13_0"></a><a id="Tc_0hYtUcSQhU2oj57-bJz9Nw_14_0"></a><a id="Tc_QlcQRm5AGUGuE7FUOVnZvw_15_0"></a><a id="Tc_zjJH_Gvm4E-ez1HER5-S4w_15_9"></a><a id="Tc_SKNsTlEGb0KyC47MEyEk3g_16_0"></a><a id="Tc_dLk_jIq95USRQxxyXC7TEQ_16_2"></a><a id="Tc_VYD9pG6QXkeoppw9j20BtA_16_3"></a><a id="Tc_4L01WiG3Y0i_nLwYVHHt-g_16_5"></a><a id="Tc_MnE7si_wtUapUByA4svI1Q_16_6"></a><a id="Tc_UV5ZSlRqzUW4zeTP9_Odlw_16_8"></a><a id="Tc_C6IlQCiD0kupHgzLzX0dvA_16_9"></a><a id="_1e1dcd83_8b3f_4eac_95f2_e793ab1e40c0"></a><a id="Tc_P-Umy4SQUUmWr1y102-NkQ_1_2"></a><a id="Tc_DEWQXgAim0GTRUtoTY6Jrg_2_2"></a><a id="Tc_gRSp290Ao0ShK-d4UHf80g_2_4"></a><a id="Tc_2npQkl_-gk6iUmvNlQpZ9g_2_6"></a><a id="Tc_5Gj-Q4Q300WwWcOthrKa9A_3_0"></a><a id="Tc_InSKtSQid0-6E7Km1kfUTg_3_3"></a><a id="Tc_60o72gNjyUiAA7HJMe11Qg_3_5"></a><a id="Tc_mEUBmn4IU0mq68VzEFc1UQ_3_7"></a><a id="Tc_IglJf5bQLkKNB0-NXLZe1w_4_0"></a><a id="Tc_44mxNOIMUE-tqTrHjTOwRw_5_0"></a><a id="Tc_1A4jrBFhhk2In8_RLmBqPw_6_0"></a><a id="Tc_sZP-A9J-tUWUaZshTnXFLw_7_0"></a><a id="Tc_iN7fmN_yhkWOgRsPP71wjQ_8_0"></a><a id="Tc_KIyIcAR3rU6dLCuby3kAuQ_9_0"></a><a id="Tc_RXzjB2lKFUCQa_QS8ZOJUA_10_0"></a><a id="Tc_8Zfj_wKHFUCKccuqnyUDag_10_4"></a><a id="Tc_ByKjUAayO06VvQB3NGVdcw_10_6"></a><a id="Tc_XsDvW7GOkk6EO-ogSnSQEQ_11_0"></a><a id="Tc_CK5trbJxEkel9XiSW386Mg_11_3"></a><a id="Tc_P-VUsZAhiE-Dl1PudF7Pmg_11_5"></a><a id="Tc_hclXCQOru061rTYr0QhgpQ_11_7"></a><ix:continuation id="Tb_-atYA5VEBUqxAZ6evMS3Dw_cont2"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_mliAeQhdTEyRhtFGRd21Tw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The principal components of the Company&#8217;s deferred tax assets and liabilities are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net operating loss carry forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_nuuu-DMeuEixjARBwx3yLw_4_3">31,570,846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_8cAFDWIixEGndwhr49yaiw_4_6">27,190,654</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_TMVPtJT8mkuB1uOy-NEJHg_4_9">22,301,154</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="0" id="Tc_dibnrEwKokmJmxftkQ2YHQ_5_3">500,975</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="0" id="Tc_r8zvLbNis0q5rVogbpOFwg_5_6">1,203,272</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" scale="0" id="Tc_eRcCh9LFBkygl5pFKrhLVA_5_9">305,982</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development credit carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_VxLb3GtiKUC9QEs95fIyHA_6_3">3,982,147</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_TFXGdMwCakGqZqCXBOEhaw_6_6">2,687,591</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_cZ9AoIjLakivBlAjhMHu0g_6_9">2,194,211</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accruals and others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="0" id="Tc_Hal2rt-bBEKwy0KvTk9wHQ_7_3">24,121</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="0" id="Tc_8Vm8otM0Y0WhZ8c3Kdl1Rg_7_6">232,665</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" scale="0" id="Tc_ehM5cSeScEqmam2pbHTIpQ_7_9">135,330</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="ctso:DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability" scale="0" id="Tc_JhPzIqeU7UWlQ_fPAs0REA_8_3">3,724,840</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="ctso:DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability" scale="0" id="Tc_p6yD4g2SkkCZKvppIqnyeg_8_6">3,997,114</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w" decimals="0" format="ixt:numdotdecimal" name="ctso:DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability" scale="0" id="Tc_1Jg7bZB1vUCh3MLY2TkTeg_8_9">289,287</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#167;174(b) research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOtherTaxCarryforwards" scale="0" id="Tc_3w0usQNMGE-EzPtBCOcmZQ_9_3">3,331,625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_xF2UbFVr1kuqQz3wyHgObQ_10_3">43,134,554</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_VZ_Lc7T1tk27kmN2jWQNcw_10_6">35,311,296</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_47Zp92CGF0ynSTiZvPEBwQ_10_9">25,225,964</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_iX2KszzLk0SGO4ROWO77DQ_11_3">39,303,451</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_fVwmysI8VUibSOHKe829vQ_11_6">31,242,130</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_Y7EEpeyBc0uiER_IaVurPQ_11_9">24,794,474</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_j4UDk2SRS0ygxtVPhvIKsw_12_3">3,831,103</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_wNCDEqhem0mo0R27dUOrCQ_12_6">4,069,166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_a4k_E4f6HUiAEwv1Awz6_A_12_9">431,490</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liability:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" id="Tc_ZQK2RiK79kCr1YDfkXgDDA_14_3">288,145</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" id="Tc_2SjkIykQt0asonifq9GmVw_14_6">183,941</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" id="Tc_I8uqIyzD1UijtOuDLgxJ4g_14_9">431,490</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right of Use Asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="ctso:DeferredTaxLiabilitiesRightsOfUseAssets" scale="0" id="Tc_hv_RFnrl_U6lhn5mRbuYLQ_15_3">3,542,958</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="ctso:DeferredTaxLiabilitiesRightsOfUseAssets" scale="0" id="Tc_ECnBnHeeR0axQp8PcYe6Pg_15_6">3,885,225</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on this assessment, management has established a full valuation allowance against all of the deferred tax assets for each period because it is more likely than not that all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The increases in valuation allowance for the years ended December 31, 2022, 2021 and 2020 were $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" id="Narr_qiV5rF8m0EiJJelK2wG_gA">8,061,321</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" id="Narr_w4RiXZ-w6UOSc6E3KBhgZw">6,447,656</ix:nonFraction>, and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" id="Narr_bzxeuocPu0KNyl0aigeDJg">1,936,732</ix:nonFraction>, respectively.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_RbU1ft7wSkCxYdEfCQY3WA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A reconciliation of income tax (expense) benefit at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-4" id="Tc_Ekl-0_daQUe3M9Rw6Eymvg_3_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-4" id="Tc_SX6Fvki0nEWMBD7EH0E5aw_3_4">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-4" id="Tc__zeL5mEIqE6ssKlrLUnLGg_3_6">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" sign="-" scale="-4" id="Tc_Owv6rxRu5EOjO4MClbuF-w_4_2">2.8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" sign="-" scale="-4" id="Tc_NopQGpvOJ0WoFyYs34W3ug_4_4">2.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" sign="-" scale="-4" id="Tc_GadhH9UyVk2M664-uYk2nw_4_6">9.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign rate differential</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-4" id="Tc_MW_ORsfcFkq6077bycvWWw_5_2">3.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-4" id="Tc_39CJs-Ekk02SmI9c8dtSyQ_5_4">2.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-4" id="Tc_5lroOVgQLE68nd_fc8_v3w_5_6">3.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="5" format="ixt:numdotdecimal" name="ctso:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent" sign="-" scale="-4" id="Tc_FU-8tlE4uU6c899GJ0qPkw_6_2">1.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="5" format="ixt:numdotdecimal" name="ctso:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent" sign="-" scale="-4" id="Tc_MmigEdHb3UiGLQ-usJXy5g_6_4">6.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="5" format="ixt:numdotdecimal" name="ctso:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent" sign="-" scale="-4" id="Tc_PKC3W6lENkqM4l23dGC3Xg_6_6">2.0</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rate change and true-up</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-4" id="Tc_ZQ12bS0gpEO9dwYXuov22A_7_2">0.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-4" id="Tc_62_T6BER-UqfECVAZj8KHg_7_4">11.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-4" id="Tc_gKULL7lwGUuaBtJXQ6IMmQ_7_6">17.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-4" id="Tc_l6zP6y4JSUezPFF0jfGGXw_8_2">22.8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-4" id="Tc_9y-y_YOK1EOh0IJDjR7k8g_8_4">25.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-4" id="Tc_l5tDDqgoREGDtX177-LRxw_8_6">21.6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">R&amp;D credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-4" id="Tc_Ic_-L81U30qtSjunKR3z2g_9_2">2.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-4" id="Tc_yfJQ35m3rEGBqLtbPkTOag_9_4">1.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-4" id="Tc_XcQTt2hYw0OBhkhZx5npFQ_9_6">4.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sale of state R&amp;D credit and NOL</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-4" id="Tc_J6S1BUZIKUaADCRYWBBloA_10_2">3.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-4" id="Tc_OHYE0XcBkkmpiavcxVVZ9A_11_2">3.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-4" id="Tc_8RLa6Nu6ck6ee9070843yQ_11_4">2.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-4" id="Tc_55gnavwUvEKcLl2CzePA5Q_11_6">12.6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_4-nVwyOV_kiw-2dKUo8pVQ" continuedAt="Tb_4-nVwyOV_kiw-2dKUo8pVQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. COMMITMENTS AND CONTINGENCIES:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Payroll Tax Examination</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In December 2021, the Company was notified that its European subsidiary, CytoSorbents Europe GmbH, would be subject to an audit of their payroll tax and social cost filings for the four-year period from 2018 through 2021. The Company has determined that payroll taxes and social costs were not paid on certain employee expense reimbursements as is required by German tax rules. Accordingly, the Company accrued approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExaminationInterestAccrued" scale="0" id="Narr_NX4vQoBk6kq1LAvHJPvoYQ">598,000</ix:nonFraction> as an estimate of this liability as of December 31, 2021. In January 2023, the Company received an assessment from the German tax authorities for the payroll tax audit of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_1_31_2023_us-gaap_LossContingenciesByNatureOfContingencyAxis_ctso_PayrollTaxAuditMember_UY7_k4-eREeBnQGR_XMpGA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExaminationInterestAccrued" scale="0" id="Narr_BFeCz6n1Lkm5LZvxDTwjyQ">90,000</ix:nonFraction>. In addition, it was determined that the Company would owe additional social security and VAT taxes related to this matter of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_us-gaap_LossContingenciesByNatureOfContingencyAxis_ctso_AdditionalSocialSecurityAndVatTaxesMember_dTAIANEpM0y9wSbH-curug" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExaminationInterestAccrued" scale="0" id="Narr_C1-umgQrBkKZlpahov9DfQ">83,000</ix:nonFraction>. Accordingly, the Company has adjusted its accrual related to this payroll tax audit to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_us-gaap_LossContingenciesByNatureOfContingencyAxis_ctso_PayrollTaxAuditMember_5kmrsmoK8EWvYJIbVVsujg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExaminationInterestAccrued" scale="0" id="Narr_LB0w7YE2l0i2wgCjCEYJhg">173,000</ix:nonFraction> as of December 31, 2022. This liability is included in accrued expenses and other current liabilities in the consolidated balance sheet as of December 31, 2022. </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_4-nVwyOV_kiw-2dKUo8pVQ_cont1" continuedAt="Tb_4-nVwyOV_kiw-2dKUo8pVQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The expense related this examination is included in selling, general and administrative expenses on the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employment Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July&#160;30, 2019, CytoSorbents Corporation entered into amended and restated executive employment agreements with its principal executives, Dr.&#160;Phillip P. Chan, Chief Executive Officer, Vincent Capponi, President and Chief Operating Officer, and Kathleen P. Bloch, Chief Financial Officer. Each of the agreements has an initial term of <ix:nonNumeric contextRef="Duration_1_1_2019_To_1_1_2019_Qy5PqaSx0EaQbNj8WsHlmA" format="ixt-sec:durwordsen" name="ctso:ExecutiveEmploymentAgreementsInitialTerm" id="Narr_RUUpiJPUEUS7FhwtTwQFXQ">three&#160;years</ix:nonNumeric> and was retroactively effective as of January&#160;1, 2019. On April 12, 2020, CytoSorbents Corporation entered into an executive employment agreement with Dr. Efthymios Deliargyris, who began employment as Chief Medical Officer on May 1, 2020, with an initial term that expired on December 31, 2021. After the expiration of the initial terms, the employment agreements will automatically renew for additional terms of <ix:nonNumeric contextRef="Duration_1_1_2022_To_1_31_2022_ifdIznn7QEeHunrEw3Jhtw" format="ixt-sec:durwordsen" name="ctso:EmploymentAgreementsAutomaticRenewalPeriod" id="Narr_VxFrVdAysUG1WS0gOqTUFw">one&#160;year</ix:nonNumeric> unless either party provides written notice of non-renewal at least 60 days prior to a renewal.In January 2022, these employment agreements automatically renewed for an additional <ix:nonNumeric contextRef="Duration_1_1_2022_To_1_31_2022_ifdIznn7QEeHunrEw3Jhtw" format="ixt-sec:durwordsen" name="ctso:EmploymentAgreementsAutomaticRenewedPeriod" id="Narr_Rz2EZm3LC0e4vyJGhBfpkg">1 year</ix:nonNumeric>. The foregoing employment agreements each provide for base salary and other customary benefits which include participation in group insurance plans, paid time off and reimbursement of certain business-related expenses, including travel and continuing educational expenses, as well as bonus and/or equity awards at the discretion of the Board of Directors. In addition, the agreements provide for certain termination benefits in the event of termination without &#8220;Cause&#8221; or voluntary termination of employment for &#8220;Good Reason&#8221;, as defined in each agreement. The agreements also provide for certain benefits in the event of a &#8220;Change of Control&#8221; of the Company, as defined in each agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 30, 2022, Ms. Bloch notified the Company of her intention to retire effective March 31, 2023. A search has been initiated for Ms. Bloch&#8217;s replacement. Ms. Bloch and the Company expect to enter into a consulting arrangement under which Ms. Bloch will continue to provide services to the Company in a limited capacity following the effective date of her retirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Litigation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is, from time to time, subject to claims and litigation arising in the ordinary course of business. The Company intends to defend vigorously against any future claims and litigation. The Company is not currently a party to any legal proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Royalty Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to an agreement dated August&#160;11, 2003, an existing investor agreed to make a $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_8_11_2003_To_8_11_2003_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_RoyaltyAgreementsMember_xFt-mbbZrkmdsbIlITDLxQ" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" id="Narr_kkCloJGY9kW8-ej4v9oF3g">4</ix:nonFraction> million equity investment in the Company. These amounts were received by the Company in 2003. In connection with this agreement the Company granted the investor a perpetual royalty of <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_8_11_2003_To_8_11_2003_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_RoyaltyAgreementsMember_xFt-mbbZrkmdsbIlITDLxQ" decimals="2" format="ixt:numdotdecimal" name="ctso:RoyaltyPaymentRate" scale="-2" id="Narr_fIAiV71sHEyICI0bp3AC-A">3</ix:nonFraction>% on all gross revenues received by the Company from the sale of its CytoSorb device which such rights were assigned to an existing investor in 2017. For the years ended December 31, 2022, 2021 and 2020, the Company recorded royalty expenses of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_RoyaltyAgreementsMember_BXoz6wUE6keu3xUP3R0XpQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="0" id="Narr_eBa1MxAefU67wIx3YyAhHQ">849,000</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_RoyaltyAgreementsMember_rdfbeFkWfkyrD5IQ3VfUwg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="0" id="Narr_H_4OqnhQ50exvEOsXqkkrQ">1,193,000</ix:nonFraction>, and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_RoyaltyAgreementsMember_CA354vfky0OFd_1E5K6eQw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="0" id="Narr_g9GacNkbtUaCCT49CV9m5g">1,172,000</ix:nonFraction>, respectively. These expenses are included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 1, 2022, the Company entered into the Marketing Agreement with Fresenius, which expands the Company&#8217;s strategic partnership with Fresenius by establishing a multi-stage global collaboration to combat life-threatening diseases in critical care. The Marketing Agreement has an initial term of three years, with an automatic renewal for an additional two years at the end of such initial term, subject to earlier termination by either of the parties (the &#8220;Term&#8221;) To help support the increased marketing and promotional efforts of the expanded collaboration, the Company has agreed to subsidize a portion of the marketing costs through royalty payments to Fresenius. Initially, the Marketing Agreement provides for royalty payments equal to 0.9% of the Company&#8217;s net sales of CytoSorb products made during the Term (excluding net sales in the United States). This initial royalty rate was determined based on certain assumptions regarding the percentage of the Company&#8217;s sale of CytoSorb products that are used with the Fresenius critical care platforms in the intensive care unit outside of the United States but is subject to adjustment if the Company determines that the underlying assumptions have changed significantly. For the year ended December 31, 2022, the Company did not record any expense related to this agreement as Fresenius did not commence any marketing activities as defined by the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In an agreement dated September&#160;1, 2006, the Company entered into a license agreement which provides the Company the exclusive right to use its patented technology and proprietary know how relating to adsorbent polymers for a period of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_LicenseAgreementMember_raDmOQBLY0ys677paSR3hw" format="ixt-sec:durwordsen" name="ctso:LicensePeriod" id="Narr_OV7pkT6cP0qp5eF5j5uQPA">18&#160;years</ix:nonNumeric>. Under the terms of the agreement, the Company has agreed to pay license fees of <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_LicenseAgreementMember_vd_rm61d5EKX2A6aRANNWw" decimals="3" format="ixt:numdotdecimal" name="ctso:RoyaltyRateLowerLimit" scale="-2" id="Narr_mT0y3WVas02PnV279yL_Kw">2.5</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_LicenseAgreementMember_vd_rm61d5EKX2A6aRANNWw" decimals="2" format="ixt:numdotdecimal" name="ctso:RoyaltyRateUpperLimit" scale="-2" id="Narr_VtDY_YAbcUStCCewYBxbgQ">5</ix:nonFraction>% on the sale of certain of its products if and when those products are sold commercially for a term not greater than <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_LicenseAgreementMember_raDmOQBLY0ys677paSR3hw" format="ixt-sec:durwordsen" name="ctso:LicensePeriod" id="Narr_nbWB5CMai0WhdJz5mXrUVQ">18&#160;years</ix:nonNumeric> commencing with the date of the agreement. For the&#160;years ended December 31, 2022, 2021 and 2020 per the terms of the license agreement, the Company recorded licensing expenses of </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_4-nVwyOV_kiw-2dKUo8pVQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_LicenseAgreementMember_raDmOQBLY0ys677paSR3hw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="0" id="Narr_S9e49JABXEay5vCU-G7_xA">1,416,000</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_LicenseAgreementMember_S4h6KrieY0yFrU840BqKzQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="0" id="Narr_ebrXD_vamUurLVtj0H8rIw">1,988,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_LicenseAgreementMember_U7A4z9C5Qk6CY4PDRbXTqQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="0" id="Narr_g6ufS89vWUCNxMBUtL8HVw">1,954,000</ix:nonFraction>, respectively. These expenses are included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_i3s19FObfU2CICZnXwPPnQ" continuedAt="Tb_i3s19FObfU2CICZnXwPPnQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. STOCKHOLDERS&#8217; EQUITY:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2019, the Company amended and restated its certificate of incorporation. The amended and restated certificate of incorporation authorizes the issuance of up to <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_6_30_2019_hE-GjhoHb06AQqRidhWP3A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_xAf9WnIwZ0aeoblomHc-BA">5,000,000</ix:nonFraction> shares of &#8220;blank check&#8221; preferred stock, with such designation rights and preferences as may be determined from time to time by the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2019, the Company amended and restated its certificate of incorporation. The amended and restated certificate of incorporation increased the number of shares of common stock authorized for issuance from <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_5_31_2019_88geVJQ2uUywvKJuak2-eg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_7H5t5WQZNkWeRQFBSGJZAA">50,000,000</ix:nonFraction> shares to <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_6_30_2019_hE-GjhoHb06AQqRidhWP3A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_oI9xGqusFEWDoGtBjgMpLQ">100,000,000</ix:nonFraction> shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Shelf Registration</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July 14, 2021, the Company filed a registration statement on Form S-3 with the SEC, which was amended on July 20, 2021 and declared effective by the SEC on July 27, 2021 (as amended, the &#8220;2021 Shelf&#8221;). The 2021 Shelf enables the Company to offer and sell, in one or more offerings, any combination of common stock, preferred stock, senior or subordinated debt securities, warrants and units, up to a total dollar amount of $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_7_14_2021_ia1syTvHG0S77AERC2Hqwg" decimals="-6" format="ixt:numdotdecimal" name="ctso:AggregateRegisteredAmountForOfferings" scale="6" id="Narr_58-MfwaqOkO-oTPbudVI2Q">150</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Open Market Sale Agreement with Jefferies LLC </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 30, 2021, the Company entered into an Open Market Sale Agreement (the &#8220;Sale Agreement&#8221;) with Jefferies LLC (the &#8220;Agent&#8221;), pursuant to which the Company could sell, from time to time, at its option, shares of the Company&#8217;s common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_12_30_2021_To_12_30_2021_dei_LegalEntityAxis_ctso_JefferiesLlcAndB.RileyFbrIncMember_XwgIgRkXJ0ileyIAI7HBTQ" decimals="-6" format="ixt:numdotdecimal" name="ctso:CommonStockValueAuthorized" scale="6" id="Narr_O0w6I03J_ESgZYKb1G2nWg">25</ix:nonFraction> million through the Agent, as the Company&#8217;s sales agent. All shares of the Company&#8217;s common stock offered and sold, or to be offered and sold under the Sale Agreement, would have been issued and sold pursuant to the Company&#8217;s 2021 Shelf by methods deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, in block transactions or if specified by the Company, in privately negotiated transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the terms of the Sales Agreement, the Agent is required to use their commercially reasonable efforts consistent with their normal sales and trading practices to sell the shares of the Company&#8217;s common stock from time to time, based upon the Company&#8217;s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company is required to pay the Agent a commission of up to <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="As_Of_12_30_2021_dei_LegalEntityAxis_ctso_JefferiesLlcAndB.RileyFbrIncMember_7Vao9teehUSAKLxbCXXGsA" decimals="3" format="ixt:numdotdecimal" name="ctso:CommissionRateAsPercentageOfAggregateGrossProceeds" scale="-2" id="Narr_QZU_liLox0yYfDMDdRTpaQ">3.0</ix:nonFraction>% of the gross proceeds from the sale of the shares of the Company&#8217;s common stock sold thereunder, if any. There were no sales pursuant to the Amended Sale Agreement during the years ended December 31, 2022 and 2021, respectively. In addition, during the year ended December 31, 2021, the Company paid approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Narr_GZMKZ7noh0mmUWIMbHJsUg">90,000</ix:nonFraction> related to the Amended Sale Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Option Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company had <ix:nonFraction unitRef="Unit_Standard_item_00R0j3K4HUiRlSslEJQMxQ" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="INF" format="ixt-sec:numwordsen" name="ctso:NumberOfLongTermIncentivePlans" scale="0" id="Narr_UHKIKI4mBkmnmt8LFsciVA">two</ix:nonFraction> Long Term Incentive Plans (the &#8220;2014 Plan&#8221; and the &#8220;2006 Plan&#8221;) to attract, retain, and provide incentives to employees, officers, directors, and consultants. The Plans generally provide for the granting of stock, stock options, stock appreciation rights, restricted shares, or any combination of the foregoing to eligible participants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A total of <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_ctso_TwoThousandFourteenStockOptionPlanMember_283few-Y1k-s142NM7ToRA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_oLy8pEeH90qZK35Mx58Rww">13,400,000</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_ctso_StockOptionPlanOneMember_RNyPCy3gyE2TqeZtAiyN2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_Jm_IheN4SUWMBenod0HlTA">2,400,000</ix:nonFraction> shares of common stock are reserved for issuance under the 2014 Plan and the 2006 Plan, respectively. As of December 31, 2022, there were shares remaining to purchase approximately <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_ctso_TwoThousandFourteenStockOptionPlanMember_283few-Y1k-s142NM7ToRA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_1ZQIJZN-mUWpkUIpT7UVAQ">3,713,000</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_ctso_StockOptionPlanOneMember_RNyPCy3gyE2TqeZtAiyN2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Narr_eBPHJly72kyPTtAhH_tbWQ">258,000</ix:nonFraction> units of common stock reserved under the 2014 Plan and the 2006 Plan, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2014 and 2006 Plans as well as grants issued outside of the Plan are administered by the Compensation Committee of the Board of Directors (the &#8220;Compensation Committee&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Compensation Committee is authorized to select from among eligible employees, directors, advisors and consultants those individuals to whom incentives are to be granted and to determine the number of shares to be subject to, and the terms and conditions of the options. The Compensation Committee is also authorized to prescribe, amend and rescind terms relating to options granted under </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_hYJ4tPvb60qKGyBngUL6gA_1_7"></a><a id="Tc_g-m7KdOXi0e9fe-boKq44w_2_4"></a><a id="Tc_kMAvbTENMUCvznSKjoKEnA_2_7"></a><a id="Tc_baJ3dykSWEKR0YCBLmZxsQ_3_4"></a><a id="Tc_Iwuquwyob0uEdtoH1ORiiQ_3_7"></a><a id="Tc_OfOCuhgZdEK0JISLermPcQ_4_4"></a><a id="Tc__-owm1m8E0KMefd3uueFVw_4_7"></a><a id="Tc_sHnOWXuI9USmTfr0d9FEUg_5_2"></a><a id="Tc_KwRksggPnUeniK3M_6iz1g_5_4"></a><a id="Tc_O21hEgg34E-KjOyBxn7K4A_5_7"></a><a id="Tc_mU8_lhog_0mUq5mIIOhRYQ_7_0"></a><a id="Tc_4G9cxC1eBUGqdK9txM24Yw_7_4"></a><a id="Tc_NQFEBPmb1k6OU75HoaI9EQ_8_0"></a><a id="Tc_VdBNpuTuGkSfNL7c5kSNlA_8_4"></a><a id="Tc_VzEoHlCXHU-gU9fPnxobMw_9_0"></a><a id="Tc_a_AzY9SwqESjgsR0xzqnvA_9_4"></a><a id="Tc_pjvLpfTRt0et8V6815uM7A_10_0"></a><a id="Tc_JU-l99KUiUiJYObVRLLskQ_10_4"></a><a id="Tc_Ibu6sYIiJ0OF9nZSUPmbDA_11_0"></a><a id="Tc_TUoKwWyjkECZ9eHUYTP6QQ_11_4"></a><a id="Tc_1plyAPLXDkiE3cm7bxrtkw_12_0"></a><a id="Tc_BnlyS1Me1UKz8D0V5ZsoyQ_12_4"></a><a id="Tc_Uc6yTKGIXEG8Sm8Kq4boBg_13_0"></a><a id="Tc_DJ26G50ldUeWXOptqZGzCQ_13_4"></a><a id="Tc_RAo7AYhMTUKW7RtBn4iPCQ_14_0"></a><a id="Tc_0A4sSlQPRUSJTTcwGZiJqA_14_4"></a><a id="Tc_NV_-dS1wjUeQx1JT5vA6Sg_15_0"></a><a id="Tc_R_rqoVD360anfw_wA0ncUA_15_4"></a><a id="Tc_aruW4aQsYUSr1nAAbAGtxA_16_0"></a><a id="Tc_plaEroNtgkulZSEZvq_IcQ_16_4"></a><a id="Tc_y3tiHpINUkKpjFiqCV0_HA_17_0"></a><a id="Tc_Elus5aWcTUybk56oj_KU4Q_17_4"></a><a id="Tc_RDVMwIp19kShtVNj8BrhMg_18_0"></a><a id="Tc_1rOD3Tg-qkGCeV0b96h5qw_18_4"></a><a id="Tc_uUfN7Oh3_UelmzK_Twz0lg_19_0"></a><a id="Tc_Lqth8lXYykaisZWlxzhFvw_19_4"></a><a id="Tc_P7x0mY3yb0SNwLkpASb6IA_20_0"></a><a id="Tc_tVmXRcqZcUaolIUCKVjE8A_20_4"></a><a id="Tc_28bF1c-mqECE9KoqC_9eTw_21_0"></a><a id="Tc_9gbhYhUqz0KIGiRWMOTJ0Q_21_2"></a><a id="Tc_BA-cMFv--k-Q9CiX5ysbsQ_21_4"></a><a id="Tc_XWjT91xSL0aFQoY58LeCKw_21_5"></a><a id="Tc_YcWme4KwHU2toY53vB2LBA_22_0"></a><a id="Tc_1Ubfqry_ck-XkVLwIUNexw_22_4"></a><a id="Tc_DggUooZJ8ky_yrxr-mHDxQ_1_7"></a><a id="Tc_1i1p0m7VOkuWs6sYOw-uoA_2_7"></a><a id="Tc_e391uClRZU-YLl2sO9MbRQ_3_7"></a><a id="Tc_S5ld33eLRUKsUIS0q9p-wg_4_7"></a><a id="Tc_w4ITfQUyv0-vjkgKP9uS3g_5_2"></a><a id="Tc_X7pJy5f2EkaDdlEyPGP6YA_5_5"></a><a id="Tc_aNlhDIkLdkGypIIENWkaGQ_5_7"></a><a id="Tc_WD4gJiGO4kGJtLp8u6PfJw_5_13"></a><a id="Tc_gbl9YjHjEUWjzSj8em_kDA_6_2"></a><a id="Tc_Air2kfeOuUiCrzyV_J57PQ_6_5"></a><a id="Tc_jyQXOzIJLEiW6xygnMhLfA_6_7"></a><a id="Tc_0zQ-LH2ALUO7a637CNIQaA_6_10"></a><a id="Tc_hmZ-29apbkSc1Tehn_P98Q_6_13"></a><a id="Tc_VXR85F-dWkSuP-3dfOFQPA_7_0"></a><a id="Tc_HwqsGehXZk2f1kl_99ms1Q_7_2"></a><a id="Tc_3EKILZ4nLUmH0qG4iE5pww_7_5"></a><a id="Tc_EYdtwg_8Y0ayrTkguA3C1w_7_7"></a><a id="Tc_22tUu-9pmkySHugfQaLYPA_7_10"></a><a id="Tc_53Mbf3mSXE-p1wNkQTygXA_7_13"></a><a id="Tc_rpcdL52ZHkKref4fMrWKqg_8_0"></a><a id="Tc_CniY4WjW70u69HjdxDxJjw_8_2"></a><a id="Tc_hb2mraHR0E2DClafXIKOwQ_8_3"></a><a id="Tc_AxE28sDhJE-wM8FgOQaVHQ_8_7"></a><a id="Tc_dIKlif5MxU6Qs1X2iFe9BA_8_8"></a><a id="Tc_57KIz4u7iUCfRHHcQD63-w_8_11"></a><a id="Tc_L8v4lWeyyk2TnX_cVRlCSw_8_13"></a><a id="Tc_XCzBWOzQxkqY377yi76JCw_8_14"></a><a id="Tc_9wef6ucqeEOqAMAqA0CsMQ_9_0"></a><a id="Tc__BRcTn0Th025wB3ftzGJ1g_9_2"></a><a id="Tc_gC208Z_5tEu5L5FGa4rYqg_9_3"></a><a id="Tc_aQcaqs8EY068_u_2SmCcIw_9_7"></a><a id="Tc_MNryh6Nh1keuYmYhlkVBAA_9_8"></a><a id="Tc_Q0QELvt1dUiYwD1HzUY4lw_9_11"></a><a id="Tc_qYi1GgaXiEmvC5NzCLp63w_9_13"></a><a id="Tc_9knEvJV4XECB6HDkWNZVyQ_9_14"></a><a id="Tc_SX1P0ZMwWk2GQ-A8J6GCuQ_10_0"></a><a id="Tc_xJ8A2Gbh0UaCNV6-ahNP_g_10_2"></a><a id="Tc_awrxpfXb4kCV26WovGVNGw_10_3"></a><a id="Tc_Zg2EXsd-x0yuDSqhhGhl9Q_10_7"></a><a id="Tc_IwIXO_X0fUytwNNByhJKJA_10_8"></a><a id="Tc_JK918jaDv0KQ-Y1oWAFwiw_10_11"></a><a id="Tc_O2UN1cwHNESV58NI5_DC3A_10_13"></a><a id="Tc_SmmO7go1Y0SV0xy7yrKyHg_10_14"></a><ix:continuation id="Tb_i3s19FObfU2CICZnXwPPnQ_cont1" continuedAt="Tb_i3s19FObfU2CICZnXwPPnQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the Plans. Generally, the interpretation and construction of any provision of the Plans or any options granted hereunder is within the discretion of the Compensation Committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2014 Plan provides that options may or may not be Incentive Stock Options (&#8220;ISOs&#8221;) within the meaning of Section 422 of the Internal Revenue Code. Only employees of the Company are eligible to receive ISOs, while employees and non-employee directors, advisors and consultants are eligible to receive options, which are not ISOs, i.e., &#8220;Non-Qualified Options.&#8221; Because the Company has not obtained shareholder approval of the 2006 Plan, all options granted thereunder to date are &#8220;Non-Qualified Options&#8221; and until such shareholder approval is obtained, all future options issued under the 2006 Plan will also be &#8220;Non-Qualified Options.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2014, the Company&#8217;s received shareholder approval authorizing the Board of Directors to implement the form, terms and provisions of the 2014 Plan. Accordingly, any options issued to employees under the 2014 Plan will be ISOs within the meaning of Section&#160;422 of the Internal Revenue Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Total share-based employee, director, and consultant compensation for the&#160;years ended December 31, 2022, 2021 and 2020 amounted to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_3ldt3xlPsEqZ6hJJi1WAxQ">3,424,000</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_mGabWDA9Z06py5oAfDh49Q">4,021,000</ix:nonFraction>, and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_xZiLBHQ88kWPH6IYswvIRg">3,514,000</ix:nonFraction>, respectively. These amounts are included in selling, general, and administrative expenses on the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The summary of the stock option activity for the&#160;years ended December 31, 2022, 2021 and 2020 is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_WlnsxwvgdU6ShXRLB15lPg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per&#160;Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life&#160;(Years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding January 1, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2019_6_oqjbutzEKQogf2y7UC6g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_mJpxs3PwBUqiv1X-wvYHyA_7_2">4,218,189</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2019_6_oqjbutzEKQogf2y7UC6g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_2MQ73R5nW02fS4XIQ1UZtg_7_5">6.16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019_9CuY3bMLoUmlRHItGFexPg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_yHxmp_T5KE6R4KH77s3pdQ_7_7"> 7.0</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_CtjojD4a8E2gMAneveDPYA_8_2">1,579,106</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_STlqQiafCE-NawuoVdw0HQ_8_5">6.37</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" format="ixt-sec:duryear" name="ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm" id="Tc_wUhi6eo4tUOJp7EeOFzm2A_8_7"> 9.0</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_TaViyzPFXU631syXJB9-7w_9_2">34,644</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_hjZdZzeTsESKTudPmTjaMQ_9_5">7.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_1iWKOSTEYEW4rgjnocsyQg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Tc_oOU9bXMGqEa928y1GmN18A_10_2">226,440</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_ho4ofgXmQ0K6fq8jORv5xA_10_5">5.60</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_gFEztX83IEan5vGYiG_KkA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_d05jJHA_ZEKgUzDc37kg4w_11_2">371,007</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc__WEw3vPchEy826z0GLAAiQ_11_5">4.46</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_7Cm8_uxCP0mv3QQAha4gkQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding, December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_4IrA9eI6DkiA4VYNGCt59A_12_2">5,165,204</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_UavghJkLO0OU0N7cldde9A_12_5">6.36</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_0XZwxU7d3UOz8dMS84xCUg_12_7"> 7.26</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_PijLXDDYtkGobZzz0djgcQ_13_2">2,051,980</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_dxX_OFg9_0CVVH_WqjV61A_13_5">8.78</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" format="ixt-sec:duryear" name="ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm" id="Tc_yFXl0ujtHEOAa3xYrXr0BA_13_7"> 9.30</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_8S24bGdSdE6Zj24fWyio3w_14_2">138,037</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_vyy-heJsP0O89lQy1qZYbw_14_5">6.73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_rBumodlmnUK-p_-iado5iw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Tc_o1w4jwFeQE6dTQF_xJnQiw_15_2">21,756</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_M_aUC0miU0uuVbcvm1mJHw_15_5">7.46</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_GQpp15AqqkCIMuMwEM8NqQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_YZyjqDTOZEKtdpuWHB-3AQ_16_2">171,413</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_Z3dB7nJIsUeXVf1x0RCsNg_16_5">5.73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_amo3-ZcwWEWCT2ol91T9ZQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding, December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_zD6w4TXIlU2efoJM6aBkUg_17_2">6,885,978</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_1lPqXZYZgUuTZTfeX7nr5g_17_5">7.09</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_Bf28NeSamESiplnyWkVtCQ_17_7"> 7.15</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_YA05eD4GFEejZs0hUZDkSw_18_2">2,721,205</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_683bnr7fA0uQmEQ2hWL2fg_18_5">1.99</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" format="ixt-sec:duryear" name="ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm" id="Tc_apPwhSz0h0mRluqvft36Uw_18_7"> 9.60</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_jV196Rhc60etwfknF4UDew_19_2">1,270,155</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_npFRz4RmAkO_KZtgzvn98g_19_5">8.65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_SbJXsQ3BuU-Usd0OT4w7GA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="Tc_b2bnaWi0zUmJfo4kxYBC8Q_20_2">227,204</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_4LgUldAYJ0OS3YbHkuPkHA_20_5">7.71</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_4-HPXTyq0kWo5cJ4Z0sPVw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_We0d8r7iWEWg62NYW1m7vA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding, December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_jxeDLYSIF0eRxtpXinWBag_22_2">8,109,824</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_sfrmjL6G7kS2Sga4XwJ0Dg_22_5">5.11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_854VUoOnW0aG5OifIkEBgQ_22_7"> 6.91</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of each stock option was estimated using the Black-Scholes pricing model which takes the following factors into account.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_5OE1T4LF-Ua7hHrvlMtI4Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;of&#160;the</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Underlying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Stock&#160;and&#160;its&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant&#160;Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expected&#160;Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expected</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Risk&#160;Free</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;of&#160;the&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Volatility</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expected</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Interest&#160;Rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year - Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Range</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Range</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Dividends</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Range</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_DYCHwOrJcUSzRA20VoqbmQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_KiVkXpOd_U2X4YobugCz8w">5.00</ix:nonFraction> - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_9h926km2lEC7N26veE3DSA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_qKfdODGJzUm8TwMyAcVfCg">10.58</ix:nonFraction> per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_Mkkar0ZT7EGL5951qJggtw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_K1BhxKOJjkmnDf7NGXbfZg_8_5">6 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_uD4JXkNMnUCEqqr147HBXw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_OY7h1YzrlkyvE9d2MVZ1rA">61.7</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_a0ICslhLlEaiPjkyJ39i8w" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_rh5OXP7gI0ebJfoIRghDqw">69.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_Mkkar0ZT7EGL5951qJggtw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_Tb7TucHw10iDPJaWsnN_vw_8_10">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_uD4JXkNMnUCEqqr147HBXw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_MyeWpeqLj0697iDK6k6oRg">0.28</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_a0ICslhLlEaiPjkyJ39i8w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_RP6_0EX1IE-DpJMIcUZYGQ">0.96</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_jZM8bjchokCOiKcRmPF3Ug" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_A4bpowpiK0qW_3wQm0-qXg">4.26</ix:nonFraction> - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_8gw5_ggnZkerQU2oAT6--g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_izcnC_1_mUWR7nIbvn061A">11.39</ix:nonFraction> per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_4nmfCjwDv0eiv9Xvjheotg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_tdvoxL46Yk6J6D5zfNZhgA_9_5">6 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_wMhxRA4mxUGyr5aQSg53cQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_AHECqUKnNUmUsV9k8nXHhQ">58.2</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_eGE4Htw5vUiAfnNKM05dQg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_AeXo7Qs73EKw3D9tNzaDxw">60.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_4nmfCjwDv0eiv9Xvjheotg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_nKqe8CU52E2LdIsS-na0oA_9_10">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_4nmfCjwDv0eiv9Xvjheotg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_xm05VkdoQkOkqsjzX50pJw">0.47</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_4nmfCjwDv0eiv9Xvjheotg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_1HfSztfFL0mOFtvIlcvL9A">1.39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_ntPA1TgJd0OfX_mWQ4DWuA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_49VTaXQnk02GylfGmBZK7Q">1.11</ix:nonFraction> - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_cXJTOYaNgUKPUItB-_WwrQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_853UvCQRoUWkj8BCHnFO9Q">3.91</ix:nonFraction> per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_A3_FWcLzlUqUUdWwNDHlOw" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_hNTULV47qkeIFzJMRbIyBw_10_5">6 years</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_SozA6YZi2kKt1YD5fTj12g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_3HCHXPcnJUO_4oyYnjs0BA">59.3</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_rxvDjksKlEOKtNVfXCde1g" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_m6vf3NuN80ykBYWwdJg_IQ">67.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_A3_FWcLzlUqUUdWwNDHlOw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_ClEIQt2PDE-4fjeAXVgHPQ_10_10">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_A3_FWcLzlUqUUdWwNDHlOw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_0GlU5LON-0Snpa8u8YbAug">1.52</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_A3_FWcLzlUqUUdWwNDHlOw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_DvUusw1Gukanxx-xaLmaEw">4.20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company recognizes forfeitures as they occur.</p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b40154c1_b147_4274_82ac_136cd4ace650"></a><a id="Tc_nQxtAc9u7kWtBtEbaT6eyA_1_0"></a><a id="Tc_StZx-80rOkih9fpuJ-_4uQ_2_2"></a><a id="Tc_-CkBkGqmHUuWLiFRPbJbFw_2_4"></a><a id="Tc_UZ0oRi6zs0mvQ8IQxP-gNw_2_7"></a><a id="Tc_cGKYHQNAXkS0DtP6cqQLOw_3_0"></a><a id="Tc_49afp6dlTEO_mFkAVdGO7Q_3_2"></a><a id="Tc_znt1pY244UiXQeBymM0e5g_3_4"></a><a id="Tc_LqYT6YIqwEaMdTVWrgsrrQ_3_7"></a><a id="Tc_aAW5jIdrHka3wN468eOFKw_3_9"></a><a id="Tc_SJJMhLcbL0m2JAuY7AEtcg_4_0"></a><a id="Tc_w9cfxh75gEujNwBcqxBx1Q_4_2"></a><a id="Tc_Q1P7VZLDXUikBVw-uNWwMQ_4_4"></a><a id="Tc_iAAoaI_EHUyhEF7NLWJ2MQ_4_7"></a><a id="Tc_5WWiVbnwzUyNZnDVYtgzYQ_4_9"></a><a id="Tc_UWyvySR5EEiLKuZvXUE9jA_5_0"></a><a id="Tc_Bj2BSgf5hk67Hutc-MtoqQ_5_2"></a><a id="Tc_mvpfQkMieU6baXRlkG9bMA_5_4"></a><a id="Tc_HVroe6eHzkKrh5LsQ295fQ_5_7"></a><a id="Tc_cH_yp8fU1EqbE7bedE15wA_5_9"></a><a id="Tc_7Z1DZI5GZkWsPUWZxAh_BQ_6_0"></a><a id="Tc_9lbiZoodz0GHUT_0SS7h-w_6_4"></a><a id="Tc_tmMpKVn6Y0uPaZ590d0e1Q_6_9"></a><a id="_a4a3be2d_7936_4564_aac4_d65d2355810b"></a><a id="Tc_XzgeF6ddn0-w7NGBBsO18Q_1_0"></a><a id="Tc_iugR5gbl00u6trxun_HBXg_2_0"></a><a id="Tc_v_DkO3JZW0KrVVL7fn7Czw_2_2"></a><a id="Tc_cui3XAH0C0uUTx8Ue2iHcA_3_0"></a><a id="Tc_wzHBNdmqsUe91etLDanucg_3_2"></a><a id="Tc_W6zrudZ55EKD8G0_fIK7vA_3_5"></a><a id="Tc_VteKeKiftEm90ttntlEgKA_4_0"></a><a id="Tc_SFdaRFyMSUiNbNhOMmoklw_4_2"></a><a id="Tc_OzQAVsZMEUSGDCpUFNAmhQ_4_5"></a><a id="Tc_u68sKl0yP0eVRETzV7KAlg_5_0"></a><a id="Tc_vCiwr0snF0ecqZh_xlIVRg_5_2"></a><a id="Tc_52j48184yEuNYR0ozPXyGA_5_5"></a><a id="Tc_hiFmGq0tc0K5lLu2039Zlw_6_2"></a><a id="Tc_bmPSS4AilU2it4YIBY-A7Q_6_5"></a><a id="Tc_eL3h0bxDd06QmkhOL2cGOw_1_4"></a><a id="Tc_gUZ8VNKMiUSMFUcb3lcAoA_2_4"></a><a id="Tc_ekF8-04-0EGX5FolLgKLzg_3_4"></a><a id="Tc_n77ZBAJKpkinRB-lGPxQlg_4_2"></a><a id="Tc_uJ0w70nrp0mRDKWSSFqBbA_4_4"></a><a id="Tc_2xj-o1Cj-EeQwMwcnMPj5Q_6_0"></a><a id="Tc_Mshn3TYx60aFw9LnAB61zQ_6_4"></a><a id="Tc_e1TjFDMaKEWZPi6q7QtnXw_7_0"></a><a id="Tc_GlIPjyqFMEq1o8G2eWu6Qw_8_0"></a><a id="Tc_uL0lnczDKUqKrMacy2Ht9g_9_0"></a><a id="Tc_qOxBQM4dBE60mcyZQDKpng_10_0"></a><a id="Tc_m3gnwc3IhEOlMxzsHpfyTQ_10_4"></a><ix:continuation id="Tb_i3s19FObfU2CICZnXwPPnQ_cont2" continuedAt="Tb_i3s19FObfU2CICZnXwPPnQ_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The intrinsic value is calculated at the difference between the market value as of December 31, 2022 of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_669VMyr630KE25WzYDQx8w">1.55</ix:nonFraction> and the exercise price of the shares.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="Tb_13jAzhdl-UCP87OaNoyNVQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="11" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Range of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ctso_ExercisePriceRangeOneMember_L6XbyOqHWUaHFIu4xBQwEA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="Narr_Yx5kqtOBYU2L4_7ilSXAbQ">1.11</ix:nonFraction> - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ctso_ExercisePriceRangeOneMember_L6XbyOqHWUaHFIu4xBQwEA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="Narr_FOnyAlJKm0KLko5SKT_68A">13.20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ctso_ExercisePriceRangeOneMember_HTSesPowQUOWzfbwBPWjzg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" id="Tc_tBq_t3mgL0ixhgTNTHrzBw_6_2">8,109,824</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ctso_ExercisePriceRangeOneMember_HTSesPowQUOWzfbwBPWjzg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="Tc_bqCXDEk_jUiAYCuf8MU1qw_6_5">5.11</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ctso_ExercisePriceRangeOneMember_L6XbyOqHWUaHFIu4xBQwEA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="Tc_on5k4VcRw0GVuzfg_rr9cA_6_7">6.91</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ctso_ExercisePriceRangeOneMember_HTSesPowQUOWzfbwBPWjzg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_bvIelpuYakafVSQSz3ViMg_6_10">7,280</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:56.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" id="Tc_zG68KKLgD0uKmdobREtjeA_6_0">4,623,085</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="Tc_AdCaa4gack-ZQ08xUi29ZQ_6_3">6.32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="Tc_jaMs7hWt6U66Svwcu-zihg_6_6">1,250</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The summary of the status of the Company&#8217;s non-vested options for the&#160;year ended December 31, 2022, is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_PD6J30gR5EKT9_6EoKYJeg" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" id="Tb_DOQakDn2-Uaq64sm3MY1xQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant&#160;Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-vested, January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="Tc_UB2nOJOCY0CIt3JYrkyHXw_6_2">2,994,846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_oOTZ62S1yEq_4zEQUS6DKA_6_5">4.68</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_BlEsZOQskkuw2nDMwtvxOw_7_2">2,721,205</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_PCKmt56stkKB8ZvlWbNbmA_7_5">1.99</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" scale="0" id="Tc_4CfQEOQ6kEG20bAuumXarQ_8_2">1,270,155</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="Tc_sGGEo9Yd0kiJmpdTl-et-A_8_5">8.65</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="Tc_h9_GN7iVyE2XmZ_ODddkVQ_9_2">959,157</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_GYqzU1gXU0eF85f6S8TeIQ_9_5">3.65</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-vested, December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="Tc_eWMx6rni5EaVpu3jlNF5gA_10_2">3,486,739</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_NCL5MnyniU29vH8c1Fa3SA_10_5">2.10</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company had approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="Narr_ctSRTFkIu0i0-6zXEJswTQ">4,745,000</ix:nonFraction> of total unrecognized compensation cost related to stock options which will, on average, be amortized over <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_nhE5lMMddEeYc1ttMrhyDQ">43 months</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Awards of Stock Options:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 10, 2022, the Board of Directors granted options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_8_10_2022_To_8_10_2022_srt_TitleOfIndividualAxis_ctso_EmployeeOneMember_eZMz_a7KzUiEra_Pmj1NYQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_l-P4ftWj8kGMOTMPSTwaaQ">1,163,800</ix:nonFraction> shares of common stock to the Company&#8217;s employees which will be awarded based upon each employee&#8217;s 2022 individual performance evaluation. Once awarded, these options will vest one quarter on February 15, 2023, one quarter on February 15, 2024, one quarter on February 15, 2025 and one quarter on February 15, 2026. The grant date fair value of these unvested options amounted to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_ctso_EmployeeOneMember_apbG-USk6kiuOe_Y22t91A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_NTVqZSdV8EmOMtr1TfMc6Q">1,381,000</ix:nonFraction>. The Company has recorded approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_9TJLsXlp6keoHyL-cuizXQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockOptionPlanExpense" scale="0" id="Narr_4jvM4KlC9UO-xZWYvQdOdQ">180,440</ix:nonFraction> in stock option expense related to these options for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 10, 2022, the Board of Directors granted options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_8_10_2022_To_8_10_2022_srt_TitleOfIndividualAxis_ctso_EmployeeTwoMember_n4em8eT-K0OI3zntmzwTHQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_bqXYujP94EKlEBXx9leLeQ">772,905</ix:nonFraction> shares of common stock to the Company&#8217;s employees. These options will vest one eighth on the six-month anniversary of the grant date, one eighth on the first anniversary of the grant date, one quarter on second anniversary of the grant date, one quarter on third anniversary of the grant date and one quarter on fourth anniversary of the grant date. The grant date fair value of these unvested options amounted to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_ctso_EmployeeTwoMember_hcg34RZmk0K7-aUhwgreaA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Narr_aEnHFmsRIUibjP3JZw-9KQ">917,000</ix:nonFraction>. The Company has recorded approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_ctso_EmployeeTwoMember_5EVkiMRvd0id4GEDS-DjOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_9aVv9P3E_0qU4tKRLUfZgw">89,662</ix:nonFraction> in stock option expense related to these options for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 10, 2022, the Board of Directors granted options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_8_10_2022_To_8_10_2022_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_kivuCiqiL0uHjYHAlIe0SA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_Ddmj23BzHkqIANNlu_weXA">113,850</ix:nonFraction> shares of common stock to members of the Company&#8217;s Board of Directors. These options will vest one quarter on the grant date, one quarter on September 30, 2022, one quarter on December 31, 2022, and one quarter on March 31, 2023. The grant date fair value of these unvested options amounted to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_LDp3_ulEB0afY5sDrxWyfA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Narr_5SzeXXZBs0eVW2lE-WmjvQ">135,000</ix:nonFraction>. The Company has recorded approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xyJVnNq5GE65HtHRW1yDeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockOptionPlanExpense" scale="0" id="Narr_Hpm-U7TvEUqoxFT4hkGpRA">101,336</ix:nonFraction> in stock option expense related to these options for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 10, 2022, the Board of Directors granted options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_8_10_2022_To_8_10_2022_srt_TitleOfIndividualAxis_ctso_SeniorManagerOneMember_aJeyvmrvQEamT-sApwGPVA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_2Ng6vphVg020gUReyErZ1Q">473,750</ix:nonFraction> shares of common stock to certain senior managers of the Company. These options will vest one quarter on the grant date, one quarter on the first anniversary of the grant date, one quarter on second anniversary of the grant date, one quarter on third anniversary of the grant date. The grant date fair value of these unvested options amounted to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_ctso_SeniorManagerOneMember_cYnbKOhq3E6GCga5UwXuXA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Narr_aDi9bMvH3ku8YSdLMugCFg">562,000</ix:nonFraction>. The Company has recorded approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_ctso_SeniorManagerOneMember_EkCzFw0rWU-KctkMbIExAQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockOptionPlanExpense" scale="0" id="Narr_OV_L3vqnik6YPGcWzXc3EQ">160,944</ix:nonFraction> in stock option expense related to these options for the year ended December 31, 2022.</p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-27</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_lO0C7Wy1AkOUMN9NnLBpAA_1_2"></a><a id="Tc_MnvvWW7XBkWfUbEByBHxpQ_1_4"></a><a id="Tc_TtemlJOUmkCsnx9-rsE4Gg_1_6"></a><a id="Tc_pQ1cHo6VBkeseCvRAl-rOQ_2_2"></a><a id="Tc_z5i34ekmhEyQGaSttKv-Bw_2_4"></a><a id="Tc_i5JUu0cGI0eJrl8QfGVtKQ_2_6"></a><a id="Tc_4JSW_MXZNkqYDVQ3R0AFSg_2_8"></a><a id="Tc_u1EjdsKzqki4RM2Fme8CTA_2_10"></a><a id="Tc_vm3d7FL5Tk6dqH_UibhYWA_3_0"></a><a id="Tc_kOVU5NFtikuSgJ6h2jgMeQ_3_10"></a><a id="Tc_l9-9gIAC4UKk70JOodSkwg_4_0"></a><a id="Tc_MlmoSSPvuECp4Jro6G-l7g_5_0"></a><a id="Tc_4OdBoLgk2kSzpjv51Dmk8g_6_0"></a><a id="Tc_gL8aG4X2Ukia1Kmm26NDeQ_6_10"></a><a id="Tc_pH2l00DJekioSND32LI1dg_7_0"></a><a id="Tc_1o3UWBCNFEmzlobSnenzOA_8_0"></a><a id="Tc_ZzxJ6orFRUejmz8qm_kotw_9_0"></a><a id="Tc_Zf3P2sFMMkWgLXLLAe2adQ_9_10"></a><a id="Tc_6JQVkhGNyEmyaHlFRwvUTw_10_0"></a><a id="Tc_bJvjvTGBIUyU-pEJbu1kVA_11_0"></a><a id="Tc_tF1AQkUnQ0ylDD5noRA5Gg_12_0"></a><a id="Tc_iQYf-n3yj02UOzXxL1hmcA_12_10"></a><ix:continuation id="Tb_i3s19FObfU2CICZnXwPPnQ_cont3" continuedAt="Tb_i3s19FObfU2CICZnXwPPnQ_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 10, 2022, the Board of Directors granted options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_8_10_2022_To_8_10_2022_srt_TitleOfIndividualAxis_ctso_SeniorManagerTwoMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1_iS7zVj_kqq7qBilIFwhQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_ImFoww6u-Ui4Kcx6Z2JmUQ">1,365,000</ix:nonFraction> shares of common stock to certain senior managers of the Company which will only vest upon the achievement of certain specific, predetermined milestones related to the Company&#8217;s long-term performance goals. The grant date fair value of these unvested options amounted to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_ctso_SeniorManagerTwoMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QTMNRUs4tkaHSWZeL2Z8fQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Narr_w5gr4xKNrE-9fx_DwXSSNQ">1,620,000</ix:nonFraction>. As of December 31, 2022, none of these milestones has been met. Accordingly, no charge for these options has been recorded in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 12, 2021, the Board of Directors granted options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_4_12_2021_To_4_12_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_s_j74aK2uUqG5xOlSbxT3A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_FmiBr5Oe7kmT9NprRa-8zg">1,323,400</ix:nonFraction> shares of common stock to the Company&#8217;s employees which will vest upon the achievement of certain specific, predetermined milestones related to the Company&#8217;s 2021 operations. Once awarded, these options will vest in four equal tranches, the first tranche vesting on the date of the award. The grant date fair value of these unvested options amounted to approximately $<ix:nonFraction unitRef="Unit_Standard_USN_5UGkHjTMLU6EeMbjOjtcEQ" contextRef="Duration_4_12_2021_To_4_12_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_s_j74aK2uUqG5xOlSbxT3A" decimals="0" format="ixt:numdotdecimal" name="ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue" scale="0" id="Narr_JEbTfO51IUaEt3lKFSLshw">7,042,000</ix:nonFraction>. On March 1, 2022, Board of Directors determined that the Company met approximately <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_4_1_2022_To_4_1_2022_AQ3DZUBay0mJk2oEUwh-kQ" decimals="2" format="ixt:numdotdecimal" name="ctso:ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage" scale="-2" id="Narr_bL5GLBmlT0uoFXT7CY_56A">19</ix:nonFraction>% of these milestones, and accordingly, the Company has recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_f4vXsZkMOkGxq_tl33elVw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockOptionPlanExpense" scale="0" id="Narr_zkIYhXC13kOH9m9wWNzOww">314,000</ix:nonFraction>, and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_aC79nG-enkiG4Z0Gnm5v8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockOptionPlanExpense" scale="0" id="Narr_3jJt9KvnSEmHIOBg-We_AA">273,000</ix:nonFraction> in stock option expense related to these options for the years ended December 31, 2022, and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 28, 2020, the Board of Directors granted options to purchase <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_2_28_2020_To_2_28_2020_mNnHVlwuKUOZDnoPp6ppuw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_viowhh1Ul0KLZ0EIHZAFYw">1,114,325</ix:nonFraction> shares of common stock to the Company&#8217;s employees which will vest upon the achievement of certain specific, predetermined milestones related to the Company&#8217;s 2020 operations. The grant date fair value of these unvested options amounted to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Narr_NbTIuXg_R06Rj49jCnzhJg">3,883,000</ix:nonFraction>. On April 12, 2021, Board of Directors determined that the Company met approximately <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_4_12_2021_To_4_12_2021_4mWKwyxxWEKyj2QfIoh1PQ" decimals="2" format="ixt:numdotdecimal" name="ctso:ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage" scale="-2" id="Narr_yAst-yJpvkORENEq9JgFzw">88</ix:nonFraction>% of these milestones, and accordingly, the Company has recorded $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_W4GwiG3lh02utgH-gE4rTQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockOptionPlanExpense" scale="0" id="Narr_qcIV3AkH2UivBhUVhWqj8A">951,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockOptionPlanExpense" scale="0" id="Narr_jqhdTj4Av0ic77PpkaLLaw">1,070,000</ix:nonFraction> in stock option expense related to these options for the years ended December 31, 2022, and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Change in Control-Based Awards of Restricted Stock Units:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Board of Directors has granted restricted stock units to members of the Board of Directors, to the Company&#8217;s executive officers, and to employees of the Company. These restricted stock units will only vest upon a Change in Control of the Company, as defined in the Company&#8217;s 2014 Long-Term Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table is a summary of these restricted stock units:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="Tb_eJksAPBX10yQwHqCHlZ4Hw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Board&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Executive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Directors</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Management</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Employees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2019_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_FP86LptQuUeU7YsuzIQCcg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_ppkb9qSbHkSZHq37sJobnw_3_2">277,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2019_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_K10SpTMdF0G5KR4K3WxOyw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_qg91RfFjdEOzL50GsGnjuQ_3_4">604,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2019_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_yN5CzvOjU0uH_kVOetojHQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc___g75RYMaUy7ZJPfxyClTQ_3_6">1,205,050</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_tP00N7KMo06ixWdu6bREiw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_kCbNqcxqikCVgTa5vnx7VA_3_8">2,086,750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2019_6_oqjbutzEKQogf2y7UC6g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="0" id="Tc_61vhonNz10u3Sybv14beHA_3_11">8,033,988</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Qq1T1vf_pkWNzHvrbos3EA" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" id="Tc_WQVwTpSQckCGF6Z7VzLjKA_4_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_tCzPxpUUDkurigM_UymlEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" id="Tc_6Mad08U1vUKPKbFGttAJpg_4_4">120,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_HkkTwSE4WEOHm13LfqHxoQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" id="Tc_rdk5mSwUK0-zhQoeNFTJRw_4_6">265,700</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lKSpWReKk0eWMdrErwptxw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" id="Tc_3J9PobnJ20WRxxXjNdZZyQ_4_8">385,700</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Qq1T1vf_pkWNzHvrbos3EA" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" scale="0" id="Tc_k8bvHfxL9Um47O9txXPqRA_5_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_tCzPxpUUDkurigM_UymlEA" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" scale="0" id="Tc_yw1QHG7IPUO7tYBM78zeWg_5_4">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_HkkTwSE4WEOHm13LfqHxoQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" scale="0" id="Tc_eH9p7WD-Kkigx2RfDXS-zg_5_6">25,250</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lKSpWReKk0eWMdrErwptxw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" scale="0" id="Tc_adrQE02mkESqsByqZuPuiQ_5_8">25,250</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_CN57L8kRSkSlPVn_ICCXgQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_H8nJS25n-E2Y-RdfOcCh3Q_6_2">277,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2020_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Jxgd6wgc-UifuA3mjZhm-Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_fijQ0nb5rEeGc_f1v4C4vg_6_4">724,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2020_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_psdWAFNFkke9A5usGouslg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_8qBQTmJBtk6Mm1x2fE6DGw_6_6">1,445,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YALsQfAeSkWG8axpq3Cw1w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_ltv8URcdz0-jrfimoKA2EA_6_8">2,447,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="0" id="Tc_v18vHeeE0Uu3KfCYYnbrUA_6_11">19,504,184</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_-zjLmD1sFUWIlQznMjsRvQ" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" id="Tc_nNMclg42XUyhnEAvLdj4Bw_7_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q_I0IFjrfEKL74vm4tWeYQ" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" id="Tc_1mZEvWPBo0idc9-BjMOAmQ_7_4">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_vk8cRgr4tEGiUUmMORIpUg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" id="Tc_sA4NA-NmcEiNxWo0erm3TQ_7_6">396,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_L5xd_BU2AUihTjDpJG0EAQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" id="Tc_QpyKM3w1p0e3v9NPv594rA_7_8">396,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_-zjLmD1sFUWIlQznMjsRvQ" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" scale="0" id="Tc_yNUyjq-sEUSHgiM5jUj_4Q_8_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q_I0IFjrfEKL74vm4tWeYQ" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" scale="0" id="Tc_mwgbcWd1p0SAT_qeFS_4Pw_8_4">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_vk8cRgr4tEGiUUmMORIpUg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" scale="0" id="Tc_0tFoZTLbJ0e0zPVRYTd9Sg_8_6">132,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_L5xd_BU2AUihTjDpJG0EAQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" scale="0" id="Tc_xsPeVErD6EG2EH43KYIUww_8_8">132,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_trOIsNzUZk6mTrRFdkZXPw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_8IQBdAr2-kqtqQOg0gnx1Q_9_2">277,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JpCj6cd7kkiLmP4iVXwtlw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_YjmFGW1MoUG2n5LTVLIWhw_9_4">724,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_04OJEbPdOkKtPazUq59qpA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_CJ2N9S-R2kqNI9wJ7k4xsg_9_6">1,709,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_9vRyYMxhI0WaNHqaWqGMHQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_ZsmnwwNzYkiXEci63wNZzQ_9_8">2,711,200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="0" id="Tc_IMlX5JvR0EWQS_zf6UTYCA_9_11">11,359,928</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_DdpipDIQPE6CFjGjSAk4pw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" id="Tc_KarVyfaA2U-AgYmNBdxQYQ_10_2">69,300</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Jq6o95e4y0O88aEPmR333A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" id="Tc_LH8bmLXs2UWCKJbtS7wWVg_10_4">55,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_6fnzkcGGB0ChZUoAaGWn2g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" id="Tc_MhLRgOY1nUqpmSQawcG3Fg_10_6">373,750</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" id="Tc_yTEqBHpbvUCtY3e3r2byHQ_10_8">498,050</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_DdpipDIQPE6CFjGjSAk4pw" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" scale="0" id="Tc_w7DEwbBB9EWkFmpkUgZYeg_11_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Jq6o95e4y0O88aEPmR333A" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" scale="0" id="Tc_e6ue7c_cNUyvJHH2pa3ykw_11_4">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_6fnzkcGGB0ChZUoAaGWn2g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" scale="0" id="Tc_Cdmt9yeT_kG5dhGR0E-JTA_11_6">318,750</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" scale="0" id="Tc_OaoP3x1btk-xHW2ntNTJkg_11_8">318,750</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2spOJmTsWEmdS8OMyOGHWQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_8tyKrKDmakaJD9h2ljN5Ug_12_2">346,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_-5TVQVqcmkOUL9z5tTJN-w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_JRpX6rX2PUuS-ZvMJL8Cng_12_4">779,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Nt-mKk9tE0qaMLa__XLlLA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_Z2uXC3RFNE-y7K0rjsMxnA_12_6">1,764,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_S71qz6TZI0CfuhmZ6yul1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" scale="0" id="Tc_yIDP-fzbokGRt12yRirZ6w_12_8">2,890,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="0" id="Tc_kSm4KPWmiUyuK78KdMuIRw_12_11">4,480,275</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Due to the uncertainty over whether these restricted stock units will vest, which will only happen upon a Change in Control, no charge for these restricted stock units has been recorded in the consolidated statement of operations and comprehensive loss through the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Performance-Based Awards of Restricted Stock Units:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to a review of the compensation of the senior management of the Company and management&#8217;s performance in 2020, on February 28, 2020, the Board of Directors granted <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_5NQR2_FtYk-1wNb9Sb1pdw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Narr_i5z-6C6ltU2er2R6SHcM1A">168,100</ix:nonFraction> restricted stock units to certain senior managers of the Company. These awards were valued at approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_5NQR2_FtYk-1wNb9Sb1pdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" id="Narr_MYUJepsgHkW_h8I2W-d9fA">1,014,000</ix:nonFraction> at the date of issuance, based upon the market price of the Company&#8217;s common stock at the date of the grant, and vest <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_7_22_2019_To_7_22_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_July222019PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_i5Y6ctTfQkOWKcDW4oDCbw" decimals="3" format="ixt-sec:numwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_qlyDZa-s5EiivOjojhstIA">one</ix:nonFraction> third on the date of the grant, <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_MBhOBM-5iEqeLJwUm4lpZw" decimals="3" format="ixt-sec:numwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_UZqc60UQN0CqMdDI0yE7CA">one</ix:nonFraction> third on the first anniversary of the date of the grant, and <span style="-sec-ix-hidden:Hidden_bnG0W-eC-kmqWIE1UDcudQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> third on the second anniversary of the date of the grant. For the years ended December 31, 2022 and 2021, the Company recorded (income) expense of approximately $(<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_nkcE0lA3-kOw0oD7CH9c4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" sign="-" scale="0" id="Narr_oLDxjCXSa0KZXSh6hCJPiA">65,000</ix:nonFraction>) and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_psiceOjXQ0i-ao__lRK5JQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" id="Narr_mwi3qo0DmUegIhVwhlp4cA">528,000</ix:nonFraction>, respectively, related to these restricted stock unit awards.</p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_sJ3_xRfaVkSkQCkg8yvUgA_1_4"></a><a id="Tc_QewY7CKuU0aYougz5CNwjQ_2_4"></a><a id="Tc_HbfCK0iTS0K-JWs6r8YqRQ_3_4"></a><a id="Tc_AgbOiwYNnUapXtdd8eBbGQ_4_2"></a><a id="Tc_K9SVhpp-Ck2ohyK_UcjnsA_4_4"></a><a id="Tc_Y5XOB0-wh0aFn8JpnAlJjQ_5_0"></a><a id="Tc_HkbK74yGAkODeLG9B7y8lQ_5_4"></a><a id="Tc_0QVVkKH9hky02dtbGRLksw_6_0"></a><a id="Tc_c_ItCMQ6iEW2p0IzwcoCoQ_6_4"></a><a id="Tc_4FSX-3_T6EK-nDaCIy66gg_7_0"></a><a id="Tc_7BeQ2WS0wEi9qE_9FUD3eQ_7_4"></a><a id="Tc_6mdfV3sahUi66ETUn9la5Q_8_0"></a><a id="Tc_4RBu3b-hIESqSo5Egz-OrQ_8_4"></a><a id="Tc_DOOBNNb7S027xFLQEziiZA_9_0"></a><a id="Tc_VJRomfv2pkCHbj1D4hj1Kg_9_4"></a><ix:continuation id="Tb_i3s19FObfU2CICZnXwPPnQ_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to a review of the compensation of the senior management of the Company and management&#8217;s performance in 2021, on April 12, 2021, the Board of Directors granted <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_4_12_2021_To_4_12_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_SBFV77lhyUaB_1ayr35kYw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Narr_8v7Qg5TvPUuzcFoTRvNH5A">235,765</ix:nonFraction> restricted stock units to certain senior managers of the Company. These awards were valued at approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_4_12_2021_To_4_12_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_SBFV77lhyUaB_1ayr35kYw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" id="Narr_ptfe6ZOszUifZ-ZDz5ZhTA">2,120,000</ix:nonFraction> at the date of issuance, based upon the market price of the Company&#8217;s common stock at the date of the grant, and vest <span style="-sec-ix-hidden:Hidden_yBkqj_djEEmSnjqOn-lNAA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> third on the date of the grant, <span style="-sec-ix-hidden:Hidden_NhvWl8VkYEiywUdQUWqfYg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> third on the first anniversary of the date of the grant, and <span style="-sec-ix-hidden:Hidden_riKmZAfAA0-fmSAyyqKphA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> third on the second anniversary of the date of the grant. For the years ended December 31, 2022 and 2021, the Company recorded a charge of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_SehbEFp_LU-TNiW5F5VEKA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" id="Narr_DelK9S9ptU2ma29OOPqZ1A">226,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_XLL9youqcUedryG1mnniUQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" id="Narr_sIF_DZvT7Eif0nXyV89Vdg">1,207,000</ix:nonFraction>, respectively, related to these restricted stock unit awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 10, 2022, certain named executive officers and senior managers were granted <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_8_10_2022_To_8_10_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_iCD0wE1zAkmoNYobFgX5Pg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Narr_L9SR20aR-0SKGKGKGEUTuQ">288,500</ix:nonFraction> restricted stock units. These awards were valued at approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_8_10_2022_To_8_10_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_iCD0wE1zAkmoNYobFgX5Pg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" id="Narr_aAbGPXZKF0m9td3tIcEzLQ">563,000</ix:nonFraction> at the date of issuance, based upon the market price of the Company&#8217;s common stock at the date of the grant, and vested (or will vest) <span style="-sec-ix-hidden:Hidden_IU4zNU0S4UKy1kEa3REKsg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> third on the date of the grant, <span style="-sec-ix-hidden:Hidden_CzwcUS2bLUKcKWPHYGPuIw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> third on the first anniversary of the date of the grant, and <span style="-sec-ix-hidden:Hidden_Qn9ZRP_XUUuujsh4uxHgPw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> third on the second anniversary of the date of the grant. For the year ended December 31, 2022 and 2021, the Company recorded expense of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_1LwXDf6m7E-dzAi4ZxI8Aw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" id="Narr_LYF-Dh1ylUm2INQY4Sm_1A">260,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_HkC9ceLZZUStae-rY3krow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" id="Narr_Q4Z77RjevUe0X7iSb9IHDg">0</ix:nonFraction>, respectively, related to these restricted stock unit awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, in 2021 and 2020 certain employees were offered <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Narr_NMNF59K6dU6qJF3dXeQ9sw">91,750</ix:nonFraction> restricted stock units as a condition of their employment. These awards were valued at approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" id="Narr_CJ6DJs34Y0eTyTrgO1KBCA">713,868</ix:nonFraction> at the date of issuance. <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_ctso_SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Nw7O66qjS0-HrTuFoxU-Ig" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Narr_MhoR-PNe8UyLXujjt1X1Yg">46,750</ix:nonFraction> of these restricted stock units vest upon the earlier of a Change in Control or <span style="-sec-ix-hidden:Hidden_9VkzXAfHnkmSs1ntMN_DvA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> third after the second anniversary of the award, <span style="-sec-ix-hidden:Hidden_FavK8EuO0EiMvQzxKsEdyg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> third on the third anniversary of the award, and <span style="-sec-ix-hidden:Hidden_XAf3tkw7FEWYcbQI9IZMZw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> third on the fourth anniversary of the award. The other <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_ctso_SecondFortyFiveThousandRestrictedAwardMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OfWgsCZPdEyRfpWz5t_BNg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="Narr_VP3s4fR5QkeN9jO3WI-zmg">45,000</ix:nonFraction> of these restricted stock units vest upon the earlier of a Change in Control or <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_txTVvBn5BUGuQ5cAlm4PIQ">four years</ix:nonNumeric> from the date of the award. For the years ended December 31, 2022 and 2021, the Company recorded (income) expense of approximately $(<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" sign="-" scale="0" id="Narr_lGYQkfcEFEKsAS0ir99IeQ">16,000</ix:nonFraction>) and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_L5xd_BU2AUihTjDpJG0EAQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="0" id="Narr_0XiHZtYEPUy6sUP9dI7C5g">178,000</ix:nonFraction>, respectively, related to these restricted stock unit awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table outlines the restricted stock unit activity for the&#160;year ended December 31, 2022:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="Tb_ryx3rH_R6EqK8ASJ7JUcdA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant&#160;Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-vested, January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_9vRyYMxhI0WaNHqaWqGMHQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_qTUeNuRXa02tNRZ8UPlLJQ_5_2">304,962</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_9vRyYMxhI0WaNHqaWqGMHQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_QA9WmXyuIkasUVT_hNMB8Q_5_5">8.08</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_ssugteKWbU-_Rw-wdlX6vg_6_2">288,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_sHykc8HT-kGf1SBlpErpTw_6_5">1.95</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_Wc3P90z1iE-DT6zZhavHcw_7_2">45,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_Me33uXnVfkiczLqxQNi-hQ_7_5">8.35</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_6Z3q-gTo7Eej70ac4BbwlQ_8_2">236,370</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_iDsd9xNMYUit3KNgewvSWg_8_5">5.38</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-vested, December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_S71qz6TZI0CfuhmZ6yul1Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_Oh185wF8UUOjELIb6dPW_A_9_2">312,092</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_S71qz6TZI0CfuhmZ6yul1Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_AGKhyUk04kem-Gvv6GoqRg_9_5">4.42</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Warrants:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2022, the Company had <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_BAQEQ2xbeEKBqBKZKbLO8A">no</ix:nonFraction> warrants outstanding.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:EarningsPerShareTextBlock" id="Tb_tCDBE_Ao_UW7yiG-ioOeSg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. NET LOSS PER SHARE:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Basic net loss per share and diluted net loss per share for the&#160;years ended December 31, 2022, 2021 and 2020 have been computed by dividing the net loss attributable to common shareholders for each respective period by the weighted average number of shares outstanding during that period. All outstanding warrants and options and restricted stock awards representing approximately <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ctso_StockOptionsAndWarrantsMember_yk7BYg1b80i8SXV12unwZQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_gOvRSlWRF0imv_jWbSk2Uw">11,312,000</ix:nonFraction>, <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ctso_StockOptionsAndWarrantsMember_N7MNifr70EazP8jJCCRNdQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_PjvRb_uW-k2VShaAnLOTeQ">9,902,000</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ctso_StockOptionsAndWarrantsMember_yWq0uJF810qiMA_nrGtcuw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_zdqvdR80Cke8S5YRFjBdMw">7,786,000</ix:nonFraction> incremental shares at December 31, 2022, 2021 and 2020, respectively, have been excluded from the computation of diluted net loss per share as they are anti-dilutive.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="Tb_iKX_Ex5Z0UqGeZuXcwxffg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. RETIREMENT PLAN:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June&#160;2014, the Company formed the CytoSorbents 401(k)&#160;Plan. The plan is a defined contribution plan as described in section 401(k)&#160;of the Internal Revenue Code (&#8220;IRC&#8221;) covering substantially all full-time employees. Employees are eligible to participate in the plan on the first day of the calendar quarter following <span style="-sec-ix-hidden:Hidden_wRQ8gwA2pEGU2CW7c2BqBw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> full&#160;months of employment. Participants may defer up to <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_6_1_2014_To_6_30_2014_xxa151rza0iR7WYHq7r7TA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="Narr_u91Z9YSjaESP4XNDeU4qIw">100</ix:nonFraction>% of their eligible compensation subject to certain IRC limitations.Prior to 2021, the Company provided for a matching contribution of <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_99EL90jnCU2OoWyaSsqmAg">twenty</ix:nonFraction>&#160;percent of the participants&#8217; contribution on a maximum of <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_OG4uNBwIQE-0VrL7LstdKw">five</ix:nonFraction>&#160;percent of compensation. Effective January 1, 2021, the Company changed its matching contribution to <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2021_To_1_1_2021_srt_StatementScenarioAxis_ctso_ParticipantsContributionUpto3PercentMember_MgDr1mCwaUS6-T40vC8X3A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_Bkz3UXP_qkShobRYpyL-uQ">100</ix:nonFraction>% of the participants contribution up to <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2021_To_1_1_2021_srt_StatementScenarioAxis_ctso_ParticipantsContributionUpto3PercentMember_MgDr1mCwaUS6-T40vC8X3A" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_UyAK16neQkmZdrcohVrpuw">three</ix:nonFraction> percent of compensation plus <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2021_To_1_1_2021_srt_StatementScenarioAxis_ctso_ParticipantsContributionOver3AndMaximum5Member_VI70pNF1dE6bwaLkkkQQzw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_LjaZ2wgtHES7c4Bb9gNtcQ">50</ix:nonFraction>% of the participants contribution over <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2021_To_1_1_2021_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_ctso_ParticipantsContributionOver3AndMaximum5Member_MBEUr3qmWkaFIgPeH_HMOQ" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_XOTfAS1yJkKSpjfpxIOnVg">three</ix:nonFraction> percent of compensation up to a maximum of <ix:nonFraction unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ" contextRef="Duration_1_1_2021_To_1_1_2021_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_ctso_ParticipantsContributionOver3AndMaximum5Member_QRs03j8L6kalwqqJ7bMG6A" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_gj3f0X-s_EmCqKEOS10WdQ">five</ix:nonFraction> percent of compensation. Matching contributions amounted to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" id="Narr_jAPvK6vvIkinkiz1tjbBPw">442,000</ix:nonFraction>, $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" id="Narr_ThDYV4qthki2x4ExlJcsOg">355,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" id="Narr_uI5o-nSyNEmS4caw0WozJw">59,200</ix:nonFraction> for the&#160;years ended December 31, 2022, 2021 and 2020, respectively.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-29</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_-qfR9V5yPU6piaHRx1GG8Q_1_2"></a><a id="Tc_Fj-teisTiE--oTFuct8-gw_2_2"></a><a id="Tc_OXL-kjJNuUebvBwjhxlSxg_2_5"></a><a id="Tc_ZzHAKqXHK0qAOmlLo30NLQ_2_8"></a><a id="Tc_hT763EhIXUCctL0OIg316w_2_11"></a><a id="Tc_ETTCDAww2keijpTx2I7cVg_3_0"></a><a id="Tc_OuUYQEFljUyoICehA2g6qQ_4_0"></a><a id="Tc_i-X3hpByqU6Xig7VtSzF9w_4_2"></a><a id="Tc_EQDPCQDYo0uZ0JkWg3Ui9Q_5_0"></a><a id="Tc_og1R-4FBdUS-40apHf2bMg_6_0"></a><a id="Tc_z3inqUjHwEOHRv3l2F6Xbg_7_0"></a><a id="Tc_4P_2XlAPDkaG8JT5s5FN8A_8_0"></a><a id="Tc_xo9lmeweXk6NFYG20NCTqA_10_0"></a><a id="Tc_Reme9rqLIUyNmPBXF3rGRw_11_0"></a><a id="Tc_NOJiT-zma0WHCVDemnZXBQ_11_2"></a><a id="Tc_CXe7OiiidUyooEmMgYVBww_11_5"></a><a id="Tc_YJRv03j2DUm9eBif6tlQZw_11_8"></a><a id="Tc_z76Z55e5eU2aMH6PQeRgyw_11_11"></a><a id="Tc_29ihKxz8_ku3jABhza_gtg_12_0"></a><a id="Tc_7WleMzADzkOg8MtkKTSWmg_13_0"></a><a id="Tc_FAcieA0QB0WK7Gd2aYw5SA_14_0"></a><a id="Tc_HW5uZfoaJEiIx_luaZllDw_15_0"></a><a id="Tc_q4dSWgoel06u4IBUrFF_lA_17_0"></a><a id="Tc_5hRiGXBoNESb866XGgcBaw_18_0"></a><a id="Tc_fER1tkwOWEeWXGpekzOWBA_18_2"></a><a id="Tc_drrkIXS510G2z1yJdz1q1A_18_5"></a><a id="Tc_TrZ_MDpbtUWV1i_k2G_8Vg_18_8"></a><a id="Tc_P9v2SFSskES_8hMcGBx0Kw_18_11"></a><a id="Tc_T6_CGwmJV0-hk_gwxEds2Q_19_0"></a><a id="Tc_XeC4RMb_6E2R5gLCdFkvPQ_20_0"></a><a id="Tc_1psgi5_jg0qeeJ2MtsDOzg_21_0"></a><a id="Tc_DoB7E5Yb9kinZylAsMMx5g_22_0"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="Tb_UsnhTTAh5E-Xxdwqh0Vgiw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. QUARTERLY FINANCIAL RESULTS (UNAUDITED):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Summarized quarterly data for 2022, 2021 and 2020 are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg" name="srt:ScheduleOfCondensedIncomeStatementTableTextBlock" id="Tb_XSstP3ERq0OhWU3AG1UlaA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Quarters Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_3_31_2022__Bto-66MgUq_eQRwKUyq1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_nlaFSU9Y30yoJ_cdbr-XGg_4_3">8,691,424</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_4_1_2022_To_6_30_2022_mLayX3PX1Eqci3SfMDv1YQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_IooBqZ8320CPopGiaX2gmA_4_6">8,495,558</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_7_1_2022_To_9_30_2022_2eoa-jebUE-H6uey7YKWmQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_Bfrm9jViZUKY2hq5LDBQRA_4_9">8,111,353</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_10_1_2022_To_12_31_2022_7D4gmEOvZEuddtCJGzA8ow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_Ad_hkewSkUC0-sJZLxiLGA_4_12">9,390,474</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross margin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_3_31_2022__Bto-66MgUq_eQRwKUyq1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="0" id="Tc_4wrXQQgcRk67LFnoXF6Pcw_5_3">6,413,788</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_4_1_2022_To_6_30_2022_mLayX3PX1Eqci3SfMDv1YQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="0" id="Tc_RAmmQTcU2Uu8o9SqxSwOdw_5_6">4,944,856</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_7_1_2022_To_9_30_2022_2eoa-jebUE-H6uey7YKWmQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="0" id="Tc_q1Kj2JoN9Ey5kJXuchtVwA_5_9">3,617,377</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_10_1_2022_To_12_31_2022_7D4gmEOvZEuddtCJGzA8ow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="0" id="Tc_gZlcd2Vt-EaNxCsOgYntUg_5_12">5,757,036</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_3_31_2022__Bto-66MgUq_eQRwKUyq1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_7VdAiTmOsES1E9-9PN0Oaw_6_3">7,791,135</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_4_1_2022_To_6_30_2022_mLayX3PX1Eqci3SfMDv1YQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_REUj6gexkE-izv9wDNixrw_6_6">8,357,050</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_7_1_2022_To_9_30_2022_2eoa-jebUE-H6uey7YKWmQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_9d252wYa1U-MI3XMsmKi-Q_6_9">9,017,338</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_10_1_2022_To_12_31_2022_7D4gmEOvZEuddtCJGzA8ow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_lljaFIJ_kkCVfGv7RZTESg_6_12">6,356,356</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2022_To_3_31_2022__Bto-66MgUq_eQRwKUyq1Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_NlzgMqxA1Uu8sNHWRcRMHg_7_3">8,966,398</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_4_1_2022_To_6_30_2022_mLayX3PX1Eqci3SfMDv1YQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_plqwy7uBakupMvQH-De1HA_7_6">10,879,222</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_7_1_2022_To_9_30_2022_2eoa-jebUE-H6uey7YKWmQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_n5wjHkYCaEmPrP20skzIMQ_7_9">12,200,837</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_10_1_2022_To_12_31_2022_7D4gmEOvZEuddtCJGzA8ow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_EG64onNYaUOEWH7UXqqMvw_7_12">766,128</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2022_To_3_31_2022__Bto-66MgUq_eQRwKUyq1Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_yUPuc7sH5EaMjPZxad753g_8_3">0.21</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_4_1_2022_To_6_30_2022_mLayX3PX1Eqci3SfMDv1YQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_FbCHyxdwzUKlPJ7ZyulN5Q_8_6">0.25</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_7_1_2022_To_9_30_2022_2eoa-jebUE-H6uey7YKWmQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_bQQ_z6R_sEWFK1fpF3R0sQ_8_9">0.28</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_10_1_2022_To_12_31_2022_7D4gmEOvZEuddtCJGzA8ow" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_JzD4riRv60G6uuoYBZVxDA_8_12">0.02</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total &#160;revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_3_31_2021_zXigQoQBgUGOxC_vaZv8ag" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_nfXDWazie0KzfAxr4TJVgA_11_3">10,598,847</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_4_1_2021_To_6_30_2021_KUS8bQMU0UaIknV605S_VA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_D-8zoTk2402Cxj2vVOUFCw_11_6">12,024,069</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_7_1_2021_To_9_30_2021_bc1_H1o8GkWXj53DijdBKA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_UlAkFT5zW0GOB56i9Xfczw_11_9">9,760,416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_10_1_2021_To_12_31_2021_PTkhRTY9_0uo1BKc7O3ElQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_udYeItQvG0KATHHBGgRETw_11_12">10,782,195</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross margin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_3_31_2021_zXigQoQBgUGOxC_vaZv8ag" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="0" id="Tc_ksDIqoR7WEuuul4LpPzJLw_12_3">7,847,403</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_4_1_2021_To_6_30_2021_KUS8bQMU0UaIknV605S_VA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="0" id="Tc_mCpssDZoF0Cx1QeMiYoagw_12_6">9,313,852</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_7_1_2021_To_9_30_2021_bc1_H1o8GkWXj53DijdBKA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="0" id="Tc_wrZcea_AN0yPaMygnw6w8w_12_9">7,297,470</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_10_1_2021_To_12_31_2021_PTkhRTY9_0uo1BKc7O3ElQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="0" id="Tc_gbxfYBvXlUCLxmvBCU1oww_12_12">7,659,452</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_3_31_2021_zXigQoQBgUGOxC_vaZv8ag" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_1d6UREn3lkSJ4f4ca_VM1g_13_3">2,852,191</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_4_1_2021_To_6_30_2021_KUS8bQMU0UaIknV605S_VA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_LP2cWajlB0SSD35Tc9b1Cg_13_6">4,924,733</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_7_1_2021_To_9_30_2021_bc1_H1o8GkWXj53DijdBKA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_0xzluJHXXkiYvOnEl9hUhQ_13_9">5,406,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_10_1_2021_To_12_31_2021_PTkhRTY9_0uo1BKc7O3ElQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_i8sC9joyH0C1S2pFLbFgbg_13_12">9,561,821</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2021_To_3_31_2021_zXigQoQBgUGOxC_vaZv8ag" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_iqXcODJQG06N_d7T19E_0A_14_3">4,167,821</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_4_1_2021_To_6_30_2021_KUS8bQMU0UaIknV605S_VA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_aIKMkvdNYkC91OnaMpSwMQ_14_6">4,677,530</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_7_1_2021_To_9_30_2021_bc1_H1o8GkWXj53DijdBKA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_iQmSzA3LOEKJMELvPvsAow_14_9">6,406,285</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_10_1_2021_To_12_31_2021_PTkhRTY9_0uo1BKc7O3ElQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_MIDDNZoJnUShdH0mzo_OpA_14_12">9,307,012</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2021_To_3_31_2021_zXigQoQBgUGOxC_vaZv8ag" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_LiOX7E8BlkmVOZ5dGK1I8Q_15_3">0.10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_4_1_2021_To_6_30_2021_KUS8bQMU0UaIknV605S_VA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_Z1ZyQsVwMUuJksNDA5ukIw_15_6">0.11</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_7_1_2021_To_9_30_2021_bc1_H1o8GkWXj53DijdBKA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_tNkFvMa8Pk21uRRUkhrn1Q_15_9">0.15</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_10_1_2021_To_12_31_2021_PTkhRTY9_0uo1BKc7O3ElQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_iuLpe77Dpkm-L3dB1OEL9Q_15_12">0.25</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2020:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total&#160;&#160;revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_3_31_2020_0j8Adr0DO0CTdQHPhErCZw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_QGWda9i3CEKjQZjlzgWLPA_18_3">8,707,310</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_4_1_2020_To_6_30_2020_pfUWsTXCTUSP48AZxdHHPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc__rWLX9DS6UeVSe8-tS6xPA_18_6">9,794,903</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_7_1_2020_To_9_30_2020_BlNvdmBrgEeKoL8Hm4r3Dw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_a4BGeCu-W0CMPdUwCln88Q_18_9">10,546,612</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_10_1_2020_To_12_31_2020_asiudZouf0qo-UGg2Gf0lw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" id="Tc_QxzaB6BbYkmoBoGtol5ENg_18_12">11,955,776</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross margin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_3_31_2020_0j8Adr0DO0CTdQHPhErCZw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="0" id="Tc_cWlAlkmt10y97kKJFVIa5w_19_3">6,322,468</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_4_1_2020_To_6_30_2020_pfUWsTXCTUSP48AZxdHHPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="0" id="Tc_QoALG-bGgUWSP9nhV4vpjQ_19_6">6,545,136</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_7_1_2020_To_9_30_2020_BlNvdmBrgEeKoL8Hm4r3Dw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="0" id="Tc_5gZtUcRmxk6n8IhWJWCing_19_9">7,656,230</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_10_1_2020_To_12_31_2020_asiudZouf0qo-UGg2Gf0lw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="0" id="Tc_Pj6P79ZwjkekTjO03PD72g_19_12">9,428,358</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_3_31_2020_0j8Adr0DO0CTdQHPhErCZw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_fpMR0nxLzEOfm5PrGrp7_A_20_3">2,478,754</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_4_1_2020_To_6_30_2020_pfUWsTXCTUSP48AZxdHHPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_W3Kc4W8RYUWoSwMeswPmTg_20_6">3,297,667</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_7_1_2020_To_9_30_2020_BlNvdmBrgEeKoL8Hm4r3Dw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_z45aKy53TESvIWxiro6yiw_20_9">1,959,652</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_10_1_2020_To_12_31_2020_asiudZouf0qo-UGg2Gf0lw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_i0PS05oKRkOYtUTCXggHiw_20_12">2,634,264</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_1_1_2020_To_3_31_2020_0j8Adr0DO0CTdQHPhErCZw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_SGbXiTE0p0uYo56MIATuMw_21_3">3,452,779</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_4_1_2020_To_6_30_2020_pfUWsTXCTUSP48AZxdHHPw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_qGngdmmKFUyzibJwnuhZCg_21_6">2,866,956</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_7_1_2020_To_9_30_2020_BlNvdmBrgEeKoL8Hm4r3Dw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_82EAbV8NQ0qcyK28QVlCsQ_21_9">839,729</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q" contextRef="Duration_10_1_2020_To_12_31_2020_asiudZouf0qo-UGg2Gf0lw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_0sCQvqP49Ua3hZNKy6486w_21_12">677,724</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_1_1_2020_To_3_31_2020_0j8Adr0DO0CTdQHPhErCZw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_A9N83F8iGEeYZcvfEpuBGA_22_3">0.10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_4_1_2020_To_6_30_2020_pfUWsTXCTUSP48AZxdHHPw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_wkKb274600if5wJLIe--fQ_22_6">0.08</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_7_1_2020_To_9_30_2020_BlNvdmBrgEeKoL8Hm4r3Dw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_N-nxs5_A4UGKq6hLmskAdQ_22_9">0.02</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA" contextRef="Duration_10_1_2020_To_12_31_2020_asiudZouf0qo-UGg2Gf0lw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc__bSBXkOXk0umuGUvV6ydoA_22_12">0.00</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:8.65pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-30</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>2
<FILENAME>ctso-20221231xex10d11.htm
<DESCRIPTION>EX-10.11
<TEXT>
<html><head></head><body link=blue lang="EN-US"><div><div align="center"><div align="center"><div style="position:absolute; top:17px; right:64px; font-family:'Times New Roman'; font-size:10pt; font-weight:bold;">Exhibit 10.11</div><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="ctso-20221231xex10d11g001.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;"></font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="ctso-20221231xex10d11g002.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;"></font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="ctso-20221231xex10d11g003.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;"></font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="ctso-20221231xex10d11g004.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;"></font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="ctso-20221231xex10d11g005.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;"></font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="ctso-20221231xex10d11g006.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;"></font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:avoid;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>3
<FILENAME>ctso-20221231xex10d30.htm
<DESCRIPTION>EX-10.30
<TEXT>
<html><head></head><body link=blue lang="EN-US"><div><div align="center"><div align="center"><div style="position:absolute; top:17px; right:64px; font-family:'Times New Roman'; font-size:10pt; font-weight:bold;">Exhibit 10.30</div><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="ctso-20221231xex10d30g001.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">BOS 48669274v2
SIXTH AMENDMENT TO THE AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT
THIS SIXTH AMENDMENT to the Amended and Restated Loan and Security Agreement (this
&#x201C;Amendment&#x201D;) is made effective as of March 8, 2023 (the &#x201C;Sixth Amendment Date&#x201D;) and made by and among
WESTERN ALLIANCE BANK, an Arizona corporation (&#x201C;Bank&#x201D;) and CYTOSORBENTS CORPORATION, a
Delaware corporation and CYTOSORBENTS MEDICAL, INC., a Delaware corporation (individually and
collectively, jointly and severally &#x201C;Borrower&#x201D;).
WHEREAS, Bank and Borrower have entered into that certain Amended and Restated Loan and Security
Agreement, dated as of March 29, 2018 (as amended, supplemented, restated or otherwise modified from time to
time, the &#x201C;Loan Agreement&#x201D;) pursuant to which Bank has provided to Borrower certain loans in accordance with
the terms and conditions thereof; and
WHEREAS, Bank and Borrower desire to amend certain provisions of the Loan Agreement as provided
herein and subject to the terms and conditions set forth herein.
NOW, THEREFORE, in consideration of the promises, covenants and agreements contained herein, and
other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, Bank and
Borrower hereby agree as follows:
1. Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them
in the Loan Agreement.
2. Section 1.1 of the Loan Agreement is hereby amended by adding the following definition thereto in
alphabetical order:
&#x201C;Sixth Amendment Date&#x201D; is March 8, 2023.
3. Section 1.1 of the Loan Agreement is hereby amended by amending and restating the following definition
therein as follows:
&#x201C;Third Draw Period&#x201D; means the period commencing on the Fourth Amendment Date and ending on the
earlier of (i) March 24, 2023 and (ii) the occurrence of an Event of Default; provided further that no Term
C Loan as would cause the aggregate principal amount of Term C Loans to exceed Five Million Dollars
($5,000,000.00) shall be made during the Third Draw Period unless on the Funding Date of such Term C
Loan, the Required Reserves Test is met and on or before the Funding Date of such Term C Loan (but no
earlier than ten (10) days prior to the Funding Date), the Seventy Five Percent Test is met.
4. Limitation of Amendment.
a. The amendments set forth above are effective for the purposes set forth herein and shall be limited
precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or
modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any
right, remedy or obligation which the Bank or Borrower may now have or may have in the future
under or in connection with any Loan Document, as amended hereby.
b. This Amendment shall be construed in connection with and as part of the Loan Documents and all
terms, conditions, representations, warranties, covenants and agreements set forth in the Loan
Documents, except as herein amended, are hereby ratified and confirmed and shall remain in full
force and effect.
5. To induce the Bank to enter into this Amendment, Borrower hereby represents and warrants to the Bank as
follows:
DocuSign Envelope ID: 322987CA-FFCE-4C0A-A445-762265F5C225</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="ctso-20221231xex10d30g002.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">2
BOS 48669274v2
a. Immediately after giving effect to this Amendment (a) the representations and warranties
contained in the Loan Documents are true, accurate and complete in all material respects as of the
date hereof (except to the extent such representations and warranties relate to an earlier date, in
which case they are true and correct in all material respects as of such date), and (b) no Event of
Default has occurred and is continuing;
b. Borrower has the power and due authority to execute and deliver this Amendment and to perform
its obligations under the Loan Agreement, as amended by this Amendment;
c. The organizational documents of Borrower delivered to the Bank on the Effective Date, and
updated pursuant to subsequent deliveries by the Borrower to the Bank, if any, remain true,
accurate and complete and have not been amended, supplemented or restated and are and continue
to be in full force and effect;
d. The execution and delivery by Borrower of this Amendment and the performance by Borrower of
its obligations under the Loan Agreement, as amended by this Amendment, will not constitute an
event of default under any material agreement with a Person binding on Borrower, or a breach of
any provision contained in the Articles of Incorporation or Bylaws of Borrower; and
e. This Amendment has been duly executed and delivered by Borrower and is the binding obligation
of Borrower, enforceable against Borrower in accordance with its terms, except as such
enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium
or other similar laws of general application and by general equitable principles.
6. Except as expressly set forth herein, the Loan Agreement shall continue in full force and effect without
alteration or amendment. This Amendment and the Loan Documents represent the entire agreement about
this subject matter and supersede prior negotiations or agreements.
7. This Amendment shall be deemed effective as of the Amendment Date upon the due execution and delivery
to the Bank of this Amendment by each party hereto.
8. This Amendment may be executed in any number of counterparts, each of which shall be deemed an
original, and all of which, taken together, shall constitute one and the same instrument.
9. This Amendment and the rights and obligations of the parties hereto shall be governed by and construed in
accordance with the laws of the State of California.
[Balance of Page Intentionally Left Blank]
DocuSign Envelope ID: 322987CA-FFCE-4C0A-A445-762265F5C225</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="ctso-20221231xex10d30g003.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">ACTIVE 685692146v5
IN WITNESS WHEREOF, the parties hereto have caused this Sixth Amendment to the Amend and
Restated Loan and Security Agreement to be executed as of the date first set forth above.
CYTOSORBENTS CORPORATION, A DELAWARE
CORPORATION
By:
Name: _____________________________________
Title:
CYTOSORBENTS MEDICAL, INC., A DELAWARE
CORPORATION
By:
Name: _____________________________________
Title:
WESTERN ALLIANCE BANK, AN ARIZONA
CORPORATION
By:
Name: _____________________________________
Title:
DocuSign Envelope ID: 322987CA-FFCE-4C0A-A445-762265F5C225
Kathleen P. Bloch
Chief Financial Officer
Chief Financial Officer
Kathleen P. Bloch
Christian Ebert
Vice President</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="ctso-20221231xex10d30g004.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">Certificate Of Completion
Envelope Id: 322987CAFFCE4C0AA445762265F5C225 Status: Completed
Subject: Western Alliance Bank &#x2013; Loan Documents_Cytosorbents
Source Envelope:
Document Pages: 3 Signatures: 3 Envelope Originator:
Certificate Pages: 4 Initials: 0 Kaeleen Weber-Turner
AutoNav: Enabled
EnvelopeId Stamping: Enabled
Time Zone: (UTC-08:00) Pacific Time (US &amp; Canada)
1 E Washington St Ste 1400
Phoenix, AZ 85004
KWeber-Turner@westernalliancebank.com
IP Address: 38.29.192.249
Record Tracking
Status: Original
 3/9/2023 12:26:34 PM
Holder: Kaeleen Weber-Turner
 KWeber-Turner@westernalliancebank.com
Location: DocuSign
Signer Events Signature Timestamp
Kathleen P. Bloch
kbloch@cytosorbents.com
Chief Financial Officer
CytoSorbents Corporation
Security Level: Email, Account Authentication
(None), Authentication
Signature Adoption: Pre-selected Style
Using IP Address: 69.248.11.122
Sent: 3/9/2023 12:28:56 PM
Viewed: 3/9/2023 12:31:44 PM
Signed: 3/9/2023 12:31:59 PM
Authentication Details
ID Check:
 Transaction: 31020865162555
 Result: passed
 Vendor ID: LexisNexis
 Type: iAuth
 Recipient Name Provided by: Recipient
 Information Provided for ID Check: Address,
SSN9, SSN4, DOB
 Performed: 3/9/2023 12:31:37 PM
 Question Details:
 passed person.known.single.fake
 passed vehicle.historical.association.real
 passed county.lived.single.real
 passed property.city.real
 passed corporate.association.real
 passed corporate.association.real
Electronic Record and Signature Disclosure:
 Accepted: 3/9/2023 12:31:44 PM
 ID: 4b9aa82b-a392-4988-94e4-e214206703b3
Christian Ebert
christian.ebert@bridgebank.com
Vice President
Security Level: Email, Account Authentication
(None) Signature Adoption: Pre-selected Style
Using IP Address: 38.29.192.249
Sent: 3/9/2023 12:32:00 PM
Viewed: 3/9/2023 12:33:12 PM
Signed: 3/9/2023 12:33:22 PM
Electronic Record and Signature Disclosure:
 Accepted: 3/9/2023 12:33:12 PM
 ID: fcef229f-aa11-4f8d-8f7b-66cba39cb1ba
In Person Signer Events Signature Timestamp
Editor Delivery Events Status Timestamp
Agent Delivery Events Status Timestamp
Intermediary Delivery Events Status Timestamp
Certified Delivery Events Status Timestamp
Carbon Copy Events Status Timestamp</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="ctso-20221231xex10d30g005.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">Witness Events Signature Timestamp
Notary Events Signature Timestamp
Envelope Summary Events Status Timestamps
Envelope Sent Hashed/Encrypted 3/9/2023 12:28:56 PM
Certified Delivered Security Checked 3/9/2023 12:33:12 PM
Signing Complete Security Checked 3/9/2023 12:33:22 PM
Completed Security Checked 3/9/2023 12:33:22 PM
Payment Events Status Timestamps
Electronic Record and Signature Disclosure</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="ctso-20221231xex10d30g006.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">ELECTRONIC COMMUNICATIONS, RECORD AND SIGNATURES
You agree that Western Alliance Bank ("we," "us," "our," or similar terms) may use electronic
communications to enter into agreement and contracts between ourselves and you and otherwise
to establish terms and conditions for products and services you receive from or through us.
Electronic agreements may be provided to you though such things as hyperlinks or "click-through" agreements on our web site. Your consent to or agreement with the electronic
communication in these circumstances may occur by your clicking "agreed" or similar terms, or
by your subsequent use of a product or service, or otherwise as may be specified in the
communication or as provided by law (subject to any limitations set forth in the communication).
Your signature and agreement may be obtained by us electronically and includes mouse clicks,
key strokes, your use of passwords or other authentication systems, or as is otherwise set forth in
the particular electronic communication.
You agree not to contest the authorization for, or validity or enforceability of, our electronic
records and documents, or the admissibility of copies thereof, under any applicable law related to
whether certain agreements, files or records are to be in writing or signed by the party to be
bound thereby. Records and electronically "signed" documents, if introduced as evidence on
paper in any judicial or other proceedings, will be admissible to the same extent and under the
same conditions as other documentary business records. Upon our request, you agree to
manually sign or place your signature on any paper original of any record or "signed" document
which we provide to you containing your purported signature.
If you choose not to agree to these terms, it will not limit our ability to otherwise communicate
with you electronically, to the extent not prohibited by applicable law. However, it may slow the
speed at which we can complete certain steps and complete transactions with you.
We reserve the right, from time to time, to deliver one or more communications in paper form
instead of electronic form by mailing or emailing a communication to the last known mailing or
email address on our records for you. In the event that we do so, we may continue to provide
communications to you in electronic form.
If you download or print any confidential materials, be sure that you store them in a secure
environment, just as you would paper-based bank records.
Getting paper copies
You may obtain paper copies of any of the communications the Bank provides to you
electronically by sending your written request to Western Alliance Bank, Atten: Treasury
Management Support, One East Washington Street, Suite 1400, Phoenix, AZ 85004. If you
request a paper-based copy, the Bank will provide the first copy to you free of any Bank fees or
charges. Although we do not currently impose a fee or other charge for additional paper copies
of electronic communications, we reserve the right to impose a fee or charge in the future and to
change such fee at any time.
Required hardware and software
In order for you to access and retain the electronic communications, you will need a computer
with sufficient memory to store electronic records as well as a working connection to the
internet. The requirements are as follows:
Operating System Microsoft Internet
Explorer
Apple
Safari&#xAE;
Mozilla
Firefox&#xAE;
Windows Vista&#xAE; 9.0 4.0, 5.0 33.0, 34.0
Windows 7 10.0, 11.0 N/A 33.0, 34.0
Electronic Record and Signature Disclosure created on: 2/10/2021 7:23:23 AM
Parties agreed to: Kathleen P. Bloch, Christian Ebert</font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:always;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div align="center"><table border="0" cellspacing="0" cellpadding="0" style="width:100%;border-collapse:collapse;"><tr style="page-break-inside:avoid;"><td width="92.3%" valign="top" style="padding:0in 5.4pt 0in 5.4pt;width:92.3%;"><p align="center" style="margin:0in 0in .0001pt;text-align:center;"><img src="ctso-20221231xex10d30g007.jpg" alt="GRAPHIC"></p></td><td width="7.7%" valign="middle" style="padding:0in 5.4pt 0in 5.4pt;width:7.7%;"><p style="margin:0in 0in .0001pt;"><font size="1" color="white" face="Arial" style="color:white;font-size:1.0pt;">Windows 8 10.0 N/A 33.0, 34.0
Windows 8.1 11.0 N/A 33.0, 34.0
Mac OS X 10.9
(Maverick&#x2122;) N/A 6.01 33.0, 34.0
Hardware: Browser configured to support:
&#x2022; 1 GHz Celeron processor &#x2022; 128-bit encryption
&#x2022; 1024x768 SVGA resolution at
256 colors &#x2022; JavaScript
&#x2022; 500 MB RAM &#x2022; Cookies
&#x2022; 128 Kbps (slowest DSL) or
better &#x2022; Cascading Style Sheets
&#x2022; Browser page cache should be set to get a new version
every visit to the page
In addition, you will need to have Adobe&#xAE; Reader installed on your device to be able to view
and/or save the electronic documents.
Access, Retention and Agreement Acknowledgement
By checking the 'I Agree' box, I confirm and acknowledge each of the following:
&#xF0B7; I can access and read this ELECTRONIC COMMUNICATIONS, RECORDS AND
SIGNATURES document;
&#xF0B7; I can print or electronically store and save this document, for future reference and access;
and
&#xF0B7; I agree to all of the terms of this ELECTRONIC COMMUNICATIONS, RECORDS
AND SIGNATURES document.
Western Alliance Bank. Member FDIC. </font></p></td></tr></table></div><div style="margin-left:2.6515151515151%;margin-right:2.65151515151515%;page-break-after:avoid;" ><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>ctso-20221231xex21d1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/9/2023 09:43:15 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 21.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CytoSorbents Corporation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">List of Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:48.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:top;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:48.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Jurisdiction</b></p></td></tr><tr><td style="vertical-align:top;width:48.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CytoSorbents Medical Inc.*</p></td><td style="vertical-align:top;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delaware</p></td></tr><tr><td style="vertical-align:top;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CytoSorbents Europe GmbH*</p></td><td style="vertical-align:top;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Germany</p></td></tr><tr><td style="vertical-align:top;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CytoSorbents Switzerland**</p></td><td style="vertical-align:top;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Switzerland</p></td></tr><tr><td style="vertical-align:top;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CytoSorbents Poland Sp. z.o.o.**</p></td><td style="vertical-align:top;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Poland</p></td></tr><tr><td style="vertical-align:top;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CytoSorbents France SAS</p></td><td style="vertical-align:top;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">France</p></td></tr><tr><td style="vertical-align:top;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CytoSorbents UK Limited***</p></td><td style="vertical-align:top;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:48.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">United Kingdom</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*Wholly-owned subsidiary of CytoSorbents Corporation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">**Wholly-owned subsidiary of CytoSorbents Europe GmbH</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">***Wholly-owned subsidiary of CytoSorbents Medical Inc.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ctso-20221231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/9/2023 09:43:16 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CONSENT OF REGISTERED INDEPENDENT PUBLIC ACCOUNTING FIRM</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We hereby consent to the incorporation by reference of our report dated March 9, 2023 relating to the consolidated financial statements of CytoSorbents Corporation (the &#8220;Company&#8221;) as of December 31, 2022 and 2021 and for each of the three years in the period ended December 31, 2022 and the effectiveness of the Company&#8217;s internal control over financial reporting which appears in this annual report on Form 10-K into the Company&#8217;s previously filed Registration Statements on Forms S-3 (Registration Nos. 333-226372, 333-194394, 333-193053, and 333-205806) and Forms S-8 (Registration Nos. 333-233459, 333-220630, 333-199852, and 333-203244) and to the reference to our Firm under the caption &#8220;Experts&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">/s/ WithumSmith+Brown, PC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">East Brunswick, New Jersey</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 9, 2023</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ctso-20221231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/9/2023 09:43:29 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION 302 OF THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">I, Phillip Chan, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;min-width:18pt;white-space:nowrap;">1.</font>I have reviewed this annual report on Form 10-K of CytoSorbents Corporation;</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;min-width:18pt;white-space:nowrap;">2.</font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;min-width:18pt;white-space:nowrap;">3.</font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;min-width:18pt;white-space:nowrap;">4.</font>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting;</font></td></tr></table><div style="margin-top:12pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;min-width:18pt;white-space:nowrap;">5.</font>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the registrant&#8217;s board of directors (or persons performing the equivalent function):</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal controls over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March 9, 2023</p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dr. Phillip P. Chan</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dr. Phillip P. Chan</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ctso-20221231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/9/2023 09:43:32 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO SECTION 302 OF THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">I, Kathleen P. Bloch, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;min-width:18pt;white-space:nowrap;">1.</font>I have reviewed this annual report on Form 10-K of CytoSorbents Corporation;</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;min-width:18pt;white-space:nowrap;">2.</font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;min-width:18pt;white-space:nowrap;">3.</font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;min-width:18pt;white-space:nowrap;">4.</font>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;min-width:18pt;white-space:nowrap;">5.</font>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the registrant&#8217;s board of directors (or persons performing the equivalent function):</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal controls over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dated:&#160; March 9, 2023</p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Kathleen P. Bloch</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Kathleen P. Bloch</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>ctso-20221231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/9/2023 09:43:34 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with the Annual Report of CytoSorbents Corporation (the &#8220;Company&#8221;) on Form 10-K for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Dr. Phillip Chan, President and Chief Executive Officer of the Company, certifies, pursuant to 18 U.S.C. section 1350 of the Sarbanes-Oxley Act of 2002, that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;min-width:18pt;white-space:nowrap;">1.</font>The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;min-width:18pt;white-space:nowrap;">2.</font>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March 9, 2023</p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dr. Phillip P. Chan</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dr. Phillip P. Chan</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form with the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>ctso-20221231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/9/2023 09:43:34 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In connection with the Annual Report of CytoSorbents Corporation (the &#8220;Company&#8221;) on Form 10-K for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Kathleen P. Bloch, Chief Financial Officer of the Company, certifies, pursuant to 18 U.S.C. section 1350 of the Sarbanes-Oxley Act of 2002, that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;min-width:18pt;white-space:nowrap;">1.</font>The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="display:inline-block;min-width:18pt;white-space:nowrap;">2.</font>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dated: March 9, 2023</p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:45.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Kathleen P. Bloch</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Kathleen P. Bloch</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form with the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ctso-20221231xex10d11g001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ctso-20221231xex10d11g001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 20 SD# 2(  A$! Q$!_\0
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M_N)_[-3Z,B6Z+)Z5!8_ZD_[[?SJ=NE06/^I;_?;^9H6S$_B18HHHI&@4444
M5=2.+4?]=(__ $,597I5;4_^/4?]=(__ $,597[HI]$9+^(_1?J+1112-0HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "HG'[Q/J:EICX\R/UR?Y4"8K]!]13J:YP!]:=0,****
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MO]]OYFA=1/XE\RS1112- HHHH J:GD6HQ_STC_\ 0Q5I?NBJNI\VH_ZZQ_\
MH8JTOW13Z(R7\1^B_46BBBD:A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2Q .UO[IQ4N_VE?#=G\2+SP$VD^()?%MI8?VG+IMMI_G,+;<J^8&1BK#+J,
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MM\3?"NN:Q-)%:8D&KV3:A<R>3*@P78PR*R#@O&^!DM&R[GQ0\!:/\:_@_P"
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M/(4>;G<V=^<[CZFNF\'>!?#_ ,/M(_LKPUH]IH>EARZV5A$(H4)Z[4'"YQT
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MBZ^&?AZ[\0Z3K;6<T>H:3#]GL3;W<T,5O'QE%B1PFTX4$;<,%4'(48 /FO\
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M?M3^&9IOAU\0?&=GXIUW3;WPYX1U,V5GH^L7-E'#>+;M,D\JPRJ)'4!-H<$
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M[GXGQ2>._$=E9:+XVEL+620F&YBT^(EA $DCRKM\BLSKO !&5-4/V9;[Q_\
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M*N_:F650I.<N?H!Q^]CX[G^5 F.D. /J*=39.@^HIU PHHHH **** "BBB@
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M<\5TOQ)^,/A[X6W7ARSU=[B;4O$6H+IFEV-G$'EN9V'09(55' +,0HW+DC-
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M]<XS1??'[P3INFZ5?7.H7L4.J7<FGV:G2+PRRW4;.CV_EB+>)08W_=D!CM)
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M* "BBB@ HHHH **** "BBB@ HHHH **** "@=:*!UH ?1110 RBBB@ HHHH
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MAJ5U:07S%0C-/##(L<I90%8NI+* K9 Q0!\N>$?">M>+?V,/!'C^SO3!XW\
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M?C<3RV!G.* /'/#'QV\;>(/AW\+9[_Q%=6T_B'P]JU[/?Z596\U]-?Q2QI;
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MI@;6/W=HQC QIC]FV_U6PU*"\O\ PG=QZAJPUFX\_P /7A9[U&^6?(U($.
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MZ9HNH:7<ZU)XL\8ZC>1K8/+<3&VNB?-CA,BQQV^]OWC22J1E$0L[C'UUX_\
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M4NH=V]5 6%L\A0>M_9]^'-YX:\>^*=*@OK>]^'_AO4IKCPU% Y;[/)>QI-+
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MG?#RZN)&BL+?PSJ]M<W8W+'!)*]L8T>0<1LP1RN2"=O%4NI$MT?29Z56T_\
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M!\,?B%XRT#P-I?AB_N="U33V^%4'B*P233'*V[111Q-!,/._?HRNI)^3)#8
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MXAL9?"^GV>J7^G21VKW(MKG=Y3@)<,H.48,CLKC'W<$&@#UWPIX*T#P)I/\
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MJHMDM@D=Y8B[VE&?87!5XT).,O&6#8(8 ^I#63-XMT2V@6:;5K&*%BX61[E
MI*/L?!SCY6(4^A.#S7+?"^]\4ZYH&M6'C,64>I6M]-:QR:?.IE:V*J\+3!"5
MCFV2#<%.#@,,!@HYC0O@1<>"X+2Z?QKK6MQ:?H4^CRV=_#:"&\BWR/$76.!=
MIC#E!Y>T,%3<#MH ]7TO7=-UOS#IU_:WXCP'-M,LFW/3.TG%7Z^$/@5X)\1Z
M=\+/@_\ %6QMO#OA?3/"7P]G\Z]N[]HSK32V:- EWMC C@C9/,9F9B&)VC^(
M]?>?M2?$+1O"7Q%G:VTB\U3PR/#\]K+?:9<6:72:C*89%,9E\Q%5P2CL VW
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M&]LC+;G&,Q@C"\$CC'!Q5:Z^'OA>^2-;GP[I5PL=J;%!+91.%MSUA&5_U?\
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MF.&%MHC#$A_,41,FT*B@$[?JNB@#RB\_9C\"WMF;1X-46W/A_P#X1;RTU:Y
M_LSC-O\ ?[X W_?Q_%2ZI^S;X5U@:R+JZUF3^U] C\,WA.H/F2P3=B,>A^>3
M+##'S&YZ8]6HH \CU[]EWP3XC\2:5KMTVM0ZE9V46FW,EEJ\]JNJVL>=D%ZD
M;*MP@)/##G)!R.*FU/\ 9M\+ZI_;6^[U6'^U]>M?$MUY5RHS?6XB$$@^3@+]
MG@^3[I\I<@Y;/JU% '&^ _A5I'PZU3Q)>Z3<:@1KVH2ZG<6MS=-);Q3R'=*T
M2=$WMECUY)Q@<5SL?[/VGV>K:[J>G>)_$6F:AK&M+KTTUO-;G9<BV-KPK0LK
M(8=B%'##]VC<,"Q]4HH XBR^$.AZ5\*I_A_I[7.GZ)-:3VCR0,GG8G+F9P2I
M4,S2.>%P"W    Y3Q5^S!X?\3Z3X+@CU_P 2Z'J_A*V^PZ;X@T:_6VO_ +,4
M1'AD<1E'1Q''D%.J@C!SGV*B@#S"/X!:/;^,=+U^+5-5/]G:.^A1:=-)%+;2
M6DC1M*LF^,R.SM$C,Y?<2#SR:XJ#]BWPQ#X UKP4WBOQA=>&[^PETNULKO4X
MYETFSDQOAM=\)P"H"!I/,95R%903GZ$HH \^F^$$-WX]\)>+;GQ#K%QJ'AS3
MKC388'^S"&Y2?RO.DF"P!M[&"(_(R*"G"@$@\AX;_9,\.>'9];LSKWB'4/!^
MH_;#%X0N[Q3IED;I9%G\E502!2LLH"%RJ^8Q S@CW"B@#Q;X=_LU)X!\8>'?
M$,OCGQ+X@GT#1Y] L8-4^R%/L4CQ.(Y&2W5W93!%\^[<=G).2#K_ !#^ &D_
M$CQA=ZSJ6I7\=GJ/A^;PWJ>DP^5Y%]:2,S89F0NA!=^493]WGCGU*B@#S?P3
M\&U\-ZYH^L:QKU[XIU/1=,DT?3+J_CB1X+>1HVE9MB@/+)Y$ 9^,B,85<MNY
M'XG_ ++2?$?Q%XHU)?&6J:1!X@?29[FSAMK:54FT^=)H"KO&7$99 3&"!NRW
M\3!O=J* /(++]G\M\3O#_C+6=??6KW0)KR;3II;***\ N$D1X9KA,>9 JR$K
M&%4!E4DD*H&)\8?V7)OBIXA\5:C#XSO=$@\1:59Z;<VBV4-P$-M,TL;([C<B
M$L=\:D;B =P(Y]ZHH K:;;2V>GVT$]P]Y/'&J/<2*JM*P&"Y"@*">I  '/ K
M@_B_\+=0^)TWA%K36[?1T\/ZY;ZZJRV!N3/+"&"H3YB;5.]LXYZ8([^BT4 >
M<?%;X5:A\0]1\'ZA8Z_'I-SX>U!K[R+FQ%Y:W.Z)H\M$77$B;]T<F3L89VL"
M0>#^%'[+FI_#/5OA[=3>,(=8A\'V&J:;#&=*,+7$5[-%*^YA,0K*8(^<$'+\
M %0OT'10!\X>)/AW!\./!/C;PKK]MJWC_P .^/-4U%[72=%T)WEM9+PR3.EQ
M.K,JKYC$),PC5/EW'C=7L'PD\$-\.OASH&@37<FH7UI:J+V^F<L]W<M\TTS$
M\DO(7;\:Z^B@#!\>^&[KQAX)U_0K+5KC0;S4K">SAU6S_P!=9O)&RK,G(^92
M0PY'(ZBOFV]_8\\6ZCX?\6Z4WB_PWI\7B/PWIVA3C3O#DD4<#6TTTAE1?M7.
M[SW)R<ECG( P?K"B@#YZ\=?LX>)_&/B;5O$=OXGTW2M8&IZ3K.D,M@\L=O<V
M4<D>R<&0>;'*LTJG;L*@@@DBNT^$'PLU[P'XA\?:UKNMZ=JUWXLU.'4WCT^P
M>V2W=+2"V*@O+(6&(%(Z'J<G.!ZC10!X%X/_ &?_ !?X6U'6_#S>,[2X^%E]
M?WNI1Z0M@R:DANG>62U-T)-OD"661_\ 5[R#M+8I?!GP(\0:':?#C2]<U;3M
M7L/AYYAT22*)HI;UEM9+6V:XZB/RX975MF[>V'^3&P^^5%(!YT?U- F?-GA+
M]F37_#.@_!W1[O4M-O;3P0=0BO'C,L;7L=U!+!\@P=A59B<$G)7&1G(SM!_9
M.\9R_"Z^^'6O^+=&_L&RT\Z=H>KZ5I9BU0A-OV:2[=FV-Y6U?E0#>0"6!'/U
M-(,@?44^@9\]>*/@Y\4_B-\.)+'Q7XC\-R^([?4])U"R@TVUGAL";&]BNB96
M8L^^8Q[257" # /).YH_P3U/4/'7Q0U#Q6FE7^A^-](L-+N+:UDDW8@AFBER
MC)@*_GMCYB1M'7/'M-% 'S3/^RWXD_X9]T?PLOB>RO\ QYI6HVNKC6=3MC-:
M7T]MMCACN(\ M&;>..)B.>-W)SG3E^#/C>^_X0+4+^+PE:7VC>)$UN^L-(\V
MWLXH5LY;81P'RBTCYF+EG"] N !FOH.B@#YR^#V@^'O'?QP\3_$7P?K)U/P5
M=Q6]SY$,16TDUL)+;S7,9(!WK;B.-\#!,AR2P.-W]H3X2^,?B?JNG1:/)HMW
MX=.E:A8WFFZQ=36Z"YF6,07.(XG$XCVO^Z?:N6#9W*N/<** /E+1?V:O'4$7
M@"X==!T#Q1X:MM'L&\2:%K-TLLME:^6MQ:3PFW5+J.15D*"0KM:7(QM^;ZLY
M"^]+1TH !R**** "BBB@ HHHH **** "@=:*!UH ?1110 RBBB@ HHHH ***
M* "BBB@ HHHH \Z\2?L]_#_Q;>ZW>:GX?6:YUIX9=1DBN9H3<O#L\MF\MUY'
ME1<]3Y29SM7#-9_9X^'OB>W\40ZQX<CU:'Q,\,FK1WMQ-,MR\("Q/AG.QD 4
M*R;2,#!XKT@]*1>E &%X)\"Z%\.?#T&B>'=.CTS3(2S+$C,Y9B<EF=B6=CW9
MB3[UHZUH]MK^E7.G7?G?9KA#')]GGD@DVGKB2-E9?J"#5VB@#B[#X.>$=.^&
M,OP\ATIF\&R6;Z>VESW4TRBV92IB#NY<+M.  PV]L8KD[C]DWX9W<.I13Z3J
MEPNIP6EM>F7Q%J3-<):OOMM[&XRS1M]UB=P'&<<5[!10!QFJ?"+PUJ_C&U\5
M307L6OV]@=+6\MM1N(2]ON+!)%20+)M9F92X)4DD$'FN%D_9*^&DCZ#;0Z7J
M6GGPY:&STVZT_7+VVNHK5V9GMFN(YA+)$3_ [,.3ZFO;:JI_R$+@_P"PG_LU
M-=2);HXF;X'>%)=8M[]K>[\JWN[:_BTT7DHLDN+>..."58,[046*/  "Y4$@
MD9KH? _ABU\(:#_9MG/>W, N;B?S-0O)+J7=),\C#S)&9L L0!G   ' K>-5
M[ 8@;_?;^9H6S!_$BS1112+"BBB@"IJAQ:C_ *ZQ_P#H:U:7I575/^/4?]=8
M_P#T,5:7[HI]#)?Q'Z+]1:,8HHI&H4444 %'>BB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J-S^\3ZFI*C
MD \R/ZF@3'2=!]13J:_;ZBG4#"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *!UHH'6@!]%%% #**** "BC&:* "BBB@ HHHH **** "C.:#2+TH
M 6BBB@ HHHH *JI_R$)_]Q/_ &:K55$_Y"%Q_N)_-J:ZD2W1;/%5K Y@)_VV
M_F:LFJU@<P'_ 'V_F:%LQ/XE\RS1112- HHHH J:G_QZC_KK'_Z&*M+]T55U
M3_CU'_76/_T,5:7I3Z(R7\1^B_46BBBD:A1110 4444 %%%% !1110 4444
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M_B\-Z$-:M=4@M+B.#4'02F:W: S$PL!&F&\V0'S,XXQ0![S17RS#^T+\4'^
MJ?%(:1X9?2D\+OXEGC99T)8*S"TC_>-DA4),IP/F4!.M>A_ 'XE^.?B=H?A[
MQ%KVDZ-:^'M?T"'5[6737E,L$S[#Y$@<X/R/D,.NUN!QD ]CHKR#X._M':)\
M8OB!\1_"NG+Y=SX1OTM1(6S]JB9 /-7V\U9EXR"H1L_.*POA1\?/$OCW]H7X
MC_#B^TO2[6S\&"W,FHV[2&2\\]-Z80\1XSSDM[>M 'OE%>(_$/\ :)7PS\<-
M,^%]A)HUCK=YI/\ :L4_B&Z>WANV:4Q1VL!5#ND8HY)Z@ ;5?YMOIGP^U_5?
M$_A#3]3US1F\/ZM,'%QIC2&0V[+(R[=^!N&%!#8 (.1P: .BHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "C%%% !4<G^LC^
MIJ2HW_UL?U- F+(0 ,^HI]-?H/J*=0,**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ H'6B@=: 'T444 ,HHHH **** "BBB@ HHHH **** "B@TB
M]* %HHHH **** "JJ?\ (0G_ -Q/_9JM54C(.I7 [A$_]FIK9D2W1;-5K#_4
M'_?;^=62<"JVGC$!_P!]OYFA;,3^)?,LT444C0**** *FJ?\>H_ZZQ_^ABK2
M_=%5=4_X]1_UUC_]#%6E^Z*?1&2_B/T7ZBT444C4**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KS']I;P=K?Q$^!WB[PKX=LX;W5M:L9+&);F<0
MQ)O&"[L0> .P!)_4>G44 ?$'@3]E3QU\&_''PV\?^"=&TJWU6WT2V\/^--!E
MNT2*^2**-#=VT@&/,.S/S!22HS@.Y.AI7P!\4P_M(?$;XFZQ\/CJD.KWFF:A
MX?$5_9+=V4]I$$;S&=B(EDQAC&7)4X^GV?10!\I:Y\&_B1:?&/X?_&ZSL;+5
M/$D&C'2/$WA9;U(CY3F1Q]EF*A&:-I<8?:'$:_,"2:[OXTVGCOXH?!+XA:':
M^$&LY]:TF;2],T^:]MS=^;+&ZM+.PE\E(P2N CNQ&3CL/<J* /F.V^&7C%/V
M%Y/AK)X;G7Q<WAF30/L0NK;9YIA,8E\SS-OEY(/7=C^&M_P1I'CSX??LG>&_
M"UAX;O!XVTW1K?13!#=6F876)8WN4<S!&5.64%@S$ $*"2/?:* /BU_@)XW^
M#?[2O@/QQX%T;7_%^A'1%T/Q$EW=:5:M%:JJI"$"&'S'CVH6RIR(E <YP-7X
M5^&?B'X"_:;^-?CZ\^%VO7>B>*5LAIAM;_23+)Y$6QMRM>KLW$<9/UQ7U[10
M!\@>/_ACJOQ]TR2R^,7PEOKNU:P6XT^]T:ZLGU'1KN2><O;!UE&]5C%H-PWQ
MLP)<8!(]N_9B\&>*/A]\"_"OA_QE?OJ'B"RAD6:267S7C0RNT43/DAF2,HA(
M)&5X)&#7J-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !4<A_>1_4U)43_ZQ/J:!,?)P!]13J:_0?44Z@84444 %
M%%% !1110 4448H ***,XH **** "BC%% !1110 4#K10.M #Z*** &4444
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MGB./Q?J<=MI.K6EU"TEI80QZA=2FY,AEV@>1<GY(LDL%RN237EOC+]GCQ_\
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M!I@A#01+=^7-YAD9@ZFU3 Z$,P.3@@ ^KKV]M]-M)KJ[GCMK:%&DEFF<*D:
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MXYW9 !]CT5XEJ/[-&G:EX@O]4%S+:_:O$UIXC5(M0O<0RP@AW4><!OE#%&7
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MO^$W@L+"X^'T7BC_ (1>X4%_MZ?Z?_9YO <[2HN>/)V[C'\^_/[N@#T[PMX
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M9:QXE^.ND_##2-1ET*TCT23Q%J^HVRH;EXO.$$-O"75E3<YD9WQN 0!2"VX
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MT'4],\<6OA#Q/X5B\0>&IUM9)/$NHBVL%DQ$SEW4EPBB4+N QO\ E[&@#O\
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M0@CJ*DH **** "BBB@ HHHH **** "@=:*!UH ?1110 RBBB@ HHHH ****
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ML0K[A@]<=[X7\4Z9XRT6#5=)N/M-G*73)0HZ.C%'C=& 9'5E961@"K*00"*
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M;SOEPT2[F&P%?LBJ-[KVFZ;?65E=W]M:WEZYCM;>:94DG8*6*HI.6(4$X&>
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M[0'C[6O&_P ,/$/A_P !:!XEN]9N-/DN'EETB\T[]Q&R>;#%)<0JK3RJS(B
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M7_ASHFO:?J]AHUY:7&G:G+K%C!#K%ZMK:74H82O#;^=Y48<2/N15"G<<@YH
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MY;:E#IT.HPZ/>ZP(4:SL;Z78$@E<.2#NEC0R*K1JS;6<$$#@[7]G[Q))\$?
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M:VA&YPCPL'PQ.S#9; R4MO 7Q$\.?&3X@^,-,TWPQ>V?B2WTZUMH[O6;B&2
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MKY;+)*CADCD#@(I!Y*A3]1T %%%% !1110 4444 %%%% !0.M% ZT /HHHH
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ML/5O$^G:+?:?8W-PJW^HO)'9VH^_<,D;2,%'3A4)R2 .!G)&<'X/_$N#XN^
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M +8ZJ#M"D@'T'H'Q_P#AWXIU33]-TKQ?I=[J%_-+;6]I'./-::/=YD14\K(
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MFW?I^H6J3V[;3E<QN"IP0,<<8K3M;:*RMXK>"-(8(E")'&H554<  #H!4M%
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M1110 4444 %5(Q_Q,K@_["?S:K=58_\ D(7'^XG_ +-374SENO4LGI5?3QB
M_P"^W\S5@]*KZ><P-_OM_,T+9@_C7S+-%&,T4C0**** *>JC-J/^NL?_ *&M
M6UY6JNJ?\>HXS^]C_P#0Q5I?NBGT1DOXC]%^I4M-'L;"]N[RWM(8+N\*M<SQ
MQA7F*J%4N0,L0H &>@&*N444C4**** "BBB@ HHHH **** "C HHH ,4444
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MS\+SQ;<_#ZS\7QRGQ390V]C(EBT<=LT@22>"4J5::0'D@X&!7O'P>U74]/\
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M186!922N_(!*@U:\>?L]^+O&NM:IXH_XD=KX@U'5_#=U)8_;YFMH[72;QKH
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MV?XM^)?"GB35K?6K:+P_I6N6\T5BMJ;=[A[F.2$ $[D_T=6&XE@2P)/&/:J
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M!((/J*\T^/6BZ5:^#]8UJ/1M/OO%E]!#HFF7-Y;K,RSSR^5;@;@<*LLV\X[
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M/VA_&'PR\0_$'1HK+2;G4=,T:TUWPW:_9)I'U6%YF@GA.V7F1)/+'  Q*A.
M3@ ^CIIHX%#2.J*6"@L<#). /Q) HFGCMU#2.J!F" L<9). /Q-?)7QC^($O
MQ1T[X?Z]H*:5K.D1>-?#ITBZDC:$RSRQB=F\S+XCVRQ+E%+ ^8IR5YU]>^,>
MH>(O!MA_PE?A+0=7OM(^)MAX8N<R2""*7[= L%[;HRLV]1-&P#,,,"<D<$ ^
MHJ:I5UR.1TKQ[P[\4-?^(MY;WFG:!INJ^ KS6=0T"[=[D+<P);O- URZN=KH
M\\+1>2HW;9$?)RRKY7^QU\2==T7P5\&/!=_HVG1:)K_AB\OK"]M+IVG1[:2
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MOAMY+'1?M?B&:YCTR9]>5=-OA$J,H@O/**O)*'_=H0N[9("P*X.9K/QP\/\
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M E.<X&.:/[4_A.'PPNIWEO>Z5J!U>YT-M%U*2UM[E+NW!:9&D:?[. J#=O\
M-VD,H!+,%/9^!/'FB?&OX>6VO^'K^Y73;]9(UFCQ'/!(CM'(IZ@,KJPR,@XR
M"002 :OC/P'X<^(VBG1_%.A:=XCTEI%E:QU2U2Y@9U^ZQ1P02,\<<5S^B? /
MX;^&O#>I^'](\"^']*T+4V5[W3K+388H+AEQM9T50"1@8/4$9'-?,OP-^.WC
M3Q@_P@CLO&5UXU\1ZM)+)XOT2>SM5BL-/S,JWA>*&,PLKQQHJEB)-S@*2,CZ
M0UKX]^&-!U"=+I;W^R;;4H]&N]=CA5K&UO79$6"1@V\?/(BEPAC5FVLZD$
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ME7XV^!GFL8O^$FL$DO5@: /)MR)V*6^[/W/-96$>[&\@A<UYZW[24?@[Q?\
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MM[[2+.RD@9#,_F!WE,L+EBPFE!Y'WR>N"/75NCIFDBXU6[MU,$1>YN@ODPC
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M]\7_ +*]WXM\0>+->7QI/HVM:KJ>FZUIU[IUD VF7EG;FWC;#NRS(T;.'1@
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MH(N-*U&.*"[AGNII&EAC),4!=G+^4F3MBSL7)PHR:-3^ ?@76AXA&HZ*U_\
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MD4I()15 "G)D7D#)H XC5?V?(-<\8Z%JM]K4MQI>@ZC!JFDZ>]NK36,D5LL
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M28U WJ.=F6]%T[XN:%XZ\/66IP^%]:U:VE\13>&WA_LY9FM)XY9()9Y5#'9
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M1+74M,OO#MM:Z;/#J:Z>XNH[AY)8[H@;YU*E?*1CY2L7) 8[J]ZM/B_X7O\
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M2"\@\3BSTBZTJ59YI;NZO);,QHR98MYT+9'W">=NTXWI/"5K\-_&WP9U[0?
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M:WX@\.Z=<QW=CI6I16A,;QR>;'OG2!99-D@5@2VXE?G+Y;/K+1(ZX901[\T
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MPW5:A^SG\/M3^(I\<S:$1XD?R3-/#>3Q0W+1?ZEYK='$4KQX&UG1BN%P?E&
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M!IG@'PUHB3)IV@:98)-*D\JVMG'$))$;<CL%4996Y!/(/(I%GQE8ZWJW[/\
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M*[[7KW0? UOX:T"'X5:>;/47FEN&>[^TV]QYRP+ 8RI5G2%FE:3<09 02V0
M><_$G]H_XA_#S2X[FYLM :\M=#L]:OM,2PN9;A?.NF1XI=LVVT$<*A1+(7\V
M3?L7$;+7-_&G7-9\%:I^T-JWA34(=#U11X:CEN5MR[[)BT3E2&7:Y$I^?D@
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M7#J<4)DM&O5NI(94(WB6/+(" 5*JN#P%/UJN<#.,]\4 +1110 4444 %%%%
M!1110 4444 %%%% !1110 4#K10.M #Z*** &4444 %%%% !1110 4$XHHH
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MA_B_XOO\6_"_AJ^BMVTN?1_BGI6B2FRO7D@NE6XA?S%8K&71XY4.UDX.X#<
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M$*VMO-8Z7_9ZL@/,LR^8^^9L#)7:H P%Y8GT:@ HHHH **** "BBB@ HHHH
M*!UHH'6@!]%%% #**** "BBB@ HHHH **** "BBB@#X]\*?&7Q1J_P 6M M8
M?&<U]X=\23>)8(YS!;0JHM)0EN;>$HSIY1_=[Y3^];<3'C8:PO!?[0WQ \-^
M#? OB[4];N?%[Z_\+M7\67&D2V5O'&+RT6SDB\KR8T<;A<.K LP/4!< #ZP;
MX0>!3>O>'P;H!NWG>Z>?^RX/,:9U*O(6V9+LI(+=2"0:DTWX7>#M-N[&\M/"
MFB6EW81O!:3P:="DEM&Q)9(V"Y126.0, Y/K0!X%\+Y;N^_:D\(:G=>+IO%X
MU/X8W%['=20V\2 27UDQ:(0QIB-LC:&+$8^\:ZCXL?$7Q/X=^,.L:'INLFST
MR/X=ZEX@CB^S1/Y5Y!<0(D@+(21M=AM)(YZ=*]0\/?![P'X/U*+4-"\&>']%
MU"/S-EUI^EP02KO)+X=$!&XDD\\]ZNZU\-O"?B35I=4U;PSH^IZE+:-I\EW>
M6$4LKVS?>@+LI)C/="<'TH ^-/B#\3?'EQ\+?'&GZCXUN[EKWX3VGBV.Y@M+
M6V>WN9/-CEBC*QY\N0*I.27!W;&4$ >C>)OB%X\'B[Q/X2\*^*M&TV^\(Z/8
MZE&WB6XB@6\23S'DDN EH^;=0@BS"8F0J2S,67'N[_!KP&Z2(?!N@A)-._LA
MP--A&ZQP1]E/R_ZGD_N_N\]*I7_P"^&^JS:!+>^!M NY= _Y!3S:=$YLOFW?
MN\K\OS?-_O<]>: / O$?QD^(GAG3_BSXPE\3Z<VA^#];72X=,ETH",I/;616
M668$.J0/=&0X&65'SC(V;NI^./B?X;M];@6XB\41M-IUS9C1;FTDUPV,D<YG
M,2O#';2R;H2\8VY:,2]652?=;+X7^$]/77UM_#]A&FOLSZM'Y"E-09@58S*1
MB0E3M);.1@= !7-Z!^SW\./#&EOH6C>#]+T?2H[I=1CM].@%OLN=K()E9,,)
M K%0P.0#@'%-$OH>/?";QYJ_Q%^/WA.[@\8ZAJ.B3^#-0O3:RV,=H/-35(8'
M26%HPZ2C8$<$_*T;;< G=W_C?Q?KND_&G0-&TXZ4MO=^&-;OXI;JP,TT-Q;S
M6BJ2XD4F(B?YD7:25'S=,=[;?!WP59:EHNH6_AK3H;W18I(;">. *T".XD<#
M'7+@.<Y^;YNO-&I_#'PYXKU6'6=3L7FU."WGL8KJ.ZFB>."4_O8UV,,!\+NQ
MU*(3RJX%LQ/XE\SQG]G[XU>./%_B#X90^);O3-0L_&O@-O$Q2TL#;/97$;V8
M*@^8V]7%WSD#!3(X.!-^T9\?/%GPQU?Q!)X<.G:E;>']-L;^?3HK9YY@9KED
MD^UN618$,8'E!&:1F+L495P?6O#WP4\&^%-3T/4-)T@V5UH>GMI6FE+J8K:V
MC$$P(A<J$RJ?+C'R)_<7%3QS^S[\/_B3J>HZAXC\.0ZC=ZC:1V5XYGEC$\4;
M%H@ZHX!9&)*N1N7)P12+/'O&OQW^(OA[Q9\098+OP^?#_@[Q1H6EM9MIDOGW
MEK?_ &,.#+Y^$>/[62&"$,47Y5&0<+XI>/-7^*&I>&-4CFTV'0-%^+5CX>CL
M?LK/=%[>[6.29IM^%)D5\)LQL*DDD\>]77[._@&\@U:&71IS%JUS;7EZBZE=
M*)Y;<*+=CB4?ZL1Q[0.!L7^Z,0:E^S5\.M7\12:Y<Z!(=0DOX-5D,6HW443W
ML( CN6B641F8  &0KN..2: .9_:*U?Q38^._@_I^@ZW::99ZMXC>VNH+FR:<
M3%+&ZG0MME0E T0.T$9;:22 5./%^T-XED\.:!XY@M])N?!NI>+1X9DTM;:5
M=0A1]0;3XY_.,NPN)@KM$8AA6*[LIEO6?B5\-?#OQ$LM)&O64ET^E7\5[92P
M74UM+!-S&662)U;!1W4KG#!B""*KV'P1\&Z;KKZO;:5)%<2:@VJM;B]N/L?V
MQNMP+7?Y(D)^;<$SN^;[W-5T,U\;]%^IQWQEU_Q79_&KX0Z'HNKVNGZ3J]WJ
M)O;>>S>7SS#8RNH8K*F4YSMQC<%8YP!7D/[/OQ(UWX;Z5X+TH0:/_P (;X@\
M9>+=-6"*&0WENT-WJEV)0X<)M_T=X_*$9/*MOYV#Z>\;?"WPY\0]0T.^UNUN
M);W1)WN;"XM+V>UDA9XS&XW1.I961B&1B5/<&N?TO]G/P+HA\/FQL+Z :!JM
MUK6G+_:MTX@N[GS/M$GS2'<'\Z;*ME?WKX S4FAQ?P7^.7C[XEW_ (3UB^\&
MQ6/@7Q3IK7MKJ/VBU22TD91+!$0+N1[C?%OR5BC*-&<K@G;YU^TN^A>%?VDK
M3Q!J'P_3QY%;?#K5[VZTRWM+>6:?RKVQ"R,),9\M6<9&YPKMM4\@^\_#;]G+
MP+\)-:O-1\,:==V'GM*\5B^HW$UE9&1@TOV:W=S'!O(R?+4>G3BM:[^$NCWG
MQ/M/'SW6HC7[6P?2XMMQ^X6U=T>2+RL;?F>-&+?>RHP0 !0!XY\&?&&I> ?@
MS\&_!]IXFT[Q7XD\6+<'3];F::XLX[54EN\C<5DF$41CA569&; )VX(J>Y_:
M:\1:2EM/JNE:;:6&D^,1X.\57L?F-'9R.L;6]Y$2P_<RB>W5@QS$TW)D"'/;
M6?[+O@C2K%+33$U+2[>UU=]>TQ+6]8#2;QR^][4'(C1O,D#0\Q,'8%"":SOB
M%\*+ZZ\,W/P^T'PY8:CX8\6"\_X237-4U)EN8))BN^<1"(^?*P+;,.@C,<8&
M%   ,?X@_M%>(O"?AF37++2],N;"4:M=V4DAD>2YM[/'EJL,1:1O/^=Q.JM'
M'&@=Q\ZBN+\=>/KR+QZGQ*\-6%C9:W/\'[_6X?M\9=!B>SF5)"A!?:I(QQSC
MD U[7XW_ &=_"7CJXTN6Y_M'3!I^CW6@(FDWC6JR:?.(Q);OMYV9AB(P005Z
MX)!S;/\ 9?\ "UJMM')J6NWEK#X8F\(_9KJ\619+"7'F*Q*;MY*KA@PVA0%
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MPN3M,A9AT+, !0!SW@S]L5M3T/0/$/BGPFGAOPWKG@R\\96MU;ZG]LGCAM!
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M*N\#(49(+$8KJ_#/Q!U#Q7XNOM,LM'@FT;3@(KO6X[PF'[2,B2WB7RP9'C8
M.<A1G&=ZLB^!?$[Q)XN^-G[/VDZ5KWP]\1^'O%C:YI$VI:990S$"&"_@EN)[
M>XB.57RT=E&Y900 !G!/0_!_5/&/P/\ %"?#;4M+UKQ?X BM8Y?#WBN'3I&G
MLXV)"V-Z HW.N!B8#H1YFTY( /I*Z:9+>5K=$DG"DQI(Y16;L"P!P/?!^AKA
M?@M\4V^,7@B/Q/'I+Z193SW%O##-,))2T,TD+E@HP!NC)&"<@C..E:/@/XD6
MGC[P/!XEBTO5M(C<S)+IVJ692\@>*1HW1XD+98,AX4MFO#?V;_%VI?#SX'Z5
MX<F\)^)O^$J.I7H2PN="O(HA]HU"5HY))VC\I(PDBR,2V0H(QN^6@#U[X;?%
M:3XB^(O&.E)H[Z<?"VI_V3>327"NLMQY4<W[H 9*>7,ARVTY)&WC-3:O\58E
M\:WGA'0-+G\1:]I]M%=ZBD,L<4%A'*6\D2R.W#R!'*HJL<+EMH*D^5?!_P 3
M/X!\5_&N_P!7\/\ B>.+5?%+:EIPA\/7TQNX!8VL6Y-L1',D+@ D=,].:B\!
MWVN?"GXR^.M?\4>&]9;1_'D6FZK;WFD6,^J_V?=1VRP36,ZP1M(H7:K))LV$
M%LL",4 >X^!?&G_";6%[.^E7VB7%G>264]EJ(C$J.F.?W;,I4@AE(8@@@]ZZ
M6L7PMKLWB.Q>^DTVYTN%Y#]GCO5,<\D8QB1XSS'NY(1OF QN"DE1LDYSCK0
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M:'_"BO'>A>/;W7_#/Q$BMX/$%G;VOB&/5M)^TS22PJRBZM626-89"K;<,KH
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MBGT,U\;]%^HZBBBD:!2*H4  8%+0!B@ HHHH **** "C&*** "BBB@ HHHH
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M\ ^%M!NO$4EM)J$RSZM))<GR89YM_F31PK,@"EL,86+9X ]JM?V98H/C_?\
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M9+>N+'Q!IK2,_,HAW+-&S!HV*=0RG*D$;?@_X#^*]*\<:Q::GX0\&:CX>O\
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M9WOQ9TOQ/X>T[5/#D[W>FKJHGO[>?2M2L8T0RBXMB[,EU$0ZQRPCJ(\L5S@
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M;9]AE5'P[<ALD+@8QVR>Y'C[PTVM7FCC7],.K6<1GN; 7D?GP1@ EWCW;E4
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MR/4?VF4TB7XL?!:'Q#>7%MH-W?:K#?(MY-!!(G]G2E1+Y; ;=V,D\8)!X)H
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M^#_&7B#0K[0I?'OB&QFN+.>W>2UT^V2TD\B+4(8T+SPL8]WE$INDFC5G55H
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MW));V5^(R&:X649@NFE=XPB, R@X0A%( /O:QNEOK."X4$+*@< ]0",\U'&
M-1N/]Q/_ &:OGWX%^($M?V@O&?A:R\1W>K:,GA/0]7AM;S5'O?+N97O%F>/>
M[>6K(EN2B;4&5(4;N?*?BU\:3HOQVD>R\;RZ2NF^.-%T>_LM3UHVNRUDCC^T
M+'9#$;6Q64N;B7+%R0I 1331+5VC[:U+3K75K*:SO;>*[M)E*2P3H'1U/4,I
MX(]C6;X6\.Z1X2T@V>C:9::38H[L+:PMUAC!SR0B #/X5\9-XSU71_A'K?Q
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MQ&U?PN?$T?P_?4='U'PU)KFF+9(!*EQL62*TQYS&ZWQOD/&J$F)AL^=<>D?
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M0^V DD^;\O[S))/S9ZGUK+UGX/\ A/4],N+2#0=*T^2:R.G"Y@TRV9XK<_\
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M@_X@U[5/VC?BM9:NFH:?;VVD:%+#IEQJ+7=K%)(;TR2P MM0,%C5L*N6B/!
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MKJ$S;O/8Q$JJ[0-@/SKYTP( /S>Q444 %(:6D;!&#0 M% HH **** "BBB@
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MK.,_:G4Y5I?E^<@\@MG%;]%(LP-3\ >&=9TBTTK4/#VEW^EV95K:QN;*.2"
MJ,*40KM7 X&!Q4FI^"O#^MZA9W^H:)I]_?6?%M<W-K'))!\P;Y&8$KRJGCN
M>U;=% 'G-K\/-</CJ\\1>(O$ZZW803L=$TF+3TMDTY9-BN7<,QG?"L%<A=HD
MD&#D$=;XF\'Z%XWTAM*\1Z-I^O:8TBRFSU.UCN82ZG*L4<$9!Y!QP:TKT9@_
MX$O_ *$*F7I3Z&:^-G%7?P/^'=_HUWI%UX$\-7.DW=W]ON+&;2+=X)KG_GLZ
M%-K2<GYR,^]6[OX4>"M0N9+BZ\):'<W$FGG27EETZ%F:R(P;8DKS"1QY?W?:
MNKHI&APX^!GPZ6VN+9/ OAR.VN;--/GACTJ!4FM5.5@<!,-$#T0_*/2I[KX.
M^";ZZL;FX\+Z9-/901VT$CVRDB&,[HHSQ\RHWS*K9"GD8-=C10!0ET+3YM:M
M]8DLX6U2WMY;2*[*#S$BD9&D0-U 9HHR1ZH/2L34/A;X5U31=#T>XT6V.EZ'
M+#/IEG&#'%9R0C$+QJI 4ICY2/N]L5U5% '#V'P0\!Z7X^O?&UIX5TRV\5WJ
MD7&JQP 2R9&UF/;<1D%L;B"020:YF]_9A\"Z9I%^?"7AO1_#WB :?>V>EZB]
MF+B/3VN5PQ2%CMV;@K&,87[P&-S9]>HH ^</A%^R]%X.U&VDN_"V@^&+*&WD
MM+NTT77K_4K?5XGA,1CF@N4CC2/D-L(E)*K\P .[O-%_9=^%GA[P=J_A73_!
MMA;Z#JQC-Y:9=_,\MMT6'9BR^6V63:1L8DK@\UZG10!XWK/[+G@Z5(SH]D^F
M7<VLV>L7FH27UW-<RRVZ;$D#M-DR%0%W/N')8JS8KO\ QY\.M ^)FEVFG^(;
M.2[M[2\BO[9H+J6VE@N(\[)$DB974C)'!Y!(.02*Z6B@#S5_V=/ 4BSJ=,O@
ML^M1^(9 NLWJ[M0CV[)^)N"-B8 ^7Y%X^48=X4_9V^'_ ('\;7WBO1-"-AK%
MY/+=2;;VX:V6>0$231VS2&&.1P2&=$5B&8$\G/I%% '(:]\)_#?B7QUH7C'4
M+>\D\0:&LJ:=<QZC<1I LH42CR5<1MO"J#N4]*Q_B5^S]X-^+.J-J'B"VOVN
MY-+N-%G>PU.XLQ<64W+P2B)U$B9 8!LX/U.?1Z* //O"GP-\,>#]8U/4K,:E
M<3ZGID.D7BW^HS7236T.X1*PD8\J))/FZ_O&S[9WA[]G'PEX7;PA]AEU=XO"
ML4UOI<-YJ,ETD4,D2Q-$?-+$IY:(@7.%"Y&&))]2HH \=\*?LI^!_!.GW]AH
M\NOVMC.ICM+5M<N9(=*C,@D*62,Y6W!=5/R '@#..*[?P/\ #?3? 4>L/97%
MW=ZCK-S]LU#4KQD:>YF$21*[!55!B.*-0%4#Y<D$DD]710!Y+IW[-7AO3!X>
M6/4]9DBT/5KS6K6*6>)U:XNO,^T&0&/YE?S[CCMYS8QA=N1I/[('@W1/".N^
M&+35O$XT'4K&?3(+&XU=[B+2[6;B6&T20,L8*G;DAF5>%(R:]QHH \D\:_LV
MZ'XUF\,7SZ_XET;7M M380ZYHFI?8[RYMCMWPSLB[71BBL1M!##*E32ZS^S;
MX;U+5;NZM]0UC2K2^T6#P_J6GV=RAAO[&$R%(I#(CR+Q-,I>-T8B0Y8G!'K5
M&,T >''P3-\0OC!H4VI^!!H&B?#ZXE;1]6EN(F&H"2!$1(8XR2D2GYB' P\$
M)7)!V]Q\7OA%I/QD\.6FF:E>:CI5S87L6I:?JVCSB"\L;F/(66)RK '#,I#*
M00Q!%=S10!Y)'^SGIEI-X>U2T\1Z]'XLT=[AO^$EFGAFO;U9U19TN \1C=&$
M4.%"*$\F/;M"X,GB+]FWPGXH^&=GX*O_ +9+80ZJFLR7?G 74]W]I-Q-*[@
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MBXL=#GTFVTR[UV"X30;V_N[^VTC3/+1;B"TF=5?<S*[HK*(T+[<8&3[?110
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MPQHK1D-%MSEAM;)/6O4: "BBB@ HHHH **** "BBB@ HHHH ***.M !1110
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M\7ZGXQ@\.>*9M7M!9::=2T(2/I4*JP6-',I8C+NY*^6Q9B0P 4+P>C_L1@?
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M7BS4-2-KHDFL?$*T\1:/JFK:=K%E!:F*&-5\V9[ "*0BUP %F#>:R;2/FHZ
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MC#3[S0;3Q/<ZK\*-+TI;8W%F0MRUSJ(,4LK2 )D[,NI(78"3]S,^EZ'>^#]
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M1110 4444 %%%&><4 %%%% !1110 4444 % ZT4#K0 ^BBB@!E%%% !1110
M4444 %%%% !1110 4#/>BB@ HHHH **** "JB+_Q,9SWV)_[-5NJB?\ (0N/
M]Q/_ &:FNI$MT6FZ52@M8KJQEAFC66*1G5T<95@2<@@]15XC-5[#_4M_OM_.
MA;,3^)?,?;VT-I D,$20PQJ%2-% 50.@ '05)@4M%(T$P!2T44 5[X P?\#7
M_P!"%3KTJ"^_U'_ U_\ 0A4Z]*?0A?$Q<<T444BPHHHH *8\22'+*&^HI]%
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M(ENC1UCXT:?X=^"$?Q&U!+::S:P@NO*TR\6ZADDEVK&D4^%5U+NJB0@#!W$
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M)H7[-7ASPXNE?8=7U]7TO1)?#UH\UZLQCLI F8QO0CCRH<'MY8]6W2:'*?\
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M&FB:H_V:#S'M[>"\CDN) >V(U;@<MT .<5Y):?#G5=-TSQ[ITVA>(O#=VWQ
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MS0 4444 %%%% !1110 4444 % ZT4#K0 ^BBB@!E%%% !1110 4444 %%%%
M!2$X!/6EH.<''6@#P+PA^T-HVEZ-I<2Q^+_$][KOB36=*LTN;.W,Z75M)<-)
M;?(4143R)$1F/W5!=@,L/4?AG\2-,^*'@6R\4Z9%=6EE<&9&M[Z,)/;R12O%
M+%(JEAN22-U.TD<<$C!KR'PK^SEXI\,7OA&;^W=)N5T/Q?K'BN51;R1_:#J
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MN?ATFFVWBZ[\':YXX,TUOKVG?V<D43:9<Q7"QVT-O!Y%L\QMU?< CNSXX)+
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M4/#>CZGH'Q0O]1\-ZSXXT"..72C=Z39VRL^V[AB,MP\C HJ/(I)6-R" K%L
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M:^2_%$WB71_VC?C3XET[3H?&'ACPWJ&@WOB+PK#E;N\C72U*SQ'=MD:!@9!
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M\9>%]5UK2]"LM/CU#3M#TG4=(TRYLWF?7I;J>2*:*+;(NWR]B  <@ON;Y!R
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MW@N\D>7;EV<Q/)C!&"P)7-8WB;]I'QMX@\'>-++3+O2]/U/1+WPZG]K+I=S
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M=0=QP0#TO2OVE=%UKP]>:K::#KDDEOKS^&ETX);?:KB^1RDB1+Y^&"$,6;<
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MF-I_;5S=):Q:7$UB\T5@^HHDREWECW!RF\+(J9!9'JI8:[\1-=\;_#+PA/\
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M4A\RVY0.AW'<6V$, Q  /3_ O@WP/)J]]X_\+BWU&Y\1HLS:S;WSW<5Q&50
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M(.\ 'U!C-%?)WC7]I#Q_#X*\:1#3M!TK6(/ </C*PN;:>:=8HI/,1XG!"$R
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MB+Q%J&HW.H645CI0M92T]FF^54D,ZHZLFUT=2596 R'^2O9M>\5V7ACPC?\
MB+5!+:V-C:/>7"[-TB(J%F&U<Y; Q@9R>!F@!V@^#]%\*^&;7P]HFFV^BZ):
MPF"WL=.06\<*<\($QMZDY&#DYZUSUK\$? ]CX8M?#MOX>MH-&L[G[;9VL;.H
ML[C+'SH"#F%\NYW1E3EVY^8YX#]F7XG^*_$>I^//!_Q!CCM?&6@:@M_Y,6#&
M-/O5\^V5&P-XB)EMR<=8!DDFK^F?M4>'=7ET?['HFN7-KK>FW>L:3>1QVWE7
M]G;,HFFCS/D "2%@KA6(E4@<-M .[C^$OA*&_P!$O8M&ABN]%>633YHV96MW
ME),S@@\M(2=[')?)W$Y-9@^ O@2V\?7?CJR\,Z=:>-+A#G6!#E_,V%!(4R%+
M[25WXW%21NP:X6P_;&\*7WAG1]:ET;7=*M];A@GT=-7CMK'^THY(//9X7FG6
M/:@PK%W4;BH7<'0M-=_MF_#>'PEIWB"VOYM1M;O3)=8>&#RDF@MHI'BE9EDD
M3<RR12IY<9=V,3[0P&: .>^$?[+%QX"U'1IIM/T?1[O3Y%DN]8T'5K\'52H(
M(:R;;!"K[B67,J@$A0IVLOK_ (>^"W@[PHJII&DM8QQP36MM''=3;+.&4@R1
MVRE\6ZL54D1;!\J_W1CA]2_;!\!:?_:LZ1:Y?:7I3:>;W5+/37DMH8;T*;:?
M=G+(P=/N!FPP.T@$C=M/VCO",NG^);B^74M$F\/WUOI]W9:G:&&X:6X$9M=B
M9.1+YJ;<D$'.X+M; !=TG]GSP)H4>E)IVD3V2Z5I<NBV0@U*Z7[/92$%X%Q+
MPI*J?4;$QC:N/,O%W[+?F^*=(&C:-:W?A;2M'M]*TR!?&.K:)=Z<L4DC;1+;
M!VG0AT"AW7RQ'A1@FNM@_:R\"SM9VX&L-JMQJ\FA'3+?3I+F:&]2W-SY3-#O
MC^:(;U9796!R"0K%:7_#56C:IK'PWM=$T75[^#Q?J5[ISN]KY;Z?+:Q3F>*5
M"VX2I) 5*X("AFS]W< =M_PJ;3_$'PFM/ _C":X\1VHMX8KFXDNYTFE>-E='
M$P?S0RLJD/OWY4$L3DUDV?[-?@?3=4N=3LH=;M-2N;Y-3EO(_$.H&1[E;?[,
M)6)G.XF+Y#G(8 ;@2!CU*B@#S#_AF[P&MK!9QZ=>1:;';V]J^G)J=S]FN(X)
M6FB$T?F8D82NSEVRSDD.6'%<C\4OV=/M.C30^$;>Y=-4\1+K^NP#Q)>:;<W,
M@@>/S+>XBW&*3<(,J-J%8L?*>:]]HH \+\!?L]S+#ITGBC5-<FBTC4XM5T:Q
MO/$4VIRV<R1-&7>XD16?<KLIB)=!DD$EN.@TW]G'PQI.MZ1JUM>:N+W2M3OM
M8M&DNPXCNKP.+E\%2#O$C_*<JNX[0*]4HH \K\/?LX>%/##>%#92ZEL\,7-Y
M=:;'+<!U1[O?]HWY7YP_F2?>SC>=N.,9>A?LE^!_#>AZWHFGSZ[#H6I6]Q:1
MZ3)JTLUIIT-P")TM(7+)%O#.,@$J'8*5R:]HHH \AU']F+PKJZWR7M]K%Q%>
M^&1X2FC-Q&@:P7=M7*Q@AP79@^<Y/.1Q73>+OA'I?CCX=#P?JU_JD]H)()QJ
M'VG_ $P3PS+/'+O*D;A(BMC;MXQMQQ7<44 >-1_LN>'X[^YN_P"W_$4DUSX@
MM?$\QFNHI/,OX(TC5SNB.%(C3*#"C: H5?EI+[]EW0KJ5[RW\0^(--UQ=>G\
M1VFLVDUN+FRNYH_*F$8:$QF-X_E,<B.I';/->S44 <1\-/A3I_PQ\.ZGI%IJ
M6IZG%J-_=ZE/-J,R-+YMQ(TDN&1$P-S$CN/6O.?#O[(FF^%4TM=-\>>,K<Z7
MH4WARQD6ZLP\%F[HZJ&%J#OC:-"KDECCYR]>^T4 >.1_LVZ?9/K<]GXBU.WO
M-=NC=:O(;6Q:'4<P+"5GM_L_E,"J[L[-Q8\L1\M86J_L=>'YM&31](\1Z[H.
MEMX/'@JY@M)('-U8KYGE[FDB8JZF:7E-N=V,8&*^@** / M:_9*LM8T?QEIK
M>+]9$'BG3].TV\:2.W9XXK(8A,9$:@,03N)!!SP!5SQ1^R[8^-;WQ]<ZQX@O
MC)XNBTTR26"K;RZ?<V)W6US;.,E75_GYW#(';(/N-% 'D"_ O5YO#$>F:KX[
MO_%-U*[#4;CQ!I]K<0:A 4*"WDMD2./RUSN&T!BV2Q;)%6M7^ &GWO[/L7PH
ML]7O['3(+"&PAO\ *23!(F5E#J1L=#LVM'@*R%DP%.*]5HH ^>M5_92N]6TS
MQK:3>-[B4^*=3TO5;AI=-AVP2V7V8QB-4V?+FSA !Z)N!+,0X](\%_#6\\+_
M !#\:>*;G5X[X^)OLA>TCM#$+<V\7E+M;>V05Y.1UZ8'%=[10!XQJ?[.$5Z_
MC+2HM<9/!GB[4EU75M$EM1))YQ$?GI#/O'EQS&)2ZLCGYGV,FX;>E\%?#*_\
M)?$GQOXIDU>VO(?$\EM(UBEB8FMO(A$*8D\P[\H.<J.>1@<5Z%10!X)\3_V8
M;OX@W7Q56V\5II>F_$'2[;3KZWDTWSI+=H8VBWQR>:N08W/RE<[@#NQE3#XX
M_9;O_'>N^,]8N?&/]FZEKUKHHM;K3=/,<FFWFF323VUS'OE<.#)-)NC8<KM&
MX8)/T#10!QGPW\)^)?#>ESCQ9XK'BW69]H>[@L186R*HPJQVX=]N<DLQ9BQ/
M4*JJO!>&OV;)- T[PMX?F\0K?^$?"^NRZ[I5BUDRW:N6F>&&6X,I#I$T[D8C
M5B$B!/#[_<** /"?!/[-U]X:TOP3H^I>(K?5=&\&:G<ZOI4,.GFWEEN)%G6,
MW#^:P81K=3<(J[CL/ 4JU+P?^S3K7A&U^&L9\3V5[_PAWB#5]<<C37C^VB_-
MWNC \X^64%[+@Y;=L7(&37T'10!\*?!?1/$DNLZ6VG'3H[R6>_$6GS>&=6LM
M1\-&^E=[AQYT[V431[@?DB1)2C(A._<W<6W[&WBBYLO$,&H^*]!637O ESX.
MU"[L]'F%Q<2R!\7LDCW+&25F<,Y;).-H_O#ZSHH ^>O%G[-^O?$2>UB\1ZQI
MWV&3P7J7A&];3H9(I!]K:$^=$'9ON"WC&&/S$L?E^[4GC'X ^*OB-HQ;Q#JV
ME-X@M/"NH^&;2\M5D6*9[U(4FO)%()0@0KB$%ADMESD%?H&B@#Y]O_@'XDO]
M8U"]N4\-:E:WGA/3O#,^FZ@LDL$ZV]P\DV\%,;)$E=,8RN%.3T':? OX6:E\
M+/#&K:1>ZC)/87%\]QIVF&^FO4TFV,:*+6.XF DD0,KN,A=OF;0,*"?3J* /
MG[P;^SSKVA:!\//#.J:AIVI:)X U%[_2;Q&D2[O%2&:&UBF4J1&46<AW5GW^
M4#M&\@=K^SW\/=<^%WPWB\.:ZUA)<Q7U]=++I\[RHPN+N:XP=\:$%?.V]\[<
M\9Q7IE% 'S-:_L\>.;5=(L#<^'YM-TGXB7'C."?[3.DTT$TUU*8G3RB$=3=;
M1AB#LSD9P,/4OV9?'EIJ$.NZ8O@_4=9M_$^M:NND:X\TVGW=IJ+HSQR.(-T<
ML9BCVNJ,#SD8-?6M1.!YT?XT"9Q7AWP=J?AOX8'1K5=(TO6O(G,*:3:BWL;:
M>0NRA$"_<5F'S$;FP6(R2*\XD^!.NZC\8_#_ ,1?[*\.>'-=T^QNX=3N-&OI
MMVNF2+9'#<?N$ C5R)0[>8RE5 !ZU[^_0?44Z@9\V?#CX$>._!9^$/VH>'Y1
MX.\)WVA7H@U&<F:XE%ML>+-N,I_HW);!&_@''/$^$/"7B[X3_%+X$>%Y-.TK
M6/$.C?#[6K">*#4I([:39<:8N])&@R<D+P4& 6QD@!OLFLZ;P[I=SJT6J2Z=
M:2ZE$,1WCP*9D&",!\9'#-W[GUH ^7%_9,\2P^&/"GA2.^LX]-M/!_B#0;[4
M;>X96@N=4>.3=!"4^:*)D90&93M9,#(.-+0_A[;:%X(U9?C9HO@'P=8WVD_\
M(W?:K::L2NJ"0@9WSQ1?9U)!9(@SG<Y.05&[ZBJGJFCV&N6RV^HV=O?6ZNLH
MBN8ED4.IRK8((R" 0>Q% 'EO[,/A;6]$^&MAJ'BC4SK?B"_MXHSJ,D+122V<
M*F.TWJW(9H_WK@]))Y.!TKUZ@# Q10 444$XH ,4444 %%%% !1110 448S1
M0 4#K10.M #Z*** &4444 %%%% !1110 4444 %%%% ')+\+/#B_$1_'(M[O
M_A)GL1IK71U&X,9M@Y<1^1YGE8#$M]S.3UK.@^!W@U-%\;:4=-FFT[QG+--K
MEO/?3RK=/+$(I& 9SY>Y%5?W>T85?2N^HSF@#RNR_9J\&:?<7EW$=<?4KNVL
MK6;4)]>O);ADM)3+;G<TIP5<DY Z$C[I(J:+]G+P5!<Z5>16^H0:EI^J7&LK
MJ$.HS1W$UW/'Y4\DKJP+[TPI'0!0!C%>G44 <CXU^%VB>/-8T'5M0-[;ZGHC
MS-97>GWDEM*BRILEC+(02KJ!D>JJ000#7)^%_P!F3PAX,'A[^QIM7LSH&FW>
ME6!>^:<QP7+(\X/FAMQ9HXR,\#8,  MGUJB@#QB/]D_P59Z;HMG87&MZ6NE:
M(WAN.:RU%HI)M,/W;65@/G52<JWWQD_-R<U4_91\&PZOHTEA?>(M(?2-&MM"
M+:;K,T!OK"/?Y<%R0<NJY;!&UAD@$#BO<:J1_P#(1G_W$_FU-;,B3U1RW@/X
M4Z5\.M:\4ZEIEU>2/XANTOKJWG,?DQR)"D*^4J(NT"**),$GB,'J6)Y?Q9^S
MQH/C[5_$NJW&J:QITGB+1_\ A']4AT^>-8[FU5I]F0\;$,HN9@"I ^?)!(!'
MK9Z57T\ 0'']]OYTULQ/XU\SR/Q!^RSX7\7?VR-<U+6=2BU;1;30YXWGBBV1
M6TC2V\D;1Q*R2I(S.&!QD],  =I\./AM'\/;&9)=>UKQ1J,RI'+JVOW*373Q
MIN\N,E$10J[GQA026))))-=C14FAXQ<?LK^&-5T_XA:?K6IZOKMAXWNEOM0@
MO'MT\BY6....:W:*%&C=%ABVG)P4!ZDDWK?X "RU*/58/&_B4:W)I2Z+?ZI(
MUFT^HVZ,S0F8?9PGF1F27;(JJ?WC[MW&/6:* /G?7_A/8^)?%?@CPC!X$N](
M\*_#NZM;O3M=ENHQ!<0K;&,6L(60RL-S1B02J%81');*UI^+?V6(/%/BG6]9
MB\:Z]I*:IK6G:^]G;Q6DB1W=F(EC*O+ [[-L*8C+%0Q8@?,17MUZ,P?\"7_T
M(5,O2GT(7Q,\,U+]ER#4'UZ?_A*=0@O-3\76GC)+F."$FUO((XHE55*E6C,4
M,:X8$YRV>< \,>$4^(7QNM_&M_X4USP]/X7L[G1%O-9:",ZP_FCRYECA=@\:
M+YS([!.;DX48./=,\T4BSS[XS?"VY^+6B:3IL6M?V)'I^K6>LK*MJ)W:>UG2
M>$<L %WH-PQDC@%>_/>/_@/JOQ6TS4;/Q1XSG >"(:<VAVGV+^SKJ*XBN([M
M=TDA>19((<;C@!6  WM7L5% 'A^I_L^^)=>T+P^=8^)-YJWBG1M;@UF#6)],
M@2 >5'-$(EM8RJ*"D\A+9+%B"2554&/K?[*6IW]MK/\ 9WQ N]'U!O%3>,-$
MOX-/C:33;YXS%()5+;;B-D>5-F$&V0@Y(!'T110!X[8_!3Q-_P )?X&\1ZMX
MY76M0T"2\FO#/I81;QKB)8BL024"W1%1=J@/DY+%B2:Z?XK_  ^U'XDV6CZ7
M'J>GVNA1:A#>:K87^FM=C48HG$BP9$R!%+JK'(<-M (VE@W=T4 >'7O[/D?A
M+XQZ5\1? YTGPS96.DSZ;JGA[3-#4-J\3.)5 =9HT2164;&*'&YP20V!\_?
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M$WAR_P#B1LAT^*.Q^(&F:!+J=I8;#96%Q:V+O=2KN8RR*)]GF-\H^1BNU2M
M'U!17RL/C-\51#X34WFA6]KK_CZX\+V%_<Z),'N=.2UNYHKP#[2H8N;8 $*J
ML/F7Y66F#]H[QM9> 8M5U*#=::3XFUS0M>\0Z1H[7GV:*QNI88KI[-9-XB<1
MYD,9<KCC ;*@'U916'X&UI_$G@O0=6DN[*_>^L(+EKK3B3;3%XU8O$6Y*-G*
MYYP16Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[Y- F.?H/J*=37Z#ZBG4#"BBB@ HHHH **** "BBC.* "BBB@ HHHH ****
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MOB3]H;QCH:^-&2/0I/[!^(>C^%HPUG,/-LKW[!N)_?\ ^N7[:V''R_(/DYH
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MPTF>%!- F>]/R!]13J\[\4_&S0O"TNHPWL-VLMIJ$&EQ >4!>7<L(G$,3-(
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MI! XS+I7[1/@_6K646\]T=6CU-=&?11#OO!>-%YPB"H2K?N<R;U8IL!.[ .
M"/Q)^S)\./%IG.J:%-/]IL8M-NQ'J=W"+VWB_P!4EP(Y5$^S^$R;B.Q%==XP
M^'>@^/?!L_A77;26^T*=$CEMOM4T;2*I! :1'#GD#/S<]\UP7[-?C;5_B%X,
M\37NJZE=WTMMXDU73K6>[M8[:XCMX9VCB5XUC0!U YRN<]:YK]G#]HVV\6>%
M_#ND^*]1O9O%FI7&KK#>7&F/!;72VM[.OEI,L:0LZ0(A(7LK$\AJ .\U?]G7
MP)KR^(UO]-OK@>(I+675,ZQ>J;E[;;Y#'$PVE=B<KC.T9S47B#]FSP!XGU?4
M-2O]+O7N=0O;74KE8=7O(8I+NV\OR+CRDE""51#$/, #$( 214-Y^T]\/=.L
M+J^O-5N[.RATI]=CN)M-N0MU8(5#W,'[O,L:[UR5!P&5C\K*QF_X:1\"#3KN
M^:]U18;..:>Y5M#OO,A@C.&G>/R=RPGJLA&U@&*DA6P 69OV>_ =SX-\3>%;
MG17O= \1W<M_J=I>WUQ/YUQ(P=Y SR%HVWJ&&PKA@",&MSX??#31?AGI$EAH
MYOYA*P>:[U749[^ZF( 5=\T[N[    9PH& !7%ZE\;_#7ASQ/XJU?4?&9?PS
MH_A^TU6XL(=&GD2W@D:4K?)<(A\^.15QA P7RF)/6NP\$_%?PQ\0]3U;3M#O
MIY[[2A"]U;W-E/:NL<H8Q2J)D3S(W"-MD3<C;3@G!H YT_LW>"%ENYHK;4;>
MYFUI_$,,T6IW :SOW+F2:W&_$6\RR;E4;7#LK K@#M/"G@S2_!EG=6^FQ2*U
MW</=W4\TADEN9VP&DD<\EB%4>@"JH 4 #(USXQ>$/#?B.#0]2U<6M]-=PV 9
MK>4VZ7,HW10/.%\I)7!4K&S!CO3 ^9<MB^,W@Z;6H]*&K[;F::>V@D>WE6WN
M)H=WG113E?+ED39)N1&+#RWR/E; !S^F?LV^%-&O-$GLKG681HNKW.MZ?"VH
M/+%;W$_G"7:K[@%(N;@;?^FI[JI7+OOV3/!M[9::D6H>(=-U+3=1O=2L]9TW
M5&MKZ![N0RW:"5 ,QRR$LR$$9/&  !U'A7X_> /&^I6-AHGB."_N+Y)Y+4K%
M(L<_D-B94D90I9."R [@"&Q@@UD^+OVE?"/ACPY-JL)U'4]D]E D$&EW67^U
MS>3;R ^5CRG;.)1E3C"EF*@@'97WPZT+4?A]>^"KBUDD\/7MA+IMQ T\ADEA
ME1DDW2YWEF#,2Y;<222<G-<=J'[-?A'Q!H&I:7XA;4/$AOM,BT<WFH3J+B&U
MB<21I$T2H$*R*LF\#>61"6.U<9'C3]HO2/A[-XTUO4M=M;_0]%TJQN1H-GIT
M_P#:=M-,9MIN#D[%EVJJAD3858L17:W/QK\%Z?9ZW<WNNPV<6B6T5YJ9N$>,
MV<$N_P N6164%4;RW^8C'R-SP: .8M/V:-&ATO1+:Y\2^)]6O=+U2WU<:KJF
MH+=7=Q+!N\E)'>,CRTWOA$"C+,3\S$FAK/[)OAK5K>X:+7O$>EZPVO3^)+77
M-.O(H+VQNYDV3>4PBV^6Z *T;JRD <5TNF?M ^#M2\7>+=!_M(6LGAA(VU"X
MND:&*,LNYAN8 8"F,[LX._ S@UUWAKQIHGC"RNKK1M2@OH;69[:X\ML-;RJ
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M\27$SVD)=+BR^S^2JX &T_8[;=QSM?& V!U>N_M#?#S1- &L_P#"6Z1?V/\
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M7PDU.61Y+"%I/+B#N2RX\V49!!Q(1G 4+4^ /[0-GXNTK3-#\2ZOYWC.]O\
M5X80FFRP6]PMK>SQA$E"^295BC1C&'+[?F(QS7:>,?C9X*^%<UM9^*-<32[J
M[2>YMX6@ED>6.,_O"H16+;<@G'(!!/%"V8G\:^9@^)/V5_ WBNYUB:__ +87
M^V[>UM]7CM-5FMX]1^S@"%YEC907  &X 9  .<#'7>/?A7HWQ%T/2=-U*74(
M/[)OH-1L;RSO'CN8+B($(XDR2QVLRG=G<&.<YJ-?C-X,.LQ:6VN0Q7,LD\,4
MDR.EO++"I::-)V41N\:JQ9%8LNQ\@;6Q3N/C]X!L=/DOK[Q#%I=HCVJ&74X9
M;0'[2Q2W9?-5=R2,K!7&5.T\\&I-#%T?]FKP_P"'+6^@T?6_$6G)>WE[>7!_
MM 7'FF[96N$83I("K,N<D;LDG=G!#[']FGPEIL^B1V\NI)HNBW-G>Z?H;7"M
M:6]Q:VZ6]O(F5,@*)&ORB3:QR6!)K?T;XX>!O$.BWFJZ;XBMKVUL[S^SIUA5
MVF2ZX(@\G'F&1@050+E@00""*=<?&SP/:Z)#J[^([3[!*)V#IN=E6 XN&= "
MR"(\2%@!&?O[: /$OB_^SS=Z=H.@:1H5IXH\1^'4UR^US4(]*U:S@U%;JY)/
MRK<>7;RQ,\UPS*YW*2FSY<@=IX!^">J7%SH6O^(]?\0KJ6A27B:-%?S64MS;
MVMQ%$CQW#10^6[AHR1M+!05&YL&NEL/CIX7\2_$B[\$Z9>B[U"VL;343-&C&
M&1)V<Q^6^-K@K$S;@<<@ DYQ=M_C5X8F^)6L>"3?"+5=)L8KZ[,J,D:))YI
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MMEN]4W7"9M4;?M##.0QV'Y>OS+Q\PSU8UFQ_T8&ZA4W+%8 9%S*1U"\\GZ4
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M:_-XH\-:?JMQI-[H4]U'ODT[451;BW;."CA&9<C'8D&MB@#S+X'?#SQ%\.-
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M8=3Q]<Z7XOTO6?$.MZ':3R2:EHQA6]C:WD18S*GF1[790KY4Y.PG'0X/%;-
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MKXB^*^O:/J'CR_\ "VJ%],OO"$.FV5U<-JEKY$$CBUV7"6TQ>?[1'()(WPK
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M<8=>:R_B/\3+'X9PZ#+J%C?7D6L:Q9Z)$]FL9$,US*(HVDWNIV;F&2NXCTH
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MU_:%^%/CCQ3>_'.ST'PR^JP^-_!UEI&GWD=Y;11I<1?;%9)!)(K@_P"D1D$
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MI?"?X>6_PF^&_ASP;97MQJ%CH5E'I]M<7842M#&NV/?M !8* "0!G&<5UF*
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MY/"FI^/_  Y+YET\]G:6K+.JSK9^8J21A43S)&4X#N2&#!\?;U% 'BO[,U]
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M"BBB@ HHHH **** "@C-%% !1110 4444 %%%% !1110 9H'6B@=: 'T444
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MM5\.VNLZ:T]C,]R\C2?/<+$\$\;(CLLG'E+D<8K[>_X0;PY_T -,_P# ./\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J-Q^\C/N:DJ-_\
M6Q_4_P J!,=)T'U%.IDG0?44^@84444 %%%&* "BBB@ HHHH **** "BBB@
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MCCT52?PH TJ*XGP#\1;KQE!>75]X;O\ P[81V\%Y;7E]+ T-U!*F\,"CMM9
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M>V$,ZO-;+)N\LR(#E-VUL9QG!Q6M0 4444 %%%(3@9H 6BBB@ HHHH ****
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M\;8/#*>"IY'>@#X'\*^!=1O/A5XA:_\ "?Q MOB+9>#]4TO75N](B2UU&Z>
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M8J"IVL.E?>=%(T/A3XDVZW!^-EK9C5K2QF\5>%7TQ(&NK9OL^+(7?E!=K*B
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M** "BBB@ HHHH **** "BBB@ HHS10 4444 %%%% !4<@'FQGOD_RJ2HY/\
M61_4T"8Z3H/J*=37[?6G4#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *!UHH'6@!]%%% #**** "BB@C- !1110 4444 %%%% !1G-%% !1110
M 4444 %5$_Y"$_\ N)_[-5NJJ?\ '_/_ +B?^S4ULR);HM'I5:P_U!_WV_F:
MLU7L3F%O]]OYFDNHG\2^98HHHH- HHHH @O?]1_P)?\ T(5,.E0WO^H_X&O\
MQ4R]*?0A?$Q:***184444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%&.<T4 %%%&,T %%%% !1110 5&Y_>1_4U)4;@;T^IH$Q
MS]!]13J;)R!]13J!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M ZT4#K0 ^BBB@!E%%% !1110 4444 %%%% !1110 44?RHS0 4444 %%%&<4
M %54YU"?_<3_ -FJU56/_D(S_P"XG_LU/HR);KU+1Z57L/\ 4'_?;^9JP>E5
MK#_4'_?;^9I+J)_$OF6:***#0**** (+W_4?\"7^8J9>E0WO^H_X$O\ Z$*F
M7I3Z$+XF+1112+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBC&* "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ IC_ZR/ZFGTQ_OQ_4T"8KC('UI
MU-?H/J*=0,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H'6B@=:
M 'T444 ,HHHH **** "BBB@ HHQS10 4444 %%!I <T +1110 4444 %54'_
M !,)S_L)_P"S5:JJG_(0G_W$_P#9J:V9$MT66Z5!8_ZD_P"^W\S5@C-5[$YA
M/^^W\S0MF)_$OF6****1H%%%% $%[_J/^!+_ .A"IEZ5#>_ZC_@2_P#H0J9>
ME/H0OB8M%%%(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M* "BBB@ HHHH **** "BBB@ J.3_ %D?U/\ *I*B<_O8Q]:!,>_0?44ZF2'
M'U%/H&%%%% !1110 4444 %%%(3@9H 6BBB@ HHHH **** "BBB@ H'6B@=:
M 'T444 ,HHHH **** "BBB@ HHHH **** "D3I2TB]* %HHHH ***,<T %5D
M_P"/V;_=7^M6:K)_Q^S<?PK_ %IDO=%@U!8C$)_WV_F:G-06./)./[[?S-"V
M8G\2+%%%%(L**** (;OB$?[R_P#H0J5>E0WG^H_X$O\ ,5,.E/H0OB8M%%%(
ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ H!R*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *B=?WL9]S_ "J6HW/[Q![F@0L@R!]13Z:_0?44
MZ@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0.M% ZT /HHHH
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M10 4444 %%%% !1110 4444 %%%% !1110 4#K10.M #Z*** &4444 %%%%
M!1110 4444 %%%% !1G-%% !1110 4444 %5DS]MF]-J_P!:LU76-A>S.1A6
M10#],Y_G3(ENB=NE06./)./[[?SJ<U%:1F.(@C!W,?UHZ _B1-1112+"BBB@
M""]_U/\ P)?_ $(5,.E172%XL#D[E/ZBI5Z4$+XF+11106%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5"YQ+']34U1NI,B$#(!.: '2' 'U%.ILBE@,>H-.H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ H'6B@=: 'T444 0T445 !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4HZBDI1U%,"6BBBJ AHHHJ "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I1U
M%)2CJ*8$M%%%4!#1114 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2CJ*2E'44P):***H"&
MBBBH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "E'44E*.HI@2T4450!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
21110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ctso-20221231xex10d11g002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ctso-20221231xex10d11g002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 20 SD# 2(  A$! Q$!_\0
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M_P#N)_[-374B6Z+)J"R_U)_WV_G4YZ5!9',)_P!]OYT= ?Q(L4444BPHHHH
M@O?]2!ZLO_H0J93D5#>C,(_WU_\ 0A4RC I]"%\;%HHHI%A1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ?\ ']/_ +J?UJU59#_ITPQ_ G]:?1D2W19/-5[$8A./[[?SJ<G%06/^I/\
MOM_,T+9B?Q(L4444C0**** (+T9@_P"!+_Z$*F'2H;W_ %'_  )?YBIEZ4^A
M"^)BT444BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "HY/OI]3_*I*BDQYB?4T /?H/J*=37[?
M44Z@ HHHH **** "BBB@ H/ HHZ4  Y%%%% !1110 4444 %%%% !0.M% ZT
M /HHHH 91110 4444 %%%% !1110 4444 %(#D4M &* "BBB@ HHHH *JI_Q
M_P _^XG_ +-5JJJC_3YC_L)_[-374F6Z+55[$8A/^^W\ZL56L/\ 4-_OM_.A
M;,E_&OF6:***1H%%%% $%[_J/^!+_,5,O2H;W_4?\"7_ -"%3#I3Z$+XF+11
M12+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *C?_61_4_RJ2HY/]9']30)CGZ#ZBG4U^@^HIU
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MZIG)5<C)Q@9%:] !1110 4444 %%175U#8VTMQ<2I!;Q(9))96"JB@9+$G@
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MO$&IQ>&/#5MKNA:/XB30-2D%\(KI&*QO/<(K *4A\Y05)W-M<KT7=?\ AS\
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MIK[3IXIU6ZUJ*_MK7R9=-NI9%FC>,;SN,4J*ZDD'Y<$]ZM>/OV>)=:?P1?\
M@WQ5=>!=?\(VTFGV%_#;)>1RV4JQK+;S12$"13Y,3 DY5ER.: ,71OVKV\5>
M)?"NBZ!\/?$FH7&MZ7;ZS*9_L]J;&TDN5MY7D224-F%RVY0,G;E RY(]_KRO
MPO\ !6]\._%*T\9S^)9=7EA\/'098[NV'G7#-<_:'N&D5@H)<M\BQJH!P
M*[GP;I6L:+X>@M->UL>(M4229I-1%HEKO5I6:-?+0D#8A5,_Q;,GDF@#;HHH
MH *#GM110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %'>BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *C<_O8Q]:DJ*0?O8S[G^5 F/<9 ^HIU-DX ^HIU PHHHH **** "BBB@
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M_$OF6****1H%%8_A+Q?HWCS0;?6_#^HPZKI4[2)%=6YRC,CM&X'T96'U%;%
M$%[_ *C_ ($O_H0J9>E9_B#4[/1M)FOM0NH+&R@P\MS<R"..-01DLQ( 'N:A
M\+>+M#\;:1%JGA[6+#7=,E)$=[IMREQ"^.N'0E3^!ID+XF:]%%%(L**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ J.3_ %D?U/\ *I*C?_61_4T"8Z3H,>HIU-<9 ^HIU PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "@=:*!UH ?1110 RBBB@ HH
MHH **** "BC/-% !1110 4@/%+0#F@ S7R+XCUKQ*GQ\^&NJZW\-_$<&IW/B
MN[M[>Z:[TMX!9)IFH1Q)$%O2X 1VN)-RJ3EP-Q$:'ZZJK=:59WUS:W%Q:PSW
M%HYDMY9(PS0L5*ED)Y4E689'8D=Z &Z9K-AK*3O87MO>K;S/;3&WE63RY4.'
MC;!.&4\%3R.]7*J:;I%CHZSK8V<%FMQ,]S,((E3S)7.7D; Y8GDD\FK= 'SU
M\%[R2Q_:4^.&FZZWE^)+NXL+W2WN 1]HTA;94C$(/WDCG\\/M/#R'."PSP?A
M[XU:]KGC*7P_/<6&@6VI_$2]\*WNL:'9F!R;6TED7<97E"2SM%%&"!PH;!W,
MI7W+QG\"X?']PSZWXGU&_MUE>6WL[O2](NH;7=VC\ZQ=@ .,EB<#DFL(_LY6
M[://X:7Q1>+X?Q')_99T/13:E@Q8'ROL.SA@"..O-/HR7NCR[Q#\3_'O@C2=
M?UB;Q'>7GAOX?>.8-,U>ZDMK<OJ6B2PV[R/(WE</;/=?,\>W<L#;N235_P 0
M?%+QBNI^!=#AU^'1_P#A,DUC5K6YU*ZATYECCDA^QV<<IM)AO\F;S65HRY,9
M&[:"I].F^ NI+X5F\-VOCR^AT*6&2!],;0])-JR/G>IB%H%*MDY&,')]:S?$
M'[/5Y\1/#ZZ3XM\56_BK3(Y_-2TUKPWI]S$CJ2 P4Q8!P2,^G'<T=!/XD</X
M0UGXH^-/B%X:\-W'Q.M[3'A5=4U"\\/Z;:W%M>7,5^(':%YH<A)(U;.!C+90
MA0,Y/P7^+'C_ %C4_@[=:SXNGU:#QG<>(=.O+.2QM(HHOL;7!@F0QQ*_F 0A
M3EBA!^X#S7L4/P(N[76(]5@UW38=4CLO[.2]C\.6JSI:X \A7&&$? ^0';QT
MK,L_V8K;3?[+^QZEI=F=*DEET_[-X?MX_L;R?ZUHMI'EE\G<5QNR<YR:19YA
M\/?B5\0OB#IOP:M6\:W&ER^)W\1Q:I>6VG6;2NMI/(L#1[XBB.H"C[I!QRIY
M-&D?&SQ[XB\"?#]WU6^MKO4_#>KWDVJZ#I$=Y-=:A:S10VZO (Y-D<@9V.U%
M!<H@=<A6])T_]EV/1I-*?3-9T_3WTDSG3VMM#BC-F9O]<82KCR_,YW;<;N^:
M\X^(O[%&L:T?#EOI'_"O]:T?2$FCM],\3>'9!'9-+(LDDMN8)E*L64$CH2.H
MW-D ]YT.?Q#=? RRN/%JB/Q//I"3:E$%51#<-&&DC 7C",2HQGA>IZUR'[(6
ML6ND?LB_"FYOYUMHCH=C"'E.,N^V-%^K,R@?45!X?^!OCCPKX"M_"J^/M*N-
M%13&UI)H$NT!Y2YC5A>!Q&-Q55+'" +DTWP_^S/=^&!I@TRY\&6J:9(LME$O
MAF[\JV=?NE(_[1V*0<XP..U/H0OB9Q/P]^+_ (^\?^/;3PW;:^IMO$/A;5M8
MT[78K& 60G@O;>.![,,/->#9<;6\]<OL#1G#;CA>%OVK_$MQ<^$KJ^>ZN+75
M]&N-&O;00P1BT\6Q!\6 DV9#2&&7",."T)Y#X'IWA;]E=?!&M:?JVA1^!-,U
M+3UF2TN(?"MWN@25@[HN=2.$W*"%Z*<[0,FNE7X0>)$B2,:EX*"1ZHVM*/\
MA$[CB^+%S<9_M'[^6;GWQTI%GI^AVMY8Z/96^H7?V^^CA1)[K8J>:X W-M4
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MM,TK5;+7=-M=1TV[@O\ 3[J-9K>ZM9%DBFC895T920RD$$$'!H M4444 %%
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M%.IK\ ?44Z@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0.M%
MZT /HHHH 91110 4444 %%%% !1110 48Q110 4B]*S/$OBK1O!FD2ZKK^K6
M6B:9$0)+S4+A((4)X +L0!DUI)R/QH =167K7BK1O#<MA%JVK6.F27]PMI:)
M>7*1&YF8X6.,,1O<D@!1DFET/Q1H_B87ATC5+/5!9W#6ER;*X2803* 6B?:3
MM<!E)4\C(]: -.BL_1O$&E^(X)I]*U&TU.&&9K>62SG654E7[R,5)PPR,@\B
MM"@#P7]J*^AAUWX.JV]C;>-K2]G*1LX@@6WN5::0@$)&"Z@LV "PYK@OV@]
MTWQ-\?M4.I)<2V4?PRU$1-#--$ANOM,;Q)N1E#.0K.J$DY0,!E01];U40_\
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MX2BOQ<W\VK1.H=VA5[I!?R/,)(#$_FMA5V;22:^O6\.Z7(H#:=:L!C&Z%3C
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M"MGP5\.?#'PXLKJT\+Z%8:%;74[W,\=C L0EE8Y9VP.2?>@#Y T";Q/K^B?
M"[O/$TEWK-W\0M>5=0O;6.3RRD.LH3M38&)5>!]T'&!M&VNN\*_M%^.O%@\)
M>%H&L1XEU!O$D,NH)"D1N7TR_P#LB&*.1]H+@^:Z@DX1@NT?,ONEE\ _ .FZ
MC:W]EX;M[*[M;^74[>6V>2,Q7,F[S)%VL,%O,D! XQ)(,8=LT-7_ &9?ACK_
M (=MM"U'PC9WNF6M[)J5O%,\A:"XD;=))&^[<A=B6;:0&)).230!0\2?$/Q?
MH7[,6N>,IO[#A\:Z1H-W?W*VZO=:>;JVC<R*HWJQ4M&P^]\N>K8YXRS\8>.+
M#XD?!VV\477AK7$\4S:A/'/;:,\%Q81KIHF$<<C3/SOW!F"C<N!@<@^WZQ\/
MO#^N^"9?"%UIL8\-2VHLFTZV9K>/[/C;Y0\LJ0FWY=HP".#P<5F7_P (_#UU
M/X<O([:5-1\,Q21Z+<27<[BT+1^625\P>9E?E.\G(R,\T >&^#_C3XZ^),VE
MVD]K8I97^E:M/XCT\Z=(9-!N+>41PVQE\P+F16;!8,6\EG4;&PO!_!OXH^./
M"'P5^'_ANWU;3%M;WX0/XBTJYCTPB:PDLX;-0'+3,LQ=;GNJ@% <$$BN]^%?
M[(L_A*[TI;W3-,T$V2[+W5/#OB74R=74Q,CJUD1'#;ARQ. 9-O(3:=K+['IO
MP \":1_9(M=$*1Z3I$F@V437D[QPV$FT/;A&<J4.Q,@@_<3^Z, 'AD7QW\9?
M#OX6_#._UB]@CT;4?#%I=W'BFXT>:[M(;N2*/RX[XQS&2!&#?\?&UE+DD[0N
MUO</C-X\U/P5H.A2Z//I\5WJ>K06)^V12W$KQ,KLXMH(OFFFVIPN0JC<[':A
M!JQ?LT_#^+2+32AI5Z=,MK-=.%F^LWK136RDE89D,V)HQD@))N 7Y<;>*Z?Q
MW\,O#WQ(LM,MM=M)YAIEXM_93VE[/9SVTZJRATE@='7Y792 V"&(((- 'A/A
MGX[?$GQEJOPUTFT?PYI-YXGL=?\ M<EYI4\WV>YTV[2#>$2Z *N)!F/>=I!(
MD<<&CX<^/_B+X\>!=)TRRM]"TO4=2\ +XHU9;^SENH)//:6!(84$J%5WPS,6
M8O@&,8;)->MZ#^S-\/O#&HZ=?:7I=_9W6G"]%D\>MWV+87;;KD1J9L*'(!X'
M!5<8VC%>#]E;X:6FGZ!9VNB7EE'H5E+IMA)9ZS?0S):2'<]L\B3!Y82>?+D+
M*.P% '(?"SXBP_"3]@OP-XQF@^VQ:-X#TZ[$+/L\UELH]H9L'8"V,M@[1D\X
MKA_VK_'>OV_PS^)O@'QE'HNKIJ'P_P!3U_3]0TRSDMQ$UNT44L;QR2RY(:YA
M=)%9>C#:, GZ7T?X7^&=#^'4'@2VTM9?"4%C_9B:9>2O<H;7;L\EC*S,R;3M
MP2<# Z"L2+]G_P $+X>U'1+G3;G5-.O],.C3)J>H7%V_V'G_ $=9)'9T3GG:
M03A222H( /G+]ICQQXJN/A7\8_A]XTLM#U&,^ )_$>EWFDPR((E4F-X91*[[
MI$;8RS+L##)V*1@>F^-OB+<> _BGX^U.W\(Z?K>K:)\/8M7M9[.W(U*\59KG
M%F9,D^7OB9@JKG,G )&#WE_^SWX-UCPOK6@ZK;7^KVNM62:9J%Q?:E<275Q:
M)NV0&??Y@0;WX5ADLQ.69B</XI?L_6OB/0/%-UH1DF\6ZOX>'ALSZKJEPD$M
MF-W[I]F[:?WDI$H1F#.20P^4@'%6?[1_BR>R\;W%I<>$]?TS1+#2[FT\06HE
MMK&>2]?!C.99-SPH!(8U??)YL*@*SC//:M^T!X^\8:7IT&EWNG:#=VGQ,MO"
M5W<3:/<QM=P-#!=1O]GDG62#*R!'C9B6&>4SBNI\-?LR3Z^MU:^*9_$UMH$\
M4<ITV_\ &][J\T5['<0SP3P32?- 86A.UD?+[SN4!?F[-/V5_ L5OJ,:C7 ]
M]K4'B&2=M=O'E6_B18UF1VD)5BJA6/4C /W5P <)8?%]O!_C[X@Z-!H6A:;X
MCO?&VF>'(=0MXG6.]GN=-@N%N;D;@69(-P"!AN,:IN&[<)_$_P"TCXN\->(9
MO"@TC1KWQ':>+].\.373M-!:3V]];^?!<(HWLC !D9"S8,>1D.,>A7O[.'@_
M4G\227BZC<S:]J%KJUQ.]ZXEAO+9(TM[B&08:-XTAB4$'D(-V[+9GU+X >&=
M6%C)<RZC)>VNM0^(FOOM \^XOXHQ'%+*=N&"(JH$P$P!\O% 'F,W[3^O:5X&
MO]2UNSL],?2/%U]X9U;7[;3;F^TZRC@5V2ZE@C<2QQN?+0L6*QER6;& ?2?$
MGQB/A+X&Z=XZO(K"^N[NUL D6GW7F6<MU=O%#$$G .83+,G[P _)\V#TI++]
MGW1-)>_ETS6-=TRXOM4N=8GFM[M<M<7  GRK(5*,%7Y""H(!4 \UM7'P9\(7
M?PH3X;2Z2K>#DL$TU;#S7RL* !<29WAP0&#YW!@&SGF@#QOXS_&/QEX9\)?%
MSPM>/I]IXDTCP3=>)]-UO2XY(XY+?RYD<>6SLT<T<D8PV]E8.K8&"M;UMX:D
M^#/P#\5>+O">E:#I7BJ30%U">6&WD6UN&M[8F-GB#C+[ 1D$9.,G &.NU3]G
M[0M>\.^)=+U;5-8U2;Q%IHT;4-4N9X_M<E@ X^S*RQA43$LF2JAR7)+%L$=7
M+X$L+SP!-X0U":ZU'2I]/?3)GGD"S20,AC(+(%P=IQD 'OUYH ^6+;Q'XPTS
MXE>%O%5K9Z)JWBAOA1=:A<SW<LD$<ZK<6DBEF5&8L<8(X W$C.T ]W)^U=J>
MOV$$_@_P?<Z]=KX>TSQ#+IZ),[S"]C:6.VC=(V1'\M&^>0A2Q4=-S)V6G?LU
M:'IMQ:SQ^(?$4DUMX>E\,I)/=12'['(RLWWHC\V43!&,;!QR<YR_LC>#[>X\
M/3V.K>)M)GTG1X- DDTS56M3J-A",0P77EA=X0$@.-KX)^:@#-_;7OV_X90\
M8:Q!Y]G>P6L%S;31GRY[9VFC&58'*MM9E)!Z$CH:YZ+4O&'PJ\;>//%FE^';
MS3/A\+"PMK?2-?UB""W:_-SY<]Y'F1Q;P1Q.N\#:9#'E48D,?:OBK\(]'^+G
MP[O/!6IW%YIVAW:QQRII;1Q.41E94!9&VC*KT /&,T[XA?"NQ^)7A&RT/5-3
MU*%[*]M=1M]3LWCCN8[FWE66*7[AC)#*"5*%3Z4 >,P?M8^(]4TS0H]'\'V&
MHZQJ7B^\\'!+C4)K.+SX;66XCGQ);[UC98OF#+N7G:).,X'B[XI>,M4\'?'Y
M/'?A?1-1TGPSH]NUUH-GK5Q;C8U@MS/$+A(=[,0[C>-OW$  Y:O4=+_98T'2
MM;LM43Q%XCFGM/$<GBJ-;BX@D4WTD#02,<PYVLCR#:",;SC&U M[QC^S?HOC
M*[^(#S:YKEE:^-[..TU:RM)H!$0L*P[X]\+,K&)0A^8CN &YH YO6?VCK_2=
M=U'1_#?@R^\20^'I[&RU.&PANI9]TT4,KB$I T1,44\;D22(7^8 # +;7@KX
M]CQK\6-7\'QVVG6MQI-S<P75G/?/'J421MMCN#;/$N^"4<K)&[  KDDDA$O?
MV7=!N_&LWB6/Q#XEL9;^V@MM;TZSOTBLM;$*"-&NHA'][8 I,1CRHP>,@[-G
M\#M,@^(>D^+;[6-5UC4-+DO9--BOC;[++[5DRHCI"LC)AB%61W &.,A2 #R?
MXL>/=;^&'[0GC3Q%HND)X@BTSX?P:M=V5[JKVD0BBNKDR&(^7*/,*Q !=JJ2
MOS.O&>G\0?M42VVH7D?ASP5K'BNVTZ.PDO?L%K=O<?Z3'',$A2*WDC=TAEC<
MB22+K@'J:ZGQW\ =-\=>(O$^L7>NZS:R^(?#Q\,7,%JUL(XK0L[$Q[H68/F6
M3YF+#YNG QB?\,HZ-;^(XM7T_P 6^*M*\[3[73=7L[&\AB@UJ*WC\N)KE1#E
M7\OY"\)B.W@$4 8TO[56KV)\87M[X&$?A_PYK<GAZ6_M]4\^:XO2ULELD=NL
M.\B1[I02,E=O"OG MVW[3NJQ26L6J^ ]0TIY?$NG^'C/<K=6]O,MYQ'/;M<V
ML+3;#E70HFT@8+ @G>G_ &8_#FH>$/'OAO4=2U>_T_QCJC:S=,\T4<MI='RR
MKVSQQ(4V&&)EW;B"@R3DYK7?[-$6I^$X=-U/QQXGUC6[?4;+5+;Q)?RVSWL,
MMI)O@4*L A* E\AHR6\QB23@@ R+_P#:COK:X6TM_!PN[P^.)/ ^U=358_/%
MN)UGW-&#L*Y!&,C:?O< W/#/[1%_XVTVRTRS\,0Q^,[C5=5TBYTI]6*6MN=/
MD\NYF^U+#O:/+0A2L6XF9 0O)#[']E;3+*YMKAO%>OW,T/BP^,RTQM3YM_Y)
MAPVV ?NRA.5&.>A4#%0VW[*MII5];:II?C'7--UVWUW4==BU&)+5F5K\@WEN
M4:$HT+$*0""RE%.XXH \^^"WQ[O_  K\*-$TR/1M3\3>++F37M1>QFN+F[EB
M@@U2>)4>:.*=V<LR1J67:=C9<8 /I.@?M$ZUXK\;:=X?TKX<:PK3Z;IFL73:
MG<164UC:W<DD;^;#)\PEB:)\Q]6VM@]-V/9?L>6V@VGAR?P_\0/%&A>)-$DO
M_+U^W^QO/<07EP;B>WFC>W,4B>8=Z[D)4\@UZ!X/^#B>#_B'>>*8-;O+G[3H
M]KHK65RJ.#' \DBRM)C>TI>>8LQ.#NZ#&: /1Z#GM12'B@!:*** "BBB@ HH
MHH **** "@=:*!UH ?1110 RBBB@ HHHH **** "BBB@ [T$X!HHH ^(OC#\
M8?$'BOX*?%#PYXJ+:/XAA\--J+:1/9J(I$^TQJ+JRN8V=+BV(91RPD4E=X&X
M >DZS\;?&GAG5_B%X<N]6\/S:II-[H<6FWSV$T0D&H.R/ D"/(TLP\J3RAD
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M>VG/FX+1-/;EM@'R2%N-AS83X[>.KWQ+KUOX<\+6VL:+X<\0)HFJS236UO\
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M'&$=08]@&P9&&R30!S'[0/[0LNN_ WQW/X&M-?\ M>G^&UU2?5;)TLYM*>>
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M.:[+XP?"[5/BAX?\/V=KKMII=YI6JV^J2K=Z<;RQOO+5@8IK?S4+(2P<?/\
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M?!2:'K'A?QAHVG^+-*U'6Y"U[I\MSI]Y9:G>?;)8)8ED1]\4NW8ZN,[.0-Q
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MQ,T[Q7IOAVS\-^.=$M;&ZM=)O[F\GBG2*2*1FEFB1I2?,+^<QWEL9'R[C9\
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MV\)*0PRN4^9:],^+OQ>TWX0Z5I-YJ%G?WS:GJMGI4,=C:2S[7GF2/<WEHV
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MF9&C+2-<1%%$ 4C"_,VX9/'2M6Q\5:-JFDV^J6>JV5WIMRXCANX+A'BE8MM
M5P<$EN, ]>*^3O%WP^\7#XD?$K5])\,W,^CW'BGPWK5Q810!%UFSM8@MXL6X
M .ZRXDPV#(8L#.ZJ'Q,^%5YXD\2ZCX@M/"U[=^&-6\=>&]4ATN?29#(L=NR_
MVE>M R;HUECV(RNJL_D'Y3N&0#[ /BK11HXU8ZM8_P!ED[1>_:$\DG.W&_.W
MKQUZ\5G^-]<N=/\ A]KNL:-<0?:;?3I[JVG=?-B)6-F4X!&X<>M?*</@#4H[
M+QE;65IXC\(R0_$>ZUK0KVS\./>6L,4FGK"'DM#&?-MI&^THP3:P:17RH(8^
MY_"*^U#4/!'AOP5XJ\#3Z%<2>&8YKZ&TASI,'/E&S5RY8/M^;R^0J<;CCD [
MSX=ZU<^)/ 'AK5[PJ;R_TRVNIBB[5+O$K-@=ADFNAJII.E6FA:7::=80):V-
MI$L$$$8PL<:C"J/0   5;H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%CINF>+[/7[_ $O7M)B,C_8;>V4GS49B#()/,LF5L ;;M>#M.>>^)X\3:?\
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M+$T >UZ/\>_ NN-XA%MK@C&@VL=_?M=VLULJ6T@<QW"-*BB6)O+?;)'N4[2
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M0(W+K*2G5/6V_9]\9_VI/<B;0BC_ !(7QL%-W,#]G%NL/D_ZCA_E!STYQ[T
M>@V_[2/@V\T^PFMVU*>^OM1N])ATE;"07INK57>YC,9 QL6-F))P1C!)8 XM
MK\6I?%OQ@^%[^&]9:Z\%>*_#6I:L(&MU3S3$UGY$OSH)$^6X<%<CMD<&N1;]
MGSQ_%J+[+SP_>:'>^*-7UK4M%N;NX6"YBNU @+E8LR&$AB86_=R;N64JI$/@
M#X'>/OAG8?#"\N)/#+R>!/".H:#(R7=P8Y6D6W,<@7R,[0;1"PR#B0@9VY<
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MK 5]"_!WPI-H_P 'M7M?#6FZKX5;4)+V[TVW\0R W,$LV6\QXAD0 REG$0Z
MY(4DJ #U6TUBQO[FYM[:[@GN+8@3Q1R*SQ$] P!ROXTMIJUE?RO';74,\B*K
MLD<@8JK<J2!T![>M?('A_P %W6I:!\,Y4\&:KH>M>&=!U"Q\817&DR-]L0V3
M1O;[MFV_,MV(YE,9<':S$AFP>,T;X;>(M)\)^&=/\%^%=5\.^*;WX/7>D7-W
M'I$]ENU8"V\N*>X**J2YBN=K.>-V0<,,@'WK::A;:@)#;7$5PL;F-S$X8*PZ
MJ<="/2@:A;&]>S%Q$;M$$K0!QO"$X#;>N,]Z^=_V6=$L9=<UGQ%8>'/&7AR2
MYTZVLKZ#Q1ID&E1^9$6V)%;0P1+*45G!GQ@J44,V"$\EU72[X_'_ $/6Y?!/
MB*RMK;Q]J8U-(?#MY="XLY--N(%N7NRC>;#,P@"Q1D11C <9 8 'W)%=PS2&
M-)49P,E0P) R1_,$?A7&:E\3ET_XO:%X&&G&7^U=-O-074%G7;$;=H T13KD
MBY0@Y'&:^1?A?X%U/PQIGPCN_#GA'5= \5-I/B>RN+R?0+BV:*60EK)+MVB&
MR/>J%%D(7@8KJ?@99V*?%CX07]IX(U_P_JMOX/U'3O$=W?\ AZZ@;^T"]B2+
MBY:,+*[.EPWF[F#%B=QW\@'U+XB\>:=H>HW&D1R)>:^FF3ZM'I<<@$DD$3(I
M;)X4%I%4%L9.<?=.(_A7XZC^*'PT\*^,(;1K"'7M,M]32U=][1+-&KA2P R0
M&QG%>%_%+P]I.E_M5V_B/4?"\UY%/X'O((-4M]%DNPEZEQ&1NDCC;9((LA2Q
M!(^4'G%>'>%O"&N>&?!_A"W\#Z#J>B>--0^#5[8W\L%I):SRZM&+06T,TSH,
M7"[+L1ASN0 XP * /T.HKYJ_90TCPZ^LZUKWA>#QK86UW806^H6'B31XM(MH
M+I&;"I EK ))P&99)EW*0$&YB/EXS7EU#PY\9]>UBQT2X\:07,^JSN;'3I;/
MQ%H\D5A.H2.X *7%I*5V0@[2LDT6-Q7  /LC-%?FAK*RV_@'Q_9Z/:ZE;0:E
MX*T*XL[?3-'O[-9+U;R<3;G90;BY$9599R%,A'*J5VCLOBQH&GZ/+\>Y?#RW
M4;6']@:EX9%G/.X6])7[3<6JAB&F.R/S)%!8Y(8_,V0#[]K$\3Z]?:$VD"RT
M.\UL7M_':3M9M$HLHF#%KB3>ZY1=H!"[F^884\U\AZY>3>(_CSXATOQ!J7B+
M3O$C:]9:EX1N=&T=YUO-.$<&Q8+T(R10[A,)U8JI$CDYW5[3^TI>1V=_\*W:
MZN+=_P#A,[+S!#*RH8=DNXR*#@H#LR6! )7UY /;JHZ[KECX:T:]U;4[E+/3
MK*%[BXN)#A8HT4LS'V !-?#?A62/3?$?@_7X=2O?[6D^,>LZ<]U/J,TI.CN+
M[8A#N1Y+?Z(0<8),1SDJ:YKQY:2ZQ\/OB-I%U:VOC.W;PY<ZQ!XDTJ*1;@_Z
M;;MY.JVAW8O$ )24'+)%)\J[1@ _196#J&'0TN<5\J^$="\(_$+]I/Q!:V^K
M:E<>'K'PYHVH:;IMMJ]W#:&<7-[YK"$.%92GD;E(V,LP)!#Y/C/@7X@277A3
MX-6EWXBU2/5[;X?>([/Q!*+RYAEBOXEM/+CGF4@K-&WFD G>N_/ <;@#]$**
M^!M+CTBZMM"CN?%6LF.]^$!U.]C'B6[3S=1B6(1R./._UJAYL+VQ]WY!@\5?
M$F\U4>#-.\7>/;CPKHVO?#_3&TC7S:7ET\FLGSEO##);3QXO5S;E0ZR'((4#
M<ZN ??-5;35+2_N;VWM[B.::RE$-RB,"8I"BR!6]#LD1L'LP/>O@WQYXK_LZ
MT^+&L7OC;5[?7?#&M>%C9FYUV2#[,[I9&YW6ZS&(!V:Y5X\,B_O0/XJ]F^&7
MC?P)\-/B#\=KK5=<@TSR/%%I<2++=R2;(+G2])2.9H\GB2X<J'QR<@'"D  ^
MEB< FN8\$_$GP_\ $2;Q#%H-^M\^@ZI+H]^%&/*NHPI=/?&\#/J#Z5D?&KXC
M1?#GP+/=Q7MC::WJ$L>EZ.NH3+'')?3N(H0V>JJSAFP"0JL<<5\^_#R-OV:O
MVE-&T+5XM)T'1?B%HJ6<<<&L-=F75;!55)Y&D@AQ)/#(5) ;>\2Y.2!0!]0>
M-/&UAX'L+.>[CGNKB^NDL;*RM0IFNKAP2L:;F5<[59B68 !6)( J;P9XG7QE
MX:L]773=2T<W 8-8:O:FWNH&5V1E=#[J<$$JPPRDJ03X7^UC;:-/XT^!\>IZ
MG-8/<>,EA(BU>:R/EG3[W+*(Y$^;?Y:[QAAOV@X8@^/V'QMN8/CAX;.D^,I[
MJ*Z\4>(]*N-(U;7&,\AAM;E;>VELB1';H)X(EB)!ED!#$@NP(!]W5B^*?%,7
MA2VL9I=/U+41=WT%BJ:99O<O&97"B20+]V)<Y9SPH!)KY%\!?%/1O%WPTGUK
M1OBSJEIXRG\'RP^(;/5+J:>VT34CM5KJ[A)W6+1S^9&%CV JQ*J5BW*P_$K5
MXO".FPRW.K^']<T_XG:!I>I"/Q)-J=E-%,UIO2VNG;?);R1'>8I/F4R.&'(R
M ?:]8WBCQ1!X4MK*>>RU"^6ZO8+%5TZS>Y9&E<()'" [8USEG/"@$FOB]->U
MRYU&UO4\=^)(Y9?C)=>$ML>KR&(::RRJ;<1DE"?E4JY!=#RC*:UK3QSKVF>!
MK6"'Q5J[+I/QKA\-13SZC)+-+I_]IQK]FFE=B\H\MROSL25X)- 'U;X3^(FC
M>-=9\3Z7I<EP]WX<OET[4%GMWAV3-"DP"[@"PV2H=PX.>":Z:OA_QK\1I_ O
MQ'^)LCZPGASP[J/Q)T_3M8UJ1Y$CM83X=MVC\R6-T>%&N$@1I RX#') )KW_
M .">L7Z?"G6[NT\61?$P6US>OI>HVV6CGC&6CMDGWN;@1L3%YQ8D[,'+ D@'
ML-12#]]&?<_RKY'\&>--<UC1?@MX@TCQ3J6I7?C+3;I?%-HUVSI ZV+RRW$<
M;Y%LUO=(L&U H_>A6!(4CT#]D"+5]3^"7A#QGK_BO6O$NJ>)=#L;VZ75)D>*
MWD\DEO)54!7=N&[).2@/7)()GO4OW1]13Z^#O"WQMUN^\063V?CNYN['7_!V
MO:NEY)>QF::>"YA%K,+)O,2R(625%C5CO"DNJNI ]*_9P\3^)9?'G@&WU/Q/
MJNNV_B;X96OB*]BU*59%6\$ELN^,!1LRL[@@?>PI;+9)!GU/1110 49Q110
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M#FKWP)X;$ *^']*4[UY%E'_>'^S4X\!>&<?\B[I7_@%%_P#$UKWO^H_X$O\
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M;RVJ*HP"NQA=9W#<>.!ZZ'P(^(UU\6OA#X9\87UI#876K6QN)+:W8M'&=[#
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MS?Z UBD;S$*& 3>HR&QVZD' !]@V?B_0]0FLXK75[&YEO8S-;)%<HS3QCJZ
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M">: /K"VN$NH(YH\[)%#+N4J<'U!Y%)=7<-E&LD\J0HSK&&=@ 69@JKSW)(
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M-I=UX>^(5\;!-,BLV,^EM-#-+:MO$G[W88=DZG')9EV!"" ?25%?*OPY^/\
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M_9UL;2YU6^MO%&N0:QK%R+C5-32*PWWX$'DB.:(VODLNW_IGN)QEC@5S]_\
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M!I6>1]Q;<4Y7U'PYX"3QE\5="L/$'AK4YO#-[\*T\/WQO=-GC@\]IT9[=W9
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M5?"RYUGPGJ[?$C2OB9?S>(M570+F3_0Y(]2$$@NEB*/;^6UDJ8<A%55.-AP
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M4\BQ_P"/&TO]:O+VVLOEV@00SRND6%)5=H&U6*KA3BO0**  #%8?C;P=I_Q
M\*ZCX>U5KI=/OX_*E:RNI+:8#((*R1D,IR!T/L<@D5N49S0!F>&?#6G>#]"L
M]'TF VUA:KMC1I&D8Y)+,SL2SLS$LS,2S$DDDDFM.BB@ HQFBB@ H/(HHH S
M]"T"P\-V L].@\B#>\A!=G9W9BSNS,2S,Q))9B22>36A110 8HHHH *,444
M)@5Q'C?X5V_CSQ#HVH7VN:U;Z=IY;SM#L[I8[#4<LC+]I386<*R# #*""P;<
M"17<44 (HP,=J6BB@!,"HW7][&?K_*I:C<_O8_J?Y4"82KD#ZBG>6O' XZ42
M=!]13J!C(X(XMVQ NXY.!C)]:CMK&WLQB"%(EP!A% &!P*GHH @:PMVG:8PH
M96 #/M&2!G&3[9/YFJLWAW3+A2LNGVLJGJ'A4C^5:-% %&WT/3[6\^UPV5O%
M=;/+\](E#[<YV[@,XSSBKU%% !0<]J** "BBB@ HHHH **** "BBB@ H'6B@
M=: 'T444 ,HHHH **** #/-%%% !1110 4444 !Z4BC I:08[4 +7&>*/A#X
M:\7>)(?$%[%J5KK,<"VIO=(UB\TZ26%2S+'*;:6/S55G<A7W %B1C-=G10!2
MT71;+P[ID&GZ= MM9P A(U)/4DDDGDDDDEB222222:NT44 %5$_Y",_7[B?^
MS5;JJG_'_/\ [B?^S4ULR);HLGI5>P&(#_OM_,U9/2J]B<PG_?;^="V8G\2^
M98HHHI&@444"@"O?#-O_ ,#7_P!"%3KTJ&].(/\ @2_^A"IATI]"%\3%QFBB
MBD6%8OC3PG9^._"6L>'=1DN8K'5+62SG>SF,,RHZE24<<@X/^.16U10!PGA7
MX73:)J%E>ZSXMUOQA/IZL+(ZNEG&+=F4HSA;:WA!<J2N6S@$XQDY[O%%% ";
M1Z4TPH65BH++P#CD4^B@"!K"W=LM"C'&W)4=/2ECLX8?-V1(GFDL^U0-Q/!)
M]>@J:B@"E;Z+86<B2065O#(B[$>.)5*KZ @=/:EO=&L-2D62[L[>Y=4:-6FB
M5R%888 D=".".]7** *<>C6$,YF2SMTF,(M_,$2AO*'1,X^[[=*KV_A;1K33
MX+"#2K*&Q@E$\5M';HL:2!MP=5 P&#<Y'.>:U** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0#: !T%+110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !4;_P"MC^IJ2HW/[Q/J:!,<_0?4
M4ZFOT'U%.H&%%%% !1110 4444 %%%% !1110 448HH **** "BBB@ H'6B@
M=: 'T444 ,HHHH **** "BBB@ HHHH **** "@'-!I ,4 +1110 4444 %5D
M_P"/Z<_[*_UJS59?^/V;_=7^M/HR7NBP:@L?]2?]]OYU.:@L?]2?]]OYFA;,
M3^)%BBBBD6%%%% $%X,PC_>7^8J9>E17?^I'^\O\Q4J]*?0A?$Q:***18444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11C%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %1R9\V/TR?Y5)44G,T?U/\ *@0^3H/J*=3)" !GU%/H
M&%%%% !1110 4444 %%&:* "BBB@ HHHH **** "BBB@ H'6B@=: 'T444 ,
MHHHH **** "BBB@ HHHH **** "C&**1>10 M%%% !1110 573B\F_W5_K5B
MH$ ^URG_ &5_K3)>Z)C4%B,0G_?;^9J<U#9\Q-_OM_.A;"?Q(GHHHI%A1110
M!!>_Z@?[Z_S%3#I4-Y_J1_OK_,5,.E/H0OB8M%%%(L**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M J&3_6Q_4_RJ:HG_ -;']30 LV0J_P"\*>*9,-RK_O"I* #G/M1110 4444
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M!3FD'?.!37RX(_*@"0=!BEJ/) QC)'>F98G H F)P*8S8Y!I K$]*#$<\=*
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M1)#!&H1(XU"JJCH !P![4 24444 %%%% !1110 4444 %%%% !1110 4444
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M[!'<AE/_ !\WLCN I/'$<"$X'.X<\8H ]JHHHH **** "BBB@ HHHH ****
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M1(^2J$\G'7 _$?G4E !1110 4444 %%%(3@9H 6BBB@ HHHH **** "BBB@
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MTVV1XE8\'RXA$A9>&9Y3QNP #V2BH+Z^M]-M);J[GCMK:)2\DTSA411U))X
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MOM1^*_C]],UF^O\ 13'IUMXBTA]&DDMI+>WDGEB,<S$X<R)'&2K("N]P,8H
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M0> /@)<^%K&:6ZU[Q;?6VBHZD+<:A<74J1S.3QAC'O.20  !D4BR?X3ZW8?
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M,%T9YKJ\DQMMH"P&$7 RP544!WVJ.*Z?5?B=_P (OIFE6>JV?V_QK>6RR_\
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M\-67C7P?H-EHNB>!/!VFZ591"&WM+?Q+<JD:#H /[._7J3R:]%O1F#_@:_\
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M\"OC1?>%=2NO#^N:?JU_IVL_$?Q#X>L->NKY;@12QW-W);P%7D:4H(K9D#$
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M)*SNVY@W*J,=Z]DHH Y+4/AGX0-AH\#>%]&:#1IEDTV,Z?$5L6WJ<PC;B,Y
M.5QR!5;4?ACI>FOXAUSP?H_A_P />.M4MGC/B!M)C>5Y",JTY38\JA@"5+\X
MKK[W_4?\"7^8J9>E/H0OB9RGPX\'7OA+2+I]8U"'5_$6IW'VW5=0M[?[/%-/
MY:1CRX]S%$6.*-%!9CA!DDDFDU[X1^!_%.LKK&M>#]!UC5U3REU"_P!,@GN
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M3?&ND?$Q-'\;QI<VE_=MHGVC3[NSE=&CMUM6GS$(O*3:PE)W&1B#O(JAXO\
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M4;>26 K0\"_%\>(-0^(4>MQ6&AV/A36ETL7GVW=%-&UK;7"RL[*@0G[2!MY
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MBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHVP@EMR?9F!0Y_AD:@#WKQ%XKT7PA9Q7>NZO8Z-:RS+;QSZA<I CRMG:@9R
M6.#@=3BM..19HU=&#HPR&!R"/6OAKQI\0S^T%9_!OX@+;7&GZ78^,=!L8;.9
M&C*ZC),&OL@_>\HJD"MCAA<#G->E-\:?%DOQJT'3+74X]1\/ZGXMU#PY*\%G
M$ME D&GSRB)68B=[E)K<[V&8?F91\RG: ?3M%?(WA#XZ^.=/G^'^J:[XFTV[
MTWQ+%XCCNX[NP6UMK/[!YKQ7&]3O Q"0^3@JV0JLI)AT;]H;XBZ58^.%DA_M
MZ_LO %GXML3?6<=LKW$KW"2&%%*/]E_<ADCG"S\$,06& #ZPUW7M-\,:1>:K
MJ]_;:7I=G$T]S>WDJQ0P1J,L[NQ 50.I)JW;7,5Y;QSP2+-#*H=)$8%64\@@
MCJ#7RWXK^*7C[3?AG\:]:M;RWU;P[X=T$WNB:CKFAM&][-]F:6XCD3,2NL97
M;Q&,&3:Q8QL#!\1OC3\0O"]]\4;C3=6T>.Q\%VFBWL-B^E,6G%R6,D4DGF\?
M*IY50<[2,8(8 ^KZH:OX@TSP_'#)JFHVFG1S/Y<;7<ZQ!VQG:"Q&3@'@>E?/
M?Q$^,7Q"M/'WBG1?#,-LFJ:7JNBV>E:5<::]U'JEG=>5]KNV970KY.^4\.JH
M+?+Y$JD=K^T]X1MO'OP4N/#.LKY]GJ^J:-87?D KE)-3M4<KR2O!)')Q[T >
ML7-W#9VTEQ<2I!!&I=Y9&"JB@9))/  ]:;I^HVNJVD=U97,-W;29V30.'1L$
M@X(X/((_"OA'QGX[U_XB?LH^.OAMKTK_ /"5> ]!UA/%]RNY#)]AMG-@X/7%
MVWD7 )^5D@N$/6O3KKXR>/;8S^%?A]HEM?7WA?PUI%^T=W]G2"<S1N2LTDES
M$T46R+ =$<ALDY"[6 /JBJ>I:U8:,+<W][;V0N9DMX3<2K'YDKD*B+DC+,2
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M 07O, _WU_F*F7I4-[_J/^!+_,5,O2GT(7Q,6BBBD6%%%% !1CFBB@ HHHH
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M **** "@=:*!UH ?1110 RBBB@ HHHH **** "BBB@ HHHH *,8HHH ****
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MH **** "BBB@ HHHH **",TF>U "T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%!.* "BBB@ HHHH ****
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MS1112- HHHH @O?]1_P)?YBIEZ5#>_ZC_@:_^A"IATI]"%\3%HHHI%A1110
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MA?L):Q\1=&TR!_''AE-<O-(U".W0S*YM2NTG&67HVP\$HO'%=3X;\!>'I_\
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MB@=: 'T444 ,HHHH **** "BBB@ HHHH *!Q110 49YHHH **** "BBB@ J
M?\?4G^ZO]:GJ!.;J7_=7^M,E]"<U6L/]0W^^W\ZL-TJ"R_U+9_OM_.A;,E_$
MOF6****1H%%%% $%Z,P?\"7_ -"%3#I4-[_J!_O+_,5,.E/H0OB8M%%%(L**
M** "C/-%% !1WHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ J)_]='^-2U')]^/ZG^5 F.?H/J*=37Z#ZBG4#"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *!UHH'6@!]%%% #****
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT5\/? 6E?#7PO:Z)I,'EP199Y3@R3R'[TCG RQ/X#@    >?? 7QIIL%U=^
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M#-)TWH%DO=2$\9SW)0JP [X4^V:W^JU/M67JTOPO<S]O![7?R9ZK17D-[/\
M'5;>9[:+P 9%4LD;->DN<?=SP!D]Z](\*7FK:AX:TVYUVQ@TS698$:[L[:?S
MHX92/F57P-P![XK.I2]FD^9/T9<9\SM9HUJ***P- HHHH **** "BBB@!KR;
M"HVLVXXR.W&>:=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %1R']Y&/<_P JDJ.3[Z?4_P J!,<_0?44ZFR<@?44Z@84444
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M_"FJ>#K3Q1X3UVW\ 1%KZ+3M)MI+ZYO+P$D&\$?6=SM(!X16VI@J67V[P_\
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M8+;Z[HNLMI_BWQ$L'A_X=Z8P@\-:'Y.V74)^0KK .68]$106.,# +[^[\>_
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MH **** "BBB@ HHHH **** "HY/OI]34E1R?ZR/ZG^5 AS]!]13J;)T'UIU
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M[/2K73I;^."Z:&2U:;>Y1LE WFKM*Y/R_,%->S:;?ZV_BS5;&YT>WMO#\%O
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MBB@ !R**** "BBB@ H'6B@=: 'T444 ,HHHH **** "BBB@ HHH Q0 4444
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M^52U'(/WD9[Y/\J!#I.@^HIU-?H/J*=0,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ H'6B@=: 'T444 ,HHHH **** "BBB@ HHHH **** "N,
M\%_"O2_ NO>)M8L+N_FOO$=RMYJ+7,JNLLZQ)$L@ 4!2(XT7"X&%'&>:[.C&
M* /)8OV9O"=O;:''%=ZU#-HVM7FNVEW#?F.=;B[\S[4I=0#LE,TI([;_ )2N
M!BEK/[)_@W6]&N+&:]UVWNGUZ;Q-;ZK97_V>]LM0ESYLL,L:C:'#,"A!7!Z"
MO9Z* .*\/?"C3O#%UH4UEJVO$:5%<HT4^J2RI?O.59YKH,3YT@*Y5C]W<P4
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M *$*F'2H;W_4#_>7^8J8=*?0A?$Q:***184444 %%%% !1110 4444 %%%%
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ J-_\ 61^N3_*I*C<?O8S[G^5
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MY3S\*?B!^%A:'_VYIA^/UPJY;X6_$)3Z?V5 W\IS7K-%!9Y,W[0BHFY_AO\
M$%>O T+<?R$AIX_:&LMH+>!?B N>W_",7)Q^0->K44 >27G[0=@80/\ A"?'
MP^9>OA6[]1_LTY_VB]-B^]X(^()_W?"=X?Y)7J-]_J/^!K_Z$*G'2GT(7Q,\
MA3]IO0B7$O@_XBP;?[W@?4VS]-D!S_\ 7J9?VFO"ID*OH/Q"0@=3\/->8?\
MCMF:]9ZT4BSRK_AI;PC_ - CQ_\ ^&Y\0_\ R#4$W[4O@BVSYUAXYAP,GS/A
M[KZX_.RKURC/- 'CX_:P^'F#O?Q3#CKYW@O6H_\ T*T%3I^U-\.9.FH:P/\
M>\-ZF/YV]>LT4 >5#]J#X=D9_M+50/?P[J0_]MZB/[5/PU7[VL:BGNV@Z@!^
ML%>M44 <#X.^._@CQ]K0TC0M9:]U$H\@@:SGB.U<;CET4<9'>N^HHH ****
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MG4#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *!UHH'6@!]%%%
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MB@ HHHH *CD_UD?U/\JDIDGWT^O]*!,5SC'3KWIU-?H/J*=0,**** "BBB@
MHHHH **** "BBB@ HHHH  <BBBB@ HHHH *!UHH'6@!]%%% #**** "C&:**
M "BBB@ HHHH **** #O111G- !1110 4444 %0KS<R#V7^M35"I_TF3UPO\
M6FB7NB4]*@LO]2W^^W\ZG-061S"W^^W\Z%L)_$BQ1112+"BBB@""]_U _P!Y
M?YBIEZ5%=_ZG_@2_S%2KTI]"%\3%HHHI%A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %&<444 %%%% !1110 4444 %%%% !1110 4QQET^
MI_E3ZB<_O8_J: 'OT'U%.IKG 'U%.H **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ H'6B@=: 'T444 ,HHHH **** "BBB@ HHHH ****  T@.:
M6D7I0 M%%% !1110 5"/^/B3Z+_6IJA'_'Q)]%_K30GNB4U#9?ZIO]]OYU,:
MALO]4W^^W\Z%L2_B1/1112+"BBB@""\_U(_WE_F*F4Y%0WG^I'^^O\Q4R]*?
M0A?$Q:***184444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !43K^\0_6I:8YPZ?6@!7Z#ZBG4C=!]1
M2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4#K10.M #Z***
M&4444 %%%% !1110 4444 %%%% !2 Y%+1C% !1110 4444 %0C_ (^)/HO]
M:FJ$?Z^3Z#^M-">Z)34-G_JF_P!]OYU,:@LAB%O]]OYT+8E_$BQ1112+"BBB
M@""]_P!0/]Y?YBIATJ&]/[G_ ($O\Q4R]*?0A?$Q:***184444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM%%%4!#1114 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !2CJ*2E'44P):***H"&BBBH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "E'44E*.HI@2T4450$-%%%0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %*.HI*4=13 EHHHJ@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ctso-20221231xex10d11g003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ctso-20221231xex10d11g003.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 20 SD# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%(?WL
M?U/\JEJ-S^\C'UH$.DZ#ZBG4R0X ^HI] PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "@=:*!UH ?1110 RBBB@ HHHH **,\T4 %%%% !1110
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M)CGZ#ZBG4V0X ^HIU PHHHH **,XHH **** "CK11C- !1110 4444 %%%%
M!1110 4#K10.M #Z*** &4444 %%%% !1110 4444 %%%%  3BD!S2T4 %%%
M% !G-%%% !4(_P!?)ZX']:FJ$?\ 'Q)]!_6F)DQYJO8_ZD_[[?SJP>*KV!S
M?]]OYT+9D/XE\RQ1112- HHHH @O?]1_P)?YBIATJ&]_U'_ E_F*F'2GT(7Q
M,6BBBD6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5$Y_>Q^F3_ "J6HI#^^C^I_E0)CY!D#ZBG
M4R7HO^\*?0,**** "BBB@ HHHH ***1L8YH 6B@44 %%%% !1110 4444 %
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M 4444 %&:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ J-Q^]C/UJ2HW_UL?U/\J!,<_0?44ZFOV^HIU PHHHH **** "BBB@
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MB@ J.3_6Q_4_RJ2HW_UD?U/\J!,<_0?44ZF2#(7ZBGT#"BBB@ HHHH ****
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M\+?C#\-O%]CJ"_$36Y;E(TNK2:8Z@[VZ1QRF15DV$2!YANZ^8"A9FK](Z,4
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MQDG3#,$10H&:MZM^R/KFF^#?A5+H?A[0+;Q98>(HK[Q-/:S!&GM#<-,T;3%
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M@6#PKXBL_"L&IZG:2>)[2YTW3M8MX+ZTCU'4)+N&Y@N)4,>X952#C@\@Y*J
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MJ36/B/\ &;5?#5E_PB.F:%8RV*I#JFI20ZM=I<6<5R&@AVE9"!(01D8V]\\
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M7X>:;KGCOQ!:Z-+J^IZI'I\D6FW20O:07LT$<DA*L(R4C4L7*8)Z"O4OC?\
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M'_@%XB^%_P"T!-JGD03>#I='O)H)H9_^/2^NY;)[J#RV;<5>6VEG#* N9F&
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MR1]F$QC9WRJ?*1SS7Z74A4$<B@#\U=#\4Z;K:0Z9X/T3X::3=6OQ*\-P#4?
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M413CLBCH!67KO[+GPP\0Z*FE7'A:.VLDCLX433;J>Q98[5)$MT#P2(P5%FE
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MS>:MTICMD65R2RD2*=RM\V2%*VM8_9#UN\\%7.@VOQ2U,3ZCX@_X275=0O\
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MU;]DCQQXG\#ZSI6K>(]#.IWGP]B\&12VL4ZP^;%<.Z3,&+-@QF,$\G<6(7
M-'6OV+?$NI_&B;7Y-2T^]\(:C?Z7?WUB=8U&SE0VL42%?)A(BN.8R4:3;LSC
M!%?8M% "$9%?&V@_!'XU_#WPCXQ^'>CV'A36_"FM?VD[:E>W,L4[K<6K*%"I
MC#F38#GA1G! VA?INS^+/A:]\+>(/$:ZDT&BZ!/>6VI7=W;2VZV[VK,MQD2*
MI95*-\R@J<<$U#\+?C1X'^->E7.I>!_$MCXDL[640SO9R9:%R,A74X921R,@
M9_"@#X0U_P#8\^)M[X;?2SX"T77[W5?#^B:7'JFI:G '\/FT6)95B.PL-_ER
M%C#@,)1W#!I]4_9?^*NI:_\ %:>W\ 1QOK>BZG;1ZIJ.IZ=<37MQ)$40VTJ*
MD\0E;:2DS"-%RG(537Z"ZIXQT31==TC1;[4[:UU;5VD33[*64++=&--\GEKU
M;:HR<=*V* /S=OOV=_&?@K5Y/&=QX+GCU'2_%UE=_P!I6EQ#NBTF*R,D[H/,
M*X60$;F7?G 4^D/_  3H70&^-6JO<W#WOB"307GM9(((FC9&D@:[GFG^TR3/
M,\K! )(X_DB#84R;:_2=U5U*L 5(P0>]8NA>"O#_ (6N+F?1M$T[29KGF>2R
MM8X6E/\ M%0"WXT ?G5XB\%^.O&NA?$OX4VWPQ\23ZIXD\=76JV?B#4[22#3
M;*V610)OM+)L<LBR#Y3RK_+N;Y*Q;:P\8:_\2?'%@N@>,-#^T1>);>\$<FKR
M07X%I>-#EI93"R^8(PBI&F=RC!R*_41+J"2YDMUE1IXU#/$&!90<X)'4 X/Y
M&I<"@#\K?$GBSQ7X5^'/A%=,UOQKX7\-,DPG:274M/A@U%A/YD2O;PLZPIBT
M9(53RSF8@_>-?:WP9^"OA*_\,>&?B-KFG_VAXSU31UN]5U.ZN;DQ7,US:PI<
M2-!+L1=R1(N/*3:HVA5&17ON,U3UG2+7Q!I%]I=]&9K*]@>VGC#%=T;J589&
M",@GD<T ?-?[#OQ+T^3X2>"O!-UJ,MSK3:3=ZKIT#1N[#2$O7@MF>4$IG;L
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MM<Z)'+JL<U]/IJJTQE)7SUWAS'NBB+((U++N8* .[\'?M2?%'QC>>"[/^S=
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M1/B.:XWI^\09B!=>2@]6_:^\/>'O&G@GP%<WGBKPAJUSI8EUFQTKQG-$-/\
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M7ZBGTR49"\XY%/H&%%%% !1110 4444 %&<444 %%%% !1110 4444 %%%%
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MH KZ?I]KI-A;V5E;Q6EG;QK%#;P($CC0#"JJC@ #@ =*L444 %%%% !1110
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M< ],GUK%U'X8>#]8\*V_AF_\*Z+?>'+=E:'2+G3X9+2,J25*PE2@P2<8'&:
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M110 4444 %1/_KH_J:EJ)_\ 71_C0)CY.0/J*=3)>@^HI] PHHHH ***,9H
M**** "D/0TM&,T (.E+110 4444 %%%% !1110 4#K10.M #Z*** &4444
MYHHHH **** "BBB@ HHQS10 49S110 4444 %%%% !40_P!<_P!!_6I:A'^O
MD^@_K3$^A,:KV)S ?]]OYU8(S5>Q&(3_ +[?SH6S(?Q+YEBBBBD:!68?$VD#
MQ"-!.J68UPVYNQIOVA/M)A#!3+Y>=VS) W8QGBM.OSYU;Q'XK@^/UM\=I=&$
M'@L>,1X62_FU!FD&G MIL@^R"(D W0DF#B0= -AW9 !]P^%?'>A?$7PVNL^'
M;]=1TTW,EMYRQNF)(I3'(I5P",,I'3GJ,@@UT@Z5\Y?LQR*WB[X\K91C^Q1X
M^F\B7>SEKC[/;?:AEB>!*#@#@$L.@%?1J]*?0A?$Q:**R?%E[?Z;X7U>[TJW
M%WJ<%I-):VYZ2RA"47\6 'XTBS6HKX#^&8CT;1?V?/B1I/C?6M=\7^.=<BB\
M012ZU)<6UW'/:W$UQ&8&<Q0^0P0%44%=NP<MS[#^S7^TAX]^*/B3PS9^,M T
M'3+'Q1X6F\3:8^D33-+$D5Q!"4F#Y7YQ.L@VG@<')YH ^FZ*^*O&?[5ATK]M
M&ST1?$26_A*PO['PQ=Z>USMCENKB&Z=Y\%<9CF:SB(W9^]QA37=M^VBEK'H,
M][X3,%KJ&H>)[&X,5^9)(1HZS.SQH8E$AE$!^5BFPD#+4 ?35%?'GPZ_X*#/
MXXUW1].N/ (LUU#5M*T@SV.OP7JV\M^D\D0DVH-K*EN[.GWEX! )Q6]=?MXZ
M+%J7A_3(?"U[)J6K>(+W0UCGU"UMXA]EN%ADECDDD43$AU98X\L>0<94L ?4
MM%>*? 7X\ZS\6?$_C;2-5\)WNC+H6J7-I'>>6HA18V0+;SDN2+HJPE(13'Y<
MD9#DD@9O@SXT_$/6?'7QAT#4/"^B3:CX3T^TO-&T;3=1/F7CS_;#%'/<N L9
MD6WA/W,)YASNH ]]HKRK]G?XL:S\7/#GB.\U[2[71]2T?7[S19;6T=G5# 4!
M!8_>(9F4L.&VY  -8?[1?QF\<_!:W_M[3/#&AZKX.M1:)>7=]JSP7CRSW/D^
M7#"(BK;0T;99QG>0 =IH ]QHKYGU']KW6+'QWJ<?_"OW?X=:7X@?PO>^)CJL
M8N([U$W,RV@4EHLE4SO#9/(&"*J>#_VR/$_B<2)+\'=7L[O4?#__  DOAFR3
M5[2676;0R1(-V2JV[#SXW8,254G@G"D ^HZ*\K^ /QQ;XW:5XADN?#]QX8U;
M0=5ET?4-,N+A+@Q3HJLP$B<'&_!]P<9&"<'XH_M;>&OA-\35\':KH7B&\\NT
MM;Z^UC3K)9[+3;>>9HA+<-O#HBLH+,%. PZ\X /<J*S$\3Z1)KS:(NIV;:TM
MO]K;3A.OV@0[@OF&/.[9D@;L8R<5)9^(-,U&:^BM=0M;B6Q?R[I(IE8V[8SM
M< _*<<X.* +]%>8?$?\ :&\*_"WQ%H.DZR;YSK-E=7]M<Z?:FZ3RX#"&&R/,
MC$^>I 1&X5B< 9I?A=^TM\-_C1K$NE>#?$8UB_CM6O6B^Q7$.(5=4+9DC4'#
M.HP#GGIP: /3J**Q?#?C+2/%SZLFDW1NFTJ^DTV\!B=/*N$"ED^8#=@.O(R#
MG@T ;5%9\/B'2[C7KG1(]0M9-8MK>.ZGL%F4SQ0NS*DC)G<%8HX#$8)5L=#6
MA0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5%)_KX_Q_E4M12']]']3_ "H$QTG 'U%/IDOW
M5_WA3Z!A1110 4444 %%%% !0>E%(PR"*  =*6@<"B@ HHHH **** "BBB@
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MO_",Z;J%A?6^HFY06L/DM<2W2(D*S>29Y",. ,8X[_P+X9USP[\;=-\5)?\
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M[!VK^(]4USQ%+J_CW5/%$=QIEG<S:=K9OY+BVN&>0,X-S;0I$#A@8HMR\ \
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MQ;<3BYUWQ=JFN:';)8ZG]KU"#2Y;^T>^EACMQ()&*(WE)#%MRZJ,$YSO:_\
MM3_%WQMX(UWPY/X,L/#&MP>$=:U_5IM6COM+E-E!,8(WM(FS+'*R9<>9@ E2
M&QU^M/$WP(^'OC+3];LM;\'Z1J5MK<D4VH+/:J3<2QQB.*0MC(=$ 57!#*.A
M%<Q?_L@?!W4?#FEZ#+X!TM-)TQ9H[6"!7A,:2DF5-Z,&*L6+%22"V#C(! !\
MY^"_CUXC^&?B:U\*:7:OX@\1ZO9>$M+TR#6M;G^P(9M/F>:X(*,8C^X.X+N:
M0LIY/%=QX[_;2\3_  N\8Z-X4\2>"O#4VNW,EI#=:?I7BN2:Z!GN6A#0Q&S
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MHKXE^&_Q\^)NH^+? &IZGXKTR^\/>(?&.J^%I=&.CK$Z)!)<%)A.&!9L1H@
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MD. /J*?0,**** "BBB@ HHHH *:W2G4C' H 444#D44 %%%% !1110 4444
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M?OM6\#:#=:#X-U"QT;Q9JEEK[H8;J=HA)):1/;_O8HC,JG>R,S9 'RDTZ_\
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M^0W?_!/^[;0A96GC31+:47]I>-''X.@MK2<0031*)XK6:%YFS,S M+M4Y"J
M<5I^"?V)-;\'ZSX$NU\=:68?"LT)22TT":WO;JW6XDGEMGN1>G?$[R [95D"
M[>/O-N /9OBC^TG\-O@OJUIIGC+Q1!HU_=1>>EN8)9F6+.WS9!&C>7'GC>^U
M>#SP:Y+PI^TS)X^_:-U/X>>'M.L+O0M+LGN+O6)KN5)I'3:)!!&(BDB*\UNI
M8R+_ *PE0P%8'QO_ &9/&/C7X@^+_$7@_P 2:+I\'C#PJWA75K;7;*6X,,9+
M#SH#&Z_,%=OE?(SSG' [CX-_!"]^%?C;QOJ)OX+W3-5M-(LM-,A+7,<=G9B
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M4 %%%% !4<@_>1GW-25&X_>QGMS0)BR#('U%/IDW1?\ >%/H&%%%% !1110
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MN/CE\.M;NY)-9\.>$=$EC&HZM=BYU&\OQ*OV;SV9-SK&KSR!MP/F%3VY^@Z
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MI!DCB1G*P D*?W07E$_NC&5/^PG\)+R:Q:YTS5[F"&WAMKJTDUV\\C4EA8/
M;M!+B8QMDKNXYP00% ^@J* /*OC'^S=X3^-^I:1?:_/K%M<:?#<69.E:E):"
MYM+A0L]M+L/,<@5=VW:WR@;L$@YWAO\ 9=T#PQ\2M$\7P>(?$MX-"@FM](T:
M_ODN+*PCEB$3I&7C,VW:%PK2$#:,#KGV:B@#X@\6_#+X^VOQ4\9^(_#NBWEA
M:ZUJ0N);?1?&5K;QWR)"MM%(5FL)#&PABBS@@AA_%R:X#0O@!\5/"#:=9Z7\
M(/$-QIUAK6C^)!:W_P 1-/N(Y-0L5VM+YCVYD8S*$#CY!E?E5  #^CU&* /S
MAUSX3?%[7M1U>[C^!VN:=)J<GB.YN8XO%NESQM+JT"02.-[)CREB7:N.>IP2
M:73M$^)_AB:RO_%OPV\>ZMJ&GSZ"8GTNST^X"VVD233I;[8;@[RYED!ES\V0
M F< _H[10!^?O@?XE^-?"GP5\4?#R+X:_%53JJZD=%U6W\$(LNG1W4DLA:?=
MJ)\V17G. /*X7[IQ6)H=KJ_PZO\ 3[OX=?#KXEW.IQ>%I_#DOA_QSH%W/IMS
M@P&VPPF>.&)7,Q*&3&UG P>6_1W%)@4 9_AR/4(= TU-6%H-46WC%W]@5A;^
M=M&_RPWS!-V<9YQC-:-%% !1110 4444 %%%% !1110 4444 %%&,T4 %%%%
M !1110 8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*3_
M %L?/<_RJ6HW'[V,_6@0Z0@!<^HIU,DQA<^HI] PHHHH **** "BBC- !37Z
M&G4C'B@ '2EI!TI: "BBB@ HHHH **** "@=:*!UH ?1110 RBBB@ HHHH *
M*** "BBB@ HHHH *0#%+2 Y% "T444 %%%% !4(_X^)/HO\ 6IJA'_'Q)]!_
M6F)DIZ5!8',+?[[?SJP>*KV/^I/^^W\S0MF0_B7S+%%%%(T..^,/Q#3X2_"_
MQ-XRDLCJ,.AV,E_):K)Y;2H@RRAL'!P#CCK7B<_[7^KPZ=J\UYX(;1;WPWKF
MCV/B"PEO!>O;V=^ !-&T (,BLZY0X..3R5!]:_:$^'^K?%3X*>,/"6AW-K::
MMJ]@]K;S7K,D*LV/O,JLRC&1D*2,YP:^0;S]G/QQ\,OA=XD\(W6E:-9K\0-7
MT'1K;2? R7EU8Z<L<H-Y?R^;$!$S1KDL J95 >1D@'WU>']Q_P "7^8J8=*K
MW:[;8#T9?YBK Z4^A"^)BUR?Q+^)VB?"?P_#K.O_ &\V<UY#8QKINGSWLSS2
MMMC410HSG+8 P#DD#J0*ZRO&?VH= \4^)_#_ ()T[PHLT5W)XNTZ2ZOX+2.Y
M:PMT+R-<;9/E&QD3DAN2!CG(19Z#\.?B/X?^+'A&S\3>%[YM0T:[:1(IG@D@
M?=&[1NK1R*KH0RL"& /%=+7Y^_&3X7>-?@=KEQHWA#2?'OCJQUOP/J^F-K&E
M@32G6;N_:Z:XN2C1K']Z4[@"1O"J#S2:EX0\8"T^*OB#6M<^)/ATZ!I>@6&@
M"&]U"14>2Q@BNIC:V\H\[]YS(T>67#LH\Q: /T#HK\VK#XL>+O#?@F:6<?$6
MTCUWP3K&F:/)+<:I?/+JZW;B*Z1ILS0AD"NK2 /&C8S\N:-4^/OBG2/CU\-]
M(L?&>O6>J7TWA:TU'2-4U!I8+N.YM[<W)CM#:[5X?+N;C?O9BH(#  'Z2.ZQ
MJ68A549)/0"A'#J&4Y!Z$5^7]K\6?'^O^&M0M]<\;ZUK-KXH\#:_JE[IDD43
MQPQ6=S-'&(56(,JRQVQB=O2Z9@V50CUSQ7KL]Y_P3FTS6M-\?R:O9V-K8M>S
MVT41$D0DCC>P+QJ'40E@N]2)3Y.&8DMD ^Y:*_/[Q]^U)XR\*W7B6]TGXN>'
M+S3?!6B:9>VR7VGVC#QNUPSF66!DE4HJX$(\GCS PZYKU?XZ^*?%Y^/_ ,"[
M?3_&%MX,M-8M]1D:RNHFFA,T4,;RQSA952?<C[$!*^6P+@N2% !]1V-_;:I:
MI<V=Q%=6[YVRPN'1L'!P1QU!'X5/7YA>"OC%XR\+_L_ZWX0OTTZ]\,W?P_U+
MQ'I,,!EL[NV OWB EE20,2S.6)4I@%0"ISGZ<^#O[07C+6OC.?!?B'3=/T/0
M)K9FT5+FUO#<WT<<*$R0W9+PS_Q%XV*2Q\@[B": /J&BOA[XE?M81Z3^VSX>
MT*R\4QKH%E?VGAR_T87##SIIX[OSIRF[9MBE:P4EAO!5]OR[]VM8?\%!+[4]
M?\116?@>RO-*T:RUJ^N3:ZU))>6L>GK-@W,8M?+A\]XT6,>:QPQ;G 4@'V71
M7QKXJ_X*)IX"T+0-0\2^ ETN76-/36HH#XBM6!L)7(MG1B%\R:4+(_D@?*J<
MOGBNBUO_ (*">#_#_P 3-6\)7>AZCC3896ENX[JR\YI8K(WCHMHTXG*",%/-
MV;?,!7L30!]445\II_P4+\+0QQRWW@+QQ:6S6T.I&Y73X)84L)&""\9UG(\G
MS,H",EN, ]!U[_MJ^ $^)ESX,\G66FAO;C2_[46R5K)[V%'>2V5P^\OB-@/D
MVDX&[)H ]]HKY@N/V\_">L^ =<UGPUHGB*35;715UJPM-8T2ZMH;V!F""42A
M& @5V4/-]Q1ELD*37N7PI^(EM\5? &D^*+2RN]/AOXRWV>]@>&1&5BK !P"5
MW X;&&&".#0!UM%>%77[4EA!^TY#\)TL(S:_90DVM-.P":DT;3I9;-FW<8$,
MF=_.X #(-74_;(^#DEAK%\OCBT>RTF>*VNKA;><Q^9([I&(V$>)=S1N 8]P^
M6@#VBBO%K']JSP7+=^([Z^U33=.\%:5INF:G#XFEU!#%=)>^;Y8\K&^,@Q'A
MN3GI6Q8_M1_"/4=-_M"'XC>&Q9<_OY=2BB4X9%/+D=Y(_P#OM?44 >HT5S]]
M\0O"^F:_9:%>>(M*M=<O4\RUTR>]B2YG7.,I$6W,,]P#4OA_QQX=\6.Z:)KN
MFZNZ1B5UL+R.<JA)4,0K' )5AGU4^E &W17G]Q\8]+C^+FE^ ;>WFO;V^TZZ
MU$WT$D306XMY(HY(W^?=OW3)P%/7GOCO(KF*>(2QNKQGHRG(- $E%<]H/CO2
M?$GB7Q%H-DURVHZ#)#'?"6UECB#2QB1-DC*$D^4C.PG;WQD5T- !137=8D9W
M8*BC)8G  J'3]0M=6LH;RRN(KNUF7='/ X=''J&'!% %BBBB@ HHHH ****
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MC==7K[KCSOO7+-AXMJ;8B0P_0*V\):+9MJ[0:59PMJ\GFZB8X%4WC^6L>Z7
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M69HM=\,VFJ3*]G%%"6MYI?F@\V.",-]\[AN!SC !]5 Y&:*0#:,"EH ****
M"BBB@ J-S^]C^IJ2HW'[V/ZG^5 F.DZ#ZBG4R3H/J*?0,**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ H'6B@=: 'T444 ,HHHH **** "C/-%%
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MET\^&IO ]UX\T_QU-?W-W/'J*-##%$]JL0C9& \K<K;EZXX[?75% 'YRZ/\
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MU43_ &B-]/N6FC6$H"H1PS!MV<[B !]ZN-\+_ +QS\1O'_B0W$5EX;\):?\
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M@@E%E?PG^R9J'PZ\9C7O"'Q*U?1HKFVT>RU2QETVQN$OX-/A2!$+M"'0O&K
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MUKP3\7_B!XKU"ZL)K#Q#IVCVEO';/(95DM('CE+JRA5!+#;M)X!R >OR[?\
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M0 RBBB@ HHHH ,YHHHH **** "BBB@ HHHQB@ HHHH **** "O*?VC_A9?\
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M_B!ID^HW=WX7BA\1ZCH<*+HT>JQ3M*_EI(JN(C" OFYY;+$*?E[C]EGQK+X
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M#8V2V$]K\;?M >)/A5^S[?\ Q"\8^$]/LM5MY(U72K361) $FE2.%I+EHU"
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MB$+_ +R*0O(5&%*=<AOTCK-UOQ)I/AJW6?5]2M-+@9MJRWDZ1*3C. 6(YP*
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MZ!^QL^D>/['6;OQYJ.I>'K+Q'=>+(_#\EE"BG4IF8^<9E^8@!L;<8Y;&-QH
M]%^''[1O@OXJ:WIFD>'KNXO;Z^\/P>)<)#NCM[:9@L:2R*2BRDD_N\DX4GIC
M.%#^V'\.E@\4RZC-K7A__A'+?[7=QZUHMS:/+#YHB#PJZ R R,B?+SEUXYK
M_9#^ %S\(+#QQ?ZGIS:7J.M:U=):0R31S/#I<4T@LHPZ,0%".6"C&T,!@8Q7
ME'@O_@GOXE\$C7KB'QGHUYJDEE:0Z=??V=/')+<VNIQW\5Q=EII#([-'L;;@
M8V\';R >I)^VGX5;X@Z=;SW)TSPA<Z)+=-+J&F746HF_^WP6L4"0%=S;O,<X
M"$G@@X#5Z/HG[2'PU\1>-[CP?I_BVQF\26[SQ26!#HP>'=YJ990I9 K$J#D
M9Z$&O%/&/[-/Q>\=Z]H?C+4O&'AF#QMHD$<UH+"UN(;&2YBOS/'#("2YMS S
M1DYW[FW<X%4[[]D/QAJ>D:#I-QJ6F6R_V[XJU#4M0M;F8R)%J<%U%!(@VH7E
M47"[@2 -I 8C% 'M6A?M6_"#Q*VIC3OB'H5P--=$NG^UJB)NE6%6#-@,AD=$
MWJ2NY@,\UU=W\6/!UFNI;O%&CF33KN+3[N,7\6Z"ZE8+%!(-WR2.Q"JK8))K
MY#M_V./B'XW\.R:3XVL?"MA9:)X N?!VC0:+J%P?M=QNA>"YDW1CRTWP(QY8
MDYRI'!K^#/V1/B'9?$+P_KVM^5+#<A]=UQH=04D:I'/?RP1(FT#:#=PA67"A
M4ES@E20#Z9^'/[1?AGQ7X"\$:YXCU+1_!FK^++-+NRT2_P!7A,SA_NK&6V&0
MX(^ZO4XJ[X\^/'AWP3XL\->&DGAU;7=8UF#2)-.LKF-KBR\V*659I8L[E3;$
M><=P:^'/$/[(OQ)U'2_ EKKWP^U+Q';1^"='T.]C\.Z]I5K/IES:SR,X,EXD
MA)*NC9MV +(1D@@C?N?@MXX^'_C\>)+OX81*-$\>:EXMU#XB/>:?++=:/Y4Q
MCB):1KKY0PS&L8&8P0"Q+  ^]-.\:Z!K%_+96&MZ??7L1826UM=1R2)MV[LJ
M"2,;TSZ;AZBK2:_I\UB+R&\AN+=LA9(I%96(!) (.">#Q[5^.?PA\$7/CKP-
MXBTC3=&AU+QIJ'ANR:TM?"2:5^]TY+Z"6]6YD@N7?[5*'V@7*(66%AU+(OM>
ME_ "^LO"/A\WWPZ\:^)?!B^*;[4+KPS-H5GI$R.^F^3;RQ6MM< )&)@F6)0@
MJS$<DL ?H+\*?B3IOQ?^'FA^,='@N[;3-7@^T6\5]&J3*NXK\P5F Z=B:G'Q
M)\-GQ^W@G^U(_P#A*%LQ?G3]K9\G=C<&QM)[[<[L$'&.:\3_ &3?%L_AKP;X
M<^%6H:5=+KWA?PI:7VLS(JE;::5W"6[H"665E1Y-I .W! YX\&T_0_B-I_BW
M0_V@-8\(2V%G>^+);B[L[2WO)_$<&FSI_9\5O):>0"T486.;8I)R=P5N 0#]
M"3@]:S;#Q-I.JZUJFD6FH6]QJFE^5]NM(Y 9;?S%WQ[UZC<N2">N#Z5^6,$N
MN:5\//$]LNK>+VV:_97L?B*<>(K$^(D\F\E:PE7&Z"XW%%+PKY;,8N,@&NM\
M9_$[Q)INL7EE!<^-=!T^\F\'VR6:ZC=V]T5&E3SW,'VA8Q)YIVPI(ZH6)V[E
M7@@ _3/ ]*7%?F%HGBSQQ>?#'[9I_P 8?$MY=Z%\.]3\4W4]CJCS(^HPWLBQ
MPSM<1M(!L(4QD*?W/! R:[C5_CMXP;XF:SJ-W\2)]!UJS\5Z-9Z;\.%2(_VI
MI,OV02W"(09'#*]Q*60D($8$\9H _03 Q2XKYV_9PU_Q'K?PY\2?$3Q!\0[_
M %K0=0DU.33["33K<#2H(+NY4,&C0O,VQ$X)Q\N #FOE71?VK_BU=^&M=DLO
M&UWJ(O+33+W2-2U#2M)2:!)]2@MPS16[R(JRI,P*2$R+M'RKD.0#],=H&33(
M98KJ%)8F62)QN5U.01Z@U\,Z7^T'\6-3-EX.'C7P]I^NP>-]=\.7'BC5=*7R
M;B&PM/-4M LBK'O<D'#9 V\M@[M_PK\5_P#A3O\ P3J\/^(-+NH#JUWI[6NE
MOM=(OMMS/($VAOFV(SLW0';'T7H #[(\D<^E*T:D<BOS^^$W[3'BOP!\ KK3
M?#_G>+;WPUXI:RO=4U72[V[GM]&F$\ZWL]M&5N!AHY$.X A5W8(Q78^/OVH?
M%P.LZ%J$NC1:%+X2?4+;6--CU#3Y=:<Z/+=22:7>?-"A61. [AU4$Y++@@'V
M9);HZE6Y']T]*3['$'+[1O(QG'./\@5\1^$/VSO%EM?^!?!6CZ)IFN7,UIX>
MTZ2?6]9=M3NIKRQ2XEN=JQ9EBA5X_-EVJ0T@^7FNP\(_MNZW=I#?^*O 5KH&
M@7FCZSK.GZC;ZV+E[F/3G"2J8O)7878C;\Q^\O!.< 'T'XY^$?A;XC>&)?#^
MN:6D^DS%1)!!(\!9!*LIC+1E6V,R*67.&Q@@UJZWX&\/^)M(M]+UC1-.U;3;
M=TDAM+ZTCFAC900K*C*0" 2 0.,U\F>'?^"C5MJ?A;7-3U'PGI=G=V-WI5K
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M]<MX&^'6G^ 'UDV%[JETFI79NC%J-Z]PEJ-JJ(8%8XCB 7(0=R:ZF@ HHHH
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M\'8?L,_$+3H_%-M)KNG:E"-.\16GA^ZN-;O6DC?4%E6,RP-&8D9A+F1HS@L
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M7WI@B?/(XI3$V>!0 X3<'FI(I<L,GJ>E0&)N>*>D3"1"?44 7J*** &4444
M%%%% !1110 4448YH **** "BBB@ HHHH **"<4F: %I@4!V;N<"GU'NS*Z^
M@% F2>E1P+M0C_:)_6GFHK5]\9/^TP_6FB7\2)J***18454U#5[+25B:]NX+
M199%AC:>14#NQ"JHR>6)( '4D@5;H ANAF'_ ($/YU*.E0WK;(,_[:C_ ,>%
M3+TI]"%\3%HHHI%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
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MEAIMCJ-EKH1C',MQ")OWH('E;E=/+Y)?;(>-IKW.O@_X1?#CXM:?XZURTL-
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M2NIW \ 'Z.*P=0P.0>AI:^ OB=\3O'_PC3QUX;MOB/JE[:6GC#1=.G\3:O\
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M010!H449HH *:QPR^].J%S^^C_'^5 B8G%%,E;:H/^T*<#DT#%HHHH ****
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M<6D4*H7'4DC SYII7[>NCZEX2U+6O^$.UAI(M'T_5K&QMV2674#=7:V)@CZ
MO'=DQ'&01AA]X"O4?C1^S;X9^.&IZ-JFJZCKVBZOI,-Q;VM_H&HM:2B*=0LJ
M-@$%6"@'CID="17/I^QI\/8+WX:2P6UQ%;> XS'86C&.2.Y^<2JTY9"Q99AY
MH*%/F)SD'% '&O\ \%!_!D/C#6-&?1[^2WLH-4D@N[>[LY)9Y-/@EGN8WMA-
MYT&4@D,;3(@DP#D @U[9\'?BA<?%OPDWB)_"^K^%[.:9A90:RL2S7=OM5DN%
M5';:CAC@-AN"<8()\=N?V$-",NOVUIXQUZT\/ZG;:I;QZ,8K.5+3[=!)%+LF
M> SX7SI&53(<9QT+!OHGPKH7_",^%M(T;[0UW_9]G#:?:'4*TFQ NX@< G&<
M#CF@#RJP_:V\"W/@_P .>))QJ=EIVO6&K:E:F>V7>L&G!FN6<*[;3M4LHY)'
M7!R*Y#5_V]/!:> _$_B'0]%\0:G<:!=:?#/IMYIEQ9RR0WCXAN5W1MB-D5V4
ML!N(1>#(F[DY/V!=:73GT9?BG<W/AJQT77]&T/3KS25::P34XY48O<+,#-L\
MQ#\RC=Y:@%>:O_%#]C3Q'XY@\<BS\4:=#-KFCZ!8V;7%J^(Y=.G$K&3:WW9"
MB'*\CW Y /5!^UO\+_\ A-=,\)RZW>6NN:A):P107>CWD CGN55K>"5I(E$4
MKAU(C<AAGD"NT^+OQ+TWX/?#7Q#XRU;YK+1[1[EH@VUIG'$<2GLSN50>["OF
M23]D;XG:YK&K:7K/B#PG'X'\3^)+#Q7XDM["*[%V]U"L+3P6Y9L+%)+ A!9B
MR 9'/%>U_M(?"'7OC;HWAOPYI^K)H^@_VQ#>:W<1/LN_(B5GB^S$QNHD$PB;
M+ 8"Y!R!0!4T3]K/P%'\(O#7C[Q=K5AX0L-;GDLXUN;DRQBXCEDB=%<*-RAH
MG^<JHQ@G%6OB!^U/X \$Q>(+2UUW3M>\3Z+;+=S>'++4($O'C.SE1(ZKPKJW
M)Z?45\P>/OV3/BYX=:]T[PH)O%2PZK?WOA[Q3=>+/L.I:>;R"#[1]JA6U$$T
M#S)([Q*NYL9!0L2V9\0?V8_BQ?:I\4K;PUX%@TK0_$"7$MQ;_P!N6ES'JUVU
MS$R7%L6CCEM6D56>6-G6,E0%XP* /N)?B_X)7Q"/#TOBW1(O$.P.VDMJ,(NE
M!&1F+=NZ ]NQK7T?QIH'B*VO+G2M:T_4[>R<Q74MG=)*D#[0Y5RI(4[65L'L
M0>]?EG<);>)OVDO'FCP:7;:U<7GB7Q#;:?I-G+9RZFFHO;2V\<\L4D9N$M%!
M,F7=(EDVR*V5VMZSXQ_9=UK2?AQK6G>&?AVEK'=>$?"0O[+3[6V#WUY;WEU)
M?(T981SRJ&B=E<XDQC<>, 'Z!QZG:RVT5REQ&]M+MV3*X*-NX7!Z'.1CZU9K
M\J]>^ WC?_A6'A:RA\,^+;WP_'JVOS2:3)X153I\\L%NEM-#I<=Z!$H9;EXI
M%EQ')(QQAL'[A\<P>(]%_8]EM;?2=2\7>)XO#$%LUA*LMO>7<QA1'WK;RB17
MY8LL<F[@@/GF@#TKQW\2]#^'!\/#6YIHO[>U>#1++R86EW74V[RU.W[J_(V6
M/ [T[X;?$;0OBUX+T_Q7X:N9+O1;_P T032PO$Q,<C1."K $8=&'3G&1Q7YY
M?"?PQXT-IX:LCX2U72M,M/B=H^I+I@T35+6"-$M+AI9XH[P22QQ[EC#%W(W+
MP4W+7U!^R18:_P"$_P!BG1H4TVZL/$,%GJT]O975K)'*)6N[J2+]U( W.Y"
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M+:XO8]4A\J&5R0B.Q;"EMK8!ZX.* /E2T_9O^)'A+7?#/BZT\ :1XGU""_\
M$-YJ>AZYX@BO#(]_%:I'(D[6T: DP,74(.#)@DR5B-^SM/I/C;X9?!W4);5T
M\0^'M-G\9P689HKF'2969-I;D(Q>.#.,D!"-N,U]LV?QG\ ZAKNF:+:^-O#U
MQK&J6R7EAI\6J0-<7<#IYB2Q1A]SHR L&4$$#(XKG-9_:5^$6AL;Z;QUX>N9
MDO8](D?3[R.[EAFD;B.01%FC VEF+8"A&9B I( -#]H3PT?%_P %/%^AKHM[
MXA^W:?)!_9FG7$4%Q/GM&\OR!AU&X$'&"#G%?!WB?]G#Q^?"7AAM8^'+3>&K
M:YU4+HVB>&]':^C\V"!+:\N;&&=+4W#*DJF2-G:,10D %BJ_H?XP^(.F^$/
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MG'I0 ^H9/]=']3_*IJAD_P!=']30 Z;@+_O"I*9+]U?]X4_% !1110 4444
M%%%% !2.,J:6FOTH 4=*6D'2EH **** "BBB@ HHHH *!UHH'6@!]%%% #**
M** "BBB@ HHHH  <T44#F@ HHHH *![44@&* %HHHH **** "HA_KW^@_K4M
M1#_7/]!3$R0]*@LAB%A_MM_.K!JO9<PM_OM_,T+9D/XD6****1H%%?/'QP^,
M'Q'^$GQ \+F%?"&I>%]>UJTT:RT3_21K5T92@DD1L^6/+_>,<C;MQN93U^AZ
M *U__J >V]/_ $(5.@P*@OS^X'^^G_H0J=#D4^AFOC?H.HHKR*Q_:/T2^_:$
MU/X4)93K?V%G]HEU%I%$0E$44QAVGYL^5.C[NG4=J1H>NT5YY:?M$?#"^L-8
MOH?'_AQK'1Y%BU"[.J0K#;,Q*J'<MM&2" <X)!'8UN1?%'P=/_8WE^*M%D_M
MI=^E[-0B/V]<$Y@^;]Z, G*YZ&@#IZ*PU\=>''OKBR77M--Y;Q/--;B\C\R.
M-&97=EW9"JR."3P"I!Z&HO!GQ T#X@^&=)\0:!J"WVDZK$)K.<QO$95(S]QP
MK X!X(!'I0!T-%%% !1110 445F3>)]'M_$-OH,NJ6<>MW$#74.FM<(+F2%2
M%:18\[B@+*"P& 2/6@#3HHHH **** (I+6&5P[QJS#!!(!/!R/UJ6BB@ QFC
M%%% "8%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^9OP1'@ \[J/[%'Q&G^)?[0OA_4-6^([?$/7G^&TEW>![..W.E3S7ED9K7Y
MH;:R]=HQGJ01CZ:N/V1?AO<21,L'B.T,<@DQ:>+=5@W$*5 ^2Y& ,YXQR!56
MX_9(T"2X2:#QW\4+1T)*[/'NJ. "<XQ),V0..O7:,YYR <G^W#X[FBT+PC\-
MM*M[S4]8\9:J@GT[2[=9KR33;;$]V8E>2-,X1$^9@"';KBO!;?\ :G^('@3X
M/>!=/35M,\.#PH+O1_&$UW8P7VH6<MLT*6^ZR:ZBD:$Q2J7DA\U@>@QRWTW<
M?LE))>K=Q?%KXF13QH5BD;78I6B)X+*TD#$9'!&=OMGFO-_'7['W@:QU0:AX
MD^+>H)K0$NI1WWB>R\.W,ZI"JM+.'GT[?B,!69PW  +'I0!SVN?M@_%#PKJG
MCV'5G\)6K6%W!)HENUBTL$^GOJ]O8_:6NXKUE4;)&+1R)&Z.P)^52M=AK_[4
M'Q%UCQ9?Z!X#M/"FH3GQ?>>'K"YU6.X6W:&WTF&^=Y'BE;G<TJAE!W!4&Q<E
M@FD_L+1+%K5W8?$II(/$<>[4)4\'^'F&H(S"0&1EL1Y@+ /D\;L-UYI-+_8Q
MU'P"^C_\([\1--T::SN9)K$R>$K-/]*DMQ#+(%A:$,[PH4(Q]TMC!Y !R^@_
MMP_$F'X=WWBS7_!?A[[/=^&+7Q-HL6GWDR[HI;V*UV7)<81F\WS!@X4 9)R=
MB>,?VMOBU;ZA!X:'AC1M+\6:3XNT[1M4@M+[=#>_:H?/M;6*26,JOG 2(\F<
MQ@*P&7PMCQ)^Q#\0=>\*KX9_X61X5@L8]'@T*,VWA*>"1;&&=)TB&-0( \R-
M<MC.,C/-5H_V&O'6D^!Y_".F:EX"AT>YU*/5YY8+'68+PW<:A8YQ<G4I) RJ
M H4$* ,C!S0!<\(?M5^-M&U?7- LO#%[\0O&&I>,]8TK3M*N=9MK:WM(;.&*
M65$N/LZ8C42802*6)!RW2M _\%"+B]M)O[(^%VIZGJ&G:3=:QK=L=3@@73(;
M:ZEM[@L[#]YL:('"C)WC X..1\1?L8?%:[\F;2U\&6.I0ZQ=ZY'JNF^(]:T^
M]CNKJ...Y99=LQPXACR#GJV",G++/]CGXGZ+X<U2QTSPOX!L[JX\'7GA%;J#
MQ3J#NT-S*9I92)+$@S-([MYA(!S@@#& #[@\)^(K?Q?X7TC7+3<+34[.&]A#
M#!V2('7/OAA6M7D7[/WPHUSP!I9U/Q)K&I2ZU?Z=8V=QH1U5KW2]-^RQ>4OV
M,-&A0R*%:3J&?..F3Z[0!\W_ !=_:IO?AU\>= \)6^F12^$K<VR^*=:EA>0:
M>UX9$LP'1P(_GB)<NI&UU^[G-:^H_MF>"-+U'QO;S:=XBEM_"4[6=[?0:;YD
M$MR)HH!;Q$-N:0R3HH5E7."0=N":'C#]B3P'XYE\=ZCK,+7OB;Q-<7$T&O2+
MFZTH2P)"(X#G 50A.#UW$'(XKE]9_8Y\5:IXH\0^([GQOX;US5=0TW^RU&L^
M"K=X[R#[1!,8[\1RHMR +<(K!8V3<2#D"@#K+K]KK1]'O9]8UVTO= \'IH<=
M^L%_I=PNKM</J#V840*&RA(CQC)/F*>AJQ)^W)\([.TBN-0U?5M+CEEGA1;O
M0+Y9"\*Q-*OEB$OE1,N>."'!P5('SK\5?V(/$7@3X/R1:/J$_BNXCBM;6;3]
M(T[:]M"-3FO96LX&N!E(_.54@$BL50@.">-O]F#]F/Q)?VGA+6M;TV/PA8^&
MY-9@L;2XT^6UU#4HKRTBMQ=7,?VJ40RDB0L&9FPD8&T9) /H[4OVM?A%I%WH
MUO>>-["W?5[6VO;1G23R_)GQY+R/MVQ!\C'F%>#GIS6O8_M%_#74OB-+X"M?
M&6ES^+XI7MVTI)LRB55W/'GH74=5!R,'C@U\QZG^P1XAGU'0DDG\,^(=&&B:
M-I.IVNI7>J6(C-E&L;O&EG-&MP&"[E6;[K'/3(.]\.OV/?$_@OXVPZY>C2=5
M\*VOB.]UZSG_ .$EU5;J S"0)FR(:V>4!\-+D%QG.3DD ^AOCE\5$^"_PZNO
M%<EG'?16UY96\D4L_D*$GNHH&<OM;&T2%N1_#U'6B/X__#5_!R>+/^$^\-#P
MP\PMAK!U:#[)YQ&?+\W?M#XYVYR/2LK]I;X=:G\5_A5/X8TJ*WFGN]3TV247
M3[8Q!%>PRS$\'/[N-_E[]*^4_'O[(WQ#O/$E_K5GH\.I6 \>:QK4>DV^K6]O
M</9W5K!%%+&\T,L*,&A8[&4MAA@J22 #[8B^*'@^>^M;*/Q5HLEY=1)/;VZZ
MA"9)HV7<CHN[+*5^8$<$<]*Y;Q_^T5X0\">'](UF.['B.RU+6+714;0YX;CR
MYI\[&8^8 % !)YSCH#7RWX!_8Y\10:'\0;:Z\*QV%Q+X/BL/"LNMZI!J,]A?
M207"7*++&J!#^]2(RJB90*!D!L\);_LE^-=-\%0L/A[XDEO!-HO]L>'[N;P^
MMI?P6KNTHA%H\?G/@M%ON"&:.9R2S "@#])+35K._&;:ZAG^7?\ NY W&<9X
M/3-6E=74,""I&01WK\QO$7P8\4_#SP]:ZKHFEP_#K4O&GB?6_">D>'KLIYEG
MIVJ+"(1A)&2(H]HS_NMX'FYY VG]%-!\+6/P]^'5EX=T*S*:?H^FK9V5HCL3
MLCCVHF[.XG  SG/XT =-D49S7Y/>"? GC:W\'>,8(/A_XIT+2]5L]!?6-+T[
MP[JUGA4U)3<10_:9)IKB1(2S.\398$X7"Y/I6LV'A6/XA:!#J&D?%S2_A>VE
M31>'K2WBUBWN[#5O[0Q*-@/F*OE^7Y>_"A<@*6Y !^B^:JZEJEGH]HUU?74-
MG;*0&FGD"(I) &6/ R2 /<U^:OA_6?'/_"VO'SW_ (HU;3=2 \4"^TF].M":
M>V2WN1;^67B-@%0I%)$8GC;:P&YL!6YC5M>UGQ#\(OB#]A\8^+/%FD:9X*TO
M5]?@U6\FN[*UUM;M3);QF3)\@(LK%8SL(16W, " #]6E8, 1TI:^&?AI\7;9
M/VL/#7AS2OB+K7CGPYJ6GVR:1966L)+]GC73?->74;>2%697#+*DT;_>(!R?
MEKUK]NB)(OA+H]_-XBNO#5M:^)M(\R^A,8CM]][$@N9-RD_N"WGKAE&^)=VY
M<J0#WRQ\0Z7J>HZAI]IJ-K=7^G,B7MK#,KRVS.H9!(H.4+*0P!QD'(XJS9WU
MOJ, GM9X[B$D@21.&4D$@C(]""/PKX,?Q]XM\ ?$?Q!XE\,^.!J'AC4?B'X=
MT*XLGL+><:VUQI5@);GSUC79YD?DF/RF9<DDKAQCF?AU\<]<\'W7@"SLO$%K
MX0^']UKEW%>6NAZ=IBWTT\FN7-O&)[1SO6!TC5&EMPVV3?RP3@ _2"@'/2N2
M^+/Q!LOA7\-O$7BR_.+?2K*2XV<9D<#"(H) +,Q50,C)8#O7PM^S=\5_'GPY
M\(?%W0EL=1NOB'/:6WC&RL=9TB>VN+JYN"D6IM':R1P%U6XR4"##F0 $ME0
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M-6TKQ9HVDZK>Z>/$.A7=O8WLEG$78QRE569!\C$1MDH=PXYJU\!OC9KWQ/\
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M-=3W4EY"XNHBL_F3M]_>HXXPNT^/:E\6M4\??&KX;?VYXWL?$6HV/Q&U2)?
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MHHH **** "BBB@ H'6B@=: 'T444 ,HHHH **,8HH **** "BC&** "BBB@
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MF3T9<D@^]? ?[2VO7F@_%_\ : TK5/&\4%M>> [B>/0KE(8GU*)K.18X(2S
MGR")Y=Z#<Q8*Q(7%=%K/[4'Q*^%7@_XDZ1?:IHVJ:MX9OM"TNSU0:>D,-L+R
MT\Z3,9F57*<(F^1%8E<L2=M 'U/XD_9I^&7B[1+[2-7\'Z?>6%[JDNMS(P96
M:]E&))PX(969?E.T@$<=.*V(/@KX&M8_#*1>%M,C7PS%)#HX6  62.FQU3V8
M=<]2 >HS7FG[+'Q6\8_%#X>^+;WQA]G:;3=4N+*ROHXH+=IX%BC;=+'#<3K&
MX9V! ?@;>^37R%\"/C!KOP6\+/XJDBNX&_X5I;:S#I^N^)+F^AUVYDNXHAJ
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MB@ HHHH **** "BBB@ H'6B@=: 'T444 ,HHHH **** "BBB@ HHHH ****
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MBV5"@8P*]R7I4%]_J/\ @:_^A"IUZ4^A"^)H7/-%%%(L**** "BBB@ HHHH
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M+=I[R2)X75EAC7EG()P/7N.M?"_A'XQ:[X2/@RSCUC5]3^'7AWQ5ID \:_\
M".7FFSWMF;"[#6EY'LS,(?W,>[9@YB)Y&:19^CU%?F7_ ,+2O;W1_ %GX]^+
MGC7X6>&+K1];U2+Q MU+%<W]XVL2"*WD+H69DMU!6(C(# +QP9M:_:&\0:9X
M9^)_BP?&.]L?B);76HZ>WP_E\IHM%MTU*&V2?;(-N4B='$A"!O,8Y.QP0#]+
MJ*_,:_\ V@_BSI_P6BO5^)>F26UEKUT3?Z9XET+4]:ELX[>-V"[9%@N!&TI8
MQ@B4[XP5"X+=1KG[87C[PCXK\9:O)XN@UOP]#X>O=3\-Z?:Z;9SV=T8K5"#<
MRQ2"XM;A)'5I(9$VG+*&4%30!^B-%? 5_P#M)_%WPAK%WX);QGX9\7>(;S4/
M#\%EX@ATT16MLVHO)&T+(A;>JE58/D-@,2OS #TCX>?'#XJZ7^T=:?#[Q]?Z
M##H<T?EV6HIHTL2:U)':CS#;7*W#1I+YXD+0.F51< Y*Y /K6BOFG]K?]IKQ
M!\!=0T>#PY'H&HW$MC<W]QIFH6VH3WDZ1;2/*^S1-'$F!)NDG=5!P>@8US7_
M  V/XNG^*L6GVOA[0YO [^*]*\+&]%Q+]O66]LX[A7"D")D4N06#;AP-ASNH
M ^NZ*^,?AW\??%/QD_:/^&FI36#^'?".HVFMR:7:6VHM.=1MXB83-=1* L;*
M\0*\N")1@J00W9?MP_&;Q%\.?#>A:-X,U#^SO$VI->7WG^9$@2WM+26;:QD!
M4"2?[/$.A8R%0030!].45\WV'[9MAXC^)7AWPSX=\-2ZQI^J:-::Y+J+ZI:V
ML\5M<1NZM%:2N)+G9L ?RMQ4L!@G@\SX<_:YUWXK)X U32=%G\'Z!JWBFTTT
MRRS66IG4X);>[D\K,4Y-LR^1&7##>I<*!PV0#ZVHKY9A_P""@WA$V]W=W'@S
MQC9Z=#96^HQW<EI:N+BVGO(K.*1%2X9OGDE)52 S+&^ 6&T[UO\ MS> 9M+T
MJ4Z1XM_MK4-0O-+'AN/0Y)=4AN+6-)+A'A0MRBRQD[23\WLV #Z(HIL;B1 P
MS@^HQ7F7Q^^(WBWX3>#+WQ;H.@Z+KVC:-9W6H:Q%JFJ36,RP11%QY!CMY@S'
M#<,%' &><@ ]/HKYE_X:ZOO!?B3PS!\5],\-_#33-7TRYO\ Y]<:_E!5[5;=
M RPQKN<SSY4!N(&(8@&N_N/VD_"NF>)M>@U6^T_3/"VF:)I^N)XFEU"(VMS#
M=O*D6W'0$PM@D_-D;0: /6Z*S?#OB/2_%VA66M:)J%MJNDWL0FMKVSE$D4R'
MHRL."*X+X:?M$>$_BCJWC.PTZ6:S?PI=O:WLM\8DC=4>1#/&RR-^ZWPRKN;:
M?D.0!@D ]/HKF=/^)W@_5[*UO+'Q3HU[:7;F*WGM]0AD29QC*HP8ACR.!ZBJ
MGA;XJ:+XHM=2F(N=&^PZE=:6\>L1?96DD@;:[QAC\\9X*L."#VH [&BH+>^M
M[M$>"9)4<!E9&!!! ((QVP0?QJ<$$9'2@ HHILDB0QL[L$1069F.  .IH =1
M532=6LM>TNTU+3;N"_T^[B6>WN[619(IHV&5='4D,I!!!!P0:H^)_&6A^"X+
M&;7=5M=)AOKR+3[:2[E$:RW$AQ'$I/5F/ % &S10>!7./\2/"<>KS:4_B72$
MU.&ZBL9;)K^(31W$J%XH63=D2.H+*I&6 ) (H Z.BJ=SK%C9W]K93W<$-Y=;
MOL]N\@62;:,ML4G+8!!..F:N4 %%&<44 %%%% !1110 4444 %%%% !1110
M4444 &:*,9HH **** "BBB@ J.3_ %L?U/\ *I*B?_71_4_RH$QTO1?3(I],
MD^Z/J*?0,**** "BBB@ HHHH ***0YQQ0 M% Y%% !1110 4444 %%%% !0.
MM% H ?1110 RBBB@ HHHH **** "BBB@ HHHH #2+TI32+TH 6BBB@ HHHH
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M,LVNM7NM8<QZ!/%%I%Q(L"QR:6$N-ULR^4[E0VQFE(*[0!7'_'C]G/QWH^K
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M+AF*CCYB44?5E%-CW;!OP&[@=*=0!6O_ /CW'^^G_H0JPO2H+_\ U _WT_\
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MJQU'[8?$5]!+!;1PB**QM8+:.W@MU /S;0C?/QD$#'&3S&H_L@> ]1\877B
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M0?44^@84444 %%%!&: "BBB@ H-%(V,'- "CD44@Z4M !1110 4444 %%%%
M!0.M% ZT /HHHH 91110 4444 %%%% !1110 4444 %&,444 %%%% !1110
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MT#"BBB@ HHHH *,444 %!.**0\B@!:*!Q10 4444 %%%% !1110 4#K10.M
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M-DIGCD<819]A^#_VL?A]XSUV#18;G5-+U26YO;+[-K&E7%FT=Q:PQ3SQ/YB
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MURFFI\)/$?@;PUXJ\5?#C2/#JZQ?PV&GV6N:-:3W'VB>810 >4)5'F'80P;
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M5A+J>HR6T/D6D$+2O*PN(C@(H);H<@#I7S'INI^(/">@^)O'7AK7?'<OP_\
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M.I)=6%E%>ZDF^WM1<WL%NT[KN4$1K,S\D#Y>>*\%\4?&WXG:1KUGX.TGXH>
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M!UHH'6@!]%%% #*,\T44 %%%% !1110 49YHHH  <T4&C.:  T@&!2T@&!0
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MTQ!>0@8W-@ 9/4X 'M5BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;C]Y&?<U)43_ .NC_&@3'2_='U%/ILAP!WY%.H&%%%% !1110 4444 %%%%
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M;G][&/<T"8LAP!]13Z9*,A?J*?0,**** "BBB@ HHHH **** "BBB@ HHHH
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M H%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-_OM_.FMF0_B7S+-%%%(T"BBB@"O?_\ 'O\ \#3_ -"%3KTJOJ&/L_/]]/\
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MJ<>O\J!,67[H^HI]-DZ#ZBG4#"BBB@ HHHH **** "C&:*1C@$T +10.110
M4444 %%%% !1110 4#K10.M #Z*** &4444 %%%% !1110 449S1GF@ QFBB
MB@ HHH% !11G%% !1110 5$/]<_T%2U$/]=)]!0)DC=*@L/]2?\ ?;^9J=NE
M06./)./[[?SIK8A_$OF6****1H%%%% %>^_U'_ U_P#0A4Z]*KZ@?W _WT_]
M"%3H<BGT,U\;'4444C0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH **** "BBB@ J-_]9']34E1O_K(Q]:!#I.@^HIU-?H/J*=0,**** "BBB@
MHHHH **** "BBB@ HHHH **,8HH **** "@=:*!UH ?1110 RBBB@ HHHH *
M*** "BBB@ H'%%% !1G-%% !1110 4444 %18_?/]!_6I:B'^N?Z"@3):KV/
M^I;_ 'V_F:L&J]D,0M_OM_.A=2'\2^98HSS110:!1110!7O_ /CW_P"!I_Z$
M*G4<5#>_ZC_@2_\ H0J9>E/HB%\3%HHHI%A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%&,T '>BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *C?_
M %D?U-25&Y_>)QW- F.?H/J*=37Z#ZBG4#"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *!UHH'6@!]%%% #**** "BBB@ HHHH **** "BBB@ I
M <TM% !WHHZ44 %%%% !47_+5_H*EJ(#]\Y]A_6@3)",U!8<0'_?;^9J<]*@
ML0!"<?WV_G36S(?Q+YEBBBBD:!1110!7OO\ 4?\  U_]"%3KTJ"^_P!1_P #
M7_T(5.O2GT(7Q,6BBBD6%%%% !1110 4444 %%%% !1110 4444 %%%% !11
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBC&: "HW/[V,?6I*CD_UL?ID
M_P J!,<_0?44ZFN< ?6G4#"BBB@ HHHH *,T44 %%%% !1110 4444 %%%%
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M=: 'T444 ,HHHH **** "BBB@ HHHH **,9HH *1>E+2#IQ0 M%%% !1110
M5$/]:_T']:EJ(#]_)]!_6@3)#TJ"R_U+?[[?SJ<]*@L/]0?]]OYFFMB7\2+%
M%%%(L**** (+W_4?\#7_ -"%3#I4%\,P?\#7_P!"%3KTI]"%\3%HHHI%A111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %1/\ ZV/ZG^52U#)_KH_J?Y4 .G.%7_>%2"HYAD+_ +PJ
M3% !1110 4444 %%%% !03BBB@ HHHH **** "BBB@ HHHH *!UHH'6@!]%%
M% #**** "BBB@ HHHH **** "BBB@ -(#FEHQB@ HHHH **** "H@<S./8?U
MJ6HQQ*_T']:!,>>E06/^I/\ OM_,U.>E06/^I;']]OYFFMB7\2+%%%%(L***
M* (+W_4?\"7_ -"%3+TJ"^_U'_ U_P#0A4Z]*?0A?$Q:***184444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !43_ZU/QJ6HW \Q/7F@!9#@#ZBGTR3H,^HI] !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 % ZT4#K0 ^BBB@!E%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5$O^ND^@J6HP#YK^F!0)CS4%C_J6_WV_F:G
M/2H;-"D1!&#O8_K3Z$OXD3T444BPHHHH @O3B#_@:_\ H0J8=*AO%+P@ 9.]
M?YBIEZ4^A"^)BT444BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** #&:*** "BBB@ HHHH *BD/[V,>Y_E4M1.I,D9'0
M$T /?H/J*=3)064 >HIXXH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ H'6B@=: 'T444 0T445 !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4HZBDI1U%,"6
MBBBJ AHHHJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ I1U%)2CJ*8$M%%%4!#1114 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !2CJ*2E'44P):***H"&BBBH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "E'44E*.HI@2T4450!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ctso-20221231xex10d11g004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ctso-20221231xex10d11g004.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 20 SD# 2(  A$! Q$!_\0
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M33Z8_P!Y?QH 5S@#ZBG4UQG'UIU !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 % ZT4#K0 ^BBB@!E%%% !1110 4444 %%%% !1110 4444 %%
M%-DE2%=SL%7(&2<=: '4444 %1C_ %S_ $']:DJ(?ZY_H/ZT"9(>E06/^I/^
M^W\ZG-06/$)_WV_F::V)?Q(L4444BPHHHH KWW^H'^^O_H0J=>E0WO\ J./[
MR_\ H0J9>E/H0OB8M%%%(L**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BC-% !1110 4444 %%%% !FBBB@ HHHH **** "F/]]*?4<GWT^I_E0
MY^@^HIU(W0?44M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "F/]]/K3ZB?_6I]30 ]^@^HIU-?H/J*=0 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^$-7TE-%;1=/6Y\/Z/IVH6D=M<%I=LL@NMP>4JK*Q5R?EY'()\SE\5^(-?\
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M+2?V3/A;H7Q0D^(5AX:%KXH>ZDOA/'>3B%+B172280A_+W.LC G;WSP228/
M/[(OPS^&GC#3_$^@Z5?P:OIYE6S>XU:ZN([>-T9/*2.21D6-5=]J@87<<5Y%
M^SQ^U:9_@_X6T/7K?Q%!XGNO#%[J5GXEUZ".2TU26U0M-L<SAY&3<"0P0$ X
M; S7;^!?VL](B\ >"&U>#Q#XJ\0:AH5MJ^IS:)X>D(LX9&\M;BXCC9Q$&99,
M*K.2(W91M&: .V^*W[-GA/XQW^K7>OR:DDNIZ/%HDQLKKRMMO'=+=*5X.'\Q
M%R?08KI-$^%NF:#\3O$/CBWNKUM2UO3[/3;BVDD4VZ1VQE,910H8-^^?)+$>
M@'.?'_A3^TO8I\0O%WA+Q;?ZE)J,GC.\T?2+DZ7(+&.,",06IN4C$0E)WX1F
M,G<\$&OI*@#Y^OOV28;CXHW'B>W\9ZM:Z'/XCM_%<GAE+> V[:E&J*93+L\S
M:PC7Y,X!+GDD;=&S_9=L=-E\)2P>(+QWT#Q;?^+2TT*,;F6[-P9(B1@@ W)P
MQ).% .>WH/B#XM>%/"VJ:UIVJ:L+6]T;38M7O83!(S1VLLDD<<@PIWY>&1=J
M9;(''(SP7QE_:8T/P#X>TVXT;5M(N-1O9=)N<:B\B6\>FWE[';F\9P,!%5G;
M)( VDG@8(!C_  &^#T^@_&OXJ^-M0TBZTI+O4I;'2%NKHR>= [K<7-RJ E46
M69E  P<09(!)SH?$O]G75/&Z_&5[7Q%:VLGC[0[/1K97LF_XE_D1SH79_,/F
MEC<,1A4V[0/FZUVVF?'WX;ZSX/O_ !79^.= G\-6#!+O5AJ,0MK=B0%$CEL*
M6W+@'&=RXSD5H0?%[P-=:38ZI#XQT"73+\2FTO4U.!H;@1J6E\MP^'V $M@G
M '.* /GSXI?LE>-/$FN^*O\ A&O%.BV>A>*[#3+;5[>_LI6G1[#;]G%LX<A%
M)#%BP;&X\$\C6^)W[+OB'QS/\3KF'4]+$GBO6]#O[:&X\P)%;V A#I)A6R[E
M),<,OS+D<&OH[1];T_Q%I\5_I5];:E8RY\NYM)EEB?!(.&4D'!!'U!K O/BE
MX;L/B/:>!9]0\OQ+=:>^IQ6IC;:8%D6/)?&T$LX 4G)P< XH \#^(_[,/C37
M?B%XJ\5:'>: 9;[Q/H7B&QMM0N)XE8:?9O%LF*1,1F4HPV$\#JIKC_'/[*OQ
M(\6PZKXWNK;2%\:7OB:VUN7P[I'B&ZLH/LD%F;=8HK^*&.6.Y.XMOP$W!<Y
M(/UYXY\867P_\&ZWXEU%97L-(LIKZ=( ID9(T+L%W$#<0N!D@9ZD4O@?Q7;>
M//!F@^);**6"SUBP@U""*?;YB1RQK(H;:67< PS@D9Z$T ?+/P[_ &=/$FD^
M*OAAK5SX/319+/Q)J.N:]]L\32:Y<$R:>;>!Y)YE5I)-^S[@(7RP<DDFO4/V
MK/!'B+Q3H?@G5O#NFMX@?PKXFM==N]!CG6*34;>)9 \<>_Y&D&\,JN5!P1D'
M%>XT4 ?%-S\'?&7BZYO/%%]X*ET.V\4_$#0=6_X1U)87N=/LX8DANKBY,;!
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M_P#1(O+"Q@H6)?>3@+BOHNW_ &6/A59^%=4\-VG@RPL-%U1;=;VUL6DM_/\
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M@#Q.#]DSPG;ZA!J#:MXAN]037[+Q'-=WE^)I;JYM4=8EE9D.8\2'*C!^50"
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M41J!&<$948X."1QZT:9HMAHWVC[!96]G]IF:XF^SQ*GFRM]YVP!EC@9)Y.*
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M2=<UV'Q ;F"]LHKHR"2*-0OSR9BDV[@J_)\Q^88^CI/]9&2.<G^5><0?"1O
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M<6)&WI7L/P'^ K?!75O&5V=8&JQZ]-921KY'E-"L%I'!@G)W%F5F]@0.<9H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !111B@ HHHH **** "BBB@ HHHH **,9HH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "HG_P!;']34M1/_ *V/\:!#W[<9YIU-?H/J*=0,****
M "BBB@ HHHH ***",T %%%% !1110 4444 %%%% !0.M% ZT /HHHH 91110
M 4444 %%%% !1110 4444 %%%&,4 %%%% !G-%%% !48_P!<_P!!_6I*B'^N
M?Z"@3)#4%C_J3_OM_,U.:ALO]4W^^W\Z:V)?Q(GHHHI%A1110!!>?ZC_ ($O
M_H0J8=*AO>(!_OK_ .A"IATI]"%\3%HHHI%A1110 4444 %&,444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%)C
MS$_&I:CD_P!9']3_ "H <_0?44ZFOT'U%.H **** "BBB@ HHHH *.M%!&:
M"BBB@ HHHH **** "BBB@ H'6B@=: 'T444 ,HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "HQ_KG^@J2HQ_KG^@H$R2J]E_J3_OM_.ISTJ"Q_U)
M_P!]OYTULR7\2+%%%%(L**** (+W_4?\#7_T(5,.E0WG^H_X$O\ Z$*F'2GT
M(7Q,6BBBD6%%%% !1110 48S110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 %%%% !1110 4#K10.M #Z*** &4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !47_+9_H/ZU+48_US_0?UH$QYJ"Q_U)_P!]OYU.
M:@LO]2W^^W\Z?0E_$BQ1112+"BBB@"O??Z@?[Z_^A"IUZ5#>_P"H_P"!+_Z$
M*F'2GT(7Q,6BBBD6%%%% !1110 4444 &**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ ICXWI]3_ "I]1O\ ZR/ZG^5
MF/;H/J*6FOT'U%.H&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4#K10.M #Z*** &4444 %%%% !1110 4444 %%&.:* "BBB@ HHHH **** "
MHP/WK_05)48_US_04"9(:KV(Q"?]]OYU.>E06'^H/^^W\S36S(?Q+YEBBBBD
M:!1110!7OO\ 4#_?7_T(5.O2H+X9@_X&O_H0J=>E/H0OB8M%%%(L**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ J-\>8GKDU)4<A_>1_4T +)T';D4^FOT'U%.H *,444 %%%% !
M1110 4=:** "BBB@ HHHH **** "BBB@ H'6B@=: 'T444 ,HHHH **** "B
MBB@ HHHH **** "C&*** "BBB@ HHHSF@ J(?ZY_H*EJ,#]\_P!!_6@3'D9J
M"Q_U+8_OM_.K!JM8?Z@_[[?SIK9DOXD6:***184444 5[[_4?\#7_P!"%3KT
MJ"^_U'']]?\ T(5.O2GT(7Q,6BBBD6%%%% !1110 4444 %%%% !111C- !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !43_ZU/QJ6
MHI%_?1GZT"8^09 ^HIU-?H/J*=0,**** "BBB@ HHHH **** "BBB@ HHHH
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M:_\ H0J<=*@OO^/?_@:_^A"IUZ4^A"^)BT444BPHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HY
M/OQ_4_RJ2HG'[U/J: 'OV^HIU-?H/J*=0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !0.M% ZT /HHHH 91110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %1#_7/]!4M1C_7/]!_6@3'FH++_4G_ 'V_G4[=*@L?]2>_
MSM_.GT)?Q(L4444BPHHHH @O1F#_ (&O_H0J9>E0WG^I_P"!+_Z$*F'2GT(7
MQ,6BBBD65+2^:ZN;R(VT\"V\@C624 +,"BMN3!.5&XKS@Y5N,8)MT44 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !11C%% !1110 4444 %%%% !1110 4444 %%%% !1THHH **** "BBB
M@ HHQ10 4444 %1R?ZR/ZG^525&X_>Q_4_RH$QSG&/K3J:YP!]13J!A1110
M4444 %&:** "@G%%% !1110 4444 %%%% !1110 4#K10.M #Z*** &4444
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MHHHI%A1110 4444 %%%% !1110 4444 %%(>.>II<YH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ J.3_61_4_RJ2HY/\ 61_4_P J!,<_
M;ZBG4U^@^HIU PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@=:
M*!UH ?1110 RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHQBB@ J+_E
ML_T%2U%_RV?Z"FA,D-0V7^I;_?;^=3&H++_4M_OM_.A;$OXD6****184444
M5[[_ %'_  -?_0A4Z]*AO1F#_@:_^A"IEZ4^A"^)BT444BPHHHH **** "BB
MB@ HHHH ,4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %1OGS(_3)J2HW'[R,^YH$QS]!]13J:XR!]:=0,**** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *CD_UD?U-25')]]/J?Y4"8Y^@^HIU-<9 ^HIU PHHHH *
M*** "BBB@ I"<4M% !1110 4444 %%%% !1110 4#K10.M #Z*** &4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !40_US_05+48_P!<_P!!0)CS
M4%CS"?\ ?;^=3GI4%B<P$_[;?S--;,E_$BQ1112+"BBB@"O??ZC_ (&O_H0J
M=>E0WHS!_P #7_T(5,O2GT(7Q,6BBBD6%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1CG-%% !1110 4444 %%%% !1110 4444 %%%% !4<G^LC
M^I_E4E1O_K(_K_2@3'/T'U%.I&Z#ZBEH&%%%% !1110 4444 %%%% !1110
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M12+"BBB@""]_U'_ E_\ 0A4R]*@OO]1_P-?_ $(5..E/H0OB8M%%%(L****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHSB@ HHHH **** "HW'[Q#[G^525&_\ K(_J: '/T'U%.IKC('U%.H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H'6B@=: 'T444 ,HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "F*?WK?04^HU_US_04 /-067^
MI/\ OM_.IS4%B,0G_?;^9IK8A_$BQ1112+"BBB@"&[_U(_WE_F*E7I4-[_J1
M_OK_ .A"IEZ4^A"^)BT444BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *,444 %,?[\?U/\J?4+_P"M
MC^IH D?H/J*=3)3A0?<4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^!+_ #%3#I3Z$+XF+1112+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ",U$T>)$/H34M(W44 -
MD0MC!P<T[FEQFB@ HQBBB@!  *6BB@ HHHH 3 ]*, ]J6B@ QQBDVC&,<4M%
M !1110 48%%% !@>E%%% !0!S10.M #Z*** &44'VHH **** "BBB@ HHHH
M**** "D7I2@YHH **** "BBB@ J-?]<_T%24P?ZUOH* '&H+'_4G_?;^=3GI
M4%EQ"1_M-_.FMB'\2+%%%%(L**** (+T9@Y_OK_Z$*F7I4-X,PC_ 'E_F*F7
MI3Z$+XF+1112+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *:QPR#U-.J)S^^C_ !H E)Q13)3@
M#G'(I] !1110 4444 %%%% !112$X&: %HH'-% !1110 4444 %%%% !0.M%
M ZT /HHHH 9C-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4T?ZP
M_A3J8/\ 6M]!0 YNE16@Q$?]YOYU*W2H;,8B/^\W\Z:V(?Q(GHHHI%A1110!
M#=_ZD?[R_P Q4J]*BN_]4,?WE_F*E7I3Z$+XF+1112+"C/-%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%&,T4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !43\S1_4U+4;G,B?4T +*< ?44^FOT'U%.H **** #'.:*** "BBB@
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J)QB6/\:EJ.0_.GU/\
M*@!TG0<XY%.IK]!]13J "BBB@ HHHH **** "D;&.:6B@ %%%% !1110 444
M4 %%%% !0.M% ZT /HHHH 91110 4444 %%%% !1110 4444 %%%% !1110
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M 5[[_4#_ 'U_]"%3J<BH+[_4#C.'7_T(5.HP*?0S7QL6BBBD:!1110 4444
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M2+"BBB@""]_U'_ E_P#0A4R]*@OL>1S_ 'U_]"%3KTI]"%\3%HHHI%A1110
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M_P JDJ-_]9']3_*@3'/T'U%.IK]!]13J!A1110 4444 %%%% !1110 4444
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M !1110 4Q_OQ_6GU&_\ K8_J:!,63H/K3Z:_0?44Z@84444 %%%&* "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M48Q110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>1S_ 'E_]"%3+TJ&]_U'_ U_]"%3+TI]"%\3%HHHI%A1110 4444 &,4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4Q_OI]:?3''[R/ZG^5 F*_0?44ZFOCC/J*=0,**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ H'6B@=: 'T444 ,HHHH **"<44 %&<T44 %%%
M% !1110 4@P!Q2T8Q0 4444 %%%% !31_K&^@IU-'^L;Z"@!6Z5!8?ZD_P"^
MW\ZG;I4%C_J3_OM_.FMC-_$OF6****1H%%%% $%[_J/^!+_Z$*F'2H+[_4?\
M#7_T(5.O2GT(7Q,6BBBD6%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5&_^MC_&I*CD_P!9']30
M)CGZ#ZBG4UQD#ZBG4#"BBB@ QS1110 4444 %%%% !1110 4444 %%%% !11
M10 4#K10.M #Z*** &4444 %%%% !1110 4444 %%%% !1G-%% !111]* "B
MBB@ IF,R-^%/IB_ZQOH* '$<5!8_Z@X_OM_.K!XJO8?ZD_[[?S--;,A_$OF6
M****189S1110!7OO]1_P-?\ T(5.O2H+XX@_X&O_ *$*G7I3Z$+XF+1112+"
MBBB@ HHHQF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ J.3_ %D?U-25&Y_>)]?Z4"8Z3H/K3J:_0?44Z@84
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0.M% ZT /HHHH 9111
M0 4444 %%%% !1110 4444 %%%% !1110 48YHHH *8#B1OH*?3 /WC?04 /
M/-5['_4G_?;^9J<\"H+$YA;_ 'V_F::V9F_B7S+%%%%(T"BBB@"O??\ 'O\
M\#7_ -"%3KTJ&]_U'_ E_P#0A4R]*?1$+XF+1112+"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*B?_ %T?XU+4;G]Y&/<T"'/T'U%.IKG&/J*=0,**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ H'6B@'F@!]%%% #**** "BBB@ HHHH **** #&*
M*** "C.:** "BBB@ HHHH *8/]:WT%/IH_UC?04 *:@L/]0?]]OYFISTJ"R.
M86_WV_G36Q#^)%BBBBD6%%%% %>^&8/3YU_]"%3KTJ"^_P!1_P #7_T(5.O2
MGT(7Q,6BBBD6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!7OO]2O^^O\ Z$*F3I4-]CR!GLZ_^A"IU&!3Z&:^-^B%HHHI&@4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5!!?6]
MS<7$$,T<LMNP29$<$QL5#!6'8[64X/8@]ZGJ"&QMK>YN+B*"..>X(,TB( TA
M  !8]\  <]A0!/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4R3_61_4_RI],?_61_4T"8K]!]13J:YP!]13J
M!A1110 4444 %%%% !111C- !1110 4444 %%%% !1110 4#K10.M #Z***
M&4444 %%%&.: "BBB@ HHHH *,8HHH * <T44 %%%% !1110 4P?ZQOH*?3,
MXD;Z"@!YJO9',3?[[?S-3GI4%D,0MC^^W\Z:V9#^)%BBBBD6%%%% $%Z<0?\
M"7_T(5,O2H;W_4?\"7_T(5,O2GT(7Q,6BBBD6%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5')_
MK(_J:DJ-S^\3Z_TH$QS]!]13J:_0?44X'(H&%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4#K10.M #Z*** &4444 %%%% !1110 448YHH ***
M* "BBB@ HHHH **** "F _O6^@I]-'^L;Z"@!34%C_J6_P!]OYFIVZ5!9#$)
MQ_?;^=-;$/XD6***,YI%A1110!!>_P"H_P"!+_Z$*F7I4%]_J/\ @:_^A"IU
MZ4^A"^)BT444BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "HY/]9']3_*I*C?_ %L?U/\ *@3'
M/T'U%.ILG0?44Z@84444 %%%% !1110 444'/:@ HHHH **** "BBB@ HHHH
M *!UHH'6@!]%%% #**** "BBB@ HHHH **** "BBB@ HHHH **** "BBCO0
M4P'$C?04^F 9D;Z"@!S=*@LAB$_[[?SJ=NE06)S"W^^W\S36QF_B7S+%%%%(
MT"BBB@"O>_Z@ =2Z_P#H0J=3D5!??Z@?[Z_^A"IU&!3Z&:^-BT444C0****
M"BBB@ HHHH **** "BBB@ HHHS0 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !0.M% ZT /HHHH 91110 4444 %%%% !CFBBB@ QWHSFBB@
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M %'_  -?_0A4R]*@OCBW_P"!K_Z$*G7I3Z$+XF+1112+"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5&^/,3UR:DICX\R/ZG^5 F.;H/J*6D;H/J*6@84444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !0.M% ZT /HHHH 91110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %1_P#+1OH*DI@&9&^@H <>@J"Q_P!2W^^W\S4Y
MZ5#9<PM_OM_.FMB'\2)Z***184444 5[[_4#M\Z_^A"IU.14%]_J5_WU_P#0
MA4R?=I]#-?&_0=1112- HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHS10 4444 &,T444 %%%% !1110 5&Y_>)]34E1OCS$^IH$
MQS]!]13J:_0?44Z@84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M0.M% '- #Z*** &4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !31
M_K&^@IU-'^L;Z"@!34%CS"?]]OYU.:@LO]2W^^W\S36Q#^)%BBBBD6%%%% %
M>^_U'_ U_P#0A4Z]*@OCB$>[K_Z$*G0Y%/H0OC8M%%%(L**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1N@^HI:!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 % ZT4#K0
M^BBB@!E%%% !1110 4444 !&:*** "BBB@ H[T44 %%%% !1110 4T?ZQOI3
MJ:/]8WT% "MTJ"R_U)Q_?;^9J<U#9?ZEO]]OYTUL0_B1/1112+#&:*** (+W
M_4?\"7_T(5,O2H+[_4?\#7_T(5.O2GT(7Q,6BBBD6%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4Q_OI]33Z8_WX_J:!,<W0?44M(W0?44M PHSS110 4444 %%%% !1110 444
M4 %%%% !1110 4444 % ZT4#K0 ^BBB@!E%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M,<?/']3_ "I],?[Z?6@0YNWUI:1NWUI:!A1110 4444 %%%% !1110 4444
M%%%% !1110 4444 % ZT4#K0 ^BBB@!E%%% !1110 4444 %%%% !1110 4
MYHHH **** "BBB@ I@_UC?A3Z8!^];Z"@!QJ&S_U)_WV_G4QJ&R_U+?[[?SI
MK8A_$B>BBBD6%%%% $%Z,P?\#7_T(5,O2H;TXA'^^O\ Z$*E0Y%/H0OC8ZBB
MBD6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI'09H <XR!]:=37S@8]:=0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !0.M% ZT /HHHH AHHHJ "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I1U%)2CJ*8$M
M%%%4!#1114 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !2CJ*2E'44P):***H"&BBBH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "E'44E*.HI@2T4450$-%%%0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %*.HI*4=13 EHHHJ@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ctso-20221231xex10d11g005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ctso-20221231xex10d11g005.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 20 SD# 2(  A$! Q$!_\0
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M[_J/^!+_ .A"IEZ4^A"^)BT444BPHHHH **** "BBB@ HHHH **** "BBB@
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.3[Z?4_RJ2HY/OQ_4T
M.<X ^HIU-<X ^M.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "HW'[R/ZFI*8_WT^IH <W0?44M-?H/J*=0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !0.M% ZT /HHHH 91110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %,'^L;Z"GTP9\QO3 H <:@L?]2?]]OYU.W2H++_4
MM_OM_.FMB'\2+%%%%(L**** (+W_ %'_  )?YBIATJ&]_P!1_P "7_T(5,O2
MGT(7Q,6BBBD6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5'(/G3ZFI*C?'FQ_4T .<9 [<BG4U
MS@#ZBG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4#K10.M #
MZ*** &4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !31_K&^@IU-'
M^L;Z"@!6Z5!9<0G_ 'V_G5@]*KV'^H/^^W\S36S,W\2^98HHHI&@4444 5[[
M_4?\#7_T(5.O2H;W_4?\"7_T(5,O2GT(7Q,6BBBD6%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4QQ^\C^I_E3Z8YP\8]S0 KC('U%.I&Z#ZBEH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ H'6B@=10 ^BBB@!E%%% !1110 4444 %%%% !111
M0 4#VHH!S0 4444 %%%% !4?_+1OH*DI@'[UOH* ''I4%C_J3_OM_.ISP*@L
M3F%NWSM_,TUL0_B18HHHI%A1110!7OO]1_P-?_0A4Z]*@OO]1_P-?_0A4Z]*
M?0A?$Q:***184444 %%%% !11G-% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!6O]0A
MTV%)9RX1Y8X1LC9SN=PB\*"<989/0#DX )JS110 4444 %%%% !1110 4444
M %%%% !1110 5')]^/ZG^525')_K(_J:!,<_0?44ZFOT'UIU PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "@=:*!UH ?1110 RBBB@ HHHH **
M** "BBB@ HQBBB@ HHHH **** "BBB@ IH_UC?04ZFC_ %C?04 .JO8?ZD_[
M[?S-3FH+'_4G_?;^9IK9F;^)?,L4444C0**** *]]_J!_OK_ .A"IQTJ&]_U
M'_ E_P#0A4R]*?0A?$Q:***18448S10 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1G-%% !1110 4444 %%%% !UHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CD_UD?U-25'
M(/WB'Z_RH$Q[=!]12TV3H/K3J!A1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 % ZT4#K0 ^BBB@!E%%% !1110 4444 %%%% !1110 48Q0:0'-
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M_P!]?_0A4T?W?QJ&^_U _P!]?_0A4ZC I]"%\;%HHHI%A1110 4444 %%%%
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M9*\4>+/"-Y'??#NXLM8T_P"'J66EH=9@(;Q EW=R-,'2?!:1IS+ND&T><P+
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MT^YTJ]U/2+T0VX.JKYD"V<]OY3,D"@"6#<FQ=YPS;J /T+4AAD=*6OS=E_:
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MQGS58!@1QSP ?1=%?$VB?M!^-_B!\5?!7B:^&GZ1X,>?Q(=*TJRO[J":[-C
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M !QT K1HHH *CD_UD?U-25%(?WJ#ZT /?&!GU%.IK]!]13J #%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4#K10.M #Z*** &4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !3 ?WC?04^F#F1OH* ''I4%C_J6_P!]
MOYFISTJ"Q&(6_P!]OYFFMF9OXE\RQ1112- HHHH @O?]1_P)?_0A4R]*AO?]
M1S_?7^8J9>E/H0OB8M%%%(L**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J-QB2/ZFI*C<?O$^IH
M <_0?44ZFN,X^M.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MH'6B@=: 'T444 ,HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F#
M_6-]!3Z8/]:WT% #FZ5!8_ZD_P"^W\S4[=*@LO\ 4G_?;^=-;&;^)?,L4448
MS2- HHHH KWW, _WU_\ 0A4Z]*@OO]1_P-?_ $(5..E/H0OB8M%%%(L****
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M10 4444 %%%% !0.M% ZT /HHHH 91110 4444 %%%% !1110 4444 %%%%
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 % ZT4#K0 ^BBB@!E%%%
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MYQXB_:6BO/#UU<_#_P %^*_'=\UNS6C6VC36=G)(5S%F>Z\E6C8E<O$7P,T
M=3\8/BF_P]L=/T[2--;7_&6N2/:Z)HRML$\H7+22O_RS@C!5I)#T!  9F53=
M^#W@"3X;^ M/TF]O6U36GW7>K:DS$F\OI3ON)AGD*SEMJ]%4*HP *\5^!OB&
MV\,^-?M'Q"\->*])^(/B65K>+Q)XFL+9;><,QD33K-K>ZN5MHE"$K \@+%2Q
M+MDUZY\5?C[X'^#,'_%2ZRL6H-!)<PZ39QM<WT\:*6=T@C!<HH!+.0$4 EF
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MI%A1110!!>_ZC_@2_P#H0J9>E0WO^H_X$O\ Z$*F7I3Z$+XF+1112+"BBB@
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M#\&_A)XEUR;2?'?Q4UB35?$ZKY^G>'[-Q%I&A*Q?:L4*';+,$?:9I"[ #:I
MR6]XKX?M?%GQEL+2.WD\/?&/14M@L06WO="U)G4;54F22PD9R "6)/.,Y8M6
MQX8^-OC?2-0L;O5_#?Q]U2.U8B;3Y?#FBO!='+?>:.UA?:!MP49#GC!QD@'V
M117S=_PVK$ES)#<_!;XPV6PX,DWA(E,8SD,DK ]?6K0_;:\+6JVHU/P1\1]'
MDN(A+&M[X2N0"I)P=RAE]#G..><<X /H>BOGQOVW_ ,";KK1O&]EPI_?^$K\
M @]PPC*D=.02#D8S3D_;S^"AD\M_$^HP/G&V?PUJD9!SC'S6PH ^@:*\.C_;
M<^![V[SR_$+3K*-/O?;HIK8KSCD2(I']>*T[/]K_ .!]\DCQ?%KP;MCX._6[
M=#^ +C/7MZ'T- 'KU%>;P?M*_".ZMVGA^*/@R6!6"&5/$%HRAB< 9$G7)'%:
M5I\</AW?VHN;;QWX:N+<QF42Q:O;LA0#);(?& #G- ';45C-XRT&.#SGUFP2
M'RWE\QKI NQ=N]LYQA=Z9/;</44RS\<^'=1V_9-=TVZW%%'DW<;Y+G"=#_%@
MX]<<4 ;E%(K!U#*05/((I: "HW \R/ZFI*BDSYL?ID_RH >_0?44ZF2=!]:?
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0.M% ZT /HHHH 9
M1110 4444 %%%% !1110 4444 %&>:** "BBB@ HHHH *8/]:WT%/IH_UC?0
M4 *1FH+'_4G_ 'V_G4Y.*@LN(6_WV_F::ZF;^)?,L4449Q2- HHHH KWW^H_
MX&O_ *$*G7I4-[_J/^!+_P"A"IEZ4^A"^)BT444BPHHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HKYQ^-/Q7\8/\7KCP)X9UV+PA8:3X>C
M\1:EK*:!+K5Y*KW#0)!!;H?5=S':QQTQ@FJ7A+]K.&QT1+>]N#X[:W\&ZAXR
M;Q'I>GOIL-Y!;W+PB)+65F=)#@ Y.,\@8/ !]-T5\O1_M":_XA^+-I8:;J4,
M/AJ?7-'@2$Z?B;[+<Z+=7SH[EB68M%$1M5=HR,DDXS_AI^W#I47PU\'77BRS
MU75M=N](75];O=%TT&TTRV:9HUN)\LN 0"Q2,.X",=HXR ?6-%>*WG[7/@6Q
MN==6:V\2?9-%U/\ L:ZOXM!NI;=K[SS#]GB9$)FDW '$8; 9<X)Q2:!^UQX!
M\6ZK%HVEW&I6VM7+75O;Q:UI%Y8P?:K=':6W>=XM@D39\R EP#G:: /:Z#P*
M\!\*_MH_#JZT'PG)XHUVT\/:WKNG6VHK;I'=2VBQSN4C?[2T"*$9P5#2!.2
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M HHHH **** "BBB@ H'6B@=: 'T444 ,HHHH *,9HHH **** "BBB@ HHHH
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M'-U)9K>OJ]T^FQ#0+M94,^I0Q2E3(8R!AE5I&7=T6ONRDP*6@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "HW)\Q/3FI*8_P!^/ZF@0KC./K3J
M:_0?44Z@84444 %%%% !1110 48S11UH **** "BBB@ HHHH **** "@=:*!
MUH ?1110 RBBB@ HHHH **** "BBB@ HHHH ***,8H **** "BBB@ IH_P!8
MWT%.IF<2-]!0 YNE06/^I/\ OM_.ISTJ"Q_U+?[[?S-/H9OXE\RQ1112- HH
MHH KWW^I7_?7_P!"%3)TJ&]_U0_WU_\ 0A4T?W?QI]#-?&_0=1112- HHHH
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MG7_T(5.O2H+[_4?\#7_T(5.O2GT(7Q,7.****184444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4<
M@_>Q_4U)4;X\V/\ &@!SC('U%.IK]!]13J "BBB@ HHHH **** "BB@G% !1
M110 4444 %%%% !1110 4#K10.M #Z*** &4444 %%%% !1110 4444 % &*
M** "BBB@ HHHH *.]%% !3,9D;Z"GTQ?]:WT% #CTJ"Q_P!2W^^W\S5@C-5[
M'_4M_OM_,TULS-_$OF6****1H%%%% %>^_U'_ U_]"%3KTJ"^_U'7'SK_P"A
M"IUZ4^A"^)BT444BPHHHH **** "BBB@ HHH Q0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %1O_K(_J?Y5)4;_ .LC^IH$
MQ[=!]12TU^WU%.H&%%%&: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MH'6B@=: 'T444 ,HHHH **** "BBB@ HHHH 0C/TI:** "BBC.: "BBB@ HH
MHH *8#^\;Z4^F@?O&^@H 4U!8G,)_P!]OYFISTJ"R_U+?[[?SIK8A_$BQ111
M2+"BBB@"O??ZC_@:_P#H0J=>E07W^H_X&O\ Z$*G7I3Z$+XF+1112+"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BC.** "BBB@ HHHH
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M@ HHHH **** "BBB@ H'6B@=: 'T444 ,HHHH **** "BBB@ HHHH ****
MTG0<TM% !1110 4444 %,QF1OH*?3,XD;Z"@!QZ5!8G,+?[[?S-3GI4%ES">
M,?.W\S3Z&;^)?,L4444C0**** *]]_J/^!K_ .A"IUZ5#>_ZC_@2_P#H0J9>
ME/H0OB8M%%%(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLQ547[7!(\:,Q; 60KGMD\5[0K!AD<B@!:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HW_UD?U/\JDJ-_P#6
MQ_4T"8]N@^HI:9+R!]13Z!A1110 4444 %%%% !1110 4444 %%%% !1110
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M832>#I9U("D_\L'DQDC SW(S@9( .HNIOV@[DS&VL_AKIP,>V-9;K4+O:_\
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M%\6OB5#9E-OE#6XV;.[=N\UH#+G/^WC'&,8% 'EGP9_:,\7?"[X;Z!X=\?\
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M !_?-KLJ)+Y@BMG_ ./:('I@(2P[CS,'I@>^TV*,11JBC"J, >@IU !1110
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M%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% ' Z=X%U(_'#7/&.H2V\FF_V
M'::3I$2,3)"?.FENV8%>-Y-L,AN1",@8R>^HHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "FL<,H]33JBD;$T8]2?Y4 2YQ13)6P!ZY%/H **** "B
MB@G% !1110 444C' )H 6B@<B@>] !1110 4444 %%%% !0.M% ZT /HHHH
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M1110 4444 %%%% !1110 49Q110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M1GFB@ HHHH **** "HY/]9']34E1R'][&/K_ "H$QSG&/K3J:W;ZT[% PHHH
MH **** "BBB@ I#FEHH !R**** "BBB@ HHHH **** "@=:*!UH ?1110 RB
MBB@ HHHH **** "BBB@ HHHH ***,8H **** "BBB@ IHQO/K3J;_P M#0 K
M=*@L?]2?]]OYU.:@L3F$_P"^W\Z:V9F_B7S+%%%%(T"BBB@"O>G$ ]W7_P!"
M%3J<BH+[_4#_ 'U_]"%3J,"GT,U\;%HHHI&@4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444  &**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H9!
MF6/ZG^534Q_OI]30 LG0<XY%.IK'I]:=0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !0.M% ZT /HHHH 91110 4444 %%&>:* #O1110 4448
MQ0 444=Z "BBB@ QBBBB@ IH_P!8:=3!_K#0 YNE06/^I;_?;^9J=NE067^I
M;_?;^=-;&;^)?,L4444C0**** (+W_4?\"7_ -"%3+TJ&]&8/^!+_P"A"IAT
MI]"%\3%HHHI%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %1R?ZR/ZFI*8_^LC^IH$Q9.WUIU-?
M&!GUIU PHHHH **** "BBB@ I"<#-+10 4444 %%%% !1110 4444 % ZT4#
MK0 ^BBB@!E%%% !C%%%% !1110 4444 %%%% !1110 4444 %%%% !30/WC?
M04ZFC'F'UH 5NE06/,)_WV_F:G;I4-E_JF_WV_G36QF_B7S)Z***1H%%%% %
M>^_U*_[Z_P#H0J:/[OXU#?#]P/\ ?7_T(5.HP*?0S7QOT%HHHI&@4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !4;G]Y']34E1R']Y'^- F.<X ^M.ILG0?44Z@84444 %%%% !1
M110 48S110 4444 %%%% !1110 4444 % '-% ZT /HHHH 91110 4444 %%
M%% !1110 444=Z "BBB@ HHHH **** "FC_6'Z"G4T?ZP_2@!6Z5!8\PG_?;
M^=3MTJ"R.83_ +[?SIK8S?Q+YEBBBBD:!1110!!>_P"H_P"!+_,5,.E0WO\
MJ/\ @2_^A"IEZ4^A"^)BT444BPHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HY/OQ_4_P JDJ.0
M#S(_J: '.< ?44ZFN,@?44Z@ HHHH **** "BBB@ HHH.>U !111B@ HHHH
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M0 4444 %%%% !110* "BB@^U !11C/6B@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ,449S10 4444 %%%% !1110 4444 %%%% !1110 5&X'F1_4U)4;\R)
M^/\ *@!SC('U%.IKC('UIU !1110 4444 % -%% !1103B@ HHHH **** "B
MBB@ HHHH *!UHH'6@!]%%% #**** "BBB@ HHHH **** "BBB@ HHHH ****
M #.:*** "FC_ %AIU-!_>'Z4 *W2H+'_ %+?[[?S-3MTJ"Q_U+?[[?S--;$/
MXE\RQ1112+"BBB@""]_U'_ E_P#0A4R]*@OO]2/]]?\ T(5,G(I]#-?&QU%%
M%(T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *,8HHH **,XHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "HY!^\C^I_E4E1R'][']30)CGXQ]:=39.@^
MHIU PHHHH **** "BBB@ HHHSB@ HHHH **** "BBB@ HHHH *!UHH'6@!]%
M%% #**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IH&)"?6G4T?ZQ
MOH* %;I4%E_J6_WV_G4YJ"R_U)_WV_G3Z$/XD6****184444 07O$'_ E_\
M0A4R]*AO?]1_P)?_ $(5,.E/H0OB8M%%%(L**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSFB@ HHHH **** "BBB@ HHHH ***,XH **** "BBB@ HHHH **** "BBB@
MHHHH **,<T4 %%%% !1110 448HH * ,"BB@ HHHH *C=?WB'ZU)4;\21^Y-
M #I.@^HIU-<X ^M.H **** "BBB@ HHHH ,4444 %%%% !1110 4444 %%%%
M !0.M% ZT /HHHH 91110 8Q1110 4444 %%%% !101FB@ HQBBB@ HHHH *
M*** "F#_ %C?04^F#_6-]!0 YNE061S"W^^W\ZG-060Q"W^^W\Z:(?Q(L444
M4BPHHHH @O?]1_P)?_0A4R]*@O?]2/\ ?7_T(5,G(I]#-?&QU%%%(T"BBB@
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M HHHH **** "BBB@ HHHH **** #%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !44A/FQCMDU+4<A'F1COD_RH$.<X ^HIU-<X ^M
M.H&%%%% !1110 4444 %(1D8I:*  <"BBB@ HHHH **** "BBB@ H'6B@=:
M'T444 ,HHJ&V6=8V^T/'(^]B#&A4!<_*""3R!@$]^N!TH FHQBBB@ HHHH *
M*** "BBB@ HHHSF@ HHHH **** "F#_6M]!3Z;_RT- "D9J"Q_U+?[[?S-3D
MXJO8#$!_WV_F::V9F_B7S+-%%%(T"BBB@""].(/^!+_Z$*F'2H;T9@_X&O\
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M@ HHHS0 5&^?,C^IJ2F2??C^IH$Q7&<?6G4UQD#ZBG4#"BBB@ HHHH ****
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M,U\;%HHHI&@4444 %%%% !110.: "BBB@ HHHH **** "BBB@ HHHH ****
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MT"'-T'U%+37[?6G4#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*!UHH'6@!]%%% #**** "BBB@ HHHH **** "BBB@ HHHSF@ HHHH **** "
MF@?O#]*=31]\T *W2H++_4M_OM_.IVZ5!8_ZEO\ ?;^=-;&;^)?,L4444C0*
M*** *]Z1Y S_ 'U_]"%3J<BH+WB$'_;7_P!"%3J,"GT,U\;%HHHI&@4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !12=?I2T %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *4=124HZBF!+1115
M0T445 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4HZBDI1U%,"6BBBJ AHHHJ "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ I1U%)2CJ*8$M%%%4!#1114 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2C
MJ*2E'44P):***H HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
IHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ctso-20221231xex10d11g006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ctso-20221231xex10d11g006.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 20 SD# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"!+_,5,.E/H0OB8M%%%(L**** "BBB@ HHHH **** "BBB@ HHHH ****
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MG;I4%C_J6_WV_G36S,W\:^98HHHI&@4444 5[W_4?\#7_P!"%3KTJ"^_U'_
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MO@2?Q('XU]/?M_9_X4?IBE]D?_"4:0TKF$2*D:7*R,S#!.U0A8E03@<_+NH
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MSR6>*1G82!)6C.W._>?T5L?%N@_#;X=Z#-XHUG2_#MK%90Q-/?WD4$(98LL
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M'&?6G4 %%%% !1110 4444 %%%&<4 %%%% !1110 4444 %%%% !0.M% ZT
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MV%C#,V[G  SWK>^*%Y>WGBJRTN29A:^'M$TK0[-%^6..*.Q@=BH']Z21R3W
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M^/)/MMG$\4UG"V^=5)*V4!.<GCDXP!V/)Z#]-ZH:=K>FZS/?0V-];WDMA/\
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MQ-<Z!?7%[)]MTV"/S?,LY+55B$000X\UG9L.6)(&U3@>N=Z* "BBB@ HHHH
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MV]I,XTJ:PM]-TNZ@W>0B7#JUP&N6=#<;8Y&C7)4*5KT_PS\)/&EC)HHET>Y
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MMY887W!9E!+P[A\OF*%8F,'< K9 P:X3X#0^!_"O@V'P=X/U^3Q1-9K]OO\
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M &>X+"V^!O@2'3+N:]L(M&M4AFN81#(5$:C#1@D(1C&S)VXQDXR0#T*BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *Y3XC_#'0/BKHEMIGB""X>*TO(M0M+BRNY;
M2YM;B,G9+%-$RO&P!894C(9AT)KJZ* .7\!?#C1OAQ97EOI7VV>2]N#=7=YJ
M=]->W5Q)M5 TDTK,[81$0 G 50!748HHH ",C%1BWC$+1;%\MLY7'!SUX]\F
MI** .7\3?#70/%C>&_MUF OA_4(M2L$AP@CEC5@@X'W1NSM&.57TJ+Q%\(O
MOB_49K_7?!GA_6KZ90LESJ&EP3R. , %G4DX P*ZVB@#BIO@QX)N/$Z>('\.
MV9U5/*(E"D(6B*&&0Q@[#)'Y4820KN4* I XJ"\^!G@J\UG^U?[':VOA]J=)
M+*\GMA%-<AA/<1K&ZJEPX=@;A0)<,0'KO** .0\%_"O0O M]-J%D=0OM6FM8
M[*74M7U&>^N7@C=W2,O*[$ &1NF,\%LD9KKZ** "BBB@ HHHH *CD'[V,^Y_
ME4E1O_K(_J:!,>W0?44M-?H/K3J!A1110 4444 %%%% !2$9&*6B@ HHHH *
M*** "BBB@ HHHH *!UHH'6@!]%%% #**** "BBB@ HHHH **** "BCO10 44
M48Q0 4444 %%%% !4,D*3F2.10Z,N&5AD$>AJ:FC_6'Z4 96@^$]$\*13QZ+
MI%CI,<\K3RK8VR0B21OO.P4#+' R3R<5?L %@('3>W\S5@C-5['F%O\ ?;^9
MIK9F;^)?,L50GT'3KK6;75IK*"34[6&6W@NWC!EBCD*&1%;J QCC) Z[%]*O
MT4C0**** *]\!Y'_  -?_0A35TRS%Q<7 M81/<*J32B,;I%&<!CU(&3@'U-/
MO?\ 4?\  E_]"%3#I3Z$+XF51I-DL$D M81#(@B>/RQM9 -H4C'(QQCTKF_$
M'P>\">+=,BTW7?!GA_6M.A=9([34=+@N(4=8_+5@CH0"(_D! X7CIQ77T4BS
MC=%^#/@/PS96=GHG@W0M$L[*>6ZMK?2].AM4AFDB:*21!&JA6:-F4L.2#BNE
MT31+'PWH]CI.EVL=CIMC"EM;6T*[4BB10JHH[   #Z5=HH **** "BBB@ HH
MHS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %1N/WL?U-25$^/,3UYH >XZ?44ZFN,@?44Z@ HQ110 4444 %%%% !1103B
M@ HHHH **** "BBB@ HHHH *!UHH'6@!]%%% #**** "BBB@ HHHH **** "
MBBB@ HSFBC&* "BBB@ KB_C%X^G^&7P\U+Q!:6<.H7L#V\%M:W$QBCEFFGCA
MC5G"L5&Z1><&NTKAOC7X!NOB;\/;GP]9RP0S3WMA.S7+$)Y<-Y#/(,@$Y*1,
M!QU(S@<T 5M2^)VH>&_BGI?A?6]"BM='UJ.7^R==M[[S%DGBB\V6">)D3RFV
MB1DVM(&6-B=A&*W_  G\0?#7CI;J7P]KNGZW';LB2O87*3!&9 Z@[2>J,K#U
M!!%>=?&GX-^(_C)J+P2ZG8Z/H>GZ=?IIGDM))<37]S926JSR\*(TB6>;"H6+
M$AMRXVUP,?PL\>ZC=>'->O/AWX8TWQ'IVH:9]ODMM::^:XMK."<1FV\^$) 1
M)*5Z%MLKD,'"L #Z:M=9L;ZVAN+>[AG@G0212QR!ED4XPRD<$'(P1ZBN5\6_
M$C3_  .--L&BEU'Q!K$MQ%I.D6P_>WLL4;RLH8_+&H5>7D*H"5!(+#/@/PQ_
M9FO+CQ7X 'CWP5HVH:-H?A74;.XCO1;WT46H3:A#,&CW+N^95=@P4!>1QG!]
M$\7^$=9TCX[>%OB+I^DS>(=-CTJ[\/ZA:03()[(2W$4L=U#&^ XRC)( P;:5
M(#;2*:ZF;^-?,[?P/\3F\4^(M1\.ZEX>U/PUKUC:PWKVU\J212PRE@KQ31,R
M-AD=67(8%>FTJQZ7Q!X@3P]#9R/97U\+F[ALPMA;-,T9D;:)' ^[&O5G/"CD
MU\V_$FZ\7^(-=\6:_;6?BH^$;$^&;VPL392"4RQ:IYFHM%;*GGN5MX8CM"MN
MW,%!)(K%BUG6);;6=0T^S\=V$5Y\5M(NK.*2SU&V86$T=FUQOB8 _9CFZWH1
ML5C\R@@81H?1-U\9_"EE?W5I<7EU%-;:W;^'9"=/N"@OIXXY(8]P0C:RRQ_O
M,[ 7 + D"NWKY-OHI8O$_CRYN+"5K.^^+.@^4TD;Q ^7:Z:IE7(&]1)%C*DC
M*G/ (KD]+\:>+],\!:UJ=SXXUB+QS%#:Q:WI+Z?=>7ITS:C;(<-+(\",!)=*
MIA1%EC96VGRMQ /M>]_U'_ E_P#0A5+Q%XFTKP?HMQJVMZA;:5I=N5$UY=R"
M.*/<P5=S'@99@.?6OEOXOZ]XE^'<7Q;TJR\>ZL3X9\"VOB;3KFZN+=[M;E;K
M49#N5H-KQL(H8FR,[409W-NK3\7_ !#\0^&_&?B#3(O%YN[>.Z\(7D=I=06K
M^2VHZK);7%L#L'[HQ)&Z@DR*22'Y%/H0E[S/J6BOEN?XQ^+X_%VLZI_PDME)
MH.D?$&+PFVCK;P*DL$\=L-SS$EU>)IW;'!.S!!%;G[.GQD\2>/?%,%IK&J6>
MJ:;K'AQ/$MB\-HML522[DC41+O,C0F,1L&E16^9>22P5%GT11110 4444 %%
M%% !1110 4444 %&<444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 49Q110 4444 %%%% !1110 4
M444 %%%% !4;C]ZA^M25')]^/ZG^5 #GZ#ZBG4U^@^HIU !1110 4444 %%%
M% !2$XI:* "BBB@ HHHH **** "BBB@ H'6B@=: 'T444 ,HHHH **** "BB
MB@ HHHH **** "@#%%% !1110 4444 %,'^L;Z"GTT?ZQOH* '$XJO8_ZD_[
M[?S-3MTJ"Q&(3G^^W\S36S,W\2^98HHHI&@4C*'&",CT-+10!G:OIMK>VTJS
MV\4RS&-)!(@8.H;(!SU )/YTDOAW2[F[:[FT^UENF$:M.\*ER$8M&"Q&?E8D
MCT)R*M7W^H_X&O\ Z$*G7I3Z$+XF8:^!/#:$E=!TQ<WO]I'%G&/]+P1]H^[_
M *W!/S_>Y/-<[XJ^!'@;Q9X5U?0)O#FGV-KJ=M):RS:?:QV\Z*[^861U7*L)
M0LH/]]0W)KO^]%(L;%&(HU1>BC IU%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5')_K(_P ?Y5)4
M<A_>Q_4T"8YQD#ZTZFOT'U%.H&%%%% !1110 4444 %%%% !1C-%% !1110
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M#FJ'C']E/0/&8TQ;C7];LX]/TVPTV&*V%F8]MI*98I&22W=2V_!((V':N%!
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MX[N&_M[@J(YXY&9/-4*P)*_WA[>] RQ13(I4GC62-@Z,,JRG((]:?0 4444
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M=:[I>J7NEBYL()+6VNC"Y19/+9Y6CR1R-[XQU["?0?@%\-_"MJ;;1/ V@:+
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ME\#QKFMB^N+[Q)XFOHKFX:,&>TMX]0BA8% JX$4T1Z8QSG.,[WPN\17GA/\
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M2]0.HV%YJ-UODM7:T%J\<9 &V)E#.T8^4R.S8SC&OXJ^'D?BKQIX/\037]Q
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M4O@YXE\::[HVJ6_CO3-/T_6].O9+99-/E0)=P?>BG:!99C;EE(S&TCGC.<,
M #T*BO"?#7[0>N:W?>$M4O/#UC8^#O%.L76AV$R7DDU]'+$+CRY9HQ'Y823[
M+(,*[%=\9).6VG[/W@22\N[_ .(6IZA?GQ#?7NL:?<V\>J33V-Q$FI2+ _E2
M !6BCA6-"@ "ENN[@ ]VHKXWT'4_%>E?M9ZKHWC3QYJ?AN\OIENO#]DEYY^F
M:G9&YN-EMY)41QS&"$CH)-RLX9^<>D_ SQ%K%O\ &#QCX2O_ !EXC\3V=EIT
M%TB^+-)CL+C[2;FXCG>U*6L FML)%AAO4%@%;!Q0![_17BWQBU?Q]X)\0Z5K
MNE>)],GTN\UC3=,M/";Z,3+=K-*L=P#<^<6WJC/,&5%5%A.Y6&YJRM.^-GBW
M4/VC)?!=ZVD^&-$\Z0:=8ZMHUY]MUJ"*%3-/;7?F+;C$C?ZO:[;$+'&X;0#W
MZBN,\>_&'PC\,;W3+/Q)JW]GW>I+,]G;I;RSR3B)0TFU8U8D@,.,9.>,UD3_
M +1_PW@L=&O?^$IMIK/5K=+NUN;:.2:+R6?RUDD9%(A7>&7,A4;D<=5; !Z5
M4<A_>QCW/\JYC0_BKX1\2^*+SPYI>OV5]KEH)C<6,$H:2/RI%CER/]EW53Z$
MBJ%C\3(-3^,&L^!(]/G6YTG2K;59;XO&8F6=Y41 H;<&S YY & /6@3.X?H/
MJ*=7)>$OB)8>+O#=UK>TZ;8VU]?6;R7<B 8M;F6"23(8@)NA8Y.#CJ!4VO\
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MM?\ #=]([-,BR"W,:A6@>2*6-XY'^7)4'[W&U!^T;X7A?7O[2BU33TTK7)]
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M[*M@K)D8.5SAR" >S3VD-S;/;S1)+ ZE&C=0593U!'<4L5M% FV.-8UVA0%
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M!F\-6G]M>(M1TFQOT54TB.XLV6'S8D)"+)<F27RU)($V#@@A8/V4O"]IX?\
MB#8S6?PZU3P;>2>";:#6;N\T>6U%SJ27+>?YLY79/(V5=7#,65CD\87ZVHH
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MQ\</B#XF\2Z9;^#Y[(6OB*+4M3T87'V=UFL[06\41BEW;&$CRO.P9MZIM
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M_!SQA>_"27PUJWP?AOKW1/#]OX4AOK+7DN&U>(W%LSSPPNRJJ#R?.+7&V56
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M@N+,A;&/RXY659XDR'*[G4Y9MK$$+0!]-WO^H_X$O_H0J9>E>8?!+5[KQ7\
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M #BBBB@ HHHH **** "BBB@ H'6B@=: 'T444 ,HHHH **** "BBB@ HHHH
M**** "@>U% SWH **** *>L:O9>'])O=3U&YCL]/LH7N;FYE.$BB12SNQ[
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MZ7?6]W-+''>>0"/(D BN(RK G<(AOD0)71W7QH\<R_$*T\"6D^A0:M/XCO\
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MQ-L/"?C-;"]UB.QM;+0KS7;^T?2;F:26VA>)3-%<)\@\O<=T05W;S$("@?,
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MIUU;BVL[=T-T8K:4QJN-B,0=S=T  %(L^TJ*^0]-\(^+-%^).FV-GX(UC3=
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M8TUG:/[1;/N4.IPRGN"/0\T#-VBBB@ HHHH **** "BB@Y[4 %%%% !1110
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M %%%% !1110 4#K10.M #Z*** &4444 %%%% !1G%%% !1110 4444 %%%%
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M)_P'% 'S;9_'?Q=#?>&]9U;Q#HNGZ3J%QXLM)+:XM1';H-.FN1;RM)N+_+'
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M\J?,0!3_  ;^T-X;\1?"JQ\;:DYTF";1O[?FL(E>[N(++)Q*8XD+E2!GA>S
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M05+"@#UQ6#C(Z4M>%^$])MM1_:G^,-O<QK-;3>&/#\,D#<JZL^I!L\]Q@'V
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M4^O]*!,>W0?44M(W0?44M PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(PU?9A'.:R9/%>G+J^F::K33S:C%+-;RP6\DL!6/;NW2J"B'YQ@,PW<XS@T
M?%NA_&#QCK?P[35H?BA-%<Z7X!U'6WN++[#+]KN+?4)$C>3S4D7:5B$;D 9W
M'&QNGT7\,?$NIR?&GXD^%[OQ+/K^G:=9:7J-I'=1VX:T:Z:[,D2&)%+1@11;
M?,W, ?O'.:]5N-+M+N"2&>VBFBD78Z2(&5E]"#U%.@TZVMIY9HH(XYI0JR2*
MH#.!]T$]\9./2@#YF^''Q0\5:A/X.T&+Q#'-+XAU[Q5+<:I=1BX:&*SOY%AL
MXAP.492"W(2%L#GBQ\4O'-Y\0_V%_B#K.JI%%?-H6KV=Q-:X2&9H'F@,\66;
M:C^5YBY)P&&3WKUO5_"?PTUK5;GP?J>D>&;_ %&\)UZ?0[JVMY)9SN\LWC0L
M"6.[Y?-(Z\9KHM1\$:!JOA";PK=:1:2>');7["^EB(+;FWV[?*"# "[>,#C%
M 'S-X3\87/@CQ'\3O%MQ8_V++X)\&6\%QX>6=I/[76*%IK:^S@*B826%<9;A
M]^W:%'867Q<^*_A74;'3?%GAO1]0&HZSIUA9:S9*UC:SQW$,CS*L8FNGWP-%
M@NY17W< 8!;U+6?A'X.U>\TZ^OM&A:;3;-]/A<2/&OV1T*O;R!6 EA(Y,<@9
M,A6QE01R7A/]E#X7>"?[.;1- N;&33[^+4K>9=7O6D$T2.D09VF+/&BRR*(G
M)C =OEY- '.R_M0ZGI_P_P!?\2WWA*U4:'8:Y<W<=OK =9)=-NS;O'"&B$KJ
MY1F\PQA4^4'EA73> -6N=3^/GQ.AEN)VM8M*T,QVTDI,<1=;LL47.%)^7)&,
M[1Z4FL_LK?#W78=02ZLM2'V^+48+HP:O=0B:*^FDFN(W1) CJ9)G8!E.TXQC
M%=-X,^$^E>!M9UW4].O=2EGU>VL[647ESY_EI;0^5'L9ANR026+%B6)/>@#Q
M+P5\1+OX6?!3PC\0=:U'Q5XPUGQ#:QZ?!HBS?:$N[F1I9HY%4IN0B)&RR\%%
MR59L&NY\,?M.V7B+0(+D^$/$\>LI9->:AHL&GF2YLPMS]GQM8JT@=Q(R%%)9
M(G8JIPIVM1_9_P!&NOAAX7\&6FK:QI,?AE[>;2M7L9XUO;>6%&19,M&T;DJ[
MA@\95MQRM9O_  S[?0>*;37[3XC^)X-1:P33=4N2MB9=3ACGDGBW_P"C!(V5
MIYES&B_(Y4;2 P ,WX.?%N\>ZNM*\2R:G>RZKXLUS3-%U.>WC$#QVT]P4@W*
M%Y$=O-M)7D1'YB>NI8?%:_\ AAH*+\3+MKS6;J>_NK>/1-(D9UT^!@3*T$+S
MG"(R$[7=CYB\9)46-'^ XTB?PL?[>FNX]"\3ZGXG GMTW32WBWH:/*[=H4W\
MI!P2< 'UJ'XZ?!;4_B_=:2EOJ]II-M9K,8KV."6/4]/N'0HMU:74<JF-E!(,
M;*R.&(;(XH T_B]\4]3\'/X1T;PSID&J^)O%>H_8+)+Z0Q06L:Q/+-=2CAF6
M-$SY8(9R54%2<CG]=\6?%#X=:-K5SXIUKP/-9I9;[+Q NFW-A:P7C31Q0V\]
MN;J>1PYDX>-QS\NW.-W1?%/X87_B^3PMK6BZI%IOBKPO>/>Z?<W</FVTQ>%X
M)89T4JQC=)#RK JRHW.-IH^/_!GC3XF?!6^\/ZDF@V/B6]DA$HM[B:2R\M+E
M'8!S&'R8U(^Z,,1SWH L:O\ &NPDN?$VEZ1<V<&L:#J&G:;<2ZX)+:RDN+N2
M,) D@4EI&610-JD;I(QR":;\-OCKIGC/Q'XC\/:G=:5I/B'3=;O=,M=(74%>
MZNH(=I6<1,%<95LD!2!C(8CFO/-6^"'CUM7\>VUK_8MYH^O>.M"\76MQ/?S0
MS1QVLMB]Q"ZB!QD#3X]F#\WFMDKMYRF^#?Q"GU34;!_#VAM#:>,;_P 66VM2
MZB0+V)UG:VM1&$+AB9(XI2^%";RF_P"4  ^AK'XE>$M4MKFXL_$VCW<%M,EO
M/+!?Q.L4KG:D;D-A68\!3R3TK(UOXM:;IWBCP/I%D@U>+Q1>W-G'?6DZ/#;F
M&UEG8L03NSY6W Z$\].?FC3?@5X]'AVSL=6\+"Y21?!]H;%+NP^SV$.FZNUQ
M=1Q1JL8$'D'Y03([;MI[TSX@?!GXBZSJDFG>&]"DT*S?Q'K]W:WD<\444-O)
MIB0Q-F&421+/(9T!C_>(6WD+T(!]JT5X%X[TNZU#]ES3[#1OAI=:4LG]GK/X
M*LI(K>2S@%W$;B("%@CJJ!R45E$BY7(W&O([_P /3:%?Z18^)/!7BN+X>?VS
MK[)9>'-)N)S8221V[:=,;:T$C[!&UV@95(29@2!U !]LYHKXF\(C6+#4IM%U
M*'XDP^,-(GTZZ\'QZ@MS+%<6?]FP+Y%[<0AK;#3K<"Y+,O(4CHM<MXG\7:_;
M?"NYU#P;KGCJ7Q W@C4[[Q=)=W.H2_V?JD4$+1;!*S):SB<3+Y5N%39YF5"*
MK* ?H%17R)XX^.-WXH\3^-;;PO\ $.UBT9F\*1:'<V%S;.OFW.J2VMVR/M.]
M& C1@2V"K;2N:J:CXMU/4OB+IN@ZIXQN)K/0?BY]G6]GGM(G^R?V(]\+>3Y5
M5E65VB&%WA0!G>N0 ?8U16]U#=J6AE250S(61@1N4E6''<$$'T(KE_BOK[^%
M_ACXJUJ&YFM)-.TNYNUGMA"98S'$S;D\[]WN&.-_RYZ\5\@_#K6/&?@B[\V"
MSU34=4TK3%TN:6/PW-=)8:IJ<Z7^IS2^26DD6("WF"X!E,X&5ZJ ?==%?'O@
MS4=+N_V1_B^UI+K>IIIEWXAO%N==@NK*XDFBFGE5][+&P82)E@N"K95@K BN
MU^-OA&6__9@AO88M=UW7M&\.[[-=+UJ?3Y&G," 73%)4#M&5\P!R<8;'S$4
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MQ*0Z$Y*D8Y'/2JB>"?#\>LV^L+HFG#5K:$6\-^+6/SXH@,!%DQN"X)& <<T
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M#'&3G)CC4@$\D^]4%_9\U]/%FG:T_C:2_;3?%4OB.U.IVIN9O*EL6M9;/>9
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M+/+.L*Q>;))(6)*KP, A1U^5%&3BO0 ,4C]!]13J $SZ4M%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4#K10.M #Z*** &4TH">E.'YT4 (% H*T
MN<44 %%%% !11G-% !1110 4BC I:* #&:,<T44 %%%% !3 /WK'Z4^D_BH
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M PI,&,1)(P=VQ\8)^Z?2@#:HHI"P49)P/4T +10#D44 %%%% !1110 4444
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MO$GAC4HS=:--)]JU.3[3:O<RWV(UVN#,JQR"1S\TFXC,:COOV:M>U'Q#\%]
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M[BGYS0 4444 %%%% !1110 4449Q0 4444 %%%% !1110 4444 % ZT4#K0
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M **** "BBB@ HHHH *0C(Q2T4  X%%%% !1110 4444 %%&<44 % ZT4#K0
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ME['<MUPS/&;?L"^<#"DT =GXP_9_T+QA:75O+J>LV$5UH2>'919W2C=:K*)
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M8(R/?!(_$T >.?%WXIWWA+XM>"O#+Z]8^%-%UG3-6F;5-0C1DDO(DA%O""Y
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M@I\3H? OP]\%WMSH]SJNI67PUT"=;I=6E)NI+R<Q10&WV^2G[U<F?)958@C
MH ^QJBD_UT?U/\J\?\7_ +0DOA7Q7?\ AU?#KWVIV^JZ38Q)'=@+-!J!D6*?
M.WY2KP3JR'L@;.&%='X6^*O]O_#_ %#Q/>:)>V4^ERZA!=Z7;C[5,9;266*1
M8MG^M+&([<8SD"@3/0'Z#ZBG5X+KW[5=G;Z%K\VC^'+O6-7T4Z&9]/%W;*K_
M -IRHD2B59' ==QRK[2?E(^5@]>\H=R@F@8M%%% !1110 48S110 444=: "
MBBB@ HHHH **** "BBB@ H'6B@=: 'T444 ,HHHH **** "BBB@ HHHH ***
M* "C&**![4 %9/BW6G\-^%M8U=(A.]A9S70B8X#E$+8SVSC%:U8OC;P^_BSP
M?KFB13I:R:C8SV:SR1^8L9DC9 Q3(W ;LXR,],B@#PRX_:7\4>'[))M?\-Z)
M#-?Z-8Z[ID-CJDLF^&6ZMK>:.4O"I5U-U'M(!#9Q@8-=9-\=M2T/1_&]WKWA
MF&*?P;8)?:M%I.H_:D^8/*4B:2.$N5MU60Y5>7V#.-U;%C\&O!MYIRZ1J=M%
MK5_;66G6ET\US*[[+5DDMQAI&9%,D0<KGYR,OOY-2>,?@)X2\<:W<ZIJ$>HP
MSWT4=OJ4-CJ4]M;ZG%'G9'=0HX29<,R_,,E3M)*\4 <-<?M61/XF>PTO08M=
MLY=7AT*Q2RU6!+^ZN'M!>-(+>;RU6$1.GS>87SNRB@9.AI?[3D&JQZ5-%X%\
M4(-7OYM)L(I#IX>XO()+I)X1B[PNP6<SEF(0KC#%CMK#T?X(^/D^*MUKESJ9
MTO3I=0>\%YI_B>6ZRA;/E+I]S8.D*NJJCB.X&-S,I!XKL[O]GO29_".DZ%:Z
M]KVF7>CZG<:Q8:Y97$27L-S.\[RMS$8F!^TRJ4:,J5."#0!:\'?'O0_&ICL+
M:RU&S\3&W%W)X>OXEM[Q(OM,ML[C>P1U5X9"2CME=I&=Z9;\(/CGI/Q;D<:+
MH^MQ::\4MS;:Q=6BBRND68QD)(CMM?//ER!'QSMX-9]]^SE8ZW:Q6VM^)]>U
MZ*VEM+JSN-0>WDN[.XAN//>:&X\D21F7"HRH0JH,($SQE^ /@!K/A77]6\0+
MXT4:O?Q1VTL]AH\-HMV$F5VGNXPQ2>Y<*T9F"IA&(55/):V9#MS(]3\;VGBF
M]TB.+PCJFDZ/JGG*7NM9TZ2^A$6#N BCGA)8G;@[P!SP:\(TOXX?$2^_9XO_
M (IK>>$;BTL--U:YD@&F74(GDM;F=(F0FY;:CQQ+E3DJQ)R0=J_2YKQ.Q^ >
MI:5^R_/\+8=5L;C4)+*>T-^UN\4#>;*[L2@=G^ZY!.[)/.1FD6;^H_&K1]1T
MP+H.OZ7#JD6N6>CSIJL4T:B5YE#PA<!M[QB01MRI;;R1FNE\.?$WPOXMU>ZT
MO2-8M[V_MY+B)X4R"Q@9$G*9 $BH\J(S)E0Y*D[@0/-_%GP6\3ZUX^U[6[2_
MTI++4M7\.WHCD:591!I\WFRHV 5+LWW2.,<'H#4OP4^$OBGX?>)[V]O/[)T?
M1KM;IKG1M'U"ZNK26Y>6*2.YACN%_P!$X-PKQ1L48E'Z\  [;Q!\7/ ^BZLN
MC:AXPT&PUCSQ#]@NM2ACGW@1N4V,P.X)+&V,9PZGH16[/XLT6QUR'0[C5[&'
M6IXO/BTY[E!<21Y(WK&3N*Y!&0,<&O$_B;\%M?\ %7A[XU)-I6A7UYXH$<.A
M.;F3>L?V.*W(FW1XC8.LC90D,&4$C%>-?%3Q3HWB/]HG5?#-]I+:E8G6-&4:
M>FO:?;7L]S9[9D,-G=A91"3*5+POB3:ZC;N)9]"$O>;/K3P)\3['QK/KUOL2
MQN-*U:ZTLQO<1N9_(*[I5VG[OS#(/*G(."*Z+2O$VE:YH<>LZ?J%M>:3(K2)
M>PRAH65206#@X(&#STXKYU\/?!#5].\5^'-5D\+6J747CW7]6U'49)H)9CIE
MU'?"(!OO;7:>WS",@;/FZ UVGPN\#:AH_P"R=I/@_6/#Z6FI6_AM]+N=&"PR
MJ[B%HRI /EMOZGG:2YSC-(L]GCD69%=&#(PR&!R"*S/$?B2V\+VMK<74-Y.E
MQ>062BSM9+AE>:18U9@@.U 6&YSA5&22!7REIGA;QG'\/K[2;K0_$MOKESX*
MT2R\/RVI:---OH 83')Y<FU'CN76=W)^:$D981[1[I\<[G5XM.\%6^EVU_=2
MW7BS2X[DZ>DI\NW6;S97E,8^6(+&=Q8A>0"3D @'IU&.<U\F_#6X\5ZC>^ 6
MU>]\5V^H>(-2\3Z?J*W$]XGE6*3736LABDPD$B_N CE Q#  D8 I7_CCQ[;_
M  SL]0UK5]9TIO#^L1>%-?U1=)E<SI'<XGU)!'(FZ"0+;KYR*K(KW) 4X* '
MUIJ6D6.L1Q1W]G!>I#*LT:W$2N$D7[K@$<,.QZBL#Q#\*?!?BZ2RDUWPEH>L
MR62NEJVH:;#.8%<$.$WJ=H8$@XZY.:^:)?BUJ_@&XT+3;?XGQ^+_  _K4]O+
M;W/V>*/6;"SGU3R;9HHY4;[=#C_1IWYF4%)0 6S7K_[*WB/_ (2+X6W3S:J^
MJ7\/B'7$N!/<)+/!G5+IHXY-OW"(VCPIQ@$<8Q0!U.O?#;P#?^,[#6]7T72I
M?$<T8M+>:Y5?,N$1781[3Q)L5G8 @[>2,8S6_J7@O0=8N-1N+[1K"ZN-1LO[
M-O)I;9&DN+3YSY$C$9:/,DAV$X^=N.37RGH>H:GXSUKX1WMUJZ:WJ5O\4?$M
MK:ZO?PQ3G[+!;:O&BILVC:8X4^Y@;@#C@5TG@+XU?$[XIPVPT&[\,'7+'1=)
MU6ZTF2!X(M0-Q=7$=P59I)'AC2*!2A ?+L02>P![7\//@SX3^%EQ>S^'+*[M
M9+M5CD^U:G=7@5%)*QQB:1Q&@R<(FU0.  *Q?B+\+-8\;?%;P-X@M-9DT72]
M!M-06XELI]MU)+,UMY:!&C>-HR(9-^[!^Z!U-+\9OB;JG@&31;33)-*CN]3^
MT*OVR&ZNYMT<1=3';0+ETW8$DCR1I&&4DDL ?"/BW\>/%WQ4^ 7BN^\,V<?A
MN*R\/:==:JYFG%_!=7MM%<B"V9/+&8HYHLL3ERY7:N 6 /?-,_9X\%Z2GD0V
M=Q+8-HMUH,UE=7+31W%O<S>=.9&?+L[.7)8M_&WMB3PE\#M)\-:AI%Y=ZGJO
MB.XTC29M%L7UF:.7R;65HBZD+&H=B((E,CY<A<$G)SYC\0?BWXE\47VER>&[
M>VM/#%AX^L= DU.+5I8;FX>.[ABNE,"PE9(B6NH2K2#YH5;Y@V%W_"WQ1U6?
M6?"5II&F226FOZ]XA@U'^U;Z2YFMELI;F(>2P^5$::*/ )PBMM"DG<H!U%O\
M!=(L_AYX8\'P:IJG]F^'M6MM5LWEF623]Q=?:8K=B5QY*X6-5 !5%4 \9KC=
M6_9*M?$'AG3?#6I^*;Z[T#3]<O\ 6+>#R$294NXKN*2V,HY90M[+AR"V0N2<
M5:\+_M#Z=%\+/[9L[#7=?N['1(?$M_9W+0?:XK&>2X(8N"D3,HMYL("&*QCJ
M:Z1OV@M%;6/L]OIFIW.E+J=EI3ZY']G^QK+=PV\MLPS,)&23[5"@*H?F)R .
M2 <3#^S?XTATO0?.\=Z+J6M>&IK1M%O[GPNL8,4"SQA+L1W"M,2DY ,;1(K(
MK!,EL^C_  I^'>H^ ]3\>7>H7ME=_P#"1^()=9B6SADC\E&@@A5'WR/N8" 9
M*[5YX4=*X[Q/^TOI6H>%?&2>'4U*QUW3?#FIZW8RZGIQCCE6T9HG8(Y!.)#&
M</MW+(K*2"2-_P 8?%+5_!_P#M?'+:>EY?16=C>W\,43RK%"[1?:I52,LS".
M-I9 JDYV=30!A?&SX5^,?%WB'7K_ ,-KH\UOJW@O4/#A_M"]EMY;>XE#-%(H
M6%U="Q4-DH5 R-_W:Y+XS_ GQIXRNM;FTN*VGA33O#BV]I%JDMB=1DL+VYGG
MB::'9);G;*GER*QPP!P,&NZ'Q*\3Z%\"/$_CFYN=%\1QV.BOJ^CWUG!-:I?Q
MK9K+NG@8LT),HD&T,Q"[<X;(KM?$GQ5\*> Q!%XK\2Z1H%T]J;MA?7B0)Y2N
MB/("Y'R!Y$!8]-PSC- &9\#_  >W@_P1Y<_A]O#%[?7EQ?76FOK<^KE))')+
M&>7DE@ Q5?E!)QGJ><T/PAX@\$?M(^*M?CL)M9\,^-+*R62^BEB7^QY[..10
MDB.X9XY1)E3$&*N&#* =U=_8?$SPEJANA9^)]'NC:0Q7%QY-_$_DQ2J&BD;#
M?*KAE*L>&!&,U>3Q=H<C*JZO8L6N39J!<H<SC.8AS]_@_+UX/% 'A'QY^'UU
MXM^(.N76I>"IO&.G1>$3'X?>..%Q8ZKY[AV3>X,4Q#VS),H!40OA@1SQNM_#
MWQI&UQ]J_P"$BOO%MG?^$K-=:L9+H0S!# -0N$565&7:)_,9N,'##H&^P,XK
M*@\4:3=>);SP]%?0R:U9VL5[<62M^\C@E:1(W([!FBD _P!TT ?*WB.ZU31_
MCE?:+JMUXOL? ]WXDNG5X;G4ML\#^'S)-'"R$L8UN%DD'ED*C_<^;(7/MM=\
M;Z1\+=;EN$\=QZUIVD6,NGS7'VJ4/:OJT[1_($W/<I:);^>SLS[6 91\^[VG
MQ1X\\-7OQ/CEE\)ZWK%]X-NA92:U9HK1:;-=Q6X"^5YHDE#QW*$LL;J@5B2N
M.>O\+?%[0?%GBZ\\,V\.JV&LV]NUX+?5=+N+/S[=9!&98S(@#*'('KR#C!!(
M!X>?&.OVWC6ZN_[;UB&)OB@OA^UM+F0""2RDTZ!W01L/F4.LK(1R,D_WJZ+X
M*^)_'GB3XC7OA[6;O4);/P5)J-CJVH7T=LAU>::=)-.8+"@'R69#MM"#=,@(
M8@X[SXE_%[P9X9NI_"^N>(KO0+Z]@CB-_;6TVRQ^T,T4#O<B-H8&9PP0RL 6
M7O5+P_XQ^''PF\267P^E\7VG_"9:F4N&MM3O4?4M0D91&LLO0L[+$J@X&0@
M[4 ,_:1\07WASPGX9FL)[2*6Y\6:+921WMHEPDL<M[$CJ P.Q@&W*X&04&,'
MD<K\)/BEKVL?%/6M.\0Z\&T\Q7]W8+;QV<^EW5K'>+''+;W<3>8CQHZ1RQ3K
MDR.2IVK7N.HV.E:_(ME?6]IJ#VLD=T(+A$E,+@DQR;3G:05)5NN1QTKB?$O[
M._P\\3>'/$&C/X3TC3K?7@1J$VGZ=;Q33$LK%RWEG+Y53N/((!!! ( /1<AT
M)'0BOE[PE\3O%2PV&E>%[3PUHMYK.H>+]0EGGTJ:2';8:CY*NT:W*,9)6E5G
M;=@Y) 7 !^H40(@4= ,<UQUG\&_!FGV45I;>'[6"WBBOX(TCR-D=[();M0<Y
M E<!C[@8Q0!<^&'B]_'_ ,-?"OBB2*."36=*M=1:*%MR(98ED*@]P-V/PKRJ
M]_:(US0KW7K"_P! @N;W1-=N8[];8NGV?1([1KI;\@[LE@%B525#2,0/N-7M
MNA:'8^&-$L=(TJVCLM-L($MK6VB&$BB10J(H]   /I7GWA?X337OBKQ+XJ\:
MVNBW>N:U8#0Y$TJ.40G3HY9FC1_,8EG83'>0%'"J,A<D Y76/VG+G0=5@M+O
MPS'C4_#]OXBTEUU 8EA,MO%<0RD(0DD;7*LNW>LBYY7!KI-=^->H:/K.MZ?!
MX3GU-]/UVQT2/[-=QJ9OM%O'-YI\S:J[?,"[=S$G!X!S5*/]ECPC_9-_9W&H
M>(+^:>P72[:_O=3::YTZU65)1%;NP.Q=\<1.02_EH'+!15[3_P!GO3+#49;T
M^(M>NYIM6T_6YC<RV[&6ZM;9+<.Q$(;]['%&) "/N_+LRP(!Z-H-[>:AH=C=
MZC8G2[^:!)+BQ,JRFWD(!:/>O#;3D9'!QQ7FD_[2.@P+:3?V/K3V6HV^H2:9
M=B&%8]0FLS*9+:(-*&\UHX)94WJJLBD[NU>LD9%?.GCC]F]M%^#K:-IE]J'B
M"W\,:=J\OA[0Q%"K&>>TN(((]V%W>7'<2Q(,J,.">5!H T_$G[4.@W'ACQ*+
M275O"NJV.C+K5I=:KH4DPGM&9%^U00!U,R(TB!EW*READ#-=?9?M >%;KQ'-
MH4@U:UOH=8?06GN-(N4M!>+''(J&?9Y:AUE3868!R<+DD \;XA_9OOO&UB]Q
M>>(;6*\?PO;^&[>*;2C+!%%YL,MRTL9F!D,AA5<!DVJ,?,>3=O?@)K%Y<7;G
M5M-V77CVV\6LGV>9=MO#%"@@XEYES &WGY.?N<"@"UX4_:/\-/X<CU'6_$,-
M\;J?4I(6TO0;^(V]M:7!AE-Q"RO)#Y+822238F[D!0<5V"?&CP3+JO\ 9L?B
M*SEO?,LHQ'$2X)NP3:D, 05EP=K X)XSGBO+-"_9Z\8>$)I+K2==T.YN+K3M
M;L;F&_L7,*O>ZA/>Q3)R2<-,$E1N),!L@J <63]EWQ3X=\$:GHNA7^CWUR;?
MPKIUI<WTLD!>UTEXGE,I$<A5I-LH51NQN!+"@#ZBKF=?^)_@[PIJ?]G:WXKT
M31[_ &AQ:W^HPP2E3T.UV!P><'%0_#[Q1KGB4>(%US03H;Z?J]S8VC"0NE]:
MH5,5RN54KN#;2,$;D;!92"?'?C]\(O$/C7Q)\0[[2M"M]1;5OAU<>'-.N'GB
M1OMDLLIV'>057#QMNZ?*>A R >_6GB#3-0ENXK6_MKF6TE$-PD4RLT,A (1P
M#\K$,IP><$>M<[K'Q/T_2/B%X6\(FTN[J[\0V]W<V]U;*CP0I;B,N93NW*"9
M4 (4C) )!(SX3X^^$/B9OBK!JFB>!=/U+P\EUX2D827:QR(+"XOGFG4">,O+
M"L]KM\PE6"'Y9-H4^>ZA\$_B-!X>TW2M(\(WEO+8W7BN_P#+EN[>"%K>[U))
MH[.*6";,37%MYT8<+^[:0G"?*Z@'VLNL2'Q(=+_LV\,/V7[3_:6$^S;M^WRL
M[MV_'S?=QCOGBM3I7Q-\4/!TDGAWQI)X2\#^)O"^C_\ "M6BTK2])TZXM94U
M,W,A@B6.U)8RQN$8@9 #%B2I)I/'TVN?#[_A:5KH\OBBST&35_#!M(?)U;[1
MJ<LL^=2BMI5C:3,D2@,;4/LPP"JU 'V7J>@:9K9A.H6%M?>2XDB^TPK)Y;#H
MRY!P>!R/2F7OAO2M2U'3]0N]-M+J_P!/+M9W4T"O+;%AAC&Q&4)'!P1D5X_^
MR>(H?#/BF!=;NM1D&NSR+IE]?7]S/HT#(GD6CB]"RQD1A6V;54;SMW#YCSOQ
MJ^)MUX>^-EKI]IXEO)["VT^S;4M T2>)-0L!)>J%OA#+&1=0N=D,BJ=\:G*C
M,F: /??$O@_0_&5K;6VO:/8:U;VUPEW!%J%LDZQ3IRDJAP0'7)PPY&>*Y"3X
M9?#>Z\0R:6-/TU-;34X_%TME!<>7.;L-M2\>-6#,"RD98%21W(KY7O/CSJUY
M:WXTWXHWWB*#4_!OB74[]$6SM+G2+BU*M;K'%$I>W=4<H0[L3@,0K<CNK'XL
M>(-+U'4++PS>:5XIOK+P9X<NK:Y,D#7FI/->3P7 6X=U5W*0.8U9B/-<YSG:
M0#US6/@W\+?#2:?+?P1:&L,%[86LAUB>TQ'>R$W$:D2KDO)+D=U8J5P0N+*?
MLW^ 1IDUA'IEVEC+H-MX:$(U*YPEC;LS0*I,F5D1G)64'S >=U?/6J>/;;X@
M>*K'6?%$UCJFCV7@CQ=-=V6OZ<+6WC,&I002174"-.RA!$$9U+E@K%5&X@=E
M:?M'>*K?4+;PXTGAR/4]0@\,0Z=>K87"6T5QJ,5T\Q>!YED9%%HQCC)C?YU5
MNA:@#U.7]GW0&BTYTU+68]1L[ZWOVU;[6'O;MH$=(8[B9E+2HJR. K$_>/.3
M5VW^#ND6_P /-;\%27=]<Z=KHU+[;<R/&+AVO7E>=@50*#F9\?+QQUQ7FVO_
M !]\6> -3U#_ (21O#E_9:'X7UG7;[^Q/-_TR2UN4BB1#(Q\EMK?O$/F;7<#
M<0 6CU']HWQ=X.\17'A;Q'X8TBZ\5!M)ELUTS4)8[.>&_O39J6=XF9&BD(W#
M#!E^88^Z 3-K5/V5["[T'6M/_P"$P\0L^IV>DV?G3K9.L/\ 9THEMG6,6RK]
M[[ZXVL"0 O4>XVT;Q01H[F1U4!G( W'UXKQ73OCKXHM]4\8Z!XD\&:=8>+-$
ML;2_T_2]*UXW2:NMP9%18I9K>WVD21^6<J<$CU&[VQ"64$]:!CJ*** "CK11
M0 4444 %&<44&@ HHHH **** "BBC/- !1110 4#K10.M #Z*** &4444 %%
M%% !1110 4444 %%%% !111G- !7 _'_ %.^T3X&?$+4M,OI=,U*R\/W]S:W
ML! >"5+>1D=201D$ ]*[ZH+^PMM4LI[.\@CNK2=#'+!,@=)$(P593P002"#U
MH ^./$/CK5_!?Q6^(_B;1]18W=I;>!;2XBD195OX[FYN(I(UW?=+";(((.X#
MD FNSO\ XM_$6UNOMT.LZ1)INI^,;CP=I]L=$=OLA^TLJ7<TPN/G")%*H0(H
M=GBR5^;/O]UX&\.W\$L%SH6G7$$H@$D<MI&ROY)W0Y!'/EGE?[IZ8JG=?"WP
M=>Z#=:)-X7T=]'NIC<SV'V&(0R3'K(4"X+\#YNO YXH \@^''QS\6:C\4H?
MFM-I&IRV.H:KIFH:E9VKVS2M;V]C<6\B1F5]N4O&60<C<H*X'7/N/VF?$0\,
M>'=16PT/3Y;_ $35M6NK[4GGCM ]FXCC@CV@D-(SAR"Q(2-P%8G(]=?X&^ V
MLM&M%\+:=#;Z-*\VGK;Q"(V[O]\J4P?GX+9)W$ G) KS3Q-^S==6OBOPROA"
M*SL?"&EVAL#IL>MZGI5S:)+<F:XEAGM9,RY 0+%)A5(R&4$@@'!ZG\<O&'A;
MQ+X@^(2Z&S6L/@+0?$&K^&M2UNYBALEE>]-Q]G1H67[0JQ1)@I%NP=Q!KU_]
MHO7M2T;X-2W>CZA?Z5?3ZWI-JEUIN//5)M3MHG"Y5AED=EY!'-2ZG^R]X-UO
M2->L=2N?$-^=<TBVT._NY]=NFN);2"1Y(D,F_.<R.&8_,X9MY;<Q/3>+?AEI
MGQ#\%6_AW5+F_BL[>]M;Q)K6XV3^9;3I-$2Y!)^>-23U/K36S,W\:^9P'B;X
MKS^"KZZUZWT3QC>ZOJMZVBV/A+4$46\DD$+7$MU"8DE8(88W.5+;F4*$W&N/
M'[2?B>3QM8:_;^#/%]YHO_"(S7VI^%([6VMKBQN([O8TY6[:"5\+'(H";MX*
MD(">?;OBG\)-,^*MII8NM0U31-3TJ[^V:?J^BW(M[RTD*-&VQRK JR.RLK J
M0>1D CFM;_9Y74;ZWO[+QUXJTK4%TF31;B[CGMIY;JW>4RL7::!\2!B0K+C:
M. .E(T,^Z_:O\/)%JUY8>'?$6MZ/IEA;:I<:QI\-L;06T]N+A) [SKGY&Y7&
M[(X!!!/2:I\>_#^B:_KVC7UCK,6H:3/86_E16+3F\>\#^1Y(C+$@F*0%FVA2
MIR0.:R#^S5H%MX.\;^&-.N[K3M(\3Z9;Z2(8EC(L8(;1;5%BW*<_*N3OW<^U
M9&I?LU:MJ&N7^M?\+ OTU6\ETV:9Q8Q+#,UD+@1++&A7?&3<!BF0-T,9Z94@
M&_>?M*>!&T?1KM;S5)CJ\5S<V5M:Z'>W-Q*MK.D-R!%%"S;HY'4%<9.<C(YK
M=\.?&3P=XGT_0M3T^]N"NNW\VDV*7.FW-M<27,'G&6)X98UDCV>1-DR*H&T\
M\C/ ^$/V=/\ A7/B'0M9&MQW>GZ"=;:VT^UTL0,W]HW<%RWW'VDQF)U "#<)
M!TV\T?@7X=TCQS\3?$GQ-TVRUNTT&^VSZ3::U8_8UCNY8HX[RYBA=1( Z6]N
M S 9+3D9$C$OH0OB9U'QI^(_COX6SGQ%:Z5X>U#P'9FT2\26\F3596EG\I_)
M79Y65WQE5+9<Y7@D5GZ+\>-=U#X@7NE3:!;R:6/$Q\,Q16;R27MJ4M9+AKRY
M&W8D3@1;%R/ED#;B2$$?Q-\%?%KQ'\0;?4=(_P"$,O/#6GE7L=.UF:Z&9OD8
M3S(L;*TD<B;HRI7'KDY&/X8^ OBW2/BPWBV5=$M=3.O75U>^([>\EDN]6TF9
M9-EA- T("+#MM%0"5E'DEQ@LZLBSW;Q1JUYH>A7=[I^DW&N7D2YBTZUDC22=
MN@4-(RH/<LPP >O2O)X/VD+B/1=3AU'P;>Z?XULM7M=$7PVU[ _VFXN(UEA:
M.X5MAC,99V)PRB*3Y"0N[L8_%/C/4/AI+JEMX1AM_%XDE@71+O4A'%E)VC\P
M7 C;Y2B^:OR<@J"!GCQ@> /%ND:7X=UJ3P;?SZWH?BN'Q)J;+J4%Y>Z]-)8W
M%A/(O,4<91)HBJY1 D855 4*0#T"W_:3L[W2]-^Q>$/$>I^([JYO[6;PY9QV
MWVNV:RE6*[9FDG2(HC/'AE<[Q(FT'=BNAN_CUX*M=%\%:HFJ-<VWC)[5=#6"
M!S)=K<&/9)L(!1 )4+,X&W(!^8@'Q'P=X.\6_#3QVWQ0U3PEJNJ3ZR-=230;
M P3W>EFYO+:2T0D2$-YL5L@D82,L;[>D8)7-M?V=OB-X1\#_  GL8KGPU>ZI
MI=YI$%_/%H<TUQ:Q6[-.P>Z^V(984E+G'E@DR X'8 ^P2 :B@M(;4.(8DB#L
M7;8H&YCU)QW/K5#0?$":ZVH*+*]LWLKM[1OMENT0E*@'S(R?OQG<,,.#R.H(
MK5QS0!0AT#3K=P\5E;QN)6GWK$H/F,,,^<?>()!/4UD7/PR\(WMUI%S<^&-'
MN+C1RK:;+-81.]D5.5,)*YCP0"-N,&NFHH Y_P 3_#[PQXUN+*X\0>'],UJ>
MQ+FTEO[2.9[<N '\MF!*[@J@XZ@#-<AJW[,OPQUF&*"?PE:0VT=K'9BVLGDM
M86BCQY2O'$RJ^S:NPL"4P-I%>GT4 >=S_L_^!I_$2ZV=+N8KX:BFK[(-3NHK
M8WJ]+DVZRB(RGNY3+9.XG-3V'P1\*Z2^@/80W]E)HEQ?W5J\>I7#,SWKO)=>
M:S.3*'DD+_.3A@I&,5WM% 'D:_LQ^$K?18=)L[W7=/L?['30;J.TU-T-[9H7
M*1RGJ2OFS .NU\2-STQH7?P%T2=)X8+V_L[.77M.UXVD!A$2264=ND$* QDK
M%_HD+$ [LJ<, 2*],HH \ 7]D#2(--UN"+Q5K;WFJZ+J6@S:C=1V<UR]O>2^
M;(9)3!YDKHV=I9L8/(8\UZ5XE\%:U=_#ZST#P_XB.BZC:)!&FH2V_G"5(\!D
M= RG#@$$JRD9R#Q7:T4 >%Z-^S(FA_!+Q?X"L=:BL)O%%KY5U=VM@B6UM(]E
M#;3O#;*550YB>4C.=TK$DUW&L_#F\U+XE>%O$\6I116VBZ5J.G&T>$L\KW+6
MQ5P^[@+]G.1@YW=1CGO** /E#Q%^R/XHN?A=X?\ "-CJ>@7@TSP1)X9EEOX7
M1;BY>YLYC(0%?$8%J^!R<N,^H[+Q%\ -3U.^\=W%KIWAE!KFL:-J%DLD9_=B
MV>$W$LA$61*0LNS!;/RY9=QQ[[10!Y)\;?AMKOQ!U*PBL-(\.:KI+Z5J.G7;
M:U/)'-;M<+"BR0JL,BN JR[E;;GY,,.:I_!3X5^(O WBR?5==@TK=/X0T+1I
M)K"=Y6^U69N_/ +1J3&?.C*L3DX.0,5[/10!\T^.?"7B]/C_ *3XJ\'^$;C2
MM2><6FK:M%+:FQU.QWVX+W>Z192R1)((U1"XD1,GR]V=_P *6'B?5_C>_CQ/
M#VN:+I#^'Y;+4+#7Y+5Y#,LJ-#'9I%(Y3I*9&+A'S%@$Y*^[T4 >!_$_Q+J'
MQ)TR/PUJ/@3QA9>&[F&"[U-H;:!IYP#'*+-=CN.<-'*<J1@A&.=P2TLVG^,$
M.O>#T\4:7>WNJ26_B.PUVRNUTZ[MXH40RQ/*A2-AF QF%E23;("&(8K[[10!
MXMX5\ ^--"^*?BGQ!J6OPR65U9V<,]VVGH#=Q0K<$+$B2_N3&TQ)9E8OD <"
MO+=?^*?C?PE\-?!NIW'BO6)]>UWP=?:S)'<Z3:QP&^ATZ&58M_D[H27$C^5Y
M4A8L_**@4_7=% 'RC?\ [0&J^%_$/C*[.NVG[C5/#D-T-7A?[)HVEW-I&\MY
MY:R(50R-,#([ *1\QVQXJSK'C'4_%7BWPMXHT+QGX,U>\M-!\57.EZO:P-<V
M$EO'=:<$#!9P2X0;9)$D"Y+$+@@#ZC>)9%964,K#!!'6J\^EVETX>:VBF8(T
M0:1 Q"-C<O/8X&1WP* /FO3/VE_%/B[XBZ/H>C6WANR1+K3A>Z?JFII%=WEI
M<V<4\D]LA(9MAE(3:'#&"4':<;?2_A1\0=5\2_LVZ!XUU6\LGU:\\/C59;D1
M[( S1&0,R9&T 8RN[C!&[O7='P9H+:C8Z@=%T\W]C%Y-I=?98_-MX\$;(VQE
M5P3P"!S4FC^%-%\/:,VD:7I%CINE,9";&TMDB@)D8M(=B@+\S,Q;CDL2>M '
M@>E_M+ZW:?#S5KPZ-;:OJOA3PIH_B+6GN;HVANEN+>6:X\I?*PI5825SA69B
MGR;<UUGQX\57MY\+/"FK>&[ZXLVU3Q'X>$4\,SP.UO/J-L'5M@)*M&[*R\ A
MCD\8/0W_ .SS\-]3;2#<>#M+*:5:K8VD,</EQ+;*VY(&C7"O&IR51P5&6P!D
MYZ/Q?X!T'Q[I=GIVNV OK*SO(-0@B\UXPD\+AXG^0@G:P! /&0.* /,_^&D9
M1-HEZ?"\[>&=<U.YT+3M0CNT:XEOXI+E%1H, )%+]F(20R9#. ZHH+5/H7[5
M'A77&TF%;#6(K_5/#$GB:ULC: RRK$2)K) &R]VC!@8ER>#S73Z9\"_!ND^(
MSK4&FRM=+?R:I!!/=S2VUK=R*RRSP0LQ2)V#ODJH^\Q&"S9?I?P.\&:+J=KJ
M-CI/V6]M]:N_$"313.K->W,;QSNV#\P9)"-C9487 ^48 .';]K'1XO$"64WA
M;Q-'IP%U'-JD>G_:(8+FWWB:!_*9]I5HY$+DA=R$9P0:]!\-?%?1_%'@NX\5
M6]KJMOHT5K]M5[G3I5DG@\H2B2*, O)E3P%!8GC&>*Y'5/V9](OM6\07-MXG
M\4:78ZP]Q<OI%E?HMG!=SQ/'+=(AC)9R)&;RY&>'=AO+R :Z[5O";Z!\'+WP
MSHB3WDEGH,FG6*,Z++*4MS'&"Q 4,<#G &3TQ0!S-G^U)\/+NPNKQM0U.S@@
MTQ=:7[;HE[!)<6#-&OVF*-X0\D8:5%)525)!( ()GTCXX:+JGBS4%EURTTO1
M;6PMG;3]9TRZTW4HIY;J2!)'%R(_W4C($C 3+,&(9@17GUK^RS>>-?A]H4'B
MK6VMM;L_#UMH5L+6S6-;"U\RVEGC*>8ZR2N;6-#+G: H**.<]%\3_P!FV?XB
M>+O$?B"+Q&FF7>I6&BVUJIL3*+6;3=0>^BE8B53(K.X5D&PX'# F@#J_$/[0
MWP^\+6=U<ZCX@5%M+JXL[B*"UGGFBE@4-.&BC1G 165F;;M"LISA@3UEYXTT
M'3M#LM9N]8LK32KTPBVO)[A8XIC+@1!&) 8N6 4#DD@#.:\K\2_!GQSK^OZ3
MXG?Q5X8N?$=G97^D3PWGAJ633+FPN6A8Q^0;OS$D!MXP7\UE8%P4Z8T?BC\*
M-9\5?"O0/#5E'I.K7NG7%M-)+=SS:4R&%&*2VDUJI-K*LGEE6".H0,A4AJ )
MK+]HOPM<^/;O2'U?18O#RZ-8ZK:>(3JT7D7;7,]U$L2=%)_T1R"&.>1@8KOD
M\9Z%+KK:(FLV#:TJ>8=.%TAN O/S>7G=C@\X[&OFP?LS_$>\\">.=/U/Q#HN
MH^(=<\&:;X=M[Z9Y=IN;>>^F=YSY7S+F\"[PI+["64$G/20?!OQW/\2=+UJ]
MM/#4=C8^-9=?$MC=M$[V;Z;/9[3&+0$RY>)VW2OO8$[U 5  =SX(^/6E>-M1
M\+6$6E:E977B"WU6XA6X6,B 6%U';3+(5<X8M*"NW<" V2.,Q?$"S\'_ !:\
M;I\.=9BU>/6M(LHO$UK?Z==S636I<S6J213PR*PD&91M.5PW.>E<3\+/@SXK
M\)>+_AG?:K#9QQ:'I/B*"_-I<^8@GOK^VGB5=RJQ&R)\G'!&.>IY_P".GPNN
M];^,_B#7]2^&U]X\TJ^\,VNEZ1)93VS&UOHY;F3<?,DC:W&98_WBEAE0?E*B
M@#Z)\%>!M.\!Z5]AT^;4;O<V^6ZU;4)[ZYE;U:69V<CKA<[5SA0!Q70%0>U?
M)?P\^$OB*P^(FE3>/=)\4ZQXJTV\T^2Q\::1>P):2VL.FV\4T,Q:82"%KEKI
MWA*9D8[P#D@=3^T+#J<GQ'TV/6+3QC=_#^]T.XLHY?!<4TES8ZLTJ-'<,( 9
M5(B#A)"#&I#!@=XH ^@Y],M+I)$FMXI4D5D=70$,K## @]01U'>L6^^&_A34
MXEBO/#6D7<:B!0D]C$Z@0,6@&"O_ "S8ED_NDY&*^6=7^(^JZ#\2(-5DUCQ@
MGPN6?3=)\0WFI"6.[M=6C1G4QQK& L#XB6Z:(>6S2ILX$M94GQ3O[/PU\1=9
MD^(^OZ%\2])TG69]6\/3V,[6UL\9D>Q>"*Z1H80(UBV%% N%<LV]N5 /K#_A
M47@;$G_%':#^\LY]/?\ XED/S6LSF2> _+_JY'9G=.C,22":YRQ^ 7PIETK5
M= L?"FC+9LMO:7MK:(%*>2QF@0E3N1D,Q=<$$;P1U%>73>+[KPUX_E\':I\:
MK_0'O=,T^]T*;Q FF-<:A/=W$RR1[/LZ;]GV=%5$((-P^2P\L)1U7XG^+M(M
M];ET#RIVM_'U];W]GHD5A_:EU9Q6ZMB**5HTE<.8@Y8^;Y>,'=@T >SWO[.?
MP]OK'3;.30-MMI^E76B01Q7EQ&/L=RFR>)]L@\P. "2^X[@&!# &LJV_9E\'
MV,$,:RZQ<7JWMA>'4[W4I+F[86,_GVL'F2EB(D8D;!C(+$DLQ8^3Z7^T%KNM
M^(/"]E!XET3Q3H>K:QI^BSR6]C]G6:UGTLW$LDJ/()(K@NI=54&,1SPJ"[[@
M.%TSQ_XF\)?LU^'?"M\]A>:%K_PXUF_TVXTX7-MJ%C]EM%=&DD:5O,#+*OSC
MRR&P-N.@(^B=0^&&L^/_ (XZ#XM\4:!HNG:9X/DNO[%N+:^>[N[]I45%>5&A
M1(54;F"!I&W[2&4*0_L]?.4?QD\?7%SJ]IX6\/V.H:7X5BTR*\DNFB4WCR0V
MT]PJ2M<1"+;!<;U9HRA,;#(R /HN-BR GK0,=1110 4444 %%%% !112'..*
M %HHHH **** "BBB@ HHHH *!UHH'6@!]%%% #**** "BBB@ HHH(S0 4444
M %%%% !111GF@ HHJCKFO:;X9TN;4M7U"UTK3H,>;=WLRPQ1Y( W.Q &20.3
MU(H O48YK!LO'WAG4M)M]4L_$.E76F7,ZVL%Y!>QO#+,QPL:N&PS$D *#DYK
M>H *:/OGUP*=30?WAH 4U!9?ZEO]]OYU.W2H+'_4M_OM_,TUL0_B18HHHI%A
M1110!!>_ZC_@2_\ H0J8=*@OO]1_P-?_ $(5..E/H0OB8M%%%(L**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4 %%5IX[IKJW>*:-+==WG1M'EGZ;<-GC'/8Y]JL Y% "T444 %%%% !1110
M4444 %%%% !THHHH *!UHH'6@!]%%% #**** "BBB@ HHHH **** "BBC'-
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M@O0;SQ/JVEW%WX:NM4OXKG1(H_,DAU*&.-@[PKM9XFF5E"@;=CJ%/)UOC/\
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M[V/\:!#WQ@9]13J:YP!]13J!A1110 4444 %%%% !2'..*6B@ HHHH ****
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ML?U-2U$_^N3\: 'OT'U%.ILG0?44Z@ HHHH **** "BBB@ HHH.>U !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M R1JV=A9>H!VM@GKM/I0!9HHHH **** "BBB@ J-_P#6Q_4_RJ2H7QYT?U-
M$CXP,^M.IK\@?44Z@ HHHH **** "BBB@ HZT44 %%%% !1110 4444 %%%%
M !0.M% ZT /HHHH 91110 4444 %%%% !1110 4444 !I <TII ,4 +1110
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MZMG[=X.T"\RC1XN-,@?Y2,,O*]#W%/H0OB9?D\>^&HH7F;Q!I8A0$M(;R/:
M,9R=WN/S%5+#XJ>#-5E,=EXMT.\D!*E;?4H7(((!& WJRC\1ZURD_P"RG\%;
MEBTOPB\"R.1C>WANSW8Q@<^5FL_5OV._@OK41CG^'>BPKG(-E";5EY'0Q%2.
M@Z4BSV,$,,CD4M?/\W[!WP4=5$'A>]L2BA8S9Z]J$0CP  543[<C /3D]<UF
M?$'X(^!_A/H%QXGU3XF?$G1-/M &:(>.+V0W<I("HHFE8O(YVHJ \D@  G-
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MSW&I/+IT+ /ND$<T,,=V?W:Y*L=AW8K[IHH ^*-)T[4H?&=@=0TCQ+INA/\
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ML**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ J)S^\3\:EIDGWT^M #F[?6EIK]!]13J "BBB@ HH
MHH **** "D89%+10 #BBBB@ HHHH **** "BBB@ H'6B@=: 'T444 ,HHHH
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M+1112+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ J*ZM8;ZVEM[B))X)5*212*&5U(P00>"".,5+10!SMYX+
ML[?3M13P_';>&]4NK3[+'J=E9Q&2$*I$9PRE6"$Y"L"OM5&U^&6F7?@R?P[X
ME)\8V]V_G7SZS&D@NI-X<%HPH10"J855 &T8&:["B@#RB[MOC=!)/]EO? %Y
M'OQ")K2]MSLSU8B5^<=AW[U'%K/QVM9&63P?\/-23^&5?%=]:'M_!_9LOO\
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M].AGDB(8L-K,I*_,S'CN2>]4--^"/@+17+:;X3TK3"4$86PMEMU5!*)=H5
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M5^D(/ACX0MKBSN(?"VBQ3V=J]C;2II\(:"W?.^%#MRL;9.5'!R<BLS4/@;X
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3J8W"C'J*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0.M%
MZT /HHHH 91WHHH **** "BBB@ HHHH **** "BBC&* "BBB@ HHHH *:/\
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M.H&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4#K10.M #Z***
M&4449S0 48S110 449YHH ,\T4=Z"<"@ HHHH #TI%Z4M&,4 %%%% !1110
M4P?ZQOH*?31_K&^@H 4U!9<0M_OM_.IS4-E_JF_WV_G36Q#^)$]%%%(L****
M (+TX@_X$O\ Z$*F'2H;W_4?\"7_ -"%3+TI]"%\3%HHHI%A1110 4444 %%
M%% !111G% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5&_^L0^_]*DJ-^'C^IH$.;M]:=37&<?6G4#"BBB@ HHHH **** "
MBB@G% !1110 4444 %%%% !1110 4#K10.M #Z*** &8S1110 4444 %%%%
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M/H0OB8ZBBBD6%%!&:* "BBB@ HHHH ***/>@ HHSFB@ HHH% !1110 4444
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M%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 8S1110 4444 %%%% !1110 4444 %%%%
M!1110 4449H **** "BBB@ J.3[Z?4_RJ2HY/]9']30)CGZ#ZTZD89Q]12T#
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *!UHH'6@!]%%% #**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I@_UC?04^F@_O#]* %-
M067^I;_?;^=3MTJ"R_U+?[[?S-/H0_B18HHHI%A1110!7OO]1_P-?_0A4Z]*
MAO?]1_P)?_0A4R]*?0A?$Q:***184444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1C-%% !1110 4444 %&*** "BBB@ HHHH *8_WT^M/J.3
M_61_4_RH$Q[=!]12TC=OK2T#"BC/-% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4#K11GD4 /HHHH 91110 4444 %%%% !1110 48Q110 448YHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBBB@ HHHH *,8HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %,D^_']3_*GTQP/,0^YH <W0?44M
M-?'&?6G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4#K10.M
M#Z*** &4444 %%%% !1110 4444 %%%% !1G-&:* "BBB@ HHHH *8/]8WT%
M/I@_UC?04 .-067^I;_?;^=3FH;+_5-_OM_.FMB'\2)Z***184444 07O$/_
M  )?_0A4PZ5#>_ZC_@2_S%3#I3Z$+XF+CFBBBD6%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !111W]J "BBB@ HHHH ****
M"HW_ -9'Z9-24Q_OI]30 K#./K3J:_0?6G4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4#K10.M #Z*** &4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !2CJ*2E'44P):***H"&BBBH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "E'44E*.HI@2T4
M450$-%%%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %*.HI*4=13 EHHHJ@"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
6*** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ctso-20221231xex10d30g001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ctso-20221231xex10d30g001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1, U$# 2(  A$! Q$!_\0
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MBB@ HHHH **8TJ)(B,ZJ[YVJ3R<=<"GT %%%% !1110 4444 %%%% !1110
M4444 %%%% !13)94A7=(ZQKD#+' S3Z "BBB@ HIDLJ0(7D=8T'5F. *?0 4
M44C,%!)( '))[4 +138Y%E171@Z,,AE.013J "BBB@ HHHH **** "BBB@ H
MHHH ***9%*DR[HW61<D94Y&: 'T444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&-1X-IYSYVD9,>#_ *K;@ 8K[YF@CN8S'+&DJ'JKJ"/R-24 >)W?CGQ)X?\
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M(.X21(NV-4)^]G 5?7(]:^4?V=_''B?X7?M>>,/ ?CB:^%O\1;5/%.COJ*A
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M-)P^G:S DDOV6XV=I%8/PWI]U=H% 'U'9>+=#U*Y2WM-9T^ZN'^[%#=([M]
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M#:. >.U=/^P[+?V/Q?\ VB= THO_ ,*WTKQ.(]$B4DVUM.P8W4,'8(&VY5>
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MM(S6I10!R%S\'O 5YK&J:M<>"/#D^JZK%Y&H7TFDV[3WD?'R3.4W2+P.&)'
MK3U/P-X;UK3+O3=0\/Z5?Z==P):W%I<V4<D4T*YV1NC*0R#<V%(P,GUK<HH
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MHVI:_IP(L]5O-/BENK;/7RY64LG_  $BM^6))XGCE19(W!5D<9# ]01WI]%
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M)EG!)PQ.:Z37O#NE>*=,?3M9TVTU;3Y&5GM+Z!9HF*D,I*,"#@@$9'45HT4
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M'8J!BM+7?"VC>*-$FT;6=(L-7T>9/+ET^_MDGMY%Z;6C8%2/8BM2B@#.\/\
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M;.SM].M8;6U@CMK:%0D<,*!$11T"@< #T%3444 %%%% !1110 4444 %%%%
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M[4'B'Q9HNFVWAWP/'JOC*6RO[RXTE=25(?\ 1+MK5DCE=5)#R*<,5&T$9'-
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M?>- 'U+HWPI\,:9?Z;JEFE_)=6<D]Q;W,VL7DY9I@/,9R\K"7("@;]V  %P
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MTK3;;P'X;BL-*N/M=A;_ -DP%+2?IYL0*_(^ !N&#P.:;<? CX;7.A6FBR>
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M?!C:[\5M:\5?'_X7_#[4UU*T\*^)--O-#TS5[UE2YB8-/<:0LS,"$94;"%@
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M8U?P+\8O@K\,M.UK5[;P3XY\4W-YJSO?2EW2.*(IIZS%BZPL0?D! P=HX&*
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M=QM QU- 'L?C;]GCP%\1;#PG:>(-(N;Z+PI<1W6C,NJWD,EI*@ 1Q)'*K,0
M.6)Z5TEG\.] L].UW3S9R7ECKDDDFH6VH74UW'.9%VN-LKL%4J,;5P/:O$/&
MW[5^M^!-+BN+OPA97<^H:!#XBTU+?5&\MH6G@ADBD8P\.GVF)@0-KY897'/J
M'PJ^).J^-M8\9Z-KFD6FD:KX:U)+*06%XUU#,DD$<\;AFCC(.V3!&WJO!YH
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MI^-/^"=WB[XRZOKU_P#\+-<7^LIXA2Z=+BPG@N&6*"$@_NX@$"F$84ACD'-
M'W#X4^$'A7P3K<6KZ/8W-OJ$6EP:*DDNHW,ZBSA),46R21E^4L?FQNY.36EI
MW@/1M+N_$%S;PW/GZ])YFH-+?3R^81&(QM#.1& H  CV@8Z5^='BCXVZF_Q;
M\ >+_%^CZ]JMI??"!]>UC0=!D,;/<[L&Y$?F( RCG</F5>G2K7CS7/%MG^PU
M\"-9U/QI<>+-9U'QAIP_M73[Z1IIK.:60BTDF8JTA"A8WWG[RX/3- 'W/X/_
M &>? G@*;PU+H>F7UHWANWGM=*636;V9;:&8@RQA9)F#*2J\,#C QC%06W[-
MO@"SU&ROX-,U&*[L;R\U"VE77;\&&XNCFXE7]_@,_//8$@8!(/P_KOC76]/^
M%W[8>BW>NZKHNI:&T=_I'A2ZO)9[G086 V30W(9E"R9#!(G(3IWKZ _9WT>+
MQ/\ "V#7-9TJ^T+4$\.1:;&+F_+#6(Y=/M[AKIE61E+[Q(588< -G!R  >VR
M_ 7P-/>FZDT>629[:&TN"VH7)6\BB8M&MROF8N-I)P9@YY(S@TRX^ '@>ZOK
MB[ETR\:>XUN/Q%(?[6O K7Z($2;:)<#"J!L V8 ^6OC'P;XA\6_L_>+O#OPA
M^(-[J?BWP7XRU#3M2\%^)KV5YIX96GA>>PGDSD_*7QDX(/HQ"]O\9O"-KX6_
M;*^ 'A>SNM1;1=<76Y]4MI;^9EO7\LNID&[G:6^4=%P,8Q0!]+^"OV?_  +\
M/-<L]7T#2;BROK.VFL[9GU2[F2&"5Q(\2QR2L@3<,A0,+SM R:MI\$?!47Q
MN?&L>B^5XANF62XFCNIU@GD5=BRR6X?R7D"\"1D+@=#7R7^T#>>+OV?_ !IJ
M&L7/AW5/B1\&;;1;;29[S2=3<ZUX3>-27N5^8-N975S(,$@+N< ?-]%?%FPL
MOB3^S8\.F:K>16FL:?8_8M7@=HKE$F:().K##*^U\^O)H W[+]G[P'IVG75A
M;:))#8SV]S:+;+J%SY=M#<',Z6Z^9BW5^XBV>G2N6U[X!->?$GX?36$0@\%>
M&M"O=(,:ZY>0WH$WD",*R_,ZJL)!WRYY'!Q7P]XE^+_CR_\ V&OB#X#U76M6
MT_QU\+KF2RUO58;F6.XF1+B-;0^<#N/F"0G.>1!S]ZNZ^*FOZMX>^.?[/\6E
M:9?>(H[KX>WE[<:!;W7EQZC<):[D>4,ZJ[!OFW'+>F3@4 ?:DOP#\!27:SKX
M>CMQ]D@L)+>UN)H+>X@@.88YH4<1S*G;S%; )'0TV^^ ?@?4K#Q%9W.EW,D'
MB#48M6U#_B:789KN/9Y<T;"7="R^5'@Q%,;17R[^TKHL'@OQ[^S/H&CZG?KI
M^H>,Y+?4+?\ M"5S)%+MF-M*=VYHU,GRHY. 17*ZMX^\3:9#^V-\/%UG4M3\
M->$-*&HZ%>W5W)-<:9++;M(8$G8E\*W*@ME=N!0!]C67[._@'3TMA;Z1<Q-;
M:M)KD4HU6\\Q+QU*22;_ #=V'#,&3.UMQR"2:;9?LZ> =.MM/AM-(N[5K"6[
MEMKB'5KQ+B,W+E[A?.$WF%'8[C&6*YP<<"OCOP%X\USQ7XJ_91^%^H:C?6OA
M/7O")\0:O(ERZ2:U=)"S"&:4'<Z[E#,N?GW?-D5]GW>C:-\'[7Q3XJMFNH[!
M[*'&D)*[6T3Q&7:+>+)6-I#*JE4 !*J<9- %75_V=?A_K<>I17.ARI!J.D0Z
M#<6]KJ5U;Q-8Q$F.%4CE54 +-RH!Y.3S6KX^^&UOXNT31(+:3[-J.@7UOJ>E
M7$Q:3RYH<@!R26961G1CG.')ZU\Z?L@?%_Q!K?C/XN?"KXA:BNK>(M,OI-:L
M+AT94NM.NOFVQJ_.R-VVX[!@.U3?\$V/$$MY^S+<ZSKFIS75Q_;^HQRW^HW#
M2/L2;:BEW). . ,X% 'UH$:>V"S#RW=,.(I#\I(YVMP?QX/TKQS2/V.?A%HE
MO;6UOX5EFL;?5FUV.POM7OKJU^WMR;@P2S-&S^Y4X[5[(ZQ743HP66-@493@
M@]B#7YT_ +P;J'QK_9F\=:+<>)]8TO6;GXCW>FV6O6][+]KL4611$J/NW>6N
M<;,XP3TZT ?7-E^R7\,=.\96_BFVT6[AUJWUJX\013)JUV%CO9T"3.L?F[0'
M &5 P<#BE\._LD?"KPGJ6A7^E>'+BTN]#N+V[T^0:S?/Y$MV,7+ -.0=_?=D
M#MBOF/X=_M$^--+@\8:%XYT5Y?C/\+/"FJR3R%&,&KQJ(3:7BXX;< ^>_+8Q
MN('JW[+G@&W^,'[+/ACQ+KNN:G?>,?%%I_:-[XFCO9%O$F:0GRXW5ALB7&SR
M5PA (*\F@#TCP=^R7\*_A_JWAG5/#_AJ;3-0\-K<)IEQ'JUZ7A2=R\R,6F/F
MHS$G9)N4$G &:[[Q[H-YXJ\):GHEE<I9-J4+V<MTV=T,3@J[H,<N%)QG S@G
MI@]!7C7QX^/EY\&WDD@T6WU:VM; :C< W;"=D\](BJQHCE  Q;S9-L>0%SD\
M '9ZQ\(O"NO>"=(\)WNG.=$TDVS6,=M=36TMLUOCR7CEB9'1EVCE6'ZUCZ3^
MSIX!T*[TZYL-)O+6;3KB]NK5DUB]Q%+=Y^TL!YV#OR3@\ DD8)KDOVQUW_"?
M2I$DF@D;Q+HT/FP2M$_ER7T*2+N4@X9&92,\@UQGQ2\;+^S+\</#TVEWFI7/
MA+5?#VKW^L>'I+R2XB@-G&DD5S")&;R2Q;RVVD(=P)&1F@#U&7]E;X8RZ39:
M;_8%S%:6FF/HJB#6+Z-Y+%R2;>9UF#31Y8D+(6"Y.,5VFN?#CPUXG\"R^#=8
MTB'5O#,MLMG)I]\6F5XE "@LQ+$C PV<@@'.:\!^-'C3Q;XF^&.H?\)!X5?P
MS%:ZYH$^FZA;:FDJ7B2W\ ==J$,I7)4[AM8,".X'86_[06LZC\2SX/M- L6G
MO$U9=/N!>/+'YUD4 65U3R_WF_E4<O%C##)P #TCPO\ #31_"2V"6<NIW,>G
MQ^59)J&IW%T+=-NW"^8[9.W*[FRV"1G!K/T_X(>#=+^*NH?$BVTRXC\9W]HM
MC<ZD=1NF$D"D%8S$9#$ " 1A*\>\,?M<7_B._P!+L/[+L(;[5M %W90%I<_V
MLLZP3:<YZ!D9@<C)VDDJ,<]#J?[2.JZ1X_7PY)X=L;I99=1M89H+]ROG6EK]
MH^>18F1-^'7R]QDCPI9?FP #T'QK\$O!OQ$\8^&/%6OZ9/>:]X9E>;2+J/4;
MF 6KL &8)'(J,2  =P/%7/%OPI\->-/$&D:_J%D\7B'2!(EAJ]E.]O=0(XPZ
M!T(+(W=&RIZXSS7D6@_M(^-?$&@^&&M? NFS^(/$^C-K^EZ;;:R7!M4C@++*
M[Q(%D,DX4!=P"_,3_#7I'BGXK3>$_ WAK5]0T5K#6M>O+'3(M*N;I"MM=W+!
M=DDT>Y2$.[++G.W ZT 1V?[/7@/3]'&G6ND2VR'53KLEW#?W"7<U_AA]HDN
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M1@T 6_"O[/7@+P3!XSAT;1Y[6/QC++/K@DU*ZG^V22J5D<^9*VPD$C*;:TM
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M9)#QP,Y0;2Q*J050GY0M>HT4 8%AX&T;3GUUDMY9UUR0RZA%>74MS%,QC$9
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M]5_:2U6QN-<UBT\%S:CX%T&[U"RU35XKZ))K8VB.7D\IB"P+IL"#YOF5N02
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M90X4>E:6E?L_^"M%CTV.TM=66'3=.?2K*&7Q!J$L=M;N@1EC5YR%;:H7>!N
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M,@&O3J* /--3_9Q^'VK^&O"^A7.BW'V+PPGEZ/+#JMY%=V2;0I1+E)1-M*@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4$9\R6/YAN 4D]1@@'TW17A7P0DU<_';XTQ:RL$5PKZ0XBM;J2>$!K5R2N\
MKGN ,<9[U\\>--8UCP[X,^/.JZ-IVNVU[HGC67[-XJL]0"0:';*ML[L8A-YL
MD2!G8PI$RL&(QC. #[\HKP*]_:@$6FZGK^G:5!J_A/1M>M/#]_>K<,ET\D_D
M#[1%%L(**UQ'\I8%AN(Q@!LR7]I?QNN@W.MQ^!M#;35\4CPI$IU^43-/]O\
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MZU;5=)EA&HR-9(EDJ-),LOE*[;A+$ NT$%F.<+R >^45X%^S:LFI?LCZ2NH
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M)";5X&%&,GD?AA\</^%@>.M>\,W5C%HFIZ4LC2Z7>-+%?(JS&..38Z!989%
M<2Q,R_,%/(R<7Q'^TE)HTFOZG;:''>^&?#WB2W\,ZE-]I*W8EE:%#-'%L(*(
M]Q&-I8%@&(Q@!@#>7]F3X=_8=0L9-)O[G3=0U%M5O-/NM<OYK6ZN6<2,\L+S
ME'!8 E64KD#CBK"?LY?#^+Q$-<BT>Y@U%;Z?4HVAU:\2.*XF0I-)'$LH1-ZD
M[@J@$X)&0#7%_!C2+KQG\5OB-KWB5;:\O_#WB66QTNY@EF22WB^QVX,. P#1
M8<ML8$;R6QG!K@O!_P 1KWX%_%[QO9ZK<W5_X8\5W5_<^'[:65G6'4[:7RWL
M8<GY1*C1,BCC*O@4 >S_ /#+_P ./[(M-+_L:]^P6NC3^'X81K=_\MA,P:6'
M/GY(8JOS$[N  0*Z3P7\(O"WP\UC4]3\/V-Q87>II"EYG4+F6*8Q1K&CF-Y&
M3?L55+A=S8&2:^=?@3XT\0_#_P ,^.9-1E3Q)XCN?B#>Z5-=:A=N2@$*2;8H
MP&DD56W!88E) 8G "L:[+PY^T[XB\9OX'_L?PAIJ1>(/#LOB*YDO]7DC^RQP
MSQ1SQJJV[%V D)7.-Q !V]: .ZA_9J^'EOJYU.'1KJ&[\V\F4QZO>JD37?\
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MJZ'Q.^&7@>%VALO$5U>W-^Z$@R06D'F>3GT=WCW>JJPZ$US5Y^TOJEGXYN]
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M>,@'(STKDM*^.GC/6-:EMK#X?QZM::7J)T?6Y[#5H\6URL*O(\7FA#)&KNJ
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M]H;Q+X;M_&J7/A?2I]3\$:9%J^N6MKJLC*\,AE=$MW:!2SB&(N2RJ-Q" ]6
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MBKGA'X!>!O NI:/?:'I-Q93Z193:=9 ZG=RQQ6\KB22/RWE*L"RJ?F!QM &
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M._>, ;GPV\3W-K\8_B-X#=WFT_28K#5M/,C$^3'=)('AS_=$D#LH["3 X
M-'PM^S[X1\%ZTVK:3)XCCO2TTBB\\4ZI>P))+N\R18)[AX@YW-\VS(R<5:U_
MX,Z#JG@;6_#5FDVFIK$HN+N_BNIQ=2S;E/FM,LBRLXV*!E\ *!@J-M>6Z;^T
M]XJN=0TB2]\%Z;9Z#JOB'4?"T5[;ZL]Q/#>V[3B-WA," PO]G;)#[@3TQS4
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M7J,+XB>--9\5_$/X3:UH,5C>P2>([^VTES>2P6]["NFS[GE*J_R^8K8PK9"
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M 7#<]* .]\3?![PCXPUV;6-5THS:A/:"PN9(KJ:!;NW#%A%.D;JLR EL+(&
MW,.A.<[7?V?_  +XCUF]U6]TFX^V7EW:7\YMM3N[>-[BUV^1)Y<<JH&78G('
M(50V<"L#X=_&'QCX[^(NJ:!/X,T_0K+1H;*74WNM9,MU$;FV:4(B1PF-V1QL
M;]X%Q\P8]*TXOBSJVM^+]<T_0-$L[[3/#VL0:1JTUS?^1/&7A25YHT*D,J"6
M,;207);&,#< )JO[,_PZUJVFAN]$N7>35I-<%U'J]['<Q7LBA9)8IUF$D6X
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MFL+JR;3;YK:YUM?$4J'6;T[M05Q()L^=D?,JG:/EX'%5/BQXO'AKQW\.+/\
ML"VU:?4KV\CMKN>]>!K.5+*:3(548,&560DGY<Y -<U\%/VB-;^)FN>&;/6/
M"]EHEMXD\./X@L)+/4FNG01RQQR1RJT* ?ZU2I4G(!SB@#KXOV=OAY%K^N:P
M/#<;7.M^:=1MY+F=[.X:5"DLAM2YA$CJ2&D"!B"<GDU;\"_!#P?\-]7_ +4T
M&QO8+[[#'I@FN]6O+S%JC%HX@)I7 52S;0!QG P*Y/X@_M W7@7XBV.@MHMO
M=Z;+J>G:7+<QW3/,AN]P$C*B,L04A<)*RM("2O"\T5_:3O(?ARWQ&N/#UJW@
M>?39KZTN(M2'VH.LHCBBDC*  OG<64D1[2#GK0!V6O?L_P#@?Q/+XIDU+3;V
M=O%#6[:L%UB]C6X,&/*P%F CV[1]S;TYS5[Q#\&?!_BG5VU34]*>>^ELUTZX
MD2]GB%W;*2RQ7"HX$Z@D\2AOO-_>.>6U/XO^)- \4:-X5U/0-+AUW7[Y[?2)
MXM2,EK+"ELT\DKCRPZ%2K(%Q\YY! SCE-'_:;\3>+->T#0M%\&Z8NJWCZM;W
MW]I:Q)%#;3Z=<1Q3A&2W<R(PDW(V 3P"J\F@#T;4_@!X&UBYU:>ZTN[:35=1
MM=6N_+U:\C62ZMMOD.%64!-GEIA5 7Y1D'%=%X2^'^A^![C6Y]&MIK>76KYM
M1OVFO)I_-N&55+@2.VS(51A<#@<5\XW?Q9O_ !Q\2O@_X[MK&WMO#MY9Z_<6
M,7]IE'FCBMCL\\,%B3=MW9).S."3R:V%_:TULV]]&GA"RN=0MM1T.S _M&6&
M%TU)MJLK-;Y?RV!&Y05<893VH ]0LOV>? >G)HZ6NE7ENFCWES?Z>D>KWH6V
MFG5UE*#SL!2)' 3[J[CM S3--_9S\ Z1;:7;VFE7L,.EZ5<:)9J-9O3Y5G,0
M98LF;G<57YCEAM&",5R'AK]HS6/$>I0>%QX?TZU\;/J>K::8#J#M8_Z"(V9U
ME,0=MXFB 78,98GA>;5Y\>/%L^KRZ3HGP^&KZQI5O87&N6$>L0+]F-QG<D4K
M;5?RU5FW' ;;MX/- '0Z?^S1\.-*UC1M4M- D@OM*M(+""1-2N\200_ZE)U\
MW;<A/X?.#E<#'2NK\5?#OP_XUU/1-1UBQ:ZO=%F>:QE2XEB,9=-CJP1E#HR\
M%'W*>X-<G\7_ (JZC\,=9\, VUBN@ZP]S9RZE=NX%K=+ \L"L%_@D,;+GJ#C
M .[CS"^_:,N_&GP#U_Q1<^%[#4K/3]">?7=%FNI;9H+P3/')9[]I.4\MR<@'
M[O0-P >V^"_A!X2^'T\$NA:6UHUM ]K:K+=S3I:0LP9HH%D=A"A(7Y(PH^51
MC &.RKX\^.GCOQ5KG_"Q=*E>T32/#VJ^%CID-JTD,H:>YA<AW!Y!#%3D8QCC
MKGZ#^$GQ'U#Q\?%=GJ^E6VDZKX=UF32;A+*Z:Y@EQ%'*CH[1HW*RJ""HP0:
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M%<SH?[4WC;Q!I.B7=MX&T2-];\+7/B:R277I<(MNR"6*4BUZGS%VE<YP<XH
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MI/)?7%Q]H>--B-B61@I"\?*![UBZU\5]6E\;^(/#OAG1+/5I_#B6,VIB]O\
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M!Y1_PRU\,A8^(;%/#LL%AKPE6^LX-4O(X,2-NE\F-9@L&\\MY(3=WS6OXP^
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ME #KY<>6 !;8NXG%7H_@QX.B\17.MII#)?7-XFHS*+N<6\ETJ[5N#!O\HR@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9Z9 .MX@_:HM-!'C>X'@3Q/>:9X/3?JE]']CC5,V\<Z8CDN%D.Y9!QMRI!#
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MS4],O?#VKZ7K]KJ=GI5OI%R;=I;R2ZB,L#(R2L@4HKLVY@5$;9&< @&KXF^
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M7L=%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 <=XU^&=IXW\2^$M;GU34=/NO#5U+>6D=D8?+EDD
MA>$^8)(W) 21L!2O)[UY_H_[)FA>'$T!]&\7^+=(OM)MIK%K^RO+>.6^M))V
MG-O./(V%0[N5955UW'#BO<:* /*K[]G+PWJUGX^L]0U#6+VR\92P3W<+W$:&
MTDACCCB>W=(U=6411L"S.=R@^M"?L_V\R>%GU+QKXKUJ^\/ZJNK0W^H7%J\T
M\BPO"J2@6X38$D;A%0DG))/->JT4 >2>%/V;]'\(ZGX5O;;Q%K]T_AR]U*^M
M8[EK4I*]\S-.)-L"DJ"[;=I4CN32>/OV;=%^('BK4-=N?$7B'39;]M.DGM;"
M:W\DR64WG6[CS(792&)RH;:V<E<\UZY10!XS<_LM^'KYBMWKVO7=N_B.X\32
M6\KVNR6XFA:&2)L6X/E%'88!#<_>JY\/?V<M*^'/B'0=5M/$_B/4QH6F3:-I
MUGJ<UM)%!9R.C>3E8%D8*8D"LSEL#!)KUJB@#S?Q#\"-"\6^,K;Q'K5[J&IS
MV=Q)<65M,81':&2W,$B1R+$)A&RLS%#(5+'..E<C8_L@>&+?29]-N_$GB;5+
M27PZ/"XCN[BV_=V*R;XU79 OS(0,,<D@?-NKW:B@#P#XF_!B^U.-M*TRRU77
MM4UNZTN;4/%FH3V:I;P6-W%*L+QH8V^[YI7RHB"S'<1D5TZ?LW>'TU[Q+<_V
MSKYT#Q%)/<:CX4-XG]ERSS(4EE"[/-4L"25$@0L<[<\UZQ10!XY!^S)I*_#R
MX\(7GB[Q9JMG_HHL[R_O()+G3TMI5E@2$^2$(5D7F5'9@ &9@!78^/?AC9_$
M+0]%T^^U34K.?2-0MM3M=1LWB%P)X3\K'?&R'.6!&SN<8XQV5% 'EWAG]G?P
MWX5O]/>VO-3N-+TS5)]9TW1;F2)K2QNY@^]X\1B3&992%9V52YP!@8N_$;X)
M:7\2-=BU>XUC5](O%TB\T20Z8\(6:UN=OF*PEB?D%%(*XY'.0<5Z)10!XC??
MLE^%]5M)K>^USQ#<HVAV&A1.+B"*2W2RD,MM<1O'"K+.KG=NSM./NXKTOP;X
M-;PGH+:=<Z[J_B:>0DS:EK4L;W$O 49\I(XU   PB*.YR22>CHH \.TC]DS0
M_#J^'WT;QCXOTB[T:S;2TN[.]MTDN; OO6TF'D;61"3M<*)1N)\S)S6QJ_[.
M.BZSI/Q&TV77]>CM?'/EB_$<EL6M@D*0@0%H"1E(U!\S>>_6O6:* /'O$?[,
MVC^)SXI-WXF\0H?$:::EX86M!M^PL&A,>;<XR1\V<Y[8K?T#X*:1HGC]/&<^
MHZCK&OQ6]S9PW5]Y :.":59&B+11(SJI4!!(S;1T]:]"HH \@UW]FG1M<\;W
M'B;_ (27Q'97$VLVVO?8[::V,"7<,'D*R[X&?:8\@H7*C)*A3S69;_LA^$_[
M%T71[[6=>U;2M,TS4M)%I=RVP6X@OG#SB0QP*VX$#:4*XQWKW*B@#S3X>_ Z
MU^'_ (I;Q!_PE/B'Q#J+:3!HI;69+9A]FA=WBSY4$9+ NPW$DGOD\U#I7[/6
MA:/XIU[4[?5]<_LC6[F6^O/"[W2'2WN94VRS!-GF L"24\S9D[MN>:]1HH \
M/OOV2?"^I^#1X9NM=\0SV%OI,VAZ;+)-;--IMG*R%XX6,'.5CC3=*)&"J!GD
MDV]=_9=T#Q#K&JZO<^(?$*:M>76GW\%]!+;))87-G&T<,L&(,9*NX99 ZL&(
MVU[+10!X]IO[,^D:=?:?=GQ1XCNKBT\2R>*]T[VG[Z\>)HG#A;<?NRK'Y5VX
M)X(IVE_LS:#I-]H4T6O:]):Z+K%]K-I83/;- 'NQ*)H6_<;C'^_E(&[=\W+$
M  >OT4 >.67[+GAFQ\/V^B+JVMRZ;86%[IND0S2P/_9,%TNR00,8<DA#L4RF
M3:O%3:?^SAIVDWT=Y9^+O$MO<QZ+8:"'5K,YMK20O'D&V(8MN97R"K*Q&T<&
MO7:* .$\,_![2/!?P[N/!_AZ]O\ 1+*66>X6[L6BCGADEE,KM&/+\I!N8X41
M[0.-M<8?V2_"]E=VVI:%KGB#PKKT-_<W_P#;&ARVUO+(;A8Q/$T7D& QOY,9
M*B(?,NX$,2:]NHH XC0/A-IWAOQ[<^*[+4]5^U76F6VEW-I-.DD$ZP%_*E<L
MAD,@\QP3OP<Y*D@&L+Q1^SIX>\9ZSXUOM8U+5KN+Q796ME=V7F0I%;BV9F@D
M@98A(KJSE@2[<@<<5ZI10!Y'K7[-NC>(0UQJ'B+7KC69+W3KV;62UH+F;["_
MF6\3 6_EB,.68A4!)8Y-+XW_ &;=%\<ZWX@U*;Q!K^F'7)-.FO;:PDMO*:6R
MD5X)!YD#L#\H##."!P >:];HH X[P1\,K3P)J'BV\M-5U*\F\2:B=3N?MAA(
MAF,21?N@D2X7;&G#;N1[UP%C^R/X3@TG1-+O-8UW5M+TO3=2TE;2\DM@MQ!?
M.'G$AC@1L@@;2A7&.]>X44 >._\ #-=G/X4L-"O_ !UXQU>.PU"RO[:\U"[M
MI9X_LL@DAAR;?:4# 98J9&[N<"MC_A16G6_Q'U#Q?I_B+Q%I+:I)%/J>C65W
M&NGW\\:A$FD1HRZOM5 ?+= P4!@PKTJB@#Q?0_V6M$\/SZ9+;^*/$CMI\.K0
MQ>:UF01J,OFW!;%L,D-C;Z=]U=I\.?AA#\--+TG3++7]9U'3=,TF#2+>TU"2
M%HPD6=LI$<2?O2"%)Z$*/E!R3VE% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0\=^+=7\-?%GX=:3)K/B[4-'OO"5_?W=IIF6N[F:%K?RI&5!PVV1P<8!)Y%
M'U'17SSX)\5Z]XU^+FH_#T^(-5L]&\->'['49[MO+74-0GO&D9!))L^58DC
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MA^$9=3BT_6=4T;0M-T^ZUJ_+1R2V$=S$LB-+EPTKK&RR2; < Y&X\4 7;/\
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MCQ#+:Q6VCS">]\-1^([.%KJ/?<!I1";4#M,LA"D'C)&"><9OAWXRW'@_Q_\
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MFHH \2D_96TJ?4+C4I?&GBR76)[^PU)]1>:S+_:+2-HHFV?9O*P48@J4QG!
M4@&H]._9+T#0TT)](\6>+-'U'2/MD46IV=[ MQ-;7,WG2VLN8"K1^8=RG:)%
M/(<'FO<:* /(=-^';>(/C79>*;_PO<:'#X5L9M*TV]N+V.4ZHK[=LNQ'8A8U
M$@'FX?,K''<]9XY^%^G>.=:\.ZTU]?Z-KN@2RR6&IZ8T8E194V2QLLB.C(ZX
MR&4\J""",UV5% 'E^F?L^Z#HFM^#-2TW4]5L3X7:]D@MXV@,=W+=G-Q)/NB+
M,SL2?D9 "> *Z7QU\,M"^(MSX=N-9@DEET+45U.S,3[/W@1DVO\ WD(8Y7H<
M#-=710!Y,W[-7A:W\#6/A/3+O5-&TNSUY/$*&SEB:0SI<>>B$R1N/*5@JA0
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M#U?2M1A\4^));C3M<O/$,?G26C*]U=1-'-N'V?[A$CD 8(+=<  >QT4 ?/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@@XJ? +XI7?B[X*OXO\ %-\@^SW>I_:+M[4VP2WM[J9%+1XRI$<8R#SP<\T
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MZUW2+ V6RY@EF$V(Y)_,(D1#<2E0(U/W02<'/M]% 'SYX:_9@UKP[;>#+?\
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MLV><WS8;.!P*]THH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!\:67B'4M&-KX9U.TT74)9 K:A=VIN1!'R69(MRAGZ ;B ,DG.,$ WJ*\W^
M/BOQ+XO\ O<^*S:7&IVNI7NGKJ-A"88=0AAG:-+E8RS; X7. 2,YP<$5Z10
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M_:U2.9(G>)#<X^S^8P&$W[EQGIN4G ()S_C9XV\0>$_&?PKT[1M02SM/$?B
MZ5J"O;I(WD_9IILQD_=;,0&3D8)XS0!ZW17/^*O'.E>#Y+""^>>6^U!G2SL;
M.!Y[BX*+O?:B@G"J,DG ''.2 >.O/VEOA]::-9:N-8FN=-N;7[:;FWLIG6W@
M\X0%Y@$S'B4["K ,"&R %) !ZC17F<7[1?@>;Q=_PC:WFH#4!J_]A-))I-TE
MNE[Y8D6%IFC" LIRN3ANV<BNJ^('BA_!OA#4=4@@%W?(@BL[4G'VBY<A(8\_
M[4C*/;.: .BHKR3X8?'RP\1?!33O&?B@QZ-J$,O]EZO9QJSF#4TF^SR6Z*,L
M29L!1U(9:DO/VG? =C&?-N-8:Y&JR:&;2'0KV67[<D;2-;@+$0S[5)&TD'C!
M.10!ZO17ETG[2_P[M]>L](NM>^PW5TSQH;RWDA1)4B,KPN64>7(J!B5;&"K+
M]X$51'[6'PS,EQ%_;=R9X9K.$P1Z=<22-]J<I;N%5"2KL"N>Q&#@D @'K]%>
M7:'^TGX&\0:MI^FV]SJD%U>ZE+HRB\T:[MTBO45F-O*[QA8Y"JE@K$$C!'49
MH:I^UG\,-&EU%+KQ"P%E93:@7ALYI5F@B<)*\91#O"LRYQV.[[O- 'L%%>->
M(OVH_#.F:5/<:;I^L:M=VVMV&B7%BVGRVDT+W;((I2LRH3&RME6 .[IZD=GX
M^\96GAEO"JW6KW&B/JVL6]C"J6!N/M+N&(MW(4B+=@_.2,;>#0!V5%<MX4^)
M.B>-;V:WTB2XNDC$I6Z^S.+>7RY3%($D(VDJX*D9SQG&,$^8^ _C^D'Q#\7^
M&/%M_,TJ^+3H>C31:9*MNH:TAFCADF52@<EI,;V!./I0![O17DMW^U1\-+*X
MU.&77V)L-/N-49H;.:436T!"SR1;$.\(2,@<X.X97FDU7]J7X>Z#HO\ :NIZ
MA?Z;:"-KAA>Z5<P2+;J0#<;'C#&$YX< A@&(SM; !ZW17SU\/_VF=/C\7>*-
M$\5ZG/,&\5-I&B7\&DS"R*/;P200O<JAB$CF1@N]P6X]17I'A7XT^'_&5KI4
M^FQW[?VEJ%UI<<4UL8Y(I[?>)A*A.4"F-ADCT_O+D [VBN'\4?&7PMX/\1Q:
M)J=W<17;26D,CQVDKPP/<R&.V$DBJ57S'4J.>.^ 0:P9?VG/ <.KG3C<ZNT_
M]ISZ*&30KUD-]$A=K<,(L&0J"54<MCC.1D ]6HKR>]_:B^'6G^$[;Q#<:S-%
M8S)<RF%K*9;F%+>0QW!DA*[T\MP5((SD< TZX_:>^'L&KG3QJE[,RS6,$EU#
MI5T]K$;P VK-.(]@23<H#D[26'/!P >K45X9XN^/*_\ "T_AWI.@:@3H.HZK
MJ%AJEU)8-]FE^SVLSN([EAM^22+!V]<-@G:V-[3OVG_AQJEU>VUOK^ZYMH(+
ME8?LTN^YBFD\J%H%VYEW2$* N6R1D $$@'JM%>3? KXBZQ\0[[XD)J,K^7H_
MB233;%)K(VTD,(MH) KH>20TC?,>HP0<8KB?A+^U;IDWA&"#QG=:C/XG,FJL
MCP:)/'#?):7,P9+=PGERR+%&&,:,6X/!(- 'T?17)^%/B9HWC272ETK[1.FI
M:5'K,$WECRQ;2'$98@_*S<X4\\'T.*-Q\:_"5KXQ7PU-?30W[7;V FDM9%MO
MM*0?:'A\TKMW"+Y^N, C.1B@#NJ*\$'[15K<?&.PB35#:_#]O"5YKLMU>:>\
M"2>5/ JSQRN,NA61\!1S\IP=RDY=W^T%.GC#XFQ:EK5]X;\-Z-8:-/97$F@2
M&XM7NI)58M&R$NK[(QN( 7<<X(- 'T?17F<7[17@B7Q=_P (V+S4%U :O_83
MR2:3=);I?>6)%A:9HP@9E.5R<-VSD5<TGX[>#M<\2Z;H5E?74]YJCW26$D=A
M.T%T;9]EQLE"%0(VX)8@'L2* /0**\+^//QYOO!)\8>'-#L;JWU[3?"%UXD@
MU>2!9;6,QDA%*D\\J<D\ X'.3C>\,_M$^$;WP]=3ZEJ4]E?Z7#9?;XKVPFMG
M=[E?W+1*Z#S%D8,%*9'RGG H ]6HKDO WQ1\/?$KPQ=Z[X;NI-3M;2>:TGB2
M)EFCGB.)(BC8.X''L<@@D$&O*/A#\=KSQ)HFG>*]?U&]$6O0736?A2WT?S9T
M\B9MTT+Q9=HUCV*V\'YR-K#(0@'T)17SKXX^.NIWNO?:O!>OVESX;O? &J>(
MK&86@?-S;O$(W.[#8P[ H0,$<C(KK](^/^@:-X"T/4?$VH2F^&A6.K:Q/:V<
MDL=DD\8Q--Y:D1H6#GV"D\*"0 >MT5YA??M$^$=.U"]LYC?B2TUBTT.9Q;'8
MMQ=*K6YW9QY;AUQ)]WG&<\4FK_&?0K7Q/H\$NK:CIJ%]34V7]DR3)?BT3]\R
MR*K8$9!("G+] #B@#U"BO*M!_:=^'GB#3K^_AU:ZM+*STB+7GGU#3;FU62QD
MX6:+S(QYB[OE^3)R0.XKJ?!WQ/T+QSJ^M:3IK7BZIHSQQZA:W=C- ;=I$#H"
MS*$8LA#?*QX/.* .LHKPSQ=\>5_X6G\.])T#4"=!U'5=0L-4NI+!OLTOV>UF
M=Q'<L-OR218.WKAL$[6Q7\>_M<>%=/\  GC*_P#"ERVM:]HND?VK#9M;NJRP
MN2D<XSC='OX.#D<9 W D ][HKPG2/C#:_#^Z\67/C7QMJ6H6VE:7!K,VGW/A
MQH9=/M97959GA0B8EE<90 *%&X Y8[.L_M ^%-0T'59;37=2T";3-4L-/NI+
MC0[CSHWN)(_)!BDC!\N8,%$I&T;LY!% 'KM%>*Q_M!Z;KUMJ1D;5?",>G^+H
M?#274VG_ &D7DWFHGE_*&$8D9BNYL;05.03BNJ'QU\''5K>P_M"?_2YKFUM+
MH6<S6]W/;AC-#%(%*O(NQ_E'+;&"[BIP >@45YS\._V@/!GQ3U.UL/#]Y>RS
MW>G#5K0WFFW%JEU;;PC21-*BA]K,H8 D@L,UY[\:_P!HK4M"T?XGV/AVSNM*
MU7P8NG2/J=W;++!-]HD7<JKG^XW!(Y.>.!D ^B**\VB_:%\$OINHW4FH7-K)
M8:B-*FL[RQFMKG[28A*J"*158[HR'#8QMYR,&LS1OVJ/AUXBN]+M])U+4-3D
MU"V%W&;31[N18H?/,#O*PBQ&J2*RN6("8^;'% 'KE%>&^)_VO_ ND>'M?OM(
MENO$%]I5I!??V?;0M&\]O-*(8YD9P 8][ $CD<<<C/97?QS\):=?QVM[=W-H
M?MD&FSSR6DGD6MY,JF*WFE *)(V]!@G +*"06 (!Z!17&>/O&=EX5UCPC:76
ML7&ERZKJ9MH88=/:Y%\PAD<P%@I$7"E@<@G9@9S63X!_:&\$_$O6;'3-"O+Z
M2XO[2:]LWN]+N;6*YCAD$<OEO+&JL49E#*#D9Y'7 !Z31110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %<E\3_  YXE\6>%9=,\+>(K+PS?S.HEO;[39+Y3#_'&$CN
M(&4L.-P?(!.,'!'6T4 <)X/\)^,]"TS1;34O%&BW(L[EC<0Z3X?:RMY+7RMD
M5O$C7,IBVMABY=\\C '3NZ** ,7QCH^HZ_X:OK#2-7;0=2E5?(U%(?-,#!@V
M=FY=P.,$9&037C/BK]E1O&NM>)/$6H>)+;3/%>J6MC!!J6@:0+6.&6TN/M$,
M\L4DTOGN'"K\S ;!MXSFO:O%7BG3?!7A^]UO5YS;:=:*'ED6-I&Y(4 *H+,2
M2  !G)KR;QU\<6N;;PA=^$[YX(W\:V_AO6K2[L6$R9#&6+:XRK#Y"&7.0PP:
M "_^!7C6[UKPWXIB^(]K:^-M*CN;2>]3P\O]GW-I-Y>^(6GG[D(:%'#^<Q#;
ML@J0HK_$#]FO5/&3>-Q;>,TM(_%?AZUT.[>]TK[3*LD!DQ<!EFC!W"5LIM'(
M!# ?*;__  U!X+\40RZ;X?U6]MM7OK6_.E7-_HUU!;W$]L'$L:22QJCR(4),
M><X!XX-4?A%^T[H&O?#+2+[Q-J%S!X@@\.66M:F9-+GA699@$,D \O$JF4[?
MW>[D@=Q0 _5_V93J\OB^RD\1H/#GB^>RO-:TTZ>3(T\"Q*[6\OF_NED6",%6
M5R,$@C/#;/\ 9OU6UUNSOO\ A++)H[?QM/XQ\D:.X+"6%HOLV[[3Q@.3YF.W
MW:I^-OVD(;+Q=X%ET:XOY=%FUC4='US2H=&FGOA/!:/*(UB5#)N#!#\@((;.
M<5TU_P#M5_#+3O"ECXCD\1;M*N[9KS>EK*9(84D,<CRQ[=\>QU965@&!5N/E
M. #?^+?PWO/B58^'K>SU>#1SI.MV>LL\UD;GSOL\@<1@"6/;N(QNYQZ5T?\
M9^L_VQJ<YU:W;39[:..SLFLOFMIANWR-(),R!LI\N%QM/)SQY1J?[1VD7]SX
MKLA-J7ANUT+5M.TY=<6P^UQ73W)A=%55#;5D$RH';& V[(XKM;_XV>$M,UB2
MPN+ZX41SSVKWB6<SVJSPQ&66(RJI4,J*Q/.,@KG<,4 /^#/PXG^%?POT7P?=
MZI%K;:;"T'VV*U-L)5+,W^K,CX/S8^]7$^"_V;&\))X1LI?$2:EH_@VZN[KP
M_;R6!2:!IDD1%GE$N)EC69P-JQD_+D\<T_BG^T-!-\)?%FL>!]0EM-=T/^SY
MI(]0TYT80W,D?EN$D !5XV8@\X(((!&*]?\ %'C'2_!UM9RZE,ZR7MPMI:6\
M,;2S7,S D1QHH))PK'T 4DD $T <K\*?A1<_#SX06W@:_P!9BUCR8;BW^WV]
MD;7*RL[?ZLR2<C>?XN<=*\]T_P#9;URSTK1+*3QO8SC2_!EYX.C<:$Z[XYO+
M"SD?:NJK$N5_B)8Y48 [*Z_::\!V\6EF.[U2^N=2FN[:"QL=%O+BY\ZV_P"/
MB%HDB++(G=" <<@$<USGC/\ :#@@^)/P^LM%U,IX:OM2U&TU:]GT]Q;2+;6D
MTCA+A@%'ER18;'7##)VM@ ?X+_9V\0^ ?$%K=Z1X]CBTVXL;"UUFPDT17-S+
M:PI LUM(TQ-L7CC165A*.,C!YKJ/B_\ "C6/B-KW@75-)\0V6AR^%M6.K*E[
MI;WJW+F"2'8=MQ%M&)6/?D"LU_VK_AI';:G,^MSC^SC:>?&FGW#OLNI/+MY
MJH24=_ESV/#8)%=QX5^(6G>,+D06=EK-I+]D2\(U32+JR 1G= I,T:X?,9)3
M[P!4XPP) .'U;X-^*=<\7Z!XOO/&EB/$^AW$XLV@T1TL?L<T2I+ \!NB[,2H
M?S!*,$ ;<#!X/Q3^QG<:UX:DT"Q\:I;:7<6-S'/;W^D?:U2^FNVNI+R!?/01
M,7<H00QV *&4Y)^FZ* /!3^S9K4FHW%Y+XQL7>?QG:^+V T1QS# D7D?\?/\
M7E@[^V?NFO1O'?P\;Q[K?AXZA<V-QX;TV=[JZT:\L#/]LFV%8F+F0*H3<6P4
M;+8/&!7:44 ?*7Q3^ U_\/O#_P 09?#DT4OAGQ5JVG7R:!IGAB>[.CW$;Q>;
M=JEO<"60,(E9A"BN&PRD')K4^'GPJ\2>+H]"OKFYTW1X=$\3CQ']L'A_4+67
M5Y7@DBE$D-[<>?&P\P?O&+ X4!0%Y^F:* /$8OV=-1CU#QCII\9NW@+Q-->7
M5QH7]F)]L@EN583+'>;^(BS,^PQE@3P^.*I/^SSXQU'P5I/A_6?B/::JVDZE
MIUY:W1\.B$M%:3+*JS*MQ\\K[%4R JN.D>237O=% 'A+?LWZJ^I_:F\661C/
MC@^,S'_8SY/[GROLV?M/ISYF/^ UF?\ #+GB1/A;XB^'B?$6*3PQ=V<UCI*3
MZ"K7%C%(V0LTJSK]H"+E4P(S_>+8%?1-% '@WB+]FK5M?U;Q+J?_  E]G;W>
MJ7^B:C;XT9F2VETX@J''VG,BR8.0"A7/4UW?Q/\ AK>_$.+P@L.LP:;)H.N6
MNM2/+8F?[28=W[L 2ILW;C\WS8]#7?44 >2_#;X#CP!\0]7\7#5;;[5JL$D5
M[::38-8V]Y(9=ZW,\7FNC3JHV>8JH6RQ.<@#"O\ ]FS5+W6]0OO^$LLUBNO&
MUOXP\DZ.Y*B*%(OLV[[3SD(#YF!@D_+7N]% '@&G?LT>(]-^&GB7P"OQ"CG\
M,WFG7>FZ3'/H:FXL8IPP GE68?:!&K$)@1'IN+8K9U?X%^(O^$F\/^(?#_C>
M#1=5M=&BT+5%FT5;NWOX(V+(\<;3 P2JS.5;<X^;!5L5[-10!XM_PSKOU/6%
MO/$'VSP[J/B.W\436!L,71N8%AV)YXDVF/?!&Q B#=1GFF_!KP;:7WQ(\9?$
M*TL=9TC3=7=%M=+UJS>S=+C:JW=RL$BAT\WRH!\P^;RBPX;)]KHH \,^+7[.
M>K_$[QC+K"^,H+2R$VF75I97ND&[:QFM+@3$POYZ!%FP XV[CM7YL#;3(/V<
M-7AU."[/BZR;RO&\GC+9_8S@G?"T7V;/VGT8GS,?\!KW:B@#YUT7]EOQ)X4U
M:TUO0?B%:V.MI=:F;EYO#_GVMS:WEV;HQ&%KC*R1NQVRA\>J$<5H>+/V:-6\
M2W?C&5?&5M"OB&ZT6Y!GT<RO#_9[(P#%;A YD*<D*H7/ ->]44 ?.NG?LG:A
M9?V!I4GC2&Z\):'J>H7UGITFD$77E7D4\<L#7 N,$+]HD*MY8(X!W=:EC_9B
M\33^ =-\-ZC\2OMDGA^YL[KP[?QZ%'$]LUK(&A-V!*?M1VJ$)4Q @DX#'</H
M6B@#SWX3_#/5/A]?^,+[5==M=;NO$>JC59/LFG-9I!)Y$43*H::4E<1 C)R,
MGDUQFE_!"'X;Z;I>HZMJESXAT7PC?:EKFFZ=IFCR/>M+<F8L&".YG*K<2JJH
MBDDC(.*]UHH \C_9P^&T/@'PMJ5Q%%?VL&JW\US8V.IILFL+ R,UO;;" 4"A
MW8(>5\PJ>17,>+_V6-0\:^/7U[4O&<5S9?VM+?Q6\VDE[N&VELWM9+-;CSP%
MC D9TVQC:Q)8.3FOH.B@#YEN?V.M3UW0K'1-?\?K?Z;I_AB?PM:/:Z-]GNEM
MVDA>&5Y#.RM)&;>/)"*KC/RC-:/B+]F+Q3XOL_&)UCQ_ILVI>)=.TS3YKF#P
MZ\<<?V.9I5D$9NR27WD$;@ >1Z5]$T4 >#W7[.&L3ZM>WY\6V1-QXTMO&)B7
M17R##"D7V8'[3_$(P=_;/W37 ? '0O$5E\0K"];1(UB2\U%GLM2\,:MIL^CQ
M7,SRR"*XFF:R<EA&#]G0;\Y!QN)^MZ* /&_C!\ K_P")>O:QJ6G^)H-$&K>%
M;GPO=17&F&[_ '<KEUE0B:/:5).00<C'*USVO_LKZGKVH:GJ(\;II^I26FC)
MI]S::1_QYW6G-(8YF5YV$J/YKAHR%X.-W>OH6B@#G?".B:YHWAPVVLZW;:SK
M3EG>]@T_[+;AB, ) )&*J,#@R,2<_-SQY+X+_9GU;P-:>!+FP\8VK>(?"UO?
M6 O)-';[->6EU()7C>#[3N5E=4*N)/X3E3FO?** /GV+]E%M)MK*TT7Q/#9V
M5MX4U+PV4NM,,SO)>RB66Y+"= ,."1&%Z'&X4]/V6;J#3=4L(/%L<=KK_AFT
M\,Z]&VEEOM*6\30K/;_O_P!PYC=E(;S1]TXX.??Z* /#_B#^RCX>\>:A>S_V
MC=:9!<:#'HZV\"AECG@+?8[W).3+ '<+ZY'/ K0\3? 6ZU6\\#2:;XBAL8O#
M&GWUD5NM/:X>[>YM_):5F$R;2#ER,'<2>17L%% 'RIXV_9VUGP7\-9W35$\4
M_8? L?@P6%GX=DFDE F0_:_*%PS-M'S&) 6.T[3G KN?V:[#6[*3Q#+J%I;3
M6U\89VUC^QM4TJZN9E3R]DL6HRR3-MC2/# A1G !.:]RHH ^=K#]D^^LCH.E
MOXSBN?".B:IJ-_9:;+I)^UB&\BGCEMWN1. P7[3(5?RP1QG=UJR?V;_%MU\&
M=;^'FH?$>WU"SN-.&DZ=>R>'E22WMP1@SA9Q]HE"JJAP8QU)4DYKZ HH \)^
M(?[.&K^/[KQE.WBZRLCXD\+V_AM@-&=_(\J620SC_21NSYK#9QC ^8]X?%7[
M-.L>)KKQ?.?&%C;-X@NM$NB!HKL(#ISHV/\ CZ&[S"GMMS_%7OE% 'A.I_LW
M:K>6VL6EOXNM8+.^\96_B^-)=':1XG26.5X"PN%W!FC&&P-H)R&/-/T+]F0Z
M-;Z-I;>(TN_#N@:S=Z[HMG)IY$]O/,)MJ2S"7$L:-<2$ (C'Y06."3[G10!X
MC\*OV=]2^&^L^!+R;Q3:ZI#X8\.3^'C#'I+0-="26.3S=QN'V8\I1MPV<GD5
M'\2?V<-1\<7OQ$>R\66^E6GC*'3EFAGTDW+V\MHPPRN)TW*RKC;@$'G<>E>Y
M44 > >(/V9-:U7Q/KGB:Q\<0:5X@N==MM>TZX31?-AM7CLQ:/#-$T_[^.2/.
M<&,@G@\5T5E\#M3N/'$GB#7O%$&KQ77AF7P[>VL.E_9FD\R8RM)&XF(C49VA
M"K$ #+D\GUVB@#P*']FWQ)=?"#5? &L?$--4LC9PV.DW@T-(9;:.*1'C:YQ+
M_I#CRT4E3$",\9.:LO\ LS37;>(+&^\31W/AWQ#K5IXAU/3ETXK(;V(PL_DR
M^<?+BD>",E&5V'S /R"/=** ."^)WPVO?'VL>";^TUB#2O\ A&]8&K&.:R:X
M^TD02Q"/(E39Q*3GYN@XKBOAK^SEJ?@#5?A_=3>*[34HO"EGJ=FT2:0T+78O
M)EE+;C<-Y>PH!T;//2O<J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#E?BCX/U'Q[X$U70M*UZ;PU?W:H(]2AB,ACPZL5*AT+*P!5@'4E6."*\
MCTS]EW4M%M$CB\5Z;%#'XR@\9>1:>'FBB5HXE1[>-%N?E5BN0W) XPQY/T-1
M0!\J_!/X,:MXV^'FBS:[=2Z1_8NK:]<Z;I][HDUM/%-<S74:2R^9(ID01SLP
M"JF=R_-QSMQ?LI>(;/1]-M+'XB1Z?<V'@^V\*1W=KHSH["*=)?-.+K.UPFQH
MP02K'#BOH^B@#Y[\,_LMZGX4UFVU>R\5Z9%>VGB*X\0VT$6@&.TC:XLQ;30^
M4MR#MP-RD.-O0[NIGT_]E_4?!^N:;K'@SQM_8E^;>>VUG[?I*7L6H"6ZDNFD
M1/,3R)%DFEVMEU 8 JV.??:* /!_%_[-6I^(;GQD+/QA!9V?B/5-*U9X[K2#
M/)#-9&#(WK.@97%LO&U=I9C\W %_3/@-XET"]\7VNC_$6YTOPSKUS=ZC%8P:
M:OVNQO+A3O:.Z,G,0D8R",Q[@>-^.*]IHH ^9E_9"U@^&O&6FOXVTQ+CQ/9:
M7;7-Q;^'6C59;.3=YQ7[66=I!][<V=Q+9.0!ZW\3OA?-\0/^$4O[75QH_B#P
MUJ2:I8WAMC/ S^6\4B20[U+(Z2.,!P1D$'CGOJ* /%-$_9RET'Q[X>\40>(8
M#<VFK:IK.IQ'36Q?3WL:QL(SYW[E45$ !$A..3DUR\O[']W<:?I?AZ?QJDW@
MW2]0U.ZM-/;22+Q8;Z&>.6!KD3X;;]I<H_E C SNKZ3HH \$NOV>?&.L?#-?
M"6L?$>TU.2WN+![2_/AT1$16MQ',HF1+@>9*WEJID#(N,D)DDU[-;66KQ^(;
MBZGU2";2'M8XXM/2SV/'.&8O*9=YW!@5 3:,;<Y.>-6B@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M("D;"/9APRHF3D9KW*B@#YMO_P!D[7M4\/:YIEUX[L&?4_!UIX1\^/0'41)
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M9&$'FAUF<"[PTF%P<;5/4 =*VO%_[-6L>*V\;L?&%C:GQ,FC(?\ B2N_V;[
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M!G)SR,=UH-KJ%EHEC;ZM?QZIJ<4*I<WL-O\ 9TGD ^9Q'N;8">=NXX]:OT4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%<_P".Y;ZW\+WLUAK=IX<>)#)+JM[ )DMHP"6?864$X'\1
MP.I!Z$ Z"BO-?V=/'NH?$SX0:'XAU34=+U>\NC,IO](P(+A$F=$DVAF\MF15
M+)D[6)'&,5Z50 45R?Q7\1ZWX0^&_B/6O#FD/KVN6-G)/::<B%VG<#H%!!8]
M3M!!;& 037FWPL^/VF>(M U?Q3=>.]$\0>$+6&WC,]M8/9W]E>L[));W,!=F
M5R3&%4HK9)'S=: /=:*\MTW]I7P%K6G7%SIVI7.H3VTMS#<:?:64LMW"UNJM
M.6B52=JK)&=PX.]=I)8 \_XE_:6T3?XRLHY-5T+3M%T.SU@^*$TUKF-([G>8
MW6#!8@!!]Y1R3D +F@#W*BN"UOXW>$?#%Y):ZCJ4JK;36UK>7J6LCVUG-/M\
ME)Y54K&7WIU.!O7=@,,T-*_:+\$:SXLA\.VUYJ OYM3GT59)M)NHK?[;"A=X
M#,\80/M5B 3R!D9R,@'IE%>:_&[QOK?@6U\'7&C2VB1ZCXFT[2KU;FW,C-!/
M*$;RR& 1O<AOH.M>AWOG?8Y_LSQQ7&P^6\J%T5L<$J""1GMD?44 3T5YY^SY
MXWU7XC_!CPKXEUQK=M6U&U,MRUK&8XM^]A\JDD@<="3]:EL/CCX2U35K/3K2
M\N)Y]06Y.FR"UD6'46@SYR6\I 21EP> >0"5R 2 #OJ*\/\ @K\3O$'C7P!=
M_$G5[B[.CRVES*OAU=.C5XFBFDPT$H8%P8U"E7S\X)#*.*Y>W_:ID'B7P;KV
MI6^H:9X+UGP9<^()]-BTN2[N87CEM\2$Q*S%!'*Y)P!QGTH ^F**\TUW]HWX
M?>'-0TVTO?$$:&_:U2.9(G>)#<X^S^8P&$W[EQGIN4G ()S_ (V>-O$'A/QG
M\*].T;4$L[3Q'X@.E:@KVZ2-Y/V::;,9/W6S$!DY&">,T >MT5S_ (J\<Z5X
M/DL(+YYY;[4&=+.QLX'GN+@HN]]J*"<*HR2< <<Y(!XZ\_:6^'UIHUEJXUB:
MYTVYM?MIN;>RF=;>#SA 7F 3,>)3L*L P(;( 4D 'J-%>9Q?M%^!YO%W_"-K
M>:@-0&K_ -A-))I-TENE[Y8D6%IFC" LIRN3ANV<BNJ^('BA_!OA#4=4@@%W
M?(@BL[4G'VBY<A(8\_[4C*/;.: .BHKR3X8?'RP\1?!33O&?B@QZ-J$,O]EZ
MO9QJSF#4TF^SR6Z*,L29L!1U(9:DO/VG? =C&?-N-8:Y&JR:&;2'0KV67[<D
M;2-;@+$0S[5)&TD'C!.10!ZO17ETG[2_P[M]>L](NM>^PW5TSQH;RWDA1)4B
M,KPN64>7(J!B5;&"K+]X$51'[6'PS,EQ%_;=R9X9K.$P1Z=<22-]J<I;N%5"
M2KL"N>Q&#@D @'K]%>7:'^TGX&\0:MI^FV]SJD%U>ZE+HRB\T:[MTBO45F-O
M*[QA8Y"JE@K$$C!'49H:I^UG\,-&EU%+KQ"P%E93:@7ALYI5F@B<)*\91#O"
MLRYQV.[[O- 'L%%>->(OVH_#.F:5/<:;I^L:M=VVMV&B7%BVGRVDT+W;((I2
MLRH3&RME6 .[IZD=GX^\96GAEO"JW6KW&B/JVL6]C"J6!N/M+N&(MW(4B+=@
M_.2,;>#0!V5%<MX4^).B>-;V:WTB2XNDC$I6Z^S.+>7RY3%($D(VDJX*D9SQ
MG&,$^8^ _C^D'Q#\7^&/%M_,TJ^+3H>C31:9*MNH:TAFCADF52@<EI,;V!./
MI0![O17DMW^U1\-+*XU.&77V)L-/N-49H;.:436T!"SR1;$.\(2,@<X.X97F
MDU7]J7X>Z#HO]JZGJ%_IMH(VN&%[I5S!(MNI -QL>,,83GAP"& 8C.UL 'K=
M%?/7P_\ VF=/C\7>*-$\5ZG/,&\5-I&B7\&DS"R*/;P200O<JAB$CF1@N]P6
MX]17I'A7XT^'_&5KI4^FQW[?VEJ%UI<<4UL8Y(I[?>)A*A.4"F-ADCT_O+D
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M<XZ5Y[I_[+>N6>E:)92>-[&<:7X,O/!T;C0G7?'-Y86<C[5U58ERO\1+'*C
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR2,U[O\ :J^&]K,%75[RZ@$%C=/>6NE7<MM'!>'%M,\HCV+&QXW$X!X."#@
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M6_AS2M?U:T\479MK74GTJ>UMPOV>2;S%,RIYHPA!"9QALD$8(![;17A7[/\
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M*LH)8$  \_\ %_[-6L>*V\;L?&%C:GQ,FC(?^)*[_9OL#AP?^/H;O,(]MO\
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M#6S>+-I;/]IN=2D6225<3KY:(44!/F)'5L\UTR?!B^B_9O'PL77[?[2/#_\
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M)'(]O&2I1B/F ;D8[;P)\<_!GQ(\0W>AZ#JWVO4[>T34/):%X_-MG8JLR%@
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MV[\%36>N6^C#PYKT&N,L]@UU]I,2NHCR)H]@.\\_-T'%9VN?!K7'^*MYXO\
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MB.5HO$LWBG#2VHW74L+0NA(MP?+VLV "&SSNK"B_8S\-Q:!?:.?%WBR2UN]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKGP'XOCCDNM/MK:4V,:17'VR3RXBLCR*I96P'0$D;E/*G( /<Z*\'C_:5O\
M6M?\&:;I7A.>VFU/Q)?>'M5M]4N8EFLI;6"25@OELZ/D*K!@V,<=3Q[Q0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9Y H T/$?[,7A#QCJGVK7GOM6@CANK6ULIC"B6EO<0&&2".1(UE\O:20C2,
MQR.@Q9T?X#)I7AB/1)_'7BW68D= )]6N+6Y=K=4=!:NC6_ER1$.<ET+L0I+G
M:*S[/]J'PQ>V>MWD5M=36VEW?]G2+ \4EQ]K-R+=+9X ^^*1W(90X *$-GJ!
M1;]J%?MVFZ8OP[\7'6=0GOK:"SFMX+99&MHEE9D>:5 T;(P*N..&!PPVT =Q
MI/PCTSPY\--,\$:'J&HZ)I>G+&EO/:-$9@JOO*$/&T91N5*[-NTD  8QQ5A^
MR5X6\/7>F7GAK7?$7A*\LTN(9IM$NH8!>P33M.\$L9A,:H)'<KY2HR;CM*U+
MX _:#G^)7Q%\.Z9I&AF/PUJ_A5/$:WMU,%N$WS",1M&,@;2"#@G).0<#EVO?
MM"-X0^(OCK2]<TI;?PWX:TW3KI;Z"8//<S74DD:1B,X&6=511GKR2 > #MO"
MOPOT_P '>,_$OB*PO]1+:^8'NM/FD1[9)(HDB61/D\S<4C0'<[#C( ).>3NO
MV:=!O?[<>?7-=DN]2\0Q^*(;L26ZRZ=?HB(KVY6$#;L0*5D#@@MG.:ZCP7\4
M+7Q9XI\0>&+C3;O1?$.AK!-=65V4</#,&,4L;HS!E.QU/0AD((Q@GC;C]I_1
MK+7];TBXT#5XKW3=+O\ 5A;$P">6&SD5)<QM*#&6W*\>_ ="#D=* -2+]GC0
MX?$FB:\FKZPNK:=K$^NS7 :WSJ%U+;FW8SCR<;1%A0L>S  [U6O/V;-%N=2G
MNH_$6OVL4GBB/Q:MG%);&*.]4<A=T!;RV/)!8G/0J.*P9/VL;4>'=>U0>"=>
MB?2=%L_$9M9WMP\^G7&[]^FR1\;-CED;#8&0">*]4\*^-HO%NJ:M!9VX>QL/
M(5=0CE#Q3O)$LI5,#/RJZ$G_ &A[X ,KPA\(K#P9X1\0^'[35]4N+?6KR]OI
MKFY,!FADNG9Y/+VQ*N SDJ&5L=\UQ!_9#\)W&D6NEWNM>(+^QMO#,7A:..6X
M@C9;>*598I@\<*,)T=$8."!E1\M0ZM^UUH.AKXF%YX<UM+C0](FUJ2S7[/\
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MHR"?D&37L-% 'DNI_LYZ;J=]I.J'Q9XG@\0V5E<:=/K:7-NUSJ%M.0TD4ZO
MT6W< 1Y<:;2/EV\BNY^'W@JT^''@C0_"]A<W5Y8:1:1V5O->LC3-&BA5W%%4
M$@ #( Z5T-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUE(4GC(CF=@?E)!(VG!YH V(/V?/"FGQ^,1IJW>E2>*=.BTR]EMI%)CB2#R
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M6*F1N[G K0\3?'W3/"GQ$T[PE>Z/J*SZA?1Z;;7),2">9X&F4QHSAGBPA0R
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MK%*T6\%I K^848QA3\P&3MH 9\1_V:M!^(^L>(]0DUS7M!;Q)IB:5K5OI$T
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MY5ACD<T >\T5XSIG[2MI?S:$MQX9U+2DOO$<_A:]>^FAQIM]&"560H[JRR8
M1D)!9E!QFO2/!/B@^,_#T.KBS:S@GDD$ 9P_FQ*Y5901_"X&X>S"@#>HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH 1AD$ D$]QVKR+P_^S7I'ANY\
M,SVOB;Q"\GA^_P!2U&U\UK0[Y;XR&8/BW&5'FOM QCN37KK$JI(!8@9P.IKP
M&7]HVS\6>'M/U63PGXOT;1)?$=KH\&I17-G%YEU]N:V*.J7#/Y0>,;_E(97P
M,\X -#0/V2_#/AC3(+/3O$'B*W_XD[Z!>SK-;;]0LC([B.;]QMRIED"O&$<!
MR-QXIVL?LF>%;^74X]-UG7O#>DZG+87%WH^E36XM'FLS%Y$H$L,C(P6&)2$8
M!@@R">:LM^T5I6MZW9:'8:3K#IK%]J6CV>J6Y@54N+,,+AF5I R*NUBIVDG:
M?E&1GR_X;_M2:MH?P"LI=3T75-6\56G@B;Q-!?ZI<1"'55@(64EU=G4@NA^=
M%W \4 >JZM^S5I&L:9XFLI/$WB&*/Q!K]MXCNGB:T#1W$)A*)'FW($>;>+((
M)X/S#-,\5_LPZ!XOUK7]8N_$'B&WU75;NPU"*]LYX(I=.N;1#'#+;D0\':S!
MA)O5@Q&W%>E>#]6N]=\*Z3J-_;+9WEW:QS2P(^]5+*#P?3G->:ZK^TI8:/XA
M\66%QX4UX6'ABZCLK_55^RF'SI8XGMTC3SO,<RF9%7"\$_-M'- $'C#]EK1?
M&]JL>H^+/%1FDTB[T6]NENK=I+Z&X96D:3? P1]RJ08A&  %P5^6I-8_9>T3
M6=+\6:?)XF\1PVWB<61OQ%+:Y,MLL2K*FZW.&988PPY7@[57)J ?M-I_:6F:
M6WP_\6QZKJ.IS:5;03VT5O'-(ELUP'22:1 Z,BD;AT96#8(&8O#/[6.@:Y'I
M-U?^'];\/Z5J6F7^I0ZAJ MS&#9'%W$5CE=PR<X.W:VTX)XR ;T'[.OAR#5;
MR<7^J/IEWK,?B&;1'DA-FVH+@_: /*W@EU60H'"%AG;R0:_A3]F_1_".I^%;
MVV\1:_=/X<O=2OK6.Y:U*2O?,S3B3; I*@NVW:5([DU4L_VG--GN!:W'A/Q+
MI]W=S6EOI2W=D(X]2DN-VQ(I6(0,@1F=2?E49&[(KCOA-\<=7T:[O[3Q19ZG
M<PZI\0-0\/PWM]=1,NED(K00N5XVL0RIMXW,H.-U 'IGC#X!Z#XP\1:YJ\E_
MJFFMK^FII.M6EC+$(-2MTW;5E#QLRD*[KNC9&VL1G@8U/#7PHT_PI\0-<\5V
M6I:@9M6LK2P?37\C[)!%;!Q$(PL0<$"1NKG]*C?XN:9IOPPO_'>LPR:9HMHD
MT^0PD:6%'*HZ 8SYF 5'<.N<9KD/$_[4.F>#'U>TUCPOKD&LZ;_9\K:;$;>1
MY8+R?R(9D;S0I DRCC.Y2.A!!(!;UW]FG1M<\;W'B;_A)?$=E<3:S;:]]CMI
MK8P)=PP>0K+O@9]ICR"A<J,DJ%/-4-.^ EK\*+#PYK.@3^)?%NH>$;._M].T
M9KBPC:^6[E6257=XHER"HVG>@ '.:[?6?BC%X6\%Z9K>OZ+?Z/?ZC=PZ?!HD
MLD$ETUU-+Y<46Z.1HLD\Y#X"Y)/!%>,^-_CYJ5]\4_!5CH6F:\=7TS7+[2=:
M\)03VZ-=-_9SW$)WO(L3(04=6+COD!AB@#UGX%_#*W^%W@E[&*Q&FW%_>W&I
MW%FLWFK;--(66!6SC;&FU!CCY>.*IQ_L\^&XM;OKI;O4CI5YK:>(YM :2(V)
MU!2&$X!C\P9=5<J)-A9<[>3G@=+^-<GQ ^*/P[U;1I=:L]$U'0]>^W>'IRD4
MJ75I+!&4==VWS4<RJ#O*]P<<U:TG]J3PWH/PVTO4[?3O$>KV\/A=?$]RMW)%
M)>QV'F>7N=FD"R2Y#?*&QA3SRH8 Z+1_V9-%T+6=(U"S\3>(HUTF\U.]LK1I
M+5H86OMQG3FWW%078KEB1GDD  4M _9.T'PH?#SZ+XM\6Z3/I6F)HT\UI>P1
MMJEFCL\<5R!!M.TNX#Q"-P&.&K5OOVBM,TOQIH7AV]T'5;"?6;J&RMI+HP(6
MFEMVG7""0EXP%*-(FY0_R\X)')^"OV@)?%S>";SQ)I&H:%-JFO:O86ATV^1K
M/%H+D'[5DAF&R%B,*1N /'% 'JWPZ^&=G\-O^$A%EJ6H:@NMZK-J\POS$?*F
ME"AEC\N-/D^48#;C[UQGB3]E_0/$6JZQJ:>(?$>D:A?:Q'K]O<Z9=0QOIM\L
M(@:6 F%N'C4*R2^8A!.%&34$G[4^@P:?I^HRZ'K TW6-)N]9T2Y00'^TH;:/
MS)%4&0;',?[Q5?;E>X(*UN_"WXYV?Q/UNXTH>']5T"Z72;/6[<:D8"+FTN=X
MC=?*D?:0R,"K8/0XYX +&F?!:TTSQIHOB@^)-?O=5TS2[C2@UY+!(MRLTB22
M2R?N<[]\:D;"J#& H'%87AS]F31O"Z^%A:>)_$3_ /".6VHVMF96M"66];=,
M7Q;C)! VXP!CD&JVK?M.6&@^))M'U+0YK*>#Q1;^&)GFNHP(VN(A);W..IA<
M-@$<AN"!R1Q_BSXZZSH/Q8TO7(=+UK4?#O\ PB>KZA)H=C<P%9DMKJ!5NQYC
MHO,9<KSN(8<<T >GK\ /#K_!;3/AE=7>I7NC:;!;Q6E]++&M["T#J\$JNB*H
M=&12#LQQR#SFGJ7[.>C:M?6^I76O:Y)K2ZS9ZW/JF;43W4MJA2".0"#8(U!;
MY4522Q.<FLJ;]H+PS8^+[NX9->8S:'I-Y:0L\?V:Z%[.\=LL,>_Y9F<[69]H
MP!S@9K&^(_Q1\30^./AC)::'XBTR1_$%_IMYH'F0(-35+":1&1RX1XRRJRL6
M7H<C(Q0!ZI\4_A9I?Q9T&UT[4;S4-+N+&]BU&PU329A%=V5S'G9+&S*RYP6!
M#*RD,00:YR?]GG2I=3MM63Q)XB@UX:=-I5[JZW$#3ZE;R/O99P\+)PQ)4QJF
MW)"X'%-U+XZI=_LY:G\4] TB6X\C2+C48M,U"18G#Q!@\<C*6 VLC [2<XX/
M->8W_P ?M;\!_$G6]<UW3M8U'08?!FEZO>:7I\\+PZ<7N)UEG4.Z9^55)"[F
M..E '=:M^R?X6U"PU_3[75];T?3=7TS3M(:RL'MA';6]DQ: 1%X&8').XL6S
MGM4TW[+VA'6VOK;Q)XCL+-M?B\4?V3!-;&U&HK]Z8!X&=0YR60.$R20HK3/Q
M^TV?QO#H&G^']>U>V.I#2+C5["Q:6VM;CRP_[PCE8QD*S]%8C/&2.1^.?BJ^
MT'XZ_##2QK&OV6AZO9ZL;^TT..:=YFACB:%@D2.X(+MRHP<\YXH Z/1?V;-&
MT'4M'U"U\1>(!>Z7K6H:W#,TEMEGO23<0L!  8B3Q@!Q@?/5;0/V7="\+R:;
M=:7XD\16>K6/]H(NJ)):F>6"\G,\T$@-OY;()3N7Y-RD<-USPGPI_:;O[#X4
MZEK?B6*^\0&TUS5;*&:5;>TNK:UMLM&FH F-(;EE&U8R%9B4R 22.J\0_M<:
M+HD,]U!X4\0ZGIUOH%EXFN+V 6JI%87+,!)AYPQ9-IW(!GTR.: +6I?LE^%+
MS3-8TRTU;6]'TS4O#D'A=K.QDMMD-I$[NK(9(';S"9'RS%L[NE=QXV^%6F>.
M]-\/P7E]?VFH:!=Q7^FZO9O&MU!.BE-XW(T9W(SJRE"I#'CICR_X2?%J_O?B
MI\1_":7%SXGOK?Q*6C@FNE7^R].-I;L)&R.(S(SJJ@9))P,!B/4_&/Q*M_"_
MB#3/#UKIUSK?B+4K:XO+?3K1XT8P0[/,=FD95 S(B@9Y+#H,D '/2_L\:(T^
M@7$.L:Q:76E:]-XD>XA:WWW]]*CQN\^Z$@C9(0%C"  #'05:^*WP*TGXMW]K
M=ZAK.LZ3)#IU[I+KI<L*K/;72JLR,)8GP?D7#IM8<C."16!X'_:?TOXE^)=,
MTGPQX5U[4XKNPM]2FOF^RPQ6D$LLL+&0/,'W1R0NC*JELCY0PYK!^,7BV]T3
M]HKP7HSZSXCM- U'P]J=U<V6@0S7#R3PR6XB<)%&[# D<<#:<C.>* -G4OV4
MM"U73==LI_%7B8QZSI>G:3<N)+/<(K)BT+*?LW#$L=Q.0<\!>*T_!/@.?5?C
M!K'Q!U?PU<>'=0BL%T.W%S=PS/?(DKM]K9869%RI55SAP"X(48%<-\ OVC-1
M\2> M&M=46?Q9XQOKG53;64'V>"\%G:3[ ;Q<HD-P%>%6CP#O<95?F(Z70_V
MI],\7ZGHUGX8\(^(=?\ [2TI=9\V'[)"+> 3F"4.)9T(>.16#*,DX^7=UH Z
M[XC?!ZW^(OBGPEX@?Q)K6@W_ (9FFN+'^ROLI1GEB,3EQ/!+GY&( &/6LZ?X
M"6MUKVF^(9_%WB27Q5I\MP8==+V@G\F9$1[8QBW$)B_=H0/+W!EW;LDDXO@[
M]INW\;Z?X=FLO!NN6USXEA:YT2UO)K17O84CWS2?+,WEJF54[\$LZ[00212D
M_:UT>73K>_LM U":UN='U'5(1<2Q0R&:QDV75D020)T.2!G:0#AJ ':O^QYX
M1U"U^R66M>(=$L6T^UT^6UL+B I*+>Y:ZCE)EA=A)YS,S;2%8GYE/&-BR_9K
MTBRU&TO1XE\0RR6WBB7Q8JR/:$-=R1-$R-BW!\K:QX!#9/WJ2+]I+1YM%T[5
M(=.N;RTU.&Q-B;)Q,UQ<7433+   ""D:[V/8$8R>*J6_[3!OK_PWIEK\.O%\
MFLZW'>21Z?<P6]H\0M94CF+&>9 5Q(KJPX=>AR<4 =9\0/A!;?$#Q=X2\1R>
M(-9T6_\ #,L\UBNF_9C&SRQ&)RXF@D)^0D#!%8-[^S)X3U6QULZA=ZM?:_J]
M]:ZE<>)9IT_M!+BV8-;-&0@CC6+'RHL83ELJ=QSJ_$?XSK\/_%&E^'XO"^K^
M(-2U+3[S4;<:>]LB%;;9YB%I94PV)%(XP?7/%<SH7[4^E:_;K/#X2\2)'<^'
MH_$NFJ8H'DO[5G1&V*DK%&5I$SYFT8).< T 7==_9D\/ZY*FI?VYK^G^+$U0
M:NOBJQF@CU 3^0+<C'DF$H80$*&+:1SC/-0>,OV6?#_C5;Q;CQ'XFLUU#15T
M/4OLUW"6OX5D>57E:2%V$@>1VRA4'<001@5'8_M0:3J-CI]]!HURUA)XF_X1
M6^O1=0O!97)"^7(71F#Q.7159?XG4$#/':K\3HT^'VO^+Y-)NGL-*%Y(D-L\
M;RW<-N6!DCW%5PVQBNXC(QZT <IJ7[,VCZK+KDDWB?Q$'UC5].UJX*M9C;/9
M"(0A?]'X4^2FX').#@C-5=0_97T6[U>ZUJU\6>*=)\02:U/K<.KZ?<6T<]K)
M-$D4T* VY1H72*/*2(_*@@@U'I?[5V@W%O=R:GX?UK0Y5L-,U&R@NQ;L^H1W
M\ABMA%LE8*QD&TB0KC()P,XM:C^TK8:3J5QIM[X?O[/4=/UNRT75(IY8MME]
ML ^S7)=2P>%R0N1R&X*CK0 _Q3^S'HGBS_A(1=^)?$<8UW0(?#MWLGMW;[/'
M(\@D5I(&;S&:1\LQ(YX P,33_ FZT5M:N/"WC#7=*O=9U:TU2Z)FM_*5XDCC
MD(7[.2RR)$H9"0"?NE 35CX;?'FU^)EQ;V]AI$D5Q_:.H:?>1&Y1VLS:,%:1
MMO!5R\>W!Y$BGN<<'XE^-E]\+/CC\1)-5@UK7/"MEIVARM%;20F'2_M$T\3R
MA'="02(R0@9OE)[4 >O>.?A?IWCG6O#NM-?7^C:[H$LLEAJ>F-&)465-DL;+
M(CHR.N,AE/*@@@C-8G@CX :!\/O&-KXBTB_U-)H=,ETQK.5X6@F$MP;F69_W
M0<RM*S,2'"\X"@<53U#]H2RLOB&O@U= U%M7N6NX;%)7AB-U);P^<<(7WK&Z
M[@DA7:Q4]!@FKI/[3.BZEX)T[Q4^FW46F7&FK?SQHZR3VLKW MX[5D'69I=R
M8!P#&^3P"0#I-:\ 31?&+1?'FGH)I?[,ET+48-P4M;M*LL<JYX)C=6R.I60D
M9( .5X9^!NE?#BTTN?2I-3\02^'XKE-"T_4)X1'9&<_.$98T)X.W=(78+G&2
M3G?^'_Q-3QQ8ZU<7.@ZQX:;2;@P3#6+5H4E4('$L+GB2/!QD="&! Q7%2?M3
M:#!I^G:C+H>L#3=8TF[UG1+E! ?[2AMH_,D509!L<Q_O%5]N5[@@K0!T'@KX
M(Z3H?P5;X>:RJZM8WUO<IJI&56YDN7>2X8=P"\CX[@8K)U']F3P]KGAS4=+U
M?6]=U:YN])AT6/5KJ6W^UVMK%*)46,K"J$[U5BSHQ8J-V<5NZ%\7FU;X6:AX
MZN?"FLZ7I]O9'4H+.X>U:XO+;R%F$D828JN02-LC(V5.0.*X*[_:]L;+3=0O
MIO ?B98;+0K;Q,Y#V1SILV[,X_TCJNQLI]\\8'7 !N7G[,>DZA<:M<7/BOQ)
M-/J>M:=KUQ(SV>3<V:QK%C%M@*?*0L._."M1#]EC1(=#\4Z#;>*_%=KX:UV.
M[0:)'>PM:Z>;G=Y[6X:$L,[W(61G12Q*J#6E=_M"Z5:?$+3/"3:1?I=:K<-9
MV$\S11K<2"U-R&"%O,\DJK()=I&]2.V:L?#SXXP_$1=$2VT2XL[R]FOX+VRG
MG0S:8UI)Y4@F R,ERH !/WP>1D@ U=<^#F@>)M-\'6FKM=:@WA:YBN[*XD=4
MDD>.,QXEV*JLK*WS*  <#CM6#-^S7X67X:-X&TZZU/1M&;5EUG?9RQ-,)5N1
M<J@,D;@1AE10NWA%"@UP_B7XV7WPL^./Q$DU6#6M<\*V6G:'*T5M)"8=+^T3
M3Q/*$=T)!(C)"!F^4GM7;ZA^T)967Q#7P:N@:BVKW+7<-BDKPQ&ZDMX?..$+
M[UC==P20KM8J>@P2 1>*OV8?"?CS5;V_\376IZ[-<6U[9H;AX8WMX+D@O&DL
M422%5(!0.[!#@CD#'8?#[P%)\/='DM9?$NO^+IR% O-?N(I;C8HPD8\N.-..
M>2NYB<LQZUQ6D_M,Z+J7@G3O%3Z;=1:9<::M_/&CK)/:RO<"WCM60=9FEW)@
M' ,;Y/ )['X<_$<_$&VU=G\.ZUH%QIMT;9X=5M#"+CY RR0.>)$(;&1C# @@
M8H \E^"GP O)O EDGC3^V=,U*QU#69['3II;-TLC=SS@3QF)7W-Y,Q \QG"E
MV^7ICJI?V9='30/ UEIWBGQ/HNI^#K,Z=IVNZ=<VZ7DEJ556AF!@,,BL(TSF
M/(*@@@\UA^'OVCK"ST7PW!I?ACQ;X@N]?NM82TANKBT:=9+.:3SHY)'G"J/E
M.S!("@#.0 >B\7?'@6W[-=Y\5O#6EM?(='&J6MC?N(6 (!Q(1NY7/(!.<8!Y
MS0!S&E? Z?XAWWQ ;Q/INK>&M'U_2M-T>"&XO8)M00VCS/\ :/,C>5,EGC92
MQ))!W+V.Q-^RKH=Q>W>IR^*O%#^()M7M]=CUOS[47-O>16XM_,C M_+P\0VM
M&R,A!.%'&..N_CMJWP[^+?CB\\06&LZEX>M])T&XFM+2>&2'2&N)9XI) '="
MP)\LD(&;"D]J],L_CWIVI^.H/#UAX?U[4+234)]*?6[2Q:2S@N8@2XD8?=3<
MK)O/&\8. 02 85K^R;X8CFLS>ZYK^K6T%SJUS+:7LEJ8KHZBI6Z639 K;2"=
MH4KC/6IH_P!ES1)/ )\*7_BOQ;JT$#6[:9J-WJ*?;-)^SMN@^SND2C*$#YI%
M=F PQ8<5S7Q_\>:_8_$A/#\7]J6?AZT\*:AXAFN=$U);2[,D$D.&5BI!VJ7
MC<%&+_,"!Q:\?_M2R^'?"FMW6C>'9+W4K'0=+UV'[9<*D;PWLIB7=MYWH5)*
MC@\8// !ZG:_#>$> -2\*ZEKFM:XFI6\UO=ZK?W*"]E$B%&8-&B(A"] B*!C
MIUSYO;_LB:%"RN_C'Q5/+YFDR,\DEB-YTYRUKE5M0H'0-M R!V)).KK/[1=O
MX=N/$=MJ'AZZ2YT'4M)TZ[2&X1P3?E%B=#QD*9%W XZ'&>\$?[3M@;C6_-\(
M>((++3=7DT 7C_9F6XU!9$18(T29I#N#[PVW:%4Y(/RT 9?CGX&M_P (QKW@
MK3M.UCQ'I_C;6)=6U'6;J]M85T28O$_FH$$<IP4R@17(91N(!S7NFG:?;Z3I
M]K8VD8AM;:)88HUZ(B@!0/H *Y[X;^//^%B:!+J+:'J_AZ6&ZEM);/6;5H)-
MR'&],\/&PP5<<$'L00.JH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** $8%E(!*DCJ.HKR2']FW1X/ =AX3'B/7VL;+Q /$<=P6M?/-P+HW6PG[/M
M\OS6)QMW8XW5ZTY8*2H!;' )P":\9TK]IO3]3M_#TP\/:CC64UCRXXY8F=)-
M.9EF3EE!W;#M.1[[: ."^'GPI\>VGQ%O]5N+;6=!FO=3O)[Z:[MM"N+)K>:1
MMPM[F)?MI)01[?-4#*@,-J@5VUA^R5X8L]%TW29->\0WEA8^&;OPHD4\ML-]
MG<%2[,4@4^8"BX88''(/-0:'^UWX=U#2Y-1U/P_K>@6KZ#:^(;(W@MW:^M[B
M011I&(Y6Q(961-K[?O@],XP_#?QNU#PS\4?B?%XEM]8(%]I%EH^@M)'<,DLU
MK)(RQ>62 I",Y/4;3UXR >J^#_A]K'A+Q+;RGQ7JNJZ%;Z/'IRV6HR0L))D?
M(N-L<,81]N5.#ALCY5V\Y6J_L[^'M>A^(4&IZCJ][:^-IX;F]A,T<7V26*-$
MB>V>.-71E\J-@69OF4'UK'TC]IC^W?$.AZ%:?#KQ>NL:G;SW36MY!;VAMXX+
ME()7;SIDW*/,#@J#O4C;D\#J_&_Q?L_"&MW6C6NDWWB#5[/2GUN[L]/,2O%:
M*Q7=^\=0SL58*H/.PY(XR 9%K^S_  +>^%+^_P#&WBO6M3\.WLE]!>ZC/:R2
M3NT#0;90+<+M".V-BH23EBQYK-TO]E7PSI]GX>LKC6M<U33]%@U2U2TO7MO+
MN8M0)-PLNR!6(Y.W:5(]ZN^#?VBM/^(?C*WT3PUX;UG5;&2PL=4?6E:VCM8K
M6[CD>*4AYA(>8BI4(6!/3 S53XG_ !PTCX6>,O$$U_IWB.^DT;PL=9EM[*6$
MVDMN+C862-I%_>ANI('R\#=TH BB_97T?_A%;#1;KQEXQU)M)NK>[T34KS4(
M7NM(:#/E" ^2%8 ,5)F60LIPQ(Q61XP^ [P>$-8\#6%GK?BJR\9ZK)J>IZ]?
MWMI#_9%P6B8SJ(UB?=E-R")&PRC.T'->C_#GXKP_$'6/$NDOHFH^']3T&6!;
MBVU$PL7CFB\R*16BD=<,N>"000<BL5?VAM'72;KQ!+I&JQ^#(+:^NO\ A)1&
MCVNVT8K)N ;>NXJWEY7Y]IZ<9 .O\4?#K0?&'P_O?!>I6?F>'KNR^P/;1L4*
MQ!0J[6'*E< @CH0*X37/V9M%\2Z;<Q:GXD\07FIW"Z?$^M.]I]K\FSG\^"(8
MM_+V^9EF.S<V>6Z8I^*/VIM)\%6VK_VUX8URUO['3;;6$L4^SR27-G-,(1(A
M$NW*2,H="<C(QN!S2W/[4-E8FXMKGP9XBBU>#Q';^&I-,!LVD6>>$30/N$^S
M8Z,.0Q(/#8'- 'H/Q&^&^E_$_P ,QZ-JTMU"(;F"^MKZS=8[BVN87#Q31DJ5
M#*PS@J5/(((.*Y:7]G?1'UFUUY-9UF'Q/#J;:JVNH;;[1-,UM]F(=#"8MODX
M4 1C&,CDDGGX_P!K#2+K1//L_"GB._UR(7IN_#]G;I/=V_V2<P3#Y'9&)<$)
MM8AO45U&C?&^'Q1>HFA>&-<U2Q%Z--N+T0K$+2Y, F*S1NPD15W*CL5^5VQ@
MX) !%8?L]:!I&M^'=3TW4M6L)=$L[^TBBB>%DG:\=9+B:4O$S-(SJ&R"%SGY
M<<5XUXI_9WU[P[K/A?0]!M_%&J>'?#^AIING:I!%X?O26,S.XN8[Z-"F-L.&
M@4D@<\@5UW@']HA?%EM\/=8\4Z;J'AZ?64UBXA-C>H^GK#:AM_V@9#L51<K\
MN,@GC.*V=3_:MT+1='&IWWA[6HK:[\/3^)]*VB!FU&SA56DV#S0$D".C['(R
MK<$D%0 +;?LS6^I:W9^)-:\4ZXNNMJ5EKMW;V$ENMF=0@MQ 70-"T@1DR"F_
M R2H4\U?TO\ 9FT'2;[0IHM>UZ2UT76+[6;2PF>V: /=B430M^XW&/\ ?RD#
M=N^;EB  -SX:?&.V^(VNZUH[:%J>@:AIEO:7IBU$PMY]M<JQBE4Q2.!GRW!5
ML,,<CFN6;]I[3[3Q+::+J&B3:;<R^*)/"TQN+N,?9YQ")HI6'4QRHR[".[J#
MC/ !9LOV7/#-CX?M]$75M;ETVPL+W3=(AFE@?^R8+I=D@@8PY)"'8IE,FU>*
MWO GP2TWP!XF@UNTUK6+^XAT&T\.K#>M;F(V]N6,;G9"C>9EVR<X.?NBN-UW
MX[+9ZA_:$6AZP-57PCJ/B"SL9+V-=/N8(9(P"^"6$A!1E8IPCD=20."L?VC=
M=\,>,;_Q1X@TS5[_ $)O VD:Y>:5IMQ"\&GF6>82W"K(Z9!4*=J[FXQVH ]G
M\??L[>#?B1J^OZGK%M<F\UK2$T>YDMY_+VQI(9(Y4X^696/#]0 !1XJ^ 6B^
M*M8BOSJVK:6(?#MSX8CM;%K<0I:3[-Y&^%VWCRTP<X&.AKI_'/CF+P3X?AU4
MV%SJ,<T\4($&U4B#G_6RR.0L<2]6<GCW) KR;_AL+1[O1].O]*\'>(M8%YH=
M[KVRV:S4)#:3B&X4LTX!96R1C(88P3G@ T-1_9*\+:Q:RV]]KGB&Y1M#T_0X
MF%Q!$]NME(9;:XC>.%66=7.[=G:?[N.*WQ\!;66]\)W]YXN\3:EJGAV]FU".
M_O)K9Y;N62!H#YP\@*%$;$!8EC&>2"<YSS^T;8-J.IVJ:+= QZ'::]IADE13
MJT-PP1%A'.'#LJ,&Q@NG9LU4_:=U[6=!\+>";C2]4O-$NKSQ9I.G71LIMI>"
M>=4FB)Q@@@XW  CJ"* .FT'X':)H7P9N_AF;_4]0T&YM+JSDN+J2(77EW!<O
MAHXU7(,C8.WTSFN9UG]EC1M?LM:M[_Q;XGG.K^'8/#5U,7L@YMHG=U=<6V!(
M2[ G&W!X48KT/QQX\T_X?6.E&ZCFNKK4[Z+2]/LX2#)<W#YVKN<@ !59BQ/
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M=U<_M&Z/I.NWGA[6-'U+2O$T9L?LNE2&%VO1=R-' 8G5RGWT=7W$;=I/(P2
M4-,_97T/1O'/_"86?BCQ);^(CJ3ZB][&]F&E5X(X9+5P+;#0,L,3%3R&0,K*
M:[;QI\*]/\8^)M!\2+J.HZ'X@T5)X;74=,:+>89@HEA=98Y$9&*(>5R"H((K
MF9?CV]IKL&CW_A#5=+U";3]3ODBO7C3<+)D$@!!(*N)%9''!&<A:YK4/VP-)
ML=%DU2/P=XBO+2#PU9^*[J2 VF(;&X+?-\TX+,FQLJ!DXXSUH [3X?? /0/A
MEXJ_MK0[W4HE_LB+1_[/E>)K?RTEDF\S_5B0R-)-(S$O@ECQ5CQ9\&X/%/Q)
MT?QO'XGUS1=7TJPN-.MX]/%H8/*F9&D++-;R$L3$G.>,=.:PA^TMH]O-K]KJ
M6@:SI6IZ9<V-O%83)#++>_; 3;-%Y4CCYMCY#$%=IR*RIOVJ42:SLT^'7B\Z
MM<P:C.ME/;P6I(LR@E*M-*@96$BLCCA@<?>!4 &AH/[+'A?PM=:?J>CZMKFG
M>)+6]OK^7Q!'- ]W>27A4W(F#PM$RL4C.T1J%\M=NWG.IX7_ &>] \%^(+35
M=%U'5;$6NA/H$=FK0-#Y3RF9I3NB+F4R,6+%MI)/RUG_  ]^.US\2/B;#I&F
MZ,(_#-QX7L?$4&H33 3D7+2!5:/MCR\8!/))SBN]\>^-$\":(FHR:?<Z@KW$
M=OB JJ1;SCS)9&(6.)>K.3Q[D@4 <3I/[-VAZ'X<\":;8Z[KEO?>"Q)'I.M+
M);_;%BD79)%(/)\IT9< @Q_PJ001FM!OV?/![Z)X5TQ[6=X?#NJ-K%K(9<22
MW+F0RM*0/F$C2NS+@ G'  Q7.Z=^U=X8U?3O",]I977VGQ-#<2V-G<SP0O*T
M$_DRQ1LTFR64-DA$8DJI8=@>R^*_Q6MOA1I,-_=Z5>:A"ZS.\L+1Q0PK'&7(
M>61E56;&U%SEF...2 #G;G]F+PA_PKR+PCITVJZ';6NK-KECJ.FW8CO+&[,C
M.KQ.5*@*&,85E9=F%((K5TWX)VMCXN\+^))_$_B#4]5T&VN[99+Z6W<7GV@H
M97FQ",']VF!'Y:C& M<AXB_:UT;1+2[O;?PIXAU73[3P[9^*I[JW%JH2PN"V
M'"O.&+($;* 9],]:TC^TWI%O?ZOIE]X>UK3M:L[JSMK?3I4AEDO?M4<DD+Q^
M5(X VQ2E@2&4(>"< @'6>+_A/9>,?&>D>)IM8U2PO=+L+S3H8;,P>2R7(02,
MP>)F+#RUQA@!CD&O/[S]C[PU>Z%I.DR>*/% MM+\/IX<MV2:T5_LZ313*[$6
MV&</#'U&P@$%3DU-<?M2QQ)I,,?P\\7MJNHV>HW::?<6\%K(@LW59@?.E3((
M=61A\K*1@YXKE_C=^T:GB'X&^*K[P$-874+?PW;:Z^H6;Q0/IT=RI> -O;)<
MJK%E3.%!YR0" ;?B_P"!LND^"_%'A'2K/6_&47CR^DGU/4M1OK2%-)F:-%^U
MX58FX:-7"Q*Q#J,!5Z>M:AX!T^]^'5QX,BFN+#2Y=-;2A+:E?.CB,?EDJ75A
MNV]R#S7"S_M&Z1IVN)IG]BZ[J%A:W7]G:AKEG9-+:V4RPB1VE8<B-1PTF,*Q
MYXR1SWA/XJ:KXY_:&\*-;1ZMIOA/5_!UUJMK:W<L7DW/^D6PBG\M&)5]DAX;
MH''?( !J7G[)WA?4X'BO]:UZ]3^Q-/T2+?-;HT"V4IEMKA&2%2)E<[LY*GNN
M.*Z*^^ GA[6?#GB_2]8N=0UB?Q7'''JFJW#QQW<@B0+"4,4:(ACQN4J@PV3R
M37G,WQLO?AQ\:_B3!K$&M:WX:BO]!M(I(I(6@THW:>7G8SJQ5I'3(16/4GH*
M[(?M(:;/KDUI8^%_$FJZ:C7T(U>QL=]J9K7?YB,Y8! 3&ZJ[$*67!(R"0#J?
M!?P?\,_#_P 2ZUKFBVCVUYJ\-K!<*9,QA8(Q&A5>Q*A0Q_BV+GI7->.OV;]&
M\?ZEXPO+WQ!KUH?%%I8V=Y%9O:A(H[61I(O*WP,02S-N+%L@\8K%T_\ :JM=
M2\-Z3JD/@7Q-]HUBP.K:9IRI;RW%Y9K'$[2JL4K[/FE5 K[26[ <UQ6D_M)W
M?A'QS\1-8U;1?%FI>#$GT:8O/'%&?#\5S:QD^=;R.DJ@22#>J(Y7!)Z<@'I6
ME?LTZ-I'CFS\41>)?$<EQ::S=:Y#9RS6Q@6>YB,<ZG]QO9&!Z%R5P I5>*T+
MC]G/P9<>%/&GA[[-=Q:?XLOGU&]\FY*20SLP<- P_P!5MD'F*!T=F/>H_"?Q
MTC\5WHTY-"GL]8CU^?0KK3IKA#+;^5&96N&QP8V38RD'D2)W.!ZG0!RW@CP'
M_P (AH4VG7OB#6?%LL_$U_X@FCEGD7;M"$11QH !Z("<DDDDFN%L?V7/#-CX
M?M]$75M;ETVPL+W3=(AFE@?^R8+I=DJP,8<DA/D4RF0JO KV.B@#D8OAO:1?
M"M? ?]I:@VGKI/\ 8XOV,7VKR?*\K=GR_+W[>^S'M7!WW[*^A:AI6H:?+XF\
M1B"]\*0^#Y2KV@8649;:P/V;_6G>V6Z<_=%>U44 >*VW[,&CZ1XDMO$$'B3Q
M/<W-EJPUZ&Q:>T\M[H6OV9@28 VUX^"I?"G[FP5J_!SP$^G>(O%WCG4?#DOA
M36O%,\,DVDSW4=P]NL<2H68Q,T8>1@6;82" F3D&O5:* /)?'7[-^C>/]2\8
M7E[X@UZT/BBTL;.\BLWM0D4=K(TD7E;X&()9FW%BV0>,5%I7[-.C:1XYL_%$
M7B7Q')<6FLW6N0V<LUL8%GN8C'.I_<;V1@>A<E< *57BO7Z* /,+C]G/P9<>
M%/&GA[[-=Q:?XLOGU&]\FY*20SLP<- P_P!5MD'F*!T=F/>NH\!^")/!&C/9
M3^)-;\473G+ZGKLT4EPP PH_=QQQ@ >B DY+9))KIZ* /'M _9FT?PY/X;EM
M?$_B)WT&YU2ZM3*UH=[WY9I]^+<9 +MMQC'?=6Q9_ ?0[7X%M\*I-0U2[\/G
M36TO[7-)$+P1'.#N6-4W#/!V8XY!KTFB@#QCQ!^R]I'B>/Q*-0\6>)I9/$%A
M8:=>RA[,-LM)#)$R_P"C8#%F;=QCG "X%;GACX$Z=X0\;ZCX@TWQ'XBAL]0N
MVU&Y\/&[C_LU[QAA[@)Y?F*S'YB@D$98YV9KTNB@#S[Q9\%]*\9^-SXDU#4]
M4W/HEUX?DTV)H5M9+:X*F7.8C)N)1<$.,8Z5QB_LC>'I-'U6PO?%7BG4AJ&A
MVN@//<SVOF1V]M*9+=DV6ZJ'0GJ5(;'S!CDGW2B@#QOQ3^S#HWBW5=1OKKQ1
MXE@?4SITU_%;36RI=7%DZO!<-F D/\H#*I"$?P9 (L7?[-.@:AX5\2:'=:WK
MTJZUKI\2+?I<0PW6GWVY662V>.)0NUD4@.'[@Y!(KURB@##\'>%W\(Z(EC+K
M.I^(+C<7FU+5Y4>XG8X&6\M$1> !A$4<=,YK<HHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "O%;/]E;0=/U2UO+;Q/XEBBLIM3EL;,36IAM!?
M[OM"(#;EF7+%EWEBIXSCBO:J* /"YOV0/"5[HUII5_K7B"_L;7PW#X8B26>W
M1E@BE6:*8-' K"9)$1@P('R\J>:FU#]E'1=8?5KK4?&'BR]UN_GL;Q=:^TVL
M-W:W-HC)!/"8K=$#;'96#*RL&.5.:]NHH \XT'X)VNB>-]%\5R^)_$&K:MIN
MG7&FEM1EMW6Z6:1))'EVPJ0VZ-,",H@ P%Q5GQC\&]+\7>+4\2QZIJFA:R=-
MDT>XN-+DB'VJT=MWE2++&X^5LE64*P).#@XKOJ* //O ?P3T/X<>*K[6=$NK
MZ&&YTNRT==*8Q&TMX+4.(?+Q&)-V)&R6=LYK+^)O[.^C_%/6-;U#4=>URP?5
MM!/AV>'3WMA&ML9?-++YD#L'W=R2,=J]5HH XOP=\+;/P;XO\2>(X=6U/4+S
M7H[2.YBO#!Y2?9XS&A01Q(02"<Y)&>@%<II'[,/A?2K'Q!H[ZGKNH>$]8%V#
MX7N[Q6T^S^TEC.80J"0;B[D!W8(6.T+7K]% 'C6L_LNZ#XB\.7FEZIXC\0WU
MS<:=;Z0NK326INX;2&83+$A%OLY=5+,R,S;1EN*GU#]FO2-2\27>MR^)O$*W
M5UK]EXC=$:T$?VFUA$,:@?9\["JC(SDGH17KU% 'A\'[)VB:?JD6K:7XQ\6Z
M-K:7M]='4["ZMHY9([N;SI[9U^SE&B\P;ERN]3T<&NA\/_L_Z/X5\;WWB#2M
M=\0V=I?W"7MYH"WRMI]Q=)&J"X8,AEWD(I8"0*Q4%E)YKT^B@#QO0_V7O#NB
M2>&D&N:[>Z?X??4?LFG7;VS0-%>@B:%\0!F0!F"_,&YY9JC;]E7PS+X2/AV?
M6]>N;*#1;GP]ILL\UNTNF64X421P-Y/)VHB!I1(P51SU)]HHH X/P7\(;'P3
MXOU+Q%!K&JW]Y?Z99:7+#>F#RA':AQ&RB.)&WGS'R<D'/ %97CC]F[P5\0M5
M\2:CJUK=&[U^TM;2ZD@G,>S[/)YD<L?'R29" OU(C0=J]1HH \]\2_!+1?%/
MBN/6[F^U&%4T"Z\.?V=;M$ML;6<KO/,9<.-BX(< 8Z5QMQ^R3H5YHNJZ9<^+
MO%-Q#J7ANW\+32/)9;Q9PNS1E2+4 /\ .03C&.V>:]THH XGQY\++3Q_HFA6
M%SK.JZ;/HM];ZC:W]@T(F\Z($*762)XV!#'(*8S@C! (X/2/V2O#^B0"&V\4
M>)C$NE:GHR)++:/M@OIO.FP3;YW!ONDDX'4-7N5% 'B%I\(?M_CWP+9W6@WR
M:-\/+81Z=XBO[RW+ZH#"B+'Y<)!PC(KMYB(-\494'DCM?BU\)K3XO:3I-A>Z
MUJNB+IFJ6VKPS:2;<.9X'WQ[O.AD!4,,X &:[JB@#R_7O@-:^+(,Z[XL\1ZM
M?P7EK?Z=J,KVD4VF3P%BCP"*W2/G>P;S$?<#@\8%9FL?LO>'=7NXK[^W->L]
M5:XO;F]U"VEMQ+?M=0K!,)5:$H/W<:*IC5&4+P1DY]CHH \('[(7AX>'=6T8
M^*_%#6NI:3INC2NTEF76"Q8M 5/V;AN2&)!!'0"N^^*_PGL_B[X6L]"U'6=5
MTR"VOK74!<:88!*\MO*LL>[S(G7&]%) 49Z=*[FB@#RC7OV;/"WC2[UB\\77
M6I^+K[4=,DT=;G4Y8T-G:N0SK;K#'&D;,RJQ?:7)5?FP *JZ[^S#X<\4Z;=)
MK6M:]J6MRQV4<'B)[B&+4+/[)(9+=H6BB5 RNS,24.XL=V1Q7L-% 'DVK?LZ
MZ=K1T6XN?%GB=M7TZ&[MI=7^TVYN;Z&Y5%FCFS 452(X\>4D97:-I'.<8_LD
M>'3X?U#1AXG\2BSO?"T'A%_WEH66RA+%&4FV_P!9\[ L<C!Z9YKW*B@#QSQ#
M^R_X>\47.OW5_K_B%KO5H]."W,%Q!#+8S6)8VUQ;LD(*R LQ.[<IR1MQQ5QO
MV>[2XU72-4O?&/BC4=4T^POM/^V7<UJ[W"W019'D'V<*& B3:(PB#;]TY.?5
MZ* /&-._9KL_">G1'PYXI\1V6I6OAB/PO#<"YMHVDABWF"5V^S-ME0R-AE4+
MSRC8%=1XI^%!\=>$O"^FZQXAU2#5=#N;74$U?3C"DLMU"A7>R21O&P8LQ*E.
M"01@@$=_10!XE_PR?X:E\$Q^$+O7M?U'PVK3.VGWKVLJLTEP;C=N-ON1U=F"
MNA5P&/S$X(ZWXE_!C3?B=?:+=W6L:OI$VE175O&=,EB EBN(A'*CB6.0<J.&
M7:XYPPR<^@44 >'2?LF>'Y=!U'27\4>)FM;[PM!X1E8R6>\6<18HP/V;_6?.
MP)Y&/X1BK7B/]EG0/%&J:IJ=WXD\20ZI>?V=)!?6EQ;PS6$UDKK!/ 5@&'Q+
M(&#[U8.1MQQ7L]% 'EEQ\ +*]U71=3NO%GB6[U+3-.OM.^U3RVSO<B[">;))
MF# <>6FT($1<?=Q7*R_L:^%_^$>FT:U\3^*-/L[S0+?PYJ7V:>USJ5M I6!I
M@UN0)$4D!XPA(X.:]]HH \FLOV<-$L/$NK:E%X@\1C3=9(DU7P]]LC&G7\_E
M"(SR((PZNRJNX1NJ,0,J:3X>_LY:5\.?$.@ZK:>)_$>IC0M,FT;3K/4YK:2*
M"SD=&\G*P+(P4Q(%9G+8&"37K5% 'DGBS]F[1O&&J>*[ZY\0Z];/XCN]-O+J
M*V:U"1/8NKP"/= Q )4;MQ8GL14FC?L[Z7X=U/7Y=-\4>)K32=7DN;EM!6[B
M:QMKF<-YL\2M$7!8N[;&=HPS$A,XKU>B@#QV7]F71TT#P+9:=XI\3Z+J?@ZS
M.G:=KNGW-NEX]J556AF!@,,B,(TSF/(*@@@\U?N_V=O#M]J6L3S:CK$MAK(L
MAJFERW$<D%\;556(R,T9EY"+N"R -CD<G/J=% 'DOP\\!S7_ ,3O$_Q$U7PS
M/X3U;4+6+28[2:\BG>2.)FS<D1.\:LX\I1SNVQ*&QT'I'AS1Y/#^AV6G2ZG>
MZS);1[#?ZDZ-<3?[3E%52?HHK2HH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRO\ P[K6EZW8:A:Z?%I4RPRS737$)FA=#%(Z[3&CDY.5V'C. 0#V2BO(=/\
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M<GEF4=\CRZ^_;'T*#2SJEIX2\1ZAI<?A^R\3W%W$+55AL;AF4.0TX)9-C;E
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M&T$6OOXE@TV&:W^RPWKPM%*RAH"Y5U8DJSL >5VY.<D?M!Z;X=U_5;"W\/\
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M1L]KL-W)$T31G_1\^5M8X&=W^U6>W[*'AN?P<OA*[U_7]0\+JTI72KMK22)
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MG;F QC:  !BJ7[1'BK6/#FF_#G4-(EU&WEN?%FG6UQ863HCW44F_= VXA><
M<L!ZG%5XOVIM(N]!M[BT\,Z]=Z[(^H1R>'[>&.6ZB:RF$-P"4=D/SE0I#$,6
M'3D@ O:7^S1H^BV7B33+'Q3XHM_#^LI>!-#%Y"UII[7.[SGMPT)89WN0LC.B
MEB5453OOV4O#NIZ=?65UXA\0RPW?AVR\-$^9:JT<%K(9(95(MQ^]#'))RI_N
MT2_M1Z9#JNI02>$/$UO8:5I-MK>IW]Y#!;BQM9XI9$,D3S"7>#"4,80L&/3'
M-5-:_:"LM0MX8M1\+^-- $>NZ59QW*0BVCG-S,%B/FE@'C#?+*BY89Z$$-0!
MHVG[,.D6OB^U\1-XL\3W%U;ZT-?$,TUJ8FNS;?9I"V+<,5>,\KNPI^YL'%16
M/[*/ABUM]!LI]9UW4=)T4:E';Z9=R6S0/!?*RS0/M@#E &8*0P89Y9JETC]I
MC3]4\96VA/X5UVQMY_$-SX8&J7'V8P"^AB:7:529GVLJ-A@N.@."2!K_ !@^
M/.E_!C9+J^E:A<6(@%S+>0F)(U4RK'L0R.OF2C=O\M>=JD^@(!B:A^RMX=U?
MPC<:!?Z_XAO4;1#X=M;^>6V:YLK$LK-%$WD;23Y<8+R*[$(.>I.J_P"S]8MK
MNO:J/%.OK-K9M/MT)%D\,J6\#PK&T;6Q5D=9#N5LY(!&W%8VI?M166G:_>:<
M/!GB.XAM/$4?AB6[B-IL^V21))"%!G#%7\Q0&P ,C=MYQ-;_ +3VE76BPRQ>
M&];?Q!)>W^GGP^D<<ERDMFP6?+1NR%060 ACDNO3D@ WOAQ\(W^%^JV5GHNL
MWR^#K#2$TZVT.XEC>)91*7\Y0(E*'#,IPQ4@J J!!EWC_P" 'A#XE:UJ.JZW
M:SR7=_HDN@S&*78I@=BP<#'^M0L^Q^J[V]:XJ]_:]TNQ^V22>!O%L%KI]IIM
M_J,MY;06SV4%Z[1HTD4DPDW(RD,H4MP2 1@FC\5OC-=ZKK_@V+PNVJ6VDVWC
MVUT'4M4@EB2WN&&[SX&4MO9 ?E)  W*1R.: .J\>?LQ>'/'EI9VKZSKNC6EO
MH$WAIH--GAVS6<FS<&\V*0A\HIWH5)QAMPXJ:;]G'2;FP\>6LWB7Q!*OC+3(
M-+U!V>UW1QQ0F$/%BWX<HQSNW#)X XK.A_:K\.?9[S4[C0_$-MX9BTZ;4X?$
M#:>QLYTC<+L#C[KN6!C5L;P>H((IOPK\8^(/$'Q_^(^GZM'J6G6%KI.D7-KI
M5]/%(D#2_:=[)Y9(&[8H.3G*GJ,$@$_CG]EW0_'T2QWWB;Q):JV@IX>N/LDU
ML/M-NCB1&;= P60. <Q[ V &5@ *E'[,^D?;);E_%'B*267Q-;^*W+/:<W<,
M2Q*O_'O_ *LJBY'7/\0KI_BO\5K;X4:3#?W>E7FH0NLSO+"T<4,*QQER'ED9
M55FQM1<Y9CCCDCBK[]JS1;6\'D^&=>N]+CT"T\376J)]E2&VT^<.5D96F#L5
M\L@HJELGY0PYH T-+_9FT+2;_0IHM?UZ2UT76+[6;2PEDMF@#W8E$T3?N-QC
M_?RD?-N^;EB  %\*?LX67@K0I-%TKQMXOCTB,JNG64U[!-%ID(D#F"$/ =\9
M"A,3>:0F54J":Z3X<_%/_A85_K%FWAK7?#\NGB)UEU6S,<-RDBDJ8I/NL5P0
MR]5..H()\A^#WQ]ET"6YT;Q<FLWD%WXF\06=IXBNY(I($6TEFD$# /Y@"PQ-
M@[-ORXS0!Z1X$^"H^&6MZ1%X:UB]LO"UI%>M<Z,S1"WN)[B8R^8(DA4(58MC
M8RJ!\H3DFI[[X%:5<?$J\\96FN:]I$^I" :KI5A=HECJ;0C$3S*4+A@,*3&Z
M;@ &W#BN0OOVM=-T_29]3D\#^+FT[98S6MV+%%AN8[J=88]LCNJAPSH2F=VU
M@1D9QJR_M'10:G%IDW@?Q3_:$5S;VFJ6UG:QWCZ9).1L\PP.ZL K([%&.U7!
MYPP !I^&_P!GGPWX7U&PDMKO4I]+TW5;C6M-T2XDB:TL;N;?O>+$8DQF64A6
M=E4N< 8&)Y_V?/!ESI?C_3I+*=K/QO,T^JQB<KAB@4F$C!C^8&3C^-F;O7E7
MP?\ C_J>B1)H?B+2/$&L'4O%.M:/I?B*YF@>VFN(KFX,-HQ\SS$S'$55FC"9
M7&:]2^&OQMM_B;#X>>QTB>V?4K:ZN+N":93+IC03"%HI@/X_,RN 3RC<X&:
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MQ)X@6Y/B;_A*O*#6GE"Z^S?9MF/L^?*\OMG=GG=74> /A5IOP^\$7?A:WO\
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M=:_#_P 4MX@_X2GQ#XAU%M)@T4MK,ELP^S0N[Q9\J",E@78;B23WR>:]+HH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPNH?M :9X1\5>)+0:%XIU:]_X2>S\/-;>=;O&MQ/:I)$8 TP"1,I&<X.XDD
M<T >YT5XOI_[1EAXPT>VLM+T35X_%%]_:<!T??;I<69LI/*N':0R&/ <H%(9
MMQ=>VXCA?A)^TO<:+\%=)G\0V6HZWJ^G^!D\6W=[).ADNH@[)(I)Z2Y4G^Z>
M.1V /J*BO-['XV6NLZL;72/#^K:O:6]Y;V&H7MFL;)8S30K,-ZEPQ1%D3>P!
M"[QUPV(/ 7QYT_XA^);;3M.\/:^FF7MK+=V6O2V+?89E1PI!D'W&;(9 WWES
MT((H ]/HKY;^,7QK\5W&F_$6TL;:?04\)^)=$L+>\TZ[!FNTFFM6D1@0,!TG
M(QGV)KT"']IG2I(+JV?P[K,'B.#5[C1?[!9(I)VFBA6=FW1.Z;/+=#D$\L!B
M@#V2BO)/B%X_NM?_ &9?$_C'28-:\*Z@- N]0MH=0@:TOK*:.)V4/&>A#+T.
M58>H->3^ _C5K%E\1OAIIL>J^(=0TW6?"MQJ6KVNOV#Q&[N8X(Y$&GM+&CS3
M$E]T<99-A!P#@D ^LZ*\(/[7&@IHNOWS^'=8DN-%N=,M[JRMGMI9%^W.$AR1
M+@,K$JZ9W*P(P1S7+?$?]HR(7'@_59I]4\#6^C>.&T/Q!87\T0#J+&68*YB9
MU=6S"RA6)R<8S0!]045Q&L^.]7TCX3ZSXMG\.-::C8Z=/?IH]S=+O(2,N%=U
M!"D@<XSCZ\5Q.G?M)JG@^VOKWP[>7^L6GANW\2ZU9Z5)$XL[656(9=[KO9A'
M(P09.$.3G 8 ]MHKA_$GQ>T/0/"&A>(8O/U6VUYX(]*ALHRTEVTL9D3 [#8K
M,3V /!/%>>7O[6EO:1*O_"NO&/V\:3?:Q+97-O;VLD<-I*L<Q_?3)N'S!E(X
M=2,9)( ![W17@T?[4$<?B_7H[G1G_P"$7M-*T>^L;J!]]U>2Z@SK#&(N,$D*
MN,\8))YP+=Q^TZ(1I%LGP[\72:SJFIW6DVVGR6\%L99H8&GW(\\L:M&Z*=KC
MC((;:1B@#VZBO/?B'XUMO#^L_#VWOK76H9M:U<6L"V$\:1I-]GED\NY^?YDP
MC<+N&Y5.<<UY[)^UY;7.DRW5GX*UN!IK/6)=.DU*6VCAN9].+B>%C'+(R<(2
M&*X.#@F@#Z$HKQ+3OVDU3P?;7U[X=O+_ %BT\-V_B76K/2I(G%G:RJQ#+O==
M[,(Y&"#)PAR<X#;7Q3^,L_A;X?\ A?Q-X7L(?$%OKVIZ9:0-+-Y*^3=RHHD&
M1DG:XP.,$Y/3! /4Z*^;? 7QNU#PQ\1?&&C>(;76M5T^\\<KH=CJ+2PR0:>\
MME!)' 075]I<ORJ$#<,GFM71_P!I7PYHMG#!]GUI[[4M9U:SMK76[VW266>U
MGV2012-)L+$G]U$&R54],4 >^T5B>,O%EEX(\(ZKXAU)A%9Z=;/<R;B!G:,A
M<GN3@#W->(? C]H/4-4\!_$/_A+I[;7_ !/X(N9Y[X:"\3K<VCH;FW:++!#B
M,F/EAS"<G- 'T517S_=_M>V-EINH7TW@/Q,L-EH5MXF<A[(YTV;=F<?Z1U78
MV4^^>,#KCJ3^T-IESXMAT;2_#GB'7+9K\:7-JFG6)EM[>X,8DQ(<_*@R%9SP
MK$9XRP /5Z*\'\/?M?>&]5M+;4-4T#6_#6C76D7^LV^HZD+=DDBLY EPFV*5
MV##<N,C#<X)XSR^H?M!:IX*^*7C?7==TGQ"OANQ\+:5J$.AB:VD9&GNIHC*B
MB0*#C8'!8D;3C<,9 /J"BO$9OVHK2QU:_L=1\%>(M/\ [,UNST349Y7LVCM'
MN_+^S2'9.2ZOYR9V!BO.1P,SO^T_I3O?3VGA3Q-J6C6]G?7<6KVEB#;3?9-W
MF)YC,JH6VML+D!MI&0< @'L]%?.7B?\ :YEMO WB'4]*\&ZA:ZO8:5INLVMM
MK$T*1W-I>R^5'*#$[D;6#91MK=.F>/H:REFGLX9+B'[-.Z O"'W[&QR-PZX]
M: )Z*^'?%WQI\3^#_#OQ@U&S\2^)3KGA[QDVG:0\UH\^DV]MBW.R[F>(PI"/
M,DW.SAU!&&SBOH;4_P!I#0=)-U</97=YH6GZM;Z%J.N69C>VMKR81[1@OO:,
M--&K. <%QU 8@ ]<HKPB7]JZ"/3KG4A\/O%+Z7%KO_".+=*]CB2]^U_9=@7[
M3NQOP=V-N#UX.-*^_:9TS1].U+4-3\-ZO8V6B7-K9>()&>VD.D3SB,A) DK>
M8$$L9=HRP <8W8; ![+17B1_:?TZV\26>C:AHLVG7$WB=_"TS7%W&!;S"$31
M2L.ICE1EV$=W4'&>)=3_ &F;+3;:(Q^$O$&L7@M8M0N++1;;[7-#:RRND,@5
M>6+B-I @YVCUP" >T45YS\./C&?B7X@UVPL_">M:?8:/>W&G7&JW[6RPFYA9
M 8PBS-)R'W [,8!!(/%>9?"_XYW7ASQ7X@T+Q-'K.I65[XYU/1K#7+B2%X+7
MRX?.CMR-XD"A(Y,$(5''/)P ?2=%>$W?[6ND6GAS6/$'_"'>*Y]#LM'.MP:C
M'8*(+NW# 861V55DPRN$8Y*G(R05%[5OVEH]%,D$_@/Q5+JEM%'=W>EV-M%>
M7,%M)*Z12[8)'#%PC.$!W!5.0#A2 >T45\Q?#'X_:AX;U76=*\1:9XAU?3[[
MQQJ.A:=XBN)(&MH)2_\ HUJXWB5 <;0WE[02 3R<>G?#SXXP_$1=$2VT2XL[
MR]FOX+VRGG0S:8UI)Y4@F R,ERH !/WP>1D@ ]/HKR7Q1^T18>%/&GB/0KGP
MSK4MIX<L8=2U76(VMA;6]M(DS+( 9A(_,)7:J%LD<8YK+OOVHK;2[6:6\\!>
M+H9!J5CIL"M91QI<M=MMB:.221$;#?*X!RI(S\IW4 >W45X-#^UE:74UIIL'
M@+Q/+XHEUBZT&70=UDLUO>0VQN=K2-<",J\6&5U8K@\D'BM";]J/1X9[B0>%
MO%%SH]NE]YNK6>G&>".6T5S-&S(2%YC=%;.UF7&1E20#VFBO&U_::T6ZT+3K
M[3=*N]<GU0S-IL&C30WBWL44:/)+')&Q7:#(J<X._@@#FL>]_:]TNQ^V22>!
MO%L%KI]IIM_J,MY;06SV4%Z[1HTD4DPDW(RD,H4MP2 1@D ]\HKPA/VFQH=Q
MXXG\4Z5!H^D:)XFC\.VEZ;Q%B9GAB=7GD?"Q*3)]X\#<J\GD^DZE\0ETSX>Q
M^*I-%U"57BBE_LZ 1R3+O8+EF5R@5=VYGW;0H+9P* .NHKQ"S_:ITK5K+0'T
MKPQK.L7FLZO?Z'!;V,MHRBZM$D9QYK3*I1A&2K@X(ZX/%9'BK]I.T\9_"74K
MCPC8ZRNNW7A:[USRH'@BN-+C0R1;G9GV[_-C< *6SY;'(X) /H:BO(U^*TW@
M']GOPGXRU6TN=;4Z;IKZC.LH#QK,D:O<.6ZJI?<V.<9/.*=X=_:"M/$NN:QH
M]KHTTFI:5KKZ)<VT5RDCX2#SS<*%',97  ^\6^7 /% 'K5%>!R_M@:#;6.LR
MR^&M;-WI?]F--80M;/,BWTQAB#CSALD5U*R1GYE..O.->V_:)O)O$NJ:%)\,
M_%D>HZ18PZCJ4,;6,S6\4JSF/:([EC*Q,!4+'N.6'&,F@#V6BO#%_:ST-M*U
M&Z3P]JUW<V&MV&ASVMC+:S$37@C,+!_."D?O K#.58$$8&:@/[3%]JNM^#[#
M2_"5Q;RZCXBO_#^K6VI7$8GLI;6"25@GE,Z/D*K AL8XZG@ ]ZHKS_X2?&72
MOC)IUSJ&B0,=/B"8G^T0R?.2P:&148M%,FWYXW (W#K7'>!OVC;K7K9HM4\/
M>3K5]XCU'0M(TVRND<W M&D\QW=MH4*L1)/JP !H ]QHKS2V^-EKKWP>\1^-
M]#TR>6YT6*^6?2+]EAEBNK4NLL$C*6489#\RE@1@C.:\<E_:$\0^&_&=AXJU
M?2]6O]'E^',?B&_T+2[B%H;8B=3)<*)'0$^7G@$MV ZT ?5U%>47'[1&DMXH
MM])TS0-?UVW-[;Z?=:CIEBTT5G+-&DB&0#G8JR1EV_AW#J Q'-_M">*;_P .
M?%7X0V4.KZW8:1K-[J%MJ5MHR2RR7"1VC21X2)&?(< Y49QUXH ][HKYB^$G
M[1NI0>#O%-[KBZAK\.G^*+S2K%KU(;.]M+2.(2)_:(;RU@<X94WJK/NBR,L3
M6Y??MCZ%!I9U2T\)>(]0TN/P_9>)[B[B%JJPV-PS*'(:<$LFQMR@$G'RY'-
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MDJ.:Y;Q7^S_I/BKQUJ_BD:]K6D7>K: _AR]M=.-LMO/;$L0[!X'8R*7;:V[
MR1@@D5ZC10!XK??LKZ%J&E:AI\OB;Q&(+WPI#X/E*O:!A91EMK _9O\ 6G>V
M6Z<_=%:OAW]GK3?"GBV[UO2O%/B:T@O7CN+W1DNX18W5TD:QBY9/*W+(0B%@
MC+&Q4;D->JT4 >&V_P"R'X3_ +%T71[[6=>U;2M,TS4M)%I=RVP6X@OG#SB0
MQP*VX$#:4*XQWIE_^R3I&KV&J6VH^-_%^H/J.DVNB2W-Q+8F46UO.9H@"+4
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M#QS1OV9-'T/5]*U&'Q3XDEN-.UR\\0Q^=):,KW5U$T<VX?9_N$2.0!@@MUP
M!EV/[('AO2M-M+73_%'B>PFBTNZT2XO()K3S;ZRGE>5H9@UN4(5Y'*LJJZ[B
M-Q%>[T4 <K:_#C2HOAE'X$NFGU/1%TO^R'-V5,LMOY?EX8JJC.WN *YOPW^S
MMX/\*7TU[I\5['>3:!'X=EG:Z)=X%+'S2W4S'><R=3@5Z=10!X!%^QKX>CT[
M[&?&7BUT^Q:98;VEL=WE6$YGM1@6H7*L<$X^8=<GYJ[/7O@+I'B35_'-_>ZU
MK1/B_1XM%OX(I88TBAC$@5X2L0=7_?/DLS YZ8XKTRB@#Q!/V4=%S=O+XO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,W#Y#R[.,D<MC>P!] T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4V2-)49'4.C#!5AD$4ZB@!C01O
M"8FC5HB-I0@%<>F*5$6-%55"JHP% P *=10 UT65&1U#HPP589!%(8(R$!C4
MA""@P/EQTQZ4^B@!OEIYADV+YA&W=CG'IFDCB2($(BH"2Q"C&2>II]% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
7!1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ctso-20221231xex10d30g002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ctso-20221231xex10d30g002.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1, U$# 2(  A$! Q$!_\0
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MBB@ HHHH **8TJ)(B,ZJ[YVJ3R<=<"GT %%%% !1110 4444 %%%% !1110
M4444 %%%% !13)94A7=(ZQKD#+' S3Z "BBB@ HIDLJ0(7D=8T'5F. *?0 4
M44C,%!)( '))[4 +138Y%E171@Z,,AE.013J "BBB@ HHHH **** "BBB@ H
MHHH ***9%*DR[HW61<D94Y&: 'T444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&-1X-IYSYVD9,>#_ *K;@ 8K[YF@CN8S'+&DJ'JKJ"/R-24 >)W?CGQ)X?\
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M_:'^(H^$NH^.['4O U]I]UH]EJ>G0V[S3SQ227$<<L;QJRC8%D #%MRNI!#
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M#X=L_$\-Y;6FL#PWK=[8ZAJFB::7FBMDM8)XKC["UQO>-&GVR^6[.%"D#DD
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MWW[3?B+4K_4]-U6;4? ^D7@N--MO)1E:XN3_ 'WW#^ZQ.=N <]: /7K[X/>
MM4TJ\TR\\$>'+O3;V[^WW5G/I-N\,]S_ ,]G0IAI/]L@GWK7UKP?H/B30?[#
MU?1-.U31=J+_ &;>VD<UMA<;1Y; K@8&..,"O#Y_V@]9E@\7Z_:7>C?8_"^J
MZGIEUX6FC?\ M&X%M"[QF-@W^MD*!P"FWRV[D9/->,OVC_'7A;PK/J5G+H6L
M"_\  K^+[&\CLI/)M)4:(-"X$WSQN)AL;((*-G=T !]%ZM\._"NO:II6J:CX
M9T;4-3TC_D&WMWI\4LUECIY+LNZ/_@)%<=\)/@1IGPXLM9.IPZ-KFJ:CJ>H7
M[ZE'I*P2^7=3-*T+%G=F4;MOWL$ <5Y9XI^.'Q+\)WWC;S=0\.7EMX8NM#N&
M5=(FC>ZM[^14:'/VDA&3YB),-G(RHP<SV/QO^)!\2VUU<2>'M1\/'Q_/X+N-
M*MM-FCNFAW$)<K*9V&Y  60H05#'(X  /:H/AS\.O$_@FVT"'POX7U;PA!(3
M!I<>GVTUA&ZL0=L04QA@V[H,@YK7M_ 'ABTU==5@\.:1#JB!%6^CL8EG 1-B
M .%W?*GRCG@<#BOE/X6?$W6_"O@OPUX*\+S:)I&IZS?>)[JUO-<8I;E[?4I
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M_P!)Z'R^).HR?EZ8 /J3Q%X/T'Q?I::9KNB:=K6FHZ2I9ZC:1W$*NGW&"."
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M\>*M6UZ));.7P[X=U2+1=1M(Y/L<CBYF0 L,J\;Y(8 '//&*-2^+-[X6U_\
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MHD7C^\TPV-XO@34M.T^XTRXMC]HU9)U@+RHRN!&6\XB,!2,QG.<X4 ]S\3^
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M3HM[ ("7@^V EO-D:1<28*.@C5P%!WX+#'-Z1^T3X\L-7TV_UDZ-J6B7&O\
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M;KX?^%[Z\O;NY\-Z1<7=[:#3[J>6PB9[BV'2"1BN6C']PY'M7SK\2/CUX_\
MAMX<:\EU?P[K6I6^C1>()[.TTN2$QPRSQQHDN^X("8,BAT8NS8/EA5.;^O\
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M+PK)&%^Z&#,H(P#DCFM73_!_@I_&5WK]CHF@MXLM8UL[C5+>T@-]$A4%8GE
MWJ-NTA2>F.,5\O>*O%7C'X4_$OXE>)[6\TB75=.T'PS+K$<]@S+?%[BXCD5"
MDB^7P[88A^B\=:[6_P#CSJF@?%#Q!X:N/[%TE+OQA:Z#!K7V0HL22:8+E3-F
M3$DS,!$I) Y'RG&" >T:[X,\"^(_$,\>LZ%X>U37+RP:WE6_LX)KF>SW#=&P
M8%FBW$9!^7)J9OA=X,?6=/U=O".A-JNGV_V2SOSIL)GMH<8\J.3;N1,$C:I
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M9=B&96#LNXG:C;<=1M+\7O'>G>,;;POJ]]I1U7Q7IMC=^&KC28?.LQ*& U!
M[ &58E(E4D*3&WJ": /:-?\ AOX<US5AKSZ!HK^*8+9[>SURZTZ.6ZM@RD86
M3 <+R?E##/-<W\&?@7HOPI^&NF>%Y[+1]5NH=/73K[48-*2W_M", @B5"7+
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MOB#\4=&^(W_"/W&M^';ZVM/#;^*+AK;0)EFN$6Y*FU0&[(#&/"B3G#<[#G
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M02B"W/6%-R';&?[HX]JSM8\!_"_2[J*+5?#OA&SN=4O(98TO+*U1[NZB $3
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M5]7\-ZKI_@*SM+F<6^ASV[7WVB!FW$_:G\E8VVLQ ?*J1A>M 'T'X5\!>&?
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MXR<<\9-/T+P;H'A>ZU"YT;0]-TFYU&8W%[-8VD<+W4IX+R%0"[<#ELFMBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $(# @@$'@@UQ]A
M\&O &EW@N[+P-X;L[L7!O//@TBW23SR<F7<$SO)YW=?>NQHH P=4\ >&-<\1
MZ?X@U'PYI&H:]IPQ9:I=6,4EU;#TCE92R=3]TCK6=)\'O 4MK-;/X(\./;37
MG]HRPMI-N4DNO^>[#9@R<GYS\W/6NOHH Y&;X/\ @.YLK"SE\$^');/3VE:S
MMWTF QVQD_UIC4IA"^3NQC/?-/;X3>!V6Y4^#/#Y6YLETV<'2X,2VB_=MV^3
MYHAV0_*/2NKHH Q-4\#^'-<TJQTO4?#^EZAIMB\<MI9W5E')#;O'_JVC1E(4
MK@;2 ,=JRI_@YX!N3F;P/X;E/VM[_+Z3;M_I+C#S<I_K&'!?J1U-=A10!S&F
M_"_P;HUU:7.G^$M"L;FTCCBMIK;388WA1,[%0JH*A=QP!TR<=:O>(?!?A[Q:
M]J^NZ#IFM/:EC;MJ%G'.82PPQ3>#MR.N.M;-% &#?> ?#&J>(]/\07GAS2;O
M7M/3R[/5)[&)[JV7^['*5W(.3PI%1Z?\.?">D7^L7UCX8T:RO=9!&IW-OI\4
M<E\#G/GL%!DSD_>SUKHJ* .)C^!WPXAL391_#_PLEF5C7[.NBVPCQ&Q>,;=F
M,*Q+#T)R.:V[7P/X<L=1U34+;0-+M[_5(UBO[J*RC66[11M596"YD ' #$X%
M;=% '(VWP@\"6?A:;PU;^"?#L'AR:7SY='CTJ!;.23(.]H0FPMD Y(SQ6GHW
M@CPYX=TFZTO2M TO3-,NB[7%E9V4<,,Q<8<NBJ VX=<CGO6W10!Q$/P.^'%M
M9M:1?#_PM%:LL2F!-%M@A$;EXAM"8PC$LOH22,&K5W\(? E_#=Q77@KP[<Q7
MEVM_<I-I4#+/<J,+,X*?-(!P'/(]:ZVB@#&T[P;X?T?0)-"L-"TVQT2175]-
MMK2..V8/]\&, *0V3GCG-4-+^%O@S0[FTN--\(Z#I]Q9QQQ6TMKID,30(F?+
M5"J@J%W' ' R<=:ZBB@##\4>!/#7CA;-?$?A[2O$"V4PN+4:I917(@E'1TWJ
M=K>XP:6;P/X<N/$":]+X?TN37$5574WLHS<J%!"@2[=V "<<\9-;=% '*VGP
MI\$V%S:W%KX.T"VN+2ZDOK>6'2X%>&YDSYDR$+E9&R=SCDYY-16_P?\  =FT
M+0>"?#D#0I/'$8])MU*),<S*N$X$G\0'WN^:Z^B@#E+3X3>![ *+7P;X?M@M
M@=+ BTN!<69ZVW"?ZH_\\_N^U5X_@M\/8;![&/P)X92R?RBULNCVXC;RCF+*
M[,'8>5_N]L5V=% '(O\ "/P4O[RW\):#:W2W;:C%<Q:5;^9%>,N#<J=G^MQ_
M'U/<UY5\-?V1M*\$ZBEW?CPQ=3I#- ]YHWAH:==7XE1D?[:QGECN-P<LR^6J
MLV#C'RU]!T4 9'A'PKIO@?PSIN@:1;K:Z9I\*P6\**%"(.@   'T  '8 5KT
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !45S<PV=O)/<2I!!$I=Y9&"JBCJ23P!4M<[\1X8[
MCX>^)XI8UEC;3+D,CC((\INHH W+.\M]0M(;JUGCN;:9!)%-"X=)%(R&5AP0
M1W%35\O?LT^/?%7ARS^'GAGQ!>Z->^%K[P';ZQ;75K:O:RZ6(E@C\N=VE=9%
M<29#X3E&XQT^H 0P!!R#R"*  D*"20 .236;8>)]'U6X^SV6K6-Y/@GRH+E'
M;CKP#FM.OSO\86U_IWP2^*.L)H^E0:'I'Q.N[ZZUNWN"-7M8TOXBQLXC&J^;
M_""9AD,W!/! /T0HKYOD_:'\2WOGZYIMO9MIEIXWC\(3Z#-:O]L\IW2,7&_>
M,/F02A=N#'QU^:L.P^,_Q7O_  =X=UX:QX5C_MSQ@?#"6W]ASD6ZK>7,!FW?
M:_F)$49V8'0_-SD 'U917S/>_'OQIIECX@OMVF:A+X5\46'AC4-+CL'AFU 3
M?9T>YCS*QB+-<;XT^<;4P22<KB:Q^TGXK\ ^,6TSQ)<K/:Z%XAFL?$#VM@J[
M-/N$4Z7<*<G;O>1(V&#EA)C;MH ^LZ*^;;[XP?$*/Q1<^%;34/"EGKVA:?IV
MI:BGB&5K9;Q+AF,WE[ 2%0*8PR@_.!D8.*[7X+^,/&GCKQ)XSN-:U+1O[#T7
M7+[1(+&RTV2.=S$T9CE:9IV'W68%=G)YR.E 'J=AJMEJJS-97D%X()6@E-O*
MK^7(OWD;!X89&0>>:M5\A?#SQQKOPW\;ZK'9S:4GA?6OB?JNE7=G):,LT9-J
MTPF682;5 ,(!7RSD$G/3&IX7_:/\=:Z^N6UG;Z-KEV_AJSU[2#$HM([IYKIX
M2D)EE!9&108_.$3%OO8## !]4U5CU6REU&73TO('OXHUEDM5E4RHA)"L5SD
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M/C3\4-8\)>(_"'AC0Y]+TW4O$@N_(O\ 6G*P+)#&K+$O8NV\G'=8VQSR//\
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M/B!\5?BMX*U'7M.37?"]U-IO@RZ\6+/_ &#.@=HYR%MROVL\;,+OSG.3CD
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MC.PL&\MQQTP1Q6GHOA'0O#=WJ-UI&BZ?I=UJ4WVB^FLK6.%[J7&-\K* 7;
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M5W?ZMB!SVWP,^*GB_P 6>,9-&\43Z5=QW/A72_$EM)IMF]L8#<F17A;=*^\
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M?P+X:M].N8%M9[2+2+=8I85;<L;($PR!B6"D8!.:\8U[XT_$OPWK/C>2_DT
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M]ES@=A6[110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR=3ATR!+DRL,-(90N[<1P6SDU?U3P3X=US5K?5-2T#2]0U.V4+!>W5G'+-$
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MS6TU+4+8SI*\,D:+"JATZ>9N<YSMQC&<CRGP=X@O_CE\6/AGJVOV\-OINN>
M;N]O/#MU:I/;$M<VJR+AP=RMP02,XQZT ?3=]XFT?2[D6]YJUC:7! (BGN41
M\'H<$YK25@ZAE(92,@CH:^;OB]87=Q^UC\.(],T;2-7NCX3UI!;:M.8(-OFV
MF,LL4I[]-O0GFO/OV8/B;J]AI6B_##39X-'U>34_$8N;VYM_/L;:XM;A&^QV
M*B10T*_:!M)((2-AM4_= /M.BOE_X=_'/XD_%37_  Y:VLF@>&X;GPR==NTN
M-+FNC))%>M;R+&?M"8CD";T8Y*AAG=UI?AS\;_B!XGT_X6Q:QJFA6UW\0;2>
M[M[JUTF1([ P0;VA&ZX;S7D)##.W:J.,,<$ 'T_17R9<?M#?$*;P[X;U21;/
M3VU^#5M#M%@LO,B?7;:9TM63<V3!<"*3"DY!Q\_>M&Q_:7UV_P# 'A[Q/'-9
MV=OK-_8^'&?5D$,5CJ)1S=M(XZ!95$"@\!\YSTH ^HJBNKN"QMI;BYFCM[>)
M2\DLK!411R22> !ZU\[>'OB-\5]6^)7AOP==ZSX+@EFT^^O[V\TVRGO4D%M>
M0QA 3-&$=HI<,,$(X)&X8 L_M$^/K[4[SQG\.K.:PTY$\#7NNRS:A;>?]L'S
MQ>5&N]0 NTEFY(WIC'.0#Z MKF&]MHKBWE2>"5!)'+$P974C(((X(([U1C\3
MZ/,R+'JUB[/<FR4+<H2TX!)B'/+@ DKUP.E?,GPY^,GBN\L="\-^&[KPMI\7
MAO2] %Y:Z_<O%+>6UQ:PL\D94$CABD9 (+H0W7BMX&\37GA+Q*]CI]MIALM7
M^+NJ:?.+BTWR0@VKR"2!MP$;@QXR5;(8]* /K>BOG#1_C9XNL%\9Z9J[)?>(
M? TFHWVK0VUJ(TO+%8?-L/+')4RJR\@GF*8>F,2^^.WQ+A\-:5K5EK/@/4-/
MUV\T5+"6T$UU+''>7 AEWQJZC8-RE&W9R'4C^( 'U55635+.'4(;"2[@2^G1
MI(K9I%$LBKC<RKG) R,D=,U\\0_&7Q]_PE^L:,FI^$;B7PEJ-I8ZU!>++93Z
MA%)!'(TUO%ND*,YDVQ+N924()YRO/?#OQK??%#XU_!7QQ>76FNFO^%M9N8K2
MSM]KV@WVO[EI"Y+E?NMD#Y@QP <  ^LJ*^8?C#\8_$7PK^+7CC45U0W>C:5X
M7TVYMM(GB7[/%+<7LL#3.1ABJ!5D8YSM0C('->H?#KQUX@U#XF^,_!VM&UU*
M'1K:QOK36+. PK*ERLF8I%W,-ZF(D$$95UXR,D ]$O-5LM/FM8;J\@MI;J3R
MK>.:54:9\$[4!/S' )P/2K5?%6I:AXF\2>+]$>[\0Q7^IV?Q=N]/TZ6^M%=;
M*)+&<* B,A*XQ\NX9(R3DDUTVC?M(^.O%6G:'H-C<^%M+\775EJT_P!OU?S+
M>RO);*]:V"HFYBH(42.H8L W!XH ^H]2UG3]&C234+ZVL8W.U6N9EC#'T!8C
M-265_;:E;K<6=Q%=0-]V6!PZGZ$<5\]_M;SW.L?L^>';J>#3[J_GU_P],8HI
MBUJTK7UOD)(4R4)) ;;G!SCM7!#QKJ/PF^//Q@GOHM$\+:S=>'=,OK&ULFEN
MM*9?M+6XFN"B1R-=.\@0*(U!54&X@$@ ^R:JMJMDFI)IS7D U!XC,MH95\UH
MP0"X3.2H) SC'(KYAT?X^?$3Q#K^D^';:?1=-O9_&&I>&I[F^TXS2I%#8FYB
MD*17.S>#\K ,0<<;>17GU]\=]3/C#X7>.=3CM-.U?5?"FHZ=?ZU!;%K/3F_M
M*V@^URH6+>2&7.W)P7 +*N7 !]TT5YI\7OB+>_"WP1HMW%+%>W>HZMI^CG4K
MF/\ <0?:)EC-Q(JE1M&> "!DJ,UY?J?QO^(EMXT3P?;RZ(ES%XRC\.-K,^FR
MO'<6\NG-=HXC6=0)8R KC.&X(V9Q0!]-U5&JV1U(Z<+R Z@(O/-H)5\T1YQO
MV9SMSQG&,UY7\-/B%X@\=_ 34-=O[BVM/$=L-3LVO+&WVQ&6VFFA698G9L9\
MH-M)8 G'(KYJTGQIXPT*+2?'6GZW87WB6U^#R:U=WFJV)G-T4G64Q,$D0@GI
MO). >E 'WG6=J7B+2=&E2/4-3L[&1QN5+FX2,D>H#$5X1IGQT\6^,O'EW9:'
M/X6TRQT74=/MM2TW6KEX[J>WN((I3+%M!.XF7;'QM8QD'KE7?M(6<]Y\:?@(
MMI;6-U=G5]3")J )B(_L^4D' )[>G4"@#W.7Q/H\&D2:M)JUC'I<8)>^:Y00
M)@X.7SM'/O3+?Q=H5Y?VEC!K6G3WMW#]IM[:.ZC:2:+&?,10<LN/XAQ7SM\0
MM-U.WU/X2Z;]JTS1-0F\;RC5;+1H5>V:4VEU)&2&[F,1D@CJV2,UQVA:TOPH
MU3QB\<>AD#XBQZ%I,^HV44%KHQDT^$"1&4?NLH/)4# RXSG)! /M"JVHZE::
M19R7=]=0V5K'C?/<2"-%R0!EB0!DD#\:^>;?XS^-O[:LO!>J:YX,T?Q3)I6H
MZE'K$9DGT^Z:WG6..+#,A5@C!I@"Q7G:1U'*:W\4_%VD:/\ &[6IM9TW7H](
MU#28[/3+^R$UDD4T-H[^6H96QF9BI;/."0>E 'UU17A5M\2/%L'Q@U[X>WM[
M'_:+75KJNCSQVBA7T8JWG[@?O2))&\6[CF2$XY.8_@;\8?%GQ4U/2M9FN_"W
M_"*ZI;76=-M[E_[3L[F*0*(RN,':-RR!L$-M(X.* /99?%&C0WQLI-7L8[P-
MM-NUR@D!]-N<YK4KYTM/"V@^)/VOOB5!KFDZ?J=F_@[2!+'?VZ2H5,]X&W!@
M1C &?I7C?PZ^-/B?X<?"#6[?PWJ-K=Z1I]YXEO\ PW'?QO<S3Z19NOV=D9Y$
M7[,K,Z;B^\KY8C![ 'W?17R/KGQ_\1^%?&'B[Q!/K-NVE#1O#36VGW@5;*P>
M^FECDF=Q\VU#\Q)/. "0!Q[O\+/$^O7=E>VOC#5/#5SJ0U"2"Q?0[HMYT.Q9
M$$BL!B8*22$R"NUN,X !Z#17SY\??CQK_P -O$D]OH<VF74&FQ:9->64D#/*
MJW5]]G)E=G0(I7=L$>]]RDLH4#.'8_'WQY;>+H);^;1+WP^?&]_X4:QLM.E2
MX>**UDFBF64SL-^8P"NT@Y)R.  #Z5DU2SAU"&PDNX$OIT:2*V:11+(JXW,J
MYR0,C)'3-6J^3?AWXUOOBA\:_@KXXO+K3737_"VLW,5I9V^U[0;[7]RTA<ER
MOW6R!\P8X .!]94 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,
MH92" 0>"#WI:* .5TSX4^"=$L);'3O!V@6%E+=IJ$EM:Z9!'&]RK!EG*JH!D
M# $.>01G-=5110 5BKX)\.IXH?Q*N@:6/$;P_9FU@6<?VLQ?\\S-MW[?]G.*
MV'!92 Q4D8##J*^6=#_:'\87MKX.#7VEO?:FGBB.XCEM,J6TYY! ^U75AG8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*Q>&WBAET\7@W0M,V9,YB7Y\$E20<$&W^SY8^7\!OB)9W1M;HIK_ (CCE\B
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M[E#M8 C<>F: .V\0>#/#_BUK9M<T+3=9:V+- =0M(YS$2,,5W@[<C@XK$NO
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M/'6MZ-\-/[?UWPYIMWX_L9[RTNTTN2*&SD@A#&WR]PPE>1FW#[NU8W&&)#
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MK@ \BJM[\'_ >I74EU=^"?#MU<R737[S3:3 [M<E=K3$E,F0C@OUQQFNNHH
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M(Y[UNT4 <;:?!CX?6$]M-;>!?#5O-;31W$$D6D6ZM%*B[(Y%(3Y65?E!'('
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M]AMC;Q^ _#,=N;(Z<8ET>W"?92=Q@QLQY9)SL^[GM79T4 8NJ>"O#VN>&_\
MA'=1T'3-0\/^6L7]E75G'+:[%^ZOE,I7 P,#&!BLW4?A+X&U>\2[O_!GAZ]N
MT@2V2>XTJ"21848,D88H2%5@"%Z C(KK** .4F^$_@BX%R)?!OA^07-ZFHSA
M]+@/FW28V3M\GS2+@8<_,,<&M+7/!OA_Q/<Z=<ZSH>FZM<:;+Y]E+?6D<SVL
MF,;XBP)1L<97!K9HH P(O 'A>#5;W5(_#>D1ZG?!A=7JV,0FN P 82/MRV0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=Z[S)*%VJ<?,RBN2N?VH_B/J/@Z[\2:?+X;M(+#P)IGB^:TDTZ:4RRRO(LT
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M[8!=VVGBS2*UC9VBA">9(209')8M\Q.<+P*\X^'$$,?[7GQFF$<:R'1M!W2
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M2Q7<0N37A_\ PTEXW3P#/J[Z8EP=+UG6-.U6?3K2.YNK6WM'VQ7+6BS_ +Q
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M<:[X4U'P= FH:7>RZ?IK.\M];7\#_) \?1A@%)-Q4JQ4C@[: /H;PYX,\/\
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MXT^.-7U;6AHFH^$XM-\/ZG>Z'>V.LRR'4"T$3>7*$4@L[LJR;"55HV."",D
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MS_Q-U;OFN@L_#&CZ?!806NDV-M#I\)M[..&V1%MHB "D8 ^12 !@8& *TZ*
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M]T0)A9/]L#/O7844 <]H_@31M"\6:[XDL[.*'5]:6%+VXCA1&E$0(3<54%R
MQ^9RQQ@9P !G7'P8^'UW>75W/X%\-37=W)++<3R:1;L\SR+ME9V*98NI(8GJ
M#@YKLJ* .5B^$_@B!9UC\&^'XUGL5TR4+I< $EHOW;=OEYB'9#\H]*N>%O '
MACP.LX\.>'-(\/B<*)1I=C%;>9M&%W;%&<#@9Z"MZB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***P?'VJ:IHG@;Q#J.B
M6?\ :&LVFGW$]E:!=WG3+&Q1,#KE@!COF@#>HKYQ^ GQDLM8M[K7]2^*UKXG
MT:]CL;8V,NF_9WTS497*&!Y ?ED=F5?(905*Y& U?1U ",P12S$!0,DGL*\V
M_P"&D/AF9_)_X3"P\SR1<X^?_4EMHESM^X3QNZ>]>DLH=2K ,I&"#T-?/5M>
MZ0W[;^HZ29[(M_PKZ& V.].GVYR4V?[I!QCI[4 >V>%/&6B^.-.FO]"U"/4K
M.&YFLY)8@0%FB<I(G('*L"/PJUH6NV7B72H-2TZ5I[.;=Y<C1M&3ABI^5@".
M0>HKXX^$OC^X\.>--!CL?&HBTGQ!X^\4:=>:7YEJ8 BFYF2524+B0.B8)8KA
ML;>:-._:$\62?"_P#KS^*$U]KBUNWU2VT^ZMH-6F*WQB2YMXC'Y5SL4;&@78
M?G!7)Q0!]K,P12S$*H&23T%5=)U:RU[3;;4=-NX;ZPN8Q+!<V[AXY4/(96'!
M!]:\]^.'B@P:!8>%=.NK6+Q%XLG&G6=O=77V=FB*EKAP<,P*Q*X!"G#,G'-?
M-.F_$:_^ WPC^-?PSCURR\*^(_!,,FL>'!;7<5SY6G7),L,2^=&-WE2&2(@H
M" 4QU!H ^XZ*^+/&GQ>\2^$[[XAR6_Q5N;F'PW<>';ZSAG&GE9EO9%6XAD*P
M@F+;DJ%((W$[CQC>G^,>NZU\0/%-G)\2X_"6L:)?:@A\*/I:227&G+"YM[F-
MGX"$;)?/PR@Y1@00* /K6L72/&6BZ]KNM:-I^H176IZ,T2:A;1YW6[2*60-Q
MC) )XKXOTG]HCQQH'A*"_@\8S^+K_4_A[I_B*:)X+65["=KJ.*YGACAC4L$B
M=Y"C;^8\],BFWOQ,AT'QM\0=2\)?$S[1%J7B+PC;)K"SV=P;BVF_=S(&,94@
M!FY R#P3@8H ^[**^,]/^,'B?0]?M?\ BY$^NK9?$>?PHNGWAL0MY9M;-(OF
ME(E8R"0JH92HPH!!YSD/\>O%&H_!OQIXOM/BRMOK^G^'9)-2\.'2(XY]$U-9
M%&':0$1=6C$;+\X 93D%B ?<1(49) 'O6-K'C+1= US1=&U#4([;4]:DDBT^
MV8$M<.B&1P,#'"J3SCI7QW\0_'FHW#>+-$U'XAWNI:3H7BGPK>_VA]J@@>WM
MKEXVG61X$1?)5AN&X<9&2<"O6OVB9[6X^(7P-M5\0/HCW&LWGE7\4D0G5?[-
MN!O7S59<\@9*GKZXH ^A**^!]8_:F\2)\(M"U*'QX%\2V_AZ74&WK;PQWKPZ
M@86ESL;SW\N,[X55%56+E@=N/</#'Q:UB_\ VA?[#DU5-;\/WMQ.ME+HMU%(
MMJ%ME?R+VV9!)%@[G2=&97WJIQ\M 'MVF>,M%UGQ'J^@V6H1W&KZ0L+WUJH.
MZ 2AC&22,?,%;H>U;5?'GQBU#7_#OQF^*VI>&?%EWX>\41Z+HMQHVDPQ6\@U
MR9&N%\@QRQL\BDL$/E%2N_)/ K6TGXO^+==^)FMZ>?&,6E>+-%U"]C_X5Y)I
M?F/J%FL+&W=&R"$8['^T#(!)0]0  ?5M%?#4OQY\17_PSE\4Z;\94>[E?1[?
M4=(_LB&*72+R2]BCN(I7E!$9*/(ODE0?W>]2!G/T!^SWXSU'7;KXE:-?>(W\
M5OX<\1RV-K=W!@\\PFWAE57,*(IP\DB@[1P,=J /2]1\9:+I/B72?#UWJ$4&
MM:LLKV5FV=\ZQ+ND(P,84<\T[Q=XNT?P'X=O==U^_CTS2+--]Q=2@E8USC)P
M">_I7P[JOQ2U#QYJ?@/6W\4W2>/XK'Q0EWX?C:..71[Y+5_(A6(*'1@555WY
M\P<_-FK7CWXWIXX^%WQ*@?Q=#JVE2_#/3;\J9T,0OW>5+@JW][*HK*#\K<8!
MS0!]W1R++&KH<JP!!]13J^<7UCQ7I_Q9'@^+5M4O=&\716>L:-JL+YCTZW@Q
M]NMPZC&&'E;"<D_:",_*,;7[2WQ+O? .H>$+*;Q*O@;PUJ[74%[XGE@\R*UG
M5%-O&[GY8@Y,A#-@$H%SR00#W2BOCWQ!\3=9\'^*_!]WJGQ-NM6\)S6]A9>+
M-3@MTLDT^ZD?-K<",MF!;K;MD4[@BLK#8&S6M8_&'Q/KOQ0\06-KXUBL?$FB
MZC?)%\/Y-+\Q]3L5B8VLB/D$(_[N3[0N0"2AZ@  ^K*0L%ZD#/'-?&LOQRO=
M7^$<?C/1_B1J-Y>V@T:7Q!I[VD<::+.;V)+Y9F"#RAY;R*87SM6/?Q]XTM:^
M)3>*_%5C<S>-+I_#^F_%(6=O<0WWEPBSDTPO"I<<.C3'Y&;();"D\4 ?;%8N
MG>,M%U;Q+JOAZSU"*XUG2HX9;VT3.Z!9=WEEN,?-L;OVKY&TGX^^-K[P=XJ\
M3:9XQ&J^+M*TB\_M7X?#1"UQI=TDH"R'G<@C7=M4@B88(R037>_L]>(]%\0?
MM!?$2[T;Q>/&-I=^']$FAOVGAE+8-UO ,:J."02,94MC@8  /I:BOB7Q'^TC
MK5MXVUN"P\>FWLS:^)X&2X6VCFL[FS56ME^SM&WE;</M+L3*N79!QB-?V@_%
M_A;3;\IXTG\2K<^%?#NN7-R\-K+)I*W-R8KZXB2*,92.+#X</M(W'(SD ^Q-
M"\9:+XFU+6M/TO4(KV\T:X%IJ$4><V\I0.$;(QG:RGC/6C4?&6BZ3XETGP]=
MZA%!K6K+*]E9MG?.L2[I",#&%'/->(_LR:OIFH_$+XURZ1XA7Q5;2:Q93V]\
M+B*8S1G3H "'C 5ER"H;VY)(KQF/XPZIXH\4?#?Q,-9;4_B':VWB877A"7RU
M.GWR6S^3;>2%$BD[55=QS(.><YH ^U/%_C+1? 6A2ZSK^H1Z9ID3I&]Q*"5#
M.P51P">6('XU:T_7K'5;_4;.VF:2YT^18;E#&RA&9 X ) #?*P.5)'..M?%7
MB_XE_P#":_LZ>/-9E^)]MXNTJ>TTLRZ?)IPMGTF]^UQ^;'))D;7;O R@KLR,
M XKO];\;>,/$\?QM7PUXKN-1U#P;K-E>Z;8V;P@RVBVD$\]G\B@E9 9E#'+!
MB/FXH ^IJ*^5_B!\7=6T?2O"6LWOBJY\#>$_&D]W<_VYJ-N6CTM?*3[# Y;B
M#S!OD);'S_)G'%8EI\0_B!+K7CJ.R^(E[XJU7PKX0L-9L]+L=,M;9=4N7BN@
M[/;F-I0K%(I-BN#DK@@$+0!]AUS^B^/_  ]XBTW5M0TW5(;RRTFYFM+V:,';
M#+$ 9$/')7(SC-?+EO\ '74;3PM!X@T_XIIXJ\':GK6F6FIZO!IBQ-X;@D63
M[09)B"JEF6-65US#O). 5QWO[+=W:7WA3XK)8ZO_ &\G_"7ZHR7GF)(TR,D9
M1LH &!'1@.<9YH ]S\,^)=,\9>']/US1;Q+_ $G4(5N+6ZC!"RQL,JPR <$5
MIU\2_ &#QGJO@[P/X7\,_$'49;+4/!<\>HPI':G_ (1F_B$2VQ1DB#(Q8R*T
M4Q<ML8\8->Z_LZ^+/$'Q$TV;7=;CO]->Q@CT.XTVY9MIO[<LMY,,\L#)A%;H
M0A/>@#JY/CEX#@O[^SN/%%C:3Z?=+97GVIC"EM.V-L4CN J,=RX!()W#&<BN
MY!! (.0:_/SXF>(8M1TG]JO3++QOX=T^&ZU=%DTB>-9;W4@-/ME>WMW$ORO(
M08@1%(0QX!/ ]"O/C+XS73->ALY;OPGXMT9]%_X1WP3="-VU&TFBM_-1PZ;Y
MB6>>-G0CRS$#\N&R ?85%?%WB'XI>*H/!?Q#\31?%F]MIM(\<IX=MK94TXVT
M-L][:K\V8-Q<1O* =PXR2"036[XZ^(WC+P?<^/=!M_&.HOXD\.VEA<^$X+^.
MU,GB42?-)N585$Q9R8"(@NP*K<,=Q /K2BOD+XE>.OB+\//&.OQ";7-2L=%O
MK+Q=(L+%D?0W417=D,+\SQRJ[H 0Q4=2,@VOB)\1O%'A;6]&\-ZQ\09/AR=8
MTAM4T[6+^Q^UI+J#SL39#. S11F)5ASF0,W4X( /K.BO!/V?_$.N^-OB!\1)
M]4\>7NL0>']:?3(='CAM(K=8VM;:3<ZK%YH97,@7+\?,&W$9K@O%OQ]U'3_C
MQ%I%MXU-IIZ^))]$OK&Z$$+6L?\ 9CRQ[861B5\Y599W8;R64(5'(!]<5BZ=
MXRT75O$NJ^'K/4(KC6=*CAEO;1,[H%EW>66XQ\VQN_:OBKPY^T3X]TCP7H^L
M6OC";QMK.L_#RZUPZ=+!:OY5Y#<0IYL,<,:L2$DE9D.[<8^ ,8KUG]GKQ'HO
MB#]H+XB7>C>+QXQM+OP_HDT-^T\,I;!NMX!C51P2"1C*EL<#  !]#:9KMEK-
MQJ$-I*TLEA<?9;@&-EV2;5; + ;N&4Y&1SUJ^6"C)( '<U\EZS\:/%$7_"?0
MV'B[3K^XTGQP^G6]A?W]OI\D]F+!)3:0W B*1R!R[*9%^;RRI;DFNA^.'B6;
MQ#^R7H7B-M1UG24EET2[N[J[86ERL37=OYK7&SY5&TL6Q\G?I0![UH7C+1?$
MVIZUI^EZA'>7FC7"VFH11@YMY2@<(V1C.UE/&>M;5?$EY\07\(?%#QWK>A>-
M_LT'_"=^'=/FL_-MY(;ZWGM;6&0RET+YVEB"K+@J3S7H?P.^*6M_$'XEM'J'
MCV.#5K*?4+76? #Z5B:U596%O+OR#$@55(DP5E$F.3@@ ]^TSQEHNL^(]7T&
MRU".XU?2%A>^M5!W0"4,8R21CY@K=#VJUI^NV6J7^I65M*TESITBPW*&-E",
MR!P 2 &^5@<J2.<=:^3/C%J&O^'?C-\5M2\,^++OP]XHCT71;C1M)ABMY!KD
MR-<+Y!CEC9Y%)8(?**E=^2>!2>*OC1XGC\=:WH@^(3:28OB!H^BB.(61:"UN
M+)'FA7?$>DA8ACDY&"2.* /KZ[NX;"UFN;B18H(4,DDC=%4#))_"L'PW\1?#
MOB^/29=&U)=0AU:R;4;*6*)]DUN&52X8K@<LO!()STKY7\,?'O5+I]&\/^)/
M'4EGX>;4_$6ER>+6:VC>XN+6X"65M++Y?E([1,[\*ID,8 SD@\7X6^,FL>"?
M@KX3L=&\;C2T@^%&HZK'"!:DQWUO+$(Y,/&3NY=2IR.N #S0!^@%%?&E_P#'
M/Q)X4LO'\2_$*#58['3?#FKK>:G+91/:I=S%+M(G")&H**NPRY"LP)8 YKV?
M]G_Q;JOBKPOXMU<^*K7QE:_VI<#18K:^LKLV]JJ@PQ2RVN5,A).=SL=NS)!S
M0!ZGXA\0:=X3T*_UG5[I+'3+&%KBYN9 =L4:C+,<<X K/UOX@>'O#G@QO%FI
M:I%:>'5MTNC?N&V")@"K8 SR".W>ODR;XH>,/'GP]M5M]7GUV]UWPCKJ^+?#
MS0Q[]%NX[9O+4(J"2)A*3"$8G>"#R06KG_%7B76+;X$>-K%?&C^+? \GP[M[
MF6>Z%MY>E:B2L8M8Y840$,@)\MRSJ4!)^;D ^X]/\0V&J:C?6%K,9+JR$33H
M8V4*)%W)AB &R.>"<=\5HU\C>+OCUJWAW5_B0D/C2R71M'U'PTB^?<6D/V6S
MN0OVE(I6"HK-GAY6XS]X<8R=6^-FO6'@:RE;XGQ7=QJ]_K;:3/:7>GR1>1!&
M6M()+N!'3SP"C")1(TIX) #4 ?8>KZO::#IEWJ%]*8;2TA:>9PC.511ECM4$
MGCL 35BWN$N[>*>([HI%#J2",@C(X/(KX9U/XMZB4\0>-O\ A-KC3-=NOA%9
MZSI[I<1^0]XHN#.T4+J8SAPFX!>"P[D5V/B_XV^+9(/%RV/B!]-\0Z9I.DW_
M (3TU$A>/Q"98E:7 929]\I:(B,C9P1@G- 'US17QTOQE\36?Q"N;BY^(3M;
MVOQ*M?#1T23[%]G^QSVD;/&Q6(2$I(S;6# _+SGFOL6@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **:Y948JNY@,A<XR:^5?AY\7/%?BS5/ TD
M^O2MJ.IW&J6GC+PZXBC_ +"CB24I* %#P>6RQH&8D2"0'DX( /H'3?BEX7UC
M5]0TRRU5;F^L8&NIHHX9#NB5S&SQG;B4*ZLA*%L,,'!JKX9^-/@;QC-IT6C^
M*-/O)-2#-8*)=GVP+G=Y.['F8P<[,XP<UYK^QU>Z?#^S#HEZFL"]M@EV\T\U
MT)$A(GER-V<*,<G/KGO7S-\-O$,NH?"S]FM+?Q!H_BJ&Q\312KX0T=-FI*QD
MG47,DHED)C@#EV7RXP01EAT(!^C%%?)N@_&/QAK5_P"'IQX@DMO$,OB#5-,\
M2^&)$@ TFQC6X,5P%9-T>P1P,)&)63S>=VY<<[X.\>>+?$?A/X%7-Q\9-62Y
M\?3RPZC)"FF#RREE,V+?-L=K>8B9W;OF/3D  'VI17RGHWQ4\9:OKNEVB:[<
MMXJ3QI/H.K>%)%A5H](!D"W6T('7$2QSB<':Q<KT*J.>M/B#\3_#7B2PTV\D
MUS6%TO4;WP?J-PY(2ZN[G=)IEZ JCA8S$)""%'G#C*\ 'V;17RM<_$77XOC%
M=>"[WXF-X3U+1KZR2QTR^TP7$NO:>8(S-,I. Y9S+ND7B$Q@D!00>A_9K^*,
M=S\-O#7B/QG\29-:U+Q5>2:9907IM8X/M,<TX6.$0Q(=[HH)#,1\HVA<X(!]
M$45\W_M#?$_5_#WQ'L_"[>.4^&5A?:/]ITG6Y].%U'=Z@)BK0<\.ZJ(R(<@N
M)&QD@8X;7OC+XGT;QSXCN)?B1)Y&C>-M!TA=)>*SB@>WNXK<7$<BF/S!@R2%
M?GW*1R6Q0!]1S_$GPW;^+;?PS)JD:ZU<.T4=OL<J9%C\TQ>8!L$GE_/L+;MO
M.,<UTU?%6@>/F\&^-?'#6'B6>/1+_P")7]G:[JRW:2C3;4V$11R6!6(/,J1&
M0C"@XR#@C5TWXA>-_$7C?P5X5N_B'>Z1INJZWKUA9ZI91V(N-5L;>-6M9U,D
M+*6W%X]RKM<)G&2#0!]@45\EZ#\<O$6L^&_%&HV'B.^O/B1H=KK"W_@#^STD
M\F2)W^RN5"!T 55*MDB8R=^,9EM\<9'T2QU&T^,R>(-%US5;2UBECT^.S2QF
M-O,TMM/>MD0EF1#L\MI$8! N)!M /JT^,M%7Q>OA8ZA'_P ) UFVH"QP=YMP
MX0R9QC&Y@.N>:+7QEHM[XLOO#,&H1R:[8VT=Y<V0!WQ0R%E1R<8P2K#KVKXJ
MT7QWJOQ!D^'?BG4_B#<>%-;N? &I1OKUG':AI[Z.[A/D[98F1F.S+1HH8X(&
M.15[5OBUXI\,>*-4\1:B4T_QE_P@7AN37$@M_.ET]'OIOMD_V<9/[M'9RN#M
M].* /N&BO(O@]XKFO/AKK^M_\)['\0=,CFN+BPUFQT[ 2 1AA$A5B+DH=PW#
M!/W3DJ37SGHW[3WB$>'_ !5=0^/+*]LXM%T#5H;V]N;5719[MXKTAMBQ02%0
MH\MF:.%R 7')H ^Z:SY-=LHM=@T=I6&HS6[W21>6Q!C5E5CNQM'++P3GGI7R
M7+\:M4A\.13M\3X;JSUGQ+>VNCRVU_ITL<5I':N\,$][ LBQREOF _>R28C3
MC<YK"U+]I/Q1<^ -"U5/'D=EJ%Y\*+[7IA&EH -4A, $H5HS\V3(I0_+UPH(
MH ^N-"\!1:/XLU7Q#<:SJFLWE[E((M1DC:+3X206AMU2-<(2JD[RS' ^;  K
MJ,C(&>3SBOCM?C%XITV]\6Z1:?$6PU:XCL?#VIVC:[=6]HK-=&7[1:I<0PXA
M601H$=U;:SCGYLUK?"#QI)XL^/7A#4]5U77+*34O!MQ]GTW6+J,&:XCOV24*
ML7[J7"JIWQC#*J/TQ0![]KGQ@\'>&=>N=%U37K>QU2VMA>3VTRN#%;DD"9CC
M CR"-Y.W((SQ73Z9J=GK6GVU_I]W!?V-S&LL%U;2"2*5",AE920P(Y!%?+'Q
M(\51Z9^UWX@AL_'7AOP==_\ "OXH6O-=C6=(V-Y*1A#/%A@#NP2>.U<A\#/B
M!J.@?#+X8>%M0O+[X:^%Y_#NIR6^M321C[9J$5SB,B2:/:JR(7N$C*C<& P5
M7! /N"BOBJR^*_Q!\0#57U[Q]>>#M8TKX=6OB672;.&QC"WI^TABZS0NP1@D
M3%"<@L "!P>AT7XBZ]:P>!;?7_B1J-KH7BCPM+K2>)Y_L4:?VGY<&VTCD$(0
M*H,D@C;<SG<"6"D4 ?6E%?&^M^*/C+?^&O"\GVC5+/Q+XW\*J+2"V7RH=-UF
MW*RL[KM/EI- 6)5NAC*C!:M7Q!\;-;@\$^#_ !A?ZU?>!?"OB^^\NZU#4H2Z
MZ+$MKB)9"W^J$LZN3(QQ]P9&: /K.L^37;*+78-':5AJ,UN]TD7EL08U958[
ML;1RR\$YYZ5\W^!?$WB?Q%\9/"OA6\^+5WJ=LGA2/6I9-/T^TL_[4E2]V!S%
M)&[K')%C=M(R/F0H#6M\=/BCJ_A#XGZAI-EXN_L:V'@#5]7CMB+;]U=PO%Y4
MP\Q"2<,XPV5(!X[T ?15%?-O[./Q)UG7?B"=%U3QH_BJ&^\%Z1XA$=Q]F#6]
MS,95F$?DHIV$*APVX@\YYKE-0_:$UZW^.*Z9H_B/^U8VU?6=)DT&[$43B6&S
M,EK"( I= 94^25I TH9ODV@8 /KVBOCJT_:)NG^&^G^+K#QWJ.K0N-+@\6VW
M]FQEO#3/,%O96Q'F)E!*F)PVQ4\S'<]3+\4YHM9\(::WQ$NI? &MC59(O&YC
M@@5YD,;6MJ)V0QLH5I=LF 93#C)^;< ?3E8J>,M%E\7R^%DU")O$$5F-0>P&
M=ZVY?8)#QC&[CKFOD?P/\6/B?XFU/4#J'B:]/B'1_!,7B&#PO96]I'_:5TLU
MVB"1#"9 D\<<#LBE2"XVE1@5SY^-&GVOBJZ\:6OQ$N-1O)OAS UQJ"16TTEA
M=-J$8F3RL(L14L=RR?ZH L1P00#[RHKXLT?XX^(]<GT;1_\ A8PL/,^(LV@M
M<V4UI<-)ISV+3Q!99(!OPV-LFT9&,[AC)X5_:)U+4-'\.Z7XI^(<WA_3+NWU
MJSM?&$4$#FZU*VOVAMXI"(S&9/) <1@+YI/0]* /K_Q1HDWB/0+W3;?5[_09
MKE-BZCI9C%S <_>C,B.F?]Y2.>E)X8\.6OA/0K72K-I9(8 <RW#[Y978EGD=
MN[,Q9B?4FOG#PU\5O$'B/XT-X>U#X@?\(YK.FZM$B>%+O1?WVL:8T"'SE7((
M#,S.95)\HH5/'!ZG]HB\\8Z!XHT"3P]J6JI8^([2Z\/)!8D;;+4W3S+.\/RG
M"@QR*Y.5P1D4 >UZYKMEX<L/MNH2M!;>9'#O6-I#N=PB#"@GEF SC SD\54\
M1>--$\)3:5%J^HQ6,FJ7J:?9*X),UP_W8Q@'DX[\5\OWWQ8\86_P(@\<7NM7
M_A34XM3T?0)K6\,>R2:.]CM[]\2J>)&:50PP=L08$9.>0U;4[5;B^TZY\77,
M6JK\:($'VN]22:UA(S$Z+("%RI^7(*D*, @4 ?=#N(T9FX4#)JEH>N67B/2;
M34M/F,UG=QB6%V1HRRGOM8!A^(KR3X >.[_Q9\*?$DVI>)CJMUHVLZOIBZRY
M@\T107$BQ/)M41[@@7G: <9(YKP+P_\ $_5-9'PP\7:GX_\ L&JZA\.-4GCU
M*]F LGU!)8"7>%!L8J,LRJN=J9QA: /N>D#!AD$$>HKQCX#>-=6^('@CQ3%J
MQO8-4L[M[1YH;^*]M\FWC8-9W<2KYL9W;@64.K,5(^45\[^"/B[?:)\*/AEH
M3_$I_!=AJ>@W&?%-_%]M"ZRDB+]D=WX$B@EO*8Y<[E.2,4 ?>%%?%GB?XG^,
M;?PQ\=-;7XL7L%]X+MX!96T%I8P0AY;""1C)%)"SK^]9]JE]RDE26(X/&GQ>
M\2^$[[XAR6_Q5N;F'PW<>';ZSAG&GE9EO9%6XAD*P@F+;DJ%((W$[CQ@ ^TZ
M*^:M&^.MQH7QC\00>)O$$%SX2MAJ5Q'JFFWD4EK9PP;-T5] 4$MO)'\VV0,R
M2[N>=H'=?'WXGW'A'X3V?BG0;\1Z3<WEE]JUNV@-TMII\KKYET%7.5"D$MV#
M%NU 'K=%?&7C7XC^(]$\#:3KOA_XL2^-WMIKZ\NCIEI'&L^A;<27*#?^]>U+
M@I*IQ*R[2K$$CKKSXVVNJ?$$:!#\0KK0M/FTW2K[PE>VT$=V/$2NS?:=I9#Y
M[G:L912"@;?@=0 ?3](2%!). .237QQJ/QF\5ZS=^.WA^)/_  C?BKP^FN"X
M\%C1TDG2"&.5K.X4N"%3"12"8JR/O*'DKMY/QWXU\7ZU\,O$SQ_$'4/%?AJX
M\(:9K5]?PM;Q'2KYKJ(2P++;HF(WA,C-&Y8J$R3ACD ^]**\>^-7Q"M?!GP[
M\+WEGXGDT^RU/4[.RCU<R1^7-&X)_>W3@K"CA?\ 7!6/("@EA7@^G?M%>+IO
MAQX-U>;Q''J\Z)?0ZO8:==06^K.8K\PI<01R1".Z*HH5X1Y;'S P&[  !]LT
M5X7^T]\0]=\":=H=SHFI00!X[N>ZTO[;%97]W&D:G=:/,C1O+$6#>2^T29QG
MC!\KUOX[:KH_B'5].E\5WFGWJ^,?#SV6GWY6.Y72KJ*V\_?&1D1%WE!8\*V5
M!& * /I+XP:#I6N>![J36=?O_#%AIDB:F^JZ>Z![<PG>&*R1R(ZC&2KHP..F
M0*?\,/"NDZ+HW]K:;J<^O/K44-RVKW44$4EU'LS$2L$42 !6)&$!^8YR:^=K
M?XOOXY\#>.CK'C.XLO$MAI>OVVN^#)K6-8[)5$BVTC$J&B0(%VN6(E\WOCC?
M_9:\:WQ\56?A*3Q6VOZ7_P ()HFKVUK,;<FTE<21R)'Y2*=FU(^&W$'G/- '
MT[1110!ROQ$^'\7Q#TJSM&UG4]"FL[M+V"\TIHO,610P 9)HY(I%PQ^5T89P
M1@@$2^"/ EGX'M;M8+F?4+R\D$MW?W4<,<L[!0JEEACCC&% 'RH/?))-=+10
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44UR0C%
M1N8#@>M?#.J?'[Q9>_#+QIXF@^*R:/XHTG1[S^U/"3:1&)])O4E C+-*#Y0'
M*+N4B4,"IW#=0!]NZMJUEH.F7.HZC<Q6=C;1F6:>9MJ(HZDFJ'A3QEH_C>PG
MO-&NS=0V]S)9SAX7ADAF0X>-T=596&1P0.H/0U\;_%_QW->_#WXU>'-8\?R:
MS9:3<:!=65S/<6T4JBY:)I(LPH@:/<"0""1GJ<5V?C3XM>*].U3QM8:1X@FM
M_$F@W^EIX8T*0Q2KK]E*L.^3YE+S>8SS*70_N_+!XPQ(!]7T5\>/\7?$^E:-
MXW\5S^/=3U'2-'\</X>OH[:"SEATK2S/#ONB(X-^^-2R[R2H5F8J2,U>\:_&
M.YT>U\,VD/Q7?3_!FN'4OLGC^[L(S!YX:,VMOYH C90KR[9#@2F+&3SD ^L9
MYDMH9)I6"1QJ79CV &2:R/#GC/1?%WA:W\1Z/?IJ&B7$330WD2MM=%)!(!&?
MX3V[5\J3?'W7M,^*7A?2IO'0OWCUW3-(U:VN;./3A+%/IY=I$M"KR!))2C"5
MG0ASY:A@#G"^!WB'Q/X6\'>#H-&\;W5QI_\ 8FLC7]'FBM&C\//!YC03 ^5O
MB<R84I,7W;CQA> #ZVC^*WA66[M[1=64W=QI+:Y%;F&02-9+MW2[=N0!N7Y2
M-W/2M=[;3/%EGIEXP-U;9COK8,70$\-&[(<9QD$!AP0#C(%?'*_%6YU#_A!_
M%4OBF"+Q-+\'-1U(ZFKP;_M6;63S-C*4SO5N-N.#QQ6KHMSKGQ%\>2+8>/-0
MTKQ1KOPQTR^TBXBNU\N2]W3&61(L%&7<$+[1QNYQD4 ?8]%>2?L^^+]6^)>B
M7'BW48K_ $J":*+3DTF\)_<SP*4NGPW))GWQYZ$0@C[QSX7H/Q5\3:OXB\,1
MR_%>\2'5O'&N>&IXXQIP"VD*W#PLG[CB13%$ QR,-TR<T ?9]%?!WB#]ISQ'
M#\&M,N[?Q\?^$FM]%UNZBG9;:)+^6SO#%$Y<1L)91&H)@1 K!V=BH"Y]?B\2
M^*V^*<7AJ/5]3O\ 1_&L-GKFCZM ^8M/MX=IOX%8# #9C*$Y)^T8!^48 />-
M5\9:+H?B#1M#OM0CM]5UEI$L+5@2UP8T+N!@8X4$\XK:KY__ &FH%;QW\'Y)
M_$,_A*S75KZ.77('A0VN_3YE7#SH\:EC\HW*>3QSBO)_^%T>/8]/\/Z#XN^(
M7_" S7VG73Z-XJO-'5QK%Q'>RQPEHP%0R- L$@A&WS/-) Z8 /K[Q'XRT7PE
M-I,.KZA'8R:K>)I]DL@),]P^=L8P#R<'KQQ5K2==LM<^V_8I6E^QW+VD^Z-D
MVRIC<OS 9QD<C(]Z\9_:.U2&RT[X0/J5Y#%/)XVTDL\H$&]L2;B$8Y7D],G&
M<5YA9_&/Q#K?C?2]";XES6=O<_$+6M!EDM_L(E^QQ63R0J"T) *.%PV.<\Y.
M* /L-W$:,S<*!DUQ?B?0-,^,W@NP^QZWJ>EVTLL.HV>H:;MBF#1MN0F.>-E9
M<]4DC8=.,XKYM^$?QH\1:C?_  VDU3XE/JB^(=-\06]Y%,+%41[*7;!<)MB!
M$A526W$JV3\H  '->#_BQXDO6\/>,EU^\\0>*[OX5SW]A9B8-'J&H1SGS D"
M *[@!69$ /RKT&* /L3P/X L_ \=[(E[<:IJ-Z4-UJ-Y%;Q2S! 0@*P111@
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M^/KJ^\,>,[4^)HO$O@.WU?PO<:3KL\T+#SY+^)KBW$J!5D"A$D[E?,()Q@
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M$4@2/( =HX&.U>R4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)R, CG?B]\?]4\&>'_\ B0?$VXU6XMM'EUC3[R\MK>TCU"(7P4/&WEM]KVQ
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MXN-X1U'Q/91^+K?P?X:U3Q]KT%_XG\M9HK.X"0FVCD?[L0<^80S8!,87/)!
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MLKO]&TT:-I%E8">6Z%K"D(FFV[W"@#+;0!GCL /:KE% !1110 4444 %%%%
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MQ."8F :,^@8 >26_QB\1:[XWTS0#\3IK"WN?B!K>A32VXL!+]CALVDA4%H2
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MXT^++:WU&SC^)=CJ%[>^$= UV"77IK:WABNKB=HYX5EAB_=)(H5 [*^QG#4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>_"Q/'.LZ7JL?B36?#UYI\4L"G31:RQ31R%"RO%<P3(3E%PP4,.1G!(KN**
M,CPIX7L?!NAP:5IZE;>)G<LP4-)([%W<A0%RS,Q. !SP .*UZ** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K"\9^.?#_PZT"76_$VKVFB
M:3$RH]W>2!(PS'"C/J2< 5NUG:]=V&E:7<:KJ2Q"VTV-[QI9%!\D(C%G&>AV
M[N1V)H S/ ?Q'\,?%#1I-6\*:W::]IL<[6SW-E)O195"DH3Z@,I_$5TE>7_"
M74+/PGX.\.C7[J*P\1>,;N?4A;S'#S7,X:X,0]3'$ OTCKU"@#,\1^)=+\(Z
M1+JFL7L>GV$3*KSRYP"S!5''))8@ #N:X<_M*?#(6UY<'QA8"&S$WGN0^(S"
MI:53\OWD4$E>H Z5Z//#%,H\Y$=48.-X!"D'(//<'G-?&6B:UH]]^S%^TU.E
M]8W"P:]XG<2B5&$9=&53G/&X$@'ODB@#Z\U'Q1IFE>'_ .W+FY*Z7L243I&[
MY5R I"J"W.X=N]:M?$FM_&G7_ _A'XAV5A\1&F&D:)X;U/3KB;[$7MS<R&.>
M%<1 &,JJXR"PSD-S7J_A_P"*FM3_ +1DGAZ?5%UG0KJZN(K-]%NXI%M-ELK^
M1>VS()(L'<Z3HS*^]5./EH ]XU76+'0K076HWD%C;&2.$2W$@1=[N$1<GNS,
MJ@=R15ROG3]HW0I/C[>ZC\--%GTZY;2M/;4;_P W4C;O:7CAEL7^6-R3&RO+
M@@<B(YKC=#_:(O?B=X>^"/V;QNOAK4M7U*\T/Q/;6$EH[K=6]I/YH!E1]N)H
ME92."'7@Y% 'U[17Q/X%^.WC5=/\$7\'C1_&.K:UHGB1!HTR6FRXN;!B+1D6
M*-7\Q]OS?-AMQP!QAC_&_6[_ ,(:=KVB_&Q=0M]2UG0K&YMDTJ"*73)9KD1W
M4,CRJP5RK$F$J&0QY^ZV" ?;$LJ01/)(P2-%+,QZ #J:R_"?BW2/'7A^TUS0
M;Z/4M)NPQ@NH@=L@5BIQD ]5(_"OE+0/CQJMKK=GX;\0>.I8_#$7BW6M%NO%
M\K6R2J(8T>SMYI5C$49<R. ^U2WE!1R3GA?AC\0M6L/ 'A+0=+^)%QH5HG@K
MQ!JKK;?8O,-W;WV8I"9(F(R&;*]".@'- 'W]17Q7!^T%XRTC2]0O+;Q9+XGN
MKWP%I/B=[=;:WG?3Y9;CR[N2"*&-694B)?8V\Y0=<G.A;_$W5]2U_P !6>E_
M',:UX<\2Z_=VZZCIME:PE+<:?))Y*S2I()6250=P *E]C D# !]AY (&1D]!
M3994@B>21@J(I9F/8#J:^._@A\0;SQQ\2_@]K.O^+;B]N;[POJ]L&6Y6.&^N
MH;Z*/_5IA#(8UW,% X&< "O0OB1\5-:\+?'C2]*&IK=^'IIK"WEL=+NXDOK!
MY&?+SVTB9FMY!MS+&X:+RV.,;C0![;X2\7:1XZ\/6FN:#?1ZEI-V&,%U$"%D
M"L5.,@'[RD?A3?$_C+1?!D-C+K6H1Z?'?7D5A;-("?-GE;;'&, \L2!Z5\/_
M  G^+UY\.O OA,VOCB=M(U#POXEOGL(+>VN_L<UK=;HI8(@%=WP\A*NY#>P'
M%R_^,LOBO2+_ $[6/%=EJ]GI_CGPI-ILYO8IOW,S6\CD2JB!QO$AZ$*0RAB%
MX /M/P_XUT3Q2^L)I6HQ7K:1=M8WPC!_<3JJLR'(ZA74\9'-/\)>+]'\=Z%#
MK.@W\>I:9,\D<=S$"%9D=D<<@'AE8?A7E/[.NI6E]XU^-R6UU#</'XR?>L4@
M8K_H5J.<=.5(_ ^E>#_#3Q-XX\%:#I;>"]>NO$5^MYXF75/!$D-O)'9+')>3
M6\N%C$T;M*(5P[D.)@ .F #[FK%U?QEHN@ZYHNC7^H16VJ:S))%I]JV=]PR(
M7<+@=E4GG'2O'OV9/'UQ\0WU'58OB1'XWT^:RMFETP:9Y$FDWGS>;'))D;7/
M&8&4%-N1@-BO&+CXM7OB[QQ\-]5O=;:7QSI_B77;>X\'3-%&+&1+.\2TC,>T
M2#<HCPY.)/-R,_+@ ^XJ*^+M%^/OB6?X;:KXQTWXBGQ$8[.P&N:1%H):X\-2
MM<HMY,X'*LD;2?N&4\1[QP#G1LOB-K.H>*/ >E6?QP_MGP[XANM8*:IIEG:0
M9@CM%DB1)I4D$IC<L/,''.T@LN: /L"D)P,GI7PKH?[1/CNP\(^%M9M?&$OB
MW6-<\"ZAJDFF?9[63R[JUF@030Q11J[/L>9BA+!BO &,#KX/C?>V&D:1JEO\
M58O%'@'6O$5M:WOB:VL%A70H&MY&:)[ALK\\R1*6=08?-*D@E=H!]1>%/&6B
M^.-.FO\ 0M0BU*SAN9;-YH<[1-$Y21.0.58$?A6CJ6I6NCZ?<WU]<16EE;1M
M--<3,%2-%&69B>  !UKYS_9XU^[TSX!?$:_\-W'_  E&KV.O>(I[(Y61KN47
M$KQ9V  [_E(P!G/'6O+_ !G\0_\ A/?V9OBAK,GQ73Q-I<NA0M)8K9"SDTN]
M)(DAEER,,^0#;LH*E<C ;% 'U&_Q_P# ,5O+-)X@2$07!M;A);6=)+9PT:DS
M(4W1)F6+YW 7]XO/(KT*OD'QCK[^%_C;K6H^%M:N->\0Z?\ #%KW3M/%Z+AK
MF59V*CRP<R9 #;1U(%5;/X^W.GZ=I>O?\+7'B3X>ZKJUK;:MK-MI@A;P\K6\
MQ9)9\$)OF6%6#J##N/*AUP ?8=S<QVD$DTK;8XT+L<$G &2<#DU!I&K6NO:5
M9ZE8R&:SNXEGAD9&0LC#(.U@".#T(!KY0U;Q))IWQ-\'ZE<?$74KN&7P5K3Z
M?K%QY=I'>S1SPM'(L)7RG/E_-NVX=4#XVU:T?XA>-I/"_P (/%<.KW_B&S\:
M^'$T>Z2W(,5OJ\L*R0WA\L#:"5F5_P"%2%. <T ?6-%?+K?$77A\;YO!5S\1
M&\,:EH^HV*:?HM]IGVF7Q#IYAC,LBG(WEW,H:1#^Z* D 9!F_; ^,FJ_#<R6
MNB>)Y-"U:+PY?ZO:VSK%%%<RPM'M*NZ.9G4;O]'5<%69F9=HR ?3E%?-O@3X
MQZSKGQSM=+FU:/7=!U)Y?L<VAW44B6NVT20P7ML4$D6#N=)T9E?>JG'RU1^,
M/Q;\6:3XG^).G6&LRZ'K^A6UA<^$M&$<137MXS*-KJ6FW29A*H04P",$YH ]
M[UCXD>&] \16.A7^J1P:I>2QP10^6[ 22;O*1W *HS['VAB"VTXS5KQ/XTT3
MP9#92ZUJ,6GQWMY#I]N9 3YEQ*P6.,8!Y8D"O%_@K-:7'[2GQH/]KO/?I_97
MFV'VP2+&3:Y8;/\ 9;*CTSBO&_'^IVUK>_$6POO%-Q!J:_%70_+AO;Q7>V@9
MK)DD1),@#[^W(VX0\$*: /N>BOBV7X_:WIEO+HVK_$7^R_#\'BO6=#G\;7<$
M,AM_*6-K.*=XU6./=ODPY"AC$H/4Y^B!\0A\/O@;:>)?$VO6^M75OIZ%M3EM
MAIRZC.1MC*Q,Q\LRL5PN?XO2@#OK#6+'59;R*RO(+J2RF-M<K#(&,,H56*/C
M[K;64X/8BKE?(7PUGO\ ]GOX]Q:/XKO=-TNS^)VFM>?:8-3\]7URW&9I1YD:
M!?.CD&!AAF$#VKG_  '\5_%/B>'X>_;?B]?)_P )+I&OO?/$-.4Q/9SCR9(O
MW&$8KN#9R",X P, 'V[17Q)X2_:'\3^.[;PA:ZE\2+?P5JM_H.D:CI<YTI;J
M/7IVS]L1%! D?<OEF)""NX, .HL^'?CCXNL]?T._3QU)XHEO?%/B30ET&86:
MQ7$=M'<R6JKY<:OYFZ*)00V"&QCG) /KB3QEHL?BZ'PNVH1#Q!-9O?I8<[S
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MCUGP)X.U[Q?9>)=;UA/"7CS4CXFT0W)N)9=.:YD0%DP6#HK1S!1C<J$8((H
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M:/:>'M(LM,L(O)L[2)8(4SG"J,#)/)/N>M7:* "BBB@ HHHH **** "BBB@
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M@'U"3@4 @@$'(/>O@F;XU:YXZ^&BZ:OC.\O-4G^%NJW&J0V<X69=6MVC!!V
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MZB!"R!6*G&0#]Y2/PIOBSQEHO@;38M0UW4(]-LY;B*T264$AI97"1IP"<LS
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M1110 4444 %-DC65&1U#HPPRL,@CT-.HH 9%$D$:QQHL<:C"HHP /0"GT44
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M;.;]_M,ZR+.)$)VE7/";2-PYZ4 ?:6GZ[9:I?ZE96TK27.G2+#<H8V4(S('
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M% 'U717P_#^T-XAFTG7K:#XBQ1K;^*O#EM9WT%Q:71>RO! )U\UH0K*6:4Y
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MHH **** *4>C6D6KS:H(B;Z6)8#*SLV(P<A5!.%&3DX R<9S@5=HHH ****
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M7B4:0=,OQ>)JUA_:=E)'$^R:V^7$@8K@??7@D'GIUKH*^)_!_P 7M9\+^ O
M-AH'BNPMHA\(+C5H+2[,+6\=Y EN(YF(4N< R @DK\IXX-7].^/-]+X;U_Q
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M<':  ?0E<SJ'Q)\-:7XIL_#EUJL<6L7<H@B@V.5\TH9%C9P-BN45F",0Q R
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M:FU31;OXAW6HZ)+XDELM!\2W*VL OXQI_G/;O=QQ",>7,=J&.)FD9?+Q]X@
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M,*=2H !]/IXRT67Q?+X634(F\0168U![ 9WK;E]@D/&,;N.N:- \9:+XHO\
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M=0W$2!HA%&C#*R2;@2>5XQC%?6E !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,DACFV^9&LFU@R[A
MG![$>]/HH **** "BO/_ (]^,F\ ?"3Q#KJZG/HS6L2 7]O;I.T&Z1$W[7(0
M ;N78X498YQBOFKP_P#M*Z@FH-I7B?QLNE>$QXDU/3)?%-K-%,MJHMH);")[
MDQ*NQS),5E907\M!D@_, ?:M%?+;_%W4%\<Q>%-=\?ZCX?O1IFE7?AZ\.DQQ
MOXC9F;[41 R89VVJAB4KL5]^!U%'0?C)XPUJ_P##TXU^2V\0R^(-4TSQ+X8D
M2 #2;&-;@Q7 5DW1[!' PD8E9/-YW;EP ?5\LJ01/)(P2-%+,QZ #J:R_"?B
MW2/'7A^TUS0;Z/4M)NPQ@NH@=L@5BIQD ]5(_"ODSP!\7]>3P9\(-6\4_$C4
M&T'QK!,^K>(9OL45O9744.(;9)$A"P^:Q8DN22T052NXJ?-]'^.NH?#[X">'
M+30/&9L=3T[0KK4X[>8011W+KJCJ[@E&,[[ VZ%5151MY8?+@ _1*BOCGQ'\
M;->L?'OB>_MOB0S:9I7CC0M+MM*/V+[/)9WD5OYT;GRO,('FR%2&!!')..+$
M'Q]\1:AX1\4:QIWB2_E^(>B1:HFJ>!$TQ)C9B.8B";9L#J$B4,AR1,7[]@#Z
M^HKQW]G?Q2?&NF:]J-K\1X?B)H=Q+$]E<6UCY/V$F/\ >0F8']XVX;BI :,M
MM/8#QF[^(7Q*\#>+4L[EM=\06WAS7;G1=2=B=NH17XW:3,-JC)C9XXW*D 9R
M0>" #ZX37K&37)]($Q_M""W2ZDB,; +&S,JMNQM/*MP#D8Z55T?QGHNOZ[K6
MC:?J$5UJ>C-$FH6R [K<R*60,2,<@$\9KY1^.?B7Q!IMA\6_!$GC34+\:5\/
M+3452.:-+A;DRSK/+N11)AE12020 >, USNK?$5?"?C;XA^)?"_C[RH[2^\(
M186XMIXM0AFV12"5G5F9?+=L%&7UR<"@#[H>18U+.P51W-9'A+QAHWCO14U?
M0;^/4M->66%;B($*7C=HW'(!X96'X5Y%^TY=QV.K_".]N=:NM&TH>+8H[J>"
M[,$)5K6XV>8>ARX0+GN0!R17@WPQ^*&N^"M.\._\(OXC_MDZS<^,_*\-$V[P
MR7%O//-;&/:HE+L_'+D,'P .* /N^L7PYXRT7Q;-JT6D:A'?2:3>-87JQ@_N
M)U56,9R!R ZGCCFO'_V9/'UQ\0WU#58OB1'XVTZ:RMFETT:9Y$FDWGS>:DDF
M1M<\9@904VY& V*\DNOBG#X6\6?$2PL/%2Z+<:GX_NH"\4L4<<C+I,++')<,
M'\D[T^4*C-(R; ,%B #[5HKXU_X3_P"(_B[X?_#C6M(\0:A=WOCSPJ=,2:PV
MK%8:\J+*ERP"852J3AP1M'EX !-7]3^+OC.?X:Z%XT@OWT>;4W\E_#.J:BEC
M<3K;6S+<"VFF1D$PG#N%?"R+$.0&.0#Z[KFOB1!I%[X'UBRUS4)]+TR]@-G+
M<VDK1SKYOR*(BH)WDL H ))(&#G%>=?$WXGZOH'P/\+>)]--_:07\^E+JFHW
M=LJW6GV,SQBXN)(\%4958[C@JF2>BUXO\3_%=[K/AZ>VUCQ6]WX8L?B/HEMH
M&O"ZBB-[;N]O)*OF( LHA=G42 ?P\DE2: /H'X/>%O#[VEOXJT_Q/?\ C%WA
MDLK?4M3MK6WEA02!98BD%M!AM\0#"12P*8XYKM_"GC+1?'&G37^A:A'J5G#<
MS6<DL0("S1.4D3D#E6!'X5Y#^TK/'INI?!^YN-<O-*TI?%<,-U<QWAAC=6M;
MC9YC=&)<(!GJ6&.2*\'\,_%+7/ <BWGA3Q(-3DU;QAXNM%\-9MW@N)(UNIX"
MN%\WS#+'&!A\$/C'- 'WA7*W7Q4\'67B!=#N/$VEPZNUPEFMH]T@<SMC;".?
M]800=GWL'.,5Y?\ LR>/KCXAOJ&JQ?$B/QMITUE;-+IHTSR)-)O/F\U)),C:
MYXS R@IMR,!L5YGJ>N_\(#\1;BX\%>)=/\7:#J_C%8]7^'&KA3J5C?&["R7E
M@ZG>%5U\XI(K)M#,&7D4 ?8H8'."#C@XHW#.,C/7%?$NA_$M_!GA[4M*'CF_
ML=8O/'6N6<PO;M/EV&X>"*2>17,!91&R*$9I-J* %8FLOPQ\9O$=T;GQO%K=
MWJWBRZ^%VGZE;6$3>9'/=++.MX\5JH =HP [(H^\ ".0* /N^BO'?V=_%C^,
M-,U[4[/XB0?$C19I8I+&:"Q$(LR8_P!Y 9@<2'< Q4@-'NVGL!YK\//BYXK\
M6:IX&DGUZ5M1U.XU2T\9>'7$4?\ 84<22E)0 H>#RV6- S$B02 \G! ![7K.
MN>$OC!::]X%M]>N$NIK1C,^G,\,JQ"0QM)#*R[) LBE&V[ER"K#DBL#P7=>
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!C2D^)X\=ZCJ>JZ[K%LD\>F0ZC+&UOI23!!*MNJ1J1N$:C+ER!D C)SZ!10
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M45J?"NGZ7J&L^#-#\"FXUS6+"V?27?P[KUW$T$%M!I]GYR[D90[JF^0EWD=
MQVLH!^GM%?GUX<DDU+XZZ)=Z]_8I\2Z9JFF:9IO@F[@N+C5]&TZ*QBE>[@F\
M[>D:N7+,4838*.S$A1@>!/%/A32W\2ZUKLFFVGA*Q\.3VOB[Q?X;UMI)O$5]
M=747V=)I2L?E3$+)^[D;?$LC*QC7&0#])**^)M+\&>!M7^"$L>BZ7X*\0)XR
M\3);^'-!TB2'4](T&Y>%8W*E"8V>.*.6>7: I;(&<[F;\1/"?B7P5XH^&'PI
MT/P9K5K\.;'7;!-/ET_4;)5U8PYN[J:X#7"R@+Y;?NR@4G<W)\M  ?;=%?)
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MY&X '+'   P*Z>BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ctso-20221231xex10d30g003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ctso-20221231xex10d30g003.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1, U$# 2(  A$! Q$!_\0
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MBB@ HHHH **8TJ)(B,ZJ[YVJ3R<=<"GT %%%% !1110 4444 %%%% !1110
M4444 %%%% !13)94A7=(ZQKD#+' S3Z "BBB@ HIDLJ0(7D=8T'5F. *?0 4
M44C,%!)( '))[4 +138Y%E171@Z,,AE.013J "BBB@ HHHH **** "BBB@ H
MHHH ***9%*DR[HW61<D94Y&: 'T444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&-1X-IYSYVD9,>#_ *K;@ 8K[YF@CN8S'+&DJ'JKJ"/R-24 >)W?CGQ)X?\
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M8EB<8'?5\2W7C/X*_$6]UR[T_2OBO\$/$_CF.Z-Y%\FL^'M4:Z6$=>75)4"
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M4'[3FEQV/[(_QEN/$.F:1I7CS4-%N#<P:7RLEC#>,+5R=JE@%D&'9022?3@
M^R+#6].U6&26RO[6\BC^^]O,KJOU(/%4HO&OAZ:58H]>TR25V"JBWD98D] !
MNZU\&?LR7XU;]KCP.FNVJ> M4TKX;64.EV5H_F1^*X'A5FG>7:@S%G_5%6(*
MD[L+4/[(6DC4=;^,*Z[I6CR_#VV^(&M7>J7UV<S6\T7E/;E04^10REMP;=N
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M*^9/B7\<_'_ASQ)X_.CWGAYM(\,WNA)!!/ITLDEU#?.J.&E$X *[]P8+S@#
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M89 /K&BOC9OVDO%4+:;X]N=0B%A_PK*+Q'+H,<8%H+J2=$=R<E]JY#'DD*I
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M@, H;<'P!D* #ZJN_A/X(O\ P[-H%SX-\/W&A3.LDNERZ7 UK(R@!6:(KM)
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M! ((YSPD_P"QOX)N(=##7^LBYT[Q._BZXNO,MVDU/4'#!FN=T)!0JQ78@0
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MO95*D(& YQD@$'PA_:!L/BKX^^(/A1;"33+[PQ=PB 3'F^LI8PT5T@_N,PD
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M78_LE>#K+P[HOA?[5J<W@K1M9_MVQ\.2R1FVCN!(TJ(6V>8T22,75"W7&20
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M\,? +1?"NM:EK=KJ>IMKNK:RFMZIJ+F$R7LJ1-%'$P\O"Q(C$*J!2.NXDDD
M/@9\;-,^.^BW'B+0+N"ZT"2.!K8+&4N(79,RQ3@L<.C J1@8QWKTZN,^'WPC
M\-?"_4_%5YX<LO[.'B34?[5OK>/ B^TE%1W1<?+NVAB/4D]Z[.@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI]G)-+:0/<0K;W#(K21*^\(V.5#8&<'C.!FIJ\J_X7)XN_Z(3\0/_ [P]_\
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MN6EWJ9U"Q$J0/+,CA$<<H,IP-Q9^.2SMN+ XKT6WB:&)4>9YV'620*&/_?(
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MYK:%<T6[7U-FBBBH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ IK1H_WE#?49IU1R7,4,D4<DJ))*2L:,P!<@9(
M[\#- !Y$7_/-/^^11Y$7_/-/^^14E175U#8VTMQ<S1V]O$I>265@JHHZDD\
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MV&."R[0#@=<5VFI?M > ]9ACAO\ PWXXOH8Y4G2.Y^&?B"15D1@R. ; X96
M(/4$ BHM1^.OP\U><37WA7QI>S""2V$EQ\,=?D8128$D>38'Y6P-R]#@9Z5C
M"LHQ46N_XFLJ-Y.2?;\#D8OBWXF\+13'Q+XI\ZVU#PA#K\=U;:5&9+&X>:.+
MRX8P?WBL95 $A)#<EL' H:;\7O'TQO-!DOKBPU*+Q?8:(MYK5E9O=QV]Q:^:
MWF);.82X/*D'IC<.HKLK_P"+_P +]4MWM[SP5XMNH&L_[/:.;X6Z\P-MD'R,
M'3_]7D [.G XXJMH_P 3?A)X>MHK?3/ /BBPABG2Z1+?X5:Z@$R@A9>-/^^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M78FFFLEAM]TUT!@B7SW<989Y(!.*^J:* "BBB@ HHHH **** "BBB@ HHHH
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M@I=Q'^Y*C*WL2P[5] 4F "3CDTM !1110 4444 %%%% !1110 4444 %%%%
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M!J7EJ\MFK9!:1-WW<;L8..:ZVRU*TU)&>SNH;I%QEH) X&5##H>ZLI'L0>]
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3@<FNMKRK_AFGPC_ -!?X@?^''\0_P#R=1_PS3X1_P"@O\0/_#C^(?\ Y.H
M]5HKRK_AFGPC_P!!?X@?^''\0_\ R=1_PS3X1_Z"_P 0/_#C^(?_ ).H ]5H
MKRK_ (9I\(_]!?X@?^''\0__ "=1_P ,T^$?^@O\0/\ PX_B'_Y.H ]5HKRK
M_AFGPC_T%_B!_P"''\0__)U'_#-/A'_H+_$#_P ./XA_^3J /5:*\J_X9I\(
M_P#07^('_AQ_$/\ \G4?\,T^$?\ H+_$#_PX_B'_ .3J /5:*\J_X9I\(_\
M07^('_AQ_$/_ ,G4?\,T^$?^@O\ $#_PX_B'_P"3J /5:*\J_P"&:?"/_07^
M('_AQ_$/_P G4?\ #-/A'_H+_$#_ ,./XA_^3J /5:*\J_X9I\(_]!?X@?\
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M*VX@_='-<9^S[\1/%=CI?PZTK6UL+W2?$::A';3I)*]Y$\#/(&E=CM8,H88
M&W Y;ME["23;W7^3?Z%^VBVK;/\ S2_4^DJ***YSH"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6]*^&'AG1$\/+9:8(%\/F8Z;^_E;[.901)U8[LAC][.,\8JHVF_$,XV^(_#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW6B?V5]F58EAV":2=?M,?EM&V1&V"I^7DD5Z'_PCGQO_ .BA_#__ ,(.^_\
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M:G?Z+=6UEIFN:C.6MUTZ'3_LDEO-'#(A7_2I)7+)OWG&2?EX!'HO_".?&_\
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M!;HH E$:AR2O#'(.3SGUKJJ\J_X1SXW_ /10_A__ .$'??\ RYH_X1SXW_\
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M'P_KV_9]D_L+09],\K&[?YGFWMSYF<IC&S;M;.[<-H!U=%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!<L 3;*-GSLN?F(("G@\\4 =U16=XCUZT\+:!J.L7S,MG8V[W$I12S;54D@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112$9!
M )'N.U "T5\<S?M3>)= T;7[I_$VBZSXDL/'$OAFR\)26R+<:A;K<K$-NQPR
M2;&9_,(*?(<J!7T1_P +J\/_ &_Q+8^3J O?#][:Z?>6YMB)#+<%1#Y8)_>*
MV]<,O'7T. #OJP?'_B.3P?X$\1Z]#$L\NEZ;<WR1.<*[11,X4^QVXJUH/B*V
M\1+?&VAO(?L5W)92"\M)+<LZ8R4WJ-Z<\.N5/8FN=^.'_)%O'_\ V+^H?^DT
ME:TDI5(I]T9U&U"378K6/P5\.S6D3^(('\3:NR@W.I:E*\CRR'[Q5<[8UST1
M %4< 55\1_L_^$=?T<:9#;3:+:M*\DXTQE0W"O;SVSQN75OE:*YE&5PPR"&!
M%>C32&*&1PC2%5+!%ZM["OF?X)ZCXK\6^#OAM\5=:^+$ME+XKDAGO/#5_%:C
M2G2X5S'I]JNQ)4GC.Q5<R,S-&^Y6W8!*K.2LY:!&G".J1V?_  RCX21+H0ZA
MK$#SF-C*LD#.ACD21"C-"2IS&NXCF4Y:7S&PPQ?%'[&OAO6M+O[;3];U+3Y[
MM9HR\RQ30QI*RM*1"%13(=N1(VY@V&)+*I7S'X??M>^.?#'P>L-2\7^%[37+
M^3PA<>)=.NX-7Q-J(@N[>VD2X7[.%@9C=1,NPR#&0<&NK\2_M'^-?A_J7BE=
M1\*I?:Q9W.DVMY;6VHW%YI6EK/;7,KW ,%@;GR_W**Q\M_FD4_(JL:R-#M;C
M]D'P//<7,JW&K0^>%WQK/$T>X&([MC1E<DPJ6!!#EFW!N,6]2_9=\,WFMZ=J
MD-Y?07%H;2-@Q1A)! D,;1Y4*3YD<"QMN++LDF"JID)KR+6?VF_%VL:K?:A
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MVU]- BG,4?W?+* X)8*&."Q5?6: "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/DL2PED58\2>;&5"H PPH5F^7KBI-?\ &WAWPK+%%K>OZ7H\LJEHTO[R.!G
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M@+_H=_#G_@VM_P#XNNK^SQ?\\T_[Y%'D1?\ /-/^^10!RG_"X? 7_0[^'/\
MP;6__P 72#XR> &9@/''ALE>H&KV_'_C]=9Y$7_/-/\ OD4?9XO^>:?]\B@#
ME/\ A</@+_H=_#G_ (-K?_XNC_A</@+_ *'?PY_X-K?_ .+KJ_(B_P">:?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK1+*#P.ND_8?#\5E'K+7J7<D$:R9%@978SN%X;<<IZ'->DT4 >::M^TW\'M
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MQ_\ CM'_  UC\$/^BR?#_P#\*BQ_^.UZK10!Y5_PUC\$/^BR?#__ ,*BQ_\
MCM=5X%^+'@?XH?;O^$-\9>'_ !;]AV?:_P"PM4@O?L^_=L\SRG;;NV/C.,[6
MQT-=710 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
? %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ctso-20221231xex10d30g004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ctso-20221231xex10d30g004.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1, U$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M HHHH *N:/\ \A>Q_P"NZ?\ H0JG5S1_^0O8_P#7=/\ T(4 >I4444 %%%%
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M/W?PR77]1LM0L/!^E7B)!'+(Y6]E95B*;U&](;<R1*[$,<YV\G%?1_ /Q2\
M1:SX7\)-X<3P_J&LW&I6OB&]NY?MFGQ7$YGFC-GY#),X9Y C&500PW#Y<-ZS
MJ/Q \+Z1+<Q7_B32+*2V=XYTN+Z*,Q,D7G.K L-I6+]X0>B_-TYK=CD66-71
M@Z, RLIR"#T(- 'S2_[+_BG[4OC)?%;GX@KXG_X2(6C7/_$I(W^28<^1YO\
MQY?NL]-W.,5N_#3]F"P\"_#35+)K+3QXVO[74[>34X)YFB;[3)*R9W <!70'
M"=CC/?WNB@#Y\@_91TW1O@G8^'= AL-'\86UOIDQU /++;2WMF\4JE@QSY;2
M1D' !PV<9XJ+XH?#OXM?&GP3KNDZU9^%-'M94LQ:Z%%JL]Q#=2Q7<4TLDUW]
ME5XE*1E%5(V^\23T ]I\8?$'PM\/+*"\\5>)=(\,VD\GDPSZQ?Q6D<CX)VJT
MC $X!.!S@&K^@>(M*\5Z1;ZKHFIV>L:7<C=#>V%PD\,HSC*NA*L,@]#0!X+I
M_P"SMJFM:/\ V;-IVG?"Z&WOX-3C?PEKC:R+V:(/L$Z7M@BA4+!UP&^8 \;1
M53P%\!_B!\(=,\!:II5]I7C#Q%HFBSZ#J5EJEV;*&>WDE29#!/%;-@QNF,/%
M\RL<D$#/TK532M6L==T^&_TV]M]0L9QNBN;6598I!G&5920>0>E '@&N_"WX
ML7]Y+XA>X\,ZGXCUC1+[0K^UDN9K>UTV&:;S(&A=8&:?R@65MZQF3(.5Z5SS
M_L>^(&T'5;V/QA-;>+;:YLI=!CAGQIR)IZ(E@)P83)DA'+[#@&9P-W4_5=4[
M#6;#5)KV&ROK:\FLIOL]U'!,KM!+M#;' /RMM93@X.&![T ?.+?LO^+'E3QE
M_P )44^(H\2_\)$;-;K.D#+>2803!YN/L?[K./O<[<573]C;68_$VH@?$[73
MX>U'1KFPNI/)LA?22SW2SR986N&1L-N9B6.=OW:^HJ* /F33?V;/$_AKP_JE
MK>IX:^*$,OBE]:ATGQ7;Q0P_9S!Y0*-#:[(I\X.#$Z87"[<DCHOA[\ ]<\/#
MX;6VKW>G/I'AF;4]3DTVTDD:*"[G<_98H R#=#;QRS(I.TC"$*.B^P>*_&7A
M_P ":2=5\2ZYIOAW3 ZQ&]U6[CM80[?=7?(0N3V&>:/"OC/P_P".M+_M+PUK
MNF^(=.WF/[9I5Y'<P[AU7?&2,CTS0!\ZVW[-?BCPQX]NM8\.:5X3BNH-?U#Q
M':^)+BZFCO[O[1%+MT^X58"1")91N82,-J*0F[I=T/X<?&S0O!'B-[6V\(Q?
M$C7)(#>^*)O$=S<-,@)#B-3IH6W6-"1"@615+$L&.XO]+44 ?(^M?LIZS?6]
MA=IX'\%W=X-%O-$EL-5URXOTADFE$JZD+E[)7DN"[2E\QJWS K(.16]J7[-W
MB*[\3:5_Q*O"+S6M]I=ZWCY/,BUYEM8HDEB=?+;S&E\MDW^<J[)6!0D?-]-4
M4 > _#;]EZP^'_P9ET2+3-#E\:7.BS:==W=QY]S8W+OG(D0E2T9.,@!3C-<G
MIG[-7BS3M?3QCHVB^$/!NKZ;?6-YI_A32;J3^RIVA@N(+AY9%MT,;RQW)4,L
M3%1#'G=R!]23WEO;201S3QQ23OY<2.X4R-@G:H/4X!.!V!J:@#P;QAHOQ[\4
M^'-02RG\+Z)<:C>0Q'3;?5YXWL;!4;S?*OA9.3<2L0-QAVQJ/ERWS5B^)/A+
M\1]2T;PEX8L/"O@VU\ :;:_\3#PM'XKO(ENYUD)1)+C^S6::# #LI5#(['>6
M4'=[AXS^)'A/X<V]O/XJ\2Z3X<AN&*0OJM[';B4@9(7>1G Y..@ZUN6%_;:I
M907EE<17EG<(LL-Q X>.1",AE8<$$<@B@#Y_L_@/KLOQ:TO7V\->"_#R66NS
M:S-XDT)I$U.^A>%T^R2H81D$N-[F4JPC4B-2<+]#U#:WEO?1F2VGCN(P[1EX
MG# ,I(9<CN""".Q%34 %%%5-.U:QU=;AK&]M[T6\SVTQMY5D\J5#AXVP3AE/
M!4\CO0!;HHJ%KRW2[CM6GC6YD1I$A+@.RJ0&8+U(&X9/N/6@":BBB@ HHHH
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M1:U;:O&+?4Y([2ZU:YOIOM46Q#OB^W1I=+&&++MEWD$-AV7&/9Z** "BBB@
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MQBN:G_9V\!7?C'3]=N/#.D7,6FZ;'IVGZ7-IMNUK9!)FE62%"G[M\N1E<<4
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M-7LK/3=3U.YBTYQ%<V=Q<8N6@@*%H_LK\I$"5D0XSDFC8_M8ZU!X/US4M/\
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M?@IX:GT+PM9+96$U[<7SJ$129)9"Y'R*HPH(1>,A549.,UVM !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '.?$CQ'<^#_ (>>*->LTBEO
M-+TNZOH4G!,;/'$SJ& ()&5&<$''<5YKX;_:ATO4KK3;"]T#6DD>XT_3;W6(
M+>+^SH+Z[MXIHHQF;S2K>:JY",%)&XC()]8\5^'+;QAX6UC0;UY8K/5+.:RF
M> @2*DB%&*D@@'#'&01GL:X.Q_9W\.:?8/:1WNJ-&^K:=K)+2QY\ZRB@BB7_
M %?W"MNA8=22V"O  !YQX<_:OU#7);A)-*DAT^*#1I8]:^P)Y<[7M\]L4^SB
M\+I]W ;<VTJ[$,-JMI^-_P!K:TTF/4M.TW0M1TWQ#"L4]I'K\,2QW,'VZ"VE
M?RHYS-$0)P5$R1DY! (!%;-C^R;X7TZ""V@UK7TLTM[""2W\ZWVS&SO#=P.Q
M\G<&#LZG:5!5CQN 88NG_L1^"].,"IK>OM%;PM;PQ V485&N8;D[FCME:5M]
MO'\\A=R,Y8DYH ['PK^T1HOC76_$>FZ+H>MZ@^BFZ1Y8$MW6>6!_+>)568O$
MY;[HG6+>.5R.:N?$[QSX@TS6O!WAKPL-/L];\1RW!%WK5M)<06L4$)E<M%'+
M&78DHH < ;B><8.?9_LYZ79>.[SQ>GB77WUU[>[MK.ZE-F\FGK<$%_+D-N9)
M0I4;%N&E5   N*Z3Q_\ #*/QTNAW,>N:GH.N:+,TUCK.FB SH7C,<@*RQO&R
MNK'(*=0",$"@!_P?\=3_ !)^'&C>(;JUCLKVY1X[F"%BT:31R-%($)Y*[T;&
M><8KLJP? O@S3_A[X2TOP[I7FFQT^+RD>X??)(<DL[M@99F)8G Y)XK>H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *^>OB_^U#/\+_BQ/X(CLK.\O[_ $RQDT6.;?$IN[BYE@+7,^2L=NNV+)P&
M+,%&YF45]"UPGB7X+^&_&&N>(M2UB*:_77M&CT.\LY&7R#;I)(ZLH"[@^Z5O
MFW<84@ C- '/:]\>[?X<:OHN@>+=.OYKZXEL[&YURPM([;33=7#!$$4<UQYT
MB[F )B64)GYF&#C@_&'[<'A6/1_$47A<BXUFTM[J33)KYH7M;Y[=PLP$<4_G
MH!\Q'FI'N"DJ6%;LW['7AJ\U:+4KSQ1XFO[P2Z?/-<736,DUQ)9F,PL\QM?-
M /E)N175&Y.W<23:?]D?PN^G:II2Z_XBBT&\CN8H=(BGMD@LQ.^]_+80>8^#
MG:)GD" G:!Q@ ;!^V5\.'\3WVD3WTMK#:->Q_P!IR/ T$LEHCO<*L:2M.NU8
MY,,\2JVP[6;C-/2/VT_!6O+'#I^E:W?:M/<VMO;:3:&SGN)Q<B3R7!CN6C12
M8F!$CJR'&]5'-;EI^RWX6MKW4U;4]:FT"_-ZS^'6FA2R5KL,)R&2)9V!\QR%
M>5E4ME5&!B3P_P#LTZ-HESI5Q<>)?$>LRZ7>VMY:?;I;95C\A)%CCV0P1JP(
ME;<[ R-A<N<4 3Z_\:+B^^!FN^/?"VFNMYI0G:?3-9A_>1-;3%+J)Q'(1O C
ME *NRY .6'7SK7_VK-;L/$7CR"QT[3+C2+>S:/PG<,DA:_U"-K>*6.4A\,GG
M7<*@)M.$?)]/=/#/PXTKPOX:U70H6GN[#4[N]N[A;IE8EKJ5Y)5&% VYD8 8
MSC&2>M<+I7[*W@W2?#?P^T5)]5G@\%:BVIV4\]PC2W4K,SL+AM@#J7*N0 O,
M:<\8(!S7BO\ ;+\+:')X@T6UD$_B'3H;VUANG:$V<^I6UN\KP>4)_M 7,;#<
M8PAVD"0G%7[7]KKP[I7A&/4/%>D:OX;U?['87*:;>Q00O?"Z)6)X&,Y14+JX
M_?.A0+EPO6M6^_9<\.WNI:Y*FN:_9Z7J\EY<3Z-:S6Z6RSW,;I-(K>3YQSYC
M.(VD:,,<[.!58_LH>'+K33#J7B+Q'K&IPQV4-AK-]-;-=:=':,S0)"%@$1 +
MOGS8W+[B'+"@"3P?^U;X5\>ZSIFF:'IFKWUS<K<O=O&;0PZ8L$B1S-<2BXV$
M*98SF)I-P;*YJ/XN^.?'NC>(?!A\&>)/"/\ 8?B35H]'4:AH=Q?20L89I&E$
ML5_$KC,.-FP8R?F.*W_"_P"S]H'AW5/[0N[_ %+Q+<2:?=:;<C6C!+%<Q7$J
M22!XDB1 ,QJH1%5 N1MYS6S?_"#PU<0^%+:QL8]!L?#6IC5;&QTB&*V@$OER
MH0R!,;3YSDA<'.#GKD QG^.&EZ#;7UMJZW-WJ.DZS9>';Z>RM%BBEO+B.%UD
MC1IF*Q?OESEBPY'S8R>3@_:^T6ZTBPU*'P/XREM[[29M?A"VUGN_LZ+9YER1
M]JX4>8,*?G;!PIXST'B7]G#1O$_BZYUN3Q#X@LK>ZU2TUJYT>TFMQ9S7ENJ)
M'*VZ%I?NQH"HD"G&<9YJS8?L[^'-.T>PTV.]U1H+/PM-X1C9Y8]QM)-FYS^[
MQYO[L8.-O7Y30!@W_P"V#\/;'QE#X>-S<3%Y[:U>_1[<11SW"*\,1C:43L6$
MD?S+$R*7 9@<X[_X5?$F#XL^#[/Q-9:-JNCZ9?*LMG_:RPI)<1,H*R*L<CX4
MYQAMK<=,8)XVR_9@\/:7KR:AI^N:]86S/;SW.F6\MNL%W-#"D22._D^<"5C3
M<D<B(Q7E3DY]$\">#K+X>^#-$\,Z=+/-8:3:1V<$ETRM*R(H4%BH )P.< ?2
M@#>HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /+OCO\ '&+X)Z9I-R-&EU^XO9W:6U@F\MK>RA0R75U]
MUMPB09V\;BRC(SFNBU'XM^$M*75FN=81%TJ*SFO&6&1Q&ETVVW8%5.[>1_#G
M'?%<UXX_9\T+XG?$!_$/BR:75K"+2O[,L=*BDFMEMM[EKB1I(Y09/, B7:0
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M+,WF\# ^Z>:5_P!H[POX:T^Q7QAJ6GZ?J\]F=1DB\//=:S9Q6OFM'YYNH[9
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%<:CXC@U?1_#%A=:;H%G#IY@EAAGD1F-Q(97$KJD:("JH, D@D\>R4 %%%%
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MJ]];7=\'N8+.WL[!4:>XGFD6.*--[*@+,P&695'<BO+OA/X+^*/AOQQK&O\
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M3^+GA;QTT0T&_GU)9)$C\R*PN B,]LERF]C& @,4B,"Q RP7[WRUV-?$FE?
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M<!+:V6:W\O"K$8+>=AG*AI"0,G !]A-JUBFJIIC7MN-2>%KE+,RKYS1*P5I
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MPG=A_P \;G_OE?\ XJ@#HZ*YS_A.[#_GC<_]\K_\51_PG=A_SQN?^^5_^*H
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MW8?\\;G_ +Y7_P"*H Z.BN<_X3NP_P">-S_WRO\ \51_PG=A_P \;G_OE?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:6"*3;ED.=B<J1\PY(![!_P@'_3_ /\ D'_[*C_A /\ I_\ _(/_ -E77T4
M<A_P@'_3_P#^0?\ [*C_ (5_SG[?S_UQ_P#LJZ^B@#D/^$ _Z?\ _P @_P#V
M5'_" ?\ 3_\ ^0?_ +*NOHH Y#_A /\ I_\ _(/_ -E1_P (!_T__P#D'_[*
MNOHH Y#_ (0#_I__ /(/_P!E1_P@'_3_ /\ D'_[*NOHH Y#_A /^G__ ,@_
M_94?\(!_T_\ _D'_ .RKKZ* .0_X0#_I_P#_ "#_ /94?\(!_P!/_P#Y!_\
MLJZ^B@#D/^$ _P"G_P#\@_\ V5'_  @'_3__ .0?_LJZ^B@#D/\ A /^G_\
M\@__ &5'_" ?]/\ _P"0?_LJZ^B@#D/^$ _Z?_\ R#_]E1_P@'_3_P#^0?\
M[*NOHH Y#_A /^G_ /\ (/\ ]E1_P@'_ $__ /D'_P"RKKZ* .0_X0#_ *?_
M /R#_P#94?\ " ?]/_\ Y!_^RIGQF\07_A/X1>-=;TJ?[+J>G:->7=K-L5_+
ME2%F1MK J<$ X((]:\)U_P#:HUSPYJ?@>^U7PUXDT313H>HZCJ::A:V:C4WB
MMHGC$+)*Y4[V)_@'S#/ P #WG_A /^G_ /\ (/\ ]E1_P@'_ $__ /D'_P"R
MKQ?QW^TKX@\*ZKIFG:[I$?A34;'4K*[U.&PNUU*&ZTR:WO'(61H8RL@:U8,
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MG_\ \@__ &5=?10!R'_" ?\ 3_\ ^0?_ +*C_A /^G__ ,@__95U]% '(?\
M" ?]/_\ Y!_^RH_X0#_I_P#_ "#_ /95U]><:9XNU:X_:%U_PS)=[M$M?#=C
M?PVOEH-L\EQ<H[[L;CE8T&"<#' Y- &Q_P (!_T__P#D'_[*C_A /^G_ /\
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M\+,\#6'B!M/;2IIGF@GLC*)1#+#,\,BAP!N7=&V&P,C!P.E #?\ A /^G_\
M\@__ &5'_" ?]/\ _P"0?_LJZ^B@#D/^$ _Z?_\ R#_]E1_P@'_3_P#^0?\
M[*NOHH Y#_A /^G_ /\ (/\ ]E1_P@'_ $__ /D'_P"RKKZ* .0_X0#_ *?_
M /R#_P#94?\ " ?]/_\ Y!_^RKKZ* .0_P"$ _Z?_P#R#_\ 94?\(!_T_P#_
M )!_^RKKZ* .0_X0#_I__P#(/_V5'_" ?]/_ /Y!_P#LJZ^B@#D/^$ _Z?\
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M66:<1>8[X>61I9#EB3R[L<9XS@8'%:U% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"$GQ&FNOBCHFIZ-K,MG#KNBZ[_ &C:?V[?7]X95MY'C6^:4)"LP*Y584&
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M]C3Q=;>$K32K;1?!?@R_MO"]YH5YJ6B:O=7+:Y)+;>4GVA&M(A'&) )21YC
M@ =\]MK?[,OBS6AJ'A_[7H=KH%[XB_X2,^(HII3JT+^2%\A8O*"$ C8)?.'[
MOY=G>OIZB@#YNTGX ^+[[_A!(-:TOP18VOA6ZTL!],$LL]Y#:),-[2- FSYI
M$9(,,JG>?,)->K_![P)>?#OPSJ.F7LEL[3ZUJ6HQ"T9BBQ7%U),B\J,,%<9
M&,YP3UKI-+\5:7K.MZSI%G=>=J.CO%'?0^6Z^2TD8D09( ;*D'Y2<=\&M:@
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MVUW!!+*0P*YCS'S&"&Y->YUB6OC/1KSQ+JWA^*]']KZ5;PW5W;/&Z>7%+O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ(L2*B*$11@*HP /04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "O"_P!H7X:^+/$.M:7JO@>(?;]4LYO#&M3"=(C!I\[*QNAN(W-"5<JH
MRW[TX%>Z5RWC+XI^#/AW-:1>*O%>B^');O/V=-5OXK9I0" 2H=AD#(R>@R*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^HH 0# I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHM,LX+CSX[2".?G]XL8#<DD\XSR68_4GUJS110 4444 %%%% !1110 4444
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M2YMI")A\J[8W#D$OMQ0!]N45\F>,?VIO'/A_2AXBM8/"[Z1>RZ_!9Z3/#/\
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M2A+E5\P8R0#[$HKX^US]HGXC^*?"/B[18XM#\(:YH^@ZK?7NH7A8-.L)\M1
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>G?TKEOAYK?P)U'PQ-XBT30?!N@^&UL[/4'U1X--MH DCF2(/M;=&R21 _O
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M%OO&.,IM0GOM S6UK?@[0/$OA]M!U?0]-U70V18SIE[:1S6Q5<;5\I@5P,#
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MES&-.O\ 489;"32HXM6UB\ODM;1\;X+<32MY*G:O^KVGY5&<*,>HT4 >7O\
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MN(+26[A66&"6Z2+R4=@?E#LI;&<#->RT %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4C)4B@#V;3/%G@'PUK%MX6T[6?#>E:K?EKR#1;6ZMX9[DRDR-*L*D,Y<EF+
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNPC#;:Z?Q;\4O#7@C4-#L=6OIDO-;9UT^"TLI[IY]@4N0(4?"J&#%C@ 9).
M2 #JZ*\WL?VB_A[J%IJ-U%X@*6UC;_;'EGL;F%9X-XC$MN7C'VE"Y50T.\%F
M4 Y(S7T?X_Z%XH\;^'_#^AQ7%W_:+7T5T]Y!/8W%A+;1PR>7);3Q+("RSJ1N
M"\8(R#0!ZA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!5U2R_M/3+RSW^7]HA>+?C.W<I&<=^M?/'Q2^
M]]>_"?X8?#G3&OKZ\TN6VL)=?M(4ACALEA,%X907)02P/(JJNX[BOIFNI_:T
MO]4L?A3:C1YK^.\N=?TFT*:9J<NG33))>1(\0N(F5XPZDJ6!'!KQ'1_BWXN^
M%5[XV6VT[4[6^&J:3H5IX2\0^(+GQ!/9SSM(?M_FW$JEH94*JD:SA6>,@M&V
M0 #TNS^ _B+Q#X]\;0W^HP:/X"G\2:=JD&F)IX:XO!:VMKY?EW F BC\V$*R
MF)F/E\,H-2_"S]E"3X1:HM[H>LZ LUC9SV>E7$GAD?:4$CJ=UU,+C=,55=O[
MKR W5MQ K*T+]H/X@^)YK301:^&O"_B"&/5;F\U#7$+VDD5FT("B&&Z8P.WG
M@N&E<Q!"</D5E^%_CYXRUS5%TW0KSPK9?;+C7[U[[5)KO4+=DLWM]@@+3H=C
M"9CD;550&5  5(!Z_P#'#X-7?Q=M](6Q\1MX:N=/%XHN$M/M#%;BUDMVV_O$
MVL%D)!YY XKA?$7[&'A_*#P=JL_A*)]+&F7,4@EOTG$4T4]HV))AM\J2+.U>
M&61U^7.1P6D_M6^+-7\C_A'_  Y_Q-O$NIPB!)Q-?K:I_9%M=NJP274*EB9"
M L;Q# 9RK-NSK:=^U!\0]6TS4-<_LKPWI^FZ):Z1/J.GOONI[EKJZD@D6&>*
M?RXP!'O4D2==I&030!V$_P"S-K^H7USJU_XWL9]=N]>?69YHM":.VV/IWV%X
M$B^U%E^3YE<R-@]0PKMOA]\&O^$$UW0M1_M?[;_9?A2U\,>5]E\OS?)?=Y^=
MYQNZ;,'']XUYO9^*O%\W[.?QKU35/$1N-3L+OQ##I]Y8126LMHD+2K&%;S6(
M*[05(VXXZD9/GMI\=?%'P_\ $?@[PUXMUU_[9\/:%JFHRWVH33):ZW9?9(VM
M+N<1*Q=E8,D@5&8.I*CYUR ?:M%?*&D?M+_$+4]6G\-"TT6/7?[;TK3HKZ_T
M:ZLHTAO(+B0L]HURTFY#!D;I$WAN53.:SM5_:T^(/A#PQ:ZSJ^D^']4_M&+4
M+:TM=-MYH3#<VM_#9>;(\DQ#1.93)L^4H%V^8V=P /L"BO&_A=\2O%7C/PCX
MWB\3Z=%I6L:([P)-;*ENTJM;B16:!;B=H'&[&UI"2 K#@X'S[X"U3XC^&/A-
MX>^)6EV'B>TBTOPK<:MJ]UXO\73:M::V_P!B+1".U:ZF,69=K[@(B%!7O@ '
MW-17S+KOQ\^('AB+Q+<WC^%;B+PE;:=<ZG:K9W$,VIB[.X):DW#>5M4A%9A)
MYDBL,)6;X\_:.\3/HWC/0ETZRCUGPQ:ZA/KIADN;?RXUE1; Q/%*LD9FCD#D
MA\_NW QV /JRBOD'Q/\ M!>,(M8\,^,99[!?#4%YXCV>&M.::.]F%A:W("W+
M&0I+N:(/CRU\LE/OGFKWAS]IKXD:K?Z1H5_HVB:7JFOS6"Z?JUW;A+:V2XCG
MD.^V2]DDE&(-L<GF1"1GQA=I! /K"BOE5O&WBE?V-/B)KMQXA,GB2SO=:6/5
M;6\E5(C'?RHGE2%BZ1J  !GY5&.U7]6_:9\2_#;7-1M_&":%J6B:)/#%JFL:
M+!-$@%S:236P57EDVL)(O+;);=Y\3#;G% 'TW17)_#N^\5:IH%E?>*4TVUN[
MFPMIVL["*16MYV4M*C%G;(!*@8Q]ULYR,?''PWUWQ<MU\-=0NIO$NDOK/B&Y
M5O%6J>-;^^L;Y(KF;=9?V>[O$DDL:%(P50 IE6W84@'WG17Q_HW[8WC>7P[=
M>)+_ ,)64>CWNE7.HZ8LA2W-NT<T<:+(_P!ID>X0>8#(ZQ1>65((Y!K2^*WQ
MY\9_#.['VV_\):]KFEV>IW&_2YKRVMEV6]O)&MU;>>P4_O"<LTGR[6786(H
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M2L'$HW89<4 ?3MYIG@71O&/ANRFT;2;?Q'.][=Z0RZ:OFHY :[DCD"?NV;S
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK5;[5[615M)]LMT[O*ICG@DC*CS"%.S>H PV<D@'(6O[8'AC2;F2]CT&YL?
MTF@6>MVVHQK;Q--<75U)"L&PS##%UQN.%W!RS!<,?4OAO\;/#_Q2\)ZMKNCI
M=%=)GEMKZQ41W,\4J('*+]G>5)2592OE.X.X '/%<$G[)'@E++3]!B\0ZXC:
M?I4%E'"+FV:8)#=M<6UR=T).^.5G"GA&!(=7KM+/X(6MOX0O_#L_BGQ#?6>I
M?:O[1EFEMDDNUGA,17]W BPJ@(91 L8W+D[LL" </>_M=^"8))Y-4\/:M8ZW
MIT]K##8WQT]9P;L2>61*;KR8=PAD!662-@0%*Y(!Z(?M->'W\5:#X>31->;5
M-5M+>]:W:"!);2*:1HT+Q-,)9 &1MQ@24*/F)"D&L32?V/O#VAPWHL?%7B.U
MFNK:ULWD@CTZ.,PVYEV(;=;,6[J?.?<)(F!^4XW -4S_ +('A%]*\.Z1_;&N
M?V'HGDM%I;-:O!))'.9Q(-UN6MV+L<_9FA!4!<8   +5Q^UCX0L(&OK_ $[7
M-/T.9+IM,UB:T0V^K-;DB1+<)(TFXD':)$3>!E<CFI[O]H(VFL:9;WOA;Q-H
M<LD5])+H][HPGN[CR(8I 8)(+AHVR)0/D\S)RK&,J:JW/[)7A/4+7^S]0U?7
M]0T.W6Z&EZ/-<Q+;Z2TY)=[=DB60L"3L,KR; <* *J^+/V:O"GBJ6#3/%?CG
MQ%K&M:A#>1Q2:AJ%JEQ<(\<*2".%85CVQK%&2J1A3N)D#[C0!4N_VLH;^\TF
MST/PKJ<EZ_B.+0M4M;F:R=[(/:O<+(&BNFC?*J#A7)&&! ; -WPM^U;H>J:%
MI5[<:=J]]9M%8+JFOVEA'!8V$]VJ&%)4:X>1<^9&3L\T('7<XZTEK^R[X3\+
M_OCXJUFSO+C5[34X[HFPM_\ 2(('A6..)+98@K1,ZLJIGC*[3DTWPM^R_P""
MSH6F+H?BG6KSPE/%I\T]A;7EM+8ZP;54%O-*ZPESQ%%GR717"+D'N =)X$_:
M'T7Q[XELM(M]#U[3$U WR:?J&HP0K;WCVDOEW"ILE9P5/(+HH8?=)P:H>+_V
MHO#7@G4_$MKJ.DZRMOH-[!IDVH8M8[:>\F2.2*WC:2=3N*R@EF"HH5MSKQG6
MT_X":/H]OH2Z;K.L6%SHG]IFRO(G@:2-KYR\KD/"R$JS?)E<# W!J9X@_9[\
M/>)+/7X[F_U1+O5]6MM<^W1O#YMI>00Q11R1 Q%,;8AE75U.Y@1@X !S-Q^V
M'X17P8WB:UT?7-1TZW:Y34&M1:%-/:#;YBR3-<+#(V&#*D,DC..5#"NU^%GQ
M*G^(>L^-8]EO_9VDZC!;V$L*,KRP265O<!I-Q/S9F;H!P!QG)/"Z_P#L<^&/
M$T<9U'Q+XCN;O[)=6,]Y*;*22:*X8-)M#VI2W/  -LL6!Q7?_"WP+X=\"2^(
MK70M6EU2XEN;<:@DUQ%*]O+'9P0HC!%783%'$Y##)WY& 0  =Y1110 4444
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M$_Q$US1+SQ;$A\1Z?;011O?LD>CFVMFN7M;6)T9CYFX,T(\T?O A#9%?6=%
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M^ ,]ZO:M\(_ VNZ5JNF:CX-T"]T[5I$FU"UGTR%X[N1%"H\JE<.RJJ@,<D
M#I0!\7^)OV\?B;IVB6L]IHWAEAI=UJEKKFJ6EI/J$$GV.=8_M$5O'<I/%:LI
M8F8"<(RE<&O0+G]M+66OM3BM(- FC3QUH?ANRRLVZ>QOH(I7FP75BX\QMIV@
M8 RO6O?]6_9_^&.O:1HVE:E\//"]]IFB_P#(-L[C1[=XK,$Y(B0IA 3R0,9[
MU:O?@I\/=2\4KXEO/ OAN[\0KY6W59])@>Y4Q$&(B0IN!0JNTYR-HQT% 'R5
M??MD_%V'P[!J_P#9?A**UUSQC=>%-&:'3KVZDMQ;23B2>>-9AYK,L2JD:,OS
M9)./EKWO]GKXP>*?B]H?AG6M77PYI4%[I=P]YI5M*[WKW45R8O/A^<@6S*I.
M&!8,P!/!KT'5?A'X&USPM<>&M0\':#>>';BX:[FTJ;386MGG9B[2F/;M+EB6
M+8R22<YJ]HW@#PQX=N;"XTKPYI.FW%A9_P!G6DUI8Q1/;VNX-Y$;*H*Q[@#L
M&!D9Q0!OT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG@?X^_$'0-6UL>/-#M;G2;/6=)T>\O+6\2-]/N;JSM-R1P+&?-C%Q,2S-*&
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M_B3XV\8VFH>'I(;CP5XHTJUM-6N(] DMM4NM0LYHYMD=LUS&D,<YDA8,'1E
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MV!1@*ANII#&N/X5P.G'%5M9^$7A#7[O5KJ^T2&2?5=.&DWCH[Q^9;!F8( K
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 <]XS^(GA;X<V,-[XJ\1Z5X;M)G\N*;5;R.V61L9VJ7(R<
M<X%6])\6:'K[P)IFLZ?J+W%JM]"MI=)*9+=B0LR[2<QD@@,."1UKR/Q]>?\
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MR222R+$OF8AW232N3'M.YR?3 !M:;\7O!6LM"MAXHTR\>:01(D%PKLSE@NW
MYSN(4^AX/-=?7F'AC]GKPSX2\9S^(]/>]BNFL5L(Q]JD+JIO'O9W:4L9)&EG
MD+.68Y&5Z$BO3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *Y;QE\4_!GP[FM(O%7BO1?#DMWG[.FJW\5LTH! )4.PR!D
M9/09%=37S;\?;"\LOB1/JU@OBW0KZXT(6,>JZ'X>/B'3]43S)&-G=VJ02/%M
M+9#AX@PD(+_+B@#Z/BE2>))8G62-U#*Z'(8'H0>XIEW=P6%M+<W,T=O;Q*7D
MFE<*B*.I)/ 'O7Q39P?&)/&F@17D&L>$6ACT1-,T?0-+O[C3((/+B^UQ,8IE
MLT ;SE876650OEDD#,/CCX?_ ! U?X87"3-XZU:\U[3_ !-%JEA/=WTB 1SE
MK!4BSB(E5 38%,BM@[P<4 ?<*L& (((/(([USNE?$GPEKJ:NVF>*-&U(:/N_
MM+['J$4WV+;DMYVUCY>-K?>QT/I69\/&T]]#O/[/7Q#.GEP[K?7XKR-A_HT>
M$C^U@,05QNY/SEPQ#;@/F.73-0\3>.I;3PYX;\0:?H&MZ+;>&[FPU+0'TY/#
MD9NXS+:Q.J*DR-#]I9G!D"E4Q)AP" ?6.G?$3PKJ_B%] L?$ND7>O)"+A]*@
MOHGNEB(!#F(-O"D$')&.159?BMX*;6;#2/\ A+]"&K:@6%GI[:E"+BY*LR-Y
M<9;<^&1AP#RI]*^3O%FC^*_"WCB6S\+Z9J-U!H7BG4O$^R3PU<QW#"2UG&!>
MAC#-&[RHB!/WA! 95\MJZ&_T+3]-\3Z%\,V\,:]I6DV3:3=ZYXFM?"VHWG]M
M7EOL:&**XA@>*-%=5,DSN,9*@<LR@'TQ!\1O"=UJFK:9!XGT:;4M(C,NI6<>
MH1--9(.K3(&S&!ZL!5.'XP> [CPO-XEB\;>')?#D,OD2:PFK0&T23CY&FW[
MW(X)SS7RI;::VEZ1X<L=9\ >(M?N/",?B"7Q)96^A7,G]I+/*QBBA?9MN3/(
MT4@$9; 0EL;:ZSPO?VL^AZQXSUW1/$D7B76]4AEGN['P9>K_ ,(RZVKQ6\D$
M%W:K)<;$RCS)$^6DY54P  ?4NGZC:ZO8V][8W,-[97""6&XMY!)'*A&0RL,@
M@CH16%K/Q-\'^'-$BUG5O%>AZ7H\LS6T>H7NHPPV[RJS*T8D9@I8,C KG(*D
M=C7!_L\>$K@_L]:/X=\0Z?=64;17-LT4@EL[B>W:>39+(FX/"\J$.R @J7(P
MN,#R2WDN/A)\'O!FD:?X!U,>(#J&N66GWR>&;[4(/#]I)?3EIGAMH7?#1&/R
MTP!)D?,%R: /JG4_%&C:+H+ZYJ&K6-AHL<0F?4KFY2.V6,XPYD8A0IR.<XYK
M%O\ XN^!=*TC2]5O?&OAVSTO53MT^]GU6!(;P^D3E]LG_ 2:\OMM-\+>!_AK
MHMA:Z1XP\0:=I>G:9'"L^AW4C6:J[B*]6UFB \^-_G>-$,B@)E,!:\6LI[_0
M_!\GAR;PEXBFO/$5UK%N_CV7P9J-U,FDW%QODD>U@MW\NXG=FVQ%(T 02%0-
MJ, ?:/B+Q5HGA#1Y=7U[6+#1-*BQYE]J-TEO F3@9D<A1DGCFJ&H_$OPAH\.
MCRW_ (JT2RBUDJ-,>YU&&-;XG&! 2P\S.X8VYZCUKQCQQI]AX>U7X?:I867B
MG4O#?AO5+:34+:;3+ZX^SPG3)8;>6* Q[FVLZ>9Y:DJ[$N%(./((?"6L^'_"
MWB2+5?".N7,?BKPIJ.G>';*'2)YVM)9M1NYHK>540_924GMG_>; /+.2"F
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M]TV\\46NFZM,]W T8\Z0W3F#)&"T,;0QL!RNT9Q7T=0 4444 %%%% !1110
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MQ1\/_%?P0U"[TW3;.W\-:=XD.KQ66H3W2VUSJ$T$L:I)<.TLI^63>^<%MQ
M8"@#T_\ 9Z_:)L_CW>_$""VTN\TP^%_$$VD)]IL[F$3PH $E+2QH-[,)-T0R
MR#9N W*3[%7BG[/'@3Q7\.O%7Q;LM<TFWAT;6/%ESXBTG5H+U9/M4=RJ[HVB
MP&C:/RQDG(;=QTR?:Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ***^<?CWK>I?!OQ^WBG0X&EN/&VE_\(W'&BDC^UT8G3W;V*R3*3Z(M 'T=
M17PQXA\6>(?@)X@O/!/AO4-.\.Z#:7>GZ?>^)K@VEBT>W3!(/-NIK>6/?++N
M.Z9&Z%5*EA5O7_VC?BMX?T7P\[WUI>W>J:5#XC^T65CF!K&R:9M1";XD;,L:
MVI!(X,Y*<8H ^W**^&?$G[1WQ3MKW39CK^F^'HM0TN'7-'@U1H;<:G]IN93'
M;>6;666X\N$0(8X"DN7W$MD5MZ7\1K[QA\;O ;:_XZBMM>M=8U]+KPF8+>/^
MPHHK6Y2&8_()0&C"ONF9E?=E0H!% 'V736=4*AF"EC@ GJ?05Y=\4[OPA=_!
MZQE\7ZQ;:KX<NOL>=6N 6L+MV*F&:Y\DA#;.^UG!(C(;!P#7RKI$4WC+X3ZQ
MX<M]8LK+3?"<.MZF-8TPRC29%EG,4!M1$&>*U\IKR,!-^P*V"P - 'WV[K&I
M9V"J.I8X%.KXB^&FH6_B#6]9\.:58Z+X?\!ZIKVG3PV?AR_6YTZWCL[9KF]:
M.5$6/EX[4/L&T-)R=VZN6M=8\ >)O#_C#7?AKK&BZ=X>@T^WT^]L-.U.*75]
M9LO[0@-[J=_'&QD4"(2*K2#S"LDA;:& H _0:BO@KQ-XJ^$'AT^(;.2/PSJW
MA6ZU][?P7I%_?P6_APSFQ@^USDN?)$,,A8[ER0[N$!=JTOB+;>#?#_ASP,-+
M\4Z1XK\<Z+!H9BOIYGDO]6M5F7:-%F+LH,AWAS&)-R_*Y'#  ^XZ*\1_:QT'
M^T_ 6D7[:CJ%LEAK^DN+.UG\J&X9M0MU!F &7"@G"D[<G)!(4CS7QWK'PS\1
M?M.6NAZ?K>@:5XXT_6+*]U77M6U2&/4(BJ+Y6EV".PD;S1C>B#RP)&SN=L
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MYC6YE)'W6:SDD;/K!0!]^45Y7^RM$L'[-OPTB081- M%4>@$0Q7JE !1110
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M#FT_Q'8ZGK]WX3O-6LM,FT[1=1.FZC?016$DSF "6-@YN)OWBQ.'VP$<A2*
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MM!TRXOYKZ73K26]FM_L<MR\"F1X,D^4S8R4R2=IXR3QS7,)\#_AS'H$VAIX
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M&Y<J#M.1D#TKO:* .:A^&?A&W\6S>*8O"^CQ^)9E*2:NMC$+IP0%.9=NXY
M//( '054T?X.^ _#\%W!IG@OP_80WD\=S<1V^F0HLLL;[XW8!<$HPW*?X3R,
M&NPHH \]MOV=_A59W%Y/;_#+P=!/>1R17,L>@6BM.DF?,5R(\L&R=P/!SS6W
MX+^%W@SX;BZ'A+PCH7A87>W[0-%TV&S\[;G;O\M5W8R<9Z9-=/10!0T[0=,T
MC2AI=CIUI9:: ZBSMX%CA 8DL-@ ')8D\<DGUK+'PW\)")HQX6T41M;0613^
MSX<&WA;?#%C;]R-OF5>BGD 5T=% !1110 4444 %%%% !1110 4444 %%%%
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MU:TA\/F>RLO'ME=W.J)<ZKX2C$#K%:6PG :SN9Q)#/R0T19N "#\P Z7Q?\
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MIEOY&FF4,7QM,D98C;@#!H _0'0-?L/$_A_3M;TVX%SI>HVL=Y;7!5D\R&1
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW/%8']L7_P#S_7/_ '^;_&@#U*BO+?[8O_\ G^N?^_S?XT?VQ?\ _/\ 7/\
MW^;_ !H ]2HKRW^V+_\ Y_KG_O\ -_C1_;%__P _US_W^;_&@#U*BO+?[8O_
M /G^N?\ O\W^-']L7_\ S_7/_?YO\: /4J*\M_MB_P#^?ZY_[_-_C4</B&ZN
M"XBU.:0H=K!+@G:?0\\&@#U:BO+?[8O_ /G^N?\ O\W^-']L7_\ S_7/_?YO
M\: /4J*\M_MB_P#^?ZY_[_-_C1_;%_\ \_US_P!_F_QH ]2HKRW^V+__ )_K
MG_O\W^-']L7_ /S_ %S_ -_F_P : /4J*\M_MB__ .?ZY_[_ #?XT?VQ?_\
M/]<_]_F_QH ]2HKRW^V+_P#Y_KG_ +_-_C1_;%__ ,_US_W^;_&@#U*BO+?[
M8O\ _G^N?^_S?XT?VQ?_ //]<_\ ?YO\: /4J*\M_MB__P"?ZY_[_-_C1_;%
M_P#\_P!<_P#?YO\ &@#U*BO+?[8O_P#G^N?^_P W^-']L7__ #_7/_?YO\:
M/4J*\M_MB_\ ^?ZY_P"_S?XT?VQ?_P#/]<_]_F_QH ]2HKRW^V+_ /Y_KG_O
M\W^-']L7_P#S_7/_ '^;_&@#U*BO+?[8O_\ G^N?^_S?XT?VQ?\ _/\ 7/\
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ME17EO]L7_P#S_7/_ '^;_&C^V+__ )_KG_O\W^- 'J5%>6_VQ?\ _/\ 7/\
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M #_7/_?YO\:/[8O_ /G^N?\ O\W^- 'J5%>6_P!L7_\ S_7/_?YO\:/[8O\
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M_P C?_8T =?17(?\)_\ ].'_ )&_^QH_X3__ *</_(W_ -C0!U]%<A_PG_\
MTX?^1O\ [&C_ (3_ /Z</_(W_P!C0!U]%<A_PG__ $X?^1O_ +&C_A/_ /IP
M_P#(W_V- '7T5R'_  G_ /TX?^1O_L:/^$__ .G#_P C?_8T =?17(?\)_\
M].'_ )&_^QH_X3__ *</_(W_ -C0!U]%<A_PG_\ TX?^1O\ [&C_ (3_ /Z<
M/_(W_P!C0!U]%<A_PG__ $X?^1O_ +&C_A/_ /IP_P#(W_V- '7T5R'_  G_
M /TX?^1O_L:/^$__ .G#_P C?_8T =?17(?\)_\ ].'_ )&_^QH_X3__ *</
M_(W_ -C0!U]%<A_PG_\ TX?^1O\ [&C_ (3_ /Z</_(W_P!C0!U]%<A_PG__
M $X?^1O_ +&C_A/_ /IP_P#(W_V- '7T5R'_  G_ /TX?^1O_L:/^$__ .G#
M_P C?_8T =?17(?\)_\ ].'_ )&_^QH_X3__ *</_(W_ -C0!U]%<A_PG_\
MTX?^1O\ [&C_ (3_ /Z</_(W_P!C0!U]%<A_PG__ $X?^1O_ +&C_A/_ /IP
M_P#(W_V- '7T5R'_  G_ /TX?^1O_L:/^$__ .G#_P C?_8T =?17(?\)_\
M].'_ )&_^QH_X3__ *</_(W_ -C0!U]%<A_PG_\ TX?^1O\ [&C_ (3_ /Z<
M/_(W_P!C0!U]%<A_PG__ $X?^1O_ +&C_A/_ /IP_P#(W_V- '7T5R'_  G_
M /TX?^1O_L:/^$__ .G#_P C?_8T =?17(?\)_\ ].'_ )&_^QH_X3__ *</
M_(W_ -C0!U]%<A_PG_\ TX?^1O\ [&C_ (3_ /Z</_(W_P!C0!U]%<A_PG__
M $X?^1O_ +&C_A/_ /IP_P#(W_V- '7T5R'_  G_ /TX?^1O_L:/^$__ .G#
M_P C?_8T =?17(?\)_\ ].'_ )&_^QH_X3__ *</_(W_ -C0!U]%<A_PG_\
MTX?^1O\ [&C_ (3_ /Z</_(W_P!C0!U]%<A_PG__ $X?^1O_ +&C_A/_ /IP
M_P#(W_V- '7T5R'_  G_ /TX?^1O_L:/^$__ .G#_P C?_8T =?17(?\)_\
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M_P C?_8T =?17(?\)_\ ].'_ )&_^QH_X3__ *</_(W_ -C0!U]%<A_PG_\
MTX?^1O\ [&C_ (3_ /Z</_(W_P!C0!U]%<A_PG__ $X?^1O_ +&C_A/_ /IP
M_P#(W_V- '7T5R'_  G_ /TX?^1O_L:/^$__ .G#_P C?_8T =?17(?\)_\
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MVHO&VHZ/XKU#5-2U7P^]M\2K/P]:V!TVRDN+6VD W6DF1M(SD&0,S=U)KI_
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M_B]\3-&U?XZZIX"L]%UZ6QTW3K#P+%JZFW&,$RK Q!!XPQ)[U]2?LD?"N_\
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MM_%]I=KH"Q6UO/&FTQ>0DP!C)Y 4K@8'/6@#O=:_:UTC0O#?Q0U:Z\/:BO\
MP@-U;VE];"2,O.\H0_(<X^7?@Y]#63>?MGV!^*-QX.TKP9JFM&RGMK:^N+:\
MM5N(GF17#1VC2":9%##<Z+@8/XX/Q _8N\1>,[SXAV]I\2H]'T'QRUK=ZK9C
M0UFD^U0JHW(YF&V-BN2O7MN[EGQ7_8?O_BGXJ^U7GC/3_P"R7>U<//X=A?5;
M(0A<QVMZKJR(VWHX;;GO0!]7T4V&,0Q)&"S!%"@L<DX]33J "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OEC]M/6
M_BE\--%A\8^#OB;+H&F2WUCI?]A#0[.Y56EDV--YTJ,^>0=O3BOJ>O-/V@O@
MQ_PO;P'!X;_MC^P_*U.TU'[3]E^T9\F0/LV[T^]C&<\>AH \SE\<^+O@_P#%
M#PCX7\5^/]1\:M<:+J^KW.W1+*SCNE@0.BL4PR,F#C;PV?FZ5F:-^W9)XAF\
M-Q:?\)_%%Q+XIL)+SP^OVFT7[>8O]:#F4>4JC)WOC(' Y%>G_$KX!_\ "P_B
M=HGB_P#MW^S_ .S=#U'1OL?V/S/,^U)L\S?Y@QLZ[<'/J*YKP5^RC_PA]_\
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M?S:!X'UW7=6\9QWHLM)@E@CDBGMFVR1R.[A ,Y^?.,#/M6IX*_91_P"$/O\
MX17/_"4_:_\ A -*O-,V_P!G[/M_GIMWY\T^5MZX^?/J*\>U']E[QM\.O'?P
M1T+P?KUP[Z(=<N9?%/\ 8IDM;9ISYB1S1>80%;)3[X)ZC!XH ^H/@C\9-/\
MC=X0FUFST^[T:[L[V;3=1TN_V^=9W41P\;%20>H((Z@UZ#7FGP!^#/\ PI3P
MA?:=<ZP_B#6M5U*?5]4U1H! +BYF(+E8P3L48  R>E>ET %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !5S1_^0O8_P#7=/\ T(53
MJYH__(7L?^NZ?^A"@#U*BBB@ HHHH **** "BBB@ HHHH R=6\-6NLW*S322
MJZH$ C( QDGN#ZU2_P"$$L/^>US_ -]+_P#$UJ7^N66F3"*YG\N0KN V,>.G
M8>U5O^$MTG_G[_\ (;_X4 5/^$$L/^>US_WTO_Q-'_""6'_/:Y_[Z7_XFK?_
M  END_\ /W_Y#?\ PH_X2W2?^?O_ ,AO_A0!4_X02P_Y[7/_ 'TO_P 31_P@
MEA_SVN?^^E_^)JW_ ,);I/\ S]_^0W_PH_X2W2?^?O\ \AO_ (4 5/\ A!+#
M_GM<_P#?2_\ Q-'_  @EA_SVN?\ OI?_ (FK?_"6Z3_S]_\ D-_\*/\ A+=)
M_P"?O_R&_P#A0!4_X02P_P">US_WTO\ \31_P@EA_P ]KG_OI?\ XFK?_"6Z
M3_S]_P#D-_\ "C_A+=)_Y^__ "&_^% %3_A!+#_GM<_]]+_\31_P@EA_SVN?
M^^E_^)JW_P );I/_ #]_^0W_ ,*/^$MTG_G[_P#(;_X4 5/^$$L/^>US_P!]
M+_\ $T?\()8?\]KG_OI?_B:M_P#"6Z3_ ,_?_D-_\*/^$MTG_G[_ /(;_P"%
M %3_ (02P_Y[7/\ WTO_ ,31_P ()8?\]KG_ +Z7_P")JW_PEND_\_?_ )#?
M_"C_ (2W2?\ G[_\AO\ X4 5/^$$L/\ GM<_]]+_ /$T?\()8?\ /:Y_[Z7_
M .)JW_PEND_\_?\ Y#?_  H_X2W2?^?O_P AO_A0!4_X02P_Y[7/_?2__$T?
M\()8?\]KG_OI?_B:M_\ "6Z3_P _?_D-_P#"C_A+=)_Y^_\ R&_^% %3_A!+
M#_GM<_\ ?2__ !-'_""6'_/:Y_[Z7_XFK?\ PEND_P#/W_Y#?_"C_A+=)_Y^
M_P#R&_\ A0!4_P"$$L/^>US_ -]+_P#$T?\ ""6'_/:Y_P"^E_\ B:M_\);I
M/_/W_P"0W_PH_P"$MTG_ )^__(;_ .% %3_A!+#_ )[7/_?2_P#Q-'_""6'_
M #VN?^^E_P#B:M_\);I/_/W_ .0W_P */^$MTG_G[_\ (;_X4 5/^$$L/^>U
MS_WTO_Q-'_""6'_/:Y_[Z7_XFK?_  END_\ /W_Y#?\ PH_X2W2?^?O_ ,AO
M_A0!4_X02P_Y[7/_ 'TO_P 31_P@EA_SVN?^^E_^)JW_ ,);I/\ S]_^0W_P
MH_X2W2?^?O\ \AO_ (4 5/\ A!+#_GM<_P#?2_\ Q-'_  @EA_SVN?\ OI?_
M (FK?_"6Z3_S]_\ D-_\*/\ A+=)_P"?O_R&_P#A0!4_X02P_P">US_WTO\
M\31_P@EA_P ]KG_OI?\ XFK?_"6Z3_S]_P#D-_\ "C_A+=)_Y^__ "&_^% %
M3_A!+#_GM<_]]+_\31_P@EA_SVN?^^E_^)JW_P );I/_ #]_^0W_ ,*/^$MT
MG_G[_P#(;_X4 5/^$$L/^>US_P!]+_\ $T?\()8?\]KG_OI?_B:M_P#"6Z3_
M ,_?_D-_\*/^$MTG_G[_ /(;_P"% %3_ (02P_Y[7/\ WTO_ ,31_P ()8?\
M]KG_ +Z7_P")JW_PEND_\_?_ )#?_"C_ (2W2?\ G[_\AO\ X4 5/^$$L/\
MGM<_]]+_ /$T?\()8?\ /:Y_[Z7_ .)JW_PEND_\_?\ Y#?_  H_X2W2?^?O
M_P AO_A0!4_X02P_Y[7/_?2__$T?\()8?\]KG_OI?_B:M_\ "6Z3_P _?_D-
M_P#"C_A+=)_Y^_\ R&_^% %3_A!+#_GM<_\ ?2__ !-'_""6'_/:Y_[Z7_XF
MK?\ PEND_P#/W_Y#?_"C_A+=)_Y^_P#R&_\ A0!4_P"$$L/^>US_ -]+_P#$
MT?\ ""6'_/:Y_P"^E_\ B:M_\);I/_/W_P"0W_PH_P"$MTG_ )^__(;_ .%
M%3_A!+#_ )[7/_?2_P#Q-'_""6'_ #VN?^^E_P#B:M_\);I/_/W_ .0W_P *
M/^$MTG_G[_\ (;_X4 5/^$$L/^>US_WTO_Q-'_""6'_/:Y_[Z7_XFK?_  EN
MD_\ /W_Y#?\ PH_X2W2?^?O_ ,AO_A0!4_X02P_Y[7/_ 'TO_P 31_P@EA_S
MVN?^^E_^)JW_ ,);I/\ S]_^0W_PH_X2W2?^?O\ \AO_ (4 5/\ A!+#_GM<
M_P#?2_\ Q-'_  @EA_SVN?\ OI?_ (FK?_"6Z3_S]_\ D-_\*/\ A+=)_P"?
MO_R&_P#A0!4_X02P_P">US_WTO\ \31_P@EA_P ]KG_OI?\ XFK?_"6Z3_S]
M_P#D-_\ "C_A+=)_Y^__ "&_^% %3_A!+#_GM<_]]+_\31_P@EA_SVN?^^E_
M^)JW_P );I/_ #]_^0W_ ,*/^$MTG_G[_P#(;_X4 5/^$$L/^>US_P!]+_\
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MC_A+=)_Y^_\ R&_^% %3_A!+#_GM<_\ ?2__ !-'_""6'_/:Y_[Z7_XFK?\
MPEND_P#/W_Y#?_"C_A+=)_Y^_P#R&_\ A0!4_P"$$L/^>US_ -]+_P#$T?\
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MW10!PG_""7__ #VMO^^F_P#B:/\ A!+_ /Y[6W_?3?\ Q-=W10!PG_""7_\
MSVMO^^F_^)H_X02__P">UM_WTW_Q-=W10!PG_""7_P#SVMO^^F_^)H_X02__
M .>UM_WTW_Q-=W10!PG_  @E_P#\]K;_ +Z;_P")H_X02_\ ^>UM_P!]-_\
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MW^-']L7_ /S_ %S_ -_F_P :IT4 7/[8O_\ G^N?^_S?XT?VQ?\ _/\ 7/\
MW^;_ !JG10!<_MB__P"?ZY_[_-_C1_;%_P#\_P!<_P#?YO\ &J=% %S^V+__
M )_KG_O\W^-']L7_ /S_ %S_ -_F_P :IT4 7/[8O_\ G^N?^_S?XU:TK5;V
M35+-'O+AD:9 5:5B"-PXZUDU<T?_ )"]C_UW3_T(4 >I4444 %%%% !1110
M4444 %%%% 'E?Q1\%>'M?\4VFH:IH.F:E?Q6#VD=U=V<<LJ0R%A)$'8$A''#
M+G!'7-<Q:^ ?#%C)HTEOX<TFWDT6)H=+>*QB4V$;#:R0$+^Z4@ $+@$5[W10
M!\R3? 'X:7&CWNE2^ ?#;Z;>W7VZXM&TN'RY9^GFE=N-^,C/7DUOVWP_\+V8
MT00>'-)A&AAAI6RQB'V ,-K>1\O[K(X.W&17OE% 'S]=_#7PA?P:I#=>%=$N
M8=4N$N[^.;3H66\G7&V64%?WCC PS9(P.:DN_A_X7OY=8EN?#>D7$NL1)!J3
MRV,3->QJ,(DQ*YD51P V0.U>^T4 ?.>E?!_P-H7A.\\+Z?X/T.S\.7A)N=*A
MT^);:<GJ7CVX8\#D@]!Z5!8_!#X=:;IEQIMKX#\-06%Q''#/;)I%N(YDC;?&
MKC9A@K?,,YP>1S7TG10!\V:S\$OAYXBURYUG5O WAS5-5N8A#/>7NE0322H,
M85BRG(&!U]!Z5>U#P1#8Z1KP\()IOA+7]5&]]6@TR.0F<+M665 5\X@#'S-T
MXS7T+10!\J_L^_!"U^ _@B?18]2;6]2OKZ?4]2U5[=8#=7,K99A&I(0< !<G
M&.M;GBGX-> /'&K?VIXC\#>&_$&I[%C^VZII%O<S;1]U=[H3@9.!GO7T=10!
M\_:_\-_"?BKPS'X<UCPUI.IZ!$%$>F75E&]O'M^[MC(VKCM@#%+9?#?PEIL&
MB0VGAC1[>+0RQTI8[")18%AAC!\O[LD<$KC/>OH"B@#Y\;X9>#W\--X=;PGH
M;>'VF^T'23IT)M3+NW[_ "MNW=N^;.,YYZTGC3X8^$/B/:6MKXJ\,:3XBM[5
MM\$>IV4<XB/JNX';T'3K7T)10!X3%X,\/P:EIVHQ:%IL>H:;;FTLKM+2,2VL
M!QF*)\91#@?*I XZ5YO\.O@%=>%_C#XG^)7B3Q,/%/B+5;9-.M"FFI9QV-FK
M%A$ KMO;[N7.,XZ"OKZB@#P#QC\.?"?Q#AMHO%7A?1O$T5JS- FL:?%=K$3@
M$H)%.TG SCTJOX:^%/@GP79ZA:>'O!V@:%:ZBGEWD&F:7!;I<K@C;(J* XPS
M##9ZGUKZ'HH ^?[CX<^%+OP@/"DWAG2)/"X3RUT4V,7V-5!R (=NP 'G@=>:
MKZ;\*/!6CZ-IFDV7A'0[;3-,N1>V-I'IT0BM;@=)HUVX63D_./FYZU]$44 ?
M/>I_##P?K5EK=I?>%M&NK;6W675(Y;"(B^=<;7F^7]XPP,%LD8&*RKWX"_#;
M4KW2[R[\!>&[FZTN*."RFETN%FMXT^XB$KP%QP.W:OIFB@#R$# P.E%>O44
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M.5S\N!CTQQBOI&B@#R&BO7J* /(:*]>HH \AHKUZB@#R&BO7J* /(:*]>HH
M\AHKUZB@#R&BO7J* /(:*]>HH \AHKUZB@#R&BO7J* /(:*]>HH \AHKUZB@
M#R&BO7J* /(:S/$/AC1O%M@MCKFDV.M62RI,+;4+9)XQ(IRC[7!&X'D'J*]Q
MHH \*U+P?H.M:I!J6H:)IU]J,$$EK%=W-I')-'#(,21J[ D(PX90<'O5:R^'
MGA739-(>S\,Z/:OH\3P::T%A$AL8W&'2$A?W:L.H7 />O?J* /F[5O@K\/\
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M ,57.44 ='_PG=__ ,\;;_OEO_BJ/^$[O_\ GC;?]\M_\57.44 ='_PG=_\
M\\;;_OEO_BJ/^$[O_P#GC;?]\M_\57.44 ='_P )W?\ _/&V_P"^6_\ BJ/^
M$[O_ /GC;?\ ?+?_ !5<Y10!T?\ PG=__P \;;_OEO\ XJC_ (3N_P#^>-M_
MWRW_ ,57.44 ='_PG=__ ,\;;_OEO_BJ/^$[O_\ GC;?]\M_\57.44 ='_PG
M=_\ \\;;_OEO_BJ/^$[O_P#GC;?]\M_\57.44 ='_P )W?\ _/&V_P"^6_\
MBJ/^$[O_ /GC;?\ ?+?_ !5<Y10!T?\ PG=__P \;;_OEO\ XJC_ (3N_P#^
M>-M_WRW_ ,57.5\B_MZ>%=5T'PM;^.-#\?\ C;P]J$NIZ?I;6&CZ]-:V(CDE
MV.XB3'SD'[V>PXH ^W?^$[O_ /GC;?\ ?+?_ !5'_"=W_P#SQMO^^6_^*KXO
MUB[G^ OQC\%>&K;Q%XP\4P_\(]K>K&3Q!XBEN5F:*,.$F0KB3&,*3]S)QG-8
M7AG]L+XK>*[KP';V?P^\,QR>.]+GO=%\[69@(# ,R/<XA.%(R55,GD9(YP ?
M=O\ PG=__P \;;_OEO\ XJC_ (3N_P#^>-M_WRW_ ,57P;=?M^WMWX/\!/9:
M3X<T7Q-XBAO9[M_$VKFTTRT6VE:)@)=I9FD92%&..^>M1>*O^"@6H1^$O FM
M:/H&CZ1;^(+*XGGU#Q+=W L([F&4QM:1S01,"[%2P=]J[2I.,T ?>_\ PG=_
M_P \;;_OEO\ XJC_ (3N_P#^>-M_WRW_ ,57Q/%\=?B-XC_:4^&MAIZ:/'X2
MU?PK)K-UIT&J)/$WS 2R"=$*R,AX3YMA!).TUF>"_P!NG6=:^([>';_2O"]W
M#<V&HW=O_P (_JLMX]H]K&T@CN)?+$+E@O6)FQGGTH ^Z_\ A.[_ /YXVW_?
M+?\ Q5'_  G=_P#\\;;_ +Y;_P"*KX2\,_MA?%;Q7=> [>S^'WAF.3QWI<][
MHOG:S,! 8!F1[G$)PI&2JID\C)'.-+0OVR/&/CC3OA9;>&O!FDR^(O&B:E%)
M#J&HR16UG-:-M9MZHS-&<%L 9Z#WH ^V_P#A.[__ )XVW_?+?_%4?\)W?_\
M/&V_[Y;_ .*KPG]G;XRW?QF\'ZE=ZKI,>B>(-%U6XT75+*"8S0K<0D!C&Y )
M4@@C(R.GO7J= '1_\)W?_P#/&V_[Y;_XJC_A.[__ )XVW_?+?_%5SE% '1_\
M)W?_ //&V_[Y;_XJC_A.[_\ YXVW_?+?_%5SE% '1_\ "=W_ /SQMO\ OEO_
M (JC_A.[_P#YXVW_ 'RW_P 57.44 ='_ ,)W?_\ /&V_[Y;_ .*H_P"$[O\
M_GC;?]\M_P#%5SE% '1_\)W?_P#/&V_[Y;_XJC_A.[__ )XVW_?+?_%5SE%
M'1_\)W?_ //&V_[Y;_XJC_A.[_\ YXVW_?+?_%5SE% '1_\ "=W_ /SQMO\
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MM0\16/BKQ5H=AJFHQZOJ7A[2]0$%C>7:8_>-A/,7=@;E5P&Q7UK_ ,(EI/\
MSZ?^1'_QH_X1+2?^?3_R(_\ C0!\F:E^R1X0U7^V?-U+6U_M7Q9#XQGV3PC;
M>1_=C7,7$7J#EO\ :%;EK^SCX/M/CQ=_%M([H^*+FQ^PO$SH;4<!3*$V[O,*
M*%)W8QV[U]+_ /"):3_SZ?\ D1_\:/\ A$M)_P"?3_R(_P#C0!\E>"?V4-#\
M ^,+75-*\5>*H]"LKV;4;/PK_: 73;>>4DN0JH'9<DD(S%03T-1:Y\'%^%7P
M&\7^%/!GAR_\?-KD]Y,^EWVH6]N[O=D^8?,8(@12V0/O8'4FOKK_ (1+2?\
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MC_XT >4^(= L/%>@ZCHVJVZW>FZA;O:W,#])(W4JR_B":\(\'?L5>'?"VO\
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MS?"N;P[<K;7SZI/YEE-N&4>WN=JK,#TPH)!('<4 ?5/_  END_\ /W_Y#?\
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M)@2)6(/&3GCJ:],_X6KX0WZ G_"1:?NU^W>[TO\ ?#_2X43>\B'^Z%.2>@%
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M ,*/^$MTG_G[_P#(;_X5YS10!Z-_PEND_P#/W_Y#?_"C_A+=)_Y^_P#R&_\
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M$W[7'BKXA:CX:OK_ .%\MEX)\1%Q:Z_I&K)J?V':I8?;8XXQY ([L?E/![T
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MMTG_ )^__(;_ .%'_"6Z3_S]_P#D-_\ "O.:* /1O^$MTG_G[_\ (;_X4?\
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M:V?#?[2?PO\ &&O:AHNB^.-'U'4["*6:XMX)\E4CR9&4]'"@$DJ3C% 'T?\
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M /1O^$MTG_G[_P#(;_X4?\);I/\ S]_^0W_PKSFB@#T;_A+=)_Y^_P#R&_\
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M%1@9[XI]='_P@E__ ,]K;_OIO_B:/^$$O_\ GM;?]]-_\30!SE%='_P@E_\
M\]K;_OIO_B:/^$$O_P#GM;?]]-_\30!SE%='_P ()?\ _/:V_P"^F_\ B:/^
M$$O_ /GM;?\ ?3?_ !- '.45T?\ P@E__P ]K;_OIO\ XFC_ (02_P#^>UM_
MWTW_ ,30!SE%='_P@E__ ,]K;_OIO_B:/^$$O_\ GM;?]]-_\30!SE%='_P@
ME_\ \]K;_OIO_B:/^$$O_P#GM;?]]-_\30!SE%='_P ()?\ _/:V_P"^F_\
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MVH^%H((O">AZE;ZV3<6S_9;F5/W8P'/F$L3\R;@,\D5]W_\ ""7_ /SVMO\
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ME_\ \]K;_OIO_B:/^$$O_P#GM;?]]-_\30!SE%='_P ()?\ _/:V_P"^F_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
544 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ctso-20221231xex10d30g005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ctso-20221231xex10d30g005.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1, U$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXE_L7Q!>Z19:\ZJ&U"VB8".5BH"L>2-PZXKWN@ HHHH **** "BBB@ HHHH
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M_P#^?&Y_[\M_A7J5% 'EO]CW_P#SXW/_ 'Y;_"C^Q[__ )\;G_ORW^%>I44
M>6_V/?\ _/C<_P#?EO\ "K6E:5>QZI9N]G<*BS(2S1, !N'/2O2** "BBB@
MHHHH **** "BBB@ HHHH YKQ+XENM&OHX88XF1HPY,@).<D=B/2LG_A.[_\
MYXVW_?+?_%5\9?\ !0KXE?$+X>?M%_#"]\$7E]<6UAHE[JVIZ!#<NL&HVT,@
M,JM&#M=A&7*DC(QQS7"^!OVO9++_ (6[XOTJ>\\9VFI>(M(T[POI5U?,L,<E
MU;C$8+;A"H;<7"CJI[\T ?H/_P )W?\ _/&V_P"^6_\ BJ/^$[O_ /GC;?\
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MW_?+?_%5SE% '1_\)W?_ //&V_[Y;_XJC_A.[_\ YXVW_?+?_%5SE% '1_\
M"=W_ /SQMO\ OEO_ (JC_A.[_P#YXVW_ 'RW_P 57.44 ='_ ,)W?_\ /&V_
M[Y;_ .*H_P"$[O\ _GC;?]\M_P#%5SE% '1_\)W?_P#/&V_[Y;_XJC_A.[__
M )XVW_?+?_%5SE% '1_\)W?_ //&V_[Y;_XJC_A.[_\ YXVW_?+?_%5SE% '
M1_\ "=W_ /SQMO\ OEO_ (JC_A.[_P#YXVW_ 'RW_P 57.44 ='_ ,)W?_\
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M ,51_P )W?\ _/&V_P"^6_\ BJYRB@#H_P#A.[__ )XVW_?+?_%4?\)W?_\
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M_P#\\;;_ +Y;_P"*KG** .C_ .$[O_\ GC;?]\M_\51_PG=__P \;;_OEO\
MXJN<HH Z/_A.[_\ YXVW_?+?_%4?\)W?_P#/&V_[Y;_XJN<HH Z/_A.[_P#Y
MXVW_ 'RW_P 51_PG=_\ \\;;_OEO_BJYRB@#H_\ A.[_ /YXVW_?+?\ Q5'_
M  G=_P#\\;;_ +Y;_P"*KG** .C_ .$[O_\ GC;?]\M_\51_PG=__P \;;_O
MEO\ XJN<HH Z/_A.[_\ YXVW_?+?_%4?\)W?_P#/&V_[Y;_XJN<HH Z/_A.[
M_P#YXVW_ 'RW_P 51_PG=_\ \\;;_OEO_BJYRB@#H_\ A.[_ /YXVW_?+?\
MQ5'_  G=_P#\\;;_ +Y;_P"*KG** .C_ .$[O_\ GC;?]\M_\51_PG=__P \
M;;_OEO\ XJN<HH Z/_A.[_\ YXVW_?+?_%58L/&=[=7UM"\5N$DD5"55LX)
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M_"):3_SZ?^1'_P : /.:*]&_X1+2?^?3_P B/_C1_P (EI/_ #Z?^1'_ ,:
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MS7.'0K\@#@N2,>61MX/K7Z"?\(EI/_/I_P"1'_QH_P"$2TG_ )]/_(C_ .-
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M3X\-H'AA-4^+FFZ5\*KBXNWMK2WN->BOH[A5CWEA*B*H. WRD9^7WH ^EO\
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M)4Z4MP/-W@9*>A<#JN=P]* /=_\ A.[#_GC<_P#?*_\ Q5'_  G=A_SQN?\
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M3D>;)+NP46-6!88S\R\<YH ^LO\ A.[#_GC<_P#?*_\ Q5'_  G=A_SQN?\
MOE?_ (JO$)OC1X&@TO7M2D\3Z>ECH+QIJDYE^6T:0 H'/;(9<?6LW5_VC?AE
MH/C*U\*:AXWT>T\0W)C$=C+< -F0 H">BE@1@,03D>M 'T#_ ,)W8?\ /&Y_
M[Y7_ .*H_P"$[L/^>-S_ -\K_P#%5PE% '=_\)W8?\\;G_OE?_BJ/^$[L/\
MGC<_]\K_ /%5PE% '=_\)W8?\\;G_OE?_BJ/^$[L/^>-S_WRO_Q5<)10!W?_
M  G=A_SQN?\ OE?_ (JC_A.[#_GC<_\ ?*__ !5<)10!W?\ PG=A_P \;G_O
ME?\ XJC_ (3NP_YXW/\ WRO_ ,57"44 =W_PG=A_SQN?^^5_^*H_X3NP_P">
M-S_WRO\ \57"44 =W_PG=A_SQN?^^5_^*H_X3NP_YXW/_?*__%5PE% '=_\
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M]\K_ /%5PE?/W[27[1_C3X R)?VOPOB\3>%GEMK5-8/B..T8W$S;1'Y!A=L
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M@CJ".: /4O\ A.[#_GC<_P#?*_\ Q5'_  G=A_SQN?\ OE?_ (JN$HH [O\
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M%%% !1110 4444 ?!?[??P1\0?$CX[_#GQ!;?# ?%+PSI6D7<%_I1U>WT_\
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M  @'_3__ .0?_LJ/^$ _Z?\ _P @_P#V5 '(45U__" ?]/\ _P"0?_LJ/^$
M_P"G_P#\@_\ V5 '(45U_P#P@'_3_P#^0?\ [*C_ (0#_I__ /(/_P!E0!R%
M%=?_ ,(!_P!/_P#Y!_\ LJ/^$ _Z?_\ R#_]E0!R%%=?_P (!_T__P#D'_[*
MC_A /^G_ /\ (/\ ]E0!R%%=?_P@'_3_ /\ D'_[*C_A /\ I_\ _(/_ -E0
M!R%%=?\ \(!_T_\ _D'_ .RH_P"$ _Z?_P#R#_\ 94 <A177_P#" ?\ 3_\
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MEN=@X.1R "?TR_X0#_I__P#(/_V5'_" ?]/_ /Y!_P#LJ /@71?A/\5O#?Q
M^$GB+4/"ECK.I6GA"ZT'5)=/-K#;6%T\FZ-Y(P54HJ[0WE*02&P.17GO@/\
M9^^,U[XS\*ZQX@\+:M')IVEZSI][]IU73ELHI9[>18_L=K 4$4+,5!ZDDY.
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M_P#LJ .0HKK_ /A /^G_ /\ (/\ ]E1_P@'_ $__ /D'_P"RH Y"BNO_ .$
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M -E4UGX'^R7<$_VW?Y4BOM\K&<'./O4 =31110 4444 %%%% !1110 4444
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MP;X(T?X?Z3)I>A6\MI8/<RW7D274LZH\C%WV>8S;%+$D(N%&3@#- &]1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <;\9O$%
M_P"$_A%XUUO2I_LNIZ=HUY=VLVQ7\N5(69&VL"IP0#@@CUKQ6?\ :2\20^)/
M /VOPWKFA:;-H>I:CJ(UL:?:PZB\-K'(FR;SF$0#%B2QC4!N>!@?1?B+P_8>
M+- U+1=5@^U:9J-O):74&]D\R)U*NNY2",@D9!!KGO%7P>\'^-K/3[36]&6_
MMM/LI]/MHWGE41P31K'(GRL,Y55&3DC&00>: /&;3]L>YN]#UZYC\(6UY>:3
M=644LVFZE<76G)!<I(RW$EPEEYBHAB969('4%EPQ&2*.E?M3^))M?UO74T2Q
MU?P1;Z?HEQ,+;6(7-@;J:6&0P/'$PNOF"DAGC "'&&)6O5D_9J\ 1_:Y!I^J
MF\NI+>6746\0ZBU[O@5UA9;DW'FJ5661<JXRK;3D8%7;#X > M,T74=)MM!\
MNPU&.VBNX_MDY,P@E:6(LQDW;A([L6SN<L2Q:@#RB?\ ;;L;;4=:F;P=J<_A
MVQ?4((M1M5G>1Y+3>"95:W6&..1HV5&$[G)7<JYXD?XN_$.\\3^,- U2VM_#
M>J2RZ#9:3:6-RE\ENUV\QGF64PQLQ$4;,5=<*8CC(Y/I[_L\?#^75K_4)=!-
MPUZ;EIK.>^N9+(/<*5G=+1I#!&\@9MSH@8[FYY-+X5_9]\#^#->36M,T^].J
M+*DQNK_5[R^=F2*2&,DSRN?ECFD51T ;CH, 'BOP0^)?C'Q'ID/B/7==^(FH
MB)]0GE@?2-(AT.5(9)@J"9+43A<1J,[\[NI-=-IO[6&IMI5I+JG@9+'4M7TS
M3-2T2RM]8$ZW0OIQ!%'/(84$#*Y!; D&TY!)^6N\T/\ 9P\$^&VQIH\26UIN
ME?\ L\>+=6:R_>%C(/LQNC#M)=CMV8YZ5H7WP)\#:CIT-C<:'OMX=+M]&A N
MYU:*U@<20JCA]RNC@,) 0X(!W4 <7J?QU\<Z?KZ>'E^&MG-X@CTN]U6YMU\2
M*83';NB 02+;LSF0R+M$B1$<[@.,T(?VJ+OQ3XAT72_!/A*'Q#'JQ@B@OKS5
MOL<"S/9->R(Y$,A'EQ^4"0"=TF,#::]%\/\ P;\->!9YM3\,Z:+?7Q:W$$=]
MJ%Y<W3RM*ZR.9WDD9Y2SQQDNQ+X4 $#BO.-(_9(TRVT#P/IMW?&-=&U6_P!;
MU%M(EN-/:XN;J.56\F2&59(50R +AC\B!30!RMW^V+JNGZO=:Q+X>B;PT=%L
MV@TU;IVNQJ<NH36;1ML@;*"2)@64L=J;@K%MHZG1_P!I[6_%D%KI>C>!7_X2
MN=[[=;7]Y-9V?D6R1,\\,TUJLDH8SQJH,*9;<&*A<UW5[^SE\.[^VMK>3P^8
MX+;3DTN**WOKF%1 DOFQ\)( 9$DRZRG]XK$D,"3E)_V=/ 5QI,-@^F7_ .ZN
M)KH7RZW?+?O)*H24O=B;SW#JJJRM(00J@C & "_\!O$VJ>-/@OX)U[6YC<:O
MJ.D6UU=RE$3=*T8+':@"CDG@ "N\K*\*>%M+\$>&M+\/Z):_8M(TRW2TM+;S
M&?RHD&U5W,2QP .22:U: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "O"OVDO%?C/X?V@\4:'KMW!I-A]G\_3[+3K::")3-^_N;]Y TPM
MQ%P!;A7!!)W#I[K7!^-?@?X/^(6M?VKK6GW,UT\"6MRMMJ%Q;17L*.72*YCB
MD5)T#%B%D##YB.A((!XYXP^*'C"\\0M>6OB+5?#W@:ZU>_LX]7T71TU&6)K6
M&..*+:8)0%FG%R2Q0D^6JJREA5;PE\9?%/Q3\%6GB6;QA!\/=&T_0K"YU[43
M:1%HYI2\DIB$R.J2;$AVAU< 3D;6.W'M&J_ OPCJ^@Z1I$EK?6MOI33&TFT_
M5+FTN$\[/G S12*[!]QW D@\'J 13U7]G#X?ZSX;309M'N;?2X]0@U.*'3M4
MN[)H[B&)(H65X)4<!$C0*N< J#C/- 'C5C\1?BCKNFII\_B.\\-7EAX;U+Q+
M%?7.EVJW>HPI<E+(7<+Q%8@T2AI%C6-LNN#'R*W=)^(GC?7/&O@F6P\5?;;W
M7EMM3O/"-M80&RTK2)+8,TUS,4\Y93+PG[T*Y^4(0K,/2=8_9V\%:_IMC9:A
M%K=XEG'- MQ<>(M0DN98)B#+!-.TYDFA8JN8Y&9>!@"G:5^SSX)T+Q9>^(M.
MMM9L=0OKA;JZBM_$>HI9W#J@1=]H+CR&4(JJ$,97  QB@#DOA=XN\8:?\:M1
M\'>*==O-9MY=%74K:YOM/MK:&YF$H64V!@&3;HLD8*SLT@)4@D$FM?4?$WCS
M_A?-YX;BOM)M-$N?"UY>Z5;^2TC"ZCGMHUGN'.#@&5AY:8&!DL21MZ3P)\$O
M"'PWU0ZAH=C=17*VQLK?[7J%Q=)9VVX,8+=99&6&/< =D84?*HZ* -?Q%\/-
M \5WMQ>:E9R2W4^EW&C/-%=2PO\ 9)F1I8P4==I)C0[AAAC@CF@#RSX/>+O&
M>IZWXECM=<E^)/AVR^QVT6M7T5M8QR7OF,M\ML\$*K+#$NTC*L=X9/,)!*\3
MX^^)_C[P-JGBQM.\;Q>(YM+TJ_N=6B?3(1IFB7#$?V=!"T<?FO.VY08I'D)^
M\0@*@^V>#_@5X4\!Z0-+T5_$5OIR"!8K:;Q3JEPD*PL&C2(2W+>6N0 53 9?
ME8%>*RM,_9?^'ND6FJ6=O8ZT^G:H;AKS3KGQ-J<]G*TS%I7-O)<M&'+$L'"A
ME.""" : .;^ GQ%\9ZX?$VF:U!J>HWFEZE;(;?Q-':V.JVUG+;!S+*MJGD2
MR!P@3!(!#$,IKRZY^/'Q$^'W@_49?%DOBBW\:ZI8QSZ7I=_9:3)9();Z&W9[
M;[-\[/$+B/"7#@-N!/?;])>'/@OX7\+QS"T35)I[BZCN[F[O=9O+BXNGC0QH
MLTLDI:6-5) B<E.^W/-8VF?LS?#O2["_L5T:XNK.[L_[.$-[J=U<+:VN\.(;
M;S)#]G0.JL!%MP43'W5P <WX(\>^(X_AM\34U/5M7F\3>&EN"BZ]8V45[:?Z
M(LT6]K0FWF!SN5E5>#M925)/D>D_%GXGCX>/XDTOQ#XRU>U7P9>ZIJ=_XL\-
MVEA;V5Z+59+=[-EM(/.S(6^4B52HR2._U%X<^$WAKPQX=UC1;6VNKBUUDN=2
MFU"_GNKF[+QB,F2>5VD/R */FX  &*TKGP+H=YX&?P?-8[_#CZ?_ &6UEYKC
M-MY?E^7O#;_N\9W9]\T ?+$?[1GCF_T7X1Z3#JL<7B9=<M['QE<"TB/G1BZ2
MUVA2N(_/,@E!0 A5.W%?8M<"GP'\"1ZM>ZFGA^-+^\N[&^GG6XF!DFLP!;,?
MGQ\F!P.&_B#5WU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 >5>-?&OBS5/BE!X"\&W6DZ/=0Z1_;-
M_J^L6,EZJ1M*8HHHH4FARS,DA+%\*% P2W'.>)_VH[#X/6NGZ5\2(((_%:V3
MW^I)H<\/V:"V65D6Y N)8W8.%+"*/S9!AAAL9/=>//A*GB[Q)8>)-+\2:OX/
M\2V=L]B-3T<6[F:V=@QAECN(I8V4, RG:&4YP<$@\A-^R=X<VVCV7B+Q+IM^
MMH]E?:C!<P27.I1O,\S&9Y87VOYDDA#P^4R[R%*C  !G:M^U2+K5-(A\,^#]
M9U33+GQ*?#T^L2_94MRRQ2N[P@W"N^/+4Y*@$$XRPVUR6E_M6>(-1\8:&)H(
MK#PC-I>BW4VI2Z.A-U+?SL@(4:ANMT"QL!E92"&)) 4/ZU/^SUH3:5!96VJZ
MQ8F#Q%)XEBN8987E2XDWAX_WD3*8RLCK@@M@YW9P:R[3]E7PA:V.G6AO-7GM
M[&WTFU5)9HCYB:?)))"'Q&,[C*P?&,C&-O6@#'T']MCX=^(8+Z2V.H9CM%O;
M*)?L\TNI1-,D">2D4SLC-)+$H2<1-^\!( R1TOPX^+VL>-XOB1+?:#+H$GAN
M_-I;6-_&JW  LX9SYQCED1COD;!C;:5QWR:R]*_90\-:9H5QHS:_XBN],%K'
M::?;RW%N@TQ8Y4EB:$QPH7='CCVO.96 3&2"P/7^!?A%:^";+Q3')K^M>(KO
MQ)<F[O[_ %=X/.+F!(?D$,,:* D:X 7&<T >5>%OCIXYT'PO\-_&'CN]\+WG
MA;QA'$)QI&EW%C/I4DEJ]PC%I+J<3(!&RG"QD9!YY%.@_;/\/^+Y]&L_"D17
M4+S4],C\K4F@E\ZPN;@0M.@MYW*,-P^27:ZEEW1\UU'AS]EO1=*L-!TS6O%/
MB3QGHF@VK6FEZ3K;6:VUJK0F#=BVMH6D81,R!I&?&XD<\TNA_LM:#HT>G12>
M)/$FI0:9<64]C#=36RI;K:RB2*/$4";P2 &>3?(0 -XH @\&_M1:!K/AJ*YO
M8[Z74C)81+%%8I;F\-W*T4+PQF>3"AHY VY^/*<],5C1_MS?#F>*_E@CU.Z2
M&%KBT%M]EF?48UGC@8Q1I.70AI4.V=8F*G*@@5UNA_LR^$-"UGP3J<<FHW%Q
MX2M9[2S6>9"DZR%R&G4(-[1^9+L(VX\QN#FLFS_9)\,V>F2Z4OB#Q&VB*JQV
M>F>?;+#9(MQ'.%0K 'DPT2J#.TA5<A2,YH '_:\\&67C6#POJ=KJ&CZD;NWT
M^[%Y-9?Z#=S!3'!(B7#2,3O0%XD>-2P!<<XF\'?M"R^/_BEX<T72M O[+PQJ
MVD7VIV^K:G;JGVY898$CDMRDK$(1*Y(E17(V$  \[%W^SWHD_CZ[\3P:QK.G
MK?7L6HWVD6DD"VMW<1HJ!W8Q&=00B;D254;;\RG)RWP)^SUI7@#Q5IFLVGB+
MQ!?6^D6%QIFEZ1?30-:6%M-)&[1Q[(5D;!B0*9'<@#&<8P >J4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 9/BW4=1TCPKK%]H^G_
M -KZM;6<LUI8;]GVF94)2/=VW, ,^]?/'@K]JF32;;6K_P =>(M&GM=.TQ+R
M[TR/0KS0]6L;AI4C$'V6[D8S1EG"B8%5#8SD-D?17B?PY8^+_#NI:'J<;2Z?
MJ-N]K<(CLC%'4@X92"IYX(.17E.H?LLZ)XDMY8_%/BKQ/XNF2R^P6%SJL]JL
MNFQ^;'*&A,-O&&??!"V^42,=@R2"00"/1/VL_"OB>SC31=)UC6?$#W[Z>/#N
MGM9SW7F+")V;S5N#;%!&0VX38Y"_>^6MR+]H?P\UAJ5S+IFMV9TZ\TRQN+:\
MLA!.DM]Y7D@QNP(VF90^<$8. W&:<?[.%C%;V<T?C'Q/'XAL[V2]M_$*/9K<
MQ%XA"\2Q"V^S+&4 RHAZC=G=S5.Z_97T&XO(Y$\4>*H;5IM.NKRS^VPRI?SV
M3*T$TTDD+2EOD4,%=58 << T <IXG_:^:+PE-XCT'POJK6QT/4M5L;35+6!&
MOQ;/"AD61;O]W&IE;*NFYP,J1@;_ $?P_P#'O1=<O]/TI]-U2QUZYU9M&DTN
M>.(S6\RVPN6D?9(R^4(RIWJS9W*,<UFW/[+_ (4N_"VG:!)?:N;.PT.^T")Q
M/$)#!=LC2.3Y>/,4QKM(  YRK5!X&^#%WI?QRUCQQJ@9Q!H]OHMC<37"237S
M+_K;V5(XTCCD95BCPHZ1G@# H =J_C3Q]XS^(7B[P]X%N_#^BV_A6.V2>?7-
M/FO&OKN:+SA$HCGB\J,(4!?YR2QPOR\X]A^TGJ6A^.-;T/QCX7N;2UT^?2+.
M;4M)"36EC/>0Q_)/(\BNX\Y]H:.(X7!<#.:Z_P 8?!!?$/BC4M?T7Q?X@\%W
M^K6L=GJO]B&V*WT<88(S">&79(JL5$D>UL8!SA<5H?V;/"=MH^HZ7;SZG#8W
MUQI5P\?VA7*&P\KR%#,A)#>2N\L23EL$9X .9TC]MCX;:Q)J.RXNXH+>SGOK
M:;]Q+]OBB=4;RHXI7E5BSH%69(V;<" 1DB#Q%^U<GA?QWX=TC6/"^L^'X]4@
MNXTTG4[1/[2O;Q7M1;Q6ACF:&4.+ALD.0I0[BFQJV--_9.\+:?I-_HS:SK]U
MH,UG+96NE27$,<-A&[AP8FCA21V1E78TSRE,8&.<FK?LI>'?%%S)>>)?$?B7
MQ-JC6T]NFH:C<P"6 R>05EA$4*)#)&;:-D,:K\VXL&)S0 ZY_:V\!V/Q";PE
M=S7%K<QWHTN:]DEMO)AO#'O\AD$QF)'W3((C'NXWYI_P_P#C_<?$?XHZ=HME
MX>U#2O#=]X=EUNUOM5MU22]43Q)%)$4E;$;+(QVR*L@^4D 'FU8_LUZ'8^*)
MM777M>DM[FZ^WWNE-);+;7ET8Q&\LC+ )?GQN:-9%B+<[*N?#OX!:;\.?$UI
MK%OXD\0:N+#2FT33[#5)K=[>RLS(CB./RX4=L&-0&D9VP,$G P >H4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>+?'_ .*WBSX2
MO9ZO9KHJ^'/,MK<Q7MK<S3WDTDVQT,R,L5DB(0WG3;U)."%QS[37FWQ)^"5O
M\2[R[-SXH\0:7I>HVB6&J:/8SQ&UOX%9FVL)(W:(G<RLT11F4X)X! !YYXU_
M:#\0V'C%]*T^_P##/AS1[C4;ZSM=>\212/:C[';Q-+%A9H@TCRR2JIWC:L#G
M:YXJ7PI\>?%WQ;T72=2\&P:%IEK+HEEJ.IWNLB2:"P:=I"[ *\9E5$@8[=R9
M\U&+  @]KJ'P%M9_".CZ%I_B?6]$73IY[AKFS-O(;IYG9Y#+'-%)&S;F+*VP
M,A^Z1R#B:G^R?X;O/ -QX0LM>U[1-*GO;:[E-B]L[S)!"D4=O*)X)4DAQ&K,
MK*=S9SD$B@#C=*_:)\?^+-%A&BVGAZ/4+31M1UZXOKNSN#:ZI:V]RT-NUM&)
ME:%;A59P[M(%&.'!!KH8OC5XTG\3>"+A+;0&T3Q=<1#3_#\<<SZH;)K82O?/
M.)-B)&Q 9##C!7Y]S 5T&O\ [.Z>([6S^U>._$XU*.PN-(NM5B2PBGO;"9@S
M6TBQVJQ*!M&UHT1UR?FYI/#7[.%IX1\=WWB72_&GB:!;U8H)=*9-.DMQ:Q($
MCM$D:T-Q'"H'"I,#DEL[B30!6^%WQ7\4ZQ\6-:\$>*O[%:^L]+CU)ETNTN+;
M[*[2E?(#3N?MBA=I,\2HH/RE02!6I?\ Q+\6Q_&:_P#"%MX:M%TU?#EUJFG7
M%Q> 37]S%+ @7Y<B*+,VW+98D$X4 ;K?@7X)6W@SQ-;ZY=>)M>\47EC8/I>F
M_P!MRPO]BM7=7= R1(TC$QQ@O*7;"#G.2=OQ+\-K3Q'XAEUQ=4U/2M4;1;K0
MX[G3Y(U:"*=XW:5-R-B56B7:3D#G*GL <+\.OBIXNNO%7B;0?$-MIOB:31TL
M1->>$K.2&.VN9V82VD@FG<.T*[)&=6!V.,Q@X!RF^+OQ#M?BK>^"9+7PU<ZO
M=Z7>ZAIMEY5U:I;&.1! LETY*W>]'W.((U,>,'@AJZWX9_ V3X6>&5T'2_'G
MB6YTV)HFA2ZM]+5HMLF^3YHK)"YEY$CR;F.XD,K'=6==_LUV&J7S3:CXR\67
MT%NEV-*@>^C1]*>YSYDD,RQB9F )5/-=PJDC!% #/@S\9=7\:GQ#8ZI;PZS=
MZ1KB:0U[H^GRV *M"LAFEM+F5I845BR;BS;\!E!!X;H/Q0\?^*=7^)NCVOAK
M2M,U?09K.+2+:]NS('2=-QEN60[>!E_+C/0!=V3D=)X/^$)\)ZA?ZJWBW7-5
MUS4KJWGU#4[M;027<4,;)';,B0*BQ ,3\BJY.3OYQ4/B_P"!VF^++3QU$FO:
M[H<WC".VAOKO2IX8YH4A38!"7B8+N7(;<&R"<8H P/!/Q<\0ZMX!^(VJ7KZ1
MK$WAB6ZALM:TJUE@L-2,-N)&*Q/+(P"2;HFVRL"4.".0/(]$_:U\77?AAM4L
MM;\&^.G;PG>Z[<KH&D75LFB7$5NLL<=RQNYED5W)CV@QOE<CC./H?PO\)H_#
MOP]O_!USXCU76]*N;5[&)KJWL+9K2!H_+\N%;6VAC  .1N1CGVXJ_??#/2[_
M .%4G@"2>[&C2:1_8IG5U^T>3Y/E;MVW;OV\YVXSV[4 >%?\-7>(KCPW\(3;
MZ5I?_"1>(=7CT_Q+;.LABL$2X6UN#"-X(8S2)LWEAMR2#7U%7C\'[+?A"V\0
M7VLQ7.JI=7>H:;J3+Y\92.2R*L@0>7\JR,H:0=6/(*U[!0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M 'CGQE^/5Q\,_&.B>&[2ST".ZU.TENXKWQ5KITBSE9'5?LT,ODR^9.=V=AQA
M1GGI5RW_ &A=&T\NGB:!M!O5MK"3^R85GU#4//N4E?R1#!"PD($+D&)I,A68
MA .;WQ-^&?B'QCJBW6C>)]/LK.:S-E>Z)XBT8ZOILZ[BRRB$3PE)1DC=N((P
M"IP*\7U?]F[4O@P_ASQ!X0O=2UK4-(^PVD BTJ.\^SQQ6]U%(\EO]HA,J.+G
M:%C9#'A<;E!% 'K$G[5/PPCLK.\'B22:UNK5[Y)8-+O)52W29H7FDVQ'RHUD
M1E9WVJ, D@$$NN/VE/!FBM<1ZSJ2Q3K>7UO!#I5I>:@\D=JR":1ECM\KL#J6
MP&50<AV )'G7PT_9HUN\^&>HQ^)-5.EZYX@\-7VBW4#6:.UJUS>W-R)6V2[2
MP%P 8U. 5.'-==X9_9I_X1S79M2_X2/[1YD>LQ^7]AVX^WO V<^8?]7Y&.GS
M;OX<<@'33_M%?#V#6[#2O^$@\ZYOI;6W@FMK*XFMFFN%5H(C<)&8ED=75@C.
M&VG=C'-)XW^)NN67CJU\%^#M L==\0OIYU6Z?5=1>QM+2V\SRT+.D,SL[N&"
MJ$QA&)(P ? ;#X)^-_"'B;0O VBQWUQX6MM?T;5[R^N-+B$$PM88%EF2Y^U$
MQJWV=1Y!A9]_1]AKWSQU\,M>OO'=GXU\&Z_8:%X@33VTF[CU;37OK2[MO,\Q
M,HDT+JZ.6*L&QAV!!R" "!OV@M"\-Z1IS>.;>Y\'Z[- ]Q=Z5Y,M_P#8HTD,
M;3RRP1LL=N6&5FDV*01G:<@,O?VH/AM8ZM/IC:Y=3WL-Q+9[+/1[VX$MQ$,R
M0Q-'"RRR*OS%$+-M^;&WFN7U']FSQ+=V]^T?Q'>;4M=T9]$\0WVI:3]I:ZA:
M6:3=:J)D%L5%Q*BAO-4+LRI*Y.MX5_9O@\)W&@&VUQGM]'UZ_P!:BB>T^9UN
M;=X1"6W]4#@[\?-M^Z,\ &S_ ,-*_#@WMG:IXC\UKJWM;M9HK&Y>".&Y.+>2
M681F.%7(*@R,O/'7BLW2_P!I[PB-.FGU^:31+B.^O[9K>&">]$4%K=R6QNIF
MBB(@B8QYWR;4&2-QP37F7AW]ESQ3;:EX@\(R>(X;;P//HNC:;=W+:4&GU)8&
MG:40.)_]'.&52663A_EP1FKFN_L16NJ:G=7\6NZ5/<WWVV*Z.L^'A?HL,][-
M=+Y"F=0DB?:'3<XD1A@F/C% 'HUE^TWX0DU/Q+9WBZG9OH^KC1XECTJ[N)-0
MD\A9BUO''$S2@*S$[ V%4.<*RD^D^'/$>F>+M"LM9T>\CU#3+V,2V]S$?E=3
M]>0>Q!Y!!!YKP'Q9^Q\OB'7[G4H==TEHTU,:E86.K:";NWB+6<=K-'*B7$7F
M*5AB9-GEE"#RX.![1\,O T/PU\":1X;@E@F2PB*M+;6D=I&[LQ9F6*/Y4!9C
MP,^Y)R2 =11110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10!D^+=?_P"$4\*ZQK7V*XU'^SK.6[^QVB[II]B%MB#NQQ@>YKR'X:?M,1^*
M])OM<UR/PS:^&;>P6^;6O#GB,:K#;,6"_9;A/)BDCG^8855;<01P0 ?8?$^B
MOXC\.ZEI<>H7>DR7EN\"7]A)Y=Q;LRD"2-NS*>1]*\ \3?LA77Q%EU&\\8^*
M-*O=6ETY;"&]T;PX+ RE;B&=9;T-<2_:B'@3Y<QKAGP!NR #TM_VA? D>CKJ
M+:K=C=>'3_[/_LB\_M'[0(_,,9LO)^T B/Y^8_N_-TYJY8_'+P-J>F3ZC:>(
M(KFQ@FLH))XH964/=[/LP^[SO\U.GW<_-C!QYMX=_9:O_",MCK&A^(=!T?Q7
M::A-=QSV7ACRM.,<EN(&B:V%SYKG"A@[7!(/ ^7Y:DU3]F?Q%J.H3R-\0UGM
M=1O-(U'5S>:*LEU=W-@\; I(DR)$D@B4%?+8C'#=00"YXD_:Z\'Z7H%YKND_
M:-=TNUTR]U',=C>PS7'V=HE80*UMME0-+AI ^$(Z-AMO?:)\9/"6OPV#6VI2
M+->ZB=(CM9[.>*<7@B,S0M&Z!T(C!8E@!CG/(KS6\_916\\$:1X=/B@H-/\
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M/U&QN[*\O_[:L[V"73X([9HEE$DPDPI'GI[<')'&?GO1?V+O$L'A^ZT2\O\
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M\+O%_P 54_LC3[+PY=:2R0RV&J7US/;7^A7R.2;N'9&XF(7:57='AEP20QP
M;GB/]H/2M#\47/AVR\/ZYXDUJ*YDMTL](C@+2>7!%-/(&EEC0+&LT0.6!+.
MH8U'=?M&: \6C-HFDZUXI?5["WO[.#2+=#(XF=EB1O-=%C)V2DF1E51$V6!P
M#Q?B+X$^*I_#6@W%G;Z=?^*H[_4;V_NAK=WI<RF[8DK'<P(Q9 !&KHR?,$4J
M591G-\.? /XD_##X5W>@^"M2T7^WYC8:;]ON[Z6V,6FP0 2>3)]GGV3-*\Y4
MLC!1)DY(Q0!VT_[4_AY=+AN;7P]XCU&\6*]N-0TRUMX#<Z7%:2^5<O.&F"$(
M_&(FD9L'8& K37]H?0W\06-FNBZZVBWU[%IMOXE^S1#3Y;J2(2I&N9/.;((
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MX4 >C45YS_PENK?\_?\ Y#3_  H_X2W5O^?O_P AI_A0!Z-17G/_  ENK?\
M/W_Y#3_"C_A+=6_Y^_\ R&G^% 'HU%><_P#"6ZM_S]_^0T_PH_X2W5O^?O\
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M@ HHHH **** "BBB@ HHHH *N:/_ ,A>Q_Z[I_Z$*IU<T?\ Y"]C_P!=T_\
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M/ NAZ[\,/"^E:)86EY'=^.YKBW>Y,J;F1'2958@]@O (ZT ?;?\ PD]A_P!
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M2M);3+(Z ,0C*Q!5\C##M0![W_PD]A_T K;_ ,=_^)H_X2>P_P"@%;?^._\
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M#_H!6W_CO_Q-<Y10!T?_  D]A_T K;_QW_XFC_A)[#_H!6W_ ([_ /$USE%
M'1_\)/8?] *V_P#'?_B:/^$GL/\ H!6W_CO_ ,37.44 ='_PD]A_T K;_P =
M_P#B:/\ A)[#_H!6W_CO_P 37.44 ='_ ,)/8?\ 0"MO_'?_ (FC_A)[#_H!
M6W_CO_Q-<Y10!T?_  D]A_T K;_QW_XFC_A)[#_H!6W_ ([_ /$USE% '1_\
M)/8?] *V_P#'?_B:/^$GL/\ H!6W_CO_ ,37.44 ='_PD]A_T K;_P =_P#B
M:/\ A)[#_H!6W_CO_P 37.44 ='_ ,)/8?\ 0"MO_'?_ (FC_A)[#_H!6W_C
MO_Q-<Y10!T?_  D]A_T K;_QW_XFC_A)[#_H!6W_ ([_ /$USE% '1_\)/8?
M] *V_P#'?_B:/^$GL/\ H!6W_CO_ ,37.44 ='_PD]A_T K;_P =_P#B:/\
MA)[#_H!6W_CO_P 37.44 ='_ ,)/8?\ 0"MO_'?_ (FC_A)[#_H!6W_CO_Q-
M<Y10!T?_  D]A_T K;_QW_XFC_A)[#_H!6W_ ([_ /$USE% '1_\)/8?] *V
M_P#'?_B:/^$GL/\ H!6W_CO_ ,37.44 ='_PD]A_T K;_P =_P#B:/\ A)[#
M_H!6W_CO_P 37.44 ='_ ,)/8?\ 0"MO_'?_ (FC_A)[#_H!6W_CO_Q-<Y10
M!T?_  D]A_T K;_QW_XFC_A)[#_H!6W_ ([_ /$USE% '1_\)/8?] *V_P#'
M?_B:/^$GL/\ H!6W_CO_ ,37.44 ='_PD]A_T K;_P =_P#B:/\ A)[#_H!6
MW_CO_P 37.44 ='_ ,)/8?\ 0"MO_'?_ (FC_A)[#_H!6W_CO_Q-<Y10!T?_
M  D]A_T K;_QW_XFC_A)[#_H!6W_ ([_ /$USE% '1_\)/8?] *V_P#'?_B:
M/^$GL/\ H!6W_CO_ ,37.44 ='_PD]A_T K;_P =_P#B:/\ A)[#_H!6W_CO
M_P 37.44 ='_ ,)/8?\ 0"MO_'?_ (FC_A)[#_H!6W_CO_Q-<Y10!T?_  D]
MA_T K;_QW_XFC_A)[#_H!6W_ ([_ /$USE% '1_\)/8?] *V_P#'?_B:/^$G
ML/\ H!6W_CO_ ,37.44 ='_PD]A_T K;_P =_P#B:L6'B*RGOK:--&MXG>15
M$B[<J21S]VN4JYH__(7L?^NZ?^A"@#U*BBB@ HHHH **** "BBB@ HHHH ^,
M_P!LKX"^-OB'\<? 7C3PE9^"M6CT'2KJTGTSQH9VMY3,QPP2.)\X )Y(P<5Q
MC? 'XB^*;CX<S:[IWP^\-KX7\4C6)K/PB;F*"6V\DHVU7A&9BQ[X& .:^Z=6
M\-6NLW*S322JZH$ C( QDGN#ZU2_X02P_P">US_WTO\ \30!^=_PT_8F\4>$
M/&NA66IOHVH>$-"UF?5K74WUG5'NI S,T2K9>8MM%(I8Y< @CL<G/=?!'X.?
M&+X3VVC^!5U7PLGP[TFZNI#J,0EDU&_MY&=TA:)D"1L&?EPQX'%?:W_""6'_
M #VN?^^E_P#B:/\ A!+#_GM<_P#?2_\ Q- 'P!\.?V4?B%H6D?"K1]8F\-BQ
M\">*KG5EGM[N=Y+NUD\Q@0IA 60,_P!TG&!US6M\0_V<OB8/$?Q5MO!5[X9F
M\-?$L1_VA/K3SK=:8WE>5(8U1&64%<E02N#CMU^Z?^$$L/\ GM<_]]+_ /$T
M?\()8?\ /:Y_[Z7_ .)H ^*M,_95UGP_XF\6S6&HZ?-I%_\ #Z#P?8-<R2"?
MSXT9/,E 0A4.0<J6/M7*Z;^Q3XDNK%-.U?6=*@LY/ALG@V6:RDEDD6[$N_S5
M5HU!BZ<DAC_=%??_ /P@EA_SVN?^^E_^)H_X02P_Y[7/_?2__$T ?+7P+\.?
M&+09]/L/'5UX6M?#>D:5%IMO::$99I;R9,*+AWD1?+&T8V#/)[5R7B_]CK3?
MBA\9?B7XB\96>D:EX?\ $NCV=AIKA2]_83Q(0TREDQ&<X(*N<XP1CBOM+_A!
M+#_GM<_]]+_\31_P@EA_SVN?^^E_^)H _//6OV3_ (JZEX;^'5SJ&JZ%KWB;
MP0UWI\(BUB_TU-1T^10L;//;JDL,ZA0"%)5@.6/.=;3OV4/&G@+1/AEKOA1O
M#;^-/"EY?W=WI=Q<WG]GW7VP8E"SRF67>,#YF^\<G Z5][?\()8?\]KG_OI?
M_B:/^$$L/^>US_WTO_Q- 'Q-KGP:^,ESXA\"_$@ZKX4UGXB:%'?6MWI<XFM]
M.>UN"-L<4JH7WQX'S,HW9.<8YQ_ /[(/BKPWXN^'WB74]5T:ZU&Q\2:KXEU^
M.!I5B$MW$J+':@H=P4J,EROK7WC_ ,()8?\ /:Y_[Z7_ .)H_P"$$L/^>US_
M -]+_P#$T ?GY\2_V5?BAJ=M\7O"_A34/"I\*?$"_75VO-8EN$N[2;*%X=J1
MLI4E!A\Y SP37M'QS^&?C+QK\"AX5\'ZW'HWB"-+5&F^TRV\=Q'&5\V'SHQY
MB*X!&Y1GZ9-?3?\ P@EA_P ]KG_OI?\ XFC_ (02P_Y[7/\ WTO_ ,30!^;F
MG_L.>.(_#/C>P0^%-''B'5]&U2"SM=0O)X[9;5RTT;R2Q,[L1R&).XDYVBO0
MOBU^R3K_ ,3/$GQCO4U;3;&W\7:?I<>EL6D9XKBS(;]^NS 1F4#*EC@YQVK[
MA_X02P_Y[7/_ 'TO_P 31_P@EA_SVN?^^E_^)H ^.?A7\(?B8GQ]_P"%E^/'
M\+VRGPR-"&GZ#//(R.LRN')DC4$'#'KQD#!QFD^.OPG^*'B;QE>WF@1>#/''
MA'4;);=O#/CF%C%I\XX,\#)&V=PY(.#GIVQ]C_\ ""6'_/:Y_P"^E_\ B:/^
M$$L/^>US_P!]+_\ $T ?GUI'[%VO>&O"_P ,K"_UNTU#3_"VEZ[!JWV7S3,?
MMT+*$LT*G<$+$ ,RD\<<XKQOX&^)M8\<_%#]G_PI;:SHVOV7@J>]0P:787<-
M[:6ZPL@DOA,H6)CA5"+D$\Y.17ZT_P#""6'_ #VN?^^E_P#B:3_A!-/_ .>M
MS_WTO_Q- 'PCX>_9)\7Z1\,OAOX=DU+1/M_AOQNWB6[ECFF,;VQEE?;&3$"9
M,.O! '!^:N6\*?L=?$Z'XM^%?%GB/4O#^K7.A>(Y-2N-<N-6OI[[4+1RVU%B
M=#%#L4@!%P"1]X <_HQ_P@EA_P ]KG_OI?\ XFC_ (02P_Y[7/\ WTO_ ,30
M!^>5E^RE\4=(^&VGZ%:3>&)-0\+^-O\ A*=%>6[G$=_$TLCM'/B+,3?.N-N[
MH>G!JS+^R-\1M?NM<U+6]0\+C4-7\=:9XKEBM)[@PQP6Z$21#=#DOR O9L9)
M7.*_03_A!+#_ )[7/_?2_P#Q-'_""6'_ #VN?^^E_P#B: /A#]H/]E7Q=XV^
M+.L>+_"KZ5?V^OZ/'I%]9:KK.HZ:+=DR!+_H;+YZ%3@Q.<9^IKT;XK? 6_\
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MG_OI?_B: .$HKN_^$$L/^>US_P!]+_\ $T?\()8?\]KG_OI?_B: .$HKN_\
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M_GM<_P#?2_\ Q-'_  @EA_SVN?\ OI?_ (F@#A**[O\ X02P_P">US_WTO\
M\31_P@EA_P ]KG_OI?\ XF@#A**[O_A!+#_GM<_]]+_\31_P@EA_SVN?^^E_
M^)H X2BN[_X02P_Y[7/_ 'TO_P 31_P@EA_SVN?^^E_^)H X2BN[_P"$$L/^
M>US_ -]+_P#$T?\ ""6'_/:Y_P"^E_\ B: .$HKN_P#A!+#_ )[7/_?2_P#Q
M-'_""6'_ #VN?^^E_P#B: .$JYH__(7L?^NZ?^A"NO\ ^$$L/^>US_WTO_Q-
M26W@RRM;F*9);@O&X<!F7&0<^E &_1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
2%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ctso-20221231xex10d30g006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ctso-20221231xex10d30g006.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1, U$# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJUOKDNGW%VUO9IJMK;VW66Y8%MUTZP0!AG]Y+N5,CY7.%/U=)$DR%)$5U/\
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M'TWP]!IL&GWEEIVIQRZQK5G]OA-[J=]'&QD $0E57D'F%9'+;05%:'B;Q/\
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MB3X<?"G1?$5M83V^L/K.EV]WI>F*E[+(DMRB2V\190'+!BH;"GG.5ZUOZ7\
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M=;^!O@?Q'J=_?ZGH,=[<WTTEQ<F:>4I*\EK]D<E-^W!@^3&,=\;N:RXOV</
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M*O?RZ;:ZK<K>:QYD.KZY#;3E+.Z>,QV\<-LTDQPORDQJH 'F2[CD^D+^S'X
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M-:^R+8M=Z-XAU#3&>!79U1Q:SQA@&=B-P)YH \FC^.WB[P-XQ\6IJVF7.O\
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MV7?AG)9^"_$VJPW'C_Q/;:?;7UW>27,VBP&$"5())&8H"4RO/R[VQC Q+^W
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M/?$-E<>&IM.35M9O9++SMT$@_P!'C0AU$<KD.2"&VJAR,E<@'$? K]E'QA\
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M>.HO#'Q \"64.ES:W!HIDAUBSCC""&>#[0",@$9\P\,1V&.VTO\ 9KN/A_\
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M.#_%R"<_,<Z_QI^(?Q4\+>)M9MO!VB:9J.F6^C65U:R7=M+([W<FH+#,A*N
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M>X6WU[7[73Y L32O+G9 LC;(VF8 K"KM\JM(5!/ )KK@0P!!R#T(H 6BBB@
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M4_%FDZ-KNCZ->7BP:EJYE6Q@*,3,8TWO@@8&%YY(K7H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R
MWXK?$B\\/_$#X=^";"Z32KCQ=<7B-JCHKM"EO!YI2)6RIE<D ;@P #':>*XR
MV^)/C9/B-X3^%6K:_I2>(+^RU/4;OQ#I%N&W16\J+#$L<F46<K*C29! VG:!
MN!'JGQ/^$/A'XR:+;:5XPT=-6M+6X6[MF$TMO-;S+TDBFB99(VY(RK#@U1N/
M@-X%GTKP_8+H9M8_#\CRZ9<65Y/;75J[@B1EN(Y%E)?)WY<[\_-F@#P/1_VA
MOB5XDU+P/H276C:9J-QXRU?PAJMZ=,>6.Y-I;RR1W,*F4;0=BY3)^8$;L#%5
MK+X[?%/3?#<>N:CKVC7T&B?$)?!E]:QZ08VU.!KM(//+^:?*<+(I"J,94YR#
M@?0DWP'\$33^%YAI$T,GAFZEO=+-MJ-S#Y5Q(&$LKA)!YKOO?<TFXG<V<Y-9
MDO[,GP[GT>[TM]*U%K&[UH>(IHO[=U#Y]0#AQ/N\_(.]5;:#MR!Q0!X?XV^/
M'Q4T+2?BMK]KK>A?9? _BZUTN+3VTAL7MK*+3*/)YQ*$?:&.X9)([#Y:L_$K
MXV?$CX>6?QNTV?Q#8WVI>$]%T_Q!I>H6VEI %$[RJ]O)&S2!D'E9#9#<\GBO
M:=1_9G^'FK:9XGTZ[TK4)K/Q+?QZGJT9UR_'VJY39LD)$^5QY:<*0/D7C@5>
MOO@#X%U35/$NH7^D3ZA<^)--32-5^V:E=31W5J@8)&8WE*C&YL,H#98G.30!
MX_\ %?XW>./!OB+XJ6^D:G9F+0OA]#XIL(KZR65(KDO.KCY"C,I$0P&)P23R
M.*M:!\6/B+9>.;W0M4UG1]1&H> ?^$KL)$TIHEL;A7"&-@)<RH=P.25.0<8!
MQ7=K^R=\+EM=3@/A^[?^T]*_L2]GDUJ_>>YLLD^2\IG+L/F(R6SC"YP *V1^
MS_X(&KQ:I]AU'[?%HI\/)-_;=]D6!ZPX\['8'=][(SG- 'DGPT^.OBSXLV_P
M^\-1ZM:Z!XCUOP(GBNYU);5'\Z=G6-8XXWRH0,2S\$XV@%>M9OQC^.WQ"\!>
M%-9O;;7- U'6_#?AF#5;VS\.VQN(7NO-=9FN6FP([9A&5C5'$Q.\X(6O5]3_
M &4OA;K'ASPMH=WX:DDLO"\9AT>1=4O$N;.(@ QK<+,)2A  *,Y4@#BI_$W[
M+OPP\77%Q+J7A=2MSI::+<06M[<VL$]F@/EQ2112*C[-QV,RED/*D&@#S+2-
M>\4S_M!_%N]M_%%V(M.\(:7?V&FW<$4MG"\B7;E2JJKE0RYX<,2>6(  =\+_
M (\^*OBO-\,_"YU*'0M9U[P,OBS4-7@M$<R2ETC6*&-\H%#,S-D$XV@$9S7K
M8_9_\"KJSZG'I%Q#?R:4NBR3PZG=QF2T4,%5]LH#. [@2',@WMAN345K^SMX
M!L=&\+:;:Z1<VD7A>%K?1[BWU6\CN[.%AM:);E91,4( !0N5.!QP* /"_"G[
M0OQ,^(.K_#/18+O1?#]YK.H>(-$U:X_LQYU:?3MRBX@#2C"/C(0YP>K,!@OT
M_P#:/\>CX3>'O$.JVEY>6EOJ&KZ=XAUOPMIB7-Q;_9+AH8;HV;%F,#;2TOEA
MF7C& <U[X?@3X(&I^%M0BTB:TN?"Z3)I!L]0N8$MO.&)B420*[/D[F<,3G).
M:SM&_9M\ ^'K:V@TRPU6QCMY;N:,P>(-15MUTX>XRWGY8.P#%22,\@ T 5/&
M/BJ[UW]EO6/$NB^)@]])X5EU"WU_1XU59)!;%_-B616"AB.A&0#V(X\V^%'Q
M \17S?##X96GB*YM;R\\!0^)9]=N[:&:X?B**."-=@0JI8LQ968C:,@DM7T5
M;>#=$L_"*^%H-,MX?#RV9T\:<BXB%N4V&/'IMXKCK7]G/P!8:9X=LK71[JU'
MAY7CTN[@U:\CO+5'4*T8N1,)BA55&PN5PJC&%& #*^!?QBU7Q[\'-0\2^(=/
MBBUC1;O4=/O5L598;J2SEDC:2(,20K^7D DX)(R<5Y]X0^*OQ9\7>%=$\>6-
MSX?7PKKF@W%^T=[L?[)<>098!;+&P>4#:RR)(V>"P(P5KZ,\.^&=+\):';:/
MI%C%8:9;J5CMXQ\HR223GDDDDDG))))))KSOPW^RO\+O!]WK-QHGA?\ LM]6
M2:.X2VU"Z6.,39\WR(_-VVY?)!,(0F@#R'X;_&;XD^(;OX7)KOB"P>U^('@R
M[U7&FZ8L$VF74,,,@DC=V=9-WFMD,FT$# ZYR?@C\4_%UM\*/@IX8M];O-2\
M0>,](O-4?5+[[-YR&'86BBW($9F:4N2X<[5;'4%?H31/V>/ ?AV[\(W-AI=Y
M%+X3LY-/T8/K%[(EK;N KQ[6F*N"%4?.&X4#L*R;[]DOX4ZEX,L/"MQX6,FB
MZ?=F^L4_M&[$UE,>\$XE\V%>2 B.J@< 8H \TE\>_'"X\:_#[P+>Z]X4\/Z]
MK6F:N]_>V6G-?I'-:O%Y4@4S(,LDHW1\;6W?,PP*]+_:5\?^)?A7\)$U[0KN
MR&IPZCIUK/)<VAD62.:ZBADV+O&PXD)!.['H>M;NG_ 3P/I.O^&-9LM)GM-0
M\-6\UKI;PZE=(D,<I!E#1B79(7(!9I Q8C))-;/Q%^&GA[XK^'#H7B>TGOM*
M,\5R8(+V>U)DC</&2T+HQPRJ<9QD"@#YP^+/QL^*/AS5?CK/I&N:):Z=\/;?
M3]2M+632&D>ZCE@,KP2.9N,X(+@9Z8"X.:WB3XM:Y\._BI\;O&T^KZEJNF^'
M/!>E:M:^'W\D6P:471\O(BWA0P#%@V[KDD  >YZS^SAX \0'Q@=0TR_N?^$N
MABM];SK=\/MD<2[8U.)QMPO'R;<@G.<UH#X%>!_^$@?6I-$-SJ$FEKHL[7-Y
M/-'<VBAE6.:-W*2D!W =U9@&89Y- '":1\2_%OAOXO\ P[\-ZOJ-MXET;QOH
M]U>K<0VJPO874$<<K;"IPT#K)@!LL"!EVS1^T3\3?$_@Z^N+3PUJUM!/:>'+
M[6OL%I:K<WTDD./+>02 11V@PP8EUD9L!.0:]$\%?!WPE\/9[:;1--FBEM+4
MV-J]W?7%V;2W)!,,/G2/Y295?E3 ^51CY1BMXZ^!?@CXDZ_!K7B'1FO=2BL9
M-,,T5[<6XFM9#EX)5BD598R>=L@8 \C!H \7UW]H?Q;>6.@2+-:^%DU/X?CQ
M197AM?/CU#5,(?L2AL_*-RG8I$C>8-K#!RGAWX@_&KQ;\2?#'A*]UO0/"E[>
M^#+?Q-J$7_"/22/;SFZ5);?8]T3]TE,[A@Y.,XQ7\<_LY7^F^-]-B\/>$M7G
M\):=HT&DZ1<>%_'5YHU[9JKNTB7)\P&9"63:=[D!3\M>L_#/X%6'A34=*\4:
MU<ZEJWCBUL'TPZG=:U=W1%HTK2+;MN94FV94>8\89BNX\F@#S;P5\:OB/XXT
MO1?B'IL>E-X(FNKR/4]+NI8T>&")I$00,N9#<AXU#(_RMN( 7BCP9\4_BQXP
M\,:'X[L;G0%\*:[H5Q?M'>['-I<>298!;+&P>4#:RR)(V>"P*X*UZEX?_9M^
M&_A7QY?>,M)\,0V6O7L[W4SQW,_V<SN"'F%L7\E9""<NJ!CD\\FJGAG]EGX7
M^#+S6+G0_#']ER:JDR3I;7]TL<8F_P!;Y$?F[;<MDY,(0F@#QKP)\7_BUXHN
M?@PD_B?0XD^(WARXO)"NB$G39X8(I?,3]\/,+!V&&PHX.#@@V/ _[1WC7QEH
M_@7PR\MJGBO6KC7;:?5;6**'SO[.N?)!BCE+(KN"'(.[ 5\#D%?:](_9V\!Z
M#+X/DL--O[=_"-M)9Z)C6KXBSAD4*Z &8[P5 'S[N !VK*O_ -DSX5ZIX0M_
M#-WX:EN-)MM1EU>V\S5;TW%M=R,6DEBN/.\Z,LS,2$< Y/% 'G4'Q!^-,OCS
MX>^!]6UKPMHNKZSI>KOJ-UI]@UZ(Y;5XA'(N95 9DE&8^BMGEA@5ROA#XE>,
MOBQXE_9MU/4?$MUI4VJ/KL>IVNE0PI;7,UHDD8EV2(Y&X!LKN(&X[<'FOHJT
M^ /@:PUCP]JEII-S9WWA^TGL=-DMM3NXA#%,09@564*[.0"SN"Q(R3GFJ6F_
MLT?#K2-*\-Z=:Z'<1VOAR\GO]+W:K>/);RS9\[]XTQ9D?)W1L2AR<K0 [XS^
M+]8T"_\ "6E:+JL&GW&L7DT4D$$ GU*Y1(6<+:1NIBR&VEWF*HJ9Y!(KQ'P3
M\??B9\0[+X'PV^IZ-HMSXRCUJWU.:32C,T<MGO"R(OG!1G:#MZ;NY'RU]&^/
M/A-X6^)EWHMWXATZ6YO-%F>>PNK:]GM)H&==K@/"Z,59>&0DJPX(-<WX?_9A
M^&_A6\\/W6CZ%<Z=+H$MU/I@M]7O52V:XSY^U/.VD-G&"" .  * /)/AI^T9
MXL\=M\.O!M[?6EAXDUR\UVWO]=MK10&BTV=HLPQ.6199?D)SN50'P#QCJ_V+
M(+NV\$>.X;ZY2\O$\=:VLMQ'%Y8D;[2<MMR=N>N,UU@_9:^&8T&QT@:#=+;6
M&I3:Q93KK%\+NTNY6+2RPW(F\Z,N6)8(X!SR*ZSX>_"WPQ\*['4+/POIK:;;
MW]W)?W2M<S3F6=SEY"9'8Y)Y.#0!Y3\/_BEXM^)FD6_CG3-<TG3]!M_$-[IF
MH:!>P\K:P320*$D'S_:V=$8 D(0X7;G#'E-*_:+\8WOP[^&'Q0BGM+S1/&.O
M0Z1=>'!:C-E#<3/#"\4@.]I8V53(&)5LM@)@5[)I/[.GPZT+XA7GC>P\,PVO
MB.[G-W-.EQ-Y#3D8,_V??Y(E(SF0(&Y//-6M$^!'@;PYJBWVG:(;9H[V348;
M47EPUI;W4F=\T5L9##%(=S?,B Y9CU)H ^?=#^/'Q0^SZ%X@U'6M%N=,E^)$
M_@NZTNWTDQ&6W^TRPI,)3*Q1EV*0,'/.2<\8T'Q%^('P_P#AU\6_$VF>+7U;
M4[7XE?V+&FNVD4T2P-<VMN-OE+&5(1P.Z@+PH))KZ&C_ &9/AW%I<&G+I6H"
MS@UP^)(X_P"W=0^742Y<SY\_.=Q+;<[<D\4NN_LR?#CQ&-?6]T.Z,>O:A'JN
MH1V^KWMNDMTC*ZRA8YE"'=&C'8%#%%+9(% 'E7QB^)GQ+^%.C:];_P#"8:7X
M@UK1/#EWK_EZ5HPBG=EE<Q?:HY':.*U$:E,K*LLC!BH^4BMW3?BWXQ^+&M>+
M-&\*:OI?A?6/#NBZ5J,<>H0>;!=SW<'GL9LY9;=5&S*8;.3NXP?0_&O[//@#
MXAZN^J>(-$DO[V73#HUQ(-1NHA=69R?*G5)568 L2#(&()R"#S69J7[*?PKU
M>_T.^N_"B2W>C6::?;3"^N59[93E89R)!]I3/.V;>.3ZT >5:9XC\>6WQ3^/
MVHZ'K5QXGU+2].T9M)T61[9;-VFMWDV1,44\,[E,N-Q8;RW4>J?L\_%5/BAI
MOB%FU34+F[TV^6VGTO7-,&GZII;&)"8;F,*JLQ;<RN@VLI&"<$ULZ]\ O OB
M37M9UJ]T>;^TM8M8;2^FM=1NK82I"?W1VQ2*JNG19% <#@-CBNC\+>!=%\&R
M:A+I=K(ESJ$B2WEW<W,MS<7#*@1"\LK,[;5  !. .E 'QQ)XN^('POL?C]X\
M\)ZMI"Z5X>\<SW5]H%]IS2OJ4?DV@D1;@2#RFVGY<(?FZY!P/3[?XO?$GXB:
MOX@U#P4NE6=AX:\1_P!D7NG:O+''$UO'L,[2OS(DI5RT9&%P%!#9)KUQ_@=X
M)DU[4-7;1F-QJ%XFH7EO]LG^QW-RFW;-):[_ "7D&Q#N*$Y53G(&,_4OV;_A
MQJWQ(;QY<^&8CXHD:-YKJ.YGCBN6C_U;S0*XBE9<##.C$8&#P* /GW2/$?Q%
M\/?#/XX^+=&\8:IJVI>'/&UZS6EY;6LHFL;;R?.C0"$%7\@-MQP"B_+R<[6D
M?M$Z[X@^)'BOPQIWB.:XM]>@LKGP)J'V.W"31LXCO"/D_>B!LD[OX0>XW'Z%
M\/\ PG\*^%M8\2ZGIFEFWNO$<S7&J*US+)%/(P =A$SE$+ #=L5=V!G.*31?
MA%X.\.MX6;3?#]I:-X7M9;+1C&#FRAD55D1.?X@JY)R?S- 'C4?Q4^)?C77/
M$<_@R32ELO"GB4Z)?6NL21113V\6S[1)*X'F1RL&9T*@)C:"IR31X.^*_P 3
M/B==V7B?PTVCV_AA/$-UI&HV&IO&J0VT4[V^Y64^;]IW*C;6(5@VT <,?2=2
M_9O^'&K?$AO'ESX9B/BB1HWFNH[F>.*Y:/\ U;S0*XBE9<##.C$8&#P*;9?L
MU_#?3?B%>^-[3PREKXCO)C<W$\%W.D,DY&//-N)/)\W_ *:!-^><YH \.\ _
M'KXG7T/PTU[6M8T:\TSQ!XSO_"EYI=KI1A.R.6[2.=93*Q##[.ORXQ@G))YK
MVKXU?$^^\%:_\//#.FLEG>>,=:.EC4I8PXM$2"29RJG@R,(PJ[LC+9(;&"ZP
M_9E^'FF:;H=A;:3J$=IHFK2:[I\?]N7Y\B]=F9YLF?+$F1SALK\[<<FNP\<_
M#[P_\2-)ATWQ%IPO[:"XCNX&65X9;>=#E)8I8V5XW4]&1@>3SS0!\U^(_C]X
M\\-Z[K7AJ>_AEO?#GCC0]%;4TLXPFI:?J!0[94((29%8@M&5!^4[1G%)\1?C
MU\0O"D/Q?72=5L)I/#/BO1-,L#J-@K[;:\%MYB$QE.09VPQ#' QR>:]YU7X$
M>!]<\(:CX:O]%:[TO4;I+Z[:2]N#=37*%2DQNO,\[S%V)M??N 4 $ 8K!N?V
M4/A?=Z?J]F_A^Z6#5[FVO-0,6LWT;W4]OM\F1W68,S*44YSEB,MD\T ><>/_
M (L^/O@YK]MI_C7Q XT*183#XTTS0$.FQSR7#9M]0B#RR6Z^48E24$*6)9CV
MK1/Q9^)'CSQ!XEN_!!TB'3O"_B8Z->66JRQI!+;1;//>1^9$D96+QE<+C;D-
MDFO6M>^"_A'Q-J5U>ZI8W=Y)=V\-K=0OJEU]GNHHB3&LT(E\N7!)Y=23DYS6
M9J/[-WPWU3XCGQW<>&(O^$G<QM-=17,\<5PT?^K::!7$4K+@89T8C P>!0!X
M-#J'C'0M+_::UOP)>&WU_2?%XOUMQ;QS?:XH["T::$!U.&:,-M(_BV]1D5V/
MB3]HVZB\&3^/?#VI)?\ AC4KG2-%TDW21"!;BZ=!+<LX"G""5%VE@N]7!QV]
MG\(?"WPWX%U7Q)J.C6=Q!=^(KO[=J;3W]Q<+<3;0F_;+(RI\JJN$ & !CBJT
MGP6\#S?#.7X>/X:L7\%R1-"VC,I,.UG+GOD'<2P(.0>01B@#R+7_ !S\9O F
MD:NVIZ8/$5G%JEL\!T'[/-KZZ8T;F=A;8$4DB2(-NT'<F_Y"RUZ?\'/B);>/
MOA/9^)K?Q!;:[$XN2=1>V:R V2N-LT3 &)T "N".&5NU5-"_9M^'WAC0K/2=
M*TF]L;:TO%OX9XM9OA="94:-2;GSO.90CLH0N5 8C%=EH7@C0_#7AV30M.TZ
M.#2I3,TL#,TGG-*S-*TC,2SLY9BS,222<F@#YF\)_'_Q]>^)K33I-3L-2AU?
MP7J'B&WU'^SL6 NK>2,*;0;HYI+8K)C,P#-@,K%353P9^TCX]T2U^'7B'Q;?
MZ=K>C>*? M]XDGT[3].-O):SVMO#.=DF]M^\2,""  <8 [^PZ3^R7\+=#-B;
M+P]=0-864^FVK_VU?LT%K-C? C&<E8^!M4<(>4"FM72/V=/ &A7'A2:TTB[4
M^%K&73=(275[R6.WMI%"O$4>8K(K*J@B0-P .U 'A-MK7B'QI\6/V7_&&L:U
M;WT7B"WU+4!86ULJ16;2Z?O"1.#N90K!3O+$E<@J#MKUO]HCQOXB^%LGA#Q=
M::J;;P7:ZM#:>)[86\3E;28^6EP'924"2-'OQ_ 21@C-7O#?[+7PR\(ZKHFH
M:3X>GM9]#GEN=*C.JWCP6#R#$@@A:8QQ(P)RBJ%]JM?&[1_$_C721X+TKPWI
MVI^'?$5M-8ZQJU_J C_L^%@%)6W\MC.S*7P-R@,!GB@#SNT^,OB36/'_ (1\
M,P:NUI9^.;K5;[3=2:VA9[73K15$:0C;M>28MY@9PV(^Q/-<[HO[0?CJY\7>
M&-!U"ZMTNK3XAW7@S59[>T58-2MTLY+B.=0V6CDP(PP5MN0W'( ^@O$'PA\)
M>*-)T#3[_2?W.@,CZ5+:7$MK/8LB; 89H621/D^4A6 (X.16?K7P$\"^(/"M
MIX>O-$8Z=:7_ /:L#P7UQ!=)>98FX%S'(LWFDLV7WY.3DF@#'_9\\=:YXUC^
M(4&N7HOWT+Q=?Z-:3>2D;?9XA&4#!  6^8\X&:\XU7X[^,-.^*GAVVMM2L=6
MT/5/&LWAB5+&U#6-O"()&1?.?9(]VKQGS-F^(<ID,*]S^'WPI\*_"N+58O"V
MDC28]4NVOKQ$GED$L[##/AV;!.!G&.E<K/\ LL?#&YU=]2?PY)]I;5SKJA-4
MO%BBOCG=-'$)0D9?<=X10'_B!H \7T/X\_% 0:#X@U+6=$N=,D^)$_@NZTNW
MTEHC-;_:985F$IE8HR[%(&#GG).>,+XJ_$/6_C1\)=,\8#4XK+1(OB58:7%H
M:VRG;%;ZJD(>20_.)F9-YYVA6"[<_-7T3'^S)\.XM+@TY-*U 6<&N'Q)''_;
MNH?+J)<N9\^?G.XEMN=N2>*AU;]E;X7ZWJ>I7USX;D#ZE?QZK=VUOJ=Y!:RW
MB,&6Y^SQRK$)=R@EPH8]R<F@"?X[?%&\^'8\$Z;IWEP7WBSQ#;Z#'?SIOCLQ
M(KNTFW(#-MC*J#QN89R!@_/GQY^)_CA-)^(_@6Y\07-O<^&]9\./;:]IL$4,
ME[97UW&A@G!1E#KA\F,(&&W( W _6GC7X?\ A_XB>'3H?B'34U+3?,CF2-G=
M'BDC(:.2.12'1U(!#J0P/0UA:C\"?!&L>%-9\.W^CR7NG:Q-'<7[W%_<R75Q
M+&5,;M<F3SMR;$VG?E=HQB@#YN^(>J^,/ OQB^.^O^&/$%O;ZCX?\$Z1J,L^
MI:>MPUZ81>OL8*8U0-M()5>_ %=I??&CXB_$K5]?TCX?+ING:UH>D:7J*PZ@
M8S!<2W4'G8FW?.(,?)F/# ACD\"O3;O]FWX?WTGB.2?2[^1_$6FQZ1JA_MN_
M'VFTC#!(S^_XP&?YEPQW-DG)S5U[]E;X7>)M0T*_U+PP;F^T6S33K2Z_M&Z2
M5K5?NP3,LH-Q&/[LQ<>U '#>%_%WQ5^)'Q>\<>'+?Q;H?AW2_#T>E7 %EI'V
MMY5NK1Y'C65Y=ORO@B3:00H^0 G/GF@_M4^)M&NOAW/XKUR2.UL]0O- \?(E
MG;I%8WRR21VLI;9N1)70X4=5*G(_B^IO#?PI\,^$O&6N^*=*LKBVUK7$ACOY
M6O[B2*58EVQ 0O(8TVKP-BC XJ+4O@UX)U>V\0V]YX;LKB'Q#>PZCJJ.I_TN
MXB\ORY'YZKY4?3 X]SD \N3XC>//#_CSX,:/J6HV]S:^+QJ<^H07-FB7$7EV
MYG@C$B84!055ODR2I.<'%<#)^UMK_@W2/%$_BQ;C2/%NDZ2]V_AG5[!8[65F
MNHHH[NRNX_EGM%63+9<N,\D=OI;Q+\+?#?B_Q;X>\2ZK9W$^L^'S*=-GCO[B
M%(#*NV3,:2*C[EX.]3Q61I_[/_@+3]/:Q.AMJ-F=/ETI8-7O;B_2.TD(\R!!
M/(^Q&VKD+CA5'0"@#.^%M[\1E\7ZM;>++C3+SPW/:176E3B2(7XDSB562(;&
MAY0JWWAG!W<&O5*X3X5_ [P3\%;*>U\':,VEQ3A58S7D]VX1<[8U>>1V6,9.
M$4A1DX%=W0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 >7_&;XR7?PKUCP)IUIX:O=>D\3ZTNE"2VDA40_NI
M)#_K)$RQ$9Q_#P<D< NU[]HGPAX;ENY;V2]71['4$TG4-;CM]]C8WC%0(99
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M+;Q/_8D=P;1M4/AV[%L)Q="U\DR;,*_F$?*V" ?7BK6J?M>>"-&C\3?:]/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[^)>G:7K.J?M&P_\)7K5OX]T?6[>;P?9P:_=+<I=M96[1K;P>;^\#2G:5VL
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MC6X\\Q(H^:9"8RVT94 '@#(^D/ L5OXU_9#T2&YB76([WP=%'+%<)YOG/]D
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M\A+.\<6S> 69FV%R@)R%R!C2G_: \-S?$'Q;X*-Q=:3=Z!I<5_=ZS>64JV4
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M9/[,?@$_#KQ=X(_LV4:#XGO[C4[Z-)BDB3RR"3=$XP4V,%*8^Z0.M;=K\<O
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MK>#H_#VORW<B0SP7=OJ%O(L5W;74+!HKB-@NU9%89^[MY(((.*T?#'Q"\/\
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M/(RJ2,#@8Z3X2_"6R^$&EZS86&L:KJ\.J:K<ZQ(=5,!:.:=S)*$\J*/Y2Q)
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M^)OCC6I/!MQ/8>)?!>GV$;0ZA:$V]W;QW*M;N&D!+DS)AAF/[V7&!GG?@_\
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MTS55O/M/B74ETJQ:WMFDC\\JS 2/]U!A&ZG)QP#0!\RVGPR^*4_Q(\#ZY?>
M&@/A_P 9:E?W/]G:G96^GO93Q7"136]ND@)8^8K2O*HF+,<;@?EC\*?!_P"(
M.F>"_A;8S^!+^WO=%^(U]X@U!5OM/)ALI9;MEER+C#$K<1_*N6X/' S]FT4
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M4/BMX>\?^&_CQHOC[PKX43Q]HEQH$OA[4M&&H06D]J3.)EN$,Y",A^ZZYW8
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M#G?C7KT'PQ^!WB/4(_$5WX<2PL?+BUEHCJ-Q S,$1@LK_O'+, "[XR02<"N
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M=WV@M(Q+-R9#P !74>)/".A>,;..TU_1=/URUCD$J0:E:QW"*XZ,%<$ CUH
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ML#PA\/\ PO\ #VSN+3PMX;TCPU:W$AFF@T>PBM$DD_OLL:@%O<\UOT %%%%
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M*, ?IP#TKSWXV7OC#P_^RGK5QX/EU?4?%5KHD7DW$T6-2D ""638HXG\O>V
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M-:T&RLG6YEBW2@^<6RKV8CV.C<*N%"D-P>W_ &2_$%W_ ,)U/HUU)I'BN-M
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M-O<JH&YO4^IXJ2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH J7NJV6FRVL=W>6]K)=2>3;I-*J&:3&=B
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MXGA+Q)8:^UG'#-<"REW^6DREHB?]X _D: .1T?\ 9B\*Z(HL(+W5G\+)K/\
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MI;(4'!'N-% '+?"[X?6GPI^'VA>$+#4+[4]/T:U2RMKC4C$9S$@P@8QHBG
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MF6"_)&/O8SD^P)H UJ*13N4'!&1G!ZTM !1110 4444 %%%% !1110 4444
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M_P +1TOP+K_A6_L1;+<LT23VI@@D,OV-L>>EPSRJ,DLORA<$<^M?M<^)-?\
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M5L\[@,YH Y'XD:AK7P,_9U\5:EIFJ:IXLUG0],N;N"^UG9/<R,-S@OY:(K!
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M5]6WOPK\%:CHMIH]WX/T&ZTBSG%U;6$VF0/!!,#D2)&5VJ^>=P&<U6O?@O\
M#[4EU5;OP)X:NEU9TDU$3:/;N+UD^XTV4_>%>Q;..U 'AVM?$Q_%WQ&^*/AO
M5?B-+\-]3\+-ITFBE9$4-;O"DKW+0L0+H2.7BVG(& % 8Y/T_ _F0QMDG<H.
M2NTGCT[?2N?O_AIX0U76-)U:]\*:)>:KI*"/3KZXTZ%Y[)1T$+E=T8'HI%=)
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*KG<1FO7/AQX8\2^&]*E'BWQ:?&&LS,"]W%8+86Z*HP%C@5WV]R278DGL
M#A1^TM9VWQ)T/PKJGA^[T==;U"]TVQEO9ECNBULCN9Y+9@&6WD$3^7*"V[ )
M"@BO+OBE\4Y_B7XB^!'B/1=+OH/"M]XV2*RU-=0V?;8UBN!E[8$#8Y3<C,6.
M%R0F>>DLOV1=9M_$&BWUQ\04O+;2?$U[X@B670U-S<I=)+')#<3F<^8RI+M2
M0*H55 *-@89H?[(FO>'=*\$^'[3XC(_A7P7KZZUHEI<:$'NXXP)0+:6<3A9%
M42L%81J0!SNXP 75_;$4VEMJ3?#O7UT:3Q1+X2ENOM-H9([U9FAC C$OS!G4
M#<#M7<.3SBOX[_:(T;5OA5\2O^$P\!:NI\*7]M8:QH<5_%O*R^5)#*L\<B_+
MB1"=IW @C!%2C]E/71X/70_^$XT_</'/_":_:/[ ?[WVG[1]GV_:^F[C?GI_
M#3_&O[*VM^,=.^+MH?&UA:)\0+NRN2W]A.YL!;I&@4?Z4/,W")>?EP2>#0!V
MS?'>RF^)M[X'TO3X[_5-,DLTO;5KY(KM(IPK"XB@89EA16^=P1@@@ X)JMX$
M^/\ :?$X:G+HNC_VGI5JM[',]G?Q-=6\UO)Y9M[B!MI@DD^9D#-C"Y)7I6=X
MX_9OG^)'BG2]6\0:YIL_]E:E9ZGIMU;:*8M2L&A">9##=^>2L4K(Q*%#Q(PR
M>"(]#_9LN+#XA0>.;[7=,G\50Z==Z:VI:?HALY-02;'EF^Q<-]H\L*,?<.><
MCI0!XU9^.K>X\4?LW>)_ /A/69K'4-%ULV7A;^U!N*B--JR/-+Y>5)8ER2<'
M SP*])C_ &B?"WQ&@^'-WJ/@[6H-2G\8OH)M+F=(GT35H8Y=XFV2_O1M#8VA
ME(8$XXJUX,_9;U;P/H/PJBLO&=I-KG@&"\M+>\GT5C;7D-PH5P\ N0RN !AA
M+CU4U<OOV7G \(R:9XEBM;O2O%LGC'4[F[TTSMJ=Y(LBN %F00KB3 ^_@*HY
MP20#S'1?%6D>!_@]\?+[Q+I.J^*O#]EX^O();*&_83",O;!/WKR*X56*GY23
MCH"*]*T[XU^.9OB7\7=(M_"FGZKIG@ZRL9K&RMM39+FZ,L#S8&Z#&]P -I;"
ME0,G<2*6L_LK:SK'PQ^*'A%_&MC&WC;7WUS[:-#<_8@[Q.T6S[5^\_U*@-N7
MJ>#QCI1X-7X-^.?''Q3U?Q1CP_J6G6;:OI\&C22R)+:Q&(2QM&[OL*MDQB-F
MR!\^,@@&G\/_ (XQ_$>V\ W.DZ9%-!XGTJ35YV6\).GQ)L&UAY8W-O?9CY<,
MK?W35KQ7\8CIGBW5?#'A[0Y?$^O:/IB:OJ%K'<I;B*%RXC168'=*_EN53A<+
M\S+D9Y;]F+X;:9X7B\7>*-*COH-*\3:K+>:3::A$\36ED6+A4B=5:-'FDGF"
M, 0)5R.*V_$'P5O_ /A;%_X_\*^(X=!U75=)32-5MK[3C>P7*1LS0RJ!-$4E
M3>XSEE(."O&: /)_B!\5Y?C3XC^!*>'+"SUCP#XS-_<W%CJ=V]N;KRK5\PSQ
MB)\>6Q)QELN@Z;0U>T7NM:1\$-!\'^$-+@O-2O-0G_LK1;&ZO'EDD*QO(QDG
MD+,$1$8ECN(   )P*X^P_9A;PQJGPD/AKQ#;Z=H_P_2["6=[IK7,U^]Q&4E=
MI5GC"$EF;A#R?3BNG^.7P8N/BS;^&[W1_$DWA#Q7X:U$:EI.LQ6JW21.4:.1
M)(691)&Z.RE=RGIS0!3M_CU/-<Z)H<WA'4--\;:O=WMK;:)J$JQ(R6O,MUY^
M#FW(*;7"%FWJ-HYQR\G[8&GO'HUK9^#-<OM?O?$-SX6N=)CEME>RU"&)Y3&S
MM(%9650RN/EVL"2O2MG5/V?M:U/5_!OBN3QS)/\ $'P[/<R?VQ<Z:&L[F&X1
M4FMC:)(FR+"(5"R;E9=Q9B3GR;XO?#J/X9>,OA.++7;1?$VN?$*;7M2U.[M<
MPF62RGCW>0) 5B $<0'F9Y&6)/(!U'B;]I7P]XM^%7B*?Q5X#UNWO/#_ (CL
MM$UKPZUY&DMG<O/"8)?.CE >(F2)P4)R."N,UU_CG]J#3/".N:I9V6@:CXDM
M]&OX=.U1M,'F7$4D@0DQ0!291&LB%^5(!.T-@XS/&'[+5SXI\$>*]-3Q3;6O
MB'Q3KUIKNJ:PVDM)$S6SPF*&* 3J44+ BY,C'ECSGB\/V?/$^C?$O7_$/ACX
ME7'A[0?$TT5YKNA+I4<YDN5C6-YK6=GS;EU1005DZ9&#@@ WO!GQXL_'WCC4
M=!T6PCNX=-U*XTO4)%O5%W8R1*Q\R>V(W)%(5PCY.[() S5+XJ?$WQ5X8^,_
MPO\ "&BZ9IUSI?B5[\WEQ=7KPRX@@+E% B;;]Y6W Y)7;\H)-54_9S:^^+&A
M^.]8UFPN]6T6]NI[2]L=)-I?RVTJNJ6=S<"9O.B0., H,[%Z<YZ+XF?":]\<
M>.? 7BK2_$":'J/A6XNG"RV/VI+F&XB$4B8\Q-C8 *O\P!ZJ: /!OV?_ (R3
M?#73I])U'0=5O]"U7XD:MH,>O27J2K;SR7<H@C*NYE=?D"EN@R.O./4M(_:E
MTW7_ !3H=EIGAW4]4T36KN:QM-6L!YNR2/< \T>!Y4+E"%D+'DKN"9KGX/V4
MM=B\,V6D'QQIS&V\=-XW\[^P)!N9IVF^S;?M? RY&_/3'RUO?"[]GWQ/\*=3
MET[3?B5<S_#Z&[FO=.\-3:5'YUJ9':3R6O ^YX [$A-BMC"[\9! ,KP]^U]%
MK>A+KMQX$UC2-"N+Z;1[.^O+NU_?Z@ET\'V?8LA8?<=S)@J C8)(&=71OVI+
M+4RNFS^&M1L?%%QK8T*PTZ4XM[^4Q&;SX;AE : 1JQ9]NY2I783@''M/V3;T
M?!;_ (0FX\;M!K-EXAE\2Z/XCTO3/L[V%VUS)<*3"\T@D4-*ZD%AN4XX/-:V
ML_L\^)/%>F^&]1\0?$-M2\>^'=535=-UR+2%@LXB(VC:$V:R\QR([A_WNXD@
MA@   #C/CM^T1JU]\"/BQ'H%B_A_QIX4EBTW5K:XO-KVJSE-D]O*B-YBNCY4
MX0CG."N#[?\ "SX=Z;X$T^]N++3$T2YU>1+J\T^TOI;BSBE"A<PAU4)N !;:
MBY8DD$\UYQXY_9<NO&G@CXB:</%%K9^)O'5Q:RZIK)TEI(4CMP@BBBM_M *@
M"/JTC'+,>X [NTL?'5M\4]-+ZY;W?A!-':*^L5TH0*+P.-DT<QD9R6&08^54
M+DMD@4 ,UWXN2Z/\6E\")HRSW,_A^XUZUO#=[$<0R)&T3KL)0DR###=QVK@=
M"_:V;Q1:_#U='\ ZOJ.H^--$NM9L;>.\MDC3R"@>)Y'=<'YU)8J!CIN/%==\
M1O@OJGBSXFZ#XUT'Q4GAS4+'3+K1;N.;31>+<6L[QN=F9$\N16C!#$..>4-<
M;\.?V6-:^'6H?#">'QQ::A%X'T>^TB)+C0V5KM;DH=Y9;D!-OEKQ@YYY'8 U
MO"O[3&G_ !2T3PW;>&M!O+S7_$&EW.HR:3<7:VK6,$,I@E,DR[L,90438#N(
MSE0"1YS^S1\:8?!'[.O@&PN8;C4?$FL2:M+;6=_=D,(X;R7S&FF.\_+O1,@,
M2S#MDC=\ _L@:[\,KSPKK.@?$&V@\2Z-;7NF7-S-H)DM-0L;BZ:Y\IX/M09)
M$D=BLBR?532Z7^Q]K?A?PIX*B\._$N72?&'A.ZOY++7CHR2PSVUY(9)[:>U,
MH#J3@@AU(*@B@#3B_:YGU63PG8Z-\,/%%_KGB.QOKNWTRY:VLG1[1U26)FFD
M4?QAE<X5@5())P/6O'7CFY\&:!I]]'H-YJ5W>W,5K]GB($=H7!+2W,H#"*%
M#NDPP'& <BN)B^!WB%OB?X#\97WC>/5+CPY97UK=QW6DX>^:Z,9D9&695@5?
M*4(@1\#J6/-;OQK^%>H?%/3/#\.F>((]!N='U>'50MW8_;K2[\L,/*G@\R/>
MN6##YQAE4]J ."LOVP=.U3P_X5U#3_">J:K-KOB.Z\++#875M)''>0"4G$K2
M*'1_*)5P ,'+;>E+>_M8267PXU#Q9+X+N;8:'XC/ASQ!9W-_&#I;B5(S<%T5
MUDA'F(Q(P0#G!P:SM'_9+UW1KK0G7X@6]U%I?C6Y\9*EQH/S2/,LH> E+A<<
MS.=^.RC;P<V=1\):#\$O!OQ!LO'VJR>)],^(NNW<T=AI7A^Y:0RW4.TVN(VG
MSD1\.VP9Z]J /8?#WC2;Q#XQ\1:1%81BPT?R(SJ27&\2S21B0Q!-HP55D).X
M_?7WQP.J_M)VVA_$31_#.H^&[VPBU?6I=!L9KF9(KF>9(F<3K;-@FV8HRK,&
M.2/N@'-=%^SY\.)_A5\(O#N@7US/>ZM%;K+?W5T^^66X8 MO;^(KP@/H@KS*
M[_91UO\ X22+5S\18UMK/Q@WC" W&B*]SEDD1K>:X,_[Q$20K&VU=@ !#@
M 6V_;.A,.GZM>_#WQ!IOA";Q%)X8NM>FGM72RNQ<-;IOB20N4,@ +J"!N')Y
MIWB/]LI/#:>*=1G^'/B)_#/A373HNNZPL]H19#]U^_$0E+2)^]4G;G"\GG('
M%?L[_#>3XN_#K6=,U'Q!9R>%+?X@:CJTNEP61^TS&+47G@5I_-P(F94?B+++
MP&P<TOPU\ 2?&>_^/OAF3Q'9P>%-5\:R-?6<5GYEU<6XAMMWE3^:%1)#&4W>
M6W1\'/0 OWWB73?"_CS]J/4]5L=2\2^'+71M*O+C3+>]8/) UG,THB9Y%\L$
M9/RL,=AGBO4?^%WQ6>F#3O"/A2^\27FD^'K36KO2[>X E@MI4/DP1ELF6=EC
M?"\ [>7!(SD^)/V:=4UV\^,;P^++*SMOB#I-OI4</]C.YTU(H&A#;OM(\TE7
M;C"<X[<&O_PS/XFT7Q9I7B7PI\26\-:L=#M-!UT)HJ7,&I16X(BECCDE/D2J
M&8!B9!SRIH TO'_[4%K\/+F*75/"VIV6D?:-.M9+K466TFEDO&4 6T+_ .O\
MHNHEPP*$D -@UY+HOQGOO@;X[^/NK2^$]?\ %'A;3?$T%QJ>H6M[%)_9EN;&
MW+NL<TOF2 %F8H@P%S]*[7X@?LBZQXSOO%AM_B(UO8ZZVES*-1T@7UW:R631
MLB"X,ZYA=H][1[0=[%@_)!Z#4?V:;O49_B':/XM!\/>/9(I-;M6TP?:R1!'!
M*L,XE"QK(D8!!B8C<V#TP <EIWQ&T?P+^T+\8O%=]?W4OAZ'PKH6H*HE>4,9
M7N541(S84N?+  P,D9QUKU3X9?&H_$'Q9K?AZX\.WVD76G6\5VEZ,S6-U%(2
M,)-M4>8I&&C(XR""P.:X_P 4?LI0>,/$'Q!EOO$"V_A_Q5H-CH<6GV%BT5QI
MPM&=H)DN#,P9@SYQY8^ZOOGN_A/X%\:>$;9_^$U^(+^.[Q8EMX)8]*CTZ-4'
M5W1'??*<#+Y XX5<G(!Y;:>)9?!'[37QKU1++6-?CL_"^C7B:1IWF74\LA>Z
M!6"(G +;5X7 XS5[5?VN$TWPW\0[^/PPNH7_ (%>U?5[:QU5)H1;SKN\V.54
MY,8#>8A52NQL9XS<^('[,^K^.?$_Q+U6+QP-&C\8Z+9Z0B6FF-YUE]G=W5S(
M9\2J_F,K)M3*G&1UJ_X _9VN_#?BCQKJFO\ B.RUZQ\6:7::;?:39Z,MC;((
M(FA_=CS9"L91R-AR1_>/   R7]I>&+QCXY\.?V/:R7WAS2+76+7RM3W?VI'<
M<1+&!%E26VKSGETX(;-=G\6?BE_PJ#X3:QXWU/1;G4!I-G]KNM/T^5&=< ;@
M'<H"%)Z@9/93TKSOPA^Q[H/A2Z^&UY_;=_?W_@]9HYKJ8?/JT;!#$D_/W8FA
M@91SCRE'O7H?QT^&ES\8OA-XE\%6NK1:&^MVK6C7\MF;H1*W4B,21Y/I\WYT
M </J'[3=UIA>QN_ U]I_B!K>74;;2KV_@W3V*[0DP>(R;6D8LJQL <HVXJ,$
M\E8>/8O%G[2WP[\6VEGKMC9ZIX U.^?1KZ.5+A&2XML(;8G E&67@<YZGBNU
M\<? 3Q+K/BGPMXP\+>/QX1\8Z5IAT:]NAHZWEEJ5H6#['MGE!0AQN5A(2,D'
M(HUW]GS6M;\>:1XB;QW,C67AB^\.RR&P_P!-E>Z9&>Z6=956-E9%*J(R!T],
M &%=?M7W$UIXKL+7PLMEXJTOPG)XLM]-U"_ VPKD&"["H7MYUX)B*L.<;NXG
MT?\ :6OK#P!X/;5M'M]2\::KX=BUZ6PL[S;&T!1?FWF(8DD8D+&%(R""X R<
MKPQ^R#JNE3VS:GX\M[V!/!USX-FAL- 6T$L$AR)\F=\2[B6<G.\G(V<@VH?V
M7?%VC+X'U7P_\45T7QAX;T<>'I]1&@)-9:CIZ[2D4EJT^5=2@8.)<[F;C!"@
M O:U\?[?XD^#M1TSPUX;UBXU.;PP=:U"QO)CI=UIL,HD6.-C]X7#&.3:H(&$
M)+J"N=;]F/5+]/V2/A[J$*#4-27PQ;S*EY<,@FD$((#R;7(R>K88^QJCJ7[-
MVMV_CBY\5>'_ !_+9:GK&B)H?B#^UM+6]7453>4G0++%Y,J^8X&-R8(&SBN]
M^$'PSD^%OPC\/^!KC5CK0TC3UT];\6XMS(BKM!V;FP<>YH \R^#O[2.L^+?A
MO\-Y]8TBRN?&_C6VGO+#3[*\*PF"(;Y)97:,>4J;E7 60DE>N3CT[X2_%G3_
M (LZ1JL]M9W.E:GHVI3:1JNEWFTR6EU$1N7<I*LI!5E8=58'@Y \K\)?LF:E
MX-TCX=&Q\<1GQ%X#-Q;:3J,FC_N);"9=KVUQ )P9"0%/F+(GS*"% R#ZO\+O
MAA;?#6UUV3[5_:&KZ_JDVL:I>B+REFN) J_(F6V(J(B@%F.%Y)))H [:BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ I&)520"Q S@=37A?[6NA3VO@W1OB#IUF][JG@74X-:>VB4LUU9*VV[A
MVC[W[IF<#^]&I'->6_!OPIK,7Q-UGP'KOA\6OAZ[U&+XA6\[1?);VTH8)8,Q
M)^:.=1QTVA@ !Q0!]%?!OXK1_%[P[JFJII,^BMI^L7NCR6MS*DC[[:4Q,V4X
MY()P"?K7>U^=GAS6_#VB:7HGBVP\2+;:U_PNJ[L3+%K#+$;.:]F$L9B$GEE'
M5@22O/!SP*[3X?:]I?CWXH+IGBWQ;K6C?%C2/%%W]H\/6UDXGO;(S2".-F8%
M)+!K=D)Z*NW((;J ?2/CGX[Z5X33PI-86C^(;/7?$L?AAKNSG18[2X:1HV+9
MY;:R.,*#R.HKTZOS@T'_ (0O1_@UX$T!9M.T+4H?C ;?4H;9UL[B%!?WFQ69
M=K*5C92.055E(P"#6_>?$$> ['X@Z5IVMW;_  ]T+XDQ0:N;::346TW2I;)&
M8LNYG-O]I(+C.,;P>,B@#] **^"/$">#XK?X66^C?$C6M7\(Z[\0"J2-J4MA
M9FVELYO-M[7:ZEK<2; #R$9BJ,.E?0_[0\.I?"G]FJ_@\$0:HT&CI:1.EG/-
M<7RZ<L\8N3'(S-(SB#S,-N+#J#D"@#W"BOBOQQX^\(V7P\U3QE\*=6UR]\#7
M>L:4_B6;3(IIK"RLAN6=K>+ ;=_JVG"9R,[N217,>+;GP9;^%?!]WX:^)FKZ
MEX5UOXC:9LECOY=/T^**16%Q!:89<Q<(S#E4=CM*G( !]U#Q#IK>(&T,7D1U
M=;87C68.9%A+; Y'8%@0/7!]*GU6XN;/2[R>SM#J%Y%"[PV@D$9F< E4W-PN
M3@9/ S7Q?KWASP+\$/VA/&R0Z==68B^&L<VDO8LUQJ\SQ2W?FM:SS;W>9(R@
MW$MM&S/  KD/"7Q TE+KXC6VG^*H8-!U#X61:E:G2=1G6,7<?GAI6N0RB2Y'
MR"651'EB%9<\$ ^_-%NKN^T>RN;^Q.F7TT*23V1E64P2%06CWKPVTY&1P<5=
MKX0\.WGAWQSXT^#^FZYXIGGTN_\ A-+<7MJOB":&*65#:X9@DH&[B0GIG:<Y
MVU[S^R7XRE\0_LD^#-:N]3N=;NH='99[F&7[1<NT6]<9)):3"@<\DXS0![M1
M7Y_?!CXD6EW\1_"LOA[Q6UC::]X$U7S))9I;RZ6_CDB9'U"0 )->1AG9P(U*
M#*\K@F]\!?$WAKX@:MX0U-/B/I5I-IG@ZXAU^PT_QH!<ZQ?D*1>20PSB0E%$
MK%YU5U,@!4;<@ ^\Z*_.WP;J>G>$?V</@[X]N-;U6YT'6I8K+QQKCWMSJD44
M21SB#SX?,95C69D#X49^7?GOUOB#Q-I'P]\%>")XO&FLZS\%K_7[\ZCX@O[)
MY[*V62$&VC"_>-B)3(JELH&QR0HH ^Y:*^&;>P\,P>//@1H,'C_7M>\+ZI=:
M\(Y-2U6:T6[M3;[HDC4.I:!7+)&YY*C:&9<9Y+PEKNC:%X*^'WB&V\7W#:KI
MWQ6E\/6T\_B"654TO[9.GV<JTI4Q^65Y()QM.>!0!^B=%?#_ ,%?$FD^.O'>
MCCQ)XTUS1OBYHNK7B:WX?MK:2&>:$O("+AS\K60C*.C@@+A=A#<'COAKKVCZ
M=HOP:\2Q^+KFXUF[^)&IZ+<3W>ORSB6P::]'DNCRE60@0G)&22ISR* /T T;
MQ#IOB%;QM-O(KU+2YDLYVA.1',APZ$^JG@^AXK1KX"\&6^AZ!\.?%.BZ#K/A
M?P;XHMOB5J2266N6NS3[Q!/<26]E?%-I2)X\LF<C(3"D<5]"_L\_&?P[=>%O
M!_AC48/^$5\5:P=1>RT&:Z>\$ZP3R><]O<;0)(>K1DX)3& 0,T >D_$?XBVO
MP]M=&5X/MFI:WJ46D:;:F3RUEN) Q&]\'8@5&8L%8X' )P*XZ^^-OBCPU\,_
M&7C#Q/\ #2_T./P[9R7:V0U2VG>]$8<R["I 50$#!FP6##Y0<BN$_;&A\)2>
M+O@:/$2:.TDGC2"(C4A%EH#;S[E^?^#=LSVSM]J\\^(WB;3+2[_;#TQ=>1[.
MV\+6?D6DVH&1+<M8S*RQJS$1C>RC:N "0,<T ?9GAK65\1^'-*U9(C M_:17
M0B)R4#H&VY[XSBM*OA#QCXVT+4=9T3PYX\\77/A7PEJW@K3#X6UBTADEB>[V
M.+G[/+'D)=J?*V]6P !U(.WK'B&_\-_%G1W.IP_$*V6_T.RNM+U"<V7BG2)O
M+AVSQHN5G@?<))H]J\F3).TX /M2BO"?VH_$=]X<N?AM)=/)!X!G\1+#XIN4
M8K'';&&00^>P^[ 9O+WD_+C ;@FOG3XF:D^BZ5XHCM?%5W8?#<_$7P_%X;N[
M?6)(8O+D>+^T(H) X#VZL3@ E4._;C;P ?H#17D/Q/\ #6A_#?\ 9E\9Z=I-
MY=Z5I-EH=]-;7+ZM<&6-S&[J1<O(9/OD8^?N ..*^99;_P /?#WP-\&==U77
M+ZW^'WBW1U;Q+K]W<W.J69U(6D"V_P!H5I&6)/\ 7KP%4.%)&5! !]\45\-K
MXK\,^ =;\%:!X\\4Z]K'P=U+P_?0Z-XAU])5CFOVN?E#L%SE8"!;M(,X&5))
M!KH%U+2(?B))X8^(6J:O:^ V\%6I\*7_ (HNW@FGF5I!<2M(2I^VA?(89Q(J
M\@ EJ /L2N!^,?Q83X0:%I&IS:/<ZO#?ZQ9:0?L\J1B W$RQ+(VXY(!8<*"?
MIUKY)^'NF7OC_P")?P=\,?%37=6?6-0\!7LNH:8^N7-G-<2I=P&U>2..1&68
MQ#<V,%B#NSBN<\;>--%U[P3./&=XUO\ %K2?B99_;+"[ED6Z@L5U-!!Y<9.3
M:>0(R" 4+?,?G.: /T7HKY"\$^*;BU_:0M(TN]+\=Z7J>OZE'!J>FW30ZSHD
MBQRAK:_M\D2VJA2L;_+MS'QR,]!^UAXFT:#QMX:\/:I=R6EQ?:+JDMG_ &C*
MW]F2RA8PJK"@#SWHS^Z574J"[#<<"@#Z=HKX!^%.H:+\:O&WP,TGQ+XKU/4Q
MJ?PVE?4+-=?NK9KF\BFM=K,$E5O,!$A)7!8H<YVFNA^&OB'3O&/Q3@T_Q-XQ
MUS0OBYH?BFY,FA6EI(+F[L_.<1(SME9+$P%"3]U=N00W) /LS5/$.FZ+=:;;
M7UY%;7&I7'V6SB<_-/+L9RJCN=J,?H*T:^:?VK=.\-Q?%GX":SXDLK!]/@\0
MW5M->7\"NBB2QG\N,D@_>D";5[L%P,XKR>^\1:UK?@;79!?W%E^T+IOC<Q6=
MB)V2[>V-\HBC6+/S61M#D\&/ 9C\P)H ^L/C/\5T^#OAFPUF71[C5X;K5;/2
MV6"5(_)-Q.D*R,6Y(!<< $_3K7?5X%^VW:-=_ L%_.2WAU[1Y[J: LI@A2_A
M:24LO*!5!8OQM SD8KPSQB^K?#27XEZE\--4UO5?A*/[$N;Z:SOKC55A=KEO
M[2:TD9W=Q]GV-($8_>/0YP ?>%9&DZGJEYK&LVU[HS:=8VLL:65Z;E)!?(4!
M9PB\Q[6)7#<G&1Q7CW[+9\*7R>*=7\#^,K[Q;X;U*>&=%6 Q:99S;"'2T##*
MDX5G4$J&(Z$D5\[?&;QC:6GA_P#:I@B\875O-8:[HIL]FN2K) 6CMQ(B'S,A
M,F0&/[O48XX /T!HKYH^!U]I&@_M2_$[POH6NO>:3+H>DZJME+JKWO\ I+F=
M9I5,CL0641%L'^Z>XK*_:(\!7=E\7X6TW2I+^P^)FBS^%;HHK%+&_3][;WAP
M04Q&)BS @DPISG% 'U961K.IZI8ZGHT%AHS:E:74[1WMV+E(A8QA&82%6YDR
MP5=J\C=GH*^+'_M*^_92^(.O>*H)?#.N^"O"][X2M[R&9K)Y;RVWB6YC=&4X
MD98=O/)WCG<<[=U9>&?!7B;]FR\TCQ%='_A*-5:YU W/B"XN8;]FTIU+&.25
MD(WJ@PJ@!C@ $T ?5&H>,VNM%OKOPK9)XKN[.^%A-:6]VD&UUD59@9'^7,8)
M)'<J5ZUT]?G1=77A?P+^SK\2;;3KJU\,>(-.^)C1W$=C,;&5(6UA3%'+L*[D
M,+,51LC;D@8&:U/CEJ6B76K?M2ZD/%UX+SP_8:3J.B^5XAG5;2Z^S%M\2"7&
M=^!MP0-Q  R<@'Z!T5\(?'+XAZ=J?C#Q?HNI_$30].O]<\):5)X8U"_\10Z4
M-$NF,A>XC=Y$)W':YD@WMA0A &,_0GQMN?$GAG]E77)OA_>76MZ[:Z-&;2^M
M+A[NXN$^7S98I&9F=S'O93N)SC!/% 'M=%?$/CC6=*-[KFJ_#?Q$\?@*Y^'6
MI7.O2Z?JDB06]\JK]BD+JX,5TQ,@;D.P4[P<5[U^RCX9T33?@SX8U[2KRZU&
M[U_2+"ZU"]N-3FO1-.MNBL1O=E0CD$(%''(XH ]>NY98;2:2"'[1,B,R0A@O
MF,!PN3P,GC)JGX<OK_4]!T^[U73#HNI30K)<:<TZSFVD(^:/S$^5L'C(X-?&
M'@KQ6UKXCURTO=5T[Q3I5[HFMW-MXVT+4Y+2^M%#AVAU:(-\DJ-M2.8./NE0
M!DU3T[XHZ7HGP;_9AU?Q3XJL+GPK=:3+%JVGZIJD5O'?S?8P%D>:=UB=HGS\
MDC@DON&67@ ^[:*^!/"6F:.OB']GW0]7^)A\5P:NWB!M1FT_QG<7=M-'Y6Z"
M#S1.01&I6/*XR58="<Y'A;XK6VE_#OP!;>)O$\H^%T.M^(M'OM7FWZA;VTD=
MVRZ?'=L&)\ORMX1G)&=A[ @ _0VYE:"WED2)YW12RQ1D!G('09(&3[D"N'^#
M?Q63XQ?#&Q\8VND7&FB[:Y1=.FE1Y5,4SQ;2P(7),?K@9Z]Z^8=&\0:'X1\:
M_#SPYXR\5:MK'P@NM!OCHVN>*6>&WOM0-R/+260[<A8,^1YG)!RN3M->K_L%
MSVLG[,OAV"UD>1+:[U"(^:6+C_3)B-Q;DDJ5.3R<T >E?!3XIQ?&;X>V?BJ'
M3)M'2XN+JW-G<2K(\9AGDA.67CDQD\>O4UW5?GM\+?",*^&? -SX5U34HOBI
M:>.+FWU+2(]3G81Z6VH3M=)=69?9'#Y!WY9%RS(026&?4/"_@:[\.?%_6_@N
M^E23>$KW5X_&]GJ+J61+#.9+,N>ZW21HH_YY2$=!0!]4ZUX@TWP[#;2ZE>16
M<=S<Q6<)E./,FD8)&B^I)('_ -85R/P\^*Z>/O&/C[P]_8]QI<WA+4(;"22>
M5'^T^9 DRNH4G:-KC@G/KCI7EO[;.FZ#)H?PPU7Q#9V,NF:=XYTM[N[OXE:*
MWMV+K(79AA4)V@YX/&:^?/BIJGAJ&/\ :7\3:?KZV&KZ%K>B7.CR6>J/;?9Y
M!;6BY$2NH)P&0AE. &7CD4 ?HG17P]XO\7:5XO\ B]XN\.^-/&FL>$_$HU.S
MOO!SZ3:N]S>V/DPM'_9\HRC;I!*LB@$'<=W R/6?VU+I-.^'W@NZN-7OM%MQ
MXQT>&ZNK2_DM,0/.%DWF-@,8]>G48QF@#Z(HKX2U2]TWX8V'Q?.E:WKE[\()
M-3T*.PN;;6Y)+:WO)9!]L7[9)YI6T_U7GD;L!W48)..-U?QU8Q^$O&&D2>,O
ML-I9_%31A8_V5?3Z?:QV$_V1G$"F0X@;,K*,E?O.N!R #]#AXATUO$#:&+R(
MZNML+QK,',BPEM@<CL"P('K@^E:-?(7A7X6?#KP7^U_J_AO^R;5;75O!-L-.
M%_))=W%TYNKKSRDTI>1R$=03N.U=HR !5[]GWPQJD/C"+X8ZWI\SV?PMU"XN
MX-5G3(U&.X!.GOO/WG6.2;?_ +<*$T ?3^H>(--TK4M,T^[O(H+W4Y'BLX'/
MSSLB-(X4>RJ23_B*T*^8_P!IC3] L_VA_@5K6M6&G.OF:O9I=7]NK*TYM0UM
M"6(.29 2J]2W3FO,_!7B#5O$'A/X67^G:C<Q_'.'Q8EKXKT]YV%VUN9I1>I=
M0Y_X]EB"M&6&Q<1[""1D ^JOBA\5D^&>J>"K271[C44\3:Y#HBW$4J(EJ\BL
MP=P?F880\ ?4BN^KYX_;,LK2ZTCX8R:G-+9Z);^-K"34;Z.=[=;6 QS*TCS*
M08ERP&_<N,CD&O#M<U#5/A/9>*IM'U76)O@,GC#3P;\R3ZFMK9/:/]L,;%F>
M2T6Z,.[#%?\ 6#D;A0!]\45XU^S!:Z##X0U>X\*^*]1\7>&KS4GNK*ZNHRMI
M"&52T-GD9,"MG R5#%@#P0/9: "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *EYJUCIT]K!=7E
MO;37<GE6\<TJHTSX)VH"<L< G ]*MU\X_M7P7D?Q ^!-[HUA8WFOQ^*Y([0W
MTAACR;"YX>149E3(!.%.<=*J^'?VK=<N-:'@77?#NGZ9\2?^$G_X1HI;73S:
M:1]E^UB[5BJN4\G_ )9D!BQ W '( /IBBOF;6/VI/$.A:GJ.A7FCZ:GB#0O%
M^D^'=2">8UO=6M^5\FZ@.X&-MI.8VWX*D;B.:7QO^T_XI\&I\3/*T#2=6?PI
MXETG18<W$EMYL-Z(,.PP^74S@8RH.,\=* /IBJL>JV4VHS6$=Y!)?P(LDMJL
MJF6-&SM9ESD X.">N#7SS>_M2ZWX-O/'FC>*_#^F#Q%HFI:3IVFQ:7>R-;7C
MZCQ;J[O&&38V[>VT\+D#M47P=L=4L?VQ/BU_:\.EK?2^'=%D>?2HFB2?+W7S
MLK$D-QM^\V0H.1G  /I"ZNH+&VEN+F:.WMXE+R2RL%1%')))X 'K26EW!?VL
M-S:S1W-M,@DBFB<,DBD9#*1P01R"*^5_C=XA\4ZY\1OC#X1O=1TVX\&V7PX?
M4DTN33V9B\GVE2Q<RX+AHE(;;@#@*#EC#\,/VAM6^%_@_P ):3XMT:PC\/Q_
M#=?$ME<Z;=/)<^7:0P+)'*K(J[F$BD;3@<@D]: /K2BOGP_';XC6.E^(-6N?
M ,$^BVWAN;7K/43.]K"DT:[S:2E@S/E.5E10#@@JN0:H:'^T3X[U&U\)6][X
M<T6VU;QAIG]LZ/'I\MQ>^3:I!$\IN(]B$OYDR* CD!226RN& /H>35K&'4H=
M/DO+=-0F1I8K5I5$LB+C<RIG) R,D#C-6Z^--2\1?$#Q+\?_ (6:[!X'TOPW
M\0[GPMKD$^G:W>,MNHCN+8+(98D=V0CYE4@$;\'&#77:7^U1XEU#POX&\3WV
M@Z=H6CW/B67PIXK29GG;2[M)G@62*0,H:%Y55-S*-OF*3GD4 ?3M5;W5;+32
MGVN\M[7?]WSY53=],GFN9^&_BG4_&-KK.HW2VHTL:E/;:6]O&RM-;Q-Y9D<E
MB#EU?!& 5 /?CQ;]O>PM;OX:^"7N=,CU4Q^.-$"V[1QLT@-R R#>0OS#CD@'
M/)Q0![[XHT2#QUX/U72(]3N;&#4[26U_M#2Y@LT0=2I>-\$!AG@X-<!X+^!E
M[H^HZ1=>)O$T/B<Z,P?3Q%HEK8LKA"BO(\8+,0K'A=B\\J>,>-_L[ZCIUC\0
M?CA\4]/L1X+\%6,7V"\\%*JQW5O>V2,UQ=3V\?[N)W3:%V,V]<,376R_M/\
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MXR5MPIC832#[NX9^5@0#2_ /XW2:Y\!?#OBSQWJL']K7\UY$S6UL09VBN)D
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M'B>>&V!*FXC0[7>%B LJJ>&*%@IZXKK: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^>/VJKF6S\<_
M :>#39=7EC\9[ELX&C623_0;K[ID94R.O+#IUKC+GX/^/-"\3:KXJTOP:)[7
MQ+XV&LWVCVMQ9+JFFVJV7V<30322>5'-(X+2-%)O".0K;B<?2?BSX;>'O'&J
M:'J.M64MU>:'<_;-.D2[FA^SS;2OF (Z@MM9AD@\$CH373T ?!GAOPEXL^%6
MO? C2/$'A&X.HVOC7Q)<P64&HV]S+<0S17,J2I(\@7A9 ?WC*QP<@'&>CU']
MGSQ]X8U9?'NB>$XM;EN/&&I:Y=^ _P"U(K23[)=V\< *3A_)$ZF+S2-^T^8R
M[CU/U3XD^&WA[Q;XCT+7M5LI;C5="D>73KA;N:+[.[*59@J.%)*DJ<@Y!QTK
MIZ /ERR^%FOVGQ-^#FLZ?\+X?#FC:9?:Q?ZK::?>6D@L&NX!&CRDR@RRLP+.
M8@P&>"V,GT/]K7P?K_C_ . 'BCP[X8T>77-:OU@2"TAFAA)VSQNQ+3.B@ (>
M^?:O8** /D[XA_#'QOXB\2_'F\M/ ]]-#XJ\$6>C:2[7E@#/=)'<AXSFXR@!
MF3EL [3@G SZSKNA>*I_V8YM%TS0+*Y\7CPVMG%HNN^3-;R7 @"&*7YFB8$@
M]25/&>,UZQ10!\*^+?@K\4-<T?XP?9O &K2/XO\ !FGZ7:1ZCKEA)<?;(7F$
MB.!/Y48_>!@(R(PHXP?DKV?0/ASK6J?M ZQJ>L^#[BW\'ZIX$M- FGN9[1HV
MF665I(6C29GQLDQG:5Z\XYKW37M:M_#FB7^JW:S-:V4#W$HMX6ED*J,G:B@E
MC@= *\\?Q'X/_:#\"^']/O?#FHZ]X1\:::;]6N+-A;)$NR1%N'5OW;L2"HSR
M5/I0!QO[)G@76_#NF:LVO:A'J\&A3S>%O#UXI+,^F6T[[78G^,DB-B.OV=34
MOCK3Y-1_;"\&11C&_P $:S&7QPNZXM ,_B:]674-(\":#HEAH>C3W&DBYCTF
MWMM!M1+%9C)3<X4X2-"I#-_#WI/"7PN\+>!=1U"_T/1XK"\OY))9Y0[N27<N
MX7<3L5G)8JN 3SC- 'RIX#^#?Q3AL?@AH5]X.ET.'P38ZKH]_J_]JVDG,]J8
M8KJ%$D+%,D-@X<8(*# )N>"/AI\4M.TWX!:!JGP_>%OASJCQZCJT.JV;6UY;
MBTF@2X@'F^:=Q=69716!/\74?9-% 'QAIGPE^*WAS2M.\1Z7X.>?6- ^(NK^
M(E\-WFI6D9U2PO/-0-%*LKQI*JR[@)"O.17=^.?!GC3Q//\ "K5+;X=0Z1)9
M>-5U_4].TR[L]UG!Y$L;23N9$669FD#-Y6[TRV,GZ4HH ^.++X8_%&Y^)?@;
M6[[P$;8:!XSU*^N6T_4[*WTYK*>.X2*>"W20$L?,5I7E7SBS-C<#\OL/[+_A
M/Q%X-\-^,+7Q)H5QH5Q>^+-5U2V2XGMY?-M[B<R1N##(X'!Y#8(KV:D)"@DG
M '4F@#Y!D^ /CJ_^$WB/X2WVDO*EWXN;6;/QFMW 81:O?K>&5D,GGBX0;D $
M9!.T[L9(]4^"_@_Q!X?^,WQFU?5_#EQIFFZ_J=G=:9J$T]M(+J.*SCA;Y8Y6
M=?F5B ZKP?PKN+OXLZ!:?$3P]X,WW,VJZ[83ZE8SPP%K62&'9O/G?=)_>+@#
M/7M79T >'^)O"'BSPS^TC_PG^FZ)/XM\/:EX:&A7-C:7,$5Q8S1SM,DBK/)&
MC1R!RK8;<"J\$=/-_AO\ O&OP?U[X,7<.C?\)!;Z+:Z[;ZG%9WL*+IQOIXYX
MU7S67?''M*?("> 0N#Q]<44 ?&GA/X1?$+3/!WPNLI_ M_;WNB_$>^\0:@HO
MM/)ALI9;MEER+@AB5N$RJY;AN.!G8^#7PG\8>$-0T_PYXJ^%EAK0\-ZG<7VG
M>.7U>*9+B,O(Z/%;,_F1W15]A+!4Y+;\<'Z$\"?%'1?B+J?BFPTE;Q9_#>HG
M2[X7ELT'[[RTD^0-R5VNO.!GMD<UU] 'C7[(O@S7?A]\"=#\/^)=!E\/:S9S
M7?G6LLT$N1)<RRJP:&1U(*N.^<YXKP_4/"6J_$K5?VJO VE^&'U.7Q%J]M8K
MJ<DUNEM:,VGVX$DN^02?N\[QL1SD<8-?:M<QX6^&WA[P9K>NZOH]E+:ZAKLX
MN=1F>[FE^T2A0H<J[D A0%R . !T% '@%A\"_%>I:[\>=&DL+O1K+Q5X>T_1
M](\333V[B9X;%[=W*QRM*OS,#\RC(SWJIJ7P0\;_ !9TGX:66K:-)X#U#PCH
M.H:;=:D+N"9)YI['[&BV_DR,QBS^]/F!" JC&>GUC10!\N>$? 'Q)\<?!N;P
M)XI\"Z5X*UG3_"UQX;A\4?;H+LW#- (4:U$69(HFVJ[B3:>  IZCF7^"?COX
ME?"O6-+U#X7Z3X!\<VVB#3H-?N=82^%_(DD4@C@,;,\5O*8OF#[2-P&T\D?9
M-1+=0O<R6ZS1M<1JKO$&!95;(4D=0#M;![X/I0!\?>*_A!X[^)/@&\U:R^$^
MF^ ?&UI<:9=/:7NM17<VM"TNDN&M?M$;,J0':=OF'.XC*J 2;'C7P%\2/'.J
M_&W65^'-_IH\7>!;?1=.LKG4]/:=KQ!<JR/LN"@&9E.XOC ]>*^OJ* /D>+X
M8>.G\0>+;R3P'?B*_P#A9:>&+=FO-/)>_03[X?\ CXX'[U?F/RG!YZ5SNH:3
MXL\'ZE\,(=-\&Z]J'BO2OAZ=#U^RTF33[V6TBD,2('ADNX4R7AD9)$E;.T@H
M1G'VG?7::?93W,BR/'"C2,L49=R ,X"@$D^PKR71O"OPQ_:;T+0?B.?#QNGN
M[=DM-0E\RRO#"LC#RY&C=6*[@QV,2.>G)H \('PKU37_  CH$OPK\/>,?">L
M^'-"30K#4K^[LE29X9I%DL-6M))BDT8.&WQ*^/,;:> I^G?"?CW6=4^(/B#P
MIJWAI].32K2UN8-8BNXI8+\2 A\1J=\.UU8 /RP&1Q77Z1H]CX?TRWT[3+."
MPL+==D5M;QA(T'H .!3IA#IEO=W,=L6;#32);QYDE8+Z#[S$  ?@* /#?C+\
M!M5\=?%?3-5TIXH?#WB#2)O#GC%3)L>6Q#":$ICDN3YL61R%G)[5RFF?!3Q]
MI/[*WC[PUJ]O_P )+XWO=&N?#NF);W$2M-9PQR066YY'5 65C(V6&#(1U&*^
ME?#FM#Q'H.GZH+*]TT7D*S?8]1@,-S#N&=DB'[K#N.U:5 'SCH'@KQC9?&7X
M7Z]-X0OTTK1O MQH]_/]KLB8+MVMV6+:)\M_J6&Y05Y7GKCK/V2O"'B#P%\"
M]$T'Q/HTVA:S:7%X9;2:>"8[9+F65&#0R.I!5QWSG/%>Q44 ?(WA3]G[Q9??
M#SP=X"U?P]_9,GA[QJ_B23Q$;FWDA:%+V6Y3[.$<R^9(LBQG>B  ODG !M_!
M#X1^+O"NLZ5X9\6_#+3M2C\.ZK/>Z?X^GU:.:*6)I)'26.VW&6.YVR;#E0OW
MCN/0_5U% 'BOQW\/^+]9\9^"I="\,_VYH<27T6HW5A<VUKJ-JTD:K%LGE97C
M@8AO,\@^80JX!&0?&/@C\*?BM\(+WX6ZW>^"9=8ATKPM<>%=2T6UU6T-S9.;
MH3)=QM)*L3H^ K /O 53@GY1]HT4 ?&OPD^#WQ#\*WGP)75_ ]Q"GA6^\03:
MG+!J%E(ENEWYGD$?O@6SO&=H.,4S2_A#\0+/X>>&]-_X0*_CO[/XJR>*)HEO
M=/\ DL#>2RB7(N<$[)%&T'=U&*^S:Y!?BCHK?%0_#X+>#Q -*.L9:V9;<VXD
M$?$AP&;<PX7..<XH ^>9_@]XDUF3XKV^M^ ]=DL=>\;V^L:;=:1K-G:7\,*6
MT4:WEO(+@;)(Y(L[7(RIZ')%4-3^"WQ/U3PUI"ZFOB*3QKI2ZG_8_C+1+W3[
M>\CC>53!!J=NTJP7(E55,FU7&4!R"2:^Q*Y;XF?$C1OA)X*U+Q7XA-S'HFFQ
M^==SVMNT[0Q]W**"Q [X!H \-NOAE\0-:^*T-_J>A1;)_AC+X<N]8M9X$LAJ
M;N'*)'YGFB/.<'R\"H/A[\&O$]Q'\#&U?PQ+X>N/AGILL5S,]S:R2:A*;/[,
M(;<Q2M^[8YD)D*?=08R3M]OUSXJZ1X>\!VWB^\M=3&D7 A91%9.\ZK*P6,M$
M,L,EE[9&1G'-=?;S?:((Y=CQ;U#;)!AESV(]: /B;PO\&?BAX.\!?"G5!X!D
MUR_\-2ZQ9ZMX0EUFVMIY8+RX\V.X@G68PEDVKE6<9!85]1?#'PD/#OPW73(O
M#&G^#6G\^;^Q=/D$D=LTK,V'=>&<DY=EXW$X)ZGNZ* /CKX8?"/XF>!])^!F
MJW/A2:6?P';7VB:GH2:C:-+<Q3HJB]MV,HB."@^5W5BK-P#P?;/V??AKJ7@"
M'QSJ.IP_V?+XI\2W6NQZ4)%?[#'($548H2N]MF]MI(RY )QFO6:* /C7QG\(
M/B+)X#^*?ABT\$7.J'5_B##XCL+J#4+)8[JT-W;3-A9)E*E5AD!#A23MVA@2
M1:^)WP9^(WC#QG\6]6T3PVUK]NN?#NJZ0FHWUO'!JKZ>=TULYBE9XMW0,R@9
M .:^P** /*/@7X?N[7^VM=U'X;6WPWU+5/)6XMFOXKZ]N6C4C?--$S(5 (5!
MN)QG.,@#S72OA5X\T/XM7&N^%=,U#0-)O=3U&?6=$UN^M;W1;S='*(;RT42/
M/;S2L8]Z@(I#29'3/U#10!\4>"_A7\4K3Q1X8US4OAY=6DMMX+U30-0MH=5T
M]+>&ZD:)HUM;>.4116YV%4"A3T\P _,>A^&WPJ\;^'KS]FE[[P/>0KX,T"]L
M-:<7=BWV2:2VCB0#%QE\LA.4SP1GO7UM10!\,>$O@Q\4O!)\,^(&^'$WB**S
MO=?M+_PL^MVEK<"WO;_[5!=02K.8B0 %9&=3SQTKZ?T3X<LOP-O/"%EI%AX&
MDOM-N[:+3]*;?#IS3A\88 ;F4OEF  +9QQ7I%13W4-J(S--'")'$:>8P7<QZ
M*,]2?2@#Y>^#'A/QIX7TO3;KQ%\$;.'Q3X4TF2PAU:VUNVN7U4[!&%L]\@\A
M)=H9_.*8 P W:Y\ _A7XP^"OB[Q-X:7PW]H\%>)+<:Q%JMO):QII%_(&\^P\
MOS3(T )S&55@NYADYS7TU10!\2^'?A!\5/"'@'X.7/\ PKXZ]=^"K2\T/5/#
M!URWMY;R&;RRMY;3"3RQM,0PLCJQ5B"%-=WH?PMU_0?B_P#"W6]/^&<6@>']
M)TO6_MEII-W:-'8SW;PM&AW2JTDC>6Y=D4KN;J1S7T_10!\<?"SX0?$7P=I_
MP)O+GP7<"X\*ZEKT>IV!U"S#V\-X7\F<,LQ1D&X;@I+CG"&O9OCQHWBW4_$/
M@*?P_P"&O^$@TJUOK@ZK+8SVUOJ5JC0E(VMYIV7RU+$B1HF$NWA>X/L-% 'Q
MC\'?@[\1?"%[\"(=8\"W,</@ZY\0?VC<1:G9SK&MUO\ (<%I@S;MW8%@.2 >
M*A^'OPD^*7@'4? 'BD>";J^70-<\1_;?#7]HV2W#6NH7#20W4#>?Y)9%P"CR
M(<,P%?:E% 'B_P"R[X/\3>"_#OC&#Q/H1T&?4?%6I:M:PFZAG+P7$Q="3$S
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M2U+Q5/\ $3PWI6B?\3G7_!ERMG?V$@N)5&I&U)"7<)2/8P#8S$[*O.1U=O\
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M<Y:./9M0G)Y '4UTUE96^G6D-K:016MK"@CB@A0(D:@8"JHX  ["@":BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH \Z^+?QB7X5:AX/LSX=U'7IO$NJ#2;;[#)"@
MCF,3R*&\QUZB-@.WJ17G(_; :VTR]O\ 4?A[K5A:Z-XB3PWKTQO+5UT^>26.
M.-EP^9E/G1,2H& W<C%>A_%SX4ZA\2M;\!7]GKMMHZ^%M<36FBGT]KDW16*2
M,1@B:/8,2L<X;D#BO.=?_93US7/"WC_1O^$WT^#_ (2SQ3!XF,_]@NWV4Q/
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M@#@O&G[5MK\.+;QS;>(O"E_#X@\*:5'KDNFV-S%,EY8NQ3SX96*9"N"KJ5#
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M4:GH%O>&+_2+NRNRNG&3) "2R<[3P.><YKPKX(_#'7_"^F:_X6\6Z1)<^%O
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MR%5R1G!&"0#W^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$D<BGD,K#@@^HKYMO)5T/]K#XBZG8Z7975R/AO:7+VTQ\J.Y9;FY^61@C'!
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M_"/W7CKQ"GBS7[34?$,^G2V=U=6PBC4--';21!)@[0PAXBK@ G:FT;:F\(?
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MCTKI]7_9UTO6]$FT>Y\4>))=+O--DTS4K:>XM[A=25W9GEF,T#GS26;YHRF
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M>!$&IZGHMOX-OX=0TZWTTP!'DBC:)%D\R)R5",PPI7KUZ5RVN_LIZ'X@\/\
MQ$T:Y\4^)4M/'.IQZIJ1B>S#Q2H(P%A)MCM7$,8(8,?EZ\FMK6OC+X4\1>#M
M(UK0/B-I6C65YK,&GQ7[QK-]IF$P62S$;D$2/RG3<N<XKA?!_P"T_I/A[XF_
M$?PU\1_&FB:6UAXCATS0XYPMKF)[6&0*V2?XY2-[$ G XZ4 >L_$_P"%ME\5
M_ACJO@?5=5U*TT_4[46EU>V)A6Z=.-V"\3("V.<)WXQ7(ZY^R]X9\6:[K6H^
M(-4UC7(=8\.Q^&;W3[IK=;>2U1RZN/+A5UE#L6W!Q@XP!@5/XO\ C7H7P^O_
M (A:Q?\ BQ-9L?#.DPWEYX9TNR\^ZT_B0^8[1[F/F8'# ! FXD DUMCXY^$K
M3P=I?B+5M0?1;6^M!>^5>6TR2Q1 #?(Z% RQJ2,R%0G(.<$4 9UE^SWH9BF_
MMO5]9\5W3:)+X=BO-7EA\ZWLI0!*B&&*,;FPN78,QVCGKGJ/AQX!B^&O@;3/
M"]KJ^IZK;:=;K:P7FJ/&]P(U4*BG9&B?*H4#"CIDY))/ ?M!_'K3/ /PC\3Z
MMX?\2Z;'K\&AR:MI\ODF]A";"8I'"':J.1M5W(4GINZ5I>,/'&OZ?^S'J'C'
M3KNW@\1P>%SJR7$UN)(_.%MYI)C! Y(/'09Z'I0!B:5^R;H>D:5X7T^'Q;XG
M>'P]XCG\46C2/9%GNY6D9UDQ:C,>9I, 8/S=>!A;_P#9/T/4?#OB#1I/%OB=
M;;6_$R>*[EU:RWK=K+'*%0_9<"/=$GRD$\=>35KX8?M-^!?%?@^W:X\8Z9?^
M(=.T.WU36K6T/F2P@Q*99/+0$E58D-L!"]#BNYTKXJ^%];L?#%Y8:DUU:^)@
M3I$L=M-MN@$+[A\GRC:"V6P"!GI0!P?BO]EO1?&+_$@WWBKQ(@\>V=O8ZHL#
M6:B..%2B>3FV.TE202V[KVXKI--^"6FZ7\1]/\:PZWK7]JV^CQ:)<1>;"(+Z
M")F>-IE$0.]6=C\A0'/*D5N>-/BAX6^'AC7Q!K$.GR/!)=>64>1U@CQYDS*@
M)6--R[I" JY&2,U@>*_VD/A?X'=TUSQUHEA(EI'?E&NE9OL\G^KDPN3M;J#W
M )Z F@"WXT^#NE^+_&NB^,(-2U/P[XITFWELX=4TEX1));2$%X)$FCD1TW*&
M&5R",@CFN=OOV8O#+V7A%-)U36_#5_X9N[J\M-4TJXB%S-)=9^U><98W5_-+
M$L0H(/W2N!6OXB_:1^%WA2&&75/'>AVR3V"ZI%B[5S):L0%E4+DE3N&".O)'
M -<SXI^,=U)\5_@W'X;U[3;[P-XNBU&6XG@191.D-KYL<B3[L!<]<#MR>U #
M/#_[)/AWPO+X0.G>)_%$<7A?6KS7;*&6XMI@\]UYGG+(SP%F0B60 !@?FSDG
MFN^^+/PLTWXP>$UT+4[[4=+6*\M]0M[[2I4CN+>X@D62)U+HZ'#*.&5@>XK,
M\%?$W0QX&CUJ[\<V/BRTN-1N+:VU.QM@HG<2N%MXHHMQE= I3Y,EMA;'6KS?
M&[P-_P (_IVMQ>([2ZT_46E2T:T#SR3-$"9E6) 7)CVMO&WY,'=C% '#_P##
M)7AIX?$'G>(O$]S=:QK5IXB>\FNX3);ZA;J@2XB'D[,GRU)5U9.P51Q6GXO_
M &:- \;^#_%>B:EK6MF[\4/;MJVNQ/;"^N%@*F*,9@,2(NWA4C'5CU8D\IXX
M_:5T_P '_&'P--<^+]'@^%^N^&[[5#>;582R1O (G28$E@1*<*HSQW[:_C3X
MT7%UXT^"<_@S7M-U3P?XPU2XM;F>UC6<7,2V<TJ&.4-A<-& 0!GJ,CD4 =%=
M_ :QN_'6M>*V\3:\NI:KX?3PY.BFT\I;=2S"10;?(DW.[9)*Y/W<8%9/AC]F
M70O LO@*]T[7?$DMSX)TF31K0^=;[[ZS8HWDSXA4'YHDP4\L\8)()KN(_BSX
M0D\5V_AH:_:#6;EY(K>W8D">2,9DCC<C8[I@[D4EEP<@8KD/B[X]\0^$?BI\
M(=)TR[MXM'\1ZQ<V&I0/;!Y)%2SFF7;(3\N&C'09/K0!G?";PG!XM^*NO_%R
MZ\':KX.U#4=.@T>&SUQ8X[R18F9I)Y(XY'52<QHISN*Q\\$5VOQ)^$FF_$S4
M/"VH76I:II&H^&]0.H6-WI4L:/N:)XG1MZ."K([ X 89R&!YIUI\:?!5_K,F
MDVVOP7-^JW#)%#'(_P!H^SG$XA8+B9HSPRQEBIX(%5='^/?@3Q WA<:=KOVH
M>)S*-&9+.?;>^7GS-C&/'R[23G& ,].: ,&W_9A\*VKZG9Q7NK+X7U+5QKMS
MX6,L1T]KP2+*7&8O-56E59#&) A8?=P2#UGQ1^%6B_%K0[/3M7>ZM9K"]AU+
M3]1T^01W-C=1',<T3$,,C)&&5E()!!!K<\.>*--\66MQ<Z7.]Q#;W,MI(SP2
M18EC8JZ@.HSA@1D<9!YXKRK]J;XD>*/A=X9\*ZEX8O;*UFU'Q)I^BW*WUIYZ
M^5<S"-G7#KAESD<D>HH O^(OV:/#?BSPWXFT[5=4UBZU/Q%<6ES>^(/,@2^\
MRU9&MMFV(1*(R@(7R]IRQ())-5-7_9?TK7+OQQ<W?B_Q1)-XPT2'0=28R69(
MMXU=0T9-L2'/FR9)R/FX P,4_B3\1_%7ASX^_";P?I>KV)T7Q.M^-0\VS$DP
M-M L@,;AP%WDX.5..U>B-\7/!Z^(X=";7[1=2FN'LX4)(CEN%&6@23&QI0 2
M8PQ<8Z4 >?7?[)F@/X@TO6]/\7>,- U2WTRWT>_GT?48[;^V+:$;8ENE$6TL
MJY >,1L 3@BNP\$_!K3? GQ \4^++'5]5GG\0Q6L-QI]R8#:PK;1^7"(@L2R
M#"DCYG;/?FH1^T+X -C'>#76-M)JYT%7^P7/_(0! ^S$>7D29.,'OQ6]=?$W
MPU92:K'<:B89-+N([2Y1[>4-Y[H'2)!M_>N5((6/<<$4 <3KW[*_P^\1V/C*
MTO-.G,7BO5K?6=0*38(N(2C*8CCY 60D@=3))SSQT/B_X/:=XQ\>>#/%4VK:
MI87/A4W!LK.R,"V\GG1^7() T3.?DX&UEQ3+/X]^ =1G\/Q6GB."[DU^YELM
M.$$,KB>XCSYL)(4A)$P2R/AE )(&*U;CXH^&;2'4))M1:,6-X=/F1K:7>UP%
MW&*-=FZ5MOS8C#<<T <'??LI>$?$5JT/BJ^U?QB?[$F\/I/J\D FCM)&1F7S
M((HV9@8T(9RQ!7(Y))Z7X3_!N#X56SQGQ7XH\7S^4MO#=>*-06ZEMX1R(DV(
M@QG&6(+G RQP*K:C^TM\+-(TC3]3O/'FB066H0S3VTC72YD2'/FD+]X;""""
M,@C'7BO0M-U&UUC3K6_LITNK.ZB6>">,Y61& *L#W!!!H \K\1_LS>'M>^)5
M_P"-+;7?$OA^[U:**#6M.T741!9ZNL8VI]H386R%^7=&R$KP2:-2_9D\+7]_
MXK,-]JVG:+XKE2?7?#]G+$+&_D555F8-$9(RZJJOY;H& YYR:@\:?'C0?AG!
M\3/$5_XI7Q)8>&;>W>X\/:39>;<:8Y1OED>/<3YI .7 " <\5Z/:>,]+E\(+
MXENISI>DBW-S+-J4;VODH!EBXE"E0/4@>M 'F_B+]E[0O$<GQ)\WQ'X@M(?'
MEC!IVHV]J;-4MX8HS$BV^;<E?D8CYBW7UJOXL_94T;QC<W4][XN\3QO<^%7\
M(2B!K%0UDQ!9N;4XD)'WNGH!6];?M._"F\8+#X\T:1FLAJ* 7',D!VX9./G/
MS+\JY;YAQR*UQ\;O TGAG2/$$'B2TO-*U<2-I\MF&N'N@@)DV1H"[; K%OE^
M7!W8Q0!@V?[/=A9>+=&\11^*O$)U#2?#K>&H QL_+-LQ4EV'V;F3*(<@@<?=
MQD5B:-^R7H'A[1O 5EIOBKQ397/@R&XM+#4H+FV6YEM9R#+;S$6^TH=J\JJN
M, A@>:[R#XS^"[O5_#&FVVO0W=UXGMVNM&^S1R2QWT2KN9XY%4H0HY// (SB
MMW0?%NE>)DU%].N6F33[J2RN6>%XA',GWURZC..Y&1[T >4^$?V3_#_@B?P(
M^E^)O$R)X,>_DTV*>>VE5C=Y\X2EK<LPY.,$8]Z9I?[)VAZ3IGAFQB\6>)WA
M\/\ B2?Q3:F1[+<]W*TC.KXM1F/,TF ,'YNO Q=^+GQOM;;X0^/-5\$:W;?\
M)#HV@SZS:O<6<CQO&BL4E0-M$D;%2 ZDJ?>NBM?B]H/A_P %^'=0\4:S#:7M
MYI,.HS@1LS*GEJ9)V5 =D0+<N0%&>2* ,'PI^S%X<\%>,]0UO2M;\26^E7NH
M/J[^%/[0']D)>.=S3K$$W@E_GV%RF[G;D#&7X6_9%\.>$M7\*7UIXI\5RQ>%
MKZ[O=)LI[V PVZW.[SH.(0S1DN3EF+CIOQQ7?7/QG\&6VLC2O[:6>^;2SK<<
M=K;RSK+8C&;A&1"KIR.5)ZBK&@?%CPMXIMO#EQI6I/>V_B*-YM+ECM)MES&@
MRS@E,!<$'+8!R,9H \RD_8V\*'P;I7A^W\2>*]/;1-3EU30M6LM0BBO='>1G
M9XK=Q%M,9\QP5D5R00"3@8]=\%>$(?!&@Q:;%J&H:M(&,D^H:K/YUU<R'J\C
M8 SP!A0%      KF?%_QKTCPI\3_  UX!EM]1?6M?MKBY@GATZ>:")(MHRS(
MA!^9UR 1M'+%01G@?V</VC[#QIH&GZ1XP\4Z7)X[O=5U2SALXD$!F6WNYHT5
M4&0&\N,':3N(!//6@#Z"HKDH_BSX0D\5V_AH:_:#6;EY(K>W8D">2,9DCC<C
M8[I@[D4EEP<@8KK: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)EC<2,&578\ X/2OKRN0L?BCHNH?%#4O ,2W@U[3]-BU68R6S) 8)'**4D.
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M(JCU(KWV4ZQJOPANHYO#]S::U/I,D(T9KB!YED,958RX?RMW3HY4?WC7:T4
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M1'J=Q81/<H%.5"RE=PP>1@\56U[X6^#/%6KOJNM>$="UC5'MC9M>W^FPSS-
M>L1=U+%#D_+G'M0!=\-^)-/U:"WM(M3M;O4X[."YGMXYU:9$=?E=E!R Q#8)
M&#@XK;K)TSPEH>BZC+?Z=HVGV%]-!':R75K:QQRO#'GRXRR@$HN3M4\#)Q6M
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=5TRPENDC7S3<JD$LI4$B)G(W GIW(Q5K4O$&EZ,&.H:E9V(6(S$W,ZQXC!
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M4$ ^U_%'B3Q!HE[X@EM!H=U966BM>VMG+<R)>-<*7)\P!2!"0% 8 G=FN?\
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MT5C86RVT,>XEFQ&H 4DDD\=2:U: "BBB@ HHHH **** "BBB@ HHHH ****
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ML+[AM*G!Z$ ^CJY_Q)X^\/>$-3T/3M9U>VT^_P!;NA9:;;2M^\NIL$[$ Y/
M)ST%<[\*-4\:P>$]5'Q".F3:OI]W.L<NE.&:6U #Q-,@X28J?F5?E/!& <5\
MU:SX[UWXOZ3^SK\1+O5(5TO7/'$4\6APVR[;2,172Q 2_?,@52'W$@D\*N.0
M#[7HKY/B_:2\77?PL\.?%NTDMI]$U'Q0NC7/A8VPW16CWQLU9)0=_P!H5MKM
MG*')4*,;J]F^//C'Q+X(\)V6H^&](O\ 6?\ 3XTU&'1HXIM12SVL9)+6&3Y9
M9%(7Y<$[=Q"DB@#TJBOF/X?_ +0-_P#%OQ5X9\&^'O%D3?;M!OM=F\1II@BG
MD,=X;>.V^SRC$;I_RU!7.5P-N<UZ5^S?\3]7^+'PV.J:_:06NMV.I7NCWC6B
MLL$\MM.\)FB#$D*^S."3@DC)Q0!ZE17C?[0/CK7OACJG@7Q#!JYL?!DFL1Z7
MXBC\F)O*BN 4AN [J2@68QANV&[8KSOX,_'#Q7X[OKKPOJ.LW:^)M*UV>[NV
M:QMXVFT$1":UE$83"^<LD*YZ[B_3&  ?5%%?.7P=^*/Q*^)[^!_&MNVCCP+K
MZR_;[*YEC1[4'=Y(MF7+M*K+MD60\_,1LQBM_P"*GC3QO:_';P+X)\.:SINC
MZ9XATK4[B:XN-,-S-#+;^3M9<RJ",2G@@8(R=PXH ]NHKY#^'WQ[^)>H:;\(
M_$&M:MHUU8>(_$MSX5U'3;;2S$7,1ND%TLID)5BUL#L VX8CWK:\*_'/QCJ?
MQ9\#Z3-JMIJFA>*[G6[1[S3;118PFU#- ;.5PLLC*% D9U:-FSL.!0!]145\
MR_#WXK>--8UNX^&VL:^Q^(FE>)Y(K^YCLX$631E3SX[A8]F LD9CCSU$C'G
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M6XAM5A>PNH(XY6V%3AH'63 #98$#+MFH_B7XN^(]]\?['X?>$O$>C^';&_\
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M@C) J?5OCMX T2UL[JZ\5Z>+2ZM([]+F&0S0K;2-MCGD= 5CB9C@2.0I/&:
M&W/P)\$75Y)/)H\@BE6U62P2_N4L7%MM\C=:B00G9L7&4_A&<XJSH/P;\)>&
MM7MM2LM/N&N[2:XN+7[7J-S=1VLDY)F:&.61DB+;F'R 8#$# )%8,_[0'AN;
MX@^+?!1N+K2;O0-+BO[O6;RRE6R@$HE*L9&41[5$>[<6"MG:"2#C2T/XH:!H
M_@#PSJ.K>+[?Q =1LEG@U2TM"&U)50,]Q';Q!F"8.X[00H/) H UO&'PN\->
M.]4TK5-7L96U72O,^Q:C97D]G=0!QAU6:!T?8P RN=IP,C@5F'X$^"!J?A;4
M(M(FM+GPNDR:0;/4+F!+;SAB8E$D"NSY.YG#$YR3FC4_CY\.='MM'N+OQKHL
M<.L6SW>G,MXC_:X4&6>/:3N Z<=3P.>*M6WQE\%W_AK2_$%EK]OJ&DZFDDMG
M/8J]P9DC_P!8P1%+83'SDC"_Q8H N?#SX9^'OA5HDVD>&;2>RT^:ZFO7BGOI
M[HF:5R\C!IG=AN9BQ .,D\5DZ=\"? ^DZW+JEIHGDS2:@=6-J+N<V0O#UN!:
ME_)67/.\(#GG.>:V/$?Q$T7PU\/+SQK---=Z!;6!U/SK&W>X>2#9O#(B L<K
MSTZ<G S6#X?^.WA?5_ ?A[Q1=SW&E1:U:+=V]C<6DWVDKY:N^V+9O=4##,BJ
M5QSG!H SM:_9<^&/B'6M2U6_\-M/=ZCJ$6K7"C4;M(3>1E2MPL2RB-),HN71
M06Q\Q-=1X*^%?AOX>:IX@U'0K2ZMKO7[O[=J+SZC<W(GGVA-X661E0[54?*!
MPH]*VM'\3:5XB\/V^N:3?P:KI%S#]H@O+%O/CF3&<H4SN^@R>U<SH_QM\%^(
M/"UIXCT[6#>:+=WXTR"ZBM)R)+DR>7Y879NSO!7.,9!&<T 77^%WAQ_B0GCT
MVMU_PE*6/]F"[&H7(C^S;M_E^1YGE8W?-]S.>:Y_P_\ LV_#;PKX\OO&.E>&
M(;+7KV=[J=X[F<VYG<$/,+8OY*R$$Y=4#')YY-;D'Q=\'7/B&+0X]?M7U*>2
M6&"(;MMQ+%GS8HGQMED3!W(A++@Y Q52T^./@>]L=+O(==0VNIZJVB6LK6\R
MAKY7*&W;*#8^Y6&&QR#Z4 9W@?\ 9L^&OPXU/4K[P]X5M["74!*LT+3336Z+
M*<RK%#([1PJ_\2QJH/<&KGAOX"^"/",,4.E:5<6\4%K+96B/J5U*+&"3&^.V
MWRG[.IP!B+9P .@%7/BCXHM?#&EZ4;CQA9>#I;O5+6VAN+R%)C=EI5!MD1B/
MFD'RY&2N<XXK,U3]HSX8Z+J]QI=[XXT6"_M[Y--G@-T"8;A]NV-R.%/S*,G
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MP^8=L9E<#;$&;A2Y4$C S3M:^+7A#P[K<.DZEK]K:7LMQ%: .3Y:3RC,43R
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M$T?5?MFIW4T=U:(&"1M&\I48W-A@ V6)SDU1T;]F/X::'->S0^&OM4M]I?\
M8MV^I7]S>M=6>6(BE,\C^8!N(!;) P <  >HT4 <)\*_@=X)^"ME/:^#M&;2
MXIPJL9KR>[<(N=L:O/([+&,G"*0HR<"K&I_!SP=K/C*]\4WVBI=:S?:?_9=V
M\D\IAN;;YP$E@W>5)@2. S(6 =@" 379T4 <7X*^#OA+X>SVTVB:;-%+:6IL
M;5[N^N+LVEN2"88?.D?RDRJ_*F!\JC'RC'G7C;X3ZGXQ_:AT+Q+=:3J(\+6?
MABYTI]2L-6-DZW$L\<@'[F9)2FU&!XQDC@]1[S10!P5M\#/!-CXA\+ZW::1)
M97_ABUDLM)^R7]S##;0R8\Q/)601ONVKDNK$X&:2Y^!/@>[\0ZAK,FB8NM1N
M8KV^@2[G2TN[B/&R::V5Q#(XVJ=S(3\JY/ KOJ* ,35/!6AZUXFT7Q#?:9!<
MZUHRS+I]ZX.^V$RA9=O^\ !S7/:A\#/!&K^(O$VMZAHIU"^\2V":9JRWEY/-
M;W5LF[;&8&<Q #<V-J@_,>>:[RB@#RSP]^S#\-?#-]'=VOA^:XGCTR31E.IZ
MI>7P%B_WK;;/*X,7HF,#MBM+X5_ /P)\%$N$\&Z%_9*SJ(SYEY<71CC!R(XS
M-(_EQYYV)M7/:O0:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /$?V@O"_C?_A,?AQXY\$Z*
MGBR?PO>78O?#K7D=I)=07,'E&2*24B,21XR Q (9AD5SDO@+QQI?Q4\!?$>T
M\%VD-I;V>IZ?J?A+1KFW2:S%U)'*MRKNT<,LNZ+][AAG?\I?&3ZW\4_B]X?^
M#FDV.I^)/MT=C>WD6GQ2V=F]Q^_E8)$A" D;F( )&,]ZJ^.?C3H_@6?[+-IV
ML:QJ,=B-4N=.T>T^T75M:;PAF>,,"0&.-J;G.UL*0IP > Z%\!/&7A3Q3\.M
M0C\.37EJGCW6/%>H6]O=6NS1[>[@FCCB^>5=[ NK,(@P!+X)P":%[\(?B"WP
M]\1:=#X"OQ?W?Q6C\4PQ"]T\%K 7L4QES]IP#L1OE)W9(&*^R8)EN(8Y4W!'
M4,-RE3@C/(/(/L:DH ^,_'7P>\?Z[X$^/.G6W@.]FO/%7BZRU32HVO=/'VFV
MC^R;G)-QA<?9Y.&(/(XY.-;XM?!KQS\0_$?QT&G^&)[.U\4^#]/TW2KJ[N[5
M8Y[N!IG:)@DS,G^L50S*%Z\X&3];44 ?&OCSX=_%#QY>?$S5?^%;W6G_ /"1
M?#=/#=E92:O8/.+U7G^1\3;%'[T'<'(QCG.5'41?#[QI%\2M/U=/!%_'I\/P
MQ?PZ["[L1B^WJZP[?M&>Q&[[N3UQS7N?Q*^*.B_"G3--O]<6\,&H:C;:7";2
MV:;$T\@CCWD<(NYARQ'XGBNOH ^-OA[\./BQ\)X?A1KMMX!/B;[%X)3PCKOA
MJ35;.&XLI5D603QNTAAD1B"K /NP%.#C%-^.?P@^)GB_1O%OA[2_A_IT5CJ7
M@^&QTYO#-Y:6%O'=JTK-;7+LT<TD:!E$2@>22S%E7.5^RZ* /FG3/!'CK2_B
M;XXUJ3P;<3V'B7P7I]A&T.H6A-O=V\=RK6[AI 2Y,R889C^]EQ@9YWX/_"KX
MB?#&^^$/B2Z\+7>H+I7@C_A$]8T"&]L_M-A.LB2+<1LTPAD1BFUL2;L!3@\@
M?1_Q.^(VD_"7P+J_BW75NVTG2X3/<?8K=IY H[A1_,X [FNCL[I+ZT@N8\^7
M-&LB[A@X(R,_G0!\D> O@'XP^'WC3X17)\.S:C8:5JWB/6-2-K=6OE:6-0W&
M"W4/*K/MS@E%(!S@XK'\/_ GQJ_@+2;"[\)^*?#'B73]8U_4-.U[P[K&GI=:
M=]INS+"KQM<&*:"5&P\;;L%!P.M?:M<]\0/'&F_#3P7K/BG6!<G2])MGN[G[
M';M/*(T&6(11D\#Z#N0* .3E\)^*M=_9PNO#.M_8'\97OAB73[G[&HBMC=O;
M&,[0.%7<>W [<5Y'\/O 7Q&\'>*_A?XQNO!UW<PZ;X+'A'5/#\>H6;7=G*AB
M=;J,F80NCM&5($F[&PXSE1]-:#K-OXBT/3M6M-XM;ZWCNHO,&&V.H9<CL<$5
M?H \K_9K^&&H?";X:OI&IE([N[U6_P!5-G$X>.R6YN7F6!2.#L#@''&<XXKS
M[P?\*-1TW]HKQCI5I>Q#P#%(OBJ&TCSOL]7NXY(74#H%PKS@=FE!]*^DIH4N
M(7BE4/&ZE64]"#P17-_#WX9^%OA1X?&A^$-#M- TH2-,;:T3 9VZLQ.2QX R
M2> !T H ^;/"GP'\<W'PO^&?PVUK1FL9O!7BB#4W\6)=P/;W5M;S22J\2B0S
M"64.$97C4#<YW$8SEGX1?$[3K33_  Y!X':[M-)^*3>+1JXU6T2*ZL9+F6;,
M:&3>'42897"\@;=V>/L35;\:5I=Y>FWN+L6T+S?9[2/S)I-H)VHO\3'& .YQ
M3-%U,:UH]EJ M;FR%U"DWV:]B\J>+<H.V1#]UAG!'8T >3?M4>$/$7C;P-X?
ML/#6A3Z]>6_B;2M1FB@GMX3'!;W22R.3-(@/RJ< $DGM7CWQ*^$7C[Q#H/[1
MUM8>!;V>Y\8:GIL^BG[;8+]ICABMT=B3<#9AHG(#X/(QUK["DNH89H89)HTE
MF)$<;, SX&3M'? YXJ6@#RC]H7P)XB^)OP/U#1_#JQ6WB/\ T2^MK2_EV1RR
MP31S_9Y70D /Y90L"0,YSCFO&/'OPQ\7^//@=X]^P?!>/PEXQUVWL;,V*ZS:
M75]>&*=9"SW!E$8A10=@+[CD_*O0_7U% 'R?XE^%GC%?BKXR-[\+[3XB^#_&
MBVERDM]K$-NNDS);QPR07<#.?-BS&K@Q"0]1@Y!K4\#^!?B)X#\9>,/"MSX"
MTGQ5X2USQ%_PD%AXFNKV#[-8AQ&3'+:N3*7B,?[LH".%^9<9'TY10!\:>-O@
M_P#$27P!\5/#%KX&N-7.L?$"'Q)87$.H62QW5H;NVF;"R3*5*K#("'"Y)7;N
M!)'J&J>#_%_AGX^^(O&=GX;N/%7AWQ/X:MM,>R@NK:.?3;B!I6"NLTJ(T4@F
M.2C,0P/!!S7O=% 'R'\*O@)XQ^$_C'X:P3:#<:[IOA[P-J.D76I6MS:^6EW<
M7,<RP1K)*LA50K(&V@8"] 3BI\,O@[\0='TW]G"QU'P??Z<WA*VU6VUJ<7UB
MXL?/@:*)AMN"7&2#\@8@#IVKWCQG^T#HOA#4[ZR@T/Q'XHDT^YCL;T^'-.^V
M_9KF2/S(X756#[F4J<A2HW*&9217:>*/%UEX/\(:CXDU&.Z73]/M'O9T@MWE
MF6-5W-B-022 .E 'A7[.'A3XB>#]'\+^"/%_@#2XX?"!F@M_&;WT%PMY#\P1
M[:(9FBE=64/O"C ;[V<5TW[1/ACQ+XD\1?">X\/^&[O78-$\5PZMJ,EO<VT0
M@MTAFC)Q-*A8YD7A0> :]2\'^*;+QOX3T;Q%IOF?V?JMG%?6_G+M?RY$#KN&
M3@X(XK8H ^3/$?P3\=7/A7XY^ 6T$ZQ8?$#4YM1TOQ";NW$-F+B.-&2Y1I!*
M# 8\KY:." N"#70>#_AOXK\-^/\ XUW4WA>_NK+6-%TVQTG47N;,MJ+VUD\#
MC'G[D+,P(,@4=>17T9+>P13-"9%:X$9E\A6!D*CC(7KC/'UJCX6U\>*?#]CJ
MHT_4-*%U'YGV/5+<P7,7)&)(S]T\=* /E[X;?"KQOX>O/V:7OO ]Y"O@S0+V
MPUIQ=V+?9)I+:.) ,7&7RR$Y3/!&>]=K^SAI'CKX:>!M+T#4_ EU ;WQ+JT]
MY++J5GBPM)KB:XAGVQR/Y@;>B;%.X$DD8%>IZK\4-%T?XEZ#X%N%O!KFM6ES
M>VK+;MY!C@V^9F0\;OG7@9//.*ZZ@ HHHH **BM[J&[5V@FCF".T;&-@VUE.
M&4XZ$'@BI: "BLBT\1"[\3:AHO\ 9NHPFS@BG^WRVQ6TFWEALCDZ,Z[?F';<
MOK6;\3OB-I/PE\"ZOXMUU;MM)TN$SW'V*W:>0*.X4?S. .YH ZFBH;.Z2^M(
M+F//ES1K(NX8.",C/YU-0 45R'@?XHZ-\0=:\5Z7I:WB77AF_&FWXN[=H1YI
MC60;-W++M=><#.>*Z^@ HHHH **** "BHKFZALX3+<31P1 A2\C!5R2 !D^I
M( ]S7+>%OBAHWB_QKXM\+6"WBZIX8:W2_P#M-NT29G1GC\LM]\;5/(&.F":
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YT_;J('PG\,Y./\
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MIND9"S;2 1D\8&*OS?#WPK<>(DU^7PSH\NNQA FJ/81&Z4*,+B4KN&,\<\4
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M+QF98[ 6V<PF,(C^:%W$ EB0>/JRWMXK2WB@A18H8E"(BC 50,  >F*P]/\
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M;2&\.H10#1K<(ET3DSJNS DSSO'S>]30_!_P';ZH^I1>"?#D>HO>#46O$TF
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MG4]"* /&_P!M.Q2^^'/@YIKN\M5'C+0DD:SO)K4,KWL:MNV,N1SD;OND C!
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M%.H7/A'4]/L]<G$"64]Y<>3!,SRH/*$H#>69 3&K@':S@]J^;/\ AH345N]
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M-ZJ8QM$^W>!CC&: .BHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^#8IM'%YI?B#5XM&DU$W7E+8S2@^4778V59AL!!'S,H[Y'E_A']DK6_"MWX
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MKW@O6]!U7P#\3K[PY=VVAVOA_5O[2TR/4UU2"WSY,N'=?*F7>X#Y88(!4XY
M,;]H'XVIX]^"/Q1L/"FCZG=G2O#)O-2NC=-IT]@\]L9HHPO#M,J;7="5 ! R
MQ.VM?XV&27]A#79_M%S%<1>"EN$F@G>*0.MJK [E(/4=,\]Z7Q3^RCJMY?\
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M_9@U/P1X?N?!>H?$"\U_X9I%<VVG^''T]()X8)@Z^1-=JY:9$$C;1M3^');
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M7B#X=^(=<U35-2TW7]+FBE\/7@1XVNH+AE"-%-D*I5B'5L%24W#[NH ****
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M8&&<_NV.0=I- 'NO@3P=:?#WP;HOAG3Y[BXL-)M([*V>[96E\I%"H&*JH)
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M0?V=+<QV[M&ZE>78NZLV_P"4ICGFO-_VCOB%KGQ;^!GQRN+35(M*T;PKK2Z
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MDQ/G.^4G"@C#(,_>( /9OA#\.[;X7>!+/1((+6"=I9KV\^Q1[(6NIY&EF*#
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M_DK+GG>$!SSG/-<38?MD> ;_ $J_OQ'JT$4'A]_%5LD]JJR:AI:LRM<P+OY
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M0HK,C?*K*X5L%>G-8VN?"+Q[KOB#X3:O/'X5BE\-ZU<:KJMM8S36T,:2VTD
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M7N;2_-YC;"R"*,?(BM(?]:I)8<?+SU?@KQMI/Q"\/Q:UHDTL^GRRRPJT]O)
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M\D @$CI/&'Q/\,>!?AY?>.=8U>WM_"UI9_;WU!6W(T1 *E,?>+9 4#J2 .M
M'R1\2?V./BAK/C_6-:TG6=!UU]?^&H\%:AJ.MW<UO*EV% -SM2&3S Y&<9!!
M))SC!T[']D+X@VLG[+S/<>&''PLC=-7']H7'^DED5 ;?_1N<!=WS[.>/>OKO
MPUK]IXK\.Z7K>GL[6&I6L5Y;M(NUC'(@=<CL<$<5S/Q%^,7A_P"%VI>'+'7%
MU#S_ !#?+ING?9+-YUFN6!*Q$J"%)"DY; P#S0!X/^UMX$\/_'3X@> ] \/^
M*H=(^*/A/6K2]*6Q(NHM.N-PN.W0QQLWMLYQN&?JFQLH--LK>TMHUAMK>-8H
MHUZ*JC  ^@%><>+/B?X4\)>-91_PC]]K&OVT5K#J-YHVF+=7&GP7$A6'SBO[
MS865CA ^T#<P YKTZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R7]I'P5IGQ(\*Z'X5UF(3
MZ7K.K+8W"$?P/;SJ2/<9R/<"O@;X>:1XPL_V2OC9\*_%UI,+'X21:O!;WLGW
M+MY8&^S!?4(DDTG_ &TB]*_3S7O"&@^*9+*36M$T[5Y+&43VCW]I'.;>0='C
M+ [6]Q@U'K?@?PYXFTW4-.UC0-+U73]18/>VE]91S17+!0H,B,I#G:JC+ \
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MW[P)DD\Y]\U\W?"K5_C?\$?B??\ P<^)FK6_CW3Y?"FHZCX:\:VFY-0M8HE
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MM_M; ,@9.!T&:9XD^#O@'QCKT&MZ_P"!_#FN:U  L.HZEI-O<7$8]%D="P_
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M _/GX+?'/XB^(?BOX@T"S\8W=O::C\*UURSO/$%R9(5U#A$U#9(\AMDDSO\
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M (DZ5^R/\1]4\9ZOXEM[&]\<VZ:!:ZGJ<QG_ +(-P%B6>-F) .2=K_-PI89
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M%(S+,00RH^"P/8\5KP_M=Z/9+XPCUW1)]*O/#6AV_B"ZMX;I+AHX)F9!'-@
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M@@L#FO%OB#=:78_MKSV&L_\ "27>B3^!?MS:;H@U&X4W(O"GFB&UR5;8-N[
M[<YKW3X3^!?&GA&V?_A-?B"_CN\6);>"6/2H].C5!U=T1WWRG R^0..%7)SS
MFM?!/Q3/\?Y?B=I'B_2+%VT$:"FEWV@2W(6/SO.WF1;R/+;N/N@8_.@#S/\
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M(7: 0U=Q\!_A+<?!;P1-X=GUYO$2MJ5YJ"7<EHMNX^T3O,RE58@D,YY&/H*
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MZHV@'DYKC_"W[(7B/PW/X?G/Q%L[F?1_#U_X<5AX<""XBN2C>=+_ *22TVY
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ML=1T'X$:9X>U71=3T/5M(N;RWN(M3LI+?<YNIG#1[P/,3:RD.N5.>"<'' ?
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MOB9X%TWP9\3XP?AOXAOOA9XD\._81;^"-$W&TO'E=KC[3;(@=//1H\R%1S$
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MPSX0\1_&3Q1:^,/ UWXBFOOAGH^ZSD\.SW5Q]J/VE&+IY1:*8X"AW"D8^\*
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MDB^,DVIM>_\ ",7@NTTUKR5C+N\G>(#&^<_=^8^]:.G6&NS_ !8^'^IK\/\
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M:O#OC[>_$8? 3XSVWBRXTR]\-S^&&NM*G$D0OQ)TE5DB&QH>4*M]X9P=W!H
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M>M?'CXKZ=H7BKQ%'KF@O!X>^(B>%O[..CL%NK:2>"$%G\XLA7SMW&22#DX(
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M5<  G(\9LOV@_BCXJN_!?AZTO]$T75[KQ?K'@_4]2;2GGCF:TMY9([N%#*,
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MX@U[QQ\2?!7B-HK^Z\(7]M%;ZQ!"(OMEO<0":/S$'RB5.5;;@'Y2%7.*]=H
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MESLR&9E*JN,DXR!D9 .I_P"&?O JVGAN&+2KJU?P[9'3M,N[75;R&[@M2 #
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M:)G*;PJA?,"[B!@DTS5OA+X3USQNGBZ^TD7&O+8G3&G,\HCFMB6/ERPAO+E
M+L1O5B-QQC-=?10!P_@OX*>#?A[<64VAZ3);M80O;6*W%[<7*6,3D%X[=)9&
M6!3A1MC"C  Z "KOB[X7>'/'6O>'-:UFTN;C4O#UPUWIDL.H7%N()60HS;(Y
M%5R59E^<'@GUKJZ* /+/^&9/AV-&&E?V5J'V :W_ ,)'Y7]NZA_R$/,\SS]W
MGYSO^;;G;GM7GWQ^_9NM]7MX;KP?X=U'4-5UCQ7I6M:_*-;E7S(K1URR^=<
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M+T?P5;74.D6C0&[G-S<SS3R3SW$I 7?)+(S.[;54 LQP% ' %;E%% !1110
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M#@X84 :=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ!7WKX<^'?A7P?X=E\/Z#X9T?1-!EW^9I>G6$5O:OOX?,2*%.[OQSWK(\._
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M!@=A7,^(?@#\-/%NI:SJ.M> O#FJZAK,<<6HW5WID,DMVJ$%!(Q7+8*KC/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^<_VY?-M_AEX9
MNK6\O+"Y_P"$MT:U,UC=R6[M#+=QI+&3&P)5E)!!XJSXV_:LC^'VH>/K"+P!
MK=]8> 4LY-5NXKFU1$M9H]XEC!DW/A1D+]XX.=O&>P_:&^#>I?&_PKI.BV'B
M&V\.K8ZQ9ZNTUQIK7ID:VF65$ $T6T$J 3D\=*X[QG^S!KOC%?C$)/&FGVO_
M  L6QM+%]NA.WV 00F+</]+'F;@2<';@XZT >N>.OB/HGP[^'^H^,M8F>/1;
M&V%T[1KN=P<!%5>[,650/4BO/-=_:57P9JFJ:1XE\)W]AK,'A^?Q+8VEK=0S
MK?VL('G(KL4"S1Y7<AXP<JSUUOCWX1V7Q/\ @Y?> /$5VTEO?6"6<U[8IY+*
MZ;2DL:L6VE756 );I@YKBM;_ &<]7\803WGB/Q=9ZEXDC\-7?AG3]1AT9H8K
M>.Y55GGDA^T,9)6")T=%&#A>: '>'OVEKG7M/\,O)X&U+2]0\6M%_P (W:7E
M];_\3")K;[1+.QC9C#'$OWMR[CE<*2<#S7X#_%U/A[8?$./6;:Z&LZG\1=1T
M^PTN\OVG*.MO'(P,[;CY2JC'< 3@@!<G%>BZK^S7J=SX7^%0T_QC'IGC/X>1
MK#I^MKI7F6MS$8!!+'-:F;)5T5<[9001D$=*YV;]D#6GMM1U"W^),FG>,&\5
M2^+=-UNTT9!'97$L(AFA:W:5A-"Z9&TL#[T :)_:[:6W\-06WPX\23ZUKFJW
MNBPV#-! AN;>%Y?DEE=0\4BKE90 N"<X(VUV?QN\:^)?#W[./BSQ1IFF_P!C
M^([;0)[W[)=W2A[&00,S?/&)%=XSTQ\K$?> YK'U+X$>+-<\0?#K7-6^($&I
MZIX6U2;5+J2;1-J7C26[6YBB1+A1;H$<D9\P[N23FN\^+_@:Z^)OPQ\3^$K/
M4X=&EUNPFT\WTUH;D0K(A1F\L21[C@G'S#GUH \9^$VJ67@>XT*RT;PX+KXB
M^)O#=OK%_I]OK4GV-[>%5074C.@59Y6DVDB,EF!W-A=U:"_MAV6LV_@Y/#'@
M?7?$.I^)FU*VAT\36ML]M>60/GVLIDE 5PRD;ON8Y#'I6W!^S[JNE^(_!7BK
M2O%=I9^+?#^A_P#".W5S)I#26>I67RD*T'V@,CJZ!@PE/5@00>,_0_V6W\*^
M*OAYJ^D>)((H_#-[JFI7T5SIADDU.YU#/VA]ZS*(ADG:-KXP <XH [+XP?%N
M_P#A+\+O^$TE\,2W\-L()-3L3>+')81.5$DC,JNKB(MEMN?E5B,XK/\ %G[0
M-AX2UF[M)M.^W6ZOIUE9SV=T&:\U"\8^3:JI4 ?*!(SEL!&4XYQ71_%[QEX5
M\'>"[G_A,4N9M%U0_P!EO;VNGSWK7#3*RB+RX4=OF&1D@#D<\UY'X2_93BN?
MV=?#'A*\U;4-,\2:=?6VOVNKW&+BYL[V%@;=9 <"01Q*D)7(RJGD'F@#5\8_
MM7P^!;7QE;ZMX8EA\1>%#8S7^F"]4I/:7<HBBN;:79^\7<2"K*A!4^V?0/#?
MQ3&O?%OQ;X$DTPVMQH-E97XO5GWI<1W)E"C;M!5@8FR.1R.:X3QK^RX/B-I7
MCJ;7_$4;>*O%.GV>G?VMI^G>3!916LGG0A('E<M^])9MTGS< ;<5N_#?X+Z_
MX1^*7B#QSKOC*'Q#J&N:79Z?=6UOI LX4:W,A5X_WKD*?-/RL6/^T>@ ,;6?
MCKK/AGX]>+=!UBTTNR\"^'/"L7B"ZU$W;F<(TDP:0IY6"1Y)&P-T.<DG:-K0
MOV@(;OQ=X/T36_#]WH">,K.2\T"[DG299]D8E:&8+_JIO+8.%&Y2 1NR,56\
M=?L[0^._B1KNOW>M[-#\0^&?^$9UC1OL>YYX0\K*\4^\>609FR"C9P,%:;X-
M_9_O=+U#P%<>*/%$?BA? UO+!HOEZ;]ED+/$(1+<-YKB1UB!7*K&,LQ(Z  &
MM\9/C6WPDAEF;P]<:A:6VFW&J7-_/.MI9QI$0/(6=@5:X?)V1'&[:?F%4Y?V
M@K?6+>T3PCH%WXGU.;P[%XH?3Q*L#QV<H)B3)#;II"&"H."4.648)J?%_P"
M6J?$WQG'K=EXO71K5] N] N+"YTP7H5)_O7%NQE00S8^4L5<%>,#K7+Z;^RK
MXF\*WWA#6?"WQ-;0_$>D^'X?#.IW;:''<6VJ6<)S$1 TH\J1"3A][]3D$4 =
M?J'[0,TT6J#P_P""M:UZ_P!%T^TU'5]) 6&^M1<+O2W2(Y\RX" L8\J ,#=D
M@5G>,/VI],\-:G?PV/AW5-?M]*O8+#5!8*6NX))5C8^7;@$R^6LJ%^5(YP&P
M:@O/V;_$&E_$>Z\5>#_B7J'AS^V+"VL?$%O=:?'?OJ!@4I'<1R,R^3/M)!;:
MZ]/DXJ2+]G;Q'X=^(^N:WX2^)5[X?\-^(I8KG6="ETZ.[EDG2-8FFM[IW#0.
MZ(H8E7Y&1@XP :FB_M&:;XA\0Z_9Z;IWVZRT&ZN[/5#;W2M?636\;.7EM,!U
MCD*;8VR=VX<#-;/P=^,4/QBTU=5TVRMFT2>UANK74K'4$NXI"^[= ^T QS1X
M&]#G!88)YKC]6_9GNM>^(%CXQO?$EE#XATN:^;3M9T_1OL^H"&>.1([>XG\\
MBXBB\P$*47)C7D<YVOA1\ (?AQX\USQC+>Z<^LZU806>H1Z'I9TVUNI8V9C=
M2P^;(&F;=@N".!CG- %7XI?M)6OPIUN:#5/#MXND6][86$FHSRK;FYDNG5 ;
M.-Q_I*QEU\PJP*YX#8-8/BW]KJ/PG?>.!)X"UNXTOP9JEKI^LZ@+FU58HYUB
M99D3S"SC$RG:.< YVG ,'Q1_92UGXB:]XUNX/'R:?9>))]-NEAN=%%W/926;
MQND<<QG7_1V:/<8@H.YB0_)!9XI_94U[Q1H?Q:TZ7QU8QGQ_=V=U).= 9FL_
M(CBCQ@70$A80J<_+@D\=J ,7]KGXKOXE^"7QCTCPSIUY?1^&K'R-3U6UU VA
MMKEHUD"1!2#+L5T9P2HPV!O.5'M7B[X@Q_"WX)WGC"XTZZU>#1M&%_-:V;()
M9$2(,V"[*.@)ZY] 3Q7E?B_]DG6-:@^).GZ-X^BT;0_B%;J=:L)M$^U&.\\E
M8GN+5_M">6'"+NC<2=.&!YKU'X@?#&^\<_!'6/ (UR*TN]2T=])DU:2Q,JJ'
MC\MI!")%YP20-_!]: .)'[3\ZQ6D%UX(O=*U?4K9]1TNRU#4( +NR5(F,Y:(
MR&/+2J@1EW;NNT9(R_#7[2/B/QS\6? NF:7X7;3/#>M^&[S6KFWUEI+?4HGA
MN(H60P^4PRA9MH#8DW [E &=CQ7^SQXBU*3P%KGASQ^/"_C?PKIS:2VJIHXN
M;/4+1@F^*6T>;(RT:,")<J0>35W4_@'K-]XX\+>*D\=W(U73='O=&U&XFL%>
M6]CN9(Y6>(JZK;LKQC;\K@+QC(W4 5O"W[2]MXH\7CPM>^%K_3=4N]"GUVVT
MY[B/[8L,;JC0W,+%#;3D2(P1B1@_>!!%<WX"_:,TG2_!?PDTSPA\/M;FM?&-
MA=S:/8_;H3]G$"EVBEEEESGN6.0 >"2,%WP^_90\0^!M<\)ZH_Q!M+^?P]HE
M[H2*OAX1"ZBG:-Q-*?M!+3;XP7?/[S)P$.2;/@/]EK6_!$?P>0>-;"\7X>07
MUNN="=#?BY382?\ 2CY94?[V3Z4 >G_!WXIV_P 8OA_;>);33;C2I7FN+2?3
MKQU+V]Q!*\,L99<@@.APPZC!]J^6_B!\5?%WQ&^$L6O:YIT5A-I'Q3L]*M(-
M$U*1FE2'4U@:)E*1*X(7AG)!+9PF*^E_@/\ "F]^#G@RZT&]UN#7FFU2]U);
MF"P:T"_:9WF*%3+)G:7(!R. .*\VU#]E#6I?#^H:'9>.[6#2YO&B>,;:.XT(
MRO"XN_M30,PN5WYD& ^%PO&TGF@#H+/]J338+/Q-%KWA^]T#7]$UJWT)M)FN
M(I3//<1K+ 5E0E=I1BS'^'8W7 SUWPC^+7_"T8]=CET&_P!"O=&O/LDPN%+6
M]R"H99;>8JHEC(.,X!!!! [^;>*OV3;_ ,6:IX\U.7QR=,U/7M8T_7])O=,T
MORY='O;.(11/\\SK.I4'<I5<[B,UZY\./#'B7PWI4H\6^+3XPUF9@7NXK!;"
MW15& L<"N^WN22[$D]@   <!J/[46F0>*(+"PT#4=:TEM;.@7&H:<#+)!<!S
M&TIA"Y,"R HTF[(()VE>3Y_\'OBE8_#"/XD6EW)<:A?:A\2-3T[2[:YNG;<5
MACD(:5]S+&B*Q)PQ'  .<5WWA7]GSQ)X&\=:U=:#\2+NQ\!ZOJDFLW'A=M,C
M>:*XD;?,L-YOW1Q2/DE-A/+;67.:YJ]_9&UB>'5KZS^(7]D>*3XOG\7Z/K%C
MHPVV$LT?E2V\L+SL+B-H_E/*'F@#K/#/[2MMXIL='M8/#.I67BO5=2N]+MM&
MU']PCM;)OEN!.5(:WV%2)%4D[E 7.0,$?'[QOJGQ;^'OAV#P0=#L]9L]5N+^
MSUFZ,5X'M'CC(C C92A\P.C;AY@(SL'70\8_L[>)_%MCX3U<_$NXM?B1X<OI
M;VU\2+I,;6I66,12VYLO, \ED ^7S-V1NW$FM"[^ ^OW/C+P+XM/CQ[CQ#X?
MCOH;VYO=+62.^CNO+WK'&LBBW"F) OWP!G.XDM0!@^'_ -KV'5_"]QXGO/ F
MMZ3X<%W)I5M>3W-HSW6HK>_9$M$C64MN9^=Y^0 -\W&3;\:?M6VOPXMO'-MX
MB\*7\7B#PKI4>N2Z;8W,4R7EB[%!/#*Q3(5P5=2H8'& P(-5=/\ V3VD^!E[
M\/-9\5"ZN/[;EU_3M:T[3C:O9737C7<;>6TT@?9(Q'4;EXX/-/\ B+^R]J/Q
M/T?QG+K/BRR'BSQ'H,?AO^U;;166VM+-9#(^RW-R6+N[$DF7'"@#@Y +-_\
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M@?LIZYH?A?X?:/\ \)OI\X\)^*9_$PF_L%U^U&5YV,./M9V8^T.-V6Z+QUR
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M="^.GA+PQ=_$*XA\.:EIFK)XO@T"6TEN5EDU34YH81$8_P!XR1H59.X 5&)
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M!CT&;4HVM+F]FOIYQ:6%ND(4[)+AE*K+(6 C0CYB&Y &:X;P9^SAXKT+Q?\
M#K6M;^(L&OIX)LKK3+2)=!%O+=6TR1H//D^T,#(JQ*-ZJH/]T'.>C^+'P2U3
MXB>.-!\0Z?XK71H]/T^\TZ:PNM-%[$ZW 4&:',B"*=0I42$.,,1MP30!T>B_
M%_P_J_P<M/B9))+I_AJ?1UUMVN4_>0P&+S#N"D_,!V!//2N4O_VB!X6TG4-;
M\5^$M5T'PY!HJZW#JJLMQ%(C.$6V?;@)<DLF(P64[OO\&K_@WX$6^C_L\6WP
MF\0:JWB'3ET9M#FO8K<6C20&,Q@A-S[6"XYW'GGV'(6?[+FM:]\*]4\ >/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH R/$7BS2?"::>VK7BV:W]Y%I]L61F\R>0D
M(GR@XS@\GCWK7KR;]H'X@^(/AX/A]+H<]I%!J_BS3]&OTN;8R.]O.S!O+;<
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M6_Z#NG_^!D7_ ,57544 <K_PM'PM_P!!W3__  ,B_P#BJ/\ A:/A;_H.Z?\
M^!D7_P 57544 <K_ ,+1\+?]!W3_ /P,B_\ BJ/^%H^%O^@[I_\ X&1?_%5U
M5% '*_\ "T?"W_0=T_\ \#(O_BJ/^%H^%O\ H.Z?_P"!D7_Q5=545U_QZS?[
MA_E0!S7_  M'PM_T'=/_ / R+_XJC_A:/A;_ *#NG_\ @9%_\54_@.9+?X>>
M'9976.--*MF9V. H$*DDFMC2=6LM=TNTU+3KJ*^L+N)9[>Y@</'+&PRK*1P0
M00<T 8'_  M'PM_T'=/_ / R+_XJC_A:/A;_ *#NG_\ @9%_\57544 <K_PM
M'PM_T'=/_P# R+_XJC_A:/A;_H.Z?_X&1?\ Q53Z3\1O"^N^+M5\*Z?KUC=^
M)-*19;[2HY@;FV1L;6=.H!R,'H<UT= '*_\ "T?"W_0=T_\ \#(O_BJ/^%H^
M%O\ H.Z?_P"!D7_Q5=510!RO_"T?"W_0=T__ ,#(O_BJ/^%H^%O^@[I__@9%
M_P#%5U5% '*_\+1\+?\ 0=T__P #(O\ XJC_ (6CX6_Z#NG_ /@9%_\ %5U5
M% '*_P#"T?"W_0=T_P#\#(O_ (JC_A:/A;_H.Z?_ .!D7_Q5=57,>+)%AU_P
ME(^0J7\S' ).!9W'84 ,_P"%H^%O^@[I_P#X&1?_ !5'_"T?"W_0=T__ ,#(
MO_BJA\#?&#P1\3+_ %2Q\*>*M*\07NE,$O[:PNEEDM6)( D4'*G*L.>X--L/
MC)X'U7QW>>"K'Q5I=[XML\FYT6VN5DNH  "2\:Y*CYAR<=10!8_X6CX6_P"@
M[I__ (&1?_%4?\+1\+?]!W3_ /P,B_\ BJZJH;V\@TZSGN[J9+>U@C:66:5@
MJ1HHRS$GH  3F@#F_P#A:/A;_H.Z?_X&1?\ Q5'_  M'PM_T'=/_ / R+_XJ
MLK3/C[\.=9C\,R67C31KE/$S.FBE+I?^)@RL598?[[ C! Y%;G@SXC>&/B)%
MJ,GAG7K#7$TZY:SO#93"3[/.OWHG ^ZP[@\T 0?\+1\+?]!W3_\ P,B_^*H_
MX6CX6_Z#NG_^!D7_ ,57544 <K_PM'PM_P!!W3__  ,B_P#BJ/\ A:/A;_H.
MZ?\ ^!D7_P 57544 <K_ ,+1\+?]!W3_ /P,B_\ BJ/^%H^%O^@[I_\ X&1?
M_%5U5% '*_\ "T?"W_0=T_\ \#(O_BJ/^%H^%O\ H.Z?_P"!D7_Q5=510!RO
M_"T?"W_0=T__ ,#(O_BJT-%\9:+XBNGMM.U*UO)U0R-'!.CL%! SA23C)'YU
MM5C75[-'XQTNT5\6\MA=RNF!RR26P4YZ\!V_/Z4 ;-%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $3?\?4?^XW
M\UJCJ?B?1]$NH+;4=6L;"XG_ -3#=7*1O)V^4,03^%)XAOIM,TN^O+:+S[BW
MLYY8XO[[*H(7\2,5\3?\$VM&LOCA\"_'_C/QY;0>)?$OBW7;RUUBXU*,2N8%
M1 EN-V=L:AFP@P!G@<4 ?=M%?EE^SE^U]X_^#W[+UQ)%;6WBNVTGX@+X0TQM
M:EER;24911*ISB,C R&P& Z "OH+6?V[]6^%MQ\;M'\?>']-GU_X?6]I>VC:
M')(EMJ$=T46)6\S<R,KR(&;G()( Q@@'V717QW\0/VQ/B#\._A'\0_%5YX*C
ME;PW;Z;>Z?JESI=Y8Z?JL=SL66)!,0X>)V(W!B&&#@9KJK[X^?%KPWX)B\4^
M(O!7A^QT75+_ $U+*]M=1,B:983Q[I[J]$C1@F,E1L1@"6QN. 6 /IJH/M]L
M+T6?VB+[88_-^S[QYFS.-VWKC/&:_/3XJ_ML^._&?['/C?Q1H8T_P_KVE>+C
MX2NKZTBE430&15\Z!7;="[*XR&+%><'."/1%\>7&B?MD'3=4\,>'+OQK;_#B
M74D\4VRW*.(U<D6YB:4J4)&2W#<XSB@#[.HKX;^"O[>?C;X@:_\  \Z[X7T&
MRT3XE/J=JJZ?-,US:RVK$!\M\NUL8VX)[[N<"72_VY/'?B:^\-3Z=X<T:RM=
M>\>W/@N/1[J">74+-(0";F4K*H)ZED"#:,'<U 'VU=74%C;27%S-';V\2EWE
ME8*J =22> *BL-4L]5MXY[*[@O()%WI+;R*ZLN2,@@X(X/Y5\_?MO^!O'WC;
MX;:%)\-GL;WQ+H>MV^MIX?U%U$.L)!N8P%6(#X)5]I(!V]0<5XY\'?VG9O%V
M@_%[7O#'PS_X0OXZZ!ID%QKW@S5872"]6 R'S8RH1M[!V'S#/$8^8'=0!]W4
M5\H:5^V%KWBO]G^?XH>%M%LO$D5EX4&KWNE6D,OG1Z@9"A@!#GY4\N5F&-V$
M&/O#'EGQL_;.\2^,OV--;\>> O$.B'S]5L](-]8V\L-U;QSA!*C0M(Q@F5V9
M<[F!7#*>00 ?H%17R1XP_:S\9>&?&NM> ]"\-P>*_%7A;P[;:UJ%OIVFWDYU
M*25UV6UNL98PGRCN,LA8;B!MK#^)O[:/Q"\/?$#XD^'M!\,Z#%#X3\'0>+PV
MN"X2X"NB.UM)&C#YQO*YRN".0>E 'VG17R1\'OVQ/%GCOXS?#;POKGAW1K'1
MO'GA$^);%K">62XLV7.8Y68!7!"D_*HQD#+8R?K>@ HHHH **** "BBB@ HH
MHH \3^+6CV?B+X:_$K2M0@6YL+[6+6VN(7&0\;K9*RGZ@FOC[]F.PUSP!>?%
MK]E758[F>PT747U>VO'4E&T5U,K(3TQ(PA7'?SY/0U]VOX,TKQY%XPTG64N9
M;%M:CE9+6]GM&+);VS+\\+HV P!QG''-;-Q\-?#ESJ6JZBVG;=3U2PCTN\OX
MIY([F:VC+E$,JL'X,C\@YYY/2@#\M_@WX^U/X9?\$Q8=<TJ#3;N9/'7D-:ZM
MI\-[;R*\Z#)CE4C<IP588((%?6UO\9OBA\8OC5\2_!WP^UO1_#=UX#N-(2.Q
MU>V#PZG%*"]T\S!&D4;<*GE[<$<DYX]'@_8F^#=M\,F^'D7A6Z3P:U^NIG21
MKNH[/M(.1)N^T;ASSC.,C.*W-2_9A^'NI_$>+QW_ &9?6?B86B6-Q>6&K7=M
M]N@0 +'<K'(!.!M'^LW9P <@4 >&>%?B?\:?BC^TG\7O >@>,-'T31/!FIZ9
M+%+>Z.EQ-+;2#?-;@@J!E=V'()& .,EJX32?VXO'ESX?T'XB2F%M#U;XFOX,
M/A?[+&!%8[=JR"3;YGGAOF)+%3G&T5]D^#_@?X,\!>/?$_C/0]*FLO$GB4HV
MK7;:A<RK<E.$_=/(T:[1P-JC XK$MOV7OAM:>*8M>C\/XGBU=]?BLS<RFRCU
M%UVM=K;[O+$A'?& ?F #<T ?,NF?MK^,/"'Q1^(?ASX@6]WH^NZ!;ZOJ^F:%
M)91_8=9T^&)WMC:W"IO# )E]S,&&[!4J4J[\)?VIOB!KGC'X(:/KFJ1W\7Q6
M\,7NIR-!90H='NH]SQF#"_-&%PI67><C.[J*^FK']GCP+9>(;;6GTJ74+NUB
MO(;5-1O)KJ&V2Z.;D1QR,542=" , 9  !.:O@C]F7X>?#S5;/4=%T::*ZT^P
MDTO36GOIYO[.M)'+O#;;G/E L3RN#C !P * /S%TF+5O#G_!//Q3XIT[66MM
M8F\;W&D/>I9P?:?LLURHGB$^SS%20[690P!VXZ$@_K%;V-WIWPSDM[[49-6N
MDTV3?>2Q)&TG[LD95 %&!@<#M7!K^QY\)HOA1JWPWB\,RQ^#]3O/[1N+!M4N
MY"+G<'\U)'E9T;<H/RD#VKTNU\&Z99^$E\-I]K.EBW-L=]],T[(>I:<OYA8Y
M.6W;CGK0!^:'[.'Q6\2?!'_@EIXF\:^$KR.RUW2_$,[0O- DT;![F&-@RL#D
M8<],'(%>QZ+^T+\4+KQE\;_!FI^*()Y=&\ 6_BG2]3M--B@DLKB2V61T1?F#
M+E^-^XC'6O?;']C3X0Z;\)]1^&=MX7N8_ VH7(N[G1_[;ORCRA@V[>9]X^95
M) 8 D#(K;T?]F;X<:%XIUGQ':Z!*=8UG24T+4)[C4[N=;BQ6-8UA9))63 50
M,XSWSDF@#XV^"'Q[\:>!_@M^S3X6M]8U#4[_ .(TUW)-J'DVK75M'$7=HH6F
MVQO))(P)>8L0-V.2,=UXU^.?Q]\*^)O@#X4U;^RO"_BKQC?:AIFKQ3V\-Y 5
MBQY-T!&YPQ1@[1K( 2,?+7M;_L4_"5_A_HO@[^PKX:3H=[_:&DRC6+O[7ITV
M<@V\_F^9$!_=5@O?&>:Z?5/V;OA_KFM^$-9U#2;R\U;PG*]QI%[)K%[YL,KD
M&21V$W[YVP-S2[B>AXH ^;?B!\5OC;X ^-7@/X7W/CW3;B^U+P?J6K:IK$.A
MPX>Y@$[(\,9X7Y4C!!W#()QSBL7P/^VMXZ\8_#/]G.VF79XE^(EW?6^HZGIM
MO;B7;:LZ@0).1"LDAV9W< ;L#)&/K3Q?^SYX$\=^/[/QMK6D7%UXGL]/FTNW
MOHM4NX/+MI599(PD<JI\P=LG;GG.<@5R]U^QG\([CX<Z!X(C\-3V>@^'KTZA
MH_V;5;M;K3K@MN+PW!E,J9)S@-CVX% 'S/\ $;Q1\9=6^-'[+V@>-]4E\&ZS
MJ.H:DU_8Z<+::&26!&$-T0I="S1ORA)523@ U^@: JBAFWL!@L1C/O7E_B?]
MF?X?^,)?"4^J:9>S7WA:XDN=,U!-5NDNT>08E,DXD\R7?@;M['/>O454*H &
M !@ 4 +1110 4444 %%%% !45U_QZS?[A_E4M177_'K-_N'^5 'AOQ)U#[?\
M$?"_@R*XU"UN/%6F0V$USI5I+<W%M9_9U^T3*D2,WW2(P<8#2J:\"_8,^+.M
MZ+\!_B7\*M7NI[/QK\+ENXK5[F I*UIM=[>3RY5S@,",,O"E!BOK#P'\/=$G
M3PGXQ>*\.OP:!!81S#4;@0K R(S+Y D\KDJI)V9^4<\5S'BK]F/P5:Z]XW^(
M'A_P]=-\1M=TBYL9;Q-7N@+O?#L6-HGF\G'"8RN!M![4 ?+OPM_:Y^++Z7^S
MAXL\1Z[8ZYI?Q+U.YT74='@TJ.W^S,LI2.>.1<L6'5@?E('W0>:R-:_:_P#C
M+H/PW^)OQ 'B;3[NR\">/_\ A'UT:32(1_:%EYJH5DE&"KX88*!><YSD >[_
M +('[)<'P^^%/PV_X6%H4S>./!HN_L<<NI&YM;6261B9H8UD,88H5&2 00<
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M/\0/&&O:)<06]H+V6:T2YBMX7#1QJ1;[#RJY=U9SC&['%;GQ3_9FT?XK>"O
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M6/@U/XJ^)MGH6K_$WQQJL5I8W4=JL,4[6B/M$<4:JJ[4#LY'S,Q'7  'M5%
M'B'P;_9TTCX>?"'5?#6B?VAX/;7=5N-:D>Q=!=6;RS^:B E67*(L:8(8<$<U
MSFN?L'^ =?\ AQXX\*3W>H6I\7ZO%KE_J-@L%N\=U$5,9BC6/RU4;22-IR68
MD\\?25% '@UY^R3IQ^*&D_$/2_''BC0_%\&EKH^I:C9O:DZO; Y G1X&0,.,
M-&J[0!@# (A\6?L8>$_&'C;QUXGNO$GBB"^\8^'U\-:A%#<6S1I:!5 \LO;L
M^_"?>9FSD_A[_10!X'X*_8U\*^!?'7P]\5V?B/Q+<W_@?0SX>TR&ZEM##):D
M,#YP6W5F;Y^JLO0>^??*** "BBB@ HHHH **** "BBB@#YQ_:=\5ZWX#_9[^
M-GB?PWJMQHNNZ/*;NSO+;:2CBVM1RK JPP3P0:Y/]E;Q]JWQL\-^!=0L_B;J
MFJ>(M+TW3]3\56;O;R6EQ]ICE!@*K%F.0%%?"L,< ]:] ^.WPSU[XR_!KXO^
M!_#;:=%JNNW/V..;5+B2&"+-M:DL2D<C'IT"_C6-\(OA#\4/ACX ^'_AFWT_
MP?9WFFVNGZ7KNOVVLW4LTUE;.6*P0FS0%FW. 7<8#GKQ0!T^C?M:>$]=^)6N
M> +72=>_X2_1[N&TN=+EMHDE/F!BLJ9E^>(*I8N. "">M<_XG_;N^'OA+4O&
MEG?:9XG8>#+V*R\07-OI8E@T_P QMJ2NX?!3./NY;G[O!QS/C[]G7XI:K^T_
MX9^,_AB7PII6I:?(^EZCITVI7 CU#1RJX#LMH3Y^XR'G*KB, G!)\%TWX:^*
M/C5\1OVT/ 7AJ+3$G\0:QIUI->ZC=/&EHN"S/M6-B^%5N,@YQ[D 'N6D_M!W
MVG_MJ>-=,U#Q?GX66/@.#Q-''*$-O#N9"TZN%WX*9.,D<\"O4O!G[6/@KQM>
MP65M#JMC?WN@GQ+IEK?P)&^I:>"09H,2$?PYV.48 @E0*\,U#]@WQ%JGQ \6
M"75]*A\&:M\.8/ UO<)<S-J"21(@6X>+R0FTLG*B3.*T?A]^R#XUM?&O@GQ'
MXAGT:VF\$> I/".GVUG>22)?W+(\9G=C$#'%M8<89LD\<<@'H/@K]N_X8^.M
M*CUBR7Q!:>'O[,N]5FUR^TB2.QMX[9]LL;S<KYG0A%R3D#@D"M*^_;+\!Z3X
M8\3ZSJ-MK.GGP[IMIK5[I\]JGVK[!<X\FY11(0RG."-V]3PR@UYY\._V./$F
MG_L(:K\"/$FJ:3:ZW=0744>I:3-+/;;GG,T;-OBC;&[ 88/ .#6?=_LL^//%
M/[*_B/P#=^%?AUX:\<7^APZ$=;TR60?;Q&Z'SII5M0Z*0F?+Q)ECG<O2@#WW
MX0?M!>'?C==ZC%X>T_78;:SM;6\6^U/3)+6VNH[A"Z&!V_UF ""1QZ$CFO3:
MY'X1>%]0\$?"SPCX=U46HU'2=*MK"<V4K20EXHU0E&9$)!VYY4=:ZZ@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *BNO^/6;_</\JEJ*Z_X]9O]P_RH
M ^*?CO\ M,S_  #\5_""T\8MKNC?"/4_#J"YUS04.Y-1VH(UF=07"(@+;$Y8
MMDA@I%>Q^%?CUX?\'^ ?#5_JGCA/B#_PENLR67AJ^L! )=1#EFBA./+B1T4;
M6+;!D8.&.*D3PGXJU_3=-AGT70/&/P[U'PO86MQX?UB<J_VE0Q:15:)XV4JR
M AL'Y00?EP?&-)_8P\>_#GX9>&O"?@J^T6#3)?&LWB'6])DOIH5M[%R-MG:7
M8B:1=J@*SA49LD< D$ N_M)?MM&3]DF[^(7PJ-_#>3ZPFA27-S:1B73)A,J3
M*ZLQ7?@X4C>N6!SWKJ[#]I#0_P!GGP[J^E^-_$WB'QIJVG6@\2WZ264"W>C:
M9<3*D,<H\T>;Y;-@E"[XY( Q7C\7["/Q.7]DSQ+\)(KCPI#J-YXT.OVM[)J%
MPMN;7S4< JMLS*WR8"\CGKQSV/[47[+/Q8^/.M>)[6WN_#:>&+WPG'IVG6TE
M]-"\&HK(KL\H2#_2%^5E0N0$W;@H;.0#V'QY^V)X!^'WB30-#O(M;U*^U_1F
MUW25TC36NC>VZH7Q&JG?O('W2H]20 2//K']I>UO/C-XBN[+Q!XD9AX-M-4L
M_ 6KZ3%:V\;321B&8SAC('9I51D(^7YCD@"DT']F3Q]!\<O@5XXO#X<BT[P/
MX2_L#4[9-0G>=YC$8R\(^SA64<'YF4GGTYU=4_9=\1>(_P!K'QI\0=3N-)3P
M;K_A6/P_&EM>2_VC#*CHZS;##Y8PRY'[PX(!YZ4 <--^T3XEMOC%?^ [FZU"
M]\60>);705FTK44+&.:U\][M-/,!0V\.0'WL7"D'S<XKZN^&OBRX\9>$X;Z^
MACM]2AGGL;V*'/EBX@E>&0IGG:60D9YP1FO )?V5=6;QQ<^*VBCF\9RZQ#K2
M>(X]8\F&.>.$P;A;BU+*CQ8#P;V5@!^\!^:OHGP-X2B\$>&+328[A[R2,R37
M%W* 'N)Y':264@< L[L<#IG':@#?HHHH **** "N8\61B77_  DA+*&OYAE3
M@C_0[CH>U=/7,>+"XU_PD8U5I!?S;59L G['<8!.#C\C0!\+? +]H'6O&GC;
MXK^$_&?Q7UNSU6'QH/#'A:"SDM4N%5Y)5#!#"?,"!0Q9@?NXSDU[1X4^-'_"
M"_%GXEV/BKQSX@\177@WPI97NJ^'_P"RH$MH-D2F6\MYE8&0R<ML(7&2,< !
MG[*W[+'B?X2>+OBKJ'C:/P]J%AXK\3+XDT\:7>SS26LB2.Z!Q)!&,@L.03T(
MQBJ'BO\ 97\?:U\:/CSXNM9_#8TSQ[X3'A_38IK^X6:&58EC$DP%L0JGD_*S
M$<=<\ ':Z!^W1\,]?\.7WB)5U^Q\.VNCQ:S_ &O?:1+%:SI)*(EAA?I)-YA"
M[%SSD9X..)_:E_;)F\*?L^?$;5/ UOJ&E^./#EQ:Z=>6U_;1-+I37!0QS.-[
M(P:-SM*EQNP"!@T[Q!^QWXE\6?L&:/\ !.\U/2;#Q9I-I;B"]MI9)K&2>"7S
M$W%HU?8V,'Y,C/?'-;XJ_LO^./BU^S#XA\&6WA/X=^!O&6N"P2[FTN:1()S;
MR*[2RS1VH9L[<+'L.W)^<YP #HO!'QVM?@[I0T;Q;XB\2>.?$-_ID_B_^S6L
M8/M>BZ2J*6$S>: ZJV[!W,[9X7 KK?$W[9/PZ\+3>!'N)[^?2O&\'GZ'K4,*
M"QN/EW%&E=U\MP,?*X!R<=<UYOX__94\9W'Q(O?''A]]'NM0UOX?2^"M1L+N
M]DCCMIB@5+B.3RB7C'.X%5;@$ YP,GX@_L/^)=<_9:\'?!K1M0T8'PS9B\M?
M$5U=2Q7 U5&+H500/LAW/)E@V_&T8ZT =_\ 'S]H+6_#GP\UGQ!H>FWNEVVB
M:#'XAU"UO&CMKV6.64QPVZMME6$L$D=FVEAM4#:22N=\&?CUJ?B'6;^XMUN[
MOPE::];^'GNIK[^T+>XEGC4I-:W)C5R8YF6&6-BX!;*L-I!VO%WP$\7?%#X6
M6NG^,;G37\37^C)HGB:#2+Z2.VU.%'WJ\4[VY:)PVYAF(C$CKZ,+7PP_9TE\
M*^(9[IE?1O#TNIQZY+HOV\7?VC4$C""8XAC6$9 D95W!W"M\F"& /?Z*** "
MBBB@ HHHH *Y^]_Y'[1O^P9??^C;2N@KG[W_ )'[1O\ L&7W_HVTH Z"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#"UU-;GU2QATJ>ULX##,\]Q<VYGPP:,(@42(>07.>?N^]5_[,\6?]#!I
M?_@H?_Y(K<NDDD8I%)Y,K1.%DV[MI^7!QWQZ5\;^(?VEOB7X<^ ?Q/U^[U31
M(O'/P^\2/IVHV;:6WD7%GYD?E-&GF[M[PR!U.X@D$8Q0!]6?V9XL_P"A@TO_
M ,%#_P#R11_9GBS_ *&#2_\ P4/_ /)%<DGCR^UWQCX371M=L_\ A&I-";7-
M5N)K93OA;8+=EDW 1[R9&.01B(].M0>&?CIX*T3P=X?N=>^)VB:W)J[7/V+5
M1Y=JM^(WD+>7&I((0*5W#@E?4XH [3^S/%G_ $,&E_\ @H?_ .2*/[,\6?\
M0P:7_P""A_\ Y(JC8?&/P7JW@ZT\4V/B*SO-#O)OLUM=6Y,AGGW%?)1 -[2;
ME8>6!NR#QQ7F_P !OCTWBO0?'^K^*=?L9[#2_%USHNG7,%J;<21*L7E1+%EG
M:4L[#;RY.1CL #U;^S/%G_0P:7_X*'_^2*/[,\6?]#!I?_@H?_Y(K&F^._@.
M#2K'46\0PM9WFI#1HGCAE=EOB=HMI%"EHI<\;'"GVJ:/XU^#9H?$<J:K(R>'
M;E++5 +&XW6LS8VQL/+R2=RGC/#*>A% &G_9GBS_ *&#2_\ P4/_ /)%']F>
M+/\ H8-+_P#!0_\ \D4VV^)?AN\\0Q:)#J8?4II9+>./R9 CRQJ7DC60KL+H
MH)9 <KCD"O,_VGOB3XO^$$'A'Q/I5]8V_@W^VK6P\2_:;(S2VMK,^P7,;[P%
MVNR!L@C#9[4 >G?V9XL_Z&#2_P#P4/\ _)%']F>+/^A@TO\ \%#_ /R16!XC
M\2:[-\6/#^BZ-JEG;:-!83:GKHGM?,80[@D 23> A=O,Y(/RQ-47@OXHZ$/!
MUOJ=SXWM?&$-W?W<-KJ&FV9_?;)')BCBAWE_*52K.,\(6.* .D_LSQ9_T,&E
M_P#@H?\ ^2*/[,\6?]#!I?\ X*'_ /DBN2LOVC/">I_$O3O!UB][=R7NB?V\
MFIQV4YL_LY=51O-V;=I!8ER0J[<$Y.*TK;X[>"M4LM3FTK68]4GLK)=0%K K
M+)<0.VV.2$. )(W?Y5D7*$D<T ;?]F>+/^A@TO\ \%#_ /R11_9GBS_H8-+_
M /!0_P#\D5X:/VC/% \:2Z->6]OIEPOB&/PRL9TX7%J+R2W%Q'&TJW8E*E&
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M *&#2_\ P4/_ /)%'A'_ )"WBW_L+#_TEMZZ6@#FO[,\6?\ 0P:7_P""A_\
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MLDK7T@B==+=0C?99\DCSSN&,C'')!SQ@^B5S7B?_ )&3P?\ ]A"7_P!([B@
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M?X4 >)Z+\._BWI'C30-?U/P]IGB'5Y_AY-X>OKE)+>&RAU 7!E3SX=P)C=<
MB)67=D?*IS6+\-?@O\0+[XAZ-J6O>$KWPY:3>"/["O+J?4K*1+"_CN(YD,-M
M;R&-( 4'EI$ ,+\X4]?H;_A,O'?_ $3K_P KD'^%'_"9>._^B=?^5R#_  H
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M$T'@3[0\NHAYD_MB%?)?[/"-F2/F^4*V1Q\V.U;?_"9>._\ HG7_ )7(/\*
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MK_RN0?X4?\)EX[_Z)U_Y7(/\* /0**\__P"$R\=_]$Z_\KD'^%'_  F7CO\
MZ)U_Y7(/\* /0*YKQ/\ \C)X/_["$O\ Z1W%8G_"9>._^B=?^5R#_"L37O%?
MC*76_#;S>!/(EBO)&@B_MB%O/;[-,"N0/EPI9LG^[CO0!ZW17G__  F7CO\
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MK"_9CUJ]^&G[(_ANXU;POXE;4-*CECN-$BT>==1+-=/C;;R*K-PX;(XQD]J
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MY*XR#CZQ\"?$JQ\?WOB.SMM-U?2KK0M0;3[F+5[%K9I" "LL6?OQ.#E7'44
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MJ2*K;4!C7)&-Q8#[IH ]YHHHH *Y^]_Y'[1O^P9??^C;2N@KG[W_ )'[1O\
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M?9X4S]WCYD8<^E;7_#0'@?\ Z"TG_@)+_P#$UZ+10!YU_P - >!_^@M)_P"
MDO\ \31_PT!X'_Z"TG_@)+_\37HM% 'G7_#0'@?_ *"TG_@)+_\ $T?\- >!
M_P#H+2?^ DO_ ,37HM% 'G7_  T!X'_Z"TG_ ("2_P#Q-'_#0'@?_H+2?^ D
MO_Q->BT4 >=?\- >!_\ H+2?^ DO_P 31_PT!X'_ .@M)_X"2_\ Q->BT4 >
M=?\ #0'@?_H+2?\ @)+_ /$T?\- >!_^@M)_X"2__$UZ+10!Y?J/QI^'>K?9
M_ME\URMO*L\:26LQ42+RK%=N"0>1GH0".0*M_P##0'@?_H+2?^ DO_Q->BT4
M >=?\- >!_\ H+2?^ DO_P 31_PT!X'_ .@M)_X"2_\ Q->BT4 >=?\ #0'@
M?_H+2?\ @)+_ /$T?\- >!_^@M)_X"2__$UZ+10!YU_PT!X'_P"@M)_X"2__
M !-'_#0'@?\ Z"TG_@)+_P#$UZ+10!YU_P - >!_^@M)_P" DO\ \31_PT!X
M'_Z"TG_@)+_\37HM% 'G7_#0'@?_ *"TG_@)+_\ $T?\- >!_P#H+2?^ DO_
M ,37HM% 'G7_  T!X'_Z"TG_ ("2_P#Q-,G^/O@B2&1!JSY92!FUE]/]VO2*
M* /(_!_QP\':3X2T2QNM3>.YMK&"&5!;2G:ZQJ&&0N#R#6O_ ,- >!_^@M)_
MX"2__$UZ+10!YU_PT!X'_P"@M)_X"2__ !-'_#0'@?\ Z"TG_@)+_P#$UZ+1
M0!YU_P - >!_^@M)_P" DO\ \31_PT!X'_Z"TG_@)+_\37HM% 'G7_#0'@?_
M *"TG_@)+_\ $T?\- >!_P#H+2?^ DO_ ,37HM% 'G7_  T!X'_Z"TG_ ("2
M_P#Q-'_#0'@?_H+2?^ DO_Q->BT4 >=?\- >!_\ H+2?^ DO_P 31_PT!X'_
M .@M)_X"2_\ Q->BT4 >=?\ #0'@?_H+2?\ @)+_ /$UBZ[\;?!][K/ARYAU
M-VBL[R268FVE!53;3(#]WGYG4?C7K]% 'G7_  T!X'_Z"TG_ ("2_P#Q-'_#
M0'@?_H+2?^ DO_Q->BT4 >=?\- >!_\ H+2?^ DO_P 31_PT!X'_ .@M)_X"
M2_\ Q->BT4 >=?\ #0'@?_H+2?\ @)+_ /$T?\- >!_^@M)_X"2__$UZ+10!
MYU_PT!X'_P"@M)_X"2__ !-5-.^-/P[TG[1]DOFA:YE,\SBUF+2R' +,Q7).
M !ST  ' %>H44 >=?\- >!_^@M)_X"2__$T?\- >!_\ H+2?^ DO_P 37HM%
M 'G7_#0'@?\ Z"TG_@)+_P#$T?\ #0'@?_H+2?\ @)+_ /$UZ+10!YU_PT!X
M'_Z"TG_@)+_\31_PT!X'_P"@M)_X"2__ !->BT4 >=?\- >!_P#H+2?^ DO_
M ,33_#WQ T/QUX^L?[&NVNOLNF7?F[HG3;NEMMOW@,_=->A44 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ctso-20221231xex10d30g007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ctso-20221231xex10d30g007.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1, U$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"?JG_@39_P#QZNEHH YK_A)]8_Z$_5/_  )L_P#X]1_PD^L?]"?JG_@39_\
MQZNEHH YK_A)]8_Z$_5/_ FS_P#CU'_"3ZQ_T)^J?^!-G_\ 'JZ6B@#FO^$G
MUC_H3]4_\";/_P"/4?\ "3ZQ_P!"?JG_ ($V?_QZNEHH YK_ (2?6/\ H3]4
M_P# FS_^/4?\)/K'_0GZI_X$V?\ \>KI:* .1L_'-_?RW<4'A/5'>TF\B8>?
M:#8^Q7QS-S\KJ<CCFK/_  D^L?\ 0GZI_P"!-G_\>H\(_P#(6\6_]A8?^DMO
M72T <U_PD^L?]"?JG_@39_\ QZC_ (2?6/\ H3]4_P# FS_^/5TM% '-?\)/
MK'_0GZI_X$V?_P >H_X2?6/^A/U3_P ";/\ ^/5TM% '-?\ "3ZQ_P!"?JG_
M ($V?_QZC_A)]8_Z$_5/_ FS_P#CU=+10!S7_"3ZQ_T)^J?^!-G_ /'J/^$G
MUC_H3]4_\";/_P"/5TM% '-?\)/K'_0GZI_X$V?_ ,>H_P"$GUC_ *$_5/\
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M $)^J?\ @39__'J/^$GUC_H3]4_\";/_ ./5TM% '-?\)/K'_0GZI_X$V?\
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MKFO^%E^$_P#H9-+_ / M/\:/^%E^$_\ H9-+_P# M/\ &@#I:*YK_A9?A/\
MZ&32_P#P+3_&C_A9?A/_ *&32_\ P+3_ !H Z6BN:_X67X3_ .ADTO\ \"T_
MQH_X67X3_P"ADTO_ ,"T_P : .EHKFO^%E^$_P#H9-+_ / M/\:/^%E^$_\
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MMSI_C+2=>CN?'UMJLDD'@N=YK+B4)/<2+?$/#$FV/&V,8"\KW^IO^%E^$_\
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MWJ,,TGVJ2%V.Z;>ZR29Y."<]*J^%3_QFO\0/^Q-TC_TINZ />:*** "BBB@
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MWPM_T+6C_P#@!%_\36!XF7X8>#)8(M=@\+:1-.I:&&\AMXY)%'WF52,D#/)
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MH5B?\*]\+?\ 0M:/_P" $7_Q-'_"O?"W_0M:/_X 1?\ Q- &W]J@_P">T?\
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M"UH__@!%_P#$T ;?VJ#_ )[1_P#?0H^U0?\ /:/_ +Z%8G_"O?"W_0M:/_X
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MW_0M:/\ ^ $7_P 30!M_:H/^>T?_ 'T*/M4'_/:/_OH5B?\ "O?"W_0M:/\
M^ $7_P 31_PKWPM_T+6C_P#@!%_\30!M_:H/^>T?_?0K"NI4E\?:/L=7QIE]
MG:<_\M;2G?\ "O?"W_0M:/\ ^ $7_P 35:TTC2O#WC&PMM,T?3K#[3874DDM
MM:I'(=DEN N5 X_>$D>H% '4T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 1-_Q]1_[C?S6OA;X;^+(_V6OB->
MZK<QNWA#XE+J5S# G0:_:W,RB)?1KF+8 .[QU]S7$2SR")BP5XG4E'*M@[>A
M!!!]QS7'6'P3\&:?HVDZ4-(:\LM)U/\ MBQ34;R>\:WN]S-YJO,[,#ND<XSC
MYCQ0!\J?"XZI\'?B3^TMJ+ZII-EXFBTK1-0N]2UHR?8Q?302N[.(P790[[55
M020$45U<O[3_ (K\(7?CO2-6)D;3]7\/Z;INI:U9QP20+J6%:6XCB8+M0@LH
M(1N0KX.:]IU7]FCX=:[J7C"^U'0[F^N/%T,5OK?VC5KQTNTC_P!4-AFVH4_A
M*!2O8BH!^RS\+VM]?@N/"XU&/7[.*PU3^TK^ZNVO(HO]67:65B9%[2YW\#YN
M!@ Z7P)!XHTW5_$.G^(M>T_7K6.6*;2Y(HA%>I;LG(N54!,^8K[60#*CGD&O
M%_V6KBYU;XZ?M$WFODOXFMO$L5A")OOPZ6L"M:*F>D;;G;C@L2>M>W_#GX6>
M&/A-HKZ5X7TUK"TD<22--<S74TK   O-,[R/@  ;F. ,# IGB#X4^&?$OB :
M]<V=Q:ZWY'V5]2TN_N+"XEA!R(Y)+>1&D4$D@,2 22,9H ^2+?P'<_$#XB?M
M&^"M*\1MX4T%?$NBWVAWPB$MM;:[L2>5!&?E<-(D1=.Y;U->K_!+XB^)+GXT
MW_A'XI^#K'0OB=#H8F@U_0IC+INMZ>D^"Z;OGB99'_U;Y(WD@X->JW?P2\$W
MO@M?";Z%&FA+=+?>1!/+%(URK^8)VE5Q(TN\;BY8L3R235WPM\+?#G@[6;K6
M-/MKN;5[F!;:34=3U&YU"Y\E26$2RW$CLJ9).U2 3SC- 'G?[7/@BR\;_#>U
MAMY9;7QU:W\5SX0N[-0;F+5%^:/9DCY" WF9.!'O)Z5'^R+XR@\>> -2U34H
MY(/B$FH26GB^VN0!-;ZC'\IBQVA5=OE <;"#R2Q/I=Q\-- N_']IXTFBOI?$
M%I;O:V\K:G=&"*-\;PMMYGD@MM7+;,G YK,\/_!#P=X5^(^N^.]+L+RU\3ZX
M$&I70U6[:*ZV+M3= TIB^4<#Y..V* ."_:_16\+_  ]) )7Q[H6"1T_TH52+
M37O[==[!J7S6%M\/0VGI)]S,E\1<$>^%B!]L5ZW\0/A=X<^*-KIEMXDM;F\A
MTV]BU&U2WU"XM=EQ&VZ.0^3(FXJ>1NR*3Q?\+] \;75C=ZC#<QW]E#+;0WUE
M>2VUP(90!+$9(V#%&VKD$]0",$ T >0_L71ZCKG[)NC6DMQ+;F3^TK2PN#G=
M';BZG2W8>RIMQ[ 5Y#I.D>-O#FK?LS?"W5?#IL/%?A?5Y;B?5[6\AF@N=-M[
M>6.:X0(QD5)1)&K"54^=@!NZCZ\M?A9X7L-1\-WUGI2V5QX<LY+#2A;2R1QV
ML$BJK((PVQN$7EE)&.,9-6?#OP_T7PSJ]_K%M;R3ZU?JL=UJ=Y,T]S(BY*Q[
MV)VH"20BX4$D@9)H Z.BBB@ HHHH **** "BBB@ HHHH **** .:\(_\A;Q;
M_P!A8?\ I+;UTM<UX1_Y"WBW_L+#_P!);>NEH **** "BBB@ HHHH **** "
MBBOEO]HS3?'7ACXS^'_&/PTFNKS4],T:[U'5?"QN9#;Z]:QS6Z/$L9;8DX61
MF1PN2R@'(- 'U)17@/PW^(OA/XE?$3_A8&B:A++H=QX3CO6$D[JMO(MQ*LHD
MA+;4E0(4;(R-N*UW\37_ ()^",VO,RQ>)_$MP9K2.Y; 2[O),6Z-GH(D:/=Z
M+$QH ]GHKP/]COX@:MXB\":QX0\4ZI_:_C+P-JDNAZE?,^YKR,'?;76<G(DB
M93GU#5[Y0 4444 %%%% !1110 4444 %177_ !ZS?[A_E4M177_'K-_N'^5
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M=#L7>21BS.Q@0DDGDDGO784 %%%% !7->)_^1D\'_P#80E_]([BNEKFO$_\
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M_:H\1_#FPDF/AJX\*VFOV]I+*THM;@7#V\NPL20) $8C."RLW5B2 >^4444
M%<_>_P#(_:-_V#+[_P!&VE=!7/WO_(_:-_V#+[_T;:4 =!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!5O+F*
MR+7$SB.&*&21W/15&"3^5?,'BWQUXY^)_P"R_/X_\'>(+GPSXCU^^@/AX1!&
MBM[:2\6"!9$92KF1#O8D9!? P%%?3&M::FLV5UI\C%8[NUF@9AU 8!3_ #KY
MW^%/@;Q/#^S7X7^'EG;Z=_PDO@_4;2RU"'4[J2W3R[2\259%*12$B6)%93@
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M 3_"WX0>#?"$LHFFT32;:QED7HSI& Q'MD&NVH **** "BBB@ HHHH ****
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MHH Y[X>^&;GP7X$\/^'[N^BU*?2K&&R:[AMS LPC0(&$9=RN0!QN/-=#110
M4444 %<UXG_Y&3P?_P!A"7_TCN*Z6N:\3_\ (R>#_P#L(2_^D=Q0!TM%%% !
M7(>+=.\<WFM6C>&];T'3]&,#QW4&IZ5-<S^83\LD;I<1K@#@HRG/7=VKKZ*
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M\*7PT[5[>XMGA-O.=WR@L,-]T\J2* *7_"\M+_Y\_P#RJ6'_ ,D4?\+RTO\
MY\__ "J6'_R17I5% 'FO_"\M+_Y\_P#RJ6'_ ,D4?\+RTO\ Y\__ "J6'_R1
M7I5% 'FO_"\M+_Y\_P#RJ6'_ ,D4Q_C9HTDD;OIZL\9)1CJ5@2N1@X/G\<5Z
M;10!YK_PO+2_^?/_ ,JEA_\ )%'_  O+2_\ GS_\JEA_\D5Z510!YK_PO+2_
M^?/_ ,JEA_\ )%'_  O+2_\ GS_\JEA_\D5Z510!YK_PO+2_^?/_ ,JEA_\
M)%'_  O+2_\ GS_\JEA_\D5Z510!YK_PO+2_^?/_ ,JEA_\ )%'_  O+2_\
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MU_7+!=4TFSU73KBT_M"V*[A)"\B!'X!.T-NX/'% &A_PO+2_^?/_ ,JEA_\
M)%'_  O+2_\ GS_\JEA_\D5Z510!YK_PO+2_^?/_ ,JEA_\ )%'_  O+2_\
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M$%Q':M<P6SS[))#M0%4!;!/&<4 9_P#PO+2_^?/_ ,JEA_\ )%'_  O+2_\
MGS_\JEA_\D5Z-%,D\*2H<QNH8$\<$9JOI&KV6OZ;!J&FW<5]8SKNBN('#I(,
MXR".".* .!_X7EI?_/G_ .52P_\ DBFR_&_2Y8G3[)C<I&?[3L/_ )(KTRB@
M#R;P]\7=+T'0-,TSR//^Q6L5MYO]I6"[]B!=V/M!QG&<9-7_ /A>6E_\^?\
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M7_A>6E_\^?\ Y5+#_P"2*/\ A>6E_P#/G_Y5+#_Y(KTJB@#S7_A>6E_\^?\
MY5+#_P"2*/\ A>6E_P#/G_Y5+#_Y(KTJB@#S7_A>6E_\^?\ Y5+#_P"2*/\
MA>6E_P#/G_Y5+#_Y(KTJB@#S7_A>6E_\^?\ Y5+#_P"2*/\ A>6E_P#/G_Y5
M+#_Y(KTJB@#S7_A>6E_\^?\ Y5+#_P"2*/\ A>6E_P#/G_Y5+#_Y(KTJB@#S
M7_A>6E_\^?\ Y5+#_P"2*/\ A>6E_P#/G_Y5+#_Y(KTJB@#S7_A>6E_\^?\
MY5+#_P"2*N>%_%D?C?QC;W=I;>5;V-A<12O]KMYOFED@*#$4CD<1/UQTKOJP
MKR>1?'&DPB1Q"^G7KM&&.UF$MJ 2/4!FQ]3ZT ;M%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $3?\?4?^XW\U
MK\U?V6;?7)]+_;,;2]2TZSM5US4_M$5Y827#R#RKG[CK/&$XSU5OZ5^DUT(F
MD5)]AB>-U99,;6!QD'/6N-TOX-?#/1(-6AT[P-X3L(=7!&HQVND6T:WH.21,
M%0>9G)^]GK0!\%?LX>/[SP%_P3]^#;V'B9]"FU'Q8;)K"UA9[O64:\EW64#J
MZ>2S\?O-ZA0#EAGG)OOVA?B7'^Q%\5]<3Q?JMMXB\,_$!M(TW41?-+<06OGQ
M#R6FZS* [#<^21CT%?H%+\!_A3+X=MO#Y\ >$DT*VNEOH=,CTFV2VCG&<2B,
M(%#<GG'<^M#? GX5/I^JV$G@+PG/8ZK=B_O[6;2;:2*YN!TED1E(9ADX)'&3
MZT ?+GQOU3QU\%M3^$FC2?$GQ)J^E_$?QG:+K&I7DRPO8P>7'FSMY(U4PQR,
M6/RX;"X!ZD^??"KPSXEU>U_;5M? ?B75-.\4V'B3[5I>I6=T3/)+"LK"-F'W
M]P4H<YY.3R,U]_>*?A_X,\;^&$\-^(- T;6= CV>7IE[;1R6\>S[A5",+M[8
MQCM47@WX:>!?AW-?S>%O#.@^'9K\@W<NEV4-N]QCIO* %@.P/3M0!^?_ (%^
M/?Q3\4^/?A9K+76OIX3^*?AZ30[*R-W-BPU:&-$FO1\V0-RR..>BDU=_;&^/
M/C'X=:U\1X_"GC[4;RY\*SZ"+9+*62"/1@[;9(+DL^V\DGR6(9'VJ#EE("G]
M [3PKX9L(-&AMM,TV"+1B6TU(XD LR49"8A_!E68<=B:YOQ#\#/A=XMU+6=1
MUKP1X9U74-9CCBU&ZN].@DENU0@H)&*Y;!5<9_NCT% 'S#XSO_'7Q-_;:U+X
M:Z;\2?$/@SP[?> HM5<:/,N^&Y,JKYD6\,$)XSMP2,@$$DUG>'/'_P 5OB5\
M:?BKX?T?QG9Z'J7P^U[38+9==U22WADTM%Q,TMLD3),;CDF5R"I9-NVOL2P^
M&O@32O$D/B&R\+>';3Q!!;K9Q:M!I\"7<<"@*L2RA=X0  !<XP*@U+X4_#_6
M/&]MXQOO"N@7GBNV4+#K4]E$]V@'W<2$;N.QSQVQ0!S'PJBM4^+7Q/:'XK2^
M-9FN[?S?"KS1.OAP[#^Z55)*[^O('W><G)KURN=T3P=X5\-:[K6M:3H^E:;J
M^M2++J5]:P1QS7CJ,*TK@9<@9Z^IK=^U0?\ /:/_ +Z% $M%1?:H/^>T?_?0
MH^U0?\]H_P#OH4 2T5%]J@_Y[1_]]"C[5!_SVC_[Z% $M%1?:H/^>T?_ 'T*
M/M4'_/:/_OH4 2T5%]J@_P">T?\ WT*/M4'_ #VC_P"^A0!+147VJ#_GM'_W
MT*/M4'_/:/\ [Z% $M%1?:H/^>T?_?0H^U0?\]H_^^A0!+147VJ#_GM'_P!]
M"C[5!_SVC_[Z% $M%1?:H/\ GM'_ -]"C[5!_P ]H_\ OH4 2T5%]J@_Y[1_
M]]"C[5!_SVC_ .^A0!\B?M]_\F??'C_K]MOY65>":9)<>#OVCOV2-4\6^7XU
MCU;PO;6&@V&F(;.31&,**UQ(FYS<##YW%D VL0.*^^Y?!/ASQO'XJTWQ9H.E
MZ_I-QJJS)9ZU9QW,$H%M;@.$D4J<,I&<=0?2KOAGX5_#WP7?K?>'O"'AG0KU
M81;BYTS3+>WD$0X$>Y%!V^W2@#XT_9RUCXD_$#1_BIXSN?B/XGOCX \6:RFF
M>'$E5X-1BB@/EVTY*EW7=LVC=Q@\$G(Q?@G\<?B#J^L?LT37/B35M;F^)]KK
M2^)K>2Y=DC$;MY<T*9Q;&+H/+"C YR>:^\O"7@7P;X!^W?\ ",>'M#\.?;Y3
M/=_V390VOVB0]7D\M1O;W.357P[\,_ OA'6I=7T3PWHFE:I*'5KNSM8XY ';
M>X! ^4,WS,!C<>3DT ?FYK_Q@^-_@/PKXNCN=?\ $6HWWPA\9K)X@OI+N3_B
M<Z//+'Y$1 .,[-S$@#"D>IKW;]H[Q?\ %7P+X \">-/#0U37]+#7VO\ B7PO
M#JTUMJ?V&4*8S$RMOVVRR*"@W*&VEE89Q]?7OA;PUJ,&LPW6F:=<1:R -222
M)&%YA @\W^_A5"\]@*K^*O OA#QPMN/$&BZ5K/V='BA-Y"DAC1P ZJ3T#!0"
M!P0,'(H ^&;'XV?$#XW_ !1?P3X-\7S:%L^'NG:UX:U#7+^33WGN'$;RWEPD
M<<@N2!\K1M\F YYZUT"3?$7XL_MA^-OAO_PM36_"^D1>#=-U9G\-W :-+MC#
MYCVYD4[8W)8_+M)!'(!(/UGXE^#WPX\8WNC7FN^#_#FKW6C*(].EO+"&1K1!
MT2/*_*HX^4<>U:=IX"\&6'BZX\56WAW0K?Q1<1^3-K<5C"M[*F -K3A=Y7
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MM+\0:M8SZG9PWXMH)DCAN8EDC&]HB6PP/S#8 #Z$^M1?\*]\+?\ 0M:/_P"
M$7_Q-:]TTBL3"H>81.45C@%N, FOGS]C_P <?'GQF/&W_"[?"=GX9%KJ CT<
MVR!#+'\V\ !VW(N$VOWW'KC@ ]0U.U^&NC>)-+\/WUIX9M==U3?]ATR6" 7%
MR%4LQ2/&X@!22<8%;A^'WA4 D^&M' '_ $X1?_$UY-\<U'_#0?[/;8&[^U]5
M&>__ "#I:@_;SUS6_#O[*/CR\T%YX;D6\45S/;9$D5H\R+<,I'(Q$S\]ADT
M='=>-_@K90R7$\WA>*PCE\@ZBUG']C\W.WRQ<;/*+[OEVALYXQFM<7/PM/C4
M^#Q:^'3XH$/VG^R/L47VCRNGF;-N=F>-W3/>N1^-OC;1?A!^RQ/K6E^%=/\
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M&U\27>E:G9:A-;+;QV<4\EOE,+YPN0RHV&;:VXC:,@T >]?\*]\+?]"UH_\
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MT:^;O610DBR,<C<0%(Q0!] ?\*]\+?\ 0M:/_P" $7_Q-'_"O?"W_0M:/_X
M1?\ Q-?-7A[XV?$/5/#_ (FLK;^W9_B%I5KI\NH>#=5T^SMM0MU,Q%W/82!%
M@N8W0,(B6<;DPW)Q5_PU^T3>>)[WX?\ AC2O$U[<W/BG7M3LKG4]2TN.TU+2
MH[2#SFLY;=HA&MR"57)0J5RP!R#0!]#?\*]\+?\ 0M:/_P" $7_Q-'_"O?"W
M_0M:/_X 1?\ Q-?+6N?'3XEVUU<>%8=>M[;5M(^)%CX2EUQM-BD%_8W4(F1V
MCX5945@K;, D X&<5]8^&=-U#2-!L[/5=7DU[4(4VS:C+!'"T[9/S%(P%7Z
M <4 4_\ A7OA;_H6M'_\ (O_ (FC_A7OA;_H6M'_ / "+_XFN@HH Y__ (5[
MX6_Z%K1__ "+_P")H_X5[X6_Z%K1_P#P B_^)KH** .?_P"%>^%O^A:T?_P
MB_\ B:/^%>^%O^A:T?\ \ (O_B:Z"B@#S_POX'\.7&I^*$E\/Z7*L.IB.-7L
MHR$7[- VU?EX&6)P.Y/K70?\*]\+?]"UH_\ X 1?_$UXG^T1XI^*_@_X8^.M
M1^#>@P>(?&*Z_"@MIHQ*R0&VM_,=(RRAV'RC&>A)P<5['\+-1\3ZO\-_#5[X
MTT^#2?%EQ80R:I8VS9CAN"H+JO)X!]SCU- &9X=M_AIXNGU6'0[7PQJ\FE3_
M &6^%E!!*+:;:&\MRH(# $$CJ.]87@7QE\%/B;KNIZ+X3O?!WB'5=-YN[/3T
MMY9(QG!; '*YXW#(SQFN8^ ]A;W_ ,5/VBK.>)9+:X\2V\4L?0,K:9;!AQZ@
MFM&3P)I7BSX^:!XMTZV@L-'\$Z3>:0;VW41K<RS;%-LA'6.%8V)[!W '*M@
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M=JEE\;-6\,WMGI9^&<YABTN\M1(FI&.U2YE,[$AD5PQ1#&5QMW'=G  /=O\
MA7OA;_H6M'_\ (O_ (FC_A7OA;_H6M'_ / "+_XFOEOQ/^T%\3M87XE:EH&J
MZ3H6G>'O!FF>+K*SN](::8F>&>5[:5C*!SY04N /90<D_5OA#6G\2^$]$U>2
M-89+^Q@NVC7HI>-6('TS0!6_X5[X6_Z%K1__   B_P#B:/\ A7OA;_H6M'_\
M (O_ (FN@HH Y_\ X5[X6_Z%K1__   B_P#B:/\ A7OA;_H6M'_\ (O_ (FN
M@HH Y_\ X5[X6_Z%K1__   B_P#B:/\ A7OA;_H6M'_\ (O_ (FN@HH Y_\
MX5[X6_Z%K1__   B_P#B:/\ A7OA;_H6M'_\ (O_ (FN@HH Y_\ X5[X6_Z%
MK1__   B_P#B:/\ A7OA;_H6M'_\ (O_ (FN@HH Y_\ X5[X6_Z%K1__   B
M_P#B:/\ A7OA;_H6M'_\ (O_ (FN@HH Y_\ X5[X6_Z%K1__   B_P#B:/\
MA7OA;_H6M'_\ (O_ (FN@HH Y_\ X5[X6_Z%K1__   B_P#B:/\ A7OA;_H6
MM'_\ (O_ (FN@HH Y_\ X5[X6_Z%K1__   B_P#B:/\ A7OA;_H6M'_\ (O_
M (FN@HH Y_\ X5[X6_Z%K1__   B_P#B:/\ A7OA;_H6M'_\ (O_ (FN@HH
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MF"\&I77E_9@VX1>1YGE;=W/W.O-7_P#A7NC_ -_5/_!Q>?\ QVC_ (5[H_\
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MEZLEY8;OLJW_ (DU.^@B+*5)$-Q</'G#,,[<C/&*[C_A7NC_ -_5/_!Q>?\
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M_P '%Y_\=H Z6BN:_P"%>Z/_ ']4_P#!Q>?_ !VC_A7NC_W]4_\ !Q>?_':
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M'M9T77(!XITW7-1U^ZFN[1C9WT]\I2X4Q+)NC 4J$8,Q4+SNR: -G]EC5_\
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M4(, <9- 'IM%%% '->$?^0MXM_["P_\ 26WKI:\9^(OQW\'_ +.GACQGXO\
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MY^]_Y'[1O^P9??\ HVTH Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M *!^N?\ @ENO_C='_"?6/_0/US_P2W7_ ,;KI:* .:_X3ZQ_Z!^N?^"6Z_\
MC='_  GUC_T#]<_\$MU_\;KI:* .:_X3ZQ_Z!^N?^"6Z_P#C='_"?6/_ $#]
M<_\ !+=?_&ZZ6B@#FO\ A/K'_H'ZY_X);K_XW1_PGUC_ - _7/\ P2W7_P ;
MKI:* .:_X3ZQ_P"@?KG_ ();K_XW1_PGUC_T#]<_\$MU_P#&ZZ6B@#FO^$^L
M?^@?KG_@ENO_ (W1_P )]8_] _7/_!+=?_&ZZ6B@#FO^$^L?^@?KG_@ENO\
MXW1_PGUC_P! _7/_  2W7_QNNEHH YK_ (3ZQ_Z!^N?^"6Z_^-T?\)]8_P#0
M/US_ ,$MU_\ &ZZ6B@#FO^$^L?\ H'ZY_P""6Z_^-T?\)]8_] _7/_!+=?\
MQNNEHH YK_A/K'_H'ZY_X);K_P"-T?\ "?6/_0/US_P2W7_QNNEHH YK_A/K
M'_H'ZY_X);K_ .-T?\)]8_\ 0/US_P $MU_\;KI:* .:_P"$^L?^@?KG_@EN
MO_C='_"?6/\ T#]<_P#!+=?_ !NNEHH YK_A/K'_ *!^N?\ @ENO_C='_"?6
M/_0/US_P2W7_ ,;KI:* .:_X3ZQ_Z!^N?^"6Z_\ C='_  GUC_T#]<_\$MU_
M\;KI:* .:_X3ZQ_Z!^N?^"6Z_P#C='_"?6/_ $#]<_\ !+=?_&ZZ6B@#FO\
MA/K'_H'ZY_X);K_XW1_PGUC_ - _7/\ P2W7_P ;KI:* .:_X3ZQ_P"@?KG_
M ();K_XW1_PGUC_T#]<_\$MU_P#&ZZ6B@#FO^$^L?^@?KG_@ENO_ (W1_P )
M]8_] _7/_!+=?_&ZZ6B@#FO^$^L?^@?KG_@ENO\ XW56RUA->\<:?-;V>H0P
MV^G7:/)>6,UNNYI;8J 9%&20C=/2NOK"O)Y%\<:3")'$+Z=>NT88[682VH!(
M]0&;'U/K0!NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 5KJ-IF,:2&)FB=1(O52<<CZ5\^?L?_LV>-OV>1XV
M_P"$P^)5Y\0/[<U 75HMR92+91NRY\QFP[[AN"\?(.M>[:WXCTKP]/;-JFHV
MNGK*KB,W,RQ[\%<XR><9'YU0_P"%E^$_^ADTO_P+3_&@#YX_:*\-?#GQ5KVN
MZUX.UVTTS]H'0C!'8OI%^4U*2<!6BMIH W[Z%U.&#*5"ECD8)K&UV<_#?QA^
MT\GB%DBOO%.BVE]H\9/.H9L7M3# .KL)P%VKD_O%X^89^FE\?^"UNFN1KNCB
MY90C3"XCWE?0G.<>U.E^(7@V:2-Y-?TB1XCN1FN8R4.,9!SQ0!\@_![0+G]G
M6]\=67C>5;.YU#X=:)]C:=A_I$EI9R6\]M'G[\BR,GR#)/F+QS7N_P $_#EW
M\+/V/O#&C^)Y$TZ]TOPNJ7OVEP@@;R22C$\#;G;^%>CR_$+P;<-&TNOZ1(8V
MWH7N8SM;U'/!J3_A9?A/_H9-+_\  M/\: /CCP3HVL^%?%.D:'X05KOP3\8O
M#ME<7.I6+AH=*O+>")+^7<#A3+;=#U\P#WKBM=\0^&[/]E']KBPL=5TZ&!?%
MM_#;0Q7"8V'[.L809Y!VD#'H?2OOS_A9?A/_ *&32_\ P+3_ !H_X67X3_Z&
M32__  +3_&@#Y&\3WUI<?'+]GS5?#7C4_%?45NOLEQH<LMM=1:1:208FU%/L
MB1B)T V[YMV0V%P:]&_X*$ZK9:=^SZB7>HPZ:\WB'1Q'))(BM\M]"S,H;(.T
M MT(&.>*]S_X67X3_P"ADTO_ ,"T_P :/^%E^$_^ADTO_P "T_QH ^<_A1K>
MG_"S]H[Q?:?$S5[:^\4>(;5;GPSXYU":.&/4](4[OL2A=L,<D+'++&J^8&#D
M&N0^,'AW6?C5\+_&/Q:\-WF@RO8ZA%KGAO5&O6\VWBTQG\I!A2@$I^T,06'%
MP,]*^N_^%E^$_P#H9-+_ / M/\:/^%E^$_\ H9-+_P# M/\ &@#YX\<>,O '
M[5O@KX66TVL:>=,\:VM[']G-RGFPR/I\@*@9R)(Y"/<,HKPOXLZUXD\4?L@>
M+[WXDQ?V7JG@BU3PE ]XX0:C?1WL*SWD>3\P:&.$*>OS3=J^^_\ A9?A/_H9
M-+_\"T_QH_X67X3_ .ADTO\ \"T_QH UM!O;?4=$L+FUGCN;:6!&CFA<.CC:
M.01P15^N:_X67X3_ .ADTO\ \"T_QH_X67X3_P"ADTO_ ,"T_P : .EHKFO^
M%E^$_P#H9-+_ / M/\:/^%E^$_\ H9-+_P# M/\ &@#I:*YK_A9?A/\ Z&32
M_P#P+3_&C_A9?A/_ *&32_\ P+3_ !H Z6BN:_X67X3_ .ADTO\ \"T_QH_X
M67X3_P"ADTO_ ,"T_P : .EHKFO^%E^$_P#H9-+_ / M/\:/^%E^$_\ H9-+
M_P# M/\ &@#I:*YK_A9?A/\ Z&32_P#P+3_&C_A9?A/_ *&32_\ P+3_ !H
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M_P# M/\ &@#I:*YK_A9?A/\ Z&32_P#P+3_&C_A9?A/_ *&32_\ P+3_ !H
MZ6BN:_X67X3_ .ADTO\ \"T_QH_X67X3_P"ADTO_ ,"T_P : .EHKFO^%E^$
M_P#H9-+_ / M/\:/^%E^$_\ H9-+_P# M/\ &@#I:*YK_A9?A/\ Z&32_P#P
M+3_&C_A9?A/_ *&32_\ P+3_ !H Z6BN:_X67X3_ .ADTO\ \"T_QH_X67X3
M_P"ADTO_ ,"T_P : .EHKFO^%E^$_P#H9-+_ / M/\:/^%E^$_\ H9-+_P#
MM/\ &@#I:*YK_A9?A/\ Z&32_P#P+3_&C_A9?A/_ *&32_\ P+3_ !H Z6BN
M:_X67X3_ .ADTO\ \"T_QH_X67X3_P"ADTO_ ,"T_P : .EHKFO^%E^$_P#H
M9-+_ / M/\:/^%E^$_\ H9-+_P# M/\ &@#I:*YK_A9?A/\ Z&32_P#P+3_&
MC_A9?A/_ *&32_\ P+3_ !H Z6BN:_X67X3_ .ADTO\ \"T_QH_X67X3_P"A
MDTO_ ,"T_P : .EHKFO^%E^$_P#H9-+_ / M/\:/^%E^$_\ H9-+_P# M/\
M&@#I:*YK_A9?A/\ Z&32_P#P+3_&C_A9?A/_ *&32_\ P+3_ !H Z6BN:_X6
M7X3_ .ADTO\ \"T_QH_X67X3_P"ADTO_ ,"T_P : .EHKFO^%E^$_P#H9-+_
M / M/\:/^%E^$_\ H9-+_P# M/\ &@#I:*YK_A9?A/\ Z&32_P#P+3_&C_A9
M?A/_ *&32_\ P+3_ !H Z6N?O?\ D?M&_P"P9??^C;2HO^%E^$_^ADTO_P "
MT_QJE9^)=)\1>/M,_LO4K74/)TR]\S[-*K[,RVN,X/&<'\J .RHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH I
MRV4,FKVUVR9N(H)8D?)X5VC+#'3DHOY?6KE5KII%8F%0\PB<HK' +<8!-?/G
M['_CCX\^,QXV_P"%V^$[/PR+74!'HYMD"&6/YMX #MN1<)M?ON/7' ![AJ?C
MCP]HWB32_#]]K=A:Z[JF_P"PZ9+<*+BY"J68I'G<0 I).,"L'QA\=?AY\/\
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M/''B#X,VVCPZ:=4T#X?VFCO#)KVA:=#?C2KE=JPO>0.CN+0(#EXER"#D@8H
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M8Z7:*^+>6PNY73 Y9)+8*<]> [?G]*V:Y^]_Y'[1O^P9??\ HVTH Z"BBB@
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M9Z_X5O9_V)X:\=>)-+\&H[-!X=!M9([1&))A@G>$S)%R<+O)7/RLO&,'QO\
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M$9@. OS$E2<$<_I/[*6A:/HOA;3(O%'B62W\.^(YO$]HTCV99[J5Y7=9"+8
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M5H?_ (,YO_D>@#I:*YK[7XP_Z!6A_P#@SF_^1Z/M?C#_ *!6A_\ @SF_^1Z
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M5H?_ (,YO_D>@#I:*YK[7XP_Z!6A_P#@SF_^1Z/M?C#_ *!6A_\ @SF_^1Z
M.EHKFOM?C#_H%:'_ .#.;_Y'H^U^,/\ H%:'_P"#.;_Y'H /"/\ R%O%O_86
M'_I+;UTM>?\ AR[\2?VAXB^RZ5I7F_VB/M/G:G)M\S[/#]S%O]W;LZ\YW=L5
MM_:_&'_0*T/_ ,&<W_R/0!TM%<U]K\8?] K0_P#P9S?_ "/1]K\8?] K0_\
MP9S?_(] '2T5S7VOQA_T"M#_ /!G-_\ (]'VOQA_T"M#_P#!G-_\CT =+17-
M?:_&'_0*T/\ \&<W_P CT?:_&'_0*T/_ ,&<W_R/0!TM%<U]K\8?] K0_P#P
M9S?_ "/1]K\8?] K0_\ P9S?_(] '2T5S7VOQA_T"M#_ /!G-_\ (]'VOQA_
MT"M#_P#!G-_\CT =+17-?:_&'_0*T/\ \&<W_P CT?:_&'_0*T/_ ,&<W_R/
M0!TM%<U]K\8?] K0_P#P9S?_ "/1]K\8?] K0_\ P9S?_(] '2T5S7VOQA_T
M"M#_ /!G-_\ (]'VOQA_T"M#_P#!G-_\CT =+17-?:_&'_0*T/\ \&<W_P C
MT?:_&'_0*T/_ ,&<W_R/0!TM%<U]K\8?] K0_P#P9S?_ "/1]K\8?] K0_\
MP9S?_(] '2T5S7VOQA_T"M#_ /!G-_\ (]'VOQA_T"M#_P#!G-_\CT =+17-
M?:_&'_0*T/\ \&<W_P CT?:_&'_0*T/_ ,&<W_R/0!TM%<U]K\8?] K0_P#P
M9S?_ "/1]K\8?] K0_\ P9S?_(] '2T5S7VOQA_T"M#_ /!G-_\ (]'VOQA_
MT"M#_P#!G-_\CT =+17-?:_&'_0*T/\ \&<W_P CT?:_&'_0*T/_ ,&<W_R/
M0!TM%<U]K\8?] K0_P#P9S?_ "/1]K\8?] K0_\ P9S?_(] '2T5S7VOQA_T
M"M#_ /!G-_\ (]'VOQA_T"M#_P#!G-_\CT =+17-?:_&'_0*T/\ \&<W_P C
MT?:_&'_0*T/_ ,&<W_R/0!TM%<U]K\8?] K0_P#P9S?_ "/1]K\8?] K0_\
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M+('R,<XK#^!OAV?3;'6-6O/A[;?#J^U:>.6>P%['>7D[(FWS+B:)F1C_  J
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MMW^TJ[B4;6.\>6CY XYXH ]N\4_%OP=X*N(H=<\06FG%_*S)*Q,<0D.V(RN
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC4/A?P_HWBC3&O18>)=*"SRP>1JE_>02GRW*;PIF^XVW<I[J0>] ';_:H/\
MGM'_ -]"C[5!_P ]H_\ OH5S_P#PKW1_[^J?^#B\_P#CM'_"O='_ +^J?^#B
M\_\ CM '0?:H/^>T?_?0H^U0?\]H_P#OH5S_ /PKW1_[^J?^#B\_^.T?\*]T
M?^_JG_@XO/\ X[0!T'VJ#_GM'_WT*/M4'_/:/_OH5S__  KW1_[^J?\ @XO/
M_CM'_"O='_OZI_X.+S_X[0!T'VJ#_GM'_P!]"C[5!_SVC_[Z%<__ ,*]T?\
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M_P"_JG_@XO/_ ([1_P *]T?^_JG_ (.+S_X[0!T'VJ#_ )[1_P#?0H^U0?\
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M.+S_ ..T?\*]T?\ OZI_X.+S_P".T =!]J@_Y[1_]]"C[5!_SVC_ .^A7/\
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M?#7B;Q'\)]8;P9JM_I?BC3U%_8?8;EX?M3Q'>;9RI&5E4,GL6!&"*\(\0?M
MZEK_ (+T[XF>'M0U+2O"?B/6=%\-B>:5BFG6[N/MMUL?*K)YC?9]Y'RF,GJ:
M^F_B);^,[K1(8_ U[H>GZLUP@EGUZUFN(5@YWE$BD0^8.",G;P0>N:?X>^'F
MC:'X"M/",UI!JFD1VWV>>&]A61+K/,C2(05.]BS$8QEC0!\G_'+QWXT^'I^,
M6B:7XDU:31/#UGHFLZ;JKW;&XTZ6XN_+GMGFSF6,QJ7 D+%0_7&W'L/PW\<3
M:O\ M3?%#0(?$#ZEH]GHVD7<%C]L\Z.WGD-P)2@R=N0L>0..G'->K6?P^\+:
M=X>NM!M/#>D6NA7:LMQID-A$EM,&&&#Q!=K @ '(Z4SPW\./"7@V99O#_A?1
M=#E2!;59--T^&W80J25C!11\@))"]!DT ?/OQ^U/Q)X-^++Z=::YKB:=X_T&
M;2M"CM;^5%T_78F#1-'@D()$;<<@@"!^,$@Y?P_\?>)O'_P0\2>)_P"UM:T#
M6O"'A>ZT>](N7?.MP+(;F0K+N5RAC3#$'B5NX&/J^ZTZTO9K6:XM8;B6UD,M
MO)+&&:%RI4LA/W3M9AD=F([U3O/">AZAI-_I5UHVGW.F:@SM>64UJCPW)<Y<
MR(1M<L>N0<]Z /F7PKK5[XB^+/[+^JZE<O>:C?>"=2N;BXD.6ED>VLF9C[DD
MFNU_8N&[X+7@#%2?$VNC<.H_XF5Q7I]O\)_!%G=:1<P>#?#\%QH\!MM-FCTN
M!7L8CUCA(7,:GNJX%:/A?P3X=\$:=+I_AW0-+T"PED::2UTNSCMHG=CEF*HH
M!8]SU- 'QWH/CKQW9Z=X>\47'Q UO495^+%QX5DL+@6XM9[!KN6':Z)$I+!5
M7# C;M& .<[_ (%^)_B7XC:ZFO1_$;3_  _K&D^*[O2]2\)SRF22>!)Y(H[+
M[)QM=D$;K,,MR225R!]%K\$OAVEJEJO@+PPMM'>?VBD(T:WV+=9SYX&S DSS
MO^][UI1_#CPG%XO?Q8GA?1D\4NGE-KBZ?"+UDQC:9]N\C'&,T ?)OP_^,OBG
MQ/X3TCXE6?Q!T^ZU2.SU%M5\"^8T\UY=1PRN+1;?@VSQ/']Y1RH^;=G=4?AC
M7HO%WQ$_95\97'B^XU^^\06VIW5X);I6M_M#6&7$40XBV,6CVK@?*-P+#-?6
MVE_#CPGH?B:_\1Z;X7T73_$-^"MWJUKI\,5W<CKB255#OT'4FJ.F?!SP#HNK
MC5=/\#^&[#5!.UU]MMM)MXY_./WI-ZH&WGNV<T >1_M,:;:W7QF^ 4EW?WUE
M;-KU['+]GU*>UCP-/N'!(1U&01][K@D9P2#YY>_&'QGJOPAUSXD:;K5[!XTT
M;QNVBGPP'!MG@%^MLMB\!'+/$ZR"3[^Y@0VWBOKCQ%X1T+Q?%:1:[HNG:U':
M3K=6Z:C:1W AF7[LB!P=KCLPY%5S\/\ PN?$I\1?\(WI'_"0$@G5OL$7VLD#
M:#YNW=P"1UZ4 >0?MH127'PS\+1QS-:2OXST!5F0*6C)OHOF (()'N"*\\G^
M(NN>$M1^)/@_4/'FM2QV7C+1M+TFYG2*6_N5NX(II+(39B6(.?, E)!C4G;D
MA17U/XH\$^'?'%K;VWB/0=,\06]O,MQ##JEG'<I%*OW9%#J0&'8CD5CWGP8^
M'^HKJRW?@7PU=+J[I)J(FTBW<7K)]QILI^\*]BV<=J /E>V\:>.==^"_Q!UJ
MQ\27]YK'PZ\:W,JV-AJSS->:3 \3S6;RJ$:8>690KL-V4 SUSUOCWXRW>F>$
MM#\<V>O3:5X5\=>)K:QCU*_NI([:PTTPN(Y 3D0>?*@RX (65<$'!'TEHG@?
MPYX92_71] TO25OV#7BV-E'"+DA0@,FU1O(4!><\#'2I=0\):'J_AQO#]]HV
MGWN@M"+=M+N+5)+4Q  !#$05V@ 8&,<4 <'\ UU:VTG7[34_'-IXZB@U-S9W
M%J3*UE"R*RVTD^?WS+G.X_-A@&SUKQ[]I7P5K/[0UQXMTW1-#N=33PS:BUT/
M4K>ZAC6TUM62X:8!W!)CV01Y4<;IA7U!X<\+Z-X/T:WTC0=(L=$TFW!$-AIU
MLEO!&"<D+&@"CGT%5] \$>'/"=K>VVB:!I>C6U[*TUU#I]E' D\C?>=PB@,Q
MR<DY)S0!\U3?M.S^./AQ\"[^.]?PY:^-=9&C^(;^-Q')87$4,GFVH<_ZIY)X
MO+#<, 3M()!'G^A^.KSX8^,O'^C:=K=U_9^M?%FRT74M;FG66XL[66PAX,A'
M#,ZK")&^8;LYW<U]>VGP5^'EAX?U#0K7P'X9MM#U&3SKW3(M'MUMKJ3.=\D0
M3:[9[L":LV?PH\$:=I6H:7:>#M M=,U!52\LH=+@2&Y50 HD0+AP  !D'  H
M ^/_ (\ZWXDCM_B3X'N=7N]1\-Z)XH\*3:3JUVPEN+-[B[B:2V:1@?,\LJK@
MON8"0!B1BM3Q]\4/'7P#\1_$/13XRU'Q)X3M#H4[^(==6)YM#-Y=-%<JTL<2
MKM$:B097Y X/3%?6\/@#PO;^')_#\7AO2(]!GSYNEI8Q"UDSUW1;=IS@=1VJ
M2Q\$>'=,T&?0[/0-+M-%N%99M-@LXTMI PPP:,+M((X.1S0!\^Z!-=Z5J%U>
M:YX_L/''@RUU**^6WMI&OO[(22UF1/-N,DRH9=K*&R4W YQ@CR?X!>#+CP)H
M^G77C+PW?:7%J/@R31M+BM-)EM1<S-.S/;7J,NXW.[RS"YVJ59]HR"3]M>%O
M WAOP-HIT?PWX?TOP_I)9F^P:791VT&6^\?+10N3WXYJ+1OAYX5\.WXOM)\,
MZ/IEZ 5%S9V$4,@!ZC<J@\T >7?M4175K^QS\1HK^3S+V/PG<).^<[I!!ACG
MZYKR'X7P75Q^T9\-S\3KJ 7%CX51_A]/IT)M[&[\RWC6]27<SLUTBA<+O"E#
MN"YS7UUXF\*:)XTT>;2?$.CV&O:5/Q+8ZG:I<02?[R."I_$5F7WPL\%ZIHFF
M:->^$-!N](TN19K#3Y],A>WM'4$*T497:A )P5 (S0!\V?#WXE^(?B7XFM];
M_P"%E:=X:U32_%MUI6J>%KB4R/+;I</$EG]DXVNR".19AENI)*Y P]!^.NO6
MOQ%\!:KIWBFZ\3:)XB?Q&)!=SK"-2%LKO;K%9 L+=4=!$KAE>3!+H"17UG!\
M-O"-MXL/BF'PMHL7B<Q^2=:33H5O2F,;?."[\8XQG&*JV/P@\!Z7J2ZC9>"?
M#MIJ"W;:@MW!I,"2BY8$-.'"9\P@D%\YY/- 'R#IGC%_'K?LN?$&\\3W&L:S
MK>L7=Q>V372_9H[@V%SF&.'I$8F_=8&"?X]S8-=1\'OB)XE^*MEX6\70_%:R
MTR]ODO+;6?#,<@N+@W 1_P!RENX(MI(&3.[:057Y]V<U]*6WP<\ V>M/K%OX
M'\-P:L]S]L:_CTBW6=I\$>:9 FXOR?FSGD\U/!\*_!5KK6JZQ#X/T&'5]5C:
M+4+^/3(%N+Q#]Y9I NZ0'N&)H \M_8W3Q#XB^#OAGQOXD\::WXFU+7M*A::U
MOVA^S0.K/\\2I&K!F! 8EB#@8 KRKXK_ !+\<:+X>_:3>P\::G:W'AK6='32
M9E2#-K%-';F2%1Y>-I,K<_>Z?-7UUX7\):'X(T>+2?#FC:?H&E0DF.QTNUCM
MH$)Y.$0!1GV%8E_\&?A_JIU8WO@7PU>'5Y$FU$W&D6[_ &V1?N/-E/WC#L6R
M10!\^ZIK_C_P[X[^+O@[1O&TNIW4.EZ+J6E2^);B.()<7,\L<MNDT<8\I91&
MJ*=IV,X(KC/&GBC_ (3_ ,-^#8-7'BWPWJNE_%33=.U31M6U>3?IY>)7\I+F
M&3%Q%]V2.4DL-_8U];77P<\ WUQ?7%SX'\-W$]]#';W<LNDV[-<11D&..0E,
MLJD @'(&!BK=U\,_!]]X>;0+GPIHEQH3RBX;3)=.A:V,@((<Q%=NX$ YQGB@
M#Y7NOC+JEK\3_"%]H_C6YU30;[Q_<>'+F:[NEA@:U2WD#6L=L2^\1/&I-TQ2
M1F.<%6!KG_B:1_PJ/]K;D?\ (WVO_HK3Z^O6^#G@%M3GU$^!_#9U">YCO9;L
MZ3;^;)/'_JY6?9DNN3AB<C/!I+GX,_#^]MM6MKCP-X:GM]7G%SJ44ND6[)>R
M@Y$DP*8D8=F;)H ^=/$'Q)\0^,_'WQ TBV^).G?#O6/".JVB65M?3'Y[(PPR
M;VM3@7*S%I$SDD' 7:1SQ7Q\\=W'Q1^#G[0<VL>(;K2K[PGKL6DVVAPW ABC
MM%DMRCRQ'_6>>6=@S9P  A&#G[*O/A?X-U'7=+UN[\):%=:SI2+%I^HS:;"]
MQ9HOW5BD*[HP.P4C%1>(/A)X&\6:P^K:YX+\/:SJKQ"!K[4-*@GG:,=$+NA8
MK[9Q0!PW[2_Q+U/X9?!J#6]&F^S"?4-.L;G5$57%A:SW$<<UR,@K\J,<$@@$
M@GI7BWQY\=^.?AG)\8M$\-^+-5.C:;X+@\1V&I2R)<W&FWC3M&81-(K%DE5"
MX#$LNUMI /'V%<:/87>E/I<]C;3::\7D/9R0JT+1XQL*$8*XXQC&*P/^%3>!
M_P#A&KKP[_PAOA__ (1^Z(:XTG^RX/LDQ&,%XMFUL8'4=A0!Y1\*M8\1Z-^T
M;X@\)ZAXIU/Q'I%SX3L->2/5#$3;W+SRQ2>5L1=J%57Y><$9[FJOQW\9ZI\#
M/BQX=\;75_JVH>"=:M)]#N=(CN9&AMM3*[[.5(P< RE6A] S(1@DFO:M,^'/
MA/1==&MZ=X7T:PUE;9;,:C:Z?%'<"!?NQ>8JAM@[+G ]*YSQ-X*\4^,/']B-
M2OM$_P"%>V$D&H16$=I*=1GO(B6422F3RQ$K[' 5-V4 )QU /'_#U[XEO?B3
MJWPO\0^+=8T>;1O!UMK%MJ$%ZRS7=Y-)+]HN/,;)D2!E1!&<I@_,IR,<O\)_
MC%XI\5^)?A]>>,];GTB/7_AUJ%_?P_:VM;>:XANHDCNHUW 1,T1W_)CA\U]8
M>)? ?AGQG):R>(/#NDZ[):[C;MJ5C%<&'=PVPNIVY[XZTW7O 'A?Q5-I<VM>
M&](UB;2W\RPDO[&*=K-\ ;HBZGRSP.5QTH ^._AEXL\:_%2T_9_TJ3XE^(=.
M@\4>$]5N-4NM,DMS<23P-#LE$CQ.0_SD'.1CH 3FO=_VD?B+??#;2/A_I\6J
M2Z58>(/$EGH>I:^Q57M;=U<EMY&U'D9%CWX&-Y(P<8[^Q^$7@72]0TN_L_!?
MAZTOM*5DT^Y@TJ!);-6Y80L$S&#W"XS6[K_A[2O%>D7.E:WIEGK&EW*[)[+4
M+=)X)1UPR."K#ZB@#X>OO'\OP6\=?&O[#XA>.SN?&F@:=?:UJ5UYKZ=:36:!
MG>4@L%!"Q^8V2H?.<C-=MXOM_&^C?"_Q9X@T7XER^,9/"NK6^NP6&C7LCM_9
MRA7NM/FN%;,^Z,.Z%OG7*C)!&?H_3OA+X&T?3;_3[#P9X?LK#4(EM[RUMM+@
MCBN8P,!)$" .H   ((P*T_#G@OP_X.T%=$T#0M,T/15#!=.TVSCM[<;OO8C0
M!>>_'- 'S7\5_'VMR_ W5?B?X8\3:KIEMK6NZ4VEJDVZ,Z>UU! <)(&V"8-(
M^4VG#+SUS;F^)C>-/'OQ.TK4_B/+\/=;\(Z[:0:99HZ8>R,<,F\VS$?:?M#-
M(G.XCY0@#=?H/7/A_P"%_$^@6^AZQX;TC5M$M_+,.FWUC%-;1;,;-L;*5&W
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^T7>GW*NQ^UVER)D,,F&4?=;E%/(R#Q_C#]D?6O$NK^()X/B)Y%IJ6M:9KD
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MQR*^(/V8_ DW]H>(_"WQ'\&:]_PMCP]XLU76M \22V%W]DD-VFT78ND A9<
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MY^"O$'P?\97W[+G[5.BVG@3Q!%/=^.CJVC:?)HMQ"UQ:?:(R9;9&0;UVJ?N
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M.'N?@HLVNZ/\0[+XG>$_">M>'+K1KC1FBLG682-PPMP;HR.490LDC[B3C'-
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MLZXDVA<J3@-NX( %'@+]H_QM\2M"^'N@6S6MGXLUW2=3OKG4+:.)!*]G="V
MBCF)4;B?,9?F( P,=0 ?4USH=C>ZK9ZE/;K->V886\CDGR=PPQ49P&(XW 9P
M2,X)K/LO'OA[4?&6H>$[75K>?Q'I]M'>7>GQDF2&%R51F[#)!XSGBO"_#/Q.
M^)7C+Q,WPZO]4T'PQX\TWPQ_:]W=Z:@N[:ZNVN)8(U4.#MA4Q RJ 6!D"AEV
MY/F_C/XJZCX)_::7[9J5CI^M>(_!NBZ0_B:RC\[2M.NI+NZ_?'>#F-G4H@;
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MC\KYE8'=N/\ =Z  ](HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** .-^)GPA\+?&#3]/L?%5G=WUK87<=_;):ZG=66RXC.8Y,P2(25/(SG!JE
MIOP;\,>%?$5QXNTS2;C5?%L=D]I;7NLZM=7LRQ]?)CDN))#"K,!NV 9ZD&N_
MHH \N^$G@[5F\0Z]X_\ %GAS3O#7B_7X;:TEL+"[%Z;>V@#;$>X$:>8Q9W8D
M+@#8.<5N?%#X,^#?C+86%IXOT8:HFGW'VJSFCN)K:XMI<8W1S0NDB$C@[6&1
MUS7:T4 >?0_ 7P/:ZUX=U6VTFXLKWP]9S6.F-::E=0);PRX\T;$E"L7(!+,"
MQ(!SGFL"^_9)^%.H^$-&\,W/AF632]&NI;W36_M6]%U9RRL6D,5R)O.4,225
M#[3Z5[!10!Y;XG_9A^&/C"/P\NI^%82V@0M;Z=+:74]K+%$W+1L\4BM(C'EE
M<L&))())I_B+]FGX<^*[O6;C5/#\EP=7TF/0KR%=1NHX'L4.8X5B24)&%))!
M15(/(->GT4 >=0_ #P7#K.E:L+357U+2]+DT:TNI=>U!WCM),;XR6G.[.U?F
M;+?*.>!5"R_9P\%>&K#PL- TJXM[OP?#./#BW.M7[PV;R(5(8&8[T.<$,&XX
M%>J44 ?)7P;^ 'C#PWJ&@B73_$?@V[TZ>.:^N8?'UU?Z/=8?=,L%@S%-DGS
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M8!5&70GY1Z"DU[X&>"/$OB#4=:O]&9K_ %.&.WU'R+R>"'4(X_N+<PQNL<X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-><>'OVGO"'BKPW)X@TNR\1WFB13RV\M]'H=R8XWCD,<@;Y<@*P()Q@8)Z4
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M3<V+)_K%FMRHE1EX)4J#@@XP<UU&@^-]#\3>"[+Q9IVH17'AZ\LEU&&^SA#
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MCP!\'I/#'Q'\3^/=9U2UU7Q/KUK;6$SZ=IYL;9+>#<4'EM+*S.2[9=G/ 4
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M"#&?+E41,"IR,\;N]8]A^R5=?#_Q%H^I?##QW<^"(8=$MM U*TGTV/4%OK>
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MBOBWX!ZOI6A_&GX/1:;XEFNI?$_PW:YU2&XUB2Z%W<QFU\MRCR, ZAI@-H'
M88P*Z+XZV7A75?VJ]%T;QOXBN])\+ZAX)O))K>37KBPMI)DNX0I^65 &"DGC
M&<#.<4 ?6%9&DZGJEYK&LVU[HS:=8VLL:65Z;E)!?(4!9PB\Q[6)7#<G&1Q7
MPC\/]&F\4>*_@3X/^(GB36IUU/0_$$+6=UKMS:7-[:+<1_V>TJI(K^8T."&X
M9L<DX(H^+WBFQTKPO^U+96WB^[MFTS6]$6QQKTWFP9CM@Z*QE+;<F0%"2N<\
M<4 ?>^MZW8>&]'O=5U2[BL=.LH6N+BYF;:D4:C+,3Z "K<,R7$,<L;;HY%#*
MWJ",BOS\^-5EH(@_:9\(:1??VYI7_"&Z;KD.G7&H/J)6\S/YMP@D=V#;5B8D
M?[)]*^G?&NKWD/[*.MZC\(HX)[]= EET0:1&NQWV'YH !AC]XKC@G&,YH ]I
MHKXJFUK2;W6_#>J_#WQ!,GA>[\%:E)XQ:WU.1%@=8$-M+<.'!BN_.+J6)60@
M.#G;QZO^Q1X=T:/X"^#O%-E?WFJZOKNAV#:G>W.JSW@EFCBVXVN[)&5)*D(%
MZ#.<4 >_5P7PF^*R?%1/%972+C1I/#^NW.A2Q7,J2-(\(0F3Y"0 =_ R>G6O
MF#1?$FG^+OC'J>B^+?&.N>&OBEH_B^6;3]*L+-Q=7NG^;_HZQ.<H]F\!&\8V
MC#LV#\QY>7XE0>'H?&5Z^K>7X$_X6UJ4?BB^LHS=I;6SVH$#W"(<^09@H;/R
M\<Y&10!^@E9^H>(--TK4M,T^[O(H+W4Y'BLX'/SSLB-(X4>RJ23_ (BOC*[\
M7Z#\,]#^'=W-XJUKQ-\#+[Q#J#:GK%_#(;*$20 VD60-QL5F+@;LIN &2H%.
M\1:+\.M,^(W[/^K%[F_\(->:[;6FL^)@7=UDAWV\<4CJ'\L.6$ /.%!7/!(!
M]MT5^?'@_P VU_9DU3Q_X:U;6M<UN#Q-<Z7K5];:U=7DT&B#66:<(@E8!A
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M<*3SM<92Y8$AU!R0H+#."0#U[QY\3M.\$Z'XHNHT.L:GX?TIM8N=)M9$6?R
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M&H^,O%^E7ESXKO(/"MHJ27'A>*U@\F]N(Y!)')),4,H (7**P4[1GN#W5%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ1I/PA\?>+_"OQIM]4M)?"8U2QL]-G6^N(+A'7-R)74^4CAMIBP "/DVX(H
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M=Q'RA &Z@'U-7%_%;XMZ!\&?#T.N>)3>QZ9+<Q6?G6=H]QMED<)&I5 2-S,
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MN>*VD\/:5%KLNMIIEFFLRP+:R:BL""X>%6++&9,;B@8DA<X!)-:%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
@% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>23
<FILENAME>ctso-20221231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/9/2023 9:43:32 PM-->
<!--Modified on: 3/9/2023 9:43:32 PM-->
<xsd:schema xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" targetNamespace="http://www.cytosorbents.com/20221231" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ctso="http://www.cytosorbents.com/20221231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2">
        <link:definition>00202 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" id="DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails">
        <link:definition>40202 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetDetails">
        <link:definition>40401 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails" id="DisclosureOtherAssetsDetails">
        <link:definition>40501 - Disclosure - OTHER ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>40601 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureLongTermDebtPrincipalPaymentsDetails" id="DisclosureLongTermDebtPrincipalPaymentsDetails">
        <link:definition>40703 - Disclosure - LONG-TERM DEBT - Principal payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" id="DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails">
        <link:definition>40803 - Disclosure - LEASES - Maturities of the lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureIncomeTaxess" id="DisclosureIncomeTaxess">
        <link:definition>40901 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureIncomeTaxesBenefitFromIncomeTaxesDetails" id="DisclosureIncomeTaxesBenefitFromIncomeTaxesDetails">
        <link:definition>40902 - Disclosure - INCOME TAXES - The benefit from income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails" id="DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>40903 - Disclosure - INCOME TAXES - The principal components of the Company's deferred tax assets and liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails" id="DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails">
        <link:definition>40904 - Disclosure - INCOME TAXES - Reconciliation of income tax (expense) benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" id="StatementConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureBasisOfPresentationDetails" id="DisclosureBasisOfPresentationDetails">
        <link:definition>40101 - Disclosure - BASIS OF PRESENTATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails" id="DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>40201 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails" id="DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails">
        <link:definition>40301 - Disclosure - REVENUE - Revenue by customer type and geographic area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureRevenueReceivablesAndContractLiabilitiesDetails" id="DisclosureRevenueReceivablesAndContractLiabilitiesDetails">
        <link:definition>40302 - Disclosure - REVENUE - Receivables and contract liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails" id="DisclosureRevenueAdditionalInformationDetails">
        <link:definition>40303 - Disclosure - REVENUE - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>40402 - Disclosure - PROPERTY AND EQUIPMENT, NET - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureOtherAssetsAdditionalInformationDetails" id="DisclosureOtherAssetsAdditionalInformationDetails">
        <link:definition>40502 - Disclosure - OTHER ASSETS - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails" id="DisclosureLongTermDebtAdditionalInformationDetails">
        <link:definition>40701 - Disclosure - LONG-TERM DEBT - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureLeasesDetails" id="DisclosureLeasesDetails">
        <link:definition>40801 - Disclosure - LEASES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureLeasesRightOfUseAssetAndRelatedLeaseLiabilityDetails" id="DisclosureLeasesRightOfUseAssetAndRelatedLeaseLiabilityDetails">
        <link:definition>40802 - Disclosure - LEASES - Right-of- use asset and related lease liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureIncomeTaxesConsolidatedLossBeforeIncomeTaxesDetails" id="DisclosureIncomeTaxesConsolidatedLossBeforeIncomeTaxesDetails">
        <link:definition>40901 - Disclosure - INCOME TAXES - Consolidated loss before income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>40905 - Disclosure - INCOME TAXES - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>41001 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" id="DisclosureStockholdersEquityStockOptionActivityDetails">
        <link:definition>41101 - Disclosure - STOCKHOLDERS' EQUITY - Stock option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquityFairValueOfStockOptionDetails" id="DisclosureStockholdersEquityFairValueOfStockOptionDetails">
        <link:definition>41102 - Disclosure - STOCKHOLDERS' EQUITY - Fair value of stock option (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails" id="DisclosureStockholdersEquityIntrinsicValueDetails">
        <link:definition>41103 - Disclosure - STOCKHOLDERS' EQUITY - Intrinsic value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails" id="DisclosureStockholdersEquityNonVestedOptionsDetails">
        <link:definition>41104 - Disclosure - STOCKHOLDERS' EQUITY - Non-vested options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails" id="DisclosureStockholdersEquityRestrictedStockUnitDetails">
        <link:definition>41105 - Disclosure - STOCKHOLDERS' EQUITY - Restricted stock unit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails" id="DisclosureStockholdersEquityRestrictedStockUnitActivityDetails">
        <link:definition>41106 - Disclosure - STOCKHOLDERS' EQUITY - Restricted stock unit activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>41107 - Disclosure - STOCKHOLDERS' EQUITY - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquityWarrantsDetails" id="DisclosureStockholdersEquityWarrantsDetails">
        <link:definition>41108 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureNetLossPerShareDetails" id="DisclosureNetLossPerShareDetails">
        <link:definition>41201 - Disclosure - NET LOSS PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureRetirementPlanDetails" id="DisclosureRetirementPlanDetails">
        <link:definition>41301 - Disclosure - RETIREMENT PLAN (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnauditedDetails" id="DisclosureQuarterlyFinancialResultsUnauditedDetails">
        <link:definition>41401 - Disclosure - QUARTERLY FINANCIAL RESULTS (UNAUDITED) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
        <link:definition>10101 - Disclosure - BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPolicies" id="DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureRevenue" id="DisclosureRevenue">
        <link:definition>10301 - Disclosure - REVENUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>10401 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureOtherAssets" id="DisclosureOtherAssets">
        <link:definition>10501 - Disclosure - OTHER ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>10601 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureLongTermDebt" id="DisclosureLongTermDebt">
        <link:definition>10701 - Disclosure - LONG-TERM DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>10801 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>10901 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11001 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>11101 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>11201 - Disclosure - NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureRetirementPlan" id="DisclosureRetirementPlan">
        <link:definition>11301 - Disclosure - RETIREMENT PLAN</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnaudited" id="DisclosureQuarterlyFinancialResultsUnaudited">
        <link:definition>11401 - Disclosure - QUARTERLY FINANCIAL RESULTS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTables" id="DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureRevenueTables" id="DisclosureRevenueTables">
        <link:definition>30303 - Disclosure - REVENUE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>30403 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureOtherAssetsTables" id="DisclosureOtherAssetsTables">
        <link:definition>30503 - Disclosure - OTHER ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>30603 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureLongTermDebtTables" id="DisclosureLongTermDebtTables">
        <link:definition>30703 - Disclosure - LONG-TERM DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>30803 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>30903 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>31103 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnauditedTables" id="DisclosureQuarterlyFinancialResultsUnauditedTables">
        <link:definition>31403 - Disclosure - QUARTERLY FINANCIAL RESULTS (UNAUDITED) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureLongTermDebtDetails" id="DisclosureLongTermDebtDetails">
        <link:definition>40702 - Disclosure - LONG TERM DEBT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.cytosorbents.com/role/DisclosureRevenueContractWithCustomerAssetAndLiabilityDetails" id="DisclosureRevenueContractWithCustomerAssetAndLiabilityDetails">
        <link:definition>9940303 - Disclosure - REVENUE - Contract with customer asset And liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="ctso-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ctso-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ctso-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ctso-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xsd:element name="AccruedExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="ctso_AccruedExpensesAndOtherCurrentLiabilities" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodValueStockCashOptionsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ctso_StockIssuedDuringPeriodValueStockCashOptionsExercised" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodSharesStockCashOptionsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ctso_StockIssuedDuringPeriodSharesStockCashOptionsExercised" substitutionGroup="xbrli:item" />
  <xsd:element name="StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ctso_StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions" substitutionGroup="xbrli:item" />
  <xsd:element name="NatureOfBusinessPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ctso_NatureOfBusinessPolicyPolicyTextBlock" substitutionGroup="xbrli:item" />
  <xsd:element name="PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <xsd:element name="OneDistributorMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ctso_OneDistributorMember" substitutionGroup="xbrli:item" />
  <xsd:element name="PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm" substitutionGroup="xbrli:item" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm" substitutionGroup="xbrli:item" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm" substitutionGroup="xbrli:item" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm" substitutionGroup="xbrli:item" />
  <xsd:element name="ExercisePriceRangeOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ctso_ExercisePriceRangeOneMember" substitutionGroup="xbrli:item" />
  <xsd:element name="AggregateRegisteredAmountForOfferings" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="ctso_AggregateRegisteredAmountForOfferings" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="ctso_CommissionRateAsPercentageOfAggregateGrossProceeds" name="CommissionRateAsPercentageOfAggregateGrossProceeds" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element name="SaleRevenuesGoodsNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ctso_SaleRevenuesGoodsNetAbstract" substitutionGroup="xbrli:item" />
  <xsd:element id="ctso_TermOfCustomerContracts" name="TermOfCustomerContracts" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="LongTermDebtAndFinalFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="ctso_LongTermDebtAndFinalFee" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element name="CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ctso_CommitmentsAndContingenciesDisclosureTable" substitutionGroup="xbrldt:hypercubeItem" />
  <xsd:element name="LicenseAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ctso_LicenseAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ctso_CommitmentsAndContingenciesDisclosureLineItems" substitutionGroup="xbrli:item" />
  <xsd:element name="RoyaltyPaymentRate" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ctso_RoyaltyPaymentRate" substitutionGroup="xbrli:item" />
  <xsd:element name="LicensePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="ctso_LicensePeriod" substitutionGroup="xbrli:item" />
  <xsd:element name="RoyaltyRateLowerLimit" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="ctso_RoyaltyRateLowerLimit" substitutionGroup="xbrli:item" />
  <xsd:element name="RoyaltyRateUpperLimit" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="ctso_RoyaltyRateUpperLimit" substitutionGroup="xbrli:item" />
  <xsd:element id="ctso_AdditionalOperatingLeasesRentExpenseNet" name="AdditionalOperatingLeasesRentExpenseNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="StockOptionsAndWarrantsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="ctso_StockOptionsAndWarrantsMember" substitutionGroup="xbrli:item" />
  <xsd:element id="ctso_JefferiesLlcAndB.RileyFbrIncMember" name="JefferiesLlcAndB.RileyFbrIncMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_ExecutiveEmploymentAgreementsInitialTerm" name="ExecutiveEmploymentAgreementsInitialTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ctso_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" name="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ctso_NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed" name="NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ctso_NumberOfPatentsUnitedStates" name="NumberOfPatentsUnitedStates" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="ctso_NumberOfPrimaryRevenueStreams" name="NumberOfPrimaryRevenueStreams" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ctso_OtherAssetsTable" name="OtherAssetsTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_OtherAssetsLineItems" name="OtherAssetsLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_AccruedSalariesAndCommissionsCurrent" name="AccruedSalariesAndCommissionsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ctso_ClinicalStudyCostsPayableCurrent" name="ClinicalStudyCostsPayableCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ctso_SalesPayrollAndIncomeTaxesPayableCurrent" name="SalesPayrollAndIncomeTaxesPayableCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ctso_CongressesPayableCurrent" name="CongressesPayableCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ctso_AccruedDirectorFeesCurrent" name="AccruedDirectorFeesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ctso_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent" name="EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ctso_ProceedsFromSaleOfNetOperatingLossCarryforwards" name="ProceedsFromSaleOfNetOperatingLossCarryforwards" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ctso_EmploymentAgreementsAutomaticRenewalPeriod" name="EmploymentAgreementsAutomaticRenewalPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ctso_TwoThousandFourteenStockOptionPlanMember" name="TwoThousandFourteenStockOptionPlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_StockOptionPlanOneMember" name="StockOptionPlanOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_NumberOfLongTermIncentivePlans" name="NumberOfLongTermIncentivePlans" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="ctso_ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage" name="ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ctso_DefinedContributionEligibilityTerm" name="DefinedContributionEligibilityTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ctso_CytoSorbSalesMember" name="CytoSorbSalesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_OtherSalesMember" name="OtherSalesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_DirectMember" name="DirectMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_DistributorsAndStrategicPartnersMember" name="DistributorsAndStrategicPartnersMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_UnitedStatesGovernmentAgenciesMember" name="UnitedStatesGovernmentAgenciesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_AllOtherCountriesMember" name="AllOtherCountriesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_July222019PerformanceBasedAwardMember" name="July222019PerformanceBasedAwardMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_CustomerRebates" name="CustomerRebates" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ctso_DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability" name="DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ctso_AccruedTravelAndEntertainmentExpenseCurrent" name="AccruedTravelAndEntertainmentExpenseCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ctso_AmortizationOfLoanAcquisitionCosts" name="AmortizationOfLoanAcquisitionCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ctso_February282020PerformanceBasedAwardMember" name="February282020PerformanceBasedAwardMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_CommonStockValueAuthorized" name="CommonStockValueAuthorized" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ctso_WesternAllianceBankMember" name="WesternAllianceBankMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_TermLoanMember" name="TermLoanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_TermBLoanMember" name="TermBLoanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_NonRefundableClosingFeeMember" name="NonRefundableClosingFeeMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_TwoThousandAndEighteenSuccessFeeLetterMember" name="TwoThousandAndEighteenSuccessFeeLetterMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_ClosingFeeMember" name="ClosingFeeMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent" name="DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ctso_PercentageOfSuccessFee" name="PercentageOfSuccessFee" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ctso_PercentageOfClosingPriceOnCommonStock" name="PercentageOfClosingPriceOnCommonStock" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ctso_NumberOfDaysForStockPriceThreshold" name="NumberOfDaysForStockPriceThreshold" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ctso_ExercisePriceRangingFrom5.00To10.58Member" name="ExercisePriceRangingFrom5.00To10.58Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument" name="PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ctso_NewTermLoanMember" name="NewTermLoanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember" name="FiniteLivedIntangibleAssetsPatentApplicationsPendingMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember" name="FiniteLivedIntangibleAssetsPatentsIssuedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_ParticipantsContributionUpto3PercentMember" name="ParticipantsContributionUpto3PercentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_ParticipantsContributionOver3AndMaximum5Member" name="ParticipantsContributionOver3AndMaximum5Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_ShareBasedCompensationAwardTrancheFourMember" name="ShareBasedCompensationAwardTrancheFourMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_ShareBasedCompensationAwardTrancheFiveMember" name="ShareBasedCompensationAwardTrancheFiveMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_OperatingLeaseInitialEarlyTermMember" name="OperatingLeaseInitialEarlyTermMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_OperatingLeaseEarlyTermMember" name="OperatingLeaseEarlyTermMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_OperatingLeaseFirstYearOfRemainingLeaseTermMember" name="OperatingLeaseFirstYearOfRemainingLeaseTermMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_CytosorbentsMedicalIncMember" name="CytosorbentsMedicalIncMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_CytosorbentsEuropeGmbhMember" name="CytosorbentsEuropeGmbhMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_TwentiethAmendmentToLeaseMember" name="TwentiethAmendmentToLeaseMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_NumberOfTimesLeaseRenewalAvailable" name="NumberOfTimesLeaseRenewalAvailable" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="ctso_OperatingLeasesAnnualRentExpenseIncrementRate" name="OperatingLeasesAnnualRentExpenseIncrementRate" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ctso_OperatingLeasesRentAbatementTerm" name="OperatingLeasesRentAbatementTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ctso_PercentageOfTotalBuildingSpaceOccupied" name="PercentageOfTotalBuildingSpaceOccupied" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="ctso_OperatingLeasesBuildingImprovementAllowanceReceivable" name="OperatingLeasesBuildingImprovementAllowanceReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ctso_OperatingLeaseBaseRentForRemainingSpace" name="OperatingLeaseBaseRentForRemainingSpace" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ctso_ForeignCurrencyTransactionGainLossExcludingTax" name="ForeignCurrencyTransactionGainLossExcludingTax" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ctso_April122021PerformanceBasedAwardMember" name="April122021PerformanceBasedAwardMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ctso_ThresholdUsedForCalculatingConcentrationOfRisk" name="ThresholdUsedForCalculatingConcentrationOfRisk" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock" id="ctso_LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ExercisePriceRangingFrom4.46To11.39Member" id="ctso_ExercisePriceRangingFrom4.46To11.39Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock" id="ctso_ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent" id="ctso_ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent" id="ctso_ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DebtInstrumentCapInterestRate" id="ctso_DebtInstrumentCapInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="FirstTrancheMember" id="ctso_FirstTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SecondTrancheMember" id="ctso_SecondTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ThirdTrancheMember" id="ctso_ThirdTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MonthlyOperatingExpenses" id="ctso_MonthlyOperatingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TermCLoanMember" id="ctso_TermCLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EmploymentAgreementsAutomaticRenewedPeriod" id="ctso_EmploymentAgreementsAutomaticRenewedPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests" id="ctso_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MiscellaneousIncome" id="ctso_MiscellaneousIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PaymentsForEquityContributionsNetOfFeesIncurred" id="ctso_PaymentsForEquityContributionsNetOfFeesIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ExercisePriceRangingFrom2.98To3.91Member" id="ctso_ExercisePriceRangingFrom2.98To3.91Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember" id="ctso_SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SecondFortyFiveThousandRestrictedAwardMember" id="ctso_SecondFortyFiveThousandRestrictedAwardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" id="ctso_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EmployeeOneMember" id="ctso_EmployeeOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeniorManagerOneMember" id="ctso_SeniorManagerOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeniorManagerTwoMember" id="ctso_SeniorManagerTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EmployeeTwoMember" id="ctso_EmployeeTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockholdersEquityTable" id="ctso_StockholdersEquityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="StockholdersEquityLineItems" id="ctso_StockholdersEquityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="August102022PerformanceBasedAwardMember" id="ctso_August102022PerformanceBasedAwardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PayrollTaxAuditMember" id="ctso_PayrollTaxAuditMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AdditionalSocialSecurityAndVatTaxesMember" id="ctso_AdditionalSocialSecurityAndVatTaxesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="InsuranceSettlementReceivableForLossOnInventoryRecordedAsReductionToCostOfGoodsSold" id="ctso_InsuranceSettlementReceivableForLossOnInventoryRecordedAsReductionToCostOfGoodsSold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ConsolidationAndForeignCurrencyTranslationPolicyPolicyTextBlock" id="ctso_ConsolidationAndForeignCurrencyTranslationPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ShippingAndHandlingCostsPolicyPolicyTextBlock" id="ctso_ShippingAndHandlingCostsPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockMarketListingPolicyPolicyTextBlock" id="ctso_StockMarketListingPolicyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="WroteOffPatentsCosts" id="ctso_WroteOffPatentsCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DeferredTaxLiabilitiesRightsOfUseAssets" id="ctso_DeferredTaxLiabilitiesRightsOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>24
<FILENAME>ctso-20221231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/9/2023 9:43:32 PM-->
<!--Modified on: 3/9/2023 9:43:32 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" roleURI="http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" roleURI="http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureOtherAssetsDetails" roleURI="http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureLongTermDebtPrincipalPaymentsDetails" roleURI="http://www.cytosorbents.com/role/DisclosureLongTermDebtPrincipalPaymentsDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" roleURI="http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureIncomeTaxess" roleURI="http://www.cytosorbents.com/role/DisclosureIncomeTaxess" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureIncomeTaxesBenefitFromIncomeTaxesDetails" roleURI="http://www.cytosorbents.com/role/DisclosureIncomeTaxesBenefitFromIncomeTaxesDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails" roleURI="http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails" />
  <calculationLink xlink:role="http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638139950104340276" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638139950104340276" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638139950104340276" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638139950104340276" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638139950104340276" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638139950104340276" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638139950104340276" xlink:to="us-gaap_AccountsReceivableNetCurrent_638139950104340276" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638139950104340276" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638139950104340276" xlink:to="us-gaap_InventoryNet_638139950104340276" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638139950104350273" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638139950104340276" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638139950104350273" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638139950104350273" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent_638139950104350273" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638139950104350273" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638139950104350273" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638139950104350273" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638139950104350273" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638139950104350273" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638139950104350273" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638139950104350273" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638139950104350273" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638139950104350273" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638139950104350273" xlink:to="us-gaap_LongTermDebtNoncurrent_638139950104350273" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638139950104350273" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638139950104350273" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638139950104350273" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638139950104360273" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638139950104350273" xlink:to="us-gaap_LiabilitiesCurrent_638139950104360273" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638139950104360273" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638139950104360273" xlink:to="us-gaap_AccountsPayableCurrent_638139950104360273" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="ctso_AccruedExpensesAndOtherCurrentLiabilities_638139950104360273" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638139950104360273" xlink:to="ctso_AccruedExpensesAndOtherCurrentLiabilities_638139950104360273" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638139950104360273" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638139950104360273" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638139950104360273" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638139950104360273" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638139950104360273" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638139950104360273" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638139950104360273" xlink:to="us-gaap_PreferredStockValue_638139950104360273" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638139950104360273" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638139950104360273" xlink:to="us-gaap_CommonStockValue_638139950104360273" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638139950104360273" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638139950104360273" xlink:to="us-gaap_AdditionalPaidInCapital_638139950104360273" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638139950104370273" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638139950104360273" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638139950104370273" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638139950104370273" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638139950104360273" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638139950104370273" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638139950104370273" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638139950104370273" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638139950104370273" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638139950104370273" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638139950104370273" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638139950104370273" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638139950104370273" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638139950104370273" xlink:to="us-gaap_NonoperatingIncomeExpense_638139950104370273" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_638139950104370273" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638139950104370273" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_638139950104370273" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_MiscellaneousIncome" xlink:label="ctso_MiscellaneousIncome_638139950104380274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638139950104370273" xlink:to="ctso_MiscellaneousIncome_638139950104380274" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638139950104380274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638139950104370273" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638139950104380274" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638139950104380274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638139950104370273" xlink:to="us-gaap_OperatingIncomeLoss_638139950104380274" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638139950104380274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638139950104380274" xlink:to="us-gaap_OperatingExpenses_638139950104380274" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638139950104380274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638139950104380274" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638139950104380274" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees_638139950104380274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638139950104380274" xlink:to="us-gaap_ProfessionalFees_638139950104380274" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638139950104380274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638139950104380274" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638139950104380274" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_638139950104380274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638139950104380274" xlink:to="us-gaap_GrossProfit_638139950104380274" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638139950104380274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_638139950104380274" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638139950104380274" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638139950104390272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit_638139950104380274" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638139950104390272" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" xlink:type="extended" xlink:title="00202 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Calc 2)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638139950104390272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638139950104390272" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638139950104390272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_638139950104390272" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139950104390272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139950104390272" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638139950104390272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139950104390272" xlink:to="us-gaap_NetIncomeLoss_638139950104390272" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_638139950104390272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139950104390272" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_638139950104390272" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_638139950104390272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139950104390272" xlink:to="us-gaap_DepreciationAndAmortization_638139950104390272" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638139950104390272" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139950104390272" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638139950104390272" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_638139950104400275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139950104390272" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_638139950104400275" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_638139950104400275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139950104390272" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_638139950104400275" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638139950104400275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139950104390272" xlink:to="us-gaap_ShareBasedCompensation_638139950104400275" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AmortizationOfLoanAcquisitionCosts" xlink:label="ctso_AmortizationOfLoanAcquisitionCosts_638139950104400275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139950104390272" xlink:to="ctso_AmortizationOfLoanAcquisitionCosts_638139950104400275" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638139950104400275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139950104390272" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638139950104400275" order="9" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638139950104400275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139950104390272" xlink:to="us-gaap_IncreaseDecreaseInInventories_638139950104400275" order="10" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638139950104400275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139950104390272" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638139950104400275" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_638139950104400275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139950104390272" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_638139950104400275" order="12" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638139950104410284" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139950104390272" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638139950104410284" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638139950104410284" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139950104390272" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638139950104410284" order="14" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638139950104410284" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139950104390272" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638139950104410284" order="15" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638139950104410284" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638139950104410284" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638139950104410284" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638139950104410284" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638139950104410284" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638139950104410284" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638139950104410284" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638139950104410284" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638139950104410284" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638139950104410284" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638139950104410284" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638139950104410284" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638139950104410284" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_638139950104420275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638139950104410284" xlink:to="us-gaap_RepaymentsOfLongTermDebt_638139950104420275" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_PaymentsForEquityContributionsNetOfFeesIncurred" xlink:label="ctso_PaymentsForEquityContributionsNetOfFeesIncurred_638139950104420275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638139950104410284" xlink:to="ctso_PaymentsForEquityContributionsNetOfFeesIncurred_638139950104420275" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument" xlink:label="ctso_PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument_638139950104420275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638139950104410284" xlink:to="ctso_PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument_638139950104420275" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638139950104420275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638139950104410284" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638139950104420275" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638139950104420275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638139950104420275" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" xlink:type="extended" xlink:title="40202 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638139950104430274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638139950104430274" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_638139950104430274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_638139950104430274" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40401 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637031108260166149" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638139950104430274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_637031108260166149" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638139950104430274" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638139950104430274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_637031108260166149" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638139950104430274" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - OTHER ASSETS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637031108260166149" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638139950104430274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent_637031108260166149" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638139950104430274" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638139950104430274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_638139950104430274" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638139950104430274" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638139950104430274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_638139950104430274" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638139950104430274" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_638139950104430274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent_637031108260166149" xlink:to="us-gaap_SecurityDeposit_638139950104430274" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)">
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="ctso_AccruedExpensesAndOtherCurrentLiabilities" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AccruedSalariesAndCommissionsCurrent" xlink:label="ctso_AccruedSalariesAndCommissionsCurrent_638139950104440274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ctso_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="ctso_AccruedSalariesAndCommissionsCurrent_638139950104440274" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ClinicalStudyCostsPayableCurrent" xlink:label="ctso_ClinicalStudyCostsPayableCurrent_638139950104440274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ctso_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="ctso_ClinicalStudyCostsPayableCurrent_638139950104440274" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638139950104440274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ctso_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638139950104440274" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638139950104440274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ctso_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638139950104440274" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_638139950104440274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ctso_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_AccruedRoyaltiesCurrent_638139950104440274" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_SalesPayrollAndIncomeTaxesPayableCurrent" xlink:label="ctso_SalesPayrollAndIncomeTaxesPayableCurrent_638139950104440274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ctso_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="ctso_SalesPayrollAndIncomeTaxesPayableCurrent_638139950104440274" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638139950104440274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ctso_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638139950104440274" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AccruedTravelAndEntertainmentExpenseCurrent" xlink:label="ctso_AccruedTravelAndEntertainmentExpenseCurrent_638139950104440274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ctso_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="ctso_AccruedTravelAndEntertainmentExpenseCurrent_638139950104440274" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CustomerRebates" xlink:label="ctso_CustomerRebates_638139950104440274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ctso_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="ctso_CustomerRebates_638139950104440274" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_638139950104450274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ctso_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_InterestPayableCurrent_638139950104450274" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AccruedDirectorFeesCurrent" xlink:label="ctso_AccruedDirectorFeesCurrent_638139950104450274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ctso_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="ctso_AccruedDirectorFeesCurrent_638139950104450274" order="11" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CongressesPayableCurrent" xlink:label="ctso_CongressesPayableCurrent_638139950104450274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ctso_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="ctso_CongressesPayableCurrent_638139950104450274" order="12" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cytosorbents.com/role/DisclosureLongTermDebtPrincipalPaymentsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - LONG-TERM DEBT - Principal payments (Details)">
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_LongTermDebtAndFinalFee" xlink:label="ctso_LongTermDebtAndFinalFee" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638139950104450274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ctso_LongTermDebtAndFinalFee" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638139950104450274" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638139950104450274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ctso_LongTermDebtAndFinalFee" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638139950104450274" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="40803 - Disclosure - LEASES - Maturities of the lease liabilities (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638139950104450274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638139950104450274" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638139950104450274" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638139950104450274" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638139950104460275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638139950104460275" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638139950104460275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638139950104460275" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638139950104460275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638139950104460275" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:label="ctso_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_638139950104460275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="ctso_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_638139950104460275" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cytosorbents.com/role/DisclosureIncomeTaxess" xlink:type="extended" xlink:title="40901 - Disclosure - INCOME TAXES">
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests" xlink:label="ctso_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638139950104460275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ctso_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638139950104460275" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638139950104460275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ctso_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638139950104460275" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cytosorbents.com/role/DisclosureIncomeTaxesBenefitFromIncomeTaxesDetails" xlink:type="extended" xlink:title="40902 - Disclosure - INCOME TAXES - The benefit from income taxes (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637031108260335327" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_638139950104460275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_637031108260335327" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_638139950104460275" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="40903 - Disclosure - INCOME TAXES - The principal components of the Company's deferred tax assets and liabilities (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638139950104470276" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_638139950104470276" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638139950104470276" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638139950104470276" xlink:to="us-gaap_DeferredTaxAssetsGross_638139950104470276" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638139950104470276" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638139950104470276" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638139950104470276" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_638139950104470276" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638139950104470276" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_638139950104470276" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638139950104470276" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638139950104470276" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638139950104470276" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_638139950104470276" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638139950104470276" xlink:to="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_638139950104470276" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_638139950104470276" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638139950104470276" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_638139950104470276" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability" xlink:label="ctso_DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability_638139950104470276" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638139950104470276" xlink:to="ctso_DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability_638139950104470276" order="6" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638139950104470276" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638139950104470276" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638139950104470276" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638139950104480290" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638139950104480290" order="2" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_DeferredTaxLiabilitiesRightsOfUseAssets" xlink:label="ctso_DeferredTaxLiabilitiesRightsOfUseAssets_638139950104480290" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="ctso_DeferredTaxLiabilitiesRightsOfUseAssets_638139950104480290" order="3" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails" xlink:type="extended" xlink:title="40904 - Disclosure - INCOME TAXES - Reconciliation of income tax (expense) benefit (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637031108260491834" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638139950104480290" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637031108260491834" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638139950104480290" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638139950104480290" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637031108260491834" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638139950104480290" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_638139950104480290" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637031108260491834" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_638139950104480290" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent" xlink:label="ctso_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent_638139950104480290" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637031108260491834" xlink:to="ctso_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent_638139950104480290" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638139950104480290" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637031108260491834" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638139950104480290" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638139950104480290" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637031108260491834" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638139950104480290" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638139950104490275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637031108260491834" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638139950104490275" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638139950104490275" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637031108260491834" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638139950104490275" order="8" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>25
<FILENAME>ctso-20221231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/9/2023 9:43:32 PM-->
<!--Modified on: 3/9/2023 9:43:32 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails" roleURI="http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureRevenueAdditionalInformationDetails" roleURI="http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureOtherAssetsDetails" roleURI="http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureLongTermDebtAdditionalInformationDetails" roleURI="http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureLeasesDetails" roleURI="http://www.cytosorbents.com/role/DisclosureLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" roleURI="http://www.cytosorbents.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureStockholdersEquityFairValueOfStockOptionDetails" roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquityFairValueOfStockOptionDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureStockholdersEquityIntrinsicValueDetails" roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureStockholdersEquityRestrictedStockUnitDetails" roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureStockholdersEquityRestrictedStockUnitActivityDetails" roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.cytosorbents.com/role/DisclosureNetLossPerShareDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureRetirementPlanDetails" roleURI="http://www.cytosorbents.com/role/DisclosureRetirementPlanDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.cytosorbents.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="ctso-20221231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.cytosorbents.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByBenchmarkAxis_1 To us-gaap_ConcentrationRiskBenchmarkDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:title="us-gaap_ConcentrationRiskByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_1" xlink:title="us-gaap_ConcentrationRiskTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:to="us-gaap_ConcentrationRiskTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByTypeAxis_1 To us-gaap_ConcentrationRiskTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis_1" xlink:title="us-gaap_InvestmentTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_1" xlink:title="us-gaap_InvestmentTypeCategorizationMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_InvestmentTypeAxis_1" xlink:to="us-gaap_InvestmentTypeCategorizationMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_InvestmentTypeAxis_1 To us-gaap_InvestmentTypeCategorizationMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_1" xlink:title="us-gaap_OptionIndexedToIssuersEquityEquityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" xlink:title="us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis_1" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_OptionIndexedToIssuersEquityEquityAxis_1 To us-gaap_OptionIndexedToIssuersEquityTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis_1" xlink:title="us-gaap_LineOfCreditFacilityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_1" xlink:title="us-gaap_LineOfCreditFacilityLenderDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LineOfCreditFacilityAxis_1" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LineOfCreditFacilityAxis_1 To us-gaap_LineOfCreditFacilityLenderDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis_1" xlink:title="us-gaap_AwardDateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_1" xlink:title="us-gaap_AwardDateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardDateAxis_1" xlink:to="us-gaap_AwardDateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardDateAxis_1 To us-gaap_AwardDateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_1" xlink:title="us-gaap_LossContingenciesByNatureOfContingencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain_1" xlink:title="us-gaap_LossContingencyNatureDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis_1" xlink:to="us-gaap_LossContingencyNatureDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LossContingenciesByNatureOfContingencyAxis_1 To us-gaap_LossContingencyNatureDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_1" xlink:title="us-gaap_LeaseContractualTermAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_1" xlink:title="us-gaap_LeaseContractualTermDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LeaseContractualTermAxis_1" xlink:to="us-gaap_LeaseContractualTermDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LeaseContractualTermAxis_1 To us-gaap_LeaseContractualTermDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_1" xlink:title="us-gaap_RetirementPlanTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_1" xlink:title="us-gaap_RetirementPlanTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanTypeAxis_1" xlink:to="us-gaap_RetirementPlanTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanTypeAxis_1 To us-gaap_RetirementPlanTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_1" xlink:title="us-gaap_CreditFacilityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_1" xlink:title="us-gaap_CreditFacilityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CreditFacilityAxis_1" xlink:to="us-gaap_CreditFacilityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CreditFacilityAxis_1 To us-gaap_CreditFacilityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CytoSorbSalesMember" xlink:label="ctso_CytoSorbSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ProductMember" xlink:to="ctso_CytoSorbSalesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OtherSalesMember" xlink:label="ctso_OtherSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ProductMember" xlink:to="ctso_OtherSalesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ProfessionalFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_MiscellaneousIncome" xlink:label="ctso_MiscellaneousIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="ctso_MiscellaneousIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockIssuedDuringPeriodValueStockCashOptionsExercised" xlink:label="ctso_StockIssuedDuringPeriodValueStockCashOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="ctso_StockIssuedDuringPeriodValueStockCashOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockIssuedDuringPeriodSharesStockCashOptionsExercised" xlink:label="ctso_StockIssuedDuringPeriodSharesStockCashOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="ctso_StockIssuedDuringPeriodSharesStockCashOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions" xlink:label="ctso_StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="ctso_StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_RevenueFromContractWithCustomerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OneDistributorMember" xlink:label="ctso_OneDistributorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="ctso_OneDistributorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CargoAndFreightMember" xlink:label="us-gaap_CargoAndFreightMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_CargoAndFreightMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CreditFacilityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditCardMember" xlink:label="us-gaap_CreditCardMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditCardMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed" xlink:label="ctso_NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ctso_NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NumberOfPatentsUnitedStates" xlink:label="ctso_NumberOfPatentsUnitedStates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ctso_NumberOfPatentsUnitedStates" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ForeignCurrencyTransactionGainLossExcludingTax" xlink:label="ctso_ForeignCurrencyTransactionGainLossExcludingTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ctso_ForeignCurrencyTransactionGainLossExcludingTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCollateralAmount" xlink:label="us-gaap_DebtInstrumentCollateralAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentCollateralAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InventoryFinishedGoods" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InventoryWorkInProcess" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InventoryRawMaterials" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryAdjustments" xlink:label="us-gaap_InventoryAdjustments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InventoryAdjustments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_WroteOffPatentsCosts" xlink:label="ctso_WroteOffPatentsCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ctso_WroteOffPatentsCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AdvertisingExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ThresholdUsedForCalculatingConcentrationOfRisk" xlink:label="ctso_ThresholdUsedForCalculatingConcentrationOfRisk" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ctso_ThresholdUsedForCalculatingConcentrationOfRisk" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_InsuranceSettlementReceivableForLossOnInventoryRecordedAsReductionToCostOfGoodsSold" xlink:label="ctso_InsuranceSettlementReceivableForLossOnInventoryRecordedAsReductionToCostOfGoodsSold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ctso_InsuranceSettlementReceivableForLossOnInventoryRecordedAsReductionToCostOfGoodsSold" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails" xlink:type="extended" xlink:title="40301 - Disclosure - REVENUE - Revenue by customer type and geographic area (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_DirectMember" xlink:label="ctso_DirectMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="ctso_DirectMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_DistributorsAndStrategicPartnersMember" xlink:label="ctso_DistributorsAndStrategicPartnersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="ctso_DistributorsAndStrategicPartnersMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_UnitedStatesGovernmentAgenciesMember" xlink:label="ctso_UnitedStatesGovernmentAgenciesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="ctso_UnitedStatesGovernmentAgenciesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE" xlink:label="country_DE" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_DE" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AllOtherCountriesMember" xlink:label="ctso_AllOtherCountriesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="ctso_AllOtherCountriesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_GrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_SaleRevenuesGoodsNetAbstract" xlink:label="ctso_SaleRevenuesGoodsNetAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="ctso_SaleRevenuesGoodsNetAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ctso_SaleRevenuesGoodsNetAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails" xlink:type="extended" xlink:title="40303 - Disclosure - REVENUE - Additional information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NumberOfPrimaryRevenueStreams" xlink:label="ctso_NumberOfPrimaryRevenueStreams" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="ctso_NumberOfPrimaryRevenueStreams" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_TermOfCustomerContracts" xlink:label="ctso_TermOfCustomerContracts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="ctso_TermOfCustomerContracts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent" xlink:label="ctso_ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="ctso_ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent" xlink:label="ctso_ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="ctso_ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40401 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - OTHER ASSETS (Details)">
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OtherAssetsTable" xlink:label="ctso_OtherAssetsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ctso_OtherAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember" xlink:label="ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember" xlink:label="ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OtherAssetsLineItems" xlink:label="ctso_OtherAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ctso_OtherAssetsLineItems" xlink:to="ctso_OtherAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ctso_OtherAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ctso_OtherAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ctso_OtherAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ctso_OtherAssetsLineItems" xlink:to="us-gaap_SecurityDeposit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ctso_OtherAssetsLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails" xlink:type="extended" xlink:title="40701 - Disclosure - LONG-TERM DEBT - Additional information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_WesternAllianceBankMember" xlink:label="ctso_WesternAllianceBankMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="ctso_WesternAllianceBankMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NewTermLoanMember" xlink:label="ctso_NewTermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ctso_NewTermLoanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_TermLoanMember" xlink:label="ctso_TermLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ctso_TermLoanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_TermBLoanMember" xlink:label="ctso_TermBLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ctso_TermBLoanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_TermCLoanMember" xlink:label="ctso_TermCLoanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ctso_TermCLoanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NonRefundableClosingFeeMember" xlink:label="ctso_NonRefundableClosingFeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ctso_NonRefundableClosingFeeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_TwoThousandAndEighteenSuccessFeeLetterMember" xlink:label="ctso_TwoThousandAndEighteenSuccessFeeLetterMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ctso_TwoThousandAndEighteenSuccessFeeLetterMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_FirstTrancheMember" xlink:label="ctso_FirstTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="ctso_FirstTrancheMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_SecondTrancheMember" xlink:label="ctso_SecondTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="ctso_SecondTrancheMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ThirdTrancheMember" xlink:label="ctso_ThirdTrancheMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_VestingDomain" xlink:to="ctso_ThirdTrancheMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ClosingFeeMember" xlink:label="ctso_ClosingFeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="ctso_ClosingFeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_DebtInstrumentCapInterestRate" xlink:label="ctso_DebtInstrumentCapInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ctso_DebtInstrumentCapInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent" xlink:label="ctso_DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ctso_DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_PercentageOfSuccessFee" xlink:label="ctso_PercentageOfSuccessFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ctso_PercentageOfSuccessFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_PercentageOfClosingPriceOnCommonStock" xlink:label="ctso_PercentageOfClosingPriceOnCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ctso_PercentageOfClosingPriceOnCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NumberOfDaysForStockPriceThreshold" xlink:label="ctso_NumberOfDaysForStockPriceThreshold" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ctso_NumberOfDaysForStockPriceThreshold" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cytosorbents.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - LEASES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE" xlink:label="country_DE" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_DE" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OperatingLeaseInitialEarlyTermMember" xlink:label="ctso_OperatingLeaseInitialEarlyTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ctso_OperatingLeaseInitialEarlyTermMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OperatingLeaseEarlyTermMember" xlink:label="ctso_OperatingLeaseEarlyTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ctso_OperatingLeaseEarlyTermMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OperatingLeaseFirstYearOfRemainingLeaseTermMember" xlink:label="ctso_OperatingLeaseFirstYearOfRemainingLeaseTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ctso_OperatingLeaseFirstYearOfRemainingLeaseTermMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_LetterOfCreditMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_ConsolidatedEntitiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CytosorbentsMedicalIncMember" xlink:label="ctso_CytosorbentsMedicalIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="ctso_CytosorbentsMedicalIncMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CytosorbentsEuropeGmbhMember" xlink:label="ctso_CytosorbentsEuropeGmbhMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="ctso_CytosorbentsEuropeGmbhMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_TwentiethAmendmentToLeaseMember" xlink:label="ctso_TwentiethAmendmentToLeaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ctso_TwentiethAmendmentToLeaseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NumberOfTimesLeaseRenewalAvailable" xlink:label="ctso_NumberOfTimesLeaseRenewalAvailable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ctso_NumberOfTimesLeaseRenewalAvailable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OperatingLeasesAnnualRentExpenseIncrementRate" xlink:label="ctso_OperatingLeasesAnnualRentExpenseIncrementRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ctso_OperatingLeasesAnnualRentExpenseIncrementRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OperatingLeasesRentAbatementTerm" xlink:label="ctso_OperatingLeasesRentAbatementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ctso_OperatingLeasesRentAbatementTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_PercentageOfTotalBuildingSpaceOccupied" xlink:label="ctso_PercentageOfTotalBuildingSpaceOccupied" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ctso_PercentageOfTotalBuildingSpaceOccupied" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OperatingLeasesBuildingImprovementAllowanceReceivable" xlink:label="ctso_OperatingLeasesBuildingImprovementAllowanceReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ctso_OperatingLeasesBuildingImprovementAllowanceReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AdditionalOperatingLeasesRentExpenseNet" xlink:label="ctso_AdditionalOperatingLeasesRentExpenseNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ctso_AdditionalOperatingLeasesRentExpenseNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OperatingLeaseBaseRentForRemainingSpace" xlink:label="ctso_OperatingLeaseBaseRentForRemainingSpace" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ctso_OperatingLeaseBaseRentForRemainingSpace" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_MonthlyOperatingExpenses" xlink:label="ctso_MonthlyOperatingExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="ctso_MonthlyOperatingExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_SecurityDeposit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfLand" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cytosorbents.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="extended" xlink:title="40905 - Disclosure - INCOME TAXES - Additional information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ProceedsFromSaleOfNetOperatingLossCarryforwards" xlink:label="ctso_ProceedsFromSaleOfNetOperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="ctso_ProceedsFromSaleOfNetOperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="41001 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CommitmentsAndContingenciesDisclosureTable" xlink:label="ctso_CommitmentsAndContingenciesDisclosureTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ctso_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyAgreementsMember" xlink:label="us-gaap_RoyaltyAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_RoyaltyAgreementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_LicenseAgreementMember" xlink:label="ctso_LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="ctso_LicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ctso_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_PayrollTaxAuditMember" xlink:label="ctso_PayrollTaxAuditMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="ctso_PayrollTaxAuditMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AdditionalSocialSecurityAndVatTaxesMember" xlink:label="ctso_AdditionalSocialSecurityAndVatTaxesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="ctso_AdditionalSocialSecurityAndVatTaxesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="ctso_CommitmentsAndContingenciesDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ctso_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="ctso_CommitmentsAndContingenciesDisclosureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationInterestAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ctso_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationInterestAccrued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ExecutiveEmploymentAgreementsInitialTerm" xlink:label="ctso_ExecutiveEmploymentAgreementsInitialTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ctso_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="ctso_ExecutiveEmploymentAgreementsInitialTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_EmploymentAgreementsAutomaticRenewalPeriod" xlink:label="ctso_EmploymentAgreementsAutomaticRenewalPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ctso_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="ctso_EmploymentAgreementsAutomaticRenewalPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_EmploymentAgreementsAutomaticRenewedPeriod" xlink:label="ctso_EmploymentAgreementsAutomaticRenewedPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ctso_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="ctso_EmploymentAgreementsAutomaticRenewedPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ctso_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_RoyaltyPaymentRate" xlink:label="ctso_RoyaltyPaymentRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ctso_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="ctso_RoyaltyPaymentRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ctso_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_LicensePeriod" xlink:label="ctso_LicensePeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ctso_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="ctso_LicensePeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_RoyaltyRateLowerLimit" xlink:label="ctso_RoyaltyRateLowerLimit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ctso_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="ctso_RoyaltyRateLowerLimit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_RoyaltyRateUpperLimit" xlink:label="ctso_RoyaltyRateUpperLimit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ctso_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="ctso_RoyaltyRateUpperLimit" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cytosorbents.com/role/DisclosureStockholdersEquityFairValueOfStockOptionDetails" xlink:type="extended" xlink:title="41102 - Disclosure - STOCKHOLDERS' EQUITY - Fair value of stock option (Details)">
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockholdersEquityTable" xlink:label="ctso_StockholdersEquityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ctso_StockholdersEquityTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ExercisePriceRangingFrom5.00To10.58Member" xlink:label="ctso_ExercisePriceRangingFrom5.00To10.58Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ctso_ExercisePriceRangingFrom5.00To10.58Member" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ExercisePriceRangingFrom4.46To11.39Member" xlink:label="ctso_ExercisePriceRangingFrom4.46To11.39Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ctso_ExercisePriceRangingFrom4.46To11.39Member" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ExercisePriceRangingFrom2.98To3.91Member" xlink:label="ctso_ExercisePriceRangingFrom2.98To3.91Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ctso_ExercisePriceRangingFrom2.98To3.91Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ctso_StockholdersEquityTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockholdersEquityLineItems" xlink:label="ctso_StockholdersEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="ctso_StockholdersEquityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails" xlink:type="extended" xlink:title="41103 - Disclosure - STOCKHOLDERS' EQUITY - Intrinsic value (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ExercisePriceRangeOneMember" xlink:label="ctso_ExercisePriceRangeOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ctso_ExercisePriceRangeOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails" xlink:type="extended" xlink:title="41105 - Disclosure - STOCKHOLDERS' EQUITY - Restricted stock unit (Details)">
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockholdersEquityTable" xlink:label="ctso_StockholdersEquityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ctso_StockholdersEquityTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ManagementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficerMember" xlink:label="srt_OfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_OfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ctso_StockholdersEquityTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockholdersEquityLineItems" xlink:label="ctso_StockholdersEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="ctso_StockholdersEquityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails" xlink:type="extended" xlink:title="41106 - Disclosure - STOCKHOLDERS' EQUITY - Restricted stock unit activity (Details)">
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockholdersEquityTable" xlink:label="ctso_StockholdersEquityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ctso_StockholdersEquityTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockholdersEquityLineItems" xlink:label="ctso_StockholdersEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="ctso_StockholdersEquityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="extended" xlink:title="41107 - Disclosure - STOCKHOLDERS' EQUITY - Additional information (Details)">
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockholdersEquityTable" xlink:label="ctso_StockholdersEquityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ctso_StockholdersEquityTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ExercisePriceRangingFrom5.00To10.58Member" xlink:label="ctso_ExercisePriceRangingFrom5.00To10.58Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ctso_ExercisePriceRangingFrom5.00To10.58Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ExercisePriceRangingFrom2.98To3.91Member" xlink:label="ctso_ExercisePriceRangingFrom2.98To3.91Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ctso_ExercisePriceRangingFrom2.98To3.91Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ctso_StockholdersEquityTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_JefferiesLlcAndB.RileyFbrIncMember" xlink:label="ctso_JefferiesLlcAndB.RileyFbrIncMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="ctso_JefferiesLlcAndB.RileyFbrIncMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ctso_StockholdersEquityTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockOptionPlanOneMember" xlink:label="ctso_StockOptionPlanOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="ctso_StockOptionPlanOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_TwoThousandFourteenStockOptionPlanMember" xlink:label="ctso_TwoThousandFourteenStockOptionPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="ctso_TwoThousandFourteenStockOptionPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_July222019PerformanceBasedAwardMember" xlink:label="ctso_July222019PerformanceBasedAwardMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="ctso_July222019PerformanceBasedAwardMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_February282020PerformanceBasedAwardMember" xlink:label="ctso_February282020PerformanceBasedAwardMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PlanNameDomain" xlink:to="ctso_February282020PerformanceBasedAwardMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_April122021PerformanceBasedAwardMember" xlink:label="ctso_April122021PerformanceBasedAwardMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PlanNameDomain" xlink:to="ctso_April122021PerformanceBasedAwardMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_August102022PerformanceBasedAwardMember" xlink:label="ctso_August102022PerformanceBasedAwardMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PlanNameDomain" xlink:to="ctso_August102022PerformanceBasedAwardMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ctso_StockholdersEquityTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_EmployeeOneMember" xlink:label="ctso_EmployeeOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ctso_EmployeeOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_EmployeeTwoMember" xlink:label="ctso_EmployeeTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ctso_EmployeeTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_SeniorManagerOneMember" xlink:label="ctso_SeniorManagerOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ctso_SeniorManagerOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_SeniorManagerTwoMember" xlink:label="ctso_SeniorManagerTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ctso_SeniorManagerTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="ctso_StockholdersEquityTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="ctso_StockholdersEquityTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ShareBasedCompensationAwardTrancheFourMember" xlink:label="ctso_ShareBasedCompensationAwardTrancheFourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_VestingDomain" xlink:to="ctso_ShareBasedCompensationAwardTrancheFourMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ShareBasedCompensationAwardTrancheFiveMember" xlink:label="ctso_ShareBasedCompensationAwardTrancheFiveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_VestingDomain" xlink:to="ctso_ShareBasedCompensationAwardTrancheFiveMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="ctso_StockholdersEquityTable" xlink:to="us-gaap_GranteeStatusAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="8" xlink:from="ctso_StockholdersEquityTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="9" xlink:from="ctso_StockholdersEquityTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_SecondFortyFiveThousandRestrictedAwardMember" xlink:label="ctso_SecondFortyFiveThousandRestrictedAwardMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ctso_SecondFortyFiveThousandRestrictedAwardMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember" xlink:label="ctso_SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ctso_SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockholdersEquityLineItems" xlink:label="ctso_StockholdersEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="ctso_StockholdersEquityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CommonStockValueAuthorized" xlink:label="ctso_CommonStockValueAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="ctso_CommonStockValueAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AggregateRegisteredAmountForOfferings" xlink:label="ctso_AggregateRegisteredAmountForOfferings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="ctso_AggregateRegisteredAmountForOfferings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_StockOptionPlanExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage" xlink:label="ctso_ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="ctso_ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CommissionRateAsPercentageOfAggregateGrossProceeds" xlink:label="ctso_CommissionRateAsPercentageOfAggregateGrossProceeds" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="ctso_CommissionRateAsPercentageOfAggregateGrossProceeds" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NumberOfLongTermIncentivePlans" xlink:label="ctso_NumberOfLongTermIncentivePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="ctso_NumberOfLongTermIncentivePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cytosorbents.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="41201 - Disclosure - NET LOSS PER SHARE (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockOptionsAndWarrantsMember" xlink:label="ctso_StockOptionsAndWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="ctso_StockOptionsAndWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.cytosorbents.com/role/DisclosureRetirementPlanDetails" xlink:type="extended" xlink:title="41301 - Disclosure - RETIREMENT PLAN (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ParticipantsContributionUpto3PercentMember" xlink:label="ctso_ParticipantsContributionUpto3PercentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ctso_ParticipantsContributionUpto3PercentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ParticipantsContributionOver3AndMaximum5Member" xlink:label="ctso_ParticipantsContributionOver3AndMaximum5Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ctso_ParticipantsContributionOver3AndMaximum5Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_DefinedContributionEligibilityTerm" xlink:label="ctso_DefinedContributionEligibilityTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="ctso_DefinedContributionEligibilityTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>26
<FILENAME>ctso-20221231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/9/2023 9:43:32 PM-->
<!--Modified on: 3/9/2023 9:43:32 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">LONG-TERM DEBT, NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Grants and accounts receivable, net of allowance for doubtful accounts of $76,041 and $60,539 at December 31, 2022 and 2021, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment - net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted Cash, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="ctso_AccruedExpensesAndOtherCurrentLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="ctso_AccruedExpensesAndOtherCurrentLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US">Amount of accrued expenses and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US">Accrued Expenses and Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ctso_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Less current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Lease liability - current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Lease liability, net of current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Long-term debt net of current maturities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Par Value $0.001, 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2022 and 2021</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Par Value $0.001, 100,000,000 shares authorized; 43,635,715 and 43,478,487 shares issued and outstanding at December 31, 2022 and 2021, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Grants and accounts receivable, net of allowance for doubtful accounts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Number of preferred stock authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Total product sales [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Total product sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product sales</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CytoSorbSalesMember" xlink:label="ctso_CytoSorbSalesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_CytoSorbSalesMember" xlink:to="ctso_CytoSorbSalesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_CytoSorbSalesMember_lbl" xml:lang="en-US">Represent the information relating to the cyto sorb sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_CytoSorbSalesMember_lbl" xml:lang="en-US">CytoSorb sales [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_CytoSorbSalesMember_lbl" xml:lang="en-US">CytoSorb sales</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OtherSalesMember" xlink:label="ctso_OtherSalesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_OtherSalesMember" xlink:to="ctso_OtherSalesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_OtherSalesMember_lbl" xml:lang="en-US">Represent the information relating to the other sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_OtherSalesMember_lbl" xml:lang="en-US">Other sales [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_OtherSalesMember_lbl" xml:lang="en-US">Other sales</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantMember" xlink:to="us-gaap_GrantMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantMember_lbl" xml:lang="en-US">Grant income [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantMember_lbl" xml:lang="en-US">Grant income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GrantMember_lbl" xml:lang="en-US">Government grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenue:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Total revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Total revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of Goods and Services Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross Profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross margin</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Legal, financial and other consulting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US">Interest (expense), net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Gain (loss) on foreign currency transactions</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_MiscellaneousIncome" xlink:label="ctso_MiscellaneousIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_MiscellaneousIncome" xlink:to="ctso_MiscellaneousIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_MiscellaneousIncome_lbl" xml:lang="en-US">Amount of miscellaneous income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_MiscellaneousIncome_lbl" xml:lang="en-US">Miscellaneous Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_MiscellaneousIncome_lbl" xml:lang="en-US">Miscellaneous expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense), net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before benefit from income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Benefit from income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit), Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to common stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss attributable to common stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic net loss per common share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted net loss per common share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of shares of common stock outstanding, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average number of shares of common stock outstanding, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">Comprehensive loss:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xml:lang="en-US">Other comprehensive income (loss):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Foreign currency translation adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Other comprehensive income (loss), foreign currency translation adjustment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Paid-In Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation - employees, consultants and directors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock - offerings, net of fees incurred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Sale Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock - offerings, net of fees incurred (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Legal/audit fees related to ATM offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Issuance of restricted stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Issuance of restricted stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockIssuedDuringPeriodValueStockCashOptionsExercised" xlink:label="ctso_StockIssuedDuringPeriodValueStockCashOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_StockIssuedDuringPeriodValueStockCashOptionsExercised" xlink:to="ctso_StockIssuedDuringPeriodValueStockCashOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_StockIssuedDuringPeriodValueStockCashOptionsExercised_lbl" xml:lang="en-US">Value stock issued during the period as a result of the exercise of cash options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_StockIssuedDuringPeriodValueStockCashOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period Value Stock Cash Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ctso_StockIssuedDuringPeriodValueStockCashOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockIssuedDuringPeriodSharesStockCashOptionsExercised" xlink:label="ctso_StockIssuedDuringPeriodSharesStockCashOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_StockIssuedDuringPeriodSharesStockCashOptionsExercised" xlink:to="ctso_StockIssuedDuringPeriodSharesStockCashOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_StockIssuedDuringPeriodSharesStockCashOptionsExercised_lbl" xml:lang="en-US">Number of shares issued during the period as a result of the exercise of cash options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_StockIssuedDuringPeriodSharesStockCashOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period Shares Stock Cash Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ctso_StockIssuedDuringPeriodSharesStockCashOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Cashless exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions" xlink:label="ctso_StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions" xlink:to="ctso_StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions_lbl" xml:lang="en-US">Number of cashless stock options (or share units) exercised during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions_lbl" xml:lang="en-US">Stock Issued During Period Shares Cashless Exercise Of Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ctso_StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions_lbl" xml:lang="en-US">Cashless exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Stock issued to vendor in lieu of cash payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Issuance of common stock to vendor in lieu of cash payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Stock issued to vendor in lieu of cash payment (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Non-cash compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of right-of-use asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for Doubtful Accounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Bad debt expense (recovery)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Loss on disposal of fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US">Impairment of patents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Foreign currency transaction (gains) losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AmortizationOfLoanAcquisitionCosts" xlink:label="ctso_AmortizationOfLoanAcquisitionCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_AmortizationOfLoanAcquisitionCosts" xlink:to="ctso_AmortizationOfLoanAcquisitionCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_AmortizationOfLoanAcquisitionCosts_lbl" xml:lang="en-US">The amount of amortization of loan acquisition costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_AmortizationOfLoanAcquisitionCosts_lbl" xml:lang="en-US">Amortization of Loan Acquisition Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_AmortizationOfLoanAcquisitionCosts_lbl" xml:lang="en-US">Amortization of loan acquisition costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Grants and accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Patent costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US">Proceeds from long-term debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_lbl" xml:lang="en-US">Amount drawn down</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Repayments of Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xml:lang="en-US">Repayment of long-term debt</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument" xlink:label="ctso_PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument" xlink:to="ctso_PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument_lbl" xml:lang="en-US">The cash outflow of non-refundable final fees on termination or maturity for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument_lbl" xml:lang="en-US">Payment of Non-Refundable Final Fee Upon Termination Or Maturity of Debt Instrument</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ctso_PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument_lbl" xml:lang="en-US">Final fee on long-term debt</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_PaymentsForEquityContributionsNetOfFeesIncurred" xlink:label="ctso_PaymentsForEquityContributionsNetOfFeesIncurred" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_PaymentsForEquityContributionsNetOfFeesIncurred" xlink:to="ctso_PaymentsForEquityContributionsNetOfFeesIncurred_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_PaymentsForEquityContributionsNetOfFeesIncurred_lbl" xml:lang="en-US">The cash outflow for equity contributions - net of fees incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_PaymentsForEquityContributionsNetOfFeesIncurred_lbl" xml:lang="en-US">Payments for Equity contributions - Net of Fees Incurred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ctso_PaymentsForEquityContributionsNetOfFeesIncurred_lbl" xml:lang="en-US">Equity contributions - net of fees incurred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of exchange rates on cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Total cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid during the year for interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital expenditures included in accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Stock Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Settlement of accrued bonuses with restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">BASIS OF PRESENTATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US">Basis of Accounting [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US">BASIS OF PRESENTATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US">REVENUE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xml:lang="en-US">REVENUE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">OTHER ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Other Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US">OTHER ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">LONG-TERM DEBT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">Long-term Debt [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">LONG-TERM DEBT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xml:lang="en-US">LEASES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">RETIREMENT PLAN</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">RETIREMENT PLAN</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US">QUARTERLY FINANCIAL RESULTS (UNAUDITED)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US">Quarterly Financial Information [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US">QUARTERLY FINANCIAL RESULTS (UNAUDITED)</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NatureOfBusinessPolicyPolicyTextBlock" xlink:label="ctso_NatureOfBusinessPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_NatureOfBusinessPolicyPolicyTextBlock" xlink:to="ctso_NatureOfBusinessPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_NatureOfBusinessPolicyPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for Nature of Business Policy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_NatureOfBusinessPolicyPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Business Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_NatureOfBusinessPolicyPolicyTextBlock_lbl" xml:lang="en-US">Nature of Business</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockMarketListingPolicyPolicyTextBlock" xlink:label="ctso_StockMarketListingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_StockMarketListingPolicyPolicyTextBlock" xlink:to="ctso_StockMarketListingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_StockMarketListingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for stock market listing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_StockMarketListingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Stock Market Listing Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_StockMarketListingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Stock Market Listing</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ConsolidationAndForeignCurrencyTranslationPolicyPolicyTextBlock" xlink:label="ctso_ConsolidationAndForeignCurrencyTranslationPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ConsolidationAndForeignCurrencyTranslationPolicyPolicyTextBlock" xlink:to="ctso_ConsolidationAndForeignCurrencyTranslationPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ConsolidationAndForeignCurrencyTranslationPolicyPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for basis of consolidation and foreign currency translation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ConsolidationAndForeignCurrencyTranslationPolicyPolicyTextBlock_lbl" xml:lang="en-US">Consolidation and Foreign Currency Translation Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ConsolidationAndForeignCurrencyTranslationPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Consolidation and Foreign Currency Translation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash, Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Trade and Other Accounts Receivable, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Grants and Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Patents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Common Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ShippingAndHandlingCostsPolicyPolicyTextBlock" xlink:label="ctso_ShippingAndHandlingCostsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ShippingAndHandlingCostsPolicyPolicyTextBlock" xlink:to="ctso_ShippingAndHandlingCostsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ShippingAndHandlingCostsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ShippingAndHandlingCostsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Shipping And Handling Costs Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ShippingAndHandlingCostsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Shipping and Handling Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Effect of Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock" xlink:label="ctso_ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock" xlink:to="ctso_ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of the components of cash and cash equivalents and restricted cash and cash equivalents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule Of Cash And Cash Equivalents And Restricted Cash And Cash Equivalents [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of reconciliation of cash and cash equivalents and restricted cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of disaggregation of Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US">Contract with Customer, Asset and Liability [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of receivables and contract liabilities from contracts with customers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfOtherAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Other Assets</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="ctso_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="ctso_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of accrued expenses and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses and Other Current Liabilities Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US">Schedule of Long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Principal payments of long-term debt</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock" xlink:label="ctso_LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock" xlink:to="ctso_LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of Lessee's right-of-use-assets and lease liability under operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Balance Sheet Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock_lbl" xml:lang="en-US">Schedule of right-of- use asset and related lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of maturities of the lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock options activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value of each stock option estimated using the Black-Scholes pricing model</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of intrinsic value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Company's non-vested options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of restricted stock unit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of the restricted stock unit activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl" xml:lang="en-US">Condensed Income Statement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_lbl" xml:lang="en-US">Summarized quarterly information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCapitalizationLineItems" xlink:label="us-gaap_ScheduleOfCapitalizationLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCapitalizationLineItems" xlink:to="us-gaap_ScheduleOfCapitalizationLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCapitalizationLineItems_lbl" xml:lang="en-US">Schedule of Capitalization [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfCapitalizationLineItems_lbl" xml:lang="en-US">BASIS OF PRESENTATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Disclosure of information about principal business activity and summary of significant accounting policies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Principal Business Activity and Summary of Significant Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerMember" xlink:to="us-gaap_RevenueFromContractWithCustomerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_lbl" xml:lang="en-US">Sales Revenue, Net [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_lbl" xml:lang="en-US">Sales Revenue, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OneDistributorMember" xlink:label="ctso_OneDistributorMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_OneDistributorMember" xlink:to="ctso_OneDistributorMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_OneDistributorMember_lbl" xml:lang="en-US">The member stands for one distributor/strategic partner.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_OneDistributorMember_lbl" xml:lang="en-US">One Distributor/strategic partner [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_OneDistributorMember_lbl" xml:lang="en-US">One Distributor/strategic partner</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CargoAndFreightMember" xlink:label="us-gaap_CargoAndFreightMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CargoAndFreightMember" xlink:to="us-gaap_CargoAndFreightMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CargoAndFreightMember_lbl" xml:lang="en-US">Cargo and Freight [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CargoAndFreightMember_lbl" xml:lang="en-US">Cargo and Freight</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US">Credit Facility [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LetterOfCreditMember_lbl" xml:lang="en-US">Letter of credit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LetterOfCreditMember_lbl" xml:lang="en-US">Letter of credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditCardMember" xlink:label="us-gaap_CreditCardMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditCardMember" xlink:to="us-gaap_CreditCardMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditCardMember_lbl" xml:lang="en-US">Credit Card [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CreditCardMember_lbl" xml:lang="en-US">Credit Card</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Federal [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Federal</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Line items represents the Principal Business Activity and Summary of Significant Accounting Policies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Principal Business Activity and Summary of Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed" xlink:label="ctso_NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed" xlink:to="ctso_NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed_lbl" xml:lang="en-US">Number of countries where the entity's flagship product is marketed and distributed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed_lbl" xml:lang="en-US">Number of Countries Where Flagship Product is Marketed and Distributed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed_lbl" xml:lang="en-US">Number of countries where the entity's flagship product is marketed and distributed</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NumberOfPatentsUnitedStates" xlink:label="ctso_NumberOfPatentsUnitedStates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_NumberOfPatentsUnitedStates" xlink:to="ctso_NumberOfPatentsUnitedStates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_NumberOfPatentsUnitedStates_lbl" xml:lang="en-US">Number of patents issued to the entity in the United States.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_NumberOfPatentsUnitedStates_lbl" xml:lang="en-US">Number of Patents, United States</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_NumberOfPatentsUnitedStates_lbl" xml:lang="en-US">Number of patents</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ForeignCurrencyTransactionGainLossExcludingTax" xlink:label="ctso_ForeignCurrencyTransactionGainLossExcludingTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ForeignCurrencyTransactionGainLossExcludingTax" xlink:to="ctso_ForeignCurrencyTransactionGainLossExcludingTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ForeignCurrencyTransactionGainLossExcludingTax_lbl" xml:lang="en-US">Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ForeignCurrencyTransactionGainLossExcludingTax_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Excluding Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ForeignCurrencyTransactionGainLossExcludingTax_lbl" xml:lang="en-US">Foreign currency transaction gain (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCollateralAmount" xlink:label="us-gaap_DebtInstrumentCollateralAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCollateralAmount" xlink:to="us-gaap_DebtInstrumentCollateralAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCollateralAmount_lbl" xml:lang="en-US">Debt Instrument, Collateral Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentCollateralAmount_lbl" xml:lang="en-US">Cash collateral</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Inventory, Finished Goods, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Inventory - finished goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Inventory, Work in Process, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Inventory - work in process</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Inventory, Raw Materials, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Inventory - raw materials</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryAdjustments" xlink:label="us-gaap_InventoryAdjustments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryAdjustments" xlink:to="us-gaap_InventoryAdjustments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryAdjustments_lbl" xml:lang="en-US">Inventory Adjustments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryAdjustments_lbl" xml:lang="en-US">Inventory</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_WroteOffPatentsCosts" xlink:label="ctso_WroteOffPatentsCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_WroteOffPatentsCosts" xlink:to="ctso_WroteOffPatentsCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_WroteOffPatentsCosts_lbl" xml:lang="en-US">Amount of write-down of patents cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_WroteOffPatentsCosts_lbl" xml:lang="en-US">Wrote Off Patents Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_WroteOffPatentsCosts_lbl" xml:lang="en-US">wrote-off patent costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized tax benefits</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ThresholdUsedForCalculatingConcentrationOfRisk" xlink:label="ctso_ThresholdUsedForCalculatingConcentrationOfRisk" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ThresholdUsedForCalculatingConcentrationOfRisk" xlink:to="ctso_ThresholdUsedForCalculatingConcentrationOfRisk_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ThresholdUsedForCalculatingConcentrationOfRisk_lbl" xml:lang="en-US">For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ThresholdUsedForCalculatingConcentrationOfRisk_lbl" xml:lang="en-US">Threshold Used For Calculating Concentration Of Risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ThresholdUsedForCalculatingConcentrationOfRisk_lbl" xml:lang="en-US">Concentration risk</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_InsuranceSettlementReceivableForLossOnInventoryRecordedAsReductionToCostOfGoodsSold" xlink:label="ctso_InsuranceSettlementReceivableForLossOnInventoryRecordedAsReductionToCostOfGoodsSold" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_InsuranceSettlementReceivableForLossOnInventoryRecordedAsReductionToCostOfGoodsSold" xlink:to="ctso_InsuranceSettlementReceivableForLossOnInventoryRecordedAsReductionToCostOfGoodsSold_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_InsuranceSettlementReceivableForLossOnInventoryRecordedAsReductionToCostOfGoodsSold_lbl" xml:lang="en-US">Amount of insurance settlement receivable for loss on inventory recorded as a reduction to cost of goods sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_InsuranceSettlementReceivableForLossOnInventoryRecordedAsReductionToCostOfGoodsSold_lbl" xml:lang="en-US">Insurance Settlement Receivable For Loss On Inventory Recorded As A Reduction To Cost Of Goods Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_InsuranceSettlementReceivableForLossOnInventoryRecordedAsReductionToCostOfGoodsSold_lbl" xml:lang="en-US">Insurance settlement receivable for loss on inventory recorded as a reduction to cost of goods sold</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US">Disaggregation of Revenue [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_DirectMember" xlink:label="ctso_DirectMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_DirectMember" xlink:to="ctso_DirectMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_DirectMember_lbl" xml:lang="en-US">This member stands for Direct.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_DirectMember_lbl" xml:lang="en-US">Direct [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_DirectMember_lbl" xml:lang="en-US">Direct</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_DistributorsAndStrategicPartnersMember" xlink:label="ctso_DistributorsAndStrategicPartnersMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_DistributorsAndStrategicPartnersMember" xlink:to="ctso_DistributorsAndStrategicPartnersMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_DistributorsAndStrategicPartnersMember_lbl" xml:lang="en-US">This member stands for distributors/strategic partners.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_DistributorsAndStrategicPartnersMember_lbl" xml:lang="en-US">Distributors/Strategic Partners [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_DistributorsAndStrategicPartnersMember_lbl" xml:lang="en-US">Distributors/Strategic Partners</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_UnitedStatesGovernmentAgenciesMember" xlink:label="ctso_UnitedStatesGovernmentAgenciesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_UnitedStatesGovernmentAgenciesMember" xlink:to="ctso_UnitedStatesGovernmentAgenciesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_UnitedStatesGovernmentAgenciesMember_lbl" xml:lang="en-US">This member stands for united states government agencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_UnitedStatesGovernmentAgenciesMember_lbl" xml:lang="en-US">United States Government Agencies [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_UnitedStatesGovernmentAgenciesMember_lbl" xml:lang="en-US">United States Government Agencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US">United States [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US">United States</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE" xlink:label="country_DE" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_DE" xlink:to="country_DE_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_DE_lbl" xml:lang="en-US">Germany [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_DE_lbl" xml:lang="en-US">Germany</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AllOtherCountriesMember" xlink:label="ctso_AllOtherCountriesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_AllOtherCountriesMember" xlink:to="ctso_AllOtherCountriesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_AllOtherCountriesMember_lbl" xml:lang="en-US">This member stands for All other countries.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_AllOtherCountriesMember_lbl" xml:lang="en-US">All other countries [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_AllOtherCountriesMember_lbl" xml:lang="en-US">All other countries</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">Disaggregation of Revenue [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US">REVENUE</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_SaleRevenuesGoodsNetAbstract" xlink:label="ctso_SaleRevenuesGoodsNetAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_SaleRevenuesGoodsNetAbstract" xlink:to="ctso_SaleRevenuesGoodsNetAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_SaleRevenuesGoodsNetAbstract_lbl" xml:lang="en-US">Sale Revenues Goods Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_SaleRevenuesGoodsNetAbstract_lbl" xml:lang="en-US">Sale Revenues Goods Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ctso_SaleRevenuesGoodsNetAbstract_lbl" xml:lang="en-US">Product sales:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US">Contract with Customer, Asset, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US">Contract receivables, which are included in grants and accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Contract liabilities, which are included in accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NumberOfPrimaryRevenueStreams" xlink:label="ctso_NumberOfPrimaryRevenueStreams" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_NumberOfPrimaryRevenueStreams" xlink:to="ctso_NumberOfPrimaryRevenueStreams_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_NumberOfPrimaryRevenueStreams_lbl" xml:lang="en-US">Number of primary revenue streams.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_NumberOfPrimaryRevenueStreams_lbl" xml:lang="en-US">Number of Primary Revenue Streams</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_NumberOfPrimaryRevenueStreams_lbl" xml:lang="en-US">Number of primary revenue streams</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_TermOfCustomerContracts" xlink:label="ctso_TermOfCustomerContracts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_TermOfCustomerContracts" xlink:to="ctso_TermOfCustomerContracts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_TermOfCustomerContracts_lbl" xml:lang="en-US">Represents the term of customer contracts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_TermOfCustomerContracts_lbl" xml:lang="en-US">Term Of Customer Contracts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_TermOfCustomerContracts_lbl" xml:lang="en-US">Term of customer contracts</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent" xlink:label="ctso_ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent" xlink:to="ctso_ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent_lbl" xml:lang="en-US">Value of free of charge goods and credit rebates as on the balance sheet date, classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent_lbl" xml:lang="en-US">Contract With Customer Liability, Value of Free Of Charge Goods And Credit Rebates, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent_lbl" xml:lang="en-US">Value of free of charge goods and credit rebates</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent" xlink:label="ctso_ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent" xlink:to="ctso_ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent_lbl" xml:lang="en-US">Amount of contract with customer liability net of free of charge goods and credit rebates as on the balance sheet date, classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent_lbl" xml:lang="en-US">Contract With Customer Liability, Net Of Free Of Charge Goods And Credit Rebates, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent_lbl" xml:lang="en-US">Contract liabilities net of Value of free of charge goods and credit rebates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and fixtures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Equipment and computers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Equipment and computers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Depreciation/Amortization Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OtherAssetsTable" xlink:label="ctso_OtherAssetsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_OtherAssetsTable" xlink:to="ctso_OtherAssetsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_OtherAssetsTable_lbl" xml:lang="en-US">Table represents the other assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_OtherAssetsTable_lbl" xml:lang="en-US">Other Assets [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember" xlink:label="ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember" xlink:to="ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember_lbl" xml:lang="en-US">Represents information pertaining to Patent applications pending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember_lbl" xml:lang="en-US">Patent applications pending [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember_lbl" xml:lang="en-US">Patent applications pending</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember" xlink:label="ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember" xlink:to="ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember_lbl" xml:lang="en-US">Represents information pertaining to Patents issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember_lbl" xml:lang="en-US">Patents issued [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember_lbl" xml:lang="en-US">Patents issued</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OtherAssetsLineItems" xlink:label="ctso_OtherAssetsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_OtherAssetsLineItems" xlink:to="ctso_OtherAssetsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_OtherAssetsLineItems_lbl" xml:lang="en-US">Line item represents the other assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_OtherAssetsLineItems_lbl" xml:lang="en-US">Other Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_OtherAssetsLineItems_lbl" xml:lang="en-US">OTHER ASSETS:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Patents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Less accumulated amortization of patents issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Patents, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentForAmortization" xlink:to="us-gaap_AdjustmentForAmortization_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xml:lang="en-US">Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentForAmortization_lbl" xml:lang="en-US">Amortization expense</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AccruedSalariesAndCommissionsCurrent" xlink:label="ctso_AccruedSalariesAndCommissionsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_AccruedSalariesAndCommissionsCurrent" xlink:to="ctso_AccruedSalariesAndCommissionsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_AccruedSalariesAndCommissionsCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for salaries and commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_AccruedSalariesAndCommissionsCurrent_lbl" xml:lang="en-US">Accrued Salaries and Commissions Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_AccruedSalariesAndCommissionsCurrent_lbl" xml:lang="en-US">Accrued salaries and commissions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract liabilities, which are included in expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ClinicalStudyCostsPayableCurrent" xlink:label="ctso_ClinicalStudyCostsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ClinicalStudyCostsPayableCurrent" xlink:to="ctso_ClinicalStudyCostsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ClinicalStudyCostsPayableCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical study costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ClinicalStudyCostsPayableCurrent_lbl" xml:lang="en-US">Clinical Study Costs Payable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ClinicalStudyCostsPayableCurrent_lbl" xml:lang="en-US">Clinical studies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Accrued Royalties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Accrued royalties</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CustomerRebates" xlink:label="ctso_CustomerRebates" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_CustomerRebates" xlink:to="ctso_CustomerRebates_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_CustomerRebates_lbl" xml:lang="en-US">The amount of customer rebates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_CustomerRebates_lbl" xml:lang="en-US">Customer rebates</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AccruedTravelAndEntertainmentExpenseCurrent" xlink:label="ctso_AccruedTravelAndEntertainmentExpenseCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_AccruedTravelAndEntertainmentExpenseCurrent" xlink:to="ctso_AccruedTravelAndEntertainmentExpenseCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_AccruedTravelAndEntertainmentExpenseCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for travel and entertainment. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_AccruedTravelAndEntertainmentExpenseCurrent_lbl" xml:lang="en-US">Accrued Travel And Entertainment Expense Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_AccruedTravelAndEntertainmentExpenseCurrent_lbl" xml:lang="en-US">Travel and entertainment</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AccruedDirectorFeesCurrent" xlink:label="ctso_AccruedDirectorFeesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_AccruedDirectorFeesCurrent" xlink:to="ctso_AccruedDirectorFeesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_AccruedDirectorFeesCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for board of Director fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_AccruedDirectorFeesCurrent_lbl" xml:lang="en-US">Accrued Director Fees Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_AccruedDirectorFeesCurrent_lbl" xml:lang="en-US">Board of Director fees</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_SalesPayrollAndIncomeTaxesPayableCurrent" xlink:label="ctso_SalesPayrollAndIncomeTaxesPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_SalesPayrollAndIncomeTaxesPayableCurrent" xlink:to="ctso_SalesPayrollAndIncomeTaxesPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_SalesPayrollAndIncomeTaxesPayableCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales, payroll and income taxes payable. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_SalesPayrollAndIncomeTaxesPayableCurrent_lbl" xml:lang="en-US">Sales Payroll and Income Taxes Payable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_SalesPayrollAndIncomeTaxesPayableCurrent_lbl" xml:lang="en-US">Sales, payroll and income taxes payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CongressesPayableCurrent" xlink:label="ctso_CongressesPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_CongressesPayableCurrent" xlink:to="ctso_CongressesPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_CongressesPayableCurrent_lbl" xml:lang="en-US">The element represents the carrying value of congresses classified as current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_CongressesPayableCurrent_lbl" xml:lang="en-US">Congresses Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ctso_CongressesPayableCurrent_lbl" xml:lang="en-US">Congresses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xml:lang="en-US">Lender Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_WesternAllianceBankMember" xlink:label="ctso_WesternAllianceBankMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_WesternAllianceBankMember" xlink:to="ctso_WesternAllianceBankMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_WesternAllianceBankMember_lbl" xml:lang="en-US">This member stands for western alliance bank.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_WesternAllianceBankMember_lbl" xml:lang="en-US">Western Alliance Bank [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_WesternAllianceBankMember_lbl" xml:lang="en-US">Western Alliance Bank</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NewTermLoanMember" xlink:label="ctso_NewTermLoanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_NewTermLoanMember" xlink:to="ctso_NewTermLoanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_NewTermLoanMember_lbl" xml:lang="en-US">This represents New Term Loan member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_NewTermLoanMember_lbl" xml:lang="en-US">New Term Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_NewTermLoanMember_lbl" xml:lang="en-US">New Term Loan</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_TermLoanMember" xlink:label="ctso_TermLoanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_TermLoanMember" xlink:to="ctso_TermLoanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_TermLoanMember_lbl" xml:lang="en-US">This member stands for term a loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_TermLoanMember_lbl" xml:lang="en-US">Term A Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_TermLoanMember_lbl" xml:lang="en-US">Term A Loan</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_TermBLoanMember" xlink:label="ctso_TermBLoanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_TermBLoanMember" xlink:to="ctso_TermBLoanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_TermBLoanMember_lbl" xml:lang="en-US">This member stands for term b loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_TermBLoanMember_lbl" xml:lang="en-US">Term B Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_TermBLoanMember_lbl" xml:lang="en-US">Term B Loan</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_TermCLoanMember" xlink:label="ctso_TermCLoanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_TermCLoanMember" xlink:to="ctso_TermCLoanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_TermCLoanMember_lbl" xml:lang="en-US">This member stands for term c loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_TermCLoanMember_lbl" xml:lang="en-US">Term C Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_TermCLoanMember_lbl" xml:lang="en-US">Term C Loan</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NonRefundableClosingFeeMember" xlink:label="ctso_NonRefundableClosingFeeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_NonRefundableClosingFeeMember" xlink:to="ctso_NonRefundableClosingFeeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_NonRefundableClosingFeeMember_lbl" xml:lang="en-US">This member stands for non refundable closing fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_NonRefundableClosingFeeMember_lbl" xml:lang="en-US">Non refundable Closing Fee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ctso_NonRefundableClosingFeeMember_lbl" xml:lang="en-US">Non refundable Closing Fee</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_TwoThousandAndEighteenSuccessFeeLetterMember" xlink:label="ctso_TwoThousandAndEighteenSuccessFeeLetterMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_TwoThousandAndEighteenSuccessFeeLetterMember" xlink:to="ctso_TwoThousandAndEighteenSuccessFeeLetterMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_TwoThousandAndEighteenSuccessFeeLetterMember_lbl" xml:lang="en-US">Represents the information pertaining to 2018 success fee letter.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_TwoThousandAndEighteenSuccessFeeLetterMember_lbl" xml:lang="en-US">2018 Success Fee Letter [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_TwoThousandAndEighteenSuccessFeeLetterMember_lbl" xml:lang="en-US">2018 Success Fee Letter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_FirstTrancheMember" xlink:label="ctso_FirstTrancheMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_FirstTrancheMember" xlink:to="ctso_FirstTrancheMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_FirstTrancheMember_lbl" xml:lang="en-US">This member stands for first tranche Member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_FirstTrancheMember_lbl" xml:lang="en-US">First Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_FirstTrancheMember_lbl" xml:lang="en-US">First Tranche</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_SecondTrancheMember" xlink:label="ctso_SecondTrancheMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_SecondTrancheMember" xlink:to="ctso_SecondTrancheMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_SecondTrancheMember_lbl" xml:lang="en-US">This member stands for second tranche Member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_SecondTrancheMember_lbl" xml:lang="en-US">Second Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_SecondTrancheMember_lbl" xml:lang="en-US">Second Tranche</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ThirdTrancheMember" xlink:label="ctso_ThirdTrancheMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ThirdTrancheMember" xlink:to="ctso_ThirdTrancheMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ThirdTrancheMember_lbl" xml:lang="en-US">This member stands for third tranche Member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ThirdTrancheMember_lbl" xml:lang="en-US">Third Tranche [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ThirdTrancheMember_lbl" xml:lang="en-US">Third Tranche</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US">Balance Sheet Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US">Balance Sheet Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ClosingFeeMember" xlink:label="ctso_ClosingFeeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ClosingFeeMember" xlink:to="ctso_ClosingFeeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ClosingFeeMember_lbl" xml:lang="en-US">This member stands for closing fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ClosingFeeMember_lbl" xml:lang="en-US">Closing Fee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ClosingFeeMember_lbl" xml:lang="en-US">Closing Fee</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">LONG-TERM DEBT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt instrument , Face amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Security amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayments of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayments of debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long-term debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Maximum borrowing capacity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_lbl" xml:lang="en-US">Current borrowing capacity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">Rate of interest added to reference rate as per debt agreement</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_DebtInstrumentCapInterestRate" xlink:label="ctso_DebtInstrumentCapInterestRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_DebtInstrumentCapInterestRate" xlink:to="ctso_DebtInstrumentCapInterestRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_DebtInstrumentCapInterestRate_lbl" xml:lang="en-US">The cap interest rate during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_DebtInstrumentCapInterestRate_lbl" xml:lang="en-US">Debt Instrument, Cap Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_DebtInstrumentCapInterestRate_lbl" xml:lang="en-US">Interest rate cap</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Debt Instrument, Periodic Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Equal monthly payments of principal with accrued and unpaid interest payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Debt Issuance Costs, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Debt issuance costs</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent" xlink:label="ctso_DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent" xlink:to="ctso_DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent_lbl" xml:lang="en-US">Non-refundable fee to be paid upon termination or maturity of debt instrument, representing the percent of the principal amount of debt funded.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent_lbl" xml:lang="en-US">Debt Instrument, Non-refundable Fee Upon Termination or Maturity, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent_lbl" xml:lang="en-US">Non-refundable fee percent</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_PercentageOfSuccessFee" xlink:label="ctso_PercentageOfSuccessFee" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_PercentageOfSuccessFee" xlink:to="ctso_PercentageOfSuccessFee_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_PercentageOfSuccessFee_lbl" xml:lang="en-US">The average effective success fee rate during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_PercentageOfSuccessFee_lbl" xml:lang="en-US">Percentage Of Success Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_PercentageOfSuccessFee_lbl" xml:lang="en-US">Percentage of success fee</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_PercentageOfClosingPriceOnCommonStock" xlink:label="ctso_PercentageOfClosingPriceOnCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_PercentageOfClosingPriceOnCommonStock" xlink:to="ctso_PercentageOfClosingPriceOnCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_PercentageOfClosingPriceOnCommonStock_lbl" xml:lang="en-US">The percentage of closing price on common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_PercentageOfClosingPriceOnCommonStock_lbl" xml:lang="en-US">Percentage of Closing Price on Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_PercentageOfClosingPriceOnCommonStock_lbl" xml:lang="en-US">Percentage of closing price on common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Average selling price</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NumberOfDaysForStockPriceThreshold" xlink:label="ctso_NumberOfDaysForStockPriceThreshold" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_NumberOfDaysForStockPriceThreshold" xlink:to="ctso_NumberOfDaysForStockPriceThreshold_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_NumberOfDaysForStockPriceThreshold_lbl" xml:lang="en-US">Number of days for stock price threshold set in success fee letter.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_NumberOfDaysForStockPriceThreshold_lbl" xml:lang="en-US">Number of Days for Stock Price Threshold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_NumberOfDaysForStockPriceThreshold_lbl" xml:lang="en-US">Number of days for stock price threshold set in success fee letter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Principal amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US">2025</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_LongTermDebtAndFinalFee" xlink:label="ctso_LongTermDebtAndFinalFee" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_LongTermDebtAndFinalFee" xlink:to="ctso_LongTermDebtAndFinalFee_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_LongTermDebtAndFinalFee_lbl" xml:lang="en-US">Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt and final fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_LongTermDebtAndFinalFee_lbl" xml:lang="en-US">Long term Debt And Final Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ctso_LongTermDebtAndFinalFee_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OperatingLeaseInitialEarlyTermMember" xlink:label="ctso_OperatingLeaseInitialEarlyTermMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_OperatingLeaseInitialEarlyTermMember" xlink:to="ctso_OperatingLeaseInitialEarlyTermMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_OperatingLeaseInitialEarlyTermMember_lbl" xml:lang="en-US">This member stands for initial early term of operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_OperatingLeaseInitialEarlyTermMember_lbl" xml:lang="en-US">Initial early term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_OperatingLeaseInitialEarlyTermMember_lbl" xml:lang="en-US">Initial early term</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OperatingLeaseEarlyTermMember" xlink:label="ctso_OperatingLeaseEarlyTermMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_OperatingLeaseEarlyTermMember" xlink:to="ctso_OperatingLeaseEarlyTermMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_OperatingLeaseEarlyTermMember_lbl" xml:lang="en-US">This member stands for early term of operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_OperatingLeaseEarlyTermMember_lbl" xml:lang="en-US">Early term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_OperatingLeaseEarlyTermMember_lbl" xml:lang="en-US">Early term</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OperatingLeaseFirstYearOfRemainingLeaseTermMember" xlink:label="ctso_OperatingLeaseFirstYearOfRemainingLeaseTermMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_OperatingLeaseFirstYearOfRemainingLeaseTermMember" xlink:to="ctso_OperatingLeaseFirstYearOfRemainingLeaseTermMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_OperatingLeaseFirstYearOfRemainingLeaseTermMember_lbl" xml:lang="en-US">This member stands for first year of remaining operating lease term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_OperatingLeaseFirstYearOfRemainingLeaseTermMember_lbl" xml:lang="en-US">First year of remaining lease term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_OperatingLeaseFirstYearOfRemainingLeaseTermMember_lbl" xml:lang="en-US">Early term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xml:lang="en-US">Consolidated Entities [Domain]</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CytosorbentsMedicalIncMember" xlink:label="ctso_CytosorbentsMedicalIncMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_CytosorbentsMedicalIncMember" xlink:to="ctso_CytosorbentsMedicalIncMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_CytosorbentsMedicalIncMember_lbl" xml:lang="en-US">This member stands for CytoSorbents Medical, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_CytosorbentsMedicalIncMember_lbl" xml:lang="en-US">CytoSorbents Medical, Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_CytosorbentsMedicalIncMember_lbl" xml:lang="en-US">CytoSorbents Medical, Inc</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CytosorbentsEuropeGmbhMember" xlink:label="ctso_CytosorbentsEuropeGmbhMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_CytosorbentsEuropeGmbhMember" xlink:to="ctso_CytosorbentsEuropeGmbhMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_CytosorbentsEuropeGmbhMember_lbl" xml:lang="en-US">This member stands for CytoSorbents Europe GmbH.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_CytosorbentsEuropeGmbhMember_lbl" xml:lang="en-US">CytoSorbents Europe GmbH [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_CytosorbentsEuropeGmbhMember_lbl" xml:lang="en-US">CytoSorbents Europe GmbH</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xml:lang="en-US">Lease Arrangement, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_TwentiethAmendmentToLeaseMember" xlink:label="ctso_TwentiethAmendmentToLeaseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_TwentiethAmendmentToLeaseMember" xlink:to="ctso_TwentiethAmendmentToLeaseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_TwentiethAmendmentToLeaseMember_lbl" xml:lang="en-US">This member stands for twentieth amendment  to lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_TwentiethAmendmentToLeaseMember_lbl" xml:lang="en-US">Twentieth Amendment To lease [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ctso_TwentiethAmendmentToLeaseMember_lbl" xml:lang="en-US">Twentieth Amendment To lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US">LEASES:</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NumberOfTimesLeaseRenewalAvailable" xlink:label="ctso_NumberOfTimesLeaseRenewalAvailable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_NumberOfTimesLeaseRenewalAvailable" xlink:to="ctso_NumberOfTimesLeaseRenewalAvailable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_NumberOfTimesLeaseRenewalAvailable_lbl" xml:lang="en-US">The number of times lease renewal options available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_NumberOfTimesLeaseRenewalAvailable_lbl" xml:lang="en-US">Number of Times Lease Renewal Available</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_NumberOfTimesLeaseRenewalAvailable_lbl" xml:lang="en-US">Number of times lease renewal options available</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Renewal term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Remaining lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Monthly payments of base rent and other costs</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OperatingLeasesAnnualRentExpenseIncrementRate" xlink:label="ctso_OperatingLeasesAnnualRentExpenseIncrementRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_OperatingLeasesAnnualRentExpenseIncrementRate" xlink:to="ctso_OperatingLeasesAnnualRentExpenseIncrementRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_OperatingLeasesAnnualRentExpenseIncrementRate_lbl" xml:lang="en-US">The percentage of annual increment in operating lease rent expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_OperatingLeasesAnnualRentExpenseIncrementRate_lbl" xml:lang="en-US">Operating Leases, Annual Rent Expense Increment Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_OperatingLeasesAnnualRentExpenseIncrementRate_lbl" xml:lang="en-US">Annual rent expense increment rate</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OperatingLeasesRentAbatementTerm" xlink:label="ctso_OperatingLeasesRentAbatementTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_OperatingLeasesRentAbatementTerm" xlink:to="ctso_OperatingLeasesRentAbatementTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_OperatingLeasesRentAbatementTerm_lbl" xml:lang="en-US">Rent abatement term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_OperatingLeasesRentAbatementTerm_lbl" xml:lang="en-US">Operating Leases, Rent Abatement Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_OperatingLeasesRentAbatementTerm_lbl" xml:lang="en-US">Rent abatement term</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_PercentageOfTotalBuildingSpaceOccupied" xlink:label="ctso_PercentageOfTotalBuildingSpaceOccupied" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_PercentageOfTotalBuildingSpaceOccupied" xlink:to="ctso_PercentageOfTotalBuildingSpaceOccupied_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_PercentageOfTotalBuildingSpaceOccupied_lbl" xml:lang="en-US">The percentage of total building space occupied.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_PercentageOfTotalBuildingSpaceOccupied_lbl" xml:lang="en-US">Percentage Of Total Building Space Occupied</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_PercentageOfTotalBuildingSpaceOccupied_lbl" xml:lang="en-US">Percentage of total building space occupied</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OperatingLeasesBuildingImprovementAllowanceReceivable" xlink:label="ctso_OperatingLeasesBuildingImprovementAllowanceReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_OperatingLeasesBuildingImprovementAllowanceReceivable" xlink:to="ctso_OperatingLeasesBuildingImprovementAllowanceReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_OperatingLeasesBuildingImprovementAllowanceReceivable_lbl" xml:lang="en-US">The amount of allowance for building improvement receivable from landlord.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_OperatingLeasesBuildingImprovementAllowanceReceivable_lbl" xml:lang="en-US">Operating Leases, Building Improvement Allowance Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_OperatingLeasesBuildingImprovementAllowanceReceivable_lbl" xml:lang="en-US">Allowance for building improvement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease lability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Incremental borrowing rate</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AdditionalOperatingLeasesRentExpenseNet" xlink:label="ctso_AdditionalOperatingLeasesRentExpenseNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_AdditionalOperatingLeasesRentExpenseNet" xlink:to="ctso_AdditionalOperatingLeasesRentExpenseNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_AdditionalOperatingLeasesRentExpenseNet_lbl" xml:lang="en-US">Additional rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_AdditionalOperatingLeasesRentExpenseNet_lbl" xml:lang="en-US">Additional Operating Leases Rent Expense Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_AdditionalOperatingLeasesRentExpenseNet_lbl" xml:lang="en-US">Additional operating leases rent expense</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OperatingLeaseBaseRentForRemainingSpace" xlink:label="ctso_OperatingLeaseBaseRentForRemainingSpace" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_OperatingLeaseBaseRentForRemainingSpace" xlink:to="ctso_OperatingLeaseBaseRentForRemainingSpace_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_OperatingLeaseBaseRentForRemainingSpace_lbl" xml:lang="en-US">Amount of operating lease base rent for remaining space.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_OperatingLeaseBaseRentForRemainingSpace_lbl" xml:lang="en-US">Operating Lease Base Rent for Remaining Space</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_OperatingLeaseBaseRentForRemainingSpace_lbl" xml:lang="en-US">Operating lease base rent for remaining space</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_MonthlyOperatingExpenses" xlink:label="ctso_MonthlyOperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_MonthlyOperatingExpenses" xlink:to="ctso_MonthlyOperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_MonthlyOperatingExpenses_lbl" xml:lang="en-US">The amount of monthly operating expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_MonthlyOperatingExpenses_lbl" xml:lang="en-US">Monthly Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_MonthlyOperatingExpenses_lbl" xml:lang="en-US">Monthly operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of Land.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of Land</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Other costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating lease paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2027</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:label="ctso_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:to="ctso_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_lbl" xml:lang="en-US">Amount of lessee's undiscounted obligation for lease payment for operating lease due fifth and after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_lbl" xml:lang="en-US">Lessee Operating Lease Liability Payments Due Year Five And After Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Present value discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Domestic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests" xlink:label="ctso_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests" xlink:to="ctso_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests_lbl" xml:lang="en-US">Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interests</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ctso_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests_lbl" xml:lang="en-US">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US">State and Local Income Tax Expense (Benefit), Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US">State Tax, including sale of New Jersey losses &amp; credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_lbl" xml:lang="en-US">Stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development credit carryforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xml:lang="en-US">Accruals and others</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability" xlink:label="ctso_DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability" xlink:to="ctso_DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability_lbl" xml:lang="en-US">Amount of deferred tax assets, tax credit carryforwards, lease liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability_lbl" xml:lang="en-US">Lease liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_lbl" xml:lang="en-US">Deferred Tax Assets, Other Tax Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_lbl" xml:lang="en-US">174(b) research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Gross deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets, net of valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US">Deferred tax liability:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US">Fixed assets</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_DeferredTaxLiabilitiesRightsOfUseAssets" xlink:label="ctso_DeferredTaxLiabilitiesRightsOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_DeferredTaxLiabilitiesRightsOfUseAssets" xlink:to="ctso_DeferredTaxLiabilitiesRightsOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_DeferredTaxLiabilitiesRightsOfUseAssets_lbl" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from property, ROU</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_DeferredTaxLiabilitiesRightsOfUseAssets_lbl" xml:lang="en-US">Deferred Tax Liabilities Rights Of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ctso_DeferredTaxLiabilitiesRightsOfUseAssets_lbl" xml:lang="en-US">Right of Use Asset</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayTable" xlink:label="us-gaap_IncomeTaxHolidayTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxHolidayTable" xlink:to="us-gaap_IncomeTaxHolidayTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxHolidayTable_lbl" xml:lang="en-US">Income Tax Holiday [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayLineItems" xlink:label="us-gaap_IncomeTaxHolidayLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxHolidayLineItems" xlink:to="us-gaap_IncomeTaxHolidayLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxHolidayLineItems_lbl" xml:lang="en-US">Income Tax Holiday [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxHolidayLineItems_lbl" xml:lang="en-US">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Foreign rate differential</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent" xlink:label="ctso_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent" xlink:to="ctso_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent_lbl" xml:lang="en-US">Effective income tax rate reconciliation permanent income tax rate percent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation Permanent Income Tax Rate percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent_lbl" xml:lang="en-US">Permanent items</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Rate change and true-up</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US">R&amp;D credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Sale of state R&amp;D credit and NOL</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign Tax Authority</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US">Foreign Tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">INCOME TAXES</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ProceedsFromSaleOfNetOperatingLossCarryforwards" xlink:label="ctso_ProceedsFromSaleOfNetOperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ProceedsFromSaleOfNetOperatingLossCarryforwards" xlink:to="ctso_ProceedsFromSaleOfNetOperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ProceedsFromSaleOfNetOperatingLossCarryforwards_lbl" xml:lang="en-US">The proceeds received from the sale of previously unused net operating loss carryforwards, allowed due to participation in the Technology Business Tax Certificate Transfer Program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ProceedsFromSaleOfNetOperatingLossCarryforwards_lbl" xml:lang="en-US">Proceeds From Sale Of Net Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ProceedsFromSaleOfNetOperatingLossCarryforwards_lbl" xml:lang="en-US">Proceeds from the sale of prior unused net operating loss carryovers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US">Tax credit carryforward, amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase, Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xml:lang="en-US">Operating Loss Carryforwards, Limitations on Use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_lbl" xml:lang="en-US">operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CommitmentsAndContingenciesDisclosureTable" xlink:label="ctso_CommitmentsAndContingenciesDisclosureTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_CommitmentsAndContingenciesDisclosureTable" xlink:to="ctso_CommitmentsAndContingenciesDisclosureTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_CommitmentsAndContingenciesDisclosureTable_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_CommitmentsAndContingenciesDisclosureTable_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ctso_CommitmentsAndContingenciesDisclosureTable_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyAgreementsMember" xlink:label="us-gaap_RoyaltyAgreementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyAgreementsMember" xlink:to="us-gaap_RoyaltyAgreementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyAgreementsMember_lbl" xml:lang="en-US">Royalty Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RoyaltyAgreementsMember_lbl" xml:lang="en-US">Royalty Agreements</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_LicenseAgreementMember" xlink:label="ctso_LicenseAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_LicenseAgreementMember" xlink:to="ctso_LicenseAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_lbl" xml:lang="en-US">Loss Contingency Nature [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="us-gaap_LossContingencyNatureDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyNatureDomain_lbl" xml:lang="en-US">Loss Contingency, Nature [Domain]</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_PayrollTaxAuditMember" xlink:label="ctso_PayrollTaxAuditMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_PayrollTaxAuditMember" xlink:to="ctso_PayrollTaxAuditMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_PayrollTaxAuditMember_lbl" xml:lang="en-US">Represents information pertaining to payroll tax audit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_PayrollTaxAuditMember_lbl" xml:lang="en-US">Payroll Tax Audit [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_PayrollTaxAuditMember_lbl" xml:lang="en-US">Payroll Tax Audit</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AdditionalSocialSecurityAndVatTaxesMember" xlink:label="ctso_AdditionalSocialSecurityAndVatTaxesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_AdditionalSocialSecurityAndVatTaxesMember" xlink:to="ctso_AdditionalSocialSecurityAndVatTaxesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_AdditionalSocialSecurityAndVatTaxesMember_lbl" xml:lang="en-US">Represents information pertaining to additional social security and VAT taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_AdditionalSocialSecurityAndVatTaxesMember_lbl" xml:lang="en-US">Additional Social Security and VAT Taxes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_AdditionalSocialSecurityAndVatTaxesMember_lbl" xml:lang="en-US">Additional Social Security and VAT Taxes</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="ctso_CommitmentsAndContingenciesDisclosureLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="ctso_CommitmentsAndContingenciesDisclosureLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_CommitmentsAndContingenciesDisclosureLineItems_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_CommitmentsAndContingenciesDisclosureLineItems_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_CommitmentsAndContingenciesDisclosureLineItems_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationInterestAccrued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationInterestAccrued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationInterestAccrued_lbl" xml:lang="en-US">Income Tax Examination, Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationInterestAccrued_lbl" xml:lang="en-US">Accrued tax liability</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ExecutiveEmploymentAgreementsInitialTerm" xlink:label="ctso_ExecutiveEmploymentAgreementsInitialTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ExecutiveEmploymentAgreementsInitialTerm" xlink:to="ctso_ExecutiveEmploymentAgreementsInitialTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ExecutiveEmploymentAgreementsInitialTerm_lbl" xml:lang="en-US">Represents the initial term of executive employment agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ExecutiveEmploymentAgreementsInitialTerm_lbl" xml:lang="en-US">Executive Employment Agreements , Initial Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ExecutiveEmploymentAgreementsInitialTerm_lbl" xml:lang="en-US">Initial term (in years)</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_EmploymentAgreementsAutomaticRenewalPeriod" xlink:label="ctso_EmploymentAgreementsAutomaticRenewalPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_EmploymentAgreementsAutomaticRenewalPeriod" xlink:to="ctso_EmploymentAgreementsAutomaticRenewalPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_EmploymentAgreementsAutomaticRenewalPeriod_lbl" xml:lang="en-US">Automatic renewal period for employment agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_EmploymentAgreementsAutomaticRenewalPeriod_lbl" xml:lang="en-US">Employment Agreements, Automatic Renewal Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_EmploymentAgreementsAutomaticRenewalPeriod_lbl" xml:lang="en-US">Automatic renewal period for employment agreements</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_EmploymentAgreementsAutomaticRenewedPeriod" xlink:label="ctso_EmploymentAgreementsAutomaticRenewedPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_EmploymentAgreementsAutomaticRenewedPeriod" xlink:to="ctso_EmploymentAgreementsAutomaticRenewedPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_EmploymentAgreementsAutomaticRenewedPeriod_lbl" xml:lang="en-US">Automatic renewed period for employment agreements, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_EmploymentAgreementsAutomaticRenewedPeriod_lbl" xml:lang="en-US">Employment Agreements, Automatic Renewed Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_EmploymentAgreementsAutomaticRenewedPeriod_lbl" xml:lang="en-US">Additional automatic renewed period for employment agreements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Equity investment by an existing investor</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_RoyaltyPaymentRate" xlink:label="ctso_RoyaltyPaymentRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_RoyaltyPaymentRate" xlink:to="ctso_RoyaltyPaymentRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_RoyaltyPaymentRate_lbl" xml:lang="en-US">The rate of royalty payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_RoyaltyPaymentRate_lbl" xml:lang="en-US">Royalty Payment Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_RoyaltyPaymentRate_lbl" xml:lang="en-US">Future royalty payment percentage on gross revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty cost</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_LicensePeriod" xlink:label="ctso_LicensePeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_LicensePeriod" xlink:to="ctso_LicensePeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_LicensePeriod_lbl" xml:lang="en-US">The duration of license period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_LicensePeriod_lbl" xml:lang="en-US">License Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_LicensePeriod_lbl" xml:lang="en-US">Term of license agreement</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_RoyaltyRateLowerLimit" xlink:label="ctso_RoyaltyRateLowerLimit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_RoyaltyRateLowerLimit" xlink:to="ctso_RoyaltyRateLowerLimit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_RoyaltyRateLowerLimit_lbl" xml:lang="en-US">The rate of royalty rate lower limit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_RoyaltyRateLowerLimit_lbl" xml:lang="en-US">Royalty Rate Lower Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_RoyaltyRateLowerLimit_lbl" xml:lang="en-US">Royalty rate, lower limit</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_RoyaltyRateUpperLimit" xlink:label="ctso_RoyaltyRateUpperLimit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_RoyaltyRateUpperLimit" xlink:to="ctso_RoyaltyRateUpperLimit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_RoyaltyRateUpperLimit_lbl" xml:lang="en-US">The rate of royalty rate upper limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_RoyaltyRateUpperLimit_lbl" xml:lang="en-US">Royalty Rate Upper Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_RoyaltyRateUpperLimit_lbl" xml:lang="en-US">Royalty rate, upper limit</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockholdersEquityTable" xlink:label="ctso_StockholdersEquityTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_StockholdersEquityTable" xlink:to="ctso_StockholdersEquityTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_StockholdersEquityTable_lbl" xml:lang="en-US">Schedule that describes stockholders' equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_StockholdersEquityTable_lbl" xml:lang="en-US">Stockholders Equity [Table]</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockholdersEquityLineItems" xlink:label="ctso_StockholdersEquityLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_StockholdersEquityLineItems" xlink:to="ctso_StockholdersEquityLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_StockholdersEquityLineItems_lbl" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_StockholdersEquityLineItems_lbl" xml:lang="en-US">Stockholders Equity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_StockholdersEquityLineItems_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US">Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding, end of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding, beginning of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of option granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Expired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US">Weighted Average Exercise Price per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding, end of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Outstanding, beginning of the year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Expired</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (Years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US">Options Exercisable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Outstanding, beginning of the year</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm" xlink:to="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Granted</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm" xlink:to="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted average remaining contractual term for option awards cancelled during the period, in PnYnMnDTnHnMnS format, for example, P1Y5M13D represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Cancelled in Period Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Forfeited</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm" xlink:to="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award Options Outstanding Expired In Period Weighted Average Remaining Contractual Term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Expired</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm" xlink:to="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted average remaining contractual term for option awards exercised during the period, in PnYnMnDTnHnMnS format, for example, P1Y5M13D represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Exercised in Period Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Outstanding, end of the year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ExercisePriceRangingFrom5.00To10.58Member" xlink:label="ctso_ExercisePriceRangingFrom5.00To10.58Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ExercisePriceRangingFrom5.00To10.58Member" xlink:to="ctso_ExercisePriceRangingFrom5.00To10.58Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ExercisePriceRangingFrom5.00To10.58Member_lbl" xml:lang="en-US">Represents information pertaining to exercise price ranging from 5.00 to 10.58.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ExercisePriceRangingFrom5.00To10.58Member_lbl" xml:lang="en-US">Exercise Price Ranging from 5.00 to 10.58 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ExercisePriceRangingFrom5.00To10.58Member_lbl" xml:lang="en-US">Exercise price ranging from 5.00 to 10.58</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ExercisePriceRangingFrom4.46To11.39Member" xlink:label="ctso_ExercisePriceRangingFrom4.46To11.39Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ExercisePriceRangingFrom4.46To11.39Member" xlink:to="ctso_ExercisePriceRangingFrom4.46To11.39Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ExercisePriceRangingFrom4.46To11.39Member_lbl" xml:lang="en-US">Represents the information pertaining to Exercise Price Ranging From 4.46 to 11.39.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ExercisePriceRangingFrom4.46To11.39Member_lbl" xml:lang="en-US">Exercise Price Ranging From 4.46 To 11.39 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ExercisePriceRangingFrom4.46To11.39Member_lbl" xml:lang="en-US">Exercise price ranging from 4.46 to 11.39</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ExercisePriceRangingFrom2.98To3.91Member" xlink:label="ctso_ExercisePriceRangingFrom2.98To3.91Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ExercisePriceRangingFrom2.98To3.91Member" xlink:to="ctso_ExercisePriceRangingFrom2.98To3.91Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ExercisePriceRangingFrom2.98To3.91Member_lbl" xml:lang="en-US">Represents information pertaining to exercise price ranging from 1.11 to 3.91.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ExercisePriceRangingFrom2.98To3.91Member_lbl" xml:lang="en-US">Exercise Price Ranging From 1.11 To 3.91 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ExercisePriceRangingFrom2.98To3.91Member_lbl" xml:lang="en-US">Exercise price ranging from 1.11 to 3.91</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Grant Date Exercise Price Range</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected Life of the Stock Option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Current Price of the Underlying Stock and its Expected Volatility Range</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected Dividends</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk Free Interest Rate, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk Free Interest Rate Range</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ExercisePriceRangeOneMember" xlink:label="ctso_ExercisePriceRangeOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ExercisePriceRangeOneMember" xlink:to="ctso_ExercisePriceRangeOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ExercisePriceRangeOneMember_lbl" xml:lang="en-US">Represents exercise price range one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ExercisePriceRangeOneMember_lbl" xml:lang="en-US">Exercise Price Range One [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract_lbl" xml:lang="en-US">Options Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xml:lang="en-US">Range of Exercise Price, Lower Range Limit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xml:lang="en-US">Range of Exercise Price, Upper Range Limit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Number Outstanding at December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Life (Years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Grant date fair value of these unvested options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Number Exercisable at December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl" xml:lang="en-US">Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Non-vested, December 31, 2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Non-vested, January 1, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Non-vested, December 31, 2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Non-vested, January 1, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Equity Award [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Relationship to Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of directors</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ManagementMember" xlink:to="srt_ManagementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ManagementMember_lbl" xml:lang="en-US">Executive Management</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficerMember" xlink:label="srt_OfficerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OfficerMember_lbl" xml:lang="en-US">Other Employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Restricted Stock Units, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Restricted Stock Units, Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Restricted Stock Units, Intrinsic Value Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Restricted Stock Units, Intrinsic Value Beginning Balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Restricted Stock Units, Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xml:lang="en-US">Restricted Stock Units, Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Non-vested, December 31, 2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Non-vested, January 1, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Non-vested, December 31, 2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Non-vested, January 1, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US">Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_JefferiesLlcAndB.RileyFbrIncMember" xlink:label="ctso_JefferiesLlcAndB.RileyFbrIncMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_JefferiesLlcAndB.RileyFbrIncMember" xlink:to="ctso_JefferiesLlcAndB.RileyFbrIncMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_JefferiesLlcAndB.RileyFbrIncMember_lbl" xml:lang="en-US">Represents information pertaining to Jefferies LLC and B. Riley FBR, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_JefferiesLlcAndB.RileyFbrIncMember_lbl" xml:lang="en-US">Jefferies LLC and B. Riley FBR, Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_JefferiesLlcAndB.RileyFbrIncMember_lbl" xml:lang="en-US">Jefferies LLC and B. Riley FBR, Inc</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockOptionPlanOneMember" xlink:label="ctso_StockOptionPlanOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_StockOptionPlanOneMember" xlink:to="ctso_StockOptionPlanOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_StockOptionPlanOneMember_lbl" xml:lang="en-US">Stock Option Plan One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_StockOptionPlanOneMember_lbl" xml:lang="en-US">Stock Option Plan One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_StockOptionPlanOneMember_lbl" xml:lang="en-US">Stock option plan one</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_TwoThousandFourteenStockOptionPlanMember" xlink:label="ctso_TwoThousandFourteenStockOptionPlanMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_TwoThousandFourteenStockOptionPlanMember" xlink:to="ctso_TwoThousandFourteenStockOptionPlanMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_TwoThousandFourteenStockOptionPlanMember_lbl" xml:lang="en-US">Represents information pertaining to 2014 Long Term Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_TwoThousandFourteenStockOptionPlanMember_lbl" xml:lang="en-US">Two Thousand Fourteen Stock Option Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ctso_TwoThousandFourteenStockOptionPlanMember_lbl" xml:lang="en-US">2014 Stock Option Plan</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_July222019PerformanceBasedAwardMember" xlink:label="ctso_July222019PerformanceBasedAwardMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_July222019PerformanceBasedAwardMember" xlink:to="ctso_July222019PerformanceBasedAwardMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_July222019PerformanceBasedAwardMember_lbl" xml:lang="en-US">Represents the information pertaining to July 22, 2019 Performance-Based Award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_July222019PerformanceBasedAwardMember_lbl" xml:lang="en-US">July 22, 2019 Performance-Based Award [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_July222019PerformanceBasedAwardMember_lbl" xml:lang="en-US">July 22, 2019 performance-based award</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_February282020PerformanceBasedAwardMember" xlink:label="ctso_February282020PerformanceBasedAwardMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_February282020PerformanceBasedAwardMember" xlink:to="ctso_February282020PerformanceBasedAwardMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_February282020PerformanceBasedAwardMember_lbl" xml:lang="en-US">Represents information pertaining to February 28 2020 performance based award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_February282020PerformanceBasedAwardMember_lbl" xml:lang="en-US">February 28 2020 Performance Based Award [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_February282020PerformanceBasedAwardMember_lbl" xml:lang="en-US">February 28 2020 performance based award</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_April122021PerformanceBasedAwardMember" xlink:label="ctso_April122021PerformanceBasedAwardMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_April122021PerformanceBasedAwardMember" xlink:to="ctso_April122021PerformanceBasedAwardMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_April122021PerformanceBasedAwardMember_lbl" xml:lang="en-US">Represents the information pertaining to April 12, 2021 performance based award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_April122021PerformanceBasedAwardMember_lbl" xml:lang="en-US">April 12, 2021 Performance Based Award [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_April122021PerformanceBasedAwardMember_lbl" xml:lang="en-US">April 12, 2021 performance based award</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_August102022PerformanceBasedAwardMember" xlink:label="ctso_August102022PerformanceBasedAwardMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_August102022PerformanceBasedAwardMember" xlink:to="ctso_August102022PerformanceBasedAwardMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_August102022PerformanceBasedAwardMember_lbl" xml:lang="en-US">Represents the information pertaining to August 10, 2022 Performance Based Award.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_August102022PerformanceBasedAwardMember_lbl" xml:lang="en-US">August 10, 2022 Performance Based Award [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_August102022PerformanceBasedAwardMember_lbl" xml:lang="en-US">August 10, 2022 performance based award</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_EmployeeOneMember" xlink:label="ctso_EmployeeOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_EmployeeOneMember" xlink:to="ctso_EmployeeOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_EmployeeOneMember_lbl" xml:lang="en-US">This member stands for Employee One.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_EmployeeOneMember_lbl" xml:lang="en-US">Employee One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_EmployeeOneMember_lbl" xml:lang="en-US">Employee one</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_EmployeeTwoMember" xlink:label="ctso_EmployeeTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_EmployeeTwoMember" xlink:to="ctso_EmployeeTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_EmployeeTwoMember_lbl" xml:lang="en-US">This member stands for Employee Two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_EmployeeTwoMember_lbl" xml:lang="en-US">Employee Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_EmployeeTwoMember_lbl" xml:lang="en-US">Employee two</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_SeniorManagerOneMember" xlink:label="ctso_SeniorManagerOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_SeniorManagerOneMember" xlink:to="ctso_SeniorManagerOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_SeniorManagerOneMember_lbl" xml:lang="en-US">This member stands for Senior manager one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_SeniorManagerOneMember_lbl" xml:lang="en-US">Senior Manager One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_SeniorManagerOneMember_lbl" xml:lang="en-US">Senior manager one</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_SeniorManagerTwoMember" xlink:label="ctso_SeniorManagerTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_SeniorManagerTwoMember" xlink:to="ctso_SeniorManagerTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_SeniorManagerTwoMember_lbl" xml:lang="en-US">This member stands for Senior Manager Two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_SeniorManagerTwoMember_lbl" xml:lang="en-US">Senior Manager Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_SeniorManagerTwoMember_lbl" xml:lang="en-US">Senior manager two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">On the date of the grant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">First anniversary of the date of the grant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US">Share-based Payment Arrangement, Tranche Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xml:lang="en-US">Second anniversary of the date of the grant</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ShareBasedCompensationAwardTrancheFourMember" xlink:label="ctso_ShareBasedCompensationAwardTrancheFourMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ShareBasedCompensationAwardTrancheFourMember" xlink:to="ctso_ShareBasedCompensationAwardTrancheFourMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ShareBasedCompensationAwardTrancheFourMember_lbl" xml:lang="en-US">Fourth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ShareBasedCompensationAwardTrancheFourMember_lbl" xml:lang="en-US">Third Anniversary Of the Date of The Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ShareBasedCompensationAwardTrancheFourMember_lbl" xml:lang="en-US">Third anniversary of the date of the grant</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ShareBasedCompensationAwardTrancheFiveMember" xlink:label="ctso_ShareBasedCompensationAwardTrancheFiveMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ShareBasedCompensationAwardTrancheFiveMember" xlink:to="ctso_ShareBasedCompensationAwardTrancheFiveMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ShareBasedCompensationAwardTrancheFiveMember_lbl" xml:lang="en-US">Fifth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ShareBasedCompensationAwardTrancheFiveMember_lbl" xml:lang="en-US">Fourth Anniversary Of the Date of The Grant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ShareBasedCompensationAwardTrancheFiveMember_lbl" xml:lang="en-US">Fourth anniversary of the date of the grant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US">Share-based Payment Arrangement, Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US">Employees</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_SecondFortyFiveThousandRestrictedAwardMember" xlink:label="ctso_SecondFortyFiveThousandRestrictedAwardMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_SecondFortyFiveThousandRestrictedAwardMember" xlink:to="ctso_SecondFortyFiveThousandRestrictedAwardMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_SecondFortyFiveThousandRestrictedAwardMember_lbl" xml:lang="en-US">Represent information pertaining to second Forty five thousand restricted award granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_SecondFortyFiveThousandRestrictedAwardMember_lbl" xml:lang="en-US">Second 45,000 Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_SecondFortyFiveThousandRestrictedAwardMember_lbl" xml:lang="en-US">Second 45,000 restricted stock</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember" xlink:label="ctso_SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember" xlink:to="ctso_SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember_lbl" xml:lang="en-US">Represent information pertaining to second Forty six thousand and seven hundred fifty restricted award granted.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember_lbl" xml:lang="en-US">Second 46,750 Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember_lbl" xml:lang="en-US">Second 46,750 restricted stock</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CommonStockValueAuthorized" xlink:label="ctso_CommonStockValueAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_CommonStockValueAuthorized" xlink:to="ctso_CommonStockValueAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_CommonStockValueAuthorized_lbl" xml:lang="en-US">Common Stock Value Authorized For Shares Authorized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_CommonStockValueAuthorized_lbl" xml:lang="en-US">Common Stock Value Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_CommonStockValueAuthorized_lbl" xml:lang="en-US">Aggregate offering price</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AggregateRegisteredAmountForOfferings" xlink:label="ctso_AggregateRegisteredAmountForOfferings" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_AggregateRegisteredAmountForOfferings" xlink:to="ctso_AggregateRegisteredAmountForOfferings_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_AggregateRegisteredAmountForOfferings_lbl" xml:lang="en-US">On July 29, 2015, the Company's registration statement on Form S-3, as filed with the SEC on July 23, 2015, was declared effective using a "shelf" registration process. Under this shelf registration statement, the Company may issue, in one or more offerings, any combination of common stock, preferred stock, senior or subordinated debt securities, warrants, or units, up to a total dollar amount of $100 million.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_AggregateRegisteredAmountForOfferings_lbl" xml:lang="en-US">Aggregate Registered Amount for Offerings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_AggregateRegisteredAmountForOfferings_lbl" xml:lang="en-US">Aggregate registered amount for offerings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Expenses incurred</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue" xlink:to="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue_lbl" xml:lang="en-US">Represents the grant date fair value of unvested options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue_lbl" xml:lang="en-US">Grant date fair value of unvested options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionPlanExpense" xlink:to="us-gaap_StockOptionPlanExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionPlanExpense_lbl" xml:lang="en-US">Stock or Unit Option Plan Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionPlanExpense_lbl" xml:lang="en-US">Stock option expense</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage" xlink:label="ctso_ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage" xlink:to="ctso_ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage_lbl" xml:lang="en-US">Percentage of Milestone activity met by the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage_lbl" xml:lang="en-US">Share based Compensation Option Milestones met By the Company Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage_lbl" xml:lang="en-US">Percentage of milestone activity met by the company</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CommissionRateAsPercentageOfAggregateGrossProceeds" xlink:label="ctso_CommissionRateAsPercentageOfAggregateGrossProceeds" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_CommissionRateAsPercentageOfAggregateGrossProceeds" xlink:to="ctso_CommissionRateAsPercentageOfAggregateGrossProceeds_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_CommissionRateAsPercentageOfAggregateGrossProceeds_lbl" xml:lang="en-US">The commission rate as a percentage of the aggregate gross proceeds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_CommissionRateAsPercentageOfAggregateGrossProceeds_lbl" xml:lang="en-US">Commission Rate As Percentage Of Aggregate Gross Proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_CommissionRateAsPercentageOfAggregateGrossProceeds_lbl" xml:lang="en-US">Commission rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NumberOfLongTermIncentivePlans" xlink:label="ctso_NumberOfLongTermIncentivePlans" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_NumberOfLongTermIncentivePlans" xlink:to="ctso_NumberOfLongTermIncentivePlans_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_NumberOfLongTermIncentivePlans_lbl" xml:lang="en-US">Number of long-term incentive plans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_NumberOfLongTermIncentivePlans_lbl" xml:lang="en-US">Number of Long Term Incentive Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_NumberOfLongTermIncentivePlans_lbl" xml:lang="en-US">Number of long-term incentive plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common stock reserved for issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Total unrecognized compensation cost related to stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Amortized period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Number of options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock issued during period, shares, restricted stock award, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock issued during period, value, restricted stock sward, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Vesting percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of shares to be purchased</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockOptionsAndWarrantsMember" xlink:label="ctso_StockOptionsAndWarrantsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_StockOptionsAndWarrantsMember" xlink:to="ctso_StockOptionsAndWarrantsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_StockOptionsAndWarrantsMember_lbl" xml:lang="en-US">Represents the information pertaining to stock options and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_StockOptionsAndWarrantsMember_lbl" xml:lang="en-US">Stock Options and Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_StockOptionsAndWarrantsMember_lbl" xml:lang="en-US">Stock options and warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xml:lang="en-US">NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xml:lang="en-US">Defined Contribution Plan [Table]</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ParticipantsContributionUpto3PercentMember" xlink:label="ctso_ParticipantsContributionUpto3PercentMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ParticipantsContributionUpto3PercentMember" xlink:to="ctso_ParticipantsContributionUpto3PercentMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ParticipantsContributionUpto3PercentMember_lbl" xml:lang="en-US">Represents the information pertaining to participants contribution up to 3 percent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ParticipantsContributionUpto3PercentMember_lbl" xml:lang="en-US">Participants Contribution Up to 3 Percent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ParticipantsContributionUpto3PercentMember_lbl" xml:lang="en-US">Participants contribution up to 3 percent</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ParticipantsContributionOver3AndMaximum5Member" xlink:label="ctso_ParticipantsContributionOver3AndMaximum5Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_ParticipantsContributionOver3AndMaximum5Member" xlink:to="ctso_ParticipantsContributionOver3AndMaximum5Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_ParticipantsContributionOver3AndMaximum5Member_lbl" xml:lang="en-US">Represents the information pertaining to participants contribution over 3% and maximum 5%.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_ParticipantsContributionOver3AndMaximum5Member_lbl" xml:lang="en-US">Participants Contribution Over 3% and Maximum 5% [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_ParticipantsContributionOver3AndMaximum5Member_lbl" xml:lang="en-US">Participants contribution over 3% and maximum 5%</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US">RETIREMENT PLAN</label>
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_DefinedContributionEligibilityTerm" xlink:label="ctso_DefinedContributionEligibilityTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctso_DefinedContributionEligibilityTerm" xlink:to="ctso_DefinedContributionEligibilityTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ctso_DefinedContributionEligibilityTerm_lbl" xml:lang="en-US">Term of employment required to be eligible to participate in defined contribution plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ctso_DefinedContributionEligibilityTerm_lbl" xml:lang="en-US">Defined Contribution, Eligibility Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ctso_DefinedContributionEligibilityTerm_lbl" xml:lang="en-US">Term of employment required</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US">Compensation subject to IRC limitations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Matching contribution, Percent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US">Compensation for participant contributions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US">Defined Contribution Plan, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US">Matching contributions, Amount</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>27
<FILENAME>ctso-20221231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/9/2023 9:43:32 PM-->
<!--Modified on: 3/9/2023 9:43:32 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#StatementConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureBasisOfPresentation" roleURI="http://www.cytosorbents.com/role/DisclosureBasisOfPresentation" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureRevenue" roleURI="http://www.cytosorbents.com/role/DisclosureRevenue" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNet" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureOtherAssets" roleURI="http://www.cytosorbents.com/role/DisclosureOtherAssets" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities" roleURI="http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureLongTermDebt" roleURI="http://www.cytosorbents.com/role/DisclosureLongTermDebt" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureLeases" roleURI="http://www.cytosorbents.com/role/DisclosureLeases" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureIncomeTaxes" roleURI="http://www.cytosorbents.com/role/DisclosureIncomeTaxes" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingencies" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureStockholdersEquity" roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquity" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureNetLossPerShare" roleURI="http://www.cytosorbents.com/role/DisclosureNetLossPerShare" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureRetirementPlan" roleURI="http://www.cytosorbents.com/role/DisclosureRetirementPlan" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureQuarterlyFinancialResultsUnaudited" roleURI="http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnaudited" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTables" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureRevenueTables" roleURI="http://www.cytosorbents.com/role/DisclosureRevenueTables" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosurePropertyAndEquipmentNetTables" roleURI="http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetTables" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureOtherAssetsTables" roleURI="http://www.cytosorbents.com/role/DisclosureOtherAssetsTables" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureLongTermDebtTables" roleURI="http://www.cytosorbents.com/role/DisclosureLongTermDebtTables" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureLeasesTables" roleURI="http://www.cytosorbents.com/role/DisclosureLeasesTables" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.cytosorbents.com/role/DisclosureIncomeTaxesTables" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureStockholdersEquityTables" roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquityTables" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureQuarterlyFinancialResultsUnauditedTables" roleURI="http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnauditedTables" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureBasisOfPresentationDetails" roleURI="http://www.cytosorbents.com/role/DisclosureBasisOfPresentationDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" roleURI="http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails" roleURI="http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureRevenueReceivablesAndContractLiabilitiesDetails" roleURI="http://www.cytosorbents.com/role/DisclosureRevenueReceivablesAndContractLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureRevenueAdditionalInformationDetails" roleURI="http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" roleURI="http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureOtherAssetsDetails" roleURI="http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureOtherAssetsAdditionalInformationDetails" roleURI="http://www.cytosorbents.com/role/DisclosureOtherAssetsAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureLongTermDebtAdditionalInformationDetails" roleURI="http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureLongTermDebtDetails" roleURI="http://www.cytosorbents.com/role/DisclosureLongTermDebtDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureLongTermDebtPrincipalPaymentsDetails" roleURI="http://www.cytosorbents.com/role/DisclosureLongTermDebtPrincipalPaymentsDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureLeasesDetails" roleURI="http://www.cytosorbents.com/role/DisclosureLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureLeasesRightOfUseAssetAndRelatedLeaseLiabilityDetails" roleURI="http://www.cytosorbents.com/role/DisclosureLeasesRightOfUseAssetAndRelatedLeaseLiabilityDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" roleURI="http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureIncomeTaxesConsolidatedLossBeforeIncomeTaxesDetails" roleURI="http://www.cytosorbents.com/role/DisclosureIncomeTaxesConsolidatedLossBeforeIncomeTaxesDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureIncomeTaxesBenefitFromIncomeTaxesDetails" roleURI="http://www.cytosorbents.com/role/DisclosureIncomeTaxesBenefitFromIncomeTaxesDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails" roleURI="http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" roleURI="http://www.cytosorbents.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureStockholdersEquityStockOptionActivityDetails" roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureStockholdersEquityFairValueOfStockOptionDetails" roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquityFairValueOfStockOptionDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureStockholdersEquityIntrinsicValueDetails" roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureStockholdersEquityNonVestedOptionsDetails" roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureStockholdersEquityRestrictedStockUnitDetails" roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureStockholdersEquityRestrictedStockUnitActivityDetails" roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureStockholdersEquityWarrantsDetails" roleURI="http://www.cytosorbents.com/role/DisclosureStockholdersEquityWarrantsDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.cytosorbents.com/role/DisclosureNetLossPerShareDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureRetirementPlanDetails" roleURI="http://www.cytosorbents.com/role/DisclosureRetirementPlanDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureQuarterlyFinancialResultsUnauditedDetails" roleURI="http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnauditedDetails" />
  <roleRef xlink:type="simple" xlink:href="ctso-20221231.xsd#DisclosureRevenueContractWithCustomerAssetAndLiabilityDetails" roleURI="http://www.cytosorbents.com/role/DisclosureRevenueContractWithCustomerAssetAndLiabilityDetails" />
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638139950105320288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638139950105320288" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638139950105330289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_638139950105330289" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638139950105330289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638139950105330289" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638139950105330289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638139950105330289" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638139950105330289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638139950105330289" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638139950105330289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638139950105330289" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638139950105330289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638139950105330289" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638139950105330289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638139950105330289" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638139950105330289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638139950105330289" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638139950105330289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638139950105330289" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638139950105330289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638139950105330289" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638139950105330289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638139950105330289" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638139950105330289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638139950105330289" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638139950105340290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638139950105340290" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638139950105340290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638139950105340290" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638139950105340290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638139950105340290" order="16" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638139950105340290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638139950105340290" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638139950105340290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638139950105340290" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638139950105340290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638139950105340290" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638139950105340290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638139950105340290" order="20" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638139950105340290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638139950105340290" order="21" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638139950105340290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638139950105340290" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638139950105340290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638139950105340290" order="23" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638139950105350288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638139950105350288" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638139950105350288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638139950105350288" order="25" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638139950105350288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638139950105350288" order="26" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638139950105350288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_638139950105350288" order="27" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638139950105350288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638139950105350288" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638139950105350288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638139950105350288" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638139950105350288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638139950105350288" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638139950105350288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638139950105350288" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638139950105360289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638139950105360289" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638139950105360289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638139950105360289" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638139950105360289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_638139950105360289" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638139950105360289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_638139950105360289" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638139950105360289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_638139950105360289" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_29" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638139950105360289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29" xlink:to="us-gaap_AssetsAbstract_638139950105360289" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638139950105370289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638139950105360289" xlink:to="us-gaap_AssetsCurrentAbstract_638139950105370289" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638139950105370289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638139950105370289" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638139950105370289" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638139950105370289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638139950105370289" xlink:to="us-gaap_AccountsReceivableNetCurrent_638139950105370289" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638139950105370289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638139950105370289" xlink:to="us-gaap_InventoryNet_638139950105370289" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638139950105370289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638139950105370289" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638139950105370289" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638139950105370289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638139950105370289" xlink:to="us-gaap_AssetsCurrent_638139950105370289" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638139950105370289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638139950105360289" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638139950105370289" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638139950105370289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638139950105360289" xlink:to="us-gaap_RestrictedCashNoncurrent_638139950105370289" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638139950105370289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638139950105360289" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638139950105370289" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638139950105370289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638139950105360289" xlink:to="us-gaap_OtherAssetsNoncurrent_638139950105370289" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638139950105370289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638139950105360289" xlink:to="us-gaap_Assets_638139950105370289" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638139950105370289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638139950105370289" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638139950105370289" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638139950105370289" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638139950105370289" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638139950105380288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638139950105370289" xlink:to="us-gaap_AccountsPayableCurrent_638139950105380288" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="ctso_AccruedExpensesAndOtherCurrentLiabilities_638139950105380288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638139950105370289" xlink:to="ctso_AccruedExpensesAndOtherCurrentLiabilities_638139950105380288" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638139950105380288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638139950105370289" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638139950105380288" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638139950105380288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638139950105370289" xlink:to="us-gaap_LiabilitiesCurrent_638139950105380288" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638139950105380288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638139950105370289" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638139950105380288" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638139950105380288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638139950105370289" xlink:to="us-gaap_LongTermDebtNoncurrent_638139950105380288" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638139950105380288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638139950105370289" xlink:to="us-gaap_Liabilities_638139950105380288" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638139950105380288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638139950105370289" xlink:to="us-gaap_CommitmentsAndContingencies_638139950105380288" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638139950105380288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638139950105370289" xlink:to="us-gaap_StockholdersEquityAbstract_638139950105380288" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638139950105380288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638139950105380288" xlink:to="us-gaap_PreferredStockValue_638139950105380288" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638139950105390292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638139950105380288" xlink:to="us-gaap_CommonStockValue_638139950105390292" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638139950105390292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638139950105380288" xlink:to="us-gaap_AdditionalPaidInCapital_638139950105390292" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638139950105390292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638139950105380288" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638139950105390292" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638139950105450288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638139950105380288" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638139950105450288" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638139950105450288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638139950105380288" xlink:to="us-gaap_StockholdersEquity_638139950105450288" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638139950105450288" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638139950105370289" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638139950105450288" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_112" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_638139950105460290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_112" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_638139950105460290" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638139950105460290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_112" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638139950105460290" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638139950105460290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_112" xlink:to="us-gaap_PreferredStockSharesAuthorized_638139950105460290" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638139950105460290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_112" xlink:to="us-gaap_PreferredStockSharesIssued_638139950105460290" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638139950105460290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_112" xlink:to="us-gaap_PreferredStockSharesOutstanding_638139950105460290" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638139950105460290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_112" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638139950105460290" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638139950105460290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_112" xlink:to="us-gaap_CommonStockSharesAuthorized_638139950105460290" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638139950105460290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_112" xlink:to="us-gaap_CommonStockSharesIssued_638139950105460290" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638139950105460290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_112" xlink:to="us-gaap_CommonStockSharesOutstanding_638139950105460290" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_243" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638139950105460290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_243" xlink:to="us-gaap_StatementTable_638139950105460290" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638139950105470294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638139950105460290" xlink:to="srt_ProductOrServiceAxis_638139950105470294" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638139950105470294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638139950105470294" xlink:to="srt_ProductsAndServicesDomain_638139950105470294" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638139950105470294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638139950105470294" xlink:to="us-gaap_ProductMember_638139950105470294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CytoSorbSalesMember" xlink:label="ctso_CytoSorbSalesMember_638139950105470294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductMember_638139950105470294" xlink:to="ctso_CytoSorbSalesMember_638139950105470294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OtherSalesMember" xlink:label="ctso_OtherSalesMember_638139950105470294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductMember_638139950105470294" xlink:to="ctso_OtherSalesMember_638139950105470294" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember_638139950105470294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638139950105470294" xlink:to="us-gaap_GrantMember_638139950105470294" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638139950105470294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638139950105460290" xlink:to="us-gaap_StatementLineItems_638139950105470294" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract_638139950105470294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105470294" xlink:to="us-gaap_RevenuesAbstract_638139950105470294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638139950105470294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract_638139950105470294" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638139950105470294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638139950105470294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105470294" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638139950105470294" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_638139950105470294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105470294" xlink:to="us-gaap_GrossProfit_638139950105470294" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638139950105470294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105470294" xlink:to="us-gaap_OperatingExpensesAbstract_638139950105470294" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638139950105470294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638139950105470294" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638139950105470294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees_638139950105480291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638139950105470294" xlink:to="us-gaap_ProfessionalFees_638139950105480291" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638139950105480291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638139950105470294" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638139950105480291" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638139950105480291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638139950105470294" xlink:to="us-gaap_OperatingExpenses_638139950105480291" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638139950105480291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105470294" xlink:to="us-gaap_OperatingIncomeLoss_638139950105480291" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638139950105480291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105470294" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638139950105480291" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_638139950105480291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638139950105480291" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_638139950105480291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638139950105480291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638139950105480291" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_638139950105480291" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_MiscellaneousIncome" xlink:label="ctso_MiscellaneousIncome_638139950105480291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638139950105480291" xlink:to="ctso_MiscellaneousIncome_638139950105480291" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638139950105480291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638139950105480291" xlink:to="us-gaap_NonoperatingIncomeExpense_638139950105480291" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638139950105480291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105470294" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638139950105480291" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638139950105490291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105470294" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638139950105490291" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638139950105490291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105470294" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638139950105490291" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638139950105490291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105470294" xlink:to="us-gaap_EarningsPerShareBasic_638139950105490291" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638139950105490291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105470294" xlink:to="us-gaap_EarningsPerShareDiluted_638139950105490291" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638139950105490291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105470294" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638139950105490291" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638139950105490291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105470294" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638139950105490291" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638139950105490291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105470294" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638139950105490291" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638139950105490291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638139950105490291" xlink:to="us-gaap_NetIncomeLoss_638139950105490291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_638139950105490291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105470294" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_638139950105490291" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638139950105500290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_638139950105490291" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638139950105500290" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638139950105500290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105470294" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638139950105500290" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_411" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638139950105500290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_411" xlink:to="us-gaap_StatementTable_638139950105500290" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638139950105500290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638139950105500290" xlink:to="us-gaap_StatementEquityComponentsAxis_638139950105500290" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638139950105500290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638139950105500290" xlink:to="us-gaap_CommonStockMember_638139950105500290" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638139950105500290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638139950105500290" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638139950105500290" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638139950105500290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638139950105500290" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638139950105500290" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638139950105500290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638139950105500290" xlink:to="us-gaap_RetainedEarningsMember_638139950105500290" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638139950105510290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638139950105500290" xlink:to="us-gaap_EquityComponentDomain_638139950105510290" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638139950105510290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638139950105500290" xlink:to="us-gaap_StatementLineItems_638139950105510290" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638139950105510290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105510290" xlink:to="us-gaap_StockholdersEquity_638139950105510290" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638139950105510290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105510290" xlink:to="us-gaap_SharesOutstanding_638139950105510290" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638139950105510290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105510290" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638139950105510290" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638139950105510290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105510290" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638139950105510290" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638139950105510290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105510290" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638139950105510290" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638139950105510290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105510290" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638139950105510290" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_638139950105510290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105510290" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_638139950105510290" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_638139950105510290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105510290" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_638139950105510290" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockIssuedDuringPeriodValueStockCashOptionsExercised" xlink:label="ctso_StockIssuedDuringPeriodValueStockCashOptionsExercised_638139950105510290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105510290" xlink:to="ctso_StockIssuedDuringPeriodValueStockCashOptionsExercised_638139950105510290" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockIssuedDuringPeriodSharesStockCashOptionsExercised" xlink:label="ctso_StockIssuedDuringPeriodSharesStockCashOptionsExercised_638139950105510290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105510290" xlink:to="ctso_StockIssuedDuringPeriodSharesStockCashOptionsExercised_638139950105510290" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638139950105520290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105510290" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638139950105520290" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions" xlink:label="ctso_StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions_638139950105520290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105510290" xlink:to="ctso_StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions_638139950105520290" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638139950105520290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105510290" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_638139950105520290" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_638139950105520290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105510290" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_638139950105520290" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_638139950105520290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105510290" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_638139950105520290" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638139950105520290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105510290" xlink:to="us-gaap_NetIncomeLoss_638139950105520290" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638139950105520290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105510290" xlink:to="us-gaap_StockholdersEquity_638139950105520290" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638139950105520290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638139950105510290" xlink:to="us-gaap_SharesOutstanding_638139950105520290" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_772" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638139950105530291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_772" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638139950105530291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638139950105530291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638139950105530291" xlink:to="us-gaap_NetIncomeLoss_638139950105530291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638139950105530291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638139950105530291" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638139950105530291" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_638139950105530291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638139950105530291" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_638139950105530291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization_638139950105530291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638139950105530291" xlink:to="us-gaap_DepreciationAndAmortization_638139950105530291" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638139950105530291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638139950105530291" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638139950105530291" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_638139950105530291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638139950105530291" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_638139950105530291" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638139950105530291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638139950105530291" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638139950105530291" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_638139950105530291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638139950105530291" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_638139950105530291" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638139950105530291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638139950105530291" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638139950105530291" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638139950105530291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638139950105530291" xlink:to="us-gaap_ShareBasedCompensation_638139950105530291" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AmortizationOfLoanAcquisitionCosts" xlink:label="ctso_AmortizationOfLoanAcquisitionCosts_638139950105540290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638139950105530291" xlink:to="ctso_AmortizationOfLoanAcquisitionCosts_638139950105540290" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638139950105540290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638139950105530291" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638139950105540290" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638139950105540290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638139950105540290" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638139950105540290" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638139950105540290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638139950105540290" xlink:to="us-gaap_IncreaseDecreaseInInventories_638139950105540290" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638139950105540290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638139950105540290" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638139950105540290" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_638139950105540290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638139950105540290" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_638139950105540290" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638139950105540290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638139950105540290" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638139950105540290" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139950105540290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638139950105530291" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638139950105540290" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638139950105540290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_772" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638139950105540290" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638139950105540290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638139950105540290" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638139950105540290" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638139950105540290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638139950105540290" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638139950105540290" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638139950105550294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638139950105540290" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638139950105550294" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638139950105550294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_772" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638139950105550294" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638139950105550294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638139950105550294" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638139950105550294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt_638139950105550294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638139950105550294" xlink:to="us-gaap_RepaymentsOfLongTermDebt_638139950105550294" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument" xlink:label="ctso_PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument_638139950105550294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638139950105550294" xlink:to="ctso_PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument_638139950105550294" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_PaymentsForEquityContributionsNetOfFeesIncurred" xlink:label="ctso_PaymentsForEquityContributionsNetOfFeesIncurred_638139950105550294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638139950105550294" xlink:to="ctso_PaymentsForEquityContributionsNetOfFeesIncurred_638139950105550294" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638139950105550294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638139950105550294" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638139950105550294" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638139950105550294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638139950105550294" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638139950105550294" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638139950105560291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_772" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638139950105560291" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638139950105560291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_772" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638139950105560291" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638139950105560291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_772" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638139950105560291" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381399501055602911" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_772" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381399501055602911" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638139950105560291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_772" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638139950105560291" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638139950105560291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638139950105560291" xlink:to="us-gaap_InterestPaidNet_638139950105560291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638139950105560291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_772" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638139950105560291" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_638139950105560291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638139950105560291" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_638139950105560291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638139950105570291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638139950105560291" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638139950105570291" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1_638139950105570291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638139950105560291" xlink:to="us-gaap_StockIssued1_638139950105570291" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureBasisOfPresentation" xlink:type="extended" xlink:title="10101 - Disclosure - BASIS OF PRESENTATION">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_817" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting_638139950105570291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_817" xlink:to="us-gaap_BasisOfAccounting_638139950105570291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_638139950105570291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_638139950105570291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureRevenue" xlink:type="extended" xlink:title="10301 - Disclosure - REVENUE">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_329295" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_638139950105580291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_329295" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_638139950105580291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNet" xlink:type="extended" xlink:title="10401 - Disclosure - PROPERTY AND EQUIPMENT, NET">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637031108260009923" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638139950105580291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637031108260009923" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638139950105580291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureOtherAssets" xlink:type="extended" xlink:title="10501 - Disclosure - OTHER ASSETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract_637031108260009923" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsDisclosureTextBlock" xlink:label="us-gaap_OtherAssetsDisclosureTextBlock_638139950105580291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract_637031108260009923" xlink:to="us-gaap_OtherAssetsDisclosureTextBlock_638139950105580291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" xlink:title="10601 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637031108260009923" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_638139950105580291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637031108260009923" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_638139950105580291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureLongTermDebt" xlink:type="extended" xlink:title="10701 - Disclosure - LONG-TERM DEBT">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_329342" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock_638139950105590291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_329342" xlink:to="us-gaap_LongTermDebtTextBlock_638139950105590291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureLeases" xlink:type="extended" xlink:title="10801 - Disclosure - LEASES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_638139950105590291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_638139950105590291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="10901 - Disclosure - INCOME TAXES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637031108260009923" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638139950105590291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637031108260009923" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638139950105590291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11001 - Disclosure - COMMITMENTS AND CONTINGENCIES">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_23" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638139950105590291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_23" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638139950105590291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="11101 - Disclosure - STOCKHOLDERS' EQUITY">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_26" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638139950105600291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_26" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638139950105600291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="11201 - Disclosure - NET LOSS PER SHARE">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_61" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638139950105600291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_61" xlink:to="us-gaap_EarningsPerShareTextBlock_638139950105600291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureRetirementPlan" xlink:type="extended" xlink:title="11301 - Disclosure - RETIREMENT PLAN">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_638139950105600291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_638139950105600291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnaudited" xlink:type="extended" xlink:title="11401 - Disclosure - QUARTERLY FINANCIAL RESULTS (UNAUDITED)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_637031108260009923" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_638139950105600291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_637031108260009923" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_638139950105600291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_73" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NatureOfBusinessPolicyPolicyTextBlock" xlink:label="ctso_NatureOfBusinessPolicyPolicyTextBlock_638139950105610293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_73" xlink:to="ctso_NatureOfBusinessPolicyPolicyTextBlock_638139950105610293" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockMarketListingPolicyPolicyTextBlock" xlink:label="ctso_StockMarketListingPolicyPolicyTextBlock_638139950105610293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_73" xlink:to="ctso_StockMarketListingPolicyPolicyTextBlock_638139950105610293" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ConsolidationAndForeignCurrencyTranslationPolicyPolicyTextBlock" xlink:label="ctso_ConsolidationAndForeignCurrencyTranslationPolicyPolicyTextBlock_638139950105610293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_73" xlink:to="ctso_ConsolidationAndForeignCurrencyTranslationPolicyPolicyTextBlock_638139950105610293" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638139950105610293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_73" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638139950105610293" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638139950105610293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_73" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638139950105610293" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_638139950105610293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_73" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_638139950105610293" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_638139950105610293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_73" xlink:to="us-gaap_InventoryPolicyTextBlock_638139950105610293" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638139950105610293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_73" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638139950105610293" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_638139950105610293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_73" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_638139950105610293" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638139950105610293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_73" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_638139950105610293" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638139950105620292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_73" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638139950105620292" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638139950105620292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_73" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638139950105620292" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_638139950105620292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_73" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_638139950105620292" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638139950105620292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_73" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638139950105620292" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638139950105620292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_73" xlink:to="us-gaap_UseOfEstimates_638139950105620292" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638139950105620292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_73" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638139950105620292" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_638139950105620292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_73" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_638139950105620292" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638139950105620292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_73" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638139950105620292" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638139950105620292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_73" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638139950105620292" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ShippingAndHandlingCostsPolicyPolicyTextBlock" xlink:label="ctso_ShippingAndHandlingCostsPolicyPolicyTextBlock_638139950105620292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_73" xlink:to="ctso_ShippingAndHandlingCostsPolicyPolicyTextBlock_638139950105620292" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638139950105620292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_73" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638139950105620292" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock" xlink:label="ctso_ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock_638139950105630290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ctso_ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock_638139950105630290" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureRevenueTables" xlink:type="extended" xlink:title="30303 - Disclosure - REVENUE (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_329320" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_638139950105630290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_329320" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_638139950105630290" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_638139950105630290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_329320" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_638139950105630290" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetTables" xlink:type="extended" xlink:title="30403 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637031108260009923" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638139950105630290" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637031108260009923" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638139950105630290" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureOtherAssetsTables" xlink:type="extended" xlink:title="30503 - Disclosure - OTHER ASSETS (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract_637031108260009923" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsTableTextBlock_638139950105640292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract_637031108260009923" xlink:to="us-gaap_ScheduleOfOtherAssetsTableTextBlock_638139950105640292" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" xlink:title="30603 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637031108260009923" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="ctso_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_638139950105640292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637031108260009923" xlink:to="ctso_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_638139950105640292" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureLongTermDebtTables" xlink:type="extended" xlink:title="30703 - Disclosure - LONG-TERM DEBT (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_329352" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_638139950105640292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_329352" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_638139950105640292" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_638139950105640292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_329352" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_638139950105640292" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="30803 - Disclosure - LEASES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock" xlink:label="ctso_LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock_638139950105650297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="ctso_LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock_638139950105650297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638139950105650297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638139950105650297" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="30903 - Disclosure - INCOME TAXES (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637031108260009923" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_638139950105650297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637031108260009923" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_638139950105650297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638139950105650297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637031108260009923" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638139950105650297" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638139950105650297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637031108260009923" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638139950105650297" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638139950105650297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637031108260009923" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638139950105650297" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureStockholdersEquityTables" xlink:type="extended" xlink:title="31103 - Disclosure - STOCKHOLDERS' EQUITY (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_132" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638139950105660292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_132" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638139950105660292" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638139950105660292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_132" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638139950105660292" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_638139950105660292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_132" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_638139950105660292" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_638139950105660292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_132" xlink:to="us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_638139950105660292" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_638139950105660292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_132" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_638139950105660292" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_638139950105660292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_132" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_638139950105660292" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnauditedTables" xlink:type="extended" xlink:title="31403 - Disclosure - QUARTERLY FINANCIAL RESULTS (UNAUDITED) (Tables)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_637031108260009923" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:label="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_638139950105660292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_637031108260009923" xlink:to="srt_ScheduleOfCondensedIncomeStatementTableTextBlock_638139950105660292" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureBasisOfPresentationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - BASIS OF PRESENTATION (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_142" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash_638139950105660292" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_142" xlink:to="us-gaap_Cash_638139950105660292" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_166" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable_638139950105670293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_166" xlink:to="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable_638139950105670293" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_638139950105670293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable_638139950105670293" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_638139950105670293" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_638139950105670293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_638139950105670293" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_638139950105670293" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember_638139950105670293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638139950105670293" xlink:to="us-gaap_AccountsReceivableMember_638139950105670293" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_638139950105670293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638139950105670293" xlink:to="us-gaap_RevenueFromContractWithCustomerMember_638139950105670293" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_638139950105670293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable_638139950105670293" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_638139950105670293" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_638139950105670293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_638139950105670293" xlink:to="us-gaap_ConcentrationRiskTypeDomain_638139950105670293" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OneDistributorMember" xlink:label="ctso_OneDistributorMember_638139950105670293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638139950105670293" xlink:to="ctso_OneDistributorMember_638139950105670293" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638139950105670293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable_638139950105670293" xlink:to="srt_ProductOrServiceAxis_638139950105670293" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638139950105670293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638139950105670293" xlink:to="srt_ProductsAndServicesDomain_638139950105670293" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CargoAndFreightMember" xlink:label="us-gaap_CargoAndFreightMember_638139950105670293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638139950105670293" xlink:to="us-gaap_CargoAndFreightMember_638139950105670293" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis_638139950105670293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable_638139950105670293" xlink:to="us-gaap_CreditFacilityAxis_638139950105670293" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_638139950105680297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis_638139950105670293" xlink:to="us-gaap_CreditFacilityDomain_638139950105680297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember_638139950105680297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_638139950105680297" xlink:to="us-gaap_LetterOfCreditMember_638139950105680297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditCardMember" xlink:label="us-gaap_CreditCardMember_638139950105680297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain_638139950105680297" xlink:to="us-gaap_CreditCardMember_638139950105680297" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638139950105680297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable_638139950105670293" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638139950105680297" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638139950105680297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638139950105680297" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638139950105680297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638139950105680297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638139950105680297" xlink:to="us-gaap_DomesticCountryMember_638139950105680297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems_638139950105680297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable_638139950105670293" xlink:to="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems_638139950105680297" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed" xlink:label="ctso_NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed_638139950105680297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems_638139950105680297" xlink:to="ctso_NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed_638139950105680297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NumberOfPatentsUnitedStates" xlink:label="ctso_NumberOfPatentsUnitedStates_638139950105680297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems_638139950105680297" xlink:to="ctso_NumberOfPatentsUnitedStates_638139950105680297" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ForeignCurrencyTransactionGainLossExcludingTax" xlink:label="ctso_ForeignCurrencyTransactionGainLossExcludingTax_638139950105680297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems_638139950105680297" xlink:to="ctso_ForeignCurrencyTransactionGainLossExcludingTax_638139950105680297" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638139950105680297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems_638139950105680297" xlink:to="us-gaap_RestrictedCashNoncurrent_638139950105680297" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCollateralAmount" xlink:label="us-gaap_DebtInstrumentCollateralAmount_638139950105690296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems_638139950105680297" xlink:to="us-gaap_DebtInstrumentCollateralAmount_638139950105690296" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods_638139950105690296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems_638139950105680297" xlink:to="us-gaap_InventoryFinishedGoods_638139950105690296" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess_638139950105690296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems_638139950105680297" xlink:to="us-gaap_InventoryWorkInProcess_638139950105690296" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials_638139950105690296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems_638139950105680297" xlink:to="us-gaap_InventoryRawMaterials_638139950105690296" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryAdjustments" xlink:label="us-gaap_InventoryAdjustments_638139950105690296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems_638139950105680297" xlink:to="us-gaap_InventoryAdjustments_638139950105690296" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_WroteOffPatentsCosts" xlink:label="ctso_WroteOffPatentsCosts_638139950105690296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems_638139950105680297" xlink:to="ctso_WroteOffPatentsCosts_638139950105690296" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense_638139950105690296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems_638139950105680297" xlink:to="us-gaap_AdvertisingExpense_638139950105690296" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638139950105690296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems_638139950105680297" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638139950105690296" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638139950105690296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems_638139950105680297" xlink:to="us-gaap_UnrecognizedTaxBenefits_638139950105690296" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ThresholdUsedForCalculatingConcentrationOfRisk" xlink:label="ctso_ThresholdUsedForCalculatingConcentrationOfRisk_638139950105700294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems_638139950105680297" xlink:to="ctso_ThresholdUsedForCalculatingConcentrationOfRisk_638139950105700294" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold_638139950105700294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems_638139950105680297" xlink:to="us-gaap_CostOfGoodsAndServicesSold_638139950105700294" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_InsuranceSettlementReceivableForLossOnInventoryRecordedAsReductionToCostOfGoodsSold" xlink:label="ctso_InsuranceSettlementReceivableForLossOnInventoryRecordedAsReductionToCostOfGoodsSold_638139950105700294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems_638139950105680297" xlink:to="ctso_InsuranceSettlementReceivableForLossOnInventoryRecordedAsReductionToCostOfGoodsSold_638139950105700294" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails" xlink:type="extended" xlink:title="40202 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638139950105700294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638139950105700294" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_638139950105700294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_638139950105700294" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638139950105700294" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638139950105700294" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails" xlink:type="extended" xlink:title="40301 - Disclosure - REVENUE - Revenue by customer type and geographic area (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_637031108260166149" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable_638139950105710296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract_637031108260166149" xlink:to="us-gaap_DisaggregationOfRevenueTable_638139950105710296" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_638139950105710296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638139950105710296" xlink:to="srt_MajorCustomersAxis_638139950105710296" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638139950105710296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_638139950105710296" xlink:to="srt_NameOfMajorCustomerDomain_638139950105710296" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_DirectMember" xlink:label="ctso_DirectMember_638139950105710296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638139950105710296" xlink:to="ctso_DirectMember_638139950105710296" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_DistributorsAndStrategicPartnersMember" xlink:label="ctso_DistributorsAndStrategicPartnersMember_638139950105710296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638139950105710296" xlink:to="ctso_DistributorsAndStrategicPartnersMember_638139950105710296" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_UnitedStatesGovernmentAgenciesMember" xlink:label="ctso_UnitedStatesGovernmentAgenciesMember_638139950105710296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638139950105710296" xlink:to="ctso_UnitedStatesGovernmentAgenciesMember_638139950105710296" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638139950105710296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638139950105710296" xlink:to="srt_StatementGeographicalAxis_638139950105710296" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638139950105710296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638139950105710296" xlink:to="srt_SegmentGeographicalDomain_638139950105710296" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US_638139950105710296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638139950105710296" xlink:to="country_US_638139950105710296" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE" xlink:label="country_DE_638139950105710296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638139950105710296" xlink:to="country_DE_638139950105710296" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AllOtherCountriesMember" xlink:label="ctso_AllOtherCountriesMember_638139950105710296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638139950105710296" xlink:to="ctso_AllOtherCountriesMember_638139950105710296" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638139950105710296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638139950105710296" xlink:to="srt_ProductOrServiceAxis_638139950105710296" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638139950105710296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638139950105710296" xlink:to="srt_ProductsAndServicesDomain_638139950105710296" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638139950105720295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638139950105710296" xlink:to="us-gaap_ProductMember_638139950105720295" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember_638139950105720295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductMember_638139950105720295" xlink:to="us-gaap_GrantMember_638139950105720295" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_638139950105720295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638139950105710296" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_638139950105720295" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_SaleRevenuesGoodsNetAbstract" xlink:label="ctso_SaleRevenuesGoodsNetAbstract_638139950105720295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_638139950105720295" xlink:to="ctso_SaleRevenuesGoodsNetAbstract_638139950105720295" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638139950105720295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_SaleRevenuesGoodsNetAbstract_638139950105720295" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638139950105720295" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureRevenueReceivablesAndContractLiabilitiesDetails" xlink:type="extended" xlink:title="40302 - Disclosure - REVENUE - Receivables and contract liabilities (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_637031108260166149" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_638139950105720295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract_637031108260166149" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_638139950105720295" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue_638139950105720295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract_637031108260166149" xlink:to="us-gaap_DeferredRevenue_638139950105720295" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails" xlink:type="extended" xlink:title="40303 - Disclosure - REVENUE - Additional information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_637031108260166149" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable_638139950105720295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract_637031108260166149" xlink:to="us-gaap_DisaggregationOfRevenueTable_638139950105720295" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638139950105730293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638139950105720295" xlink:to="srt_RangeAxis_638139950105730293" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638139950105730293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638139950105730293" xlink:to="srt_RangeMember_638139950105730293" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638139950105730293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638139950105730293" xlink:to="srt_MaximumMember_638139950105730293" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638139950105730293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638139950105730293" xlink:to="srt_MinimumMember_638139950105730293" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638139950105730293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638139950105720295" xlink:to="srt_ProductOrServiceAxis_638139950105730293" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638139950105730293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638139950105730293" xlink:to="srt_ProductsAndServicesDomain_638139950105730293" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638139950105730293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638139950105730293" xlink:to="us-gaap_ProductMember_638139950105730293" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember_638139950105730293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638139950105730293" xlink:to="us-gaap_GrantMember_638139950105730293" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_638139950105730293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable_638139950105720295" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_638139950105730293" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NumberOfPrimaryRevenueStreams" xlink:label="ctso_NumberOfPrimaryRevenueStreams_638139950105730293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_638139950105730293" xlink:to="ctso_NumberOfPrimaryRevenueStreams_638139950105730293" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_TermOfCustomerContracts" xlink:label="ctso_TermOfCustomerContracts_638139950105730293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_638139950105730293" xlink:to="ctso_TermOfCustomerContracts_638139950105730293" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent" xlink:label="ctso_ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent_638139950105730293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_638139950105730293" xlink:to="ctso_ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent_638139950105730293" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent" xlink:label="ctso_ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent_638139950105730293" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_638139950105730293" xlink:to="ctso_ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent_638139950105730293" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_638139950105740296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems_638139950105730293" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_638139950105740296" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40401 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637031108260166149" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638139950105740296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637031108260166149" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638139950105740296" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638139950105740296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638139950105740296" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638139950105740296" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638139950105740296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638139950105740296" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638139950105740296" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638139950105740296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638139950105740296" xlink:to="us-gaap_FurnitureAndFixturesMember_638139950105740296" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_638139950105740296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638139950105740296" xlink:to="us-gaap_ComputerEquipmentMember_638139950105740296" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638139950105740296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638139950105740296" xlink:to="us-gaap_LeaseholdImprovementsMember_638139950105740296" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638139950105740296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638139950105740296" xlink:to="srt_RangeAxis_638139950105740296" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638139950105740296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638139950105740296" xlink:to="srt_RangeMember_638139950105740296" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638139950105740296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638139950105740296" xlink:to="srt_MaximumMember_638139950105740296" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638139950105740296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638139950105740296" xlink:to="srt_MinimumMember_638139950105740296" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638139950105740296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638139950105740296" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638139950105740296" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638139950105750296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638139950105740296" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638139950105750296" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638139950105750296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638139950105740296" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638139950105750296" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638139950105750296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638139950105740296" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638139950105750296" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638139950105750296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638139950105740296" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638139950105750296" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="extended" xlink:title="40402 - Disclosure - PROPERTY AND EQUIPMENT, NET - Additional information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637031108260166149" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638139950105750296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637031108260166149" xlink:to="us-gaap_Depreciation_638139950105750296" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - OTHER ASSETS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract_637031108260166149" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OtherAssetsTable" xlink:label="ctso_OtherAssetsTable_638139950105750296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract_637031108260166149" xlink:to="ctso_OtherAssetsTable_638139950105750296" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638139950105750296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_OtherAssetsTable_638139950105750296" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638139950105750296" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638139950105750296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638139950105750296" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638139950105750296" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember" xlink:label="ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember_638139950105760296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638139950105750296" xlink:to="ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember_638139950105760296" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember" xlink:label="ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember_638139950105760296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638139950105750296" xlink:to="ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember_638139950105760296" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OtherAssetsLineItems" xlink:label="ctso_OtherAssetsLineItems_638139950105760296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_OtherAssetsTable_638139950105750296" xlink:to="ctso_OtherAssetsLineItems_638139950105760296" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638139950105760296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_OtherAssetsLineItems_638139950105760296" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638139950105760296" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638139950105760296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_OtherAssetsLineItems_638139950105760296" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638139950105760296" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638139950105760296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_OtherAssetsLineItems_638139950105760296" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638139950105760296" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_638139950105760296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_OtherAssetsLineItems_638139950105760296" xlink:to="us-gaap_SecurityDeposit_638139950105760296" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638139950105760296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_OtherAssetsLineItems_638139950105760296" xlink:to="us-gaap_OtherAssetsNoncurrent_638139950105760296" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureOtherAssetsAdditionalInformationDetails" xlink:type="extended" xlink:title="40502 - Disclosure - OTHER ASSETS - Additional information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract_637031108260166149" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638139950105760296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract_637031108260166149" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_638139950105760296" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638139950105760296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract_637031108260166149" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_638139950105760296" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638139950105760296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract_637031108260166149" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_638139950105760296" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638139950105760296" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract_637031108260166149" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_638139950105760296" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638139950105770298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract_637031108260166149" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_638139950105770298" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization_638139950105770298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract_637031108260166149" xlink:to="us-gaap_AdjustmentForAmortization_638139950105770298" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637031108260166149" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AccruedSalariesAndCommissionsCurrent" xlink:label="ctso_AccruedSalariesAndCommissionsCurrent_638139950105770298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637031108260166149" xlink:to="ctso_AccruedSalariesAndCommissionsCurrent_638139950105770298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638139950105770298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637031108260166149" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638139950105770298" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ClinicalStudyCostsPayableCurrent" xlink:label="ctso_ClinicalStudyCostsPayableCurrent_638139950105770298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637031108260166149" xlink:to="ctso_ClinicalStudyCostsPayableCurrent_638139950105770298" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638139950105770298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637031108260166149" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638139950105770298" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638139950105770298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637031108260166149" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638139950105770298" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_638139950105770298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637031108260166149" xlink:to="us-gaap_AccruedRoyaltiesCurrent_638139950105770298" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CustomerRebates" xlink:label="ctso_CustomerRebates_638139950105770298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637031108260166149" xlink:to="ctso_CustomerRebates_638139950105770298" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AccruedTravelAndEntertainmentExpenseCurrent" xlink:label="ctso_AccruedTravelAndEntertainmentExpenseCurrent_638139950105770298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637031108260166149" xlink:to="ctso_AccruedTravelAndEntertainmentExpenseCurrent_638139950105770298" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AccruedDirectorFeesCurrent" xlink:label="ctso_AccruedDirectorFeesCurrent_638139950105770298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637031108260166149" xlink:to="ctso_AccruedDirectorFeesCurrent_638139950105770298" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_SalesPayrollAndIncomeTaxesPayableCurrent" xlink:label="ctso_SalesPayrollAndIncomeTaxesPayableCurrent_638139950105770298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637031108260166149" xlink:to="ctso_SalesPayrollAndIncomeTaxesPayableCurrent_638139950105770298" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent_638139950105780298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637031108260166149" xlink:to="us-gaap_InterestPayableCurrent_638139950105780298" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CongressesPayableCurrent" xlink:label="ctso_CongressesPayableCurrent_638139950105780298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637031108260166149" xlink:to="ctso_CongressesPayableCurrent_638139950105780298" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="ctso_AccruedExpensesAndOtherCurrentLiabilities_638139950105780298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637031108260166149" xlink:to="ctso_AccruedExpensesAndOtherCurrentLiabilities_638139950105780298" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails" xlink:type="extended" xlink:title="40701 - Disclosure - LONG-TERM DEBT - Additional information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638139950105780298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_638139950105780298" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis_638139950105780298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638139950105780298" xlink:to="us-gaap_LineOfCreditFacilityAxis_638139950105780298" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_638139950105780298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis_638139950105780298" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_638139950105780298" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_WesternAllianceBankMember" xlink:label="ctso_WesternAllianceBankMember_638139950105780298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain_638139950105780298" xlink:to="ctso_WesternAllianceBankMember_638139950105780298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638139950105780298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638139950105780298" xlink:to="us-gaap_DebtInstrumentAxis_638139950105780298" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638139950105780298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638139950105780298" xlink:to="us-gaap_DebtInstrumentNameDomain_638139950105780298" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NewTermLoanMember" xlink:label="ctso_NewTermLoanMember_638139950105780298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638139950105780298" xlink:to="ctso_NewTermLoanMember_638139950105780298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_TermLoanMember" xlink:label="ctso_TermLoanMember_638139950105790297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638139950105780298" xlink:to="ctso_TermLoanMember_638139950105790297" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_TermBLoanMember" xlink:label="ctso_TermBLoanMember_638139950105790297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638139950105780298" xlink:to="ctso_TermBLoanMember_638139950105790297" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_TermCLoanMember" xlink:label="ctso_TermCLoanMember_638139950105790297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638139950105780298" xlink:to="ctso_TermCLoanMember_638139950105790297" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NonRefundableClosingFeeMember" xlink:label="ctso_NonRefundableClosingFeeMember_638139950105790297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638139950105780298" xlink:to="ctso_NonRefundableClosingFeeMember_638139950105790297" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_TwoThousandAndEighteenSuccessFeeLetterMember" xlink:label="ctso_TwoThousandAndEighteenSuccessFeeLetterMember_638139950105790297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638139950105780298" xlink:to="ctso_TwoThousandAndEighteenSuccessFeeLetterMember_638139950105790297" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638139950105790297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638139950105780298" xlink:to="us-gaap_VestingAxis_638139950105790297" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638139950105790297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638139950105790297" xlink:to="us-gaap_VestingDomain_638139950105790297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_FirstTrancheMember" xlink:label="ctso_FirstTrancheMember_638139950105790297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638139950105790297" xlink:to="ctso_FirstTrancheMember_638139950105790297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_SecondTrancheMember" xlink:label="ctso_SecondTrancheMember_638139950105790297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638139950105790297" xlink:to="ctso_SecondTrancheMember_638139950105790297" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ThirdTrancheMember" xlink:label="ctso_ThirdTrancheMember_638139950105790297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638139950105790297" xlink:to="ctso_ThirdTrancheMember_638139950105790297" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_638139950105790297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638139950105780298" xlink:to="us-gaap_BalanceSheetLocationAxis_638139950105790297" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_638139950105790297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_638139950105790297" xlink:to="us-gaap_BalanceSheetLocationDomain_638139950105790297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ClosingFeeMember" xlink:label="ctso_ClosingFeeMember_638139950105800298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_638139950105790297" xlink:to="ctso_ClosingFeeMember_638139950105800298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638139950105800298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638139950105780298" xlink:to="srt_RangeAxis_638139950105800298" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638139950105800298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638139950105800298" xlink:to="srt_RangeMember_638139950105800298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638139950105800298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638139950105800298" xlink:to="srt_MinimumMember_638139950105800298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638139950105800298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638139950105800298" xlink:to="srt_MaximumMember_638139950105800298" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638139950105800298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638139950105780298" xlink:to="srt_StatementScenarioAxis_638139950105800298" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638139950105800298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638139950105800298" xlink:to="srt_ScenarioUnspecifiedDomain_638139950105800298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember_638139950105800298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638139950105800298" xlink:to="srt_ScenarioForecastMember_638139950105800298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638139950105800298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638139950105780298" xlink:to="us-gaap_DebtInstrumentLineItems_638139950105800298" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638139950105810297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638139950105800298" xlink:to="us-gaap_DebtInstrumentFaceAmount_638139950105810297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638139950105810297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638139950105800298" xlink:to="us-gaap_RepaymentsOfDebt_638139950105810297" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638139950105810297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638139950105800298" xlink:to="us-gaap_LongTermDebt_638139950105810297" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638139950105810297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638139950105800298" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_638139950105810297" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_638139950105810297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638139950105800298" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_638139950105810297" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638139950105810297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638139950105800298" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_638139950105810297" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_DebtInstrumentCapInterestRate" xlink:label="ctso_DebtInstrumentCapInterestRate_638139950105810297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638139950105800298" xlink:to="ctso_DebtInstrumentCapInterestRate_638139950105810297" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638139950105810297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638139950105800298" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt_638139950105810297" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_638139950105820298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638139950105800298" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_638139950105820298" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet_638139950105820298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638139950105800298" xlink:to="us-gaap_DeferredFinanceCostsNet_638139950105820298" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent" xlink:label="ctso_DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent_638139950105820298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638139950105800298" xlink:to="ctso_DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent_638139950105820298" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_PercentageOfSuccessFee" xlink:label="ctso_PercentageOfSuccessFee_638139950105820298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638139950105800298" xlink:to="ctso_PercentageOfSuccessFee_638139950105820298" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_PercentageOfClosingPriceOnCommonStock" xlink:label="ctso_PercentageOfClosingPriceOnCommonStock_638139950105820298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638139950105800298" xlink:to="ctso_PercentageOfClosingPriceOnCommonStock_638139950105820298" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638139950105820298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638139950105800298" xlink:to="us-gaap_SharePrice_638139950105820298" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NumberOfDaysForStockPriceThreshold" xlink:label="ctso_NumberOfDaysForStockPriceThreshold_638139950105820298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638139950105800298" xlink:to="ctso_NumberOfDaysForStockPriceThreshold_638139950105820298" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureLongTermDebtDetails" xlink:type="extended" xlink:title="40702 - Disclosure - LONG TERM DEBT (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount_638139950105830297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_DebtInstrumentCarryingAmount_638139950105830297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638139950105830297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_LongTermDebtNoncurrent_638139950105830297" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureLongTermDebtPrincipalPaymentsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - LONG-TERM DEBT - Principal payments (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_329398" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638139950105830297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_329398" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_638139950105830297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638139950105830297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_329398" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_638139950105830297" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_638139950105830297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_329398" xlink:to="us-gaap_LongTermDebtNoncurrent_638139950105830297" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_LongTermDebtAndFinalFee" xlink:label="ctso_LongTermDebtAndFinalFee_638139950105830297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_329398" xlink:to="ctso_LongTermDebtAndFinalFee_638139950105830297" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - LEASES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638139950105840299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638139950105840299" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638139950105840299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638139950105840299" xlink:to="srt_StatementGeographicalAxis_638139950105840299" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638139950105840299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638139950105840299" xlink:to="srt_SegmentGeographicalDomain_638139950105840299" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US_638139950105840299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638139950105840299" xlink:to="country_US_638139950105840299" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE" xlink:label="country_DE_638139950105840299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638139950105840299" xlink:to="country_DE_638139950105840299" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638139950105840299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638139950105840299" xlink:to="srt_StatementScenarioAxis_638139950105840299" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638139950105840299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638139950105840299" xlink:to="srt_ScenarioUnspecifiedDomain_638139950105840299" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OperatingLeaseInitialEarlyTermMember" xlink:label="ctso_OperatingLeaseInitialEarlyTermMember_638139950105840299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638139950105840299" xlink:to="ctso_OperatingLeaseInitialEarlyTermMember_638139950105840299" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OperatingLeaseEarlyTermMember" xlink:label="ctso_OperatingLeaseEarlyTermMember_638139950105840299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638139950105840299" xlink:to="ctso_OperatingLeaseEarlyTermMember_638139950105840299" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OperatingLeaseFirstYearOfRemainingLeaseTermMember" xlink:label="ctso_OperatingLeaseFirstYearOfRemainingLeaseTermMember_638139950105840299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638139950105840299" xlink:to="ctso_OperatingLeaseFirstYearOfRemainingLeaseTermMember_638139950105840299" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638139950105840299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638139950105840299" xlink:to="us-gaap_DebtInstrumentAxis_638139950105840299" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638139950105840299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638139950105840299" xlink:to="us-gaap_DebtInstrumentNameDomain_638139950105840299" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember_638139950105850297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638139950105840299" xlink:to="us-gaap_LetterOfCreditMember_638139950105850297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_638139950105850297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638139950105840299" xlink:to="srt_ConsolidatedEntitiesAxis_638139950105850297" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_638139950105850297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis_638139950105850297" xlink:to="srt_ConsolidatedEntitiesDomain_638139950105850297" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CytosorbentsMedicalIncMember" xlink:label="ctso_CytosorbentsMedicalIncMember_638139950105850297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain_638139950105850297" xlink:to="ctso_CytosorbentsMedicalIncMember_638139950105850297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CytosorbentsEuropeGmbhMember" xlink:label="ctso_CytosorbentsEuropeGmbhMember_638139950105850297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain_638139950105850297" xlink:to="ctso_CytosorbentsEuropeGmbhMember_638139950105850297" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_638139950105850297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638139950105840299" xlink:to="us-gaap_LeaseContractualTermAxis_638139950105850297" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_638139950105850297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis_638139950105850297" xlink:to="us-gaap_LeaseContractualTermDomain_638139950105850297" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_TwentiethAmendmentToLeaseMember" xlink:label="ctso_TwentiethAmendmentToLeaseMember_638139950105850297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638139950105850297" xlink:to="ctso_TwentiethAmendmentToLeaseMember_638139950105850297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638139950105850297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638139950105840299" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638139950105850297" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NumberOfTimesLeaseRenewalAvailable" xlink:label="ctso_NumberOfTimesLeaseRenewalAvailable_638139950105850297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638139950105850297" xlink:to="ctso_NumberOfTimesLeaseRenewalAvailable_638139950105850297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638139950105850297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638139950105850297" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638139950105850297" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_638139950105860301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638139950105850297" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_638139950105860301" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_638139950105860301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638139950105850297" xlink:to="us-gaap_OperatingLeaseExpense_638139950105860301" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OperatingLeasesAnnualRentExpenseIncrementRate" xlink:label="ctso_OperatingLeasesAnnualRentExpenseIncrementRate_638139950105860301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638139950105850297" xlink:to="ctso_OperatingLeasesAnnualRentExpenseIncrementRate_638139950105860301" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OperatingLeasesRentAbatementTerm" xlink:label="ctso_OperatingLeasesRentAbatementTerm_638139950105860301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638139950105850297" xlink:to="ctso_OperatingLeasesRentAbatementTerm_638139950105860301" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_PercentageOfTotalBuildingSpaceOccupied" xlink:label="ctso_PercentageOfTotalBuildingSpaceOccupied_638139950105860301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638139950105850297" xlink:to="ctso_PercentageOfTotalBuildingSpaceOccupied_638139950105860301" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OperatingLeasesBuildingImprovementAllowanceReceivable" xlink:label="ctso_OperatingLeasesBuildingImprovementAllowanceReceivable_638139950105860301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638139950105850297" xlink:to="ctso_OperatingLeasesBuildingImprovementAllowanceReceivable_638139950105860301" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638139950105860301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638139950105850297" xlink:to="us-gaap_DebtInstrumentFaceAmount_638139950105860301" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638139950105860301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638139950105850297" xlink:to="us-gaap_OperatingLeaseLiability_638139950105860301" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638139950105900297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638139950105850297" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638139950105900297" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_638139950105900297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638139950105850297" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_638139950105900297" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AdditionalOperatingLeasesRentExpenseNet" xlink:label="ctso_AdditionalOperatingLeasesRentExpenseNet_638139950105900297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638139950105850297" xlink:to="ctso_AdditionalOperatingLeasesRentExpenseNet_638139950105900297" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_OperatingLeaseBaseRentForRemainingSpace" xlink:label="ctso_OperatingLeaseBaseRentForRemainingSpace_638139950105910299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638139950105850297" xlink:to="ctso_OperatingLeaseBaseRentForRemainingSpace_638139950105910299" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_MonthlyOperatingExpenses" xlink:label="ctso_MonthlyOperatingExpenses_638139950105910299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638139950105850297" xlink:to="ctso_MonthlyOperatingExpenses_638139950105910299" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_638139950105910299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638139950105850297" xlink:to="us-gaap_SecurityDeposit_638139950105910299" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand_638139950105910299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638139950105850297" xlink:to="us-gaap_AreaOfLand_638139950105910299" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638139950105910299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638139950105850297" xlink:to="us-gaap_OperatingLeaseCost_638139950105910299" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_638139950105910299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638139950105850297" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_638139950105910299" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638139950105910299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638139950105850297" xlink:to="us-gaap_OperatingLeasePayments_638139950105910299" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638139950105920297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638139950105850297" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638139950105920297" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureLeasesRightOfUseAssetAndRelatedLeaseLiabilityDetails" xlink:type="extended" xlink:title="40802 - Disclosure - LEASES - Right-of- use asset and related lease liability (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638139950105920297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638139950105920297" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638139950105920297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability_638139950105920297" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638139950105920297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638139950105920297" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638139950105920297" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638139950105920297" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails" xlink:type="extended" xlink:title="40803 - Disclosure - LEASES - Maturities of the lease liabilities (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638139950105930298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638139950105930298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638139950105930298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638139950105930298" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638139950105930298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638139950105930298" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638139950105930298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638139950105930298" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638139950105930298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638139950105930298" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:label="ctso_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_638139950105930298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="ctso_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_638139950105930298" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638139950105930298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638139950105930298" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638139950105930298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638139950105930298" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638139950105930298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability_638139950105930298" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureIncomeTaxesConsolidatedLossBeforeIncomeTaxesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - INCOME TAXES - Consolidated loss before income taxes (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637031108260335327" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638139950105930298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637031108260335327" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_638139950105930298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638139950105930298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637031108260335327" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_638139950105930298" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests" xlink:label="ctso_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests_638139950105930298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637031108260335327" xlink:to="ctso_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests_638139950105930298" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureIncomeTaxesBenefitFromIncomeTaxesDetails" xlink:type="extended" xlink:title="40902 - Disclosure - INCOME TAXES - The benefit from income taxes (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637031108260335327" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_638139950105940298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637031108260335327" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_638139950105940298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638139950105940298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637031108260335327" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638139950105940298" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" xlink:title="40903 - Disclosure - INCOME TAXES - The principal components of the Company's deferred tax assets and liabilities (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637031108260335327" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638139950105940298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637031108260335327" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638139950105940298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638139950105940298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638139950105940298" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638139950105940298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_638139950105940298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638139950105940298" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_638139950105940298" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638139950105940298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638139950105940298" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638139950105940298" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_638139950105940298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638139950105940298" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_638139950105940298" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability" xlink:label="ctso_DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability_638139950105940298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638139950105940298" xlink:to="ctso_DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability_638139950105940298" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOtherTaxCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_638139950105940298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638139950105940298" xlink:to="us-gaap_DeferredTaxAssetsOtherTaxCarryforwards_638139950105940298" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638139950105940298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638139950105940298" xlink:to="us-gaap_DeferredTaxAssetsGross_638139950105940298" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638139950105950300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637031108260335327" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638139950105950300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638139950105950300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637031108260335327" xlink:to="us-gaap_DeferredTaxAssetsNet_638139950105950300" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_638139950105950300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637031108260335327" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_638139950105950300" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638139950105950300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638139950105950300" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638139950105950300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_DeferredTaxLiabilitiesRightsOfUseAssets" xlink:label="ctso_DeferredTaxLiabilitiesRightsOfUseAssets_638139950105950300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638139950105950300" xlink:to="ctso_DeferredTaxLiabilitiesRightsOfUseAssets_638139950105950300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638139950105950300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638139950105950300" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638139950105950300" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails" xlink:type="extended" xlink:title="40904 - Disclosure - INCOME TAXES - Reconciliation of income tax (expense) benefit (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637031108260491834" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638139950105950300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637031108260491834" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638139950105950300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638139950105950300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637031108260491834" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638139950105950300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_638139950105950300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637031108260491834" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_638139950105950300" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent" xlink:label="ctso_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent_638139950105950300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637031108260491834" xlink:to="ctso_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent_638139950105950300" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638139950105950300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637031108260491834" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638139950105950300" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638139950105960298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637031108260491834" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638139950105960298" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638139950105960298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637031108260491834" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638139950105960298" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638139950105960298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637031108260491834" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_638139950105960298" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638139950105960298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637031108260491834" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638139950105960298" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="extended" xlink:title="40905 - Disclosure - INCOME TAXES - Additional information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637031108260542265" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638139950105960298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637031108260542265" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638139950105960298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638139950105960298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638139950105960298" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638139950105960298" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638139950105960298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638139950105960298" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638139950105960298" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638139950105960298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638139950105960298" xlink:to="us-gaap_DomesticCountryMember_638139950105960298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638139950105960298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638139950105960298" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638139950105960298" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember_638139950105960298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638139950105960298" xlink:to="us-gaap_ForeignCountryMember_638139950105960298" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638139950105960298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638139950105960298" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638139950105960298" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ProceedsFromSaleOfNetOperatingLossCarryforwards" xlink:label="ctso_ProceedsFromSaleOfNetOperatingLossCarryforwards_638139950105970298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638139950105960298" xlink:to="ctso_ProceedsFromSaleOfNetOperatingLossCarryforwards_638139950105970298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638139950105970298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638139950105960298" xlink:to="us-gaap_OperatingLossCarryforwards_638139950105970298" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_638139950105970298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638139950105960298" xlink:to="us-gaap_TaxCreditCarryforwardAmount_638139950105970298" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638139950105970298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638139950105960298" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638139950105970298" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_638139950105970298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638139950105960298" xlink:to="us-gaap_OperatingLossCarryforwardsLimitationsOnUse_638139950105970298" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="41001 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_514" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CommitmentsAndContingenciesDisclosureTable" xlink:label="ctso_CommitmentsAndContingenciesDisclosureTable_638139950105970298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_514" xlink:to="ctso_CommitmentsAndContingenciesDisclosureTable_638139950105970298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638139950105970298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_CommitmentsAndContingenciesDisclosureTable_638139950105970298" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638139950105970298" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638139950105970298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638139950105970298" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638139950105970298" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyAgreementsMember" xlink:label="us-gaap_RoyaltyAgreementsMember_638139950105970298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638139950105970298" xlink:to="us-gaap_RoyaltyAgreementsMember_638139950105970298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_LicenseAgreementMember" xlink:label="ctso_LicenseAgreementMember_638139950105970298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638139950105970298" xlink:to="ctso_LicenseAgreementMember_638139950105970298" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis_638139950105980300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_CommitmentsAndContingenciesDisclosureTable_638139950105970298" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis_638139950105980300" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain_638139950105980300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis_638139950105980300" xlink:to="us-gaap_LossContingencyNatureDomain_638139950105980300" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_PayrollTaxAuditMember" xlink:label="ctso_PayrollTaxAuditMember_638139950105980300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain_638139950105980300" xlink:to="ctso_PayrollTaxAuditMember_638139950105980300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AdditionalSocialSecurityAndVatTaxesMember" xlink:label="ctso_AdditionalSocialSecurityAndVatTaxesMember_638139950105980300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain_638139950105980300" xlink:to="ctso_AdditionalSocialSecurityAndVatTaxesMember_638139950105980300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CommitmentsAndContingenciesDisclosureLineItems" xlink:label="ctso_CommitmentsAndContingenciesDisclosureLineItems_638139950105980300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_CommitmentsAndContingenciesDisclosureTable_638139950105970298" xlink:to="ctso_CommitmentsAndContingenciesDisclosureLineItems_638139950105980300" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationInterestAccrued_638139950105980300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_CommitmentsAndContingenciesDisclosureLineItems_638139950105980300" xlink:to="us-gaap_IncomeTaxExaminationInterestAccrued_638139950105980300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ExecutiveEmploymentAgreementsInitialTerm" xlink:label="ctso_ExecutiveEmploymentAgreementsInitialTerm_638139950105980300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_CommitmentsAndContingenciesDisclosureLineItems_638139950105980300" xlink:to="ctso_ExecutiveEmploymentAgreementsInitialTerm_638139950105980300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_EmploymentAgreementsAutomaticRenewalPeriod" xlink:label="ctso_EmploymentAgreementsAutomaticRenewalPeriod_638139950105980300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_CommitmentsAndContingenciesDisclosureLineItems_638139950105980300" xlink:to="ctso_EmploymentAgreementsAutomaticRenewalPeriod_638139950105980300" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_EmploymentAgreementsAutomaticRenewedPeriod" xlink:label="ctso_EmploymentAgreementsAutomaticRenewedPeriod_638139950105980300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_CommitmentsAndContingenciesDisclosureLineItems_638139950105980300" xlink:to="ctso_EmploymentAgreementsAutomaticRenewedPeriod_638139950105980300" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638139950105980300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_CommitmentsAndContingenciesDisclosureLineItems_638139950105980300" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_638139950105980300" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_RoyaltyPaymentRate" xlink:label="ctso_RoyaltyPaymentRate_638139950105980300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_CommitmentsAndContingenciesDisclosureLineItems_638139950105980300" xlink:to="ctso_RoyaltyPaymentRate_638139950105980300" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense_638139950105980300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_CommitmentsAndContingenciesDisclosureLineItems_638139950105980300" xlink:to="us-gaap_RoyaltyExpense_638139950105980300" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_LicensePeriod" xlink:label="ctso_LicensePeriod_638139950105980300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_CommitmentsAndContingenciesDisclosureLineItems_638139950105980300" xlink:to="ctso_LicensePeriod_638139950105980300" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_RoyaltyRateLowerLimit" xlink:label="ctso_RoyaltyRateLowerLimit_638139950105990300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_CommitmentsAndContingenciesDisclosureLineItems_638139950105980300" xlink:to="ctso_RoyaltyRateLowerLimit_638139950105990300" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_RoyaltyRateUpperLimit" xlink:label="ctso_RoyaltyRateUpperLimit_638139950105990300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_CommitmentsAndContingenciesDisclosureLineItems_638139950105980300" xlink:to="ctso_RoyaltyRateUpperLimit_638139950105990300" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" xlink:type="extended" xlink:title="41101 - Disclosure - STOCKHOLDERS' EQUITY - Stock option activity (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_537" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638139950105990300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_537" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638139950105990300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638139950105990300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638139950105990300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638139950105990300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638139950105990300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638139950105990300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638139950105990300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638139950105990300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638139950105990300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638139950105990300" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_638139950105990300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638139950105990300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_638139950105990300" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638139950105990300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638139950105990300" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638139950105990300" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6381399501059903001" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638139950105990300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6381399501059903001" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638139950105990300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_537" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638139950105990300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638139950106000300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638139950105990300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638139950106000300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638139950106000300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638139950105990300" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638139950106000300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638139950106000300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638139950105990300" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638139950106000300" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_638139950106000300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638139950105990300" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_638139950106000300" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638139950106000300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638139950105990300" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638139950106000300" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6381399501060003001" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638139950105990300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6381399501060003001" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638139950106000300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_537" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638139950106000300" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638139950106000300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638139950106000300" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638139950106000300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm_638139950106000300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638139950106000300" xlink:to="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm_638139950106000300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm_638139950106000300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638139950106000300" xlink:to="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm_638139950106000300" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm_638139950106000300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638139950106000300" xlink:to="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm_638139950106000300" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm_638139950106010298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638139950106000300" xlink:to="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm_638139950106010298" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638139950106010298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638139950106000300" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638139950106010298" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureStockholdersEquityFairValueOfStockOptionDetails" xlink:type="extended" xlink:title="41102 - Disclosure - STOCKHOLDERS' EQUITY - Fair value of stock option (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockholdersEquityTable" xlink:label="ctso_StockholdersEquityTable_638139950106010298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ctso_StockholdersEquityTable_638139950106010298" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638139950106010298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityTable_638139950106010298" xlink:to="us-gaap_StatementClassOfStockAxis_638139950106010298" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638139950106010298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638139950106010298" xlink:to="us-gaap_ClassOfStockDomain_638139950106010298" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ExercisePriceRangingFrom5.00To10.58Member" xlink:label="ctso_ExercisePriceRangingFrom5.00To10.58Member_638139950106010298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139950106010298" xlink:to="ctso_ExercisePriceRangingFrom5.00To10.58Member_638139950106010298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ExercisePriceRangingFrom4.46To11.39Member" xlink:label="ctso_ExercisePriceRangingFrom4.46To11.39Member_638139950106010298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139950106010298" xlink:to="ctso_ExercisePriceRangingFrom4.46To11.39Member_638139950106010298" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ExercisePriceRangingFrom2.98To3.91Member" xlink:label="ctso_ExercisePriceRangingFrom2.98To3.91Member_638139950106010298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139950106010298" xlink:to="ctso_ExercisePriceRangingFrom2.98To3.91Member_638139950106010298" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638139950106010298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityTable_638139950106010298" xlink:to="srt_RangeAxis_638139950106010298" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638139950106010298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638139950106010298" xlink:to="srt_RangeMember_638139950106010298" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638139950106020299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638139950106010298" xlink:to="srt_MaximumMember_638139950106020299" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638139950106020299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638139950106010298" xlink:to="srt_MinimumMember_638139950106020299" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockholdersEquityLineItems" xlink:label="ctso_StockholdersEquityLineItems_638139950106020299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityTable_638139950106010298" xlink:to="ctso_StockholdersEquityLineItems_638139950106020299" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_638139950106020299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106020299" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_638139950106020299" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638139950106020299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106020299" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638139950106020299" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638139950106020299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106020299" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638139950106020299" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638139950106020299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106020299" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638139950106020299" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638139950106020299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106020299" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638139950106020299" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638139950106020299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106020299" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638139950106020299" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails" xlink:type="extended" xlink:title="41103 - Disclosure - STOCKHOLDERS' EQUITY - Intrinsic value (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_563" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638139950106030300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_563" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638139950106030300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638139950106030300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638139950106030300" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638139950106030300" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638139950106030300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_638139950106030300" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638139950106030300" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ExercisePriceRangeOneMember" xlink:label="ctso_ExercisePriceRangeOneMember_638139950106030300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_638139950106030300" xlink:to="ctso_ExercisePriceRangeOneMember_638139950106030300" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638139950106030300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_638139950106030300" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638139950106030300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract_638139950106030300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638139950106030300" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract_638139950106030300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_638139950106030300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract_638139950106030300" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_638139950106030300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_638139950106030300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract_638139950106030300" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_638139950106030300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_638139950106030300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract_638139950106030300" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_638139950106030300" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_638139950106030300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract_638139950106030300" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_638139950106030300" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_638139950106030300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract_638139950106030300" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_638139950106030300" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638139950106030300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract_638139950106030300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638139950106030300" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638139950106030300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_638139950106030300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638139950106030300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_638139950106040302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638139950106030300" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_638139950106040302" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_638139950106040302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638139950106030300" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_638139950106040302" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638139950106040302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638139950106030300" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638139950106040302" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails" xlink:type="extended" xlink:title="41104 - Disclosure - STOCKHOLDERS' EQUITY - Non-vested options (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_581" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638139950106040302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_581" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638139950106040302" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_638139950106040302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638139950106040302" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_638139950106040302" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638139950106040302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638139950106040302" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638139950106040302" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_638139950106040302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638139950106040302" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_638139950106040302" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_638139950106040302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638139950106040302" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_638139950106040302" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_6381399501060403021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638139950106040302" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_6381399501060403021" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638139950106040302" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_581" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638139950106040302" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_638139950106050298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638139950106040302" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_638139950106050298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638139950106050298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638139950106040302" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638139950106050298" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_638139950106050298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638139950106040302" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_638139950106050298" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_638139950106050298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638139950106040302" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_638139950106050298" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_6381399501060502981" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638139950106040302" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_6381399501060502981" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails" xlink:type="extended" xlink:title="41105 - Disclosure - STOCKHOLDERS' EQUITY - Restricted stock unit (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_329246" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockholdersEquityTable" xlink:label="ctso_StockholdersEquityTable_638139950106050298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_329246" xlink:to="ctso_StockholdersEquityTable_638139950106050298" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638139950106050298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityTable_638139950106050298" xlink:to="us-gaap_AwardTypeAxis_638139950106050298" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139950106050298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638139950106050298" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139950106050298" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638139950106050298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139950106050298" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638139950106050298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638139950106050298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityTable_638139950106050298" xlink:to="srt_TitleOfIndividualAxis_638139950106050298" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139950106060300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638139950106050298" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139950106060300" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember_638139950106060300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139950106060300" xlink:to="srt_BoardOfDirectorsChairmanMember_638139950106060300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ManagementMember" xlink:label="srt_ManagementMember_638139950106060300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139950106060300" xlink:to="srt_ManagementMember_638139950106060300" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficerMember" xlink:label="srt_OfficerMember_638139950106060300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139950106060300" xlink:to="srt_OfficerMember_638139950106060300" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockholdersEquityLineItems" xlink:label="ctso_StockholdersEquityLineItems_638139950106060300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityTable_638139950106050298" xlink:to="ctso_StockholdersEquityLineItems_638139950106060300" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_638139950106060300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106060300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_638139950106060300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_638139950106060300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106060300" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_638139950106060300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_638139950106060300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106060300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_638139950106060300" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_638139950106060300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106060300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_638139950106060300" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_6381399501060603001" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106060300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_6381399501060603001" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_6381399501060603001" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106060300" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_6381399501060603001" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638139950106060300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106060300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638139950106060300" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638139950106070304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106060300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638139950106070304" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails" xlink:type="extended" xlink:title="41106 - Disclosure - STOCKHOLDERS' EQUITY - Restricted stock unit activity (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_599" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockholdersEquityTable" xlink:label="ctso_StockholdersEquityTable_638139950106070304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_599" xlink:to="ctso_StockholdersEquityTable_638139950106070304" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638139950106070304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityTable_638139950106070304" xlink:to="us-gaap_AwardTypeAxis_638139950106070304" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139950106070304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638139950106070304" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139950106070304" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638139950106070304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139950106070304" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638139950106070304" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockholdersEquityLineItems" xlink:label="ctso_StockholdersEquityLineItems_638139950106070304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityTable_638139950106070304" xlink:to="ctso_StockholdersEquityLineItems_638139950106070304" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638139950106070304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106070304" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638139950106070304" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638139950106070304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638139950106070304" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638139950106070304" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638139950106070304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638139950106070304" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638139950106070304" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638139950106070304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638139950106070304" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638139950106070304" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638139950106070304" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638139950106070304" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638139950106070304" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638139950106080300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_638139950106070304" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638139950106080300" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638139950106080300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106070304" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638139950106080300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638139950106080300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638139950106080300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638139950106080300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638139950106080300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638139950106080300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638139950106080300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638139950106080300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638139950106080300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638139950106080300" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638139950106080300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638139950106080300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638139950106080300" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6381399501060803001" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_638139950106080300" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6381399501060803001" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="extended" xlink:title="41107 - Disclosure - STOCKHOLDERS' EQUITY - Additional information (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_632" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockholdersEquityTable" xlink:label="ctso_StockholdersEquityTable_638139950106090300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_632" xlink:to="ctso_StockholdersEquityTable_638139950106090300" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638139950106090300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityTable_638139950106090300" xlink:to="us-gaap_StatementClassOfStockAxis_638139950106090300" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638139950106090300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638139950106090300" xlink:to="us-gaap_ClassOfStockDomain_638139950106090300" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ExercisePriceRangingFrom5.00To10.58Member" xlink:label="ctso_ExercisePriceRangingFrom5.00To10.58Member_638139950106090300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139950106090300" xlink:to="ctso_ExercisePriceRangingFrom5.00To10.58Member_638139950106090300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ExercisePriceRangingFrom2.98To3.91Member" xlink:label="ctso_ExercisePriceRangingFrom2.98To3.91Member_638139950106090300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638139950106090300" xlink:to="ctso_ExercisePriceRangingFrom2.98To3.91Member_638139950106090300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638139950106090300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityTable_638139950106090300" xlink:to="dei_LegalEntityAxis_638139950106090300" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638139950106090300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638139950106090300" xlink:to="dei_EntityDomain_638139950106090300" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_JefferiesLlcAndB.RileyFbrIncMember" xlink:label="ctso_JefferiesLlcAndB.RileyFbrIncMember_638139950106090300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638139950106090300" xlink:to="ctso_JefferiesLlcAndB.RileyFbrIncMember_638139950106090300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638139950106090300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityTable_638139950106090300" xlink:to="us-gaap_PlanNameAxis_638139950106090300" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638139950106090300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638139950106090300" xlink:to="us-gaap_PlanNameDomain_638139950106090300" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockOptionPlanOneMember" xlink:label="ctso_StockOptionPlanOneMember_638139950106090300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638139950106090300" xlink:to="ctso_StockOptionPlanOneMember_638139950106090300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_TwoThousandFourteenStockOptionPlanMember" xlink:label="ctso_TwoThousandFourteenStockOptionPlanMember_638139950106090300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638139950106090300" xlink:to="ctso_TwoThousandFourteenStockOptionPlanMember_638139950106090300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_July222019PerformanceBasedAwardMember" xlink:label="ctso_July222019PerformanceBasedAwardMember_638139950106090300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638139950106090300" xlink:to="ctso_July222019PerformanceBasedAwardMember_638139950106090300" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_February282020PerformanceBasedAwardMember" xlink:label="ctso_February282020PerformanceBasedAwardMember_638139950106090300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638139950106090300" xlink:to="ctso_February282020PerformanceBasedAwardMember_638139950106090300" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_April122021PerformanceBasedAwardMember" xlink:label="ctso_April122021PerformanceBasedAwardMember_638139950106100299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638139950106090300" xlink:to="ctso_April122021PerformanceBasedAwardMember_638139950106100299" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_August102022PerformanceBasedAwardMember" xlink:label="ctso_August102022PerformanceBasedAwardMember_638139950106100299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638139950106090300" xlink:to="ctso_August102022PerformanceBasedAwardMember_638139950106100299" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638139950106100299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityTable_638139950106090300" xlink:to="srt_TitleOfIndividualAxis_638139950106100299" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139950106100299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638139950106100299" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139950106100299" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_EmployeeOneMember" xlink:label="ctso_EmployeeOneMember_638139950106100299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139950106100299" xlink:to="ctso_EmployeeOneMember_638139950106100299" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_EmployeeTwoMember" xlink:label="ctso_EmployeeTwoMember_638139950106100299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139950106100299" xlink:to="ctso_EmployeeTwoMember_638139950106100299" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember_638139950106100299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139950106100299" xlink:to="srt_BoardOfDirectorsChairmanMember_638139950106100299" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_SeniorManagerOneMember" xlink:label="ctso_SeniorManagerOneMember_638139950106100299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139950106100299" xlink:to="ctso_SeniorManagerOneMember_638139950106100299" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_SeniorManagerTwoMember" xlink:label="ctso_SeniorManagerTwoMember_638139950106100299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638139950106100299" xlink:to="ctso_SeniorManagerTwoMember_638139950106100299" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638139950106100299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityTable_638139950106090300" xlink:to="us-gaap_AwardTypeAxis_638139950106100299" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139950106110300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638139950106100299" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139950106110300" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638139950106110300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139950106110300" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638139950106110300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638139950106110300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638139950106110300" xlink:to="us-gaap_EmployeeStockOptionMember_638139950106110300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638139950106110300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityTable_638139950106090300" xlink:to="us-gaap_VestingAxis_638139950106110300" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638139950106110300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638139950106110300" xlink:to="us-gaap_VestingDomain_638139950106110300" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638139950106110300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638139950106110300" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638139950106110300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638139950106110300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638139950106110300" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638139950106110300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_638139950106110300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638139950106110300" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_638139950106110300" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ShareBasedCompensationAwardTrancheFourMember" xlink:label="ctso_ShareBasedCompensationAwardTrancheFourMember_638139950106110300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638139950106110300" xlink:to="ctso_ShareBasedCompensationAwardTrancheFourMember_638139950106110300" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ShareBasedCompensationAwardTrancheFiveMember" xlink:label="ctso_ShareBasedCompensationAwardTrancheFiveMember_638139950106120300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638139950106110300" xlink:to="ctso_ShareBasedCompensationAwardTrancheFiveMember_638139950106120300" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_638139950106120300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityTable_638139950106090300" xlink:to="us-gaap_GranteeStatusAxis_638139950106120300" order="7" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_638139950106120300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_638139950106120300" xlink:to="us-gaap_GranteeStatusDomain_638139950106120300" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638139950106120300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_638139950106120300" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_638139950106120300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638139950106120300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityTable_638139950106090300" xlink:to="srt_RangeAxis_638139950106120300" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638139950106120300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638139950106120300" xlink:to="srt_RangeMember_638139950106120300" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638139950106120300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638139950106120300" xlink:to="srt_MaximumMember_638139950106120300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638139950106120300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638139950106120300" xlink:to="srt_MinimumMember_638139950106120300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638139950106130298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityTable_638139950106090300" xlink:to="srt_StatementScenarioAxis_638139950106130298" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638139950106130298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638139950106130298" xlink:to="srt_ScenarioUnspecifiedDomain_638139950106130298" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_SecondFortyFiveThousandRestrictedAwardMember" xlink:label="ctso_SecondFortyFiveThousandRestrictedAwardMember_638139950106130298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638139950106130298" xlink:to="ctso_SecondFortyFiveThousandRestrictedAwardMember_638139950106130298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember" xlink:label="ctso_SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember_638139950106130298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638139950106130298" xlink:to="ctso_SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember_638139950106130298" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockholdersEquityLineItems" xlink:label="ctso_StockholdersEquityLineItems_638139950106130298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityTable_638139950106090300" xlink:to="ctso_StockholdersEquityLineItems_638139950106130298" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638139950106130298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_PreferredStockSharesAuthorized_638139950106130298" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638139950106140301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_CommonStockSharesAuthorized_638139950106140301" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638139950106140301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638139950106140301" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CommonStockValueAuthorized" xlink:label="ctso_CommonStockValueAuthorized_638139950106140301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="ctso_CommonStockValueAuthorized_638139950106140301" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_AggregateRegisteredAmountForOfferings" xlink:label="ctso_AggregateRegisteredAmountForOfferings_638139950106140301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="ctso_AggregateRegisteredAmountForOfferings_638139950106140301" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638139950106140301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_SharePrice_638139950106140301" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638139950106140301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638139950106140301" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638139950106140301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638139950106140301" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638139950106150300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638139950106150300" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6381399501061503001" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6381399501061503001" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue" xlink:label="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue_638139950106150300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue_638139950106150300" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionPlanExpense" xlink:label="us-gaap_StockOptionPlanExpense_638139950106150300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_StockOptionPlanExpense_638139950106150300" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage" xlink:label="ctso_ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage_638139950106150300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="ctso_ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage_638139950106150300" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_CommissionRateAsPercentageOfAggregateGrossProceeds" xlink:label="ctso_CommissionRateAsPercentageOfAggregateGrossProceeds_638139950106160299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="ctso_CommissionRateAsPercentageOfAggregateGrossProceeds_638139950106160299" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_NumberOfLongTermIncentivePlans" xlink:label="ctso_NumberOfLongTermIncentivePlans_638139950106160299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="ctso_NumberOfLongTermIncentivePlans_638139950106160299" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638139950106160299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638139950106160299" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638139950106160299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638139950106160299" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_638139950106160299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_638139950106160299" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638139950106160299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638139950106160299" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638139950106170301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638139950106170301" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638139950106170301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638139950106170301" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638139950106170301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_638139950106170301" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638139950106170301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_638139950106170301" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638139950106170301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638139950106170301" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638139950106180299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638139950106180299" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638139950106180299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638139950106180299" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_638139950106180299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_638139950106180299" order="27" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_638139950106180299" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_638139950106180299" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_638139950106190298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_638139950106190298" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638139950106190298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638139950106190298" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638139950106190298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638139950106190298" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_638139950106190298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_638139950106190298" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638139950106190298" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638139950106190298" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638139950106200305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctso_StockholdersEquityLineItems_638139950106130298" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638139950106200305" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureStockholdersEquityWarrantsDetails" xlink:type="extended" xlink:title="41108 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_618" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638139950106200305" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_618" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638139950106200305" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="41201 - Disclosure - NET LOSS PER SHARE (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_726" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_638139950106210300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_726" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_638139950106210300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638139950106210300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_638139950106210300" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638139950106210300" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638139950106210300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638139950106210300" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638139950106210300" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_StockOptionsAndWarrantsMember" xlink:label="ctso_StockOptionsAndWarrantsMember_638139950106210300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638139950106210300" xlink:to="ctso_StockOptionsAndWarrantsMember_638139950106210300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems_638139950106210300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_638139950106210300" xlink:to="us-gaap_EarningsPerShareBasicLineItems_638139950106210300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638139950106210300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems_638139950106210300" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638139950106210300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureRetirementPlanDetails" xlink:type="extended" xlink:title="41301 - Disclosure - RETIREMENT PLAN (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable_638139950106210300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable_638139950106210300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638139950106210300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_638139950106210300" xlink:to="srt_RangeAxis_638139950106210300" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638139950106210300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638139950106210300" xlink:to="srt_RangeMember_638139950106210300" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638139950106210300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638139950106210300" xlink:to="srt_MinimumMember_638139950106210300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638139950106210300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638139950106210300" xlink:to="srt_MaximumMember_638139950106210300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638139950106210300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_638139950106210300" xlink:to="srt_StatementScenarioAxis_638139950106210300" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638139950106220301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638139950106210300" xlink:to="srt_ScenarioUnspecifiedDomain_638139950106220301" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ParticipantsContributionUpto3PercentMember" xlink:label="ctso_ParticipantsContributionUpto3PercentMember_638139950106220301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638139950106220301" xlink:to="ctso_ParticipantsContributionUpto3PercentMember_638139950106220301" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_ParticipantsContributionOver3AndMaximum5Member" xlink:label="ctso_ParticipantsContributionOver3AndMaximum5Member_638139950106220301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638139950106220301" xlink:to="ctso_ParticipantsContributionOver3AndMaximum5Member_638139950106220301" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_638139950106220301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable_638139950106210300" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_638139950106220301" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="ctso-20221231.xsd#ctso_DefinedContributionEligibilityTerm" xlink:label="ctso_DefinedContributionEligibilityTerm_638139950106220301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638139950106220301" xlink:to="ctso_DefinedContributionEligibilityTerm_638139950106220301" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_638139950106220301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638139950106220301" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_638139950106220301" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638139950106220301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638139950106220301" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638139950106220301" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638139950106220301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638139950106220301" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638139950106220301" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_638139950106220301" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems_638139950106220301" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_638139950106220301" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnauditedDetails" xlink:type="extended" xlink:title="41401 - Disclosure - QUARTERLY FINANCIAL RESULTS (UNAUDITED) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_637031108262170499" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638139950106230300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_637031108262170499" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_638139950106230300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit_638139950106230300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_637031108262170499" xlink:to="us-gaap_GrossProfit_638139950106230300" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638139950106230300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_637031108262170499" xlink:to="us-gaap_OperatingIncomeLoss_638139950106230300" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638139950106230300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_637031108262170499" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638139950106230300" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638139950106230300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_637031108262170499" xlink:to="us-gaap_EarningsPerShareBasic_638139950106230300" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638139950106230300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_637031108262170499" xlink:to="us-gaap_EarningsPerShareDiluted_638139950106230300" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.cytosorbents.com/role/DisclosureRevenueContractWithCustomerAssetAndLiabilityDetails" xlink:type="extended" xlink:title="9940303 - Disclosure - REVENUE - Contract with customer asset And liability (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_638139950106230300" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_638139950106230300" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566249728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 07, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CYTOSORBENTS CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0373793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">305 College Road East<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Princeton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">329-8885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CTSO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="nump">$ 61,461,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,663,009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001175151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">WithumSmith+Brown, PC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">East Brunswick, New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523571162800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 22,144,567<span></span>
</td>
<td class="nump">$ 52,137,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Grants and accounts receivable, net of allowance for doubtful accounts of $76,041 and $60,539 at December 31, 2022 and 2021, respectively</a></td>
<td class="nump">5,664,941<span></span>
</td>
<td class="nump">4,523,430<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">3,461,586<span></span>
</td>
<td class="nump">4,766,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,488,597<span></span>
</td>
<td class="nump">2,871,655<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">33,759,691<span></span>
</td>
<td class="nump">64,298,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment - net</a></td>
<td class="nump">10,743,032<span></span>
</td>
<td class="nump">5,150,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,687,459<span></span>
</td>
<td class="nump">1,687,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">12,603,901<span></span>
</td>
<td class="nump">13,423,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4,437,447<span></span>
</td>
<td class="nump">4,958,575<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">63,231,530<span></span>
</td>
<td class="nump">89,519,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,655,173<span></span>
</td>
<td class="nump">2,805,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">7,950,440<span></span>
</td>
<td class="nump">10,314,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liability - current portion</a></td>
<td class="nump">108,939<span></span>
</td>
<td class="nump">570,566<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,714,552<span></span>
</td>
<td class="nump">13,690,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">13,142,005<span></span>
</td>
<td class="nump">13,250,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">27,856,557<span></span>
</td>
<td class="nump">26,941,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, Par Value $0.001, 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2022 and 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Par Value $0.001, 100,000,000 shares authorized; 43,635,715 and 43,478,487 shares issued and outstanding at December 31, 2022 and 2021, respectively</a></td>
<td class="nump">43,635<span></span>
</td>
<td class="nump">43,478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">287,000,021<span></span>
</td>
<td class="nump">283,194,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">2,329,195<span></span>
</td>
<td class="nump">525,585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(253,997,878)<span></span>
</td>
<td class="num">(221,185,295)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">35,374,973<span></span>
</td>
<td class="nump">62,578,197<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 63,231,530<span></span>
</td>
<td class="nump">$ 89,519,282<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566146288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Grants and accounts receivable, net of allowance for doubtful accounts</a></td>
<td class="nump">$ 76,041<span></span>
</td>
<td class="nump">$ 60,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par Value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par Value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued</a></td>
<td class="nump">43,478,487<span></span>
</td>
<td class="nump">43,635,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding</a></td>
<td class="nump">43,478,487<span></span>
</td>
<td class="nump">43,635,715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523565266336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 34,688,809<span></span>
</td>
<td class="nump">$ 43,165,527<span></span>
</td>
<td class="nump">$ 41,004,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">13,955,752<span></span>
</td>
<td class="nump">11,047,350<span></span>
</td>
<td class="nump">11,052,409<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">20,733,057<span></span>
</td>
<td class="nump">32,118,177<span></span>
</td>
<td class="nump">29,952,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">15,118,907<span></span>
</td>
<td class="nump">16,380,930<span></span>
</td>
<td class="nump">8,810,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Legal, financial and other consulting</a></td>
<td class="nump">2,847,899<span></span>
</td>
<td class="nump">2,731,515<span></span>
</td>
<td class="nump">3,048,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">34,288,130<span></span>
</td>
<td class="nump">35,750,477<span></span>
</td>
<td class="nump">28,463,723<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">52,254,936<span></span>
</td>
<td class="nump">54,862,922<span></span>
</td>
<td class="nump">40,322,526<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(31,521,879)<span></span>
</td>
<td class="num">(22,744,745)<span></span>
</td>
<td class="num">(10,370,334)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest (expense), net</a></td>
<td class="nump">132,597<span></span>
</td>
<td class="nump">28,007<span></span>
</td>
<td class="num">(1,201,067)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Gain (loss) on foreign currency transactions</a></td>
<td class="num">(2,448,583)<span></span>
</td>
<td class="num">(2,577,913)<span></span>
</td>
<td class="nump">2,607,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_MiscellaneousIncome', window );">Miscellaneous expense</a></td>
<td class="num">(67,303)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(2,383,289)<span></span>
</td>
<td class="num">(2,549,906)<span></span>
</td>
<td class="nump">1,406,072<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before benefit from income taxes</a></td>
<td class="num">(33,905,168)<span></span>
</td>
<td class="num">(25,294,651)<span></span>
</td>
<td class="num">(8,964,262)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="nump">1,092,585<span></span>
</td>
<td class="nump">736,003<span></span>
</td>
<td class="nump">1,127,074<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (32,812,583)<span></span>
</td>
<td class="num">$ (24,558,648)<span></span>
</td>
<td class="num">$ (7,837,188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share</a></td>
<td class="num">$ (0.75)<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share</a></td>
<td class="num">$ (0.75)<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares of common stock outstanding, basic</a></td>
<td class="nump">43,573,215<span></span>
</td>
<td class="nump">43,359,186<span></span>
</td>
<td class="nump">38,818,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares of common stock outstanding, diluted</a></td>
<td class="nump">43,573,215<span></span>
</td>
<td class="nump">43,359,186<span></span>
</td>
<td class="nump">38,818,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (32,812,583)<span></span>
</td>
<td class="num">$ (24,558,648)<span></span>
</td>
<td class="num">$ (7,837,188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">1,803,610<span></span>
</td>
<td class="nump">2,259,663<span></span>
</td>
<td class="num">(2,260,056)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(31,008,973)<span></span>
</td>
<td class="num">(22,298,985)<span></span>
</td>
<td class="num">(10,097,244)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">29,359,910<span></span>
</td>
<td class="nump">40,108,567<span></span>
</td>
<td class="nump">39,452,502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ctso_CytoSorbSalesMember', window );">CytoSorb sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">28,572,709<span></span>
</td>
<td class="nump">39,996,700<span></span>
</td>
<td class="nump">39,342,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ctso_OtherSalesMember', window );">Other sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">787,201<span></span>
</td>
<td class="nump">111,867<span></span>
</td>
<td class="nump">110,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 5,328,899<span></span>
</td>
<td class="nump">$ 3,056,960<span></span>
</td>
<td class="nump">$ 1,552,099<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_MiscellaneousIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of miscellaneous income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_MiscellaneousIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ctso_CytoSorbSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ctso_CytoSorbSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ctso_OtherSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ctso_OtherSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523565000608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 32,616<span></span>
</td>
<td class="nump">$ 191,648,907<span></span>
</td>
<td class="nump">$ 525,978<span></span>
</td>
<td class="num">$ (188,789,459)<span></span>
</td>
<td class="nump">$ 3,418,042<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">32,616,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation - employees, consultants and directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,513,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,513,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock - offerings, net of fees incurred</a></td>
<td class="nump">$ 10,162<span></span>
</td>
<td class="nump">80,203,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,214,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock - offerings, net of fees incurred (in shares)</a></td>
<td class="nump">10,163,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock options</a></td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">657,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">657,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock options (in shares)</a></td>
<td class="nump">87,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockIssuedDuringPeriodValueStockCashOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">$ 342<span></span>
</td>
<td class="nump">1,508,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,509,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockIssuedDuringPeriodSharesStockCashOptionsExercised', window );">Proceeds from exercise of stock options (in shares)</a></td>
<td class="nump">341,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Cashless exercise of stock options</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions', window );">Cashless exercise of stock options (in shares)</a></td>
<td class="nump">13,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive income (loss), foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,260,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,260,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,837,188)<span></span>
</td>
<td class="num">(7,837,188)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 43,222<span></span>
</td>
<td class="nump">277,533,082<span></span>
</td>
<td class="num">(1,734,078)<span></span>
</td>
<td class="num">(196,626,647)<span></span>
</td>
<td class="nump">79,215,579<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">43,221,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation - employees, consultants and directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,020,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,020,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock - offerings, net of fees incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock options</a></td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">928,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">928,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock options (in shares)</a></td>
<td class="nump">106,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockIssuedDuringPeriodValueStockCashOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">805,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockIssuedDuringPeriodSharesStockCashOptionsExercised', window );">Proceeds from exercise of stock options (in shares)</a></td>
<td class="nump">139,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Cashless exercise of stock options</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="num">(2,842)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,832)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions', window );">Cashless exercise of stock options (in shares)</a></td>
<td class="nump">10,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive income (loss), foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,259,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,259,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,558,648)<span></span>
</td>
<td class="num">(24,558,648)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 43,478<span></span>
</td>
<td class="nump">283,194,429<span></span>
</td>
<td class="nump">525,585<span></span>
</td>
<td class="num">(221,185,295)<span></span>
</td>
<td class="nump">62,578,197<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">43,478,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation - employees, consultants and directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,423,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,423,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Legal/audit fees related to ATM offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,358)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,358)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock options</a></td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">379,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock options (in shares)</a></td>
<td class="nump">144,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive income (loss), foreign currency translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,803,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,803,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued to vendor in lieu of cash payment</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">42,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,499<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued to vendor in lieu of cash payment (in shares)</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,812,583)<span></span>
</td>
<td class="num">(32,812,583)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 43,635<span></span>
</td>
<td class="nump">$ 287,000,021<span></span>
</td>
<td class="nump">$ 2,329,195<span></span>
</td>
<td class="num">$ (253,997,878)<span></span>
</td>
<td class="nump">$ 35,374,973<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">43,635,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of cashless stock options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_StockIssuedDuringPeriodSharesStockCashOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the exercise of cash options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_StockIssuedDuringPeriodSharesStockCashOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_StockIssuedDuringPeriodValueStockCashOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value stock issued during the period as a result of the exercise of cash options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_StockIssuedDuringPeriodValueStockCashOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523565170672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (32,812,583)<span></span>
</td>
<td class="num">$ (24,558,648)<span></span>
</td>
<td class="num">$ (7,837,188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Non-cash compensation</a></td>
<td class="nump">376,574<span></span>
</td>
<td class="nump">2,183,317<span></span>
</td>
<td class="nump">1,193,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">882,621<span></span>
</td>
<td class="nump">731,578<span></span>
</td>
<td class="nump">660,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of right-of-use asset</a></td>
<td class="nump">249,008<span></span>
</td>
<td class="nump">398,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Bad debt expense (recovery)</a></td>
<td class="num">(8,354)<span></span>
</td>
<td class="num">(512)<span></span>
</td>
<td class="num">(102,310)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">132,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of patents</a></td>
<td class="nump">635,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Foreign currency transaction (gains) losses</a></td>
<td class="nump">2,448,583<span></span>
</td>
<td class="nump">2,577,913<span></span>
</td>
<td class="num">(2,607,139)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,423,517<span></span>
</td>
<td class="nump">4,020,819<span></span>
</td>
<td class="nump">3,513,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_AmortizationOfLoanAcquisitionCosts', window );">Amortization of loan acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Grants and accounts receivable</a></td>
<td class="num">(1,288,422)<span></span>
</td>
<td class="nump">420,578<span></span>
</td>
<td class="num">(326,860)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">945,352<span></span>
</td>
<td class="num">(2,350,547)<span></span>
</td>
<td class="num">(461,512)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(22,187)<span></span>
</td>
<td class="nump">280,915<span></span>
</td>
<td class="num">(1,076,849)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">52,678<span></span>
</td>
<td class="num">(135,857)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(3,248,978)<span></span>
</td>
<td class="nump">2,426,810<span></span>
</td>
<td class="nump">1,107,352<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(28,234,282)<span></span>
</td>
<td class="num">(14,005,599)<span></span>
</td>
<td class="num">(5,613,286)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(6,087,365)<span></span>
</td>
<td class="num">(3,641,248)<span></span>
</td>
<td class="num">(708,395)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Patent costs</a></td>
<td class="num">(368,211)<span></span>
</td>
<td class="num">(640,013)<span></span>
</td>
<td class="num">(967,823)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(6,455,576)<span></span>
</td>
<td class="num">(4,281,261)<span></span>
</td>
<td class="num">(1,676,218)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,410,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,410,900)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument', window );">Final fee on long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(375,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_PaymentsForEquityContributionsNetOfFeesIncurred', window );">Equity contributions - net of fees incurred</a></td>
<td class="num">(40,358)<span></span>
</td>
<td class="num">(90,000)<span></span>
</td>
<td class="nump">80,214,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805,199<span></span>
</td>
<td class="nump">1,509,322<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">4,959,642<span></span>
</td>
<td class="nump">715,199<span></span>
</td>
<td class="nump">66,348,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rates on cash</a></td>
<td class="num">(262,924)<span></span>
</td>
<td class="num">(24,774)<span></span>
</td>
<td class="nump">130,357<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(29,993,140)<span></span>
</td>
<td class="num">(17,596,435)<span></span>
</td>
<td class="nump">59,189,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">53,825,166<span></span>
</td>
<td class="nump">71,421,601<span></span>
</td>
<td class="nump">12,232,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of year</a></td>
<td class="nump">23,832,026<span></span>
</td>
<td class="nump">53,825,166<span></span>
</td>
<td class="nump">71,421,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the year for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,127,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock to vendor in lieu of cash payment</a></td>
<td class="nump">42,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures included in accounts payable</a></td>
<td class="nump">359,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Settlement of accrued bonuses with restricted stock units</a></td>
<td class="nump">$ 380,091<span></span>
</td>
<td class="nump">$ 928,417<span></span>
</td>
<td class="nump">$ 657,780<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_AmortizationOfLoanAcquisitionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortization of loan acquisition costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_AmortizationOfLoanAcquisitionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow of non-refundable final fees on termination or maturity for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_PaymentsForEquityContributionsNetOfFeesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for equity contributions - net of fees incurred</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_PaymentsForEquityContributionsNetOfFeesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566232880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">BASIS OF PRESENTATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. BASIS OF PRESENTATION:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements include the results of CytoSorbents Corporation (the &#8220;Parent&#8221;), CytoSorbents Medical Inc., its wholly owned operating subsidiary (the &#8220;Subsidiary&#8221;), and CytoSorbents Europe GmbH, its wholly owned European subsidiary (the &#8220;European Subsidiary&#8221;). In addition, the consolidated financial statements include CytoSorbents Switzerland GmbH, CytoSorbents Poland Sp. z.o.o., CytoSorbents Medical UK Limited, and CytoSorbents France SAS, the wholly owned subsidiaries of CytoSorbents Europe GmbH, and CytoSorbents UK Limited, a wholly owned subsidiary of CytoSorbents Medical, Inc. These entities are collectively referred to as the &#8220;Company&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In years prior to December 31, 2020, the Company&#8217;s consolidated financial statements were prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As of December 31, 2022, the Company&#8217;s cash, cash equivalents and restricted cash balances were approximately $23.8 million, which the Company expects will fund the Company&#8217;s operations beyond twelve months from the issuance of these consolidated financial statements. As a result, the Company has determined that the going concern risk has been substantially mitigated.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566553632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Nature of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification. The Company, through its subsidiary CytoSorbents Medical, Inc. (formerly known as CytoSorbents, Inc.), is engaged in the research, development and commercialization of medical devices with its blood purification technology platform which incorporates a proprietary adsorbent, porous polymer technology. The Company, through its wholly owned European subsidiary, CytoSorbents Europe GmbH, conducts sales and marketing related operations for the CytoSorb device. In March 2016, the Company formed CytoSorbents Switzerland GmbH, a wholly owned subsidiary of CytoSorbents Europe GmbH. This subsidiary, which began operations during the second quarter of 2016, provides marketing and direct sales services in Switzerland. In November 2018, the Company formed CytoSorbents Poland Sp. z.o.o., a wholly owned subsidiary of CytoSorbents Europe GmbH. This subsidiary, which began operations during the first quarter of 2019, provides marketing and direct sales services in Poland. In the third quarter of 2019, the Company formed CytoSorbents UK Limited, a wholly owned subsidiary of CytoSorbents Medical, Inc., which is responsible for the management of the Company&#8217;s clinical trial activities in the United Kingdom. In March 2022, the Company formed CytoSorbents Medical UK Limited to provide marketing and direct sales services in the United Kingdom and the Republic of Ireland. In October 2022, the Company formed CytoSorbents France SAS to provide marketing and direct sales services in France. CytoSorb, the Company&#8217;s flagship product, was approved in the European Union (&#8220;EU&#8221;) in March 2011 and is currently being marketed and distributed in more than 75 countries around the world, as an effective extracorporeal cytokine absorber, designed to reduce the &#8220;cytokine storm&#8221; or &#8220;cytokine release syndrome&#8221; seen in critical illnesses that may result in massive inflammation, organ failure, and patient death. In May 2018, the Company received a label extension for CytoSorb covering use of the device for the removal of bilirubin and myoglobin which allows for the use of the device in the treatment of liver failure and trauma, respectively. CytoSorb is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. In January 2020, CytoSorb received EU CE Mark label expansion to include the removal of ticagrelor during cardiopulmonary bypass in patients undergoing cardiothoracic surgery. In May 2020, CytoSorb also received EU CE Mark label expansion to include rivaroxaban removal for the same indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2020, CytoSorb received United States Food and Drug Administration (&#8220;FDA&#8221;) Emergency Use Authorization (&#8220;EUA&#8221;) of CytoSorb for use in adult critically-ill COVID-19 patients with imminent or confirmed respiratory failure. The CytoSorb device has neither been cleared nor approved for the indication to treat patients with COVID-19 infection. The EUA will be effective until a declaration is made that the circumstances justifying the EUA have terminated or until revoked by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2020, the Company also announced that the FDA had granted Breakthrough Designation for its DrugSorb-ATR Antithrombotic Removal System for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery. The Breakthrough Devices Program provides for more effective treatment of life-threatening or irreversibly debilitating disease or conditions, in this case the need to reverse the effects of ticagrelor in emergent or urgent cardiac surgery that can otherwise cause a high risk of serious or life-threatening bleeding. Through Breakthrough Designation, the FDA intends to work with CytoSorbents to expedite the development, assessment, and regulatory review of CytoSorbents&#8217; technology for the removal of ticagrelor, while maintaining statutory standards of regulatory approval (e.g., 510(k), <i style="font-style:italic;">de novo</i> 510(k) or premarket approval) consistent with the FDA&#8217;s mission to protect and promote public health. In July 2021, the Company received full approval of its Investigative Device Exemption (&#8220;IDE&#8221;) to conduct the pivotal STAR-T (Safe and Timely Antithrombotic Removal &#8211; Ticagrelor) double-blind randomized control trial (&#8220;RCT&#8221;) for up to 120 patients in the United States to support FDA marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2021, the Company announced that it was granted a second Breakthrough Device designation for its DrugSorb-ATR Antithrombotic Removal System by the FDA. This Breakthrough Device designation covers the removal of the Direct Oral Anticoagulants (DOACs) apixaban and rivaroxaban in a cardiopulmonary bypass circuit to reduce the likelihood of serious perioperative bleeding during urgent cardiothoracic surgery. In October 2021, the Company also received full FDA approval of an IDE application to conduct a double-blind, randomized, controlled clinical study for up to 120 patients entitled, &#8220;Safe and Timely Antithrombotic Removal &#8211; Direct Oral Anticoagulants (STAR-D),&#8221; in the United States to support FDA marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If FDA marketing approval is obtained for either the removal of ticagrelor or direct oral anticoagulants indications, the device would be marketed as DrugSorb-ATR in the United States. The DrugSorb-ATR Antithrombotic Removal System is based on the same polymer technology as CytoSorb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2022, the Company announced that the Company entered into a 3-year preferred supplier agreement with Asklepios, making CytoSorb available without restrictions to all of the approximate 170 healthcare facilities across 14 states throughout Germany at which Asklepios operates. This includes Asklepios Klinik St. Georg in Hamburg, Germany, which pioneered the use of CytoSorb to remove antithrombotic drugs during cardiothoracic surgery, and is well-known for their seminal publication on CytoSorb use for this application during emergency cardiac surgery in patients at high risk of bleeding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2022, the Company announced that, following a successful pilot program in three countries, the Company signed an expanded non-exclusive agreement with Nikkiso Europe GmbH (&#8220;Nikkiso&#8221;) to distribute Nikkiso&#8217;s PureADJUST stand-alone hemoperfusion pump and accessories in a total of 14 countries. In addition to securing the rights to sell Nikkiso&#8217;s stand-alone pump and accessories in Germany, Austria, and Luxembourg, the Company entered into an expanded multi-country reseller agreement with Nikkiso covering the following countries: Belgium, Bosnia and Herzegovina, Croatia, Finland, France, Iceland, Lichtenstein, Poland, Serbia, Slovenia and Switzerland. The Company will also be able to provide field support services in these countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2022, the Company entered into a Marketing Agreement (the &#8220;Marketing Agreement&#8221;) with Fresenius Medical Care Deutschland GmbH (&#8220;Fresenius&#8221;), which expands the Company&#8217;s strategic partnership with Fresenius by establishing a multi-stage global collaboration to combat life-threatening diseases in critical care. The Marketing Agreement provides for the combined marketing and promotion of CytoSorb with Fresenius&#8217; critical care products by Fresenius&#8217; marketing organization worldwide, excluding the United States. The Marketing Agreement has an initial term of three years, with an automatic renewal for an additional two years at the end of such initial term, subject to earlier termination by either of the parties (the &#8220;Term&#8221;). Compared to the prior co-marketing agreement between the parties, the Marketing Agreement intends to increase the commitments from both parties and to ensure an ongoing and consistent level of marketing and promotional activity specifically focused around CytoSorb, where Fresenius will actively market and promote CytoSorb as the featured blood purification therapy for removal of cytokines, bilirubin, and myoglobin on its critical care platforms. Specifically, the Marketing Agreement provides that various Fresenius-led in-person, virtual, social media, and web-based marketing programs and events will feature the CytoSorb therapy and highlight the cooperation between the two companies in the field of critical care during the Term. To help support the increased marketing and promotional efforts of the expanded collaboration, CytoSorbents has agreed to subsidize a portion of the marketing costs through a royalty payment to Fresenius Medical Care based on CytoSorb sales in the intensive care unit on Fresenius Medical Care platforms, excluding the United States. In addition to strengthening and expanding the global marketing of CytoSorb, the Company and Fresenius also plan to work together to bring new innovative solutions to the market. The Marketing Agreement also includes the certification of compatibility of CytoSorb for usage on Fresenius&#8217; current critical care platforms. Certain initial activities have been completed with the formal launch of this program expected to occur sometime in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The technology is based upon biocompatible, highly porous polymer sorbent beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company has numerous products under development based upon this unique blood purification technology, which is protected by 18 issued U.S. patents and multiple international patents, with applications pending both in the U.S. and internationally, including HemoDefend, ContrastSorb, DrugSorb, DrugSorb-ATR and others. These patents and patent applications are directed to various compositions and methods of use related to the Company&#8217;s blood purification technologies and are expected to expire between 2023 and 2038, absent any patent term extensions. Management believes that any near-term expiring patents will not have a significant impact on the Company&#8217;s ongoing business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Market Listing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;17, 2014 the Company&#8217;s common stock was approved for listing on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;), and it began trading on Nasdaq on December&#160;23, 2014 under the symbol &#8220;CTSO&#8221;. Previously, the Company&#8217;s common stock traded in the over-the-counter-market on the OTC Bulletin Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Consolidation and Foreign Currency Translation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of CytoSorbents Corporation and its wholly owned subsidiaries, CytoSorbents Medical, Inc. and CytoSorbents Europe GmbH. In addition, the consolidated financial statements include CytoSorbents Switzerland GmbH, CytoSorbents Poland Sp. z.o.o., CytoSorbents Medical UK Limited and CytoSorbents France SAS, wholly owned subsidiaries of CytoSorbents Europe GmbH, and CytoSorbents UK Limited, a wholly owned subsidiary of CytoSorbents Medical, Inc. All significant intercompany transactions and balances have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Translation gains and losses resulting from the process of remeasuring into the United States of America dollar, the foreign currency financial statements of the European subsidiary, for which the United States of America dollar is the functional currency, are included in operations. Foreign currency transaction gain (loss) included in net loss amounted to approximately $(2,448,000), $(2,578,000) and $2,607,000 for the years ended December 31, 2022, 2021 and 2020, respectively. The Company translates assets and liabilities of the European subsidiary, whose functional currency is their local currency, at the exchange rate in effect at the balance sheet date. The Company translates revenue and expenses at the daily average exchange rates. The Company includes accumulated net translation adjustments in accumulated other comprehensive income (loss) as a component of stockholders&#8217; equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid instruments purchased with an original maturity of three&#160;months or less to be cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of cash and cash equivalents and restricted cash and cash equivalents to amounts shown in the consolidated balance sheets and consolidated statements of cash flows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">22,144,567 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52,137,707</p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,687,459</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,687,459</p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,832,026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53,825,166</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s total restricted cash in the amount of $1,687,459 consists of cash of $1,467,459 that the Company is obligated to maintain as collateral for the outstanding letter of credit with Bridge Bank that was provided to the landlord of the College Road facility as security and cash of $220,000 that the Company is obligated to maintain as collateral for the credit limit on the Company&#8217;s credit card account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grants and Accounts Receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grants receivable represent amounts due from U.S. government agencies and are included in grants and accounts Receivable in the accompanying consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable are unsecured, non-interest-bearing customer obligations due under normal trade terms. The Company sells its devices to various hospitals and distributors. The Company performs ongoing credit evaluations of customers&#8217; financial condition. Management reviews accounts receivable periodically to determine collectability. Balances that are determined to be uncollectible are reserved in the allowance for doubtful accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Inventories</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Inventories are valued at the lower of cost or net realizable value. Cost is determined using a first-in first-out (&#8220;FIFO&#8221;) basis. At December 31, 2022 and 2021, the Company&#8217;s inventory was comprised of finished goods, which amounted to $1,567,871 and $3,084,606, respectively, work in process which amounted to $1,280,368 and $1,322,736, respectively, and raw materials which amounted to $613,347 and $358,756, respectively. Devices used in clinical trials or for research and development purposes are removed from inventory and charged to research and development expenses at the time of their use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2022, the Company experienced an equipment failure of a refrigeration unit at its new College Road manufacturing facility. This equipment stored various items of work-in-process inventory. The Company determined all the items that were stored in this unit were required to be scrapped. The value of this inventory was approximately $599,000. Accordingly, this inventory was written off and was included in cost of goods sold at the time of the loss in September 2022. The Company filed a claim with its insurance carrier related to this loss. In December 2022, the claim was approved in the amount of approximately $299,000 and, accordingly, has been recorded as a reduction to cost of goods sold in the accompanying consolidated statement of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are recorded at cost less accumulated depreciation. Depreciation of property and equipment is provided for by the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the lesser of their economic useful lives or the term of the related leases. Gains and losses on depreciable assets retired or sold are recognized in the statements of operations in the&#160;year of disposal. Repairs and maintenance expenditures are expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Legal costs incurred to establish patents are capitalized. When patents are issued, capitalized costs are amortized on the straight-line method over the related patent term. In the event a patent is abandoned, the net book value of the patent is written off.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment or Disposal of Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company assesses the impairment of patents and other long-lived assets under accounting standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value. During the year ended December 31, 2022, the Company wrote-off patent costs of approximately $636,000 related to the impairment of certain issued patents and pending patent applications in certain specific jurisdictions, the abandonment of certain patent defense costs that are no longer being pursued and the abandonment of certain pending patent application costs in the ordinary course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Product Sales:</i> Revenues from sales of products to both direct and distributor/strategic partner customers are recognized at the time when control passes to the customer, in accordance with the terms of their respective contracts. Recognition of revenue occurs as each performance obligation is completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Grant Revenue: </i>Revenue from grant income is based on contractual agreements with various agencies of the U.S. government. Certain agreements provide for reimbursement of costs, other agreements provide for reimbursement of costs and an overhead margin and certain agreements are performance based, where revenue is earned based upon the achievement of milestones outlined in the contract. Revenues are recognized when the associated performance obligation is fulfilled. Costs are recorded as incurred. Amounts invoiced in excess of costs actually incurred on fixed price contracts are classified as deferred revenue and are included in accrued expenses and other current liabilities in the consolidated balance sheets. Costs subject to reimbursement by these grants have been reflected as costs of revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All research and development costs, payments to laboratories, research consultants and costs related to clinical trials and studies are expensed when incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Advertising Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Advertising costs are charged to activities when incurred. Advertising expense amounted to approximately $582,000, $615,000 and $285,000 in 2022, 2021 and 2020, respectively, and is included in selling, general, and administrative expenses in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Income taxes are accounted for under the asset and liability method prescribed by accounting standards for accounting for income taxes. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax asset will not be realized. Under Section 382 of the Internal Revenue Code, the net operating losses generated prior to the previously completed reverse merger may be limited due to the change in ownership. Additionally, net operating losses generated subsequent to the reverse merger may be limited in the event of changes in ownership. In 2017, the Tax Cuts and Jobs Act reduced the U.S. federal corporate tax rate from 35% to 21%. See Note&#160;9 for the impact of the tax rate change on deferred tax assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company follows the accounting standards associated with uncertain tax provisions. The Company had no unrecognized tax benefits as of December 31, 2022 or 2021. The Company files tax returns in the U.S. federal and state jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company utilizes the Technology Business Tax Certificate Transfer Program to sell a portion of its New Jersey Net Operating Loss tax carryforwards and Research and Development credits to an industrial company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CytoSorbents Europe GmbH, CytoSorbents Switzerland GmbH, CytoSorbents Poland Sp. z.o.o., CytoSorbents UK Limited, CytoSorbents Medical UK Limited and CytoSorbents France file an annual corporate tax return, a VAT return and a trade tax return in Germany, Switzerland, Poland, France and the United Kingdom, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets, liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. The valuation of options granted, allowance for doubtful accounts and recoverability of patents are significant estimates in these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of the Company&#8217;s revenues are from product sales in Germany. Substantially all of the Company&#8217;s grant and other income are from grant agencies in the United States. (See Note&#160;3 for further information relating to the Company&#8217;s revenue.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, two distributors accounted for approximately 27% of outstanding grants and accounts receivables. As of December 31, 2021, one distributor accounted for approximately 12% of outstanding grants and accounts receivables. For the years ended December 31, 2022, 2021 and 2020, no agency, distributor/strategic partners or direct customer represented more than 10% of the Company&#8217;s total revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their short-term nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss per Common Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed using the treasury stock method on the basis of the weighted-average number of shares of common stock plus the dilutive effect of potential common shares outstanding during the period. Dilutive potential common shares include outstanding warrants, stock options and restricted shares. The computation of diluted net loss per share does not assume conversion, exercise or contingent exercise of securities that would have an anti-dilutive effect on earnings (see Note&#160;12).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its stock-based compensation under the recognition requirements of accounting standards for accounting for stock-based compensation for employees and directors whereby each option granted is valued at fair market value on the date of grant. Under these accounting standards, the fair value of each option is estimated on the date of grant using the Black-Scholes option pricing model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company also follows the guidance of accounting standards for accounting for equity instruments that are issued to non-employees for acquiring, or in conjunction with selling, goods or services for equity instruments issued to consultants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Shipping and Handling Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The cost of shipping product to customers and distributors is typically borne by the customer or distributor. The Company records shipping and handling costs in cost of revenue. Total freight costs amounted to approximately $297,000, $276,000 and $560,000 for the&#160;years ended December 31, 2022, 2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Effect of Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2021, the Financial Accounting Standards Board (the &#8220;FASB&#8221;), issued Accounting Standards Update No. 2021-10 entitled, &#8220;Government Assistance (Topic 832) Disclosures by Business Entities about Government Assistance&#8221; (the &#8220;ASU&#8221;). This ASU will require enhanced disclosures related to the Company&#8217;s contracts with the U.S. government. The ASU is effective for annual periods beginning after December 15, 2021. The Company implemented the provisions of this ASU during 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June 2016, the FASB, issued ASU No. 2016-13 entitled, &#8220;Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#8221;. This ASU provides guidance on the calculation of credit losses, which includes the allowance for doubtful accounts on trade accounts receivable. The updated guidance is effective for public entities for fiscal years beginning after December 15, 2022. The Company is evaluating the impact of the updated guidance but does not believe that this will have a significant impact on its financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566530960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>REVENUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3. REVENUE:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table disaggregates the Company&#8217;s revenue by customer type and geographic area for the&#160;year ended December 31, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">United&#160;States</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Distributors/</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Government</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Direct</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Strategic&#160;Partners</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Agencies</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Product sales:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 787,201</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 181,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 968,951</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Germany</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,566,437</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,566,437</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">All other countries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,705,580</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,118,942</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,824,522</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total product revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,059,218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,300,692</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,359,910</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,328,899</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,328,899</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,059,218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,300,692</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,328,899</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,688,809</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table disaggregates the Company&#8217;s revenue by customer type and geographic area for the&#160;year ended December&#160;31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">United&#160;States</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Distributors/</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Government</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Direct</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Strategic&#160;Partners</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Agencies</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Product sales:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 189,167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,500,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,689,867</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Germany</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,006,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,006,432</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">All other countries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,846,256</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,566,012</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,412,268</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total product revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,041,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,066,712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,108,567</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,056,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,056,960</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,041,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,066,712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,056,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,165,527</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table disaggregates the Company&#8217;s revenue by customer type and geographic area for the&#160;year ended December&#160;31, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">United&#160;States</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Distributors/</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Government</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Direct</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Strategic&#160;Partners</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Agencies</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Product sales:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,148,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 192,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,341,200</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Germany</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,257,410</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,257,410</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">All other countries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,275,619</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,578,273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,853,892</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total product revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,681,329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,771,173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,452,502</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,552,099</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,552,099</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,681,329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,771,173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,552,099</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,004,601</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has two primary revenue streams: (1)&#160;sales of the CytoSorb device and related device accessories and (2)&#160;grant income from contracts with various agencies of the United States government. Both of these revenue streams are within the scope of this accounting pronouncement. The following is a brief description of each revenue stream.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">CytoSorb Sales</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company sells its CytoSorb device using both its own sales force (direct sales) and through the use of distributors and/or strategic partners. The majority of sales of the device are outside the U.S., as CytoSorb is not yet approved for commercial sale in the United States. However, in April 2020, the Company was granted Emergency Use Authorization (&#8220;EUA&#8221;) of CytoSorb for use in critically-ill patients infected with COVID-19 by the FDA. Direct sales outside the United States relate to sales to hospitals located in Germany, Switzerland, Austria, Belgium, Luxembourg, Poland, the Netherlands, Sweden, Denmark, Norway and the United Kingdom. Direct sales are fulfilled from the Company&#8217;s office in Berlin, Germany. There are no formal sales contracts with any direct customers relating to product price or minimum purchase requirements. However, there are agreements in place with certain direct customers that provide for either free of charge product or rebate credits based upon achieving minimum purchase levels. The Company records the value of these items earned as a reduction of revenue. These customers submit purchase orders and the order is fulfilled and shipped directly to the customer. Prices to all direct customers are based on a standard price list based on the packaged quantity (6 packs vs. 12 packs).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Distributor and strategic partner sales make up the remaining product sales. These distributors are located in various countries throughout the world. The Company has a formal written contract with each distributor/strategic partner. These contracts have terms ranging from <span style="-sec-ix-hidden:Hidden_4sWYxGr9T0-FAHL1y2CyEw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span> to 5 years in length, with three years being the typical term. In addition, certain distributors are eligible for volume discount pricing if their unit sales are in excess of the base amount in the contract.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Most distributor&#8217;s/strategic partner&#8217;s contracts have minimum annual purchase requirements in order to maintain exclusivity in their respective territories.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There is no additional consideration or monetary penalty that would be required to be paid to CytoSorbents if a distributor does not meet the minimum purchase commitments included in the contract, however, at the discretion of the Company, the distributor may lose its exclusive rights in the territory if such commitments are not met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Government Grants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has been the recipient of numerous grant contracts from various agencies of the U.S. government. The purpose of these grant contracts is to perform various research and development activities. The type of research required is outlined in each contract. These contracts fall into one of the following categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Fixed price &#8211; the Company invoices the contract amount in equal installments over the term of the contract without regard to the timing of the costs incurred related to this contract. If billings on fixed price contracts exceed the costs incurred, revenue will be deferred to the extent of the excess billings.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cost reimbursement &#8211; the Company submits monthly invoices during the term of the contract for the amount of direct costs incurred during that month plus an agreed percentage that relates to allowable overhead and general and administrative expenses. Cumulative amounts invoiced may not exceed the maximum amount of funding stipulated in the contract.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Cost plus &#8211; this type of contract is similar to a cost reimbursement contract but this type also allows for the Company to additionally invoice for a fee amount that is included in the contract.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Performance based - the Company submits invoices only upon the achievement of the milestones listed in the contract. The amount to be invoiced for each milestone is documented in the contract.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">These government contracts have terms ranging from three months to four years. The Company may apply for an extension of the term of the contract in order to complete its research and development activities but would not receive additional funding during the extension period in excess of the original contract. See Note 2 regarding the accounting policies related to these contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In summary, the contracts the Company has with customers are the distributor/strategic partner contracts related to CytoSorb product sales, agreements with direct customers related to free-of-charge product and credit rebates based upon achieving minimum purchase levels, and contracts with various government agencies related to the Company&#8217;s grants. The Company does not currently incur any outside/third-party incremental costs to obtain any of these contracts. The Company does incur internal costs, primarily salary related costs, to obtain the contracts related to the government grants. Company employees spend time reviewing the program requirements and developing the budget and related proposal to submit to the grantor agency. There may additionally be travel expenditures involved with meeting with government agency officials during the negotiation of the contract. These internal costs are expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table provides information about receivables and contract liabilities from contracts with customers:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.89%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contract receivables, which are included in grants and accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,822,452</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000,708</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contract liabilities, which are included in accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,694,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,251,177</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Contract receivables represent balances due from product sales to distributors amounting to $2,944,031 and $2,265,159 at December 31, 2022 and 2021, respectively, and billed and unbilled amounts due on government contracts amounting to $878,421 and $735,549 at December 31, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Contract liabilities represent the value of free of charge goods and credit rebates earned in accordance with the terms of certain direct customer agreements, which amounted to $178,134 and $303,824 at December 31, 2022 and 2021, respectively, and deferred grant revenue related to the billing on fixed price government contracts in excess of costs incurred, which amounted to $1,516,772 and $1,947,343 at December 31, 2022 and 2021, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566447248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4. PROPERTY AND EQUIPMENT, NET:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Property and equipment&#160;- net, consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Depreciation/</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Period</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,306,267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,424,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">7&#160;years</p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Equipment and computers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,131,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,863,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3 to 7&#160;years</p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,201,523</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,623,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Lesser of term of lease or estimated useful life</p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,639,724</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,911,505</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,896,692</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,760,619</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Property and Equipment, Net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,743,032</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,150,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Depreciation expense for the&#160;years ended December 31, 2022, 2021 and 2020 amounted to $688,565, $571,156 and $553,946 respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523568405312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>OTHER ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">OTHER ASSETS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5. OTHER ASSETS:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Other assets consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Patent applications pending</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,466,341</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,717,701</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Patents issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,773,191</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,641,603</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less accumulated amortization of patents issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (848,999)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (657,320)</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Patents, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,390,533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,701,984</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,914</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 256,591</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,437,447</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,958,575</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Amortization expense amounted to $194,056, $160,422 and $106,842 for the&#160;years ended December 31, 2022, 2021 and 2020, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Amortization expense for the next five&#160;years will be approximately $201,000 for the&#160;year ending December&#160;31, 2023; approximately $201,000 for the&#160;year ending December&#160;31, 2024; approximately $201,000 for the&#160;year ending December&#160;31, 2025; approximately $200,000 for the year ending December 31, 2026 and approximately $196,000 for the year ending December 31, 2027.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566390928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued expenses and other current liabilities consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued salaries and commissions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,862,930</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,270,715</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,516,772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,947,353</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical studies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,115,123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,767,826</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 850,630</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,044,088</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 622,353</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 314,068</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 592,398</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 769,262</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer rebates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 166,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 214,119</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Travel and entertainment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 99,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 88,850</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Board of Director fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97,426</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 71,381</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales, payroll and income taxes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,871</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 785,818</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Congresses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,861</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,950,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,314,341</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566455536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">LONG-TERM DEBT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7. LONG-TERM DEBT:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On June&#160;30, 2016, the Company and its wholly owned subsidiary, CytoSorbents Medical,&#160;Inc. (together, the &#8220;Borrower&#8221;), entered into a Loan and Security Agreement with Bridge Bank, a division of Western Alliance Bank, (the &#8220;Bank&#8221;), pursuant to which the Company borrowed $10 million in two equal tranches of $5 million (the &#8220;Original Term Loans&#8221;). On March&#160;29, 2018, the Original Term Loans were refinanced with the Bank pursuant to an Amended and Restated Loan and Security Agreement by and between the Bank and the Borrower (the &#8220;Amended and Restated Loan and Security Agreement&#8221;), under which the Bank agreed to loan the Borrower up to an aggregate of $15 million to be disbursed in two tranches (1)&#160;one tranche of $10 million (the &#8220;Term A Loan&#8221;), which was funded on the Closing Date and used to refinance the Original Term Loans, and (2)&#160;a second tranche of $5 million which may be disbursed at the Borrower&#8217;s sole request prior to March&#160;31, 2019 provided certain conditions are met (the &#8220;Term B Loan&#8221; and together with the Term A Loan, the &#8220;Term Loans&#8221;). On July 31, 2019, the Borrower entered into the First Amendment to the Amended and Restated Loan and Security Agreement (the &#8220;First Amendment&#8221;) with the Bank, which amended certain provisions of the Amended and Restated Loan and Security Agreement and the 2018 Success Fee Letter (the &#8220;2018 Letter&#8221;). In connection with the execution of the First Amendment, the draw period for the Term B Loan was extended to August 15, 2019 and the Company drew down the full $5.0 million Term B Loan on the Settlement Date, bringing the total outstanding debt to $15 million at July 31, 2019. The proceeds of Term Loans were used for general business requirements in accordance with the Amended and Restated Loan and Security Agreement. On December 4, 2020 (the &#8220;Third Amendment Closing Date&#8221;), the Company closed on the Third Amendment (the &#8220;Third Amendment&#8221;) of its Amended Loan and Security Agreement with Bridge Bank. Under the terms of the Amendment, the Company repaid the outstanding principal balance of its existing $15 million term loans and simultaneously received a commitment from Bridge Bank to provide a new term loan of $15 million, if needed. On January 19, 2022 (the &#8220;Fourth Amendment Closing Date&#8221;), the Company closed on the Fourth Amendment (the &#8220;Fourth Amendment&#8221;) of its Amended Loan and Security Agreement with Bridge Bank. Under the terms of the Amendment, the Company received a commitment from Bridge Bank to provide a new term loan of up to $15 million, if needed and entered into the Fourth Amendment Success Fee Letter (the &#8220;2022 Success Fee Letter&#8221;). On December 28, 2022 (the &#8220;Fifth Amendment Date&#8221;), the Company entered into the Fifth Amendment of its Amended Loan and Security Agreement with Bridge Bank. The Fifth Amendment extends the draw period under the Fourth Amendment to the earlier of (i) March 1, 2023 and (ii) the occurrence of an Event of Default. On March&#160;9,&#160;2023, the Company entered into the Sixth Amendment of its Amended Loan and Security Agreement. The Sixth Amendment further extends the draw period to March&#160;24,&#160;2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Fourth Amendment provides a tranche of term loans (the &#8220;Term C Loans&#8221;) in the aggregate amount of $15 million, which are available for the Company to draw down at its sole discretion in three tranches of $5 million each at any time during the period commencing on the Fourth Amendment Date and ending on the earlier of (i) December 31, 2022 and (ii) the occurrence of an Event of Default (as defined in the Amended Loan and Security Agreement). The Term C Loans shall bear interest at the Index Rate (defined in the Amendment as the greater of 3.25% or the Prime Rate as published by the Wall Street Journal on the last business date of the month immediately preceding the month in which the interest will accrue) plus 1.25%. Pursuant to the Fourth Amendment, interest on the Term C Loans is subject to an interest rate cap of 8.00%. On December 27, 2022, the Company drew down the first $5 million tranche of the Term C loans available under the terms of the Fourth Amendment. Under the terms of the Fourth Amendment, commencing on February 1, 2023, the Company is required to make monthly payments of interest only through December 2023. The interest-only period will be further extended through June 2024 provided the Company has met both the required reserves test and the seventy-five percent test, as set forth in the Fourth Amendment, as of November 30, 2023. Commencing on January 1, 2024, if the Company does not meet both the required reserves test and the seventy-five percent test, the Company shall make equal monthly payments of principal of $208,333, together with accrued and unpaid interest. Commencing on July 1, 2024, if the Company meets both the required reserves test and the seventy-five percent test, the Company shall make equal monthly payments of principal of $277,778, together with accrued and unpaid interest. In either event, all unpaid principal and accrued and unpaid interest shall be due and payable in full on December 1, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On the Fourth Amendment Closing Date, the Company was required to pay a non-refundable closing fee of approximately $18,750, which was amortized as a monthly charge to interest expense. On the Third Amendment Closing Date, the Company paid a non-refundable closing fee of $75,000, which was amortized as a charge to interest expense. In addition, the Amended and Restated Loan and Security Agreement requires the Company to pay a non-refundable final fee equal to 2.5% of the principal amount of the Term Loan funded upon the earlier of the (i) the maturity date or (ii) termination of the Term Loans via acceleration or prepayment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s and CytoSorbents Medical, Inc.&#8217;s obligations under the Amended and Restated Loan and Security Agreement are joint and severable and are secured by a first priority security interest in favor of the Bank with respect to the Company&#8217;s Shares (as defined in the Amended and Restated Loan and Security Agreement) and the Borrower&#8217;s Collateral (as defined in the Amended and Restated Loan and Security Agreement, which definition excludes the Borrower&#8217;s intellectual property and other customary exceptions).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">2018 Success Fee Letter:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the amended 2018 Letter, the Borrower shall pay to the Bank a success fee in the amount equal to 6.37% of the funded amount of the Term B Loan (as defined in the Restated Loan and Security Agreement) (the &#8220;Success Fee&#8221;) upon the first occurrence of any of the following events: (a)&#160;a sale or other disposition by the Borrower of all or substantially all of its assets; (b)&#160;a merger or consolidation of the Borrower into or with another person or entity, where the holders of the Borrower&#8217;s outstanding voting equity securities as of immediately prior to such merger or consolidation hold less than a majority of the issued and outstanding voting equity securities of the successor or surviving person or entity as of immediately following the consummation of such merger or consolidation; (c)&#160;a transaction or a series of related transactions in which any &#8220;person&#8221; or &#8220;group&#8221; (within the meaning of Section&#160;13(d)&#160;and 14(d)(2)&#160;of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) becomes the &#8220;beneficial owner&#8221; (as defined in Rule&#160;13d-3 under the Exchange Act), directly or indirectly, of a sufficient number of shares of all classes of stock then outstanding of the Borrower ordinarily entitled to vote in the election of directors, empowering such &#8220;person&#8221; or &#8220;group&#8221; to elect a majority of the Board of Directors of the Borrower, who did not have such power before such transaction; or (d)&#160;the closing price per share for the Company&#8217;s common stock on the Nasdaq Capital Market being the greater of (i)&#160;70% or more over $7.05, the closing price of the Company&#8217;s common stock on March&#160;29, 2018 (after giving effect to any stock splits or consolidations effected after the date thereof) for <span style="-sec-ix-hidden:Hidden_TWKGB9Ns70-hcCjqFg2ORA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span> successive business&#160;days, or (ii)&#160;at least 26.13% more than the average price of Company&#8217;s common stock for the 365-day period ending on the date of the funding of the Term B Loan. This obligation shall terminate on the fifth anniversary of the funding of the Term B Loan and shall survive the termination of the loan agreement and the prepayment of the Term B Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2022 Success Fee Letter:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the 2022 Success Fee Letter, the Borrower will pay to the Bank a success fee equal to (i) 1% of $5 million if the Company draws down the first tranche of the Term C Loan and is payable only if the Company&#8217;s stock price equals or exceeds $8 for <span style="-sec-ix-hidden:Hidden_0ax9yhmTV0OKMkdCNohxKw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span> consecutive trading days; (ii) 1.5% of $5 million if the Company draws down the second tranche of the Term C Loan and is payable only if the Company&#8217;s stock price equals or exceeds $10 for <span style="-sec-ix-hidden:Hidden_2iU3HFYDDUKoxhoqRgX4wQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span> consecutive trading days; and (iii) 2% of $5,000,000 if the Company draws down the third tranche of the Term C Loan and is payable only if the Company&#8217;s stock price equals or exceeds $12 for <span style="-sec-ix-hidden:Hidden_pwbH1ZIm4UCeZREcP1cczw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span> consecutive trading days (together, the &#8220;Success Fee&#8221;). Borrower may pay the Success Fee in cash or in shares of common stock, at Borrower&#8217;s sole discretion. The right of Bank to receive the Success Fees and the obligation of the Borrower to pay the Success Fees hereunder shall terminate on the date that is fifth anniversary of the funding date of the last Term C Loans made but shall survive the termination of the Loan Agreement and any prepayment of the Term C Loans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Long-term debt consists of the following as of December 31, 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Principal amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,000,000</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Less Current maturities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Long-term debt net of current maturities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,000,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Principal payments of long-term debt are due as follows during the years ending December 31:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,500,000</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,500,000</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,000,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566443520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">8. LEASES:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company leases its operating facilities in both the United States and Germany under operating lease agreements. In March 2021, CytoSorbents Medical Inc. entered into a lease agreement for a new operating facility at 305 College Road East, Princeton, New Jersey, which contains office, laboratory, manufacturing and warehouse space. The lease commenced on June 1, 2021. The Early Term commenced on June 1, 2021 and lasted until September 30, 2021. The lease also contains two five-year renewal options; however, the Company has determined that it is not likely that they will exercise these options. Commencing on September 30, 2021, the remaining lease term will last for 15.5 years. The lease requires monthly rental payments of $25,208 for the Initial Early Term, $88,254 for the Early Term and initial monthly payments of approximately $111,171 in the first year of the remaining term. Following the first year of the remaining term, the annual base rent will increase by approximately 2.75% annually over the remaining term. The lease also contains six months of rent abatement (months 1, 2, 3, 25, 26 and 27 of the remaining lease term). In addition to the base rent, payments of operating expenses and real estate taxes will be required. These payments are to be based on actual amounts incurred during 2021 multiplied by the Company&#8217;s share of the total building space (92.3%). The landlord will also provide an allowance of approximately $1,455,000 related to certain building improvements as outlined in the lease. In April 2021, the Company provided the landlord with a letter of credit in the amount of approximately $1,467,000 as security. The Company has determined that this lease should be treated as an operating lease in accordance with the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) 842. On April 1, 2021, the Company recorded a Right-of-Use asset and related lease <span style="-sec-ix-hidden:Hidden_i35CHnl1HUSihsVEqT6O2A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liability</span></span> of approximately $11.6 million, which represents the estimated present value of the lease payments at the commencement date discounted at the Company&#8217;s incremental borrowing rate of 9.8%. In addition, due to the six months of rent abatement and annual base rent escalations during the remaining lease term that commenced on September 30, 2021, the Company will recognize rent expense on this lease on a straight-line basis over the remaining term of the lease for the difference between the rent expense recognized and the required payments under the lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2021, the Company entered into a Twentieth Amendment to Lease with the landlord at the existing Monmouth Junction facility which became effective May 31, 2021. This amendment extended the term of the lease for the Company&#8217;s previous facility to May 31, 2022. The Company&#8217;s base rent was approximately $35,000 per month. In addition, the Company was obligated to pay monthly operating expenses of approximately $30,000 per month. Under the terms of this amendment, the Company vacated a portion of the space as of May 31, 2022. The Company continued to lease the remaining space until December 31, 2022, at which time the lease terminated and the Company vacated the space. The Company&#8217;s base rent for the remaining space was approximately $20,000 per month. Monthly operating expenses were approximately $11,000 per month. In addition, the Company agreed to increase its security deposit by approximately $54,000 to a total of $150,000. At the end of the lease term, the entire security deposit was paid to the landlord for the purpose of making any needed repairs to the vacated premises, and the Company has no further obligation to pay for repairs to the vacated premises. Effective April 1, 2021, the Company adjusted its incremental borrowing rate to the incremental borrowing rate used in the College Road lease and recalculated the right of use asset and lease liability under the amended terms of this lease. In addition, the Company also adjusted the incremental borrowing rate and related right of use asset and lease liability on the existing Germany office lease effective April 1, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2021, the Company extended its two operating leases for its office facility in Germany. These leases require combined base rent payments amounting to approximately $12,100 per month. The initial lease term of both leases ends August 31, 2026. In addition, the Company is obligated to monthly operating expenses of approximately $3,000 per month. Both leases have a five-year option to renew that would extend the lease term to August 31, 2031. There are no provisions in the leases to increase the base rent during the renewal period. There were no lease incentives and no initial direct costs were incurred related to these leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January 2021, CytoSorbents Europe GmbH entered into a lease for 1,068 square meters of additional warehouse space. The lease commenced on April 1, 2021 and requires monthly payments of base rent of $7,784 and other costs of approximately $239 and has a term of five years. The lease also has an option to extend the lease term for an additional five-year period through March 31, 2031. The Company has determined that this lease should be treated as an operating lease in accordance with the provisions of ASC 842. On April 1, 2020, the Company recorded a Right-of-Use asset and related lease <span style="-sec-ix-hidden:Hidden_cxtzS31VrUm4rMIV9MB8Iw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">liability</span></span> at the estimated present value of the lease payments at the commencement date of approximately $594,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Right-of-Use Asset and Lease Liability:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s consolidated balance sheets reflect the value of the right-of-use asset and related lease liability. This value was calculated based on the present value of the remaining base rent lease payments. The remaining lease payments include all expected renewals for all periods as the Company has determined that it is probable that the renewal options will be exercised under each of the lease agreements. The discount rate used was the Company&#8217;s incremental borrowing rate, which is 9.8%, as the Company could not determine the rate implicit in the lease. As a result, the value of the right-of-use asset and related lease liability is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:70.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,603,901</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,423,472</p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,250,944</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,821,509</p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108,939)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (570,566)</p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease liability, net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,142,005</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,250,943</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The maturities of the lease liabilities are as follows as of December 31, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,266,346</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,656,678</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,695,677</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,735,747</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,776,920</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,232,300</p></td></tr><tr><td style="vertical-align:middle;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,363,668</p></td></tr><tr><td style="vertical-align:middle;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,112,724</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,250,944</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2022, 2021 and 2020, operating cash flows paid in connection with operating leases amounted to approximately $2,935,000, $1,968,000 and $937,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2022 and 2021, the weighted average remaining lease term was 12.4 years and 14.3 years, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566417792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. INCOME TAXES:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for income taxes under FASB ASC 740 (&#8220;ASC 740&#8221;). Deferred income tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company&#8217;s consolidated loss before income taxes for the years ended December 31, 2022, 2021 and 2020 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:60.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21,155,203)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18,829,797)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,682,628)</p></td></tr><tr><td style="vertical-align:top;width:60.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,749,965)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,464,854)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,281,634)</p></td></tr><tr><td style="vertical-align:top;width:60.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33,905,168)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,294,651)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,964,262)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The benefit from income taxes consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:60.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">State Tax, including sale of New Jersey losses &amp; credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,092,585</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 736,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,127,074</p></td></tr><tr><td style="vertical-align:top;width:60.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Foreign tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:60.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,092,585</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 736,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,127,074</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has deemed any foreign earnings will be indefinitely reinvested. Currently, foreign operations have resulted in an accumulated deficit. The Company will continue to analyze their stance if their circumstances change in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company had federal net operating loss (&#8220;NOL&#8221;) carryforwards of approximately $87.4 million, state NOL carry forwards of approximately $5.5 million, and foreign NOL carry forwards of approximately $42.7 million, which may be available to offset future taxable income, if any. The federal NOL carryforwards of $47.8 million, if not utilized, will expire between 2022 and 2037. The federal NOL carryforwards of $39.6 million generated since 2018 are subject to an 80% limitation on taxable income, do not expire and will carry forward indefinitely. The state NOL carryforwards of $5.5 million, if not utilized, will begin to expire in 2042. As of December 31, 2022, the Company had Federal and state research and development tax credit carryforwards of approximately $3.7 million and $0.3 million, respectively, available to reduce future tax liabilities, which will begin to expire at various dates starting in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The NOL carry forwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. The NOLs may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Section 382 of the Internal Revenue Code of 1986, as amended, as well as similar state tax provisions. In addition to the new provisions enacted under the Tax Cuts and Jobs Act, this could limit the amount of NOLs that the Company can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will generally be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We record tax benefits related to uncertain tax positions taken or expected to be taken on a tax return when such benefits meet a more likely than not threshold. We recognize interest related to unrecognized tax benefits in interest expense and penalties in operating expenses. Currently, the Company is not accounting for any uncertain tax positions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">U.S. Tax Reform</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Due to The Tax Cuts and Jobs Act of 2017 (TCJA) there was a change in the deductibility of research and experimental expenditures that took effect for taxable periods that begin after December 31, 2021. Prior to January 1, 2022, the Company expensed research and experimental expenditures under &#167;174(a) in the year that books recognized the expense. The Company has adopted &#167;174(b) for taxable years 2022 and beyond. Domestic and foreign research and experimental expenditures will be capitalized and amortized over a period no less than 60 months and 180 months, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Sale of Net Operating Losses (NOLs)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company may be eligible, from time to time, to receive cash from the sale of its New Jersey Net Operating Losses and R&amp;D tax credits under the State of New Jersey Technology Business Tax Certificate Transfer Program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company will receive a net cash amount of approximately $1,093,000 from the approved sale of the 2021 state NOL and research and development credits in the first half of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The principal components of the Company&#8217;s deferred tax assets and liabilities are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net operating loss carry forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,570,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,190,654</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,301,154</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,203,272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 305,982</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development credit carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,982,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,687,591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,194,211</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accruals and others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 232,665</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 135,330</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,724,840</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,997,114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 289,287</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#167;174(b) research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,331,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,134,554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,311,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,225,964</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (39,303,451)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (31,242,130)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24,794,474)</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,831,103</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,069,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 431,490</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liability:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (288,145)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (183,941)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (431,490)</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right of Use Asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,542,958)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,885,225)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on this assessment, management has established a full valuation allowance against all of the deferred tax assets for each period because it is more likely than not that all of the deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The increases in valuation allowance for the years ended December 31, 2022, 2021 and 2020 were $8,061,321, $6,447,656, and $1,936,732, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A reconciliation of income tax (expense) benefit at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign rate differential</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rate change and true-up</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">R&amp;D credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sale of state R&amp;D credit and NOL</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523571461584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10. COMMITMENTS AND CONTINGENCIES:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Payroll Tax Examination</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In December 2021, the Company was notified that its European subsidiary, CytoSorbents Europe GmbH, would be subject to an audit of their payroll tax and social cost filings for the four-year period from 2018 through 2021. The Company has determined that payroll taxes and social costs were not paid on certain employee expense reimbursements as is required by German tax rules. Accordingly, the Company accrued approximately $598,000 as an estimate of this liability as of December 31, 2021. In January 2023, the Company received an assessment from the German tax authorities for the payroll tax audit of approximately $90,000. In addition, it was determined that the Company would owe additional social security and VAT taxes related to this matter of approximately $83,000. Accordingly, the Company has adjusted its accrual related to this payroll tax audit to approximately $173,000 as of December 31, 2022. This liability is included in accrued expenses and other current liabilities in the consolidated balance sheet as of December 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The expense related this examination is included in selling, general and administrative expenses on the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employment Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July&#160;30, 2019, CytoSorbents Corporation entered into amended and restated executive employment agreements with its principal executives, Dr.&#160;Phillip P. Chan, Chief Executive Officer, Vincent Capponi, President and Chief Operating Officer, and Kathleen P. Bloch, Chief Financial Officer. Each of the agreements has an initial term of three&#160;years and was retroactively effective as of January&#160;1, 2019. On April 12, 2020, CytoSorbents Corporation entered into an executive employment agreement with Dr. Efthymios Deliargyris, who began employment as Chief Medical Officer on May 1, 2020, with an initial term that expired on December 31, 2021. After the expiration of the initial terms, the employment agreements will automatically renew for additional terms of one&#160;year unless either party provides written notice of non-renewal at least 60 days prior to a renewal.In January 2022, these employment agreements automatically renewed for an additional 1 year. The foregoing employment agreements each provide for base salary and other customary benefits which include participation in group insurance plans, paid time off and reimbursement of certain business-related expenses, including travel and continuing educational expenses, as well as bonus and/or equity awards at the discretion of the Board of Directors. In addition, the agreements provide for certain termination benefits in the event of termination without &#8220;Cause&#8221; or voluntary termination of employment for &#8220;Good Reason&#8221;, as defined in each agreement. The agreements also provide for certain benefits in the event of a &#8220;Change of Control&#8221; of the Company, as defined in each agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 30, 2022, Ms. Bloch notified the Company of her intention to retire effective March 31, 2023. A search has been initiated for Ms. Bloch&#8217;s replacement. Ms. Bloch and the Company expect to enter into a consulting arrangement under which Ms. Bloch will continue to provide services to the Company in a limited capacity following the effective date of her retirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Litigation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is, from time to time, subject to claims and litigation arising in the ordinary course of business. The Company intends to defend vigorously against any future claims and litigation. The Company is not currently a party to any legal proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Royalty Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to an agreement dated August&#160;11, 2003, an existing investor agreed to make a $4 million equity investment in the Company. These amounts were received by the Company in 2003. In connection with this agreement the Company granted the investor a perpetual royalty of 3% on all gross revenues received by the Company from the sale of its CytoSorb device which such rights were assigned to an existing investor in 2017. For the years ended December 31, 2022, 2021 and 2020, the Company recorded royalty expenses of approximately $849,000, $1,193,000, and $1,172,000, respectively. These expenses are included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 1, 2022, the Company entered into the Marketing Agreement with Fresenius, which expands the Company&#8217;s strategic partnership with Fresenius by establishing a multi-stage global collaboration to combat life-threatening diseases in critical care. The Marketing Agreement has an initial term of three years, with an automatic renewal for an additional two years at the end of such initial term, subject to earlier termination by either of the parties (the &#8220;Term&#8221;) To help support the increased marketing and promotional efforts of the expanded collaboration, the Company has agreed to subsidize a portion of the marketing costs through royalty payments to Fresenius. Initially, the Marketing Agreement provides for royalty payments equal to 0.9% of the Company&#8217;s net sales of CytoSorb products made during the Term (excluding net sales in the United States). This initial royalty rate was determined based on certain assumptions regarding the percentage of the Company&#8217;s sale of CytoSorb products that are used with the Fresenius critical care platforms in the intensive care unit outside of the United States but is subject to adjustment if the Company determines that the underlying assumptions have changed significantly. For the year ended December 31, 2022, the Company did not record any expense related to this agreement as Fresenius did not commence any marketing activities as defined by the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In an agreement dated September&#160;1, 2006, the Company entered into a license agreement which provides the Company the exclusive right to use its patented technology and proprietary know how relating to adsorbent polymers for a period of 18&#160;years. Under the terms of the agreement, the Company has agreed to pay license fees of 2.5% to 5% on the sale of certain of its products if and when those products are sold commercially for a term not greater than 18&#160;years commencing with the date of the agreement. For the&#160;years ended December 31, 2022, 2021 and 2020 per the terms of the license agreement, the Company recorded licensing expenses of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">approximately $1,416,000, $1,988,000 and $1,954,000, respectively. These expenses are included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523567307424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. STOCKHOLDERS&#8217; EQUITY:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2019, the Company amended and restated its certificate of incorporation. The amended and restated certificate of incorporation authorizes the issuance of up to 5,000,000 shares of &#8220;blank check&#8221; preferred stock, with such designation rights and preferences as may be determined from time to time by the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2019, the Company amended and restated its certificate of incorporation. The amended and restated certificate of incorporation increased the number of shares of common stock authorized for issuance from 50,000,000 shares to 100,000,000 shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Shelf Registration</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On July 14, 2021, the Company filed a registration statement on Form S-3 with the SEC, which was amended on July 20, 2021 and declared effective by the SEC on July 27, 2021 (as amended, the &#8220;2021 Shelf&#8221;). The 2021 Shelf enables the Company to offer and sell, in one or more offerings, any combination of common stock, preferred stock, senior or subordinated debt securities, warrants and units, up to a total dollar amount of $150 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Open Market Sale Agreement with Jefferies LLC </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 30, 2021, the Company entered into an Open Market Sale Agreement (the &#8220;Sale Agreement&#8221;) with Jefferies LLC (the &#8220;Agent&#8221;), pursuant to which the Company could sell, from time to time, at its option, shares of the Company&#8217;s common stock having an aggregate offering price of up to $25 million through the Agent, as the Company&#8217;s sales agent. All shares of the Company&#8217;s common stock offered and sold, or to be offered and sold under the Sale Agreement, would have been issued and sold pursuant to the Company&#8217;s 2021 Shelf by methods deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, in block transactions or if specified by the Company, in privately negotiated transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the terms of the Sales Agreement, the Agent is required to use their commercially reasonable efforts consistent with their normal sales and trading practices to sell the shares of the Company&#8217;s common stock from time to time, based upon the Company&#8217;s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company is required to pay the Agent a commission of up to 3.0% of the gross proceeds from the sale of the shares of the Company&#8217;s common stock sold thereunder, if any. There were no sales pursuant to the Amended Sale Agreement during the years ended December 31, 2022 and 2021, respectively. In addition, during the year ended December 31, 2021, the Company paid approximately $90,000 related to the Amended Sale Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Option Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company had two Long Term Incentive Plans (the &#8220;2014 Plan&#8221; and the &#8220;2006 Plan&#8221;) to attract, retain, and provide incentives to employees, officers, directors, and consultants. The Plans generally provide for the granting of stock, stock options, stock appreciation rights, restricted shares, or any combination of the foregoing to eligible participants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A total of 13,400,000 and 2,400,000 shares of common stock are reserved for issuance under the 2014 Plan and the 2006 Plan, respectively. As of December 31, 2022, there were shares remaining to purchase approximately 3,713,000 and 258,000 units of common stock reserved under the 2014 Plan and the 2006 Plan, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2014 and 2006 Plans as well as grants issued outside of the Plan are administered by the Compensation Committee of the Board of Directors (the &#8220;Compensation Committee&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Compensation Committee is authorized to select from among eligible employees, directors, advisors and consultants those individuals to whom incentives are to be granted and to determine the number of shares to be subject to, and the terms and conditions of the options. The Compensation Committee is also authorized to prescribe, amend and rescind terms relating to options granted under </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the Plans. Generally, the interpretation and construction of any provision of the Plans or any options granted hereunder is within the discretion of the Compensation Committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2014 Plan provides that options may or may not be Incentive Stock Options (&#8220;ISOs&#8221;) within the meaning of Section 422 of the Internal Revenue Code. Only employees of the Company are eligible to receive ISOs, while employees and non-employee directors, advisors and consultants are eligible to receive options, which are not ISOs, i.e., &#8220;Non-Qualified Options.&#8221; Because the Company has not obtained shareholder approval of the 2006 Plan, all options granted thereunder to date are &#8220;Non-Qualified Options&#8221; and until such shareholder approval is obtained, all future options issued under the 2006 Plan will also be &#8220;Non-Qualified Options.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2014, the Company&#8217;s received shareholder approval authorizing the Board of Directors to implement the form, terms and provisions of the 2014 Plan. Accordingly, any options issued to employees under the 2014 Plan will be ISOs within the meaning of Section&#160;422 of the Internal Revenue Code.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Total share-based employee, director, and consultant compensation for the&#160;years ended December 31, 2022, 2021 and 2020 amounted to approximately $3,424,000, $4,021,000, and $3,514,000, respectively. These amounts are included in selling, general, and administrative expenses on the consolidated statements of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The summary of the stock option activity for the&#160;years ended December 31, 2022, 2021 and 2020 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per&#160;Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life&#160;(Years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding January 1, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,218,189</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.0</p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,579,106</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.0</p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34,644)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_1iWKOSTEYEW4rgjnocsyQg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (226,440)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_gFEztX83IEan5vGYiG_KkA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (371,007)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_7Cm8_uxCP0mv3QQAha4gkQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding, December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,165,204</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.26</p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,051,980</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.30</p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (138,037)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_rBumodlmnUK-p_-iado5iw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21,756)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_GQpp15AqqkCIMuMwEM8NqQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (171,413)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_amo3-ZcwWEWCT2ol91T9ZQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding, December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6,885,978</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.15</p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,721,205</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.60</p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,270,155)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_SbJXsQ3BuU-Usd0OT4w7GA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (227,204)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_4-HPXTyq0kWo5cJ4Z0sPVw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_We0d8r7iWEWg62NYW1m7vA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding, December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,109,824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.91</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of each stock option was estimated using the Black-Scholes pricing model which takes the following factors into account.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;of&#160;the</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Underlying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Stock&#160;and&#160;its&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant&#160;Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expected&#160;Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expected</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Risk&#160;Free</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;of&#160;the&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Volatility</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expected</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Interest&#160;Rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year - Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Range</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Range</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Dividends</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Range</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.00 - $10.58 per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">61.7% to 69.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.28% to 0.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">4.26 - $11.39 per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">58.2% to 60.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.47% to 1.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1.11 - $3.91 per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">59.3% to 67.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1.52% to 4.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company recognizes forfeitures as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The intrinsic value is calculated at the difference between the market value as of December 31, 2022 of $1.55 and the exercise price of the shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="11" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Range of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$1.11 - $13.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,109,824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,280</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:56.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">4,623,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,250</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The summary of the status of the Company&#8217;s non-vested options for the&#160;year ended December 31, 2022, is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant&#160;Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-vested, January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,994,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.68</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,721,205</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.99</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,270,155)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.65</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (959,157)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.65</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-vested, December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,486,739</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.10</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company had approximately $4,745,000 of total unrecognized compensation cost related to stock options which will, on average, be amortized over 43 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Awards of Stock Options:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 10, 2022, the Board of Directors granted options to purchase 1,163,800 shares of common stock to the Company&#8217;s employees which will be awarded based upon each employee&#8217;s 2022 individual performance evaluation. Once awarded, these options will vest one quarter on February 15, 2023, one quarter on February 15, 2024, one quarter on February 15, 2025 and one quarter on February 15, 2026. The grant date fair value of these unvested options amounted to approximately $1,381,000. The Company has recorded approximately $180,440 in stock option expense related to these options for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 10, 2022, the Board of Directors granted options to purchase 772,905 shares of common stock to the Company&#8217;s employees. These options will vest one eighth on the six-month anniversary of the grant date, one eighth on the first anniversary of the grant date, one quarter on second anniversary of the grant date, one quarter on third anniversary of the grant date and one quarter on fourth anniversary of the grant date. The grant date fair value of these unvested options amounted to approximately $917,000. The Company has recorded approximately $89,662 in stock option expense related to these options for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 10, 2022, the Board of Directors granted options to purchase 113,850 shares of common stock to members of the Company&#8217;s Board of Directors. These options will vest one quarter on the grant date, one quarter on September 30, 2022, one quarter on December 31, 2022, and one quarter on March 31, 2023. The grant date fair value of these unvested options amounted to approximately $135,000. The Company has recorded approximately $101,336 in stock option expense related to these options for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 10, 2022, the Board of Directors granted options to purchase 473,750 shares of common stock to certain senior managers of the Company. These options will vest one quarter on the grant date, one quarter on the first anniversary of the grant date, one quarter on second anniversary of the grant date, one quarter on third anniversary of the grant date. The grant date fair value of these unvested options amounted to approximately $562,000. The Company has recorded approximately $160,944 in stock option expense related to these options for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 10, 2022, the Board of Directors granted options to purchase 1,365,000 shares of common stock to certain senior managers of the Company which will only vest upon the achievement of certain specific, predetermined milestones related to the Company&#8217;s long-term performance goals. The grant date fair value of these unvested options amounted to approximately $1,620,000. As of December 31, 2022, none of these milestones has been met. Accordingly, no charge for these options has been recorded in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 12, 2021, the Board of Directors granted options to purchase 1,323,400 shares of common stock to the Company&#8217;s employees which will vest upon the achievement of certain specific, predetermined milestones related to the Company&#8217;s 2021 operations. Once awarded, these options will vest in four equal tranches, the first tranche vesting on the date of the award. The grant date fair value of these unvested options amounted to approximately $7,042,000. On March 1, 2022, Board of Directors determined that the Company met approximately 19% of these milestones, and accordingly, the Company has recorded $314,000, and $273,000 in stock option expense related to these options for the years ended December 31, 2022, and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 28, 2020, the Board of Directors granted options to purchase 1,114,325 shares of common stock to the Company&#8217;s employees which will vest upon the achievement of certain specific, predetermined milestones related to the Company&#8217;s 2020 operations. The grant date fair value of these unvested options amounted to approximately $3,883,000. On April 12, 2021, Board of Directors determined that the Company met approximately 88% of these milestones, and accordingly, the Company has recorded $951,000 and $1,070,000 in stock option expense related to these options for the years ended December 31, 2022, and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Change in Control-Based Awards of Restricted Stock Units:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Board of Directors has granted restricted stock units to members of the Board of Directors, to the Company&#8217;s executive officers, and to employees of the Company. These restricted stock units will only vest upon a Change in Control of the Company, as defined in the Company&#8217;s 2014 Long-Term Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table is a summary of these restricted stock units:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Board&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Executive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Directors</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Management</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Employees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 277,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 604,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,205,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,086,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,033,988</p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 120,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 265,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 385,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,250)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,250)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 277,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 724,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,445,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,447,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,504,184</p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 396,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 396,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (132,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (132,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 277,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 724,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,709,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,711,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,359,928</p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 373,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 498,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (318,750)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (318,750)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 346,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 779,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,764,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,890,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4,480,275</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Due to the uncertainty over whether these restricted stock units will vest, which will only happen upon a Change in Control, no charge for these restricted stock units has been recorded in the consolidated statement of operations and comprehensive loss through the year ended December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Performance-Based Awards of Restricted Stock Units:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to a review of the compensation of the senior management of the Company and management&#8217;s performance in 2020, on February 28, 2020, the Board of Directors granted 168,100 restricted stock units to certain senior managers of the Company. These awards were valued at approximately $1,014,000 at the date of issuance, based upon the market price of the Company&#8217;s common stock at the date of the grant, and vest one third on the date of the grant, one third on the first anniversary of the date of the grant, and <span style="-sec-ix-hidden:Hidden_bnG0W-eC-kmqWIE1UDcudQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> third on the second anniversary of the date of the grant. For the years ended December 31, 2022 and 2021, the Company recorded (income) expense of approximately $(65,000) and $528,000, respectively, related to these restricted stock unit awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to a review of the compensation of the senior management of the Company and management&#8217;s performance in 2021, on April 12, 2021, the Board of Directors granted 235,765 restricted stock units to certain senior managers of the Company. These awards were valued at approximately $2,120,000 at the date of issuance, based upon the market price of the Company&#8217;s common stock at the date of the grant, and vest <span style="-sec-ix-hidden:Hidden_yBkqj_djEEmSnjqOn-lNAA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> third on the date of the grant, <span style="-sec-ix-hidden:Hidden_NhvWl8VkYEiywUdQUWqfYg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> third on the first anniversary of the date of the grant, and <span style="-sec-ix-hidden:Hidden_riKmZAfAA0-fmSAyyqKphA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> third on the second anniversary of the date of the grant. For the years ended December 31, 2022 and 2021, the Company recorded a charge of approximately $226,000 and $1,207,000, respectively, related to these restricted stock unit awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 10, 2022, certain named executive officers and senior managers were granted 288,500 restricted stock units. These awards were valued at approximately $563,000 at the date of issuance, based upon the market price of the Company&#8217;s common stock at the date of the grant, and vested (or will vest) <span style="-sec-ix-hidden:Hidden_IU4zNU0S4UKy1kEa3REKsg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> third on the date of the grant, <span style="-sec-ix-hidden:Hidden_CzwcUS2bLUKcKWPHYGPuIw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> third on the first anniversary of the date of the grant, and <span style="-sec-ix-hidden:Hidden_Qn9ZRP_XUUuujsh4uxHgPw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> third on the second anniversary of the date of the grant. For the year ended December 31, 2022 and 2021, the Company recorded expense of approximately $260,000 and $0, respectively, related to these restricted stock unit awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, in 2021 and 2020 certain employees were offered 91,750 restricted stock units as a condition of their employment. These awards were valued at approximately $713,868 at the date of issuance. 46,750 of these restricted stock units vest upon the earlier of a Change in Control or <span style="-sec-ix-hidden:Hidden_9VkzXAfHnkmSs1ntMN_DvA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> third after the second anniversary of the award, <span style="-sec-ix-hidden:Hidden_FavK8EuO0EiMvQzxKsEdyg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> third on the third anniversary of the award, and <span style="-sec-ix-hidden:Hidden_XAf3tkw7FEWYcbQI9IZMZw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> third on the fourth anniversary of the award. The other 45,000 of these restricted stock units vest upon the earlier of a Change in Control or four years from the date of the award. For the years ended December 31, 2022 and 2021, the Company recorded (income) expense of approximately $(16,000) and $178,000, respectively, related to these restricted stock unit awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table outlines the restricted stock unit activity for the&#160;year ended December 31, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant&#160;Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-vested, January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 304,962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.08</p></td></tr><tr><td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 288,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.95</p></td></tr><tr><td style="vertical-align:bottom;width:74.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (45,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.35</p></td></tr><tr><td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (236,370)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.38</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-vested, December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 312,092</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.42</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">Warrants:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As of December 31, 2022, the Company had no warrants outstanding.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566536560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. NET LOSS PER SHARE:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Basic net loss per share and diluted net loss per share for the&#160;years ended December 31, 2022, 2021 and 2020 have been computed by dividing the net loss attributable to common shareholders for each respective period by the weighted average number of shares outstanding during that period. All outstanding warrants and options and restricted stock awards representing approximately 11,312,000, 9,902,000 and 7,786,000 incremental shares at December 31, 2022, 2021 and 2020, respectively, have been excluded from the computation of diluted net loss per share as they are anti-dilutive.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523567624064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RETIREMENT PLAN<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>RETIREMENT PLAN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">RETIREMENT PLAN</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. RETIREMENT PLAN:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In June&#160;2014, the Company formed the CytoSorbents 401(k)&#160;Plan. The plan is a defined contribution plan as described in section 401(k)&#160;of the Internal Revenue Code (&#8220;IRC&#8221;) covering substantially all full-time employees. Employees are eligible to participate in the plan on the first day of the calendar quarter following <span style="-sec-ix-hidden:Hidden_wRQ8gwA2pEGU2CW7c2BqBw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> full&#160;months of employment. Participants may defer up to 100% of their eligible compensation subject to certain IRC limitations.Prior to 2021, the Company provided for a matching contribution of twenty&#160;percent of the participants&#8217; contribution on a maximum of five&#160;percent of compensation. Effective January 1, 2021, the Company changed its matching contribution to 100% of the participants contribution up to three percent of compensation plus 50% of the participants contribution over three percent of compensation up to a maximum of five percent of compensation. Matching contributions amounted to approximately $442,000, $355,000 and $59,200 for the&#160;years ended December 31, 2022, 2021 and 2020, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566436160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>QUARTERLY FINANCIAL RESULTS (UNAUDITED)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>QUARTERLY FINANCIAL RESULTS (UNAUDITED)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">QUARTERLY FINANCIAL RESULTS (UNAUDITED)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14. QUARTERLY FINANCIAL RESULTS (UNAUDITED):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Summarized quarterly data for 2022, 2021 and 2020 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Quarters Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,691,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,495,558</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,111,353</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,390,474</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross margin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,413,788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,944,856</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,617,377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,757,036</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,791,135)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,357,050)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,017,338)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,356,356)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,966,398)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,879,222)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,200,837)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (766,128)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.21)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.25)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.28)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.02)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total &#160;revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,598,847</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,024,069</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,760,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,782,195</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross margin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,847,403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,313,852</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,297,470</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,659,452</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,852,191)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,924,733)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,406,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,561,821)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,167,821)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,677,530)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,406,285)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,307,012)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.25)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2020:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total&#160;&#160;revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,707,310</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,794,903</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,546,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,955,776</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross margin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,322,468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,545,136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,656,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,428,358</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,478,754)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,297,667)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,959,652)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,634,264)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,452,779)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,866,956)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (839,729)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (677,724)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.08)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.02)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.00</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI https://asc.fasb.org/topic&amp;trid=2126967<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL124452896-108306<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523564965584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_NatureOfBusinessPolicyPolicyTextBlock', window );">Nature of Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Nature of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification. The Company, through its subsidiary CytoSorbents Medical, Inc. (formerly known as CytoSorbents, Inc.), is engaged in the research, development and commercialization of medical devices with its blood purification technology platform which incorporates a proprietary adsorbent, porous polymer technology. The Company, through its wholly owned European subsidiary, CytoSorbents Europe GmbH, conducts sales and marketing related operations for the CytoSorb device. In March 2016, the Company formed CytoSorbents Switzerland GmbH, a wholly owned subsidiary of CytoSorbents Europe GmbH. This subsidiary, which began operations during the second quarter of 2016, provides marketing and direct sales services in Switzerland. In November 2018, the Company formed CytoSorbents Poland Sp. z.o.o., a wholly owned subsidiary of CytoSorbents Europe GmbH. This subsidiary, which began operations during the first quarter of 2019, provides marketing and direct sales services in Poland. In the third quarter of 2019, the Company formed CytoSorbents UK Limited, a wholly owned subsidiary of CytoSorbents Medical, Inc., which is responsible for the management of the Company&#8217;s clinical trial activities in the United Kingdom. In March 2022, the Company formed CytoSorbents Medical UK Limited to provide marketing and direct sales services in the United Kingdom and the Republic of Ireland. In October 2022, the Company formed CytoSorbents France SAS to provide marketing and direct sales services in France. CytoSorb, the Company&#8217;s flagship product, was approved in the European Union (&#8220;EU&#8221;) in March 2011 and is currently being marketed and distributed in more than 75 countries around the world, as an effective extracorporeal cytokine absorber, designed to reduce the &#8220;cytokine storm&#8221; or &#8220;cytokine release syndrome&#8221; seen in critical illnesses that may result in massive inflammation, organ failure, and patient death. In May 2018, the Company received a label extension for CytoSorb covering use of the device for the removal of bilirubin and myoglobin which allows for the use of the device in the treatment of liver failure and trauma, respectively. CytoSorb is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. In January 2020, CytoSorb received EU CE Mark label expansion to include the removal of ticagrelor during cardiopulmonary bypass in patients undergoing cardiothoracic surgery. In May 2020, CytoSorb also received EU CE Mark label expansion to include rivaroxaban removal for the same indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2020, CytoSorb received United States Food and Drug Administration (&#8220;FDA&#8221;) Emergency Use Authorization (&#8220;EUA&#8221;) of CytoSorb for use in adult critically-ill COVID-19 patients with imminent or confirmed respiratory failure. The CytoSorb device has neither been cleared nor approved for the indication to treat patients with COVID-19 infection. The EUA will be effective until a declaration is made that the circumstances justifying the EUA have terminated or until revoked by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2020, the Company also announced that the FDA had granted Breakthrough Designation for its DrugSorb-ATR Antithrombotic Removal System for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery. The Breakthrough Devices Program provides for more effective treatment of life-threatening or irreversibly debilitating disease or conditions, in this case the need to reverse the effects of ticagrelor in emergent or urgent cardiac surgery that can otherwise cause a high risk of serious or life-threatening bleeding. Through Breakthrough Designation, the FDA intends to work with CytoSorbents to expedite the development, assessment, and regulatory review of CytoSorbents&#8217; technology for the removal of ticagrelor, while maintaining statutory standards of regulatory approval (e.g., 510(k), <i style="font-style:italic;">de novo</i> 510(k) or premarket approval) consistent with the FDA&#8217;s mission to protect and promote public health. In July 2021, the Company received full approval of its Investigative Device Exemption (&#8220;IDE&#8221;) to conduct the pivotal STAR-T (Safe and Timely Antithrombotic Removal &#8211; Ticagrelor) double-blind randomized control trial (&#8220;RCT&#8221;) for up to 120 patients in the United States to support FDA marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2021, the Company announced that it was granted a second Breakthrough Device designation for its DrugSorb-ATR Antithrombotic Removal System by the FDA. This Breakthrough Device designation covers the removal of the Direct Oral Anticoagulants (DOACs) apixaban and rivaroxaban in a cardiopulmonary bypass circuit to reduce the likelihood of serious perioperative bleeding during urgent cardiothoracic surgery. In October 2021, the Company also received full FDA approval of an IDE application to conduct a double-blind, randomized, controlled clinical study for up to 120 patients entitled, &#8220;Safe and Timely Antithrombotic Removal &#8211; Direct Oral Anticoagulants (STAR-D),&#8221; in the United States to support FDA marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If FDA marketing approval is obtained for either the removal of ticagrelor or direct oral anticoagulants indications, the device would be marketed as DrugSorb-ATR in the United States. The DrugSorb-ATR Antithrombotic Removal System is based on the same polymer technology as CytoSorb.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May 2022, the Company announced that the Company entered into a 3-year preferred supplier agreement with Asklepios, making CytoSorb available without restrictions to all of the approximate 170 healthcare facilities across 14 states throughout Germany at which Asklepios operates. This includes Asklepios Klinik St. Georg in Hamburg, Germany, which pioneered the use of CytoSorb to remove antithrombotic drugs during cardiothoracic surgery, and is well-known for their seminal publication on CytoSorb use for this application during emergency cardiac surgery in patients at high risk of bleeding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2022, the Company announced that, following a successful pilot program in three countries, the Company signed an expanded non-exclusive agreement with Nikkiso Europe GmbH (&#8220;Nikkiso&#8221;) to distribute Nikkiso&#8217;s PureADJUST stand-alone hemoperfusion pump and accessories in a total of 14 countries. In addition to securing the rights to sell Nikkiso&#8217;s stand-alone pump and accessories in Germany, Austria, and Luxembourg, the Company entered into an expanded multi-country reseller agreement with Nikkiso covering the following countries: Belgium, Bosnia and Herzegovina, Croatia, Finland, France, Iceland, Lichtenstein, Poland, Serbia, Slovenia and Switzerland. The Company will also be able to provide field support services in these countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2022, the Company entered into a Marketing Agreement (the &#8220;Marketing Agreement&#8221;) with Fresenius Medical Care Deutschland GmbH (&#8220;Fresenius&#8221;), which expands the Company&#8217;s strategic partnership with Fresenius by establishing a multi-stage global collaboration to combat life-threatening diseases in critical care. The Marketing Agreement provides for the combined marketing and promotion of CytoSorb with Fresenius&#8217; critical care products by Fresenius&#8217; marketing organization worldwide, excluding the United States. The Marketing Agreement has an initial term of three years, with an automatic renewal for an additional two years at the end of such initial term, subject to earlier termination by either of the parties (the &#8220;Term&#8221;). Compared to the prior co-marketing agreement between the parties, the Marketing Agreement intends to increase the commitments from both parties and to ensure an ongoing and consistent level of marketing and promotional activity specifically focused around CytoSorb, where Fresenius will actively market and promote CytoSorb as the featured blood purification therapy for removal of cytokines, bilirubin, and myoglobin on its critical care platforms. Specifically, the Marketing Agreement provides that various Fresenius-led in-person, virtual, social media, and web-based marketing programs and events will feature the CytoSorb therapy and highlight the cooperation between the two companies in the field of critical care during the Term. To help support the increased marketing and promotional efforts of the expanded collaboration, CytoSorbents has agreed to subsidize a portion of the marketing costs through a royalty payment to Fresenius Medical Care based on CytoSorb sales in the intensive care unit on Fresenius Medical Care platforms, excluding the United States. In addition to strengthening and expanding the global marketing of CytoSorb, the Company and Fresenius also plan to work together to bring new innovative solutions to the market. The Marketing Agreement also includes the certification of compatibility of CytoSorb for usage on Fresenius&#8217; current critical care platforms. Certain initial activities have been completed with the formal launch of this program expected to occur sometime in 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The technology is based upon biocompatible, highly porous polymer sorbent beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company has numerous products under development based upon this unique blood purification technology, which is protected by 18 issued U.S. patents and multiple international patents, with applications pending both in the U.S. and internationally, including HemoDefend, ContrastSorb, DrugSorb, DrugSorb-ATR and others. These patents and patent applications are directed to various compositions and methods of use related to the Company&#8217;s blood purification technologies and are expected to expire between 2023 and 2038, absent any patent term extensions. Management believes that any near-term expiring patents will not have a significant impact on the Company&#8217;s ongoing business.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockMarketListingPolicyPolicyTextBlock', window );">Stock Market Listing</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock Market Listing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December&#160;17, 2014 the Company&#8217;s common stock was approved for listing on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;), and it began trading on Nasdaq on December&#160;23, 2014 under the symbol &#8220;CTSO&#8221;. Previously, the Company&#8217;s common stock traded in the over-the-counter-market on the OTC Bulletin Board.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_ConsolidationAndForeignCurrencyTranslationPolicyPolicyTextBlock', window );">Basis of Consolidation and Foreign Currency Translation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Consolidation and Foreign Currency Translation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements include the accounts of CytoSorbents Corporation and its wholly owned subsidiaries, CytoSorbents Medical, Inc. and CytoSorbents Europe GmbH. In addition, the consolidated financial statements include CytoSorbents Switzerland GmbH, CytoSorbents Poland Sp. z.o.o., CytoSorbents Medical UK Limited and CytoSorbents France SAS, wholly owned subsidiaries of CytoSorbents Europe GmbH, and CytoSorbents UK Limited, a wholly owned subsidiary of CytoSorbents Medical, Inc. All significant intercompany transactions and balances have been eliminated in consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Translation gains and losses resulting from the process of remeasuring into the United States of America dollar, the foreign currency financial statements of the European subsidiary, for which the United States of America dollar is the functional currency, are included in operations. Foreign currency transaction gain (loss) included in net loss amounted to approximately $(2,448,000), $(2,578,000) and $2,607,000 for the years ended December 31, 2022, 2021 and 2020, respectively. The Company translates assets and liabilities of the European subsidiary, whose functional currency is their local currency, at the exchange rate in effect at the balance sheet date. The Company translates revenue and expenses at the daily average exchange rates. The Company includes accumulated net translation adjustments in accumulated other comprehensive income (loss) as a component of stockholders&#8217; equity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly liquid instruments purchased with an original maturity of three&#160;months or less to be cash equivalents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table provides a reconciliation of cash and cash equivalents and restricted cash and cash equivalents to amounts shown in the consolidated balance sheets and consolidated statements of cash flows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">22,144,567 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52,137,707</p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,687,459</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,687,459</p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,832,026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53,825,166</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s total restricted cash in the amount of $1,687,459 consists of cash of $1,467,459 that the Company is obligated to maintain as collateral for the outstanding letter of credit with Bridge Bank that was provided to the landlord of the College Road facility as security and cash of $220,000 that the Company is obligated to maintain as collateral for the credit limit on the Company&#8217;s credit card account.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Grants and Accounts Receivable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Grants and Accounts Receivable</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Grants receivable represent amounts due from U.S. government agencies and are included in grants and accounts Receivable in the accompanying consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable are unsecured, non-interest-bearing customer obligations due under normal trade terms. The Company sells its devices to various hospitals and distributors. The Company performs ongoing credit evaluations of customers&#8217; financial condition. Management reviews accounts receivable periodically to determine collectability. Balances that are determined to be uncollectible are reserved in the allowance for doubtful accounts.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Inventories</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Inventories are valued at the lower of cost or net realizable value. Cost is determined using a first-in first-out (&#8220;FIFO&#8221;) basis. At December 31, 2022 and 2021, the Company&#8217;s inventory was comprised of finished goods, which amounted to $1,567,871 and $3,084,606, respectively, work in process which amounted to $1,280,368 and $1,322,736, respectively, and raw materials which amounted to $613,347 and $358,756, respectively. Devices used in clinical trials or for research and development purposes are removed from inventory and charged to research and development expenses at the time of their use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2022, the Company experienced an equipment failure of a refrigeration unit at its new College Road manufacturing facility. This equipment stored various items of work-in-process inventory. The Company determined all the items that were stored in this unit were required to be scrapped. The value of this inventory was approximately $599,000. Accordingly, this inventory was written off and was included in cost of goods sold at the time of the loss in September 2022. The Company filed a claim with its insurance carrier related to this loss. In December 2022, the claim was approved in the amount of approximately $299,000 and, accordingly, has been recorded as a reduction to cost of goods sold in the accompanying consolidated statement of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are recorded at cost less accumulated depreciation. Depreciation of property and equipment is provided for by the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the lesser of their economic useful lives or the term of the related leases. Gains and losses on depreciable assets retired or sold are recognized in the statements of operations in the&#160;year of disposal. Repairs and maintenance expenditures are expensed as incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Legal costs incurred to establish patents are capitalized. When patents are issued, capitalized costs are amortized on the straight-line method over the related patent term. In the event a patent is abandoned, the net book value of the patent is written off.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Impairment or Disposal of Long-Lived Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company assesses the impairment of patents and other long-lived assets under accounting standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value. During the year ended December 31, 2022, the Company wrote-off patent costs of approximately $636,000 related to the impairment of certain issued patents and pending patent applications in certain specific jurisdictions, the abandonment of certain patent defense costs that are no longer being pursued and the abandonment of certain pending patent application costs in the ordinary course of business.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Product Sales:</i> Revenues from sales of products to both direct and distributor/strategic partner customers are recognized at the time when control passes to the customer, in accordance with the terms of their respective contracts. Recognition of revenue occurs as each performance obligation is completed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Grant Revenue: </i>Revenue from grant income is based on contractual agreements with various agencies of the U.S. government. Certain agreements provide for reimbursement of costs, other agreements provide for reimbursement of costs and an overhead margin and certain agreements are performance based, where revenue is earned based upon the achievement of milestones outlined in the contract. Revenues are recognized when the associated performance obligation is fulfilled. Costs are recorded as incurred. Amounts invoiced in excess of costs actually incurred on fixed price contracts are classified as deferred revenue and are included in accrued expenses and other current liabilities in the consolidated balance sheets. Costs subject to reimbursement by these grants have been reflected as costs of revenue.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All research and development costs, payments to laboratories, research consultants and costs related to clinical trials and studies are expensed when incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Advertising Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Advertising costs are charged to activities when incurred. Advertising expense amounted to approximately $582,000, $615,000 and $285,000 in 2022, 2021 and 2020, respectively, and is included in selling, general, and administrative expenses in the consolidated statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Income taxes are accounted for under the asset and liability method prescribed by accounting standards for accounting for income taxes. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax asset will not be realized. Under Section 382 of the Internal Revenue Code, the net operating losses generated prior to the previously completed reverse merger may be limited due to the change in ownership. Additionally, net operating losses generated subsequent to the reverse merger may be limited in the event of changes in ownership. In 2017, the Tax Cuts and Jobs Act reduced the U.S. federal corporate tax rate from 35% to 21%. See Note&#160;9 for the impact of the tax rate change on deferred tax assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company follows the accounting standards associated with uncertain tax provisions. The Company had no unrecognized tax benefits as of December 31, 2022 or 2021. The Company files tax returns in the U.S. federal and state jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company utilizes the Technology Business Tax Certificate Transfer Program to sell a portion of its New Jersey Net Operating Loss tax carryforwards and Research and Development credits to an industrial company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CytoSorbents Europe GmbH, CytoSorbents Switzerland GmbH, CytoSorbents Poland Sp. z.o.o., CytoSorbents UK Limited, CytoSorbents Medical UK Limited and CytoSorbents France file an annual corporate tax return, a VAT return and a trade tax return in Germany, Switzerland, Poland, France and the United Kingdom, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets, liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. The valuation of options granted, allowance for doubtful accounts and recoverability of patents are significant estimates in these consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of the Company&#8217;s revenues are from product sales in Germany. Substantially all of the Company&#8217;s grant and other income are from grant agencies in the United States. (See Note&#160;3 for further information relating to the Company&#8217;s revenue.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, two distributors accounted for approximately 27% of outstanding grants and accounts receivables. As of December 31, 2021, one distributor accounted for approximately 12% of outstanding grants and accounts receivables. For the years ended December 31, 2022, 2021 and 2020, no agency, distributor/strategic partners or direct customer represented more than 10% of the Company&#8217;s total revenue.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their short-term nature.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss per Common Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed using the treasury stock method on the basis of the weighted-average number of shares of common stock plus the dilutive effect of potential common shares outstanding during the period. Dilutive potential common shares include outstanding warrants, stock options and restricted shares. The computation of diluted net loss per share does not assume conversion, exercise or contingent exercise of securities that would have an anti-dilutive effect on earnings (see Note&#160;12).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its stock-based compensation under the recognition requirements of accounting standards for accounting for stock-based compensation for employees and directors whereby each option granted is valued at fair market value on the date of grant. Under these accounting standards, the fair value of each option is estimated on the date of grant using the Black-Scholes option pricing model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company also follows the guidance of accounting standards for accounting for equity instruments that are issued to non-employees for acquiring, or in conjunction with selling, goods or services for equity instruments issued to consultants.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_ShippingAndHandlingCostsPolicyPolicyTextBlock', window );">Shipping and Handling Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Shipping and Handling Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The cost of shipping product to customers and distributors is typically borne by the customer or distributor. The Company records shipping and handling costs in cost of revenue. Total freight costs amounted to approximately $297,000, $276,000 and $560,000 for the&#160;years ended December 31, 2022, 2021 and 2020, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Effect of Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Effect of Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2021, the Financial Accounting Standards Board (the &#8220;FASB&#8221;), issued Accounting Standards Update No. 2021-10 entitled, &#8220;Government Assistance (Topic 832) Disclosures by Business Entities about Government Assistance&#8221; (the &#8220;ASU&#8221;). This ASU will require enhanced disclosures related to the Company&#8217;s contracts with the U.S. government. The ASU is effective for annual periods beginning after December 15, 2021. The Company implemented the provisions of this ASU during 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_ConsolidationAndForeignCurrencyTranslationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of consolidation and foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_ConsolidationAndForeignCurrencyTranslationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_NatureOfBusinessPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Nature of Business Policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_NatureOfBusinessPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_ShippingAndHandlingCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_ShippingAndHandlingCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_StockMarketListingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock market listing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_StockMarketListingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566611312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock', window );">Schedule of reconciliation of cash and cash equivalents and restricted cash and cash equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">22,144,567 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 52,137,707</p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,687,459</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,687,459</p></td></tr><tr><td style="vertical-align:bottom;width:69.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,832,026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53,825,166</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents and restricted cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523571154864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>REVENUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of disaggregation of Revenue</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table disaggregates the Company&#8217;s revenue by customer type and geographic area for the&#160;year ended December 31, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">United&#160;States</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Distributors/</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Government</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Direct</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Strategic&#160;Partners</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Agencies</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Product sales:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 787,201</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 181,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 968,951</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Germany</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,566,437</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,566,437</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">All other countries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,705,580</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,118,942</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,824,522</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total product revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,059,218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,300,692</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,359,910</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,328,899</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,328,899</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,059,218</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,300,692</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,328,899</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 34,688,809</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table disaggregates the Company&#8217;s revenue by customer type and geographic area for the&#160;year ended December&#160;31, 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">United&#160;States</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Distributors/</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Government</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Direct</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Strategic&#160;Partners</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Agencies</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Product sales:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 189,167</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,500,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,689,867</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Germany</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,006,432</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,006,432</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">All other countries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,846,256</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,566,012</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,412,268</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total product revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,041,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,066,712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,108,567</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,056,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,056,960</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,041,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,066,712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,056,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,165,527</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table disaggregates the Company&#8217;s revenue by customer type and geographic area for the&#160;year ended December&#160;31, 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">United&#160;States</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Distributors/</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Government</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Direct</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Strategic&#160;Partners</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Agencies</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Product sales:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,148,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 192,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,341,200</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Germany</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,257,410</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 20,257,410</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">All other countries</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,275,619</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,578,273</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,853,892</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total product revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,681,329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,771,173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,452,502</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Grant income:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">United States</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,552,099</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,552,099</p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,681,329</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,771,173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,552,099</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41,004,601</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of receivables and contract liabilities from contracts with customers</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.89%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contract receivables, which are included in grants and accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,822,452</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000,708</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:72.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contract liabilities, which are included in accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,694,906</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,251,177</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566421376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Depreciation/</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Period</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,306,267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,424,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">7&#160;years</p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Equipment and computers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,131,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,863,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3 to 7&#160;years</p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,201,523</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,623,356</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Lesser of term of lease or estimated useful life</p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,639,724</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,911,505</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,896,692</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,760,619</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Property and Equipment, Net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,743,032</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,150,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566417792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>OTHER ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Schedule of Other Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Patent applications pending</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,466,341</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,717,701</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Patents issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,773,191</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,641,603</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less accumulated amortization of patents issued</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (848,999)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (657,320)</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Patents, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,390,533</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,701,984</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 46,914</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 256,591</p></td></tr><tr><td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,437,447</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,958,575</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566196304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of accrued expenses and other current liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued salaries and commissions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,862,930</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,270,715</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,516,772</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,947,353</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Clinical studies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,115,123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,767,826</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 850,630</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,044,088</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 622,353</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 314,068</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 592,398</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 769,262</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Customer rebates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 166,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 214,119</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Travel and entertainment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 99,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 88,850</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Board of Director fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 97,426</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 71,381</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sales, payroll and income taxes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,871</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 785,818</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Congresses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 40,861</p></td></tr><tr><td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,950,440</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,314,341</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523567465328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Long-term debt consists of the following as of December 31, 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Principal amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,000,000</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Less Current maturities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Long-term debt net of current maturities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,000,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Principal payments of long-term debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Principal payments of long-term debt are due as follows during the years ending December 31:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,500,000</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,500,000</p></td></tr><tr><td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,000,000</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566125104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock', window );">Schedule of right-of- use asset and related lease liability</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:70.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,603,901</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,423,472</p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,250,944</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,821,509</p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (108,939)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (570,566)</p></td></tr><tr><td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease liability, net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,142,005</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,250,943</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of the lease liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The maturities of the lease liabilities are as follows as of December 31, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,266,346</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,656,678</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,695,677</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,735,747</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,776,920</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,232,300</p></td></tr><tr><td style="vertical-align:middle;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,363,668</p></td></tr><tr><td style="vertical-align:middle;width:84.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,112,724</p></td></tr><tr><td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,250,944</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of Lessee's right-of-use-assets and lease liability under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523567619648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income before Income Tax, Domestic and Foreign</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company&#8217;s consolidated loss before income taxes for the years ended December 31, 2022, 2021 and 2020 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:60.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Domestic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21,155,203)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18,829,797)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,682,628)</p></td></tr><tr><td style="vertical-align:top;width:60.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,749,965)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,464,854)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,281,634)</p></td></tr><tr><td style="vertical-align:top;width:60.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (33,905,168)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,294,651)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,964,262)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The benefit from income taxes consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:60.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">State Tax, including sale of New Jersey losses &amp; credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,092,585</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 736,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,127,074</p></td></tr><tr><td style="vertical-align:top;width:60.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Foreign tax provision</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:60.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,092,585</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 736,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,127,074</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The principal components of the Company&#8217;s deferred tax assets and liabilities are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net operating loss carry forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31,570,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,190,654</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,301,154</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 500,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,203,272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 305,982</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development credit carryforward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,982,147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,687,591</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,194,211</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accruals and others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 24,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 232,665</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 135,330</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Lease liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,724,840</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,997,114</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 289,287</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#167;174(b) research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,331,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,134,554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,311,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 25,225,964</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (39,303,451)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (31,242,130)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24,794,474)</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,831,103</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,069,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 431,490</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liability:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (288,145)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (183,941)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (431,490)</p></td></tr><tr><td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right of Use Asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,542,958)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,885,225)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A reconciliation of income tax (expense) benefit at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:top;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign rate differential</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.0)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rate change and true-up</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 0.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (22.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (25.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21.6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">R&amp;D credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sale of state R&amp;D credit and NOL</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523570976368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock options activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per&#160;Share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life&#160;(Years)</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding January 1, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,218,189</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.0</p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,579,106</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.37</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.0</p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34,644)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_1iWKOSTEYEW4rgjnocsyQg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (226,440)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_gFEztX83IEan5vGYiG_KkA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (371,007)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_7Cm8_uxCP0mv3QQAha4gkQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding, December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,165,204</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.26</p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,051,980</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.78</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.30</p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (138,037)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_rBumodlmnUK-p_-iado5iw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21,756)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_GQpp15AqqkCIMuMwEM8NqQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (171,413)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_amo3-ZcwWEWCT2ol91T9ZQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding, December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6,885,978</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.15</p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,721,205</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.60</p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,270,155)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_SbJXsQ3BuU-Usd0OT4w7GA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Expired</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (227,204)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_4-HPXTyq0kWo5cJ4Z0sPVw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_We0d8r7iWEWg62NYW1m7vA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding, December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,109,824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.91</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value of each stock option estimated using the Black-Scholes pricing model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;of&#160;the</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Underlying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Stock&#160;and&#160;its&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant&#160;Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expected&#160;Life</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expected</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Risk&#160;Free</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;of&#160;the&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Volatility</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expected</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Interest&#160;Rate</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year - Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Range</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Range</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Dividends</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;Range</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5.00 - $10.58 per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">61.7% to 69.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.28% to 0.96</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">4.26 - $11.39 per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">58.2% to 60.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.47% to 1.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:19.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1.11 - $3.91 per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">59.3% to 67.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1.52% to 4.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="11" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Range of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life (Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$1.11 - $13.20</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,109,824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">5.11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,280</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:56.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercisable at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">4,623,085</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,250</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of Company's non-vested options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant&#160;Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-vested, January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,994,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.68</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,721,205</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.99</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,270,155)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.65</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (959,157)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.65</p></td></tr><tr><td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-vested, December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,486,739</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.10</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of restricted stock unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Board&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Executive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Directors</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Management</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Employees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 277,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 604,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,205,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,086,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,033,988</p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 120,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 265,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 385,700</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,250)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (25,250)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 277,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 724,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,445,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,447,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,504,184</p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 396,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 396,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeited 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (132,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (132,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 277,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 724,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,709,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,711,200</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,359,928</p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 69,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 373,750</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 498,050</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (318,750)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (318,750)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 346,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 779,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,764,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,890,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4,480,275</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of the restricted stock unit activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant&#160;Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-vested, January 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 304,962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.08</p></td></tr><tr><td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 288,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.95</p></td></tr><tr><td style="vertical-align:bottom;width:74.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (45,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.35</p></td></tr><tr><td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (236,370)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.38</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Non-vested, December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 312,092</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.42</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523575768096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>QUARTERLY FINANCIAL RESULTS (UNAUDITED) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>QUARTERLY FINANCIAL RESULTS (UNAUDITED)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock', window );">Summarized quarterly information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Quarters Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2022:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,691,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,495,558</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,111,353</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,390,474</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross margin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,413,788</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,944,856</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,617,377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,757,036</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,791,135)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,357,050)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,017,338)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,356,356)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8,966,398)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,879,222)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12,200,837)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (766,128)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.21)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.25)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.28)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.02)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total &#160;revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,598,847</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,024,069</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,760,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,782,195</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross margin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,847,403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,313,852</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,297,470</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,659,452</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,852,191)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,924,733)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,406,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,561,821)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,167,821)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,677,530)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,406,285)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (9,307,012)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.11)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.15)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.25)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2020:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total&#160;&#160;revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,707,310</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,794,903</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,546,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,955,776</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross margin</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,322,468</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,545,136</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,656,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,428,358</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,478,754)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,297,667)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,959,652)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,634,264)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to common stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,452,779)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,866,956)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (839,729)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (677,724)</p></td></tr><tr><td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss per share, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.08)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.02)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.00</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Paragraph (a)<br> -Subsection 04<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedIncomeStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566361392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 23.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523561218384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>patent </div>
<div>country</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed', window );">Number of countries where the entity's flagship product is marketed and distributed | country</a></td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_NumberOfPatentsUnitedStates', window );">Number of patents | patent</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_ForeignCurrencyTransactionGainLossExcludingTax', window );">Foreign currency transaction gain (loss)</a></td>
<td class="num">$ (2,448,000)<span></span>
</td>
<td class="num">$ (2,578,000)<span></span>
</td>
<td class="nump">$ 2,607,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,687,459<span></span>
</td>
<td class="nump">1,687,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Inventory - finished goods</a></td>
<td class="nump">1,567,871<span></span>
</td>
<td class="nump">3,084,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Inventory - work in process</a></td>
<td class="nump">1,280,368<span></span>
</td>
<td class="nump">1,322,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Inventory - raw materials</a></td>
<td class="nump">613,347<span></span>
</td>
<td class="nump">358,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryAdjustments', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 599,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_WroteOffPatentsCosts', window );">wrote-off patent costs</a></td>
<td class="nump">636,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expenses</a></td>
<td class="nump">$ 582,000<span></span>
</td>
<td class="nump">$ 615,000<span></span>
</td>
<td class="nump">$ 285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="nump">0.21%<span></span>
</td>
<td class="nump">0.21%<span></span>
</td>
<td class="nump">0.21%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_ThresholdUsedForCalculatingConcentrationOfRisk', window );">Concentration risk</a></td>
<td class="nump">27.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">$ 13,955,752<span></span>
</td>
<td class="nump">11,047,350<span></span>
</td>
<td class="nump">$ 11,052,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateralAmount', window );">Cash collateral</a></td>
<td class="nump">1,467,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_CreditCardMember', window );">Credit Card</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCollateralAmount', window );">Cash collateral</a></td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_CargoAndFreightMember', window );">Cargo and Freight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of revenue</a></td>
<td class="nump">297,000<span></span>
</td>
<td class="nump">$ 276,000<span></span>
</td>
<td class="nump">$ 560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_InsuranceSettlementReceivableForLossOnInventoryRecordedAsReductionToCostOfGoodsSold', window );">Insurance settlement receivable for loss on inventory recorded as a reduction to cost of goods sold</a></td>
<td class="nump">$ 299,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | One Distributor/strategic partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_ThresholdUsedForCalculatingConcentrationOfRisk', window );">Concentration risk</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Sales Revenue, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_ThresholdUsedForCalculatingConcentrationOfRisk', window );">Concentration risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_ForeignCurrencyTransactionGainLossExcludingTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_ForeignCurrencyTransactionGainLossExcludingTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_InsuranceSettlementReceivableForLossOnInventoryRecordedAsReductionToCostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of insurance settlement receivable for loss on inventory recorded as a reduction to cost of goods sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_InsuranceSettlementReceivableForLossOnInventoryRecordedAsReductionToCostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of countries where the entity's flagship product is marketed and distributed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_NumberOfPatentsUnitedStates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of patents issued to the entity in the United States.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_NumberOfPatentsUnitedStates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represents the Principal Business Activity and Summary of Significant Accounting Policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_ThresholdUsedForCalculatingConcentrationOfRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_ThresholdUsedForCalculatingConcentrationOfRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_WroteOffPatentsCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of patents cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_WroteOffPatentsCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCollateralAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets pledged to secure a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCollateralAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_CreditCardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_CreditCardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_CargoAndFreightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_CargoAndFreightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=ctso_OneDistributorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=ctso_OneDistributorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566253408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 22,144,567<span></span>
</td>
<td class="nump">$ 52,137,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">1,687,459<span></span>
</td>
<td class="nump">1,687,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 23,832,026<span></span>
</td>
<td class="nump">$ 53,825,166<span></span>
</td>
<td class="nump">$ 71,421,601<span></span>
</td>
<td class="nump">$ 12,232,418<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523557296640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE - Revenue by customer type and geographic area (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="12">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 9,390,474<span></span>
</td>
<td class="nump">$ 8,111,353<span></span>
</td>
<td class="nump">$ 8,495,558<span></span>
</td>
<td class="nump">$ 8,691,424<span></span>
</td>
<td class="nump">$ 10,782,195<span></span>
</td>
<td class="nump">$ 9,760,416<span></span>
</td>
<td class="nump">$ 12,024,069<span></span>
</td>
<td class="nump">$ 10,598,847<span></span>
</td>
<td class="nump">$ 11,955,776<span></span>
</td>
<td class="nump">$ 10,546,612<span></span>
</td>
<td class="nump">$ 9,794,903<span></span>
</td>
<td class="nump">$ 8,707,310<span></span>
</td>
<td class="nump">$ 34,688,809<span></span>
</td>
<td class="nump">$ 43,165,527<span></span>
</td>
<td class="nump">$ 41,004,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,359,910<span></span>
</td>
<td class="nump">40,108,567<span></span>
</td>
<td class="nump">39,452,502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,328,899<span></span>
</td>
<td class="nump">3,056,960<span></span>
</td>
<td class="nump">1,552,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">968,951<span></span>
</td>
<td class="nump">1,689,867<span></span>
</td>
<td class="nump">1,341,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,328,899<span></span>
</td>
<td class="nump">3,056,960<span></span>
</td>
<td class="nump">1,552,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany | Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,566,437<span></span>
</td>
<td class="nump">21,006,432<span></span>
</td>
<td class="nump">20,257,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=ctso_AllOtherCountriesMember', window );">All other countries | Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,824,522<span></span>
</td>
<td class="nump">17,412,268<span></span>
</td>
<td class="nump">17,853,892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ctso_DirectMember', window );">Direct</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,059,218<span></span>
</td>
<td class="nump">27,041,855<span></span>
</td>
<td class="nump">26,681,329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ctso_DirectMember', window );">Direct | Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,059,218<span></span>
</td>
<td class="nump">27,041,855<span></span>
</td>
<td class="nump">26,681,329<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ctso_DirectMember', window );">Direct | United States | Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">787,201<span></span>
</td>
<td class="nump">189,167<span></span>
</td>
<td class="nump">1,148,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ctso_DirectMember', window );">Direct | United States | Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ctso_DirectMember', window );">Direct | Germany | Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,566,437<span></span>
</td>
<td class="nump">21,006,432<span></span>
</td>
<td class="nump">20,257,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ctso_DirectMember', window );">Direct | All other countries | Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,705,580<span></span>
</td>
<td class="nump">5,846,256<span></span>
</td>
<td class="nump">5,275,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ctso_DistributorsAndStrategicPartnersMember', window );">Distributors/Strategic Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,300,692<span></span>
</td>
<td class="nump">13,066,712<span></span>
</td>
<td class="nump">12,771,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ctso_DistributorsAndStrategicPartnersMember', window );">Distributors/Strategic Partners | Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,300,692<span></span>
</td>
<td class="nump">13,066,712<span></span>
</td>
<td class="nump">12,771,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ctso_DistributorsAndStrategicPartnersMember', window );">Distributors/Strategic Partners | United States | Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181,750<span></span>
</td>
<td class="nump">1,500,700<span></span>
</td>
<td class="nump">192,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ctso_DistributorsAndStrategicPartnersMember', window );">Distributors/Strategic Partners | United States | Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ctso_DistributorsAndStrategicPartnersMember', window );">Distributors/Strategic Partners | Germany | Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ctso_DistributorsAndStrategicPartnersMember', window );">Distributors/Strategic Partners | All other countries | Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,118,942<span></span>
</td>
<td class="nump">11,566,012<span></span>
</td>
<td class="nump">12,578,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ctso_UnitedStatesGovernmentAgenciesMember', window );">United States Government Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,328,899<span></span>
</td>
<td class="nump">3,056,960<span></span>
</td>
<td class="nump">1,552,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ctso_UnitedStatesGovernmentAgenciesMember', window );">United States Government Agencies | Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ctso_UnitedStatesGovernmentAgenciesMember', window );">United States Government Agencies | United States | Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ctso_UnitedStatesGovernmentAgenciesMember', window );">United States Government Agencies | United States | Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,328,899<span></span>
</td>
<td class="nump">3,056,960<span></span>
</td>
<td class="nump">1,552,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ctso_UnitedStatesGovernmentAgenciesMember', window );">United States Government Agencies | Germany | Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ctso_UnitedStatesGovernmentAgenciesMember', window );">United States Government Agencies | All other countries | Total product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SaleRevenuesGoodsNetAbstract', window );"><strong>Product sales:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_SaleRevenuesGoodsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Revenues Goods Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_SaleRevenuesGoodsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=ctso_AllOtherCountriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=ctso_AllOtherCountriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ctso_DirectMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ctso_DirectMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ctso_DistributorsAndStrategicPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ctso_DistributorsAndStrategicPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ctso_UnitedStatesGovernmentAgenciesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ctso_UnitedStatesGovernmentAgenciesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523564054912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>REVENUE - Receivables and contract liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>REVENUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract receivables, which are included in grants and accounts receivable</a></td>
<td class="nump">$ 3,822,452<span></span>
</td>
<td class="nump">$ 3,000,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Contract liabilities, which are included in accrued expenses and other current liabilities</a></td>
<td class="nump">$ 1,694,906<span></span>
</td>
<td class="nump">$ 2,251,177<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523565112496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE - Additional information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>REVENUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_NumberOfPrimaryRevenueStreams', window );">Number of primary revenue streams | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_TermOfCustomerContracts', window );">Term of customer contracts</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent', window );">Value of free of charge goods and credit rebates</a></td>
<td class="nump">$ 178,134<span></span>
</td>
<td class="nump">$ 303,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent', window );">Contract liabilities net of Value of free of charge goods and credit rebates</a></td>
<td class="nump">1,516,772<span></span>
</td>
<td class="nump">1,947,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract receivables, which are included in grants and accounts receivable</a></td>
<td class="nump">3,822,452<span></span>
</td>
<td class="nump">3,000,708<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>REVENUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract receivables, which are included in grants and accounts receivable</a></td>
<td class="nump">2,944,031<span></span>
</td>
<td class="nump">2,265,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Government grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>REVENUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract receivables, which are included in grants and accounts receivable</a></td>
<td class="nump">$ 878,421<span></span>
</td>
<td class="nump">$ 735,549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>REVENUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_TermOfCustomerContracts', window );">Term of customer contracts</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>REVENUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_TermOfCustomerContracts', window );">Term of customer contracts</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contract with customer liability net of free of charge goods and credit rebates as on the balance sheet date, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of free of charge goods and credit rebates as on the balance sheet date, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_NumberOfPrimaryRevenueStreams">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of primary revenue streams.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_NumberOfPrimaryRevenueStreams</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_TermOfCustomerContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the term of customer contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_TermOfCustomerContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523565121488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY AND EQUIPMENT, NET:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 12,639,724<span></span>
</td>
<td class="nump">$ 9,911,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="nump">1,896,692<span></span>
</td>
<td class="nump">4,760,619<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">10,743,032<span></span>
</td>
<td class="nump">5,150,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY AND EQUIPMENT, NET:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 1,306,267<span></span>
</td>
<td class="nump">1,424,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Depreciation/Amortization Period</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Equipment and computers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY AND EQUIPMENT, NET:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 5,131,934<span></span>
</td>
<td class="nump">5,863,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Equipment and computers | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY AND EQUIPMENT, NET:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Depreciation/Amortization Period</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Equipment and computers | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY AND EQUIPMENT, NET:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Depreciation/Amortization Period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>PROPERTY AND EQUIPMENT, NET:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 6,201,523<span></span>
</td>
<td class="nump">$ 2,623,356<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566741296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET - Additional information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 688,565<span></span>
</td>
<td class="nump">$ 571,156<span></span>
</td>
<td class="nump">$ 553,946<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523564760528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_OtherAssetsLineItems', window );"><strong>OTHER ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization of patents issued</a></td>
<td class="num">$ (848,999)<span></span>
</td>
<td class="num">$ (657,320)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">4,390,533<span></span>
</td>
<td class="nump">4,701,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposits</a></td>
<td class="nump">46,914<span></span>
</td>
<td class="nump">256,591<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total</a></td>
<td class="nump">4,437,447<span></span>
</td>
<td class="nump">4,958,575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember', window );">Patent applications pending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_OtherAssetsLineItems', window );"><strong>OTHER ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Patents</a></td>
<td class="nump">2,466,341<span></span>
</td>
<td class="nump">2,717,701<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember', window );">Patents issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_OtherAssetsLineItems', window );"><strong>OTHER ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Patents</a></td>
<td class="nump">$ 2,773,191<span></span>
</td>
<td class="nump">$ 2,641,603<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_OtherAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line item represents the other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_OtherAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523564858960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ASSETS - Additional information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>OTHER ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 201,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">201,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">201,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">196,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization expense</a></td>
<td class="nump">$ 194,056<span></span>
</td>
<td class="nump">$ 160,422<span></span>
</td>
<td class="nump">$ 106,842<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566145104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_AccruedSalariesAndCommissionsCurrent', window );">Accrued salaries and commissions</a></td>
<td class="nump">$ 2,862,930<span></span>
</td>
<td class="nump">$ 3,270,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">1,516,772<span></span>
</td>
<td class="nump">1,947,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_ClinicalStudyCostsPayableCurrent', window );">Clinical studies</a></td>
<td class="nump">1,115,123<span></span>
</td>
<td class="nump">1,767,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued accounts payable</a></td>
<td class="nump">850,630<span></span>
</td>
<td class="nump">1,044,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">622,353<span></span>
</td>
<td class="nump">314,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">592,398<span></span>
</td>
<td class="nump">769,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_CustomerRebates', window );">Customer rebates</a></td>
<td class="nump">166,065<span></span>
</td>
<td class="nump">214,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_AccruedTravelAndEntertainmentExpenseCurrent', window );">Travel and entertainment</a></td>
<td class="nump">99,316<span></span>
</td>
<td class="nump">88,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_AccruedDirectorFeesCurrent', window );">Board of Director fees</a></td>
<td class="nump">97,426<span></span>
</td>
<td class="nump">71,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_SalesPayrollAndIncomeTaxesPayableCurrent', window );">Sales, payroll and income taxes payable</a></td>
<td class="nump">21,871<span></span>
</td>
<td class="nump">785,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest</a></td>
<td class="nump">5,556<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_CongressesPayableCurrent', window );">Congresses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,861<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 7,950,440<span></span>
</td>
<td class="nump">$ 10,314,341<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_AccruedDirectorFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for board of Director fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_AccruedDirectorFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_AccruedSalariesAndCommissionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for salaries and commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_AccruedSalariesAndCommissionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_AccruedTravelAndEntertainmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for travel and entertainment. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_AccruedTravelAndEntertainmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_ClinicalStudyCostsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical study costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_ClinicalStudyCostsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_CongressesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The element represents the carrying value of congresses classified as current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_CongressesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_CustomerRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of customer rebates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_CustomerRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_SalesPayrollAndIncomeTaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales, payroll and income taxes payable. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_SalesPayrollAndIncomeTaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523559964368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LONG-TERM DEBT - Additional information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2024</div></th>
<th class="th"><div>Jan. 01, 2024</div></th>
<th class="th"><div>Dec. 27, 2022</div></th>
<th class="th"><div>Jan. 19, 2022</div></th>
<th class="th"><div>Dec. 04, 2020</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 29, 2018</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Amount drawn down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 1,410,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent', window );">Non-refundable fee percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ctso_TermCLoanMember', window );">Term C Loan | First Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_PercentageOfSuccessFee', window );">Percentage of success fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Average selling price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_NumberOfDaysForStockPriceThreshold', window );">Number of days for stock price threshold set in success fee letter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ctso_TermCLoanMember', window );">Term C Loan | Second Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_PercentageOfSuccessFee', window );">Percentage of success fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Average selling price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_NumberOfDaysForStockPriceThreshold', window );">Number of days for stock price threshold set in success fee letter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ctso_TermCLoanMember', window );">Term C Loan | Third Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_PercentageOfSuccessFee', window );">Percentage of success fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Average selling price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_NumberOfDaysForStockPriceThreshold', window );">Number of days for stock price threshold set in success fee letter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ctso_NonRefundableClosingFeeMember', window );">Non refundable Closing Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=ctso_WesternAllianceBankMember', window );">Western Alliance Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument , Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=ctso_WesternAllianceBankMember', window );">Western Alliance Bank | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Equal monthly payments of principal with accrued and unpaid interest payable</a></td>
<td class="nump">$ 277,778<span></span>
</td>
<td class="nump">$ 208,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=ctso_WesternAllianceBankMember', window );">Western Alliance Bank | Closing Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=ctso_WesternAllianceBankMember', window );">Western Alliance Bank | New Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument , Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Rate of interest added to reference rate as per debt agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=ctso_WesternAllianceBankMember', window );">Western Alliance Bank | Term A Loan | First Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument , Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=ctso_WesternAllianceBankMember', window );">Western Alliance Bank | Term B Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=ctso_WesternAllianceBankMember', window );">Western Alliance Bank | Term B Loan | Second Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument , Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=ctso_WesternAllianceBankMember', window );">Western Alliance Bank | Term C Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Current borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_DebtInstrumentCapInterestRate', window );">Interest rate cap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=ctso_WesternAllianceBankMember', window );">Western Alliance Bank | Term C Loan | First Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Amount drawn down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=ctso_WesternAllianceBankMember', window );">Western Alliance Bank | 2018 Success Fee Letter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_PercentageOfSuccessFee', window );">Percentage of success fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.37%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Average selling price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_NumberOfDaysForStockPriceThreshold', window );">Number of days for stock price threshold set in success fee letter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=ctso_WesternAllianceBankMember', window );">Western Alliance Bank | 2018 Success Fee Letter | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_PercentageOfClosingPriceOnCommonStock', window );">Percentage of closing price on common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=ctso_WesternAllianceBankMember', window );">Western Alliance Bank | 2018 Success Fee Letter | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_PercentageOfClosingPriceOnCommonStock', window );">Percentage of closing price on common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_DebtInstrumentCapInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cap interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_DebtInstrumentCapInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-refundable fee to be paid upon termination or maturity of debt instrument, representing the percent of the principal amount of debt funded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_NumberOfDaysForStockPriceThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of days for stock price threshold set in success fee letter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_NumberOfDaysForStockPriceThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_PercentageOfClosingPriceOnCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of closing price on common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_PercentageOfClosingPriceOnCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_PercentageOfSuccessFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective success fee rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_PercentageOfSuccessFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ctso_TermCLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ctso_TermCLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=ctso_FirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=ctso_FirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=ctso_SecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=ctso_SecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=ctso_ThirdTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=ctso_ThirdTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ctso_NonRefundableClosingFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ctso_NonRefundableClosingFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=ctso_WesternAllianceBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=ctso_WesternAllianceBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ctso_ClosingFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ctso_ClosingFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ctso_NewTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ctso_NewTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ctso_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ctso_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ctso_TermBLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ctso_TermBLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ctso_TwoThousandAndEighteenSuccessFeeLetterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ctso_TwoThousandAndEighteenSuccessFeeLetterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566062304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LONG TERM DEBT (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt net of current maturities</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523565017632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LONG-TERM DEBT - Principal payments (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>LONG-TERM DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523559006432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>m&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>LEASES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease lability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,250,944<span></span>
</td>
<td class="nump">$ 13,821,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,603,901<span></span>
</td>
<td class="nump">13,423,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,914<span></span>
</td>
<td class="nump">256,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,935,000<span></span>
</td>
<td class="nump">$ 1,968,000<span></span>
</td>
<td class="nump">$ 937,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years 4 months 24 days<span></span>
</td>
<td class="text">14 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ctso_TwentiethAmendmentToLeaseMember', window );">Twentieth Amendment To lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>LEASES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Monthly payments of base rent and other costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_AdditionalOperatingLeasesRentExpenseNet', window );">Additional operating leases rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_OperatingLeaseBaseRentForRemainingSpace', window );">Operating lease base rent for remaining space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_MonthlyOperatingExpenses', window );">Monthly operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ctso_CytosorbentsMedicalIncMember', window );">CytoSorbents Medical, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>LEASES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_NumberOfTimesLeaseRenewalAvailable', window );">Number of times lease renewal options available | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_OperatingLeasesRentAbatementTerm', window );">Rent abatement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ctso_CytosorbentsEuropeGmbhMember', window );">CytoSorbents Europe GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>LEASES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Monthly payments of base rent and other costs</a></td>
<td class="nump">$ 7,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease lability</a></td>
<td class="nump">594,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">594,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of Land | m&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Other costs</a></td>
<td class="nump">$ 239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | CytoSorbents Medical, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>LEASES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_OperatingLeasesAnnualRentExpenseIncrementRate', window );">Annual rent expense increment rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_PercentageOfTotalBuildingSpaceOccupied', window );">Percentage of total building space occupied</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_OperatingLeasesBuildingImprovementAllowanceReceivable', window );">Allowance for building improvement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,455,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease lability</a></td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Incremental borrowing rate</a></td>
<td class="nump">9.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Letter of credit | CytoSorbents Medical, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>LEASES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Security amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,467,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Initial early term | CytoSorbents Medical, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>LEASES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Monthly payments of base rent and other costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Early term | CytoSorbents Medical, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>LEASES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Monthly payments of base rent and other costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Early term | CytoSorbents Medical, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>LEASES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Monthly payments of base rent and other costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 111,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>LEASES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Monthly payments of base rent and other costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_AdditionalOperatingLeasesRentExpenseNet', window );">Additional operating leases rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_AdditionalOperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_AdditionalOperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_MonthlyOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of monthly operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_MonthlyOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_NumberOfTimesLeaseRenewalAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of times lease renewal options available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_NumberOfTimesLeaseRenewalAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_OperatingLeaseBaseRentForRemainingSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease base rent for remaining space.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_OperatingLeaseBaseRentForRemainingSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_OperatingLeasesAnnualRentExpenseIncrementRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of annual increment in operating lease rent expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_OperatingLeasesAnnualRentExpenseIncrementRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_OperatingLeasesBuildingImprovementAllowanceReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of allowance for building improvement receivable from landlord.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_OperatingLeasesBuildingImprovementAllowanceReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_OperatingLeasesRentAbatementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rent abatement term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_OperatingLeasesRentAbatementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_PercentageOfTotalBuildingSpaceOccupied">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of total building space occupied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_PercentageOfTotalBuildingSpaceOccupied</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ctso_TwentiethAmendmentToLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ctso_TwentiethAmendmentToLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ctso_CytosorbentsMedicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ctso_CytosorbentsMedicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ctso_CytosorbentsEuropeGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ctso_CytosorbentsEuropeGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ctso_OperatingLeaseInitialEarlyTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ctso_OperatingLeaseInitialEarlyTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ctso_OperatingLeaseEarlyTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ctso_OperatingLeaseEarlyTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ctso_OperatingLeaseFirstYearOfRemainingLeaseTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ctso_OperatingLeaseFirstYearOfRemainingLeaseTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523567158192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Right-of- use asset and related lease liability (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">$ 12,603,901<span></span>
</td>
<td class="nump">$ 13,423,472<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">13,250,944<span></span>
</td>
<td class="nump">13,821,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current portion</a></td>
<td class="num">(108,939)<span></span>
</td>
<td class="num">(570,566)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability, net of current portion</a></td>
<td class="nump">$ 13,142,005<span></span>
</td>
<td class="nump">$ 13,250,943<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523564856416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Maturities of the lease liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,266,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">1,656,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">1,695,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">1,735,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">1,776,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive', window );">Thereafter</a></td>
<td class="nump">17,232,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">25,363,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Present value discount</a></td>
<td class="nump">12,112,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 13,250,944<span></span>
</td>
<td class="nump">$ 13,821,509<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due fifth and after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523567120560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Consolidated loss before income taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (21,155,203)<span></span>
</td>
<td class="num">$ (18,829,797)<span></span>
</td>
<td class="num">$ (5,682,628)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(12,749,965)<span></span>
</td>
<td class="num">(6,464,854)<span></span>
</td>
<td class="num">(3,281,634)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests', window );">Total</a></td>
<td class="num">$ (33,905,168)<span></span>
</td>
<td class="num">$ (25,294,651)<span></span>
</td>
<td class="num">$ (8,964,262)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523571038544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - The benefit from income taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">State Tax, including sale of New Jersey losses &amp; credits</a></td>
<td class="nump">$ 1,092,585<span></span>
</td>
<td class="nump">$ 736,003<span></span>
</td>
<td class="nump">$ 1,127,074<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit), Total</a></td>
<td class="nump">$ 1,092,585<span></span>
</td>
<td class="nump">$ 736,003<span></span>
</td>
<td class="nump">$ 1,127,074<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523564876384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - The principal components of the Company's deferred tax assets and liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">$ 31,570,846<span></span>
</td>
<td class="nump">$ 27,190,654<span></span>
</td>
<td class="nump">$ 22,301,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Stock options</a></td>
<td class="nump">500,975<span></span>
</td>
<td class="nump">1,203,272<span></span>
</td>
<td class="nump">305,982<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit carryforward</a></td>
<td class="nump">3,982,147<span></span>
</td>
<td class="nump">2,687,591<span></span>
</td>
<td class="nump">2,194,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and others</a></td>
<td class="nump">24,121<span></span>
</td>
<td class="nump">232,665<span></span>
</td>
<td class="nump">135,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">3,724,840<span></span>
</td>
<td class="nump">3,997,114<span></span>
</td>
<td class="nump">289,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards', window );">174(b) research and development</a></td>
<td class="nump">3,331,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">43,134,554<span></span>
</td>
<td class="nump">35,311,296<span></span>
</td>
<td class="nump">25,225,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(39,303,451)<span></span>
</td>
<td class="num">(31,242,130)<span></span>
</td>
<td class="num">(24,794,474)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">3,831,103<span></span>
</td>
<td class="nump">4,069,166<span></span>
</td>
<td class="nump">431,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(288,145)<span></span>
</td>
<td class="num">(183,941)<span></span>
</td>
<td class="num">$ (431,490)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_DeferredTaxLiabilitiesRightsOfUseAssets', window );">Right of Use Asset</a></td>
<td class="num">$ (3,542,958)<span></span>
</td>
<td class="num">$ (3,885,225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets, tax credit carryforwards, lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_DeferredTaxLiabilitiesRightsOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, ROU</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_DeferredTaxLiabilitiesRightsOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherTaxCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherTaxCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523558911248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Reconciliation of income tax (expense) benefit (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="nump">0.21%<span></span>
</td>
<td class="nump">0.21%<span></span>
</td>
<td class="nump">0.21%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="num">(0.028%)<span></span>
</td>
<td class="num">(0.02%)<span></span>
</td>
<td class="num">(0.095%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">0.034%<span></span>
</td>
<td class="nump">0.023%<span></span>
</td>
<td class="nump">0.033%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent', window );">Permanent items</a></td>
<td class="num">(0.015%)<span></span>
</td>
<td class="num">(0.065%)<span></span>
</td>
<td class="num">(0.02%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Rate change and true-up</a></td>
<td class="nump">0.006%<span></span>
</td>
<td class="nump">0.118%<span></span>
</td>
<td class="nump">0.17%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(0.228%)<span></span>
</td>
<td class="num">(0.255%)<span></span>
</td>
<td class="num">(0.216%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">R&amp;D credit</a></td>
<td class="nump">0.021%<span></span>
</td>
<td class="nump">0.017%<span></span>
</td>
<td class="nump">0.044%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Sale of state R&amp;D credit and NOL</a></td>
<td class="nump">0.032%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.032%<span></span>
</td>
<td class="nump">0.028%<span></span>
</td>
<td class="nump">0.126%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation permanent income tax rate percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523558936720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Additional information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_ProceedsFromSaleOfNetOperatingLossCarryforwards', window );">Proceeds from the sale of prior unused net operating loss carryovers</a></td>
<td class="nump">$ 1,093,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">47,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase, Amount</a></td>
<td class="nump">$ 8,061,321<span></span>
</td>
<td class="nump">$ 6,447,656<span></span>
</td>
<td class="nump">$ 1,936,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">operating loss carryforwards</a></td>
<td class="text">80% limitation on taxable income<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 87,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">$ 42,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_ProceedsFromSaleOfNetOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proceeds received from the sale of previously unused net operating loss carryforwards, allowed due to participation in the Technology Business Tax Certificate Transfer Program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_ProceedsFromSaleOfNetOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523559779408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Aug. 11, 2003</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationInterestAccrued', window );">Accrued tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 598,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_ExecutiveEmploymentAgreementsInitialTerm', window );">Initial term (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_EmploymentAgreementsAutomaticRenewalPeriod', window );">Automatic renewal period for employment agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_EmploymentAgreementsAutomaticRenewedPeriod', window );">Additional automatic renewed period for employment agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=ctso_PayrollTaxAuditMember', window );">Payroll Tax Audit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationInterestAccrued', window );">Accrued tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=ctso_AdditionalSocialSecurityAndVatTaxesMember', window );">Additional Social Security and VAT Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationInterestAccrued', window );">Accrued tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember', window );">Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Equity investment by an existing investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_RoyaltyPaymentRate', window );">Future royalty payment percentage on gross revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">849,000<span></span>
</td>
<td class="nump">1,193,000<span></span>
</td>
<td class="nump">$ 1,172,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ctso_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,416,000<span></span>
</td>
<td class="nump">$ 1,988,000<span></span>
</td>
<td class="nump">$ 1,954,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_LicensePeriod', window );">Term of license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_RoyaltyRateLowerLimit', window );">Royalty rate, lower limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_RoyaltyRateUpperLimit', window );">Royalty rate, upper limit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_EmploymentAgreementsAutomaticRenewalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Automatic renewal period for employment agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_EmploymentAgreementsAutomaticRenewalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_EmploymentAgreementsAutomaticRenewedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Automatic renewed period for employment agreements, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_EmploymentAgreementsAutomaticRenewedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_ExecutiveEmploymentAgreementsInitialTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the initial term of executive employment agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_ExecutiveEmploymentAgreementsInitialTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_LicensePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The duration of license period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_LicensePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_RoyaltyPaymentRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate of royalty payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_RoyaltyPaymentRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_RoyaltyRateLowerLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate of royalty rate lower limit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_RoyaltyRateLowerLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_RoyaltyRateUpperLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate of royalty rate upper limit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_RoyaltyRateUpperLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=ctso_PayrollTaxAuditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=ctso_PayrollTaxAuditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=ctso_AdditionalSocialSecurityAndVatTaxesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=ctso_AdditionalSocialSecurityAndVatTaxesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ctso_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ctso_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523558791808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Stock option activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning of the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,885,978<span></span>
</td>
<td class="nump">5,165,204<span></span>
</td>
<td class="nump">4,218,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">1,114,325<span></span>
</td>
<td class="nump">2,721,205<span></span>
</td>
<td class="nump">2,051,980<span></span>
</td>
<td class="nump">1,579,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,270,155)<span></span>
</td>
<td class="num">(138,037)<span></span>
</td>
<td class="num">(34,644)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(227,204)<span></span>
</td>
<td class="num">(21,756)<span></span>
</td>
<td class="num">(226,440)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(171,413)<span></span>
</td>
<td class="num">(371,007)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end of the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,109,824<span></span>
</td>
<td class="nump">6,885,978<span></span>
</td>
<td class="nump">5,165,204<span></span>
</td>
<td class="nump">4,218,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning of the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.09<span></span>
</td>
<td class="nump">$ 6.36<span></span>
</td>
<td class="nump">$ 6.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.99<span></span>
</td>
<td class="nump">8.78<span></span>
</td>
<td class="nump">6.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.65<span></span>
</td>
<td class="nump">6.73<span></span>
</td>
<td class="nump">7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.71<span></span>
</td>
<td class="nump">7.46<span></span>
</td>
<td class="nump">5.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.73<span></span>
</td>
<td class="nump">4.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end of the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.11<span></span>
</td>
<td class="nump">$ 7.09<span></span>
</td>
<td class="nump">$ 6.36<span></span>
</td>
<td class="nump">$ 6.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Life (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, beginning of the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">9 years 3 months 18 days<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm', window );">Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Outstanding, end of the year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 10 months 28 days<span></span>
</td>
<td class="text">7 years 1 month 24 days<span></span>
</td>
<td class="text">7 years 3 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards cancelled during the period, in PnYnMnDTnHnMnS format, for example, P1Y5M13D represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards exercised during the period, in PnYnMnDTnHnMnS format, for example, P1Y5M13D represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement by Share based Payment Award Options Outstanding Expired In Period Weighted Average Remaining Contractual Term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement by Share based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523571135408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Fair value of stock option (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Grant Date Exercise Price Range</a></td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom5.00To10.58Member', window );">Exercise price ranging from 5.00 to 10.58</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life of the Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom5.00To10.58Member', window );">Exercise price ranging from 5.00 to 10.58 | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Grant Date Exercise Price Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Current Price of the Underlying Stock and its Expected Volatility Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk Free Interest Rate Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.96%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom5.00To10.58Member', window );">Exercise price ranging from 5.00 to 10.58 | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Grant Date Exercise Price Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Current Price of the Underlying Stock and its Expected Volatility Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk Free Interest Rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.28%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom4.46To11.39Member', window );">Exercise price ranging from 4.46 to 11.39</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life of the Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk Free Interest Rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.47%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk Free Interest Rate Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.39%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom4.46To11.39Member', window );">Exercise price ranging from 4.46 to 11.39 | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Grant Date Exercise Price Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Current Price of the Underlying Stock and its Expected Volatility Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom4.46To11.39Member', window );">Exercise price ranging from 4.46 to 11.39 | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Grant Date Exercise Price Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Current Price of the Underlying Stock and its Expected Volatility Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom2.98To3.91Member', window );">Exercise price ranging from 1.11 to 3.91</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life of the Stock Option</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividends</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk Free Interest Rate, minimum</a></td>
<td class="nump">1.52%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk Free Interest Rate Range</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom2.98To3.91Member', window );">Exercise price ranging from 1.11 to 3.91 | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Grant Date Exercise Price Range</a></td>
<td class="nump">$ 3.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Current Price of the Underlying Stock and its Expected Volatility Range</a></td>
<td class="nump">67.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom2.98To3.91Member', window );">Exercise price ranging from 1.11 to 3.91 | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Grant Date Exercise Price Range</a></td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Current Price of the Underlying Stock and its Expected Volatility Range</a></td>
<td class="nump">59.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_StockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_StockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom5.00To10.58Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom5.00To10.58Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom4.46To11.39Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom4.46To11.39Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom2.98To3.91Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom2.98To3.91Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566267024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Intrinsic value (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 3,883,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Options Exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Number Exercisable at December 31, 2022 | shares</a></td>
<td class="nump">4,623,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 6.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 1,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ctso_ExercisePriceRangeOneMember', window );">Exercise Price Range One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Range of Exercise Price, Lower Range Limit</a></td>
<td class="nump">$ 1.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Range of Exercise Price, Upper Range Limit</a></td>
<td class="nump">$ 13.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number Outstanding at December 31, 2022 | shares</a></td>
<td class="nump">8,109,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Life (Years)</a></td>
<td class="text">6 years 10 months 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 7,280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ctso_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ctso_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523559947728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Non-vested options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested, January 1, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,994,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">1,114,325<span></span>
</td>
<td class="nump">2,721,205<span></span>
</td>
<td class="nump">2,051,980<span></span>
</td>
<td class="nump">1,579,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,270,155)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(959,157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested, December 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,486,739<span></span>
</td>
<td class="nump">2,994,846<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested, January 1, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested, December 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="nump">$ 4.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523559934832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Restricted stock unit (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Restricted Stock Units, Intrinsic Value Beginning Balance</a></td>
<td class="nump">$ 11,359,928<span></span>
</td>
<td class="nump">$ 19,504,184<span></span>
</td>
<td class="nump">$ 8,033,988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Restricted Stock Units, Intrinsic Value Ending Balance</a></td>
<td class="nump">$ 4,480,275<span></span>
</td>
<td class="nump">$ 11,359,928<span></span>
</td>
<td class="nump">$ 19,504,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Restricted Stock Units, Beginning Balance</a></td>
<td class="nump">2,711,200<span></span>
</td>
<td class="nump">2,447,200<span></span>
</td>
<td class="nump">2,086,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Restricted Stock Units, Granted</a></td>
<td class="nump">498,050<span></span>
</td>
<td class="nump">396,000<span></span>
</td>
<td class="nump">385,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Restricted Stock Units, Forfeited</a></td>
<td class="num">(318,750)<span></span>
</td>
<td class="num">(132,000)<span></span>
</td>
<td class="num">(25,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Restricted Stock Units, Ending Balance</a></td>
<td class="nump">2,890,500<span></span>
</td>
<td class="nump">2,711,200<span></span>
</td>
<td class="nump">2,447,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="nump">312,092<span></span>
</td>
<td class="nump">304,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 4.42<span></span>
</td>
<td class="nump">$ 8.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock | Board of directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Restricted Stock Units, Beginning Balance</a></td>
<td class="nump">277,200<span></span>
</td>
<td class="nump">277,200<span></span>
</td>
<td class="nump">277,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Restricted Stock Units, Granted</a></td>
<td class="nump">69,300<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Restricted Stock Units, Forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Restricted Stock Units, Ending Balance</a></td>
<td class="nump">346,500<span></span>
</td>
<td class="nump">277,200<span></span>
</td>
<td class="nump">277,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock | Executive Management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Restricted Stock Units, Beginning Balance</a></td>
<td class="nump">724,500<span></span>
</td>
<td class="nump">724,500<span></span>
</td>
<td class="nump">604,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Restricted Stock Units, Granted</a></td>
<td class="nump">55,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Restricted Stock Units, Forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Restricted Stock Units, Ending Balance</a></td>
<td class="nump">779,500<span></span>
</td>
<td class="nump">724,500<span></span>
</td>
<td class="nump">724,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock | Other Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Restricted Stock Units, Beginning Balance</a></td>
<td class="nump">1,709,500<span></span>
</td>
<td class="nump">1,445,500<span></span>
</td>
<td class="nump">1,205,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Restricted Stock Units, Granted</a></td>
<td class="nump">373,750<span></span>
</td>
<td class="nump">396,000<span></span>
</td>
<td class="nump">265,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Restricted Stock Units, Forfeited</a></td>
<td class="num">(318,750)<span></span>
</td>
<td class="num">(132,000)<span></span>
</td>
<td class="num">(25,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Restricted Stock Units, Ending Balance</a></td>
<td class="nump">1,764,500<span></span>
</td>
<td class="nump">1,709,500<span></span>
</td>
<td class="nump">1,445,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_StockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_StockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566098880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Restricted stock unit activity (Details) - Restricted stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, January 1, 2022 | shares</a></td>
<td class="nump">304,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">288,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited | shares</a></td>
<td class="num">(236,370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested | shares</a></td>
<td class="num">(45,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested, December 31, 2022 | shares</a></td>
<td class="nump">312,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested, January 1, 2022 | $ / shares</a></td>
<td class="nump">$ 8.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted | $ / shares</a></td>
<td class="nump">1.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited | $ / shares</a></td>
<td class="nump">8.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested | $ / shares</a></td>
<td class="nump">5.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested, December 31, 2022 | $ / shares</a></td>
<td class="nump">$ 4.42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523549752416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Additional information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 10, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Apr. 01, 2022</div></th>
<th class="th">
<div>Dec. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 12, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 12, 2021 </div>
<div>USN ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Jul. 22, 2019</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 14, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2019 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Number of preferred stock authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_AggregateRegisteredAmountForOfferings', window );">Aggregate registered amount for offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Expenses incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of option granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,114,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,721,205<span></span>
</td>
<td class="nump">2,051,980<span></span>
</td>
<td class="nump">1,579,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,883,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Grant date fair value of these unvested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,883,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,070,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage', window );">Percentage of milestone activity met by the company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.00%<span></span>
</td>
<td class="nump">88.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_NumberOfLongTermIncentivePlans', window );">Number of long-term incentive plans | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,424,000<span></span>
</td>
<td class="nump">4,021,000<span></span>
</td>
<td class="nump">$ 3,514,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Grant Date Exercise Price Range | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation cost related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Amortized period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">43 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(959,157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 380,091<span></span>
</td>
<td class="nump">$ 928,417<span></span>
</td>
<td class="nump">$ 657,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,109,824<span></span>
</td>
<td class="nump">6,885,978<span></span>
</td>
<td class="nump">5,165,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,218,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares to be purchased | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of option granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,323,400<span></span>
</td>
<td class="nump">1,323,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue', window );">Grant date fair value of unvested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,042,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 273,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock issued during period, shares, restricted stock award, gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Stock issued during period, value, restricted stock sward, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 713,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (16,000)<span></span>
</td>
<td class="nump">178,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock | Second 45,000 restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock issued during period, shares, restricted stock award, gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock | Second 46,750 restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock issued during period, shares, restricted stock award, gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock | Second anniversary of the date of the grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock | Third anniversary of the date of the grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock | Fourth anniversary of the date of the grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee stock options | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Grant date fair value of these unvested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ctso_EmployeeOneMember', window );">Employee one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,381,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of options granted | shares</a></td>
<td class="nump">1,163,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ctso_EmployeeTwoMember', window );">Employee two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of option granted | shares</a></td>
<td class="nump">772,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">917,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Grant date fair value of these unvested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">917,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of option granted | shares</a></td>
<td class="nump">113,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ctso_SeniorManagerOneMember', window );">Senior manager one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of option granted | shares</a></td>
<td class="nump">473,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">562,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Grant date fair value of these unvested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">562,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ctso_SeniorManagerTwoMember', window );">Senior manager two | Employee stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of option granted | shares</a></td>
<td class="nump">1,365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,620,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Grant date fair value of these unvested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,620,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ctso_StockOptionPlanOneMember', window );">Stock option plan one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ctso_TwoThousandFourteenStockOptionPlanMember', window );">2014 Stock Option Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,713,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ctso_July222019PerformanceBasedAwardMember', window );">July 22, 2019 performance-based award | Restricted stock | On the date of the grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ctso_February282020PerformanceBasedAwardMember', window );">February 28 2020 performance based award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 951,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ctso_February282020PerformanceBasedAwardMember', window );">February 28 2020 performance based award | Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock issued during period, shares, restricted stock award, gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Stock issued during period, value, restricted stock sward, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,014,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,000)<span></span>
</td>
<td class="nump">528,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ctso_February282020PerformanceBasedAwardMember', window );">February 28 2020 performance based award | Restricted stock | First anniversary of the date of the grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ctso_February282020PerformanceBasedAwardMember', window );">February 28 2020 performance based award | Restricted stock | Second anniversary of the date of the grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ctso_April122021PerformanceBasedAwardMember', window );">April 12, 2021 performance based award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ctso_April122021PerformanceBasedAwardMember', window );">April 12, 2021 performance based award | Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock issued during period, shares, restricted stock award, gross | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235,765<span></span>
</td>
<td class="nump">235,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Stock issued during period, value, restricted stock sward, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,000<span></span>
</td>
<td class="nump">1,207,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ctso_April122021PerformanceBasedAwardMember', window );">April 12, 2021 performance based award | Restricted stock | On the date of the grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ctso_April122021PerformanceBasedAwardMember', window );">April 12, 2021 performance based award | Restricted stock | First anniversary of the date of the grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ctso_April122021PerformanceBasedAwardMember', window );">April 12, 2021 performance based award | Restricted stock | Second anniversary of the date of the grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ctso_August102022PerformanceBasedAwardMember', window );">August 10, 2022 performance based award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockOptionPlanExpense', window );">Stock option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ctso_August102022PerformanceBasedAwardMember', window );">August 10, 2022 performance based award | Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock issued during period, shares, restricted stock award, gross | shares</a></td>
<td class="nump">288,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Stock issued during period, value, restricted stock sward, gross</a></td>
<td class="nump">$ 563,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ctso_August102022PerformanceBasedAwardMember', window );">August 10, 2022 performance based award | Restricted stock | On the date of the grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ctso_August102022PerformanceBasedAwardMember', window );">August 10, 2022 performance based award | Restricted stock | First anniversary of the date of the grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ctso_JefferiesLlcAndB.RileyFbrIncMember', window );">Jefferies LLC and B. Riley FBR, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_CommonStockValueAuthorized', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_CommissionRateAsPercentageOfAggregateGrossProceeds', window );">Commission rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom5.00To10.58Member', window );">Exercise price ranging from 5.00 to 10.58</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life of the Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom5.00To10.58Member', window );">Exercise price ranging from 5.00 to 10.58 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Grant Date Exercise Price Range | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Current Price of the Underlying Stock and its Expected Volatility Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk Free Interest Rate Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.96%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom5.00To10.58Member', window );">Exercise price ranging from 5.00 to 10.58 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Grant Date Exercise Price Range | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Current Price of the Underlying Stock and its Expected Volatility Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk Free Interest Rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.28%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom2.98To3.91Member', window );">Exercise price ranging from 1.11 to 3.91</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life of the Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk Free Interest Rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.52%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk Free Interest Rate Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom2.98To3.91Member', window );">Exercise price ranging from 1.11 to 3.91 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Grant Date Exercise Price Range | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Current Price of the Underlying Stock and its Expected Volatility Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom2.98To3.91Member', window );">Exercise price ranging from 1.11 to 3.91 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_StockholdersEquityLineItems', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Grant Date Exercise Price Range | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Current Price of the Underlying Stock and its Expected Volatility Range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_AggregateRegisteredAmountForOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>On July 29, 2015, the Company's registration statement on Form S-3, as filed with the SEC on July 23, 2015, was declared effective using a "shelf" registration process. Under this shelf registration statement, the Company may issue, in one or more offerings, any combination of common stock, preferred stock, senior or subordinated debt securities, warrants, or units, up to a total dollar amount of $100 million.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_AggregateRegisteredAmountForOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_CommissionRateAsPercentageOfAggregateGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The commission rate as a percentage of the aggregate gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_CommissionRateAsPercentageOfAggregateGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_CommonStockValueAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Value Authorized For Shares Authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_CommonStockValueAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_NumberOfLongTermIncentivePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of long-term incentive plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_NumberOfLongTermIncentivePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the grant date fair value of unvested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Milestone activity met by the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_StockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_StockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionPlanExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionPlanExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ctso_SecondFortyFiveThousandRestrictedAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ctso_SecondFortyFiveThousandRestrictedAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ctso_SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ctso_SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=ctso_ShareBasedCompensationAwardTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=ctso_ShareBasedCompensationAwardTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=ctso_ShareBasedCompensationAwardTrancheFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=ctso_ShareBasedCompensationAwardTrancheFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ctso_EmployeeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ctso_EmployeeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ctso_EmployeeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ctso_EmployeeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ctso_SeniorManagerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ctso_SeniorManagerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ctso_SeniorManagerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ctso_SeniorManagerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ctso_StockOptionPlanOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ctso_StockOptionPlanOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ctso_TwoThousandFourteenStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ctso_TwoThousandFourteenStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ctso_July222019PerformanceBasedAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ctso_July222019PerformanceBasedAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ctso_February282020PerformanceBasedAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ctso_February282020PerformanceBasedAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ctso_April122021PerformanceBasedAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ctso_April122021PerformanceBasedAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ctso_August102022PerformanceBasedAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ctso_August102022PerformanceBasedAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ctso_JefferiesLlcAndB.RileyFbrIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ctso_JefferiesLlcAndB.RileyFbrIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom5.00To10.58Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom5.00To10.58Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom2.98To3.91Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ctso_ExercisePriceRangingFrom2.98To3.91Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523575696736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Warrants (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares to be purchased</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566723232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ctso_StockOptionsAndWarrantsMember', window );">Stock options and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">11,312,000<span></span>
</td>
<td class="nump">9,902,000<span></span>
</td>
<td class="nump">7,786,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ctso_StockOptionsAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ctso_StockOptionsAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523557106480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RETIREMENT PLAN (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>RETIREMENT PLAN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ctso_DefinedContributionEligibilityTerm', window );">Term of employment required</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Compensation subject to IRC limitations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Matching contribution, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Compensation for participant contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Matching contributions, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 442,000<span></span>
</td>
<td class="nump">$ 355,000<span></span>
</td>
<td class="nump">$ 59,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ctso_ParticipantsContributionUpto3PercentMember', window );">Participants contribution up to 3 percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>RETIREMENT PLAN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Matching contribution, Percent</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Compensation for participant contributions</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ctso_ParticipantsContributionOver3AndMaximum5Member', window );">Participants contribution over 3% and maximum 5%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>RETIREMENT PLAN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Matching contribution, Percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Participants contribution over 3% and maximum 5%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>RETIREMENT PLAN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Compensation for participant contributions</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Participants contribution over 3% and maximum 5%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>RETIREMENT PLAN</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Compensation for participant contributions</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctso_DefinedContributionEligibilityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of employment required to be eligible to participate in defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctso_DefinedContributionEligibilityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctso_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ctso_ParticipantsContributionUpto3PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ctso_ParticipantsContributionUpto3PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ctso_ParticipantsContributionOver3AndMaximum5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ctso_ParticipantsContributionOver3AndMaximum5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523565051712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>QUARTERLY FINANCIAL RESULTS (UNAUDITED) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="12">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>QUARTERLY FINANCIAL RESULTS (UNAUDITED)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 9,390,474<span></span>
</td>
<td class="nump">$ 8,111,353<span></span>
</td>
<td class="nump">$ 8,495,558<span></span>
</td>
<td class="nump">$ 8,691,424<span></span>
</td>
<td class="nump">$ 10,782,195<span></span>
</td>
<td class="nump">$ 9,760,416<span></span>
</td>
<td class="nump">$ 12,024,069<span></span>
</td>
<td class="nump">$ 10,598,847<span></span>
</td>
<td class="nump">$ 11,955,776<span></span>
</td>
<td class="nump">$ 10,546,612<span></span>
</td>
<td class="nump">$ 9,794,903<span></span>
</td>
<td class="nump">$ 8,707,310<span></span>
</td>
<td class="nump">$ 34,688,809<span></span>
</td>
<td class="nump">$ 43,165,527<span></span>
</td>
<td class="nump">$ 41,004,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">5,757,036<span></span>
</td>
<td class="nump">3,617,377<span></span>
</td>
<td class="nump">4,944,856<span></span>
</td>
<td class="nump">6,413,788<span></span>
</td>
<td class="nump">7,659,452<span></span>
</td>
<td class="nump">7,297,470<span></span>
</td>
<td class="nump">9,313,852<span></span>
</td>
<td class="nump">7,847,403<span></span>
</td>
<td class="nump">9,428,358<span></span>
</td>
<td class="nump">7,656,230<span></span>
</td>
<td class="nump">6,545,136<span></span>
</td>
<td class="nump">6,322,468<span></span>
</td>
<td class="nump">20,733,057<span></span>
</td>
<td class="nump">32,118,177<span></span>
</td>
<td class="nump">29,952,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(6,356,356)<span></span>
</td>
<td class="num">(9,017,338)<span></span>
</td>
<td class="num">(8,357,050)<span></span>
</td>
<td class="num">(7,791,135)<span></span>
</td>
<td class="num">(9,561,821)<span></span>
</td>
<td class="num">(5,406,000)<span></span>
</td>
<td class="num">(4,924,733)<span></span>
</td>
<td class="num">(2,852,191)<span></span>
</td>
<td class="num">(2,634,264)<span></span>
</td>
<td class="num">(1,959,652)<span></span>
</td>
<td class="num">(3,297,667)<span></span>
</td>
<td class="num">(2,478,754)<span></span>
</td>
<td class="num">(31,521,879)<span></span>
</td>
<td class="num">(22,744,745)<span></span>
</td>
<td class="num">(10,370,334)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (766,128)<span></span>
</td>
<td class="num">$ (12,200,837)<span></span>
</td>
<td class="num">$ (10,879,222)<span></span>
</td>
<td class="num">$ (8,966,398)<span></span>
</td>
<td class="num">$ (9,307,012)<span></span>
</td>
<td class="num">$ (6,406,285)<span></span>
</td>
<td class="num">$ (4,677,530)<span></span>
</td>
<td class="num">$ (4,167,821)<span></span>
</td>
<td class="num">$ (677,724)<span></span>
</td>
<td class="num">$ (839,729)<span></span>
</td>
<td class="num">$ (2,866,956)<span></span>
</td>
<td class="num">$ (3,452,779)<span></span>
</td>
<td class="num">$ (32,812,583)<span></span>
</td>
<td class="num">$ (24,558,648)<span></span>
</td>
<td class="num">$ (7,837,188)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share</a></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.75)<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per common share</a></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.75)<span></span>
</td>
<td class="num">$ (0.57)<span></span>
</td>
<td class="num">$ (0.20)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140523566599360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>REVENUE - Contract with customer asset And liability (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>REVENUE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities, which are included in expenses and other current liabilities</a></td>
<td class="nump">$ 1,516,772<span></span>
</td>
<td class="nump">$ 1,947,353<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>ctso-20221231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:ctso="http://www.cytosorbents.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ctso-20221231.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xyJVnNq5GE65HtHRW1yDeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_ctso_SeniorManagerOneMember_EkCzFw0rWU-KctkMbIExAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ctso:SeniorManagerOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_W4GwiG3lh02utgH-gE4rTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:February282020PerformanceBasedAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_9TJLsXlp6keoHyL-cuizXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:August102022PerformanceBasedAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_f4vXsZkMOkGxq_tl33elVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:April122021PerformanceBasedAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_aC79nG-enkiG4Z0Gnm5v8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_nkcE0lA3-kOw0oD7CH9c4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:February282020PerformanceBasedAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_1LwXDf6m7E-dzAi4ZxI8Aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:August102022PerformanceBasedAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_SehbEFp_LU-TNiW5F5VEKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:April122021PerformanceBasedAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_psiceOjXQ0i-ao__lRK5JQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:February282020PerformanceBasedAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_HkC9ceLZZUStae-rY3krow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:August102022PerformanceBasedAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_XLL9youqcUedryG1mnniUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:April122021PerformanceBasedAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_10_2022_To_8_10_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_iCD0wE1zAkmoNYobFgX5Pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:August102022PerformanceBasedAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-10</startDate>
            <endDate>2022-08-10</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_ctso_SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Nw7O66qjS0-HrTuFoxU-Ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ctso:SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_ctso_SecondFortyFiveThousandRestrictedAwardMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OfWgsCZPdEyRfpWz5t_BNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ctso:SecondFortyFiveThousandRestrictedAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_12_2021_To_4_12_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_SBFV77lhyUaB_1ayr35kYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:April122021PerformanceBasedAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-12</startDate>
            <endDate>2021-04-12</endDate>
        </period>
    </context>
    <context id="Duration_2_28_2020_To_2_28_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_5NQR2_FtYk-1wNb9Sb1pdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:February282020PerformanceBasedAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-28</startDate>
            <endDate>2020-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2mGFz-g8vkCyKxzLGK8rRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AUSvWy58u0K_IquBEJ7-vQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oumECbNlIE2GMtb6QWOHIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yxInglK_2kaHDsFiaiSgNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_v2r2g5cGPUySlMPbJ6gPWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2fpskYPtCkGXfgvSbLwICg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0_qpfUCFWUSQSBVH2kIqyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pIxGvrDdvkqEyu4JVd03fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5CrlobMDMUOFaODMa0mJMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_NadUN92cUUGeapWWnvOPNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dtYzBB8BaU-3fEcIk5-5qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cDcxImQXYUeh0lvoITev4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_KPMkIaBOA06ekPfEU2CpFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4ADrrvzo1k2uJb6rtAoZXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CCqJgm4tjU2Hhj1W3f863A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PV_DrHkTQkGQmIt0QmW81A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_93L6HhBk5E-Lnf3ZqLpS2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TwoThousandAndEighteenSuccessFeeLetterMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_fb08ojpZuEqeebxD3osGJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TwoThousandAndEighteenSuccessFeeLetterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ctso_ExercisePriceRangeOneMember_L6XbyOqHWUaHFIu4xBQwEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ctso:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_10_2022_To_8_10_2022_srt_TitleOfIndividualAxis_ctso_EmployeeOneMember_eZMz_a7KzUiEra_Pmj1NYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ctso:EmployeeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-10</startDate>
            <endDate>2022-08-10</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_9CuY3bMLoUmlRHItGFexPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_LDp3_ulEB0afY5sDrxWyfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_ctso_SeniorManagerTwoMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QTMNRUs4tkaHSWZeL2Z8fQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ctso:SeniorManagerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_ctso_SeniorManagerOneMember_cYnbKOhq3E6GCga5UwXuXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ctso:SeniorManagerOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ctso_ExercisePriceRangeOneMember_HTSesPowQUOWzfbwBPWjzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ctso:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_ctso_EmployeeTwoMember_hcg34RZmk0K7-aUhwgreaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ctso:EmployeeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_8_10_2022_To_8_10_2022_srt_TitleOfIndividualAxis_ctso_SeniorManagerTwoMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1_iS7zVj_kqq7qBilIFwhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ctso:SeniorManagerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-10</startDate>
            <endDate>2022-08-10</endDate>
        </period>
    </context>
    <context id="Duration_8_10_2022_To_8_10_2022_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_kivuCiqiL0uHjYHAlIe0SA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-10</startDate>
            <endDate>2022-08-10</endDate>
        </period>
    </context>
    <context id="Duration_8_10_2022_To_8_10_2022_srt_TitleOfIndividualAxis_ctso_SeniorManagerOneMember_aJeyvmrvQEamT-sApwGPVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ctso:SeniorManagerOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-10</startDate>
            <endDate>2022-08-10</endDate>
        </period>
    </context>
    <context id="Duration_8_10_2022_To_8_10_2022_srt_TitleOfIndividualAxis_ctso_EmployeeTwoMember_n4em8eT-K0OI3zntmzwTHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ctso:EmployeeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-10</startDate>
            <endDate>2022-08-10</endDate>
        </period>
    </context>
    <context id="Duration_2_28_2020_To_2_28_2020_mNnHVlwuKUOZDnoPp6ppuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <startDate>2020-02-28</startDate>
            <endDate>2020-02-28</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Nt-mKk9tE0qaMLa__XLlLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_-5TVQVqcmkOUL9z5tTJN-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2spOJmTsWEmdS8OMyOGHWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_04OJEbPdOkKtPazUq59qpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JpCj6cd7kkiLmP4iVXwtlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_trOIsNzUZk6mTrRFdkZXPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_psdWAFNFkke9A5usGouslg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Jxgd6wgc-UifuA3mjZhm-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_CN57L8kRSkSlPVn_ICCXgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YALsQfAeSkWG8axpq3Cw1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_yN5CzvOjU0uH_kVOetojHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_K10SpTMdF0G5KR4K3WxOyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_FP86LptQuUeU7YsuzIQCcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_tP00N7KMo06ixWdu6bREiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_6fnzkcGGB0ChZUoAaGWn2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Jq6o95e4y0O88aEPmR333A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_DdpipDIQPE6CFjGjSAk4pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_vk8cRgr4tEGiUUmMORIpUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q_I0IFjrfEKL74vm4tWeYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_-zjLmD1sFUWIlQznMjsRvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_L5xd_BU2AUihTjDpJG0EAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_HkkTwSE4WEOHm13LfqHxoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_tCzPxpUUDkurigM_UymlEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Qq1T1vf_pkWNzHvrbos3EA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lKSpWReKk0eWMdrErwptxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_SozA6YZi2kKt1YD5fTj12g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom2.98To3.91Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_rxvDjksKlEOKtNVfXCde1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom2.98To3.91Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_wMhxRA4mxUGyr5aQSg53cQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom4.46To11.39Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_eGE4Htw5vUiAfnNKM05dQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom4.46To11.39Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_uD4JXkNMnUCEqqr147HBXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom5.00To10.58Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_a0ICslhLlEaiPjkyJ39i8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom5.00To10.58Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_A3_FWcLzlUqUUdWwNDHlOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom2.98To3.91Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_4nmfCjwDv0eiv9Xvjheotg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom4.46To11.39Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_Mkkar0ZT7EGL5951qJggtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom5.00To10.58Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_ntPA1TgJd0OfX_mWQ4DWuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom2.98To3.91Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_cXJTOYaNgUKPUItB-_WwrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom2.98To3.91Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_jZM8bjchokCOiKcRmPF3Ug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom4.46To11.39Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_8gw5_ggnZkerQU2oAT6--g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom4.46To11.39Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_DYCHwOrJcUSzRA20VoqbmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom5.00To10.58Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_9h926km2lEC7N26veE3DSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ctso:ExercisePriceRangingFrom5.00To10.58Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_S71qz6TZI0CfuhmZ6yul1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_9vRyYMxhI0WaNHqaWqGMHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_8_10_2022_To_8_10_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_WpLhK-DurECWLOlefRpvAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:August102022PerformanceBasedAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-10</startDate>
            <endDate>2022-08-10</endDate>
        </period>
    </context>
    <context id="Duration_8_10_2022_To_8_10_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_hiVRtHV7O0qUATFHrPDRvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:August102022PerformanceBasedAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-10</startDate>
            <endDate>2022-08-10</endDate>
        </period>
    </context>
    <context id="Duration_8_10_2022_To_8_10_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_VaRbgm5QaE6YvFr9Fe1yBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:April122021PerformanceBasedAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-10</startDate>
            <endDate>2022-08-10</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_csIBECZEpEyijv9iV3T9sQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_ctso_ShareBasedCompensationAwardTrancheFourMember_8iSlUywhskW943wT9Tsmag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ctso:ShareBasedCompensationAwardTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_ctso_ShareBasedCompensationAwardTrancheFiveMember_FzLPW6Bz_0Ck1LOSUNIRiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ctso:ShareBasedCompensationAwardTrancheFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_12_2021_To_4_12_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1MKAMb2CmEmA_P42dMcHxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:April122021PerformanceBasedAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-12</startDate>
            <endDate>2021-04-12</endDate>
        </period>
    </context>
    <context id="Duration_4_12_2021_To_4_12_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_qyOWI6GyLE-X4I8r0-tdDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:April122021PerformanceBasedAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-12</startDate>
            <endDate>2021-04-12</endDate>
        </period>
    </context>
    <context id="Duration_4_12_2021_To_4_12_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_fFXJv_RDXUGqaL5uxC9OHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:April122021PerformanceBasedAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-12</startDate>
            <endDate>2021-04-12</endDate>
        </period>
    </context>
    <context id="Duration_2_28_2020_To_2_28_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_MBhOBM-5iEqeLJwUm4lpZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:February282020PerformanceBasedAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-28</startDate>
            <endDate>2020-02-28</endDate>
        </period>
    </context>
    <context id="Duration_2_28_2020_To_2_28_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_odV670fJEUWMoiqxIvk3sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:February282020PerformanceBasedAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-28</startDate>
            <endDate>2020-02-28</endDate>
        </period>
    </context>
    <context id="Duration_7_22_2019_To_7_22_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_July222019PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_i5Y6ctTfQkOWKcDW4oDCbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:July222019PerformanceBasedAwardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-22</startDate>
            <endDate>2019-07-22</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_4_30_2021_us-gaap_LeaseContractualTermAxis_ctso_TwentiethAmendmentToLeaseMember_wrqHEmK560ePWOyCLlAXAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ctso:TwentiethAmendmentToLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_LeaseContractualTermAxis_ctso_TwentiethAmendmentToLeaseMember_jYak7TFeK0qURMnjm2T8DA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ctso:TwentiethAmendmentToLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_PD6J30gR5EKT9_6EoKYJeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_RoyaltyAgreementsMember_BXoz6wUE6keu3xUP3R0XpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_RoyaltyAgreementsMember_rdfbeFkWfkyrD5IQ3VfUwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_LicenseAgreementMember_S4h6KrieY0yFrU840BqKzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ctso:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_RoyaltyAgreementsMember_CA354vfky0OFd_1E5K6eQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_LicenseAgreementMember_U7A4z9C5Qk6CY4PDRbXTqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ctso:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_nqaL2-pOqECJbRrVf3pvdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ctso:AllOtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_OsNNOJGgGESiK9DlqyfB8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_dfAHrsFp2E6oinjJ00Mtqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_hvHgr5Vvo06FhAv5d7bNKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_GB3izD4hs0eaNYDtQMtZdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ctso:AllOtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_sb5j1GuT4Eys3LqScvVX2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_NZxEE0JdaUaTuS77svmYtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_vmt8r9ikk0aev-F4z3pADg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_gmpCbnM0wEWJOVVOWqPBQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ctso:AllOtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_tOnDtJIL0UqvBIiQr68NeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_ZscEfHJXA0ChpTkNTqDj8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_WXkclWPOXk-aO6LslEVKtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_ZhVhCO9-WUWruNBvh_NrbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ctso:AllOtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_eeMsQ5mBMEaBmXTojZOwqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_3PyNg5XDT0qvzYh6YJ8lww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_73_wiDAntkqkT8Vf6yVyrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_4xdvMPyNJE2TidM1dnfXSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_xMUd5SWGqEmdLXxwWDooqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_qMcmuIE2xU-kOZeBMfsP5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_H13OncAn9U2imjaSPSyd5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_HBdMLlMQGE-9IpPghuUK2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_T8rLz83ayUi_sdvVUUukQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_ctso_OtherSalesMember_IHmx8Gx6dUC4YavDmDyL_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctso:OtherSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_Gir4cGdvtkGYyi8G96HfRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DirectMember_XS_Uh4IEcEeCPxJehbgjrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_ctso_CytoSorbSalesMember_kZjj3Qm1nkaD0BliSjoSlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctso:CytoSorbSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_dHpKJ66LdEuPGffrdOOnGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ctso:AllOtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_-zkrbwSc80qnJ_4yNjEqoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_3K7sqcTX4UWhfYo-xNN6bA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_JVeLOYDILkWMpirfcvOUkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_NeBUdimYUkWFDNDnPD3CnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ctso:AllOtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_ZANpAs_ejE2twTb1k2pdig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_RJXSLiJzd02uK0ssKMKg7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_sQvISkQQ3UKBDgXPufGqUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_tKPWLILXVE2h95fQt2uIvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ctso:AllOtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_I2ChB-9AP0S0q8UrImX6ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_ZlfzimG38UyKkvdPjtVHWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_b8AI_7G0G0umDEyvgW9dOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_nymBapNFM0u97cDmYtNcKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ctso:AllOtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_4RHTqNRNFESnd9qrz5_cCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_l7Cg7koCpUySLneSLrO0Zg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_BjelKy9GsEOR7gq0nA95tQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_YIGCSpdP6UqYoJUTKv7p7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_EtLLdZY6mEyFOKLjp4Uv1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_O-d7ZVaWAUytjn4uAGiAxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_KSZxi4zg7keBU37J2Y0-8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_FklCHZPwzUeeNeeNvzpgvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_2s9vyN8oyESnIA9BeyMmsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_ctso_OtherSalesMember_3KZRlFeRi0y0ti0yyXPoAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctso:OtherSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_Ahb2Ft23iEuFgHVNXLFShQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DirectMember_agZO3qBuDE-w-pXujZLoyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_ctso_CytoSorbSalesMember_F2WUYm6g20mo5wFD0_w32Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctso:CytoSorbSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_mH41MxVhmkGct0J07XEN1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ctso:AllOtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_ix4FCkAs6kWXANuYn55BGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_REqz0wSSUEO2inn9gwE8Rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_gfv9AQKB10GMbME_bmBdWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_MriDhsC_C0qBVC8cxkY0Bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ctso:AllOtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_d8LbBpFImkegbFV6bTyQPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_yC2fiJcIZ028vV2ALBTiiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_2dyyoRP_xEmVYml_OXHP7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_7NOqCHyL_kKAzrJSLXbLAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ctso:AllOtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_Tv8sVQFDs0OjBBDw_jDtKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_ZzNQcZHrw0GnVCIADz0a6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_KOQGfIkSGE2fpCi1ZL7vYA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_QXov_wgwTEe9iec6EImaQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ctso:AllOtherCountriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_GHt6jI9HW0amSQTDjBZQSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_fzhPwuLPukmrUdi_ToPDPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_BQH7e5DFwU-i1ithowcxIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_S0fxf7nq1EOlWiL9Q6JU9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_ht_XRtUdc0KZKqw23eRvcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_0DuN_YUs0k2g6B7WoQuymA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_dd7aX6AZn0ivW75vs1ACmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_0YTXyfGCvkOAHMRBYujAGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_cwj5unG_WkCRIuQlwJ3dwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:UnitedStatesGovernmentAgenciesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_ctso_OtherSalesMember_k-QiwnuCrUiE_vu6WfajCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctso:OtherSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_UrGxGvJgzkO7B8scLF4L5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DistributorsAndStrategicPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DirectMember_tT74xtzFukKomPVrAOvfwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctso:DirectMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_ctso_CytoSorbSalesMember_Q4Ry_8jnRU-WR-Sk5cdeNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctso:CytoSorbSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_4_2020_To_12_4_2020_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_p4SKdwcjlUmUAUo8kjQ2Mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-04</startDate>
            <endDate>2020-12-04</endDate>
        </period>
    </context>
    <context id="Duration_7_31_2019_To_7_31_2019_us-gaap_DebtInstrumentAxis_ctso_TermBLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_dfnbFaTYTUmSkV-OaNfp9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermBLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-31</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_zAGlt-XrpU6zeCKAysx8Ww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_ajPw7PYg8UiVzGNH8PRoGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_IZ1_4AiozUyl0mH6SNTEkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_qNxrnXfXMEWT6PBBrE_I6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_xx0SVCBDQUagyE9b8Y2GGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_6WgRDm9zw06JdogbPOBBsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_RcD8hxX4B0W360TpBmU_BA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_p-0pfYqTZ0CXdqB9tDZcLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_GAn4Sc5mekKFBtkNb6Zzyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_12_27_2022_To_12_27_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_us-gaap_VestingAxis_ctso_FirstTrancheMember_u7MsHPmZk0W0eFrHTCS5fA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ctso:FirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-27</startDate>
            <endDate>2022-12-27</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_x19ESOfGok2hRnIOnFg4-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_VA7E7P_1tEG-K6jM8v-kFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_v7r-si-0bUuq1lcCsElNgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_ERD_klH89EySV0xsixbjKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_3Qdgi4LpIkSQMymN-mkajA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_9IC6hTCjW06NGRwHHe3tNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_HgsYwDdKM0Wf4EOABgWuUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_1_2021_To_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_srt_StatementScenarioAxis_ctso_OperatingLeaseInitialEarlyTermMember_lxWMtc2sTkqH38xAKIWoPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ctso:CytosorbentsMedicalIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ctso:OperatingLeaseInitialEarlyTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2021_To_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_srt_StatementScenarioAxis_ctso_OperatingLeaseFirstYearOfRemainingLeaseTermMember_9vqNICnuOkyckL02PYBIQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ctso:CytosorbentsMedicalIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ctso:OperatingLeaseFirstYearOfRemainingLeaseTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2021_To_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_srt_StatementScenarioAxis_ctso_OperatingLeaseEarlyTermMember_tAFcc_W5NUuJIEBULRt2Ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ctso:CytosorbentsMedicalIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ctso:OperatingLeaseEarlyTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_4_1_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsEuropeGmbhMember_qOdCgqh6606refmoxrQP8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ctso:CytosorbentsEuropeGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_OhlDyppT50CWSs02U8PSrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5uYZTUv4DUKuTOvKAyxCSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_41gqsgDpOECDOvWP118t8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_7_31_2019_us-gaap_DebtInstrumentAxis_ctso_TermBLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_hAgUOUh5k0aAxSE_lGDIoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermBLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_ThirdTrancheMember_NUg-LV9OMEK0n6Tmc-tODA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ctso:ThirdTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_SecondTrancheMember_djf_g158KE-plo3cylyfTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ctso:SecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_FirstTrancheMember_FBkEgEL2JUK-hSNbubMUvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ctso:FirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_19_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_xoInVW7g4UOFsRz944IiQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-19</instant>
        </period>
    </context>
    <context id="As_Of_4_1_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsEuropeGmbhMember_eGPb2XlfmU655buQQmU81A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ctso:CytosorbentsEuropeGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-01</instant>
        </period>
    </context>
    <context id="As_Of_4_1_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_Ayo8OWQvq0qpn_0X3Xab7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ctso:CytosorbentsMedicalIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-01</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_lBauhAm9gkWSn63bQjLUkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2023_us-gaap_LossContingenciesByNatureOfContingencyAxis_ctso_PayrollTaxAuditMember_UY7_k4-eREeBnQGR_XMpGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ctso:PayrollTaxAuditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_LossContingenciesByNatureOfContingencyAxis_ctso_PayrollTaxAuditMember_5kmrsmoK8EWvYJIbVVsujg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ctso:PayrollTaxAuditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_LossContingenciesByNatureOfContingencyAxis_ctso_AdditionalSocialSecurityAndVatTaxesMember_dTAIANEpM0y9wSbH-curug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">ctso:AdditionalSocialSecurityAndVatTaxesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember_q-pVwR_fx0mA5G4MI1uuxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ctso:FiniteLivedIntangibleAssetsPatentsIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember_zXch2gFj5k-awN9bccQ9Eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ctso:FiniteLivedIntangibleAssetsPatentApplicationsPendingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember_s0omtWKNx0m-GCD2Twq8Aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ctso:FiniteLivedIntangibleAssetsPatentsIssuedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember_JaV5Z95jAEioF4LjVm9rgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ctso:FiniteLivedIntangibleAssetsPatentApplicationsPendingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_8lddL3hShE2PxAKw1cffhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2017_To_12_31_2017_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember__1pqeGKP1UqWAJ53fXSkdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_12_31_2022_7D4gmEOvZEuddtCJGzA8ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_2eoa-jebUE-H6uey7YKWmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_mLayX3PX1Eqci3SfMDv1YQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022__Bto-66MgUq_eQRwKUyq1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2021_To_12_31_2021_PTkhRTY9_0uo1BKc7O3ElQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_9_30_2021_bc1_H1o8GkWXj53DijdBKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_KUS8bQMU0UaIknV605S_VA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_3_31_2021_zXigQoQBgUGOxC_vaZv8ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_12_31_2020_asiudZouf0qo-UGg2Gf0lw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2020_To_9_30_2020_BlNvdmBrgEeKoL8Hm4r3Dw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_pfUWsTXCTUSP48AZxdHHPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_3_31_2020_0j8Adr0DO0CTdQHPhErCZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_1_1_2021_srt_StatementScenarioAxis_ctso_ParticipantsContributionOver3AndMaximum5Member_VI70pNF1dE6bwaLkkkQQzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ctso:ParticipantsContributionOver3AndMaximum5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_1_1_2021_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_ctso_ParticipantsContributionOver3AndMaximum5Member_MBEUr3qmWkaFIgPeH_HMOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ctso:ParticipantsContributionOver3AndMaximum5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_1_1_2021_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_ctso_ParticipantsContributionOver3AndMaximum5Member_QRs03j8L6kalwqqJ7bMG6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ctso:ParticipantsContributionOver3AndMaximum5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_1_1_2021_srt_StatementScenarioAxis_ctso_ParticipantsContributionUpto3PercentMember_MgDr1mCwaUS6-T40vC8X3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ctso:ParticipantsContributionUpto3PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="As_Of_1_19_2022_us-gaap_DebtInstrumentAxis_ctso_NonRefundableClosingFeeMember_3fpymeUzzE2FKaJZ7vfyhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:NonRefundableClosingFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-19</instant>
        </period>
    </context>
    <context id="As_Of_12_4_2020_us-gaap_BalanceSheetLocationAxis_ctso_ClosingFeeMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_VrBaHTNN5kGqpNZC5_45yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ctso:ClosingFeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-04</instant>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_7_1_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_46J-BH5GlUuzquHLcvZsUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_1_1_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_ZrffNf8uWkC-rlhEGrcMag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-01-01</endDate>
        </period>
    </context>
    <context id="As_Of_1_19_2022_us-gaap_DebtInstrumentAxis_ctso_NewTermLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_KKLXo5WGZkqln7K51iiuOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:NewTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-19</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_us-gaap_DebtInstrumentAxis_us-gaap_LetterOfCreditMember_qtkd0jaAzUeu79V_NBPfXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ctso:CytosorbentsMedicalIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="As_Of_12_4_2020_us-gaap_DebtInstrumentAxis_ctso_NewTermLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_sKTK-0jXM02ZfmOBWGS5TQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:NewTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-04</instant>
        </period>
    </context>
    <context id="As_Of_3_29_2018_us-gaap_DebtInstrumentAxis_ctso_TermLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_us-gaap_VestingAxis_ctso_FirstTrancheMember_yHGvHKFK2USNqJh92uWr0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ctso:FirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-29</instant>
        </period>
    </context>
    <context id="As_Of_3_29_2018_us-gaap_DebtInstrumentAxis_ctso_TermBLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_us-gaap_VestingAxis_ctso_SecondTrancheMember_e3qGkUg1VUKoGjKsBJiqOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermBLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ctso:SecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-29</instant>
        </period>
    </context>
    <context id="As_Of_3_29_2018_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_yAsPHUNuqEirJNj907ZTrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-29</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2016_us-gaap_DebtInstrumentAxis_ctso_NewTermLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_ArZA6xiPjEidCYt_-Y-R-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:NewTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2016_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_hpLFtiZhmUiQm4GvwoFZtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_pd77Iy0ZEkG2yi4BhLTLbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CreditFacilityAxis_us-gaap_CreditCardMember_10pNVCROt0uc0geHUcOPJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CreditCardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_19_2022_To_1_19_2022_us-gaap_DebtInstrumentAxis_ctso_NewTermLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_V4YNPqwfQU-fUTcMCuVGXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:NewTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-19</startDate>
            <endDate>2022-01-19</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_CargoAndFreightMember_3_4JFM6ghEqxTBICweYCOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:CargoAndFreightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_CargoAndFreightMember_XgZFDtyGV0-mrreoqyHhdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:CargoAndFreightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_gIfXHjckYEyJZbVZyvB2YQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_nWvJKC0AfUO7Aa2fnEopNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_njwH72hw8kSaSTYNHO-w9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_7s12QoX9F0W4teGHuyLFlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2019_hE-GjhoHb06AQqRidhWP3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2019_88geVJQ2uUywvKJuak2-eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_ctso_TwoThousandFourteenStockOptionPlanMember_283few-Y1k-s142NM7ToRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:TwoThousandFourteenStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_ctso_StockOptionPlanOneMember_RNyPCy3gyE2TqeZtAiyN2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctso:StockOptionPlanOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_6_oqjbutzEKQogf2y7UC6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsEuropeGmbhMember_WYlLNzD2gES86ALGoqLgDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ctso:CytosorbentsEuropeGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ctso_StockOptionsAndWarrantsMember_yk7BYg1b80i8SXV12unwZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ctso:StockOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ctso_StockOptionsAndWarrantsMember_N7MNifr70EazP8jJCCRNdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ctso:StockOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ctso_StockOptionsAndWarrantsMember_yWq0uJF810qiMA_nrGtcuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">ctso:StockOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_ctso_EmployeeTwoMember_5EVkiMRvd0id4GEDS-DjOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ctso:EmployeeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_ctso_EmployeeOneMember_apbG-USk6kiuOe_Y22t91A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ctso:EmployeeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5G127XWFxUipm8wjbbrV0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_7_2023_CcpBUzS37kyiXYDxNeBq9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <instant>2023-03-07</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_ctso_OneDistributorMember_XK7cgrbnyk-5EtW1e3KAjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">ctso:OneDistributorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_v0fFN3Ebi0qVBjU54fspcg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_KP3JJIYFZk6xK_VoVW7UbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_Ow1UbuwxYkCiv37yEeEpfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_cD_zR9lLbk6OW7lmBqw0ow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_Df_fcOfuVUyrXQ2v2oxuSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T3OJIOaoZ0K5JyfOQDRhQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WaPfkCKsqkGJrOEo8CCMJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jAS_rLmGI0SmIJDwwikaWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ymoFl7EJPE6epQ4SBcMfbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_4_1_2022_AQ3DZUBay0mJk2oEUwh-kQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="Duration_4_12_2021_To_4_12_2021_4mWKwyxxWEKyj2QfIoh1PQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <startDate>2021-04-12</startDate>
            <endDate>2021-04-12</endDate>
        </period>
    </context>
    <context id="Duration_4_12_2021_To_4_12_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_s_j74aK2uUqG5xOlSbxT3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-12</startDate>
            <endDate>2021-04-12</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_LicenseAgreementMember_vd_rm61d5EKX2A6aRANNWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ctso:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_8_11_2003_To_8_11_2003_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_RoyaltyAgreementsMember_xFt-mbbZrkmdsbIlITDLxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2003-08-11</startDate>
            <endDate>2003-08-11</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ctso_TwoThousandAndEighteenSuccessFeeLetterMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_V6EvzE1VNkqz5b11S3A0zQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TwoThousandAndEighteenSuccessFeeLetterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ctso_TwoThousandAndEighteenSuccessFeeLetterMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_x3N7mO34SEWKzky3MgxbHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TwoThousandAndEighteenSuccessFeeLetterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2021_To_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_id_BW-goZE-wjX2tVerJSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ctso:CytosorbentsMedicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_-_7LrVATRkuKuxUmrfdQ2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ctso:CytosorbentsMedicalIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="Duration_3_1_2021_To_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US__KJwJevVx06LgV-mH407GA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ctso:CytosorbentsMedicalIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_soDgpwwWtUaODzy8fGjUCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ctso:CytosorbentsMedicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TwoThousandAndEighteenSuccessFeeLetterMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_jQs_7-pzMUy3U65XTi21yQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TwoThousandAndEighteenSuccessFeeLetterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_ThirdTrancheMember_4sLxmtU1v0S4Yllbg0FfOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ctso:ThirdTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_SecondTrancheMember_QxsVP0Jock-3r1DvUA8aiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ctso:SecondTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_FirstTrancheMember_GIGD6kvI2kuyoTLKEpk95A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">ctso:FirstTrancheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_LicenseAgreementMember_raDmOQBLY0ys677paSR3hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ctso:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_CargoAndFreightMember_vWKDoEIhEUOKRvy4A7Wi5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:CargoAndFreightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_1_1_2019_Qy5PqaSx0EaQbNj8WsHlmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_31_2022_ifdIznn7QEeHunrEw3Jhtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2014_To_6_30_2014_xxa151rza0iR7WYHq7r7TA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <startDate>2014-06-01</startDate>
            <endDate>2014-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_19_2022_To_1_19_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_g4Y2bbaH8UunO1A9gJrzYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ctso:TermCLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ctso:WesternAllianceBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-19</startDate>
            <endDate>2022-01-19</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_30_2021_To_12_30_2021_dei_LegalEntityAxis_ctso_JefferiesLlcAndB.RileyFbrIncMember_XwgIgRkXJ0ileyIAI7HBTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ctso:JefferiesLlcAndB.RileyFbrIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-30</startDate>
            <endDate>2021-12-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_30_2021_dei_LegalEntityAxis_ctso_JefferiesLlcAndB.RileyFbrIncMember_7Vao9teehUSAKLxbCXXGsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ctso:JefferiesLlcAndB.RileyFbrIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_7_14_2021_ia1syTvHG0S77AERC2Hqwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <instant>2021-07-14</instant>
        </period>
    </context>
    <context id="Duration_9_1_2021_To_9_30_2021_srt_StatementGeographicalAxis_country_DE_R18Zrff15UWiG7PQAHXLAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_4_30_2021_us-gaap_LeaseContractualTermAxis_ctso_TwentiethAmendmentToLeaseMember_gauFszu_JEOFrdWykocnUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ctso:TwentiethAmendmentToLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001175151</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <unit id="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_country_S-K5wYygeEuMMDPQgfGhxg">
        <measure>ctso:country</measure>
    </unit>
    <unit id="Unit_Standard_item_00R0j3K4HUiRlSslEJQMxQ">
        <measure>ctso:item</measure>
    </unit>
    <unit id="Unit_Standard_patent_iyucGb4rrEygLz5tIoEXtA">
        <measure>ctso:patent</measure>
    </unit>
    <unit id="Unit_Standard_USN_5UGkHjTMLU6EeMbjOjtcEQ">
        <measure>iso4217:USN</measure>
    </unit>
    <unit id="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_sqm_5jCoQZf8skWtJMe7yh0D_w">
        <measure>utr:sqm</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      id="Hidden_D3AsnHpxPkq8SV8Mnnog1w"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      id="Hidden_rqgEISEScES0gDtBbJYfdg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      id="Hidden_hEV81X3h9UOJEdBsx3b6bQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      id="Hidden_WcE7qIcf6U2Unn00kGtBEA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="2"
      id="Hidden_zNIJAnaRR0CqAJo82LC6XA"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="2"
      id="Hidden_A3L_kI-Jk0-EUNRql5ERcw"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.57</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="2"
      id="Hidden_v5TbsPJIpkCU_eSgu2R0tQ"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Hidden_1BftEmQrCEGZd_4tI3AJmA"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">43573215</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Hidden_HOA4Wyebo0eApwihM9dwIA"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">43359186</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Hidden_N8FoVDtPi0CNhRZPSqthVQ"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">38818990</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      id="Hidden_1iWKOSTEYEW4rgjnocsyQg">P0Y</ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm>
    <ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      id="Hidden_gFEztX83IEan5vGYiG_KkA">P0Y</ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm>
    <ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      id="Hidden_7Cm8_uxCP0mv3QQAha4gkQ">P0Y</ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm>
    <ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      id="Hidden_rBumodlmnUK-p_-iado5iw">P0Y</ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm>
    <ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      id="Hidden_GQpp15AqqkCIMuMwEM8NqQ">P0Y</ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm>
    <ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      id="Hidden_amo3-ZcwWEWCT2ol91T9ZQ">P0Y</ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm>
    <ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Hidden_SbJXsQ3BuU-Usd0OT4w7GA">P0Y</ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm>
    <ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Hidden_4-HPXTyq0kWo5cJ4Z0sPVw">P0Y</ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm>
    <ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Hidden_We0d8r7iWEWg62NYW1m7vA">P0Y</ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_3_31_2022__Bto-66MgUq_eQRwKUyq1Q"
      decimals="2"
      id="Hidden_MUpMpWeHk0aBUZ2MDd26VA"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_4_1_2022_To_6_30_2022_mLayX3PX1Eqci3SfMDv1YQ"
      decimals="2"
      id="Hidden_oXJA3y4UJUasTNz9MDnPsg"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2022_To_9_30_2022_2eoa-jebUE-H6uey7YKWmQ"
      decimals="2"
      id="Hidden_3-kL6JZPV0i6pqW7QNx0aA"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_10_1_2022_To_12_31_2022_7D4gmEOvZEuddtCJGzA8ow"
      decimals="2"
      id="Hidden_-0c_lfDGEkqIWrJYOWqHZg"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_3_31_2021_zXigQoQBgUGOxC_vaZv8ag"
      decimals="2"
      id="Hidden_gC8GmjKZIE-UrlDfCE1KUg"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_4_1_2021_To_6_30_2021_KUS8bQMU0UaIknV605S_VA"
      decimals="2"
      id="Hidden_SAhtz1HqJEKTOk7YM9gT3A"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2021_To_9_30_2021_bc1_H1o8GkWXj53DijdBKA"
      decimals="2"
      id="Hidden_W735XDkRFEey5S0CoME8Fg"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_10_1_2021_To_12_31_2021_PTkhRTY9_0uo1BKc7O3ElQ"
      decimals="2"
      id="Hidden_boXR5GlxQkyOQtUsZQrz_g"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_3_31_2020_0j8Adr0DO0CTdQHPhErCZw"
      decimals="2"
      id="Hidden_SqGHfpNVQUevlbriuIdhVg"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_4_1_2020_To_6_30_2020_pfUWsTXCTUSP48AZxdHHPw"
      decimals="2"
      id="Hidden_Lb2al7sI0EWr3LUyy8IGLw"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2020_To_9_30_2020_BlNvdmBrgEeKoL8Hm4r3Dw"
      decimals="2"
      id="Hidden_3AW966jREEaC8BynrHPevA"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_10_1_2020_To_12_31_2020_asiudZouf0qo-UGg2Gf0lw"
      decimals="2"
      id="Hidden_cLNeaf2svkq70K-ImasqNw"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">0.00</us-gaap:EarningsPerShareDiluted>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tc_CU_sydlIsUWfqRKartI5UA_2_1">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tc_I-I0qkxrPkWdVvYG2lwFuA_3_1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tc_sz6AbnUQxkO4eLsvlZzBzw_4_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tc_OvFDZXlxJ0aXCVNZpJRkKQ_6_1">0001175151</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tc_kA3xcw_Dmk-N1BD6VL27Wg_7_1">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="INF"
      id="Hidden_z7CAybzy_UCwWIryUIV6Kw"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">43635715</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="INF"
      id="Hidden_VfGFfPUiNEutikrelXHK5g"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">43478487</us-gaap:CommonStockSharesOutstanding>
    <ctso:DefinedContributionEligibilityTerm
      contextRef="Duration_6_1_2014_To_6_30_2014_xxa151rza0iR7WYHq7r7TA"
      id="Hidden_wRQ8gwA2pEGU2CW7c2BqBw">P3M</ctso:DefinedContributionEligibilityTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_odV670fJEUWMoiqxIvk3sw"
      decimals="3"
      id="Hidden_bnG0W-eC-kmqWIE1UDcudQ"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_4_12_2021_To_4_12_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_fFXJv_RDXUGqaL5uxC9OHA"
      decimals="3"
      id="Hidden_yBkqj_djEEmSnjqOn-lNAA"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_8_10_2022_To_8_10_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_WpLhK-DurECWLOlefRpvAg"
      decimals="3"
      id="Hidden_CzwcUS2bLUKcKWPHYGPuIw"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_8_10_2022_To_8_10_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_VaRbgm5QaE6YvFr9Fe1yBQ"
      decimals="3"
      id="Hidden_Qn9ZRP_XUUuujsh4uxHgPw"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_csIBECZEpEyijv9iV3T9sQ"
      decimals="3"
      id="Hidden_9VkzXAfHnkmSs1ntMN_DvA"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_ctso_ShareBasedCompensationAwardTrancheFourMember_8iSlUywhskW943wT9Tsmag"
      decimals="3"
      id="Hidden_FavK8EuO0EiMvQzxKsEdyg"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_VestingAxis_ctso_ShareBasedCompensationAwardTrancheFiveMember_FzLPW6Bz_0Ck1LOSUNIRiw"
      decimals="3"
      id="Hidden_XAf3tkw7FEWYcbQI9IZMZw"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_4_1_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_Ayo8OWQvq0qpn_0X3Xab7g"
      decimals="-5"
      id="Hidden_i35CHnl1HUSihsVEqT6O2A"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">11600000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_4_1_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsEuropeGmbhMember_eGPb2XlfmU655buQQmU81A"
      decimals="0"
      id="Hidden_cxtzS31VrUm4rMIV9MB8Iw"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">594000</us-gaap:OperatingLeaseLiability>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="INF"
      id="Hidden_iXELXapUCkaeE4AvVxSU8g"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="INF"
      id="Hidden_OpzAs5-aA0elOwLb22GMjg"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="INF"
      id="Hidden_ftW8B_sRc0q8TfEsntsdDA"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="INF"
      id="Hidden_a7ThlUoBZUCRE07FyDdzfQ"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_4_12_2021_To_4_12_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1MKAMb2CmEmA_P42dMcHxw"
      decimals="3"
      id="Hidden_NhvWl8VkYEiywUdQUWqfYg"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_4_12_2021_To_4_12_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_qyOWI6GyLE-X4I8r0-tdDg"
      decimals="3"
      id="Hidden_riKmZAfAA0-fmSAyyqKphA"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_8_10_2022_To_8_10_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_hiVRtHV7O0qUATFHrPDRvg"
      decimals="3"
      id="Hidden_IU4zNU0S4UKy1kEa3REKsg"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <ctso:NumberOfDaysForStockPriceThreshold
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TwoThousandAndEighteenSuccessFeeLetterMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_jQs_7-pzMUy3U65XTi21yQ"
      id="Hidden_TWKGB9Ns70-hcCjqFg2ORA">P5D</ctso:NumberOfDaysForStockPriceThreshold>
    <ctso:NumberOfDaysForStockPriceThreshold
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_FirstTrancheMember_GIGD6kvI2kuyoTLKEpk95A"
      id="Hidden_0ax9yhmTV0OKMkdCNohxKw">P5D</ctso:NumberOfDaysForStockPriceThreshold>
    <ctso:NumberOfDaysForStockPriceThreshold
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_SecondTrancheMember_QxsVP0Jock-3r1DvUA8aiw"
      id="Hidden_2iU3HFYDDUKoxhoqRgX4wQ">P5D</ctso:NumberOfDaysForStockPriceThreshold>
    <ctso:NumberOfDaysForStockPriceThreshold
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_ThirdTrancheMember_4sLxmtU1v0S4Yllbg0FfOA"
      id="Hidden_pwbH1ZIm4UCeZREcP1cczw">P5D</ctso:NumberOfDaysForStockPriceThreshold>
    <ctso:TermOfCustomerContracts
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_cD_zR9lLbk6OW7lmBqw0ow"
      id="Hidden_4sWYxGr9T0-FAHL1y2CyEw">P1Y</ctso:TermOfCustomerContracts>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_S5u_0h0_skSBh-VyCnAFqQ">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tc_PR3oEAMVDUm8OoCClF7iYw_1_1">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_BwvrGGm8hU6Y8XvxqfUbaQ">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tc_gp5C8JrliEif7M9UEbgXOA_1_1">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_d0yzbZseakemo4TE_EX0Og">001-36792</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_ajiwCEgs_kSNF8JZkYEIsA">CYTOSORBENTS CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tc_riOKXFGLUUmF3Vaji7rIWg_0_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tc_JU7U16amYkmsfKWGf_Uo9g_0_2">98-0373793</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_xpXk5YJSpEm-52jgg6Iz0Q">305 College Road East</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_qJ6X_hnVl0aJW8aoct8Lqw">Princeton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_XNUIeCgnJEurw0NYcOcNIQ">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_r9kDdiA8MkemyKDTd9ro-Q">08540</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_pB-hy_jBrECpjpaBOrfypw">732</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_xMTs8fT4QEmGa8lc2ahlWw">329-8885</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tc_vOlxE-1hLUuAlYz9Wa9p2g_1_0">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tc_cfgt9FCyj06D7Sc4VQwXXw_1_2">CTSO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_jW7RdxQ9pEu-JaxSivzjcw">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_YjqBsL4qrUaqEXN7utZtgQ">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_3YMGim3JoEi42QpjKAD_7A">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_ckrk4I8GUEe6oarCzpmPog">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_cwFHZdtjv0aFOzrSYAECQA">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_jO__zmSLY0mCWcvauUAC9A">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_ZStrR_tMOE6QTMVDBLxYXw">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_v0qdsNMOxkie0d3jw6UiHw">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_fLev7MtxBUON3hCarerVGQ">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_0kkpjSlGxkGMSUDvWJN4ug">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Narr_Rwvzej4ZoEm_N8e799jA9w"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">61461000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_7_2023_CcpBUzS37kyiXYDxNeBq9w"
      decimals="INF"
      id="Narr_w8NO2vY5p028AOY-84d2zw"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">43663009</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_pf0M0V_IKkaKhmJVI-He8w">WithumSmith+Brown, PC</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr__TfgQajlNECl4SFifW16Ww">East Brunswick, New Jersey</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_8rebRNMZ9kOZJfDRgzellw">100</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_foiSZEzqTUuVbv93UmvntQ_6_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">22144567</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_zyw7udcjV0qdkhyYlYTcpg_6_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">52137707</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Narr_frA9Wpx4s0Svh01VfjO9jg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">76041</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Narr__GA0vGLIsUqIVtoWQt1gpQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">60539</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_RRTtWwLj6EyaJwKagDtI4Q_7_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5664941</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_8ec2B1stb0CGOjGk5zk1gQ_7_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">4523430</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_slG4AF0khUaIroPh67PHLA_8_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3461586</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_Y9FUnE5XGUqHgd8zSsViXA_8_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">4766098</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_UoYG6mNX-k6zvhF8JB_7zg_9_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2488597</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_97qA0oIMrkaEtnK97Vzm1g_9_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2871655</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_EEo5fqI-rEuooMAEiE5Jdw_10_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">33759691</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_zQ3nS2esSkC7N_kmOT0zxw_10_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">64298890</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_xqJmKi9pRkiXhH2TRw87Gw_12_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">10743032</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_YdbIJzuF5ECBlJrHlxbQPg_12_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5150886</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_5ZD7aMs_tUeUlpWcRJ-NDw_13_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1687459</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_usLa3-TeVUe329ixZTFjNw_13_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1687459</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_hOVWDauFhkq08pRFin2nmg_14_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">12603901</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_n8T75im19EepbqkXoK-xow_14_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">13423472</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_BGcAHe5bIkeIMo1tSQWJ3A_15_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">4437447</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_ItpRCjtfWUy3RJgVPEhQWw_15_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">4958575</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_CmABNI3F6kaaLtlK0oQcAQ_16_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">63231530</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_rN3323m9d06PS2nKAEl8fg_16_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">89519282</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_x7TEzPLIukqaxAw_bJ3u5w_20_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1655173</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_IkkYjrYClEWmaC8Bfbpegg_20_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2805235</us-gaap:AccountsPayableCurrent>
    <ctso:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_-7TPPO-6QUeFuZRxR1E90A_21_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">7950440</ctso:AccruedExpensesAndOtherCurrentLiabilities>
    <ctso:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_61aVREOFuk66VjFWl7lj_A_21_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">10314341</ctso:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_x_e5gN5fHkyfq9gLqqcrHQ_22_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">108939</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_7j4gnNHTtUWVQTrM2qHRQQ_22_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">570566</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_INrz1lGQvU2qeDys9KbV6w_23_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">9714552</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_RoCMQhjtsUy_PE4VHXA7uQ_23_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">13690142</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_k_BAW7GhEUCZ2z8trQktuA_24_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">13142005</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_Jcpu7km_pkC_SxS4rxpcfw_24_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">13250943</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc__t_HmH_3zUKKRYXbOh6M1g_25_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_rEkrQHzi9EqczpzaIBwy-w_26_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">27856557</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_pU-PxCoBWEqSc67QLr6sbA_26_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">26941085</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="INF"
      id="Narr_zDRLB8HDskezTG9bLWAQBg"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="INF"
      id="Narr_zY1DU_uL1Uec2zMbCXTqQQ"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="INF"
      id="Narr_gbeaPxxgyk-6Zvz2nGSWLQ"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="INF"
      id="Narr_H1kN4L8ZsUiYr3niMmwSTg"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="INF"
      id="Narr_gAkKkF-cWUeNVvnwFmqhfA"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="INF"
      id="Narr_L-kbCvBA4EquzhCTcTisoQ"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="INF"
      id="Narr_ojb-JIYP106cxQj-ZF-b5g"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="INF"
      id="Narr_3xjYID6QTkKVmN2pjwqpXg"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="INF"
      id="Narr_XIxQECPQc0C2zZhO3s62yQ"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">43635715</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="INF"
      id="Narr_uQeBcALoQECKEaUBzAKpYg"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">43478487</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_sHhsbGSxDUKLDpl6dxUt-g_31_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">43635</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_721Vc5vLRUCEjGecMSDe1w_31_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">43478</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_FtyEtTUHdkyI420WPcDOYw_32_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">287000021</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_b7AtcIfo0UOcHUC-JSXWbA_32_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">283194429</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_9lIxuZy9MUGA8aeWjJfG7Q_33_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2329195</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_DKz3aMuBl0KB6y7KndfxGQ_33_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">525585</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_cWPJd_-nF0-QwvFXPHdv4A_34_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-253997878</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_E6QZHwny80i5Wr2s9g5XMw_34_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-221185295</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_sbxyq1YlK0qTrojW2jWJJg_35_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">35374973</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_WjKbbQ3mCkaNWByhJisdFQ_35_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">62578197</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_atXpyeUMMES7d7SJ9kBL6A_36_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">63231530</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_mqSkmJicfUq5DFAqf6X-Lw_36_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">89519282</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_ctso_CytoSorbSalesMember_kZjj3Qm1nkaD0BliSjoSlg"
      decimals="0"
      id="Tc_GB98JvSPbkiIoiRZQR2qcA_5_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">28572709</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_ctso_CytoSorbSalesMember_F2WUYm6g20mo5wFD0_w32Q"
      decimals="0"
      id="Tc_HanlCTyKu0iKKYw6uBBOqg_5_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">39996700</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_ctso_CytoSorbSalesMember_Q4Ry_8jnRU-WR-Sk5cdeNA"
      decimals="0"
      id="Tc_DxcX0JYuM0y01a7_n5jq6A_5_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">39342102</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_ctso_OtherSalesMember_IHmx8Gx6dUC4YavDmDyL_g"
      decimals="0"
      id="Tc_wR8PzHzA70afj8WKYwS0NQ_6_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">787201</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_ctso_OtherSalesMember_3KZRlFeRi0y0ti0yyXPoAQ"
      decimals="0"
      id="Tc_VgNrUtTBcEeQUGMY4dGrlg_6_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">111867</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_ctso_OtherSalesMember_k-QiwnuCrUiE_vu6WfajCg"
      decimals="0"
      id="Tc_O7HtHyRJfk6B7O4C4w4UZA_6_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">110400</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_H13OncAn9U2imjaSPSyd5g"
      decimals="0"
      id="Tc_jVzB526lYkir29UtPBZ1_Q_7_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">29359910</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_KSZxi4zg7keBU37J2Y0-8w"
      decimals="0"
      id="Tc_tgpG37ObjEewoaw3TBccaA_7_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">40108567</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_dd7aX6AZn0ivW75vs1ACmA"
      decimals="0"
      id="Tc_Co4yr_dJF0KqQ-fZGvEUbg_7_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">39452502</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_HBdMLlMQGE-9IpPghuUK2Q"
      decimals="0"
      id="Tc_lmQURR2ohEyePBKnjVoMrw_8_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5328899</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_FklCHZPwzUeeNeeNvzpgvw"
      decimals="0"
      id="Tc_gRyBXgewOUaSyHTxN2ksXA_8_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3056960</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_0YTXyfGCvkOAHMRBYujAGg"
      decimals="0"
      id="Tc_Yazz5GeLs0uhHZTKMo_QMg_8_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1552099</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_yiGBOS8ZNkqUR8YNj52ddA_9_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">34688809</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_ZiBrtZyrNU6fWEtlNpABlg_9_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">43165527</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_sCbWmYyq8k2Natht0l61eA_9_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">41004601</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_V2BlHn58LkuexrvEqBhkcA_10_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">13955752</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_Qros_KRK4UyVfSy3u1WtWQ_10_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">11047350</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_mpamAiMF6U6WtmUhQkF2Ag_10_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">11052409</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_I8RNJ8Gfh0WCqQsUFZprwg_11_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">20733057</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_fPMYN_FR1kOzbwP3TSd2-Q_11_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">32118177</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_RZZMOcBJr06FfoRmTx4sBw_11_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">29952192</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_jkSz2w5oy0eiuxWWjfI4aA_13_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">15118907</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_MZYNCjzo90yOFsF3j_mT7A_13_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">16380930</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_j8asV9Pn4UO86SJzWTjrUA_13_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">8810561</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ProfessionalFees
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_n6HQa_R1Ak-dflrnwtp0Bg_14_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2847899</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_ZsJWsaXL20GsE4tvYAT0Dg_14_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2731515</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_aIP3jQ4bEUCUclHXPl6CAw_14_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3048242</us-gaap:ProfessionalFees>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_0M42NyJj9kOOQMEzanswYw_15_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">34288130</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_zsHJjSulWEaYpaFs_XQ5Jg_15_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">35750477</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_CqqtkG5mt0mxwc68PyAVAg_15_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">28463723</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_O9Exfeu3606657-fxHLotg_16_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">52254936</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_JyjNLUo8F0-qcysL2ANNhQ_16_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">54862922</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_Bh9k_bw8L0KM-Y8QeRF9tA_16_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">40322526</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_qAFKBCxJukS-KUkOquCH1w_17_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-31521879</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_UXnd9DEtckaSaniXSXtNOg_17_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-22744745</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_3n4q7JSOXkKReDib77R0zA_17_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-10370334</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_nx5ODGSmYU-BhGLV9_s47Q_19_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">132597</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_flLn3AOud0q3RkkUtBy8NA_19_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">28007</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_3ft3gwNEyEi_M18LMyeoFw_19_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-1201067</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_IsFh7K9GpkCvstj0umOoYg_20_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-2448583</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_8-5hFgjMiE-FDaxb9jGZbA_20_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-2577913</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_djAhv8zD00KxcijDjpOWeA_20_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2607139</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <ctso:MiscellaneousIncome
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_KDaGJ21cF0Sg7Ff4N7jRXQ_21_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-67303</ctso:MiscellaneousIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_Cpw5BsUEmE2hsuFASStY4A_22_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-2383289</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_A1lFAULxg0eoeoZt-Nnq7w_22_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-2549906</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_UUPC4g0KWESIU8dTpSFh-Q_22_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1406072</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_zedBc21PA0-bsOrpTmN9vw_24_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-33905168</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_9m_rfK7lGkeZzwvsop7CsA_24_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-25294651</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_C_rZXp9Xk0-y34Es7pq1OA_24_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-8964262</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_hTh56gUgkEiVEUBI1i_QAA_26_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-1092585</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_N0oCwIdWpU63qil1hAPo0w_26_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-736003</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_-7kqjE5RmkimwQCVGhdWLw_26_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-1127074</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_mapN4D6likmStI8HzfOSGg_28_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-32812583</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_3JNpIIN_JESXkPK9GLdwhw_28_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-24558648</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_YXffGfVt6E-gnoyPJFzl_Q_28_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-7837188</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="2"
      id="Tc_NJH6P-nmL0SZOU2qIdgusQ_30_3"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="2"
      id="Tc_9rHNx-Npsk-5kk4EtAe27w_30_6"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="2"
      id="Tc_Q2QjOvEuxEWZjqnBX8PL0A_30_9"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.20</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_J4wClybs006lYF2qnxzF6w_32_3"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">43573215</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_Y4xxPBoijUa9CDy80tJCVg_32_6"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">43359186</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_dJa5jjbPbUmd3zmZ9zijQQ_32_9"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">38818990</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_r2bST1YteU-40M1QaWiIbQ_35_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-32812583</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_NAeCRf64wEepccK0jxbLDQ_35_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-24558648</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_q4I_gTumIk-hx0eba-W8vg_35_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-7837188</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_uWn0zbEZ-UmShzz-CpVsKg_37_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1803610</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_x73oJWCxCkyOgViv8ukY_w_37_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2259663</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_6VLY66j1VUSSCvIOuTCzUw_37_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-2260056</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_NvzhNhE9TUONDhbrpbZ1XQ_38_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-31008973</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_mvbckGb-Z0GkRrPecLKztg_38_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-22298985</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_hocOg9GLtkaXCCUPKX9Tew_38_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-10097244</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_93L6HhBk5E-Lnf3ZqLpS2A"
      decimals="INF"
      id="Tc_L-LwGGXlJ0qTBxm7LTK-Xw_6_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">32616107</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_93L6HhBk5E-Lnf3ZqLpS2A"
      decimals="0"
      id="Tc_4kA0qYfiHkqYXhSq0Qyu9g_6_5"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">32616</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cDcxImQXYUeh0lvoITev4A"
      decimals="0"
      id="Tc_GBVR54qu_kmLiVJAn5f8fQ_6_8"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">191648907</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_KPMkIaBOA06ekPfEU2CpFw"
      decimals="0"
      id="Tc_xyCBNfMEr0C8lFz3OSAT_Q_6_11"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">525978</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dtYzBB8BaU-3fEcIk5-5qw"
      decimals="0"
      id="Tc_hccLjRLdS0GHoZhE7tESEw_6_14"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-188789459</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_6_oqjbutzEKQogf2y7UC6g"
      decimals="0"
      id="Tc_gADO-iJgpUu9wJhpxjGDZQ_6_17"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3418042</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WaPfkCKsqkGJrOEo8CCMJw"
      decimals="0"
      id="Tc_nz9zUzk39UugyxxcQ74jEg_7_8"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3513671</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_jeav7TfzIE-YtMnPoHlzXA_7_17"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3513671</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ymoFl7EJPE6epQ4SBcMfbw"
      decimals="INF"
      id="Tc_xQqPtdp9ZkOoO-SqQUyctQ_8_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">10163256</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ymoFl7EJPE6epQ4SBcMfbw"
      decimals="0"
      id="Tc_n4E4aU4iWEeWRKe7NAAc2Q_8_5"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">10162</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WaPfkCKsqkGJrOEo8CCMJw"
      decimals="0"
      id="Tc_RyZGbt6d80arb3Tcqetfgw_8_8"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">80203846</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_5dOiml91XkCqas6Y-ElRsw_8_17"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">80214008</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ymoFl7EJPE6epQ4SBcMfbw"
      decimals="INF"
      id="Tc_NKk6_XP8mESI80O5pMzMoA_9_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">87728</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ymoFl7EJPE6epQ4SBcMfbw"
      decimals="0"
      id="Tc_7yejkmqjGEevTqTaHUr4jw_9_5"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">88</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WaPfkCKsqkGJrOEo8CCMJw"
      decimals="0"
      id="Tc_V3Pl7j6MMEOvVWvFrpWqkQ_9_8"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">657692</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_YUhhSDSb00GpNvGQLrMDUQ_9_17"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">657780</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <ctso:StockIssuedDuringPeriodSharesStockCashOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ymoFl7EJPE6epQ4SBcMfbw"
      decimals="INF"
      id="Tc_DF6GTzdD7U6wNdSw10jHsg_10_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">341507</ctso:StockIssuedDuringPeriodSharesStockCashOptionsExercised>
    <ctso:StockIssuedDuringPeriodValueStockCashOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ymoFl7EJPE6epQ4SBcMfbw"
      decimals="0"
      id="Tc_kDbbb6mvQU-TIrGH5M_xNA_10_5"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">342</ctso:StockIssuedDuringPeriodValueStockCashOptionsExercised>
    <ctso:StockIssuedDuringPeriodValueStockCashOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WaPfkCKsqkGJrOEo8CCMJw"
      decimals="0"
      id="Tc_K3pC_9U5gkCgV63DVvJrkA_10_8"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1508980</ctso:StockIssuedDuringPeriodValueStockCashOptionsExercised>
    <ctso:StockIssuedDuringPeriodValueStockCashOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_wVV1EfsmqkykUmXqPcOcDw_10_17"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1509322</ctso:StockIssuedDuringPeriodValueStockCashOptionsExercised>
    <ctso:StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ymoFl7EJPE6epQ4SBcMfbw"
      decimals="INF"
      id="Tc_mrZp-ZYLMUqvMpsVCyNgkw_11_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">13401</ctso:StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ymoFl7EJPE6epQ4SBcMfbw"
      decimals="0"
      id="Tc_BXa9eC96zESPWAU51YW3Uw_11_5"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">14</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WaPfkCKsqkGJrOEo8CCMJw"
      decimals="0"
      id="Tc_OGWPzwTsRkyq6bpG8eCNYg_11_8"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-14</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_v7r-si-0bUuq1lcCsElNgA"
      decimals="0"
      id="Tc_8P_kQ3vXsU-DKrEC4PuCIg_12_11"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-2260056</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_UsGzNTn8IUSQR36Bgm1uQA_12_17"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-2260056</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_41gqsgDpOECDOvWP118t8w"
      decimals="0"
      id="Tc_wlhr7UyM3kGJF9N8mB_H_w_13_14"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-7837188</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_WZr3uxNIS0yw47hgIqRY_w_13_17"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-7837188</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PV_DrHkTQkGQmIt0QmW81A"
      decimals="INF"
      id="Tc_x30RCdmbqEiAhDaCyqSCIg_14_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">43221999</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_PV_DrHkTQkGQmIt0QmW81A"
      decimals="0"
      id="Tc_zToQ4arwok65z3dmmqyn_g_14_5"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">43222</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5CrlobMDMUOFaODMa0mJMQ"
      decimals="0"
      id="Tc_tuTKeIynAU2molaIFMLFbA_14_8"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">277533082</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_NadUN92cUUGeapWWnvOPNw"
      decimals="0"
      id="Tc_ce3DmRe49EyCN6Biebs_Kg_14_11"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-1734078</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pIxGvrDdvkqEyu4JVd03fw"
      decimals="0"
      id="Tc_5EOgkuFy2UO3GM4jFkUTvQ_14_14"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-196626647</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w"
      decimals="0"
      id="Tc_tLBEYTabOUGekk4Vufra3w_14_17"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">79215579</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T3OJIOaoZ0K5JyfOQDRhQA"
      decimals="0"
      id="Tc_wR94-m_KUEe5TSMBa0ctQQ_15_8"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">4020819</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_LVk5fBlauEumBoFW7FXhTg_15_17"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">4020819</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T3OJIOaoZ0K5JyfOQDRhQA"
      decimals="0"
      id="Tc_NlQPZC_T0EW7yVo3r85FcQ_16_8"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-90000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_UD6DPFmrqEmRjbv_Boeh_A_16_17"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-90000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jAS_rLmGI0SmIJDwwikaWw"
      decimals="INF"
      id="Tc_vqQWZB6oGUmNpFb9WBYicg_17_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">106662</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jAS_rLmGI0SmIJDwwikaWw"
      decimals="0"
      id="Tc_INJmsIIAv0K1nK55Q4ygfQ_17_5"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">107</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T3OJIOaoZ0K5JyfOQDRhQA"
      decimals="0"
      id="Tc_1rxdyNPrIEWK9QZFOYKGxg_17_8"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">928310</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_QzEHnrtDp0CdEJFfToPkqQ_17_17"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">928417</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <ctso:StockIssuedDuringPeriodSharesStockCashOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jAS_rLmGI0SmIJDwwikaWw"
      decimals="INF"
      id="Tc_wU7HWYLLRUi79xBRZ8CWxQ_18_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">139102</ctso:StockIssuedDuringPeriodSharesStockCashOptionsExercised>
    <ctso:StockIssuedDuringPeriodValueStockCashOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jAS_rLmGI0SmIJDwwikaWw"
      decimals="0"
      id="Tc_-endv7KjdkqUSjI7vIu8vQ_18_5"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">139</ctso:StockIssuedDuringPeriodValueStockCashOptionsExercised>
    <ctso:StockIssuedDuringPeriodValueStockCashOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T3OJIOaoZ0K5JyfOQDRhQA"
      decimals="0"
      id="Tc_uaCAKaeYXkyt3axF6styIQ_18_8"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">805060</ctso:StockIssuedDuringPeriodValueStockCashOptionsExercised>
    <ctso:StockIssuedDuringPeriodValueStockCashOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_j0zhq8f5WUm6hjSUcS5YVg_18_17"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">805199</ctso:StockIssuedDuringPeriodValueStockCashOptionsExercised>
    <ctso:StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jAS_rLmGI0SmIJDwwikaWw"
      decimals="INF"
      id="Tc_R4G-xXui7EO9O-Wxoxu60Q_19_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">10724</ctso:StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_jAS_rLmGI0SmIJDwwikaWw"
      decimals="0"
      id="Tc_w_tzmTf9AESSCZraB6MRUg_19_5"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">10</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T3OJIOaoZ0K5JyfOQDRhQA"
      decimals="0"
      id="Tc_cOhoDdp_TEei2bad3Ej8gQ_19_8"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-2842</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_NGG1-rfQy0Sw6XQ1T7d5MQ_19_17"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-2832</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_VA7E7P_1tEG-K6jM8v-kFA"
      decimals="0"
      id="Tc_fQXiGRSvq06TcUOH0R6wCQ_20_11"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2259663</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_E5mraqrrg0uvF845vFfvEQ_20_17"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2259663</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5uYZTUv4DUKuTOvKAyxCSQ"
      decimals="0"
      id="Tc_c-uACdKNP0mQ3drgj6i5ZQ_21_14"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-24558648</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_ABha_BuwOE2vlk89M3hVEA_21_17"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-24558648</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CCqJgm4tjU2Hhj1W3f863A"
      decimals="INF"
      id="Tc_-vavTwvETk-nGsieuVROlA_22_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">43478487</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CCqJgm4tjU2Hhj1W3f863A"
      decimals="0"
      id="Tc_fQ9Al2VNU06I2VALHuHIYQ_22_5"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">43478</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_2fpskYPtCkGXfgvSbLwICg"
      decimals="0"
      id="Tc_G1Amz3WZ7EujibCBK0cHoQ_22_8"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">283194429</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0_qpfUCFWUSQSBVH2kIqyw"
      decimals="0"
      id="Tc_90jusGUgJUuu_zlyjO8ufw_22_11"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">525585</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_v2r2g5cGPUySlMPbJ6gPWg"
      decimals="0"
      id="Tc_Jng_m0jL80GVEMyQR-qCKA_22_14"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-221185295</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_g-_nPvCZB0qHqnBTe9vu2w_22_17"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">62578197</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5G127XWFxUipm8wjbbrV0Q"
      decimals="0"
      id="Tc_bKrbggeSHEKiZDLDZbYM7w_23_8"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3423517</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_1yNAMj4R5k6KbXVmVh1yrQ_23_17"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3423517</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5G127XWFxUipm8wjbbrV0Q"
      decimals="0"
      id="Tc_bvvPLl7WiUeIuEyL_RwIaw_24_8"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">40358</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_sIoS0hElykG5iaoNqfP1eQ_24_17"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">40358</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2mGFz-g8vkCyKxzLGK8rRg"
      decimals="INF"
      id="Tc_PI04fhskO0GLe3rB5FByZQ_25_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">144728</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2mGFz-g8vkCyKxzLGK8rRg"
      decimals="0"
      id="Tc_swk1-WS31E2oivtvT5mEhg_25_5"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">145</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5G127XWFxUipm8wjbbrV0Q"
      decimals="0"
      id="Tc__E40p5XDlUSWYkg3QKZomQ_25_8"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">379946</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_QtcSIcAoIEupmVGRQ_MX4Q_25_17"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">380091</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_x19ESOfGok2hRnIOnFg4-w"
      decimals="0"
      id="Tc_KWPvPkFCnEO8VLNOpzgFJQ_26_11"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1803610</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_poXnq8EFbkW1VcH2GAt5Yw_26_17"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1803610</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2mGFz-g8vkCyKxzLGK8rRg"
      decimals="INF"
      id="Tc_vAWi9OfmOkKh6Qn8XWvZKA_27_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">12500</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_2mGFz-g8vkCyKxzLGK8rRg"
      decimals="0"
      id="Tc_AprNp-P3IE-izAd_TR2d3g_27_5"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">12</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_5G127XWFxUipm8wjbbrV0Q"
      decimals="0"
      id="Tc_c4qI9eDRikGY6YpUM75N7Q_27_8"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">42487</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_Nggsyvku1k632WyNC0dJsw_27_17"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">42499</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_OhlDyppT50CWSs02U8PSrA"
      decimals="0"
      id="Tc_s_qHGZGCpkewuhv0AG5mRA_28_14"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-32812583</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_NKnbz4o5QE-F1i9wztRqpw_28_17"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-32812583</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4ADrrvzo1k2uJb6rtAoZXA"
      decimals="INF"
      id="Tc_X8PA6czPgkCFb96ziti-0g_29_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">43635715</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4ADrrvzo1k2uJb6rtAoZXA"
      decimals="0"
      id="Tc_5lof_pof_EuVB02pV-pSRQ_29_5"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">43635</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_oumECbNlIE2GMtb6QWOHIw"
      decimals="0"
      id="Tc_gkPXNaDMakap-uIqwa88Ow_29_8"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">287000021</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_yxInglK_2kaHDsFiaiSgNQ"
      decimals="0"
      id="Tc__U0MBF3RhEyZ7oSFfUZ5tA_29_11"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2329195</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_AUSvWy58u0K_IquBEJ7-vQ"
      decimals="0"
      id="Tc_F5ZQ-DGDU0eYnbzHJbtIBA_29_14"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-253997878</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_OV1xtWTsekOe7uLxCO08_w_29_17"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">35374973</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_nbT6oafBRkmY_3YaN5JCjg_5_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-32812583</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_TJNs5UpU9EG6dCywj7RaYQ_5_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-24558648</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_0Jwf52hxF0qA2RHZEDdLTQ_5_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-7837188</us-gaap:NetIncomeLoss>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_FGZLts0dbE63RWzwh3NjfQ_7_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">376574</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_T_bBLtE0UE-8g9zqKTnyAw_7_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2183317</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_YaqhkgCst0KTCwk7CkeDuA_7_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1193949</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_ujqepajiQkyt2Ho7NGh5oA_8_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">882621</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_c_FZOwWGRECZOJJ3h6_xeQ_8_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">731578</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_oJp5hVpNlUyWE5WnSCmOiQ_8_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">660788</us-gaap:DepreciationAndAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_N_0TYcDjvkuwzgEIJrz8ww_9_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">249008</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_jx4hGj4BQ0a60cWlOeqWDg_9_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">398035</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_7K2NUj6q3EW1UCb9896g8w_10_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-8354</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_9NdsOF23Q0S_O1jL5Lg-Sw_10_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-512</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_RbNZtEldsUquq08A338IuQ_10_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-102310</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_5q-iwi7Fnkmum9hppY5Srg_11_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-132303</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_UIIsZhcpj0SPu3iot2r2Xg_12_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">635606</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_L6hhrydNtkinpuPJX7zL_w_13_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-2448583</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_E94zkNK3VUitj_eOvU6oNA_13_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-2577913</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_4RCzzDnBfk2IoRG1x-ZHCQ_13_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2607139</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_kevs0H5e80iwlRY_lqYT5Q_14_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3423517</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_daA4VdUgPEqQ28zENMD6kw_14_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">4020819</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_K2I_-ixvA0mmAXgmqKbvLg_14_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3513671</us-gaap:ShareBasedCompensation>
    <ctso:AmortizationOfLoanAcquisitionCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_taRp8WTMXkq-KYTAIxuw8g_15_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">322812</ctso:AmortizationOfLoanAcquisitionCosts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_MCifYyChI0em5emB1P_z2A_17_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1288422</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_ZxvRV9KAmUiIPzWJGcrXsA_17_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-420578</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_-60tM55gv0W28nc6_C9QIg_17_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">326860</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_-MXP0CRmSUuYl7v0JFkQfQ_18_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-945352</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_G981KidXrUyVay_uBv8JBQ_18_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2350547</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_q60Qa5eRGk-EVBTxLv3nuA_18_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">461512</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_8yXN6nTHeECRSp3CFPgpCg_19_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">22187</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_OQSTpmlTu0GuP5kTljM5gA_19_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-280915</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_3tY9mrBzV0CzkuLrsn-jWA_19_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1076849</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_gX6hiYoJNk-xQQzW1QWQzQ_20_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-52678</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_DPB8lKWsvkGtOpbV63K37w_20_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">135857</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_7Caj_Hl-6kaN90G5YVxECQ_21_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-3248978</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_580b1fBC90iqg-68Tf_wKA_21_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2426810</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_ATM6nytMdUu9yKwC8DOhdg_21_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1107352</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_NYTe4aMqYU-4S2W0DleLHw_22_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-28234282</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_Wc7e2dsqtkielLWuo2GxZg_22_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-14005599</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_iRz-W3IPjEWFrVrL8sm_Pg_22_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-5613286</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_SPdGxKXhnk2VwGRHP0bR9Q_25_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">6087365</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_0FDvnhNMbk-MQFS83_WtmA_25_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3641248</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_uEKfzgTS4kKrS9s03-HSwQ_25_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">708395</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_tzTlXlXAakSwQtHlxw3Ivw_26_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">368211</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_Eu-IAxV0E0eztV4FD-tjDQ_26_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">640013</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_zApAYlb4OE66u1a6RHt5qA_26_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">967823</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_NsT-Y6AsnkSGxF5ebm-yPA_27_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-6455576</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_pGMMu_-cHUKyoWZkGLIvIA_27_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-4281261</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_gSrV36DZzkaAW8FGPW2qOA_27_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-1676218</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_AGmAS_wKBUKayTXEEcmo5A_30_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_wj56BM0U8020bfnuEp7S0Q_30_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1410900</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_ogDDZvcZBUScSNtv_5NwAQ_31_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">16410900</us-gaap:RepaymentsOfLongTermDebt>
    <ctso:PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_PbwdGumjlkGr6VsSEph1Ng_32_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">375000</ctso:PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument>
    <ctso:PaymentsForEquityContributionsNetOfFeesIncurred
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_h3mmkbgrvEum_Ho7naPI3g_34_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">40358</ctso:PaymentsForEquityContributionsNetOfFeesIncurred>
    <ctso:PaymentsForEquityContributionsNetOfFeesIncurred
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_HKaKbOOR5kGudjecTQ5oHQ_34_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">90000</ctso:PaymentsForEquityContributionsNetOfFeesIncurred>
    <ctso:PaymentsForEquityContributionsNetOfFeesIncurred
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_v-LWfDzinUqvDU8C2Ajz2Q_34_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-80214008</ctso:PaymentsForEquityContributionsNetOfFeesIncurred>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_nMUC6sveW0GmBcGZ6568LQ_35_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">805199</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_Q4gEVdgfEUqzmaKjtWA9-A_35_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1509322</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_X3vkwFu7x0ivdGJSwPTDSg_37_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">4959642</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_tZVVIsdALE2BOOcqVPegnw_37_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">715199</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_OmKDlWhnI0ixO4OLDlSVwg_37_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">66348330</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_D9nYyIpLOUW9t0Qt8qHIWw_38_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-262924</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_IZOHKoVqM0eEcTijt91WvA_38_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-24774</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_TZwr_hYLqU6FbBsgJhyyCw_38_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">130357</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_nzw-9TBva0ywf0i_Jl4f0A_39_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-29993140</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_vo_Leb_n3kacsYpbQrEmYQ_39_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-17596435</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_1vHptUUEFEmnyG6nSdOnPQ_39_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">59189183</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_vhatQPCY5kKuqHy0rRFKBA_41_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">53825166</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w"
      decimals="0"
      id="Tc_o-TMaovzMUy236uBYGwcbA_41_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">71421601</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_6_oqjbutzEKQogf2y7UC6g"
      decimals="0"
      id="Tc_aTpBlzrXAkSwUPo7XyJH9A_41_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">12232418</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_N1mfcS_780ymDaP8K7V86A_42_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">23832026</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_Yz8xsLsvGEK6Wm5Gz0BkGw_42_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">53825166</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w"
      decimals="0"
      id="Tc_9S69T09G-kiWHHa2qhvX9w_42_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">71421601</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_m4u_fk_Nb0SLiRV9OGBPxw_45_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1127647</us-gaap:InterestPaidNet>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_AxDIIYmSoU-TOxI1AXF5fw_48_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">42499</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_L0_moJA-LkOMR9_azdhpzQ_49_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">359965</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:StockIssued1
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_zUeMbrfQ906MZ1W8yrIGtQ_50_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">380091</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_b3jdQTVlJE6fOil42UgzhA_50_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">928417</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_CcJB_dqsLEi5OUJhwHeXXg_50_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">657780</us-gaap:StockIssued1>
    <us-gaap:BasisOfAccounting
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_XtKZNXh82U-5YtCRue-g_Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;1. BASIS OF PRESENTATION:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements include the results of CytoSorbents Corporation (the &#x201c;Parent&#x201d;), CytoSorbents Medical Inc., its wholly owned operating subsidiary (the &#x201c;Subsidiary&#x201d;), and CytoSorbents Europe GmbH, its wholly owned European subsidiary (the &#x201c;European Subsidiary&#x201d;). In addition, the consolidated financial statements include CytoSorbents Switzerland GmbH, CytoSorbents Poland Sp. z.o.o., CytoSorbents Medical UK Limited, and CytoSorbents France SAS, the wholly owned subsidiaries of CytoSorbents Europe GmbH, and CytoSorbents UK Limited, a wholly owned subsidiary of CytoSorbents Medical, Inc. These entities are collectively referred to as the &#x201c;Company&#x201d;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In years prior to December 31, 2020, the Company&#x2019;s consolidated financial statements were prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As of December 31, 2022, the Company&#x2019;s cash, cash equivalents and restricted cash balances were approximately $23.8 million, which the Company expects will fund the Company&#x2019;s operations beyond twelve months from the issuance of these consolidated financial statements. As a result, the Company has determined that the going concern risk has been substantially mitigated.&lt;/p&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:Cash
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="-5"
      id="Narr_PNGhVCBj_ku--JN-2T496A"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">23800000</us-gaap:Cash>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_d0tM0TDKMkeqOpBAImrrxQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2. PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Nature of Business&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification. The Company, through its subsidiary CytoSorbents Medical, Inc. (formerly known as CytoSorbents, Inc.), is engaged in the research, development and commercialization of medical devices with its blood purification technology platform which incorporates a proprietary adsorbent, porous polymer technology. The Company, through its wholly owned European subsidiary, CytoSorbents Europe GmbH, conducts sales and marketing related operations for the CytoSorb device. In March 2016, the Company formed CytoSorbents Switzerland GmbH, a wholly owned subsidiary of CytoSorbents Europe GmbH. This subsidiary, which began operations during the second quarter of 2016, provides marketing and direct sales services in Switzerland. In November 2018, the Company formed CytoSorbents Poland Sp. z.o.o., a wholly owned subsidiary of CytoSorbents Europe GmbH. This subsidiary, which began operations during the first quarter of 2019, provides marketing and direct sales services in Poland. In the third quarter of 2019, the Company formed CytoSorbents UK Limited, a wholly owned subsidiary of CytoSorbents Medical, Inc., which is responsible for the management of the Company&#x2019;s clinical trial activities in the United Kingdom. In March 2022, the Company formed CytoSorbents Medical UK Limited to provide marketing and direct sales services in the United Kingdom and the Republic of Ireland. In October 2022, the Company formed CytoSorbents France SAS to provide marketing and direct sales services in France. CytoSorb, the Company&#x2019;s flagship product, was approved in the European Union (&#x201c;EU&#x201d;) in March 2011 and is currently being marketed and distributed in more than 75 countries around the world, as an effective extracorporeal cytokine absorber, designed to reduce the &#x201c;cytokine storm&#x201d; or &#x201c;cytokine release syndrome&#x201d; seen in critical illnesses that may result in massive inflammation, organ failure, and patient death. In May 2018, the Company received a label extension for CytoSorb covering use of the device for the removal of bilirubin and myoglobin which allows for the use of the device in the treatment of liver failure and trauma, respectively. CytoSorb is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. In January 2020, CytoSorb received EU CE Mark label expansion to include the removal of ticagrelor during cardiopulmonary bypass in patients undergoing cardiothoracic surgery. In May 2020, CytoSorb also received EU CE Mark label expansion to include rivaroxaban removal for the same indication.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In April 2020, CytoSorb received United States Food and Drug Administration (&#x201c;FDA&#x201d;) Emergency Use Authorization (&#x201c;EUA&#x201d;) of CytoSorb for use in adult critically-ill COVID-19 patients with imminent or confirmed respiratory failure. The CytoSorb device has neither been cleared nor approved for the indication to treat patients with COVID-19 infection. The EUA will be effective until a declaration is made that the circumstances justifying the EUA have terminated or until revoked by the FDA.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In April 2020, the Company also announced that the FDA had granted Breakthrough Designation for its DrugSorb-ATR Antithrombotic Removal System for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery. The Breakthrough Devices Program provides for more effective treatment of life-threatening or irreversibly debilitating disease or conditions, in this case the need to reverse the effects of ticagrelor in emergent or urgent cardiac surgery that can otherwise cause a high risk of serious or life-threatening bleeding. Through Breakthrough Designation, the FDA intends to work with CytoSorbents to expedite the development, assessment, and regulatory review of CytoSorbents&#x2019; technology for the removal of ticagrelor, while maintaining statutory standards of regulatory approval (e.g., 510(k), &lt;i style="font-style:italic;"&gt;de novo&lt;/i&gt; 510(k) or premarket approval) consistent with the FDA&#x2019;s mission to protect and promote public health. In July 2021, the Company received full approval of its Investigative Device Exemption (&#x201c;IDE&#x201d;) to conduct the pivotal STAR-T (Safe and Timely Antithrombotic Removal &#x2013; Ticagrelor) double-blind randomized control trial (&#x201c;RCT&#x201d;) for up to 120 patients in the United States to support FDA marketing approval.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2021, the Company announced that it was granted a second Breakthrough Device designation for its DrugSorb-ATR Antithrombotic Removal System by the FDA. This Breakthrough Device designation covers the removal of the Direct Oral Anticoagulants (DOACs) apixaban and rivaroxaban in a cardiopulmonary bypass circuit to reduce the likelihood of serious perioperative bleeding during urgent cardiothoracic surgery. In October 2021, the Company also received full FDA approval of an IDE application to conduct a double-blind, randomized, controlled clinical study for up to 120 patients entitled, &#x201c;Safe and Timely Antithrombotic Removal &#x2013; Direct Oral Anticoagulants (STAR-D),&#x201d; in the United States to support FDA marketing approval.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;If FDA marketing approval is obtained for either the removal of ticagrelor or direct oral anticoagulants indications, the device would be marketed as DrugSorb-ATR in the United States. The DrugSorb-ATR Antithrombotic Removal System is based on the same polymer technology as CytoSorb.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In May 2022, the Company announced that the Company entered into a 3-year preferred supplier agreement with Asklepios, making CytoSorb available without restrictions to all of the approximate 170 healthcare facilities across 14 states throughout Germany at which Asklepios operates. This includes Asklepios Klinik St. Georg in Hamburg, Germany, which pioneered the use of CytoSorb to remove antithrombotic drugs during cardiothoracic surgery, and is well-known for their seminal publication on CytoSorb use for this application during emergency cardiac surgery in patients at high risk of bleeding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2022, the Company announced that, following a successful pilot program in three countries, the Company signed an expanded non-exclusive agreement with Nikkiso Europe GmbH (&#x201c;Nikkiso&#x201d;) to distribute Nikkiso&#x2019;s PureADJUST stand-alone hemoperfusion pump and accessories in a total of 14 countries. In addition to securing the rights to sell Nikkiso&#x2019;s stand-alone pump and accessories in Germany, Austria, and Luxembourg, the Company entered into an expanded multi-country reseller agreement with Nikkiso covering the following countries: Belgium, Bosnia and Herzegovina, Croatia, Finland, France, Iceland, Lichtenstein, Poland, Serbia, Slovenia and Switzerland. The Company will also be able to provide field support services in these countries.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2022, the Company entered into a Marketing Agreement (the &#x201c;Marketing Agreement&#x201d;) with Fresenius Medical Care Deutschland GmbH (&#x201c;Fresenius&#x201d;), which expands the Company&#x2019;s strategic partnership with Fresenius by establishing a multi-stage global collaboration to combat life-threatening diseases in critical care. The Marketing Agreement provides for the combined marketing and promotion of CytoSorb with Fresenius&#x2019; critical care products by Fresenius&#x2019; marketing organization worldwide, excluding the United States. The Marketing Agreement has an initial term of three years, with an automatic renewal for an additional two years at the end of such initial term, subject to earlier termination by either of the parties (the &#x201c;Term&#x201d;). Compared to the prior co-marketing agreement between the parties, the Marketing Agreement intends to increase the commitments from both parties and to ensure an ongoing and consistent level of marketing and promotional activity specifically focused around CytoSorb, where Fresenius will actively market and promote CytoSorb as the featured blood purification therapy for removal of cytokines, bilirubin, and myoglobin on its critical care platforms. Specifically, the Marketing Agreement provides that various Fresenius-led in-person, virtual, social media, and web-based marketing programs and events will feature the CytoSorb therapy and highlight the cooperation between the two companies in the field of critical care during the Term. To help support the increased marketing and promotional efforts of the expanded collaboration, CytoSorbents has agreed to subsidize a portion of the marketing costs through a royalty payment to Fresenius Medical Care based on CytoSorb sales in the intensive care unit on Fresenius Medical Care platforms, excluding the United States. In addition to strengthening and expanding the global marketing of CytoSorb, the Company and Fresenius also plan to work together to bring new innovative solutions to the market. The Marketing Agreement also includes the certification of compatibility of CytoSorb for usage on Fresenius&#x2019; current critical care platforms. Certain initial activities have been completed with the formal launch of this program expected to occur sometime in 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The technology is based upon biocompatible, highly porous polymer sorbent beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company has numerous products under development based upon this unique blood purification technology, which is protected by 18 issued U.S. patents and multiple international patents, with applications pending both in the U.S. and internationally, including HemoDefend, ContrastSorb, DrugSorb, DrugSorb-ATR and others. These patents and patent applications are directed to various compositions and methods of use related to the Company&#x2019;s blood purification technologies and are expected to expire between 2023 and 2038, absent any patent term extensions. Management believes that any near-term expiring patents will not have a significant impact on the Company&#x2019;s ongoing business.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Market Listing&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December&#160;17, 2014 the Company&#x2019;s common stock was approved for listing on The Nasdaq Capital Market (&#x201c;Nasdaq&#x201d;), and it began trading on Nasdaq on December&#160;23, 2014 under the symbol &#x201c;CTSO&#x201d;. Previously, the Company&#x2019;s common stock traded in the over-the-counter-market on the OTC Bulletin Board.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Consolidation and Foreign Currency Translation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements include the accounts of CytoSorbents Corporation and its wholly owned subsidiaries, CytoSorbents Medical, Inc. and CytoSorbents Europe GmbH. In addition, the consolidated financial statements include CytoSorbents Switzerland GmbH, CytoSorbents Poland Sp. z.o.o., CytoSorbents Medical UK Limited and CytoSorbents France SAS, wholly owned subsidiaries of CytoSorbents Europe GmbH, and CytoSorbents UK Limited, a wholly owned subsidiary of CytoSorbents Medical, Inc. All significant intercompany transactions and balances have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Translation gains and losses resulting from the process of remeasuring into the United States of America dollar, the foreign currency financial statements of the European subsidiary, for which the United States of America dollar is the functional currency, are included in operations. Foreign currency transaction gain (loss) included in net loss amounted to approximately $(2,448,000), $(2,578,000) and $2,607,000 for the years ended December 31, 2022, 2021 and 2020, respectively. The Company translates assets and liabilities of the European subsidiary, whose functional currency is their local currency, at the exchange rate in effect at the balance sheet date. The Company translates revenue and expenses at the daily average exchange rates. The Company includes accumulated net translation adjustments in accumulated other comprehensive income (loss) as a component of stockholders&#x2019; equity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid instruments purchased with an original maturity of three&#160;months or less to be cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash and cash equivalents to amounts shown in the consolidated balance sheets and consolidated statements of cash flows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;22,144,567 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 52,137,707&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,687,459&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,687,459&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,832,026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 53,825,166&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s total restricted cash in the amount of $1,687,459 consists of cash of $1,467,459 that the Company is obligated to maintain as collateral for the outstanding letter of credit with Bridge Bank that was provided to the landlord of the College Road facility as security and cash of $220,000 that the Company is obligated to maintain as collateral for the credit limit on the Company&#x2019;s credit card account.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Grants and Accounts Receivable&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Grants receivable represent amounts due from U.S. government agencies and are included in grants and accounts Receivable in the accompanying consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accounts receivable are unsecured, non-interest-bearing customer obligations due under normal trade terms. The Company sells its devices to various hospitals and distributors. The Company performs ongoing credit evaluations of customers&#x2019; financial condition. Management reviews accounts receivable periodically to determine collectability. Balances that are determined to be uncollectible are reserved in the allowance for doubtful accounts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Inventories&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventories are valued at the lower of cost or net realizable value. Cost is determined using a first-in first-out (&#x201c;FIFO&#x201d;) basis. At December 31, 2022 and 2021, the Company&#x2019;s inventory was comprised of finished goods, which amounted to $1,567,871 and $3,084,606, respectively, work in process which amounted to $1,280,368 and $1,322,736, respectively, and raw materials which amounted to $613,347 and $358,756, respectively. Devices used in clinical trials or for research and development purposes are removed from inventory and charged to research and development expenses at the time of their use.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In September 2022, the Company experienced an equipment failure of a refrigeration unit at its new College Road manufacturing facility. This equipment stored various items of work-in-process inventory. The Company determined all the items that were stored in this unit were required to be scrapped. The value of this inventory was approximately $599,000. Accordingly, this inventory was written off and was included in cost of goods sold at the time of the loss in September 2022. The Company filed a claim with its insurance carrier related to this loss. In December 2022, the claim was approved in the amount of approximately $299,000 and, accordingly, has been recorded as a reduction to cost of goods sold in the accompanying consolidated statement of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are recorded at cost less accumulated depreciation. Depreciation of property and equipment is provided for by the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the lesser of their economic useful lives or the term of the related leases. Gains and losses on depreciable assets retired or sold are recognized in the statements of operations in the&#160;year of disposal. Repairs and maintenance expenditures are expensed as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Patents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Legal costs incurred to establish patents are capitalized. When patents are issued, capitalized costs are amortized on the straight-line method over the related patent term. In the event a patent is abandoned, the net book value of the patent is written off.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Impairment or Disposal of Long-Lived Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company assesses the impairment of patents and other long-lived assets under accounting standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value. During the year ended December 31, 2022, the Company wrote-off patent costs of approximately $636,000 related to the impairment of certain issued patents and pending patent applications in certain specific jurisdictions, the abandonment of certain patent defense costs that are no longer being pursued and the abandonment of certain pending patent application costs in the ordinary course of business.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Product Sales:&lt;/i&gt; Revenues from sales of products to both direct and distributor/strategic partner customers are recognized at the time when control passes to the customer, in accordance with the terms of their respective contracts. Recognition of revenue occurs as each performance obligation is completed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Grant Revenue: &lt;/i&gt;Revenue from grant income is based on contractual agreements with various agencies of the U.S. government. Certain agreements provide for reimbursement of costs, other agreements provide for reimbursement of costs and an overhead margin and certain agreements are performance based, where revenue is earned based upon the achievement of milestones outlined in the contract. Revenues are recognized when the associated performance obligation is fulfilled. Costs are recorded as incurred. Amounts invoiced in excess of costs actually incurred on fixed price contracts are classified as deferred revenue and are included in accrued expenses and other current liabilities in the consolidated balance sheets. Costs subject to reimbursement by these grants have been reflected as costs of revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;All research and development costs, payments to laboratories, research consultants and costs related to clinical trials and studies are expensed when incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Advertising Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Advertising costs are charged to activities when incurred. Advertising expense amounted to approximately $582,000, $615,000 and $285,000 in 2022, 2021 and 2020, respectively, and is included in selling, general, and administrative expenses in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes are accounted for under the asset and liability method prescribed by accounting standards for accounting for income taxes. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax asset will not be realized. Under Section 382 of the Internal Revenue Code, the net operating losses generated prior to the previously completed reverse merger may be limited due to the change in ownership. Additionally, net operating losses generated subsequent to the reverse merger may be limited in the event of changes in ownership. In 2017, the Tax Cuts and Jobs Act reduced the U.S. federal corporate tax rate from 35% to 21%. See Note&#160;9 for the impact of the tax rate change on deferred tax assets and liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company follows the accounting standards associated with uncertain tax provisions. The Company had no unrecognized tax benefits as of December 31, 2022 or 2021. The Company files tax returns in the U.S. federal and state jurisdictions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company utilizes the Technology Business Tax Certificate Transfer Program to sell a portion of its New Jersey Net Operating Loss tax carryforwards and Research and Development credits to an industrial company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;CytoSorbents Europe GmbH, CytoSorbents Switzerland GmbH, CytoSorbents Poland Sp. z.o.o., CytoSorbents UK Limited, CytoSorbents Medical UK Limited and CytoSorbents France file an annual corporate tax return, a VAT return and a trade tax return in Germany, Switzerland, Poland, France and the United Kingdom, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets, liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. The valuation of options granted, allowance for doubtful accounts and recoverability of patents are significant estimates in these consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A significant portion of the Company&#x2019;s revenues are from product sales in Germany. Substantially all of the Company&#x2019;s grant and other income are from grant agencies in the United States. (See Note&#160;3 for further information relating to the Company&#x2019;s revenue.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022, two distributors accounted for approximately 27% of outstanding grants and accounts receivables. As of December 31, 2021, one distributor accounted for approximately 12% of outstanding grants and accounts receivables. For the years ended December 31, 2022, 2021 and 2020, no agency, distributor/strategic partners or direct customer represented more than 10% of the Company&#x2019;s total revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their short-term nature.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss per Common Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed using the treasury stock method on the basis of the weighted-average number of shares of common stock plus the dilutive effect of potential common shares outstanding during the period. Dilutive potential common shares include outstanding warrants, stock options and restricted shares. The computation of diluted net loss per share does not assume conversion, exercise or contingent exercise of securities that would have an anti-dilutive effect on earnings (see Note&#160;12).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for its stock-based compensation under the recognition requirements of accounting standards for accounting for stock-based compensation for employees and directors whereby each option granted is valued at fair market value on the date of grant. Under these accounting standards, the fair value of each option is estimated on the date of grant using the Black-Scholes option pricing model.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company also follows the guidance of accounting standards for accounting for equity instruments that are issued to non-employees for acquiring, or in conjunction with selling, goods or services for equity instruments issued to consultants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Shipping and Handling Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The cost of shipping product to customers and distributors is typically borne by the customer or distributor. The Company records shipping and handling costs in cost of revenue. Total freight costs amounted to approximately $297,000, $276,000 and $560,000 for the&#160;years ended December 31, 2022, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Effect of Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2021, the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;), issued Accounting Standards Update No. 2021-10 entitled, &#x201c;Government Assistance (Topic 832) Disclosures by Business Entities about Government Assistance&#x201d; (the &#x201c;ASU&#x201d;). This ASU will require enhanced disclosures related to the Company&#x2019;s contracts with the U.S. government. The ASU is effective for annual periods beginning after December 15, 2021. The Company implemented the provisions of this ASU during 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In June 2016, the FASB, issued ASU No. 2016-13 entitled, &#x201c;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&#x201d;. This ASU provides guidance on the calculation of credit losses, which includes the allowance for doubtful accounts on trade accounts receivable. The updated guidance is effective for public entities for fiscal years beginning after December 15, 2022. The Company is evaluating the impact of the updated guidance but does not believe that this will have a significant impact on its financial statements.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <ctso:NatureOfBusinessPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_k7jeSVsjRU-R4aEg4WMzJw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Nature of Business&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification. The Company, through its subsidiary CytoSorbents Medical, Inc. (formerly known as CytoSorbents, Inc.), is engaged in the research, development and commercialization of medical devices with its blood purification technology platform which incorporates a proprietary adsorbent, porous polymer technology. The Company, through its wholly owned European subsidiary, CytoSorbents Europe GmbH, conducts sales and marketing related operations for the CytoSorb device. In March 2016, the Company formed CytoSorbents Switzerland GmbH, a wholly owned subsidiary of CytoSorbents Europe GmbH. This subsidiary, which began operations during the second quarter of 2016, provides marketing and direct sales services in Switzerland. In November 2018, the Company formed CytoSorbents Poland Sp. z.o.o., a wholly owned subsidiary of CytoSorbents Europe GmbH. This subsidiary, which began operations during the first quarter of 2019, provides marketing and direct sales services in Poland. In the third quarter of 2019, the Company formed CytoSorbents UK Limited, a wholly owned subsidiary of CytoSorbents Medical, Inc., which is responsible for the management of the Company&#x2019;s clinical trial activities in the United Kingdom. In March 2022, the Company formed CytoSorbents Medical UK Limited to provide marketing and direct sales services in the United Kingdom and the Republic of Ireland. In October 2022, the Company formed CytoSorbents France SAS to provide marketing and direct sales services in France. CytoSorb, the Company&#x2019;s flagship product, was approved in the European Union (&#x201c;EU&#x201d;) in March 2011 and is currently being marketed and distributed in more than 75 countries around the world, as an effective extracorporeal cytokine absorber, designed to reduce the &#x201c;cytokine storm&#x201d; or &#x201c;cytokine release syndrome&#x201d; seen in critical illnesses that may result in massive inflammation, organ failure, and patient death. In May 2018, the Company received a label extension for CytoSorb covering use of the device for the removal of bilirubin and myoglobin which allows for the use of the device in the treatment of liver failure and trauma, respectively. CytoSorb is also being used during and after cardiac surgery to remove inflammatory mediators that can lead to post-operative complications, including multiple organ failure. In January 2020, CytoSorb received EU CE Mark label expansion to include the removal of ticagrelor during cardiopulmonary bypass in patients undergoing cardiothoracic surgery. In May 2020, CytoSorb also received EU CE Mark label expansion to include rivaroxaban removal for the same indication.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In April 2020, CytoSorb received United States Food and Drug Administration (&#x201c;FDA&#x201d;) Emergency Use Authorization (&#x201c;EUA&#x201d;) of CytoSorb for use in adult critically-ill COVID-19 patients with imminent or confirmed respiratory failure. The CytoSorb device has neither been cleared nor approved for the indication to treat patients with COVID-19 infection. The EUA will be effective until a declaration is made that the circumstances justifying the EUA have terminated or until revoked by the FDA.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In April 2020, the Company also announced that the FDA had granted Breakthrough Designation for its DrugSorb-ATR Antithrombotic Removal System for the removal of ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery. The Breakthrough Devices Program provides for more effective treatment of life-threatening or irreversibly debilitating disease or conditions, in this case the need to reverse the effects of ticagrelor in emergent or urgent cardiac surgery that can otherwise cause a high risk of serious or life-threatening bleeding. Through Breakthrough Designation, the FDA intends to work with CytoSorbents to expedite the development, assessment, and regulatory review of CytoSorbents&#x2019; technology for the removal of ticagrelor, while maintaining statutory standards of regulatory approval (e.g., 510(k), &lt;i style="font-style:italic;"&gt;de novo&lt;/i&gt; 510(k) or premarket approval) consistent with the FDA&#x2019;s mission to protect and promote public health. In July 2021, the Company received full approval of its Investigative Device Exemption (&#x201c;IDE&#x201d;) to conduct the pivotal STAR-T (Safe and Timely Antithrombotic Removal &#x2013; Ticagrelor) double-blind randomized control trial (&#x201c;RCT&#x201d;) for up to 120 patients in the United States to support FDA marketing approval.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2021, the Company announced that it was granted a second Breakthrough Device designation for its DrugSorb-ATR Antithrombotic Removal System by the FDA. This Breakthrough Device designation covers the removal of the Direct Oral Anticoagulants (DOACs) apixaban and rivaroxaban in a cardiopulmonary bypass circuit to reduce the likelihood of serious perioperative bleeding during urgent cardiothoracic surgery. In October 2021, the Company also received full FDA approval of an IDE application to conduct a double-blind, randomized, controlled clinical study for up to 120 patients entitled, &#x201c;Safe and Timely Antithrombotic Removal &#x2013; Direct Oral Anticoagulants (STAR-D),&#x201d; in the United States to support FDA marketing approval.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;If FDA marketing approval is obtained for either the removal of ticagrelor or direct oral anticoagulants indications, the device would be marketed as DrugSorb-ATR in the United States. The DrugSorb-ATR Antithrombotic Removal System is based on the same polymer technology as CytoSorb.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In May 2022, the Company announced that the Company entered into a 3-year preferred supplier agreement with Asklepios, making CytoSorb available without restrictions to all of the approximate 170 healthcare facilities across 14 states throughout Germany at which Asklepios operates. This includes Asklepios Klinik St. Georg in Hamburg, Germany, which pioneered the use of CytoSorb to remove antithrombotic drugs during cardiothoracic surgery, and is well-known for their seminal publication on CytoSorb use for this application during emergency cardiac surgery in patients at high risk of bleeding.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2022, the Company announced that, following a successful pilot program in three countries, the Company signed an expanded non-exclusive agreement with Nikkiso Europe GmbH (&#x201c;Nikkiso&#x201d;) to distribute Nikkiso&#x2019;s PureADJUST stand-alone hemoperfusion pump and accessories in a total of 14 countries. In addition to securing the rights to sell Nikkiso&#x2019;s stand-alone pump and accessories in Germany, Austria, and Luxembourg, the Company entered into an expanded multi-country reseller agreement with Nikkiso covering the following countries: Belgium, Bosnia and Herzegovina, Croatia, Finland, France, Iceland, Lichtenstein, Poland, Serbia, Slovenia and Switzerland. The Company will also be able to provide field support services in these countries.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2022, the Company entered into a Marketing Agreement (the &#x201c;Marketing Agreement&#x201d;) with Fresenius Medical Care Deutschland GmbH (&#x201c;Fresenius&#x201d;), which expands the Company&#x2019;s strategic partnership with Fresenius by establishing a multi-stage global collaboration to combat life-threatening diseases in critical care. The Marketing Agreement provides for the combined marketing and promotion of CytoSorb with Fresenius&#x2019; critical care products by Fresenius&#x2019; marketing organization worldwide, excluding the United States. The Marketing Agreement has an initial term of three years, with an automatic renewal for an additional two years at the end of such initial term, subject to earlier termination by either of the parties (the &#x201c;Term&#x201d;). Compared to the prior co-marketing agreement between the parties, the Marketing Agreement intends to increase the commitments from both parties and to ensure an ongoing and consistent level of marketing and promotional activity specifically focused around CytoSorb, where Fresenius will actively market and promote CytoSorb as the featured blood purification therapy for removal of cytokines, bilirubin, and myoglobin on its critical care platforms. Specifically, the Marketing Agreement provides that various Fresenius-led in-person, virtual, social media, and web-based marketing programs and events will feature the CytoSorb therapy and highlight the cooperation between the two companies in the field of critical care during the Term. To help support the increased marketing and promotional efforts of the expanded collaboration, CytoSorbents has agreed to subsidize a portion of the marketing costs through a royalty payment to Fresenius Medical Care based on CytoSorb sales in the intensive care unit on Fresenius Medical Care platforms, excluding the United States. In addition to strengthening and expanding the global marketing of CytoSorb, the Company and Fresenius also plan to work together to bring new innovative solutions to the market. The Marketing Agreement also includes the certification of compatibility of CytoSorb for usage on Fresenius&#x2019; current critical care platforms. Certain initial activities have been completed with the formal launch of this program expected to occur sometime in 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The technology is based upon biocompatible, highly porous polymer sorbent beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company has numerous products under development based upon this unique blood purification technology, which is protected by 18 issued U.S. patents and multiple international patents, with applications pending both in the U.S. and internationally, including HemoDefend, ContrastSorb, DrugSorb, DrugSorb-ATR and others. These patents and patent applications are directed to various compositions and methods of use related to the Company&#x2019;s blood purification technologies and are expected to expire between 2023 and 2038, absent any patent term extensions. Management believes that any near-term expiring patents will not have a significant impact on the Company&#x2019;s ongoing business.&lt;/p&gt;</ctso:NatureOfBusinessPolicyPolicyTextBlock>
    <ctso:NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="INF"
      id="Narr_rqZ6K_yZqkCl6zrIJfXanQ"
      unitRef="Unit_Standard_country_S-K5wYygeEuMMDPQgfGhxg">75</ctso:NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed>
    <ctso:NumberOfPatentsUnitedStates
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="INF"
      id="Narr_Yl04DjUm5Eu9v3S8Q2AvSA"
      unitRef="Unit_Standard_patent_iyucGb4rrEygLz5tIoEXtA">18</ctso:NumberOfPatentsUnitedStates>
    <ctso:StockMarketListingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_Y62CZ6wEj0O2eXCy7UTlyg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Market Listing&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December&#160;17, 2014 the Company&#x2019;s common stock was approved for listing on The Nasdaq Capital Market (&#x201c;Nasdaq&#x201d;), and it began trading on Nasdaq on December&#160;23, 2014 under the symbol &#x201c;CTSO&#x201d;. Previously, the Company&#x2019;s common stock traded in the over-the-counter-market on the OTC Bulletin Board.&lt;/p&gt;</ctso:StockMarketListingPolicyPolicyTextBlock>
    <ctso:ConsolidationAndForeignCurrencyTranslationPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb__vortbNCa0G6ITGW_bEDnA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Consolidation and Foreign Currency Translation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements include the accounts of CytoSorbents Corporation and its wholly owned subsidiaries, CytoSorbents Medical, Inc. and CytoSorbents Europe GmbH. In addition, the consolidated financial statements include CytoSorbents Switzerland GmbH, CytoSorbents Poland Sp. z.o.o., CytoSorbents Medical UK Limited and CytoSorbents France SAS, wholly owned subsidiaries of CytoSorbents Europe GmbH, and CytoSorbents UK Limited, a wholly owned subsidiary of CytoSorbents Medical, Inc. All significant intercompany transactions and balances have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Translation gains and losses resulting from the process of remeasuring into the United States of America dollar, the foreign currency financial statements of the European subsidiary, for which the United States of America dollar is the functional currency, are included in operations. Foreign currency transaction gain (loss) included in net loss amounted to approximately $(2,448,000), $(2,578,000) and $2,607,000 for the years ended December 31, 2022, 2021 and 2020, respectively. The Company translates assets and liabilities of the European subsidiary, whose functional currency is their local currency, at the exchange rate in effect at the balance sheet date. The Company translates revenue and expenses at the daily average exchange rates. The Company includes accumulated net translation adjustments in accumulated other comprehensive income (loss) as a component of stockholders&#x2019; equity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ctso:ConsolidationAndForeignCurrencyTranslationPolicyPolicyTextBlock>
    <ctso:ForeignCurrencyTransactionGainLossExcludingTax
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Narr_atXaV90tyE64yFEmOchDCA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-2448000</ctso:ForeignCurrencyTransactionGainLossExcludingTax>
    <ctso:ForeignCurrencyTransactionGainLossExcludingTax
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Narr_EgXE6xtpaUqLjptdeOSVGA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-2578000</ctso:ForeignCurrencyTransactionGainLossExcludingTax>
    <ctso:ForeignCurrencyTransactionGainLossExcludingTax
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Narr_Depquy9HHUGQZAKGrg0Nbw"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2607000</ctso:ForeignCurrencyTransactionGainLossExcludingTax>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_-nu9ZPiv-0i1kkTtpA-kuQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly liquid instruments purchased with an original maturity of three&#160;months or less to be cash equivalents.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash and cash equivalents to amounts shown in the consolidated balance sheets and consolidated statements of cash flows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;22,144,567 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 52,137,707&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,687,459&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,687,459&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,832,026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 53,825,166&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <ctso:ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_aWE5qIXHiUCaxNwGqMlpFw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;22,144,567 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 52,137,707&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,687,459&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,687,459&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:69.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,832,026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 53,825,166&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ctso:ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_v4zLB0VDNk-MENAm4AFgpw_3_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">22144567</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_mhiLrj-LoUS07DiHL4cnIw_3_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">52137707</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_Iq9JC6HRZEWPFzn5QTDVfg_4_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1687459</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_mTgOhxiTJE694iNGc5g1_w_4_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1687459</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_FuBbsDET0kyaXDL-m_5XdA_5_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">23832026</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_GNPm7nVHtUOj-HSuKuKW0A_5_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">53825166</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_1aSdw7tW_EWKYbltcYoroQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s total restricted cash in the amount of $1,687,459 consists of cash of $1,467,459 that the Company is obligated to maintain as collateral for the outstanding letter of credit with Bridge Bank that was provided to the landlord of the College Road facility as security and cash of $220,000 that the Company is obligated to maintain as collateral for the credit limit on the Company&#x2019;s credit card account.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Narr_vXqEoIA8fkC9AnTBLxAIrw"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1687459</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:DebtInstrumentCollateralAmount
      contextRef="As_Of_12_31_2022_us-gaap_CreditFacilityAxis_us-gaap_LetterOfCreditMember_pd77Iy0ZEkG2yi4BhLTLbw"
      decimals="0"
      id="Narr_zLu5zeILHkGW7crrLes-Fg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1467459</us-gaap:DebtInstrumentCollateralAmount>
    <us-gaap:DebtInstrumentCollateralAmount
      contextRef="As_Of_12_31_2022_us-gaap_CreditFacilityAxis_us-gaap_CreditCardMember_10pNVCROt0uc0geHUcOPJg"
      decimals="0"
      id="Narr_aMpsK-Xhm0aS-DhVyfl6GA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">220000</us-gaap:DebtInstrumentCollateralAmount>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_FjJbYhLOxEi9Xv2gM-0O6w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Grants and Accounts Receivable&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Grants receivable represent amounts due from U.S. government agencies and are included in grants and accounts Receivable in the accompanying consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accounts receivable are unsecured, non-interest-bearing customer obligations due under normal trade terms. The Company sells its devices to various hospitals and distributors. The Company performs ongoing credit evaluations of customers&#x2019; financial condition. Management reviews accounts receivable periodically to determine collectability. Balances that are determined to be uncollectible are reserved in the allowance for doubtful accounts.&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_ZK8YUadA_0-RVaE35Npe3g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Inventories&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Inventories are valued at the lower of cost or net realizable value. Cost is determined using a first-in first-out (&#x201c;FIFO&#x201d;) basis. At December 31, 2022 and 2021, the Company&#x2019;s inventory was comprised of finished goods, which amounted to $1,567,871 and $3,084,606, respectively, work in process which amounted to $1,280,368 and $1,322,736, respectively, and raw materials which amounted to $613,347 and $358,756, respectively. Devices used in clinical trials or for research and development purposes are removed from inventory and charged to research and development expenses at the time of their use.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In September 2022, the Company experienced an equipment failure of a refrigeration unit at its new College Road manufacturing facility. This equipment stored various items of work-in-process inventory. The Company determined all the items that were stored in this unit were required to be scrapped. The value of this inventory was approximately $599,000. Accordingly, this inventory was written off and was included in cost of goods sold at the time of the loss in September 2022. The Company filed a claim with its insurance carrier related to this loss. In December 2022, the claim was approved in the amount of approximately $299,000 and, accordingly, has been recorded as a reduction to cost of goods sold in the accompanying consolidated statement of operations and comprehensive loss.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Narr_bLoj7FiQ-UC1EFkQKP-Jyg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1567871</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Narr_QUOTk2A-8ky1b1OWds1icg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3084606</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryWorkInProcess
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Narr_Lmh9QnwbiUut8px3GtCwXA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1280368</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Narr_YzcFUBQnpUuGcmDnaZtWJA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1322736</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Narr_UxRWXW_VUk2a3pbHGbGwOQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">613347</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Narr_cMNJrpE_60SO6MOWsn97Bg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">358756</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryAdjustments
      contextRef="As_Of_9_30_2022_lBauhAm9gkWSn63bQjLUkw"
      decimals="0"
      id="Narr_sfAOJHj_mkWe5vdV7YqfBg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">599000</us-gaap:InventoryAdjustments>
    <ctso:InsuranceSettlementReceivableForLossOnInventoryRecordedAsReductionToCostOfGoodsSold
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_CargoAndFreightMember_vWKDoEIhEUOKRvy4A7Wi5w"
      decimals="0"
      id="Narr_fwr3hycSRECLKudURkBVZQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">299000</ctso:InsuranceSettlementReceivableForLossOnInventoryRecordedAsReductionToCostOfGoodsSold>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_Lol91fFtZkqurTyJGcpXUg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are recorded at cost less accumulated depreciation. Depreciation of property and equipment is provided for by the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized over the lesser of their economic useful lives or the term of the related leases. Gains and losses on depreciable assets retired or sold are recognized in the statements of operations in the&#160;year of disposal. Repairs and maintenance expenditures are expensed as incurred.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_YbLOQKQkUkOjXBYav-LjWQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Patents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Legal costs incurred to establish patents are capitalized. When patents are issued, capitalized costs are amortized on the straight-line method over the related patent term. In the event a patent is abandoned, the net book value of the patent is written off.&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_yYzwdMj-7ku7EYitshRDcg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Impairment or Disposal of Long-Lived Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company assesses the impairment of patents and other long-lived assets under accounting standards for the impairment or disposal of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value. During the year ended December 31, 2022, the Company wrote-off patent costs of approximately $636,000 related to the impairment of certain issued patents and pending patent applications in certain specific jurisdictions, the abandonment of certain patent defense costs that are no longer being pursued and the abandonment of certain pending patent application costs in the ordinary course of business.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <ctso:WroteOffPatentsCosts
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Narr_Zki293W9f0CVl9C_LvFMMQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">636000</ctso:WroteOffPatentsCosts>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_BPfgeEcJY0Cz8CGyq5E6BA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Product Sales:&lt;/i&gt; Revenues from sales of products to both direct and distributor/strategic partner customers are recognized at the time when control passes to the customer, in accordance with the terms of their respective contracts. Recognition of revenue occurs as each performance obligation is completed.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Grant Revenue: &lt;/i&gt;Revenue from grant income is based on contractual agreements with various agencies of the U.S. government. Certain agreements provide for reimbursement of costs, other agreements provide for reimbursement of costs and an overhead margin and certain agreements are performance based, where revenue is earned based upon the achievement of milestones outlined in the contract. Revenues are recognized when the associated performance obligation is fulfilled. Costs are recorded as incurred. Amounts invoiced in excess of costs actually incurred on fixed price contracts are classified as deferred revenue and are included in accrued expenses and other current liabilities in the consolidated balance sheets. Costs subject to reimbursement by these grants have been reflected as costs of revenue.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_626F5jiU_0iyMjKUNQYW5A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;All research and development costs, payments to laboratories, research consultants and costs related to clinical trials and studies are expensed when incurred.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_Nr_UwEugdk6SGO75Zr59sQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Advertising Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Advertising costs are charged to activities when incurred. Advertising expense amounted to approximately $582,000, $615,000 and $285,000 in 2022, 2021 and 2020, respectively, and is included in selling, general, and administrative expenses in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Narr_mDUv65SLU0WqGG9RKwcdmQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">582000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Narr_PZSeHs5D70K2-0vabgkOrA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">615000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Narr_SB-pi8FKcUq2N9JSFe3a_g"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">285000</us-gaap:AdvertisingExpense>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_XXq03edQ7UK9ncqo5hpDGQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes are accounted for under the asset and liability method prescribed by accounting standards for accounting for income taxes. Deferred income taxes are recorded for temporary differences between financial statement carrying amounts and the tax basis of assets and liabilities. Deferred tax assets and liabilities reflect the tax rates expected to be in effect for the years in which the differences are expected to reverse. A valuation allowance is provided if it is more likely than not that some or all of the deferred tax asset will not be realized. Under Section 382 of the Internal Revenue Code, the net operating losses generated prior to the previously completed reverse merger may be limited due to the change in ownership. Additionally, net operating losses generated subsequent to the reverse merger may be limited in the event of changes in ownership. In 2017, the Tax Cuts and Jobs Act reduced the U.S. federal corporate tax rate from 35% to 21%. See Note&#160;9 for the impact of the tax rate change on deferred tax assets and liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company follows the accounting standards associated with uncertain tax provisions. The Company had no unrecognized tax benefits as of December 31, 2022 or 2021. The Company files tax returns in the U.S. federal and state jurisdictions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company utilizes the Technology Business Tax Certificate Transfer Program to sell a portion of its New Jersey Net Operating Loss tax carryforwards and Research and Development credits to an industrial company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;CytoSorbents Europe GmbH, CytoSorbents Switzerland GmbH, CytoSorbents Poland Sp. z.o.o., CytoSorbents UK Limited, CytoSorbents Medical UK Limited and CytoSorbents France file an annual corporate tax return, a VAT return and a trade tax return in Germany, Switzerland, Poland, France and the United Kingdom, respectively.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2017_To_12_31_2017_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember__1pqeGKP1UqWAJ53fXSkdQ"
      decimals="INF"
      id="Narr_1_0QvogFVkWyRwfb5xW2vg"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_8lddL3hShE2PxAKw1cffhA"
      decimals="INF"
      id="Narr_7PwZ_v_ybUuabPsNgZrmHg"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Narr_P4teFaLYP0aNGiJC9vmhUQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Narr_I56T4INlXkuKvf3va6MP0A"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_dgmdiNS3L0mq7pIpfcysZA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets, liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. The valuation of options granted, allowance for doubtful accounts and recoverability of patents are significant estimates in these consolidated financial statements.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_ePNWe1F1m0ST-Re4tosRdA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company maintains cash balances, at times, with financial institutions in excess of amounts insured by the Federal Deposit Insurance Corporation. Management monitors the soundness of these institutions in an effort to minimize its collection risk of these balances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A significant portion of the Company&#x2019;s revenues are from product sales in Germany. Substantially all of the Company&#x2019;s grant and other income are from grant agencies in the United States. (See Note&#160;3 for further information relating to the Company&#x2019;s revenue.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022, two distributors accounted for approximately 27% of outstanding grants and accounts receivables. As of December 31, 2021, one distributor accounted for approximately 12% of outstanding grants and accounts receivables. For the years ended December 31, 2022, 2021 and 2020, no agency, distributor/strategic partners or direct customer represented more than 10% of the Company&#x2019;s total revenue.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <ctso:ThresholdUsedForCalculatingConcentrationOfRisk
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="2"
      id="Narr_RQfVNngErEKzYg8E5Kba1g"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.27</ctso:ThresholdUsedForCalculatingConcentrationOfRisk>
    <ctso:ThresholdUsedForCalculatingConcentrationOfRisk
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_ctso_OneDistributorMember_XK7cgrbnyk-5EtW1e3KAjQ"
      decimals="2"
      id="Narr_CeWLUPma4kql44fAqMwKLQ"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.12</ctso:ThresholdUsedForCalculatingConcentrationOfRisk>
    <ctso:ThresholdUsedForCalculatingConcentrationOfRisk
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_Ow1UbuwxYkCiv37yEeEpfA"
      decimals="2"
      id="Narr_bpA5JW2RPUOnvDm1616yBQ"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.10</ctso:ThresholdUsedForCalculatingConcentrationOfRisk>
    <ctso:ThresholdUsedForCalculatingConcentrationOfRisk
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_KP3JJIYFZk6xK_VoVW7UbA"
      decimals="2"
      id="Narr_CxYL8_TYTUST0RkbDFjE0g"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.10</ctso:ThresholdUsedForCalculatingConcentrationOfRisk>
    <ctso:ThresholdUsedForCalculatingConcentrationOfRisk
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_v0fFN3Ebi0qVBjU54fspcg"
      decimals="2"
      id="Narr_9WXBdyp450OENnt74f-f5A"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.10</ctso:ThresholdUsedForCalculatingConcentrationOfRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_P45j8bvkw0ORgmn7T1SdLw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities approximate their fair values due to their short-term nature.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_HkgTCpb0xkGxM5OlQsYmJw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss per Common Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed using the treasury stock method on the basis of the weighted-average number of shares of common stock plus the dilutive effect of potential common shares outstanding during the period. Dilutive potential common shares include outstanding warrants, stock options and restricted shares. The computation of diluted net loss per share does not assume conversion, exercise or contingent exercise of securities that would have an anti-dilutive effect on earnings (see Note&#160;12).&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_ygkc94GFrEORex5NIfGz4g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for its stock-based compensation under the recognition requirements of accounting standards for accounting for stock-based compensation for employees and directors whereby each option granted is valued at fair market value on the date of grant. Under these accounting standards, the fair value of each option is estimated on the date of grant using the Black-Scholes option pricing model.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company also follows the guidance of accounting standards for accounting for equity instruments that are issued to non-employees for acquiring, or in conjunction with selling, goods or services for equity instruments issued to consultants.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <ctso:ShippingAndHandlingCostsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_Mr-ikk-hX0S-B67I0SnUWg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Shipping and Handling Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The cost of shipping product to customers and distributors is typically borne by the customer or distributor. The Company records shipping and handling costs in cost of revenue. Total freight costs amounted to approximately $297,000, $276,000 and $560,000 for the&#160;years ended December 31, 2022, 2021 and 2020, respectively.&lt;/p&gt;</ctso:ShippingAndHandlingCostsPolicyPolicyTextBlock>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_CargoAndFreightMember_vWKDoEIhEUOKRvy4A7Wi5w"
      decimals="0"
      id="Narr_Mw49AgIkeEyzE0f9D88A1A"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">297000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_CargoAndFreightMember_3_4JFM6ghEqxTBICweYCOQ"
      decimals="0"
      id="Narr_4N9O4HuLwUCyaQey7EVCFA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">276000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_CargoAndFreightMember_XgZFDtyGV0-mrreoqyHhdQ"
      decimals="0"
      id="Narr_W8OEME9j_EGsDjFn_8AM1w"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">560000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_2FHDbY1jOEOHpHrLHTzFiA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Effect of Recent Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2021, the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;), issued Accounting Standards Update No. 2021-10 entitled, &#x201c;Government Assistance (Topic 832) Disclosures by Business Entities about Government Assistance&#x201d; (the &#x201c;ASU&#x201d;). This ASU will require enhanced disclosures related to the Company&#x2019;s contracts with the U.S. government. The ASU is effective for annual periods beginning after December 15, 2021. The Company implemented the provisions of this ASU during 2022.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_BgbvgOWbZkGCYav7hgiLug">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;3. REVENUE:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table disaggregates the Company&#x2019;s revenue by customer type and geographic area for the&#160;year ended December 31, 2022:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;United&#160;States&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Distributors/&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Government&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Direct&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Strategic&#160;Partners&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Agencies&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Product sales:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 787,201&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 181,750&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 968,951&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Germany&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,566,437&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,566,437&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;All other countries&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,705,580&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,118,942&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,824,522&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total product revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,059,218&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,300,692&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,359,910&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grant income:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,328,899&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,328,899&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,059,218&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,300,692&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,328,899&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 34,688,809&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table disaggregates the Company&#x2019;s revenue by customer type and geographic area for the&#160;year ended December&#160;31, 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;United&#160;States&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Distributors/&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Government&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Direct&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Strategic&#160;Partners&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Agencies&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Product sales:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 189,167&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,500,700&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,689,867&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Germany&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,006,432&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,006,432&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;All other countries&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,846,256&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,566,012&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,412,268&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total product revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,041,855&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,066,712&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,108,567&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grant income:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,056,960&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,056,960&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,041,855&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,066,712&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,056,960&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,165,527&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table disaggregates the Company&#x2019;s revenue by customer type and geographic area for the&#160;year ended December&#160;31, 2020:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;United&#160;States&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Distributors/&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Government&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Direct&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Strategic&#160;Partners&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Agencies&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Product sales:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,148,300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 192,900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,341,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Germany&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,257,410&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,257,410&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;All other countries&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,275,619&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,578,273&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,853,892&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total product revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,681,329&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,771,173&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,452,502&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grant income:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;  &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;  &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;  &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;  &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,552,099&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,552,099&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;  &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;  &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;  &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;  &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,681,329&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,771,173&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,552,099&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41,004,601&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has two primary revenue streams: (1)&#160;sales of the CytoSorb device and related device accessories and (2)&#160;grant income from contracts with various agencies of the United States government. Both of these revenue streams are within the scope of this accounting pronouncement. The following is a brief description of each revenue stream.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;CytoSorb Sales&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company sells its CytoSorb device using both its own sales force (direct sales) and through the use of distributors and/or strategic partners. The majority of sales of the device are outside the U.S., as CytoSorb is not yet approved for commercial sale in the United States. However, in April 2020, the Company was granted Emergency Use Authorization (&#x201c;EUA&#x201d;) of CytoSorb for use in critically-ill patients infected with COVID-19 by the FDA. Direct sales outside the United States relate to sales to hospitals located in Germany, Switzerland, Austria, Belgium, Luxembourg, Poland, the Netherlands, Sweden, Denmark, Norway and the United Kingdom. Direct sales are fulfilled from the Company&#x2019;s office in Berlin, Germany. There are no formal sales contracts with any direct customers relating to product price or minimum purchase requirements. However, there are agreements in place with certain direct customers that provide for either free of charge product or rebate credits based upon achieving minimum purchase levels. The Company records the value of these items earned as a reduction of revenue. These customers submit purchase orders and the order is fulfilled and shipped directly to the customer. Prices to all direct customers are based on a standard price list based on the packaged quantity (6 packs vs. 12 packs).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Distributor and strategic partner sales make up the remaining product sales. These distributors are located in various countries throughout the world. The Company has a formal written contract with each distributor/strategic partner. These contracts have terms ranging from &lt;span style="-sec-ix-hidden:Hidden_4sWYxGr9T0-FAHL1y2CyEw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1&lt;/span&gt;&lt;/span&gt; to 5 years in length, with three years being the typical term. In addition, certain distributors are eligible for volume discount pricing if their unit sales are in excess of the base amount in the contract.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Most distributor&#x2019;s/strategic partner&#x2019;s contracts have minimum annual purchase requirements in order to maintain exclusivity in their respective territories.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;There is no additional consideration or monetary penalty that would be required to be paid to CytoSorbents if a distributor does not meet the minimum purchase commitments included in the contract, however, at the discretion of the Company, the distributor may lose its exclusive rights in the territory if such commitments are not met.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Government Grants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has been the recipient of numerous grant contracts from various agencies of the U.S. government. The purpose of these grant contracts is to perform various research and development activities. The type of research required is outlined in each contract. These contracts fall into one of the following categories:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Fixed price &#x2013; the Company invoices the contract amount in equal installments over the term of the contract without regard to the timing of the costs incurred related to this contract. If billings on fixed price contracts exceed the costs incurred, revenue will be deferred to the extent of the excess billings.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Cost reimbursement &#x2013; the Company submits monthly invoices during the term of the contract for the amount of direct costs incurred during that month plus an agreed percentage that relates to allowable overhead and general and administrative expenses. Cumulative amounts invoiced may not exceed the maximum amount of funding stipulated in the contract.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;3.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Cost plus &#x2013; this type of contract is similar to a cost reimbursement contract but this type also allows for the Company to additionally invoice for a fee amount that is included in the contract.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;4.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Performance based - the Company submits invoices only upon the achievement of the milestones listed in the contract. The amount to be invoiced for each milestone is documented in the contract.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;These government contracts have terms ranging from three months to four years. The Company may apply for an extension of the term of the contract in order to complete its research and development activities but would not receive additional funding during the extension period in excess of the original contract. See Note 2 regarding the accounting policies related to these contracts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In summary, the contracts the Company has with customers are the distributor/strategic partner contracts related to CytoSorb product sales, agreements with direct customers related to free-of-charge product and credit rebates based upon achieving minimum purchase levels, and contracts with various government agencies related to the Company&#x2019;s grants. The Company does not currently incur any outside/third-party incremental costs to obtain any of these contracts. The Company does incur internal costs, primarily salary related costs, to obtain the contracts related to the government grants. Company employees spend time reviewing the program requirements and developing the budget and related proposal to submit to the grantor agency. There may additionally be travel expenditures involved with meeting with government agency officials during the negotiation of the contract. These internal costs are expensed as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table provides information about receivables and contract liabilities from contracts with customers:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.89%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Contract receivables, which are included in grants and accounts receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,822,452&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000,708&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Contract liabilities, which are included in accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,694,906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,251,177&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Contract receivables represent balances due from product sales to distributors amounting to $2,944,031 and $2,265,159 at December 31, 2022 and 2021, respectively, and billed and unbilled amounts due on government contracts amounting to $878,421 and $735,549 at December 31, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Contract liabilities represent the value of free of charge goods and credit rebates earned in accordance with the terms of certain direct customer agreements, which amounted to $178,134 and $303,824 at December 31, 2022 and 2021, respectively, and deferred grant revenue related to the billing on fixed price government contracts in excess of costs incurred, which amounted to $1,516,772 and $1,947,343 at December 31, 2022 and 2021, respectively.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_nLZWJkxoaES_H1eQuDCgnQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table disaggregates the Company&#x2019;s revenue by customer type and geographic area for the&#160;year ended December 31, 2022:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;United&#160;States&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Distributors/&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Government&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Direct&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Strategic&#160;Partners&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Agencies&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Product sales:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 787,201&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 181,750&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 968,951&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Germany&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,566,437&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,566,437&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;All other countries&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,705,580&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,118,942&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,824,522&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total product revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,059,218&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,300,692&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,359,910&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grant income:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,328,899&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,328,899&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,059,218&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,300,692&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,328,899&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 34,688,809&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table disaggregates the Company&#x2019;s revenue by customer type and geographic area for the&#160;year ended December&#160;31, 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;United&#160;States&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Distributors/&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Government&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Direct&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Strategic&#160;Partners&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Agencies&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Product sales:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 189,167&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,500,700&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,689,867&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Germany&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,006,432&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,006,432&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;All other countries&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,846,256&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,566,012&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,412,268&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total product revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,041,855&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,066,712&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,108,567&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grant income:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,056,960&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,056,960&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,041,855&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,066,712&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,056,960&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,165,527&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table disaggregates the Company&#x2019;s revenue by customer type and geographic area for the&#160;year ended December&#160;31, 2020:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;United&#160;States&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Distributors/&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Government&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Direct&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Strategic&#160;Partners&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Agencies&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Product sales:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,148,300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 192,900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,341,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Germany&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,257,410&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 20,257,410&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;All other countries&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,275,619&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,578,273&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,853,892&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total product revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,681,329&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,771,173&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,452,502&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Grant income:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;  &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;  &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;  &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;  &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;United States&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,552,099&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,552,099&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;  &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;  &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;  &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;  &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,681,329&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,771,173&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,552,099&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41,004,601&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_tOnDtJIL0UqvBIiQr68NeQ"
      decimals="0"
      id="Tc_dpH7QWwH_UKci4t-1WGgOQ_5_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">787201</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_sb5j1GuT4Eys3LqScvVX2A"
      decimals="0"
      id="Tc_xvJY4Zyn-UmnYubxBwF1hQ_5_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">181750</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_OsNNOJGgGESiK9DlqyfB8w"
      decimals="0"
      id="Tc_Mtia5gV35kGEJ_4FlfBZCQ_5_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_eeMsQ5mBMEaBmXTojZOwqQ"
      decimals="0"
      id="Tc_BxyMkaOVukeuzAumA_ibow_5_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">968951</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_ZscEfHJXA0ChpTkNTqDj8Q"
      decimals="0"
      id="Tc_gWC7OGyOu0CaJSzG4JCQlA_6_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">12566437</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_NZxEE0JdaUaTuS77svmYtA"
      decimals="0"
      id="Tc_UrL3U1PK_E-0BdyjwG41ig_6_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_dfAHrsFp2E6oinjJ00Mtqg"
      decimals="0"
      id="Tc_h6vnykgQ6UuDvS-DqjHsQw_6_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_3PyNg5XDT0qvzYh6YJ8lww"
      decimals="0"
      id="Tc_AmYvaPmdOkeaAa8EeL6SNQ_6_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">12566437</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_gmpCbnM0wEWJOVVOWqPBQA"
      decimals="0"
      id="Tc_X52IuIK30UGF5qYLKEpi_A_7_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">4705580</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_GB3izD4hs0eaNYDtQMtZdQ"
      decimals="0"
      id="Tc_qgJ_zPhYlEuQX0T8ZaqBOg_7_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">11118942</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_nqaL2-pOqECJbRrVf3pvdw"
      decimals="0"
      id="Tc_-6ruOKpE60KsKIaiUQjBng_7_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_ZhVhCO9-WUWruNBvh_NrbQ"
      decimals="0"
      id="Tc_EkFvkjn-lkKeS4U_eZ47-w_7_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">15824522</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_qMcmuIE2xU-kOZeBMfsP5g"
      decimals="0"
      id="Tc_hvi15BTFW0OyQqgmcs_Ogg_8_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">18059218</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_xMUd5SWGqEmdLXxwWDooqw"
      decimals="0"
      id="Tc_AQGhgzbAbUqkqCx4BYhCog_8_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">11300692</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_4xdvMPyNJE2TidM1dnfXSg"
      decimals="0"
      id="Tc_bIz4gscU7UGnOV-STDHR-g_8_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_H13OncAn9U2imjaSPSyd5g"
      decimals="0"
      id="Tc_AiQ6zzgwdEa0bXsNbO_aCg_8_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">29359910</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_WXkclWPOXk-aO6LslEVKtw"
      decimals="0"
      id="Tc_V9kiffZTAEC5nrVOOVp_Dw_10_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_vmt8r9ikk0aev-F4z3pADg"
      decimals="0"
      id="Tc_ec7EjicCQkCzPHxCwUCu8g_10_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_hvHgr5Vvo06FhAv5d7bNKA"
      decimals="0"
      id="Tc_2sdApeJBqUC28665oFrHMQ_10_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5328899</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_73_wiDAntkqkT8Vf6yVyrg"
      decimals="0"
      id="Tc_BpGvZNYtBk6nOdhVsF3-MQ_10_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5328899</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DirectMember_XS_Uh4IEcEeCPxJehbgjrA"
      decimals="0"
      id="Tc_VkBDLA90nEG-Hb3S_jg-4A_12_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">18059218</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_Gir4cGdvtkGYyi8G96HfRg"
      decimals="0"
      id="Tc_88BiA1kHPUuNXpLKqwGUOw_12_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">11300692</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_T8rLz83ayUi_sdvVUUukQw"
      decimals="0"
      id="Tc_AiVSz4Cq70WzeKLIH9LR2w_12_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5328899</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_s-gm_ucj_EmdynhhC1QWrA_12_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">34688809</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_I2ChB-9AP0S0q8UrImX6ag"
      decimals="0"
      id="Tc_OKdPuL7tmkiU6ZGtEqUc_g_5_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">189167</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_ZANpAs_ejE2twTb1k2pdig"
      decimals="0"
      id="Tc_pY-b4dSZhkqkzTY-UVNZrQ_5_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1500700</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_-zkrbwSc80qnJ_4yNjEqoQ"
      decimals="0"
      id="Tc_2wwv3ZX6yk2v6mZxnRO_nA_5_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_4RHTqNRNFESnd9qrz5_cCA"
      decimals="0"
      id="Tc_IfATIZfbD0isWkvMYpjpoA_5_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1689867</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_ZlfzimG38UyKkvdPjtVHWw"
      decimals="0"
      id="Tc_0XXwzreBZUGtfoIdpcnC_w_6_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">21006432</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_RJXSLiJzd02uK0ssKMKg7w"
      decimals="0"
      id="Tc_lXxRlwFOvUqN949dE8EuYg_6_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_3K7sqcTX4UWhfYo-xNN6bA"
      decimals="0"
      id="Tc_oLvJR7Uvo0y6j6d5qAAovw_6_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_l7Cg7koCpUySLneSLrO0Zg"
      decimals="0"
      id="Tc_cAwMKuDaLkCknaMWU0nd-Q_6_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">21006432</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_tKPWLILXVE2h95fQt2uIvg"
      decimals="0"
      id="Tc_UQQy4g8bqk6WvimdL-GgEA_7_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5846256</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_NeBUdimYUkWFDNDnPD3CnA"
      decimals="0"
      id="Tc_prkAtj2nEEartgaK1P1O2A_7_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">11566012</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_dHpKJ66LdEuPGffrdOOnGg"
      decimals="0"
      id="Tc_PktYwwRMz0axlZn93wEJWw_7_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_nymBapNFM0u97cDmYtNcKw"
      decimals="0"
      id="Tc_7Vf9-IlxkUaBQ7ZhTCsepA_7_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">17412268</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_O-d7ZVaWAUytjn4uAGiAxw"
      decimals="0"
      id="Tc_85ZX5bnJZEqem94GoE5MSA_8_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">27041855</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_EtLLdZY6mEyFOKLjp4Uv1g"
      decimals="0"
      id="Tc_adjnJ4xa-EuI5XmnvEIUaA_8_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">13066712</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_YIGCSpdP6UqYoJUTKv7p7w"
      decimals="0"
      id="Tc_rVDdwgc7A0e9ThCW3g0RRg_8_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_KSZxi4zg7keBU37J2Y0-8w"
      decimals="0"
      id="Tc_xZObgm1MX0Gwe-6jZxYhMA_8_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">40108567</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_b8AI_7G0G0umDEyvgW9dOw"
      decimals="0"
      id="Tc_OgFTrk9AxUGxzehuAiwE4w_10_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_sQvISkQQ3UKBDgXPufGqUw"
      decimals="0"
      id="Tc_6x3zUwHgjUWxzQUAjXUL6A_10_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_JVeLOYDILkWMpirfcvOUkg"
      decimals="0"
      id="Tc_ut621C4ao0eUzQsA3BmoaQ_10_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3056960</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_BjelKy9GsEOR7gq0nA95tQ"
      decimals="0"
      id="Tc_cCqRHPYksEiSEjD06j7oJg_10_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3056960</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DirectMember_agZO3qBuDE-w-pXujZLoyA"
      decimals="0"
      id="Tc_73pg871c6EqjdOhLTQjwNw_12_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">27041855</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_Ahb2Ft23iEuFgHVNXLFShQ"
      decimals="0"
      id="Tc_SYa6EL4sYEefUlg03YvqLQ_12_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">13066712</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_2s9vyN8oyESnIA9BeyMmsw"
      decimals="0"
      id="Tc_q_qw4duWNkCiGLmURtw4NQ_12_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3056960</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_rN1_6zQTQ0eji3iph1Moxw_12_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">43165527</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_Tv8sVQFDs0OjBBDw_jDtKg"
      decimals="0"
      id="Tc_qq7AL3aDXUmdwHi_1OHisg_5_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1148300</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_d8LbBpFImkegbFV6bTyQPA"
      decimals="0"
      id="Tc_QgnoH07rAUunQQr7LSjE-A_5_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">192900</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_ix4FCkAs6kWXANuYn55BGw"
      decimals="0"
      id="Tc_OeJuu0_7cEiWnqY2v5mTRg_5_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_GHt6jI9HW0amSQTDjBZQSg"
      decimals="0"
      id="Tc_wWNYTm2kskGQrZy_rpnBQw_5_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1341200</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_ZzNQcZHrw0GnVCIADz0a6w"
      decimals="0"
      id="Tc_PzMeQ3-tKkeayqKqiL5RAQ_6_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">20257410</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_yC2fiJcIZ028vV2ALBTiiA"
      decimals="0"
      id="Tc_Z-61zJPJ602VCl76O7BoMg_6_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_REqz0wSSUEO2inn9gwE8Rw"
      decimals="0"
      id="Tc_8vjKQaso6UmQOXV1mNdnbw_6_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_DE_fzhPwuLPukmrUdi_ToPDPw"
      decimals="0"
      id="Tc_nbWg5vrXQUCo5EGYdJzUuA_6_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">20257410</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_7NOqCHyL_kKAzrJSLXbLAA"
      decimals="0"
      id="Tc_PZpKILjbbE-dM8xjGbA43w_7_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5275619</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_MriDhsC_C0qBVC8cxkY0Bg"
      decimals="0"
      id="Tc_LtzeNgZuMkyp_FMdXu6iJQ_7_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">12578273</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_mH41MxVhmkGct0J07XEN1w"
      decimals="0"
      id="Tc_AeFe8G4YQUe61z2mRhQOIA_7_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_ctso_AllOtherCountriesMember_QXov_wgwTEe9iec6EImaQQ"
      decimals="0"
      id="Tc_uXQ_9CyWGkCeiKvV_T7bjQ_7_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">17853892</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_0DuN_YUs0k2g6B7WoQuymA"
      decimals="0"
      id="Tc_tJUp9qIu4U268zsTpHCvvw_8_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">26681329</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_ht_XRtUdc0KZKqw23eRvcg"
      decimals="0"
      id="Tc_ZRFmCWTFOkWBjGtU4L7SFA_8_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">12771173</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_S0fxf7nq1EOlWiL9Q6JU9g"
      decimals="0"
      id="Tc_KGc_y7q0Z0iugz94RT4GEA_8_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_dd7aX6AZn0ivW75vs1ACmA"
      decimals="0"
      id="Tc_Z4nS0dC060KIY0_QgTfbMg_8_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">39452502</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DirectMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_KOQGfIkSGE2fpCi1ZL7vYA"
      decimals="0"
      id="Tc_Nkvr6mXkjk6L6c8x6HgfYg_10_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_2dyyoRP_xEmVYml_OXHP7w"
      decimals="0"
      id="Tc_KFNbDwbrr0WEVN_28Ga9Rg_10_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_gfv9AQKB10GMbME_bmBdWQ"
      decimals="0"
      id="Tc_aKzeXfYAm06jmcDqRilPyw_10_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1552099</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_ProductOrServiceAxis_us-gaap_GrantMember_srt_StatementGeographicalAxis_country_US_BQH7e5DFwU-i1ithowcxIA"
      decimals="0"
      id="Tc_1DF-HIsLF0ejnbfYA8mY7Q_10_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1552099</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DirectMember_tT74xtzFukKomPVrAOvfwg"
      decimals="0"
      id="Tc_7m37bwPMCESNnZQrsFfGaw_12_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">26681329</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_DistributorsAndStrategicPartnersMember_UrGxGvJgzkO7B8scLF4L5g"
      decimals="0"
      id="Tc_AtatfeGZPkewQJAv_Trm5g_12_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">12771173</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_MajorCustomersAxis_ctso_UnitedStatesGovernmentAgenciesMember_cwj5unG_WkCRIuQlwJ3dwQ"
      decimals="0"
      id="Tc_n2FY6115ykSE9pwkMWyhuw_12_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1552099</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_Jo1WjvDjoUG4TxYnqe0Tzw_12_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">41004601</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <ctso:NumberOfPrimaryRevenueStreams
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="INF"
      id="Narr_c1z-WAM-JEyYR711VM1dHg"
      unitRef="Unit_Standard_item_00R0j3K4HUiRlSslEJQMxQ">2</ctso:NumberOfPrimaryRevenueStreams>
    <ctso:TermOfCustomerContracts
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_Df_fcOfuVUyrXQ2v2oxuSQ"
      id="Narr_jfpBaKyDGkusjnb-M_zURA">P5Y</ctso:TermOfCustomerContracts>
    <ctso:TermOfCustomerContracts
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_piAx0vYIBkO9TjaHRhTjkg">P3Y</ctso:TermOfCustomerContracts>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_Xeo-SqELpkO4p2MWxt4Kew">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:96.89%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Contract receivables, which are included in grants and accounts receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,822,452&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000,708&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:72.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Contract liabilities, which are included in accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,694,906&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,251,177&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_Fl2RmWFJvUiOMfdKU73rXQ_2_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3822452</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_BPaCrsF7Tkq41Xlmz5waDA_2_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3000708</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:DeferredRevenue
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_J6neahkOIEuT47X2pGa4SA_3_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1694906</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_yT5ayFq2DkO572Fk1bfRQA_3_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2251177</us-gaap:DeferredRevenue>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_gIfXHjckYEyJZbVZyvB2YQ"
      decimals="0"
      id="Narr_GmnL4nZS7ESPPL06qsHK_g"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2944031</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_12_31_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_njwH72hw8kSaSTYNHO-w9A"
      decimals="0"
      id="Narr_6nUuKlet30-uFMQt_qlTrA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2265159</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_12_31_2022_srt_ProductOrServiceAxis_us-gaap_GrantMember_nWvJKC0AfUO7Aa2fnEopNQ"
      decimals="0"
      id="Narr_ZXWgiJuoykOeDgUkLSSlRg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">878421</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_12_31_2021_srt_ProductOrServiceAxis_us-gaap_GrantMember_7s12QoX9F0W4teGHuyLFlQ"
      decimals="0"
      id="Narr_1zS0j1n0jEKok-LrVQup_Q"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">735549</us-gaap:ContractWithCustomerAssetNetCurrent>
    <ctso:ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Narr_CHrkGLkQoUCSba2oxwbqxg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">178134</ctso:ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent>
    <ctso:ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Narr_EED_GPwJSke7zH1ZELLWjg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">303824</ctso:ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent>
    <ctso:ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Narr_MvjvK5uzEEqI3tOc-9OoCQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1516772</ctso:ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent>
    <ctso:ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Narr_VPPrFUbWGkO3iCKuZBaH6w"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1947343</ctso:ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_z0l_9RNbXEi9xKSCDArVlQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;4. PROPERTY AND EQUIPMENT, NET:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Property and equipment&#160;- net, consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Depreciation/&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,306,267&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,424,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;7&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Equipment and computers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,131,934&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,863,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;3 to 7&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,201,523&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,623,356&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Lesser of term of lease or estimated useful life&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,639,724&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,911,505&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,896,692&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,760,619&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and Equipment, Net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,743,032&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,150,886&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Depreciation expense for the&#160;years ended December 31, 2022, 2021 and 2020 amounted to $688,565, $571,156 and $553,946 respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_V7gdo6bu20GOaywaO8cwIw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Depreciation/&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortization&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,306,267&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,424,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;7&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Equipment and computers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,131,934&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,863,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;3 to 7&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,201,523&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,623,356&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Lesser of term of lease or estimated useful life&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,639,724&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,911,505&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,896,692&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,760,619&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:37.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and Equipment, Net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,743,032&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,150,886&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_xx0SVCBDQUagyE9b8Y2GGA"
      decimals="0"
      id="Tc_ZXr1klZuPkmNr1KTKT-swg_5_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1306267</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_p-0pfYqTZ0CXdqB9tDZcLA"
      decimals="0"
      id="Tc_GA6q-eqolUivjhniycebtg_5_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1424476</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_IZ1_4AiozUyl0mH6SNTEkw"
      id="Tc_-0hSyBPmV0CbukUcGxGVQA_5_8">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_6WgRDm9zw06JdogbPOBBsA"
      decimals="0"
      id="Tc_uH-cZyj9mUqu2Jex7lqh3Q_6_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5131934</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_GAn4Sc5mekKFBtkNb6Zzyg"
      decimals="0"
      id="Tc_cLIBPT9YJ0C2PSxJuCF8hw_6_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5863673</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_zAGlt-XrpU6zeCKAysx8Ww"
      id="Narr_yLqIPd6hpk68u_pMkMDIGw">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_ajPw7PYg8UiVzGNH8PRoGQ"
      id="Narr_lazeLOBBSEuG5NFUFIvJZA">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_qNxrnXfXMEWT6PBBrE_I6w"
      decimals="0"
      id="Tc_VLUV2jbxBUGeuRHCadQiqg_7_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">6201523</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_RcD8hxX4B0W360TpBmU_BA"
      decimals="0"
      id="Tc_it93osbqWUyWa4HxGf9nKQ_7_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2623356</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_tw-covgF9UeDgK0uz68Qnw_8_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">12639724</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_-tZW-xGId0emyyWQHQaJkA_8_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">9911505</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_XQvgyy3KhkuJ6h9PfQ5Hkw_9_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1896692</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_xvSXUh1ooE-CLAh-6fOKHw_9_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">4760619</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_k_VeM1l4hkaBExv1KFfDiA_10_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">10743032</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_WP8TXYJYx0qwejO_RXZHCQ_10_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5150886</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Narr_Iq1doRGy00m4wlHeNuPYIA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">688565</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Narr_ChVBnhjbJUa6BHQCiubIQw"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">571156</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Narr_IEUrLLFPMEefs6eS43zLfw"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">553946</us-gaap:Depreciation>
    <us-gaap:OtherAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_igbrNlsCeUWdUp2jPl5r3A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;5. OTHER ASSETS:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Other assets consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Patent applications pending&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,466,341&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,717,701&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Patents issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,773,191&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,641,603&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less accumulated amortization of patents issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (848,999)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (657,320)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Patents, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,390,533&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,701,984&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Security deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 46,914&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 256,591&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,437,447&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,958,575&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Amortization expense amounted to $194,056, $160,422 and $106,842 for the&#160;years ended December 31, 2022, 2021 and 2020, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Amortization expense for the next five&#160;years will be approximately $201,000 for the&#160;year ending December&#160;31, 2023; approximately $201,000 for the&#160;year ending December&#160;31, 2024; approximately $201,000 for the&#160;year ending December&#160;31, 2025; approximately $200,000 for the year ending December 31, 2026 and approximately $196,000 for the year ending December 31, 2027.&lt;/p&gt;</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherAssetsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_dEUy5Q3dvEylM3FA_E6sLw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Patent applications pending&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,466,341&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,717,701&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Patents issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,773,191&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,641,603&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less accumulated amortization of patents issued&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (848,999)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (657,320)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Patents, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,390,533&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,701,984&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Security deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 46,914&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 256,591&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,437,447&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,958,575&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember_zXch2gFj5k-awN9bccQ9Eg"
      decimals="0"
      id="Tc_SsI6Xn4nW0ezS9eIOLZWgg_3_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2466341</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember_JaV5Z95jAEioF4LjVm9rgw"
      decimals="0"
      id="Tc_TqmdGwf3LEWmuOlsN2VCEA_3_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2717701</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember_q-pVwR_fx0mA5G4MI1uuxw"
      decimals="0"
      id="Tc_DgoMxL4VWkyKr-YfFgi24Q_4_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2773191</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember_s0omtWKNx0m-GCD2Twq8Aw"
      decimals="0"
      id="Tc_28soOJJVDUSXJuXdjpjuFQ_4_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2641603</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_E_EfLukby0WT8zAWrp--9Q_5_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">848999</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_3NKRUrg9yUWUVyLTHMWu8w_5_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">657320</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_ZfHnjpftm0WQk8-SuLnPaQ_6_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">4390533</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_PJdsSAI9OkuxxxDibjgtoA_6_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">4701984</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_RFyjhQgPa0mMqjB6Ojerzg_7_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">46914</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_BJB5bsDJVUOQRwt7Cjxxgw_7_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">256591</us-gaap:SecurityDeposit>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_m0fWIpgGKkuOeftELtV4IQ_8_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">4437447</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_91lI1lptXUqjk5pNlhzkdA_8_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">4958575</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AdjustmentForAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Narr__WJGbadd1EqFBs1RKrQeUQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">194056</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Narr_ccDh6f-Y7UahAWFIbGejPQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">160422</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Narr_S1GdBcVw-ki1EWKF7I4Z4g"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">106842</us-gaap:AdjustmentForAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Narr_cW_MDOtGzEmkIDAPYs7mnw"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">201000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Narr_iVKLl0KMjU6RJJVcCJw_XQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">201000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Narr_0T9pTV0WskWnkT7QwSjAkQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">201000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Narr_yolljL6pZ0au-glj5YOtpg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Narr_yLLd4y0rtkGzb6Z-IKBdjQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">196000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_GYWlmQWUQES4QYAQ68Bg_Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;6. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued salaries and commissions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,862,930&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,270,715&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,516,772&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,947,353&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Clinical studies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,115,123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,767,826&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 850,630&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,044,088&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 622,353&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 314,068&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued royalties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 592,398&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 769,262&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer rebates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 166,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 214,119&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Travel and entertainment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 99,316&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 88,850&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Board of Director fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 97,426&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 71,381&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sales, payroll and income taxes payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,871&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 785,818&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,556&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Congresses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,861&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,950,440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,314,341&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <ctso:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_c_3oGux8FkyluRC_6uBQ3g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued salaries and commissions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,862,930&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,270,715&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,516,772&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,947,353&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Clinical studies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,115,123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,767,826&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued accounts payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 850,630&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,044,088&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 622,353&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 314,068&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued royalties&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 592,398&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 769,262&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Customer rebates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 166,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 214,119&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Travel and entertainment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 99,316&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 88,850&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Board of Director fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 97,426&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 71,381&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sales, payroll and income taxes payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,871&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 785,818&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,556&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Congresses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 40,861&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,950,440&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,314,341&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ctso:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
    <ctso:AccruedSalariesAndCommissionsCurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_aE6iXkRkeECENd1-tsmwVA_2_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2862930</ctso:AccruedSalariesAndCommissionsCurrent>
    <ctso:AccruedSalariesAndCommissionsCurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_xLuwkDOKYUG5g1kgEIKx6A_2_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3270715</ctso:AccruedSalariesAndCommissionsCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc__Nna3E3MPkW01usf5OpZHA_3_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1516772</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_J6L_E6gpZ0quB5b5--p2_g_3_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1947353</us-gaap:ContractWithCustomerLiabilityCurrent>
    <ctso:ClinicalStudyCostsPayableCurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_mAVlAy8u7EqdSHonpsv5DA_4_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1115123</ctso:ClinicalStudyCostsPayableCurrent>
    <ctso:ClinicalStudyCostsPayableCurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_aHsXfzs_5kuMdBgm-E_4Ug_4_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1767826</ctso:ClinicalStudyCostsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_DAEMgZkK70GOblHywjd_1A_5_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">850630</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_rwG_NjqVU0Siv-g2UMSuKg_5_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1044088</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_dSeL9H_ZREOQcWuzc_ArTg_6_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">622353</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_dTlbd1tNwkGmX5JBfTDFAg_6_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">314068</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_pWv33swKIUKQB694CSCCsw_7_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">592398</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_IrHVa30m-0iNOPUkQInMtg_7_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">769262</us-gaap:AccruedRoyaltiesCurrent>
    <ctso:CustomerRebates
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_zyHWDFS80kiElccQWuIRcg_8_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">166065</ctso:CustomerRebates>
    <ctso:CustomerRebates
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_NX4-HxrsbE6oNxajYeRfyw_8_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">214119</ctso:CustomerRebates>
    <ctso:AccruedTravelAndEntertainmentExpenseCurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_f8KCD2L6mkWJgzncM2oWBA_9_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">99316</ctso:AccruedTravelAndEntertainmentExpenseCurrent>
    <ctso:AccruedTravelAndEntertainmentExpenseCurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_7EmpJ3JhHUy2nMiVSFr4jg_9_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">88850</ctso:AccruedTravelAndEntertainmentExpenseCurrent>
    <ctso:AccruedDirectorFeesCurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc__eAfcOkDbESMrqWp0JJOKw_10_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">97426</ctso:AccruedDirectorFeesCurrent>
    <ctso:AccruedDirectorFeesCurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_msBnXSuTrEOsgfD9xT_0TA_10_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">71381</ctso:AccruedDirectorFeesCurrent>
    <ctso:SalesPayrollAndIncomeTaxesPayableCurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc__XWv9gN7wEO-fgSx6G9n2w_11_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">21871</ctso:SalesPayrollAndIncomeTaxesPayableCurrent>
    <ctso:SalesPayrollAndIncomeTaxesPayableCurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_eNXCntoqHEqGcNAYjuoCCQ_11_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">785818</ctso:SalesPayrollAndIncomeTaxesPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_neLZ6ADjhE2w1ZM-_0MVJw_12_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5556</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_xaaF8v_l40WTCIxtUKnqUQ_12_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:InterestPayableCurrent>
    <ctso:CongressesPayableCurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_qYSYGe1m6ky2sotW-OnU2A_13_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</ctso:CongressesPayableCurrent>
    <ctso:CongressesPayableCurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_rXe-9bVM1ESyEX6W7GttkQ_13_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">40861</ctso:CongressesPayableCurrent>
    <ctso:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_ZYgUDd8l_kmknQ2WHhHx7w_14_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">7950440</ctso:AccruedExpensesAndOtherCurrentLiabilities>
    <ctso:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_-Sf_XE_bBUKRIdm3ifu5ug_14_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">10314341</ctso:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:LongTermDebtTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_Ey9R7XBrcU6QSvm0mD1cpQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;7. LONG-TERM DEBT:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On June&#160;30, 2016, the Company and its wholly owned subsidiary, CytoSorbents Medical,&#160;Inc. (together, the &#x201c;Borrower&#x201d;), entered into a Loan and Security Agreement with Bridge Bank, a division of Western Alliance Bank, (the &#x201c;Bank&#x201d;), pursuant to which the Company borrowed $10 million in two equal tranches of $5 million (the &#x201c;Original Term Loans&#x201d;). On March&#160;29, 2018, the Original Term Loans were refinanced with the Bank pursuant to an Amended and Restated Loan and Security Agreement by and between the Bank and the Borrower (the &#x201c;Amended and Restated Loan and Security Agreement&#x201d;), under which the Bank agreed to loan the Borrower up to an aggregate of $15 million to be disbursed in two tranches (1)&#160;one tranche of $10 million (the &#x201c;Term A Loan&#x201d;), which was funded on the Closing Date and used to refinance the Original Term Loans, and (2)&#160;a second tranche of $5 million which may be disbursed at the Borrower&#x2019;s sole request prior to March&#160;31, 2019 provided certain conditions are met (the &#x201c;Term B Loan&#x201d; and together with the Term A Loan, the &#x201c;Term Loans&#x201d;). On July 31, 2019, the Borrower entered into the First Amendment to the Amended and Restated Loan and Security Agreement (the &#x201c;First Amendment&#x201d;) with the Bank, which amended certain provisions of the Amended and Restated Loan and Security Agreement and the 2018 Success Fee Letter (the &#x201c;2018 Letter&#x201d;). In connection with the execution of the First Amendment, the draw period for the Term B Loan was extended to August 15, 2019 and the Company drew down the full $5.0 million Term B Loan on the Settlement Date, bringing the total outstanding debt to $15 million at July 31, 2019. The proceeds of Term Loans were used for general business requirements in accordance with the Amended and Restated Loan and Security Agreement. On December 4, 2020 (the &#x201c;Third Amendment Closing Date&#x201d;), the Company closed on the Third Amendment (the &#x201c;Third Amendment&#x201d;) of its Amended Loan and Security Agreement with Bridge Bank. Under the terms of the Amendment, the Company repaid the outstanding principal balance of its existing $15 million term loans and simultaneously received a commitment from Bridge Bank to provide a new term loan of $15 million, if needed. On January 19, 2022 (the &#x201c;Fourth Amendment Closing Date&#x201d;), the Company closed on the Fourth Amendment (the &#x201c;Fourth Amendment&#x201d;) of its Amended Loan and Security Agreement with Bridge Bank. Under the terms of the Amendment, the Company received a commitment from Bridge Bank to provide a new term loan of up to $15 million, if needed and entered into the Fourth Amendment Success Fee Letter (the &#x201c;2022 Success Fee Letter&#x201d;). On December 28, 2022 (the &#x201c;Fifth Amendment Date&#x201d;), the Company entered into the Fifth Amendment of its Amended Loan and Security Agreement with Bridge Bank. The Fifth Amendment extends the draw period under the Fourth Amendment to the earlier of (i) March 1, 2023 and (ii) the occurrence of an Event of Default. On March&#160;9,&#160;2023, the Company entered into the Sixth Amendment of its Amended Loan and Security Agreement. The Sixth Amendment further extends the draw period to March&#160;24,&#160;2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Fourth Amendment provides a tranche of term loans (the &#x201c;Term C Loans&#x201d;) in the aggregate amount of $15 million, which are available for the Company to draw down at its sole discretion in three tranches of $5 million each at any time during the period commencing on the Fourth Amendment Date and ending on the earlier of (i) December 31, 2022 and (ii) the occurrence of an Event of Default (as defined in the Amended Loan and Security Agreement). The Term C Loans shall bear interest at the Index Rate (defined in the Amendment as the greater of 3.25% or the Prime Rate as published by the Wall Street Journal on the last business date of the month immediately preceding the month in which the interest will accrue) plus 1.25%. Pursuant to the Fourth Amendment, interest on the Term C Loans is subject to an interest rate cap of 8.00%. On December 27, 2022, the Company drew down the first $5 million tranche of the Term C loans available under the terms of the Fourth Amendment. Under the terms of the Fourth Amendment, commencing on February 1, 2023, the Company is required to make monthly payments of interest only through December 2023. The interest-only period will be further extended through June 2024 provided the Company has met both the required reserves test and the seventy-five percent test, as set forth in the Fourth Amendment, as of November 30, 2023. Commencing on January 1, 2024, if the Company does not meet both the required reserves test and the seventy-five percent test, the Company shall make equal monthly payments of principal of $208,333, together with accrued and unpaid interest. Commencing on July 1, 2024, if the Company meets both the required reserves test and the seventy-five percent test, the Company shall make equal monthly payments of principal of $277,778, together with accrued and unpaid interest. In either event, all unpaid principal and accrued and unpaid interest shall be due and payable in full on December 1, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On the Fourth Amendment Closing Date, the Company was required to pay a non-refundable closing fee of approximately $18,750, which was amortized as a monthly charge to interest expense. On the Third Amendment Closing Date, the Company paid a non-refundable closing fee of $75,000, which was amortized as a charge to interest expense. In addition, the Amended and Restated Loan and Security Agreement requires the Company to pay a non-refundable final fee equal to 2.5% of the principal amount of the Term Loan funded upon the earlier of the (i) the maturity date or (ii) termination of the Term Loans via acceleration or prepayment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s and CytoSorbents Medical, Inc.&#x2019;s obligations under the Amended and Restated Loan and Security Agreement are joint and severable and are secured by a first priority security interest in favor of the Bank with respect to the Company&#x2019;s Shares (as defined in the Amended and Restated Loan and Security Agreement) and the Borrower&#x2019;s Collateral (as defined in the Amended and Restated Loan and Security Agreement, which definition excludes the Borrower&#x2019;s intellectual property and other customary exceptions).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2018 Success Fee Letter:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the amended 2018 Letter, the Borrower shall pay to the Bank a success fee in the amount equal to 6.37% of the funded amount of the Term B Loan (as defined in the Restated Loan and Security Agreement) (the &#x201c;Success Fee&#x201d;) upon the first occurrence of any of the following events: (a)&#160;a sale or other disposition by the Borrower of all or substantially all of its assets; (b)&#160;a merger or consolidation of the Borrower into or with another person or entity, where the holders of the Borrower&#x2019;s outstanding voting equity securities as of immediately prior to such merger or consolidation hold less than a majority of the issued and outstanding voting equity securities of the successor or surviving person or entity as of immediately following the consummation of such merger or consolidation; (c)&#160;a transaction or a series of related transactions in which any &#x201c;person&#x201d; or &#x201c;group&#x201d; (within the meaning of Section&#160;13(d)&#160;and 14(d)(2)&#160;of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;) becomes the &#x201c;beneficial owner&#x201d; (as defined in Rule&#160;13d-3 under the Exchange Act), directly or indirectly, of a sufficient number of shares of all classes of stock then outstanding of the Borrower ordinarily entitled to vote in the election of directors, empowering such &#x201c;person&#x201d; or &#x201c;group&#x201d; to elect a majority of the Board of Directors of the Borrower, who did not have such power before such transaction; or (d)&#160;the closing price per share for the Company&#x2019;s common stock on the Nasdaq Capital Market being the greater of (i)&#160;70% or more over $7.05, the closing price of the Company&#x2019;s common stock on March&#160;29, 2018 (after giving effect to any stock splits or consolidations effected after the date thereof) for &lt;span style="-sec-ix-hidden:Hidden_TWKGB9Ns70-hcCjqFg2ORA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&lt;/span&gt;&lt;/span&gt; successive business&#160;days, or (ii)&#160;at least 26.13% more than the average price of Company&#x2019;s common stock for the 365-day period ending on the date of the funding of the Term B Loan. This obligation shall terminate on the fifth anniversary of the funding of the Term B Loan and shall survive the termination of the loan agreement and the prepayment of the Term B Loan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2022 Success Fee Letter:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the 2022 Success Fee Letter, the Borrower will pay to the Bank a success fee equal to (i) 1% of $5 million if the Company draws down the first tranche of the Term C Loan and is payable only if the Company&#x2019;s stock price equals or exceeds $8 for &lt;span style="-sec-ix-hidden:Hidden_0ax9yhmTV0OKMkdCNohxKw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&lt;/span&gt;&lt;/span&gt; consecutive trading days; (ii) 1.5% of $5 million if the Company draws down the second tranche of the Term C Loan and is payable only if the Company&#x2019;s stock price equals or exceeds $10 for &lt;span style="-sec-ix-hidden:Hidden_2iU3HFYDDUKoxhoqRgX4wQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&lt;/span&gt;&lt;/span&gt; consecutive trading days; and (iii) 2% of $5,000,000 if the Company draws down the third tranche of the Term C Loan and is payable only if the Company&#x2019;s stock price equals or exceeds $12 for &lt;span style="-sec-ix-hidden:Hidden_pwbH1ZIm4UCeZREcP1cczw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&lt;/span&gt;&lt;/span&gt; consecutive trading days (together, the &#x201c;Success Fee&#x201d;). Borrower may pay the Success Fee in cash or in shares of common stock, at Borrower&#x2019;s sole discretion. The right of Bank to receive the Success Fees and the obligation of the Borrower to pay the Success Fees hereunder shall terminate on the date that is fifth anniversary of the funding date of the last Term C Loans made but shall survive the termination of the Loan Agreement and any prepayment of the Term C Loans.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Long-term debt consists of the following as of December 31, 2022:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Principal amount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Less Current maturities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Long-term debt net of current maturities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Principal payments of long-term debt are due as follows during the years ending December 31:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,500,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,500,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_6_30_2016_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_hpLFtiZhmUiQm4GvwoFZtw"
      decimals="-6"
      id="Narr_V0C-gIcN1USPVCZv8C4TQQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_6_30_2016_us-gaap_DebtInstrumentAxis_ctso_NewTermLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_ArZA6xiPjEidCYt_-Y-R-w"
      decimals="-6"
      id="Narr_fuLlDVhdtkKlfXbHj99cCg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_29_2018_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_yAsPHUNuqEirJNj907ZTrg"
      decimals="-6"
      id="Narr_S4CG1GzMckWOUU5S5VtSqg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_29_2018_us-gaap_DebtInstrumentAxis_ctso_TermLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_us-gaap_VestingAxis_ctso_FirstTrancheMember_yHGvHKFK2USNqJh92uWr0g"
      decimals="-6"
      id="Narr_KeEBRJAfi0SU9iZwSDtFhg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_3_29_2018_us-gaap_DebtInstrumentAxis_ctso_TermBLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_us-gaap_VestingAxis_ctso_SecondTrancheMember_e3qGkUg1VUKoGjKsBJiqOw"
      decimals="-6"
      id="Narr_SnUsXLTBcEaul2TPSnVV6w"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_7_31_2019_To_7_31_2019_us-gaap_DebtInstrumentAxis_ctso_TermBLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_dfnbFaTYTUmSkV-OaNfp9g"
      decimals="-5"
      id="Narr_hxap2tpSWUSyRLjVz9fZDQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5000000.0</us-gaap:RepaymentsOfDebt>
    <us-gaap:LongTermDebt
      contextRef="As_Of_7_31_2019_us-gaap_DebtInstrumentAxis_ctso_TermBLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_hAgUOUh5k0aAxSE_lGDIoA"
      decimals="-6"
      id="Narr_5zrlEVPmkE2z9ZtsQaUWuQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">15000000</us-gaap:LongTermDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_12_4_2020_To_12_4_2020_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_p4SKdwcjlUmUAUo8kjQ2Mg"
      decimals="-6"
      id="Narr_fdulep9DgUaEUrkHrAMd5A"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">15000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_4_2020_us-gaap_DebtInstrumentAxis_ctso_NewTermLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_sKTK-0jXM02ZfmOBWGS5TQ"
      decimals="-6"
      id="Narr_HHYP5aJ24U2gt8yl9uFd4g"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_1_19_2022_us-gaap_DebtInstrumentAxis_ctso_NewTermLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_KKLXo5WGZkqln7K51iiuOg"
      decimals="-6"
      id="Narr_5_y-VahBQ0KKZWRt8cxwZw"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_1_19_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_xoInVW7g4UOFsRz944IiQQ"
      decimals="-6"
      id="Narr_aviqU9Y8AUKp2xe6SU2gkw"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">15000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="As_Of_1_19_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_xoInVW7g4UOFsRz944IiQQ"
      decimals="-6"
      id="Narr_no7xNfjvc0q0Gl_3Qpl1jQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="Duration_1_19_2022_To_1_19_2022_us-gaap_DebtInstrumentAxis_ctso_NewTermLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_V4YNPqwfQU-fUTcMCuVGXg"
      decimals="4"
      id="Narr_dIDyMOsERU-dBKc0BdcNMQ"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ctso:DebtInstrumentCapInterestRate
      contextRef="Duration_1_19_2022_To_1_19_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_g4Y2bbaH8UunO1A9gJrzYg"
      decimals="4"
      id="Narr_1mDHwvKPqEm0bmAp581HRg"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.0800</ctso:DebtInstrumentCapInterestRate>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="Duration_12_27_2022_To_12_27_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_us-gaap_VestingAxis_ctso_FirstTrancheMember_u7MsHPmZk0W0eFrHTCS5fA"
      decimals="-6"
      id="Narr_CvLDB8uid06MkV-H9xtIiA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="Duration_1_1_2024_To_1_1_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_ZrffNf8uWkC-rlhEGrcMag"
      decimals="0"
      id="Narr_UY4F-GdcXkO6UbUV9vnAhQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">208333</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="Duration_7_1_2024_To_7_1_2024_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_46J-BH5GlUuzquHLcvZsUQ"
      decimals="0"
      id="Narr_3M-cuidA8k6dIqC2nDzR2Q"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">277778</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="As_Of_1_19_2022_us-gaap_DebtInstrumentAxis_ctso_NonRefundableClosingFeeMember_3fpymeUzzE2FKaJZ7vfyhg"
      decimals="0"
      id="Narr_B3FDvzvcB0Sc-vTnPnPHWA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">18750</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="As_Of_12_4_2020_us-gaap_BalanceSheetLocationAxis_ctso_ClosingFeeMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_VrBaHTNN5kGqpNZC5_45yw"
      decimals="0"
      id="Narr_8yjbf-hdk0qFquSDKb_JSQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">75000</us-gaap:DeferredFinanceCostsNet>
    <ctso:DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="3"
      id="Narr_gR6FHqy_okK4VohR7Xnd-w"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.025</ctso:DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent>
    <ctso:PercentageOfSuccessFee
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TwoThousandAndEighteenSuccessFeeLetterMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_jQs_7-pzMUy3U65XTi21yQ"
      decimals="4"
      id="Narr_JDjKQWhzQESE-0Dxxn5WPQ"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.0637</ctso:PercentageOfSuccessFee>
    <ctso:PercentageOfClosingPriceOnCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_DebtInstrumentAxis_ctso_TwoThousandAndEighteenSuccessFeeLetterMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_x3N7mO34SEWKzky3MgxbHA"
      decimals="2"
      id="Narr_NUA86jBtn0mrf1ka5Nx8mA"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.70</ctso:PercentageOfClosingPriceOnCommonStock>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TwoThousandAndEighteenSuccessFeeLetterMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_fb08ojpZuEqeebxD3osGJQ"
      decimals="2"
      id="Narr_3-NQV8k2x0KV1PmVnaQXnA"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">7.05</us-gaap:SharePrice>
    <ctso:PercentageOfClosingPriceOnCommonStock
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_DebtInstrumentAxis_ctso_TwoThousandAndEighteenSuccessFeeLetterMember_us-gaap_LineOfCreditFacilityAxis_ctso_WesternAllianceBankMember_V6EvzE1VNkqz5b11S3A0zQ"
      decimals="4"
      id="Narr_UdU9Zgq93kaHdq3LMxZgiw"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.2613</ctso:PercentageOfClosingPriceOnCommonStock>
    <ctso:PercentageOfSuccessFee
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_FirstTrancheMember_GIGD6kvI2kuyoTLKEpk95A"
      decimals="2"
      id="Narr_vRc52-OtxUGqjaXflJkftA"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.01</ctso:PercentageOfSuccessFee>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_FirstTrancheMember_FBkEgEL2JUK-hSNbubMUvw"
      decimals="-6"
      id="Narr_0jiftSAbLEenpJiLsnGgGw"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_FirstTrancheMember_FBkEgEL2JUK-hSNbubMUvw"
      decimals="INF"
      id="Narr_crjZKQ7E00GMcZacN0t-RA"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">8</us-gaap:SharePrice>
    <ctso:PercentageOfSuccessFee
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_SecondTrancheMember_QxsVP0Jock-3r1DvUA8aiw"
      decimals="3"
      id="Narr_FqHvpx8v4UefCBtD6zV3ig"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.015</ctso:PercentageOfSuccessFee>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_SecondTrancheMember_djf_g158KE-plo3cylyfTw"
      decimals="-6"
      id="Narr_-InT-Zp8WEWJbS4cevkCpw"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_SecondTrancheMember_djf_g158KE-plo3cylyfTw"
      decimals="INF"
      id="Narr_qaxeUPPcsEmt3HwKyikfkg"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">10</us-gaap:SharePrice>
    <ctso:PercentageOfSuccessFee
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_ThirdTrancheMember_4sLxmtU1v0S4Yllbg0FfOA"
      decimals="2"
      id="Narr_xDqz9dKucE6CYZyl4iMpDQ"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.02</ctso:PercentageOfSuccessFee>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_ThirdTrancheMember_NUg-LV9OMEK0n6Tmc-tODA"
      decimals="0"
      id="Narr_Zdw5BsjSNUeuPKIJVoy-uQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:SharePrice
      contextRef="As_Of_12_31_2022_us-gaap_DebtInstrumentAxis_ctso_TermCLoanMember_us-gaap_VestingAxis_ctso_ThirdTrancheMember_NUg-LV9OMEK0n6Tmc-tODA"
      decimals="INF"
      id="Narr_4ifnPTzFD0-CyTmY07VLXQ"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">12</us-gaap:SharePrice>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_GmpmhnXPC06ct5AqHUnz0Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Long-term debt consists of the following as of December 31, 2022:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Principal amount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Less Current maturities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Long-term debt net of current maturities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_1kl3DeV_JESyFKB4IFDlXA_1_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_jmvLm8PwwUS5JVnQ6JTAwg_3_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_sYw-b90wcEC_RxATBucekQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Principal payments of long-term debt are due as follows during the years ending December 31:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,500,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,500,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_FlmdHJHl-0uhZMWOqKLTAA_2_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_ozko2yp1dkacqTms8TeuZQ_3_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_OaQCV6mMR0-VJJ612aEvXw_4_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_mA9NNI4rU0WU3MmpM3LL8Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;8. LEASES:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company leases its operating facilities in both the United States and Germany under operating lease agreements. In March 2021, CytoSorbents Medical Inc. entered into a lease agreement for a new operating facility at 305 College Road East, Princeton, New Jersey, which contains office, laboratory, manufacturing and warehouse space. The lease commenced on June 1, 2021. The Early Term commenced on June 1, 2021 and lasted until September 30, 2021. The lease also contains two five-year renewal options; however, the Company has determined that it is not likely that they will exercise these options. Commencing on September 30, 2021, the remaining lease term will last for 15.5 years. The lease requires monthly rental payments of $25,208 for the Initial Early Term, $88,254 for the Early Term and initial monthly payments of approximately $111,171 in the first year of the remaining term. Following the first year of the remaining term, the annual base rent will increase by approximately 2.75% annually over the remaining term. The lease also contains six months of rent abatement (months 1, 2, 3, 25, 26 and 27 of the remaining lease term). In addition to the base rent, payments of operating expenses and real estate taxes will be required. These payments are to be based on actual amounts incurred during 2021 multiplied by the Company&#x2019;s share of the total building space (92.3%). The landlord will also provide an allowance of approximately $1,455,000 related to certain building improvements as outlined in the lease. In April 2021, the Company provided the landlord with a letter of credit in the amount of approximately $1,467,000 as security. The Company has determined that this lease should be treated as an operating lease in accordance with the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) 842. On April 1, 2021, the Company recorded a Right-of-Use asset and related lease &lt;span style="-sec-ix-hidden:Hidden_i35CHnl1HUSihsVEqT6O2A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;liability&lt;/span&gt;&lt;/span&gt; of approximately $11.6 million, which represents the estimated present value of the lease payments at the commencement date discounted at the Company&#x2019;s incremental borrowing rate of 9.8%. In addition, due to the six months of rent abatement and annual base rent escalations during the remaining lease term that commenced on September 30, 2021, the Company will recognize rent expense on this lease on a straight-line basis over the remaining term of the lease for the difference between the rent expense recognized and the required payments under the lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In April 2021, the Company entered into a Twentieth Amendment to Lease with the landlord at the existing Monmouth Junction facility which became effective May 31, 2021. This amendment extended the term of the lease for the Company&#x2019;s previous facility to May 31, 2022. The Company&#x2019;s base rent was approximately $35,000 per month. In addition, the Company was obligated to pay monthly operating expenses of approximately $30,000 per month. Under the terms of this amendment, the Company vacated a portion of the space as of May 31, 2022. The Company continued to lease the remaining space until December 31, 2022, at which time the lease terminated and the Company vacated the space. The Company&#x2019;s base rent for the remaining space was approximately $20,000 per month. Monthly operating expenses were approximately $11,000 per month. In addition, the Company agreed to increase its security deposit by approximately $54,000 to a total of $150,000. At the end of the lease term, the entire security deposit was paid to the landlord for the purpose of making any needed repairs to the vacated premises, and the Company has no further obligation to pay for repairs to the vacated premises. Effective April 1, 2021, the Company adjusted its incremental borrowing rate to the incremental borrowing rate used in the College Road lease and recalculated the right of use asset and lease liability under the amended terms of this lease. In addition, the Company also adjusted the incremental borrowing rate and related right of use asset and lease liability on the existing Germany office lease effective April 1, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In September 2021, the Company extended its two operating leases for its office facility in Germany. These leases require combined base rent payments amounting to approximately $12,100 per month. The initial lease term of both leases ends August 31, 2026. In addition, the Company is obligated to monthly operating expenses of approximately $3,000 per month. Both leases have a five-year option to renew that would extend the lease term to August 31, 2031. There are no provisions in the leases to increase the base rent during the renewal period. There were no lease incentives and no initial direct costs were incurred related to these leases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In January 2021, CytoSorbents Europe GmbH entered into a lease for 1,068 square meters of additional warehouse space. The lease commenced on April 1, 2021 and requires monthly payments of base rent of $7,784 and other costs of approximately $239 and has a term of five years. The lease also has an option to extend the lease term for an additional five-year period through March 31, 2031. The Company has determined that this lease should be treated as an operating lease in accordance with the provisions of ASC 842. On April 1, 2020, the Company recorded a Right-of-Use asset and related lease &lt;span style="-sec-ix-hidden:Hidden_cxtzS31VrUm4rMIV9MB8Iw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;liability&lt;/span&gt;&lt;/span&gt; at the estimated present value of the lease payments at the commencement date of approximately $594,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Right-of-Use Asset and Lease Liability:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s consolidated balance sheets reflect the value of the right-of-use asset and related lease liability. This value was calculated based on the present value of the remaining base rent lease payments. The remaining lease payments include all expected renewals for all periods as the Company has determined that it is probable that the renewal options will be exercised under each of the lease agreements. The discount rate used was the Company&#x2019;s incremental borrowing rate, which is 9.8%, as the Company could not determine the rate implicit in the lease. As a result, the value of the right-of-use asset and related lease liability is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:70.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right-of-use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,603,901&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;    &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,423,472&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,250,944&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,821,509&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (108,939)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (570,566)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Lease liability, net of current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,142,005&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,250,943&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The maturities of the lease liabilities are as follows as of December 31, 2022:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,266,346&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,656,678&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,695,677&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,735,747&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,776,920&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,232,300&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,363,668&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,112,724&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,250,944&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the years ended December 31, 2022, 2021 and 2020, operating cash flows paid in connection with operating leases amounted to approximately $2,935,000, $1,968,000 and $937,000, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;As of December 31, 2022 and 2021, the weighted average remaining lease term was 12.4 years and 14.3 years, respectively.&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ctso:NumberOfTimesLeaseRenewalAvailable
      contextRef="As_Of_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_soDgpwwWtUaODzy8fGjUCA"
      decimals="INF"
      id="Narr_RMSonooNNEqqPe0fIEA1Dw"
      unitRef="Unit_Standard_item_00R0j3K4HUiRlSslEJQMxQ">2</ctso:NumberOfTimesLeaseRenewalAvailable>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_soDgpwwWtUaODzy8fGjUCA"
      id="Narr_G5igBS2FaEWV15XEAhnPxQ">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="As_Of_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_-_7LrVATRkuKuxUmrfdQ2w"
      id="Narr_FOVXTUELK0Okl3usi88oaw">P15Y6M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_3_1_2021_To_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_srt_StatementScenarioAxis_ctso_OperatingLeaseInitialEarlyTermMember_lxWMtc2sTkqH38xAKIWoPg"
      decimals="0"
      id="Narr_4CKszcZCPEafLgFCjEVYgg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">25208</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_3_1_2021_To_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_srt_StatementScenarioAxis_ctso_OperatingLeaseEarlyTermMember_tAFcc_W5NUuJIEBULRt2Ig"
      decimals="0"
      id="Narr_lBUXGNO_YUe0RRLfbW_3tw"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">88254</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_3_1_2021_To_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_srt_StatementScenarioAxis_ctso_OperatingLeaseFirstYearOfRemainingLeaseTermMember_9vqNICnuOkyckL02PYBIQQ"
      decimals="0"
      id="Narr_ahCCAPhfs0GmAgRp6EPGQA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">111171</us-gaap:OperatingLeaseExpense>
    <ctso:OperatingLeasesAnnualRentExpenseIncrementRate
      contextRef="Duration_3_1_2021_To_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US__KJwJevVx06LgV-mH407GA"
      decimals="4"
      id="Narr_kaf6GezjsUOyuKOHM49zpw"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.0275</ctso:OperatingLeasesAnnualRentExpenseIncrementRate>
    <ctso:OperatingLeasesRentAbatementTerm
      contextRef="Duration_3_1_2021_To_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_id_BW-goZE-wjX2tVerJSw"
      id="Narr_skWuCRJfDkGoq4P6NsPEoQ">P6M</ctso:OperatingLeasesRentAbatementTerm>
    <ctso:PercentageOfTotalBuildingSpaceOccupied
      contextRef="As_Of_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_-_7LrVATRkuKuxUmrfdQ2w"
      decimals="3"
      id="Narr_gwJ378vwgUivM5jAuskWOA"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.923</ctso:PercentageOfTotalBuildingSpaceOccupied>
    <ctso:OperatingLeasesBuildingImprovementAllowanceReceivable
      contextRef="As_Of_3_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_-_7LrVATRkuKuxUmrfdQ2w"
      decimals="0"
      id="Narr_bj0VbKftAkyWxR3pZzApNg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1455000</ctso:OperatingLeasesBuildingImprovementAllowanceReceivable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_4_30_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_us-gaap_DebtInstrumentAxis_us-gaap_LetterOfCreditMember_qtkd0jaAzUeu79V_NBPfXg"
      decimals="0"
      id="Narr_7sh_x5PRYkmncnTwVfiusw"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1467000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_4_1_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_Ayo8OWQvq0qpn_0X3Xab7g"
      decimals="-5"
      id="Narr_aEJv7VdC4k2wiW9gnrPyMg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">11600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="As_Of_4_1_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsMedicalIncMember_srt_StatementGeographicalAxis_country_US_Ayo8OWQvq0qpn_0X3Xab7g"
      decimals="3"
      id="Narr_AWiDdHouw0SS_jarxHLOKA"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.098</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_4_1_2021_To_4_30_2021_us-gaap_LeaseContractualTermAxis_ctso_TwentiethAmendmentToLeaseMember_gauFszu_JEOFrdWykocnUw"
      decimals="0"
      id="Narr_JlPrdcjaLU248BjipyDFeg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">35000</us-gaap:OperatingLeaseExpense>
    <ctso:AdditionalOperatingLeasesRentExpenseNet
      contextRef="Duration_4_1_2021_To_4_30_2021_us-gaap_LeaseContractualTermAxis_ctso_TwentiethAmendmentToLeaseMember_gauFszu_JEOFrdWykocnUw"
      decimals="0"
      id="Narr_AM7e9zeoMEedTTRvNVzYRg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">30000</ctso:AdditionalOperatingLeasesRentExpenseNet>
    <ctso:OperatingLeaseBaseRentForRemainingSpace
      contextRef="Duration_4_1_2021_To_4_30_2021_us-gaap_LeaseContractualTermAxis_ctso_TwentiethAmendmentToLeaseMember_gauFszu_JEOFrdWykocnUw"
      decimals="0"
      id="Narr_jzvjybl6VE2TNGIV8lXYOg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">20000</ctso:OperatingLeaseBaseRentForRemainingSpace>
    <ctso:MonthlyOperatingExpenses
      contextRef="Duration_4_1_2021_To_4_30_2021_us-gaap_LeaseContractualTermAxis_ctso_TwentiethAmendmentToLeaseMember_gauFszu_JEOFrdWykocnUw"
      decimals="0"
      id="Narr_km5e9SgoqU2bZRN0TJAcIQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">11000</ctso:MonthlyOperatingExpenses>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_12_31_2020_us-gaap_LeaseContractualTermAxis_ctso_TwentiethAmendmentToLeaseMember_jYak7TFeK0qURMnjm2T8DA"
      decimals="0"
      id="Narr_cWER79EM0kS-oVtrNhEOzQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">54000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_4_30_2021_us-gaap_LeaseContractualTermAxis_ctso_TwentiethAmendmentToLeaseMember_wrqHEmK560ePWOyCLlAXAA"
      decimals="0"
      id="Narr_NjvHcM9qV0aRYD8dCiBWiw"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">150000</us-gaap:SecurityDeposit>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_9_1_2021_To_9_30_2021_srt_StatementGeographicalAxis_country_DE_R18Zrff15UWiG7PQAHXLAg"
      decimals="0"
      id="Narr_egzC1RLLGkehGmZsjmJItA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">12100</us-gaap:OperatingLeaseExpense>
    <ctso:AdditionalOperatingLeasesRentExpenseNet
      contextRef="Duration_9_1_2021_To_9_30_2021_srt_StatementGeographicalAxis_country_DE_R18Zrff15UWiG7PQAHXLAg"
      decimals="0"
      id="Narr_4vYgzP7JgUa_KLFYCd3lSQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3000</ctso:AdditionalOperatingLeasesRentExpenseNet>
    <us-gaap:AreaOfLand
      contextRef="As_Of_1_31_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsEuropeGmbhMember_WYlLNzD2gES86ALGoqLgDg"
      decimals="INF"
      id="Narr_KkDPaAFPSkeTME2YdXvGrA"
      unitRef="Unit_Standard_sqm_5jCoQZf8skWtJMe7yh0D_w">1068</us-gaap:AreaOfLand>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_4_1_2021_To_4_1_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsEuropeGmbhMember_qOdCgqh6606refmoxrQP8Q"
      decimals="0"
      id="Narr_Y5_6N6Y6yEKBHMkQmhx65A"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">7784</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_4_1_2021_To_4_1_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsEuropeGmbhMember_qOdCgqh6606refmoxrQP8Q"
      decimals="0"
      id="Narr_pJ6bZcGf8UKqnBH9RF713g"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">239</us-gaap:OperatingLeaseCost>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_4_1_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsEuropeGmbhMember_eGPb2XlfmU655buQQmU81A"
      id="Narr_bH5l24kSv0OJCw8dISuT0A">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_4_1_2021_srt_ConsolidatedEntitiesAxis_ctso_CytosorbentsEuropeGmbhMember_eGPb2XlfmU655buQQmU81A"
      decimals="0"
      id="Narr_4Jl7ir19pEGVoLNYLGRlpA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">594000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="4"
      id="Narr_y-zdy2gFDE6rQJh7dMD5KA"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.098</us-gaap:LesseeOperatingLeaseDiscountRate>
    <ctso:LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_-_CuBJ8hrU2Xte-HLI0VfA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:70.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right-of-use asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,603,901&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;    &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,423,472&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,250,944&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,821,509&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (108,939)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (570,566)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Lease liability, net of current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,142,005&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,250,943&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ctso:LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_gl87T5-v2kqiYXl_FOZBrg_3_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">12603901</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_SB6PJbQZ2kWCTgjM05GqPw_3_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">13423472</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_lkcnfstgTUS76BNNYFicWg_5_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">13250944</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_xaIOX_oHLk2QWWmql2v4OQ_5_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">13821509</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_T7mw2DYEkES9mYK3LfspAw_6_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">108939</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_v7BwObkX0kiwXOM3z-w0kw_6_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">570566</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_9_qIfZY7Zkuh-tGe_KwZ0w_7_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">13142005</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_bQDS_nIsVEW68rC9udiOKw_7_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">13250943</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_-mnXGrCUBUW2ddb9EDyIAA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The maturities of the lease liabilities are as follows as of December 31, 2022:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,266,346&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,656,678&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,695,677&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,735,747&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,776,920&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,232,300&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,363,668&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:84.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,112,724&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,250,944&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_k0PJSrHa8UeQ2KNqsqJZqQ_1_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1266346</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_GGssQJmia0i1rkEjUlCO5Q_2_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1656678</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_g7nXIHMUr06ZVsxoeWKOSw_3_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1695677</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_YvsnLhUT0USKDm1l5fMDXw_4_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1735747</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_0ILJTmxOmUegGgBcFpYAqw_5_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1776920</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <ctso:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_DXkXXBejZ0uMRKbtj9ZKvA_6_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">17232300</ctso:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_qoYpCbW4902GBZHxS_sD2A_7_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">25363668</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_XBCrERL2eUuHsmfdAgLlTg_8_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">12112724</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_A-QtHWBKpkypV8rnZFGFFw_9_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">13250944</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Narr_77KCP-XDYUeKPT6tvY87Ig"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2935000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Narr_qBK8G8R1m0GAs5spK-k9WQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1968000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Narr_LrAbLHLhpkC74vNOzvWqpQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">937000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      id="Narr_NmcwmpQQ_0WgyEPCrir_pw">P12Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      id="Narr_WyJSLOysxUu8501A-I6l0g">P14Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_-atYA5VEBUqxAZ6evMS3Dw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;9. INCOME TAXES:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for income taxes under FASB ASC 740 (&#x201c;ASC 740&#x201d;). Deferred income tax assets and liabilities are determined based upon differences between financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s consolidated loss before income taxes for the years ended December 31, 2022, 2021 and 2020 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:60.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Domestic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21,155,203)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18,829,797)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,682,628)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12,749,965)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,464,854)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,281,634)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33,905,168)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (25,294,651)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,964,262)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The benefit from income taxes consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:60.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State Tax, including sale of New Jersey losses &amp;amp; credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,092,585&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 736,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,127,074&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign tax provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,092,585&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 736,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,127,074&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has deemed any foreign earnings will be indefinitely reinvested. Currently, foreign operations have resulted in an accumulated deficit. The Company will continue to analyze their stance if their circumstances change in the future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022, the Company had federal net operating loss (&#x201c;NOL&#x201d;) carryforwards of approximately $87.4 million, state NOL carry forwards of approximately $5.5 million, and foreign NOL carry forwards of approximately $42.7 million, which may be available to offset future taxable income, if any. The federal NOL carryforwards of $47.8 million, if not utilized, will expire between 2022 and 2037. The federal NOL carryforwards of $39.6 million generated since 2018 are subject to an 80% limitation on taxable income, do not expire and will carry forward indefinitely. The state NOL carryforwards of $5.5 million, if not utilized, will begin to expire in 2042. As of December 31, 2022, the Company had Federal and state research and development tax credit carryforwards of approximately $3.7 million and $0.3 million, respectively, available to reduce future tax liabilities, which will begin to expire at various dates starting in 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The NOL carry forwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. The NOLs may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Section 382 of the Internal Revenue Code of 1986, as amended, as well as similar state tax provisions. In addition to the new provisions enacted under the Tax Cuts and Jobs Act, this could limit the amount of NOLs that the Company can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will generally be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;We record tax benefits related to uncertain tax positions taken or expected to be taken on a tax return when such benefits meet a more likely than not threshold. We recognize interest related to unrecognized tax benefits in interest expense and penalties in operating expenses. Currently, the Company is not accounting for any uncertain tax positions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;U.S. Tax Reform&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Due to The Tax Cuts and Jobs Act of 2017 (TCJA) there was a change in the deductibility of research and experimental expenditures that took effect for taxable periods that begin after December 31, 2021. Prior to January 1, 2022, the Company expensed research and experimental expenditures under &#xa7;174(a) in the year that books recognized the expense. The Company has adopted &#xa7;174(b) for taxable years 2022 and beyond. Domestic and foreign research and experimental expenditures will be capitalized and amortized over a period no less than 60 months and 180 months, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Sale of Net Operating Losses (NOLs)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company may be eligible, from time to time, to receive cash from the sale of its New Jersey Net Operating Losses and R&amp;amp;D tax credits under the State of New Jersey Technology Business Tax Certificate Transfer Program.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company will receive a net cash amount of approximately $1,093,000 from the approved sale of the 2021 state NOL and research and development credits in the first half of 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The principal components of the Company&#x2019;s deferred tax assets and liabilities are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net operating loss carry forward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,570,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,190,654&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,301,154&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 500,975&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,203,272&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 305,982&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development credit carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,982,147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,687,591&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,194,211&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accruals and others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 232,665&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 135,330&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,724,840&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,997,114&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 289,287&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#xa7;174(b) research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,331,625&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,134,554&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,311,296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,225,964&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (39,303,451)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (31,242,130)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (24,794,474)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,831,103&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,069,166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 431,490&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liability:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (288,145)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (183,941)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (431,490)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right of Use Asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,542,958)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,885,225)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. Based on this assessment, management has established a full valuation allowance against all of the deferred tax assets for each period because it is more likely than not that all of the deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The increases in valuation allowance for the years ended December 31, 2022, 2021 and 2020 were $8,061,321, $6,447,656, and $1,936,732, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;A reconciliation of income tax (expense) benefit at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign rate differential&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Rate change and true-up&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;R&amp;amp;D credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Sale of state R&amp;amp;D credit and NOL&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_kbR71WxG1kqdYFVjqjNPCg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s consolidated loss before income taxes for the years ended December 31, 2022, 2021 and 2020 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:60.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Domestic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21,155,203)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18,829,797)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,682,628)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12,749,965)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,464,854)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,281,634)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (33,905,168)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (25,294,651)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,964,262)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_kH97QOxYEUanSW0ZgOqVRQ_3_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-21155203</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_SR-ULXRSD0eCph_hKqs7BQ_3_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-18829797</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_IdcdNKaRQ0SOvg4OTQN0jQ_3_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-5682628</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_rthbTincakOnIyiI8QfdBA_4_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-12749965</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_MifFmIXIkE68J_9N7sF9_A_4_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-6464854</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_ysvCCApKx0OHVZiBDa_o8w_4_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-3281634</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <ctso:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_LLfJbAHma0mcQRFspwsshQ_5_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-33905168</ctso:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests>
    <ctso:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_JEd3JjURPE-wrsVZS9BUhA_5_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-25294651</ctso:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests>
    <ctso:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_xLHq7WB5qUOOsxgYL-lVMQ_5_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-8964262</ctso:IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_omEK38qxsUOPJ1oMI0lWfw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The benefit from income taxes consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:60.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;State Tax, including sale of New Jersey losses &amp;amp; credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,092,585&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 736,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,127,074&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Foreign tax provision&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,092,585&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 736,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,127,074&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_1DQmwvv8dk-jWGTNAgwipA_3_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-1092585</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_7yh7WXzMDE2-eDywhA_U3w_3_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-736003</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_chZ9Sc1-RkK57urHykX1WQ_3_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-1127074</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Tc_NLvKbLfzQE6hDW7J2j6lFg_5_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-1092585</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Tc_TxmxtDffvUOUEvQemrdpow_5_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-736003</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Tc_XRsSBvWp00WV3ou8jS3lKw_5_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-1127074</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_9IC6hTCjW06NGRwHHe3tNg"
      decimals="-5"
      id="Narr_kb4WWZXYOU-c36e2T4wdaw"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">87400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_ERD_klH89EySV0xsixbjKg"
      decimals="-5"
      id="Narr_Fv_bzr_EB0COfku5aBU0hQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_3Qdgi4LpIkSQMymN-mkajA"
      decimals="-5"
      id="Narr_dBicCka5VE2CxQZ2MnXXOg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">42700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="-5"
      id="Narr_NrTvJYZvgEG1gpSbBwYUGA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">47800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2018_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_HgsYwDdKM0Wf4EOABgWuUQ"
      decimals="-5"
      id="Narr_w9iCXhGpi0m3wLuPlEhJyg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">39600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsLimitationsOnUse
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_1CSdAfRRlU2oCQ3l3StC0A">80% limitation on taxable income</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_ERD_klH89EySV0xsixbjKg"
      decimals="-5"
      id="Narr_JvKUCXLQIEy4yA8ynWHTCg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_9IC6hTCjW06NGRwHHe3tNg"
      decimals="-5"
      id="Narr_xbkp0-a1wUOTaTdc6XdU7A"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_ERD_klH89EySV0xsixbjKg"
      decimals="-5"
      id="Narr_43rWi2eLFUSB-I1K3oCx1w"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">300000</us-gaap:TaxCreditCarryforwardAmount>
    <ctso:ProceedsFromSaleOfNetOperatingLossCarryforwards
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Narr_czjM3JxM6UyaLimH9N3hww"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1093000</ctso:ProceedsFromSaleOfNetOperatingLossCarryforwards>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_mliAeQhdTEyRhtFGRd21Tw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The principal components of the Company&#x2019;s deferred tax assets and liabilities are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net operating loss carry forward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31,570,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,190,654&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,301,154&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 500,975&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,203,272&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 305,982&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development credit carryforward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,982,147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,687,591&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,194,211&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accruals and others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 24,121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 232,665&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 135,330&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,724,840&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,997,114&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 289,287&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#xa7;174(b) research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,331,625&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,134,554&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,311,296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 25,225,964&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (39,303,451)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (31,242,130)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (24,794,474)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,831,103&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,069,166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 431,490&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liability:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (288,145)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (183,941)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (431,490)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Right of Use Asset&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,542,958)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,885,225)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:60.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_nuuu-DMeuEixjARBwx3yLw_4_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">31570846</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_8cAFDWIixEGndwhr49yaiw_4_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">27190654</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w"
      decimals="0"
      id="Tc_TMVPtJT8mkuB1uOy-NEJHg_4_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">22301154</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_dibnrEwKokmJmxftkQ2YHQ_5_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">500975</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_r8zvLbNis0q5rVogbpOFwg_5_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1203272</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
      contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w"
      decimals="0"
      id="Tc_eRcCh9LFBkygl5pFKrhLVA_5_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">305982</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_VxLb3GtiKUC9QEs95fIyHA_6_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3982147</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_TFXGdMwCakGqZqCXBOEhaw_6_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2687591</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w"
      decimals="0"
      id="Tc_cZ9AoIjLakivBlAjhMHu0g_6_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2194211</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_Hal2rt-bBEKwy0KvTk9wHQ_7_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">24121</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_8Vm8otM0Y0WhZ8c3Kdl1Rg_7_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">232665</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w"
      decimals="0"
      id="Tc_ehM5cSeScEqmam2pbHTIpQ_7_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">135330</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <ctso:DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_JhPzIqeU7UWlQ_fPAs0REA_8_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3724840</ctso:DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability>
    <ctso:DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_p6yD4g2SkkCZKvppIqnyeg_8_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3997114</ctso:DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability>
    <ctso:DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability
      contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w"
      decimals="0"
      id="Tc_1Jg7bZB1vUCh3MLY2TkTeg_8_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">289287</ctso:DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability>
    <us-gaap:DeferredTaxAssetsOtherTaxCarryforwards
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_3w0usQNMGE-EzPtBCOcmZQ_9_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3331625</us-gaap:DeferredTaxAssetsOtherTaxCarryforwards>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_xF2UbFVr1kuqQz3wyHgObQ_10_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">43134554</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_VZ_Lc7T1tk27kmN2jWQNcw_10_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">35311296</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w"
      decimals="0"
      id="Tc_47Zp92CGF0ynSTiZvPEBwQ_10_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">25225964</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_iX2KszzLk0SGO4ROWO77DQ_11_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">39303451</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_fVwmysI8VUibSOHKe829vQ_11_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">31242130</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w"
      decimals="0"
      id="Tc_Y7EEpeyBc0uiER_IaVurPQ_11_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">24794474</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_j4UDk2SRS0ygxtVPhvIKsw_12_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3831103</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_wNCDEqhem0mo0R27dUOrCQ_12_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">4069166</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w"
      decimals="0"
      id="Tc_a4k_E4f6HUiAEwv1Awz6_A_12_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">431490</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_ZQK2RiK79kCr1YDfkXgDDA_14_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">288145</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_2SjkIykQt0asonifq9GmVw_14_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">183941</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w"
      decimals="0"
      id="Tc_I8uqIyzD1UijtOuDLgxJ4g_14_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">431490</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <ctso:DeferredTaxLiabilitiesRightsOfUseAssets
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_hv_RFnrl_U6lhn5mRbuYLQ_15_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3542958</ctso:DeferredTaxLiabilitiesRightsOfUseAssets>
    <ctso:DeferredTaxLiabilitiesRightsOfUseAssets
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_ECnBnHeeR0axQp8PcYe6Pg_15_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3885225</ctso:DeferredTaxLiabilitiesRightsOfUseAssets>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Narr_qiV5rF8m0EiJJelK2wG_gA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">8061321</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Narr_w4RiXZ-w6UOSc6E3KBhgZw"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">6447656</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Narr_bzxeuocPu0KNyl0aigeDJg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1936732</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_RbU1ft7wSkCxYdEfCQY3WA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;A reconciliation of income tax (expense) benefit at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Foreign rate differential&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.0)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Rate change and true-up&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 0.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (22.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (25.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (21.6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;R&amp;amp;D credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Sale of state R&amp;amp;D credit and NOL&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:62.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="5"
      id="Tc_Ekl-0_daQUe3M9Rw6Eymvg_3_2"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.00210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="5"
      id="Tc_SX6Fvki0nEWMBD7EH0E5aw_3_4"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.00210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="5"
      id="Tc__zeL5mEIqE6ssKlrLUnLGg_3_6"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.00210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="5"
      id="Tc_Owv6rxRu5EOjO4MClbuF-w_4_2"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">-0.00028</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="5"
      id="Tc_NopQGpvOJ0WoFyYs34W3ug_4_4"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">-0.00020</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="5"
      id="Tc_GadhH9UyVk2M664-uYk2nw_4_6"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">-0.00095</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="5"
      id="Tc_MW_ORsfcFkq6077bycvWWw_5_2"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.00034</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="5"
      id="Tc_39CJs-Ekk02SmI9c8dtSyQ_5_4"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.00023</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="5"
      id="Tc_5lroOVgQLE68nd_fc8_v3w_5_6"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.00033</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <ctso:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="5"
      id="Tc_FU-8tlE4uU6c899GJ0qPkw_6_2"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">-0.00015</ctso:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent>
    <ctso:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="5"
      id="Tc_MmigEdHb3UiGLQ-usJXy5g_6_4"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">-0.00065</ctso:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent>
    <ctso:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="5"
      id="Tc_PKC3W6lENkqM4l23dGC3Xg_6_6"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">-0.00020</ctso:EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="5"
      id="Tc_ZQ12bS0gpEO9dwYXuov22A_7_2"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.00006</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="5"
      id="Tc_62_T6BER-UqfECVAZj8KHg_7_4"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.00118</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="5"
      id="Tc_gKULL7lwGUuaBtJXQ6IMmQ_7_6"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.00170</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="5"
      id="Tc_l6zP6y4JSUezPFF0jfGGXw_8_2"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">-0.00228</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="5"
      id="Tc_9y-y_YOK1EOh0IJDjR7k8g_8_4"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">-0.00255</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="5"
      id="Tc_l5tDDqgoREGDtX177-LRxw_8_6"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">-0.00216</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="5"
      id="Tc_Ic_-L81U30qtSjunKR3z2g_9_2"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.00021</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="5"
      id="Tc_yfJQ35m3rEGBqLtbPkTOag_9_4"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.00017</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="5"
      id="Tc_XcQTt2hYw0OBhkhZx5npFQ_9_6"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.00044</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="5"
      id="Tc_J6S1BUZIKUaADCRYWBBloA_10_2"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.00032</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="5"
      id="Tc_OHYE0XcBkkmpiavcxVVZ9A_11_2"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.00032</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="5"
      id="Tc_8RLa6Nu6ck6ee9070843yQ_11_4"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.00028</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="5"
      id="Tc_55gnavwUvEKcLl2CzePA5Q_11_6"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.00126</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_4-nVwyOV_kiw-2dKUo8pVQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;10. COMMITMENTS AND CONTINGENCIES:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Payroll Tax Examination&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In December 2021, the Company was notified that its European subsidiary, CytoSorbents Europe GmbH, would be subject to an audit of their payroll tax and social cost filings for the four-year period from 2018 through 2021. The Company has determined that payroll taxes and social costs were not paid on certain employee expense reimbursements as is required by German tax rules. Accordingly, the Company accrued approximately $598,000 as an estimate of this liability as of December 31, 2021. In January 2023, the Company received an assessment from the German tax authorities for the payroll tax audit of approximately $90,000. In addition, it was determined that the Company would owe additional social security and VAT taxes related to this matter of approximately $83,000. Accordingly, the Company has adjusted its accrual related to this payroll tax audit to approximately $173,000 as of December 31, 2022. This liability is included in accrued expenses and other current liabilities in the consolidated balance sheet as of December 31, 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The expense related this examination is included in selling, general and administrative expenses on the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Employment Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On July&#160;30, 2019, CytoSorbents Corporation entered into amended and restated executive employment agreements with its principal executives, Dr.&#160;Phillip P. Chan, Chief Executive Officer, Vincent Capponi, President and Chief Operating Officer, and Kathleen P. Bloch, Chief Financial Officer. Each of the agreements has an initial term of three&#160;years and was retroactively effective as of January&#160;1, 2019. On April 12, 2020, CytoSorbents Corporation entered into an executive employment agreement with Dr. Efthymios Deliargyris, who began employment as Chief Medical Officer on May 1, 2020, with an initial term that expired on December 31, 2021. After the expiration of the initial terms, the employment agreements will automatically renew for additional terms of one&#160;year unless either party provides written notice of non-renewal at least 60 days prior to a renewal.In January 2022, these employment agreements automatically renewed for an additional 1 year. The foregoing employment agreements each provide for base salary and other customary benefits which include participation in group insurance plans, paid time off and reimbursement of certain business-related expenses, including travel and continuing educational expenses, as well as bonus and/or equity awards at the discretion of the Board of Directors. In addition, the agreements provide for certain termination benefits in the event of termination without &#x201c;Cause&#x201d; or voluntary termination of employment for &#x201c;Good Reason&#x201d;, as defined in each agreement. The agreements also provide for certain benefits in the event of a &#x201c;Change of Control&#x201d; of the Company, as defined in each agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 30, 2022, Ms. Bloch notified the Company of her intention to retire effective March 31, 2023. A search has been initiated for Ms. Bloch&#x2019;s replacement. Ms. Bloch and the Company expect to enter into a consulting arrangement under which Ms. Bloch will continue to provide services to the Company in a limited capacity following the effective date of her retirement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Litigation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is, from time to time, subject to claims and litigation arising in the ordinary course of business. The Company intends to defend vigorously against any future claims and litigation. The Company is not currently a party to any legal proceedings.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Royalty Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to an agreement dated August&#160;11, 2003, an existing investor agreed to make a $4 million equity investment in the Company. These amounts were received by the Company in 2003. In connection with this agreement the Company granted the investor a perpetual royalty of 3% on all gross revenues received by the Company from the sale of its CytoSorb device which such rights were assigned to an existing investor in 2017. For the years ended December 31, 2022, 2021 and 2020, the Company recorded royalty expenses of approximately $849,000, $1,193,000, and $1,172,000, respectively. These expenses are included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 1, 2022, the Company entered into the Marketing Agreement with Fresenius, which expands the Company&#x2019;s strategic partnership with Fresenius by establishing a multi-stage global collaboration to combat life-threatening diseases in critical care. The Marketing Agreement has an initial term of three years, with an automatic renewal for an additional two years at the end of such initial term, subject to earlier termination by either of the parties (the &#x201c;Term&#x201d;) To help support the increased marketing and promotional efforts of the expanded collaboration, the Company has agreed to subsidize a portion of the marketing costs through royalty payments to Fresenius. Initially, the Marketing Agreement provides for royalty payments equal to 0.9% of the Company&#x2019;s net sales of CytoSorb products made during the Term (excluding net sales in the United States). This initial royalty rate was determined based on certain assumptions regarding the percentage of the Company&#x2019;s sale of CytoSorb products that are used with the Fresenius critical care platforms in the intensive care unit outside of the United States but is subject to adjustment if the Company determines that the underlying assumptions have changed significantly. For the year ended December 31, 2022, the Company did not record any expense related to this agreement as Fresenius did not commence any marketing activities as defined by the agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;License Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In an agreement dated September&#160;1, 2006, the Company entered into a license agreement which provides the Company the exclusive right to use its patented technology and proprietary know how relating to adsorbent polymers for a period of 18&#160;years. Under the terms of the agreement, the Company has agreed to pay license fees of 2.5% to 5% on the sale of certain of its products if and when those products are sold commercially for a term not greater than 18&#160;years commencing with the date of the agreement. For the&#160;years ended December 31, 2022, 2021 and 2020 per the terms of the license agreement, the Company recorded licensing expenses of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;approximately $1,416,000, $1,988,000 and $1,954,000, respectively. These expenses are included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:IncomeTaxExaminationInterestAccrued
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Narr_NX4vQoBk6kq1LAvHJPvoYQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">598000</us-gaap:IncomeTaxExaminationInterestAccrued>
    <us-gaap:IncomeTaxExaminationInterestAccrued
      contextRef="As_Of_1_31_2023_us-gaap_LossContingenciesByNatureOfContingencyAxis_ctso_PayrollTaxAuditMember_UY7_k4-eREeBnQGR_XMpGA"
      decimals="0"
      id="Narr_BFeCz6n1Lkm5LZvxDTwjyQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">90000</us-gaap:IncomeTaxExaminationInterestAccrued>
    <us-gaap:IncomeTaxExaminationInterestAccrued
      contextRef="As_Of_12_31_2022_us-gaap_LossContingenciesByNatureOfContingencyAxis_ctso_AdditionalSocialSecurityAndVatTaxesMember_dTAIANEpM0y9wSbH-curug"
      decimals="0"
      id="Narr_C1-umgQrBkKZlpahov9DfQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">83000</us-gaap:IncomeTaxExaminationInterestAccrued>
    <us-gaap:IncomeTaxExaminationInterestAccrued
      contextRef="As_Of_12_31_2022_us-gaap_LossContingenciesByNatureOfContingencyAxis_ctso_PayrollTaxAuditMember_5kmrsmoK8EWvYJIbVVsujg"
      decimals="0"
      id="Narr_LB0w7YE2l0i2wgCjCEYJhg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">173000</us-gaap:IncomeTaxExaminationInterestAccrued>
    <ctso:ExecutiveEmploymentAgreementsInitialTerm
      contextRef="Duration_1_1_2019_To_1_1_2019_Qy5PqaSx0EaQbNj8WsHlmA"
      id="Narr_RUUpiJPUEUS7FhwtTwQFXQ">P3Y</ctso:ExecutiveEmploymentAgreementsInitialTerm>
    <ctso:EmploymentAgreementsAutomaticRenewalPeriod
      contextRef="Duration_1_1_2022_To_1_31_2022_ifdIznn7QEeHunrEw3Jhtw"
      id="Narr_VxFrVdAysUG1WS0gOqTUFw">P1Y</ctso:EmploymentAgreementsAutomaticRenewalPeriod>
    <ctso:EmploymentAgreementsAutomaticRenewedPeriod
      contextRef="Duration_1_1_2022_To_1_31_2022_ifdIznn7QEeHunrEw3Jhtw"
      id="Narr_Rz2EZm3LC0e4vyJGhBfpkg">P1Y</ctso:EmploymentAgreementsAutomaticRenewedPeriod>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="Duration_8_11_2003_To_8_11_2003_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_RoyaltyAgreementsMember_xFt-mbbZrkmdsbIlITDLxQ"
      decimals="-6"
      id="Narr_kkCloJGY9kW8-ej4v9oF3g"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">4000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <ctso:RoyaltyPaymentRate
      contextRef="Duration_8_11_2003_To_8_11_2003_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_RoyaltyAgreementsMember_xFt-mbbZrkmdsbIlITDLxQ"
      decimals="2"
      id="Narr_fIAiV71sHEyICI0bp3AC-A"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.03</ctso:RoyaltyPaymentRate>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_RoyaltyAgreementsMember_BXoz6wUE6keu3xUP3R0XpQ"
      decimals="0"
      id="Narr_eBa1MxAefU67wIx3YyAhHQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">849000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_RoyaltyAgreementsMember_rdfbeFkWfkyrD5IQ3VfUwg"
      decimals="0"
      id="Narr_H_4OqnhQ50exvEOsXqkkrQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1193000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_RoyaltyAgreementsMember_CA354vfky0OFd_1E5K6eQw"
      decimals="0"
      id="Narr_g9GacNkbtUaCCT49CV9m5g"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1172000</us-gaap:RoyaltyExpense>
    <ctso:LicensePeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_LicenseAgreementMember_raDmOQBLY0ys677paSR3hw"
      id="Narr_OV7pkT6cP0qp5eF5j5uQPA">P18Y</ctso:LicensePeriod>
    <ctso:RoyaltyRateLowerLimit
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_LicenseAgreementMember_vd_rm61d5EKX2A6aRANNWw"
      decimals="3"
      id="Narr_mT0y3WVas02PnV279yL_Kw"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.025</ctso:RoyaltyRateLowerLimit>
    <ctso:RoyaltyRateUpperLimit
      contextRef="As_Of_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_LicenseAgreementMember_vd_rm61d5EKX2A6aRANNWw"
      decimals="2"
      id="Narr_VtDY_YAbcUStCCewYBxbgQ"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.05</ctso:RoyaltyRateUpperLimit>
    <ctso:LicensePeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_LicenseAgreementMember_raDmOQBLY0ys677paSR3hw"
      id="Narr_nbWB5CMai0WhdJz5mXrUVQ">P18Y</ctso:LicensePeriod>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_LicenseAgreementMember_raDmOQBLY0ys677paSR3hw"
      decimals="0"
      id="Narr_S9e49JABXEay5vCU-G7_xA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1416000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_LicenseAgreementMember_S4h6KrieY0yFrU840BqKzQ"
      decimals="0"
      id="Narr_ebrXD_vamUurLVtj0H8rIw"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1988000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ctso_LicenseAgreementMember_U7A4z9C5Qk6CY4PDRbXTqQ"
      decimals="0"
      id="Narr_g6ufS89vWUCNxMBUtL8HVw"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1954000</us-gaap:RoyaltyExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_i3s19FObfU2CICZnXwPPnQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;11. STOCKHOLDERS&#x2019; EQUITY:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June&#160;2019, the Company amended and restated its certificate of incorporation. The amended and restated certificate of incorporation authorizes the issuance of up to 5,000,000 shares of &#x201c;blank check&#x201d; preferred stock, with such designation rights and preferences as may be determined from time to time by the Board of Directors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Common Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2019, the Company amended and restated its certificate of incorporation. The amended and restated certificate of incorporation increased the number of shares of common stock authorized for issuance from 50,000,000 shares to 100,000,000 shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Shelf Registration&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On July 14, 2021, the Company filed a registration statement on Form S-3 with the SEC, which was amended on July 20, 2021 and declared effective by the SEC on July 27, 2021 (as amended, the &#x201c;2021 Shelf&#x201d;). The 2021 Shelf enables the Company to offer and sell, in one or more offerings, any combination of common stock, preferred stock, senior or subordinated debt securities, warrants and units, up to a total dollar amount of $150 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Open Market Sale Agreement with Jefferies LLC &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 30, 2021, the Company entered into an Open Market Sale Agreement (the &#x201c;Sale Agreement&#x201d;) with Jefferies LLC (the &#x201c;Agent&#x201d;), pursuant to which the Company could sell, from time to time, at its option, shares of the Company&#x2019;s common stock having an aggregate offering price of up to $25 million through the Agent, as the Company&#x2019;s sales agent. All shares of the Company&#x2019;s common stock offered and sold, or to be offered and sold under the Sale Agreement, would have been issued and sold pursuant to the Company&#x2019;s 2021 Shelf by methods deemed to be an &#x201c;at the market offering&#x201d; as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, in block transactions or if specified by the Company, in privately negotiated transactions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Subject to the terms of the Sales Agreement, the Agent is required to use their commercially reasonable efforts consistent with their normal sales and trading practices to sell the shares of the Company&#x2019;s common stock from time to time, based upon the Company&#x2019;s instructions (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company is required to pay the Agent a commission of up to 3.0% of the gross proceeds from the sale of the shares of the Company&#x2019;s common stock sold thereunder, if any. There were no sales pursuant to the Amended Sale Agreement during the years ended December 31, 2022 and 2021, respectively. In addition, during the year ended December 31, 2021, the Company paid approximately $90,000 related to the Amended Sale Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock Option Plans&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022, the Company had two Long Term Incentive Plans (the &#x201c;2014 Plan&#x201d; and the &#x201c;2006 Plan&#x201d;) to attract, retain, and provide incentives to employees, officers, directors, and consultants. The Plans generally provide for the granting of stock, stock options, stock appreciation rights, restricted shares, or any combination of the foregoing to eligible participants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A total of 13,400,000 and 2,400,000 shares of common stock are reserved for issuance under the 2014 Plan and the 2006 Plan, respectively. As of December 31, 2022, there were shares remaining to purchase approximately 3,713,000 and 258,000 units of common stock reserved under the 2014 Plan and the 2006 Plan, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The 2014 and 2006 Plans as well as grants issued outside of the Plan are administered by the Compensation Committee of the Board of Directors (the &#x201c;Compensation Committee&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Compensation Committee is authorized to select from among eligible employees, directors, advisors and consultants those individuals to whom incentives are to be granted and to determine the number of shares to be subject to, and the terms and conditions of the options. The Compensation Committee is also authorized to prescribe, amend and rescind terms relating to options granted under &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;the Plans. Generally, the interpretation and construction of any provision of the Plans or any options granted hereunder is within the discretion of the Compensation Committee.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The 2014 Plan provides that options may or may not be Incentive Stock Options (&#x201c;ISOs&#x201d;) within the meaning of Section 422 of the Internal Revenue Code. Only employees of the Company are eligible to receive ISOs, while employees and non-employee directors, advisors and consultants are eligible to receive options, which are not ISOs, i.e., &#x201c;Non-Qualified Options.&#x201d; Because the Company has not obtained shareholder approval of the 2006 Plan, all options granted thereunder to date are &#x201c;Non-Qualified Options&#x201d; and until such shareholder approval is obtained, all future options issued under the 2006 Plan will also be &#x201c;Non-Qualified Options.&#x201d;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2014, the Company&#x2019;s received shareholder approval authorizing the Board of Directors to implement the form, terms and provisions of the 2014 Plan. Accordingly, any options issued to employees under the 2014 Plan will be ISOs within the meaning of Section&#160;422 of the Internal Revenue Code.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Total share-based employee, director, and consultant compensation for the&#160;years ended December 31, 2022, 2021 and 2020 amounted to approximately $3,424,000, $4,021,000, and $3,514,000, respectively. These amounts are included in selling, general, and administrative expenses on the consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The summary of the stock option activity for the&#160;years ended December 31, 2022, 2021 and 2020 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&#160;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding January 1, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,218,189&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,579,106&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (34,644)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_1iWKOSTEYEW4rgjnocsyQg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (226,440)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_gFEztX83IEan5vGYiG_KkA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (371,007)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_7Cm8_uxCP0mv3QQAha4gkQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding, December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,165,204&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.26&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,051,980&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.30&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (138,037)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_rBumodlmnUK-p_-iado5iw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21,756)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_GQpp15AqqkCIMuMwEM8NqQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (171,413)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_amo3-ZcwWEWCT2ol91T9ZQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding, December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6,885,978&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.09&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2,721,205&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.60&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,270,155)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_SbJXsQ3BuU-Usd0OT4w7GA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (227,204)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_4-HPXTyq0kWo5cJ4Z0sPVw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_We0d8r7iWEWg62NYW1m7vA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding, December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,109,824&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of each stock option was estimated using the Black-Scholes pricing model which takes the following factors into account.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;of&#160;the&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;Underlying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;Stock&#160;and&#160;its&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant&#160;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expected&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expected&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Risk&#160;Free&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;of&#160;the&#160;Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;Volatility&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expected&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;Interest&#160;Rate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:19.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year - Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Range&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Option&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Range&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;Dividends&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;Range&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:19.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.00 - $10.58 per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;61.7% to 69.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.28% to 0.96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;4.26 - $11.39 per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;58.2% to 60.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.47% to 1.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:19.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1.11 - $3.91 per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;59.3% to 67.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1.52% to 4.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, the Company recognizes forfeitures as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The intrinsic value is calculated at the difference between the market value as of December 31, 2022 of $1.55 and the exercise price of the shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Range of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life (Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$1.11 - $13.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,109,824&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,280&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercisable at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;4,623,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The summary of the status of the Company&#x2019;s non-vested options for the&#160;year ended December 31, 2022, is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant&#160;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-vested, January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,994,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.68&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,721,205&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.99&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,270,155)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (959,157)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-vested, December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,486,739&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022, the Company had approximately $4,745,000 of total unrecognized compensation cost related to stock options which will, on average, be amortized over 43 months.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Awards of Stock Options:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 10, 2022, the Board of Directors granted options to purchase 1,163,800 shares of common stock to the Company&#x2019;s employees which will be awarded based upon each employee&#x2019;s 2022 individual performance evaluation. Once awarded, these options will vest one quarter on February 15, 2023, one quarter on February 15, 2024, one quarter on February 15, 2025 and one quarter on February 15, 2026. The grant date fair value of these unvested options amounted to approximately $1,381,000. The Company has recorded approximately $180,440 in stock option expense related to these options for the year ended December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 10, 2022, the Board of Directors granted options to purchase 772,905 shares of common stock to the Company&#x2019;s employees. These options will vest one eighth on the six-month anniversary of the grant date, one eighth on the first anniversary of the grant date, one quarter on second anniversary of the grant date, one quarter on third anniversary of the grant date and one quarter on fourth anniversary of the grant date. The grant date fair value of these unvested options amounted to approximately $917,000. The Company has recorded approximately $89,662 in stock option expense related to these options for the year ended December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 10, 2022, the Board of Directors granted options to purchase 113,850 shares of common stock to members of the Company&#x2019;s Board of Directors. These options will vest one quarter on the grant date, one quarter on September 30, 2022, one quarter on December 31, 2022, and one quarter on March 31, 2023. The grant date fair value of these unvested options amounted to approximately $135,000. The Company has recorded approximately $101,336 in stock option expense related to these options for the year ended December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 10, 2022, the Board of Directors granted options to purchase 473,750 shares of common stock to certain senior managers of the Company. These options will vest one quarter on the grant date, one quarter on the first anniversary of the grant date, one quarter on second anniversary of the grant date, one quarter on third anniversary of the grant date. The grant date fair value of these unvested options amounted to approximately $562,000. The Company has recorded approximately $160,944 in stock option expense related to these options for the year ended December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 10, 2022, the Board of Directors granted options to purchase 1,365,000 shares of common stock to certain senior managers of the Company which will only vest upon the achievement of certain specific, predetermined milestones related to the Company&#x2019;s long-term performance goals. The grant date fair value of these unvested options amounted to approximately $1,620,000. As of December 31, 2022, none of these milestones has been met. Accordingly, no charge for these options has been recorded in the consolidated statements of operations and comprehensive loss for the year ended December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 12, 2021, the Board of Directors granted options to purchase 1,323,400 shares of common stock to the Company&#x2019;s employees which will vest upon the achievement of certain specific, predetermined milestones related to the Company&#x2019;s 2021 operations. Once awarded, these options will vest in four equal tranches, the first tranche vesting on the date of the award. The grant date fair value of these unvested options amounted to approximately $7,042,000. On March 1, 2022, Board of Directors determined that the Company met approximately 19% of these milestones, and accordingly, the Company has recorded $314,000, and $273,000 in stock option expense related to these options for the years ended December 31, 2022, and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 28, 2020, the Board of Directors granted options to purchase 1,114,325 shares of common stock to the Company&#x2019;s employees which will vest upon the achievement of certain specific, predetermined milestones related to the Company&#x2019;s 2020 operations. The grant date fair value of these unvested options amounted to approximately $3,883,000. On April 12, 2021, Board of Directors determined that the Company met approximately 88% of these milestones, and accordingly, the Company has recorded $951,000 and $1,070,000 in stock option expense related to these options for the years ended December 31, 2022, and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Change in Control-Based Awards of Restricted Stock Units:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Board of Directors has granted restricted stock units to members of the Board of Directors, to the Company&#x2019;s executive officers, and to employees of the Company. These restricted stock units will only vest upon a Change in Control of the Company, as defined in the Company&#x2019;s 2014 Long-Term Incentive Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table is a summary of these restricted stock units:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Board&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Executive&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Directors&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Management&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Employees&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;December&#160;31,&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 277,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 604,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,205,050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,086,750&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,033,988&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 120,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 265,700&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 385,700&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (25,250)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (25,250)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 277,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 724,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,445,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,447,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,504,184&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 396,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 396,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;  &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (132,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (132,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;  &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 277,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 724,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,709,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,711,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,359,928&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 69,300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 373,750&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 498,050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;  &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (318,750)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (318,750)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;  &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 346,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 779,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,764,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,890,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4,480,275&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Due to the uncertainty over whether these restricted stock units will vest, which will only happen upon a Change in Control, no charge for these restricted stock units has been recorded in the consolidated statement of operations and comprehensive loss through the year ended December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Performance-Based Awards of Restricted Stock Units:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to a review of the compensation of the senior management of the Company and management&#x2019;s performance in 2020, on February 28, 2020, the Board of Directors granted 168,100 restricted stock units to certain senior managers of the Company. These awards were valued at approximately $1,014,000 at the date of issuance, based upon the market price of the Company&#x2019;s common stock at the date of the grant, and vest one third on the date of the grant, one third on the first anniversary of the date of the grant, and &lt;span style="-sec-ix-hidden:Hidden_bnG0W-eC-kmqWIE1UDcudQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; third on the second anniversary of the date of the grant. For the years ended December 31, 2022 and 2021, the Company recorded (income) expense of approximately $(65,000) and $528,000, respectively, related to these restricted stock unit awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to a review of the compensation of the senior management of the Company and management&#x2019;s performance in 2021, on April 12, 2021, the Board of Directors granted 235,765 restricted stock units to certain senior managers of the Company. These awards were valued at approximately $2,120,000 at the date of issuance, based upon the market price of the Company&#x2019;s common stock at the date of the grant, and vest &lt;span style="-sec-ix-hidden:Hidden_yBkqj_djEEmSnjqOn-lNAA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; third on the date of the grant, &lt;span style="-sec-ix-hidden:Hidden_NhvWl8VkYEiywUdQUWqfYg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; third on the first anniversary of the date of the grant, and &lt;span style="-sec-ix-hidden:Hidden_riKmZAfAA0-fmSAyyqKphA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; third on the second anniversary of the date of the grant. For the years ended December 31, 2022 and 2021, the Company recorded a charge of approximately $226,000 and $1,207,000, respectively, related to these restricted stock unit awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 10, 2022, certain named executive officers and senior managers were granted 288,500 restricted stock units. These awards were valued at approximately $563,000 at the date of issuance, based upon the market price of the Company&#x2019;s common stock at the date of the grant, and vested (or will vest) &lt;span style="-sec-ix-hidden:Hidden_IU4zNU0S4UKy1kEa3REKsg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; third on the date of the grant, &lt;span style="-sec-ix-hidden:Hidden_CzwcUS2bLUKcKWPHYGPuIw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; third on the first anniversary of the date of the grant, and &lt;span style="-sec-ix-hidden:Hidden_Qn9ZRP_XUUuujsh4uxHgPw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; third on the second anniversary of the date of the grant. For the year ended December 31, 2022 and 2021, the Company recorded expense of approximately $260,000 and $0, respectively, related to these restricted stock unit awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Additionally, in 2021 and 2020 certain employees were offered 91,750 restricted stock units as a condition of their employment. These awards were valued at approximately $713,868 at the date of issuance. 46,750 of these restricted stock units vest upon the earlier of a Change in Control or &lt;span style="-sec-ix-hidden:Hidden_9VkzXAfHnkmSs1ntMN_DvA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; third after the second anniversary of the award, &lt;span style="-sec-ix-hidden:Hidden_FavK8EuO0EiMvQzxKsEdyg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; third on the third anniversary of the award, and &lt;span style="-sec-ix-hidden:Hidden_XAf3tkw7FEWYcbQI9IZMZw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; third on the fourth anniversary of the award. The other 45,000 of these restricted stock units vest upon the earlier of a Change in Control or four years from the date of the award. For the years ended December 31, 2022 and 2021, the Company recorded (income) expense of approximately $(16,000) and $178,000, respectively, related to these restricted stock unit awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The following table outlines the restricted stock unit activity for the&#160;year ended December 31, 2022:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant&#160;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-vested, January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 304,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.08&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 288,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.95&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (45,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (236,370)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.38&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-vested, December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 312,092&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Warrants:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;As of December 31, 2022, the Company had no warrants outstanding.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_6_30_2019_hE-GjhoHb06AQqRidhWP3A"
      decimals="INF"
      id="Narr_xAf9WnIwZ0aeoblomHc-BA"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_5_31_2019_88geVJQ2uUywvKJuak2-eg"
      decimals="INF"
      id="Narr_7H5t5WQZNkWeRQFBSGJZAA"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2019_hE-GjhoHb06AQqRidhWP3A"
      decimals="INF"
      id="Narr_oI9xGqusFEWDoGtBjgMpLQ"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">100000000</us-gaap:CommonStockSharesAuthorized>
    <ctso:AggregateRegisteredAmountForOfferings
      contextRef="As_Of_7_14_2021_ia1syTvHG0S77AERC2Hqwg"
      decimals="-6"
      id="Narr_58-MfwaqOkO-oTPbudVI2Q"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">150000000</ctso:AggregateRegisteredAmountForOfferings>
    <ctso:CommonStockValueAuthorized
      contextRef="Duration_12_30_2021_To_12_30_2021_dei_LegalEntityAxis_ctso_JefferiesLlcAndB.RileyFbrIncMember_XwgIgRkXJ0ileyIAI7HBTQ"
      decimals="-6"
      id="Narr_O0w6I03J_ESgZYKb1G2nWg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">25000000</ctso:CommonStockValueAuthorized>
    <ctso:CommissionRateAsPercentageOfAggregateGrossProceeds
      contextRef="As_Of_12_30_2021_dei_LegalEntityAxis_ctso_JefferiesLlcAndB.RileyFbrIncMember_7Vao9teehUSAKLxbCXXGsA"
      decimals="3"
      id="Narr_QZU_liLox0yYfDMDdRTpaQ"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.030</ctso:CommissionRateAsPercentageOfAggregateGrossProceeds>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Narr_GZMKZ7noh0mmUWIMbHJsUg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">90000</us-gaap:PaymentsOfStockIssuanceCosts>
    <ctso:NumberOfLongTermIncentivePlans
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="INF"
      id="Narr_UHKIKI4mBkmnmt8LFsciVA"
      unitRef="Unit_Standard_item_00R0j3K4HUiRlSslEJQMxQ">2</ctso:NumberOfLongTermIncentivePlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_ctso_TwoThousandFourteenStockOptionPlanMember_283few-Y1k-s142NM7ToRA"
      decimals="INF"
      id="Narr_oLy8pEeH90qZK35Mx58Rww"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">13400000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_ctso_StockOptionPlanOneMember_RNyPCy3gyE2TqeZtAiyN2A"
      decimals="INF"
      id="Narr_Jm_IheN4SUWMBenod0HlTA"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">2400000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_ctso_TwoThousandFourteenStockOptionPlanMember_283few-Y1k-s142NM7ToRA"
      decimals="INF"
      id="Narr_1ZQIJZN-mUWpkUIpT7UVAQ"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">3713000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_ctso_StockOptionPlanOneMember_RNyPCy3gyE2TqeZtAiyN2A"
      decimals="INF"
      id="Narr_eBPHJly72kyPTtAhH_tbWQ"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">258000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Narr_3ldt3xlPsEqZ6hJJi1WAxQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3424000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Narr_mGabWDA9Z06py5oAfDh49Q"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">4021000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Narr_xZiLBHQ88kWPH6IYswvIRg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3514000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_WlnsxwvgdU6ShXRLB15lPg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;per&#160;Share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&#160;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding January 1, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,218,189&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,579,106&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.37&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (34,644)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_1iWKOSTEYEW4rgjnocsyQg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (226,440)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_gFEztX83IEan5vGYiG_KkA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (371,007)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_7Cm8_uxCP0mv3QQAha4gkQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding, December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,165,204&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.36&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.26&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,051,980&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.78&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.30&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (138,037)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_rBumodlmnUK-p_-iado5iw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21,756)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_GQpp15AqqkCIMuMwEM8NqQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (171,413)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.73&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_amo3-ZcwWEWCT2ol91T9ZQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding, December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6,885,978&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.09&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.15&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2,721,205&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.60&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,270,155)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_SbJXsQ3BuU-Usd0OT4w7GA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expired&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (227,204)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_4-HPXTyq0kWo5cJ4Z0sPVw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_We0d8r7iWEWg62NYW1m7vA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding, December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,109,824&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.91&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2019_6_oqjbutzEKQogf2y7UC6g"
      decimals="INF"
      id="Tc_mJpxs3PwBUqiv1X-wvYHyA_7_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">4218189</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2019_6_oqjbutzEKQogf2y7UC6g"
      decimals="2"
      id="Tc_2MQ73R5nW02fS4XIQ1UZtg_7_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">6.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2019_To_12_31_2019_9CuY3bMLoUmlRHItGFexPg"
      id="Tc_yHxmp_T5KE6R4KH77s3pdQ_7_7">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="INF"
      id="Tc_CtjojD4a8E2gMAneveDPYA_8_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">1579106</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="2"
      id="Tc_STlqQiafCE-NawuoVdw0HQ_8_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">6.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      id="Tc_wUhi6eo4tUOJp7EeOFzm2A_8_7">P9Y</ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="INF"
      id="Tc_TaViyzPFXU631syXJB9-7w_9_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">34644</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="2"
      id="Tc_hjZdZzeTsESKTudPmTjaMQ_9_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">7.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="INF"
      id="Tc_oOU9bXMGqEa928y1GmN18A_10_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">226440</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="2"
      id="Tc_ho4ofgXmQ0K6fq8jORv5xA_10_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">5.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="INF"
      id="Tc_d05jJHA_ZEKgUzDc37kg4w_11_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">371007</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="2"
      id="Tc__WEw3vPchEy826z0GLAAiQ_11_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">4.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w"
      decimals="INF"
      id="Tc_4IrA9eI6DkiA4VYNGCt59A_12_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">5165204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w"
      decimals="2"
      id="Tc_UavghJkLO0OU0N7cldde9A_12_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">6.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      id="Tc_0XZwxU7d3UOz8dMS84xCUg_12_7">P7Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="INF"
      id="Tc_PijLXDDYtkGobZzz0djgcQ_13_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">2051980</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="2"
      id="Tc_dxX_OFg9_0CVVH_WqjV61A_13_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">8.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      id="Tc_yFXl0ujtHEOAa3xYrXr0BA_13_7">P9Y3M18D</ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="INF"
      id="Tc_8S24bGdSdE6Zj24fWyio3w_14_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">138037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="2"
      id="Tc_vyy-heJsP0O89lQy1qZYbw_14_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">6.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="INF"
      id="Tc_o1w4jwFeQE6dTQF_xJnQiw_15_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">21756</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="2"
      id="Tc_M_aUC0miU0uuVbcvm1mJHw_15_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">7.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="INF"
      id="Tc_YZyjqDTOZEKtdpuWHB-3AQ_16_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">171413</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="2"
      id="Tc_Z3dB7nJIsUeXVf1x0RCsNg_16_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">5.73</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="INF"
      id="Tc_zD6w4TXIlU2efoJM6aBkUg_17_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">6885978</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="2"
      id="Tc_1lPqXZYZgUuTZTfeX7nr5g_17_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">7.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      id="Tc_Bf28NeSamESiplnyWkVtCQ_17_7">P7Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="INF"
      id="Tc_YA05eD4GFEejZs0hUZDkSw_18_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">2721205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="2"
      id="Tc_683bnr7fA0uQmEQ2hWL2fg_18_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">1.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tc_apPwhSz0h0mRluqvft36Uw_18_7">P9Y7M6D</ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="INF"
      id="Tc_jV196Rhc60etwfknF4UDew_19_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">1270155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="2"
      id="Tc_npFRz4RmAkO_KZtgzvn98g_19_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">8.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="INF"
      id="Tc_b2bnaWi0zUmJfo4kxYBC8Q_20_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">227204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="2"
      id="Tc_4LgUldAYJ0OS3YbHkuPkHA_20_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">7.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="INF"
      id="Tc_jxeDLYSIF0eRxtpXinWBag_22_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">8109824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="2"
      id="Tc_sfrmjL6G7kS2Sga4XwJ0Dg_22_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">5.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tc_854VUoOnW0aG5OifIkEBgQ_22_7">P6Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_5OE1T4LF-Ua7hHrvlMtI4Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;of&#160;the&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;Underlying&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;Stock&#160;and&#160;its&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant&#160;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expected&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expected&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Risk&#160;Free&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;of&#160;the&#160;Stock&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;Volatility&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expected&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;Interest&#160;Rate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:19.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year - Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Range&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Option&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Range&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;Dividends&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;Range&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:19.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;5.00 - $10.58 per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;61.7% to 69.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.28% to 0.96&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:19.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;4.26 - $11.39 per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;58.2% to 60.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.47% to 1.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:19.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;December 31, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1.11 - $3.91 per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;6 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;59.3% to 67.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1.52% to 4.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_DYCHwOrJcUSzRA20VoqbmQ"
      decimals="2"
      id="Narr_KiVkXpOd_U2X4YobugCz8w"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">5.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_9h926km2lEC7N26veE3DSA"
      decimals="2"
      id="Narr_qKfdODGJzUm8TwMyAcVfCg"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">10.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_Mkkar0ZT7EGL5951qJggtw"
      id="Tc_K1BhxKOJjkmnDf7NGXbfZg_8_5">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_uD4JXkNMnUCEqqr147HBXw"
      decimals="3"
      id="Narr_OY7h1YzrlkyvE9d2MVZ1rA"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.617</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_a0ICslhLlEaiPjkyJ39i8w"
      decimals="3"
      id="Narr_rh5OXP7gI0ebJfoIRghDqw"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_Mkkar0ZT7EGL5951qJggtw"
      decimals="2"
      id="Tc_Tb7TucHw10iDPJaWsnN_vw_8_10"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_uD4JXkNMnUCEqqr147HBXw"
      decimals="4"
      id="Narr_MyeWpeqLj0697iDK6k6oRg"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.0028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom5.00To10.58Member_a0ICslhLlEaiPjkyJ39i8w"
      decimals="4"
      id="Narr_RP6_0EX1IE-DpJMIcUZYGQ"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.0096</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_jZM8bjchokCOiKcRmPF3Ug"
      decimals="2"
      id="Narr_A4bpowpiK0qW_3wQm0-qXg"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">4.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_8gw5_ggnZkerQU2oAT6--g"
      decimals="2"
      id="Narr_izcnC_1_mUWR7nIbvn061A"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">11.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_4nmfCjwDv0eiv9Xvjheotg"
      id="Tc_tdvoxL46Yk6J6D5zfNZhgA_9_5">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_wMhxRA4mxUGyr5aQSg53cQ"
      decimals="3"
      id="Narr_AHECqUKnNUmUsV9k8nXHhQ"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.582</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_eGE4Htw5vUiAfnNKM05dQg"
      decimals="3"
      id="Narr_AeXo7Qs73EKw3D9tNzaDxw"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.607</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_4nmfCjwDv0eiv9Xvjheotg"
      decimals="2"
      id="Tc_nKqe8CU52E2LdIsS-na0oA_9_10"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_4nmfCjwDv0eiv9Xvjheotg"
      decimals="4"
      id="Narr_xm05VkdoQkOkqsjzX50pJw"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.0047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_4nmfCjwDv0eiv9Xvjheotg"
      decimals="4"
      id="Narr_1HfSztfFL0mOFtvIlcvL9A"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.0139</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_ntPA1TgJd0OfX_mWQ4DWuA"
      decimals="2"
      id="Narr_49VTaXQnk02GylfGmBZK7Q"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">1.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_cXJTOYaNgUKPUItB-_WwrQ"
      decimals="2"
      id="Narr_853UvCQRoUWkj8BCHnFO9Q"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">3.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_A3_FWcLzlUqUUdWwNDHlOw"
      id="Tc_hNTULV47qkeIFzJMRbIyBw_10_5">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_SozA6YZi2kKt1YD5fTj12g"
      decimals="3"
      id="Narr_3HCHXPcnJUO_4oyYnjs0BA"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.593</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_rxvDjksKlEOKtNVfXCde1g"
      decimals="3"
      id="Narr_m6vf3NuN80ykBYWwdJg_IQ"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.679</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_A3_FWcLzlUqUUdWwNDHlOw"
      decimals="2"
      id="Tc_ClEIQt2PDE-4fjeAXVgHPQ_10_10"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_A3_FWcLzlUqUUdWwNDHlOw"
      decimals="4"
      id="Narr_0GlU5LON-0Snpa8u8YbAug"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.0152</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom2.98To3.91Member_A3_FWcLzlUqUUdWwNDHlOw"
      decimals="4"
      id="Narr_DvUusw1Gukanxx-xaLmaEw"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.0420</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="2"
      id="Narr_669VMyr630KE25WzYDQx8w"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">1.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_13jAzhdl-UCP87OaNoyNVQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options Outstanding&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Range of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life (Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$1.11 - $13.20&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,109,824&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;5.11&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,280&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercisable at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;4,623,085&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,250&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ctso_ExercisePriceRangeOneMember_L6XbyOqHWUaHFIu4xBQwEA"
      decimals="2"
      id="Narr_Yx5kqtOBYU2L4_7ilSXAbQ"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">1.11</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ctso_ExercisePriceRangeOneMember_L6XbyOqHWUaHFIu4xBQwEA"
      decimals="2"
      id="Narr_FOnyAlJKm0KLko5SKT_68A"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">13.20</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ctso_ExercisePriceRangeOneMember_HTSesPowQUOWzfbwBPWjzg"
      decimals="INF"
      id="Tc_tBq_t3mgL0ixhgTNTHrzBw_6_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">8109824</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ctso_ExercisePriceRangeOneMember_HTSesPowQUOWzfbwBPWjzg"
      decimals="2"
      id="Tc_bqCXDEk_jUiAYCuf8MU1qw_6_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">5.11</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ctso_ExercisePriceRangeOneMember_L6XbyOqHWUaHFIu4xBQwEA"
      id="Tc_on5k4VcRw0GVuzfg_rr9cA_6_7">P6Y10M28D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ctso_ExercisePriceRangeOneMember_HTSesPowQUOWzfbwBPWjzg"
      decimals="0"
      id="Tc_bvIelpuYakafVSQSz3ViMg_6_10"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">7280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="INF"
      id="Tc_zG68KKLgD0uKmdobREtjeA_6_0"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">4623085</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="2"
      id="Tc_AdCaa4gack-ZQ08xUi29ZQ_6_3"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">6.32</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_jaMs7hWt6U66Svwcu-zihg_6_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1250</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock
      contextRef="Duration_1_1_2023_To_12_31_2023_PD6J30gR5EKT9_6EoKYJeg"
      id="Tb_DOQakDn2-Uaq64sm3MY1xQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant&#160;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-vested, January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,994,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.68&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,721,205&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.99&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,270,155)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (959,157)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.65&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-vested, December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,486,739&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.10&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="INF"
      id="Tc_UB2nOJOCY0CIt3JYrkyHXw_6_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">2994846</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="2"
      id="Tc_oOTZ62S1yEq_4zEQUS6DKA_6_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">4.68</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="INF"
      id="Tc_BlEsZOQskkuw2nDMwtvxOw_7_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">2721205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="2"
      id="Tc_PCKmt56stkKB8ZvlWbNbmA_7_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="INF"
      id="Tc_4CfQEOQ6kEG20bAuumXarQ_8_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">1270155</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="2"
      id="Tc_sGGEo9Yd0kiJmpdTl-et-A_8_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">8.65</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="INF"
      id="Tc_h9_GN7iVyE2XmZ_ODddkVQ_9_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">959157</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="2"
      id="Tc_GYqzU1gXU0eF85f6S8TeIQ_9_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">3.65</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="INF"
      id="Tc_eWMx6rni5EaVpu3jlNF5gA_10_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">3486739</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="2"
      id="Tc_NCL5MnyniU29vH8c1Fa3SA_10_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">2.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Narr_ctSRTFkIu0i0-6zXEJswTQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">4745000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Narr_nhE5lMMddEeYc1ttMrhyDQ">P43M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_8_10_2022_To_8_10_2022_srt_TitleOfIndividualAxis_ctso_EmployeeOneMember_eZMz_a7KzUiEra_Pmj1NYQ"
      decimals="INF"
      id="Narr_l-P4ftWj8kGMOTMPSTwaaQ"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">1163800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_ctso_EmployeeOneMember_apbG-USk6kiuOe_Y22t91A"
      decimals="0"
      id="Narr_NTVqZSdV8EmOMtr1TfMc6Q"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1381000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_9TJLsXlp6keoHyL-cuizXQ"
      decimals="0"
      id="Narr_4jvM4KlC9UO-xZWYvQdOdQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">180440</us-gaap:StockOptionPlanExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_8_10_2022_To_8_10_2022_srt_TitleOfIndividualAxis_ctso_EmployeeTwoMember_n4em8eT-K0OI3zntmzwTHQ"
      decimals="INF"
      id="Narr_bqXYujP94EKlEBXx9leLeQ"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">772905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_ctso_EmployeeTwoMember_hcg34RZmk0K7-aUhwgreaA"
      decimals="0"
      id="Narr_aEnHFmsRIUibjP3JZw-9KQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">917000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_ctso_EmployeeTwoMember_5EVkiMRvd0id4GEDS-DjOQ"
      decimals="0"
      id="Narr_9aVv9P3E_0qU4tKRLUfZgw"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">89662</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_8_10_2022_To_8_10_2022_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_kivuCiqiL0uHjYHAlIe0SA"
      decimals="INF"
      id="Narr_Ddmj23BzHkqIANNlu_weXA"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">113850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_LDp3_ulEB0afY5sDrxWyfA"
      decimals="0"
      id="Narr_5SzeXXZBs0eVW2lE-WmjvQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">135000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:StockOptionPlanExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_xyJVnNq5GE65HtHRW1yDeA"
      decimals="0"
      id="Narr_Hpm-U7TvEUqoxFT4hkGpRA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">101336</us-gaap:StockOptionPlanExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_8_10_2022_To_8_10_2022_srt_TitleOfIndividualAxis_ctso_SeniorManagerOneMember_aJeyvmrvQEamT-sApwGPVA"
      decimals="INF"
      id="Narr_2Ng6vphVg020gUReyErZ1Q"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">473750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_ctso_SeniorManagerOneMember_cYnbKOhq3E6GCga5UwXuXA"
      decimals="0"
      id="Narr_aDi9bMvH3ku8YSdLMugCFg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">562000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:StockOptionPlanExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_ctso_SeniorManagerOneMember_EkCzFw0rWU-KctkMbIExAQ"
      decimals="0"
      id="Narr_OV_L3vqnik6YPGcWzXc3EQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">160944</us-gaap:StockOptionPlanExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_8_10_2022_To_8_10_2022_srt_TitleOfIndividualAxis_ctso_SeniorManagerTwoMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_1_iS7zVj_kqq7qBilIFwhQ"
      decimals="INF"
      id="Narr_ImFoww6u-Ui4Kcx6Z2JmUQ"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">1365000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_ctso_SeniorManagerTwoMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_QTMNRUs4tkaHSWZeL2Z8fQ"
      decimals="0"
      id="Narr_w5gr4xKNrE-9fx_DwXSSNQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1620000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_4_12_2021_To_4_12_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_s_j74aK2uUqG5xOlSbxT3A"
      decimals="INF"
      id="Narr_FmiBr5Oe7kmT9NprRa-8zg"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">1323400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue
      contextRef="Duration_4_12_2021_To_4_12_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_s_j74aK2uUqG5xOlSbxT3A"
      decimals="0"
      id="Narr_JEbTfO51IUaEt3lKFSLshw"
      unitRef="Unit_Standard_USN_5UGkHjTMLU6EeMbjOjtcEQ">7042000</ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue>
    <ctso:ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage
      contextRef="Duration_4_1_2022_To_4_1_2022_AQ3DZUBay0mJk2oEUwh-kQ"
      decimals="2"
      id="Narr_bL5GLBmlT0uoFXT7CY_56A"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.19</ctso:ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage>
    <us-gaap:StockOptionPlanExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_f4vXsZkMOkGxq_tl33elVw"
      decimals="0"
      id="Narr_zkIYhXC13kOH9m9wWNzOww"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">314000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_aC79nG-enkiG4Z0Gnm5v8A"
      decimals="0"
      id="Narr_3jJt9KvnSEmHIOBg-We_AA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">273000</us-gaap:StockOptionPlanExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_2_28_2020_To_2_28_2020_mNnHVlwuKUOZDnoPp6ppuw"
      decimals="INF"
      id="Narr_viowhh1Ul0KLZ0EIHZAFYw"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">1114325</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Narr_NbTIuXg_R06Rj49jCnzhJg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3883000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <ctso:ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage
      contextRef="Duration_4_12_2021_To_4_12_2021_4mWKwyxxWEKyj2QfIoh1PQ"
      decimals="2"
      id="Narr_yAst-yJpvkORENEq9JgFzw"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.88</ctso:ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage>
    <us-gaap:StockOptionPlanExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_W4GwiG3lh02utgH-gE4rTQ"
      decimals="0"
      id="Narr_qcIV3AkH2UivBhUVhWqj8A"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">951000</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Narr_jqhdTj4Av0ic77PpkaLLaw"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1070000</us-gaap:StockOptionPlanExpense>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_eJksAPBX10yQwHqCHlZ4Hw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Board&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Executive&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Directors&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Management&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Employees&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;December&#160;31,&#160;2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 277,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 604,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,205,050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,086,750&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,033,988&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 120,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 265,700&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 385,700&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (25,250)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (25,250)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;December&#160;31,&#160;2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 277,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 724,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,445,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,447,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,504,184&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 396,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 396,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;  &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeited 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (132,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (132,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;  &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 277,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 724,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,709,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,711,200&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,359,928&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 69,300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 373,750&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 498,050&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;  &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (318,750)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (318,750)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;  &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 346,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 779,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.74%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,764,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,890,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4,480,275&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2019_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_FP86LptQuUeU7YsuzIQCcg"
      decimals="INF"
      id="Tc_ppkb9qSbHkSZHq37sJobnw_3_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">277200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2019_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_K10SpTMdF0G5KR4K3WxOyw"
      decimals="INF"
      id="Tc_qg91RfFjdEOzL50GsGnjuQ_3_4"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">604500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2019_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_yN5CzvOjU0uH_kVOetojHQ"
      decimals="INF"
      id="Tc___g75RYMaUy7ZJPfxyClTQ_3_6"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">1205050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_tP00N7KMo06ixWdu6bREiw"
      decimals="INF"
      id="Tc_kCbNqcxqikCVgTa5vnx7VA_3_8"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">2086750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="As_Of_12_31_2019_6_oqjbutzEKQogf2y7UC6g"
      decimals="0"
      id="Tc_61vhonNz10u3Sybv14beHA_3_11"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">8033988</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Qq1T1vf_pkWNzHvrbos3EA"
      decimals="INF"
      id="Tc_WQVwTpSQckCGF6Z7VzLjKA_4_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_tCzPxpUUDkurigM_UymlEA"
      decimals="INF"
      id="Tc_6Mad08U1vUKPKbFGttAJpg_4_4"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_HkkTwSE4WEOHm13LfqHxoQ"
      decimals="INF"
      id="Tc_rdk5mSwUK0-zhQoeNFTJRw_4_6"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">265700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lKSpWReKk0eWMdrErwptxw"
      decimals="INF"
      id="Tc_3J9PobnJ20WRxxXjNdZZyQ_4_8"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">385700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Qq1T1vf_pkWNzHvrbos3EA"
      decimals="INF"
      id="Tc_k8bvHfxL9Um47O9txXPqRA_5_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_tCzPxpUUDkurigM_UymlEA"
      decimals="INF"
      id="Tc_yw1QHG7IPUO7tYBM78zeWg_5_4"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_HkkTwSE4WEOHm13LfqHxoQ"
      decimals="INF"
      id="Tc_eH9p7WD-Kkigx2RfDXS-zg_5_6"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">25250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_lKSpWReKk0eWMdrErwptxw"
      decimals="INF"
      id="Tc_adrQE02mkESqsByqZuPuiQ_5_8"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">25250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2020_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_CN57L8kRSkSlPVn_ICCXgQ"
      decimals="INF"
      id="Tc_H8nJS25n-E2Y-RdfOcCh3Q_6_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">277200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2020_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Jxgd6wgc-UifuA3mjZhm-Q"
      decimals="INF"
      id="Tc_fijQ0nb5rEeGc_f1v4C4vg_6_4"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">724500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2020_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_psdWAFNFkke9A5usGouslg"
      decimals="INF"
      id="Tc_8qBQTmJBtk6Mm1x2fE6DGw_6_6"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">1445500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YALsQfAeSkWG8axpq3Cw1w"
      decimals="INF"
      id="Tc_ltv8URcdz0-jrfimoKA2EA_6_8"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">2447200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="As_Of_12_31_2020_N68czj8wnkKR31qAfJh86w"
      decimals="0"
      id="Tc_v18vHeeE0Uu3KfCYYnbrUA_6_11"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">19504184</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_-zjLmD1sFUWIlQznMjsRvQ"
      decimals="INF"
      id="Tc_nNMclg42XUyhnEAvLdj4Bw_7_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q_I0IFjrfEKL74vm4tWeYQ"
      decimals="INF"
      id="Tc_1mZEvWPBo0idc9-BjMOAmQ_7_4"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_vk8cRgr4tEGiUUmMORIpUg"
      decimals="INF"
      id="Tc_sA4NA-NmcEiNxWo0erm3TQ_7_6"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">396000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_L5xd_BU2AUihTjDpJG0EAQ"
      decimals="INF"
      id="Tc_QpyKM3w1p0e3v9NPv594rA_7_8"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">396000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_-zjLmD1sFUWIlQznMjsRvQ"
      decimals="INF"
      id="Tc_yNUyjq-sEUSHgiM5jUj_4Q_8_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Q_I0IFjrfEKL74vm4tWeYQ"
      decimals="INF"
      id="Tc_mwgbcWd1p0SAT_qeFS_4Pw_8_4"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_vk8cRgr4tEGiUUmMORIpUg"
      decimals="INF"
      id="Tc_0tFoZTLbJ0e0zPVRYTd9Sg_8_6"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">132000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_L5xd_BU2AUihTjDpJG0EAQ"
      decimals="INF"
      id="Tc_xsPeVErD6EG2EH43KYIUww_8_8"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">132000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_trOIsNzUZk6mTrRFdkZXPw"
      decimals="INF"
      id="Tc_8IQBdAr2-kqtqQOg0gnx1Q_9_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">277200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_JpCj6cd7kkiLmP4iVXwtlw"
      decimals="INF"
      id="Tc_YjmFGW1MoUG2n5LTVLIWhw_9_4"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">724500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2021_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_04OJEbPdOkKtPazUq59qpA"
      decimals="INF"
      id="Tc_CJ2N9S-R2kqNI9wJ7k4xsg_9_6"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">1709500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_9vRyYMxhI0WaNHqaWqGMHQ"
      decimals="INF"
      id="Tc_ZsmnwwNzYkiXEci63wNZzQ_9_8"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">2711200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA"
      decimals="0"
      id="Tc_IMlX5JvR0EWQS_zf6UTYCA_9_11"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">11359928</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_DdpipDIQPE6CFjGjSAk4pw"
      decimals="INF"
      id="Tc_KarVyfaA2U-AgYmNBdxQYQ_10_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">69300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Jq6o95e4y0O88aEPmR333A"
      decimals="INF"
      id="Tc_LH8bmLXs2UWCKJbtS7wWVg_10_4"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">55000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_6fnzkcGGB0ChZUoAaGWn2g"
      decimals="INF"
      id="Tc_MhLRgOY1nUqpmSQawcG3Fg_10_6"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">373750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw"
      decimals="INF"
      id="Tc_yTEqBHpbvUCtY3e3r2byHQ_10_8"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">498050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_DdpipDIQPE6CFjGjSAk4pw"
      decimals="INF"
      id="Tc_w7DEwbBB9EWkFmpkUgZYeg_11_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Jq6o95e4y0O88aEPmR333A"
      decimals="INF"
      id="Tc_e6ue7c_cNUyvJHH2pa3ykw_11_4"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_6fnzkcGGB0ChZUoAaGWn2g"
      decimals="INF"
      id="Tc_Cdmt9yeT_kG5dhGR0E-JTA_11_6"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">318750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw"
      decimals="INF"
      id="Tc_OaoP3x1btk-xHW2ntNTJkg_11_8"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">318750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2spOJmTsWEmdS8OMyOGHWQ"
      decimals="INF"
      id="Tc_8tyKrKDmakaJD9h2ljN5Ug_12_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">346500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_srt_ManagementMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_-5TVQVqcmkOUL9z5tTJN-w"
      decimals="INF"
      id="Tc_JRpX6rX2PUuS-ZvMJL8Cng_12_4"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">779500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2022_srt_TitleOfIndividualAxis_srt_OfficerMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Nt-mKk9tE0qaMLa__XLlLA"
      decimals="INF"
      id="Tc_Z2uXC3RFNE-y7K0rjsMxnA_12_6"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">1764500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_S71qz6TZI0CfuhmZ6yul1Q"
      decimals="INF"
      id="Tc_yIDP-fzbokGRt12yRirZ6w_12_8"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">2890500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="0"
      id="Tc_kSm4KPWmiUyuK78KdMuIRw_12_11"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">4480275</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_5NQR2_FtYk-1wNb9Sb1pdw"
      decimals="INF"
      id="Narr_i5z-6C6ltU2er2R6SHcM1A"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">168100</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_5NQR2_FtYk-1wNb9Sb1pdw"
      decimals="0"
      id="Narr_MYUJepsgHkW_h8I2W-d9fA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1014000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_22_2019_To_7_22_2019_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_July222019PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_i5Y6ctTfQkOWKcDW4oDCbw"
      decimals="3"
      id="Narr_qlyDZa-s5EiivOjojhstIA"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.01</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_MBhOBM-5iEqeLJwUm4lpZw"
      decimals="3"
      id="Narr_UZqc60UQN0CqMdDI0yE7CA"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.01</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_nkcE0lA3-kOw0oD7CH9c4w"
      decimals="0"
      id="Narr_oLDxjCXSa0KZXSh6hCJPiA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-65000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_February282020PerformanceBasedAwardMember_psiceOjXQ0i-ao__lRK5JQ"
      decimals="0"
      id="Narr_mwi3qo0DmUegIhVwhlp4cA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">528000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_4_12_2021_To_4_12_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_SBFV77lhyUaB_1ayr35kYw"
      decimals="INF"
      id="Narr_8v7Qg5TvPUuzcFoTRvNH5A"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">235765</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_4_12_2021_To_4_12_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_SBFV77lhyUaB_1ayr35kYw"
      decimals="0"
      id="Narr_ptfe6ZOszUifZ-ZDz5ZhTA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">2120000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_SehbEFp_LU-TNiW5F5VEKA"
      decimals="0"
      id="Narr_DelK9S9ptU2ma29OOPqZ1A"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">226000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_April122021PerformanceBasedAwardMember_XLL9youqcUedryG1mnniUQ"
      decimals="0"
      id="Narr_sIF_DZvT7Eif0nXyV89Vdg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">1207000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_8_10_2022_To_8_10_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_iCD0wE1zAkmoNYobFgX5Pg"
      decimals="INF"
      id="Narr_L9SR20aR-0SKGKGKGEUTuQ"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">288500</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_8_10_2022_To_8_10_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_iCD0wE1zAkmoNYobFgX5Pg"
      decimals="0"
      id="Narr_aAbGPXZKF0m9td3tIcEzLQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">563000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_1LwXDf6m7E-dzAi4ZxI8Aw"
      decimals="0"
      id="Narr_LYF-Dh1ylUm2INQY4Sm_1A"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">260000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ctso_August102022PerformanceBasedAwardMember_HkC9ceLZZUStae-rY3krow"
      decimals="0"
      id="Narr_Q4Z77RjevUe0X7iSb9IHDg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw"
      decimals="INF"
      id="Narr_NMNF59K6dU6qJF3dXeQ9sw"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">91750</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw"
      decimals="0"
      id="Narr_CJ6DJs34Y0eTyTrgO1KBCA"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">713868</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_ctso_SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_Nw7O66qjS0-HrTuFoxU-Ig"
      decimals="INF"
      id="Narr_MhoR-PNe8UyLXujjt1X1Yg"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">46750</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_StatementScenarioAxis_ctso_SecondFortyFiveThousandRestrictedAwardMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_OfWgsCZPdEyRfpWz5t_BNg"
      decimals="INF"
      id="Narr_VP3s4fR5QkeN9jO3WI-zmg"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">45000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw"
      id="Narr_txTVvBn5BUGuQ5cAlm4PIQ">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw"
      decimals="0"
      id="Narr_lGYQkfcEFEKsAS0ir99IeQ"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-16000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_L5xd_BU2AUihTjDpJG0EAQ"
      decimals="0"
      id="Narr_0XiHZtYEPUy6sUP9dI7C5g"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">178000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_ryx3rH_R6EqK8ASJ7JUcdA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant&#160;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&#160;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-vested, January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 304,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.08&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 288,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.95&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (45,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.35&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (236,370)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.38&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-vested, December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 312,092&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.42&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_9vRyYMxhI0WaNHqaWqGMHQ"
      decimals="INF"
      id="Tc_qTUeNuRXa02tNRZ8UPlLJQ_5_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">304962</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_9vRyYMxhI0WaNHqaWqGMHQ"
      decimals="2"
      id="Tc_QA9WmXyuIkasUVT_hNMB8Q_5_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">8.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw"
      decimals="INF"
      id="Tc_ssugteKWbU-_Rw-wdlX6vg_6_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">288500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw"
      decimals="2"
      id="Tc_sHykc8HT-kGf1SBlpErpTw_6_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">1.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw"
      decimals="INF"
      id="Tc_Wc3P90z1iE-DT6zZhavHcw_7_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">45000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw"
      decimals="2"
      id="Tc_Me33uXnVfkiczLqxQNi-hQ_7_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">8.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw"
      decimals="INF"
      id="Tc_6Z3q-gTo7Eej70ac4BbwlQ_8_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">236370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw"
      decimals="2"
      id="Tc_iDsd9xNMYUit3KNgewvSWg_8_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">5.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_S71qz6TZI0CfuhmZ6yul1Q"
      decimals="INF"
      id="Tc_Oh185wF8UUOjELIb6dPW_A_9_2"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">312092</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_S71qz6TZI0CfuhmZ6yul1Q"
      decimals="2"
      id="Tc_AGKhyUk04kem-Gvv6GoqRg_9_5"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">4.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg"
      decimals="INF"
      id="Narr_BAQEQ2xbeEKBqBKZKbLO8A"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_tCDBE_Ao_UW7yiG-ioOeSg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;12. NET LOSS PER SHARE:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Basic net loss per share and diluted net loss per share for the&#160;years ended December 31, 2022, 2021 and 2020 have been computed by dividing the net loss attributable to common shareholders for each respective period by the weighted average number of shares outstanding during that period. All outstanding warrants and options and restricted stock awards representing approximately 11,312,000, 9,902,000 and 7,786,000 incremental shares at December 31, 2022, 2021 and 2020, respectively, have been excluded from the computation of diluted net loss per share as they are anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ctso_StockOptionsAndWarrantsMember_yk7BYg1b80i8SXV12unwZQ"
      decimals="0"
      id="Narr_gOvRSlWRF0imv_jWbSk2Uw"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">11312000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ctso_StockOptionsAndWarrantsMember_N7MNifr70EazP8jJCCRNdQ"
      decimals="0"
      id="Narr_PjvRb_uW-k2VShaAnLOTeQ"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">9902000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ctso_StockOptionsAndWarrantsMember_yWq0uJF810qiMA_nrGtcuw"
      decimals="0"
      id="Narr_zdqvdR80Cke8S5YRFjBdMw"
      unitRef="Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA">7786000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_iKX_Ex5Z0UqGeZuXcwxffg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;13. RETIREMENT PLAN:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;In June&#160;2014, the Company formed the CytoSorbents 401(k)&#160;Plan. The plan is a defined contribution plan as described in section 401(k)&#160;of the Internal Revenue Code (&#x201c;IRC&#x201d;) covering substantially all full-time employees. Employees are eligible to participate in the plan on the first day of the calendar quarter following &lt;span style="-sec-ix-hidden:Hidden_wRQ8gwA2pEGU2CW7c2BqBw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; full&#160;months of employment. Participants may defer up to 100% of their eligible compensation subject to certain IRC limitations.Prior to 2021, the Company provided for a matching contribution of twenty&#160;percent of the participants&#x2019; contribution on a maximum of five&#160;percent of compensation. Effective January 1, 2021, the Company changed its matching contribution to 100% of the participants contribution up to three percent of compensation plus 50% of the participants contribution over three percent of compensation up to a maximum of five percent of compensation. Matching contributions amounted to approximately $442,000, $355,000 and $59,200 for the&#160;years ended December 31, 2022, 2021 and 2020, respectively.&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="Duration_6_1_2014_To_6_30_2014_xxa151rza0iR7WYHq7r7TA"
      decimals="2"
      id="Narr_u91Z9YSjaESP4XNDeU4qIw"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="2"
      id="Narr_99EL90jnCU2OoWyaSsqmAg"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.20</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="2"
      id="Narr_OG4uNBwIQE-0VrL7LstdKw"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2021_To_1_1_2021_srt_StatementScenarioAxis_ctso_ParticipantsContributionUpto3PercentMember_MgDr1mCwaUS6-T40vC8X3A"
      decimals="2"
      id="Narr_Bkz3UXP_qkShobRYpyL-uQ"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_1_1_2021_To_1_1_2021_srt_StatementScenarioAxis_ctso_ParticipantsContributionUpto3PercentMember_MgDr1mCwaUS6-T40vC8X3A"
      decimals="2"
      id="Narr_UyAK16neQkmZdrcohVrpuw"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_1_1_2021_To_1_1_2021_srt_StatementScenarioAxis_ctso_ParticipantsContributionOver3AndMaximum5Member_VI70pNF1dE6bwaLkkkQQzw"
      decimals="2"
      id="Narr_LjaZ2wgtHES7c4Bb9gNtcQ"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_1_1_2021_To_1_1_2021_srt_RangeAxis_srt_MinimumMember_srt_StatementScenarioAxis_ctso_ParticipantsContributionOver3AndMaximum5Member_MBEUr3qmWkaFIgPeH_HMOQ"
      decimals="2"
      id="Narr_XOTfAS1yJkKSpjfpxIOnVg"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_1_1_2021_To_1_1_2021_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_ctso_ParticipantsContributionOver3AndMaximum5Member_QRs03j8L6kalwqqJ7bMG6A"
      decimals="2"
      id="Narr_gj3f0X-s_EmCqKEOS10WdQ"
      unitRef="Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      decimals="0"
      id="Narr_jAPvK6vvIkinkiz1tjbBPw"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">442000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2021_To_12_31_2021_uRPZ2b99Qkic7yWhqkglmA"
      decimals="0"
      id="Narr_ThDYV4qthki2x4ExlJcsOg"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">355000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2020_To_12_31_2020_SWuaRNLnVE2QLRVPYsDpOQ"
      decimals="0"
      id="Narr_uI5o-nSyNEmS4caw0WozJw"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">59200</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_UsnhTTAh5E-Xxdwqh0Vgiw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;14. QUARTERLY FINANCIAL RESULTS (UNAUDITED):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Summarized quarterly data for 2022, 2021 and 2020 are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Quarters Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2022:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,691,424&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,495,558&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,111,353&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,390,474&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross margin&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,413,788&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,944,856&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,617,377&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,757,036&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,791,135)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,357,050)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,017,338)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,356,356)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,966,398)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,879,222)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12,200,837)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (766,128)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.21)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.25)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.28)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.02)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total &#160;revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,598,847&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,024,069&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,760,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,782,195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross margin&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,847,403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,313,852&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,297,470&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,659,452&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,852,191)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,924,733)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,406,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,561,821)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,167,821)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,677,530)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,406,285)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,307,012)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.11)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.15)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.25)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2020:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&#160;&#160;revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,707,310&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,794,903&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,546,612&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,955,776&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross margin&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,322,468&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,545,136&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,656,230&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,428,358&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,478,754)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,297,667)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,959,652)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,634,264)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,452,779)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,866,956)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (839,729)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (677,724)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.08)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.02)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <srt:ScheduleOfCondensedIncomeStatementTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg"
      id="Tb_XSstP3ERq0OhWU3AG1UlaA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:46.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For the Quarters Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2022:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,691,424&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,495,558&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,111,353&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,390,474&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross margin&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,413,788&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,944,856&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,617,377&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,757,036&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,791,135)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,357,050)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,017,338)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,356,356)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8,966,398)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,879,222)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12,200,837)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (766,128)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.21)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.25)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.28)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.02)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total &#160;revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,598,847&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,024,069&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,760,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,782,195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross margin&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,847,403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,313,852&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,297,470&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,659,452&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,852,191)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,924,733)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,406,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,561,821)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,167,821)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,677,530)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,406,285)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (9,307,012)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.11)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.15)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.25)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2020:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&#160;&#160;revenue&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,707,310&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,794,903&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,546,612&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,955,776&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross margin&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,322,468&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,545,136&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,656,230&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,428,358&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,478,754)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,297,667)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,959,652)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,634,264)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,452,779)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,866,956)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (839,729)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (677,724)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss per share, basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.08)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.02)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.00&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</srt:ScheduleOfCondensedIncomeStatementTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2022_To_3_31_2022__Bto-66MgUq_eQRwKUyq1Q"
      decimals="0"
      id="Tc_nlaFSU9Y30yoJ_cdbr-XGg_4_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">8691424</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_4_1_2022_To_6_30_2022_mLayX3PX1Eqci3SfMDv1YQ"
      decimals="0"
      id="Tc_IooBqZ8320CPopGiaX2gmA_4_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">8495558</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_7_1_2022_To_9_30_2022_2eoa-jebUE-H6uey7YKWmQ"
      decimals="0"
      id="Tc_Bfrm9jViZUKY2hq5LDBQRA_4_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">8111353</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_10_1_2022_To_12_31_2022_7D4gmEOvZEuddtCJGzA8ow"
      decimals="0"
      id="Tc_Ad_hkewSkUC0-sJZLxiLGA_4_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">9390474</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2022_To_3_31_2022__Bto-66MgUq_eQRwKUyq1Q"
      decimals="0"
      id="Tc_4wrXQQgcRk67LFnoXF6Pcw_5_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">6413788</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_4_1_2022_To_6_30_2022_mLayX3PX1Eqci3SfMDv1YQ"
      decimals="0"
      id="Tc_RAmmQTcU2Uu8o9SqxSwOdw_5_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">4944856</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_7_1_2022_To_9_30_2022_2eoa-jebUE-H6uey7YKWmQ"
      decimals="0"
      id="Tc_q1Kj2JoN9Ey5kJXuchtVwA_5_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">3617377</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_10_1_2022_To_12_31_2022_7D4gmEOvZEuddtCJGzA8ow"
      decimals="0"
      id="Tc_gZlcd2Vt-EaNxCsOgYntUg_5_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">5757036</us-gaap:GrossProfit>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_3_31_2022__Bto-66MgUq_eQRwKUyq1Q"
      decimals="0"
      id="Tc_7VdAiTmOsES1E9-9PN0Oaw_6_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-7791135</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_mLayX3PX1Eqci3SfMDv1YQ"
      decimals="0"
      id="Tc_REUj6gexkE-izv9wDNixrw_6_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-8357050</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_2eoa-jebUE-H6uey7YKWmQ"
      decimals="0"
      id="Tc_9d252wYa1U-MI3XMsmKi-Q_6_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-9017338</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_10_1_2022_To_12_31_2022_7D4gmEOvZEuddtCJGzA8ow"
      decimals="0"
      id="Tc_lljaFIJ_kkCVfGv7RZTESg_6_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-6356356</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2022_To_3_31_2022__Bto-66MgUq_eQRwKUyq1Q"
      decimals="0"
      id="Tc_NlzgMqxA1Uu8sNHWRcRMHg_7_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-8966398</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2022_To_6_30_2022_mLayX3PX1Eqci3SfMDv1YQ"
      decimals="0"
      id="Tc_plqwy7uBakupMvQH-De1HA_7_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-10879222</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_2eoa-jebUE-H6uey7YKWmQ"
      decimals="0"
      id="Tc_n5wjHkYCaEmPrP20skzIMQ_7_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-12200837</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_10_1_2022_To_12_31_2022_7D4gmEOvZEuddtCJGzA8ow"
      decimals="0"
      id="Tc_EG64onNYaUOEWH7UXqqMvw_7_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-766128</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_3_31_2022__Bto-66MgUq_eQRwKUyq1Q"
      decimals="2"
      id="Tc_yUPuc7sH5EaMjPZxad753g_8_3"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_4_1_2022_To_6_30_2022_mLayX3PX1Eqci3SfMDv1YQ"
      decimals="2"
      id="Tc_FbCHyxdwzUKlPJ7ZyulN5Q_8_6"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_2eoa-jebUE-H6uey7YKWmQ"
      decimals="2"
      id="Tc_bQQ_z6R_sEWFK1fpF3R0sQ_8_9"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_10_1_2022_To_12_31_2022_7D4gmEOvZEuddtCJGzA8ow"
      decimals="2"
      id="Tc_JzD4riRv60G6uuoYBZVxDA_8_12"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2021_To_3_31_2021_zXigQoQBgUGOxC_vaZv8ag"
      decimals="0"
      id="Tc_nfXDWazie0KzfAxr4TJVgA_11_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">10598847</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_4_1_2021_To_6_30_2021_KUS8bQMU0UaIknV605S_VA"
      decimals="0"
      id="Tc_D-8zoTk2402Cxj2vVOUFCw_11_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">12024069</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_7_1_2021_To_9_30_2021_bc1_H1o8GkWXj53DijdBKA"
      decimals="0"
      id="Tc_UlAkFT5zW0GOB56i9Xfczw_11_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">9760416</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_10_1_2021_To_12_31_2021_PTkhRTY9_0uo1BKc7O3ElQ"
      decimals="0"
      id="Tc_udYeItQvG0KATHHBGgRETw_11_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">10782195</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2021_To_3_31_2021_zXigQoQBgUGOxC_vaZv8ag"
      decimals="0"
      id="Tc_ksDIqoR7WEuuul4LpPzJLw_12_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">7847403</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_4_1_2021_To_6_30_2021_KUS8bQMU0UaIknV605S_VA"
      decimals="0"
      id="Tc_mCpssDZoF0Cx1QeMiYoagw_12_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">9313852</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_7_1_2021_To_9_30_2021_bc1_H1o8GkWXj53DijdBKA"
      decimals="0"
      id="Tc_wrZcea_AN0yPaMygnw6w8w_12_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">7297470</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_10_1_2021_To_12_31_2021_PTkhRTY9_0uo1BKc7O3ElQ"
      decimals="0"
      id="Tc_gbxfYBvXlUCLxmvBCU1oww_12_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">7659452</us-gaap:GrossProfit>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_3_31_2021_zXigQoQBgUGOxC_vaZv8ag"
      decimals="0"
      id="Tc_1d6UREn3lkSJ4f4ca_VM1g_13_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-2852191</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_KUS8bQMU0UaIknV605S_VA"
      decimals="0"
      id="Tc_LP2cWajlB0SSD35Tc9b1Cg_13_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-4924733</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2021_To_9_30_2021_bc1_H1o8GkWXj53DijdBKA"
      decimals="0"
      id="Tc_0xzluJHXXkiYvOnEl9hUhQ_13_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-5406000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_10_1_2021_To_12_31_2021_PTkhRTY9_0uo1BKc7O3ElQ"
      decimals="0"
      id="Tc_i8sC9joyH0C1S2pFLbFgbg_13_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-9561821</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_3_31_2021_zXigQoQBgUGOxC_vaZv8ag"
      decimals="0"
      id="Tc_iqXcODJQG06N_d7T19E_0A_14_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-4167821</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2021_To_6_30_2021_KUS8bQMU0UaIknV605S_VA"
      decimals="0"
      id="Tc_aIKMkvdNYkC91OnaMpSwMQ_14_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-4677530</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_7_1_2021_To_9_30_2021_bc1_H1o8GkWXj53DijdBKA"
      decimals="0"
      id="Tc_iQmSzA3LOEKJMELvPvsAow_14_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-6406285</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_10_1_2021_To_12_31_2021_PTkhRTY9_0uo1BKc7O3ElQ"
      decimals="0"
      id="Tc_MIDDNZoJnUShdH0mzo_OpA_14_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-9307012</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_3_31_2021_zXigQoQBgUGOxC_vaZv8ag"
      decimals="2"
      id="Tc_LiOX7E8BlkmVOZ5dGK1I8Q_15_3"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_4_1_2021_To_6_30_2021_KUS8bQMU0UaIknV605S_VA"
      decimals="2"
      id="Tc_Z1ZyQsVwMUuJksNDA5ukIw_15_6"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2021_To_9_30_2021_bc1_H1o8GkWXj53DijdBKA"
      decimals="2"
      id="Tc_tNkFvMa8Pk21uRRUkhrn1Q_15_9"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_10_1_2021_To_12_31_2021_PTkhRTY9_0uo1BKc7O3ElQ"
      decimals="2"
      id="Tc_iuLpe77Dpkm-L3dB1OEL9Q_15_12"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_1_1_2020_To_3_31_2020_0j8Adr0DO0CTdQHPhErCZw"
      decimals="0"
      id="Tc_QGWda9i3CEKjQZjlzgWLPA_18_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">8707310</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_4_1_2020_To_6_30_2020_pfUWsTXCTUSP48AZxdHHPw"
      decimals="0"
      id="Tc__rWLX9DS6UeVSe8-tS6xPA_18_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">9794903</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_7_1_2020_To_9_30_2020_BlNvdmBrgEeKoL8Hm4r3Dw"
      decimals="0"
      id="Tc_a4BGeCu-W0CMPdUwCln88Q_18_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">10546612</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="Duration_10_1_2020_To_12_31_2020_asiudZouf0qo-UGg2Gf0lw"
      decimals="0"
      id="Tc_QxzaB6BbYkmoBoGtol5ENg_18_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">11955776</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:GrossProfit
      contextRef="Duration_1_1_2020_To_3_31_2020_0j8Adr0DO0CTdQHPhErCZw"
      decimals="0"
      id="Tc_cWlAlkmt10y97kKJFVIa5w_19_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">6322468</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_4_1_2020_To_6_30_2020_pfUWsTXCTUSP48AZxdHHPw"
      decimals="0"
      id="Tc_QoALG-bGgUWSP9nhV4vpjQ_19_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">6545136</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_7_1_2020_To_9_30_2020_BlNvdmBrgEeKoL8Hm4r3Dw"
      decimals="0"
      id="Tc_5gZtUcRmxk6n8IhWJWCing_19_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">7656230</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="Duration_10_1_2020_To_12_31_2020_asiudZouf0qo-UGg2Gf0lw"
      decimals="0"
      id="Tc_Pj6P79ZwjkekTjO03PD72g_19_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">9428358</us-gaap:GrossProfit>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_3_31_2020_0j8Adr0DO0CTdQHPhErCZw"
      decimals="0"
      id="Tc_fpMR0nxLzEOfm5PrGrp7_A_20_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-2478754</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_pfUWsTXCTUSP48AZxdHHPw"
      decimals="0"
      id="Tc_W3Kc4W8RYUWoSwMeswPmTg_20_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-3297667</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2020_To_9_30_2020_BlNvdmBrgEeKoL8Hm4r3Dw"
      decimals="0"
      id="Tc_z45aKy53TESvIWxiro6yiw_20_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-1959652</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_10_1_2020_To_12_31_2020_asiudZouf0qo-UGg2Gf0lw"
      decimals="0"
      id="Tc_i0PS05oKRkOYtUTCXggHiw_20_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-2634264</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2020_To_3_31_2020_0j8Adr0DO0CTdQHPhErCZw"
      decimals="0"
      id="Tc_SGbXiTE0p0uYo56MIATuMw_21_3"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-3452779</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_4_1_2020_To_6_30_2020_pfUWsTXCTUSP48AZxdHHPw"
      decimals="0"
      id="Tc_qGngdmmKFUyzibJwnuhZCg_21_6"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-2866956</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_7_1_2020_To_9_30_2020_BlNvdmBrgEeKoL8Hm4r3Dw"
      decimals="0"
      id="Tc_82EAbV8NQ0qcyK28QVlCsQ_21_9"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-839729</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_10_1_2020_To_12_31_2020_asiudZouf0qo-UGg2Gf0lw"
      decimals="0"
      id="Tc_0sCQvqP49Ua3hZNKy6486w_21_12"
      unitRef="Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q">-677724</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_3_31_2020_0j8Adr0DO0CTdQHPhErCZw"
      decimals="2"
      id="Tc_A9N83F8iGEeYZcvfEpuBGA_22_3"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_4_1_2020_To_6_30_2020_pfUWsTXCTUSP48AZxdHHPw"
      decimals="2"
      id="Tc_wkKb274600if5wJLIe--fQ_22_6"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2020_To_9_30_2020_BlNvdmBrgEeKoL8Hm4r3Dw"
      decimals="2"
      id="Tc_N-nxs5_A4UGKq6hLmskAdQ_22_9"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_10_1_2020_To_12_31_2020_asiudZouf0qo-UGg2Gf0lw"
      decimals="2"
      id="Tc__bSBXkOXk0umuGUvV6ydoA_22_12"
      unitRef="Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA">0.00</us-gaap:EarningsPerShareBasic>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>95
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MOHU!S\P7[][>O+MZ<W'^X?("O3J_.G^[N$0WKR\O/]R@8_3QY@+]?O3'Z<S
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M!HCG"T+X:T<>5:JCJ?<74$L#!!0    ( /6%:59I))2(-@@  % K   8
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M6VX7R5WJ@6WK45L;+&9W6%=Q/H<R':5*;_.7VH7*ZCJC(]<3M"/*>K]W)_A
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M;NIM<7GYF,FC")1+@*J%)W2B[U_')O#I<.+E#-;<V&#K5.HQ9I;X)SL'BBI
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M)0S+Y"#0%!P3AS+F^3+D"#5EJ4,]FWF'LM51!OIBRJ#/G(XRB,QY6$D>*&4
M50M U4(HM8V5D[U'S9L_/? Q*A\2L8Q.^4+(6V^:9_7+S=/\FS=UL6J?/O]2
MU'61M2^7/)KSLBD@/E\41?WC3?- ^^YO*ES\!5!+ P04    " #UA6E6#VQ2
M868)   '+@  &    'AL+W=O<FMS:&5E=',O<VAE970V+GAM;+6:;6_;.!*
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M5_4$Y#31.Y/AX2*.KDI(\E,:75,7J^BVK.YAPIK!W7K7LYA+-.4,-C1S*Z3
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M) M*--Y6VDBJ1628B@[8C+1:^\+5"BK-I5=93K-<='DF;IR508RW;%W="9X
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M*!EV(?&D VX.X@113^S)E+ G$27=S&E5>K9L,VAN=+D&44$?4PQXJGZ'_!@
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M?D10K^E;95W-W$5?A_)2Z[KR!_8\.,*LR>4^7=0$H)Q'>>?0/&T2+N58R[[
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M]UJ##B>PZ0+K?89)UPV*8 %[\&*/TKFJ=&[/RSUX5H[086M28-OKYY\'?X)
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M.U0T1XR'G2VX(S!\I^)%:5?F^Z8]._+9PGX2EUU39?$VKRP(X+<]VS7'XC'
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M&GM$=^VPFUC5M"UHJ2PVM':XP3\(T,X!UU=*V</$!1C^2>8_ %!+ P04
M" #UA6E6M4P\KYH#  "S"   &0   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6RU5FUOXC@0_BM6=K6?K"9V7FD!"2BG1=KM5=#>W5>3#&!M$G.V*>V_WW&
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M*HO%T4PW^%<!VBG@_DHI>UHX!^U_RO G4$L#!!0    ( /6%:59*GI?/N@P
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M/X7+HJD:W8['S+QVHH+R*YQ_3IRF!X@+J+I<I+-#Q30U1CQ^X"1*PZ=<=/C
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M%]LS1&"<91@["9K#/?AX;A T0 B\W$?CY 7840>HCX?7 =VH33BH;12UX>Y
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M %48=N=5O<"9'&F>M_ LZ^J\S3E ODGK.BVEYG<E:)PES2R%?VU:L$55 )N
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M((Z+?>AAK2CP[\J1\SJP8>A:?D*;A,/> MP]1S4D9H^G) YN@-#>H%F6RCW
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MUOT"NV[G]G=XN_UNA5U)[4#ADE.3SJ>S"&R[45J%3!VF>&&(=T(02U[":'T
M^Y?&T$[Q!?9K??@+4$L#!!0    ( /6%:5:1F-Q99@0  /H,   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;,57;6_;-A#^*X0Z% U Q'RGE-H&G)=N
M&9(@C9,-^RC;="Q$$EV*CMO]^ATE1Y:!V-V: OM@BW>\>^Z.?'BB^FOKGJJ%
M,1Y]+?*R&D0+[Y<GO5XU79@BK8[MTI0P,[>N2#V([K%7+9U)9[53D?<8(:I7
MI%D9#?NU[M8-^W;E\ZPTMPY5JZ)(W;=3D]OU(*+1B^(N>USXH.@-^\OTT8R-
M?UC>.I!Z+<HL*TQ99;9$SLP'T8B>G(I@7QO\D9EUU1FC4,G$VJ<@7,X&$0D)
MF=Q,?4!(X?%LSDR>!R!(X\L&,VI#!L?N^ 7]4UT[U#))*W-F\S^SF5\,HCA"
M,S-/5[F_L^O?S*8>&?"F-J_J?[1N; 6)T'15>5MLG"&#(BN;9_IULPX=AWB?
M ]LXL#KO)E"=Y7GJTV'?V35RP1K0PJ NM?:&Y+(R;,K8.YC-P,\//S^,[NXO
M[J[^0I\N;T8W9Y>C*W1W,7ZXNA^C#P\WHX?SR_N+\Z-^ST.PX-*;;H!/&V"V
M!Y@R=&U+OZC013DSLUV 'F39ILI>4CUE!Q'/S?08<8H1(XP=P.-MZ;S&XS^_
M] 98O X<SM%)M4RG9A#!0:F,>S;1\/T[JLC' VF+-FUQ"/TM:1\&IN(8_4OP
M$S2N#W'VMYFA+ZO4>>/R;V@&#$30*.H=JO>)HK2<A0%!J3,HK6 ZAT90G:#W
M[V)&^,?_[0F'&OF%09^;]#<\;:>O4S== -W0[ZO2($[0V"R]*2;&!0&XN!G3
MNMCOEW-O?9I#&WLVY<JTVE]0C%5"L6"BU<58)!)+&7<TE%+,)6\U">8)P4(+
M]*NS504=P3UF93NML* <ZW@+(7 B!(ZE:C4<*ZHQU[K52*REQH0K=!4PY\X6
M"+J_2T/_K%JS#QIK2)ER>;35Q9 >^$K2T268A @\[N@4V-6_(W0#KYP\!$J]
M=]EDY=-);I"W:&J+ AHV]+[IT\+FL[ YG4") H"D"TH)CG6"&6-=)</P9L(Q
MUQVE!E_*XDYPJ ]5"R G#MT]F]:$G67YRG?(T/J38T:/=D2Y*\8[(NDD]-9G
M?9K>"K*/A;"",HEQ+'00&"9,8*(2$!*L%3"-JL9*QPS31+Y..QT L" [/ 4B
MQI)U;%@"-IIT-$HF6(#-8=JQ@ /!NQL M(9,-><=G80,%"9DEXI241R'S?LQ
MV@E,E6X .CJE-9:<[/ [!&>QW G."9P-ROXK[8!!E.P0BNZRC\J]9/P)="-O
M;]+[NYZ&)>&4- Q+8!^!-0T/A8+.Q() <2*A*6FUK\MQ>,T(%7<T4DCH3-LN
M%\@%^\&W= .JL="MXN_236A(4XK.$O.:O$IU6TI(,H$HW=[#L.(",R5^E&X\
MG >H/-D!C:%[):%U;KLAA]5C7:M 2<W$VZE&]K<RD-KU?.U&T^O<1POC'NM;
M=P45KTK?7$U;;7NQ'S7WV:UY\U5P76]YA7(S!U=RK&6$7'/3;@1OE_7M=F(]
MW)7KX0(^3HP+!C _M]:_""% ^[DS_ =02P,$%     @ ]85I5C!.9V!'(@
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M94+-<3'D AL?P=$N'*6<:,3JRD;2CO"5DB"3"F/9P '0Z#G%?UQ@')8D7X:
M3UJJE*N,5!J952GG)DVJVN?;'\ W%6B/V!Z3YS33!',$&:)$='2FN%R<#98V
M,7BR%/ > %J;K08;70HW7LOA4J8'K%J3>U,?A9A.@M5MWPVGBHPA$69Q<.16
MNY>S!=R#IVPH,+_7==M1?:BIJ* K&5FA[$%-]P3=>M8;="#;AYV1+!?X9WC2
M+WM:9M##A%IR\J-&-ES%K2=LI"(IF\"@J"3VG[C88TU0J"-1AQY7  'YTGD*
MR<^)1&ZU1!A-S<!ADT@AK;3.MF<QU^K#;!N(Z9G$0UR ^T+Y$YK:6#@IJMEI
MTZII'23&@W6U HA>02-6O',89XM+<3&&XZS4E0Q_UOH+.E@2>GC+8$ZB'K&*
MZX"HA6&;X[G2LE#X9-\V7B8PQ;/A&A>_ZVECIP^:2I<3:JNYDJ 0:("W& 85
MBRRA3!S;-U7>N2#%\WB[(><Y7%C!\J>P24YI2;2(N%9S:FXUD(4F1QKRU'DI
MJ:5MU]H+S)1H[T6"FBEG:27%3-4-#E/9GPA< V#,HSP!<E^(,"%NL.B<4F2I
M*8]6*8@ 4PHLF[/[A'T.A1M!#.IBU6Y)2J<KN^0<_I&U<[7>6&$:+D!CD@4E
M&F<K3235(C),60=,1EJL?6YK!97DTJM,DUG..YVQ&Z?*(,9;MK;N!$^ 8%))
MI\=RH_U%,O,="&,:+2#@VDJO1R58)C,-"O%7IW8WH@2E<8S<"G-!Y.@4'S4=
M%4+V)_L4ATD85F:^\D3Z5XMGIOA/'K'0P =ZE*(2?6%':!,0-"S'E>$H9.%]
MC>M7\/D2H3[AZ@O*%R5-*WIE<Q5Q/VOAN"[HIE$]PN7G/FEL4#G/(D)E'0<)
M2=687B9>-72SD@PH1;2V^\5HXCI\W<5SBP)HZE">\;,FHV?< @DS/S<^.#R-
MJ7XL.?V570?C,E==Q8I_]WT,4P7L=&^](;U4 D_MF5<P#SLUPQMV9&75BF(F
M'.(RW01RL*ZTM7F>]65:[#(UW6/[._K:CEQ?V]'.GK1)6Z5WQIPAQFK(I@UU
MMGW]*-&'$E%**FTXHQ/J,40L/-CO 0B')3<\2*\#8<85 1D.3Y":OD^:+/D+
M3F:I*<(V<[H8G[_UH0^+?&O:;R#1F1G)C%(%)(X/#8FBZIQH6R%LSBW2O;B=
M?# C[T<?J1( T;4@:>>::&+?3T'A,D(A)0$V?C9@T.SZA]N+Z+Q#P(U5(V!.
MZFS7/A^[?3[>N4/G2:-9G:#9\&PZ$S5A+PD+"1F,+MC)I*OH%K%WD_,#0Z+P
M/YF(]S9UK]#>(PPI&2URFD\0?E@N3U)F8+/1C71AFOOLO!N->:Z3B2..'7V-
M29GMZ/4*L$ML\.93Z7^D >^QYK3'VIDVZ/;-1/%V5NSJ;(LWQ_P;6L6B,]C"
MG@$DA4B-)VY)/)+4>P5 /W']'M/ \MKR,R420IG;[\G7'/!(1LDK;L^1KARR
M!PPD)%JM*)TF=;<"@%ZP/Z=R-BL4>.H,, &$1QEA^#JVD(JE/+52/B@(!K</
MMHB2U1.<\(1)"4OPM$!P!AO8F6-V>D;DF#^^ 7'?::.C,V W<RMZ3IQZT1N@
MA)VB3Z.D8./%KC1(VT,"OGL^CE^].HT/#@Y@@.FWHQ/YC;G_W3@^/CBAWUT:
M1[(5BJ,A9XYM5SK_=V1<,W4.]/N%0N36FNTFCX\M-C@DU\G4E@YV<1T"W RR
MT7!8PQ55:9^])L'R.5TD): [)=&X-,XU<_NUD=I(#I"0<=A*-A7>RT[9P =8
M0[DT3I80L(7@UQ0E].9L^@.Z& 06LBLZ@4ZT<VV@#TE&'1W6*O4>%21-6EBK
MA8GYJ&4:L-^(!/EH 6VE:4A@1P<3 -?IHA;U5X<P9Y_]Y\'AKB[\$^?%3G8Z
MEXND6<#ZX;_1%0:_1WP*^H><U./CB$%;&ZK'1\X/T8*X1F6"EQPH7Y,N(%3M
MA'T GMB,QL95E&6J]9S+- 7E*TRL)QF]0DYP$+ A4]-R+CHE,I0G0_;3Y]);
M3E:[I$M"=>*JI(J8#RWMDM;',BT,4G13V8X'294+<:G-@LI.!K#TW%I/FAN7
M1W/?]VT<SS&C?L$?K!C\U__V3,2VA\ATA+^,HHNMZ[:/?1?!W(Q>O8J/CD^"
M#X_PX>%)?')P$MVLL=$^-(J/3T_B5T>O!SZYY4I0RI+[I+T)R#F,3P_'\<'X
M."0''XZ/XM'Q\1,4Z]0IUNE.A0@61GP:TJBO&B#4(X>)I2:VOEPC9")Y)#/?
M>=Z9#*T7)?GZU;%\O5' YKI_KN<V6+0--F2P.,\&=!'T*59=RU4U4C'@;=,H
MG];4%R2Z?%[K#$;V/"GO9#8*3XP>NG"4X%E>U9GO9P=ZQULW59+9PC57YZ7<
MUZZ\&-)Z$%NP._QO5V/H)D"T-80TSU#MU^+G7='%:R<^KW?N_B]U8J7YS*+R
M&VYE(<,U)$W_S7B1^;KVG]2*SWQ1R&XL6 8WRL".4Q]S"KI*2=-1^3O,"H3X
M9NXG3@8FMK*:&HAJ3F%MLX[[GOJ 5LF>LBP0=*9Z-L->Z,7>%%"(!^5#C22/
M(@#FS(@RP6DI:3N.*SDSL88 J&#;<-QC#TH%R1;@'(Z=FWXG?E6O#4)E;LHN
MNKR#$1X%X]49DDA=#*G.[7N\ZYH->]D2Z:%K/(,#WG![569J*U2@5U*04BSP
M %6"Y0 JSFTL(#D72BS99S/C50'EY"5MV6[.!;I0G%O9><-(B:A]JJ4>!4O9
M+M48'?C#HP<[A?FZI H&U^@'SWP^^>TH_)F60QM!T9Z8#2S%&+"JX:Y,@GQT
M+$)_8=[RTU2BP[>Z"=DEYP(3.8D$830_4$.-*RM?O[7)CQ>4^M0DW.TF7+=
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M2I.FYZM$S6>B+U2NR@;V4Z)UO;Z;?;;,=,Y=P&F>Z,*?J=54-6?K"+Q04W=
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M+9N&JC9Z:'@]+YDN(X;]T#B0-O,]=]OB&T RF'KJ<+Y1RT37]BPX5^!9']F
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M'CIR5U/;97H=#) Y?!H<\&T$H]WE_;/LGIK:.&%P9<+(01Y^_3!1^*%WZD%
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M$ZDV& \!*A<)MZMFP=R/W"O MV8FJ;UCV:5\_6D"T1&:C&RQNZM7;F7B=*.
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M7 /4^HHQN0_T!LV7*?@%4$L#!!0    ( /6%:5:EVO;X @4  &X6   9
M>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;.U8VV[C-A#]%<)K+%J B$GJGHN!
MW)KMPQ9!+MMG6J9E8B71)>DX^?L.)4=68EE)T&RQ ?8EEH:<,S.<F2-F#E=*
M?S=S(2RZ+_+2' WFUB[V1R.3SD7!S9Y:B!)69DH7W,*KSD9FH06?5DI%/F*$
MA*."RW(P/JQDEWI\J)8VEZ6XU,@LBX+KAQ.1J]71@ X>!5<RFULG&(T/%SP3
MU\+>+BXUO(T:E*DL1&FD*I$6LZ/!,=T_"=S^:L,W*5:F]8Q<)!.EOKN7/Z='
M ^(<$KE(K4/@\',G3D6>.R!PXY\UYJ QZ13;SX_H?U2Q0RP3;L2IRO^64SL_
M&L0#-!4SOLSME5I]$>MX*@=3E9OJ+UK5>Z-D@-*EL:I8*X,'A2SK7WZ_/H>6
M0DQV*+"U JO\K@U57IYQR\>'6JV0=KL!S3U4H5;:X)PL75*NK895"7IV?'7^
M[?ROVW/TVPV?Y,+\?CBR@.K61ND:X:1&8#L0*$-?56GG!IV74S%]"C "=QJ?
MV*-/)ZP7\4RD>\BC&#'"6 ^>U\3H57A>?XQ=H=6*?K>B:XA]L^"I.!I Q1NA
M[\1@_/D3#<E!CUM^XY;?ASZ^A@:;+G.!U Q-I>%9ID7&JUH%R96X$^52=#G=
M#WLS%VBF<N@V66;(NK2VX85!%G:<JF+!RX?/GV)&HP,#_5690Y.'==4)C>S#
M0B!>3E$F5*;Y8BY3Q*'S 5Y7( ^":R1<UA'D3!034'K,VSYRV,0[^#"_MZ6T
M$,FUK0[IOZ*=26.UG"RMTF;42"_4G= ED)I]!8 &Y@)W-/B3P=%?<FU+H0TZ
MSD292O#Q1EF>HTNMIDO8:3@T\,O'WAWF$$5QA!FA+0F-*8X"TI)4Y<(.6I(D
MC'$24'0A@"++AV:%,AR$(?:]J-.1-LA+\A;4<9XC!96G4:J6)9QO*P(?1R3
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ML)\X./3]O8CN 2>C "T@:P15+]HS:BZIKC;D1#AQ@U?=881#W<^2*\+VCB3
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M<$: T9!%-([YA9,TB*D?^F2,4><K41!M]IEE\Z;"6$@9]SN2.(IIPJ,V!*R
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MH3*%JHB&?.Y=!9?7L?-O';X7L#,'8^(J62GUPTW^S>8><X1 PMHZ!(&/!_@
M4CH@I/'_'M,;4KK PW&/_JFM'6M9"0,?E/ROR.QV[DT\DD$N&FGOU.XS[.MI
M":Z5-.V=[#K?A'EDW1BKRGTP,BB+JGN*G_OW<! P>2F [P-XR[M+U++\**Q8
MS+3:$>V\$<T-VE+;:"175&Y3EE;C:H%Q=O'EYFIYLR1G]V(EP9S/?(N@;LE?
M[P&N.P#^ D# R5=5V:TA-U4&V3& CVP&2KRG=,U'$3_"^H*$ 26<<3Z"%PXE
MABU>.%KBJ<JZN.ATG#L.EZ86:YA[J'<#^@&\Q=LW0<+>C["*!E;1&/IBB<<K
M:R00E1/MI/-.Y>](8X (8_ PBBI#T4MA(2,24'=$%F)5R,(^GBIE/-G;-Q/.
MPO?D;Y^X-5"N0+?;TQO=-KE;0.[Z.I[*Z)W^(0&G"0OIE 6'QI!&'*^4_S&G
M>V6%_/T5':?@,:/3*#HV3GA 8S8E7\ 8/&E:0V5)K73[L>@]SP(VH=-P>OXL
M[5F<,AHGR3D"'*6FI,*Z<5=?PFRS!Q&GC,6G>(:]<41E\:"R^-4JPT]8HPM;
M@'$SNX7?7AHNG%+6>()[A'D%,!':*8+D2F(;,&Z(KD=R<C*Z?/6NHW?H7AKE
M24+#*'&&IPT.:!(G-$DGSAP?FJ<QFE-G3@[,:1C3-&K-Z:$Y3>B4,X)%8L/+
M+3(=%E/*0TY#QHX$6(M'[%C6/.<;TS ):9),R*W[F* N'H1L@&2%6:NFLL\B
M\+P$>*585I=A3-*GI.(?=(42]*;M?2AUEZUK$(-U:*]775=Y<N]Z\U>A-T5E
ML,@<0]E%BJ+07;_K)E;5;8]9*8L=JQUN\1<!M'/ ]5PIVT]<@N&G8_$+4$L#
M!!0    ( /6%:59AXSN41@8  %D2   9    >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;-58:6_;-AC^*X1[P $X6:3N' 9R;AW:-$C2'1]IB8Z%2J)'TCG^
M_5Y2ED2GCI<.V+!]L"52?._G/:3#!R&_J@7G&CW65:..1@NME_N3B<H7O&;*
M$TO>P).YD#73L)1W$[64G!66J*XFU/?C2<W*9C0]M'M7<GHH5KHJ&WXED5K5
M-9-/)[P2#T<C,NHVKLN[A38;D^GADMWQ&ZZ_+*\DK"8]EZ*L>:-*T2#)YT>C
M8[)_DICS]L O)7]0SCTRELR$^&H6'XJCD6\4XA7/M>' X'+/3WE5&4:@QA]K
MGJ->I"%T[SON%]9VL&7&%#\5U:]EH1='HW2$"CYGJTI?BX>?^-J>R/#+1:7L
M/WIHST;9".4KI46])@8-ZK)IK^QQ[0>'(/5?(*!K FKU;@59+<^89M-#*1Z0
M-*>!F[FQIEIJ4*YL3%!NM(2G)=#IZ8?+T\^?SM'M\6_G-VA\RV855WN'$PVL
MS8%)OF9STK*A+[ A%'T2C5XH=-X4O-AD, &=>L5HI]@)W<GQC.<>"@A&U*=T
M![^@-S2P_()7&+K-OI8ZW$YM4F-?+5G.CT: ?<7E/1]-W[\AL7^P0[>PURW<
MQ7UZ ZE6K"J.Q!Q]:')1<S3CD'"\6]VR1XS.X$[I,D>L*1! $@#7;+-DMZS;
M!4>GHEZRYNG]FY22Y$"A7#1*5&7!-"]0)93JQ)>M>,T>N4*P@S10/W$F%>(F
MS@BBQ.L9EWVD[#^Q*L*-CTJ%F"&M(/O5/C(B_>#@'[_^#CJV4-Q4L7MN5&TU
MM5KVKNV>OT5C2C")(@S+/7>;I#BE&4ZR9&,[PG%*<4S3O2XT_=,QH3@),YS%
MT4 RCG$8ASB-0F<OP#0E. Y@[U9H5KD"@@!G?H1)G&[(I:!A%N(X(AO;*4@+
M,8UIO[L#IE$/T^C5,#40$@UOM') "S!%YX_0+Q1'XQ/>\'FIMQ:3W7(,1&<M
M-9I+46_"T("U5*U< \<66V5S]Y]%UXV&Q&IS&"RI5@4HBQ1K'7D)C>MG+A5_
MLID'!KYG]?( Y9(7)5@Y!)5@/Z,X2B-G+PEB[/O!QBE"$^PG88]#<!M:2G%?
MVD;JVD+HP7>M_YX>?PW N =@_&H GO$YE^ C"[IC<!SXRE2=CR6;E56I2ZZV
M(6^W (.\I80@E4O(OGP#XWI+X2PZ)8R/V:!$-2B!&-31_T,)_-:4EW6]A&D1
MYD+)M(&R[1@YD_+)](@')@L'!R R2GR<AK&S"<@@F0]5*W0W*0Y\4W1#R!B1
M?P4)9G ;4B#R?9PE ^R(*<Z8)K3?":!"9BE%U]"BF<P7-A@%OX?9<PF3I%YG
M5:OL<UT#0XI)F PN@J*>X"@CS@Z!:DL)0<=Y+E>L:N,M !QR4)2& 'Z'* !&
ML:-W$.$@\-%'#N-DCY4G1Y$$.*2A[ZJ6@<O(X"Z:9M LC*HD3@Y($HYG>TB^
M9/; )X!XQ#3:B.BVM/]1FJ!NPW=W,@PP"4(<.3$T=A&(2C;$VO0G^$$W G.!
MXSVK5JR=QTT^L";G3O_+  $!#MUF-@:%:0A^#WQG$_R30"#"Q&F?@Y$IT!"G
M&H78CS-HG;&C/,%A]@SU?21>!OY%^0B'GWEB3-,4<.-V=Y)"R$+7C+7$/63?
M>TQ!^0+!MX7+'0 B,#6+THVA($VM$_>^"9))PUTA>OM->%^QLZ-.)WV=3EY=
MI\_G<V[?O-PAX=HTQ&L.K3P'AUL\;"O6NZ4< ]Y=#D;:,"F@,6\GD;U^EF#:
M%G$%[7BEA:E6O( :5KE4TFAFTF=CYH#Z#2^+YDV2FR?MW%$V@-X2R U#7ML^
M\2^-N]]9VR_6=@Z66S,I\7ST[MFE'5:LV1@UW"*U\U/GR#'U *'P#W >9YZ#
MS&[FL/R+$F(OP2_&28$7(NH%<!WR\HK#>[5IL*@$!RI(&\-K'-M_R[T[:0&3
M+UASUT9'RQ7_8;5$OA<C0KP4D<0;RN5I>Q "M:W<C.E:_:B50[S8$62GK[.N
M45"/(.(E*/2&*G>SGMQLV)\3&.4N/W\$,^E&8KDI-Z3$<^ 9*H@$V/,.$0JV
MO=N6C1/G=;_F\LY^U#"#\:K1[9M_O]M_-SEN/Q<,Q]N/+I^8O"NAQ59\#J2^
ME\!D+ML/&>U"BZ7]># 36HO:WBXX SB8 _!\+H3N%D9 _S5I^B=02P,$%
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M 2K-!U,SD<5"?W.\*J0L,OTX%_%$E(H _I\6A:PGZH#FJ_71OU!+ P04
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MZR)9XI3D@H.3@ B<I/Q4HL91 $Z^GK9-(>-749AQ&>M5$2OZ(-: Q.? AF<
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MX\;OXVPKG#KVS.\'RH$3"0/+LX-^7#( -O]^>%8PZP>F0T?V9].I%_8#LX'
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M)8K4(E03J!:CFD2U!-525,M0+4>U M44JFE4*U&MHK1^C>R6%H3^N;TFND(
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M+"D>5P1'A.<!ZON",;EKY!W45[6C_P!02P,$%     @ ]85I5HR6JVYU @
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M<"E[;<Q4@'P^IU2\3%0WUW7O\7]02P,$%     @ ]85I5LI-=\_G @  I0L
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M<VAE971S+W-H965T-#(N>&ULK9=?;^,V#,"_BN -PQUPJRW9ENTN"= F.5R
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M]NZWCST[._'FF[+*U[O!]1:LE]GVW^3WW0_BT0!_\LR 8#<@.'3 >#=@?.B
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MR(GW):^J?-U^>)LFB[1H'E#__]<\KWY^TDQPGQ??VLV^^B]02P,$%     @
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M&&U@R_;"+&3]#=IZO,%,"NW?J&YRPS%&V5X;6;1@ZZ#@9?-EC^T^G  H?0%
M6P#UOALA[W+&#$MC)6ND7+9E<P-?JD=;<[QT/V5IE%WE%F?2VY\_OEZM;A9W
M:'8S7:$K-%>\S'C%!*K8D]U]H]'%# SC0K^/B;&2#DBREG[:T-,7Z&>0#=!H
M>(EH0"FZ7\[0Q=MG-,0Z[FS3SC;UO*-7V>[SU>##?KP[ZA-=L0P2;,^R!G4
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M06)1<)PE=V)[<]OIA&[WP(D6.M_U_*G;"1UR]S@(TT(WV8=N8@P=3Y>YK%Z
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MT+\@@1<$/?#I^^'^(=S%/'3)"+ID!)8O/)F,/AL-+NK'F9MVK6J:P<3!JZ1
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MA^R=[CW9XY8]/L4>V]AC"WN,AM [8.]T[\D^:-D'G>P_,Z)OXY4BPI9@8$D
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MLJ?#$G4+JB>*+VU1GG*E2[P=+G37!F$ >G_&N=I.S 'M?T#R%U!+ P04
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M&9.JM)IIIKHE<FV@SE/&Y':A'33]-_P'4$L#!!0    ( /6%:59K:1&L300
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MS?XIJTM*U=!B[8[M3T*;2X![7)F+'4@;8-[G0NB7AAV@N2K._P-02P,$%
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M4S:[D<V6RL8ZA0V.!H230L<N2KNGQEN('!U:O+PB0\/5#8>35V!GF+;)+=Y
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M^OA>5 ?DYWF3-,J*_\ECN>W [9#)*E-I7!76>Q"'2?DW>*I K!6@_1T%6%6
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M+VJD2FU,QAX8; ]'M#&XYM8X&[6@[VSU)4BUVCR-8S DQ]ASN JNKC5$5.W
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M@7J_XEP^WQ09-,<!)_\"4$L#!!0    ( /6%:59D-*D8- 8  "X?   9
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MNMZ=79_DR;+<57I*\CQ9E(=S&[BGBP+@OG].DGQ[4@2HML@[?P-02P,$%
M  @ ]85I5L@D@&P^ @  /@4  !D   !X;"]W;W)K<VAE971S+W-H965T-C8N
M>&ULK53;;MLP#/T5P1N&%NCB6RY;9AMHDP[;PX8@0;IGQ69BH;+D24J<_OTH
MV3$2("WZL!>;E'@.>2B)22/5LRX!##E67.C4*XVII[ZO\Q(JJ@>R!H$[6ZDJ
M:M!5.U_7"FCA0!7WHR 8^Q5EPLL2M[9062+WAC,!"T7TOJJH>GD +IO4"[W3
MPI+M2F,7_"RIZ0Y68-;U0J'G]RP%JT!H)@51L$V]^W ZBVV\"WABT.@SFU@E
M&RF?K?.S2+W %@0<<F,9*/X., /.+1&6\;?C]/J4%GANG]B_.^VH94,US"3_
MPPI3IMX7CQ2PI7MNEK+Y 9V>D>7+)=?N2YHN-O!(OM=&5AT8*ZB8:/_TV/7A
M#! .7P%$'2!Z+R#N *YS?EN9DS6GAF:)D@U1-AK9K.%ZX]"HA@E[BBNC<)<A
MSF3+QZ?'W^M'\IG,I# *NXH%F+)+#8I0K?$NW8N"<$8WC#/S0F[F8"CC^A9A
MZ]6<W'R\37R#U5A./^\R/[29HU<RSR$?D#B\(U$015?@L_?#PTNXCSWH&Q'U
MC8@<7_QV(Z[I:('#ZT#[S*:ZICFD'KXC#>H 7O;I0S@.OEU3]9_(+C3&O<;X
M+?:L/^+343+0=Z0I65X2JH PD?-] 04:!(XX*#1H0O'HI2GQ*N1[I4!<H*^U
MJZUAY&JP0^20A:-P/)G@(1_..W$E[NMP$H_B/JX5Z9_=;CM9?E&U8T(3#EM$
M!H,)4JCVM;:.D;6[\!MI\ X[L\0!!\H&X/Y62G-R[!OJ1V;V#U!+ P04
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M=@*]'?5V KT=]78"O0/U#@*] _4. KT#]0X"O0/U#@*] _4. KUC\K&20.]
MO8- [T"]@T#O0+V#0.] O8- [XQZ9P*],^J="?3.J'<FT#NCWIE [XQZ9P*]
M,^J="?3.DY]-OE/O.GX>2KWV?*WQ^M])]7@^MUPO?UE^[9S<XQ><TVU%??X+
M4$L#!!0    ( /6%:5:E?PYQ[@$  ) F   3    6T-O;G1E;G1?5'EP97-=
M+GAM;,W:RT[#,! %T%^ILD6-ZR</T6Z +;#@!TPRI5&3V+)=*'^/DP(2""I0
MD;B;1JWMN1./=%8]OWOV%"?;KNWCO%BEY,\8B]6*.AM+YZG/*TL7.IORU_#
MO*W6]H&8F,T,JUR?J$_3--0H%N>7M+2;-DVNMOGGV+A^7@1J8S&YV&T<LN:%
M];YM*IOR.GOLZT\IT]>$,I\<]\15X^-1WE"P+Q.&E>\#7L_=/%((34V36QO2
MM>WR+K9M64S/+<5R?XDO>G3+95-1[:I-EX^4T0>R=5P1I:XM=T6/]B>G?,.T
M^^0'YX]E]@7FG;?!^9@G%NCW<6\C&4Y/?2Y$(37[7_$],9<^^/UHF'9-]0^S
M\_4^N; >YQ'9^#C\CC_.^+W^+_L0('U(D#X42!\:I \#TL<Q2!\G('V<@O3!
M9RB-H(C*44CE**9R%%0YBJH<A56.XBI'@96CR"I09!4HL@H4606*K )%5H$B
MJT"15:#(*E!D%2BR2A19)8JL$D56B2*K1)%5HL@J4625*+)*%%DEBJP*15:%
M(JM"D56AR*I09%4HLBH4616*K I%5H4BJT:15:/(JE%DU2BR:A19-8JL&D56
MC2*K1I%5H\AJ4&0U*+(:%%D-BJP&15:#(JOY3UGOG5O_<?SX+#O;]&_Y;/PC
MVN(%4$L! A0#%     @ ]85I5@=!36*!    L0   !               ( !
M     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #UA6E60'^*&.\    K
M @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M    " #UA6E6F5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE
M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( /6%:59R) A-N08  !@E   8
M          " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    " #UA6E6'[.7U5H&  !9&0  &               @(']#@  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ ]85I5DN9AF85 P  I@H
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M965T-RYX;6Q02P$"% ,4    " #UA6E6@[D<.HXA  #M8@  &
M    @($O.   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
M]85I5I""D&-A#0  7BT  !@              ("!\UD  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( /6%:59KI>\E:@,  )4(   9
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M970Q-"YX;6Q02P$"% ,4    " #UA6E6<L%J29,,  "Y(@  &0
M    @(%+B@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M /6%:58QG?8*I@L  ,X>   9              " @167  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ ]85I5L>_1M"T$P  ?$T  !D
M             ("!\J(  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    " #UA6E679][KP(#  #D!@  &0              @('=M@  >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( /6%:5;+00T9M@(
M .(%   9              " @1:Z  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ ]85I5I&8W%EF!   ^@P  !D              ("!
M [T  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #UA6E6
M,$YG8$<B  !@:P  &0              @(&@P0  >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( /6%:5:J!SD0M (  *4&   9
M      " @1[D  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ ]85I5J7:]O@"!0  ;A8  !D              ("!"><  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #UA6E6Y.Y?FAT#  #.!P
M&0              @(%"[   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( /6%:5:[?TU#R (  (D&   9              " @9;O  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ ]85I5GIG8"J2
M P  1 @  !D              ("!E?(  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    " #UA6E68=R1([<"  #Q!@  &0
M@(%>]@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( /6%
M:58@GE9P0 ,  ( (   9              " @4SY  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ ]85I5F'C.Y1&!@  61(  !D
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M=#,S+GAM;%!+ 0(4 Q0    ( /6%:58RHCIGZ0(  .,)   9
M  " @9L: 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
M]85I5K_(-VKY$@  SVD! !D              ("!NQT! 'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    " #UA6E6K:+P-6X"   =!@  &0
M            @('K, $ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( /6%:5;N)0KV(00  /$3   9              " @9 S 0!X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ ]85I5@'-Q48S!
MMA4  !D              ("!Z#<! 'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    " #UA6E6C):K;G4"  ";!@  &0              @(%2
M/ $ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( /6%:58/
MZ^:H% ,  ,D+   9              " @?X^ 0!X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ ]85I5LI-=\_G @  I0L  !D
M     ("!24(! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /6%:583';^BI L  *Z3   9              "
M@61= 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ ]85I
M5D"/>-^, @    <  !D              ("!/VD! 'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6Q02P$"% ,4    " #UA6E6NR2J0^\"  #^"@  &0
M        @($"; $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0
M   ( /6%:5;6I5<WRP(  !,(   9              " @2AO 0!X;"]W;W)K
M<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ ]85I5A>Z9=:Y @  BP<
M !D              ("!*G(! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q0
M2P$"% ,4    " #UA6E6:VD1K$T$   \$   &0              @($:=0$
M>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( /6%:5:MA<:Z
MPP,  #8.   9              " @9YY 0!X;"]W;W)K<VAE971S+W-H965T
M-3(N>&UL4$L! A0#%     @ ]85I5M5@:\V!!   I1P  !D
M ("!F'T! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " #U
MA6E63+3!,FT&   E.P  &0              @(%0@@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( /6%:58? FXFT 4  /$E   9
M          " @?2( 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#
M%     @ ]85I5MDJT/NU!@  ;SL  !D              ("!^XX! 'AL+W=O
M<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " #UA6E6K'#5&XH#  #S
M"P  &0              @('GE0$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM
M;%!+ 0(4 Q0    ( /6%:58DK777]P,  #,5   9              " @:B9
M 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ ]85I5G3.
M^R;Q!0  H2(  !D              ("!UIT! 'AL+W=O<FMS:&5E=',O<VAE
M970U.2YX;6Q02P$"% ,4    " #UA6E611]61"P#   R"@  &0
M    @('^HP$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    (
M /6%:59=4GE"*B<  /+[ @ 9              " @6&G 0!X;"]W;W)K<VAE
M971S+W-H965T-C$N>&UL4$L! A0#%     @ ]85I5NSB\TS\ 0  %@0  !D
M             ("!PLX! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"
M% ,4    " #UA6E6&#Y$/9X"  #J!P  &0              @('UT $ >&PO
M=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( /6%:5:8?2&/Z 0
M !HH   9              " @<K3 0!X;"]W;W)K<VAE971S+W-H965T-C0N
M>&UL4$L! A0#%     @ ]85I5F0TJ1@T!@  +A\  !D              ("!
MZ=@! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " #UA6E6
MR"2 ;#X"   ^!0  &0              @(%4WP$ >&PO=V]R:W-H965T<R]S
M:&5E=#8V+GAM;%!+ 0(4 Q0    ( /6%:5:@E-@11@,  - 4   -
M      "  <GA 0!X;"]S='EL97,N>&UL4$L! A0#%     @ ]85I5I>*NQS
M    $P(   L              ( !.N4! %]R96QS+RYR96QS4$L! A0#%
M  @ ]85I5AH087U[!0  BBL   \              ( !(^8! 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( /6%:58>WYE>' (  #TG   :
M  "  <OK 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M /6%:5:E?PYQ[@$  ) F   3              "  1_N 0!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@    !* $H /10  #[P 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>324</ContextCount>
  <ElementCount>394</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>84</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureBasisOfPresentation</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - REVENUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureRevenue</Role>
      <ShortName>REVENUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - OTHER ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureOtherAssets</Role>
      <ShortName>OTHER ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - LONG-TERM DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureLongTermDebt</Role>
      <ShortName>LONG-TERM DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureLeases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11301 - Disclosure - RETIREMENT PLAN</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureRetirementPlan</Role>
      <ShortName>RETIREMENT PLAN</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11401 - Disclosure - QUARTERLY FINANCIAL RESULTS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnaudited</Role>
      <ShortName>QUARTERLY FINANCIAL RESULTS (UNAUDITED)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>20202 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>30203 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30303 - Disclosure - REVENUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureRevenueTables</Role>
      <ShortName>REVENUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cytosorbents.com/role/DisclosureRevenue</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30403 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30503 - Disclosure - OTHER ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureOtherAssetsTables</Role>
      <ShortName>OTHER ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cytosorbents.com/role/DisclosureOtherAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30603 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30703 - Disclosure - LONG-TERM DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureLongTermDebtTables</Role>
      <ShortName>LONG-TERM DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cytosorbents.com/role/DisclosureLongTermDebt</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30803 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureLeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cytosorbents.com/role/DisclosureLeases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30903 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cytosorbents.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>31103 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cytosorbents.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>31403 - Disclosure - QUARTERLY FINANCIAL RESULTS (UNAUDITED) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnauditedTables</Role>
      <ShortName>QUARTERLY FINANCIAL RESULTS (UNAUDITED) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnaudited</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40101 - Disclosure - BASIS OF PRESENTATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureBasisOfPresentationDetails</Role>
      <ShortName>BASIS OF PRESENTATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cytosorbents.com/role/DisclosureBasisOfPresentation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40201 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40202 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails</Role>
      <ShortName>PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40301 - Disclosure - REVENUE - Revenue by customer type and geographic area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails</Role>
      <ShortName>REVENUE - Revenue by customer type and geographic area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40302 - Disclosure - REVENUE - Receivables and contract liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureRevenueReceivablesAndContractLiabilitiesDetails</Role>
      <ShortName>REVENUE - Receivables and contract liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40303 - Disclosure - REVENUE - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails</Role>
      <ShortName>REVENUE - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40401 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40402 - Disclosure - PROPERTY AND EQUIPMENT, NET - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40501 - Disclosure - OTHER ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails</Role>
      <ShortName>OTHER ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cytosorbents.com/role/DisclosureOtherAssetsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40502 - Disclosure - OTHER ASSETS - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureOtherAssetsAdditionalInformationDetails</Role>
      <ShortName>OTHER ASSETS - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40601 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40701 - Disclosure - LONG-TERM DEBT - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails</Role>
      <ShortName>LONG-TERM DEBT - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40702 - Disclosure - LONG TERM DEBT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureLongTermDebtDetails</Role>
      <ShortName>LONG TERM DEBT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40703 - Disclosure - LONG-TERM DEBT - Principal payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureLongTermDebtPrincipalPaymentsDetails</Role>
      <ShortName>LONG-TERM DEBT - Principal payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40801 - Disclosure - LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureLeasesDetails</Role>
      <ShortName>LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cytosorbents.com/role/DisclosureLeasesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40802 - Disclosure - LEASES - Right-of- use asset and related lease liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureLeasesRightOfUseAssetAndRelatedLeaseLiabilityDetails</Role>
      <ShortName>LEASES - Right-of- use asset and related lease liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40803 - Disclosure - LEASES - Maturities of the lease liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails</Role>
      <ShortName>LEASES - Maturities of the lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40901 - Disclosure - INCOME TAXES - Consolidated loss before income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureIncomeTaxesConsolidatedLossBeforeIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES - Consolidated loss before income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40902 - Disclosure - INCOME TAXES - The benefit from income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureIncomeTaxesBenefitFromIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES - The benefit from income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40903 - Disclosure - INCOME TAXES - The principal components of the Company's deferred tax assets and liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES - The principal components of the Company's deferred tax assets and liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40904 - Disclosure - INCOME TAXES - Reconciliation of income tax (expense) benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>INCOME TAXES - Reconciliation of income tax (expense) benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40905 - Disclosure - INCOME TAXES - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>INCOME TAXES - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41001 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41101 - Disclosure - STOCKHOLDERS' EQUITY - Stock option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Stock option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41102 - Disclosure - STOCKHOLDERS' EQUITY - Fair value of stock option (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureStockholdersEquityFairValueOfStockOptionDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Fair value of stock option (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41103 - Disclosure - STOCKHOLDERS' EQUITY - Intrinsic value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Intrinsic value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41104 - Disclosure - STOCKHOLDERS' EQUITY - Non-vested options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Non-vested options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41105 - Disclosure - STOCKHOLDERS' EQUITY - Restricted stock unit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Restricted stock unit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41106 - Disclosure - STOCKHOLDERS' EQUITY - Restricted stock unit activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Restricted stock unit activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41107 - Disclosure - STOCKHOLDERS' EQUITY - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41108 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureStockholdersEquityWarrantsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41201 - Disclosure - NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureNetLossPerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cytosorbents.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41301 - Disclosure - RETIREMENT PLAN (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureRetirementPlanDetails</Role>
      <ShortName>RETIREMENT PLAN (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cytosorbents.com/role/DisclosureRetirementPlan</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41401 - Disclosure - QUARTERLY FINANCIAL RESULTS (UNAUDITED) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnauditedDetails</Role>
      <ShortName>QUARTERLY FINANCIAL RESULTS (UNAUDITED) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnauditedTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ctso-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9940303 - Disclosure - REVENUE - Contract with customer asset And liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cytosorbents.com/role/DisclosureRevenueContractWithCustomerAssetAndLiabilityDetails</Role>
      <ShortName>REVENUE - Contract with customer asset And liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 52 fact(s) appearing in ix:hidden were eligible for transformation: ctso:DefinedContributionEligibilityTerm, ctso:NumberOfDaysForStockPriceThreshold, ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm, ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm, ctso:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm, ctso:TermOfCustomerContracts, dei:CurrentFiscalYearEndDate, us-gaap:CommonStockSharesOutstanding, us-gaap:EarningsPerShareDiluted, us-gaap:OperatingLeaseLiability, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  ctso-20221231x10k.htm 9</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies -  ctso-20221231x10k.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="ctso-20221231x10k.htm">ctso-20221231x10k.htm</File>
    <File>ctso-20221231.xsd</File>
    <File>ctso-20221231_cal.xml</File>
    <File>ctso-20221231_def.xml</File>
    <File>ctso-20221231_lab.xml</File>
    <File>ctso-20221231_pre.xml</File>
    <File>ctso-20221231xex10d11.htm</File>
    <File>ctso-20221231xex10d30.htm</File>
    <File>ctso-20221231xex21d1.htm</File>
    <File>ctso-20221231xex23d1.htm</File>
    <File>ctso-20221231xex31d1.htm</File>
    <File>ctso-20221231xex31d2.htm</File>
    <File>ctso-20221231xex32d1.htm</File>
    <File>ctso-20221231xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="925">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>101
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ctso-20221231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 27,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 1,
    "http://fasb.org/us-gaap/2022": 925,
    "http://xbrl.sec.gov/dei/2022": 36
   },
   "contextCount": 324,
   "dts": {
    "calculationLink": {
     "local": [
      "ctso-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ctso-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ctso-20221231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ctso-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ctso-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ctso-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 606,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 40,
    "http://www.cytosorbents.com/20221231": 15,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 60
   },
   "keyCustom": 69,
   "keyStandard": 325,
   "memberCustom": 51,
   "memberStandard": 32,
   "nsprefix": "ctso",
   "nsuri": "http://www.cytosorbents.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - PROPERTY AND EQUIPMENT, NET",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNet",
     "shortName": "PROPERTY AND EQUIPMENT, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - OTHER ASSETS",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.cytosorbents.com/role/DisclosureOtherAssets",
     "shortName": "OTHER ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - LONG-TERM DEBT",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.cytosorbents.com/role/DisclosureLongTermDebt",
     "shortName": "LONG-TERM DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - LEASES",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.cytosorbents.com/role/DisclosureLeases",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - INCOME TAXES",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.cytosorbents.com/role/DisclosureIncomeTaxes",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - STOCKHOLDERS' EQUITY",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.cytosorbents.com/role/DisclosureStockholdersEquity",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - NET LOSS PER SHARE",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.cytosorbents.com/role/DisclosureNetLossPerShare",
     "shortName": "NET LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - RETIREMENT PLAN",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.cytosorbents.com/role/DisclosureRetirementPlan",
     "shortName": "RETIREMENT PLAN",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - QUARTERLY FINANCIAL RESULTS (UNAUDITED)",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnaudited",
     "shortName": "QUARTERLY FINANCIAL RESULTS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ctso:NatureOfBusinessPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "menuCat": "Policies",
     "order": "21",
     "role": "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ctso:NatureOfBusinessPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ctso:ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ctso:ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - REVENUE (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.cytosorbents.com/role/DisclosureRevenueTables",
     "shortName": "REVENUE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetTables",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - OTHER ASSETS (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.cytosorbents.com/role/DisclosureOtherAssetsTables",
     "shortName": "OTHER ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ctso:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ctso:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - LONG-TERM DEBT (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.cytosorbents.com/role/DisclosureLongTermDebtTables",
     "shortName": "LONG-TERM DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ctso:LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - LEASES (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.cytosorbents.com/role/DisclosureLeasesTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ctso:LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - INCOME TAXES (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.cytosorbents.com/role/DisclosureIncomeTaxesTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31103 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.cytosorbents.com/role/DisclosureStockholdersEquityTables",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31403 - Disclosure - QUARTERLY FINANCIAL RESULTS (UNAUDITED) (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnauditedTables",
     "shortName": "QUARTERLY FINANCIAL RESULTS (UNAUDITED) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BasisOfAccounting",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - BASIS OF PRESENTATION (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.cytosorbents.com/role/DisclosureBasisOfPresentationDetails",
     "shortName": "BASIS OF PRESENTATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:BasisOfAccounting",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ctso:NatureOfBusinessPolicyPolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ctso:NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_country_S-K5wYygeEuMMDPQgfGhxg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ctso:NatureOfBusinessPolicyPolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ctso:NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_country_S-K5wYygeEuMMDPQgfGhxg",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails",
     "shortName": "PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ctso:ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_10_1_2022_To_12_31_2022_7D4gmEOvZEuddtCJGzA8ow",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - REVENUE - Revenue by customer type and geographic area (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails",
     "shortName": "REVENUE - Revenue by customer type and geographic area (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_US_eeMsQ5mBMEaBmXTojZOwqQ",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - REVENUE - Receivables and contract liabilities (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.cytosorbents.com/role/DisclosureRevenueReceivablesAndContractLiabilitiesDetails",
     "shortName": "REVENUE - Receivables and contract liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DeferredRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ctso:NumberOfPrimaryRevenueStreams",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_00R0j3K4HUiRlSslEJQMxQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40303 - Disclosure - REVENUE - Additional information (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails",
     "shortName": "REVENUE - Additional information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ctso:NumberOfPrimaryRevenueStreams",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_00R0j3K4HUiRlSslEJQMxQ",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - PROPERTY AND EQUIPMENT, NET - Additional information (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "shortName": "PROPERTY AND EQUIPMENT, NET - Additional information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - OTHER ASSETS (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails",
     "shortName": "OTHER ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "us-gaap:OtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - OTHER ASSETS - Additional information (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.cytosorbents.com/role/DisclosureOtherAssetsAdditionalInformationDetails",
     "shortName": "OTHER ASSETS - Additional information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ctso:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ctso:AccruedSalariesAndCommissionsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ctso:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ctso:AccruedSalariesAndCommissionsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - LONG-TERM DEBT - Additional information (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails",
     "shortName": "LONG-TERM DEBT - Additional information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": "3",
      "lang": null,
      "name": "ctso:DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - LONG TERM DEBT (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.cytosorbents.com/role/DisclosureLongTermDebtDetails",
     "shortName": "LONG TERM DEBT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - LONG-TERM DEBT - Principal payments (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.cytosorbents.com/role/DisclosureLongTermDebtPrincipalPaymentsDetails",
     "shortName": "LONG-TERM DEBT - Principal payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ctso:LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - LEASES (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.cytosorbents.com/role/DisclosureLeasesDetails",
     "shortName": "LEASES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "4",
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - LEASES - Right-of- use asset and related lease liability (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.cytosorbents.com/role/DisclosureLeasesRightOfUseAssetAndRelatedLeaseLiabilityDetails",
     "shortName": "LEASES - Right-of- use asset and related lease liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40803 - Disclosure - LEASES - Maturities of the lease liabilities (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails",
     "shortName": "LEASES - Maturities of the lease liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - INCOME TAXES - Consolidated loss before income taxes (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.cytosorbents.com/role/DisclosureIncomeTaxesConsolidatedLossBeforeIncomeTaxesDetails",
     "shortName": "INCOME TAXES - Consolidated loss before income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_93L6HhBk5E-Lnf3ZqLpS2A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_93L6HhBk5E-Lnf3ZqLpS2A",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - INCOME TAXES - The benefit from income taxes (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.cytosorbents.com/role/DisclosureIncomeTaxesBenefitFromIncomeTaxesDetails",
     "shortName": "INCOME TAXES - The benefit from income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40903 - Disclosure - INCOME TAXES - The principal components of the Company's deferred tax assets and liabilities (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "INCOME TAXES - The principal components of the Company's deferred tax assets and liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": "5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40904 - Disclosure - INCOME TAXES - Reconciliation of income tax (expense) benefit (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails",
     "shortName": "INCOME TAXES - Reconciliation of income tax (expense) benefit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": "5",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ctso:ProceedsFromSaleOfNetOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40905 - Disclosure - INCOME TAXES - Additional information (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.cytosorbents.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "INCOME TAXES - Additional information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ctso:ProceedsFromSaleOfNetOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExaminationInterestAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExaminationInterestAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - STOCKHOLDERS' EQUITY - Stock option activity (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Stock option activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_NDi9LFh54EqykZ7_Vc2wWA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41102 - Disclosure - STOCKHOLDERS' EQUITY - Fair value of stock option (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.cytosorbents.com/role/DisclosureStockholdersEquityFairValueOfStockOptionDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Fair value of stock option (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_ctso_ExercisePriceRangingFrom4.46To11.39Member_4nmfCjwDv0eiv9Xvjheotg",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41103 - Disclosure - STOCKHOLDERS' EQUITY - Intrinsic value (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Intrinsic value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41104 - Disclosure - STOCKHOLDERS' EQUITY - Non-vested options (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Non-vested options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_NRQitdEUdUmMQB1o_K8GQA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41105 - Disclosure - STOCKHOLDERS' EQUITY - Restricted stock unit (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Restricted stock unit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2019_6_oqjbutzEKQogf2y7UC6g",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_9vRyYMxhI0WaNHqaWqGMHQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41106 - Disclosure - STOCKHOLDERS' EQUITY - Restricted stock unit activity (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Restricted stock unit activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_YVrGc1B3_0iv_-UYCZAPsw",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41107 - Disclosure - STOCKHOLDERS' EQUITY - Additional information (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Additional information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_6_30_2019_hE-GjhoHb06AQqRidhWP3A",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41108 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.cytosorbents.com/role/DisclosureStockholdersEquityWarrantsDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ctso_StockOptionsAndWarrantsMember_yk7BYg1b80i8SXV12unwZQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - NET LOSS PER SHARE (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.cytosorbents.com/role/DisclosureNetLossPerShareDetails",
     "shortName": "NET LOSS PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ctso_StockOptionsAndWarrantsMember_yk7BYg1b80i8SXV12unwZQ",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_V9llTCMkJkS54KZtMkYMvA",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_6_1_2014_To_6_30_2014_xxa151rza0iR7WYHq7r7TA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - RETIREMENT PLAN (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.cytosorbents.com/role/DisclosureRetirementPlanDetails",
     "shortName": "RETIREMENT PLAN (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_6_1_2014_To_6_30_2014_xxa151rza0iR7WYHq7r7TA",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_BYC0wJfzX0qXR3lgM8oRLQ",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_10_1_2022_To_12_31_2022_7D4gmEOvZEuddtCJGzA8ow",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - QUARTERLY FINANCIAL RESULTS (UNAUDITED) (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnauditedDetails",
     "shortName": "QUARTERLY FINANCIAL RESULTS (UNAUDITED) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_10_1_2022_To_12_31_2022_7D4gmEOvZEuddtCJGzA8ow",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ctso:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_FvJ3rSYXpkuEuCYVOzVVJg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_Ha-ELYCJn0avtjAYs3go_Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9940303 - Disclosure - REVENUE - Contract with customer asset And liability (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.cytosorbents.com/role/DisclosureRevenueContractWithCustomerAssetAndLiabilityDetails",
     "shortName": "REVENUE - Contract with customer asset And liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - BASIS OF PRESENTATION",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.cytosorbents.com/role/DisclosureBasisOfPresentation",
     "shortName": "BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPolicies",
     "shortName": "PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - REVENUE",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.cytosorbents.com/role/DisclosureRevenue",
     "shortName": "REVENUE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctso-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_AO-wHXVfYEK4tqc0To0zFg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 84,
   "tag": {
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Germany [Member]",
        "terseLabel": "Germany"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails",
      "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States [Member]",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails",
      "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_AccruedDirectorFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 11.0,
       "parentTag": "ctso_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for board of Director fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Director Fees Current",
        "terseLabel": "Board of Director fees"
       }
      }
     },
     "localname": "AccruedDirectorFeesCurrent",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued expenses and other current liabilities.",
        "label": "Accrued Expenses and Other Current Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_AccruedSalariesAndCommissionsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "ctso_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for salaries and commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries and Commissions Current",
        "terseLabel": "Accrued salaries and commissions"
       }
      }
     },
     "localname": "AccruedSalariesAndCommissionsCurrent",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_AccruedTravelAndEntertainmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "ctso_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for travel and entertainment. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Travel And Entertainment Expense Current",
        "terseLabel": "Travel and entertainment"
       }
      }
     },
     "localname": "AccruedTravelAndEntertainmentExpenseCurrent",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_AdditionalOperatingLeasesRentExpenseNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Additional Operating Leases Rent Expense Net",
        "terseLabel": "Additional operating leases rent expense"
       }
      }
     },
     "localname": "AdditionalOperatingLeasesRentExpenseNet",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_AdditionalSocialSecurityAndVatTaxesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to additional social security and VAT taxes",
        "label": "Additional Social Security and VAT Taxes [Member]",
        "terseLabel": "Additional Social Security and VAT Taxes"
       }
      }
     },
     "localname": "AdditionalSocialSecurityAndVatTaxesMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_AggregateRegisteredAmountForOfferings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On July 29, 2015, the Company's registration statement on Form S-3, as filed with the SEC on July 23, 2015, was declared effective using a \"shelf\" registration process. Under this shelf registration statement, the Company may issue, in one or more offerings, any combination of common stock, preferred stock, senior or subordinated debt securities, warrants, or units, up to a total dollar amount of $100 million.",
        "label": "Aggregate Registered Amount for Offerings",
        "terseLabel": "Aggregate registered amount for offerings"
       }
      }
     },
     "localname": "AggregateRegisteredAmountForOfferings",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_AllOtherCountriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for All other countries.",
        "label": "All other countries [Member]",
        "terseLabel": "All other countries"
       }
      }
     },
     "localname": "AllOtherCountriesMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_AmortizationOfLoanAcquisitionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of amortization of loan acquisition costs",
        "label": "Amortization of Loan Acquisition Costs",
        "terseLabel": "Amortization of loan acquisition costs"
       }
      }
     },
     "localname": "AmortizationOfLoanAcquisitionCosts",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_April122021PerformanceBasedAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to April 12, 2021 performance based award.",
        "label": "April 12, 2021 Performance Based Award [Member]",
        "terseLabel": "April 12, 2021 performance based award"
       }
      }
     },
     "localname": "April122021PerformanceBasedAwardMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_August102022PerformanceBasedAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to August 10, 2022 Performance Based Award.",
        "label": "August 10, 2022 Performance Based Award [Member]",
        "terseLabel": "August 10, 2022 performance based award"
       }
      }
     },
     "localname": "August102022PerformanceBasedAwardMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_ClinicalStudyCostsPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "ctso_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical study costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Clinical Study Costs Payable Current",
        "terseLabel": "Clinical studies"
       }
      }
     },
     "localname": "ClinicalStudyCostsPayableCurrent",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_ClosingFeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for closing fee.",
        "label": "Closing Fee [Member]",
        "terseLabel": "Closing Fee"
       }
      }
     },
     "localname": "ClosingFeeMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_CommissionRateAsPercentageOfAggregateGrossProceeds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The commission rate as a percentage of the aggregate gross proceeds.",
        "label": "Commission Rate As Percentage Of Aggregate Gross Proceeds",
        "terseLabel": "Commission rate (as a percent)"
       }
      }
     },
     "localname": "CommissionRateAsPercentageOfAggregateGrossProceeds",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctso_CommitmentsAndContingenciesDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and Contingencies Disclosure [Line Items]",
        "label": "Commitments and Contingencies Disclosure [Line Items]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ctso_CommitmentsAndContingenciesDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and Contingencies Disclosure [Table]",
        "label": "Commitments and Contingencies Disclosure [Table]",
        "verboseLabel": "Commitments and Contingencies Disclosure [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTable",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ctso_CommonStockValueAuthorized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Value Authorized For Shares Authorized.",
        "label": "Common Stock Value Authorized",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "CommonStockValueAuthorized",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_CongressesPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 12.0,
       "parentTag": "ctso_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The element represents the carrying value of congresses classified as current liabilities.",
        "label": "Congresses Payable, Current",
        "verboseLabel": "Congresses"
       }
      }
     },
     "localname": "CongressesPayableCurrent",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_ConsolidationAndForeignCurrencyTranslationPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of consolidation and foreign currency translation.",
        "label": "Consolidation and Foreign Currency Translation Policy [Policy Text Block]",
        "terseLabel": "Basis of Consolidation and Foreign Currency Translation"
       }
      }
     },
     "localname": "ConsolidationAndForeignCurrencyTranslationPolicyPolicyTextBlock",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ctso_ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contract with customer liability net of free of charge goods and credit rebates as on the balance sheet date, classified as current.",
        "label": "Contract With Customer Liability, Net Of Free Of Charge Goods And Credit Rebates, Current",
        "terseLabel": "Contract liabilities net of Value of free of charge goods and credit rebates"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNetOfFreeOfChargeGoodsAndCreditRebatesCurrent",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of free of charge goods and credit rebates as on the balance sheet date, classified as current.",
        "label": "Contract With Customer Liability, Value of Free Of Charge Goods And Credit Rebates, Current",
        "terseLabel": "Value of free of charge goods and credit rebates"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityValueOfFreeOfChargeGoodsAndCreditRebatesCurrent",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_CustomerRebates": {
     "auth_ref": [],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "ctso_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of customer rebates.",
        "label": "Customer rebates"
       }
      }
     },
     "localname": "CustomerRebates",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_CytoSorbSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the information relating to the cyto sorb sales",
        "label": "CytoSorb sales [Member]",
        "terseLabel": "CytoSorb sales"
       }
      }
     },
     "localname": "CytoSorbSalesMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_CytosorbentsEuropeGmbhMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for CytoSorbents Europe GmbH.",
        "label": "CytoSorbents Europe GmbH [Member]",
        "terseLabel": "CytoSorbents Europe GmbH"
       }
      }
     },
     "localname": "CytosorbentsEuropeGmbhMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_CytosorbentsMedicalIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for CytoSorbents Medical, Inc.",
        "label": "CytoSorbents Medical, Inc [Member]",
        "terseLabel": "CytoSorbents Medical, Inc"
       }
      }
     },
     "localname": "CytosorbentsMedicalIncMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_DebtInstrumentCapInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cap interest rate during the reporting period.",
        "label": "Debt Instrument, Cap Interest Rate",
        "terseLabel": "Interest rate cap"
       }
      }
     },
     "localname": "DebtInstrumentCapInterestRate",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctso_DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable fee to be paid upon termination or maturity of debt instrument, representing the percent of the principal amount of debt funded.",
        "label": "Debt Instrument, Non-refundable Fee Upon Termination or Maturity, Percent",
        "terseLabel": "Non-refundable fee percent"
       }
      }
     },
     "localname": "DebtInstrumentNonRefundableFeeUponTerminationOrMaturityPercent",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctso_DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets, tax credit carryforwards, lease liability.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsLeaseLiability",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_DeferredTaxLiabilitiesRightsOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, ROU",
        "label": "Deferred Tax Liabilities Rights Of Use Assets",
        "negatedLabel": "Right of Use Asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightsOfUseAssets",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_DefinedContributionEligibilityTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of employment required to be eligible to participate in defined contribution plan.",
        "label": "Defined Contribution, Eligibility Term",
        "terseLabel": "Term of employment required"
       }
      }
     },
     "localname": "DefinedContributionEligibilityTerm",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRetirementPlanDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ctso_DirectMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Direct.",
        "label": "Direct [Member]",
        "terseLabel": "Direct"
       }
      }
     },
     "localname": "DirectMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_DistributorsAndStrategicPartnersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for distributors/strategic partners.",
        "label": "Distributors/Strategic Partners [Member]",
        "terseLabel": "Distributors/Strategic Partners"
       }
      }
     },
     "localname": "DistributorsAndStrategicPartnersMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation permanent income tax rate percent.",
        "label": "Effective Income Tax Rate Reconciliation Permanent Income Tax Rate percent",
        "terseLabel": "Permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentIncomeTaxRatePercent",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctso_EmployeeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Employee One.",
        "label": "Employee One [Member]",
        "terseLabel": "Employee one"
       }
      }
     },
     "localname": "EmployeeOneMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_EmployeeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Employee Two.",
        "label": "Employee Two [Member]",
        "terseLabel": "Employee two"
       }
      }
     },
     "localname": "EmployeeTwoMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_EmploymentAgreementsAutomaticRenewalPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Automatic renewal period for employment agreements.",
        "label": "Employment Agreements, Automatic Renewal Period",
        "terseLabel": "Automatic renewal period for employment agreements"
       }
      }
     },
     "localname": "EmploymentAgreementsAutomaticRenewalPeriod",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ctso_EmploymentAgreementsAutomaticRenewedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Automatic renewed period for employment agreements, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Employment Agreements, Automatic Renewed Period",
        "terseLabel": "Additional automatic renewed period for employment agreements"
       }
      }
     },
     "localname": "EmploymentAgreementsAutomaticRenewedPeriod",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ctso_ExecutiveEmploymentAgreementsInitialTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the initial term of executive employment agreements.",
        "label": "Executive Employment Agreements , Initial Term",
        "terseLabel": "Initial term (in years)"
       }
      }
     },
     "localname": "ExecutiveEmploymentAgreementsInitialTerm",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ctso_ExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents exercise price range one.",
        "label": "Exercise Price Range One [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeOneMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_ExercisePriceRangingFrom2.98To3.91Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to exercise price ranging from 1.11 to 3.91.",
        "label": "Exercise Price Ranging From 1.11 To 3.91 [Member]",
        "terseLabel": "Exercise price ranging from 1.11 to 3.91"
       }
      }
     },
     "localname": "ExercisePriceRangingFrom2.98To3.91Member",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityFairValueOfStockOptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_ExercisePriceRangingFrom4.46To11.39Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Exercise Price Ranging From 4.46 to 11.39.",
        "label": "Exercise Price Ranging From 4.46 To 11.39 [Member]",
        "terseLabel": "Exercise price ranging from 4.46 to 11.39"
       }
      }
     },
     "localname": "ExercisePriceRangingFrom4.46To11.39Member",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityFairValueOfStockOptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_ExercisePriceRangingFrom5.00To10.58Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to exercise price ranging from 5.00 to 10.58.",
        "label": "Exercise Price Ranging from 5.00 to 10.58 [Member]",
        "terseLabel": "Exercise price ranging from 5.00 to 10.58"
       }
      }
     },
     "localname": "ExercisePriceRangingFrom5.00To10.58Member",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityFairValueOfStockOptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_February282020PerformanceBasedAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to February 28 2020 performance based award.",
        "label": "February 28 2020 Performance Based Award [Member]",
        "terseLabel": "February 28 2020 performance based award"
       }
      }
     },
     "localname": "February282020PerformanceBasedAwardMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_FiniteLivedIntangibleAssetsPatentApplicationsPendingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Patent applications pending",
        "label": "Patent applications pending [Member]",
        "terseLabel": "Patent applications pending"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsPatentApplicationsPendingMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_FiniteLivedIntangibleAssetsPatentsIssuedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Patents issued.",
        "label": "Patents issued [Member]",
        "terseLabel": "Patents issued"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsPatentsIssuedMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_FirstTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for first tranche Member.",
        "label": "First Tranche [Member]",
        "terseLabel": "First Tranche"
       }
      }
     },
     "localname": "FirstTrancheMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_ForeignCurrencyTransactionGainLossExcludingTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Excluding Tax",
        "terseLabel": "Foreign currency transaction gain (loss)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossExcludingTax",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests": {
     "auth_ref": [],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxess": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interests",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesConsolidatedLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_InsuranceSettlementReceivableForLossOnInventoryRecordedAsReductionToCostOfGoodsSold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of insurance settlement receivable for loss on inventory recorded as a reduction to cost of goods sold.",
        "label": "Insurance Settlement Receivable For Loss On Inventory Recorded As A Reduction To Cost Of Goods Sold",
        "terseLabel": "Insurance settlement receivable for loss on inventory recorded as a reduction to cost of goods sold"
       }
      }
     },
     "localname": "InsuranceSettlementReceivableForLossOnInventoryRecordedAsReductionToCostOfGoodsSold",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_JefferiesLlcAndB.RileyFbrIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Jefferies LLC and B. Riley FBR, Inc.",
        "label": "Jefferies LLC and B. Riley FBR, Inc",
        "terseLabel": "Jefferies LLC and B. Riley FBR, Inc"
       }
      }
     },
     "localname": "JefferiesLlcAndB.RileyFbrIncMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_July222019PerformanceBasedAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to July 22, 2019 Performance-Based Award.",
        "label": "July 22, 2019 Performance-Based Award [Member]",
        "terseLabel": "July 22, 2019 performance-based award"
       }
      }
     },
     "localname": "July222019PerformanceBasedAwardMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of Lessee's right-of-use-assets and lease liability under operating lease.",
        "label": "Lessee, Operating Lease, Balance Sheet Disclosure [Table Text Block]",
        "terseLabel": "Schedule of right-of- use asset and related lease liability"
       }
      }
     },
     "localname": "LesseeOperatingLeaseBalanceSheetDisclosureTableTextBlock",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ctso_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due fifth and after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Five And After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement [Member]",
        "label": "License Agreement [Member]"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_LicensePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The duration of license period.",
        "label": "License Period",
        "terseLabel": "Term of license agreement"
       }
      }
     },
     "localname": "LicensePeriod",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ctso_LongTermDebtAndFinalFee": {
     "auth_ref": [],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtPrincipalPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt and final fee.",
        "label": "Long term Debt And Final Fee",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtAndFinalFee",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtPrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_MiscellaneousIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of miscellaneous income.",
        "label": "Miscellaneous Income",
        "terseLabel": "Miscellaneous expense"
       }
      }
     },
     "localname": "MiscellaneousIncome",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_MonthlyOperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of monthly operating expenses.",
        "label": "Monthly Operating Expenses",
        "terseLabel": "Monthly operating expenses"
       }
      }
     },
     "localname": "MonthlyOperatingExpenses",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_NatureOfBusinessPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for Nature of Business Policy.",
        "label": "Nature Of Business Policy [Policy Text Block]",
        "terseLabel": "Nature of Business"
       }
      }
     },
     "localname": "NatureOfBusinessPolicyPolicyTextBlock",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ctso_NewTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents New Term Loan member.",
        "label": "New Term Loan [Member]",
        "terseLabel": "New Term Loan"
       }
      }
     },
     "localname": "NewTermLoanMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_NonRefundableClosingFeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for non refundable closing fee.",
        "label": "Non refundable Closing Fee [Member]",
        "verboseLabel": "Non refundable Closing Fee"
       }
      }
     },
     "localname": "NonRefundableClosingFeeMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of countries where the entity's flagship product is marketed and distributed.",
        "label": "Number of Countries Where Flagship Product is Marketed and Distributed",
        "terseLabel": "Number of countries where the entity's flagship product is marketed and distributed"
       }
      }
     },
     "localname": "NumberOfCountriesWhereFlagshipProductIsMarketedAndDistributed",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ctso_NumberOfDaysForStockPriceThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days for stock price threshold set in success fee letter.",
        "label": "Number of Days for Stock Price Threshold",
        "terseLabel": "Number of days for stock price threshold set in success fee letter"
       }
      }
     },
     "localname": "NumberOfDaysForStockPriceThreshold",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ctso_NumberOfLongTermIncentivePlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of long-term incentive plans.",
        "label": "Number of Long Term Incentive Plans",
        "terseLabel": "Number of long-term incentive plans"
       }
      }
     },
     "localname": "NumberOfLongTermIncentivePlans",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ctso_NumberOfPatentsUnitedStates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of patents issued to the entity in the United States.",
        "label": "Number of Patents, United States",
        "terseLabel": "Number of patents"
       }
      }
     },
     "localname": "NumberOfPatentsUnitedStates",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ctso_NumberOfPrimaryRevenueStreams": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of primary revenue streams.",
        "label": "Number of Primary Revenue Streams",
        "terseLabel": "Number of primary revenue streams"
       }
      }
     },
     "localname": "NumberOfPrimaryRevenueStreams",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ctso_NumberOfTimesLeaseRenewalAvailable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of times lease renewal options available.",
        "label": "Number of Times Lease Renewal Available",
        "terseLabel": "Number of times lease renewal options available"
       }
      }
     },
     "localname": "NumberOfTimesLeaseRenewalAvailable",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ctso_OneDistributorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The member stands for one distributor/strategic partner.",
        "label": "One Distributor/strategic partner [Member]",
        "terseLabel": "One Distributor/strategic partner"
       }
      }
     },
     "localname": "OneDistributorMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_OperatingLeaseBaseRentForRemainingSpace": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease base rent for remaining space.",
        "label": "Operating Lease Base Rent for Remaining Space",
        "terseLabel": "Operating lease base rent for remaining space"
       }
      }
     },
     "localname": "OperatingLeaseBaseRentForRemainingSpace",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_OperatingLeaseEarlyTermMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for early term of operating lease.",
        "label": "Early term [Member]",
        "terseLabel": "Early term"
       }
      }
     },
     "localname": "OperatingLeaseEarlyTermMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_OperatingLeaseFirstYearOfRemainingLeaseTermMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for first year of remaining operating lease term.",
        "label": "First year of remaining lease term [Member]",
        "terseLabel": "Early term"
       }
      }
     },
     "localname": "OperatingLeaseFirstYearOfRemainingLeaseTermMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_OperatingLeaseInitialEarlyTermMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for initial early term of operating lease.",
        "label": "Initial early term [Member]",
        "terseLabel": "Initial early term"
       }
      }
     },
     "localname": "OperatingLeaseInitialEarlyTermMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_OperatingLeasesAnnualRentExpenseIncrementRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of annual increment in operating lease rent expense.",
        "label": "Operating Leases, Annual Rent Expense Increment Rate",
        "terseLabel": "Annual rent expense increment rate"
       }
      }
     },
     "localname": "OperatingLeasesAnnualRentExpenseIncrementRate",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctso_OperatingLeasesBuildingImprovementAllowanceReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of allowance for building improvement receivable from landlord.",
        "label": "Operating Leases, Building Improvement Allowance Receivable",
        "terseLabel": "Allowance for building improvement"
       }
      }
     },
     "localname": "OperatingLeasesBuildingImprovementAllowanceReceivable",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_OperatingLeasesRentAbatementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent abatement term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Leases, Rent Abatement Term",
        "terseLabel": "Rent abatement term"
       }
      }
     },
     "localname": "OperatingLeasesRentAbatementTerm",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ctso_OtherAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line item represents the other assets.",
        "label": "Other Assets [Line Items]",
        "terseLabel": "OTHER ASSETS:"
       }
      }
     },
     "localname": "OtherAssetsLineItems",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ctso_OtherAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table represents the other assets.",
        "label": "Other Assets [Table]"
       }
      }
     },
     "localname": "OtherAssetsTable",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ctso_OtherSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the information relating to the other sales",
        "label": "Other sales [Member]",
        "terseLabel": "Other sales"
       }
      }
     },
     "localname": "OtherSalesMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_ParticipantsContributionOver3AndMaximum5Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to participants contribution over 3% and maximum 5%.",
        "label": "Participants Contribution Over 3% and Maximum 5% [Member]",
        "terseLabel": "Participants contribution over 3% and maximum 5%"
       }
      }
     },
     "localname": "ParticipantsContributionOver3AndMaximum5Member",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRetirementPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_ParticipantsContributionUpto3PercentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to participants contribution up to 3 percent.",
        "label": "Participants Contribution Up to 3 Percent [Member]",
        "terseLabel": "Participants contribution up to 3 percent"
       }
      }
     },
     "localname": "ParticipantsContributionUpto3PercentMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRetirementPlanDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument": {
     "auth_ref": [],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow of non-refundable final fees on termination or maturity for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Payment of Non-Refundable Final Fee Upon Termination Or Maturity of Debt Instrument",
        "negatedLabel": "Final fee on long-term debt"
       }
      }
     },
     "localname": "PaymentOfNonRefundableFinalFeeUponTerminationOrMaturityOfDebtInstrument",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_PaymentsForEquityContributionsNetOfFeesIncurred": {
     "auth_ref": [],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for equity contributions - net of fees incurred",
        "label": "Payments for Equity contributions - Net of Fees Incurred",
        "negatedLabel": "Equity contributions - net of fees incurred"
       }
      }
     },
     "localname": "PaymentsForEquityContributionsNetOfFeesIncurred",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_PayrollTaxAuditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to payroll tax audit.",
        "label": "Payroll Tax Audit [Member]",
        "terseLabel": "Payroll Tax Audit"
       }
      }
     },
     "localname": "PayrollTaxAuditMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_PercentageOfClosingPriceOnCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of closing price on common stock.",
        "label": "Percentage of Closing Price on Common Stock",
        "terseLabel": "Percentage of closing price on common stock"
       }
      }
     },
     "localname": "PercentageOfClosingPriceOnCommonStock",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctso_PercentageOfSuccessFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective success fee rate during the reporting period.",
        "label": "Percentage Of Success Fee",
        "terseLabel": "Percentage of success fee"
       }
      }
     },
     "localname": "PercentageOfSuccessFee",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctso_PercentageOfTotalBuildingSpaceOccupied": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of total building space occupied.",
        "label": "Percentage Of Total Building Space Occupied",
        "terseLabel": "Percentage of total building space occupied"
       }
      }
     },
     "localname": "PercentageOfTotalBuildingSpaceOccupied",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represents the Principal Business Activity and Summary of Significant Accounting Policies.",
        "label": "Principal Business Activity and Summary of Significant Accounting Policies [Line Items]",
        "terseLabel": "PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ctso_PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about principal business activity and summary of significant accounting policies.",
        "label": "Principal Business Activity and Summary of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "PrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ctso_ProceedsFromSaleOfNetOperatingLossCarryforwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The proceeds received from the sale of previously unused net operating loss carryforwards, allowed due to participation in the Technology Business Tax Certificate Transfer Program.",
        "label": "Proceeds From Sale Of Net Operating Loss Carryforwards",
        "terseLabel": "Proceeds from the sale of prior unused net operating loss carryovers"
       }
      }
     },
     "localname": "ProceedsFromSaleOfNetOperatingLossCarryforwards",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_RoyaltyPaymentRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rate of royalty payment.",
        "label": "Royalty Payment Rate",
        "terseLabel": "Future royalty payment percentage on gross revenue"
       }
      }
     },
     "localname": "RoyaltyPaymentRate",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctso_RoyaltyRateLowerLimit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rate of royalty rate lower limit.",
        "label": "Royalty Rate Lower Limit",
        "terseLabel": "Royalty rate, lower limit"
       }
      }
     },
     "localname": "RoyaltyRateLowerLimit",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctso_RoyaltyRateUpperLimit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rate of royalty rate upper limit",
        "label": "Royalty Rate Upper Limit",
        "terseLabel": "Royalty rate, upper limit"
       }
      }
     },
     "localname": "RoyaltyRateUpperLimit",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctso_SaleRevenuesGoodsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Revenues Goods Net",
        "label": "Sale Revenues Goods Net [Abstract]",
        "verboseLabel": "Product sales:"
       }
      }
     },
     "localname": "SaleRevenuesGoodsNetAbstract",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ctso_SalesPayrollAndIncomeTaxesPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "ctso_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales, payroll and income taxes payable. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Sales Payroll and Income Taxes Payable Current",
        "terseLabel": "Sales, payroll and income taxes payable"
       }
      }
     },
     "localname": "SalesPayrollAndIncomeTaxesPayableCurrent",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of accrued expenses and other current liabilities.",
        "label": "Schedule of Accrued Expenses and Other Current Liabilities Table [Text Block]",
        "terseLabel": "Schedule of accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ctso_ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents and restricted cash and cash equivalents.",
        "label": "Schedule Of Cash And Cash Equivalents And Restricted Cash And Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of cash and cash equivalents and restricted cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsAndRestrictedCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ctso_SecondFortyFiveThousandRestrictedAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent information pertaining to second Forty five thousand restricted award granted.",
        "label": "Second 45,000 Restricted Stock [Member]",
        "terseLabel": "Second 45,000 restricted stock"
       }
      }
     },
     "localname": "SecondFortyFiveThousandRestrictedAwardMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent information pertaining to second Forty six thousand and seven hundred fifty restricted award granted.",
        "label": "Second 46,750 Restricted Stock [Member]",
        "terseLabel": "Second 46,750 restricted stock"
       }
      }
     },
     "localname": "SecondFortySixThousandAndSevenHundredFiftyRestrictedAwardMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_SecondTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for second tranche Member.",
        "label": "Second Tranche [Member]",
        "terseLabel": "Second Tranche"
       }
      }
     },
     "localname": "SecondTrancheMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_SeniorManagerOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Senior manager one.",
        "label": "Senior Manager One [Member]",
        "terseLabel": "Senior manager one"
       }
      }
     },
     "localname": "SeniorManagerOneMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_SeniorManagerTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Senior Manager Two.",
        "label": "Senior Manager Two [Member]",
        "terseLabel": "Senior manager two"
       }
      }
     },
     "localname": "SeniorManagerTwoMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards cancelled during the period, in PnYnMnDTnHnMnS format, for example, P1Y5M13D represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Cancelled in Period Weighted Average Remaining Contractual Term",
        "terseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards exercised during the period, in PnYnMnDTnHnMnS format, for example, P1Y5M13D represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Exercised in Period Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based Compensation Arrangement by Share based Payment Award Options Outstanding Expired In Period Weighted Average Remaining Contractual Term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Remaining Contractual Term",
        "terseLabel": "Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the grant date fair value of unvested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Grant Date Fair Value",
        "terseLabel": "Grant date fair value of unvested options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based Compensation Arrangement by Share based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Granted In Period Weighted Average Remaining Contractual Term",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingGrantedInPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ctso_ShareBasedCompensationAwardTrancheFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fifth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Fourth Anniversary Of the Date of The Grant [Member]",
        "terseLabel": "Fourth anniversary of the date of the grant"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheFiveMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_ShareBasedCompensationAwardTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fourth portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Third Anniversary Of the Date of The Grant [Member]",
        "terseLabel": "Third anniversary of the date of the grant"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheFourMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Milestone activity met by the company.",
        "label": "Share based Compensation Option Milestones met By the Company Percentage",
        "terseLabel": "Percentage of milestone activity met by the company"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionMilestonesMetByTheCompanyPercentage",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctso_ShippingAndHandlingCostsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.",
        "label": "Shipping And Handling Costs Policy [Policy Text Block]",
        "terseLabel": "Shipping and Handling Costs"
       }
      }
     },
     "localname": "ShippingAndHandlingCostsPolicyPolicyTextBlock",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ctso_StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of cashless stock options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Cashless Exercise Of Stock Options",
        "verboseLabel": "Cashless exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCashlessExerciseOfStockOptions",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ctso_StockIssuedDuringPeriodSharesStockCashOptionsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the exercise of cash options.",
        "label": "Stock Issued During Period Shares Stock Cash Options Exercised",
        "verboseLabel": "Proceeds from exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockCashOptionsExercised",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ctso_StockIssuedDuringPeriodValueStockCashOptionsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value stock issued during the period as a result of the exercise of cash options.",
        "label": "Stock Issued During Period Value Stock Cash Options Exercised",
        "verboseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockCashOptionsExercised",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctso_StockMarketListingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for stock market listing.",
        "label": "Stock Market Listing Policy [Policy Text Block]",
        "terseLabel": "Stock Market Listing"
       }
      }
     },
     "localname": "StockMarketListingPolicyPolicyTextBlock",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ctso_StockOptionPlanOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Option Plan One [Member]",
        "label": "Stock Option Plan One [Member]",
        "terseLabel": "Stock option plan one"
       }
      }
     },
     "localname": "StockOptionPlanOneMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_StockOptionsAndWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to stock options and warrants.",
        "label": "Stock Options and Warrants [Member]",
        "terseLabel": "Stock options and warrants"
       }
      }
     },
     "localname": "StockOptionsAndWarrantsMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_StockholdersEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Stockholders Equity [Line Items]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityLineItems",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityFairValueOfStockOptionDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ctso_StockholdersEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes stockholders' equity.",
        "label": "Stockholders Equity [Table]"
       }
      }
     },
     "localname": "StockholdersEquityTable",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityFairValueOfStockOptionDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ctso_TermBLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for term b loan.",
        "label": "Term B Loan [Member]",
        "terseLabel": "Term B Loan"
       }
      }
     },
     "localname": "TermBLoanMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_TermCLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for term c loan.",
        "label": "Term C Loan [Member]",
        "terseLabel": "Term C Loan"
       }
      }
     },
     "localname": "TermCLoanMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for term a loan.",
        "label": "Term A Loan [Member]",
        "terseLabel": "Term A Loan"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_TermOfCustomerContracts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the term of customer contracts.",
        "label": "Term Of Customer Contracts",
        "terseLabel": "Term of customer contracts"
       }
      }
     },
     "localname": "TermOfCustomerContracts",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ctso_ThirdTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for third tranche Member.",
        "label": "Third Tranche [Member]",
        "terseLabel": "Third Tranche"
       }
      }
     },
     "localname": "ThirdTrancheMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_ThresholdUsedForCalculatingConcentrationOfRisk": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Threshold Used For Calculating Concentration Of Risk",
        "terseLabel": "Concentration risk"
       }
      }
     },
     "localname": "ThresholdUsedForCalculatingConcentrationOfRisk",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctso_TwentiethAmendmentToLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for twentieth amendment  to lease.",
        "label": "Twentieth Amendment To lease [Member]",
        "verboseLabel": "Twentieth Amendment To lease"
       }
      }
     },
     "localname": "TwentiethAmendmentToLeaseMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_TwoThousandAndEighteenSuccessFeeLetterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2018 success fee letter.",
        "label": "2018 Success Fee Letter [Member]",
        "terseLabel": "2018 Success Fee Letter"
       }
      }
     },
     "localname": "TwoThousandAndEighteenSuccessFeeLetterMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_TwoThousandFourteenStockOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2014 Long Term Incentive Plan.",
        "label": "Two Thousand Fourteen Stock Option Plan [Member]",
        "verboseLabel": "2014 Stock Option Plan"
       }
      }
     },
     "localname": "TwoThousandFourteenStockOptionPlanMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_UnitedStatesGovernmentAgenciesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for united states government agencies.",
        "label": "United States Government Agencies [Member]",
        "terseLabel": "United States Government Agencies"
       }
      }
     },
     "localname": "UnitedStatesGovernmentAgenciesMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_WesternAllianceBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for western alliance bank.",
        "label": "Western Alliance Bank [Member]",
        "terseLabel": "Western Alliance Bank"
       }
      }
     },
     "localname": "WesternAllianceBankMember",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctso_WroteOffPatentsCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of patents cost.",
        "label": "Wrote Off Patents Costs",
        "terseLabel": "wrote-off patent costs"
       }
      }
     },
     "localname": "WroteOffPatentsCosts",
     "nsuri": "http://www.cytosorbents.com/20221231",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r543",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r543",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r543",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r543",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r543",
      "r544",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leader of board of directors.",
        "label": "Board of Directors Chairman [Member]",
        "verboseLabel": "Board of directors"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r202",
      "r421",
      "r422",
      "r423",
      "r424",
      "r451",
      "r495",
      "r500",
      "r586",
      "r589",
      "r590",
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by consolidated entity or group of entities.",
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r202",
      "r421",
      "r422",
      "r423",
      "r424",
      "r451",
      "r495",
      "r500",
      "r586",
      "r589",
      "r590",
      "r655",
      "r656",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity or group of entities consolidated into reporting entity.",
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r257",
      "r527",
      "r594",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ManagementMember": {
     "auth_ref": [
      "r577",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person or persons designated as part of management.",
        "label": "Executive Management"
       }
      }
     },
     "localname": "ManagementMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r282",
      "r352",
      "r453",
      "r469",
      "r496",
      "r497",
      "r524",
      "r532",
      "r539",
      "r591",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.cytosorbents.com/role/DisclosureRetirementPlanDetails",
      "http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityFairValueOfStockOptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r282",
      "r352",
      "r453",
      "r469",
      "r496",
      "r497",
      "r524",
      "r532",
      "r539",
      "r591",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.cytosorbents.com/role/DisclosureRetirementPlanDetails",
      "http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityFairValueOfStockOptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r257",
      "r527",
      "r594",
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OfficerMember": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of officer.",
        "label": "Other Employees"
       }
      }
     },
     "localname": "OfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r254",
      "r458",
      "r525",
      "r537",
      "r583",
      "r584",
      "r594",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r254",
      "r458",
      "r525",
      "r537",
      "r583",
      "r584",
      "r594",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r282",
      "r350",
      "r352",
      "r382",
      "r383",
      "r384",
      "r452",
      "r453",
      "r469",
      "r496",
      "r497",
      "r524",
      "r532",
      "r539",
      "r580",
      "r591",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.cytosorbents.com/role/DisclosureRetirementPlanDetails",
      "http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityFairValueOfStockOptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r279",
      "r280",
      "r281",
      "r282",
      "r350",
      "r352",
      "r382",
      "r383",
      "r384",
      "r452",
      "r453",
      "r469",
      "r496",
      "r497",
      "r524",
      "r532",
      "r539",
      "r580",
      "r591",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.cytosorbents.com/role/DisclosureRetirementPlanDetails",
      "http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityFairValueOfStockOptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r353",
      "r574",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.",
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r216",
      "r353",
      "r550",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails",
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureRetirementPlanDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": {
     "auth_ref": [
      "r570",
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.",
        "label": "Condensed Income Statement",
        "verboseLabel": "Summarized quarterly information"
       }
      }
     },
     "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r255",
      "r256",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r499",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r526",
      "r538",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails",
      "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r255",
      "r256",
      "r479",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r499",
      "r501",
      "r526",
      "r538",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails",
      "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r216",
      "r353",
      "r550",
      "r551",
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails",
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureRetirementPlanDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r577",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "verboseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r11",
      "r536"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r259",
      "r260"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "verboseLabel": "Grants and accounts receivable, net of allowance for doubtful accounts of $76,041 and $60,539 at December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "ctso_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued accounts payable"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "ctso_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r14",
      "r512"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "ctso_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "terseLabel": "Accrued royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r72",
      "r169"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r177",
      "r465",
      "r474",
      "r475"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r21",
      "r24",
      "r120",
      "r450",
      "r470",
      "r471",
      "r560",
      "r561",
      "r562",
      "r571",
      "r572",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r6",
      "r536"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r571",
      "r572",
      "r573",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "verboseLabel": "Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r42",
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureOtherAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r108",
      "r109",
      "r355"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock-based compensation - employees, consultants and directors"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r81",
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedLabel": "Legal/audit fees related to ATM offering"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Costs, Policy [Policy Text Block]",
        "terseLabel": "Advertising Expenses"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r394"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expenses"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r386"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Allocated share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r178",
      "r263",
      "r267"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Grants and accounts receivable, net of allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r33",
      "r42",
      "r129",
      "r307"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "verboseLabel": "Amortization of right-of-use asset"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area of Land.",
        "terseLabel": "Area of Land"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r135",
      "r147",
      "r172",
      "r198",
      "r245",
      "r248",
      "r252",
      "r265",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r421",
      "r423",
      "r429",
      "r536",
      "r587",
      "r588",
      "r641"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r164",
      "r181",
      "r198",
      "r265",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r421",
      "r423",
      "r429",
      "r536",
      "r587",
      "r588",
      "r641"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r46",
      "r47",
      "r48"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Capital expenditures included in accounts payable"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CargoAndFreightMember": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product transported between locations.",
        "label": "Cargo and Freight [Member]",
        "terseLabel": "Cargo and Freight"
       }
      }
     },
     "localname": "CargoAndFreightMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r477",
      "r478",
      "r536",
      "r552"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "verboseLabel": "Cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureBasisOfPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r44",
      "r167",
      "r510"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r45",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r39",
      "r44",
      "r49"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r39",
      "r128"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "verboseLabel": "Supplemental disclosure of non-cash financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r198",
      "r220",
      "r221",
      "r224",
      "r226",
      "r235",
      "r236",
      "r265",
      "r283",
      "r285",
      "r286",
      "r287",
      "r290",
      "r291",
      "r311",
      "r312",
      "r314",
      "r318",
      "r324",
      "r429",
      "r498",
      "r549",
      "r566",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityFairValueOfStockOptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Number of shares to be purchased"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r17",
      "r139",
      "r153"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies.",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r276",
      "r277",
      "r482",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r571",
      "r572",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common Stock, Par Value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common Stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common Stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common Stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r536"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common Stock, Par Value $0.001, 100,000,000 shares authorized; 43,635,715 and 43,478,487 shares issued and outstanding at December 31, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "RETIREMENT PLAN"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRetirementPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RETIREMENT PLAN"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r25",
      "r183",
      "r185",
      "r190",
      "r461",
      "r466"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "verboseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Equipment and computers [Member]",
        "verboseLabel": "Equipment and computers"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r56",
      "r57",
      "r126",
      "r127",
      "r257",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r56",
      "r57",
      "r126",
      "r127",
      "r257",
      "r476",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r56",
      "r57",
      "r126",
      "r127",
      "r257",
      "r481",
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r145",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r56",
      "r57",
      "r126",
      "r127",
      "r257",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Asset and Liability [Table Text Block]",
        "terseLabel": "Schedule of receivables and contract liabilities from contracts with customers"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r326",
      "r328",
      "r347"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, Net, Current",
        "verboseLabel": "Contract receivables, which are included in grants and accounts receivable"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureRevenueReceivablesAndContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r326",
      "r327",
      "r347"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "ctso_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Contract liabilities, which are included in expenses and other current liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.cytosorbents.com/role/DisclosureRevenueContractWithCustomerAssetAndLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r29",
      "r458"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditCardMember": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Card issued to user to facilitate payment for purchase of product and service, paid directly to merchant by card issuer, and later paid by cardholder to card issuer.",
        "label": "Credit Card [Member]",
        "terseLabel": "Credit Card"
       }
      }
     },
     "localname": "CreditCardMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LONG-TERM DEBT"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r136",
      "r137",
      "r146",
      "r202",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r440",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails",
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Rate of interest added to reference rate as per debt agreement"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r3",
      "r137",
      "r146",
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "verboseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentCollateralAmount": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets pledged to secure a debt instrument.",
        "label": "Debt Instrument, Collateral Amount",
        "terseLabel": "Cash collateral"
       }
      }
     },
     "localname": "DebtInstrumentCollateralAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r130",
      "r132",
      "r292",
      "r440",
      "r520",
      "r521"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument , Face amount",
        "verboseLabel": "Security amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails",
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "LONG-TERM DEBT"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r16",
      "r202",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r440",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails",
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "auth_ref": [
      "r16",
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments including both interest and principal payments.",
        "label": "Debt Instrument, Periodic Payment",
        "terseLabel": "Equal monthly payments of principal with accrued and unpaid interest payable"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r16",
      "r82",
      "r83",
      "r84",
      "r85",
      "r129",
      "r130",
      "r132",
      "r144",
      "r202",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r440",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r131",
      "r592"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r554"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "verboseLabel": "Contract liabilities, which are included in accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRevenueReceivablesAndContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r626"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r626"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r117",
      "r627"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry forward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOtherTaxCarryforwards": {
     "auth_ref": [
      "r117",
      "r627"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax carryforwards, classified as other.",
        "label": "Deferred Tax Assets, Other Tax Carryforwards",
        "terseLabel": "174(b) research and development"
       }
      }
     },
     "localname": "DeferredTaxAssetsOtherTaxCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r115",
      "r117",
      "r627"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development credit carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": {
     "auth_ref": [
      "r117",
      "r627"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r117",
      "r627"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Accruals and others"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liability:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r117",
      "r627"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesPrincipalComponentsOfCompanySDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Matching contributions, Amount"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRetirementPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "terseLabel": "RETIREMENT PLAN"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRetirementPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Compensation for participant contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRetirementPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage employer matches of the employee's percentage contribution matched.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Matching contribution, Percent"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRetirementPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Compensation subject to IRC limitations"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRetirementPlanDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRetirementPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r42",
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r42",
      "r70"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "REVENUE"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r346",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "verboseLabel": "Schedule of disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRevenueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Federal [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r191",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r217",
      "r220",
      "r224",
      "r225",
      "r226",
      "r230",
      "r427",
      "r428",
      "r462",
      "r467",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnauditedDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r191",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r220",
      "r224",
      "r225",
      "r226",
      "r230",
      "r427",
      "r428",
      "r462",
      "r467",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per common share"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnauditedDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r52",
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r634"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "Effect of exchange rates on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r399"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r200",
      "r399",
      "r415"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails",
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r624",
      "r629"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r415",
      "r624"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Rate change and true-up"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r624",
      "r629"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r624",
      "r629"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Sale of state R&amp;D credit and NOL"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r624",
      "r629"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r624",
      "r629"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "R&amp;D credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Amortized period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r622"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options",
        "terseLabel": "Total unrecognized compensation cost related to stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "verboseLabel": "Employee stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r81",
      "r162",
      "r187",
      "r188",
      "r189",
      "r203",
      "r204",
      "r205",
      "r207",
      "r213",
      "r215",
      "r234",
      "r266",
      "r325",
      "r388",
      "r389",
      "r390",
      "r410",
      "r411",
      "r426",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r450",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r124",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r170",
      "r274"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less accumulated amortization of patents issued"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureOtherAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureOtherAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureOtherAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureOtherAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureOtherAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r275",
      "r459",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r66",
      "r460"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r64",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r66",
      "r459"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Patents, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority",
        "terseLabel": "Foreign Tax"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r430",
      "r431",
      "r432",
      "r433"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Gain (loss) on foreign currency transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r43",
      "r632",
      "r633"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Foreign currency transaction (gains) losses"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and fixtures [Member]",
        "verboseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant income [Member]",
        "terseLabel": "Grant income",
        "verboseLabel": "Government grants"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r354",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [
      "r354",
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r28",
      "r198",
      "r245",
      "r247",
      "r251",
      "r253",
      "r265",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r429",
      "r518",
      "r587"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit",
        "verboseLabel": "Gross margin"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnauditedDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r564",
      "r579"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Impairment of patents"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r69",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment or Disposal of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r199",
      "r414"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxess": {
       "order": 1.0,
       "parentTag": "ctso_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "verboseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesConsolidatedLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r26",
      "r133",
      "r140",
      "r155",
      "r245",
      "r247",
      "r251",
      "r253",
      "r463",
      "r518"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before benefit from income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r199",
      "r414"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxess": {
       "order": 2.0,
       "parentTag": "ctso_IncomeLossFromContinuingOperationsBeforeIncomeTaxesNoncontrollingInterests",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "verboseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesConsolidatedLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r200",
      "r400",
      "r402",
      "r408",
      "r412",
      "r416",
      "r418",
      "r419",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationInterestAccrued": {
     "auth_ref": [
      "r625"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated interest accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination, Interest Accrued",
        "terseLabel": "Accrued tax liability"
       }
      }
     },
     "localname": "IncomeTaxExaminationInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r201",
      "r214",
      "r215",
      "r244",
      "r398",
      "r413",
      "r417",
      "r468"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesBenefitFromIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Benefit from income taxes",
        "negatedTotalLabel": "Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesBenefitFromIncomeTaxesDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r186",
      "r396",
      "r397",
      "r402",
      "r403",
      "r407",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Grants and accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r65",
      "r455",
      "r456",
      "r457",
      "r459",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "verboseLabel": "Interest (expense), net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r193",
      "r195",
      "r196"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid during the year for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "ctso_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryAdjustments": {
     "auth_ref": [
      "r63",
      "r558"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods.",
        "label": "Inventory Adjustments",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r555"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Inventory - finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r180",
      "r511",
      "r536"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r166",
      "r179",
      "r232",
      "r269",
      "r270",
      "r271",
      "r454",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r557"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Inventory - raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r556"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Inventory - work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "verboseLabel": "Non-cash compensation"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Arrangement, Type [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements [Member]",
        "verboseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASES"
       }
      }
     },
     "localname": "LesseeDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "LEASES:"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee, Operating Lease, Discount Rate",
        "verboseLabel": "Incremental borrowing rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturities of the lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r448"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Present value discount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of credit [Member]",
        "terseLabel": "Letter of credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails",
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r13",
      "r198",
      "r265",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r422",
      "r423",
      "r424",
      "r429",
      "r517",
      "r587",
      "r641",
      "r642"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r138",
      "r151",
      "r536",
      "r568",
      "r578",
      "r631"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r165",
      "r198",
      "r265",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r422",
      "r423",
      "r424",
      "r429",
      "r536",
      "r587",
      "r641",
      "r642"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r12",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "terseLabel": "Current borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r12",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r3",
      "r137",
      "r148",
      "r299",
      "r310",
      "r520",
      "r521"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-term Debt",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r79",
      "r202",
      "r303"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtPrincipalPaymentsDetails": {
       "order": 2.0,
       "parentTag": "ctso_LongTermDebtAndFinalFee",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtPrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r79",
      "r202",
      "r303"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtPrincipalPaymentsDetails": {
       "order": 1.0,
       "parentTag": "ctso_LongTermDebtAndFinalFee",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtPrincipalPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r173"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "totalLabel": "Total",
        "verboseLabel": "Long-term debt net of current maturities"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtDetails",
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtPrincipalPaymentsDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "verboseLabel": "LONG-TERM DEBT"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r77",
      "r78",
      "r278",
      "r279",
      "r280",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r77",
      "r78",
      "r278",
      "r279",
      "r280",
      "r581",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r194"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r194"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r39",
      "r40",
      "r43"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r27",
      "r43",
      "r141",
      "r154",
      "r163",
      "r182",
      "r184",
      "r189",
      "r198",
      "r206",
      "r208",
      "r209",
      "r210",
      "r211",
      "r214",
      "r215",
      "r222",
      "r245",
      "r247",
      "r251",
      "r253",
      "r265",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r428",
      "r429",
      "r518",
      "r587"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r217",
      "r218",
      "r223",
      "r226",
      "r245",
      "r247",
      "r251",
      "r253",
      "r518"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders",
        "verboseLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnauditedDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Effect of Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r245",
      "r247",
      "r251",
      "r253",
      "r518"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "verboseLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnauditedDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r445",
      "r535"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Other costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r635"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Monthly payments of base rent and other costs"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total",
        "verboseLabel": "Operating lease lability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails",
      "http://www.cytosorbents.com/role/DisclosureLeasesMaturitiesOfLeaseLiabilitiesDetails",
      "http://www.cytosorbents.com/role/DisclosureLeasesRightOfUseAssetAndRelatedLeaseLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r442"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less current portion",
        "terseLabel": "Lease liability - current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesRightOfUseAssetAndRelatedLeaseLiabilityDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r442"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesRightOfUseAssetAndRelatedLeaseLiabilityDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r443",
      "r446"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease paid"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r441"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "netLabel": "Right-of-use asset",
        "terseLabel": "Right of use asset",
        "verboseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails",
      "http://www.cytosorbents.com/role/DisclosureLeasesRightOfUseAssetAndRelatedLeaseLiabilityDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r447",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry forwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.",
        "label": "Operating Loss Carryforwards, Limitations on Use",
        "terseLabel": "operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLimitationsOnUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r50",
      "r61",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "verboseLabel": "PRINCIPAL BUSINESS ACTIVITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER ASSETS"
       }
      }
     },
     "localname": "OtherAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.",
        "label": "Other Assets Disclosure [Text Block]",
        "verboseLabel": "OTHER ASSETS"
       }
      }
     },
     "localname": "OtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureOtherAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment",
        "verboseLabel": "Other comprehensive income (loss), foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "verboseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Expenses incurred"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Patent costs"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred Stock, Par Value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Number of preferred stock authorized",
        "verboseLabel": "Preferred Stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r4",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred Stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred Stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r4",
      "r536"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred Stock, Par Value $0.001, 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2022 and 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r559"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from long-term debt",
        "verboseLabel": "Amount drawn down"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Equity investment by an existing investor"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r35",
      "r107"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Total product sales [Member]",
        "terseLabel": "Total product sales",
        "verboseLabel": "Product sales"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRevenueAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r156",
      "r157"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Legal, financial and other consulting"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r75",
      "r483",
      "r484",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "PROPERTY AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r71",
      "r168"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "PROPERTY AND EQUIPMENT, NET:"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r73",
      "r152",
      "r464",
      "r536"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment - net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r73",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Depreciation/Amortization Period"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r192",
      "r268"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Provision for Doubtful Accounts",
        "terseLabel": "Bad debt expense (recovery)"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "QUARTERLY FINANCIAL RESULTS (UNAUDITED)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r55",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "QUARTERLY FINANCIAL RESULTS (UNAUDITED)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r563"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r111",
      "r158",
      "r649"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r44",
      "r49",
      "r134",
      "r149",
      "r167"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesCashAndCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r480",
      "r553",
      "r565"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r86",
      "r150",
      "r473",
      "r475",
      "r536"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r162",
      "r203",
      "r204",
      "r205",
      "r207",
      "r213",
      "r215",
      "r266",
      "r388",
      "r389",
      "r390",
      "r410",
      "r411",
      "r426",
      "r470",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUE"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r242",
      "r243",
      "r246",
      "r249",
      "r250",
      "r254",
      "r255",
      "r257",
      "r345",
      "r346",
      "r458"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Total revenue",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureQuarterlyFinancialResultsUnauditedDetails",
      "http://www.cytosorbents.com/role/DisclosureRevenueRevenueByCustomerTypeAndGeographicAreaDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r257",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Sales Revenue, Net [Member]",
        "terseLabel": "Sales Revenue, Net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r349",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r348",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUE"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureRevenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyAgreementsMember": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement, generally for a defined period of time, entitling the entity to use the rights and property of another party. Examples include, but not limited to, licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Agreements [Member]",
        "verboseLabel": "Royalty Agreements"
       }
      }
     },
     "localname": "RoyaltyAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r30"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty cost"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "verboseLabel": "Schedule of Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r16",
      "r82",
      "r83",
      "r84",
      "r85",
      "r129",
      "r130",
      "r132",
      "r144",
      "r520",
      "r522",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "verboseLabel": "Schedule of Long-term debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r51",
      "r54",
      "r220",
      "r221",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "verboseLabel": "Schedule of Principal payments of long-term debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "terseLabel": "Schedule of Company's non-vested options"
       }
      }
     },
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.",
        "label": "Schedule of Other Assets [Table Text Block]",
        "terseLabel": "Schedule of Other Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureOtherAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]",
        "verboseLabel": "Schedule of restricted stock unit"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]",
        "terseLabel": "Schedule of intrinsic value"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r91",
      "r100",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock options activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of fair value of each stock option estimated using the Black-Scholes pricing model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of the restricted stock unit activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDeposit": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.",
        "label": "Security Deposit",
        "terseLabel": "Security deposit",
        "verboseLabel": "Security deposits"
       }
      }
     },
     "localname": "SecurityDeposit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLeasesDetails",
      "http://www.cytosorbents.com/role/DisclosureOtherAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non-vested, December 31, 2022",
        "periodStartLabel": "Non-vested, January 1, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Non-vested, December 31, 2022",
        "periodStartLabel": "Non-vested, January 1, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "verboseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Grant Date Exercise Price Range"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityFairValueOfStockOptionDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected Dividends"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityFairValueOfStockOptionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Current Price of the Underlying Stock and its Expected Volatility Range"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityFairValueOfStockOptionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk Free Interest Rate Range"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityFairValueOfStockOptionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk Free Interest Rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityFairValueOfStockOptionDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures",
        "negatedLabel": "Restricted Stock Units, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted",
        "verboseLabel": "Restricted Stock Units, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r92",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Restricted Stock Units, Ending Balance",
        "periodStartLabel": "Restricted Stock Units, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Life (Years)",
        "verboseLabel": "Options Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted",
        "verboseLabel": "Number of option granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Grant date fair value of these unvested options",
        "verboseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, end of the year",
        "periodStartLabel": "Outstanding, beginning of the year",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, end of the year",
        "periodStartLabel": "Outstanding, beginning of the year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitActivityDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "On the date of the grant"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Second anniversary of the date of the grant"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "First anniversary of the date of the grant"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r360",
      "r379",
      "r380",
      "r381",
      "r382",
      "r385",
      "r391",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]",
        "terseLabel": "Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeEndOfPeriodAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Range of Exercise Price, Lower Range Limit"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options",
        "terseLabel": "Number Exercisable at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options",
        "terseLabel": "Number Outstanding at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Range of Exercise Price, Upper Range Limit"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r356",
      "r357",
      "r358",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Employee [Member]",
        "terseLabel": "Employees"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Average selling price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "periodEndLabel": "Restricted Stock Units, Intrinsic Value Ending Balance",
        "periodStartLabel": "Restricted Stock Units, Intrinsic Value Beginning Balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityRestrictedStockUnitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected Life of the Stock Option"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityFairValueOfStockOptionDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, end of the year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Non-vested, December 31, 2022",
        "periodStartLabel": "Non-vested, January 1, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Non-vested, December 31, 2022",
        "periodStartLabel": "Non-vested, January 1, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Outstanding, beginning of the year"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "negatedLabel": "Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityNonVestedOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Life (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityIntrinsicValueDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r569",
      "r623",
      "r628"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesBenefitFromIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations",
        "negatedLabel": "State Tax, including sale of New Jersey losses &amp; credits"
       }
      }
     },
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r174",
      "r175",
      "r176",
      "r198",
      "r220",
      "r221",
      "r224",
      "r226",
      "r235",
      "r236",
      "r265",
      "r283",
      "r285",
      "r286",
      "r287",
      "r290",
      "r291",
      "r311",
      "r312",
      "r314",
      "r318",
      "r324",
      "r429",
      "r498",
      "r549",
      "r566",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityFairValueOfStockOptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r19",
      "r81",
      "r162",
      "r187",
      "r188",
      "r189",
      "r203",
      "r204",
      "r205",
      "r207",
      "r213",
      "r215",
      "r234",
      "r266",
      "r325",
      "r388",
      "r389",
      "r390",
      "r410",
      "r411",
      "r426",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r450",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "verboseLabel": "LONG-TERM DEBT, NET"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r203",
      "r204",
      "r205",
      "r234",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "verboseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r46",
      "r47",
      "r48"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Settlement of accrued bonuses with restricted stock units"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Stock issued to vendor in lieu of cash payment (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r81",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Sale Of Common Stock",
        "terseLabel": "Issuance of common stock - offerings, net of fees incurred (in shares)",
        "verboseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r81",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Stock issued during period, shares, restricted stock award, gross"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r4",
      "r5",
      "r81",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of restricted stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r4",
      "r5",
      "r81",
      "r86",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Stock issued to vendor in lieu of cash payment",
        "verboseLabel": "Issuance of common stock to vendor in lieu of cash payment"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r4",
      "r5",
      "r81",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock - offerings, net of fees incurred"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r4",
      "r5",
      "r81",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Stock issued during period, value, restricted stock sward, gross"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r81",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of restricted stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r81",
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Cashless exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionPlanExpense": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for option under share-based payment arrangement.",
        "label": "Stock or Unit Option Plan Expense",
        "terseLabel": "Stock option expense"
       }
      }
     },
     "localname": "StockOptionPlanExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r62",
      "r536",
      "r568",
      "r578",
      "r631"
     ],
     "calculation": {
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets",
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders' Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r87",
      "r197",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "verboseLabel": "Tax credit carryforward, amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r261",
      "r262",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Trade and Other Accounts Receivable, Policy [Policy Text Block]",
        "terseLabel": "Grants and Accounts Receivable"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r395",
      "r401"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r58",
      "r59",
      "r60",
      "r237",
      "r238",
      "r240",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosurePrincipalBusinessActivityAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase, Amount"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/DisclosureLongTermDebtAdditionalInformationDetails",
      "http://www.cytosorbents.com/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r219",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average number of shares of common stock outstanding, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r217",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of shares of common stock outstanding, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cytosorbents.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL124452896-108306",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r541": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r542": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r543": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r544": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r545": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r546": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r547": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r548": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "https://asc.fasb.org/topic&trid=2126967",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "11",
   "Subsection": "03",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "04",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(i)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>102
<FILENAME>0001410578-23-000234-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001410578-23-000234-xbrl.zip
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M52FL_D4??89Y/QC!BW'W7U_&P]O>9/HW&2J;_=[ 7ZSO;XA@ -9]C/$<A5Y
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M339^#&#:FTHQ+[DZO(K-AZ1P*-B;!KO UI.W*S!F8@SG#V"+##&'N]0\[XU
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M""/"X.7EQ67*WO^=1L0VJ-D-4("1#SUJ*KL?\7@^7H,P$1'N!]X K=8A6((
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M633O3)<.?<V(\,B9:O($>G71W"^1Y[WSCK!]!_+:V> ;%":J3MJ>D6*8/DW
MZ@4RI?2*O;[70!J0X1P%]*D(Q>27/S$2$0S[TV'MM)<M//V!,4BQ7 /LAC"1
MH"C?@+"$SBB KP M0F>]A*[C5T4"E&GMR30@H8)25$ 9CX'3Z?38+\\*/S*
M3VM39 #/I';RY\-H3_X8N*<+]'SFTN.[<).J(/MCKX'LAS\?IX?S0>Z#\?/_
M*A-)QOL<PZ:D>#WD2)%^,!V3I21%RO Q-*MV+H4Z@_$Q1.M=A&CQDHP2&W+H
M_97$*$94,(X_=$)_0UT3_/AXN7+&1VB9""T%/-WG?"VPH:P'LPI@#>XU%6!:
M\LD-PC^ $]+'F"F_VP\JVI"JQ&3L3Q,-28&SR(?SUK(A<5R=DC/X,2O2A\B*
MU(*#A&91V$:O5#R*RB*UX5:<3$X),0K]J]H!"C#RH4?3*0^#B @.L)Y $9/:
M<P-786/!AV.'%KB;"Q&Q!;N+*HL2R;_3V[8Y3_,=Z70N377K"F[>"NE-[RBJ
M+69_ U<(I/,%;;[Y84S?W/JZ>EK*R;U,;WHC45/N92 6+4F3X9( BT+'C6+'
MIRMG45YA+KD]%Z@5EZ=\2/9I1IQ96%# DH5JE;55Z:7+.6+V0CHK!-&R3S!Y
MR14ME/ @2GU64<2&E6FU'>7RG57@L6K@8O7RVXH;A)6ES-TDE 14["*"D4[_
MS<**>(L9&2QPPNP$!.#%\?O/#O1Y;T;*E++A J&"VJ1Q6=?-BFZWC&$ZD B[
MF:"4#;<-:W<X 2[K-7?H)5528+FP#1<76]-C&9Y%ZCPXFWA=DX47+X"(0VO#
M9<4:RN*@T7P:@_M!0%9/I+='&0MD(QTFLRCO'I1B!39<.52=S10AZM89Y:3_
ME)UX,X8[R3(VW!ULJ!D&*JT1YS,4.?Y5#'WZ"NUT[;A@[+KQ&@)FL*UL21NN
M$JHJ1A:;[KZR96.T6H?H.;&3ON^C%WK=9P)< )^YS[O7J\B&2X4->Y4L5(O6
M$6\S>POOBF&-Y<2;2.-2M+-;Z#PE5_JEUGLY:BMN&39>\N4 6:NB"7T<8#Q_
MQ.ECIU***I6QXF)A8W658%FD--;&CUX6H0, 8QDO7\R*.X@M[82+R#I?A^S?
M!66L6;-]1/F&M5I1*RXGJBXVI-%I7BI>I5ZOZ :%.Z=)LGBM7AP*BEIQ9['9
M>E" KG,5W:$@6OJ;'4.9?1P>A%306G&#454)?#@6S3QOX;7QB^:^!RX0BU31
M#X$SGM\ZP:'O@46@5P'-?0PL#!;)OCA@TC0B4DOEE%"O+IJ[#$18+-():PU(
M783C^39L0&%9?%A0[QEM>VX"&6P6Z;#(:)8XB1<%P2/6JZNNW 5[/-;JYW>0
MO"7H]9_)KPO&T2,OWZ%Z-7IUVI5/00:IV605HX#\"&;.*\#[?=LHF*-PE3Z1
MHY3&XLOYCX=I+$;W@_'=L#?K_WTX)7_N&^G!?2O&LESLU84P'CAAN"$\O3BA
MAT69+BI+:>ZE.R7VXVB9&),@%I9';$_>"TFEY+L=#Y39T;/,E3 2ED]N21RL
MV,[$^K#CTA;A@KXYZ [2I C"6UL<6AN"8ZL,JW!PQ(9AV*U [_/W ^^6U.[_
M-]ER8P^ZE!>A1BI+V1!9J:*;2D!FM40?78&+0*:SL$EMB)=4T0<;A2U+\,/9
ML+00E5ZFW-H0.:X C+W"YJP.K(D@S^=SGCH^&,_O0<1GGQE1I%J%#2.@HF+K
M ;5RDURA4ID"-@R9K?=,J]1%IH+T"GN>16$TD;"$#;'D-14FQ&61QKXY?IP^
M@[R-4MOF]:;3.HW6&"SI\Y2C0*A&]6IL"#VOJ5MUL!8I7(1Y!:,$%QX'CQ)7
M":HKL"& O?41MPS3K)^1YJ>&4>+@)OL=>A9!N :!"Q4SY5Z<ES/E#L9W=Z/9
MW?!^-NWU[Z_)W_>ST?W7X?U@5#^!+B\U@ #'CB>6[U"YM.Z]'E4RN(7/P!L%
M$1D9(.$B&2?PU>;.^0<*![Z#68E6:M5@WMM84YV%[:(*8L-;>3ZK>T8K4THI
MUV*)X[*&<4OJF0W;\&.::./XT::_"$&RV<5"SPV7V@9'9TVS+3RYR</713C;
M+71I#->N,7X2!AZE#1OX!E(78C/]O"E9(^5'^*O-/7TV!J2Q$>G/HI,SE0K,
M)RYN87Y3 6R3;C,NQ6EG1"4LF;;4+9:OO0.$G5R<=#8$II^XVGDI$46$-DPX
M$H:T]UFR871[V6"*7$C^F\6IDD[]S8F2\ V^N!4*VS#[J*A  5HGB>)DAE?>
M,4VM&O0?US0 NL\KIS -Z3^^:2_.8_CJ;-^DV[ZXVG==PA(O9%NJI,E.V5#[
M2C@[OVPR?"7#0T26M</5VD=)N.5^6Y EKN>E6Y O:_($IXW.*H^T>X4Q..C'
M$:)1@VZ6P2A]=96I,H72)D]Q6E&: E8+U :\)FK;ES9Y0*-';7NL%IW/,%^J
M#M-S^^$_8_Z5?YF")L]C6IKN9&!VW@LSQU=VKX"7[8E%93)Q4!N]BH7)HMZ3
ML2=.AG9(9#)G4$N]XA!2YST@\T/RIYH# I.I?=JP^P,XND88VL%NT0L(DT-G
MP2!S2&@T%T^+ \TA+IV"?UROY02?)S2:8*=EP>=QF8UQ2-XBIB\0@Q"GL_R-
M T,:B$,?3:<?QVOE.U47%^>7AP$/T]EX\#^_C6^OAY/IO_6&?WL<S?X@/]/6
M>L^TN1Z:]S!ML)?B;SD(H@R4&_' )35QX8":6W)VE:E#<-8CH+<D=*%"":5K
M!FPP9E=">7Z$IS4L0DL.:2HM*Z\)%HZ./%VA"W'Z./V$GN &"[H9^?'T_'R&
M+LY/?_R)?UZ@4-B&(QN^$>5=6K*(=&KCA],?_D*:OSC]_$5=&XS"-IS>-- &
M Y%.;5R>?OEIACZ??KE05T:YK UQ_ UT40:D_XDQR@[@O.R6^V9)J(7$?'S
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M^AS/QW&$(R>@;\RG]%H6N:+6;0C'??-V+!*P;29=BL6HB;F,]>!1KT*1*["
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M$?\A/CZB]E9IBJJY//WRTPQ]/OURH:Z9<ED;=M\-%%,&U-Y A8%[ND#/9 T
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MW=^;6RQ"L" ;A0E80!P!,MKV5R@.(K*6&2?I(X(%<[4@6=#DG3EE34ABLFE
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M<1*=8A<;?8 J5[)QX6\FKHQ T&D,AU>?-E_\C]M\WG)"#RW"U$_/:!GNHOC
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M# P3,=09XLBH@CV=.I$5:^P$R]##G_^&Y7-$"PY,:<0,-_2D#@2A&B(.I-K
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MHBNN?=@3W**GVL32KS@EU3%[4)+[YB*F(K+P<<3,A%M4A>,+<<%T,:T;&%5
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M.I"TQNKYV:^!\#F"/=9>%Z'+TCFT%59>947;PB]X6-_+NLV$J!VV6V,$Z_+
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M36V!JI;:B32YW6IRU*Z$5,$K##E#_=J"G:F^<O%<L"Q3Z*MLROH:9I=J&9)
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MPN1SNO2PO.;>[ M,>@U%MV^S.C#A?[Z+XBPKKL\9DH"&?0&)5%#=8*1%P*I
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MS&18MV1 OV?_@GF&L62K?)\1'0#;T;UWXC]PNO*3HG"2C@O01@5P H9B%6Y
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MB054OUQ/F%I!<C7*]!7&=?AI%[XNL1!#LR]F'"Y89EM R[N\+IKN9KL,'+C
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MHL$VY>_&"ELQ8G;,Q4L4/N'=*?38B5X0)7[X<H>Q8B&C1H!8U.B(4"YP5-!
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MS')3*^I0("HA8J&]T9@! 4UAO?FUX%+,R@_QDCABO9M2%6@;KL2TF)??B"E
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M*WN\HW%2*7](43,8B7<SY"S)L:W]]8L&2 XY!$B Q!OI_9"4+ 'H%Q!/ ]U
MMQ%*]JLJ&!2CN<)@I!\>8"A4)8<J]"#L5&U7^/DO64+ G"SYX4@8?0+2**?M
MJLB#=46ZB6EKE//]H:V0BGXZHX>DNL(,H1$C,F8@JDI@"X-FB%$U C[,57\3
MK2T!4*L":T+C: T^&MBIPJTJ@]+?9T&2>2?_ WX,(_K.U;06;!H@6?E':8!^
M)@WA'CT+[_P,D7=#&N52&J<1:E&:3C/$(3,Z0R24P:@I8E3!D\#HPF\(Y7%"
MD;P*:4M#S_<D4L_9$Y1!,KW!3+NB1[[DHX!@<KC9X!#N196R&U(PE](X(;A%
M:3HAF$-F=! LE,$H!%>H'G%8+S*]9KJ+\"/XE$TBD[P*\Y8CA:*;K_LP+WIL
M&(JXE,8)12U*TPE%'#*C@R*A#$:AJ$)U_% DKT+:TA400;P)7ES@]9M#0@['
MC%/FJ:5_+,7!R2I,A2E%^@SDJJAT7Y'K=:951W%0>KH?BX;7.*/EPPK7I9_R
M[Z/<2U0\8[_A\/&):.V2'"*#1US(]2$)5QC".QM;,5EI1L:Y$^FO<D/1$TDN
M1K>/Z2NBO?A+P1;*^2H!$E'.T*?+AS1+@E4V_@#QL!GH4A3<^Z2<3!F$W4[2
MQ.'6(<9.%5@]0]-)A+E[Z/L;"'X/U8I42-P/4Y(JA6=,F!.=''AJ4O0K6<FL
MZ"/OGVG1+5LO\Y+V#U&[,#+#]^G&M2X(:H\#,SF!(Q? J<S&2-&SI[JU0J@B
M#^/#T5X"F@53;K!YJHBJ1_^>!ZJ[E, )@[D 5F4V1@JL/=6M%5@5>1@?L/82
MT"RP<D/G4P56/?IW&G8?KH(\C.H65)68&"VD]E"U9D!5X&",<*HLGFDP;=Q1
MF"Z4#M?]N*\_'/,S'VM!I470U9#?NH.FIT"I0Y$Z8VNM!/V#P>'2&(VC5?*4
M5Q@8_?V#/FIM0/T"[_*ZH% \#GH>B)KNP@U&W__.K5,SEJ<\?=23=RT,(*1Z
M<8?\#]VR/RA'#\OYKDPWI,Z\:)L%VYPXM!)NE-ZP'7;9<&-17,CH\+X&'VF-
ME32315@O9L',?051ICA]5S/RP*#@A"'2PLET^,*4BZQW[J4^ K ?'#G*X.>'
MV'QX1I+PC#CP7*!S+3U5SB*Z+7P@SM&:9RQ',#%7[1-S54S,U6@GIB.GH:>S
M,^#"BB&C>0UUC[9;+VQE?UY&:"*'*EZ;9>S+R#@-XC!IQ7Z;((?!I(3!504&
M:8EA*+F7YR0)@*,4K0IFH.X(](%=]3[W_D,@H%;3D5_2L:CH.-:"CIY-J)3]
M?)"QGR5CQY#.Q*VFYJD8= W)D+G,(_@>&,N^G(S05 Y3NC9#V8^-<9K)(;):
M.BSF+/8[DXS,R!F8#AU'Q$%3,$(#IW4:!EP&,V;<\EL57IBWOKR,TL -4[Q&
M$]>/D;$:N2'2:CX+XH*9_YP%?9E0?6?!DK%OYBRH>2H\N/ W("!;N;8BJ89S
M0Z'A7IR,\]K' *7KO/;1@XW17?OH+:.-O&_ E?MK'W*W#KV8 Y74'98R1@89
M5<'U-DC3^88FRKO\&@K+$8C;N\K_V"% /<VCH+&#;(ZMG#0^'-H,OA;:$'V"
MIKU*20[^8JH,OZ&E! 4B\AJZ^4;$+%<_CF8KZU^%B(7.SX$UUEE;M)[/C= F
MD/66:/75V8L7R_C\Q=FKG]YA3NDLU<X.7 K*HI4^ .F>;@[MBNPUBR\?C[;5
M J+DI)SE]CR+R\,TVM-$?0DC@T"_" A!&TK*\@%WJ/ G"0@70KG0)S:.BX*B
MVH3LFCP+2/+CV8]_)3R?G[U\K8XDG,X>(8E0M$XD:?3T"TD$[+4A"6QOQ6@B
M6'5 "P$Q^D$".4_01%8!G7(M<[E\1!-E(3EH4IL\"VAR<?;ZIV7\\NSUN3J8
M-/MZA"4BP3JAY+2C7TC"YT[_EN3\[/P<V@ E3S!$4O0V"*%2+9E4/B*(JH@=
M$S>NI^AO@S#Y-=@>\&6:'G9UG[V1O,\2!$?V"%U:A5I>H'=2&\_S<TE13#B'
M@32BM%&%^&P<F35TZY.^1D!O@JR1V1Y0<F0OK/E*V.-5AM=&(FH2!$<6.)-6
MH9;X6">U\83!)$6Q"VB,_!@C6GW56<I,TV3D42OF?&9!LBELT9B(O\9;,LPV
MS)X7!+[M&!0^Y4ELVMJ4:G#WQB,[]FV<6"8G\'=D! $GD]C9*:CX^I DH"ZV
MK<LA\6.TQLGV&4ZQ#!WAWE^8I0*M.=T*ZM;:F_!SN,;1VC9LUNE."#1Y"C4.
MF56BTP#,ID1.X+)@8VI@*:'>A@[2\:/>(DS__VV"\6U$U([3#,1_%T;A[G#Z
M:,,^^0E@H(1ZC4%A"^UQ(V*G8#:!$9A!P TJV*'(.$,Y1Q. 2'5]"Y6RXRME
M(K@9?'6*FP7YJ>)F7;UV<9/1GB!N5@7S S<91U/%S59]"Y3B\HB]>L+KPQ;/
M-WS5T-^FEX?L*4["?^$U]1Q4ZM1_(/*E5\^-"#M>PCL$T2P8)NH((*VHL@:+
M1BG:!T,+XC0A,"=*KZD+X'#&_I*B(VUT .*UV *B]&> E[Q@*OI$V7#S'$*S
M0MN>WIB@Y-..1XO2NC<W@\AXLH_1((/,?3/L\J'1 ,F;<K>^5#)":70KJTMI
MFE:6B,R85E:[#-*' 37KQU^?%EY^X7F$%2Y55YO[<(^ZR;[XZO2QK2>WI4\9
M:KL@S;D&C2$=B>MKSYTR<+]LTDEXLWE\]N<NC/!MAG<&-G>MQ"9@A1JJ,V:(
M2DKCMD4G8E@U1T ;4>)>59@RI<GE_/KOO\SOWMPL[K]#-__X>+O\??Q8=1.M
MYQN66:A7Y3R=9"> 7RWJ-(9D')KCQC2A0!;1C?R696S)LXSY64S/N((Y"6/'
MCWEW\1><Y)B_"ZW@78/D!+!.H$9S.[8ZO7%C'%<8J_A&.<BW<I2'"0";G%:9
MS 3;ZXJ14,GXL.[C?F\;ZQHD)X!U C4:P[H3>N/&.JXP5K&.<C QK)/3JA#K
M.E4R/JQ[?P 'XGQ3V:SF^U<;\]%&?0((V*U<8V H)CUN7.R2RRI$,F8 *:K%
M07)^)@"7RLK.%5+51I"A-WA%PQ3HY?D, 9QY]+J_IV::&CE)?%OK<E54+[X*
MME"G2BT?@"L6?<H@X'::NG,.N.'/DRP%+H6WBO<<E.=D]_8FGXO?$Z6HMPG:
M"%%R] LO)K6%NV_!,G1.CCNC(&1MXO:@0VX/3<$X"CWX,E\MZJ-9=;[_'0=)
M^A>/G"Z]JKK?$F6$41JNZ*L>W<^%NNGYY%C1J$ MK_:ZB'GB/-$FB=$B.+5B
M+B5U]F3/)^^(.6VR+(=K>&BW@=>*G^EK198*AUB40_09IP!XL4&7$<'2A]@O
MM5P^/B;X$;32\56,UY]>*8GDP)_.H^X3[!M3KG%_>I.T)R;!D%R._.D5=B;H
M3Y=6=JZ0JC:FZ4]O:J3-Q63%?Z[,T@2\(CVGP9@K1)&?<?L_>@EK]WIO$Y6_
M!?^WGHD9C[^[5^'/^L;?0@WA!D&?\%>G"@U5!#ZAY@EVZA/%7GU?&ZX-V5.\
M385Z=HP_YG !1+]ZIC5 )9,!-7LXS^0C$D*0AN>TN<L<.GQ>VA/@T$T(67VL
M<JO+C#75(K-W'<^2!6W=E_%M,"ZJY'OG[$UO"Q>=]7SO7#^C56'>KU>P RS$
M^SAW6!>.#+:A7L3;[=LX@8:&3),,X7%N_^15JG,;V$UU=-M!69&,;@M+)JJ^
MS/S<_0E803DO+E_$.E.RPZ3F^F6VJ^&)P9M%3)L*D+E%+R-PM:>OZ6^BM0/(
M$@5<XNB'0@>=81:-2KC/@B3S4PU_"Z)#D#PC_V)-/:3/_TV,U0:'UC&]B_K(
M,5Y.N48POYWT>&V C%QV;$+Q*U3R8MI*O&9ZCJB+T8Z-Z*7NLO4HH?%7>WM;
M/JEQ@EZ;VG0B'(_.Z.!,+(11[/K5RF;6'DPIJ)$U'24@E6!\$F2G=VFA8/BQ
M((9$\CW+C(P3S/JKW,AF3IJ+T0%A7Q%M'?L;=U38!7;@K%INQXO$?CY,@YR^
M)@[#SB=I^K#K%FXG#+.FX;4=72W<E+3K8^VK[^F[775HQAM/[("G8E3P]#9B
MF70'V1:;7/CT>,JXLG6^I%5DP9/'5(;E,[J=9QRA,,K3<,ONZGUZ7V5;_[3A
MV/TEI\YKYQOW'@R-?"/?>PJL!,4\15^'HKH+G7F/R3[-RA0B;*[06)KZ.*%7
M4;GZ0W/3 U4EN:P$\*8,EL.T[3#.1X58$@(M)9E/VKB!&"ZC52"H-;"^7#G4
MFR_MH V"1OX5'*Y\ZJGHL':4,5K#(^OWP:Y/Q>&AI#SUX@Q0FY*KI@<=__PQ
MO85H5E7]YR',GIG1&50G>/#"6A 43\(507+ZGNQC%&;IXOXCMZ:P9!\WG[J4
M(-5OMK6#]8]/@AM.?>&B3_XVD?9"WY-^Z5^$!7KM[$T&RI-")WT+(DVRRF(@
M_SHN!/*//Y9A!H^';Z-U^#E<'X(M9U_1TL[N!]_),'SDPD;6/NP.#AJ33]O"
M1;EC:^T;#M7/X+<P>UK@+;4#Z5.X7\8W44: F[M_Z#6"!Y^.G)#"CZJ]N]O/
M388W#@H=.Z L1JR+ 2O=\35>Q7!2V[P)$[PB(Z;73^1 M@LBKFF6Z6#_6Y,3
MH?BTVEM;_9)D6&E\.+03(%C9#17]S!KCE@0MPX59%]VL??CO@BA@&V[AI]YL
M8O_C%K%9?,ZG?[?Z ?.)-\\A7_'JD(6?,3IVL#;/\\TF7.%$.,DG?[<_PUP&
MB^FM_='JW'(H-PM!9T^0O'.WW\;/V.7K]S[Q]?=QQ#R4[)A\&Y%CP8$>P"O9
MGME;!-VA?272GOIT-*I5RW4<!;K^^7RT"64B6@$W]/+DF;E'J<+'21)\QHOC
MBYYN-,WWD\S(SI[64,F+13F_Z^F7<LI:6B+]^!T ;^H#+.+R*<CUE989!.L)
M!RMJTQUUT\+2R$+E&J=!2_Q< S_C":IK$]:$[6H:+,0VK1GA[QB'%R;ZK)FW
M$;Y?,#<Y(D0_4:!OYF^<2O3(3.K=/^3WDNUM6$J"DSE6G:C0\&$JIS:%(U1-
M% <')\&=?-/.6F<:%8&=\[<)>I60W^4]=*29,4AT,M#&4:5A>*M0G +$-<1Q
M ',5'ISFI;&M61'<>7#7OX\J.C?!)PD8=4^%.OV1P6!?!6M!1%7BXP''?I(Y
M]$4TDM2.T)NN2>E^9TWP1#&C3IH@KP_KF12TLC996V0WYX)&OJ9HP1P^:5,W
M;@[?O/EB_*:93<A_G7TC)G,A5[;((A.3-8,<55LV> O7I8TLB^>'$?.W")(7
MTS&R*Z&=\M>3,5E7_RGYJ<$I7[UV@+1.>T(0RA/,(7B>9F\;7?A3C\)'&?3L
M%+V,;3B#2 X'4T-)H9+M &6#_(2P4B";0[@L.3*%F!:BJ-K4/M70*4MRY PS
M3\E/#3#YZK6#EG7:$X)*GF .<9*Q,V60E%*XZ[)(CGV_7G@\U;B<&M@.FBS?
M@H03=ZJJR^^'U]6/*DY.G0PZY]#W(D\6O#3^W2Z9>@4/4Q/DPEO\+5TV\:8>
M2$]_\PB2+7L\;Y-V6\-E?O\,@1IS4[,"?:;&JA]<BK,)X;^ZV.Z]Y\#LMXK[
M&N;KVW"[^X?\ROQ-#?Q[3I +S_ZW9 )Z2>Y1;.!;-05ZYDU3B"'%J[/'^/-_
MKW'(K #YX0C^Y!]_W.''8'M#\R)S,J5S6]@%P!8F 8(X?[8& D+:C>FDK<KT
MTWI2H7?/[8TXPWGSS_9GE<=>,:4W+A*/\PDW,^T.SR*^RM*8SM7YQ<MS.E_P
MFS_^AC<; ALXO=NN+J/UU=DBW.+GMP_);;3BYM:5[F5W=A6%@4F7[&+D6UC'
M*XKEU ;TT[ P/<&>,(29;VP3)SMF?/<XR<BG ZFFLAB5HZ.[NVL41&MT=88H
M!?3V:@%YJE9G1JPD;PT,DU="%+OVWKHX5DYK16&BEIII]29NSBP\-JO'ANK?
MK>_<F\0;TP]-$+1Q62Y-JM"9'R7*NHN+.2X+)E70JS+K^BT\35+#3@I 9QYA
ML5T7MW5@S;L8+VVXJ*$;R]W.3?.X3',(Y7F6Z(= >IBM^"$TPOZSWFYU>_$?
M,_[WP'\<];H.(5AYRR_Q\BD^I,2*OR629AA')QR*5Z)\7P<K4U6P<J7*=G2S
M<M6XZ[?SOGAQ_B.ZB\D_ECC9P7:.=( 2*C"\Y3WW0'E)=U3T1\4 J D*KJH7
MZ9"13E=#))WG[\/V^>*"D'G] 2?THR%?!'4!4M]?RQ%<KJ.+4[B*2,>#N$PO
M1V=Q>=;:0"%[PFU'<D($75Q YHKSUZA"Z =*B;G&;1_*!P@N)8_+S8(^X?85
MX5@\(X 1-*+$6_R00&:3BY_(WUXH(H5"9P=HH2Q:B1C2/=V@AB)[_;83!1%T
M\1.DO'E1_191Y5NT#!Q#96^(51D">8(?VF443)U&&+G<)^'VG&#>Q;DBALCV
M=  @:D*5Z"'7S0UTJ/#6?\=!J:!S:L4NSCU!CD&BGTCD(6CH%,\"7AP>#VEV
M_@+^H@H8LEU=((::6$?(D.OG"#-4F!L &I0,.G_!4NR)UIAMU!@DO*1,3G%#
MJX#FD:.H'=L:;> T<H &0E;+==]HX6:%"]AH^N6>PA3M6/)06J<J162VRW*^
MX*2WO#QE.:^RZ'*U*?.K-VY0#+O\$G<OGDHCAXNGP6IC\90MW"Z>$S:4%P_I
M[VCQ='%>9=&'Q2/-;_8EUAGNQE$8)ZP@?=(>[!:T=!'J;F7Z&.CF-G,4YF[A
M1795L3'0C@T"*&IY;2D)D7.;MW9MH_JP7E&TJ177:K-$+5VO.+'UXC?S8,7U
MM&,GW[!]:Z8D1)-;;U:<).O%BNMIXP9?Y2N,;"7FS5V>$NW=7/#K%*!ZUT_8
MV/JUOPY.6A]-E8^ACD^#9L7M U=W*?K*56[RTLI=*Z^RAX/C8TD4O7H2.BMZ
MC>#5F\TV(25>5?*Z^_+N4<R;^B++QW&XM=,G[#RBGMPU/'V,-_3G1W@*Z.G:
M$^T;>XW@Z]KC[C-[=/=P[77NAV37GKM-GCYAWX9)FJ$@BD)B4E.(\><K<#2K
MD5 ::@MK8WB[(IN"*J[)XP ^KLI3[@:L2QC*_Y79+3 F'\[:V.(4^4@Z.8?;
MR2V>$Z7^+OPI/00\>ED4.CORO2ASR,FV<TBR)[2/$WJ2(Q\:#;JB0[0&'TUE
M'>[S=1A4$F:L0W@7"F\%(%,UY,^ -*$0E-_@ +( S5 8K;:'-?G5##T<,A3%
M&=J&.UIC((MGM:#O#@<IZ8-B0A@GGT/R*U8)T+8W:+A:ET\A4>)E93G/V1)^
MDR_GY5.1!L2E[TB7H/[A%F%G$&Y5^ON)6PT!57"K[.PM;IUPR-G,;OX#6_JU
MRJS!!'!+4E)O3T,L]2F^)XOHD+:D-^"T<W.J$3)</;DT&ED_G0@X$*2>Q8@U
M=)GWH,9Q:_(#;DL/O@9Q&@1.,[=?1&M"A--O8D!6!(W>DB(IV]&^%>$-25=)
M]P"N_22R(O*=)%V]'7I(Y%A3=X^4 2Y?/",]!2T:]8K-"2^&@*OE+=DY/L,N
MH7B'O2 [P"1<99UO"-3Z.[E$HBY@Y6J)?&=7%TY4.12_*VAY4I RCQRE@S:0
M"R$KL@HD):G\U/'(\M1;O[0R6!&YV_''5[,7+UZ@8\\\N8#3:RV:A:M,&HWZ
MFT&4^_!KP>IEM+['GW'T"SF3)G@-!];G/B#3;TBWN#-$#3PHZC.><W3JS_1P
MP$K#KT>\@O]2((^>&'V"9X0!#W%,H\J*U?_7V?^\\A;:C,EK$.VNX]TN9NEJ
M:.+FRP/YT)+P7_BT"&)G:P<8U<U\"3_BIFZ0I8N?QA?!.N3?.ZM1=^P#.,&2
MG:>5WUI>^7I%<K"4E06X?'Q,:%E7%-.,J@2Z]V2=ZKSX7I)8X,<P)?P3]-C%
MAR@C,S[/B9YZ$U4ZNG@:K2+2\6&T3"]'SZ+E6>-=H6.)?E[31#^O9M13#8[P
M('K^+B70#T,F;(N0$AY8S(/\@PR^0_<_O)RA("5;@"U!@2]A]D3[W]]<0Q,V
M\LMBY"^DX1JOM@%L&B '\(IFA3ND\.$&Z$_I$]YN_E0GN4_B%4[3,_21QF(R
MN/)/VPDXJ_&/=L$S"M/T0$,P\"0$PBJ[.#DNF)2P3QJNXMU#& 5%^&?%D($:
MNQGA 9/&26']9F3[0R^^0XCF\! G:^A)_KK&#QELG Y)F(50M><+#1-EY"?2
M]!"%\--A#]NK@/PO"[9H'6^).E! IPLH_]<Y.5WLPNV6<&+[@?F S^B(1,?.
MB/6F;S+*_B[>E6N1*SG*%1SEBD5RV4EBS/Q@Z7Q#C<8M^=(AAG@=IYDP@75K
M%T<)CB7$J*4[;FEO/_EQ)S/-5,AY%UCO;/-1]$*TFQOW:@]!;KY"N!1#\BX"
M>DF_RBIJMS*Z2\F<%AGN+(9EGIP_=SYTJJ_KBH@.6E[=*-$G4%=N&NHZ87<'
M-E#2Z3,]G!"X..0#%Z^,_+@48E Q&BIM\:JP>U SRY%"?Y;]M-P$HNMYBW,#
M(PH("AH["C"WLEX+)G-;V@\<M[ ARB.?D'-8F-527^?]',6$>\C >,=\MK7O
M6/('I.1\3 Z/$4[?8;*FET\X/Z)^P ED1P\>%78E"D-ZL_-05D/'[D)Z/)]V
M$(I,-P\.90, ['(<%( C!8JG[3 UAK"%6+$QO=@@#)6;CHHXFX <AXXC4PU<
M/=><0,?AO3'P>C^$G<R'H#EF$Z8ID6!!MA&7Z9&;^:9TF/R<Q&GZ ;QW>,UU
M$/<9Q5&,IY^PM=B/VA#N8D)]^.0\XZ"?73X82F"S&:0H@!ASY;N%KS,H'6R/
M,##S]Y*1'<2.M(A^' C!2.@RK> /7'\_>A3I<*@8SU&\2;?0=*Z_KT[V7S0B
MS_L#Q*SG&R@N [5ERM(RL/GCHDQ7#P>((B=$B1[MS=T@A0Q/C:^$=8*%OR7=
M?LB@-E!8U@:"VE2V5_U ,40ECERL95,SXL0+4 F$7P?[, NV[&[! L.3* RW
M7=X>X&55X:06G Y[C./&=]!;X*I;07D0ZQZ'GARV7MR8H7RHXOY),1B-S['A
MROB*&R>%9K%9FJFD*F8HD,_*:KW<TG'QFG_6:??AR79VLR[51*LN1KF>UE>@
M"EO-8'C1&0F]\DZ=@9J$J[[W756%&^ RU)?DD+T)YDM81@-HB"!=PA63ZM\A
MEOL^SG['V0*OXL<(KI95/*BB.P.6:#M.OFA#L=Q$CB8)NTL*:5XJ<2+&G+@0
MIBJA0!8D3&=U&"/$T3/.T)'\K%8AT]$5#9?*I>.@0Y24G>K@N"+#DDW)-F!)
M#3Q(AFE,6Q]H/@:R:\M_!>W.;4^9@(F)@6BKJJV@*9>#Z<!JBW@&\14XX8(L
M8X>>:2H,30QM571^N8.D-("V+ N,3\D4NV^IL',N'&OQ^C9B<HLB^7IIN$XR
MH%%1$LD:^Q'P)9GC$.Y-7!C+'4F,'#P<^,!=>I9NN%C0V=$/G._7BK>;[NZ
M,;[?'.!R/>.]])GE3Q%I,RHI#5&U71#J,9C#.V2]16_<,5,>R<T=M)YL"NYW
MY<N6#9<OW6)-SYI/=_,U3\=U>(=-KPY"IH,UT\$^UT&:Z^#T.2][KSUC$7B?
MECR]QZIIQ7>-Y=6"EQ-<8KVW#^3+<I?A4FFUTP''M-@':("_UC\S#326>NI\
MJ0,(/73O9QY.]S/T?[^RS)J+\/$IJ]Q7:=L[Z:?E\&QA2G&-,X9N0F[.&F:D
M,''F8-67<[*(T9TYN[KJ0HF%['NAS'[[.JHB,U 7^83UDAB9IZ-%35H<'9SQ
MQ^/G$#)O'G)&Z>.0UU<%75QY4:^W09K.-[^QI!#SA.+B_)#1TI6$-]'MH<YN
MCNZL28I3NZ+6T<?^C30IAIHWL: ;^,ORCO PCG:=H4IG1[?-^HET] $R-P'$
M<!\PVA/^GF#9^;-DEL'#5GCCLZ6#1\ND)D+G J&M_5@:%5;D%P7Z1+NY26W-
M%>,NC/!MAG<B'U)7)X\^I88HG9]3V<./3^J$'97/"KHBVM=12NI> MTOY]=_
M_V5^]^9F<?\=NOG'Q]OE[VZ..JLGO#YL\7QS$R20^!,.:<5&*UQ=/;,+QU3(
M-M#M,8ZC0TM?@6LG$]5![!\_^G'8_%#S<6#Q%2/!.8$=*F:(CC:#4T9^,YV.
M.(/7,*S:#2UTR=;O.YP]Q6NGEN RRL)UN#W XY;[,DO;S5=@%J_?DB\%3A\'
M]NJ)H[MG_@ MY52,4G1T(]Z\$FO7Z,V1LW_WWK0LS<M#E0[HV,-E_1F^#.^#
M'6XM1M/=S:?ET!2G^YL^]O'DPSQE2/;KFB'H.:B>C2C!2N66\F6TSG==:4O>
M^_8.+I*CR(AP3'W2UMI18I-NEKJ2F[4DG:_>&:>)YHL,JK;3F/20LO8^@#)?
M='.:'KZW)+QI<'./G[>)[3K!=W5R=$]>2I3:O?;6'O;OH4NPT[PWKNGLX/RX
MWTOZ]S=+=#>_OT<?;A;H_I?+Q8U'&R_IW2?+F&QF9UN,[=,6KJ=B-)Y=V,">
M; 9[<2U]'BE&1S SJ#*^R// J#AZ96Q+0<=,\@C7%+2J*P@7"MH7Q8J= ,P;
MO"%(N+Z.HRP)'PY%2L8VQV%[%S=P("-&=96WM;>^>+N9:7QR>1=4[<,2>P[P
MU0D.<!^") M7X1ZVDE5Z'_=9_#*_("0^S:GT=G"T4Q>N/.?)=W5SZ%/EK_\)
M<%^A1'"N\DFRNADOB^MAE@^$@S50':"^UC[F@N6CN#PLZI6R;?HL@,K\,TY>
MDB/ON^!KN#OL7JD#BV@$C\"E7<A.@.%W]PMDVG@T 30QH8=>_IGZ/7:,)GKU
M9T_P1DD98LR95V1\5\KH(_3T%UAB4GW:)[\)T]4V3@\)[G)MJ0S@U1ZZ142)
M'36GMR_[:R%K"KOMXQ@>.+H&R[FX6=XN;M[=O%^B#W>7[S6:>PYK-]OP,7P(
MMV'V#*DO>? BT\N!69<7IC3EW5W<F&]9OIJ)A2#K*+@Q:+H->D$]P?\\A G+
M(_2 $:;C;''-;F=@W=$Z7T\UL(?$I9;M=6_I>8 P0Y6^-,&L X-L8CY]LK?Y
MAN(RB@Z0L>7X1_#4%:E?\C./&DJJC>R5A>ZC% G3K3*L+S9=G6=Y8S\K-]UL
M^%H+YN@N*)1O +W:"&A03NW14GIX^#^\R@#@;Q?7:!ON0F9IW$2<!5+G@B7O
M@FSU1,Z1M;\S8><;^D<U;:J,ZQ5<J"M$ BSD!_4%*E0Y5@&*8FQ4#'ZR4RB\
MAE /"%IX!1.#%5,*O>()/3)LT*Z[\:&!7A@8T?HWNO +@YM^5]24"1KEGGS'
M 9E= F2%K/AM:Z#@U48!DCX>TSVJZ>JTKU=+G"^8Q&JN=_1EX?*X4EFCT-^K
MA28E$->HIKQ+->3GDO8=^8G\LO@5^1\D%?C??P-02P,$%     @ ]85I5I4@
M;L'77@  J.4& !4   !C='-O+3(P,C(Q,C,Q7W!R92YX;6SMO5MSXS@2+OB^
M$?L?M+T/,Q-QJMJWNGABYIR09;E:9VS)+<G=T_M205.0Q&F*U.'%9<VO7X 7
MB10)$" ! H04,=-590,@,K\/MT0B\Q__ZWUC]]Z YUNN\\^?+C]>_-0#CNDN
M+&?USY]"_X/AFY;UT__ZG__W__6/_^?#AW_?31]["]<,-\ )>J8'C  L>C^L
M8-V;N]NMX?2>@.=9MMV[\ZS%"O1ZEQ<?KSY>?+SI??B0M'%G^+".Z_2BQJX^
M7NY_,TC:<YV_]ZY_OOWYZN+JNG?[]YOKOU]?]9Z?]N6>8/>65E5!VW+^_#OZ
MSRO\8 ^*Z?C__&D=!-N___SSCQ\_/KZ_>O9'UUO!VA?7/Z<%?XI+_OW=MW*E
M?URG92]__O?3X\Q<@XWQP7+\P'#,0RW43%F]R]O;VY^CW\*BOO5W/ZK_Z)I&
M$"F^LE\]; GTKP]IL0_H1Q\NKSY<7WY\]Q=IOPK=JA >_M8BE-^+#?7<Z_W#
M<VTP!<M>)-_?@]T6_/,GW]IL;=1@]+.U!Y;__,D,?!=V\.KJ\BKNWO][GU I
M_;/O+(9.8 6[D;-TO4VDG)]ZJ/V7Z2C7(7,7N+[KO<)*_D?3W?R,"OU,U][/
M3;L]"R!/4?L#U_%=VUH@VMX9-M+); U X+-TFJ:U%KK\;'CPUVL06*9A\^W_
M4=-BA-G_T)\L)UO@16#[D $#=[/UP!HXOO4&'EV_.3@LGQ(O[&!M."O@CYQ9
MX)I_KEU[ :?SX?\)(>VY2DK\3@MB&O[ZP79_\(4OTVIC$>XMW[1=/_0 7.,L
MV/BS!WSX&?9IC-P0QXX^>Y9C6EO#O@M]RP&^WS<#ZPTB"LD\"S<;P]M-EC-K
MY< %US3@A&J:;@AG5&?U#+5I6H )#;[?Y:B&*7@#3@CJR;*OS!47%\XKD3K0
M"-LBMHY!4%?9F,8X=G@"IW>O[_N,:Q^F 8X=@\SQ0K 8OF_AK S0)!U]:1!Z
M:$UZM(Q7R[:"VD1F:)ZC4(^NLYH#;W,/7FMR(M\"SZX!N)&LJ<RT+L?NC.!A
M9@/FQGO=/N4:X-@QN%786$&T"D4;AVAR@T>OVDPD-LBQX\UV&>1V.'833G!H
M _8,O-D:;C_K];'0"-<U)["\:!OR#+?*=9>>?!L<N_=K:'@!\.S=@^7 G;QE
MV%/@AW;@OSA&N+#@-JI>EVG:56J#(WNC(V3#T[Q;<^/5EJ>4].O\]X!-Y#IJ
M0OQ^L!D(Q";%[ V;=+BD&1G[Q"8B,']$T)ZQB0QE[7#?/S;J8*X%,7O))OTK
M:4;H]JQ)7_&MM;K5:"("?>MB#4#W(# LNZ80I/:4VA8TDI+CYY52"C(RHC,9
M_ ,-HC?#1AJ0K*J*3O'?625_W.T&H1_ &=";P]9@#[X!=^49V[5E]CU@--)*
MO2^)$-4$4*-H6DG.XIYA9M=W/E+2?H2_@/T%G#GA)&38F9LU'D*1&Q:_HVXX
M*,EMBN\^?UQJ?4C,X:&1'&7MB.DF?PRH&Y=Q'FHD&?M7!)V(^(-&W[H@D;CU
M7G1']WN99V.W:;PSHFN9^XFU69_S37#OW-1:K8/)\L4'T2P"A]D4V.@J//IU
M.LQV'&1@_1)W49^,(/2B*6.RS'VSZ53%T+P8FT/6A0'=2MP!.)5D"S02K]:'
MQ AZ!QRPM(('S]T(D*ZB=3$B[2<BY"'D.HGO"?R[X>QF]V )X'JW@"631=Y9
M\&(M[SZ(40\\RKBP;[85+8R3Y?Y7R<8@P8R7)E@_)T9H_EL.ZL;;N<=N) M-
MNT+-IM%/)ENDM]2VTD@@MB\(%>W!L+S?##L$DV6F#YREJ_B(4 %'3@ G.]\R
MHPYP%@S3N%"!QJ[S&_#A>AQKL=G08FA>J%!3^$G/,B./3/B[%Z?A#,_VA;9%
M$S2)T'Q)J*C\ES'6;P@5[W?#\XRF9U**9L6Y/C7J.:XM88Y0#8W(I4VU>E?9
M2 "&YOD;]=,KA-^M8)W>G*2G>#XV@EH?2@3=9NX^'Z%<B73H"]Q>!F65"-X#
MX"R0.UKR4RM 7[JXN+B]Z'WHI0UE_VHXBU[<:B_;;-1_*('MFKDOV.CYE^OE
M<4*2^%"4Z,65#\R/*_?MYP6PT".W*_27",0(0/B/[P/W#>KNU8_TF;9D&Z_
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M@G14KFO@T'0_!47^^3UY3A1?6:")&*HRQ&-37KQK$#%(D=Z$DH[SURW9G .
M1++>P+T1&(D,!&-S6?&N(<4@18J4_.-\-/ '1@!6KK<C7J_M2W4-E^K.IW"4
MG=S5O-29;0Q['S, "UNN5-=@J^Y\"IO,8W_<U^$&>"LX.7_SW!_!.GF,@X6E
MM'1>PD\*NU*Q"I'"5&874&UTC<REUT<>FJ[7#P+@QQI_L(U5"9KXPMT!DU&&
M%$OY_@BS-3Q85(VT;*'N8$+9]Q0+DK&A'2R>PU?;,A]LU\#O\3)ENH9$5==3
M(.3;&-!K.S<.[![Y^?N3,$ Y'I#9"G].(E3J&E3,LJ38E9D<5%N<$A$!\KJW
M1\X"O/\+X.>^HW*=0Y*B^REX9:8)U<!+CH,/EF\:]A_ \/!NPKBBW8&028+4
M6;C,;*$:BJD#[4&R!_B3LA,8IF1W,&01((6P2Z\G8KEB7W8Z$#-E\UKXK/#E
M.9L(*9!=L(3TH5B+2+3RXUGN]]T!K+K;*4A=>%Z1G"TQEY"9WW8(H(I.I_!P
MLG>T=W.<"/9@>9O1 H]6_/O.X47H=HI8F56C"XBE"0CQF*4E.H<:L>,I;IP>
M8Y3@]H^?C]\K\WC%3),J,*M[[!OFRPOTAGG?'/S[8#*>31Y']_WY\+YWUW_L
MCP?#WNR7X7 ^:_" >6GXKY'.0O_#RC"V,1V!'?CI3PZ\3'[P?=^KR7+_"O[9
MC5^=85XZPXY\9ZG^_>JVT0"K(U825JM<@/)"R@RZ6OH]#$L&Z3B]I@Z YX/'
MQMN4^C@G!UDJN(_*YO7R11[J#+#AL*81K?N0EX=2[P<#P_-VEK.* D5A*$!5
M5U%*T*!;9$9]B;O/E"0,OW^(W3X&0;F7"TT5K7C!+"@A@ ,+'>!>\M6518B1
M\P;%<[U=E)"SE #9(EH!7BD8IV@0$L?[LP>VAI7&-T_#F^>4AD&=HJ969*@K
M+R'81$<X0L,&?7&G1KBIC25P \.6-0O$.3104+J@D(49,_SQ513%G_& P"PA
MI^4^.])YN5G4(<4A<"?:"8]=QR3. +CB>I"!23H!VP)>EM<Z1)C 86 @#_TH
MG\!1 @4,&XAU]* $NXB<M@+Y\X#,*2*S!:J<'TK+:L($:M%X;15D;P:)NT ]
M0"7(PBE2EL0-7R9S!LK'6(QG338+TU97A@F<[@<:R2U@>RB/-737!_@*RC"#
M"[1$IIS&%4-J''TV=L@R2F<RSA?.:^:K/ _"FB#B+<84<DIG0#'^.OK)=^H$
MB$=0LU76!WH.<@NU(\@^/N[#YY-G"'(E?>C20-[N7SX4M4:]C]"/ 90R\KI.
MD'?VP%"]VH!054]E3O#84]93@&96Z6SVW$K*E!?6G2<,4@NU5$L@!W8[6E)"
M>QK0;3,[O)(04G#BG-GP-72G ZOHG$S54IV7F V;M%K6CQZ,DG,R@4MEQW/:
MU4AVD@]L24GE^, (8*F#$Y60G"Q5ZMQB9D(K$!VACXKEE7-[<75[U7$&4$FH
M@U/K(5WKLV$M1L[ V%J!<1S0MZ*T?OBS"-I]ZU/?-,--:*,7:K%UUMW OJ^!
MXUMO2:9ZE%EV#(+)<FZ\XZ\R6%K1D#0<%"# 1U:NYUQ@6 Y8# W/@9ML/Z.B
M>["T3 OO0U=5,:>^&XE1-KCQIZ;,W?>D*6J.^E"B'PLH9=3?\Z:FQXURC!!G
MS**7GY#KKAE;9#V>?X[4O@:!91YVJY4OZ3_1OZ3O_37WB;]I^++^\K+]#4'?
MMMT?",8'U[MWP]=@&=K%UX05/C,L;>2'PV=Y(9'KP5.RRVPLO70'&\[V*CA0
M)UZDTD5T6'\&7A08DLJ$A:NL'6\:B-U]?\V\\''8T'X8K.'!Z+^'E8)(E.-*
MFA.$2EQ.I@^%;-^QV%'^&A9:Q!5.@A($4;O_P+=,8'Q\9<I:)T&+*GF[;Z7(
MW DP[C@H:FK'D;HR\[)K*,$3RHT&H8;.O&#98C2V7"C$!^+N E-:?QY4[RN:
MQN]7B0/5FPKJ- =:LH%R.]$T*T"1$BT:-/<_]"?+Q*,9_C9R2<M<'*(K0TH#
MYQ4Y5.AL#O]X&H[GL][DH3=Y'D[[\Q$LT.N/[V')I^?I\)?A>#;Z;=A[G,S:
MCB4:7Y#N.T]AY,34^'YUTRP#8B-[[1Q9W[#75]E"2@YBHD[++JLJ)>)D;;3Y
MS=N^%V0@A?\ZP G_@:+=+$(S@%M6X+U9)NB_6\=.M+AB>05\@0JXD7T;68G/
M 50FJ;"PMH=0=/\5=]._=S>&=1P<FUA6&:R8U%Z*%J5P0B%C,K)$O7X"F]="
M;NS2,BI"1:GS,N-)E632[V<P#Z '<&LS@UN;F6$#OQ0]7#%E *0'X0 <DU"J
M8A<YI%4 =URF^ZA12=3]VZUOGN&0I]-,"650Y3&95LG5?6SW.SAXZ 0C^%?<
M@ZYB0660KK4;992K^TA/P1MP0E"5=^*XF+HHDP$K(DTEF?0%EA?.#U!IZ.TA
MDO1W*U@/0C^ 1V\/GL#M$-F]4-@U^+\%WN.^1DO*L84*="Q7&HLN@$YR'W#Y
MP63YS747V25UYMKXZP9<!>684GM>892Q^RO)-\_U?;BU6F*?5V1*Z(-SE5"\
M'FHI$#!F'T^+O%? EM<'=#81!<<=OI&PF? !U#+*TG,/ET3;C>*R)[K ;AL(
M=91C!AO 93L%5FF[O\5$DR#<]D3=?@#8&"#'Q?+:^ JU<=EM[*D$[/YZ/P,V
M;&[U#3A0738D>G^QL1P+J2JPW@!Y-J"KK!TU&HC=_0??!>71[A^THP&=A-T/
M$+67\_ .O0KS0TGE4&^^6ZP0KON)C,:NX^:%3?-UD8\,E?7T(4,]487$>Y)I
M,QHY<"4"?I!3058WI'R'U565XTL]V(OTJ2V\D+!1+9/FP?6 M7+B9Z;F;NX9
MC@]5!P7Y9E@.FE?OP!*6P1NO&5K0ED)-=2 THBVS,0/C>O!D^2;<;!L.<$,_
MUE:9]T%),>UP9Q)4L]QI6-VQ;D2T8T4]B;M_)CGLP=-K/,L)H>P'7_AX]HO+
MP3D0^,-WJ% HN>48WB[:ZZ&PSN@"T(V.\^F:C-VO"/NB<JRLO2UN6TD"8M/(
MG.?V:DD&[QUP /XB#E,ZKZC;SK.)3L"F[[QN8R8X8(6>UT@Z=X/@,(#Z;X9E
M(U^GN9MYX92$:[HS?,O$+7YLK>A#%QZ"\WH;5CJAM'\^3\,!IL^F2;PI+:L/
M.^C%2\_8%YKLGH\EO[?L,, ^(L:4UI<() %3*HCQ\6J?"K\#E& 9+/IO<#^V
M N,0>3]/EH5WLZ1Y@JD-?6C37.R43+JDI,-H)!E/M&_5&5O1GE!,@J>4TL70
M4Q+V.@UY77'W1%%3'^K4%3:EBSX^;+D]/\V!2#D2U,6RXOQ#Q%^3V8(F4C[<
MY5GN O[<0^G^[D'\9Y7O:^.&E:-9?;<',;I(J<@W,]:!C>V'\2 I"G]9UW<6
MT;_LF R+_X1^E%ZL(F&&F(_ED/IT(2^LB&#RL;&<LSZ[[R),6++8=V?*<4[$
MKHQ(!)YY&$J68TE1J09KPUD!?^04TPS\E(,1&Y+JFB4DU>"7_OC;<-8;C>$O
M)H-__3)YO!].9W_I#7]]&<W_D!>"GSI[(B8>&B'IP\UE^WNNIL&J9([PFAHN
MCG0*^=0+754'Y%@=:&)S'32L2^)94=51A@(,"!)@IQ91E;!)F2LP8JR/0CEU
M@:/&H'2AII"R^_LT3"9"(@.(=;1D [O$6B3OK$XX2.8);7T].=-(^NX_ CM.
M-TBD2GEA+7G!(&KW$UX<Z:DTC":Q;%XOEWI0@%Y2[$.QCH8)4PK!6OMZLEP:
M//;FE"Q5*:3)H)6A324;I^W_-K).P\YZ@0(W9K1.&63O@V[#3R4:I[&N%OJ'
M"PI_[F*./9%Z7@T?1)D$X(8V G4*X$#QK0 D$;#B.Y<I,-V5$[42)>?!'BG%
M?E8?;DK15/=/(]&,'N> N0\].*1CZ2.1Q^!']!O\GH:BKCX,JR^NX/!7,FXR
M2E41KP\U:7-467O>T,@K('N?\HOH05OHORCC,@HDB2-3DR;UH1AW+32-ME'Z
M)$S!&2N:O*? #SS+#)+$FOT?AK>(O \>7&\)K"#T:BV!-,WJ0T$AFA"0A5"F
MFQMQ)>#/0OIVM:=A0U4(R(38@(>8@!^D$1C];F#XZTG4=7_X#CS3\@LOV>HW
MU'T*<9:=TW-8;IM^-M;$ X8';2I:TILW=83G]896^>/B85!5T*MV.WG]7G60
M7'Q%Y_4FMXG[19UY"(T=&_A[Z1+'PT1FYLF(W%SW22-$ [R>X$IUW='NH4D7
MZ2E!/[P>^ZH3/I2T(,0_ABI,DZ[46$\+;>C#N^9B\WH,K(IAEKA6-&03IA'M
MZ<0B-Z\7G:KPJ=G3\DZSH5HL;F_7%$E^QLTSJLNP4\J68M_4HAT[QPR=XM6*
M!/SY.$9U&GTJT5+PFYJ1*<"7]7 5'BL?;/?'?LZO>*9ZP_1,M3_[I??P./E]
M)N]%ZEY MH>HA6K?OWQI?Z#"I0EUY-ESWRR(QMWNQ0>+D;-/SM&'YZLW*[ J
M\]NQ-Y0?#]?R8GJP 52ZO/,0O?L/Y!IN\212@#.43%M OO#+?067]3E!WI*.
M:=D@)_O<Y3/?B/C4Z="Q->UU_Y%'ZAB5F,/[SN)WP_,,J+G,"7[B#6S#PK[T
M86I#.1:V1I8B3YLK3LBT*M-AZ![ GIN6D=B]^QO7"ZS_1O_$L(]0X\RU^FKJ
M_M26%7&RO >OP;WEFV[H!,\>V%CA!K?V5M4[TZJILCB](E$GLFBD6)3^%T[<
M]V[X&BQ#NV]&>B#D1,96.3.L@9X$O)67:6Q,$[1-G)EAPZT"U ?4:;![MHWX
MZ7F49AQ#,KK*9[IQT5C3MRO*/2$8;;:&Y<7VHA%D@+.R7FW0]WT =ZB68P7
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MY0@C5E)FJ-%BDQMA[*()-9_=M#7JXN0*<^.=>NC=%H?>:#R8/ U[\_Z_6Q^
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M4 *8^"'7'F3UL]DK 1NA7WG@JN7HYFSY9+R3\<O^OLOX5<HA_:19"[\9U#=
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M#,_;H=>X]&X-^2IYTEZK8?TI5W35&9Y",$[.#.I8>;+C$AY 3&+$]O+"G68
M@TB<W!DJL6]S*H8+D&-:6\-.[%:,Z62_7%Q7AF'>?Z*7NHRH/6'#3W^O8-+U
MU>UU;B?2_EA-; $6\+.N.'M=CQR4&GO^PZ48R;1-*3/.&1 B#_A&DG??SY5=
M%?##N -:O<9.E5-8V15][G*B.PINK*#;6O!/Z]#P7)_+VN!$MQHVQE"+*=IM
M*)DEX^6VUGY^#F#X@''W][4D"<>P/QO.I&WP'E&F'4!])L<7;WO.C#H287 /
M?-.S(MZ0\FT0:N2)>0.)>2LY5GP%*KE)DU$N3C&EFSWR_ ;<E6=LURBA>-5#
MS^.RBJ)%C\ !0W8YI:('5L?]Q+_AQ)55!CUVW1_AQB2A"-Q\8'Y<N6\_F\CX
MYNUBZ))_')!+?O#]97:\"=G_0BU,F/2:V7F0Q5'K\,D&W?T0 ]W]4"OH,.(H
M>L)K+Z"!/FM<I8P424PXO6EM/V"![-%)#<(1>$S2B4U9,MD"ST!A'B,FCAPK
ML Q[:'CV#ITW\5'0:.JI!1:3TH_.W[6EE;Y(4L'.C/>) ,V L')A:/.21/&0
MD=EWLIP"I(ST%RRH4S2B*Q/JBM[]6+>\,L9U>\_%*"0!=E4"B?#)'*<"JI28
M5(%9(:%0.Q&3G18E#4F?(I=.W:2B>=D^J>$I0PU"F;&64D;I.[%:AZ:!Z_BN
M;2W@06,Q=((XUWOYL1=75#G$FYU\F<0DW(6U>_@MZS7V](LOK R6S$A4@TB0
M4.P1>)"YEWR"LXB)7"1,0@!P0GGE 2)H^6@#S"RF]!F6 M]AZ+E;\&WSNJ;#
M][B\IOA2B2G]I,MA[P37'*BUZ.HW-&QT>".<:'#%E2$!OW,-DZB$4#;R3C=E
M$A#/-_@*"N++@ X=N-)6V_D/**P%@G4?[O<741Q0-^H@*8$DL4HGX**?E^M(
M*^1-B!(.2(\5H6\K:BG(C>93-;O$TA.)5CS:G%L;X$<B38$#?AAV_\VP[!+?
M,\I:'8&=#-K1O%!3:LUBW\:*S!OG$SV@:98X2V!K:4:7)E(+#9C[21&Z'%_@
M,+'FN')>C9\OKB\N]24/E?":A>$]NA-^WP+'Q_E$EY;5E"'TLJH529?JPMSO
M.P[<NL/I,D@D&SFF%WG[X")9,C6@&2<X*4!HD%Q>P86.Q$0"]E\33["2U82J
MS@G0@4YFH4%N1827FJ-W4G<A5"24=+8U3# QS7!K'1XKX>)+X6OJR(8&D@N-
M@RMH5DBE&VVVGOL6<;YOV^X/%))Q"DQ@O>%.M[4:TI$Q_!3!*3"N*F=@(1F!
M.L^96N)RBH>K3C"=_*!YM(S7*%4!U7%E7UI39K!(RRLRKJK,F%JK=3!9OOB@
M#U6+FSJ(=7)ZN[W0Q6K&+K/8@+<2 G*5F'[0TVDTBY8<?FFK:<J76F+S"J.+
MFUZ8[]\QN]K^8F'%/2LYS27'^F+ =9:JFK&BL>ABP^KRXD5>KKOX8B%X<+V]
MB3@ZUE6?;[!5\\JYE.]FSOU$PR:ZV"B\O$[!3ZX3K.W=7M"$[,>W]\2R.B+/
M)*O8>+OM[R=FP(R2!MR#K>M;N+WF42G-6, B98J_(IF^&N/?]X Q63X:SK%)
MM%A 4]0K!$P!UR5E=7Z=0QEHJ,Z7J*"F!* 4-"6"&$NEA RV)6<C=/4S6:;N
MD0QGR7Q%38E24_"4.&(2>\GVN4@C0U/-(FEA30G"(&SJRR4FNY?L9>5W@$QS
M8-%_@S]=E?@FX7+/LC:3U^U5URT47-604DR,Z7-/L79"CQ[9>OO.8@IL]+@J
M?U_ &J&TF#LDCE#ZH1=]\(.[_("4US/01WMPC]CSXL_V;/3=GIU^^!S35*TK
M#V6F KJXINR2-?4=OXW'F0,".4]*^%^&=AMSLDR\7+]K1P 7A?> &/^=7$E'
M]$FB-?7=W@_Y5;1PJD2#RDP E?5T)$.%= )<M]O<TAU284R6.;DM]DCSQ3Q#
MZ3[N\)6>N^P%:W"T<T._.._=FIN.]J3=IXH*P1@B-O\![#<0W;&0WXFR-Y<?
M%"C%@N3TC^R1[#D)+3COG(R( 73:J4ACQ=;*2?"))*O0!X:*DXB4NXJUG=,A
M$E9:H>\,U7"[PRGEP0WQ4?_8FCD9(F&%5>MY8KL\LMYXS$BHF=/A$4Y8H:\7
M>3US996T[RSZ2]@E#%NXM-E)ZHB37.@;2'7GHX;S4"=)Q$5(7N\C,X9;U6)V
M['7QXBP2WWJP&+Z;L"CQ[5NMMO1E$I/$0E]-RG8IX7(9U#%JL,C$Z6%D^9S2
M6I[YD0-_".;&._"SP5(?7=^_ TLW5X#-''Q;3#PZ&@\F3\/>O/_OR"B<_6 /
M%O)[K]$G>U;TS5Z /BK-++P7G-HR3*@!&?3EXOKR\N+KU>>+Z^M/UU=?6A_>
M<?<0L@]P@"!G.<L)(=<3TD,PBHC#O_B!91(%KM6B<M,$*WC%R8.W-G0(65E#
M)P_PG]8*%Y.V?H-GQE4I@Y/AN0GA,$?R&H*B6UOD#^S:-@J) ?=S$.&"@RSG
MUC7B6!N:X66>;CT1>T;>.^" I14@_338*A4\((^V2O,U@)NCZ$L]A/!YBR3F
M'1[*5]EWX/8WSN40]S5YBI@@738*< _V:C:7'RPW79Y&A*B"F]>E1!<LC ZJ
MQDV^M(9$89&TZ88ESX.YS&7DV8,SNK4U[(&[V;H.JH$>-&VVAK.;W2?2P)*1
M*[*/!E)=-ZW;HIM6R6*S3?O3,_<=2EVWDF[]Q>\MDHZA=2CVSO<C]WP5W+JT
M6YP*+!B#8++\S;##>(2GH=XJI&1M1L,YAHL*I"=SXD^H@_D3[O@'AN?MX.;^
MA^$M\!E-J5M0CD9<2$#!+4:5:$@K-%23GR6+.EI!X)^QHIU%LL;[P\W6=G<@
M]VM:YC7ZR,F2D[_6A!B1Y"8%+NHLSJ6:&\Q3R!&([YJ!KX163IF0K&K1(8-X
MY;!$&O#>4,CX1=\TO="PJ==DJL9.F7 UM2/LX4]#8SGEF")>\M=O2'<B<=:,
M6AZ1 HX4P1IX2#NU3A-EE74G& =M:.8>6=#$-P\>I6A)%!4^6=+@I1?@$RF;
M%T7UT9*D6#.OLT\7UQ<7VIF]**7F:V97A"O%F,RDHJ? !IR8PF[I98"?N3:!
M\M*;RLOKZ4T+!IFEGX4$<>39<[? "W;/MN&@<%?#_Q-:VPT^0 9C*\KQIQ[Z
MM"QBTX,"M_S5)^R,=%&\*/\0,*K4UXRRJG;$:"R\D$V(4J>:O%YI-R?Y6MKQ
MIHG< C8N)<]S6G02F0+3=4PH==3H9(GQE6'U![FI\ ?)?Q9Y@1R\#WM_!?&W
M_[;W3]3/X>/F]O+K=?OOL8;+)3 #Z^U  90M)X]&/W@ D.6&C1SL0MB'7:XP
M1G .+2LWT[""69QC1&FE^U?Z-)HI]_ L)#;AT>2)<H])'0*B""E(NN0Y2Z[$
MO04K(L0L)&YM\E4U?:(DK*46Z5?TF(,<C<#/P-L8R/\U5R9)UEQVQ&O<J$;,
M$JB0[IN<:/0R6!O."A88.E#9T?&GX;:NO$&-*"=(&0(NZA6F6_VK-<Y?R6/Q
M6?[%;;O$K*LA 1X "K)U[W53Y7U9K[$3Y1ZE(GCY#ZA-L<CIIK_X3^@'I 1+
M=9HZ47I1J4% 9"4ER,7P>)B^@9,A$K7P F(SM6[L/Z3('CE+%YZ.T#]83?N?
M*DS[AX_TK,-7-#3A?[JYNOK<?J0^_..ON?%JX_;0%;4Z.]Y3$(KCO8[$G,SJ
MMMSG__TP6$=7BOUW"[<4E!=6C@9U0"Q2@4%8+ .D@WGOHNR U'#&Q94#E $*
M&AP)4JJ"9!J0;8!B?GJ[)[!Y!;@P\J5E.X A 882OPMJ(;M_RYF[7_O?H6?Y
M"\M$4A!I4%%+-T+4$;?[=Y')K1?-M%!65#<24,LH_>)/X [^,4TGS+R+?RQ-
M1*P"+_ALX>I*+GV>P%P3/WNN"< B"H(X,VPP6:+76K3!4NHTD5?/%Y6)08;T
MZ"J8AQJZO]%@CK-S4D2I*;3TR:,Q+4H?D1.3-Q!J:$P,5JDY;4*D!M(NWOL>
M7PVG5\9$PK VHS&+N*A":&*T]F,=D;2[L6*@_8GSXK-;KH\;T)A9#94@S--(
M].75P-U \:)+W;ZSB"_K5L Q64.47EX44X<,)D]/H_G3<#R?]?KC>_CO\7PT
M_C8<#T;#F;3[*I+$53=8L$??:[7S_=,E\UL4S,&&ZKME-U6,M949[ V5?G2:
M::@ '1)\/%B.%8!'ZPTL1A!"9V5!:6-7M;O=D_$?UQO8AN\3+K<86E"&1CS0
M+[&J-=2$*I<H!#D.4HR-#2#>DC&VH@PW>*')Q ]JC:C"D:F[,^Q@UU]Y $1#
MB&A3QY3N$N;4"!5Q9Y%>@34%EU;7,M$[X;T4I8 32FH.-JOD6'-7V[E(T1DG
MN_;=[<9& %<^E+X@_3')N86^@;P>OLI[I")F^6^H"(+]4YY!(2]3(@]QV2?4
M4 9_3HA54:!:>$ZK.>[:R]A!1=C1+?'"(DS8I0451ZM:N<=75]1"2K^@PN!Y
M</:=N:8%_PO,,'+J<A:_&4'D=(S'F+JR;K@W$USZK503RP_.PZ%&"\JP@N_:
MS4L3W?>3R<0B,C:6$T&99G^,PJ@?[+SXW&:XFAUD#QGOXM)?5PL"%IL&&T9<
MG(5W.&FBYSQQ&A&DNL-I=@2/47!>G0-O4S;/T-;5F"/-]2!@&6H0.P_'DA+!
M^F'@HD=)YA0XX(=A/P/XV>.9A+&V]DQII@D!:Y& &:521K!HPI6T]IDK1$T(
M]7]H/R9GUCUQY/LA\@J9>+&C(@I66\B30E]18R(U5(+TR"J8*28QN\-S/])3
M2=@=3"F-D6:16+,D)(G42:15\CU54DAC(C (+#U."/D^"K])R!70&$M*8:6'
MY"!/TV@>>G1_ "_RL2/,U/F">5%OM<.57FA>,3,$XONRW=+A>RAX0OA6")T:
MBBXZYU<Z"USSS[5KP_[[\3XR^LDD$J"/PL2@]XM,'J:710_3V7PR^-<OD\?[
MX73VE][PUY?1_ _T8_2I7JRLGI%\3)K#:5$58S>@\3 E5_S^Z;K]?/:S-1PL
M=X8/%KF<PYZ'O.[1&+G;'8HDN\T^<J..@?<G8> 'AK. 0VCJVO9#[&.-V9F)
M^9@RLPLKU,6=7(L*DGX_JA)UQR$IM@#O[RA#6 FT$\IY@GHYT7T;;<UG@>$%
MW23]-U@0W53$9PQ2#D\!7SH3GR?Q:14LW?M!.NDA+DM@(8^3O;H$D;[D2V?2
M\R0]K8*;WI^ID"ZUJ:Z&[ULK"= IF/8E7SK3GB?M:17<]"I0"=JCHQ.ZN@*+
M^]"#ZH[EC?3C9XP.4"G ,RT?Z]/$WM"9M/DH8USTU_1J40E.:G36O#QE2K>C
M7T[7KO%I<^ATG_2_ Y1?%BSZ;\ S5B"=,)X]RP0(Q65;=D/*CBBS$"AE4VRB
MO/,IE%*1<L= %KO/%Q=:[8":T%?:N"H%Y&2LF3Z3#4S$L.+7@_/0XC:T!(-R
M FM5E09+[&PR1A=C-\Y#K+4AQ@.9[C^X:ZS&$L.>C''&V(WS.&MMG/% IOM9
M>CFH,5:2Y%'&T(GS&&MQC#7%1?KSF;-UH^9A6A]KN"[FC;/]/%'A(>C)P4?:
MKTC%*/2;RBQ)\JWB['K2Y+#S6JVS5^8I80I0("#X<_0: VDPC,,H7)%8WFY/
ME.&^/ 9C1I$".*@;<)/C,AH9-5&8R](]*DYA98^TI'?J/)B.GY"I"8ET0[B@
M435 41%L6XG!5+<OYS'$>PQQ14+Z=D_0T(GLD4H,G'H].0\;WL.&(P[2#=7"
M!DWB(*O$L*G7ESQ@E_)#OVLP<#@BH8D%NL%A,E$G"AA+J<A+0>:%&CTYCRX!
MY@5>. B(HB4K:,>#87DHZ2*8+#,O.%CC=EQ1QNU 7^N]H<_UW&7/ST;QZ$3P
M#MI*?#89A8]@D[YABJHWB5 I^["@,HBE2@ZE&51H-!=%F6:2447(M((MKPQX
MS%"4O1QC$5(5*+.=):9'*194!KQZ"!01I!11;.Z3_!4V2N[DK%!<TT\?+R[F
M[N7%QT]?\;DRJ"LKAQVE[H\FSV;R2@\'Q$B!FX\WGZ%4EQ^O;]DI4*BL.07H
MY%75V(^3ZNKC[=>Y>_WQ]I*= <=U-2< E;C2+=;E"[CO!9G%&_[KL'##?WQ'
M4H*2_5;N=\K VV!O52V0T&R$-#"4CL.CWRH#1;4^2W1?9P5M0?M/QKNU"3=8
M_>=^G^\];.?V5C("!*WF,:B60RH*ED-&(?O[+J-0*0>GF8C:4/)(RI%&**X,
M" W6A5HR*KK6M^%<N[> ]GT_W.1O8H2XJ%=^4'46DJF$,=NWIRFAR=>NNW,-
M5JZ]+3 #L!!RVU7Y02V)W9ZFA.:+N^GZC!UK[S?7ALW85AQ]OYVIN^S+6E)=
M@LJ$YKV3-)GS5N.]]68M@+-HF_'9[Y[YSD-A0C/W=9SM4\O_\\$#(,V_BY28
MG#S;(#WA\V?N<]2; +^U!HE..S $8A.8M"$0?_X\!#CJ36B2QOT0:-_7#,KO
M68YOF9&"6'W,KBE]S/9?21S-.N%8QO* ^;.$A=Q<@T6(4L:6#XSHIRA%\1JR
M[+]@\0(Q]#+^A,^VX?AWN\)U)"CS:&OGH_F1=]V-M^L(^I+)JGU%<;*QV0J9
MBFMKB>3<Q_]+RO!6(OMHUVO^BE;%-;&!O$5IB;Z- KZD'H5;8@]7WC)IMV6_
M3#!QRIT_JHKK1 TF@*H<MRI4I.6\A+O%%_LQ]2C8\0665=?2_4[5&@5#9S%9
MQN]!:\7ZXO=9]49&>Z04/")HM2W4M^&RVP/ET?T!O 3*8C;Z-CZI]P"AY:CH
MQ8-"Y])?KZ@U,EZVV[9'QM$GSR.CA9%!H_/SYBJGLCAIVV29"9>6Q IH8Y#@
MOWX>+RV,%T;U:^(C7?!7K*F]HM9(<9WOP,IR4("-.\-&8=78G$_E=/$\"%G"
ML"B$D?2P81T;J7S"+;?>N_/X5&%\LL&C25@R/I%Y\PXQO%VXJKYW'C[",UU0
M*)R3LU>34.72AX3BB2UT&QI\+-TB5<W)2J'@H&AX5,U$,)1@IRA^/8_>#43O
M2L6!(I*K+1DI*'4O]()(DOL\KZUL486DHV8K%@K&+IV'F^CC#@] -+&Q\PFT
MF]\"MQ!A^>B#YR%#/62$J9N3Y;QL.]?^*Y:QZ_P&?#@A)+I@?<=R0_F.!7[G
MPUOTH21$LJ_?4Y:ODEQ.&E ?PA*CDF[,XH4&)=1\B!-J"IKBJC^LS%3'2@'^
M$U1-96GB-\)?<>UR6ADB2Z9C:^-"Y&"(D^[. L,+5#+$T&^XHOQY^U3@WSS7
M9S.Z-/K2>2@0AT(+RCZ?YO:0)?^&."V!U?H:0?[Z>: (7S-J -#TY'<;#QX'
MK(P R$S;WD!_O[6WGRK[U'E@B!H8U-INZH^DPRA0]6!Q>1X,[6N<DQ=0?+08
M.ET?$D=7#-'.]!X.]4,P(0I?B%8[HLRBHI"IJ9GRSL<,>D5*'P9Y!#_)3P^C
M"(EECJY23,XVK#)C1Z,!UEXOSJ.,:91)!N:\@&$-)=(7-.8.G8=>ZPL<'XQT
M?:3(:I61->0HOWX>7VV-KR: Z/J.\%3.9+K8]E0;4TU!$6K^:]\C< IUX5DH
MP4/TNQ?'"EB= C]1.@4>/M7ST;=Z(?R8=GZ!UU>W5S>?A64'+ LZ39]P3^)B
M74.%A\'/+*$J,26CF6<./T (M)PKHPQ>S"HO3M75@JD"4Z4-PL<9(0XR.@OT
M+&-L;.K$)&[V*65(0X]\#3L0+\6H0KJ2I=>?SEY*8P]3U5&.!JU!6F03NZ(4
M]9^NR-,\1_NPR7+D+%!^KM"P,>GC2\LI0Y@&BPV;<#+3RA=Z^;L5K*? CA3L
MKZWMW!TZ<%^]*UT_:K20U\!G>9$ V#"JP+:&S#(3J=^YZ.RYO+<\8,(6_<$:
MGB\WAH/-K$ZNH#:F-;#)HUU#>$[S-O]X"Q7$>#(<(UX%L50X+J(Y^%3BRIS!
M)\NE90(/BU?N]YJ#52TK]CI'D&GD$9-R@2VMGD2@&NR":LFHR7U;'=^!L>O$
M]N TNQ\\+831B203 2OV!N7M3\+P:=692:871U>/ICK3RI6JSN5'46_!&GCS
MM>&DD1E6*R]RT<_'1,BHE_<E&8<N:3D^5-(E)[\H-<8-WXDGNB\$Q( )0CZH
M)>?;TY3 <"Y=9G/BN156O&H2]M$SJQMK2YN'>B>UGY?DYJ,NS2F5=N*O\$YF
M/Z_!^%!*F9Q"=JLP;NK,.Y5Z/7H*S'NQ8/W^>5_$4W$)^;\T)+^M:O))KGIL
M_:$=QZ[ET?\"T;\Y#QL1.DU&U%=A(TH)C^B^&5AOZ'*,T3/Z<R//:"/YJG8N
MTI]N;Q7UCY8X4[#JK_+N#R^>*@Z0#9VCU9O6\2HO3NG5@JD"DU;.T1))0X]\
MC0T +\6H0CK!SM$*T* U2(ML8E>4=.?HEKV NKFVU))1D]@78D]'E"'R6^N$
MZFPE4T[* ;=*>]*GN"Z, Q6MHEU8R\735QE;*]_AU%W7H4HMY@-7M3ZF\I\_
M#RFY0XH"#7T3B_)0X#[VE+0!5>C!>4S)'5-T@ @)\W^XR;C1:(S%\:BD#;#\
MY\^C2^[HHD#CI%T2NWVH^JIJWGAMQQ,-'!IY/4KV9E#"H,?22V6&9W<L?HW5
M>SYQG9BGV&FL>HW'A9JCF32$SV9(2LN3>F.Y47S_\X!6;D#SP/-\9UUI]4+O
M!-4;S"R=.X]DQ4=R8S %!* Y!<.K>L.:L7_GD:WXR.:!IR8)*,Y'9P;454A:
M<1[&W+#4+-=%?[&P8@E&SM+U-M$G6-]T?:%\TW7X6,\Z?$V[MUR?KZ^$N7(W
M>\MU*V];P:J_2@]NO'BJO->80<5&D]7 -GQ_LHQD(+SKPI97!D1F*$IF=B8A
M58$RVUGB:ZUB067 JX= $4%*$3E!AYD9A^_ ,RT?/'N6":9P5V YJP<HYJ>/
M%Q=S]_+BXZ>OI>^BV"HKAQVE[H\FSV;R2G\$P$B!JX^W7^?N]<?;2W8&'-?5
MG !4XJIE6/:!^7'EOOV\ %8\<<._'.9K^(_OCV!EV,,H<G?)8EM20AF0&RRO
MM&*)"!5?#<D0G\/C^-?*@$&KT3P&E:*(71;_-UC"(6D!_]$V^\[B[N/4LL'N
MX=4;.29^-JRNI10JE3H^FOUJBB=]W6N\:TT?0A/.'-DBRH#,X9A1*1>G3 S<
M,"*>*D@OVA78E%0J&X^/M)DRHE=L$T1]F3@ /S_BRBH+!/W<R"2:]!D1@^7\
MASM?NZ%O.(L'-_0" )PCN?#8TM;5 .M&HBK@]XG;\X3V[NKJZN+R]AEXD579
M,>.+@>A&@+#MH:FH >[UY92>#0<#^0-X]4+#VUU]A;^[8(2=NK(&T#>35?IU
M-0;^_M:S[$O(Z*M+1NSI:N:4<7EQ<94+SM<)X!L(RNF&DS_JX2KT@\L+]!M6
MV.FJZH![ TDYQ<'N;+9?F8@W./*R"8>=T[7/]BL37C:,*K"M(;/@R[C-UG9W
M ! /T85":H-30\G'ERY4 JMZIDY[#P^-U9CN"YT*IF2!U;HQ4R$KMUY4J"F\
M GG6<,90X%BN%^>:]LBFT-*2&F/-*K6J9^:<",1)O;SD24%,-;W+.R!+CC+?
MT7,2O6!8@%5[;-&A*/.7E_+MI]7(%]G2FF)4<745&V5>!1JT!FF13>R*DGX^
M;$RH],R4N6LDD@E;_DRDNDI2X/*V,8W0^TO+61%V+)D2RE"%PWZE2BR"V3Y]
M]\W\'HD76L0]1ZZ,,HC1JAT+5 ?6>,S$%4U*</(RUUA3;HT65$66:;YM*F_W
ME_%J#>"L"C5:.!'.D.55U(S,ES/P2TUGFDP;I\*;"HE5]=NJE@PY)A),DPSU
M.TT%/M(J:XNN%LQZ(UU",-3/*^9*3QJ0I>V^O3H*SH$.NT80^H038*&<,NAS
M. ?2"4?(YRXO-7NNZ\0S84E)93!D Z("0()LZIT24]/5P;*5VI\HMVY5#:B-
M,0$KTNZMEM"*'A0K?$?0F_*RR\3<[Y0!N:&S)5F@!,"O,APLHYYA_74ROU4&
MBFI]ENB^SO!I0?M/QKNU"3=8_>=^KQX"A'[E,:B6HYN3V)/ED/'+_K[+^%7*
MH:CEJ0*_?6"CF0D< VYW,0M2:;F\'JXOKFZ_=G)QHA<N ?E6_+U1%6Y)3U\<
M?PM,:VF!!?8! +:L,OBQ@7 $'I-T@A_( ]-%#X6]8(?L"^G+X8,'0\6;*Y;Z
M:H''!,*QL::IU-*7SFHZS*SW5*Z^LYB!-^#\$CH+V+4':QGLZC"D3I-:DH:;
M(J0OX=0A31_3+%FE'*%,JM71%;N6C.D4<:'8]HPEZDW:T4CVR&3B]\-@#?<=
M_SV$&#Z.@D.LI#H=R)@6[4@UI!6P=LCT(1JXFXWKL#"$4".OL!LX$"4%9N=$
M#U91!:P'!VY\DA!;&0H^\OT0KK.A9SFK."U#K(HQ^!']"A]HF::R;HQI(+6Z
M+]<RPR *VH^=(BI*ZP)V'3$%N DT2#F$B_ZQ6GE1SNLI6%D^_!;< F_<T G@
MMGD2Q7=T5J4[2*J*6L%?7V(!G@(RKYVCJ2V*>4RZH(P*Z$( 2LD$A'J1N1M(
M;EK3P-AH)4-1;P:N'V #GQ*JZ$8&9ED)3B0GE82N-#WG-\_UL3M+_E_2C8QM
MJ0A[#]]DS]IE%D_"P \,9P%7_Y$3P$V ;YE"\JE5?2\/UR?E_$#:9C2;H@C7
M=CQX+>$HKS&O3WNJ9M24"+MV V*S.:]3*V6?@+ RL:7HS^DR#TO14TI6,<9V
M"6?E?"3PX3O2(78*+2VL"Y]J2)FR08QY_;/0J2N)'F#9D/ZN _PG ,?*? U0
M&</9P7VVB7!;,4Q/U$WJ0AEANDB))28?/"]B(8.SY?NP9U,X<?;]@U"3Y=X:
M&1W5GCW7!&!1:JEE;R6OLL_*A:5BMMIS$#]EC-KF_'&(/%<FRT?76<V!MQDY
M2%;K#:"9MI0=Y!I:,:&&J"GJ8DSWUS+O_@?&U@H,.[ZGG$(@O3> G*4>PB#T
M0&K,K/8(H&M'%R+Q54!*+S$7!NW;TOIVU"Y8E*_9Y-TO767=B-1 ZI0]8NX3
MVI^<:I\U]T?*/AQLF_C@F<O-RMMD5?E!W5C:LJ929C>]95"*V:_5ZGNE4]\6
M(%=EM(6Y)#%;R >U9'9[FDJ9W?2>0945G_/$$*OO-Q>%G+:A2.C(UL[D7?;E
M/()?3O>.N*'*4B=9,3<0G=^HQ'J\1S'7@;-HF_+9[YX)ST-A*=W%W&%TG.Y3
MR__SP0-@Y" /2C] 6DQ>3K?!>L+GS^3GJ+=T#(BYN6G_T8QX9<;1'Z2-@?CS
MYS' 46_I&!!SR=3^&-@'1P?>&SRYE^MV?^$?J=&?NX%A9W^/O&/';O '"*;
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M8H2C*)EMVUT<AZ^+S+<+LJX<HF<,T(JJ9WC%:J?-YIC2M#SE:9/PH'.MWSQ
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M1LM*_"1R/1=%?^+Y[0T7S<FR2Q/V4BC'?E;N\'H65Z!,MN$TK4\X^J5+0D?
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M3FG6<$M$8]JW\[[^G2#SV5;F##TZI.VNH+U%'1_=(T19JMK )_R$Q=I+NKY
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MC/D: #WGIN3=M.AG;6%]!=L/QTV&"4]W3-]MS@A-%9G*]$H $9GO2ZU"6QM
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MGE#X^Q&%6^WY,XEGG%5,)8P< X9'0T_A\4X@>[(ON_D0@(G T_7&<LP,!N4
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MQ(56TJ-D^]ITAR'D#R2420OA?'"#TT\<UG-?]S?6<<)VD59>^/[TG*3E->C
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M(5AJ(PB"A,-7TF6#P]MF2/PO+K/1%:O8/R +9W64+\MKIW;CA)+H(D;'<..
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MX3RJ%6^-TSK H^]D?X_=.Z <R"23I+7;GM+6::G"'MM4P'OD/)!^_3#E^.>
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M?V"=/_!E\P>^N. \KX;([5ZP'"VO+7R;T0D$:7JJ&6_L).8(<.QG\W(?#W5
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M1"55H+9Y3"68V=PH@WXU7K\5KZD:#< #(G<VQ/+N4\(U;H-Y7"14"UW$!U[
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MUA'HEJN5UZ7-^O31 VG;@--$7LGPG#RF.=G*V*$+%^)@6_N\O3?UE*'8V03
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M\\^! GE.OB@S@#%<FSW;WSUX;(" H<:"[PX<7,!J/2'F<0P6 [+S&]C 6MC
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MAJ9&/QU6=ZSG=46EN.%TM,#KK7*1;-W 3XYJ&:[6$>]SD95B?$=&\7!;&3M
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M2;TKWSO.ZEGRUZ[,Y3_IH'THV2'3W.+[O"R;)>VE$D;U[Q4PA$Q-P/KVK>A
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M&!.0\]H'\>L+QQ89-VP.7M;;23,U/*- U40S'0BN4KWA)J!L,0E5H[U#6DU
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M@%H*3/.E(ZY;8;)S$L4JX^FP<(TR+COMK%Z7PIR\BYG01^4K95C709;I!>(
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MR9]=N1O!T=(X:*A=2]^DA/+MNT1$ZB+J=@%SB^O!OS=ISWN F3=9S1W7"Z*
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MGS^ARQAONG-X<>;P;*'2,C\GC->%NN[^>% 45_^UHS6@X'J?<SZ. _,2E)$
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M<L-@O=ECGP=<1TTFS-1%;YA;2\PTGUTRW9(P_56>JM4NZUMVV0;T- !ZVM^
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M'&5748 3]&O%D>,HNTHU C:W0[:W?D[0K-HR$&0$74N94@I[O_WMCZ^/3N&
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MVY,;]K+-WKH#0Q[@*%J9#:GP6J_ RM94]59CL[?989L==C<.1JF1@^PA+-H
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M#6^;[S;ER!Y%/%"@*%\.6%)O(M9'^T2](3H8)/R,!A!LRT@+&D,8UC_5Y4*
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MD ")UY8WS&0RR^O0^G<C#]7AQ<@;07MENMJ!!(NK5@$*FEW&L.5]@V)U>./
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M16UI+48BUCMQ(6LQCV.-\L$B5X[OQMUB?$62#(G9?WSV<C,T?H3&-AZF\1A
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M>[ONV*PRHM-&\\.#>YOA4MB/27EZML3F0=,:N:2.NP<VGZ%20&>4_86RN%J
MOZQ.@^;760AY_<HR_+<@ PA6XVFH>+@@2W( TT1,[L9-/6KLX8<W:F#B<H_-
MX/<YUNNBA*]TL"FWLYS, "%VYU6*V=U2D<K]\O?;\O;$K$_1N>&%+8<2S:MK
M+6 D6QE=%6GOW.&-V#8>2X1O]*D: R]BS%#U*2$3>F'G5=<ZF\L:<PW:LH\G
M&EX/.^B48.0N<J1:4QU*LC4R-^8:#2(TQS1O09$+O +S+SPOQ1\ST) Q%74)
M(Q7+/TM9'G<5\%:>)O"MIMVJ0R.N^[])DD>G/>"G<N_4'75/\VBLMQ3^JBPL
M']+&&UYGUBL8\TPRK;O[ 6D1Y5A8T-8S44^W\&KUF(,G?'CPY,E.WT-@%'?R
M9NM9<E[E= BKVD4S&(WVY8RLS)VDU79?@KA""Y)K)O;L\*(/2OGN8 OCC"HD
M>SM+_7R-!,ZR/&<W8L^J+?:W0P4T/W W#M\<'_QX?KP98?<7-V@FFF:=U41F
MJ>L/.0SDS!0PQ&:SUTT'@EDTV"^F7N5,I1<.FT'Q9F[\HZ_*^J9:]RD34EB[
M>2(N5^YV_D%V1$N;44ZJ/@?6VV^A\A&2$JLSHK'/[>C/_G&8&_0LM(M+>MGV
MT>WB^!.3.V'LZ?FFZ'\5K)35> ,'S$V(@1%3%"36VCG,UHT7LC?. R7!6>RL
M.'!J@LU(B*9T9&#9,(&1&_B+,-.-8E>5D10AO.P?</\:X18H3/63-^62XCS#
MF8[TVX[/A:-X*]/0L40N<2; W(.4;S:I<I]P\3 IW0N%=XO)F\CK;,O/"&GG
M:9]BC@?VKL5Y@F_C)I37@W;25O[:3+>N$?9ESI*=O?H<"M^B5_S_/=WIT9]<
M_/A:_(+936F!@MB")0*D4I98(P%:RS%D27MBDL'XQ^SW!.$Z,O#!WN0'>E+N
M/7'Q)*\M5:/>:E )BW)^TQ E90LB&M!!4.J-+3$EX,!N]0Z/J5D+$1Q5KV).
MRC&/+OW>,RMK-(C]U8_#0-*X^F0>$_''[^7&6[QQD+2P;GVC+^"U.U2#+<!T
M>5I[)38R4_=6@U%-*XECD_R_SM7?,_\?[;Z_A,XR'^OS#/.<_3XH7#O_QMY
M+ B=E5@GRAY?;FKVSQZ02P96(287$\E>N>I;"20EU*;!C_F$)*RU'OSX!MF
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M5:$T?3K#5I:Y&QP?1?$*NZCV>].>?'SO9<:4L5T\F"UV7E7.1?Q6TXJ_+[[
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MTJ@<Y^C'&W =*T9,^:;2.OT%.(HCCW,.>QXH*PN\ W<RD155GO?*4<L\3&/
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MYA&N#F'Y(M.5LX)7ZX;@^"ZLS<4T\9,UST4XYU6%Q#YPGD2=A5@5MPFZAC,
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MH.IY*Z;I2_WT?''^;4P$;G(.Q>0\-$^<T+/=W968N?? C>$\;-J[&!E&%>!
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M?_B[NO>3%_AD;,?Y_%7]"3;N_^@%/[QY_P7/#(6*CW)IC\O%='ACPM'EC(@
M\>6'[&'17@FN:8W$=/9E*A%_6/04*#$Y23 /BO-BD$F/A95(*NP$.L+FRW0
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MB"+_1T+Y3UL))-4A<9QZ<]F!06]4G!R^A\N.<VV>AURK5#.^) V0^CA?W@S
M\'%U0\!0KA"89=!F(@L%)A)!_M\++W\N&SDR*:V$S-,C20E_=I=.D2H'[UQ9
MO.+O(0'9;RV![._G^E\)P5?B?X?AAY5VD]7K>U7@992]65H*=*] V:^>\-@5
M)J&5-:9_V4RG7$X:U\"3_$<#]7_I;O!OD1F><I;/')#^+5R$!]47OJS7;5-.
M'^IJ0:A!<PGOC_LO,JBD# XLTY1#C].OPZ,;K^JPKO+$5PC23@RYKPI6YL_[
MJJ1%.P++4^@7(^\"3NF$?@ZQC?Y:PKG;DCLO3/FIJBETQ8&Z8^X-'AV<G1ZX
M/SB(MSMH)W<#H\%'W"QC?*<9=*1 #L5IPNC\*N_/S]\=OGN[ZCIUJY'S(/ZS
M>&OD&RNN<_#Z=P>OWQY&+=U$0>G0R?II7I3N8FHZ0?YX5_ &1@/USY!-M',R
M/%0(B\+4' Q!!,5BI/S;R".3$;T].^C-T(_?O7EU$L%&8=2/RK#K<0 O'W$
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M46?LM<4+>=^E[B8J?#&V7L[>#8RR%_):Y7BAH%6)S_=>[@V>[<MBTA*ARRS
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MDB:!#JRNG0#-U=46MYQ;_45G<>:0:?=0K,RQUER1*P:%;[/H%LYR',E*+*F
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M?CYAU-.D7$(6!]!>>3UM(.7+53O0]AXEU,&N@[.TBJK9^'1H8&*H-"P7)GB
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MZ:L<XD&U.XPOS',&R=I7%(!U'Y:^1Q#<I5;HL9:]MI;]Y+&6_5C+_K75LD,
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MI%U*OI=++I]<2&B>TZ(:R8OB')UNA?_^_>&# Q^=1]]'2:E$RPKKJ&$.-6?
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MF!$Q9R_+<;96VFU@S0.)[=YBGK+36O(*HWT=3#"Y0J@26G5R%2*Z"@EHQ.=
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M$T1<5I%ZN(8[CITV/%JZ0J7#9P(759NJEDDT0]]Q")4,M4DCJSA,8I3Z9MV
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M TBKQ#.5<S ;C-AC4 WO9*3?B1?TC\^>-Z$^^-5 3HJ53Y%H:E?O<T;TLE(
MM<%?UU?2/LH[M:DB_[QH),.1G+"PMV ,96*69=$]S$>XBTV(U418 37'[8Y6
MI<O'5<69%L+ J'V-#?"J'WTF&2@=*/8IAP[MQ'Q'4NNS%\XP8:0(;!751)<X
MW#H*AA'/L(,&X10Q2)6+BGG,WN64#!/-EB5VJ5NO*G[D9F&"%#E((R_A"(DU
MDF(;P:?(4;,<D]:8?!YP"]O. ZU)TI?C>#9RKB$7O87%V)3L%6NX*I**]38Q
MDA9;MOM\YUC6Q5Q X^#7E"\541;FK9/*N,8T&6SD$(MF&!_NIH; >Z F@2+V
M]*+P\1!#*-9[\?6)8O)TOCQ 7QDVE]/*->51Y,?+D$CVD\M*>*<0/,98<H_-
MX9TUTK0K^HS/3E;58U33D 9PE/,VHG.P^&&MXYQ;(M/FS.G:1"X -'?831(E
MC!.%3G3?9IS;=E61_N%=.YN8+YF$;?I&(DJHTI"]08"_9!2FLIB0;"6-TURV
MG[P0SAVN,Q=\ #VGM<F[VS?)+8TQP/T*24)))I.4(!K:0,O3&65ZHOFI?;-9
M+ RU@D/1=):G5V75Y(T/&6(H8^4%Q..7?P@5X+#U\NNB6\)5[9;(.PS$0/]D
M?-VF'#:1TY F4TKV9)5<""4P,^TRPTI<U37HKY8LV&#^<9(+-O?A1%&2-^L5
M:V4A%:)'J'$Y,*.0^#YLY!FPQV,RLFE4 @C"^/%R1<2[Q*^3P8G..84(BC^Y
M@DTF-DDI[FQ"COW=%[6&?$WJ#UG;I. ?5(3XDAB3^!$6-[@R^\G/CK*I-1_C
M3B?K<*+]-G6^M=N&A=/S7A/7ATEBCP]L&@#B7AF/%!)QI'01(?-E)-PPT;3V
MXWCJB(DWZ;=U+'VV':J0DG3DT^A]ZF*4D$#P->%D$GLH>"9\'LV _(BTT:W,
M&1'NS<C-L/G2_EJ+BQRK#N"?@6*I[J)8^41_-01N\W)QUTMR:$PX-2=R==KY
M+-&/0]8',5E@<[O \8; \8.#7>!X%SC^O('CC^U^Q6Q3MI%)H&*S5H^SB,F=
MQ!8Y^R9E"(]<6]$'6)>N2:1W*6I.VZ/C<PT(E]<R1-"Q;_5X^.B,<FKW?'<'
MM(CY)TT-:ZS1IU5TJ"F"I/%E*5K7L0ZO29(;1P4B1P3I ];9GSD$@ G:3*B1
M\M:H^!OP:-@>8%@*ERXU!2EOXORX2?*X!NUT@3FKJ^2"JI0I'K+(W3QY0F4W
M:+L^I^*X^J?DSVF[*%"Y?0%*0U%A!^GP_"_>4^2?_P?6-".@%0B)JLSYZ1<@
M@O-,30-^][E/C)1WI9QT/WDR;Q?K95XUR6-7Y'"$ZSIO[&>?B8XH+U*E-('R
M,9P:)F0-X-0$9D?\6"TGF_GE&K)-%79'# 3,Z?4-P\,K3;R3L#L76O(]MI&3
MX<;<:U-8TQPYA T' +N7<HR=-,&P%NGNSO[7@F&VZ"FD,<[DY[ #:4=@=J62
MIFP@0@7^4('->*]I][GP[_!(Z]15:Z9/7TCG3%2'7 _C[O8CX!.XA2:0#4U!
M+2NCUYMQ.D$?W[-4)HZSI-'[FR(Z["JO.5F\7]EPJ*"($A3,?0D2%Q*9L:3(
M?)RXP-8$/M=*/@:8?<#YR!8*ZI?'%4.T5$*^DQ)9ETL,A!QU[+(!<@7+%3T*
M)9BX'&1"#9%&1MM6BW\?'B28BAJBSFDBSTB%].ATU<_Y5T*='- WK&>*U@][
M,X9+$\]@6K(&2XO!Y1'U7+I5&^$A AT]:X34:3GS7,HI-=><_',UZ=TE;3^Y
MV%H,VP=Z9?8NYW8,YY9(Y-Y;[!*.D-GY;TIE<J,I[*RMARFI@\-7#;S56G2B
M;Z%NE0>]3NEB?+-W,HP9VT<&%\]S>ZWN#)"9J0\9@JF2SM""B4NZPEYHJ2/N
M&F^4AQ:[S>[KB9:@ 'C+7LL#11;=)H?NM\:N7Q);;9"8DMIJ:^U:*@,5+L]^
M <8AX J;YDU.I;P!+SKYU5=)AXAR[69UEXMQ:I:,&XY: #KWTB87'Q.!^9*+
M3Q<>W/-!7<"/7%<%F&J<:?6.BM-(P5_PREN8"NKF3M<E3)RSD]^XD71J?$6Z
MV _W+HQE]!<4<U?R4:FYF['LH$ FE_QB_R#Q]S?1Y\>^K'4BF:,:'0P;!RVK
M':G'#?O;*^D?<YEH$1V\6Y+CH&8P"(HB\I0E0.^C74TO&\:&/,)"?4&@29UT
M;V$A]913[^^LLXQP61K7GX#M"8R'F3<M<Q8/7(B+)4P2M/R!Q&%U/#=)>7HZ
MQRW!)O=WGK"G%LUNN+&UQ/TECWFG9 +2=<\?D4UG8P%35)PJ:M78R+J8:%D9
M7)!;+[>1E:,KV0 R$A)*?<A4W,;]"-XD3);+6"@_#Q/[1>0;=N=+TSXJ2M_'
MMNK.!UDH ]?\H!MP5/HEV69 4^A(HP)G3D\9IKD0LU[5# M8"?!$GV?[9">?
MTK(U1N+SX# ,,7$@+_3/A@6R-)H$!<LC='C3+<<XAGH$*>U#\D%N20K:)_!1
M%@826 ADZK/Z?%DN>S^I\'(&OWQ#)3%9@SIX/1E&I4=R'_OI1L/SS-40]0Y'
M5!% 6E9@M?[;>>_IBN$A9-96=IG</O*3,XNPN7\F O.=373\Y?'Y]]XU[&%9
MXFQ F3$N5O8C<NCWT@"C*;(:1/E?R56'/1I;MSF_V&=D65?I,'^1KPJ2M3#4
MK)H,$[_><<_-"GA_]&O,7,5K0*QI]#Y:G\[MM72[GO*[GBRFURDA>J\DBC;2
MT=23'&4@4\=(;S5V30 \(=TF%'3LN@#N2.\NTD.'W;3(FX4WK]#X*#W@G+J[
MLFO@VZR?-NG<24"/8(K2F4G++-8H>SW2[WI'@SL:O+VM.*>/#%-=@)8P1CV6
MX3Q,.C?%VQ^6_"R/4NPX#=B+(+YWE+RCY+NXJ;5]I1P&R1 $-U6M(82,ZJ?5
M&%J;5,90A13G,Z''  TJ!H^AAE8[2MQ1XJV4N,%U.Y-@D2V&".@>L:_"<D^&
M=F,7V:U%R+L6E#O:?$?:]%&48FU]#*:&;M=T\DYGV@N/.C<QB'A:QL5F8D##
M62ZQ2R,%N21U-(1IT(TAR9_LW)AH<T9.O:/;CZZH<CUTJIWW/+WW\Z#9; \!
M#DT]:,(50>YPIFX$O:QEKE21O@*VUNI7N@9+TLFWDS<$(2W9S0;_U^0_SD.0
M8N@:&FR:#VH1"(^6ZBIVYVWUN.B.325UT#]%:PTSD Z*JZIQ/L(P6I YXA$;
M=D+A*,;@2G'C'2FYGXP70ZY'MJ2J!_[D79+BQB3%PUV2XBY)\>M.4KR%_T0U
M\5@U75*ST%9ZC/:KIC:$130<2A"[LVH54#P&(_I,>"DC#PP<$P;J"N&[^L86
M1R@W P/<%;2YS0+C\$-/EXD "6ZID;PE2$3UIS&XF>:";X.B\3R"\!G+')F$
M$-TPA^1^U+.Q4K%?>--O5G&/32;YK3W$Y)OZGF]>IG<4+7A&+M=9IJ%8JMD\
MSY0(TJ*/WN?XO>6?8V9K*RU;;?DP35Y*G;'@2,K2Z46>8*ABQ@[?7#A"6.[P
MS_YN16OQ'P^9&03)P<7M/KI C6#FW"G!E.L/#B+J0'YO5D"?&4X\6AKA3V+]
M(RYRSFU]J)U$7H(2E&=:NM.5KJ1,&>1<VW.!7D7<K:%,/R T!?D"[L9X1;D
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MHK T(7!O!@1.:(_H08L2Q.//#D7J2Y)*<Y2X<HR@IBB'T&+=;W2GF[OC$U>
M!C$*RXRK5&%Q)?7RRF;OP^;B8MN!LF9UFZJ/X2O&:E2>'A_8L/MJ+WBAN,LU
MU_D1QAUU,8QBN@')^]VOK=[#NV_=MD.OI!*X\OCN =)93ZO(U8=)"YK$%U+L
M:__SX&G+<5<%0H^G$:F%<YAV-; /!B>*6#$1Y[9U _/J#&^93UWSMV*X?\'_
MWMNE)+3 DG"5*K8B['I5Y$-HCD%I=P3T3ZX9^H;@"D<%9(0/B?J5QXQ$;=L4
M 879TNL,Z5X+2Y01IS7C1QO@R?=QR6]&V!_7&+>&),)^7Y&2V"L;OJ,V7)S_
M%AK'9V(,Z0@V6'15W!MN5$J#(N0CEK]01ZNB"&HF18_":U*<Q(@)_D,>Y$S/
M,-"R?IL-<SYQ03=DQ=.]5<@5=/S=-F7_%=T75&QD_5\9Q7QTAZX$ +VV8EE&
M+*5N;9<7]$5331_<$%B%")/EG5' W>VZ2J@\L22FGBW*W6+)H_W <$D:L40A
M/,'_9GDZ0[YW1=B18&!WRW1B0^GHB:'F9B0"FZ::,9(_?=5(=*M(DB6/Z4SR
M.!?Z&7TA/,H9CEX[''CB!'?,'X9WK^!9Z+.:*N36 K'0_X@++=ZD5YHT+M1%
MUJ@]FJYN4:\ETM1V0<+-0<('NR#A+DCX=0<)%5Y18SBQ'HGIQZ#(E>(SG:4K
M+^>C!NE&;3&@=#9H9QI^4/3/ZB7:3_-?C$!':LF-@&1B_L0>)5!PGTYT+VZ/
M*%*4@H0!"FX^ ,+L-B=EKPJ<0!;''9>DV%/FET<C]#!_/R(F_#VP_B8AHM!0
M1YAN=84HS63UV=$.']YSM &")0)37964<BN'[C.\*?IR50KT31E,DYX//VXR
M0[.-P?-0E-5N(2!O\'C*DDX3VBDR0P8GQG[2.;O;\=L>O&L243,Y/;0 OQ]3
M\#+YR=_I#.R+(?YY"T:C>&@-2N-<\30-H@6FBM;<W'=!:E"112")!,ZW.1RZ
M#V1FMXT50?,;2=>/G*=U#$=D<:H"B!X7&X2<=YLE1Z?HNX7I@0L4:F\.'@@S
MP^XZBHA!WY7H[1_0>_8L>N$%N7+P$!09;O:'9R\4&FX,VXPVK6'PMW:A._RW
MRY?4= C-H4E -O;)I&*2D4\HY* 1UGX^0\UKY20+F]I<((*' '.(684:%LSL
M!_A07"$ L_%[/&40LZBS1LP\8)(S1':#M5,&MV.(!FLQ$BIE)H[G954Z'S3"
M,@:T'Y%@2,FE-F$AK.#G:X^P!U*W"J"O.&KO2.D"1%+%R!$T!M4M26,UW0JS
M]!OU6XB/55J)!A05,P'*-KQQBBM&S</VT&&Z[K&%?@150[TFPN8G$V;B[#QX
MHT+[J'93KX_-(O&6CO>5*3B8IDW.Y0!LGF^S*?JX\RAO07/P*(0<OH[X)9)*
MH *+8-V5/>QPA&T/#5<&6*?;(_U_M0"3QM3JM\KN-<T5JAV#")H,-VT05;@C
M5<;WY>8-YBXVK)@1U%-/B@U*D7;0*+OZ;3&)&A ^#1=2Y[5QHU6US[]'65@!
M^[Q*O=SK=O@4.[JZ'1<@2%]A2I8+[8 E=@1T!P&A?E5A?M;$6VS6WN(DVF5%
M,0OR9[*6INK#)MH:=VBAP ^NM&W0.Y[./0@[*O"DA*\3UG]OM'$=YC!W)3NU
M@%\O*@I":J<X =# KGZ6?7/*$MNH/J&HKY&D48<P+K R"KZD@''_[Y#)+,DV
M,^XN*WF.Z/GQ,> ;B>Z,Y8/9:#Q%;3ZC%CCB>C2'L<G7N$G-1K4Q?5-R;Q%2
M!*^*:HIY)B!3JZ74<^:V_]0XNC\^IH#GMU7O"H[).(S)_K9 ?KP#^;^7=_>6
M[3-1'SX#K:#D'%"!9M2V#NB?O*[0K<N^RLP794;A(XE)^HBC*='+RWF GJ;L
M:#9^V0TZ3[!QS]7:(PM$HTCPTV>F><0%#>E9'T#_,?J8OU:2]")!1 H]^4LF
M";=8-2&Q5=Z86>\RBO@V\R/S-]"A*;>4,26U<KH>DJOF[=Q.L7%7Z'Q^_[G=
MP,5S)?N1,79,>6$TG_+N[UIO2*]P[ZJNV!4$7%#3SR/N%<++>E6GSN; DEMO
M ".$F9A?X'+>GM8R&C17:S2NY[0E]8AK!W\4)]YL[6O//1:( 8'?'@O_/$K_
MIL8)P23W %%Y8R*Y($#)_R\\&[/N"EVVI,3079,-L3 R)!%";7S<Q0..9NCV
MZ_DG.5G(=@B-MCDW^^_><N9@4ON&AR'ZS+S'H=-+")3\"0JW9<B<1;NZ:_*>
MIS_<>2Z_:4"A1K<<Y9>(%D"+@0??>.0#&@=;UE"!=-BZ_>27WFH&5!6O2O-X
M P_2(YN8^TTZ2._.,T7T$P?]9S+G47J(]$/N1,H=/;EJG?OK+"K*K*>8H!P_
M)EKI6-RC+V^E7*SQF9Q[OJ5;2/$?YI=R3I&MM=$TF+D<)A<>1SO#OXIHHXH*
MG",%81?]'X_^/]Q%_W?1_Z\[^O_4]^\44Y&#7-<4]ETMUDT. J TY8>2^41Y
M5)HAR$@Q@K4R!5XU%T8W: ]&P%MD HJ1&$<KN9.:TR! VK9NN6KC1';U8G/V
M $QS>Y2%G^LJS;BI=R_LQ- V%-Y[EUWE0LZ<(J"HXD\Q(6)0$<C>692[)<;H
M]0! Q $#*16YC-6PJ)*/Z\ZH5H#C76Q^L)E2)BB.5(Y[W)R 1($R@G'VH^K
M@*RH&=PH1(VR')?PIC4BT%'S3="B_"?#!RO?&B\DO&J)9?3ER7C'[ &]C(I1
M'XK22\ SB4X+%-2T]NJ_[;QGTERX!K&1?+X>EIAM=QG[6$#B<8*+>4*])X;4
M"<^?ZR[00:!S,_N&"S&&A2_H8^4"RPG)2.IU/.OI.1HZXA"RU8 1A GI\H:@
M^,8F(!#6Z)"R>UYO^C0ISR#OJ(6&STS^PMZ=@P_P[KQ:^'[;8VNMTU6>%8+4
M%4+>7M/C*T;03))70OXWA&F:F.[24]]M7!(&J#9<K4LTI_.Z;Z:&U'$8D6S6
MD;++)>=9^_E\ @?1AT._O5,Y;]]&P@/@NBU391**C,A<D]YCCT-)5!-V6=BY
M=Y7: B5;HXW>UM)L)?,R,.1<ZT*>UH#U8+>^!)WS$CR.9I;9&07YH03'6'7
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M(U6 9*[,.0 ?;Q1!\8Q2E&Q0E(WEI4)#^K/E5M*@>^WC.SBA MV/AF-A$%C
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M-QB62:= @U/"=27(SN@H32V0?P&[A2U--^K^WZ5%3M*LRZR&E>BC#%%"+#1
MYO'F+=.&;IREDDE\8DPTN)U2!H]NK1E:W;AI>5%@0-V%[F2-6X&0P'YA-99N
M_[/#)%_8@6Z93I*BH_@\_W+CQ+6!W0R)$UN(+KN29IZNUDPVH 91;23,@M.A
M&N9!AJLPUR8L5^#7*2?<-]H:#<D%F.T$!%&;S#'EL$(W@P&#5>Z%K^1-2XF2
MSU),(#X\H]QJ 1W$<O,BG3J",TC+1H6=4A%WXY7;JK)3FKRI4(09(1XHN?G
M\*F[:2ZU5^OJJJBF>;F!J5Y3L5;#J6!X3V6?03:O>"'%FF:N?>]0GL:SOWBR
MA\[\>ZX!YW"O=1"&&&*((N^#\P6Y>L6)5T W5W#B58T0!X'3D*/]JB(\ &'M
MG&E'T@*9?K7J"B ^7,9TO4HQC>.IR0(_D+[K9<YQ%NHN_ N*!6KR5W=7R;G!
M#,#+:V[9+X_/_0V^PD .C/$SVCR:$O>8E_K8P.MBUV3=H;$M\"N5(KW1122S
MO)YU>:LN0T<@FH*OW/$_^4U$"TQGN1=]@^5C-;!THPG]BJ41_>-S2A/4I=$O
MG_"G9NOD[W"DYP)'*'OC&5O8%S1%['H[*3(49H )<\!Z_8D2P[UX_H^GC_<.
M'R&+$90E01A=Y5P"H(S&W+ ^C:;WH]*1,\#6TG7U-IT"0Y,-'M_,>Q(;)QUS
M?85-EN[M.[85-KM-A?W FNZD*((:AJU#:L4E[9V_>ID@%"^^LYPBGA4HH+RZ
MRW6#YHZ@-.,!D_A8HE +**7 S DP ]ZL4H0'(:78;@OI]JN<?I FW;(H)!A.
M*^=%K/+K"H4SK"JKEJR/&%4C;A.M'(LH#;]Q 09$!KP)*46@P"]?G;_<>\7/
M3Q('J^K2ML=FHJVX_0C-^L/5HS;='GQ8Q"NEN[+1 D^K2A)K'<2=L#R7X>/]
M-<*U_!$D.1(W+4E*Z:E\Y1,@.W^8<NXO!\@^4A>S4&C#F/=]A3KLHM<*\)8R
M5#[U.%%1KP(<K2P4-D0FM(>29$O&8.TP^+540>8!T]!:H-.IFG8O'$9\!OJI
M=-:U+GF39R4U8&<%(M(FP$BDMJN$O8-1-5+G@5OD</B!1RP$2,.KG-*JIY.@
MP#*@.D3+#YI%'YDG$LEIUU:DKS@OEV$00B#>K.Y0H?8F58?G(@DSGC#Y>7,4
M_/XLG2U 74GWXP53&(16B(? G+I$O<AQK/#P$=7.)PM0'DJK^F!R)(9W\U&5
M3Z&18@+J??LN1:.Y70OZ+E)ROI\8E>@[UG;8+*1"%W/M2<C<E_GWIDQIVG[>
M>.=ODY3*YR*]8U0\[J%X] (QEI-P\D ;TH*F*N<Y-F@8$Y,3MCKG5#E$NL-2
MK#AFWB"P/7Y(4&>QF*A 8"0W W*4B3<,XN,UA6BT1)B-DCF.2\8Q=PR@NXZ+
MI(&!P<*-RXPP>D<*/)T\?' [_0WV;>S0Z#,J=?'@>@(WEK2?75_S$[[1"0\T
MA)%)DY:0W3%W^)'[,X"M#+\ZCP1^\MWCY^<7S?=>S@^NQWT6_/^S]^7?:2O)
MO_^*3M[,.\D;V=&&$/?.W',PQK$3QQM>DOS"$:(QB@7"6KSDKW]=U=U:0&"\
M"UOO^R8WL4'JI?;Z5%7>._7<"RI;AV!?8TN+ %*L\Q0K/ZO%QU,:G0E!FEPH
M*0GEB!J1)-+3<WV<U!VYV+R>3V*?((X\B3;UJ*;+= JUN6.6&"O^#9Y"$HU!
M[#N+:*4:H.?W70B/>+';QQF2$$^@SYM$PDFGYSBPH4%9$MQB$B$3B*(L3PV4
MB(W/H<]0+3&M LV;B1TEHQR2^ U.KTHZ'/&/\'!*3BU-R!@O&T7QM/67>XJ7
MB;4EU2\\%,3G_=*#ZL.0+\(]PX) 6SP1H;9X[%[&I"@(F.X]J[83/ORQ*TO?
M_AO&D]F\;'T=4H+4I"4B2XB)%%'0-UTIYT\HX?SGOY_IL_YA)K%,K<21OXFU
M!6M'&ZW<OS>^-&7,ZP1V&+%@DS!TY;S)FU! B;((^W/"JCD^@8 G:Z=K\ZR!
M#7 G,/HRD5$_B :^Y_KI8/I\N1*.KIDA"1Z??]M]#ZKVS_>I\DQX&K-WVM\8
MA,V'7L$+@2Z%,88.J!:BCF?_G,S&>$]0Q68,]A$;WS83^T9]"!*ELW/484(8
MPY]BY%)18#P775U06EGA&PKP#7J%;ZCP#<OB&RK%4"F&#__DK*F,<F!]BWDA
M)_;NS"D+.Q]U%;Y6R*.N::H7&DJ.R*P-A V:$JW$PL(B<<M#G:G*03N9AT,Q
M:L:*3O$GFW<%7C%^&D[[9V OLS:EN8WTZ7&$^33,7*\P?>*"$&E! F=.?);2
M$C#\F _%PI64J6]'Q;XE9-]V:[^SIBM*ZV>6>3, C@5VW/K)>A*)0]M-$)O[
MU#LHZ$^;#B:YD:XH R-BZ*5/CUN;J=7+Y%>8B?(G4?Q,L*$X\I]6UJ?/I$*L
MP"X6;8BY[<NP%IC:A='=P@06"*Z)Z+F-$_\F$++";!M+LV41,,GLZ@,2,,",
M95A($7VI"?--@0D2^![]T*X[(.)#U>5SY97KHK9#%W];2>%*"B_G7?_8S=M0
M$<-PCNE6)3$] 2@M=F#^ V/K%$:2=,C 02 XI0G]Y+4T=\S[UA1@HD3X*& =
M[P=3DFM>MC(-^WGNQ <S+;0=&%_K]J%!8M^'^.M8SD1=*VZHN&$A-YR2Z(B$
MARDG<,I$T%40CXHBT6BQ]#"0G5+VD'@3%AD2X,T9O";+#K L-[+-V!V!M<]&
M\RS$X8&YS]/B/,<PQ)'V/.\LT\]< 4B.J05\2Q8&B'RQQC@)@ ,L!4LY*HN^
MRV#[,%&;9"D1-@B@*^@]>L-/85T21Y>X0E.PVJ)L:L6/%3\NY,=\HH5SI9U-
M&=&'V.=W9(BF= X:QV-_O":0:W'(.ME"]AL<7DJJ['EHMG(32V0N%@6+LY^G
M?.2DE1.IH0Q?O(P9;!7CRJR)"V C4$5)%4]4/+$D3VQ\:2[@B7G<D.2K.2L@
MFK?)2X'H7S?P/Y"6%BEKZKF%(YOU<![Z'F<W&3M2L@DU'%3*6QM".AF_(@NH
MNJ#T(/N ++^$4]CFB@LJ+EC$!=\$@4SG^!_P7H8(6.K%#X(-O/CAL CR$ZE+
M=-'(#7A] /W!\#-F_2=^!%4FU"KFMAUGZLS@7%;S T-HF$$ZO)V0X,+VJ%%J
M5RQ>L?CBT$0&1;. EI?$ A38@#NG+-D"$T%96]*$B"EY ^1K+7##B\),"/23
M0D ,.FDC&R>&,M>-/Q(')"(ZZHI-I,0\#_O6+6L:VH>>?1FH+X/;4H8<$OHU
M$15EBOG<]4&G1K<,^R5LS^PA8?U<BHH7"P'L3^Q@+&<R#'RZFV&E7ROF6RZY
M^BR,QX(6SA!B$Q#RF&*^CV3]?%UF00:H3^O[(8=@2O!7&(?+V F>($#UG\I$
MTDI%T:6CZ T2V<]&T2.WOS:BCHT3>S;U<?#5+,Z6*:OI:6N4X ,L<XAQ,@':
M2F)*,M,X R^^D:@>8"T9'*@_B\1;$MB_-Z4%Q-ZX!A ET,!2!.:7V Y&&)+'
M4LT$FQNX'B^97,%)  7="A!WC*4"/$TQB-'Z]'LB9YFS<E/<,5.5@$M%4<1F
M>,-O "\"]2%N1D^S>;Q<H^_PUOZLB1DO'Q.M*1#\L4F@9[BH(T+//9R9 LY_
M+#5%[N1(]/P_"'SHCAY*3:Q30:MBLWETT)335S2#T6WVGVX K<Q@(!.#GU"W
M&@JBTKXEV,24KE*>02%7X,0"<*)1@1,K<.*RX,17Z/=8T)GH9:<U+RA3A2(:
MZD4Q=,=2;3-%?R"U+'LX G\J)GP:8QETW18O%%MTC%AISS/W:*L@T)!M10SP
MX^4685**P7^/5X E;/ 13"D6C (S9--J8'VIC5UTZ$4+HX@=6,&7#%U631._
M-+A[$_1/+&UD<X]GGV;)1KV.TZ%!+6K*O]<E?ED\<,VWQ;J,8G'>U$BFAJR;
MRK++H6<ZM=/IW2FRJK CX3&Q1VQ.5>2ZP1X&FZO3S?%*0+8=\54L^)HYF(;%
M1K5ANA9:8[B].*+/N?N[JESG-Y0VNUUX*M.'<M>^UWEO6LB3\^9$86%^.-.D
M&ZI414UEIC,"&Z=7>!>Z\G3WJLIF0Q'7RK9PS,9_]UVPKV'4-OW6)4S\IJS,
M1G12KL86VJSY6/'B6(^&W*],6?P2!"9R;9Z,IVYE;K>U1(XBX?/6.ZRYRPBA
MR-D6&PC2 [A"03EN;I(@SB[CT\639C'I8')L#T/-..9..4.$]+ )N8.DSY)8
M"%JG??"_ [[D*8;%%LWDW.9UE=2OL46%X\Q<0E6KLQGQRPG'ARX4#_-?ZKI2
MFZ&9\?P'TB^HUE(2KSS%@%\R\K](=M9D76LLS6)W<!@55K7Z?=0"8-3FBDY-
MUNI:HA?J!HC.I629RB8(Y":N91U%,IIX_BT1M$E<1-7V"?X4]W7M!Q=KH'S6
MAG!NT(0P#EF'$LB6B+@!_#V,$/<#'CWK=1WP61+@PK/-B25SON @6<&U DRK
MR4NO.%G#)*"G%4#E<<2KU9/7IRMZ\A;8#S<C0Q0W7+N7TQ*[6Q++.!N284:8
MF5+ 5ZHN-VIFHA[^I:JR8G K)YLCOYL)&LP6 67EANE',^H@^P27=UB866,A
M?ZD*-Q$2M9)]4,^%68C4T1K"C#8)4)GGC+"!O?+D-N$1CG6(=;""X/P"TJ7/
M*LN&];R6RNS)I8R3GB&TF&+L)IKK854T=56I=RV@LS$U;6!,(YP #,/-#\A.
MQI?R_"GVU( 9WI%T'4#LU1\,I(^LLP^.KX0XD9@]%WXJLL]3,P*%$G7<\>-A
MB"528\33?@P)D?9\JJ4T<2!%'50_<20N1A-='A"CLL1W&(:0]6#TK]-"?]BQ
M.*"<A9#Y_97OQ2.RS*.AH,GA9;9Q[AT9\<G7#V<K3C.EJ?/ #Z$O"C!R6#0-
MI*[\>TE%-F.S6<M]505PUTO)K8) 2K9=\)S(R3S)#-8 G!\]S8$;_?7T7>,?
M:ZK XB:XN$(WC[I2NGX?=V"A8Z;*NE43CIE>^[<L >HI#CF1\76 V:=KLJI:
MTYZ#&V8X D:W,N^,R23&16@ RURN"F9-!4'&4B@4/TNP%#<K4!Z@K'T8AX%(
MY0VE06#U_"NRRF1^E+6C-C-V5)O/1"\=[>\OLE?9*.H":?<OM48ILY&Q,JC?
M::DS++*,33-EE"QD'5DS4\/<^O<T-V1-DYS6F.I!*.A_[JAMV3 L]AYX7,[8
MQ=YNU"SV VQQ(IH- ]7SLMP[&AZR)HPA)(W<<9R4KL&/M\ED;7^\MN4&I. I
M?!"Y/+4W'%5#&'VQ\-F<VYS=I\GE4$8>"/,B95#05[D7 O@Y;X/=04 %%VG5
MA6F));_\Z9S6J(@*J>$";GK>P*1B#0=D32]XZJPR(J>(ALR&,6U\#EF+3_AT
M.@8]>2H<;A"YO)GNU)I89>3<$\"9WG//03>-Z0N8NYP09'$$D+MT0576;6[6
MK59EW:JLV\MFW5[8V,!I[7)FY C(GGT41_2<(,0*0J34EH?'MC#(;8%)5"?=
MPGPS1),MIJB9%:)1.UU["B-D861$5<W$!C'^O7QXA,U['Y!"M214<48I0:^-
MOC\6NMNA<M:&EN^L,U^V*1_[>[[M7H&JLAV<)HKQ@N)5J&8CJY?%EV?U<MZZ
M2J]JSG/U1AJ1RG^7J[IYWS/P.E\PJOW43-JA*A+'6GS!7"JC\&S#^2M2;A8-
MQ0;.,QNP\QO@UF<QC^J&K%D9)M5K<KTVFUQ[<E?!R+@*QI*N K0L!1N3F;U0
M@^JR24?S#+A:WI:T6<6#: "</B!Y6<X_GS+D_5O;HQ:WL.5GW]90<T)BP;/
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M.9?7NKQ;U2R'=D[0S2G:N:85HIT790MJ3/;/11"G!4^SX5'^^F<S;6;S%IG
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M/>YY."S3X^#TN;:2FH$J/AF^D_4966%QNP/71!E$R%29+K5\T8GE,F>NV(L
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MU)&45"H9=WWZ&/SL)D1X>22RE?4(TO*+3N(1R ]T"58B?]@"%QK"2,VTN."
M'H<C?.0V;\Q2KE3B,68!88!XXI_/<>806$SO!)-9P-:9*HH)%?:..P$'GL-O
MP0IP(#^9RMA\EYT 4A<0[<:P'A%,/;(OTAXVO$,U]3Q'$^:CLJ8V.*2>^^U
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MIT!Z)^DW!L[E$2Y&@XEKSK)8'$P_T_!'IM>(%<Q(Q8Q%6.LRC[,* E8HY6/
MF*\%$]K-^)P2A !PF%/P\FRNG?(#CW\QFT%P3*869\'01JPSRRQQ([,0#IL>
M4*-O#:OVN4O%FC^2:XZIQ=P;QQ"GY1RX,_K)W$9TM4Q,JE0\6DH>355+GDV+
MN#35-;[0-=E*\C2'SKDBX5Q@NH2?BUK$6;PT5G25G--KRQ %M- X7; SL RK
M<\_J1717\(/C#"L5<PXJ_7&VJVG*A@+CPLL'F!Y=@L&>Q@2?L?I3>[N08/(W
M7* FL<H$K_FOH=NG=CP2IT4W\W>V%8(MN?W_?>@ZEF+8INUT[9JA=HV&KM._
MD497:^@F,>D_>X;U@7FZ[!L[$1G5FX<X 2A"#Y;>%_VGQ__5U77-;)C\.\]^
M1M,^"2Q/JC?7&4#IOG]FMX5TF-F8M)E@.:@^Z4%%UG<6L#MRPXOR9.EX!1O5
M4GZ8;_C)XXL!76Z2]O !H@4V(O7B ];^I<?;.H@F$>SSO(-8IKX?JSBQ;PD^
M;::53:ZKB:C_X[W+ H8BR6GA7,E8MDX$MI--OO#U)%%Y!E1!U4RM;G_D.IFZ
M0SF[1@"B,'2*XZ',D3-?CNP;0"+$#BN*38550,YCT20P6_,,/WB]>X? E,^"
MMZ(.!PK-6.,. BD0[+6 19\)4B8;%_&#[&= \OO]J=@)XGSZ6)N6*;1G(1L>
MA88H/)Z22,2S1/J0  (S0W%) ;P/Z1;"@,$Q'/6ZU(*B(6IX#8F'3HXS),X%
M!GEXA1TKRJ)*A]R*9T*!49C%&V<H!'HPCN"2V6B+M*<EK@0W)68%)G/B.,@
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M";N$ZZK,$YG03*07SAIB8\)0+[+VNN+K_MB[S8%8!V;=(KU!O=NK.?VNH3<
M8J\HW1[]6]W1&TY?,6=BR*J:Q'6R#;NZFJHKQNMF+E3U4:&K-%Z5W=BK)C'N
M;[X_M>T;SAB_Q<<D"\N"?TI8QKD/96=.5*;T$YO2KYT )0ZQB-WKUOM0KV.:
M]:Y%:GIW8#3JMNFH%I4VL\)$$\,"DMB /^#-5.DS&F:]_KH217N41$DF(:21
M#U"'O#)V)C*"E)_BQ?B<%P96[:04*OC@R273O%1F&:700>)+94XFG)9"S.K.
MG7XF08%Q4=$$3/Q<YA;]=.ZB0':U6=NOK(23#CQ[G,V!5\*JC,**&'5#:30&
MW8%B*UW#LOI=RW3T+E%[BD9Z:M_I%5@^.N=<Y$F@2DI285>MUVNO#-E0]4>)
M*2&0<OO*29]C&!=L.VDU>J+>=Q(HWM."O%;05/H8?IH14W<?+90;WN8.^&FL
MI&E1V)IN'SLG/9N1CT7?;"5Q7 34>504L>_MC$.WS\8^IR5 !5N9\S1VVI6T
M+*6T'-B*Z?2UKN%H5%KV^VK7JO?,KJ4X:H.H-8W*TEEI:20J.D48=W5+T8U7
MMNF,1PG+U/#( J=%%^8.;POZNATZABC:7EL>S@C#9BP:8S"HX-;C 0I:Q?'/
MP?$#I6=1CTWK4K:O=XUZS^HV])K5[:L]3>_555U7E%D$UFE75VN&\LSXI0<"
ML$ZG\5>U]LV0'DD4TJV9NJ:\KE"J/3)TQ;8B%W57D#J<!\K3?_BC_>EY>E^(
MG?[U^CM%N?SAG^5BDD4[>OTMI"'NS*BU.R>BIV6^O*KF/L4ZN;8?K)#DWHV7
MV;[A^'D6")()#DM""-F(Z1D[CGSQ Y:<P9_D4CC*))I*X"@SR9@H$ OC+U29
MF$X[,DXW>_1%4\>&\>^L;,]T;I24]7HMEQW+IDHR+P+3?T!O1PAV\>\UZ!WY
M%TM\7=,#NS/GE/S>[M$KCB/RMVBIF=]N+CV7[SRY**UH+MBI]:(;S?0.G=WS
M'7O%;HSY'J%/<[E/G='+)?&8\>8/4G<]2BL!NZ:F&K6')?G2ZL+,HY>I,IQ*
M!3X+&3VY\$0!D#_CK34]W<%J$L=&<[>YUVIWMMOMXT[7L+2::3R,&G+#<3?X
M/*L.S+.:3?ZN\(W75OW&6_O?#X[:V^V]SLYI>W>_T^G6-;V&516/O?5.KJ1V
M/]-0$P-6HTE AF0<@E^WZX=OBBS,52>+]N')SO'/;LW2]=H#]<$"6L@4XV9S
M-KQY@,2R*6^)'NJK3@^M9F=[:W?_K-,UU7I=?WJ*@!:L6S!<Y2U=N[7JU[X'
MC1@C/WMQ!7TUNXV'T0,^G7F]D2_EJ*/8"WX[E-&8HHRG;>H^/T2X9/"O#'BZ
MY0 7"Z-<I=G+'N#] &?NP#57J-^YJ%^M0OU6J-]50OTNA[?8=4.,C(CH_%N.
M8];7+7V>NEW)T&6Z-6U=U][HUJS&NC77["SSWNYC6-]%FL]A?2UJ7<+%0=)&
MY*GH\!GVL5B^W6OU=Y+:LRW_8>X8HQHNH$4F?1WT /HKDK ^RD-7>_[ZZM#4
M0VAGE2YCDX1.X$YRL^Q707+IZ^K;):#G7F:!43D=8N&O60N)LT8_'=A.]!=A
M"B$W%O'_7L9^]/>=*V ?^_L#-]N'430)__K\&<IXZ1O6S_VKS\W &5+-&WXF
M_7,[^-RW(_NSJM9K:DW]3'E&50U#4PRUH>B*92B?HZN:IM>T1I?<Z&OJ^C :
M/<$$P3N]A@X,T>I+3=ZJG@%D$5/0QWH)G(/$AA?M)!@U[,'.(D< Y^(M*34
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MJ/P:3@Q)JJ83%4PG,JKI1.*I>.?5=*)YTXDRY*^JZS6VZ&I>T4,MV]*WLJE
MNJ]DVAJJ4JM;D#_6&KKV.9F_JS1TA<_??2GKEAFV,!%W3IB?]SA3IS+(2UFT
M6P$)R=B-DQRRU+(#0JW,. J=H0<?P7#.D^!L#V,[H*K(NRT(X!S.]OZ4] II
M6\)5ED1LK& &H/1=;"IM\[J!%,4PZG4+ RFJJM>,%R\)V25V2 KQM>:<>(FN
M*%+K".,AB\>S+Q\N49XR7L*6SR;;5,&22LJL0K"DO)1(>5-7_E_9":SRFIY
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M*PSI[Z (*-D%5;?I <E9.4+/ C4*EV'+G]$UE;?)$8/PI4N9B:^5ATW_Z]Y
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MC=+ H9\>^IVI#WL7NWP+EWF?\#/L]ZW5M#_A)-L2I$<>.3/]35[P'</4[LL
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M?<:0 .)V23L#J&,0,%,K47!9#*^</+ ?$V3$(*#BA?[_04"7Q02.^,A#]"'
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M1"^SB8=SZ@U0VD(XQQJ+"MG7&"YG[B>2+MZ?/^'*BA)?1%T?AB"!WU!^X,*
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M CI9\P=K<4@8D*"*G;P=MZKJ7ODVC)E]ZGW9$3VR76*'!'EV?W 2$DQ9%DC
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MU<B5JNV'8=>(Q,50W9\ +=9I[.-9PG;D&L>HQGC57-3HOH+GW< Q",?8%+9
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M^ROCR 0#UN7RU@7YS#Y;V@;6Y8/T)1W9LZ>2P,)\%)#A%%B7RUL7 &27N2X
MR"YU83YC+%B7RUL7 &27N2X R,Z[,+];X?HK3__#F,#\!A/.ZE-?$P<TW\D^
M_.\G[-.?ZR?[K&7^:G8PSY4^G.;/_*<E)9_^GAIJ4#(\W=#_\^_YV\C#\Z[)
MA\K#']?4  %Y0P%YWN0# G(; @*V4K"5WI4B/%XY<*PXQ5'H\00=V%>!M+R[
MM+S')ON;[ #@<F9QN;@ME_GVS%><Q2Q]Q(FC,V_%;RP>3V\B__Y6\OF95.<#
MCW._,>^R4X97M4E?/>S>E.R@5[5E TGY.$E!WF*WOLIN"@-C:WBQ\>7-=N8+
M.Q+]9KU2CGFW"YO=!YA?QS37A5U8\)-E?[M&.;GU<&&+#T0;B/9;&3<7MOA
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M%0/ Q<7#Q7F=JS^&BT-8;ZZDV!D+ZG2M5D-ETB>;9@87V7F*K#,& A'@/ 6
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M>C#GO*<K7HLY4V*_[Y5]:R6K+%])&"1J\B,SPQPJQQR<9"&4*=ZY"Q(3 ',
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M6"PN/XI45AW5TXR2&I4JAF:X<^,AT8>CT/$;#$'9-\.']V?1<Y-_#*N^55'
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M54? _]24(W71<AT6G=C\1@VI*2PX@S SY;(P=F;+H02$(,^=_KC16L^G0>O
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MD>*EEL('P,1OGU%8^DYJRH7'@9RLDF$Y!QMU981J8".N78_KC6D_0PGR$24
M0H#Z@7LI2KTLA'C^$#BV6(?VM!?Q=FVR,+?2O+UK\.99T:*&<NX!'\]H(5Y9
M<[[<0K2ZGZ-%=KB;P2&4)2 " ZV'WSF4?ZN0<8=5OJ^%C!>7]2+*9KV0^>I8
MEOI2>53'[,8F>5V/F5_!!XNLXK FFTTYCI6#DZQ$)E[L,OC(2G))C(1(A@38
M <R-VRS(/7_L\I7@\9.DQQ8+,)/4:CTYD9Q.;]ZDS-[X;0V-GX8]FYZIN,BJ
MS2"UD=!)^@-XP[?R*$:>^<!0"&5("&.+L/%VJ0^ &_>$&W=8YER C>Z@;T6Z
M(.NRV^F745]I,;57]I?ZE6U@PHK7V_*S,K*I;[SRT&"W,7:T#>A/?U,81-),
MZEZ\_0UL%Y_+R-D'S]70T//>!ZDMER>HCC(/EPQW[?B)8810MJAA[*3+'X6E
M5 9*NA486N0'H*#YPEO8@JH?T$CU*AJI D$%_:4NL+WGNY\$P[ZK"L'>-+!+
MUE",GHRK>]E:N\QN-9\'(^2/B\R^G0@+A_Y/7ISGDW,+@W]B8 R,= YANN22
M$6PMS3CVN!H8FF]Z^5/R=E<G;+EY*YB;IB'5A98UJ[0KL_FT0Z>V')Z%B7&(
MP'"(?/8N70 JH TH: -ZVX)Z2[L?: ,*!/4J!/6#VX!^N)G&B?"N/ADMID*+
MB#8:,O210_6/0]D?8%JA29?KK(@!:5.M^63DCI9H$O0STRH+D[W$MKJ?(N"V
M8:K.O]4X79?2PDC?'1AY8K04^25NV"GYBX61]6Z]TD0!* ,&S6U ^>H=E:\"
M"0=YS5LJORS,]NQGN6XL:O>M"7WV-3OPQ/MA=.I6O_EVVVL[]-B2C48L)&UE
ML&NH.P4CLH@<@4 X><ZSHP!H0-$FV$KO2,)O?"N]O-)"(.% PF^[".[CC<4/
MB!V^W, +&[Z$+ 4GL6NDI?K=S:*'&OW,P,OB@K^V\&ZT=NZ1;=F=[H$11H&E
M90% <+W[%=7&G?]Z]]>YA<5SO)A;JQY@D]G:?-+:']JU%A,,S%<<]W_NAO?!
M5['.R;A=RHR\]V_5#Q:&%<4IS0G Z#408K$,;1&IM0T\*)/5<I*U%"+S>]X)
M J*Q,Y[\O7/3X48J-"ZP/O&B TA_@A1O=2OA'\)$N+-1>"SAJ(#YUC;:#DE7
M6)H93&3WOA-G/*UWYQ!Q,R4'H#+T4F/,9X +12"0-3FI.+(TGMHFWF_-?#>W
M*K+*3YJ%6(("D 'J/D'=Y]T*ZBWM;:#N$PCJ50@JJ/M\R]CM&0RG?J1)#8WS
M&T*\=D>U05_I3(C<<,KK.AD$0E@45'7^=?H2^.S.)G %/"CWO)K%O(;-[W9K
M5$"Y)Y#P6\_@7UZY)Y!P4&=X;W6&EQUK?G&OR#W*"I*XJ/DVMAQX#=&KF@3\
MQ[TBW^V>V]:XM^W95=X31&;4[HKK@UEMIDX5E?>;1"$&P2$*14#'2;#E@K)0
M(.% PJ^O+/3#M]RWC2R^V]:X]B?>AA&J<WN,CK0Z5N,B<KK+MT;Z95OCC5:,
MYE';DI4'=[.#XEO#T_V@9'DEQS+BK(Y44\-E::TF;QI+O&?0!#6GUU9S>OP\
M!:2']A6G,AI;;FRQXL(5[=:2ZGO,9+R=99V;Z;S %(-(Y(R&]SVKT]GK2R^>
M Z N]7KJ4E\")=PZZ*[A'MX08.O Z<IP@.FXF4%)5H2* 1BYRO*'B^< J%V]
MSMK5ET"*1FP:K%$96'9M2DW7<H<FNW0_@Y2L(0)VWILQ[UFISEZG>O$< /6M
M-[V\8-\$=;$WO;Q P$$][?O5T[[$F.N:9IAL[1BU*1P;)UT>T9OA+C/F\N8'
MJ37'/G<EZ?W4SG:-**^5O=+TW\>7P,[]0#<"^/C[7]#UOA3ZCJ67_H'D_UT6
M)H!<[\>4R'ZPD'QL"2W0$* AOZR&N <-^6D)+M 0H"&_+-&]#PWY20DOT!"@
M(6 />:ZF]((UI,"-"^_J_9-+S\6E4TG6ZR&)\&,I1#"9Z4G!'U^!G#K>WPKY
MGKOO/%0V]=JLQJ]M8Q<OMPA7(]T!IV!,?M\YCD%,5CK#X*!;-P"@CRSY!0#T
M;M'1%V-'M^7-#X1/]@6XBEKL[A --NM=CAWT2['C1JMZRZJ3MX%5HU+%T'*$
M/^H(CD+';[*%NX;TT'O'0+_3<SS5<]V/YXYQ"8K^'F6[7*B(B[>LK".X2A!L
M#SYJ8W%S3@41Y\\FW"OJ=/.YB'$49K-+V7\"&"9,CZ.T0\^T^>J<I0Y69,&(
MJ6!L5HI+X!"%DQ"-@EZ.YPP3?[ >/<>A_WV[>/ MHL5+K8(/@(K?3K(N?2==
MH/ XD!-(03K^0EFG?X1X5$:P]0A>2X-^AA3D(U( E#BCEW'C*/$0$P<H<:8:
M6S]V!7[>=1H"5NM$<ZH_%NN-/SZG_R+$,.W>I*M6.JJMKN&XL=FI#"/N,L1@
M/OV-,324+BB$8,_U+@.P\=K\P<W#1IXH +#Q#JT^DGW#,YV6@MEJO1)6+=62
MS.[KRO1_!2&*C'3*57RP%)(9[4O5A3PC(RZ#D*Q-!P;A& NA+# \@.'QVD3*
M!2/(^:.6KX20G^1).%G:CA.2B9&6TMC$9:%)P]NWQ8N?!CRKY*P/5VH5&3&F
MWOQ0;\ZC1OD('$0*'"0.L2P-,?0Y[S8%V/'16G5^[,AS(!>,'>]O?52W33R0
MII.U'0LQ/QV)A]&H^;KZ[U]9">((W4?C86C8HD''[3TO(HR2.QIY=H.$<)J
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MV\]("P-0B:H9=P<1(2?,L,QXM:T7TV9&6N0 C/4;W5;;M&$V4,.@*@[C6CZ
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M*[&I##9LTI?W1J)*[5\;'[Y;H.'+F40O<_V:8SM"!G6KBS@_+/9WC4U*LPO
M]=@62G.)V"O=&;YH!*9MH)6@2&[+*AJ+T:TY,IRB/U94JOTK.G&B8$P(S!N'
M^<I(1IC5))[R8$&36L" M.)E )3E]@]-3NO?(K[4[:U2I4I[MBK-)@G:8#89
M2^0^4GL)%4E\1QZ/8C-?,C;S1C!XU@G2ZO3ZJZ7:M]FJW<XL^NK3?696 %0
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MD@ZG';;Q?+^X$=C]5F:5R9V:EEFLP^6)@9J/Y?.I6"+]D;=A0T57WQ$HOF=
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MBWMX/)TS/I*-(N%=..X 3$]2#*RU.!MD.M?U@)1\:R#K;^H;JE[BQ^5>WX(
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M1,)WXES09M@PAHP[Q;T'[G[M""W&G".,8* ;/#MMN*6AV<B-4&'K%GGQ=DD
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M_<9T^ZM;6T93J^9=X2K!/1/\2D$M$%H)W.!#P\X<4*UQNZB.LJ)A-) 9QY"
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MJX@:[D1H5]<+BGS5_^P5"X0?'HM,.U4%_35,";%]2F"E#?5F#6O?5@7-PO3
MNW#\G)>AH:OYA%RQ'A=KV^CO[ZKBZF$0 B^#NQ"RN]XJ0B-S3Z9WE'E4\7"I
MSJ)D1DIX^LO>2A!0$6DU3-!ZCO\"REH%/UKQQ6U!"YKN:9L-RQ!@/^,J.-!H
M_QS2)8,6#,8+6Y)W8HT%O%ZJLCE6)W8QDM8POF$:T )T3GAA27"05L:$16$@
M-"R\=[YGP[*\UKI8)X(BG_H24_7IJ^C@8U?@XVM5TC_YAJF>%ZW'^^!N$7'J
MT1++!K*(3-<-1X(X>SW3R+P<]CVMZ.GC4OH]O7X =:#A:PC8Z*:@WC!=M!(4
MPVE"))!6H42<$#504J"=ENGU$M),BBD*3;CXPSU&CO(>2YD9N#T+9(/ =V"A
M!MYUZ2Q^.IXV6IUZ9S%8M)X>BF-A$V\\C4*00>3TTPH-4S?0C#BT3>MXMJ1G
ME-LU_-CHBG99 P\[$-\-,\+0?_(M[>L5\X]RGGS&3MH;V-CE&%]/*J++$!;?
M$.!QO\,P(4PQ%>L:O!T&@+-SJNL+O^*+?,-]RMLG$?(2> ]XMF64'8YLR0U=
MFQ%BIM3]G/S:CP];Z?XIGEW867Z,=<%YMRR&0'X=%P6 Y2X+=A\6%B<K8^C2
M0D/_?D4;0)> ,3&\?(N13[J]T0KN*BQ))4MRP)J&L)P8"VA2IJ,2FU["BG*R
M0Y)OARX?M\7LA8 ;G&;:T).=5*4GN"XJ!A:N;J-$O%;H!H>.&36B<[G:X8"E
ML">-V*94?D"=>PRBI%=(P*NI"3F'WMJP8/!-G-K7G@R"'?&OBM@SNH;-!46F
M/<O=>3AF!68^F(=O$E[?:X7NH6**CA?M6)O::90'?5LNCX>\TVN$3:KY*[*,
MH(T .FDA?CX7>*B,G^(&0\K'MN%$6C[;-,&_%5OH\A@'*]"!%XIXGVX^O6/S
ME!$LL26[O2#!I FVLA\72C*?&N5EMC14\Z5)8U.YOP?78(H+-F3.FAV>\ISH
M]L>F[2)/&BXZ?1^#&B\"<SB_!$<;]#YBGO#)FIA%R AZ?H[$.'^9\T0)FD.:
MR.O,[H1B-9UP"W0A1>3]MD'F!G-ZZ:'/3M>3O#2W$>PY:.N$.< PB=RZ;(#X
M)\54E[;,J!CZDK;)%*V18LU+3FC\.0%5;,LSQ(MW8[9TR)6J^W6&YXJ%R_2(
MX'%A25YS%@_Y6@!VH>KG]K]*0+X,4;I$:JF!W<_T,(="77_E7\99C--3UX0O
M',.+=K\%R(<FJK1EZ7D&Q?^ KF:A&2:RE6!8&G0P<=,CSHT2OY<+9!@Y=4.'
M/JY4N%)>=W\?<QJD8-HGUH?7YIZD?QQ-K:/;G#X0DZ)YXS\;VMR+'AEI? ^-
M:A@DB',WXX,\_YAX K((?!@JLEQ[)OQ'2U(5W=/\AX&S=>F4G"Q).'0;RB@^
MN>ANFHWU#6%F(,=@)-OM^JN]5$9'83Y+=;QA2@Z@^1[@&.A.E$)93@&Y/  $
M=(LY&M-/_8BF3&K$'I@CXH&'#:..I\M9  WZ3YDL&](&J&N<;A"XZ@5#(VF5
MOL[.X/^:0U-;=P+XU+'Y@ZT)$[+-5>*//W;:(+MX<V2H,_(G)$\>:IHZN#A
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MJF-BD/3EV86\3['&!R9JR;R3MVYZ-K@T6TI*LY=JL,MU=E5;R>+>? Q!>&!
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M$5:ACQZR*5*A(IQ;3Q=*1@,;4F?724*A^U2-N#)>S@T^C0E]$E&?1.=.X\4
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MX[,@ #BLXN-'\X Z_/*QU8\GA\W]W7TA" #X<:O:,J;J_6+$]U:RLB[E%^M
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M_0<NO'B?^$CF77,$;?XU\).]_8;_!5=H&?L7\Q](>"N_4CV)(*\OW!_:-E/
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M\_Z'XY>%+S(3(6@\+_A-U!5L;?]N456<6L\\<%CV'[CPXGWB(YEWS1&T^=?
M3_;V&_X77*%E[%_,?R#AK?Q*)2>"O+YP?VC;3 &/[:FV_ST*@?UY#+A$B3J
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MM[:>?>'HMBH +MU31X $&4,]*+L_[JU5CVA3 .-'>X,)NNB9VPM1]-#_S+R
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MEG#8>G0JM3=T/JF1#AQQ 1N4$1$F\19X(<E&DHVB)C<T1/Y LL5:/Z-9^JK
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MHE)Q4B.X=J.;&:Z9#-5I-B&BGB$I!EA=A>23-<QR=$Q<V;R*6098S0PP/]C
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M/*BN/, M-^6%K0):BKIMJG"[)J*\A@P.B+=8R);+!%-#7QPS 40[WU8"%VI
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M->Y_].-G!_(;E+P,5%S (CU4'? _C[;YL@R\INHE<@&1\LL"7 O][1*"?6G
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MF%A/M[,_ -FI: !*Y;R*VHQN6F9-O,SLZ5@NN]ZM)VF\/8FN.UI#:Q1ZL/R
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M(.MQC8<XRL@X-U8(RW\.U#I<OO@?8FYZJ'G/:9NT.2YR[U<=P)U>48$#7.,
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M[#DQQ;>/5A*T-%0#B:$!?"'&'>Z?!F-'WR:DI;]1$HYYX_[K[[UG=@VEV/M
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M+LWONGUR:ZO;R:+Z86PH;,3)(YQ$ELPUIYJ;E+(".6__^#?Y<.E3/G$!DNX
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ME]AEN)TQ*/5RLU]MJN'8,@$S9%2;>RZJ"%_@YD"\VJ8M!-B#^.^S%GH&T-.
M^P?Z2 $;H)NK)32C<1:0?T\B,FV/V _?GL-4.69]9HE>&<K_[41;D7&)\H1F
M3^HI,CM4A!348.:%+1WSXEZH^L'J]5;Z)AAKH-*@5A"ZV7B9JC)F;DM!WX%\
MN(QK/ND7E/H5Q'X5BCOTFD]L)OAR5P9'-A,$6@F'&51@[XVM4'64'&(C6:KI
M0G\>TLQ&&F9AIQ$K*LW<CQ.,H#W$6#_;%BVP4>&$D#2N(-BIB$*2@EZ'$6*R
MP_B":Z,:$%0Z$#U0N* +K(TJ@R.00524 NF"5/2W%OA^.[!:<:FQT_U8,@P7
M/O-HDPOB">@E#@(A&5B.!#\,0AF0ET'DP=X/-3VX]=MS=04_\.NWHN^AZ)<Z
M564)/L:>PR7/31VB(@2V#<1."7[3 B"^@ZA(0*A731PT 5L9V!C[DN1_H,38
M.&YB0*O"A02WX)I])64X>E\D[8(N.5/!M]*H-,?B1T#!1Y?:\<\>@!(%_VO#
M!>N2=42X0RHFI%L9$D91< 5)1"?T&@-RZ&D( 0PH[(=IH0%0HXB<Z]B8'Q5S
M8A,9V4%;@XH*N[FZXA,9CY6PHN&K<X@[SEQR3O802+3]IA1P".+_+QP-PK3.
MU<@7@*>7X5>?,WSOH 2;GV_'H?=!+T<!D+9+3/^)9,-_39_C&TEWP?Z)^TFK
MRR4$%'^O6D&&6GO2/<F'+S@/1->=V&#M8@D[^Z,OJU/7@M^$8C*=8EF%3SD5
MT8 $2'SL^]'W =KH91.:>(@30:$_F\!%2"'U(#U<8Z]/6.:",J50!"0-NC&0
M9A#D@!P,GH#]YP92&/@%"\!E&Q =X8>V"Q'R\(XE@((A$4OH;D-2:8@)4*P,
M;-\@5;.1^CT0P0RA:CZ")W4]F>#A[V>K4(VG+P _U.UC%M0%'8D;&O$4P0N&
MV">!TQ-YL?'D)%E&\HF^ @$2QV:?(=+5^1PP->2HYHBG_Z.>5HQ /_^$DJBK
M,ORK\-!]P*K?096MEW O_/=NI#'OQY1[SX$34F#HIJ6(OWJY2N9OQ!PH/!Y"
MS+/@LH(V:R<X!4!?.S%G$:<M%>U5DNZS'4(GU,X]L)FF1@!?D:<^2&'8\E$_
M&.1O\KC>\H6!33T0K3V>5"0(7W O#36] Y%37CL]'[Q1IE_J'RJ5^$OZ>[]@
MO"WY$X.SMXECG4";H_^BTV ^.F"0%'.%%.GIF9._3Q:- >LI7#$!.]. :KFW
MJ4_"?*]<Q?[@0I966"P?\0F'@G ?FD7HMV#'#;99PR1TM,EB>&!)"!F&,_<E
M@^+VOY[:;A^(L+^CC-W#?72'./B/1,V_DOX7VFK_OBL%/9:>(*X(X+.0 1CS
MR\,ZZA+K,/IOS+<598!-,,F>!T-0^"!8.(+IH\OXH71 ?.[@^_GY(^?3/K)D
M_+O^I_?Z>T">&Z9NSG9$UK6A10 %"(,*.K%&5AZJ#F!)ACV%#VE9YLR2EO>S
M+U^<N>W)*.%C)TS,)S/IMF[W!W:5@GR0 5!P-P:D&\TIE(A7!%;((\=/?ES4
MF<JVS@H[J:8N2^D&,_<\/P^.B9$D>>G^'<02$W*#0H*!?*(/$: ?Q;N0.#X;
M'-G+YOZ,4[6@[3&7]*F_=>U=O<NRU%&[A-!V"734+F'_U*A=PBO;)4@I5E(X
M#HB3:9(5$\E$2I1821*9]$2A: @OLG11BM^AZ'F3*@Q$;9UAJ_46TP;ED1?6
M+H$N::5"YK&TX557D!-I:BZ*Z4Q8NX2^3C7DO%3*"+FL;E8YFJKF="^L74+3
M:>Z2S<)Z(0"R7@/JPEXZDA?6+F$Z3B?:_1D[)8OM97]J">VB59R%M4LP)XW5
ML%M@!MJZE9E[26DNNW0[K&'!8%P7K-5.+)!+KF<LZHE-L2Z@A@47*Q)WU8JW
MV;97@MM9S#MU,CWFJFCD90.(_N,N7==3DL N1]8ZF>4?@8-:&URL*)M+[H1.
M2^_RS=&CI$YS_*210JG+%_.<./E';M?K:)HDDZE6XC&EDYNVR%Z.M-)-5E-'
M:HEL@DE<+?4Z8)#TQ-3ER!'/C(U6?:4*Q22]%K)]EC6]F<B%O'U=V@J#;>%1
MHRML-;^@:68*Z9F^'-F=EH:M7(NE^8&W'7OURJZFKF9PY$5;AU&ZV.Y(2L\4
MZ-Y*6PU*JWB:1<^\:.LP,[112I'[G$:;NU153H[9?*XM4N3EZZNM#;/,K6NB
M4*33R3(YX^UD;B925$BK"JX_]V2)7)!K(:49%-OA6 H.#1$G<CYR!+G;G@NT
MN4BFXI/*8[H!%21$GMJZW.XLDYFB4'3Y5$%H]HWQ!@X-8>GCHE(2BYME@H^#
M1ZK$=Y+Q;@(/O:! M]JP>SI?G)#572Z1JO,[7F/@7$/8K]0T<5%>IY-"M]/>
M;G?#7*K'M]'02QT=Y=.K(ML>:L!<K;ST@B:S3@8-O8"(1(VD!FJ1&9&J:-2\
M4;]4<N)X A?27S?XE*V*GB-(*R&[RR3L39G"$[@0 :&?''?USOI1&"0>0:^5
M%IL*! DX]$)3<FQ9;^?4/*FYJ]+LL?8X))4-GNLIL40*4(JL<(S(39BIF "2
M+*:34UH$J30C32B0(.4+FK7BPG*7Z+8%83FPJ!U%TO&&U@X#P#P_: ]G&75)
M%GL=P3%[([9BS<( <-;IKN@TF3')[KP:5Q)":<J1:&3B E2-55O3Q?A,8U5A
MN6GH[=4XC49>T"M97,3;B39#D@-O(#>=N565TIDP "P;W:K3;:L*&6?Y5'5)
M:5.A-_,K_9R.9$DS1<\:BYV@9C*I4J4.**H]"^L7L^2%[-)(E 5RN6:Y_B-?
MD"D!E0=(7;Q]IE>FR4F[IE4;63+>&-;&@/+"X#>16&X;S7)=X./.NF>5%KVF
MU_'" )#*)!96MC"?:W39X,1.;9E=M[PP +3'K7@F78D[PD"0QO:\9PP+M5
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MX4C.RZCA!["=C+_ T'[SC6%BTS:S&JNMJ5IF4ZJT-N:H_>/?9)J+0=ONPF1
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M.UG8[,[,+.!/^--\Y?/9-:'WX.J[H%DPB?"?2I^YP3G36ID^;0F,AYA_R'2
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MZ)*SYKHG%+P?_YK&D1Q>B*%KZ,"&>XV*3>&59$'3&3HU&X@!D&+0"81;.0X
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M-9^.@-L,U@1L__!,7Q?N?"/XJ!UU *"O@*RW@\#7PTMA""6A*;H"MR_P"UZ
MS#<U8<NUS]&S0UB(82 >0BT U+G)X U>1 U 7;YLFNV4S[>'+)!Q05(!RE<(
M=O#?N\-4F:#QBAZX9MK^+ #)B@TA'[*N']^$(D4PH5B&T-^)XN,LF$_%HH]@
MP+#@Q\1*D4T@]VV@='D9B 4;&O\ N2Z,*9Y^^Z-'^CG"72 -/B:T)'R3<P/,
M!!F(=$!B@B1!^7\I?[)C;G@-;&NOO:^&(%H 9RYO[#.C>WL\<-=I5P;/#+T
M7\(@^%U@S0.'/Z "X (ZT%2"7_7CUCJO BUP]K#TWL1*^^6=8"?0QGKX91>E
M+D!Q)]5@"JT,E)TA*Q--"B8V9#=U?FY:.8VW;3],O?M.B* 'ZRJ,5:\+3E*?
M3,:6JHOVI*R5>_G:^JBH*4F](5C="BC1+@"V*]L0\(+4M& K5W/*^&;%/E9-
M'5ARJIK3S$IQE%$'Z:0T)U89LX #2R[:MY?0H0,.O:_ 2 FPXR,T9->0=7P^
M MS*ZZ9K[/+-^\SC9/-8!D,(^_8+P(@A"7MC(X@8/9#-X==DH R<4*,]D E,
MG"\DQ\]UA&SQX/*<OUKMJH@%>^WLY? 5+=ZWR8Y'UF$'E#$MTTH_A=HE9E/.
ME9') J=S2?K7G^CE&G\E@N%GT-*VH<H'%I?KYQ!/XWR?;K;#1D-HK>V<?7 D
MJ*Q#[6Z[X!\_Z!S2$0 8$$>!,#@I*WR"0E/WB4*8M/9#%8D@,A5);03.N*\(
M F_^4;8<AM3%/3$]A!\_.PWZ4KG49]!8=FAN*8]E*%5R\37;PCO(<-%^;_(L
M? L3@.QDGDS*\FA]34M3EDIYY34^VM"S$DQY$IF3>;*[3P=SI ;[$\!LB=.)
M5% '4W5CY<ER&^]/6>_=.<I7@+G$$<VE,6N3B+1>,4U[N%15"X 9O4,SIQ.2
M02STLX']N,KW,X"=HW&26 %0(\V"R*$,6:6DMO>)P)8S15YHJ!.'Y7.Y'I')
M]3,Z*?O 3F%/ -N2[(441DMWRO,AIVM)[T^3G$KY7C!-\F$_-[ 9$WOA?>1"
M'@:%X1^ \ZI*OG*@CT/!!0!PR5!</_0+M0R %^^[#P^/VSNP/E E61%\\Q^
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M$TFR@HE-P"N!W47@K; ./J&;EA3\&=::W_FI65@_<M!H<RCT[J):$R9YP8/
M_VQW$E360TDK2A-G-P1&@;U)GM]I$6I2R.[@L\"(X<$_#G"01%A0887UO?#-
MGS,E),6A1! L4'C4WO16I2+23:5HII/#2LOCDKE7E4K[@75:EF$E KP] !(1
MS+;2_D$ Z31W\#U9*DVFD_6IQR^;:C-I]EH35^R7,2@HR!,"(BR6_L+JJ0\(
MD>- \(=$3!,XRF&=2\*_1^11[55%\F$,#EZKY1)7*'X>TAS(*1'TN/7XF?,>
M%C@=_VE?ZG0")(??HN6#Q8"E#QHJ HEVN#/!'_(4R(T3O3?AE#MS$51!/=A*
MIVIOCNRG&;\*RJT2_(YW]I((]L<>^CF?%][" H/A(9 8_B9*"E>#O3@,\/2=
M@PE!>[#6-($VQ.Q]!VB/36%BE0TA#&8-/;DL=]1A!8%_*M/E5"G;>WL+AB]7
M#LP.>'FG=,+J.!0F3<2CR@A>X9BN/!Y5)V@1,P8RO([VZ<:+7=$9Q)A/&GZ'
MXE.U4["4P,_HT9KV%G3[J WM<9A]O4L$#= 3*?*GL!'/5Y!'!+X;C^A7. 5]
M@L#J/OSF(2V?VM*!K@0J6)< ,$58= 0>+X:[ 009\DE89A64*NUI<^<_'G=Q
M=ERP40(E_^;__3?Q;[^ T-5D7Q4>G&:O#Q.TX*LX-(/C/KCW"A^VFL(8%&S\
M->P 5S:$E0(\D06@$+_E\KCUP?\68)E5D-DP)-D,NR</'W(]);?=AXJW2&:W
MZ],8?9S7]<GR:$ID6($4C,,\2N1;?O>OG^?:E6["N"I4RCMM$7PK2(KMB-KP
M@24&P@="+.SLA)(OJ#AX/:V?D)-!#:.[,(V37X>=A)8;(OOOA^YO*(%]67@7
M]I0#,PM6DOKMI3Y9/&Y?7_ 6H"4'EE/![F73"(IOCVU"&+I0](5I2_^.M"<>
M@AC6"CW G_=/"5@NM S?%(-Z1XW+&41QJL^;&4>29FR7KM;6D]QP6+3I=]4)
MY?9GAR4MM-W:EYHVIWOKKPA;E78]<Z>+7=ICEM.4FKE&-J-IOIX7.[T%WX97
M/T3MO7UM;M "%;:%VM%6IS<2J"\K(>%(OG"Z"\IE@J0&< C"4:XA:SR6J73H
MZSRR2PY*@9^M[]A5=J"/$RI'HP8>/>V)ASVRHOS9"U^;Y7W[]0IO262%W71V
M<^I; +L&S!PL%C\9=2B.Z]5QRC!GB*ZS@W)]4JK8K/SDS,_C$MZG4'NA6*5_
M9& )^VAKP>D:5Z/ Z-,3#1^778JO%8Z*(^D<@G20.5XE2JS2T;JVQE3:]?5+
M!8"%506WNJ/A0G49-S?J-[?]?N79,*!?'@:H[E1Y6,,/>C:G-=.083U_V1]Y
M!?C3!_])BF-+U7*U3.A953=T)UTKV(+2IW_]<3PS2F[PN4&CP/[) 6:/_!,,
M00G_X[VI%8YUV/\=H0[__F\_BN X\#50J,""P+M=$;(_JD'9O<U7Z;N!U/8=
M-.K@]"7PD[B+S-_M9JW $1$P8A%HR&";83)7VQS-" DD-._/$PUNN Q"(X'A
M&Y3E[WZ%X@G@YC"YX M"!VAY/^WK2W'?.CX1C'&.)M[ LP 2ACGWA_DT<,?7
MPRAA;.?U-<9O#OF>*+&!N&H JGXP%7J>V9N9K@U>4C!="U@$@4\52!>X/C08
ML#0^E;SD"%63-DI@C7JJ9W;.$S;.\0L%P"*('L.K;ZV5!'9C%?SA$3O9?CJ8
M7-ND%XQ4RB#+<14GZVLRW?%@M0)^1SP52X94?%&8/P)PTY!"&'<:FU9N@\L;
M!NLMI;%#*YL&=G$85W2N/),:1)<=U+.288I(2>L!088]#>*G,D/^8(+@W<>Y
MH0=7<"_C]L)M+]4>VT7/*9N=L1;NQ))T(/M"T0#L-F$&AUT=6T0_DP]]BLA"
M)PRJ9PDXQ?"%],/TG^SF84EH=M%P7E:P,[OI.C8$#8!MH"1/TA Z;I<KXT82
MV%X+E2TO>BFV3T/;_BZ%/C6D^<>PZ=>@0,JV2A5MD\+43:OGT+,2YTP&;1@!
M>Z)\SL]%1'AXS[_O8=FK4;^]W;8#GRO<K7TX*$X.LC)A(.U1OV)P6C@?(RQ<
MDZSCX-,.BXG@"AW ST\/DSNR\4Y_>9_8NF2;7>_ILRGV8=H_B [!0);OC_,Z
MM&[W!MF!E7EH6XHKQ8; >&1DADTJ8%,*,"M=P%Y!.!X\]\!XA:@(HI2[234^
M*9H/12BG:Q>"[SPTFM[M23B(O86;V86*0A2&ENM#A.@)B,"1><=@ 2:N+5C*
M!"8(H$NYJ\(0%/A:_Y6'K8#AB_:'"G@NG@[_^AX-,N[1B'LT7MNCP>\N'9R-
M*H336DTH9%DM;K*&S-8HF>90+O4K>-M^I9S44U6Q.500*3,%5&%6EP3A<1B\
MJ/-XI5JG5Y,>TZBSN=76Z%;G9I4Q:+ R\LP)7\'%C=H=,-4.,LIE:_IX;;<Y
M//K,LN<N76]C3A"7$1VSA#8[B@)71I[9G#9S[DP>BTP5J92[-2!J6D*;(Z+/
MY)*FIZ-ZFD&J=6DJXJXK%?H>6!EYIETRFH.A6\ZP7;TWM1 Q4V!8F2/A?;W'
M*ZM>1[5EN66PDJ%4\3I'*5L4KHR\O8FA,T:6<8))5N?-379MI*H$#59&WJZS
M:4Z;F3*'Z.R2U,OEYJPS:G,I#GF\DBAFA'4.E;)L<2E6,\ZZCA$C#ZR,O+W1
M+C#9ECY!5:K)ILB2R9<S3)M+1Y_9%[.-A=MSBVIWVJBE!%+M-C0:K(P\L[]E
MS)*6&Y;8I,QFIBUC;4[J'I>)/I/GZ.THT_663'<NVQUDO5T:*QJLC#QS,5_5
M%M->QT$D)]VGTBCIUE. /I'H0RML4LMDJJS"*I51<]+OU&JVVH9+H]0T<2E[
M5%8J2+.0,<9=%D B[U_ ''EJCS6KWF S5YG<.".5V%&O1;5W%]0>+T47VH9N
MU89Y56%P04]-UI:C>M $CSPU:VB;+EJ74+:Z3>>1/CFV37CM[0EN8@5JTZL6
MRT.FF.[J:<!U$S,K<R@>?6J^@E%%$M%$5AH,@<F\'!>WN39<&GEJAS93]&A6
M[['50:KC9 U":<&E1/2I"$W87:W=ZK#=2J\G>,6Q4EG2<&F4JOI<4NRBWIR5
MVFNTTB-7--4%>R6C3^UPUM+LYW$*X8VIQWDT8@@L#9=&GLI;[H#@V_:([5JH
M0=,3NNBLP5(J^E2@K1G+;#BRZFKC+C->+;DR8'ZP-/+4#>XHI46YP:K5Q;R@
M+'-]A"N!IYY@*T9S;9(?"#UV,U%)RIQS599HPZ51N.;[=:^\0#-J=^;T&_-T
MUIK5 01.,!9J-?-X3TXNU6).ZB.3##4CEQY<&GFJRTX;J>8,YUA)T[=5X$-O
M$0T\]01KU9;.+*T-1QN55^SQ0%MO9X65!Y=&GMI*K1%]A&\F2+?AU=0%W9U0
M92"G3_"6T]>''6$Y%EC>U,ILKMJ?,VE_:>2I6'I20(6DOF1R3*9J+G-<1NH!
M/7&"MS+R9#::L<LM4BT7E<Z@WNQ5D#9<&I&K63HIU NK9%)-MC,Y94AN[(GM
M+XUL8#B8]S+HNEM#^$+;')'IFI2K^AL@'R\="0-=(JI>B<4<L!)?9;%:%ASK
M!,>B[&2ZM#:<H":':K_FE=F&M/;@TL@&\K+,FN:XDE8WW,9:6TF]E%^W3^E4
M5$$7B)[J-U5W8 .)U/22KGE24TIX!G5S6F?,)D<U#;.;F?JD<U+_=4E-Q'&I
MUF&K-EON(LO,(NG)I[2:1Y1[TS:[62')U5R5JZV,V\5/:K5A:E'9D%.,4?F\
MJ#&;5K%%C:"NBD"4;VBS?%FMB6IQLRB7F<9 Y8OM4UIMD"?DBE)L$FJQXM06
M:9=J32L>6(GB$=-CHF5&\]*<80?S;7>>EG1.!>*:BFZ45BQ,G4I-EU5RUG;3
MYRIDJM4&*R,;G6_:P^:V7*DQRH!:;V2C/JM-X3,C&T6V[62MA-$UMIGB*3R5
M:Y3;/%R)1HADIH^36(9?3-2N@/:DF<&U,FGX^NB9^L-.FBPDQ8':=5M)7)PV
M"^T6?4JIE[RE791FP[&*35%5XS(9W4:A^H^<'F>JY=J8,&JL7D*614)AR(4'
MU7_D],Q(= !1I$<(O[%ZJNS2> Z%*R.GQS"'=9.9A:YNNB57GK;YVLC?9_3T
M)%Z?3'&].V22"]1KJ.W>1A[Z2R.GMQ:"6".Q<4FM E.9F-:M074IGS(_<H8R
M(@;S00IQJ4QI+J[SZ\K< RLCIY]-,-WB2QV$P?(YC9\.R]6F!TV:R-OI-8.E
M[?RLPB2]>KH@-]M\OP171DXOEJN:,B7K:Y9JV^@04PI2)@N-GW3D\*EJ>4NX
M*87-33NEDM#.4WC2\X>W1D1T>D5H VFS4;&>,>2$?D?+=?VED9T.<]OLH+EM
MK]7E"$^E-DJ*JN3\I1&ID_&D*>4*2XEI+NDZO:21G%UOG[*^N&Q'Z!E(;X9@
MI)?%I\ZV6 $V:B8*4CF'(>DQ1SJ,2];(0I$GK-$2KHQLE&\+_-).,R.$2G,N
MAW7UG%"&ME\$I/6&M9E1C1FJ2NY('\TTM9^EH>T7 6D;:3.UE8.*K#+R\FAI
MRXX(#3XS"M+E2$&+,C]4&'V5(QO;7&U!X?[2R$XSJL&L*GUBR.2R5"FO#AKC
M_@;"*0K2[A!M(>.Z-U"Q8CM)IRM4,>>V3QJ?ZTJ:QHJ3&<+RN4:?2O*S1HN3
MX=((4'G/6B^FPPFAYOH8-3!7Q7ZCZ,&ED;V.98P9VF)RC6S<?'<YFQ5G6L;?
M0 2L9:\\;')#9,IN'*_1R&YFE6K%-Y0C<*U4,VAZSN=72+6='*'F@"YXBK^!
M*&";&-M !:_48+I],MTHDUP^A_N/C4*VJ^O-E&RB(Z3;1]:;U,:J;DH^#/:@
M?6(VP//-DV]HM;S0K62[0*E]GRCNTL-W^XEPU@(FI(-VOC#DMZOT\N?]&F$J
MV3[(\ 9!VC #_#@XMJ_:@;$W6,X6-@]'[_,X';*[PNBT'V8^&#[&._M3PTHU
MV*< _@/'\DRD@\J!PP(1._%W&%DN=YOV425T"!]=XHTP/]\-QX$3&+:#E7\!
M)QSWV G&3 -XB1*\/@K>-+6+Y#ZJK?+#L?MXKW_1A3^9.@&WX'>''(:!??3#
M2X'V]V&_)BS\U"OV505!Q38?WKT=O%FYE^[O=I'V!GAEVP5(\@M'0VC=[THK
MLI+ AX641_/"X,/,":RDV-4D!(W303)Q%:3T'^5 X*SNQ]3Z4&3FAZEAD3?<
MZW-[.ZSZ< &FM: I\^0F  OL=AF\/[R)8;>-,*UQF,0)MQO><05CUY/G][.#
MU=7PS<$U]/LV9>*H]NC@GI1P5OI)Z.V"]KM*NQ,Y&X T!=#KPZA\F.Z[.T@;
M[(67_4 1(4L_NDSX4)B%>#DLQCF9:?.1- DXZGEF#B#Q(D=?L)0MZ2<VCZ3R
MU9!4SZ_2\8DD&90J[_#RD+UZ7!CE#Z'8ZY?INP=\!0U?X>S]BX[H>6J,Q/N*
M-VE-,V&GL7@Z\?W<=!)<$QU\K;5L9CFF9I6*@@[HM5]'0&!/32>Y[4K7#P!+
M+_*309[.C!%JL2%->IJ?$1D +  H#+VB0?3=@<MW&C6CSV#M6J??&MGY1?/=
M,VX^ +#U6*EE2^UT6AVT2E1Y9'NK<D>&U$6B;YE]L[N)Y:71-W>W=.?NN\H%
M;%?WFR]VE?@'A9^[^<:;#TA(Q:_8"&X0LW]_S:P<82:)+KSEYS1]'50-V71X
M0C]Q&1VB,] ,>^VM9)&ENK-AIY9%2:TE?])8G#>C[TRSB_PB@7VBW4^*)_T)
M\0M;^KW[X7"S<"-ALAWF;(4@U[NK6O"SX'"B_NZ#( ?N?W*4*4?\1/UAGAR)
MY+P=:[>Q\(5H<')'W'W^7%T#E;I'L+\.@1:^;P? @T3TP?--\,PIH-<=U':_
M)ST+D%=05@!+T%_,Z(?(\%^\6\I/@*QP'>DKDOO(/4*>[G<^^-[K">6H1L,1
M7X&%F>)(2?   98-0.B%IXZ1<H5(R=RC,5ZN$"_8/8+&>+D^O*!^%5F,EVO#
M2_H>R\1XN3Z\Q'+L.O$"^"45X^73\/(?QX)^S-E\E@\#(7W@=_F.6.H>V[F?
MH:^9##YZ%E*3HWT<!I-__4G\]S^3$[ \7/1:<'Z>GW$Q:DJ?BL!_"3Q>,O$_
MN0'@-H#TDI[Z@73SDJD;T\TK[,X82#%SO<?^.HO"?R/9/*?<!_YODNCK^/WQ
M8S,G-G.NA:-B,^>G2V+!U."'_IU_[Z4A$K]]J1Q3Q\_5TS0X'R]+L9J.U?1U
M,E2LIG^Z(/YY:OJD4(Z)X^=JZ<YN[MF5Z^G;HX08'K&ZC27JSU:WS!H.U[=C
M?1OKVY BX&0JV!O@\MJ5:]S8,SXC(-\-HJ#G(?KOF21*H)3#JOM=\?YBG? ;
M2A*[*7>WPU[!^.);$;=?0QGG4KO?ATH6N_9?GUQB:CF7&OX^%%)3IF&[V=\C
MV&_V[RM7UF\SW+Z!4KW" W^Y@^MWK5T9$*[,1?E&Y6G7=>8OKS:+B?TZSOSI
M#O<7(OY]:OQA&/CO_Q4$29I./QT<'_?##ZZ 2%1XPX4]]T'//'(>77\!J#QW
MWIUU>RX/^>M/]QP+X(^/^^D7H: 9CN+,Y7SB.ENFVC;E*;9)L3GJV0O3+GRK
M"9P!7EFL;;SE9=FELD*'26\U*FWH8 @H<8>AZ3LTG8D,[3B;:K@RIKB4:71E
M8/C7V>R?&Q<+>7ACBN2/Z0D%0R.O9&J%&4DPRXTZ3G%] ?,&'Q<,V&7$PJXH
M,:QZV&5C6O!:X!/" JNW4WB'- 8(-NT2PW(;9<>.',P!INY1ZL?(B;,ISS L
M=.5<\OJ10(#8#T8"@=\R.7>$3^HUD]6U3JGL% O2&D[H>7QKJ.A:<&[125J?
MO$SKDS?3^KZNXR#A!*\/Q?;4OBFM]077(ZL,U2&JI53*QA=B.YAEG4@]7*G\
M<('0=4>_/FXC%X/)F[<?^SJS\7M5S/H)EN['Q\]]K>'KTZE=-EH FJ;H7YQ^
M0IOEG+DYSQ-\FL'D.FU(*RG?&M'!!'CTCDQE[E#D$U7:3[1SOX=1>TOL_CX+
M]N,,?U:#UGX3O[_1J.WVM&5;X:<Y)MG@/=?LBQ[B7]K@&[5XZGM*@#-;L%?%
M$F^88/E:PG[!7/5ON#^C7Q8:6D]0]%.FZYZD/7:F4))).&RSLD@Q4K.PU3$Z
MN(<DD3F_Y7J3 =^":4TEY6SF['?U4*\RO!LY;N+OV.H-"=H%Y]L)CA/JKL?W
ME<VV51BR%([:FV$EFTFFO."2'IRXHP@BHO#^_5W#.'&X-P[W_CAC^828>*/%
M/)N/Q?%6ZME,M]ISQ9;>F_/^C6# 8D[=D]$9[]]5?ORT,/"AN(1F<%)9)P-9
M^;OD_X=#E4&UV>TQ(V9 6/+<, 5[TY9/]D5\Z&X4_T'/7G7MW[N#8@^R^RRE
M#==OUC+KA6+%,=JKBM'&YNH)/>03:G#WQC/FJMED,Y-AO;AD^ R6WJ!%O8&F
MZ?#^0PRC[@@BJF_.9[#^1.OT>YBB5Z4Y8[OS)+^_U>XT"7,J#_4V4J6FR_2\
MV5F1:U\6 ,.3O*<^T?#\%HKP&D.U+YN4<H'9.L,T7F9X@UP51TJ1JZKT]S$I
M;S)XNF/5.'CZON#I!1O!?JBU"B\5*_M7@X)7 W@&&BAHASV\<6Q/V2<4D(B0
M\TJ)YL9,56:W>0%/J3+A<2CJ!T]3\$; :+HPCI[&T=,X>OI]K-A /+S7AN4&
MC(>O6L*,V:0Q:HL4:S2MM*$( 38L<4_$-;0_-WB:RNEISEWG6HB^PMMM>L83
MLMK^/I;N]9NU!R48=X\N0L?1N]V-Z.?J"/L6W'?YZ.K7]WH!M=2@TL)VGO8,
MM=K!T24]K<S2E'?=O5Y$V:(S4IG*JPI-]$>-8LXA,S0\%3!?R3N4(N\P))K^
M_Q9!E#B8&@=37]^S]2H&OXV>+99?R;.*6FLB319II 0-T'O ]$%]ZS>M</_6
M0=,OKV\]5SM62*SP0O-7UK2B>T)&AF-OS:9$G&UNTV*]FR;6.5:&APOZL3 J
M+FL]=X_6=W49K[*H]1*=7.B1?$ YM],:8Y-,IJTJ0FHSF"U56=/I:^_D:BGS
MVC"?'SEJT9R,MUM$G,M"FT-QOTC@#B'1NTSZYY2EQ8'9.#![_L#LVT7%[?2
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M]_0!. (&L6U7#S[K01KL@3UE-; P).X)1S89M$?4"DF63\U*UDJK.V6B_0N
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MCWGLRXT2KSY;=VA"7[/%C47R[:Y,XD+[YA(X=(G)+=FJT6!UUNYGU+0Q+,V
MHTJF[['+Q"%>@=G/-56D(D.4'(]<L0H]-1K5.D**;?GV,"L-S53;3N%,U</S
M&:>QY?-KF)I#3B1=OT7E_Z>$OV-=\N-TR9?9:U?A_+PNPV94EU(ZQY(8@]7$
MLMU-&CQB0FONDS-LL3R)Y4DL3]XL3ZXK4_)<(FRM(V1?%<VVVE27]GP[))%%
MQ8.9$N)"M6$Q^MZ0Z$)+T^[6F19JB-XL.*NR)JQJ&1@:.Q49NX5NN<_/:EU]
M(<'C1!<6MRO$C7!Q(]QKLRO89P>CL/M,NF?B]QDT?)[AM&BT)U=$I#D=<OJ@
M3>0'[JWT4!&9?H\?M@T5P8H;;5K4L^-JJ@TU"(I>*D%V$H7GC#I%4"@,*[WF
MB&_(;+7%EIULDAMXUJVT,J9)G%WEVAV3':CS=#97,@K-#$ A/%_<!1=WP;TG
MB88=6>'8V1F.QKG"0*AM-7;)LN+ :^1+6O/:FN!FC1Y;ZQ.II2J5"]M*O3,I
M;[(>AR)Q%UQ<]_M5X8S'G/C5UDW7W-+4:*Q@:M5!1WERVINCV.WE8_!2KC1L
M"4:%;7*$N1D9<QO) D^9S-SCEPETO *QGVKS6.M5?J[:58UI5IU&?SK,B1)Z
M>XC5J=44;[B--+)1LZ.!)U9DK@RL'RIU_RDAD+CU)%9!/UP%?94Q>!7>U^L2
M=#F-*;<=K)5GDL1T+M'#OEQJM:&I&/? Q8(H%D3?11!=5VKHN<P>4M18LM9L
M))&NL>#3;GHTH5TX'.F>O%!I68R]UR?V\BO6M3VTZ*J\L5XGUWQ-YQG/[UOX
M%&5R$QUL_W'XB29]@FB;N[:C3#?!1XH!I+CS&Z>.=O=8[@=_V<]4Q1:G[ED]
MA.<4_!^"/*$='L60+G% '_SP'"'PRT8"XAL2V%W"F4D)R :\L4E8DF#*!GB+
M#9EI*BD.$ AV@K?AJDW"% 37NM\?"PH$Q7#YD%!%9?7GO^"?W0$%3>(M2)VS
M?T3%7FC\YK>/Y'^.X8NE[G$2;A=\- LFI*;O*?A)2+X(\A?$T,&3CQZ7%"1-
M^^?9['#XA$]6FQBQ(_0]H M)V(JTV 'GX-__^7^'!WH@IJ1@:J;U>S>^]P"&
M(6PPGUME*3FQ)%Y-\E.P@]^\YO$;.SQN.GV/$;O)P+_W(X!QN"WR/IW^*_'P
M(P1+!'$ZOTX>0"Z4#4E-FCJ_@V_M/K+\+86?F;9/4;\M"7KV*^D1TD*L.^;B
M-X;>4Q'\?HK,P1]P\5\^,;.@[OK?7C-W<I@U_!GP*E BVM% Z_"C7W]ZD-X2
MYA3P"T"\X=A[1N?_'*#Y- \\ANHI</&^EN F!(*2A(!R$Y1(<026(K@TQ@L<
MBE."2  !3Y'(K^"M_+Z,L+UV:"'CIM2!DW68"=^CI T-M'-D9=<9KY-IQ&JJ
MRBPS7;B5)$>X;0[CL,<KDSDUJQ:7>HEU!S6ET&E-*I."!U82CU>R8\3L*-36
M1O15.UUNKUM)N0%7IAZO%(K54:G=H(=J%\D[+4I8MFM-C\.C^R0R_'1!B5J/
M:7)Z0:7[8K&9:H.5D7UN#0==C#""8)5A6\IN]#HBD3)8&=EG;3GJ4:/RTF/X
MNMCK#RS9MBSXS,@^>7I SLNB55)YW&L05%IJ%JIPGYD(/"N5^JPF3&J(CE5H
M=Y2B&4>0.2)Z(B\C3->S%"DS[KSA987E.KM&VV!EY$1MM)7JCVOY(:NHV;Z7
M=!L#KPY71DZDT+3)ESFFQ&YF3"'5J TJF+\R<B)R,%#Z$\/;LIO&V,CW1XZ\
M'<&5D1.Q@\UJT^V0#*/4JNYX-629S)SFR.B)LG,LVY6GY$RE4B77$9)UQURV
MP<K(B?358MI6ZXK$4A-^V-'48F92A\^,G*C4MTR)DDI;M6K-R)K=QC+D%#XS
M2DLE;K-(3UF464Z8U$02&93TX#,C)TJ-T?RX3!;'ZL!NL8/QFIYQV39'14^4
MT2;*V#3%+5(LL3T.Z793LZ0'5D;VZ>CU1;5O4"/$;?%C,H.(B(3"9QZ_G>,)
M'I](F,BE,CAX#$D1',\+!"=2I(CA))E&D<GC9P^WLE2@1-% DEZJ4<QF[2::
M;I_B9L65.Z0\T1#$I1QK[1I<*3N4 >=%5JZXO-K$*^,!4K7Z_5IJ:J1R6^\4
MWPNN@@_I$I)#7+:W3K,2II0$^A2/>MM2MB'J2YN5,JCDU/*\X0KR*1X=4%O+
M%<<DR53SZ2+"3<O5U H^DWR\LN](5:FJ3!U&SR".8S@:(U?I4_S4+8A\I["I
M=UFE,6G,FG7=5#7O%#\UMVVZ;X_K#-LMYG,+MM"@]1FD_<C;72IM5S5DTT*D
M?H?I;?NI*JW)IVA_E5,\"[&- B()R_&,6VOE?D<^1?LD-B?2:)K8,&YCU$',
M;6NX*4(ZC;Q]IA3TXA)Q!*1*:C47&).9L0:I+_+,B=[J=@E:T5A,<8A1.3M*
MTBE(?9%G2C5\ADS6>1&AVKHZ:]8PH0@D+AJE:)D=I_N-:EUAN_4"*TQP3:!-
M^I2\E]1".HD0280I#LF"J=7D:FU[4N(:J=0X2U>J"U4Q.MFD5FRMVYI\"D=N
M!?%2B&$M$+V3KPZZW<(R.Z%/R3QL/4^::&Z>9*2V5_<$H]Z:DR>YN6[/#+PW
M6E,(7_ R-8/.4NBV?8J;);0W+^3K?)49C%L*M4RU'6/H<:GH,XM:N37?+ MU
M9HF:Z2(F#5RJ#4=B15:Z-40SA&V^RBZK5IT7-EC)R<A<)KIRV5QGVW5"S#(4
MH@N;<3M?71@RC#%&ENJX;'@"7IXQ3:V^WMJEQ733\\.1NS,],LV#+TXX!;?1
M3*$YF;)8KIP;@].U6D:;@TNQP+L'WY!$VGEI-?X9MO3K_+0><%84P[$4PU:$
MQ JZX@G%3@##7W"!&26)"=[Q/1I1F4Z!.VX(4F(B.9XD&?['X&&JY(1?!&X-
ML.4B-9GPPZ\IA2JL*KC5'0T7JLNXN5&_N>WW*]?2O?)2:1)%9?KUC47A2)7!
MR,%VE&^OX91U])XDHZ5)O"'Z")#"YR86\,$0U/#3 (B!9_G^0A:ZF?1*P_YT
MQ%0)9RD@/1/9%N0(F(29)+J:U)R>!IC_J4V[SLRT *&*+*!%RX];!;>CM33>
ML+.;2.A*ZH%]9C6P[M>.XU!\3F]GHI9D<ZUTJLDWS$VCW_Z5D  X%V!+CN5*
ME^.EM\<\3@8X?"=\[\@&U]$ )U;C%[;T>_?#X6;A1D)G%OI$0N!+[:("OI?)
MNXZY^R#P,?U/CCS1@[!5N :)^)2.M=M8^$(T./GKJLI)ZCZ%/E<2?^#H'3S?
M!,^<:J:W@]KN]R2,R?T.W'98^/2BQQPBPW_Q;BD_L4W-=:2O<)Y?<_D3^GI"
M.8J!?#"B23T[("C&RV7PDGF^#2]&2\PN,5X.\8+$ZN4*\9*^QY\=HQ?C)99C
M,5YB?KEVO*#W,;M<)5H0/,;+]>$%B+%G&^!CO'P(+X<M_8*IP97_]PM%?[VJ
MOQ\>_/M<=1P$$NU$TW5L6'H'MOJA>X!?#%1=]J;CA'^X"$5=X+KPY^W'B]Z@
M_B40>"% <VU\TG!A8N9LMX%_'^SOY2?VDOA\FA*>5W;71@H#_S=)C(GA3*+@
M):?MVQ/ #\?_2U[(]X? 2_;^1;ILS@.3J[0?SR@,_'Q[PIS&VN!G&H8'CE."
M=V(JB W$/S0X'R]+,2W\4/OPW/C_-N@_BRCX7&B<FQ1DV9)DWI%N(*AVQF/O
M*A)C$?@SC:)=(7,PH %'[W:3&F)R^/'642P;?KAYU)%T7C$BB:;80/J)!E)Y
MUT%S#@/I^Z1E_5:.6Y&0+V5D#X<UG7EPDV\7?1^T!W/X?Q#6SV7^?!\2B#G_
M+5;/]\%[39E*B;]'<-CSOV_$,+H>"9#Z3I3@][^>Q1RZ]D%^G]+:_.IY<.=M
MN7UFDIS4-*1P>%R-&DXVS65IP/*E0MDEUMFVQYSY$H]7'2&ZR9KI25;PDZ(K
MSLE&Z]&:5)=.,SMBL1K!I12M.Z0G7WV-1XS@]R&872Q>1'"A:6QHK5+5D6I-
M-<ENM<=1:7C3%_YI$P&IR]PH]++B.IM[<E$Q[/>C'YX6?WS:UT[D#%FTG]&T
M7JZN5M0N253'3ET=U5<OC9>X*$^6>EW);IE>FVT.MM.)EVT-YMNCV1;E1N%2
M7!D4EC:G!W4$84WV8P:%<YZR2\[!=;F&*.N9W&OT2M8V&\[D2=^A2.8NC1$_
MADTO,"'9;Y.],C"<XV:WT)NZ<DGU)9-PKEQ4O=E\B%Q>]$Y!%150NSK8L-[A
MZ"M9"6 1!OFS/'B<(*$GI-EDF1OF&96;LPH]RKG3=)U%EUXP-XP\95%^5T&6
M^'I)=E,,_Z&KQ*[)"SAQ[QB\WNNR?+O/Q\%1LI#57%Z#-Y0]7#MA&J1*](6.
MAQ3[[G8J<Y:5$6C J*E??ZB#Z__.>CO9];'I1>P-_.K <"9[XS*#X#_%,X(F
M1XE/,K51KF(@_,J9TR,;ETVN?=NV!O(5(_]"H70@IO8Y83\2>LIP6)4E;>&.
M>)6?]KOM[A;O*W49R"-X"T[J#DL_%ZJXS1G_/V?>W5,B@Z3NJ7A&T14.*\#B
M8057B9?@VN08+U>'E]1]FHH1<WV(B079=>(E%F17BA<@R.*Q7E\\IBCUDZ<4
MA>XL='L^6B#SO"]Q;0 XZ_B9E_3<SZJ81V^M@>;,XT>^$S5\CGWQI862YSC/
M2WKY1XT3N2U!?Z#ASC=.XCNQ^ \4^.>=)Q 3PV-B>#88<W7$<*Z) K<E%S^W
MHSSFB9L6D&=N*8^IX:8EY-E:BJEOU5)\QM[23V>0*^DL0^/FTI@(0OGW?8C@
M0_V%+U1G7'W+X1?TNKQ\E>H5M)L<Q!F>;C?9%JETM5J3\XA;!1N<=!AG+M'!
MY<;$'87A=T@Z>L'JV63+E=4]7J+\$P8FKPP,YRC_#$L@KKW^\U9O7CY7Z7A4
M2#S7\G&JQ8,6<SQ/R #/R7$;2:]9!<N,X:7G.*P<Q[%8>,3"XYWIC6L7'I]>
M//ZRX'AS_79$<$3KMR=/U&\?R(KC^NU38F'.U^W4;.!0+$5U5Y[@)K?*#!9P
M4[_^H'<8>5WUV\=$?;[R[<==,Q<J1N_!6^]='7RV29C3A -_=7C'M7>_08+@
MC0T\ 9KZQTZ /2=7D@W40,(,"S, F<&E@0,&6YH2$GB=F-B%;1,X>I> 5'N7
M4.P$#[^@::9G__8!\?HN+_RHRPOG6GFJ@B-RAV2JO0Q',69U5)'D"&T+,TET
M@1*;-DPCV+E/RS2@K17 4@\24P^\,ZL!E1A2Z83+-]N\FC>P),LO*<+6\?H(
M70.NE  ]+\#C'<N5/D.V_/@>@O0'6PC\AZ2(>S(35Z<]&U"^4#EG)JX:O$:\
MH/=X7&=[C8B)&>9*\8+%?1Q7B)?T?2I6_%]3EGX..RR^$?8U0OZB10<7 LE+
M!LF5U;'&A'-VD)PA?0NW>DOE*Z?+^V.A&_-.+'2O!TK?F7!^H- ]66(?R]R8
M=6*9>SU0^LZ$\P-E;M'B#2?(&.8_VL_R^;+W!J7*9_/+A]31T]6[9ZE.#D7J
M]ZG:#4JXSG8SS+<@C;,)S>]#)@5>"7OD/GZ-S!4(U0M,1KXR,^.;&J"1^KEK
M@,)/Q/P+.<SO>.:7\H.W1.SO$^E75A7<V!<4WB4JO.'"2L2P7O!L;'UE1S[?
ML)?0T/TFU=#O;[Q"N4:GK3@BPXJL7F]G49.KIHMM^H.-5Q\HB=X7F^Z:K@(;
M_D0]-)O%C&:EF1LAN;*#5T:6NBD-PWM]L+M,AKA+$]3G7(=QA;QQ*2UX96 X
MSYS]U&7$_3F%PUD:K5XC'C[>:/4.X?"HI<J/BL%X&/3DGAJ ;S9[8PKKHAMF
MR1%;ILUVJ7R5#F[.(>ZI]$OM$S?E _H0@?GP;V#@GUOMWQ(;OT?'OW3+#]U,
M>J5A?SIBJH2S%)">B6P+9^^U?OTM%CZMVF6C!:!IBD7+M$^I^ZS&V.-FVU95
MU\.,?-US5NNFQZ4"=9_"T#L,^92^ZLLS0.SA_@P/]VMT_,?%P\=OXWVO<'B/
MWF_EJKI#4K:C5K/I\4H;3!H3G0:"@X1W,&<R9]?[5V82%TQK*BGG- :N[(#?
M/"P0C>___4ULAG-X N'O>R)_,6Q Y*9MIMFF5*:((1/:=?4A;[6Y-+0C@ V1
M0NY0,FI'_/N[,D\<-[BHN7%ELN;;6B"?(6K>8XS8Q2)C9D8BHBH5?2'VM*3D
M)&D@?8 QDKZGGG-@;B\(T??!]BU<L+/;&)<KGH@-CO=(@?[KDA*S#%=LI)3^
MAL&&^IAKYD51[;>Y#+0N,F0&V!:I3[0M?I8&C8,4L8EP'29"_]U)B>)HN651
M><@B4B%-3JENNB>5H;P ]@#^&?; E=G=AU4,3XRKCRL:/A2Z.+8T<&!IB*8+
MQQ==@ZEQ@9*'3YHU^R4E#]*@OJ8L0R$9OK]P\;G6*) RS:$(-"_P.R)-W:7P
MYP*:WXM[XMA%7/-PH\-EOZCFH9&KD75C8R@LEEF5T@):X/&N+S" ?8'=H_',
MR*\:/NBS+=QT2,JT/RGRQ*C'@^&1B1DO)OC%PC+7@+(<2=LD_G5; U(9?:&9
M&TGJ2M9*$:33R< ]A?MD;_=,A]<._YXS;:=A.B,);%DP90,.8SZ8PQQ1E W>
MLCC!Z79Z!;7L(@J2I+9#IF)[O38<P9XBR#M@]T0HWY_<"=\-8&KM7P2@]; 3
M\(OM)/P11N OC@GH"&QC/] 32%=AEO 43;M+@,5\P*AWB8F4X'43R&/X/#@B
M*?&&Z9VO]7P.<)*T)>&WZ%IP\I(M&5^&E"!'6S"M\".X#CW B3%C2*U>%T5&
M&@FHX]2MV28/<8(G= "!F?V84^]]]CT/NP:_P@?]5L!9%.$4 S_#KSX8((WX
MI)<(:>_W&7?X,8'2-!*T*X/O)5#D4)9D3;!Q7]8H@*H=T[(3<E <MJ=;0,@+
MUQ)F@ 8^LQPI[1NJ(44__&);#M=3'#AIMFR(4(6[O$:O%1OPL&UR.VIM&E+=
MEY6<-*YO.3Y5W;(*8_%<2Y^CC5'[ O5+@9U>MFU7$G<5"B>%D99L$5-G,$^K
MQ7JS5V]U>Q[/MV&^$:7PN_0I810 &.(-""# ':&H :@Z-5U8"H%T*(-\L0.W
M"3#M&Q<)=P&>(_'@[[OU^P= 3"24/?@3"\GRX6<(4D): >O"A\E]H@D_")_J
MTQ<@F;WX@R^%0@,(/RFQ='G+ :(.O+(@3:R@/X'T*1._>VD%\>(*,@$H\:5%
MU'T"#FKVZ3TA J&=F )C*0'/(X6#FL'^7>/18&8@K%TCE/"?JWY?$O9OY@U^
M,2DFV:Y*J8K;E+@1ACD9E'ZO^J8US13XW>3G"(LP:_ACQ.[T2;[1ZR_'7;&?
M9O1FW;'0WK0N4#[)XVGTI/X-</5@^M@)J(5]\KTL$D)H</#"AP: SP/\ X&+
M(G!9ZX%C?$#Y$B+$2J97J=E#;4&IDEG:U)*"JVR'[7=/G3^^@^(Y+!#S59VH
M:KD,VTRNQX/1JBTV18B%-')'$"?$CF(<V30)*7CXH<USS/3A$//$<_/+SZG&
M8R7YG"#H>69(<@8AZ6FIEZPBS3*^-1Q]Z_5*EU"2KR_R]2EVLAR.W'DK0S!5
MC<D.UQE-JDF 8E,I["YSHL#WO8K2ES9/*B_?U9Y!E>)/]E?62=] !3K'4(#]
M;A^,_7]0+G<GOCI5+/#(5WSM0(L!Z]T$NNUM7W)FBO7"=TYIS*GI6B^=Z]J5
M:,2'?3.SS 09)SIC746JJ23/SCS9DOAW:\V/LDK3=6P( \60CV\%.<DP/&.4
M"KK=*;/*9-["*V,OF:D"ALF@J=M2LV_&&LGT5:7>68F((A)%)M]-YN?-=VO5
M#]@Z&;Z_RK1PAD.6+.%4.S5V.I:]7W_2F3N*BE[7%"O9FU.R\"_^]IO3_>9S
M,R & 31#:E25E9M3EDH-<4OS48G6RA+2_6@C[1<HW+RHSS$\NRVIRS+=:&@N
MYTE#&IB(*/!,3UPJ](S"U7U(/'D%3A3_SROA(^WVK/+K2@LGY(8]Q3U:<B+2
M>D(=UGE ?+LE^,TIOIVGXM-!;[,(7)7=I_NXWX/_$-+N;D70-0@6P)N,CKX;
M);4'0MP]-WQ8+;_ .1<8;P@_'9%VWEH/-M,;4:9D=RL-A^.LC4C] :8QR8$^
M7T%_"3\=,[Y:9?I>2EAO*GVCL22+#$66G%)G@&[RTON1]WI/M;30DVRJMV+8
MI;DN](B96EQTH!A"T#L<C_;QQTKTYI2H;\9U)4,QK3IO\+)D'<2M*M)FI5NK
M-L/KO:1-+[QBJW\#VA-KR-1J,>O+"(;(;$?:,-88A2F-%'Z7>IOV%"3+X2%5
M^Q!*Z &('FO3<ZG,:W-.;T[7OH_.A9$QJ39G2YRABCF9)UEOZ YO1#GR>24S
MJ:]*N.JF1UVQ5G?E7$'^]8>DL-M2CN]#':/FM@4/L09LLBHX:GU29M;T5P1Q
MFWVNAJ^6AJ)2HU91&&R' LY HX1"[C($\:6J$;X+@EHQ@HS0[I*;@ZM\! T\
M!18<S?X1%7NA\9O??A')/\<%'%CJ'B>A"@0?A3<*P0:8Q>X^P]UU/P=//GI<
M4I T[9_G*E[/>V'0D_,F,6)7E/70<IO$4M%[@."___/_CFX]VM=;P>LC3>OW
MKB;S (8A;#"_ $N6DL&E2OP4[. WKWG\QMZ5<*7O,6+76?)[7]>)PVV1]^GT
M7XF''R%8(HB#-U,>0.[HYLG@6\=W3X:?O7"S4XAUQUS\QM![*H+?3ZF/PQ]P
M\5\^,;.@5/C?7C-W<N*P7Q-@0,;5CJ8.AQ_]^N-?=0JU4,[T[^VT]\5%_.%U
M3Z=YX#%43X&+W]5K:4TDEQIL4%IMLO5&IF'4L@N:AE+L5_"V_<JZL5H-!JEA
M5AU,V0F3W61+ZT4;K"0>K^P!UUBK-%E=S=G&.I.T;(8HRF E]7CEHHT*)9/J
M9U4@''*K#JTEK6:;PZ)OWY(*3DBJ/F,V[2+?=9SJ*IGUP,K(VQ6RPKJ(4"PC
M4L72TNUIL>]4X3,C;R<JW0%7'XX;ZG*4[[?Q#D(7NC)8F7Z\TD69N6A7MTM5
M(3IUK*!+Z5R/!BM1Y/'2E8Z+J4*-[*F4N"QQK#*9C08TAW.1E6JSSY*-@J.H
M;E>N4#-L+M>E-E@9?:B626;D,ITCV*J:0BI-4^RJGLP1T8?6-=WL=ELKE\DM
MB(IE4L6DEI(Y,KJ2:(I9LR:KF-K=+N8K$LWK:AK>[AQ9*=?2?)$88JRJ\&A5
MUS&JD9?@]?#1C2Y*F(8@^8JD*F:WD<>Q6AD592X5?2AJXNP@FVL4&'VKF9.N
M(1G;)NQ+C*P<;]<5RK0*'5::Z]OT4N=4T_&XS(F54[R%V85Z71W(M6&M1DL8
M+\+>ANA&J4J[K\Z*C0VC;_B25NAX*[;G09\BLG126<U7O6*VS&[8Y(*I3%Q4
M[0,60:-+G0)*MU76:",;+9\G#;-#DY#RL>A2I3V:)@U\,T<PMKD=KFOH3!=H
MN'2_V4>:;W?AL8+;:*;0G$Q9+%?.C8VAUVH9;0XNQ0.S!'Q#$FGGI=7$9ZBJ
MV/,\;=8]9!'>&RE!.:6;VO;GG+I<II9912L7O-D-)%C+>L'T/,I-L@I1%=;4
M&*OH;%"803U1&/E1G_6P*,DT@,'O^ZM^-1)<Q0LS15KY9_3?L7OF @!JJ@AW
MB84EB1*P=X"I"(@-\ 3X.O P[4<&;23@K)G 5H'?.RIGDDV G6_M;GZ<N-N]
M>J/#VH2C\J7N8"S5L'%Z^GY?YTO=5(^4+6)=;5A,,C-=<WEOV.TV? *G,.0)
M1_7):FP#1C+V!'% >M"=G4B2D= E!WQ?@(XMV)^V@=]) !%HR=+.KSKPM/9?
MV[O"2L $ /E^![A/S^"TC@\8?ULFH%X^)$ C*$BVI!D ([ > 8W;MQC:7%B*
M!C[SMX9>FWXA(./YXR^!?GGXY:Q9$IN;IPB^BKGLLDBNFUIWLN[A-Q#P+.A*
MUB*;4DK5>YG&PNKPR?16]M4'AM\1GU3*^D4* Z+Y@-U>6^ZJ!'4T"6D)2V<=
M $D!K+P[B+&&G_G+@938!6!]S1/J2O\MEU-+#8YDBVIIWJO76(J1ZI-Y<^X(
MS%.1M>M@D=<H(:@>/\P=^VZ(E[NN?"ZI,)/>M$FB999G'%RK%KHU>^;]^I.Z
M0XBG@J7-7?IYKWQ.2,0#LG9FO'-D90%-] C]K\0^D*D2EQWE$*\RW0Z1Y;"#
M:W(];79JSZ!_;X#O?Z;;>'[,9OD-HE=4S&18;Y94VV_MFWL&7Z&)LF?GN@3P
M!A@F!  073 R!RR@/4Z2V&%I88TLUK*ZUD-<LS#LI7(CCJ1@BC':,?O7*9T?
M5 SPAZK>>2K ?44URE#5HAADS^=*E*?$:FB/U7I3+:Z7G*/AN*3UO2^(;F_5
M\F@VS*&XVBQE](PW:&R;'F 5'"5.,DJ A<^&+WH$WS,+-CZ7RAC%I&2H2I$8
M(T5#)U?IKTBRX_.*DZFNC"ZCE\K-K)P<2!P-. !+X:<]OP]E$NRG3-$ A8'E
M!RP#H+9A(%3;7)6)NN\EP=+^KI%KLU*!RDU#XD0@J3[\HC>,4E_SW"K;'.<-
ML[6@%@O7NW[#<J68WFR&LAI2K8T1IEP:TX61Y_=( 4F 8^<K_;Z,88D<&98W
M%GTX;U?PU\8#&I->V1W*7 >A.G,B,\\9VQG8^Q_\+IT^+?9\6^RQBWK5QM@I
M6YS0!U5OLUX/F.IFCK6G97.&MJ[('-O0MI/<5!8KM=EA&LPR4Y$+6U@U';V)
MX1N98SNU@J6A3'C.(AL014\IXMH,P5Q'+B5EAK!Z7U%OL!3*?9Q62QBKK+(S
MMC\;+.? //F3(4\W[EW&(.NTQM@DDVFKBI#:#&9+5=;TK["AYLN9V)L3] H!
M+TZU%BI?J_&^GD)2I\.+-VQ%?;!I/C>#$AV>'V;.+5-+^E2>>&BF[P!FMA0!
M0B'HJX?4<D5=];W3)A\4+CNSSWHX0H!E2/GVB7KXZ'/NGK15UI+@0G2"Y<#P
MD*Q0VH'E#V;,Z<+ )[9S*OG")R((>O10\%:HYJ:^C@LCU5';!B42-9AJZ<%4
M2]F 4A]N'7+2Y4SZ$'E34]-,#\;<_*JAA +LJ(3MZOI#%>*30 O(\/RC.A[)
M'F$FB2Y,[)Q6LP\LXG.(SR ^ ]&0X15GXY>G],"FLAKX^Z]=8EJJJ#;=R@Y1
M9-/V2LM<21L3)> (2$"H+<#['0L83!?#S9E&^P1(W953!:/N!(!R?F%+OW<_
M'&X6;B0LJ8*5.4)0T;.K3?-KG7C7,7<?!)5._B=']5 '\[#"-4BDLLFQ=AL+
M7X@&)W_=O$:"O,>?'>EZ4&YT\'PX7F8**'X'M=WO23CLZW=0/ ;GPKQ8MQ4B
MPW_Q;BD_L4W-=:2O*.%ZS3WQZ!MF0!U6XGUP!EP:B_%R?7A)WZ>(&"_7AY>8
M7ZX3+S&_7"=>8GZY3KS$_'*=> '\$N/E"O$"^(6,\7)]>(GYY5KQ@L9Z_PKQ
MDKG'G[UF)L;+A_#RQFM,7@R+?1@(Z9=@,#EZ0]@L.#$UT9]0_Y_)"2@=+OJB
MBPJ>=R(N"Z7@VI/HOS[PSG*9P;,:[BR'?[(?^.W@\!-# 03,Z9E@$!/ #1$
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MWBGB\QN-TTW"-\\BVK$F><<=Z\;)>9/8C/*K-D(OF#[W+=;)A'UY<7W=PR\
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MDC9E!A^?@N]?X39EXN@J0*4HFPP6O-&\@_-CO;Y(GL%6]4(+U1":]TH>-$^
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MX;RO6-GMAF:>CWPX0R!*JW(#DGB9-EW/U9@! N: IU5Z0ZN0XG&-I#<<G]B
M3,>/;VE0I%)M:K!S3\N!6([06Y#@Z\KU[GI>\"ZTO+/B*W>4W)HVM*)J-6P*
M#P5J\R*2*.]@[/3XBX2,B,:X^)3#*)-;74/(7BIVZ/3:3D#16F4B5<SC8BV*
MSS,LU3=5=E;2S"&HDN1L8$>T !JIVC>1#[!FF"()1AY#;2=Q<X^- M!-I-9;
M^F>W;O2#*)$LC 4=%L!'9TQA4QB6+15OG<42"=4RZEA8-*9$&!>SX-E=JSG(
M1U92#?3(!A3)S$69=03(P"*JH4Q$AD^!="._ ($^E#TM5GFP(4S+D@CR"5CM
MF^;90A?D<:%[LR2> 4H*H$*Y.0=OM#3(,67)PKF.:1M2*AA F600%S!I^8AR
M0QN5N+P6@O'$D2?'U3+T/2%T!B;OIDRMQS8>; 1;V=-3AL1\2Y!%"CAU72M
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MF1)"ERQ*UDYR*[I$ R];\2)0<5WR5VH[0&%5.C+W**\W%3-94NJ)#WQ-C.[
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M;_J+945U0>J49O YOOD"&4\W%:T5I((2A=(=4P7$O&E(#3=4"%:6<"E8MJ8
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MU+_W'HU!&@=T(GE4+/O!0:.]-\\TKJUI:S#W_1O[A9[C_P%02P,$%     @
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M/SO)JX/L&8O?2XK/P.97^OE7/_C!_.!P*AEV@SFV@Y\YP]$#;W"*9NKL29O
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M,C,Q7V-A;"YX;6Q02P$"% ,4    " #UA6E615C]#5$Y   ZC@, %0
M        @ &U+0  8W1S;RTR,#(R,3(S,5]D968N>&UL4$L! A0#%     @
M]85I5N,)IKVUDP  #H,( !4              ( !.6<  &-T<V\M,C R,C$R
M,S%?;&%B+GAM;%!+ 0(4 Q0    ( /6%:5:5(&[!UUX  *CE!@ 5
M      "  2'[  !C='-O+3(P,C(Q,C,Q7W!R92YX;6Q02P$"% ,4    " #U
MA6E66/;\0>MD! #Y7"< %0              @ $K6@$ 8W1S;RTR,#(R,3(S
M,7@Q,&LN:'1M4$L! A0#%     @ ]85I5AD-S3A+ @  K!,  !D
M     ( !2;\% &-T<V\M,C R,C$R,S%X97@Q,&0Q,2YH=&U02P$"% ,4
M" #UA6E6C%=$8+ 7  " 30  &0              @ '+P04 8W1S;RTR,#(R
M,3(S,7AE>#$P9#,P+FAT;5!+ 0(4 Q0    ( /6%:5;>'1KPL ,  ,D:   8
M              "  ;+9!0!C='-O+3(P,C(Q,C,Q>&5X,C%D,2YH=&U02P$"
M% ,4    " #UA6E62MJU9 T$  "X"@  &               @ &8W04 8W1S
M;RTR,#(R,3(S,7AE>#(S9#$N:'1M4$L! A0#%     @ ]85I5L]"@GM6"0
MYS<  !@              ( !V^$% &-T<V\M,C R,C$R,S%X97@S,60Q+FAT
M;5!+ 0(4 Q0    ( /6%:5;YJM4V$PD  *,T   8              "  6?K
M!0!C='-O+3(P,C(Q,C,Q>&5X,S%D,BYH=&U02P$"% ,4    " #UA6E6?)]A
M]R0&   A'0  &               @ &P] 4 8W1S;RTR,#(R,3(S,7AE>#,R
M9#$N:'1M4$L! A0#%     @ ]85I5J=\"7 R!@  MQT  !@
M ( !"OL% &-T<V\M,C R,C$R,S%X97@S,F0R+FAT;5!+!08     #@ . , #
(  !R 08    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
